


東京医学

THE TOKYO JOURNAL OF MEDICAL SCIENCES

October 2023

Vol.147

**ANNUAL REPORT OF
THE GRADUATE SCHOOL OF MEDICINE
AND
THE FACULTY OF MEDICINE
THE UNIVERSITY OF TOKYO
REPORTS FOR THE PERIOD April 2022 — March 2023**



共同編集 東京医学会・東京大学医師会・東京大学医学部

JOINTLY EDITED BY
THE TOKYO SOCIETY OF MEDICAL SCIENCES
THE UNIVERSITY OF TOKYO MEDICAL SOCIETY
THE UNIVERSITY OF TOKYO FACULTY OF MEDICINE

学術刊行物

東京医学

Tokyo J. Med. Sci.

ANNUAL REPORT OF THE GRADUATE SCHOOL OF
MEDICINE

THE FACULTY OF MEDICINE

THE UNIVERSITY OF TOKYO

REPORTS FOR THE PERIOD April 2022-March 2023

Introduction

This is volume 147(the edition of year 2023) of the annual report by the University of Tokyo's Graduate School of Medicine and Faculty of Medicine.

In it are recorded the past year's research, educational, clinical, and other activities of the Graduate School of Medicine and Faculty of Medicine and the Tokyo Society of Medical Sciences.

It reports our accomplishments, and each year we make such a document freely available by publishing it on compact disk and on the Internet, expecting it to be used for internal and external evaluations.

The University of Tokyo's Faculty of Medicine was founded 160 years ago. Since then we have consistently driven Japan's progress in medical research, medical education, and clinical care, and in some fields we have become world leaders.

We have more than 1000 students in the Graduate School of Medicine, and with as many as 150 foreign researchers and students we are an international center for medical research and education.

Pursuing excellence in our research, educational, and clinical activities, we will continue meeting the needs for tomorrow's pioneers in medical sciences and clinical care.

Masaomi Nangaku, Dean
Graduate School of Medicine and Faculty of Medicine
The University of Tokyo

October, 2023

CONTENTS

Introduction

History

Organization Chart

Teaching, Research, Secretarial and Administrative Staffs

The University of Tokyo, Graduate School of Medicine

Molecular Cell Biology

1. Cell Biology and Anatomy	1
Department of Cell Biology	2
Department of Structural Biology	4
Department of Cytoarchitectonics	6
Department of Cellular Neurobiology	8
2. Biochemistry and Molecular Biology	10
Department of Molecular Biology	11
Department of Genome Informatics	15
Department of Physiological Chemistry and Metabolism	18
Department of Advanced Structural Studies	22

Functional Biology

1. Physiology	25
Department of Integrative Physiology	26
Department of Cellular and Molecular Physiology	28
Department of Neurophysiology	32
2. Pharmacology	34
Department of Cellular and Molecular Pharmacology	35
Department of Systems Pharmacology	37

Pathology, Immunology and Microbiology

1. Pathology	41
Department of Pathology and Diagnostic Pathology	42
Department of Molecular Pathology	46

2. Microbiology	49
Department of Microbiology	50
Department of Infection Control and Prevention	54
3. Immunology	59
Department of Immunology	60
Radiology and Biomedical Engineering	
1. Radiology	65
Department of Radiology	66
2. Biomedical Engineering	69
Department of System Physiology	70
Department of Chemical Biology and Molecular Imaging	75
Department of Biosystem Construction & Control	77
Division of Integrative Genomics	80
Neuroscience	
1. Basic Neuroscience	84
Department of Neuropathology	85
Department of Neurochemistry	89
2. Integrative Medical Neuroscience	95
Department of Child Neuropsychiatry	96
3. Clinical Neuroscience	98
Department of Neuropsychiatry	99
Department of Neurology	103
Department of Neurosurgery	111
Social Medicine	
1. Occupational, Environmental and Preventive Medicine	120
Department of Molecular Preventive Medicine	121
Department of Public Health / Department of Health Policy	125
2. Forensic Medicine, and Medical Informatics and Economics	130
Department of Forensic Medicine	131
Department of Biomedical Informatics	135

Internal Medicine

1. Medicine I	138
Department of Cardiovascular Medicine	139
Department of Respiratory Medicine	143
Department of Gastroenterology	148
2. Medicine II	153
Department of Nephrology and Endocrinology	154
Department of Diabetes and Metabolic Diseases	159
Department of Hematology and Oncology	166
Department of Allergy and Rheumatology	171
Department of Infectious Diseases (Internal Medicine)	175
Department of Stress Science and Psychosomatic Medicine	181
3. Clinical Laboratory Medicine and Pathology	184
Department of Clinical Laboratory Medicine (See Department of Clinical Laboratory [P.502])	
Department of Transfusion Medicine	185

Reproductive, Developmental and Aging Sciences

1. Obstetrics and Gynecology	188
Department of Reproductive Endocrinology	189
Department of Gynecologic Oncology	192
Department of Perinatal Medicine	195
Department of Molecular and Cellular Reproductive Medicine	197
2. Pediatric Sciences	199
Department of Pediatrics, Department of Developmental Pediatrics	200
Department of Pediatric Surgery	205
3. Aging Sciences	209
Department of Geriatric Medicine, Department of Aging Research	210

Surgical Sciences

1. Surgery	217
Department of Thoracic Surgery	218
Department of Cardiac Surgery	222
Department of Gastrointestinal Surgery	227
Hepato-biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division	231
Department of Urology	234

Department of Surgical Oncology	241
Department of Vascular Surgery	246
Department of Breast and Endocrine Surgery	249
2. Sensory and Motor System Medicine	252
Department of Dermatology	253
Department of Plastic and Reconstructive Surgery	256
Department of Oral-Maxillofacial Surgery	259
Department of Orthopaedic Surgery	264
Department of Ophthalmology	273
Department of Otolaryngology and Head and Neck Surgery	277
Department of Rehabilitation Medicine	284
3. Vital Care Medicine	287
Department of Anesthesiology	288
Department of Emergency and Critical Care Medicine	292
Health Sciences and Nursing	
1. Health Sciences	295
Department of Health Sociology	
(See Departments of Health and Social Behavior & Health Education and Health Sociology [P.373])	
Department of Mental Health	296
Department of Biostatistics / Epidemiology and Preventive Health Sciences	300
Department of Social Gerontology	
(See Departments of Health and Social Behavior & Health Education and Health Sociology [P.373])	
Department of Biomedical Ethics & Department of Health Promotion Sciences	303
2. Preventive and Administrative Nursing	307
Department of Nursing Administration / Advanced Clinical Nursing	308
Department of Family Nursing	311
Department of Community Health Nursing / Public Health Nursing	314
3. Clinical Nursing	316
Department of Gerontological Home Care and Long-term Care Nursing/Palliative Care Nursing	317
Department of Midwifery and Women's Health	321
Department of Psychiatric Nursing	325
Department of Gerontological Nursing / Wound Care Management	330

International Health

1. International Social Medicine	336
Department of Global Health Policy	337
Department of Community and Global Health	340
2. International Biomedical Sciences	343
Department of Human Genetics	344
Department of Developmental Medical Sciences	345
Department of Human Ecology	348
Department of Biomedical Chemistry	352

School of Public Health

1. Epidemiology and Health Sciences	355
Department of Biostatistics	
(See Department of Biostatistics / Epidemiology and Preventive Health Sciences [P.300])	
Department of Social and Preventive Epidemiology	356
Department of Clinical Epidemiology and Health Economics	359
Department of Health Communication	369
2. Behavioral Health Sciences	372
Department of Mental Health (See Department of Mental Health [P.296])	
Department of Health Sociology and Health Education	
(See Departments of Health and Social Behavior & Health Education and Health Sociology [P.373])	
Departments of Health and Social Behavior & Health Education and Health Sociology	373
Department of Biomedical Ethics & Department of Health Promotion Sciences	
(See Department of Biomedical Ethics & Department of Health Promotion Sciences [P.303])	
3. Health Services Sciences	378
Department of Health Policy	
(See Department of Public Health / Department of Health Policy [P.125])	
Department of Healthcare Informatics (See Department of Biomedical Informatics [P.135])	
Department of Clinical Information Engineering	379
Department of Forensic Medicine and Medical Law	
(See Department of Forensic Medicine [P.131])	
Department of Global Environmental Health	381

Endowed Department	383
Department of Artificial Intelligence in Healthcare	384
Department of medical research and the management of musculoskeletal pain	387

Science for joint reconstruction (See Department of Orthopaedic Surgery [P.264])	
Department of Bone & Cartilage Regenerative Medicine	
(See Central Clinical Facilities Division of Tissue Engineering [P.563])	
Department of Osteoimmunology	391
Department of Computational Diagnostic Radiology and Preventive Medicine	395
Research on Cell Therapy of Regenerative Medicine	398
Department of Home Care Medicine	400
Department of Therapeutic Strategy for Heart Failure	402
Department of Biostatistics and Bioinformatics	406
Department of Advanced Cardiology	409
Laboratory for Advanced Research on Pathophysiology of Metabolic Diseases	414
Department of Advanced Clinical Science and Therapeutics	416
Comprehensive Radiation Oncology	418
Department of Immunotherapeutics	421
Social Cooperation Program	424
Department of Eat-loss Medicine	
(See Central Clinical Facilities Division of Tissue Engineering [P.563])	
Department of Medical Information Engineering	425
Health Economy and Society Policy	427
Department of Healthcare Quality Assessment	430
Laboratory for cryo-electron microscopy	433
Department of Cellular and Tissue Communication	435
Department of Next Generation Locomotive Imaging System	438
Department of Next-generation Endoscopic Computer Vision	440
Next-Generation Precision Medicine Development Laboratory	442
Department of Tissue Stem Cells and Life Dentistry	445
Department of Digital Mental Health	447
Department of Prevention of Diabetes and Lifestyle-Related Diseases	450
Department of Pain & Palliative Medical Sciences	453
Department of Innovative Dementia Prevention	456
Department of Precision Medicine Neurology	460
Department of Health Services Research	464
Division of Chronic Kidney Disease (CKD) Pathophysiology	470
Department of Functional Genomics and Immunological Diseases	
(See Department of Allergy and Rheumatology [P.171])	
Department of Retinal Biology and Pathology	473
Department of Real-world Evidence	476
Department of Lipidomics	478

Clinical stem cell biology

(See Central Clinical Facilities Division of Tissue Engineering [P.563])

Department of Preventive Medicine for Locomotive Organ Disorders 481

University Hospital

Clinical Services 484

Internal Medicine

Cardiovascular Medicine (See Department of Cardiovascular Medicine [P.139])

Respiratory Medicine (See Department of Respiratory Medicine [P.143])

Gastroenterology (See Department of Gastroenterology [P.148])

Nephrology and Endocrinology (See Department of Nephrology and Endocrinology [P.154])

Diabetes and Metabolic Diseases (See Department of Diabetes and Metabolic Diseases [P.159])

Hematology and Oncology (See Department of Hematology and Oncology [P.166])

Allergy and Rheumatology (See Department of Allergy and Rheumatology [P. 171])

Infectious Diseases (See Department of Infectious Diseases (Internal Medicine) [P.175])

Neurology (See Department of Neurology [P.103])

Geriatric Medicine

(See Department of Geriatric Medicine, Department of Aging Research [P.210])

Psychosomatic Medicine

(See Department of Stress Science and Psychosomatic Medicine [P.181])

Surgery

Stomach and Esophageal Surgery (See Department of Gastrointestinal Surgery [P.227])

Colon and Rectal Surgery (See Department of Surgical Oncology [P.241])

Hepatobiliary Pancreatic Surgery

(See Hepato-biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division [P.231])

Vascular Surgery (See Department of Vascular Surgery [P.246])

Breast and Endocrine Surgery

(See Department of Metabolic Care and Endocrine Surgery [P.249])

Artificial Organ and Transplantation Surgery

(See Hepato-biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division [P.231])

Cardiovascular Surgery (See Department of Cardiac Surgery [P.222])

Thoracic Surgery (See Department of Thoracic Surgery [P.218])

Neurosurgery (See Department of Neurosurgery [P.111])

Anesthesiology and Pain Relief Center (See Department of Anesthesiology [P.288])

Urology and Andrology (See Department of Urology [P.234])

Gynecologic Surgery (See Obstetrics and Gynecology [P.188])

Sensory and Motor System Medicine

Dermatology (See Department of Dermatology [P.253])

Ophthalmology (See Department of Ophthalmology [P.273])

Orthopaedic Surgery and Spinal Surgery (See Department of Orthopaedic Surgery [P.264])

Otorhinolaryngology and Head and Neck Surgery

(See Department of Otorhinolaryngology and Head & Neck Surgery [P.277])

Rehabilitation Medicine (See Department of Rehabilitation Medicine [P.284])

Plastic, Reconstructive and Aesthetic Surgery

(See Department of Plastic and Reconstructive Surgery [P.256])

Oral-Maxillofacial Surgery and Orthodontics

(See Department of Oral-Maxillofacial Surgery [P.259])

Pediatrics, Perinatal and Women's Medicine

Pediatrics

(See Department of Pediatrics, Department of Developmental Pediatrics [P.200])

Pediatrics Surgery (See Department of Pediatric Surgery [P.205])

Obstetrics and Gynecology

(See Department of Reproductive Endocrinology / Department of Gynecologic Oncology /
Department of Perinatal Medicine [P.189/P.192/P.195])

Neuropsychiatry

Neuropsychiatry (See Department of Neuropsychiatry [P.99])

Radiology

Radiology (See Department of Radiology [P.66])

Emergency and Critical Care Medicine

Emergency and Critical Care Medicine

(See Department of Emergency and Critical Care Medicine [P.292])

Cross-Sectional Services

Advanced Medical Center for Heart Failure 485

Department of Clinical Genomics 488

Department of Child Psychiatry 490

Children, AYA and Family Centered Mental Care Center

(See Department of Child Psychiatry [P.490])

Department of Pain and Palliative Medicine 493

Central Clinical Services 497

Department of Pharmacy 498

Department of Clinical Laboratory 502

Department of Blood Transfusion

(See Department of Transfusion Medicine [P.185])

Department of Pathology	507
Department of Infection Control and Prevention (See Department of Infection Control and Prevention [P.54])	
Radiology Center	511
Rehabilitation Center	514
Surgical Center	517
Central Supply Service	520
Department of Endoscopy and Endoscopic Surgery	522
Department of Hemodialysis and Apheresis	525
Department of Intensive Care Unit (See Department of Emergency and Critical Care Medicine [P.292])	
Immune-Mediated Diseases Therapy Center	528
Tissue Bank	530
Department of Corneal Transplantation	532
Department of Cell Therapy and Transplantation Medicine	535
Clinical Nutrition Center	538
Swallowing Center	544
International Medical Center	546
Center for Epidemiology and Preventive Medicine	547
Palliative Care Consultation Team (See Department of Pain and Palliative Medicine [P.493])	
Medical Community Network and Discharge Supporting Center	551
Cancer Resource Center	553
 Clinical Research Services	
Clinical Research Promotion Center	555
Division of Tissue Engineering	563
Cooperative Unit of Medicine and Engineering Research	567
Genomic Research Support Center	572
BioResource Center	576
 Hospital Management Services	
Department of Clinical Research Governance	578
Department of Healthcare Information Management	580
University Hospital Medical Information Network Center	582
Department of Disaster Medical Management	585
 Center for Disease Biology and Integrative Medicine	587
Laboratory of Molecular Biomedicine for Pathogenesis	588
Laboratory of Structural Physiology	590

Laboratory of Biomedical Equipment and Biomaterials	592
Laboratory of Clinical Biotechnology	594
Laboratory of Microenvironmental and Metabolic Health Sciences	599
Laboratory of Animal Resources	604
Laboratory of Molecular Radiology	607
Laboratory of Biomedical Informatics.....	610
 The International Research Center for Medical Education (IRCME)	 613
Department of Medical Education Studies	614
Department of International Cooperation for Medical Education	616
 Global Nursing Research Center.....	 618
 Center for Diversity in Medical Education and Research	 621
 Office of International Academic Affairs	 623
 MD Scientist Training Program	 625
 Museum of Health and Medicine	 628
 Office for Human Research Studies (OHRS)	 630
 The Office for Clinical Practice and Medical Education	 632
 Advisory Office for Conflict of Interest	 634


History


1858	May	Practitioners, trained in Dutch (European) medicine in Edo (Tokyo), laid out money to establish the Shutojo (vaccination center) in Kanda Mitamagaike.
	Nov.	Shutojo was destroyed in a fire that had spread from Kanda Aioicho. Shutojo continued its operations at other sites such as the residence of Ito Genboku.
1859	Sep.	Shutojo was reconstructed at Shitaya Izumibashi Dohri.
1860	Oct.	Shutojo became an official medical institution of the Shogunate Government.
1861	Oct.	Shutojo was renamed as Seiyo Igaku-Sho (Institute of Western Medicine) and offered courses of Western Medicine in the fields of Education, Autopsy, and Vaccination.
1863	Feb.	Seiyo Igaku-Sho was renamed as Igaku-Sho (Institute of Medicine).
1868	Jul.	Igaku-Sho, affiliated with the Military Hospital which had been moved from Yokohama to Todo residence in Shitaya, was renamed as Daibyoin (the Great Hospital).
1869	Feb.	The Daibyoin was renamed as Igakko-Ken-Byoin (Medical School and Hospital).
	Dec.	Igakko-Ken-Byoin was renamed as Daigaku Toko (University East Building).
1871	Jul.	The Ministry of Education was established and Daigaku-Toko was renamed as Toko (East Building).
1872	Aug.	A School System was established. Toko was renamed as Daiichi-Daigaku-Ku- Igakko (The First University District Medical School).
1874	May	Daiichi-Daigaku-Ku-Igakko was renamed as Tokyo-Igakko (Tokyo Medical School).
1876	Nov.	Tokyo-Igakko was moved to Hongo.
1877	Apr.	Tokyo Igakko, affiliated with Tokyo-Kaisei School, was renamed as The University of Tokyo. Tokyo Medical School was renamed as The University of Tokyo Faculty of Medicine.
1886	Mar.	The University of Tokyo was renamed as Imperial University, and The University of Tokyo Faculty of Medicine was renamed as the Imperial University Medical College. A Graduate School was established.
1897	Jun.	The Imperial University was renamed as Tokyo Imperial University.
1917	Aug.	Eiraku Hospital, affiliated with the Ministry of Education Medical Practice License Examination, moved to Tokyo Imperial University and was renamed as Koishikawa Hospital affiliated with Tokyo Imperial University Medical College.
1919	Apr.	A faculty system was established renaming Tokyo Imperial University Medical College as the Faculty of Medicine.
1931	Feb.	The first building of the Faculty of Medicine was constructed.
1936	Jan.	The Brain Research Laboratory was built with funds donated by Mr. Hisasaburo Horikoshi.
	Nov.	The second building of the Faculty of Medicine (main building) was constructed.
1947	Oct.	Tokyo Imperial University was renamed as The University of Tokyo.
1950	Apr.	The Institute of Nursing was renamed as The University Nursing School.
1953	Apr.	The School of Health Care and Nursing was founded.


- Jul. The Graduate School was founded, and the Division of Medical Doctor Biological Science was established. The Brain Research Laboratory became the Brain Research Institute of the Faculty of Medicine.
- 1956 Apr. The Midwives School was established.
- 1958 Apr. The Division of Pharmaceutical Sciences became an independent faculty.
May The University of Tokyo Faculty of Medicine celebrated its centennial anniversary.
- 1961 Mar. The Medical Library was built in commemoration of the centenary.
Apr. The Institute of Medical Electronics was established.
- 1965 Apr. The Research Institute of Logopedics and Pediatrics was established. The School of Health Care and Nursing was reorganized as the School of Health Sciences. The Graduate School of The University of Tokyo was reorganized and the Division of Medical Doctor Biological Science became the Faculty of Medicine. The Health science Course was established in the Medical Science Division.
- 1966 Sep. The third building of the Faculty of Medicine was constructed.
- 1971 Apr. The Laboratory of Animal Experiments was established.
- 1973 Mar. The Animal Center for Biomedical Research was constructed.
- 1983 Jan. An annex of the third building of the Faculty of Medicine was constructed.
- 1985 Sep. The office of International Academic Affairs was established.
- 1987 Apr. Specialized courses were introduced to the Graduate School of Medicine.
- 1992 Apr. The School of Health Sciences became the School of Health Science and Nursing. The School of International Health was established in the Medical Science Division.
Jul. The Radiation Research Institute was established.
- 1995 Apr. As a result of the shift to the chair system of the Graduate School of Medicine, four divisions, Third Basic Medicine, Social Medicine, Third and Fourth Clinical Medicine, were replaced with Pathology, Immunology and Microbiology, Social Medicine, Reproduction and Development, and Aging Science and Surgery.
- 1996 Apr. As a result of the shift to the chair system of the Graduate School of Medicine, three divisions, First Clinical Medicine, Health Science, and International Health, were replaced with Internal Medicine, Health Science and Nursing, and International Health.
- 1997 Apr. As a result of the shift to the chair system of the Graduate School of Medicine, three divisions, First and Second Basic Medicine, and Second Clinical Medicine, were replaced with Molecular Cell Biology, Functional Biology, Radiology and Biomedical Engineering, and Neuroscience.
As a result of the above-mentioned reorganization, three institutes, the Institute of Brain Research, the Institute of Medical Electronics, and the Institute of Logopedics and Phoniatrics were made redundant.
- 1999 Apr. The Master course of Medical Science was established in the Graduate School of Medicine. This course accepts graduates of all faculties except those from Schools of Medicine, Dentistry, and Veterinary Medicine.

2000	Apr.	The International Research Center for Medical Education was established (A shared facility for education and research).
2001	Apr.	The University Branch Hospital was united with the University Hospital.
2002	Mar.	Nursing School and Midwives School was Closed.
2002	Mar.	Experimental Building (First Stage) was constructed.
2003	Apr.	The Center for Disease Biology and Integrative Medicine was established. The Radiation Research Institute and the Laboratory of Animal Experiments were integrated into the Center for Disease Biology and Integrative Medicine.
2004	Apr.	All the National Universities owned by the Japanese Government became National University Corporations and the University of Corporation.
2005	Mar.	Experimental Building (Second Stage) was constructed.
2007	Apr.	The School of Public Health was established. This school offers programs for Master of Public Health.
2008	May	The University of Tokyo Faculty of Medicine and the University of Tokyo Hospital celebrated their 150th anniversary.
2010	Apr.	The School of Health Science and Nursing became the School of Integrated Health Sciences.
2011	Jan.	The Museum of Health and Medicine was established.
2012	Apr.	The Office for research Ethics Support was established.
2013	Apr.	The International Research Center for Medical Education became a facility of the Graduate School of medicine.
2013	Oct.	The Life Sciences Core facility was established.
2015	Apr.	The Office for Clinical Practice and Medical Education was established.
2016	Apr.	The Advisory office for Conflicts of interest was established.
2017	Apr.	The Global Nursing Research Center was established.
2017	Apr.	The Institute for Life Science Research and Education was established.
2017	Apr.	The Research Institute for Biomedical Science and Engineering was established.
2019	May	The Bioethics Collaborative Research Organization was established.
2020	Apr.	The Collaborative Research Organization for Structural Life Sciences was established.
2021	Apr.	UTokyo Center for Diversity in Medical Education and Research was established.

Organization Chart




















Teaching, Research, Secretarial and Administrative Staffs

Chief Members of Administration

Dean, Graduate School of Medicine (Dean, Faculty of Medicine)		Shigeo Okabe
Chairman, School of Health Sciences and Nursing		Masahiro Umezaki
Director, Medical Library		Hideo Yasunaga
Director General, University Hospital		Yasuyuki Seto
Director, Center for Disease Biology and Integrative Medicine		Masanobu Kano
Director, International Research Center for Medical Education		Tatsuya Yamasoba
Director, Global Nursing Research Center		Noriko Yamamoto
Director, Center for Diversity in Medical Education and Research		Kiyoto Kasai

Graduate School of Medicine

Molecular Cell Biology

Department of Cell Biology and Anatomy	Professor	Yasushi Okada
	Professor	Masahide Kikkawa
	Professor	Shigeo Okabe
Department of Biochemistry and Molecular Biology	Professor	Noboru Mizushima
	Professor	Yukinori Okada
	Professor	Hiroki Kurihara
	Professor	Radostin Stoyanov Danev

Functional Biology

Department of Physiology	Professor	Kenichi Ohki
	Professor	Masanori Matsuzaki
	Professor	Masanobu Kano
Department of Pharmacology	Professor	Kenzo Hirose
	Professor	Hiroki Ueda

Pathology, Immunology and Microbiology

Department of Pathology	Professor	Tetsuo Ushiku
	Professor	Yasuhiro Yamada
Department of Microbiology	Professor	Makoto Takeda
	Professor	Takeya Tsutsumi
Department of Immunology	Professor	Hiroshi Takayanagi

Radiology and Biomedical Engineering

Department of Radiology	Professor	Osamu Abe

Department of Biomedical Engineering	Professor	Kiyoshi Miyagawa
	Professor	Yasuteru Urano
	Professor	Katsutoshi Oda
Neuroscience		
Department of Basic Neuroscience	Professor	Takeshi Iwatsubo
	Professor	Haruhiko Bito
Department of Integrative Medical Neuroscience		
Department of Clinical Neuroscience	Professor	Kiyoto Kasai
	Professor	Tatsushi Toda
	Professor	Nobuhito Saito
Social Medicine		
Department of Occupational, Environmental and Preventive Medicine	Professor	Shumpei Ishikawa
	Professor	Takahiro Higashi
Department of Forensic Medicine, and Medical Informatics and Economics	Professor	Hiroto Iwase
	Professor	Kazuhiko Ohe
Internal Medicine		
Department of Medicine I	Professor	Issei Komuro
	Professor	Takahide Nagase
	Professor	Mitsuhiro Fujishiro
	Professor	Masaomi Nangaku
Department of Medicine II	Professor	Toshimasa Yamauchi
	Professor	Mineo Kurokawa
	Professor	Keishi Fujio
	Professor	Takeya Tsutsumi
Department of Clinical Laboratory Medicine and Pathology	Professor	Yutaka Yatomi
	Professor	Hitoshi Okazaki
Reproductive, Developmental and Aging Science		
Department of Obstetrics and Gynecology	Professor	Yutaka Osuga
Department of Pediatric Sciences	Professor	Motohiro Kato
	Professor	Jun Fujishiro
Department of Aging Sciences	Professor	Masahiro Akishita
Surgical Sciences		
Department of Surgery	Professor	Jun Nakajima
	Professor	Minoru Ono
	Professor	Yasuyuki Seto
	Professor	Kiyoshi Hasegawa
	Professor	Haruki Kume
	Professor	Soichiro Ishihara

Department of Sensory and Motor System Medicine	Professor	Shinichi Sato
	Professor	Mutsumi Okazaki
	Professor	Kazuto Hoshi
	Professor	Sakae Tanaka
	Professor	Makoto Aihara
	Professor	Tatsuya Yamasoba
Department of Vital Care Medicine	Professor	Toru Ogata
	Professor	Kanji Uchida
	Professor	Kento Doi
Health Sciences and Nursing		
Department of Health Sciences	Professor	Daisuke Nishi
	Professor	Yutaka Matsuyama
	Professor	Hideki Hashimoto
	Professor	Akira Akabayashi
Department of Preventive and Administrative Nursing	Professor	Mari Ikeda
Department of Clinical Nursing	Professor	Noriko Yamamoto
	Professor	Megumi Haruna
	Professor	Daisuke Nishi
	Professor	Gojiro Nakagami
International Health		
Department of International Social Medicine	Professor	Masahiro Hashizume
	Professor	Masamine Jimba
Department of International Biomedical Sciences	Professor	Akihiro Fujimoto
	Professor	Moi Meng Ling
	Professor	Masahiro Umezaki
	Professor	Tomoyoshi Nozaki
School of Public Health		
Department of Epidemiology and Health Sciences	Professor	Yutaka Matsuyama
	Professor	Satoshi Sasaki
	Professor	Hideo Yasunaga
	Professor	Takahiro Kiuchi
Department of Behavioral Health Sciences	Professor	Daisuke Nishi
	Professor	Hideki Hashimoto
	Professor	Akira Akabayashi
Department of Health Services Sciences	Professor	Kazuhiko Ohe
	Professor	Hiroshi Oyama
	Professor	Hirotarō Iwase
Center for Disease Biology and Integrative Medicine		
Laboratory of Molecular Biomedicine for Pathogenesis		

Laboratory of Structural Physiology		
Laboratory of Biomedical Equipment and Biomaterials	Professor	Taichi Ito
Laboratory of Clinical Biotechnology	Professor	Ungil Chung
Laboratory of Microenvironmental and Metabolic Health Sciences	Professor	Makoto Murakami
Laboratory of Animal Resources	Professor	Atsu Aiba
Laboratory of Molecular Radiology	Professor	Kiyoshi Miyagawa
Division of Research Resources and Support		
International Research Center for Medical Education	Professor	Masato Eto
Global Nursing Research Center		
Center for Diversity in Medical Education and Research	Associate Professor	Yoshihiro Satomura
Medical Library	Professor	Hideo Yasunaga
International Academic Affairs	Professor	Shinichi Sato
Medical Scientist Training Program	Professor	Kenzo Hirose
Museum of Health and Medicine	Professor	Kazuhiko Ohe
Office for Human Research Studies	Professor	Masaomi Nangaku
Life Sciences Core Facility	Associate Professor	Yoshihiro Kita
Office for Clinical Practice and Medical Education	Professor	Masato Eto
Promotion of CPC Education and General Integrative Medicine	Lecturer	Masako Ikemura
Endowed Departments		
Artificial Intelligence in Healthcare	Project Associate professor	Yoshimasa Kawazoe
Department of Bone & Cartilage Regenerative Medicine	Project Associate professor	Yasunori Omata
Department of Immunotherapeutics	Project Professor	Kazuhiro Kakimi
Department of Advanced Clinical Science and Therapeutics	Project Associate professor	Mutsuo Harada
Computational Diagnostic Radiology and Preventive Medicine	Project Professor	Naoto Hayashi
Science for Joint Reconstruction	Project professor	Toru Moro
Therapeutic Strategy for Heart Failure	Project Associate professor	Eisuke Amiya
Department of Advanced Translational Research and Medicine in Management of Pulmonary Hypertension	Project Associate professor	Yuichi Ikeda
Medical research and Management for Musculoskeletal pain	Project Associate professor	Hiroyuki Oka
Department of Osteoimmunology	Project Associate professor	Kazuo Okamoto
Department of Biostatistics and Bioinformatics	Project Professor	Daisuke Koide
Laboratory for Advanced Research on Pathophysiology of Metabolic Diseases	Project Associate Professor	Miki Iwabu
Department of Home Care Medicine	Project Associate Professor	Takashi Yamanaka
Department of Advanced Cardiology	Project Associate Professor	Katsuhito Fujiu
Research on Cell Therapy of Regenerative Medicine	Project Associate Professor	Dehua Chang

Comprehensive radiation oncology	Project Professor	Keiichi Nakagawa
Social Cooperation Program		
Department of Lipidomics	Project Professor	Yoshiya Oda
Department of Health Services Research	Project Associate professor	Taisuke Jo
Healthcare Quality Assessment	Project Professor	Hiroaki Miyata
Department of Innovative Dementia Prevention	Project Associate professor	Tomoko Wakabayashi
Department of Next-Generation Pathology Information Networking	Project Professor	Takeshi Sasaki
Department of Prevention of Diabetes and Lifestyle-Related Diseases	Project Associate professor	Satoko Yamaguchi
Chronic Kidney Disease Pathophysiology	Project Professor	Reiko Inagi
Department of Functional Genomics and Immunological Diseases	Project Associate professor	Tomohisa Okamura
Tissue stem cell / life dentistry	Project Professor	Makoto Komura
Department of Next Generation Locomotive Imaging System	Project Associate professor	Toru Doi
Department of Eat-loss Medicine	Project Associate professor	Kazumichi Yonenaga
Department of Preventive Medicine for Locomotive Organ Disorders	Project Professor	Noriko Yoshimura
Next-Generation Precision Medicine Development Laboratory	Project Associate professor	Hidenori Kage
Department of Pain & Palliative Medical Sciences	Project Associate professor	Maiko Hasegawa
Department of Retinal Biology and Pathology	Project Professor	Sumiko Watanabe
Medical information engineering	Project Associate professor	Taichi Kin
Laboratory for cryo-electron microscopy	Project Associate professor	Chieko Saito
Department of Digital Mental Health	Project Professor	Norito Kawakami
Department of Cellular and Tissue Communication	Project Professor	Jun Yamashita
Clinical stem cell biology	Project Professor	Atsuhiko Hikita
Department of Precision Medicine Neurology	Project Associate professor	Jun Mitsui
Department of Real-world Evidence	Project Associate professor	Yusuke Sasabuchi
Next-generation Endoscopic Computer Vision	Project Associate professor	Yosuke Tsuji
Department of Healthcare economics and Health policy	Project Professor	Tomoyuki Takura

University Hospital**Clinical Services****•Department of Internal Medicine**

General Internal Medicine	Head	Masahiro Akishita
Cardiovascular Medicine	Head	Issei Komuro
Respiratory Medicine	Head	Takahide Nagase
Gastroenterology	Head	Mitsuhiro Fujishiro
Nephrology and Endocrinology	Head	Masaomi Nangaku
Diabetes and Metabolic Medicine	Head	Toshimasa Yamauchi
Hematology and Oncology	Head	Mineo Kurokawa
Allergy and Rheumatology	Head	Keishi Fujio
Infectious Diseases	Head	Takeya Tsutsumi
Neurology	Head	Tatsushi Toda
Geriatric Medicine	Head	Masahiro Akishita
Psychosomatic Medicine	Head	Kazuhiro Yoshiuchi

•Department of Surgery

General Surgery	Head	Soichiro Ishihara
Stomach and Esophagus Surgery	Head	Yasuyuki Seto
Colon and Rectal Surgery	Head	Soichiro Ishihara
Hepato-Biliary-Pancreatic Surgery	Head	Kiyoshi Hasegawa
Vascular Surgery	Head	Soichiro Ishihara
Breast and Endocrine Surgery	Head	Masahiko Tanabe
Artificial Organ and Transplantation Surgery	Head	Kiyoshi Hasegawa
Cardiovascular Surgery	Head	Minoru Ono
Thoracic Surgery	Head	Jun Nakajima
Neurosurgery	Head	Nobuhito Saito
Anesthesiology and Pain Relief Center	Head	Kanji Uchida
Urology and Andrology	Head	Haruki Kume
Gynecologic Surgery	Head	Yutaka Ohsuga

•Department of Sensory and Motor System Medicine

Dermatology	Head	Shinichi Sato
Ophthalmology	Head	Makoto Aihara
Orthopaedic Surgery and Spinal Surgery	Head	Sakae Tanaka
Otorhinolaryngology and Head and Neck Surgery	Head	Tatsuya Yamasoba
Rehabilitation Medicine	Head	Toru Ogata
Plastic, Reconstructive and Aesthetic Surgery	Head	Mutsumi Okazaki
Oral-Maxillofacial Surgery and Orthodontics	Head	Kazuto Hoshi

•Department of Pediatrics, Perinatal and Women's Medicine

Pediatrics	Head	Motohiro Kato
Pediatric Surgery	Head	Jun Fujishiro
Obstetrics and Gynecology	Head	Yutaka Ohsuga

•Department of Neuropsychiatry

Neuropsychiatry	Head	Kiyoto Kasai

•Department of Radiology

Radiology	Head	Osamu Abe

•Department of Emergency and Critical Care Medicine

Emergency and Critical Care Medicine	Head	Kento Doi

•Department of Cross-Sectional Services

Advanced Medical Center for Heart Failure	Head	Masaru Hatano
Marfan Syndrome Center	Head	Norifumi Takeda
Epilepsy Center	Head	Naoto Kunii
Dementia Center	Head	Tatsushi Toda
Scleroderma Center	Head	Hayakazu Sumida
Lupus Center	Head	Keishi Fujio
Osteoporosis Center	Head	Taku Saito
Center for Female Pelvic Medicine and Reconstructive Surgery	Head	Yutaka Osuga
Spine Center	Head	Yasushi Oshima
Department of Clinical Genomics	Head	Katsutoshi Oda
Department of Child Psychiatry	Head	Yukiko Kano
Children, AYA and Family Centered Mental Care Center	Head	Yukiko Kano
Department of Pain and Palliative Medicine	Head	Masahiko Sumitani

Central Clinical Services

Pharmaceutical Department	Head	Tappei Takada
Department of Clinical Laboratory	Head	Yutaka Yatomi
Department of Blood Transfusion	Head	Hitoshi Okazaki
Department of Pathology	Head	Tetsuo Ushiku
Department of Infection Control and Prevention	Head	Takeya Tsutsumi
Radiology Center	Head	Osamu Abe
Rehabilitation Center	Head	Toru Ogata
Surgical Center	Head	Kazuhiko Fukatsu
Central Supply Service	Head	Kazuhiko Fukatsu
Department of Medical Engineering	Head	Kento Doi
Department of Endoscopy and Endoscopic Surgery	Head	Yosuke Nakai
Department of Hemodialysis and Apheresis	Head	Masaomi Nangaku
Critical Care and Emergency Medical Center/ER	Head	Kento Doi

Department of Intensive Care Unit	Head	Kento Doi
Department of Pediatric and Neonatal Intensive Care Unit	Head	Naoto Takahashi
Perinatal Center	Head	Yutaka Osuga
Children's Medical Center	Head	Motohiro Kato
Department of Outpatient Chemotherapy Unit	Head	Kiyoshi Miyagawa
Immune-Mediated Diseases Therapy Center	Head	Hiroko Kanda
Organ Transplantation Center	Head	Jun Nakajima
Tissue Bank	Head	Sumihito Tamura
Department of Corneal Transplantation	Head	Takashi Miyai
Department of Cell Therapy and Transplantation Medicine	Head	Mineo Kurokawa
Admission and Discharge Center	Head	Keita Okada
Perioperative Assessment and Care Center	Head	Kanji Uchida
Clinical Nutrition Center	Head	Kazuhiko Fukatsu
Swallowing Center	Head	Rumi Ueha
International Medical Center	Head	Sumihito Tamura
Center for Epidemiology and Preventive Medicine	Head	Nobutake Yamamichi
Center for International Preventive Medicine	Head	Yoko Iizuka
Cancer Board	Head	Kiyoshi Miyagawa
Vascular Board	Head	Katsuyuki Hoshina
Hip Fracture Board	Head	Taro Kojima
Palliative Care Consultation Team	Head	Masahiko Sumitani
Nutrition Support Team	Head	Kazuhiko Fukatsu
Medical Community Network and Discharge Supporting Center	Head	Masahiko Sumitani
Cancer Resource Center	Head	Sachiyo Nomura
Patient Relations and Clinical Ethics Center	Head	Yoshiyuki Takimoto

Clinical Research Services

Clinical Research Promotion Center	Head	Takashi Moritoyo
22nd Century Medical and Research Center	Head	Yutaka Osuga
Department of Tissue Engineering	Head	Kazuto Hoshi
Cooperative Unit of Medicine and Engineering Research	Head	Minoru Ono
Translational Research Center	Head	Issei Komuro
Genomic Research Support Center	Head	Yutaka Osuga
Unit for Early and Exploratory Clinical Development	Head	Takeshi Iwatsubo
BioResource Center	Head	Tetsuo Ushiku
Center for Brain Imaging in Health and Diseases	Head	Kiyoto Kasai

Hospital Management Services

Medical Safety Management Center	Head	Tomotaka Yamamoto

Infection Control Center	Head	Takeya Tsutsumi
Office of Performance Monitoring	Head	Tomotaka Yamamoto
Department of Highly Advanced Novel Medical Technologies Evaluation	Head	Jun Nakajima
Department of Unapproved New Drugs and Medical Devices Evaluation	Head	Kanji Uchida
General Education Center	Head	Masato Eto
Clinical Simulation Center	Head	Masato Eto
Department of Clinical Research Governance	Head	Yutaka Osuga
Department of Healthcare Information Management	Head	Kazuhiko Ohe
Department of Medical Record Management	Head	Kazuhiko Ohe
University Hospital Medical Information Network Center	Head	Takahiro Kiuchi
Labor Safety and Health Management Office	Head	Tomotaka Yamamoto
Staff Wellness Consulting Office	Head	Kiyoto Kasai
Office of Medical Clerical Support for Physicians	Head	Sakae Tanaka
Department of Disaster Medical Management	Head	Kento Doi
Legal and Compliance Office	Head	Sakae Tanaka
Center for Liaison and Public Relations	Head	Yutaka Osuga

Hospital Management Support Organization

Office of Personnel and Human Resources	Head	Yutaka Yatomi
Office of Performance Monitoring and Risk Management	Head	Sakae Tanaka
Office of Education and Staff Development	Head	Tatsuya Yamasoba
Office of Hospital Planning and Management	Head	Jun Nakajima
Office of Research Support	Head	Yutaka Osuga

Clinical Management Organization

Office of Inpatient Services	Head	Haruki Kume
Office of Outpatient Services	Head	Kiyoshi Miyagawa
Office of Central Clinical Services	Head	Masahiko Sumitani
Office of Patient Support	Head	Yutaka Osuga

The University of Tokyo,
Graduate School of Medicine

Molecular Cell Biology

1. Cell Biology and Anatomy

Department of Cell Biology

Professor

Yasushi Okada, M.D.,Ph.D.

Lecturer

Kazuho Ikeda, Ph.D.

Research Associate

Akira Takai, Ph. D.

Homepage <https://www.okada-lab.phys.s.u-tokyo.ac.jp/en/>

Introduction and Organization

Our laboratory is one of the laboratories in Department of Cell Biology and Anatomy, since the reorganization of School of Medicine in 1997. The current lab was established in 2020 when Yasushi Okada was appointed as a professor.

Currently the lab members include: Yasushi Okada (professor), Kazuho Ikeda (Lecturer), Akira Takai (research associates).

Teaching activities

Our laboratory, together with other laboratories in this department, is in charge of teaching following courses:

- 1) Gross Anatomy for medical students.
- 2) Cell Biology and Histology for medical students.
- 3) Special training (Free Quarter) for medical students.
- 4) Advance cell biology course for graduate students.

Research activities

Our primary goal is to answer the very basic question “What is life”. To answer this question, we are trying to fill the gap between the world of molecules and the world of living cells. Direct measurement of molecules in living cells would serve as a basic technology to fill this gap. Thus, we have been

working on the development of the technologies for the visualization and non-invasive measurement of the molecular processes in living cells. High-speed, super-resolution live-cell imaging and single-molecule measurement in living cells are the two main technologies we develop.

By using these technologies, we are trying to understand the regulatory mechanisms of motor proteins during axonal transport. Despite the many studies in the past decades by our group and others, it is still unclear how the biophysical properties of motor proteins are related to their biological functions. For example, a point mutation in kinesin-1 can cause hereditary spastic paraplegia, but it is unclear why this mutation selectively affects neurons in the longest tract in the aged patients.

Through these studies and development, we have realized the importance of the cellular states, and our microscope technologies can also be applied to the measurement of the cellular states. Thus, we have proposed a project for the visualization, prediction, and control of cellular states.

References

1. Hirano M, Ando R, Shimozone S, Sugiyama M, Takeda N, Kurokawa H, Deguchi R, Endo K, Haga K, Takai-Todaka R, Inaura S, Matsumura Y, Hama H, Okada Y, Fujiwara T, Morimoto T,

Katayama K, Miyawaki A. A highly photostable and bright green fluorescent protein. *Nat Biotechnol* 40: 1132-1142, 2022.

2. Saji T, Nishita M, Ikeda K, Endo M, **Okada Y**, Minami Y. c-Src-mediated phosphorylation and activation of kinesin KIF1C promotes elongation of invadopodia in cancer cells. *J Biol Chem.* 298:102090, 2022.
3. Haraguchi T, Koujin T, Shindo T, Bilir Ş, Osakada H, Nishimura K, Hirano Y, Asakawa H, Mori C, Kobayashi S, **Okada Y**, Chikashige Y, Fukagawa T, Shibata S, Hiraoka Y. Transfected plasmid DNA is incorporated into the nucleus via nuclear envelope reformation at telophase. *Commun Biol.* 5:78, 2022.

Department of Cell Biology & Anatomy (Structural Biology)

Professor

Masahide Kikkawa, M.D., Ph.D.

Lecturer

Haruaki Yanagisawa, Ph.D.

Project Lecturer

Yoshiyuki Fukuda, Ph.D.

Research Associate

Tsukasa Makino, Ph. D, Hiroshi Yamaguchi, Ph. D

Homepage <http://structure.m.u-tokyo.ac.jp>

Introduction and Organization

Our laboratory is one of the laboratories in Department of Cell Biology and Anatomy. Since the reorganization of School of Medicine in 1997, the lab was named as “Structural Biology”. The current lab was established in 2009 when Masahide Kikkawa was appointed as a professor.

Currently the lab members include: Masahide Kikkawa (professor), Haruaki Yanagisawa (Lecturer), Tsukasa Makino, Hiroshi Yamaguchi (research associates), Akihisa Tsutsumi (project research associate), (project researcher), Ryohei Sasaki, Jiancheng An, Yuma Tani, Yuqing Liu, and Jingfei Yang (graduate students), Takeru Mutoh (MSTP students), Akiko Oosakaya, Sakamaki Yoichi, Toshie Furuya, Miku Takagishi, Tony Wang, Yoriko Akuzawa (technical assistant), and Mikako Yanagiuchi and Ai Naruse (assistant clerk).

Teaching activities

Our lab, together with Kanai and Okabe’s lab, is in charge of teaching following courses:

- 1) Gross Anatomy for medical students.
- 2) Cell Biology and Histology for medical students.
- 3) Special training (Free Quarter) for medical students.
- 4) Advance cell biology course for graduate students.

Research activities

Our lab focuses on the structure and function of epithelial structures, especially eukaryotic flagella/cilia. Flagella/cilia are both “propeller” and “antenna” of cells, whose diameter is about 250 nm. From recent studies, it is becoming clear that flagella/cilia are involved in various important cell functions.

To study the functions of flagella/cilia, we employ various imaging techniques, including cryo-electron microscopy and 3D-tracking microscope in combination with genetic manipulations.

Cryo-electron microscopy and cryo-electron tomography

One of our strengths is in high-resolution cryo-electron microscopy (cryo-EM). This technique enables preserving biological samples by quickly

freezing them and observing the frozen samples without staining. Using electron microscopy, we are able to obtain nano-meter resolution of macromolecular complexes such as axonemes. We have been developing new techniques, such as asymmetric helical reconstruction and Ruby-Helix software.

A new project for cryo-electron microscopy started in October 2017 with a grant from AMED (Japan Agency for Medical Research and Development). This project is intended to make cryo-EM techniques available to many biological/medical researchers. New state-of-the-art cryo-electron microscopes are used by many researchers in Japan, including external users.

Model Organism

Our lab currently uses *Chlamydomonas*, zebrafish, and mice as a model organism for studying cilia/flagella. To identify molecules that are involved in regulating dynein, we use various genetic tools, including classical mutagenesis, siRNA.

In addition, we are also developing 3D-tracking microscopy in collaboration with Dr. Oku in Department of Engineering. We are trying to track *Chlamydomonas* cells and simultaneously record flagella movement to elucidate the mechanism of flagella regulation.

References

- [1] K. J. Malawska, S. Takano, K. Oisaki, H. Yanagisawa, **M. Kikkawa**, T. Tsukuda, and M. Kanai. Bioconjugation of Au(25) Nanocluster to Monoclonal Antibody at Tryptophan. *Bioconjug Chem*, 2023.
- [2] Z. Chen, S. Watanabe, H. Hashida, M. Inoue, Y. Daigaku, **M. Kikkawa**, and K. Inaba. Cryo-EM structures of human SPCA1a reveal the mechanism of Ca(2+)/Mn(2+) transport into the Golgi apparatus. *Sci Adv*, 9(9):eadd9742, 2023.
- [3] C. Ito, T. Makino, T. Mutoh, **M. Kikkawa**, and K. Toshimori. The association of ODF4 with AK1 and AK2 in mice is essential for fertility through its contribution to flagellar shape. *Sci Rep*, 13(1):2969, 2023.
- [4] H. Takeda, J. V. Busto, C. Lindau, A. Tsutsumi, K. Tomii, K. Imai, Y. Yamamori, T. Hirokawa, C. Mottono, I. Ganesan, L. S. Wenz, T. Becker, **M. Kikkawa**, N. Pfanner, N. Wiedemann, and T. Endo. A multipoint guidance mechanism for beta-barrel folding on the SAM complex. *Nat Struct Mol Biol*, 30(2):176–187, 2023.
- [5] F. Eisenstein, H. Yanagisawa, H. Kashihara, **M. Kikkawa**, S. Tsukita, and R. Danev. Parallel cryo electron tomography on in situ lamellae. *Nat Methods*, 20(1):131–138, 2023.
- [6] Y. Zhang, C. Kobayashi, X. Cai, S. Watanabe, A. Tsutsumi, **M. Kikkawa**, Y. Sugita, and K. Inaba. Multiple sub-state structures of SERCA2b reveal conformational overlap at transition steps during the catalytic cycle. *Cell Rep*, 41(10):111760, 2022.

Department of Cytoarchitectonics

Lecturer

Yosuke Tanaka, M.D., Ph.D.

Homepage <http://cb.m.u-tokyo.ac.jp/>

Teaching activities

Our teaching responsibility is as follows:

- I.
 - 1) Lecture on Cell Biology, Developmental Biology, Histology and Neurocytology.
 - 2) Lecture on Gross Anatomy and Neuroanatomy. to medical students and students of other faculties
- II.
 - 1) Laboratory course of Gross Anatomy and Neuroanatomy.
 - 2) Laboratory course of Histology and Histology of the Central Nervous System.

to medical students and students of other faculties.

In addition, we offer a special training course (free quarter) of various kinds of molecular cell biology techniques such as immunocytochemistry, electron microscopy, biochemistry, molecular biology, biophysics, and cellular and molecular neurobiology technique to medical students.

Research activities

Our research field covers the molecular cell biology of the cytoskeleton. We focus on the molecular mechanisms of cell morphogenesis and intracellular transports.

Our laboratory studies molecular architecture, dynamics and function of the neuronal cytoskeleton using various new molecular cell biological approaches including new electron microscopy such as the quick freeze deep etch electron microscopy, cryo-electron microscopy at atomic resolution, and cryo-ultramicrotomy, biochemistry, immunocytochemistry, molecular biology, molecular genetics such as gene targeting and transgenic mouse approaches, molecular biophysics and structure biology including

X ray crystallography and cryoelectron microscopy.

In this way we can study structure, dynamics and functions of cytoskeleton from gene to cell, tissue and whole body.

Nerve cells as units of complicated neuronal networks in the brain develop very polarized morphology composed of dendrites, cell body and a long axon along the direction of impulse propagation. The neuronal cytoskeleton plays three major important roles.

- 1) It provides dynamic frameworks for neurite extension and maintenance.
- 2) It provides structural bases for organelle transports in the cells. Namely it works as rails and motor molecules to transport materials from cell center to periphery and from periphery to cell center.
- 3) It very importantly regulates release processes of transmitters and also contributes to anchor receptors at the postsynaptic sites.

Our laboratory studies molecular architecture, dynamics and function of the cytoskeleton focusing on these three major roles.

To study these molecular mechanisms, we use new molecular cell biological approaches including electron microscopy of molecular resolution, biochemistry, biophysics, molecular biology and molecular genetics and X-ray crystallography.

References

1. Morikawa Ma, Jerath N. U., Ogawa T., Morikawa Mo, **Tanaka Y.**, Shy M.E., Zuchner, S., and N. Hirokawa. KIF1A mutation of human neuropathies hyperstabilizes the motor-neck interaction in ATPase cycle. *EMBO J.* 41(5): e108899, Mar 1, 2022.

-
2. Wang S, **Tanaka Y**, Xu Y, Takeda S, Hirokawa N. KIF3B promotes a PI3K signaling gradient causing changes in a Shh protein gradient and suppressing polydactyly in mice. *Dev Cell.*; 57(19):2273-2289, Oct 10, 2022.

Department of Cellular Neurobiology

Professor

Shigeo Okabe, M.D., Ph.D.

Research Associate

Yutaro Kashiwagi, Ph.D., Hisato Maruoka, Ph.D., Keiichiro Minatohara, Ph.D.

Homepage <http://synapse.m.u-tokyo.ac.jp/>

Introduction and Organization

The Department of Cellular Neurobiology was initially established as the Neuroanatomy department of former Brain Institute of Medical School of Imperial University of Tokyo in 1936. Since the structural reconstruction of the School of Medicine in 1997, this department became one of the departments of Cell Biology and Anatomy of the Graduate School of Medicine. Professor Shigeo Okabe had currently organized this department since September 2007. The department is constituted of 21 members.

Education

For medical students, our department takes the following lectures and courses.

1. Cell Biology, Histology, and Neurocytology
2. Gross Anatomy and Neuroanatomy.
3. Free Quarter.

For graduate students, we offer the following lectures and seminars.

1. Cellular Neurobiology.
2. Cell Biology and Histology.
3. Discussion seminars and progress reports of the experiment.
4. Joint seminar with other departments

Research

Brain functions, which are dependent on mutual communication of a tremendous number of neuronal

cells, regulate the behavior of animals and humans. The main structure specifically differentiated for information exchange between neurons, is called "synapse." Long-term maintenance of synaptic properties underlies the stability and reproducibility of behavior in responses to external stimuli. In turn, alterations of synaptic properties are thought to be the basis of behavioral change in the course of animal development and also after learning. Therefore, synapses should be stabilized for the long term to realize fidelity of various animal behaviors, but also should be altered rapidly when animals adapt to a new environment. The molecular basis of this dichotomy, which is unique to synapses, is the main interest of our laboratory.

Synapse is the site of signal transmission between neurons. Most of the synapses are formed during the early development, and after that, they become stable after the intensive pruning. We are interested in how synapse is developed and maintained. The postsynaptic densities (PSDs) are protein-dense structures which are located closely to postsynaptic membranes. PSDs include a variety of receptors, scaffolding proteins, and signaling molecules. We focus on PSD proteins and examine their roles in synapse development.

Two-photon excitation microscopy allows imaging of the living brain. We examine synapse remodeling in vivo by observing the postsynaptic structures and PSD proteins tagged by fluorescent probes. We are also investigating synapse pathology in developmental

disorders by using mouse models. For both in vitro and in vivo analyses of synapses, the development of new imaging technologies is essential. Our laboratory has made a significant contribution to the quantitative and high-resolution imaging of synapse dynamics.

Publications

1. Terashima H, Minatohara K, Maruoka H, **Okabe S**. Imaging neural circuit pathology of autism spectrum disorders: autism-associated genes, animal models and the application of in vivo two-photon imaging. *Microscopy (Oxf)*. 2022 71(Supplement_1):i81-i99. doi: 10.1093/jmicro/dfab039.
2. Kamei R, Urata S, Maruoka H, **Okabe S**. In vivo Chronic Two-Photon Imaging of Microglia in the Mouse Hippocampus. *J Vis Exp*. 2022 6;(185). doi: 10.3791/64104.
3. Maruoka H, Kamei R, Mizutani S, Liu Q, **Okabe S**. Simultaneous Imaging of Microglial Dynamics and Neuronal Activity in Awake Mice. *J Vis Exp*. 2022 Aug 23;(186). doi: 10.3791/64111.
4. Nozawa O, Miyata M, Shiotani H, Kameyama T, Komaki R, Shimizu T, Kuriu T, Kashiwagi Y, Sato Y, Koebisu M, Aiba A, **Okabe S**, Mizutani K, Takai Y. A novel Necl-2/3-mediated mechanism for tripartite synapse formation. *Development*. 2023 Feb 15;150(4):dev200931. doi: 10.1242/dev.200931.
5. Urata S, **Okabe S** Three-dimensional mouse cochlea imaging based on the modified Sca/eS using confocal microscopy. *Anatomical Science International* 2023 Feb 11. doi: 10.1007/s12565-023-00703-z. Online ahead of print.
6. Kamei R, **Okabe S** In vivo imaging of the phagocytic dynamics underlying efficient clearance of adult-born hippocampal granule cells by ramified microglia. *Glia*. 2023 Aug; 71(8):2005-2023. doi: 10.1002/glia.24379.
7. Shima Y, Sasagawa S, Ota N, Oyama R, Tanaka M, Kubota-Sakashita M, Kawakami H, Kobayashi M, Takubo N, Ozeki AN, Sun X, Kim YJ, Kamatani Y, Matsuda K, Maejima K, Fujita M, Noda K, Kamiyama H, Tanikawa R, Nagane M, Shibahara J, Tanaka T, Rikitake Y, Mataga N, Takahashi S, Kosaki K, Okano H, Furihata T, Nakaki R, Akimitsu N, Wada Y, Ohtsuka T, Kurihara H, Kamiguchi H, **Okabe S**, Nakafuku M, Kato T, Nakagawa H, Saito N, Nakatomi H. Increased PDGFRB and NF- κ B signaling caused by highly prevalent somatic mutations in intracranial aneurysms. *Sci Transl Med*. 2023 15(700):eabq7721. doi: 10.1126/scitranslmed.abq7721.

Molecular Cell Biology

2. Biochemistry and Molecular Biology

Department of Molecular Biology

Professor

Noboru Mizushima, M.D., Ph.D.

Associate Professor

Ikuko Koyama-Honda, Ph.D.

Associate

Saori Yoshii, M.D., Ph.D., Tomoya Eguchi, M.D., Ph.D.

Project Associate Professor

Chieko Saito, Ph.D.

Project Lecturer

Taki Nishimura, Ph.D.

Project Research Associate

Junichi Sakamaki, Ph.D.

Homepage <https://molbiolut.jp/en/>

Introduction and Organization

Established in 1893 as a part of Department of Physiology, this Department became independent in 1897. It was renamed Department of Biochemistry in 1927, First Department of Biochemistry in 1974, and Department of Molecular Biology in 1997, according to the creation of new related departments and the reorganization of Faculty of Medicine. This Department has been headed by seven professors, each of whom made significant contributions to the development of biochemistry, nutrition, and molecular biology in Japan.

Professor Muneo Kumagawa, who established this Biochemistry or Medical Chemistry Department for the first time in Japan, graduated from The University of Tokyo Faculty of Medicine in 1882. In 1884 he went to Germany to study in Department of Pathology, The University of Berlin headed by Dr. Rudolf Virchow under the supervision of Dr. Ernst Salkowski. After returning to Japan, he became Lecturer and was promoted to Professor of this Department. In 1908, he discovered a lack of

glycogenecity in lipids, which has been firmly established besides some exceptions, and succeeded in purification of vitamin B1, which had been discovered by Dr. C. Eijkman in 1906. His lab produced many famous researchers including Dr. Masahiro Sakaguchi, who developed a world-famous colorimetric method for arginine and Dr. Takaoki Sasaki, who first succeeded in generating liver cancer with chemicals.

Professor Samuro Kakiuchi graduated from the Imperial University of Tokyo, Faculty of Medicine in 1906 and studied under Professor Kumagawa. After studying in the US, he came back to succeed the late Kumagawa. He launched the Journal of Biochemistry and founded the Japanese Society of Biochemistry. His students included Professors Kodama and Shimazono.

Professor Keizo Kodama graduated from the Imperial University of Tokyo in 1918. After studying at Cambridge University, he became Professor of Biochemistry at Kyushu Imperial University. In 1943, he took up a professorship at this Department. His research was on oxidation and reduction, and

nutrition.

Professor Norio Shimazono, a graduate of the Imperial University of Tokyo Faculty of Medicine in 1928, became a professor at Niigata Medical School. In 1952 he succeeded Professor Kodama. He studied vitamin B1/ cocarboxylase, ketoacid metabolism and hexose metabolism.

Professor Tamio Yamakawa graduated from the Imperial University of Tokyo Faculty of Medicine, and began studies at the Institute for Infectious Diseases, the University of Tokyo. He took up a professorship to succeed Professor Shimazono. He was a pioneer in glycolipid research and discovered the involvement of sialic acid in the ABO blood type antigens.

Professor Masami Muramatsu graduated from the University of Tokyo Faculty of Medicine in 1955. He began studies at the Department of Internal Medicine, and then went to Baylor College of Medicine to study under Dr. H. Busch. After coming back to Japan, he took a position at the Cancer Institute and then took up a professorship at Tokushima University School of Medicine. In 1982, he succeeded Professor Yamakawa. He studied ribosomal RNA and cloned interferon and p450 genes.

Professor Hiroto Okayama graduated from Kumamoto University School of Medicine in 1973. After taking a Ph.D. degree at Kyoto University School of Medicine, he went to Stanford University to study under Dr. P. Berg. After working at the NIH, USA, he became Professor of Molecular Genetics, at Osaka University Institute for Infectious Diseases. In 1993 he succeeded Professor Muramatsu. At Stanford and the NIH, he studied gene cloning and developed a full-length cDNA cloning method and a cDNA expression cloning vector system, and, after returning to Japan, he studied cell cycle control and cancer.

Professor Noboru Mizushima graduated from Tokyo Medical and Dental University, Faculty of Medicine in 1991. After receiving Ph.D., he studied at National Institute for Basic Biology in Okazaki and started works on autophagy in yeast and mammals at Dr. Yoshinori Ohsumi's laboratory. Taking a position as a PI at the Tokyo Metropolitan Institute of Medical Science in 2004, he started studies on the physiological roles of autophagy. He was promoted to Professor of Physiology and Cell Biology, in Graduate

School and Faculty of Medicine at Tokyo Medical and Dental University in 2006, and succeeded Professor Okayama in 2012.

Research Activities

Our current study focuses on the understanding of the molecular mechanism and physiological roles of autophagy and other intracellular degradation systems. In 2022, we reported the following novel findings.

1. Molecular mechanism of autophagy

Autophagy is one of the major degradation pathways in the cell. In autophagy, intracellular components are sequestered by autophagosomes and then degraded upon fusion with lysosomes. Yeast genetic studies have identified more than 40 autophagy-related (*ATG*) genes. Many of these genes are conserved in higher eukaryotes, which allows us to perform genetic analysis of autophagy in mammals. We are currently addressing some of the central questions remaining in the autophagy field and trying to elucidate the mechanisms of (1) regulation of autophagy, (2) initiation of autophagosome formation, (3) elongation of the autophagic membrane, (4) closure, fusion, and degradation of the autophagosome (5) recognition of selective substrates. In addition, we are also working on intracellular degradation systems other than autophagy.

Ferritin, an iron storage protein, forms a spherical, cage-like complex that stores iron ions inside. When cells become iron-deficient, ferritin is transported to lysosomes via autophagy (macroautophagy) or the endosomal multivesicular body pathway (microautophagy) to release the internal iron ions. It has been suggested that NCOA4 mediates autophagic degradation of ferritin as a receptor for ferritin, but the details of this mechanism remained unclear. We found that ferritin and NCOA4 form droplets by liquid-liquid phase separation (LLPS), and that these ferritin droplets (ferritin-NCOA4 droplets) are incorporated into autophagosomes and endosomes. Thus, NCOA4 is not only a receptor but also a driver molecule essential for droplet formation.

This study clarifies the role of liquid-liquid phase separation in ferritinolysis, a central process in the intracellular iron metabolism pathway, and provides new evidence for a link between liquid-liquid phase separation and microautophagy (Ohshima et al. *J Cell Biol* 2022).

It has been reported that organelles such as endoplasmic reticulum and mitochondria are involved in the formation of autophagosomes. We quantitatively analyzed the contacts between autophagy-related structures and surrounding cell organelles by three-dimensional light-electron correlation microscopy. As in previous reports, all forming autophagosomes were in contact with the endoplasmic reticulum, and the contact area decreased as they matured into autolysosomes. However, the majority of autophagosomes and autolysosomes were still in contact with the endoplasmic reticulum, indicating that autophagosomes do not need to completely detach from the ER for fusion with lysosomes. Analysis of the substrates incorporated into autophagosomes revealed that the ER is most frequently engulfed by autophagosomes (Takahashi et al. *Cell Struct Funct* 2022).

2. Physiological and pathological roles of autophagy

Using autophagosome-indicator GFP-LC3 mice and various autophagy-deficient mouse models, we have shown that autophagy is important for the maintenance of the amino acid pool during starvation and neonatal periods, preimplantation development as an amino acid supplying system, and for intracellular protein quality control to prevent neurodegeneration and tumorigenesis. Autophagy is also known to have both non-selective and selective effects. In 2019, we identified a novel endoplasmic reticulum autophagy (ER-phagy) receptor, TEX264, which is an ER membrane protein with an LC3 binding site (LIR) that binds to LC3/GABARAP family proteins of the autophagosome membrane and through which induces the endoplasmic reticulum on autophagosomes. In the present study, we found that serine residues in the LIR of TEX264 are phosphorylated by casein kinase and that

phosphorylation is required for binding to the LC3/GABARAP family and for ER-phagy function. The phosphorylated serines form hydrogen bonds with GABARAPL1, thereby enabling stronger binding. While other ER-phagy receptors have an α -helix at the C-terminus of LIR that enables strong binding to LC3, TEX264, which does not have a C-terminal α -helix, was found to be able to bind as strongly as other ER-phagy receptors by phosphoserine of LIR. This study provides new insights into the binding mode of selective autophagy receptors to LC3/GABARAP (Chino et al. *EMBO Rep* 2022).

3. Methods for monitoring autophagic activity

Measuring autophagic activity is critical to dissecting molecular mechanisms and functions of autophagy but remains challenging due to the lack of a definitive method. We have discovered that the covalent binding of a ligand to HaloTag makes it resistant to degradation in lysosomes, and we have used this finding to develop a new method for quantifying autophagy activity. This method not only allows quantification of cargo-specific autophagic flux but also of random degradation of cytosolic proteins. Thus, this new method allows for the evaluation of non-selective autophagy, unlike conventional methods that rely on LC3 and other factors (Yim et al. *eLife* 2022).

4. Autophagy-independent pathway

Ubiquitin, a protein ubiquitously present in eukaryotes, covalently binds to other proteins and acts as a signal for degradation or change in their properties. Although ubiquitin has been thought to bind mainly to proteins, we have discovered that ubiquitin can also be conjugated to phosphatidylethanolamine (PE), a phospholipid that constitutes the membrane of cell organelles. This is similar to the covalent binding of the ubiquitin-like protein ATG8 (LC3 and GABARAP in mammals) to PE, which is required for autophagy. Ubiquitination of PE is found in organelles such as endosomes and lysosomes and in some viruses. This modification is catalyzed by a series of reactions similar to protein ubiquitination, which involves the ubiquitin-

activating enzyme Uba1, the ubiquitin-conjugating enzyme Ubc4/5, and the ubiquitin ligase Tul1. Ubiquitin bound to PE is either removed by the ubiquitin deubiquitinating enzyme Doa4 or transported to the vacuole for degradation. Ubiquitination of PE recruits ESCRT protein complexes involved in membrane deformation and fission and may be involved in the process of vesicle formation in the endosomal lumen (intraluminal vesicle formation). Furthermore, the ubiquitin-like proteins NEDD8 and ISG15 were also found to covalently bind to phospholipids. These results suggest that covalent binding to phospholipids is not specific to ATG8, but is a general feature of ubiquitin and ubiquitin-like proteins.

Education

To medical students, we give lectures on biochemistry and molecular biology. General metabolism, protein synthesis, protein degradation, and metabolism of carbohydrates, amino acids, and nucleic acids are the topics in our lectures. To graduate students, the molecular biology course consisting of lectures and experiments is provided.

Publication

1. Takahashi S, Saito C, *Koyama-Honda I, *Mizushima, N. Quantitative 3D correlative light and electron microscopy of organelle association during autophagy. *Cell Struct Funct.* 47:89-99 (2022) doi: 10.1247/csf.22071
2. Yim, W.W., *Yamamoto, H., *Mizushima, N. A pulse-chasable reporter processing assay for mammalian autophagic flux with HaloTag. *eLife* 11:e78923 (2022) doi: 10.7554/eLife.78923
3. Ohshima, T., Yamamoto, H., Sakamaki, Y., Saito, C., *Mizushima, N. NCOA4 drives ferritin phase separation to facilitate macroferritinophagy and endosomal microferritinophagy. *J Cell Biol.* 221: e202203102 (2022) doi: 10.1083/jcb.202203102
4. Sakamaki, J.I., Ode, K.L., Kurikawa, Y., Ueda, H.R., Yamamoto, H., *Mizushima, N. Ubiquitination of phosphatidylethanolamine in organellar membranes. *Mol. Cell* 82:3677-3692 (2022) doi: 10.1016/j.molcel.2022.08.008
5. Chino, H., Yamasaki, A., Ode, K.L., Ueda, H.R., *Noda, N.N., *Mizushima, N. Phosphorylation by casein kinase 2 ensures ER-phagy receptor TEX264 binding to ATG8 proteins. *EMBO Rep.* 23:e54801 (2022).
6. Zhang, S., Yazaki, E., Sakamoto, H., Yamamoto, H., *Mizushima, N. Evolutionary diversification of the autophagy-related ubiquitin-like conjugation systems. *Autophagy* 18:2969-2984 (2022).
7. Yim, W.W., Yamamoto, H., *Mizushima, N. Annexins A1 and A2 are recruited to larger lysosomal injuries independently of ESCRTs to promote repair. *FEBS Lett.* 596:991-1003 (2022)
8. Yim, W.W., Kurikawa, Y., *Mizushima, N. An exploratory text analysis of the autophagy research field. *Autophagy* 18:1648-1661 (2022)
9. *Sakamaki, J.-i., *Mizushima, N. Protocols to detect ubiquitinated phospholipids by immunoblotting. *STAR Protoc.* 4:101935 (2022) doi: 10.1016/j.xpro.2022.101935
10. Holthuis, J.C.M., Jahn, H., Menon, A.K., Mizushima, N. An alliance between lipid transfer proteins and scramblases for membrane expansion. *Fac. Rev.* 11:22 (2022)
11. *Mizushima, N. SnapShot: Organelle degradation. *Mol. Cell* 82:1604-1604.e1 (2022)
12. Chino, H., *Mizushima, N. ER-phagy: quality and quantity control of the endoplasmic reticulum by autophagy. *Cold Spring Harb. Perspect. Biol.* 8:a041256 (2022)
13. Hama, Y., Morishita, H., *Mizushima, N. Regulation of ER-derived membrane dynamics by the DedA domain-containing proteins VMP1 and TMEM41B. *EMBO Rep.* 23:e53894 (2022)
14. *Morishita, H. Role of autophagy in the eye: from physiology to disease. *Current Opinion in Physiology* 100592 (2022) <https://doi.org/10.1016/j.cophys.2022.100592>
15. Koyama-Honda, I., *Mizushima, N. Transient visit of STX17 (syntaxin 17) to autophagosomes. *Autophagy* 18:1213-1215 (2022) doi: 10.1080/15548627.2022.2079337

Department of Genome Informatics

Professor

Yukinori Okada, M.D.,Ph.D.

Assistant Professor

Kyuto Sonehara, M.D.

Homepage <http://www.sg.med.osaka-u.ac.jp/index.html>

Introduction and Organization

The Department of Genome Informatics was initially established as the second department of Biochemistry in 1975. Since the structural reconstruction of the School of Medicine in 1997, this Department became one of the Departments of Biochemistry and Molecular Biology of the Graduate School of Medicine. This Department has previously been headed by the four professors (Prof. Kazutomo Imahori, Yoshitaka Nagai, Takao Shimizu, and Hiroyuki Mano). Prof. Yukinori Okada had currently organized this Department since 2022. The Department is constituted of one professor, one assistant professor, one JSPS fellow, and one administrative assistant.

Teaching activities

As one of the Departments of Biochemistry and Molecular Biology, our Department is responsible for the basic lecture series of biochemistry for medical students (M0).

To teach basic theory of statistical genetics and bioinformatics skills, our Department had an open seminar named “Statistical Genetics Summer School” (August 26th-28th, online).

Research activities

The Department is developing research activities on elucidation of disease biology, genomic drug discovery, and personalized medicine through analysis

of human omics analysis. The main research activities this year are as follows:

1) Identification of intracranial germ cell tumor susceptibility genes

Intracranial germ cell tumors account for approximately 10% of pediatric brain tumors in Japan and have a higher incidence in East Asians than in European. We performed genome-wide association analysis (GWAS) of intracranial germ cell tumors. We identified that susceptibility gene mutations in the *BAK1* gene region alter enhancer activity and confer risk of developing the disease.

2) Shared genetic background between autoimmune and allergic diseases

Through the analysis of the human genome information of 840,000 individuals in Japanese and European populations, we identified the shared genetic backgrounds between autoimmune and allergic diseases. It was practically possible to classify autoimmune and allergic diseases based solely on genetics. There are novel genetic variants that are shared in both diseases. Genetic risk was enriched in the HLA gene region in autoimmune diseases, while enriched toward the cytokine gene regions in allergic diseases.

3) Elucidation of the severe COVID-19 biology

In the COVID-19 pandemic, the Japan COVID-19 Task Force was established (Representative: Keio University), which collected genomic DNA, RNA,

plasma, and clinical information from >6,000 COVID-19-infected Japanese patients. GWAS was conducted in the young severe patients. We identified DOCK2, an immunoregulatory gene, as a responsible gene for COVID-19 severity, based on blood single-cell analysis and a Syrian hamster infection model.

4) Gene expression analysis of COVID-19

We conducted an eQTL analysis to examine the association between blood cell gene expression and individual differences in human genome sequence in 465 COVID-19-infected patients collected by the Corona Control Task Force. We quantified changes in gene expression regulation patterns according to the severity of COVID-19 infection and reported the involvement of neutrophil activation behind the changes by interaction eQTL analysis of gene expression regulation by COVID-19 severity and genomic mutations. The involvement of neutrophil activation was suggested.

5) Best practices for genomic drug discovery

Through international biobank collaboration, we proposed a best practice of genomic drug discovery to search for candidate compounds based on the GWAS results. The combination of three genomic drug discovery methods enables comprehensive search for drug candidates. The method was applied to 13 diseases including asthma, gout, COPD, and venous thromboembolism, and an drug candidate list containing more than 250 compounds was generated. This was an achievement of the methodology to search for therapeutic drug candidates based on disease genetics.

6) Germline and somatic mutation interactions in cancer development

Based on the large-scale GWAS results for various types of cancer, we constructed a polygenic risk score (PRS) that strongly reflects inborn genetic risk of cancer development. Individuals with high PRS develop cancer at a younger age and have fewer somatic abnormalities. Such characteristics associated with genetic cancer risk constitution were commonly found in several types of cancer.

7) Identification of rheumatoid arthritis risk genes

Through international collaboration, we conducted a large-scale GWAS of ~280,000 individuals comprising five ethnic groups, including Japanese, and the risk variants associated with rheumatoid arthritis were newly identified. A risk score for predicting the development of rheumatoid arthritis was constructed, and the prediction accuracy in the East Asian population was confirmed to be comparable to that in the Europeans.

8) Database of the gut microbiome bacteria and virus of Japanese

We reconstructed bacterial and viral genome sequences from the gut microbiome sequencing of 787 Japanese individuals as a database. The constructed database included bacterial and genetic information related to Japanese food (e.g., nori and natto). Using the gut virus genome database, we conducted an analysis focusing on crAss-like phage. We reported that β crAss-like phage was less common in Asians, Europeans, and Americans, while more common in Africans and Oceanians. CrAss-like phage in multiple subfamilies is decreased in autoimmune diseases.

References

1. Namba S, Saito Y, Kogure Y, Masuda T, Bondy ML, Gharahkhani P, Gockel I, Heider D, Hillmer A, Jankowski J, MacGregor S, Maj C, Melin B, Ostrom QT, Palles C, Schumacher J, Tomlinson I, Whiteman DC, Okada Y, Kataoka K. (2023) Common germline risk variants impact somatic alterations and clinical features across cancers. *Cancer Res* 83:20-27.
2. Tomofuji Y, Kishikawa T, Maeda Y, Ogawa K, Otake-Kasamoto Y, Kawabata S, Nii T, Okuno T, Oguro-Igashira E, Kinoshita M, Takagaki M, Oyama N, Todo K, Yamamoto K, Sonehara K, Yagita M, Hosokawa A, Motooka D, Matsumoto Y, Matsuoka H, Yoshimura M, Ohshima S, Shinzaki S, Nakamura S, Iijima H, Inohara H, Kishima H, Takehara T, Mochizuki H, Takeda K, Kumanogoh A, Okada Y. (2022) Prokaryotic and viral genomes recovered from 787 Japanese gut metagenomes revealed microbial features linked to diets, populations, and diseases. *Cell Genom*

- 2:100219.
3. Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K, Amariuta T, Too CL, Laufer VA, Scott IC, Viatte S, Takahashi M, Ohmura K, Murasawa A, Hashimoto M, Ito H, Hammoudeh M, Emadi SA, Masri BK, Halabi H, Badsha H, Uthman IW, Wu X, Lin L, Li T, Plant D, Barton A, Orozco G, Verstappen SMM, Bowes J, MacGregor AJ, Honda S, Koido M, Tomizuka K, Kamatani Y, Tanaka H, Tanaka E, Suzuki A, Maeda Y, Yamamoto K, Miyawaki S, Xie G, Zhang J, Amos CI, Keystone E, Wolbink G, van der Horst-Bruinsma I, Cui J, Liao KP, Carroll RJ, Lee HS, Bang SY, Siminovitch KA, de Vries N, Alfredsson L, Rantapää-Dahlqvist S, Karlson EW, Bae SC, Kimberly RP, Edberg JC, Mariette X, Huizinga T, Dieudé P, Schneider M, Kerick M, Denny JC, BioBank Japan Project, Matsuda K, Matsuo K, Mimori T, Matsuda F, Fujio K, Tanaka Y, Kumanogoh A, Traylor M, Lewis CM, Eyre S, Xu H, Saxena R, Arayssi T, Kochi Y, Ikari K, Harigai M, Gregersen PK, Yamamoto K, Louis Bridges S Jr, Padyukov L, Martin J, Klareskog L, Okada Y, Raychaudhuri S. (2022) Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. *Nat Genet* 54:1640-1651.
4. Namba S, Konuma T, Wu KH, Zhou W, Global Biobank Meta-analysis Initiative, Okada Y. (2022) A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. *Cell Genom* 2:100190.
5. The GIANT consortium. (2022) A saturated map of common genetic variants associated with human height. *Nature* 610:704-712.
6. Japan COVID-19 Task Force. (2022) The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force. *Nat Commun* 13:4830.
7. Japan COVID-19 Task Force. (2022) DOCK2 is involved in the host genetics and biology of severe COVID-19. *Nature* 609:754-760.
8. COVID-19 Host Genetics Initiative. (2023) A second update on mapping the human genetic architecture of COVID-19. *Nature* 621:E7-E26.
9. Sonehara K, Kimura Y, Nakano Y, Ozawa T, Takahashi M, Suzuki K, Fujii T, Matsushita Y, Tomiyama A, Kishikawa T, Yamamoto K, Naito T, Suzuki T, Yamaguchi S, Miwa T, Sasaki H, Kitagawa M, Ohe N, Fukai J, Ogiwara H, Kawamura A, Miyawaki S, Matsuda F, Kiyokawa N, Ichimura K, Nishikawa R, Okada Y, Terashima K. (2022) A common deletion at BAK1 reduces enhancer activity and confers risk of intracranial germ cell tumors. *Nat Commun* 13:4478.

Department of Physiological Chemistry and Metabolism

Professor

Hiroki Kurihara, M.D., Ph.D.

Associate Professor

Yukiko Kurihara, M.D., Ph.D.

Research Associate

Yasunobu Uchijima, Ph.D.

Project Assistant Professor

Akiyasu Iwase, Ph.D.

Project Researcher

Hiroki Higashiyama, Ph.D.

Homepage <http://bio.m.u-tokyo.ac.jp/home-j.html>

Introduction and Organization

The Department of Physiological Chemistry and Nutrition, the predecessor of the present department, was founded in 1952. Upon the restructuring of the university system in 1997, the department was renamed 'Department of Physiological Chemistry and Metabolism' as one unit of the Specialty of Molecular Cell Biology. The present members include the above stuffs, 4 graduate students (doctor course) and 1 secretary. Professor Tomoichiro Asano (Hiroshima University) is invited as a part-time lecturer to instruct graduate students and give lectures to undergraduate students.

Teaching activities

We give a series of lectures and laboratory courses on biochemistry and molecular biology for undergraduate students from Faculty of Medicine and Faculty of Science. We also accept undergraduate students taking the MD-researcher developing program, "Free Quarter" and "Early-Exposure-to-Medicine" courses every year. Several students are staying in our

lab beyond the term to join our research.

For graduate students, we hold progress-report meeting and journal club every week, and sometimes invite established scientists for seminar to encourage scientific discussion.

Research activities

Our research is aimed at understanding molecular mechanisms underlying morphogenesis of the cranio-facial and cardiovascular structures.

(1) Craniofacial development

The branchial (pharyngeal) arches are a segmental series of bulging structures common and characteristic for all vertebrate embryos. They are mainly formed by migratory cranial neural crests, which give rise to various skeletal components including the jaw and middle ear structures. We have revealed that endothelin-1 (ET-1), first identified as an endothelium-derived vasoconstrictor peptide, and its receptor ETAR signaling acts as a molecular switch that determines the lower jaw identity by using mouse genetics.

From this research, several new insights in the field

of evolutionary developmental biology have been obtained. In mouse embryos, the absence of the Endothelin signal results in the failure to form the eardrum and the external ear canal. In contrast, in chicken embryos, there is instead an occurrence of duplication formation. This reveals that the eardrum is a product of convergent evolution that independently evolved in mammals and reptiles/birds. Furthermore, the facial structure of mammals deviates significantly from the common facial development pattern found in jawed vertebrates. It undergoes dynamic evolution, altering the tip of the upper jaw in reptiles and amphibians to create a protruding nose while simultaneously developing new bones to reshape the mouth tip. This has been elucidated through experimental embryology and comparative studies, including the analysis of fossils.

Recently, two different recurrent mutations in the Endothelin-A receptor (ETAR) gene *EDNRA* have been identified as causative for mandibulofacial dysostosis with alopecia (MFDA), a rare congenital disorder in humans. The mechanism of its pathogenesis has been elucidated through the use of mouse genetics, pharmacological experiments, and molecular dynamics (MD) simulations. This has revealed that the single amino acid *EDNRA* mutations distant from the ligand binding site allosterically affect ligand binding, inhibiting ligand dissociation and increasing binding affinity.

(2) Cardiac development

We have advanced our analysis regarding three cell types that migrate through the cardiac outflow tract and contribute to heart formation:

- ① We clarified that mesodermal cells from the extraembryonic somatopleure, which serves as the amniotic primordium, migrate into the embryo and differentiate into cardiomyocytes and vascular endothelial cells. We also revealed that BMP and FGF signals are involved in inducing these differentiations.
- ② Through transcriptome analysis of neural crest cells migrating into the heart and spatial transcriptome analysis, we unveiled a diverse cell population, including undifferentiated cell groups resembling stem cells and precursors, as well as smooth muscle-like cells. We also conducted a

time-evolving lineage prediction for these cell populations.

- ③ In coronary artery formation, we found the involvement of lymphatic endothelial cells that are believed to originate from the periaortic capillary plexus around the aortic root during embryonic development. We demonstrated the role of Semaphorin signals in this process.

Furthermore, through comparative anatomical and developmental analysis of coronary arteries, we elucidated that in amphibians, teleost fish, and cartilaginous fish, the primary vessels formed during embryonic development directly supply the heart, whereas, in amniotes (mammals, birds, reptiles), these primary vessels undergo remodeling during development, forming a new entrance to establish the coronary arteries. This provides a new foundation for understanding the causes of congenital coronary artery abnormalities.

(3) Angiogenesis

Angiogenesis is a morphogenetic process that produces branching vascular structures during embryogenesis and various (patho-)physiological conditions. We have identified characteristic cellular behaviors in angiogenic processes, including dynamic changes in forward-backward movement, tip cell overtaking and resultant cell mixing. Although the cellular behaviors appear complex and arbitrary, different types of mathematical modeling (stochastic vs. deterministic) and experimental verification indicated that some deterministic cell-cell interactions are critical for vascular elongation and possibly branching. Recently, we found differences in branch-forming capacity among cell types and some regularities in directional cell movement using in vitro angiogenesis experiments using mouse vascular explants and an endothelial cell line by refined cell-tracking system. Together with single-cell analyses of cell movement and gene expression, novel mathematical modeling and experimental verification using constitutional approaches are under way in collaboration with Professor Tetsuji Tokihiro (Graduate School of Mathematical Sciences, The University of Tokyo, Musashino University) and his colleagues, to elucidate the possible cellular mechanisms underlying branch formation in angiogenesis.

To elucidate the collective motility characteristics of endothelial cells that enable sprout elongation, we analyzed the dynamics of mouse pancreatic islet microvascular-derived endothelial cell line MS-1 cells. We discovered that their directional movement is influenced by cell contacts, with a combination of linear motion with directionality and rotational movement as its basis. Through various inhibitors and genetic modifications using genome editing, it has become evident that these endothelial cell-specific motility characteristics are specifically regulated by adhesion molecules such as VE-cadherin. Currently, we are advancing the elucidation of the coordination mechanism between cell motility and transcriptional control by contrasting gene expression profiles and cell behavioral phenotypes.

References

1. Aouci R, Soudany ME, Maakoul Z, Fontaine A, Kurihara H, Levi G, Narboux-Nême N. *Dlx5/6* expression levels in mouse GABAergic neurons regulate adult parvalbumin neuronal density and anxiety/compulsive behaviours. *Cells* 11(11): 1739, 2022.
2. Maruyama K, Miyagawa-Tomita S, Haneda Y, Kida M, Matsuzaki F, Imanaka-Yoshida K, Kurihara H. The cardiopharyngeal mesoderm contributes to lymphatic vessel development. *eLife* e81515, 2022.
3. Hayashi T, Yura F, Mada J, Kurihara H, Tokihiro T. Pattern formation of elliptic particles by two-body interactions: A model for dynamics of endothelial cells in angiogenesis. *J. Theor. Biol.* 555:111300, 2022.
4. Higashiyama H, Koyabu D, Kurihara H. Evolution of the therian face through complete loss of the premaxilla. *Evol. Dev.* 25(1):103-118, 2023.
5. Kurihara Y, Ekimoto T, Gordon CT, Uchijima Y, Sugiyama R, Kitazawa T, Iwase A, Kotani R, Asai R, Pingault V, Ikeguchi M, Amiel J, Kurihara H. Mandibulofacial dysostosis with alopecia results from ETAR gain-of-function mutations via allosteric effects on ligand binding. *J. Clin. Invest.* 133(4):e151536, 2023.
6. Shima Y, Sasagawa S, Ota N, Oyama R, Tanaka M, Kubota-Sakashita M, Kawakami H, Kobayashi M, Takubo N, Ozeki AN, Sun X, Kim YJ, Kamatani Y, Matsuda K, Maejima K, Fujita M, Noda K, Kamiyama H, Tanikawa R, Nagane M, Shibahara J, Tanaka T, Rikitake Y, Mataga N, Takahashi S, Kosaki K, Okano H, Furihata T, Nakaki R, Akimitsu N, Wada Y, Ohtsuka T, Kurihara H, Kamiguchi H, Okabe S, Nakafuku M, Kato T, Nakagawa H, Saito N, Nakatomi H. Increased PDGFRB and NF- κ B signaling caused by highly prevalent somatic mutations in intracranial aneurysms. *Sci Transl Med.* 15(700):eabq7721, 2023.
7. Tonami K, Hayashi T, Uchijima Y, Kanai M, Yura F, Mada J, Sugahara K, Kurihara Y, Kominami Y, Ushijima T, Takubo N, Liu X, Tozawa H, Kanai Y, Tokihiro T, Kurihara H. Coordinated linear and rotational movements of endothelial cells compartmentalized by VE-cadherin drive angiogenic sprouting. *iScience.* 26(7):107051, 2023.
8. Oda H, Tonami K, Nakata Y, Takubo N, Kurihara H. Persistent homological cell tracking technology. *Sci Rep.* 13(1):10882, 2023.
9. Mizukami K, Higashiyama H, Arima Y, Ando K, Okada N, Kose K, Yamada S, Takeuchi JK, Koshiba-Takeuchi K, Fukuhara S, Miyagawa-Tomita S, Kurihara H. Coronary artery established through amniote evolution. *eLife* 12:e83005, 2023.
10. Watanabe Y, Wang Y, Tanaka Y, Iwase A, Kawamura T, Saga Y, Yashiro K, Kurihara H, Nakagawa O. Myocardial progenitor cells defined by Hey2 enhancer activity at the early stage of cardiac crescent formation specifically differentiate into cardiomyocytes of the left ventricle. *Proc. Natl. Acad. Sci. U.S.A.* 120(37): e2307658120, 2023.
11. Liu N, Kawahira N, Nakashima Y, Nakano H, Iwase A, Uchijima Y, Wu SM, Minamisawa S, Kurihara H, Nakano A. Notch and retinoid acid signals regulate macrophage formation from endocardium downstream of Nkx2-5. *Nat Commun.* 14(1):5398, 2023.
12. Agostini V, Tessier A, Djaziri N, Khonsari RH, Galliani E, Kurihara Y, Honda M, Kurihara H, Hidaka K, Tuncbilek G, Picard A, Konas E, Amiel J, Gordon CT. Biallelic truncating variants in VGLL2 cause syngnathia in humans. *J Med Genet.*

jmg-2022-109059, 2023.

13. Sakai K, Hayashi T, Sakai Y, Mada J, Tonami K, Uchijima Y, Kurihara H, Tokihiro T. A three-dimensional model with two-body interactions for endothelial cells in angiogenesis. *Sci Rep.* 13(1): 20549, 2023.
14. Haneda Y, Miyagawa-Tomita S, Uchijima Y, Iwase A, Asai R, Kohro T, Wada Y, Kurihara H. Diverse contribution of amniogenic somatopleural cells to cardiovascular development: with special reference to thyroid vasculature. *Dev. Dyn.* 253: 59-77, 2024.

Department of Advanced Structural Studies

Professor

Radostin Danev, Ph.D.

JSPS fellows

Fabian Eisenstein, Ph.D.

Irwin Selvam, Ph.D.

Homepage <http://danevlab.m.u-tokyo.ac.jp>

Introduction and Organization

Our laboratory was established in 2018. We are supported by grants from the Japan Society for the Promotion of Science (JSPS), and Takeda Science Foundation. Our research also benefits from indirect support through an instrumentation facility grant from the Japan Agency for Medical Research and Development (AMED). The lab members are Radostin Danev (professor), Fabian Eisenstein (JSPS fellow), and Irwin Selvam (JSPS fellow).

Teaching activities

We conduct training and provide support for the users of the cryo-electron microscopy (cryo-EM) facility at the Graduate School of Medicine. This includes specialized lectures at cryo-EM courses within the University of Tokyo and other research institutions in Japan and abroad. We also give introductory lectures about structural biology as part of the following programs:

- 1) MD scientist training program (MDSTP)
- 2) Master student class
- 3) Ph.D. student guidance
- 4) School of Medicine Introductory Lecture

Research activities

Our research is aimed at elucidating the structure-function relationships of proteins and cellular

components. Through our work, we hope to contribute to the fundamental knowledge about the molecular mechanisms behind chronic diseases, and thereby to help develop effective treatments.

For the past five years, we have been investigating an important class of membrane proteins called G protein-coupled receptors (GPCRs). GPCRs constitute the largest family of membrane proteins in the human genome. They are responsible for the detection and transduction of many extracellular signals that regulate various physiological processes across the plasma membrane. Because of their broad regulatory functions, GPCRs are implicated in numerous chronic diseases, such as diabetes, obesity, nervous system disorders, migraine, asthma, allergies, cardiovascular disorders, cancer, and others. Consequently, they also represent the biggest group of drug targets and are the subject of more than 30% of approved drugs.

To understand the mechanisms of GPCR activation and signal transduction on the atomic level, we use the modern and very prolific method of cryo-EM single particle analysis. In an ongoing international collaboration with a group at Monash University in Australia, which specializes in GPCR pharmacology and has substantial experience in expression and purification of target complexes, we are studying receptor activation by both native and synthetic ligands. In the past four years, our results comprise more than 40 sub-3 Å unmodified full-length GPCR

structures, approximately half of which are at resolutions better than 2.5 Å. This is an unprecedented achievement in structural biology, both in terms of the number of structures and their resolution. Our success is not coincidental. To reach such a level of performance, we conducted a careful systematic quantification and optimization of the cryo-EM experimental parameters for sample preparation and data collection. We adopted a highly efficient synergistic experimental approach that combined data collection from real samples with testing of individual experimental factors. The method had the advantage of not requiring extra observation time on the costly and heavily booked electron cryo-microscopes. The results from this work led us toward a better experimental design and allowed us to routinely produce sub-2.5 Å resolution results in our recent studies. Most prominently, in the summer of 2020 we were able to produce the first sub-2 Å resolution reconstructions of GPCR complexes that to this date remain unsurpassed.

In 2022 we expanded our structural research towards other pharmacologically important proteins. We began expression and purification trials and functional characterization of potential drug targets from *Mycobacterium tuberculosis*. Following computational interrogation, we generated several constructs that were taken forward to expression and purification. Where workable samples were obtained, negative stain EM and cryo-EM were utilized to derive preliminary structural information. This information was then fed back to the molecular biology stage in an iterative process. Cryo-EM investigation of the most promising preparations resulted in 2D classes that showed partially ordered oligomers, but unfortunately the data did not yield a 3D reconstruction. Although the high-resolution structures of the targets were not obtained, this work established a substantial basis for future research towards better understanding of the disease mechanisms of tuberculosis and the development of effective treatments.

Despite the rapid growth of the cryo-EM field, there are still many areas where further advances are possible and/or needed. To address such quiescent areas, we are working on the development of new experimental methods for cryo-EM. One of our current projects aims to develop and implement a

high-speed real-time synchronous modulation of the electron beam that will expand the capabilities of the microscope. With the so-called FADE method (fast and accurate defocus modulation), we hope to transform the instrument from a static and rigid system into a dynamic and adaptable optical platform. This will give researchers more freedom to tune their experiments for optimal performance. We finished the development and construction of the first FADE hardware prototype, and it is already installed on one of the microscopes at the facility (JEOL JEM-F200). Hardware-wise, the system performs as expected and produces data of good quality. The main challenge that remains is the analysis of the data. All existing software packages for cryo-EM data processing are designed for conventional constant defocus data. To process FADE data, we must modify or write our own data processing routines and we are currently working in this direction. In the near future, the FADE hardware will be added to the new JEOL CryoARM 200 electron microscope that was installed in the spring of 2022 at the Kashiwa II campus of the University of Tokyo. This microscope has superior optical and cryogenic performance and will demonstrate the benefits of the new method at a much higher level than the current test system.

Other areas of our research include cryo-electron tomography (cryo-ET) of cellular samples combined with advanced sample preparation through cryogenic focused ion beam milling (cryo-FIB). The ability to observe proteins and complexes in their native environment within a cell, “in situ”, offers tremendous opportunities for fundamental biological, pharmacological, and medical contributions. Nevertheless, the cryo-ET field is still quite young and there are multiple challenges related to sample preparation and data acquisition. This makes the research even more interesting and rewarding. In 2022 we started the development of a new method for high-throughput and high-resolution cryo-ET data acquisition. The new approach, called PACE-tomo (parallel cryo electron tomography), uses accurate computer-controlled optical shifts of the electron beam and the image on the detector to acquire multiple tomographic tilt series in parallel. It circumvents the need for mechanical specimen stage movements that cause significant delays and sample drift. In this way, PACE-tomo

achieves a fivefold improvement in the overall throughput of cryo-ET data acquisition. In the coming years, we will continue making further contributions to the methodology and performance of cryo-ET and thereby hope to one day reach the ultimate (utopian) goal of “visual proteomics”; where researchers will be able to identify each individual protein and its interactions with neighboring proteins within an electron cryo-tomogram of a cellular volume.

We are also expanding our investigations towards state-of-the-art deep learning experiment automation for both cryo-EM single particle analysis and cryo-electron tomography. Deep learning (DL) methods have become ubiquitous in many areas of research, and some groups are already developing DL-based experimental frameworks for cryo-EM and cryo-ET. However, at present, many experimental steps still require human intervention. Most of these actions involve image evaluation and feature recognition and are therefore perfect candidates for DL algorithms, which have already been proven to match or surpass human performance in such activities. With further automation, the experiments will become more efficient, for example, allowing researchers to easily operate the microscopes remotely while working on other important tasks. The quality and amount of data will improve and thereby the level and number of scientific results will continue to grow.

References

1. Cary BP, Deganutti G, Zhao P, Truong TT, Piper SJ, Liu X, Belousoff MJ, Danev R, Sexton PM, Wootten D, Gellman SH. Structural and functional diversity among agonist-bound states of the GLP-1 receptor. *Nat Chem Biol.* 2022;18(3):256-263.
2. Deganutti G, Liang YL, Zhang X, Khoshouei M, Clydesdale L, Belousoff MJ, Venugopal H, Truong TT, Glukhova A, Keller AN, Gregory KJ, Leach K, Christopoulos A, Danev R, Reynolds CA, Zhao P, Sexton PM, Wootten D. Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation. *Nat Commun.* 2022;13(1):92.
3. Cao J, Belousoff MJ, Liang YL, Johnson RM, Josephs TM, Fletcher MM, Christopoulos A, Hay DL, Danev R, Wootten D, Sexton PM. A structural basis for amylin receptor phenotype. *Science.* 2022;375(6587).
4. Piper SJ, Deganutti G, Lu J, Zhao P, Liang YL, Lu Y, Fletcher MM, Hossain MA, Christopoulos A, Reynolds CA, Danev R, Sexton PM, Wootten D. Understanding VPAC receptor family peptide binding and selectivity. *Nat Commun.* 2022;13(1):7013.

Functional Biology

1. Physiology

Department of Integrative Physiology

Professor

Kenichi Ohki, M.D., Ph.D.

Homepage <https://physiol1.m.u-tokyo.ac.jp/ern24596/en/>

Introduction and Organization

This laboratory was initially established in 1877 as The First Department of Physiology, and reorganized in 1997 as Laboratory of Integrative Physiology in the Department of Physiology. Our laboratory cooperates with other laboratories in the Department of Physiology, that is, Laboratory of Molecular/Cellular Physiology and Laboratory of Neurophysiology, in teaching activities for undergraduate courses and the nursing school. The fields in which our laboratory specializes span the entire spectrum of *animal functions* of physiology, including general physiology, sensory physiology, endocrinology, neurophysiology, higher nervous functions and cognitive neurosciences.

Education

The staff members as well as experts from other universities take part in giving lectures and laboratory courses to the undergraduate students of the Medical School. The lectures are aimed at providing a clear understanding of the hierarchical functional organizations of living systems. The curriculum is updated every year. For example, a new electrocardiogram experiment in humans was introduced to the laboratory course, in which students learned human physiology of electrocardiogram, its practical procedure in clinical settings and its cellular physiological origins. This practice gained popularity and interest among students. We accept *Free-Quarter* students every year. Usually these students' activities are not limited to one *Quarter*. Some of these students completed their own projects, and gave oral presentations in international meetings and published

original papers in top-rank international journals. It is not rare that students who enjoyed his/her *Free-Quarter* decided to get into the Ph-D. course after the completion of the 2-year clinical training and started to study neurophysiology in our laboratory. Furthermore, we accepted a Ph-D.-M.D course student who enjoyed his *Free-Quarter* and decided to get into the Ph-D.-M.D course. Thus the *Free-Quarter* system has proved to provide an excellent basis for bringing up M.D. researchers for future Japanese basic medicine.

To facilitate communication among research groups in our laboratory, a weekly conference is held for discussing current research activities. We also have a monthly joint seminar with Department of Pharmacology. As a part of teaching activity for the graduate students, we have another weekly seminar, in which the graduate students learn how to give presentations and hold discussions and debates.

Research

Most of our research is focused on the higher brain function of the mammalian central nervous system.

(1) Hierarchical and parallel visual networks in the cerebral cortex are conserved across mammalian species and are considered the basic structure of visual information processing in the brain. During development, the brain forms the complex visual network based on both gene expression and neural activity including spontaneous activity. The development of neural networks is an important topic in the neuroscience. However, previous investigations

have been limited to lower order pathways from the periphery to the primary sensory cortex via the thalamic nuclei. Thus, the development of the entire neural network, including higher order cortical areas and higher-order thalamic nuclei, remains largely unexplored.

To elucidate the development of neural networks, it is necessary to investigate the formation of inter-areal connections throughout the visual network, including cortical and thalamic visual areas. However, it has been technically difficult to precisely identify the locations of the visual areas in the immature, developing brain. We found that the locations of the primary (V1) and higher visual areas can be identified by analyzing spontaneous activity observed in the developing mouse cortex. Using this method, we investigated how interregional connections were formed throughout the mouse visual network. In addition, we examined the functional role of spontaneous activity in the formation of intercortical connections.

We found that early in development, the projections from the thalamic nuclei to the visual cortex (primary thalamic nuclei to V1 and higher thalamic nuclei to higher visual cortex) were established before the formation of the intercortical connections. In addition, the primary and higher thalamic nuclei each received input from the retina through independent pathways, forming parallel pathways from the retina to V1 or higher visual cortex.

Functional calcium imaging of neuronal activity revealed that, spontaneous activity propagated from the retina to the cortex through the parallel pathways, and that the activity showed retinotopic patterns in both the thalamic nuclei and visual cortical areas including V1 and higher visual areas. These results indicate that these parallel pathways have retinotopic connections even at an early stage of development and suggest that the parallel pathways may support the formation of intercortical connections based on their retinotopic structures.

To investigate the role of spontaneous retinal activity in the formation of inter-cortical connections, we removed the retinal activity immediately after birth. Removal of the retinal activity disrupted the projection from V1 to higher visual areas, indicating that spontaneous retinal activity is important for the

formation of intercortical connections.

This study not only demonstrates the developmental process of the cortical neural network, but also provides a basic knowledge for elucidating the mechanisms underlying the neural network formation depending on neural activity and gene expression.

(2) In adult mice, a higher order thalamic nucleus sends its axons not only to higher visual areas, but also to the primary visual cortex (V1). However, the function of the latter pathway has not been fully understood. Using functional axon imaging, we revealed that the higher order thalamic nucleus sends different visual information to V1 compared to the primary thalamic nucleus, indicating the different roles of the primary and higher thalamic nuclei in modulation of V1 activity.

(3) Neural activity is important for the development of projections of interhemispheric callosal connections. However, when the neural activity is important during the development of the callosal projections has not been investigated. We genetically controlled the activity of the callosal projections and showed that the neural activity during a limited developmental period is important for the proper formation of the callosal projections, suggesting a critical period for neural activity dependence in the development of the callosal connections.

Publications

- (1) Tomonari Murakami, Teppei Matsui, Masato Uemura, Kenichi Ohki. Modular strategy for development of the hierarchical visual network in mice *Nature*, 608, 578-585, 2022
- (2) Satoru Kondo, Yuko Kiyohara, Kenichi Ohki. Response Selectivity of the Lateral Posterior Nucleus Axons Projecting to the Mouse Primary Visual Cortex *Frontiers in neural circuits* 16: 825735, 1-13, 2022;
- (3) Yuto Tezuka, Kenta M Hagihara, Kenichi Ohki, Tomoo Hirano, Yoshiaki Tagawa. Developmental stage-specific spontaneous activity contributes to callosal axon projections *Elife* 11, e72435, 2022

Department of Cellular and Molecular Physiology

Professor

Masanori Matsuzaki, Ph.D.

Lecturer

Teppei Ebina, Ph.D.

Research Associate

Shin-Ichiro Terada, Ph.D.

Masashi Kondo, Ph.D.

Homepage <http://plaza.umin.ac.jp/~Matsuzaki-Lab/>

Introduction and Organization

The Department of Cellular and Molecular Physiology succeeded the former ‘Second Department of Physiology’, and belongs to the Department of Physiology. We participate in the teaching of physiology at undergraduate school and graduate school.

The present members include the above staff, 2 secretary staff, 4 technical staff, 1 project research associate, 6 graduate students.

Teaching activities

The department provides lectures and practice in physiology for undergraduate students. We teach imaging, computational neuroscience, and cellular and molecular physiology methods for free quarter students. The department provides also lectures and instructions for laboratory research for graduate and undergraduate students in the fields of neurophysiology and molecular and cellular imaging. Seminars, progress reports, and journal club for graduate students are routinely provided. Monthly joint seminars (Functional Biology Seminars) are also provided for graduate students.

Research activities

Various firing patterns of many cortical neurons represent information processing in the brain. The microarchitecture of synaptic connections control information processing in cortical circuits. The structure and location of synapses determine and modify the strength of this information processing. The aim of our laboratory is to reveal how information is formed, maintained, selected, and decoded in the brain at the levels of single cells and of single synapses. To do so, we mainly use two-photon microscopy that allows us to see fluorescence signals from deep within living tissue, developing novel photostimulation methods and animal behavioral tasks. The goals of our recent studies are to reveal how voluntary movement is memorized and represented in cortical circuits. In addition, we are working to apply two-photon microscopy to a non-human primate, the common marmoset, in order to understand information processing in the brain, which is relevant to high cognitive functions.

(1) Transition of distinct context-dependent ensembles from secondary to primary motor cortex in skilled motor performance

In practicing short-distance running, one may start running on their own timing or start running in response to the sound of a pistol. The various actions we perform daily can be divided into 'internally generated' movements, which start spontaneously, and 'externally triggered' movements, which start in response to sensory stimuli such as visual and auditory stimuli.

In patients with Parkinson's disease, it is known that while it is difficult to start movements spontaneously, they can relatively robustly initiate movements in response to exogenous stimuli. It is assumed that the neural processing pathways in the brain for these two types of movements are largely different. Previous studies reported that while the higher motor cortex shows neural activity dependent on each start signal, the primary motor cortex exhibits the same activity regardless of the signal. However, it was still unclear what information is transmitted between these areas, how these different activities converge into the same activity, and whether these are dependent on the individual's learning status.

In this study, we first constructed internally generated and externally triggered movement tasks in mice. In these tasks, mice could obtain rewards by pulling a lever either spontaneously or in response to an auditory cue. Next, we investigated the involvement of the higher motor cortex (M2) and primary motor cortex (M1) in these tasks after training the mice, by inhibiting neural activity pharmacologically and optogenetically. When we consistently suppressed activity in both M2 and M1, the success rate decreased regardless of whether the movement was internally generated or externally triggered. However, when suppression was transient after movement initiation, only inhibition of M1 caused motor dysfunction. These results suggest that both M2 and M1 are necessary for task execution, but after movement initiation, the motor execution function shifts to M1, indicating that these two areas may be hierarchically processing information.


Next, to understand what information is represented in neural activity, we conducted calcium imaging with two-photon microscopy. To clarify how M2 and M1 interact, it is important to simultaneously measure neural activity in both areas. Our laboratory previously developed microscopy called the

'wide-field two-photon microscopy', which allows sequential measurement of neural activity in separate areas at single-cell resolution using a custom-developed miniaturized optical element. In this study, we further improved this microscopy, nearly doubling the image acquisition speed from about 6 frames per second to approximately 10 frames per second, enabling the capture of more detailed activity changes.

Using this microscopy to examine the activities in the superficial layers of M2 and M1, we confirmed the presence of neural activities responding to the differences in start signals between internally generated and externally triggered movements. To further investigate the information transmitted between areas, we also imaged axons projecting from the thalamus, located beneath the cerebral cortex, to M2, from M2 to M1, and corticospinal tract neurons in the deep layer of M1, conducting comprehensive measurements from M2 input to M1 output. Using machine learning-based decoding analysis, we quantified the context dependency, i.e., whether the movement initiation was internally generated or externally triggered, at the group level for each structure. As a result, while the superficial layer of M2 always showed high context dependency, and the corticospinal tract neurons in M1 always showed low context dependency, the context dependency of axons projecting from M2 to M1 and neurons in the superficial layer of M1 varied significantly between days and animals. Further analysis revealed that the higher the context dependency in both structures, the better the task performance, such as success rate and response time to the sound cue. Additionally, the higher the context dependency in the superficial layer of M1, the better the motor proficiency, such as lever-pulling speed, duration, and reproducibility of lever trajectory.

At the individual cell level, when motor proficiency was high, the number of cells in the superficial layer of M1 with both high context information and high motor information increased, suggesting that the increase in context dependency and motor proficiency at the group level was interconnected. Even when this reorganization of activity occurred in the superficial layer of M1, there were no significant differences in information

representation at the group or individual cell levels in the superficial layer of M2. It is considered that high motor function was realized by reorganizing cell groups that generate motor commands specialized for each context downstream (see Figure below).



The finding in this study that the relationship between the reorganization of context-dependent neural activity and motor proficiency varies greatly depending on the region and layer within the frontal cortex, and that the neural network between context input and motor output dynamically changes, demonstrates the highly adaptive information processing ability of the cerebral cortex. Further research may contribute to the development of high-performance artificial intelligence algorithms that mimic the brain. Additionally, elucidating the mechanisms of internally generated and externally triggered movements is important for understanding Parkinson's disease and holds promise for the development of new treatments.

(2) Development of a bleed-free multi-site automated injection robot for accurate, fast, and dense viral delivery to mouse and marmoset brains

Minimizing invasiveness to the living body is an undoubtedly important issue in biomedical science. Robotics provide one answer to this challenge: automation, and it is awaited especially in the neuroscience and neurosurgical fields, since a brain is one of the most delicate and three-dimensionally complex organs. In the preceding automations, such as craniotomy, patch-clamping, and electrode implantation, are mainly focused on precision of robotic manipulation, which could reduce tissue damage by limiting unexpected movement of surgeons. However, surgical planning is mostly decided by human, and its automation is still in its infancy.

Here, we developed ARViS: an Automated Robotic

Virus injection System. An infrared sensor was used to accurately scan the three-dimensional brain surface with the skull removed. Based on the scanning data, we applied a neural network for retinal vessel segmentation to extract the brain vasculature structure, which were recognized up to 14 μm with 100% accuracy, and optimized the locations of more than 100 injection sites without hitting any blood vessels by developing an original algorithm. Then, a commercially accessible 6-DOF robot precisely moved the needle to each injection site and inserted it to the specified depth. The injection site could be placed as close as 60 μm from vessels and the actual injection depth could only deviate by about $\pm 50 \mu\text{m}$ from the target. Furthermore, because the soft tissue changes shape during needle insertion and because blood vessels run vertically in the brain, the needle angle was aligned perpendicular to the surface, which also contributed to improved accuracy and reduced invasiveness.

As a proof-of-concept experiment, adeno-associated virus (AAV) expressing a Ca^{2+} indicator was injected into over 120 sites of the whole dorsal cerebral cortex of mouse and 266 sites of common marmoset. The risk of major bleeding was only 0.73% in mice (2333 sites) and none was observed in marmoset (266 sites). It took only approximately 20 seconds to change the needle position and angle from one target to another. We clearly detected uniform fluorescence expression over the broad areas of $8 \times 8 \text{ mm}^2$ in the mouse, which covers from the prefrontal to visual cortex in both hemisphere, and $8 \times 14 \text{ mm}^2$ in the marmoset, ranging from area PE to A8. Furthermore, in the mouse, in vivo Ca^{2+} signals from more than 10,000 neurons were simultaneously recorded under an epifluorescence microscope. Thus, ARViS enables bleed-free multi-site automated injection for accurate, fast, and dense virus delivery.

This research provides a new solution for micron-order control of minimally invasive needle insertion into delicate three-dimensional structures avoiding high-risk areas on the surface. It paves the way to the ultra-minimal invasive drug delivery or biopsy targeting at sub-milli order cell aggregation in the future by combining the existing imaging technology such as MRI or CT, which can be applied to a wide range of clinical medicine, from early

detection of breast cancer through biopsies of very small tumors to gene therapy by injecting viral vectors.

(From an abstract in the BIO UT 2022)

References

1. Terada S., Kobayashi K., and Matsuzaki M. Transition of distinct context-dependent ensembles from secondary to primary motor cortex in skilled motor performance. *Cell Reports* 41, 111494, 2022.
2. Terada S., and Matsuzaki M. (News and Views) Silent microscopy to explore a brain that hears butterflies' wings. *Light: Science & Applications* 11, 140, 2022.

Department of Neurophysiology

Professor

Masanobu Kano, M.D., Ph.D.

Research Associate

Takaki Watanabe, Ph.D.

Research Associate

Kazuto Sakoori, Ph.D.

Homepage <http://plaza.umin.ac.jp/~neurophy/>

Introduction and Organization

This laboratory was founded in 1953 as Department of Neurophysiology, Institute for Brain Research. In 1996, it was integrated into Graduate School of Medicine. The current members of this laboratory are 4 faculty members (professor, lecturer, 2 research associate), 1 postdoctoral fellow, 7 graduate students, and 5 technicians. We teach neurophysiology for medical undergraduates and students in the Master and Ph.D. courses. Our research aims at elucidating cellular and molecular mechanisms underlying the regulation of synaptic transmission and postnatal development of neuronal circuits.

Teaching activities

We teach neurophysiology to medical undergraduates in lectures and practical courses. Lectures are designed for students to learn basic mechanisms underlying the generation of electrical signals, synaptic transmission and their regulations in the nervous system, and roles of the spinal cord, brain stem, and cerebellum in sensorimotor functions. Students also learn how functional neural circuits in the brain are formed and matured during postnatal development. In the practical courses, students perform two types of classical neurophysiology experiments. First, students make intracellular recordings from frog skeletal muscle fibers and examine the endplate potential for understanding the

basic properties of synaptic transmission. Second, students record an electromyogram (EMG) from human gastrocnemius muscles and learn how the stretch reflex works.

We accept Free-Quarter students. Students are encouraged to experience patch-clamp recordings from neurons either in brain slices or in dissociated cultures, or to experience recordings of neuronal activities from living animals.

For the training of Master and Ph.D. course students, we have a weekly conference to discuss current research activities. A laboratory member summarizes his/her recent experimental data or presents papers closely related to his/her research.

Research activities

The brain consists of neuronal circuits in which neurons are connected through numerous synapses. To understand brain function, it is necessary to elucidate mechanisms of synaptic transmission and those underlying changes in synapses related to development, learning, and memory (synaptic plasticity). We take various methodological approaches including electrophysiology, pharmacology, morphology, and genetic engineering of mice. We particularly focus on observing neuronal activities in real-time in intact neurons. We use whole-cell patch clamp recording, calcium imaging, and two-photon imaging and their combinations in various preparations (cultured neurons, brain slices,

and intact animals) and investigate molecular mechanisms of synaptic transmission and plasticity.

The main subjects of our research are as follows

(1) Refinement of synaptic organization during cerebellar development:

In early postnatal days, all Purkinje cells in the cerebellum are innervated by multiple climbing fibers. These surplus climbing fibers are eliminated eventually with the progress of postnatal development, and most Purkinje cells become innervated by single climbing fibers by the end of the third postnatal week in mice. We investigate the mechanisms of how single climbing fibers are selected and how the surplus climbing fibers are eliminated.

(2) Retrograde synaptic modulation mediated by endogenous cannabinoids:

We reported in 2001 that endogenous cannabinoids are released from postsynaptic neurons in an activity-dependent manner, act retrogradely onto presynaptic cannabinoid receptors, and suppress transmitter release. Since then, we have been investigating the mechanisms of this retrograde modulation. We are also interested in elucidating the physiological significance of this phenomenon including learning and memory, addiction, and anxiety.

(3) Neural Activity and its function in intact animals:

To understand the representation of information by specific neurons and their functions *in vivo*, we record and regulate neural activity in intact animals during behavioral tasks by using two-photon microscopy, miniaturized microscopy, and optogenetics. Alongside these, we are also developing various techniques to facilitate these *in vivo* experiments.

- (2) Harbers M, Nakao H, Watanabe T, Matsuyama K, Tohyama S, Nakao K, Kishimoto Y, Kano M, Aiba A. mGluR5 is substitutable for mGluR1 in cerebellar Purkinje cells for motor coordination, developmental synapse elimination, and motor learning. *Cells*. 2022 Jun 23;11(13):2004. doi: 10.3390/cells11132004.
- (3) Sakamoto M, Inoue M, Takeuchi A, Kobari S, Yokoyama T, Horigane SI, Takemoto-Kimura S, Abe M, Sakimura K, Kano M, Kitamura K, Fujii H, Bito H. A Flp-dependent G-CaMP9a transgenic mouse for neuronal imaging in vivo. *Cell Rep Methods*. 2022 Feb 14;2(2):100168. doi: 10.1016/j.crmeth.2022.100168. eCollection 2022 Feb 28.
- (4) Sugaya Y, Kano M. Endocannabinoid-mediated control of neural circuit excitability and epileptic seizures. *Front Neural Circuits*. 2022 Jan 3;15:781113. doi: 10.3389/fncir.2021.781113. eCollection 2021.

References

- (1) Itami C, Uesaka N, Huang JY, Lu HC, Sakimura K, Kano M, Kimura F. Endocannabinoid-dependent formation of columnar axonal projection in the mouse cerebral cortex. *Proc Natl Acad Sci USA*. 2022 Sep 13;119(37):e2122700119. doi: 10.1073/pnas.2122700119. Epub 2022 Sep 6.

Functional Biology

2. Pharmacology

Department of Cellular and Molecular Pharmacology

Professor

Kenzo Hirose, M.D., Ph.D.

Lecturer

Shigeyuki Namiki, Ph. D., Daisuke Asanuma, Ph. D.

Assistant Professor

Hirokazu Sakamoto, Ph. D.

Homepage <http://www.pharmacol.m.u-tokyo.ac.jp>

Introduction and Organization

Our department was founded in 1885 and collaborates with the Department of Systems Pharmacology in the education of undergraduate medical students.

Teaching activities

Pharmacology lectures and laboratory courses for the medical students are given by the staff members of both Departments of Pharmacology. We also invite seven outside expert lecturers to cover rapidly developing fields in pharmacology and related medical sciences. The laboratory courses include both traditional and advanced pharmacological experiments. A new intensive laboratory course for medical students started in the year 2001, and we participated in the program. We also give lectures for graduate students including master course students and Ph.D. candidates.

Research activities

A goal of our research is to elucidate regulation mechanisms of cell function through the development of novel technologies. The main subjects of our research are as follows.

1) Development of high-performance fluorescence probes for visualizing neurotransmitters

Imaging techniques which visualize neurotransmitters in living neurons are powerful methods to understand the mechanism underlying synaptic transmission in neuronal circuits. To facilitate this process, we developed a high-throughput screening system based on 96-well plate format protocol. After screening, we obtained high-performance glutamate probes showing large fluorescence changes upon glutamate binding. This result indicates that our screening system should be applicable to develop fluorescence probes for signaling molecules other than glutamate in short periods.

2) Study of the mechanism underlying the exocytosis of neurotransmitter

For understanding of regulation mechanism underlying neuronal circuit in mammalian central nervous system, elucidation of the neurotransmitter release machinery is indispensable. Aiming at imaging neurotransmitter glutamate, we developed a novel optical glutamate probe by our high-throughput screening system as described above. Using this probe, we successfully visualized presynaptically released glutamate with a single synapse resolution in cultured hippocampal neurons. We quantitatively analyzed released glutamate at individual synapses and revealed

that single hippocampal synapses contain several release units. Furthermore, we have succeeded in imaging spatiotemporal dynamics of glutamate in the extrasynaptic space in brain slices and *in vivo*. This study demonstrated that bursting synaptic activities cause glutamate spillover from the synaptic cleft to activate perisynaptic metabotropic glutamate receptors, and will provide a basis for the research of extrasynaptic glutamate transmission that is involved in many important brain functions. These results indicate that our glutamate probe is useful to directly assess synaptic functions including presynaptic modulation and plasticity.

3) Analysis of supra-molecular assemblies of synaptic molecules in central synapse

Recently, nanoscale molecular distribution in synapses is suggested to be a key determinant of synaptic function. To reveal the relationship between the nanoscale molecular assemblies and synaptic functions, we are trying to perform a super resolution microscopic analysis in combination with glutamate imaging. These advanced imaging techniques revealed that dynamics of neurotransmitter release is precisely controlled by the highly coordinated nanoscale molecular assemblies of presynaptic molecules. We are also trying to identify the functional changes in nanoscale molecular assemblies in psychiatric disease model.

References

1. Miyano, R., Sakamoto, H., Hirose, K., & Sakaba, T. (2022). RIM-BP2 regulates Ca^{2+} channel clustering and neurotransmitter release at hippocampal mossy fiber terminals. *bioRxiv*, 2022-08.
2. Sakamoto, H., Kimpara, N., Namiki, S., Hamada, S., Ohtsuka, T., & Hirose, K. (2022). Synapse type-specific molecular nanoconfigurations of the presynaptic active zone in the hippocampus identified by systematic nanoscopy. *bioRxiv*, 2022-03.

Department of Systems Pharmacology

Professor

Hiroki R. Ueda, M.D., Ph.D.

Project Associate Professor

Yoichi Minami, Ph.D.

Full-time Lecturer

Koji L. Ode, Ph.D.

Project Lecturer

Akifumi Kishi, Ph.D.

Research Associate

Daisuke Tone, Ph.D.

Project Research Associate

Yasuhiro Tomita, M.D., Ph.D.

Homepage <https://sys-pharm.m.u-tokyo.ac.jp/>

Teaching activities

Our department, in collaboration with the department of cellular and molecular pharmacology, takes responsibility for lectures and laboratory courses on pharmacology for the undergraduate students of the faculty. There are 39 lectures per year including those given by seven invited lectures to cover specialized and currently highlighted fields in pharmacology. We offer several laboratory courses, and all the members of the department participate in the courses to provide close consultation for the students.

For the graduate students, there are series of seminars on physiology and neuroscience. We also have research seminars to discuss and stimulate the research activities of the graduate students in the department.

Research activities

Department of systems pharmacology is conducting

research to establish organism-level systems biology and pharmacology using sleep-wake cycle as a model system, which is common to organisms with a central nervous system and one of the main factors that dictate the dynamics of social behavior. With our members from different backgrounds, we would like to realize systems biology at the organism level including human, leading to greater understanding and even control of organismal pathophysiology. To this end, we specifically focus on the cellular circuits controlling the sleep/wake cycle and address the hourglass mechanism of sleep, a homeostatic- and circadian-dependent regulation of sleep amount and timing. We are also planning on multi-scale research activities covering a series of length scales; molecule-to-cell, cell-to-tissue, and tissue-to-organism to envision such complicated underlying mechanism. We have been devoting our research to two technological challenges; 1) next-generation mammalian reverse genetics, where we can produce

genetically modified mice in a high-throughput fashion, 2) system-level identification and analysis of cellular circuits in the whole-organ (especially, the whole-brain) and whole-body, where we can identify individual cells or cellular circuits in the whole-organ and whole-body. Combined with these techniques, we investigate how the average (diurnality or nocturnality), the dispersion (the length of sleeping time), and the amount (insomniac or hypersomniac responses) of sleep during circadian time are determined by environments and history of activities. In addition, we are developing human sleep analysis techniques using wearable devices, and aim to realize a series of human sleep studies that incorporate large-scale human sleep phenotyping, genomic analysis, and proof of causality using animal models.

1) Next-generation mammalian reverse genetics

In the conventional method for production of genetically-modified mice, a single line of gene-targeted ES cells is injected into host embryos (typically use blastocysts) to generate chimera mice comprising a mixture of ES- and host-derived cells. In addition, multiple mating procedures are needed to generate the desired genetically modified mouse strain, which typically takes from 9 months to several years. Such multiple rounds of mating procedures are necessary to produce gene knockout / knock-in mice in the conventional method, which was usually a bottleneck to promote organism-level system biology. Therefore, we propose the concept of "next-generation mouse genetics" which creates genetically modified mice without mating and uses it for analysis. We implemented the concept by developing the triple-CRISPR method (Sunagawa et al., Cell Rep. 2016) and the ~100% ES cell-derived mice (ES mice) production method (Ode et al., Mol. Cell 2017; Ukai et al. Nat Protoc. 2017).

2) System-level identification and analysis of cellular circuits in the whole-organ and whole-body

The comprehensive identification of molecular circuits at the organism level also requires accurate (>90%) phenotype analysis. In neuroscience, sleep/wake behavior is an intriguing phenotype, because sleep disorders (e.g., insomnia or hypersomnia) are sensitive and informative symptoms

of almost all psychological disorders. Sleep/wake states have been characterized in humans by electroencephalography (EEG) and electromyography (EMG). Characteristic EEG/EMG patterns during sleep and waking are preserved in mammals and can be measured by electrodes surgically implanted in the brain and muscles. However, such recording requires special surgical skills, and the surgery is highly invasive, requiring a long recovery period (more than 10 days) after implantation before sleep/wake recording. Furthermore, the EEG/EMG data are often manually annotated and classified into sleep/wake phenotypes by visual assessment, which can be time consuming and somewhat subjective. To develop a scalable, non-invasive, fully automated sleep/wake recording method for comprehensive studies, we have developed 1) an automated EEG/EMG analysis software (FASTER) (Sunagawa et al., Genes Cell 2013), 2) a respiration-based, non-invasive, fully automated system (SSS) (Sunagawa et al., Cell Rep. 2016).

To highlight the regulatory cellular networks in the sleep/wake rhythm, we facilitate identifying sleep/wake regulating cells in the whole-brain in a comprehensive and parallelized manner. CUBIC (Clear, Unobstructed Brain/Body Imaging Cocktails and Computational Analysis) is a great leap forward. It offers a simple tissue clearing protocol by using aminoalcohols and an unprecedented rapid whole-brain and whole-body imaging at single-cell resolution (represented by Susaki et al., Cell, 2014; Tainaka et al., Cell 2014; Tainaka et al., Cell Rep. 2018; Murakami et al., Nat. Neurosci. 2018). The development of the CUBIC method has evolved into the development of microscopes for high-speed imaging (Matsumoto et al., Nat. Protoc. 2019), the extension of technology for immunostaining of three-dimensional tissues (Susaki et al., Nat. Commun. 2020), and the development of a data analysis platform for whole-brain single-cell analysis (Mano et al., Cell Rep. Methods 2021). We have also published results of the application of CUBIC to organs other than the brain through collaborative research.

3) Mechanism of dynamic homeostasis in sleep/wake cycle: phosphorylation hypothesis of sleep

Sleep amount during a day is under homeostatic

control, in which sleep pressure accumulates during awake time and gradually decreases during sleep. Sleep deprivation further promotes the accumulation of sleep pressure, resulting in the longer/deeper sleep in the next cycle. The required sleep duration in a day is mostly determined genetically as evident from the fact that each animal species shows characteristic different sleep duration. However, detailed molecular mechanisms underlying the control of sleep duration in mammals are still elusive. Using triple-target CRISPR, SSS, and CUBIC techniques together with a computational model that simulates the membrane potential of cortex neuron regulated by a group of ion channels, we have discovered and proposed that Ca^{2+} -dependent neuronal hyperpolarization pathway affects sleep duration in mammals (Sunagawa et al., Cell Reports 2016; Tatsuki et al., Neuron 2016; Yoshida et al. PNAS 2019; Yamada et al., iScience 2022).

We have further been investigating molecules that regulate the transition and consolidation of sleep and awake phases. In this regard, we have reported a phenotype of *Chrm1* and *Chrm3* double-knockout mice produced by triple-CRISPR technology, which showed a complete loss of REM sleep (Niwa et al., Cell Rep. 2018; Yamada and Ueda, Front. Neurosci. 2020). These results were the first report of essential genes of REM sleep. This study also indicated that REM sleep, defined through EEG-EMG recordings, is not critical for the survival of animals.

In the process of investigating the relationship between Ca^{2+} -dependent regulation of neuronal activity and sleep, we discovered CaMKII α/β as the first sleep-inducing protein kinase in mammals (Tatsuki et al., Neuron 2016). Since then, the relationship between protein phosphorylation and sleep regulation has been suggested by multiple genetic and biochemical findings—leading to the proposal of phosphorylation hypothesis of sleep (Ode and Ueda, Front. Psychol. 2021). Phosphorylation/dephosphorylation-mediated protein regulation represents a promising target in sleep–wake regulation because it can occur on variable dynamics and time scale from minutes to hours (Sugai et al., Cell Rep. 2017; Yamaguchi et al., iScience 2021). Furthermore, we analyzed the mouse sleep phenotype induced by comprehensive mutagenesis of CaMKII β at all

residues (serine and threonine) that can be regulated by autophosphorylation, and found that CaMKII β promotes sleep by controlling sleep "induction" and "maintenance" according to its own phosphorylation states (Tone et al., PLOS Biol. 2022; Wang et al., Front. Syst. Neurosci. 2022).

4) The development of “Human system biology” through the analysis of sleep-wake dynamics as a model platform

Do molecular mechanisms at the single amino acid residue level, such as specific protein phosphorylation, control the organism-level phenotype including human sleep-wake cycle? We will ask this question leveraging mouse genetics as a springboard to validate genotype–phenotype relationships.

We have elaborated our technology platforms for highly precise, large-scale, non-invasive measurements of sleep patterns, derived in mice, to humans. We developed a novel algorithm, ACCEL, which classifies sleep and wake with high sensitivity and specificity by using jerk of arm movement recorded by wristwatch-type accelerometers (Ode et al., iScience 2022). Using ACCEL, we estimated the sleep-wake dynamics from the arm acceleration data of 100,000 people registered in the UK biobank, and succeeded in classifying human sleep patterns into 16 types (Katori et al., PNAS 2022). Based on the ACCEL and sleep classification methods, we are working on social implementation of "sleep checkup" that will allow many people in our society to understand their own sleep status and trigger necessary changes in their own sleep behavior.

Humans provide a rich source of information on the roles of genetic and environmental factors in sleep–wake control. We hope that our research results will contribute to the understanding of sleep disorders, circadian rhythm disorders, and associated psychiatric and neurodegenerative diseases, and to the search for therapeutic strategies.

References

1. Dean B, Bakker G, Ueda HR, Tobin AB, Brown A, Kanaan RAA. A growing understanding of the role of muscarinic receptors in the molecular

- pathology and treatment of schizophrenia. *Front. Cell Neurosci.* 17, 1124333 (2023)
2. Ishii S, Chino H, Ode KL, Kurikawa Y, Ueda HR, Matsuura A, Mizushima N, Itakura E. CCPG1 recognizes ER luminal proteins for selective ER-phagy. *Mol. Biol. Cell* 34, ar29 (2023)
 3. Wang Y, Minami Y, Ode KL, Ueda HR. The role of calcium and CaMKII in sleep. *Front. Syst. Neurosci.* 16, 1059421 (2022)
 4. Tone D, Ode KL, Zhang Q, Fujishima H, Yamada RG, Nagashima Y, Matsumoto K, Wen Z, Yoshida SY, Mitani TT, Arisato Y, Ohno RI, Ukai-Tadenuma M, Yoshida Garçon J, Kaneko M, Shi S, Ukai H, Miyamichi K, Okada T, Sumiyama K, Kiyonari H, Ueda HR. Distinct phosphorylation states of mammalian CaMKII β control the induction and maintenance of sleep. *PLOS Biol.* 20, e3001813 (2022)
 5. Sakamaki JI, Ode KL, Kurikawa Y, Ueda HR, Yamamoto H, Mizushima N. Ubiquitination of phosphatidylethanolamine in organellar membranes. *Mol. Cell* 82, 3677-3692 (2022)
 6. Takahashi K, Abe K, Kubota SI, Fukatsu N, Morishita Y, Yoshimatsu Y, Hirakawa S, Kubota Y, Watabe T, Ehata S, Ueda HR, Shimamura T, Miyazono K. An analysis modality for vascular structures combining tissue-clearing technology and topological data analysis. *Nat. Commun.* 13, 5239 (2022)

Pathology, Immunology and Microbiology

1. Pathology

Department of Pathology and Diagnostic Pathology

Professor

Tetsuo Ushiku, M.D., Ph.D.

Project Professor

Takeshi Sasaki, M.D., Ph.D. (Next-Generation Pathology Information Networking)

Associate Professor

Daizo Koinuma, M.D., Ph.D. (Aug 1~)

Aya Shinozaki-Ushiku, M.D., Ph.D. (Division of Integrative Genomics)

Lecturer

Masako Ikemura, M.D., Ph.D. (Office for “Promotion of CPC Education and General Integrative Medicine”)

Mariko Tanaka (Department of Pathology, Hospital)

Hiroyuki Abe, M.D., Ph.D.

Project Lecturer

Akiko Kunita, Ph.D. (Next-Generation Precision Medicine Development Laboratory)

Research Associate

Ryohei Kuroda, M.D., Ph.D., Hirofumi Rokutan, M.D., Ph.D.,

Masaki Suzuki, Munetoshi Hinata, M.D., Ph.D.,

Noritaka Kudo (~ Jun 30) (Department of Pathology, Hospital)

Akiko Iwasaki, M.D., Ph.D., Mayu Hakozaiki, M.D., Ph.D., Atsushi Kondo, M.D., Ph.D.

Yoichi Yasunaga, M.D., Ph.D. (~Jul 31, Aug 1~ Department of Pathology, Hospital)

Technical Support Specialist

Kei Sakuma, Kimiko Takeshita, M.T.

Homepage <http://pathol.umin.ac.jp/>

Introduction and Organization

Department of Pathology and Diagnostic Pathology is responsible for the practice of diagnostic pathology, education, and research in cooperation with Department of Pathology of the University Hospital. Our aim is to perform pathology as an important part

of clinical medicine as well as to establish “next generation pathology” incorporating cutting-edge science and technology.

Dr. Yamazawa took a leave of absence on March 31, 2022, and left for the United States to engage in medical research. Drs. Kudo (Department of Pathology, Hospital) and Kondo (Department of

Pathology and Diagnostic Pathology) became research associates on Apr 1. Dr Kudo moved to Toranomon Hospital on Jul 1. Dr Koinuma joined as an associate professor on Aug 1 and Dr. Yasunaga moved to the Department of Pathology of the hospital.

Two postgraduate students (Yamamoto and Kashima) finished the course and received Ph.D. In the new fiscal year, 2023, three new students will enter the postgraduate course, and there will be 13 postgraduates.

We are responsible for the pathology practice of the University of Tokyo Hospital and are carrying forward the morphology-based research targeting human diseases. As for the education of the medical students, we take charge of the following courses: General Pathology Course for the 1st grade medical students in collaboration with Department of Molecular Pathology, Systemic Pathology for the 2nd grade, Elective Clinical Clerkship for the 4th grade, and Clinical Clerkship for the 3rd/4th grade students. Programs for postgraduates and junior residents are also included in our education activities.

"Tsunagu"- Fukushima-Kanto Pathology-Forensic Pathology Cooperation Program was planned in collaboration with Fukushima Medical University and Juntendo University, headed by Prof. Okabe, the dean of Graduate School. The program has been adopted as one of Activation Program of Basic Researcher Training of the Ministry of Education, Culture, Sports, Science and Technology. During four years between FY2018 and FY2021, 13 postgraduate students were trained to be specialized in "death investigation, remote pathology diagnosis, and genomic medicine" with the training system oriented to region support by rotating among universities. We hope the students who joined this program will be future leaders in pathology and forensic medicine. We also hold an annual seminar to recruit high school students who aim to be pathologists and forensic scientists.

Teaching activities

We provide General Pathology Course for the 1st grade of undergraduate students, especially in morphology.

Each class of Systemic Pathology Course and

exercises are held in parallel with that of Systemic Medicine Course. All the courses and exercises were conducted in person as those were before COVID-19, incorporating with the web system to access whole slide imaging. Students can look at pathology slides online, and this system works effectively in student education.

In Clinical Clerkship for all 3rd/4th grade medical students, following courses are included; autopsy pathologic practices with a case presentation by paired students, surgical pathologic practices using various tumor sections, and a tour of the pathology laboratory.

Both Clinical Clerkship course (4th grade) and Free Quarter program (1st/2nd grade) accepted several students.

We also set up the lecture series of "Infection/Immunology/Cancer II" and "Tumor Pathology. We also provided an intensive exercise course, "Integration of Neuropathology/Radiology/Clinics".

Research activities

We explore the diagnosis and pathogenesis of disease, especially focusing on gastrointestinal oncogenesis. Ongoing project includes exploration of highly aggressive type of gastric cancer with fetal phenotype (e.g. AFP-producing gastric cancer) to clarify its pathogenesis, genomic abnormalities and to find therapeutic targets (Drs. Koinuma, Shinozaki-Ushiku, Kunita, Rokutan, Kuroda, Iwasaki and Kondo). We are also working on research projects of digestive system cancers, such as cancer immune microenvironment, Epstein-Barr virus-positive gastric cancer, hereditary gastric tumors, duodenal cancer, and pancreatobiliary cancers.

Our department has pathologists with different expertise, and they are engaged in specific research projects. The research covers brain tumors and neurodegenerative disease (Drs. Ikemura and Hakozaiki), Epstein-Barr virus-associated neoplasms (Drs. Shinozaki-Ushiku, Abe and Hinata), liver and pancreatobiliary tumors (Drs. Tanaka and Yasunaga), and lung cancer (Dr. Suzuki). We also collaborate with other laboratories in and outside the University to develop new technologies such as AI, tissue clearing technique, and tissue processing robots in pathology practice (Drs. Abe and Hinata).

References

1. Abe H, Kurose Y, Takahama S, Kume A, Nishida S, Fukasawa M, Yasunaga Y, Ushiku T, Ninomiya Y, Yoshizawa A, Murao K, Sato S, Kitsuregawa M, Harada T, Kitagawa M, Fukayama M, JP-AID/NII Study Group for Gastric Biopsy Pathology. Development and multi-institutional validation of an artificial intelligence-based diagnostic system for gastric biopsy. *Cancer Science*. 2022;113(10):3608-3617.
2. Adachi Y, Ueda K, Nomura S, Ito K, Katoh M, Katagiri M, Yamada S, Hashimoto M, Zhai B, Numata G, Otani A, Hinata M, Hiraike Y, Waki H, Takeda N, Morita H, Ushiku T, Yamauchi T, Takimoto E, Komuro I. Beiging of perivascular adipose tissue regulates its inflammation and vascular remodeling. *Nat Commun*. 2022;13:5117.
3. Ishii T, Mimura I, Nagaoka K, Naito A, Sugawara T, Kuroda R, Yamada D, Kanki Y, Kume H, Ushiku T, Kakimi K, Tanaka T, Nangaku M. Effect of M2-like macrophages of the injured-kidney cortex on kidney cancer progression. *Cell Death Discovery* 2022;8:480.
4. Ito T, Kudoh S, Fujino K, Sanada M, Tenjin Y, Saito H, Nakaishi-Fukuchi Y, Kameyama H, Ichimura T, Uda N, Kudo N, Matsuo A, Sato Y. Pulmonary neuroendocrine cells and small cell lung carcinoma: immunohistochemical study focusing on mechanisms of neuroendocrine differentiation. *Acta Histochemica et Cytochemica*. 2022;3:75–83.
5. Kashima J, Hashimoto T, Yoshida A, Goto Y, Ushiku T, Ohe Y, Watanabe SI, Yatabe Y. Insulinoma-associated-1 (INSM1) expression in thymic squamous cell carcinoma. *Virchows Arch*. 2022;481(6):893-901.
6. Kato H, Tateishi K, Fujiwara H, Nakatsuka T, Yamamoto K, Kudo Y, Hayakawa Y, Nakagawa H, Tanaka Y, Ijichi H, Otsuka M, Iwadate D, Oyama H, Kanai S, Noguchi K, Suzuki T, Sato T, Hakuta R, Ishigaki K, Saito K, Saito T, Takahara N, Kishikawa T, Hamada T, Takahashi R, Miyabayashi K, Mizuno S, Kogure H, Nakai Y, Hirata Y, Toyoda A, Ichikawa K, Qu W, Morishita S, Arita J, Tanaka M, Ushiku T, Hasegawa K, Fujishiro M, Koike K. MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages. *Gastroenterology*. 2022;162(4):1272-1287.
7. Kishino Y, Matsukawa K, Matsumoto T, Miyazaki R, Wakabayashi T, Nonaka T, Kametani F, Hasegawa M, Hashimoto T, Iwatsubo T. Casein kinase 1δ/ε phosphorylates fused in sarcoma (FUS) and ameliorates FUS-mediated neurodegeneration. *J Biol Chem*. 2022;298(8):102191.
8. Ko T, Nomura S, Yamada S, Fujita K, Fujita T, Satoh M, Oka C, Katoh M, Ito M, Katagiri M, Sassa T, Zhang B, Hatsuse S, Yamada T, Harada M, Toko H, Amiya E, Hatano M, Kinoshita O, Nawata K, Abe H, Ushiku T, Ono M, Ikeuchi M, Morita H, Aburatani H, Komuro I. Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF-β-IGFBP7 axis. *Nat Commun*. 2022;13:3275.
9. Kume A, Shinozaki-Ushiku A, Kunita A, Kondo A, Ushiku T. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization. *Am J Surg Pathol*. 2022;46(10):1386-1396.
10. Liu B, Katoh H, Komura D, Yamamoto A, Ochi M, Onoyama T, Abe H, Ushiku T, Seto Y, Suo J, Ishikawa S. Functional genomics screening identifies aspartyl-tRNA synthetase as a novel prognostic marker and a therapeutic target for gastric cancers. *J Pathol*. 2022;258(2):106-120.
11. Liu PY*, Fukuma N*, Hiroi Y*, Kunita A*, Tokiwa H*, Ueda K, Kariya T, Numata G, Adachi Y, Tajima M, Toyoda M, Li Y, Noma K, Harada M, Toko H, Ushiku T, Kanai Y, Takimoto E, Liao JK, Komuro I(*; equal contributor). Tie2-Cre-Induced Inactivation of Non-Nuclear Estrogen Receptor-α Signaling Abrogates Estrogen Protection Against Vascular Injury. *JACC: Basic to Translational Science*. 2022;8(1):55-67.

12. Miyashita H, Taoka K, Kume A, Ushiku A, Ushiku T, Toyama K, Kurokawa M. Clinical usefulness of a novel classification of T cell distribution patterns in the tumor micro-environment of follicular lymphoma to detect transformation. *Ann Hematol.* 2022;101(11): 2477-2483.
13. Naito Y, Notohara K, Omori Y, Aishima S, Itoi T, Ohike N, Okabe Y, Kojima M, Tajiri T, Tanaka M, Tsuneki M, Nakagohri T, Norose T, Hirabayashi K, Fukumura Y, Mitsunashi T, Yamaguchi H, Fukushima N, Furukawa T. Diagnostic Categories and Key Features for Pathological Diagnosis of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy Samples of Pancreatic Lesions: A Consensus Study. *Pancreas.* 2022;51(9):1105-1111.
14. Saito N, Sato Y, Abe H, Wada I, Kobayashi Y, Nagaoka K, Kushihara Y, Ushiku T, Seto Y, Kakimi K. Selection of RNA-based evaluation methods for tumor microenvironment by comparing with histochemical and flow cytometric analyses in gastric cancer. *Sci Rep.* 2022;12:8576.
15. Takahashi K, Podyma-Inoue KA, Saito M, Sakakitani S, Sugauchi A, Iida K, Iwabuchi S, Koinuma D, Kurioka K, Konishi T, Tanaka S, Kaida A, Miura M, Hashimoto S, Okada M, Uchihashi T, Miyazono K, Watabe T. TGF- β generates a population of cancer cells residing in G1 phase with high motility and metastatic potential via keratin-associated protein 2-3. *Cell Reports.* 2022;40:111411.
16. Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, Abe J, Arita J, Hasegawa K, Shibata T, Ushiku T. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression. *Liver Int.* 2022; 42(10):2329-2340.
17. Yamazawa S, Ushiku T. Carcinosarcoma of the stomach: four cases that expand the morphologic spectrum of gastric cancer with a primitive phenotype. *Virchows Arch.* 2022;480(5):1051-1062.

Department of Molecular Pathology

Professor

Yasuhiro Yamada, M.D., Ph.D.

Assistant professors

Sho Ohta, Ph.D., Nao Sankoda, M.D., Ph.D.

Homepage http://molpathology2.m.u-tokyo.ac.jp/home_E/index.html

Introduction and Organization

The Department of Molecular Pathology has a history of more than 120 years, originating from the Second Department of Pathology, of which the first professor was Dr Katsusaburo Yamagiwa, who succeeded in inducing artificial cancer by applying coal tar to rabbit ears. In November 2022, Yasuhiro Yamada was transferred from the Institute of Medical Science, University of Tokyo, to succeed Professor Kohei Miyazono, who retired in March 2022. The department has been conducting basic research on cancer at the organismal level as well as research on tissue regeneration and aging. As of the end of March 2023, the department comprised one professor and two assistant professors, in addition to two researchers, ten postgraduate students and two technical experts.

Teaching activities

Our department takes responsibility for lectures on “General Pathology” for undergraduate students of the Faculty of Medicine in collaboration with the Department of Human Pathology. Since we believe it is very important for medical students to study basic oncology, we teach basic tumor biology in our lectures on General Pathology. Given that the function of oncogenes and cancer-suppressor genes, the mechanism of viral carcinogenesis, cancer epidemiology, cancer genetics, the mechanism of cancer invasion and metastasis as well as cancer epigenetics are important issues in cancer biology, we

give intensive lectures on these topics. Practical training included experiments on immunostaining of tumor tissue. During systematic lectures on oncology, we hope that undergraduate students will get an overview of cancer biology. We also supervise the research activities of the graduate students of the department.

Our laboratory is located on the 11th floor of the Research Building of the Graduate School of Medicine. The Department of Molecular Pathology holds weekly progress meetings in the department and a weekly journal club to provide research guidance to students.

Research activities

Epigenetic regulation plays a critical role in cell fate specification during normal development and stable maintenance of somatic cell fate. Impairment in epigenetic regulation is often associated with various diseases such as cancer. Recent studies also imply that altered epigenetic regulation is involved in cells of aged organisms. Together, maintaining proper epigenetic regulation is crucial for the healthy life of organisms.

The development of reprogramming technologies, as represented by iPS cell derivation, has enabled to control of somatic cell fate. The reprogramming process involves dynamic changes in epigenetic modifications. Taking advantage of reprogramming technology, we have devised reprogrammable mouse

models in which epigenetic regulation and eventually cell fate can be altered *in vivo*. By inducing perturbation of epigenetic regulation and a cellular identity at the organismal level, we aim to elucidate the impact of epigenetic regulation on pathogenesis and aging. Finally, we aim to develop a means for disease treatment, tissue regeneration, and rejuvenation through epigenetic regulation with reprogramming technologies.

Our effort should promote interdisciplinary research that connects a wide range of research fields, which eventually contributes to the development of novel strategies to control the detrimental effects of diseases and aging in humans.

From 2017, our research has been supported by a CREST program “Clarification of the Mechanism of Individual’s Functional Impairment over the Entire Life Course” from Japan Agency for Medical Research and Development (AMED) (22gm1110004h9906). From 2022, our research is also supported by a Project for Promotion of Cancer Research and Therapeutic Evolution (P-PROMOTE) (22ama221201h0001) and by a Research Center Network for Realization of Regenerative Medicine (22bm1223002h0001), both from AMED.

Followings are research projects conducted at our laboratory in 2022.

1) Dissecting cancer biology with reprogramming technology

Epigenetic regulation plays a critical role in the cellular differentiation, the stable maintenance of cellular identity, and the reprogramming process. Accumulating evidence suggests that epigenetic abnormalities represented by abnormal DNA methylation have been involved in various diseases. We are interested in unveiling epigenetic regulation in cellular differentiation, the maintenance of cellular identity, and the pathogenesis including cancer. Taking advantage of reprogramming technology, we have devised reprogrammable mouse models in which epigenetic regulation and eventually cell fate can be altered *in vivo*. By analyzing *in vivo* reprogramming process, we aim to uncover the epigenetic regulation in

cancer development, cancer cell maintenance, and progression. Finally, we will try to develop a novel approach targeting epigenetic regulation to treat cancer patients.

2) *In vivo* reprogramming for tissue regeneration and rejuvenation

We have devised *in vivo* reprogramming systems (Reprogrammable Mouse) in which iPS cells can be induced in living mice. Recent analyses of Reprogrammable Mice have revealed unappreciated mechanisms regarding senescence, tissue regeneration, and rejuvenation. By analyzing the response to cell fate perturbations at the organismal level, we aim to clarify the molecular basis of aging and tissue regeneration. Furthermore, we apply these reprogramming systems to develop innovative strategies for tissue regeneration and rejuvenation.

3) Expansion of mature islet cells as a regenerative strategy targeting diabetes

We showed that a MYCL-mediated reprogramming expands functional islet cells. We aim to apply these methods to islet transplantation therapy through amplification of cadaveric islet cells *in vitro*. We also try to induce the proliferation of mature islet cells *in vivo* by gene therapy. The goal of our study is to develop regenerative medicine and restore the function of aging pancreatic islets using reprogramming technology.

References

- 1 Hirano M, So Y, Tsunekawa S, Kabata M, Ohta S, Sagara H, Sankoda N, Taguchi J, Yamada Y, Ukai T, Kato M, Nakamura J, Ozawa M, Yamamoto T and Yamada Y. MYCL-mediated reprogramming expands pancreatic insulin-producing cells. *Nature Metabolism* 2022 doi:10.1038/s42255-022-00530-y
- 2 Ito K, Nagata K, Ohta S, Matsuda Y, Ukai T, Yasuda I, Ota A, Kobayashi R, Kabata M, Sankoda N, Maeda T, Woltjen K, Yang L, Maruyama R, Katayama R, Yamamoto T and Yamada Y. The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets. *Cell Reports* 2022 doi:10.1016/j.celrep.2022.110721

- 3 Shimada-Takayama Y, Yasuda T, Ukai T, Taguchi J, Ozawa M, Sankoda N, Ohta S and Yamada Y
Generation of mice for evaluating endogenous p16Ink4a protein expression. *Biochem. Biophys. Res. Commun.* 2022 9;599:43-50 doi:10.1016/j.bbrc.2022.02.005
- 4 Oka K, Fujioka S, Kawamura Y, Komohara Y, Chujo T, Sekiguchi K, Yamamura Y, Oiwa Y, Omamiuda-Ishikawa N, Komaki S, Sutoh Y, Sakurai S, Tomizawa K, Bono H, Shimizu A, Araki K, Yamamoto T, Yamada Y, Oshiumi H and Miura K. Resistance to chemical carcinogenesis induction via a dampened inflammatory response in naked mole-rats. *Commun. Biol.* 2022 5(1):287. doi:10.1038/s42003-022-03241-y.

Pathology, Immunology and Microbiology

2. Microbiology

Department of Microbiology

Professor

Makoto Takeda, M.D.,Ph.D.

Associate Professor

Hiroshi Katoh, Ph.D.

Associate

Yukiko Akahori, Ph.D

Homepage [http:// microbiology.labby.jp](http://microbiology.labby.jp)

Introduction and Organization

Following the retirement of Professor Masanori Hatakeyama, who served as department head until March 2022, Professor Makoto Takeda assumed the position in September 2022. Currently, one professor (Takeda), one associate professor (Katoh), and one assistant professor (Akahori) are engaged in research and educational activities.

Teaching activities

In a series of lectures (totally 64 hr) and laboratory courses (36 hr), the following subjects are covered.

- 1) Molecular biology of bacteria, phages, and animal viruses
- 2) Mechanisms of microbial diseases
- 3) Laboratory diagnosis of pathogenic microbes
- 4) Infection control and biosafety
- 5) Application of microbial organisms for bio-technology
- 6) Socioeconomic impact of microbial diseases

Research activities

Our laboratory mainly studies respiratory RNA viruses, such as paramyxoviruses, coronaviruses, and influenza viruses. Our goal is to contribute to society by elucidating molecular mechanisms of diseases caused by these viruses. We also aim to contribute to modern medicine by developing new technologies for recombinant viruses. In our research on the

mechanisms of paramyxovirus replication and pathogenesis, we search for host factors required for paramyxoviruses such as measles virus and mumps virus to multiply in cells and study the pathogenic mechanisms by clarifying their interactions with viral proteins. In the study of the activation mechanism of respiratory viruses by host proteases, we have revealed that membrane fusion proteins of various respiratory viruses, including the novel coronavirus SARS-CoV-2, are activated by a protease called TMPRSS2 in the host cell. In addition, we have been researching the development of viral vectors and their application to vaccine development, making full use of the paramyxovirus gene manipulation technology we have studied over the years.

Role of host protease TMPRSS2 in novel coronavirus SARS-CoV-2 infection

In cultured cells, SARS-CoV-2 infects cells by multiple pathways using different host proteases. We have shown that the infection pathway using furin and TMPRSS2 (early entry pathway) is particularly important for SARS-CoV-2 infection. However, recent studies have reported that the early entry pathway is not essential for the infection of the Omicron variant, which has recently become a significant epidemic strain, and that the cathepsin-dependent pathway in endosomes (late entry pathway) is the primary route. Our study also confirmed that the Omicron variant in cultured cells is mainly infected using the late entry

pathway. However, in the airways of TMPRSS2 knockout mice, Omicron variant infection was also severely restricted, as was the case with other variant strains and the Wuhan strain in the early stages of the epidemic. Thus, *in vivo*, transmission of the Omicron variant was confirmed to utilize the TMPRSS2-dependent early entry pathway. In conclusion, the early entry pathway using TMPRSS2 was shown to be critically important for the infection of SARS-CoV-2, including the Omicron variant.

Demonstration of bacterium-free very rapid reverse genetics system using mumps virus

Mononegaviruses (non-segmented negative-stranded RNA viruses) include many medically important viruses such as measles virus, mumps virus, and RS virus. In the study of mononegaviruses, genetic engineering techniques for producing recombinant viruses are essential, however, in conventional methods, the full-length genome of the virus must be introduced into a plasmid and amplified in *E. coli*, which is time-consuming and introduces mutations in *E. coli*. Thus, we attempted to develop an *E. coli*-free full-length genome construction of mumps virus, as an example of mononegaviruses.

We succeeded in constructing a full-length genome by linking and amplifying the mumps virus genome, which was divided into four fragments, by PCR or the OriCiro Cell-Free Cloning System. The full-length viral genomic DNA was transfected into BHK cells expressing T7 polymerase together with helper plasmids, and then the cells were co-cultured with Vero cells. Importantly, the virus was rescued in a shorter time with this method than with the conventional plasmid-based method. Our newly developed rapid genome construction method without using *E. coli* is useful for genetic manipulation of mononegaviruses.

SNARE protein USE1 is involved in the glycosylation and the expression of mumps virus fusion protein and important for viral propagation

We searched for host factors involved in the propagation of mumps virus, which is a causative agent of mumps, using a proximity-labeling method. The biotin ligase TurboID was split into N-terminal and C-terminal domains and introduced into the cytoplasmic regions of two membrane proteins (F and HN proteins,

respectively) of mumps virus. The two membrane proteins were co-expressed in cells and biotin was added. The resulting biotinylated proteins were purified with streptavidin and identified by mass spectrometry, resulting in the identification of 638 proteins as host factors localized close to the cytoplasmic regions of F and HN proteins. Gene ontology and interactome analyses showed that the factors categorized in "Vesicle transport" formed the largest cluster. Next, 26 proteins were selected from the factors classified as "Vesicle transport" based on the results of mass spectrometry analysis, and siRNA targeting for each factor was transfected into A549 cells. Forty-eight hours after transfection, the cells were infected with the AcGFP-expressing mumps virus, and the effect on viral growth was examined using the brightness of AcGFP. The results showed that the knockdown of 6 out of 26 factors significantly suppressed viral growth. Among them, we focused on USE1, a SNARE subfamily protein that interacts with F proteins in the ER, and analyzed its role in mumps virus infection. The results of the fusion assay and endoglycosidase assay indicated that USE1 is a host factor that contributes to the stability and glycosylation of F protein by regulating the transport of F protein between ER and Golgi.

References

1. Bae C, Katoh H, Wakata A, Sakata M, Kato F, Takeda M: Demonstration of bacterium-free very rapid reverse genetics system using mumps virus. *Microbiol Immunol* 67:44-47, 2023.
2. Takashita E, Fujisaki S, Morita H, Nagata S, Miura H, Nagashima M, Watanabe S, Takeda M, Kawaoka Y, Hasegawa H: Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors. *Antiviral Res* 216:105671, 2023.
3. Ono T, Hashimoto K, Kume Y, Chishiki M, Okabe H, Sato M, Norito S, Aso J, Sada M, Mochizuki I, Mashiyama F, Ishibashi N, Suzuki S, Sakuma H, Suwa R, Kawase M, Takeda M, Shirato K, Kimura H, Hosoya M: Molecular Diversity of Human Respiratory Syncytial Virus before and during the COVID-19 Pandemic in Two Neighboring

- Japanese Cities. *Microbiol Spectr* 11:e0260622, 2023.
4. Takahashi T, Akagawa M, Kimura R, Sada M, Shirai T, Okayama K, Hayashi Y, Kondo M, Takeda M, Ryo A, Kimura H: Molecular evolutionary analyses of the fusion protein gene in human respirovirus 1. *Virus Res* 333:199142, 2023.
 5. Miyano S, Vynnycky E, Pattamavone C, Ichimura Y, Mori Y, Nouanthong P, Phounphenghack K, Tengbriacheu C, Khamphaphongphane B, Franzel L, Yang TU, Raaijmakers H, Komada K, Ota T, Funato M, Takeda M, Hachiya M: Comparison of population-based measles-rubella immunoglobulin G antibody prevalence between 2014 and 2019 in Lao People's Democratic Republic: Impacts of the national immunization program. *Int J Infect Dis* 129:70-77, 2023.
 6. Okura T, Tahara M, Otsuki N, Sato M, Takeuchi K, Takeda M: Generation of a photocontrollable recombinant bovine parainfluenza virus type 3. *Microbiol Immunol* 67:204-209, 2023.
 7. Kidokoro M, Shiino T, Yamaguchi T, Nariai E, Kodama H, Nakata K, Sano T, Gotou K, Kisu T, Maruyama T, Kuba Y, Sakata W, Higashi T, Kiyota N, Sakai T, Yahiro S, Nagita A, Watanabe K, Hirokawa C, Hamabata H, Fujii Y, Yamamoto M, Yokoi H, Sakamoto M, Saito H, Shibata C, Inada M, Fujitani M, Minagawa H, Ito M, Shima A, Murano K, Katoh H, Kato F, Takeda M, Suga S; Surveillance Team for Mumps Virus in Japan: Nationwide and long-term molecular epidemiologic studies of mumps viruses that circulated in Japan between 1986 and 2017. *Front Microbiol* 13:728831, 2022.
 8. Iwata-Yoshikawa N, Kakizaki M, Shiwa-Sudo N, Okura T, Tahara M, Fukushi S, Maeda K, Kawase M, Asanuma H, Tomita Y, Takayama I, Matsuyama S, Shirato K, Suzuki T, Nagata N, Takeda M: Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways. *Nat Commun* 13:6100, 2022.
 9. Seki F, Takeda M: Novel and classical morbilliviruses: Current knowledge of three divergent morbillivirus groups. *Microbiol Immunol* 66:552-563, 2022.
 10. Wakata A, Katoh H, Kato F, Takeda M: Nucleolar protein Treacle is important for the efficient growth of mumps virus. *J Virol* 96:e0072222. doi: 10.1128/jvi.00722-22.
 11. Liu Y, Katoh H, Sekizuka T, Bae C, Wakata A, Kato F, Sakata M, Yamaji T, Wang Z, Takeda M: SNARE protein USE1 is involved in the glycosylation and the expression of mumps virus fusion protein and important for viral propagation. *PLoS Pathog* 18:e1010949, 2022.
 12. Mori Y, Sakata M, Sakai S, Okamoto T, Nakatsu Y, Tagawa S, Otsuki N, Maeda Y, Hanada K, Matsuura Y, Takeda M: Membrane sphingomyelin in host cells is essential for nucleocapsid penetration into the cytoplasm after hemifusion during rubella virus entry. *mBio* 13:e0169822.
 13. Shirato K, Matsuyama S, Takeda M: Less frequent sequence mismatches in variants of concern (VOCs) of SARS-CoV-2 in the real-time RT-PCR assays developed by the National Institute of Infectious Diseases, Japan. *Jpn J Infect Dis* 75:96-101, 2022.
 14. Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, Ito M, Uraki R, Halfmann P, Watanabe S, Takeda M, Hasegawa H, Imai M, Kawaoka Y: Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75. *N Engl J Med* 387:1236-1238.
 15. Takashita E, Inoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y: Efficacy of antiviral agents against the SARS-CoV-2 Omicron BA.2 variant. *N Engl J Med* 386:1475-1477, 2022.
 16. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y: Efficacy of antibodies and antivirals against a SARS-CoV-2 omicron variant. *N Engl J Med* 386:995-998, 2022.
 17. Kitai Y, Sato K, Shirato K, Ohmiya S, Watanabe O, Kisu T, Ota R, Takeda M, Kawakami K, Nishimura H: Variation in thermal stability among respiratory syncytial virus clinical isolates under non-freezing conditions. *Viruses* 14:679, 2022.
 18. Shirato K, Kakizaki M, Tomita Y, Kawase M, Takeda M: Detection of the ORF1 gene is an

indicator of the possible isolation of severe acute respiratory syndrome coronavirus-2. *Pathogens* 11:302, 2022.

19. Saso W, Yamasaki M, Nakakita S, Fukushi S, Tsuchimoto K, Watanabe N, Sriwilaijaroen N, Kanie O, Muramatsu M, Takahashi Y, Matano T, Takeda M, Suzuki Y, Watashi K: Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2. *PLOS Pathog* 18:e1010590, 2022.
20. Kanai M, Kamiya H, Okuno H, Sunagawa T, Tanaka-Taya K, Matsui T, Oishi K, Kitajima H, Takeda M, Mori Y: Epidemiology of congenital rubella syndrome related to the 2012-2013 rubella epidemic in Japan. *J Pediatric Infect Dis Soc.* 29:400-403, 2022.
21. Okura T, Shirato K, Kakizaki M, Sugimoto S, Matsuyama S, Tanaka T, Kume Y, Chishiki M, Ono T, Moriishi K, Sonoyama M, Hosoya M, Hashimoto K, Maenaka K, Takeda M: Hydrophobic alpha-helical short peptides in overlapping reading frames of the coronavirus genome. *Pathogens* 11:877, 2022.

Department of Infection Control and Prevention

Professor

Takeya Tsutsumi, M.D., Ph.D.

Lecturer

Sohei Harada, M.D., Ph.D.

Project Lecturer

Nobuhiko Satoh, M.D., Ph.D.

Kazuya Okushin, M.D., Ph.D.

Research Associate

Mayo Tsuboi, M.D., Ph.D.

Daisuke Ohki, M.D., Ph.D.

Ryu Yoneda, M.D., Ph.D.

Homepage <http://square.umin.ac.jp/ut-ict/>

Introduction and Organization

The Department of Infection Control and Prevention started at first as the Division of Hospital Infection Control Services on January 23, 1991. This division developed into the Division of Infection Control and Prevention on September 1, 1993 and the present department on June 4, 1994. Currently, our faculty consists of one professor, one lecturer, five research associates, 12 laboratory technicians, and two office assistants. For isolation and identification of microorganisms from clinical specimens, we amalgamated the microbiology unit from the Department of Clinical Laboratory in 2001.

Clinical activities

Our daily activities are as follows:

- 1) Surveillance and control of hospital-acquired infection, such as infection or colonization of methicillin-resistant *Staphylococcus aureus* and other drug-resistant microbes.

- 2) Investigation of trends in weekly bases and monthly reports to all departments; Screening of colonization; monitoring of appropriate use of antibiotics.
- 3) Microbiological investigation of wards and environment.
- 4) Detection, investigation, intervention and control of the hospital infection outbreak.
- 5) Offering of information and advice on HIV-infected patients' management.
- 6) Direct inquiries and advises on management of patients with various infections through ward rounds every week.

Education

We have been charged for education of undergraduate students on the course of medicine (lectures and practical exercises on the infection control for the 4th grade students). These lectures and exercises contain subjects not only on the hospital infection but also on clinical microbiology. We are also engaged in the

education of graduate students as well as hospital staff.

For postgraduate education, we have been committed to the guidance for new postgraduates and residents on the hospital and occupational infection control. We have been also offering our information and technique on occasions of request.

Research activities

We have been mainly studying on following subjects: Several studies are now going with the members of department of pharmacy and of surgery.

- 1) Development of preemptive strategies for the control of healthcare-associated infection
- 2) Development of new methods in infection control and treatment of viral hepatitis
- 3) Mechanisms and molecular epidemiology of multi-drug resistant microorganisms
- 4) Clinical characteristics and molecular epidemiology of hypervirulent *Klebsiella pneumoniae* infection
- 5) Prevention and therapy for COVID-19
- 6) Epidemiology of *Clostridioides difficile* infection
- 7) Molecular epidemiological analysis of MRSA
- 8) Prevention of endoscope-related infection
- 9) Usefulness of environmental monitoring

Publications

1. Takashita E, Yamayoshi S, Halfmann P, Wilson N, Ries H, Richardson A, Bobholz M, Vuyk W, Maddox R, Baker DA, Friedrich TC, O'Connor DH, Uraki R, Ito M, Sakai-Tagawa Y, Adachi E, Saito M, Koga M, Tsutsumi T, Iwatsuki-Horimoto K, Kiso M, Yotsuyanagi H, Watanabe S, Hasegawa H, Imai M, Kawaoka Y. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6. *N Engl J Med.* 2022;387:2094.
2. Adachi E, Saito M, Koga M, Tsutsumi T, Yotsuyanagi H. Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS. *Intern Med.* 2022;61:3459
3. Yamaoka Y, Sasai M, Suehiro Y, Hashimoto S, Goto A, Yamamoto N, Suzuki N, Higaki S, Fujii I, Suzuki C, Matsumoto T, Hoshida T, Koga M, Tsutsumi T, Lim LA, Matsubara Y, Tomochika S, Yoshida S, Hazama S, Yotsuyanagi H, Nagano H, Sakaida I, Takami T, Yamasaki T. Comparison of two primer-probe sets of *Fusobacterium nucleatum* using droplet digital polymerase chain reaction for the detection of colorectal neoplasia from faecal samples. *Ann Clin Biochem.* 2022;59:396.
4. Nagai H, Saito M, Adachi E, Sakai-Tagawa Y, Yamayoshi S, Kiso M, Kawamata T, Koga M, Kawaoka Y, Tsutsumi T, Yotsuyanagi H. Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy. *Jpn J Infect Dis.* 2022;75:608.
5. Mizutani T, Ishizaka A, Koga M, Tsutsumi T, Yotsuyanagi H. Role of Microbiota in Viral Infections and Pathological Progression. *Viruses.* 2022;14:950.
6. Halfmann PJ, Kuroda M, Armbrust T, Theiler J, Balaram A, Moreno GK, Accola MA, Iwatsuki-Horimoto K, Valdez R, Stoneman E, Braun K, Yamayoshi S, Somsen E, Baczenas JJ, Mitamura K, Hagihara M, Adachi E, Koga M, McLaughlin M, Rehauer W, Imai M, Yamamoto S, Tsutsumi T, Saito M, Friedrich TC, O'Connor SL, O'Connor DH, Gordon A, Korber B, Kawaoka Y. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. *Sci Transl Med.* 2022;14:eabm4908.
7. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. *Nature.* 2022;607:119.
8. Adachi E, Nagai E, Saito M, Isobe M, Konuma T,

- Koga M, Tsutsumi T, Nannya Y, Yotsuyanagi H. Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. *J Infect Chemother*. 2022;28:1015.
9. Mizutani T, Ishizaka A, Koga M, Ikeuchi K, Saito M, Adachi E, Yamayoshi S, Iwatsuki-Horimoto K, Yasuhara A, Kiyono H, Matano T, Suzuki Y, Tsutsumi T, Kawaoka Y, Yotsuyanagi H. Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization. *Microbiol Spectr*. 2022;10:e0168921.
10. Adachi E, Saito M, Nagai H, Ikeuchi K, Koga M, Tsutsumi T, Yotsuyanagi H. Transient depletion of T cells during COVID-19 and seasonal influenza in people living with HIV. *J Med Virol*. 2022;94:1789
11. Koga M, Senkoji T, Kubota M, Ishizaka A, Mizutani T, Sedohara A, Ikeuchi K, Kikuchi T, Adachi E, Saito M, Koibuchi T, Hosomichi K, Ohashi J, Kawana- Tachikawa A, Matano T, Tsutsumi T (corresponding author), Yotsuyanagi H. Predictors associated with a better response to the Japanese aluminum-free hepatitis A vaccine, Aimugen®, for people living with HIV. *Hepatol Res*. 2022;52:227
12. Ikeuchi K, Okushin K, Saito M, Adachi E, Tsutsumi T, Takura T, Yotsuyanagi H. Prevalence of HIV infection among non-elderly individuals with hepatitis C in Japan: a population-based cohort study using a health insurance claim data. *BMC Infect Dis*. 2022;22:167.
13. Sekiba K, Otsuka M, Funato K, Miyakawa Y, Tanaka E, Seimiya T, Yamagami M, Tsutsumi T, Okushin K, Miyakawa K, Ryo A, Koike K. HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA. *J Hepatol*. 2022;76:53.
14. Yamaguchi R, Okamoto K, Yamamoto T, Harada S, Tanaka T, Suzuki H, Moriya K. Impact of targeted intervention using a collaborative approach for oral third-generation cephalosporins: An interrupted time-series analysis. *Antimicrob Steward Healthc Epidemiol*. 2022;2:e115.
15. Kurano M, Jubishi D, Okamoto K, Hashimoto H, Sakai E, Morita Y, Saigusa D, Kano K, Aoki J, Harada S, Okugawa S, Doi K, Moriya K, Yatomi Y. Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries. *J Biomed Sci*. 2022;29:94.
16. Kurano M, Okamoto K, Jubishi D, Hashimoto H, Sakai E, Saigusa D, Kano K, Aoki J, Harada S, Okugawa S, Doi K, Moriya K, Yatomi Y. Dynamic modulations of sphingolipids and glycerophospholipids in COVID-19. *Clin Transl Med*. 2022;12:e1069.
17. Ohama Y, Nomura Y, Mizoguchi M, Higurashi Y, Okamoto K, Harada S. Accurate Identification of *Klebsiella variicola* by MALDI-TOF Mass Spectrometry in Clinical Microbiology Laboratories. *Microbiol Spectr*. 2022;10:e0284422.
18. Hoashi K, Hayama B, Suzuki M, Sakurai A, Takehana K, Enokida T, Takeda K, Ohkushi D, Doi Y, Harada S. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β -Lactamase-Producing *Escherichia coli* in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis. *Microbiol Spectr*. 2022 31; 10:e0220622.
19. Jubishi D, Okamoto K, Hamada K, Ishii T, Hashimoto H, Shinohara T, Yamashita M, Wakimoto Y, Otani A, Hisasue N, Ikeda M, Harada S, Okugawa S, Moriya K, Yanagimoto S. The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study. *Hum Vaccin Immunother*. 2022 30;18:2048559.
20. Jin C, Wakimoto Y, Ikeda M, Ohama Y, Ri M, Yamashita H, Ohtani A, Yamashita M, Shinohara T, Jubishi D, Kanno Y, Okamoto K, Higurashi Y, Harada S, Okugawa S, Seto Y, Moriya K. Human abdominal abscess caused by *Necropsobacter rosorum* and tips for its identification: A case report. *J Infect Chemother*. 2022;28:833.

21. Morita Y, Kurano M, Jubishi D, Ikeda M, Okamoto K, Tanaka M, Harada S, Okugawa S, Moriya K, Yatomi Y. Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries. *Int J Infect Dis.* 2022;117:302.
22. Hoshi K, Ikebe T, Ota Y, Kishimoto H, Kurata T, Kurita H, Sakamaki K, Takenobu T, Harada S, Ogasawara T, Tei K, Kirita T. Guide for surgical procedures in oral and maxillofacial areas during coronavirus disease 2019 pandemic. *J Oral Maxillofac Surg Med Pathol.* 2022;34:294
23. Nakamura M, Satoh N, Horita S, Nangaku M. Insulin-induced mTOR signaling and gluconeogenesis in renal proximal tubules: A mini-review of current evidence and therapeutic potential. *Front Pharmacol.* 2022;13:1015204.
24. Mizuno T, Satoh N, Horita S, Tsukada H, Takagi M, Sato Y, Kume H, Nangaku M, Nakamura M. Oxidized alkyl phospholipids stimulate sodium transport in proximal tubules via a nongenomic PPAR γ -dependent pathway. *J Biol Chem.* 2022; 298:101681.
25. Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, Miyata H, Izumi N, Kudo M, Koike K. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). *J Gastroenterol.* 2022;57:587.
26. Saito K, Shimamoto T, Takahashi Y, Okushin K, Takahashi M, Masuda Y, Nishikawa T, Kakushima N, Wada R, Yamamichi N. Gender-specific factors contributing to visceral obesity including the sleep-obesity relationship: a large-scale cross-sectional study from East Asia. *Sci Rep.* 2022;12:20318.
27. Yamamichi N, Shimamoto T, Okushin K, Nishikawa T, Matsuzaki H, Yakabi S, Takahashi M, Wada R, Koike K, Fujishiro M. Fibrosis-4 index efficiently predicts chronic hepatitis and liver cirrhosis development based on a large-scale data of general population in Japan. *Sci Rep.* 2022;12:20357.
28. Kawamura S, Matsushita Y, Kurosaki S, Tange M, Fujiwara N, Hayata Y, Hayakawa Y, Suzuki N, Hata M, Tsuboi M, Kishikawa T, Kinoshita H, Nakatsuka T, Sato M, Kudo Y, Hoshida Y, Umemura A, Eguchi A, Ikenoue T, Hirata Y, Uesugi M, Tateishi R, Tateishi K, Fujishiro M, Koike K, Nakagawa H. Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. *J Clin Invest.* 2022;132:e151895.
29. Ohki D, Tsuji Y, Shinozaki T, Sakaguchi Y, Mizutani H, Nagao S, Miura Y, Fukagawa K, Tamura N, Yakabi S, Yamamichi N, Fujishiro M. Long-term prognosis after endoscopic resection of T1a-MM/T1b-SM1 esophageal squamous cell carcinoma. *Medicine.* 2022;101:e32115.
30. Hisada H, Tsuji Y, Obata M, Cho R, Nagao S, Miura Y, Mizutani H, Ohki D, Yakabi S, Takahashi Y, Sakaguchi Y, Kakushima N, Yamamichi N, Fujishiro M. The impact of sarcopenia on short- and long-term outcomes of endoscopic submucosal dissection for early gastric cancer. *J Gastroenterol.* 2022;57:952.
31. Kubota D, Takahashi Y, Yamamichi N, Matsui M, Shimamoto T, Minatsuki C, Nakagawa H, Mizutani S, Tsuji Y, Sakaguchi Y, Tamura N, Yakabi S, Ohki D, Mizutani H, Niimi K, Wada R, Fujishiro M. Analysis of Barrett's Esophagus and Its Risk Factors: A Cross-Sectional Study of 10,122 Subjects at a Japanese Health Examination Center. *Digestion.* 2022;103:411.
32. Ohki D, Tsuji Y, Tanaka M, Ushiku T, Fujishiro M. A case of a tiny neuroendocrine carcinoma in a large flat-elevated rectal tumor causing multiple liver metastases. *Clin J Gastroenterol.* 2022;15: 1078.
33. Ohki D, Tsuji Y, Cho R, Obata M, Mizutani H, Sakaguchi Y, Fujishiro M. Management of intraoperative giant perforation of colorectal endoscopic submucosal dissection. *Endoscopy.* 2022;54(S 02):E995.
34. Hisada H, Sakaguchi Y, Oshio K, Mizutani S, Nakagawa H, Sato J, Kubota D, Obata M, Cho R, Nagao S, Miura Y, Mizutani H, Ohki D, Yakabi S, Takahashi Y, Kakushima N, Tsuji Y, Yamamichi N, Fujishiro M. Endoscopic

Treatment of Superficial Gastric Cancer: Present Status and Future. *Curr Oncol.* 2022;29:4678.

35. Tamura N, Sakaguchi Y, Furutani W, Matsui M, Nagao S, Sakuma N, Fukagawa K, Miura Y, Mizutani H, Ohki D, Kataoka Y, Saito I, Ono M, Minatsuki C, Tsuji Y, Ono S, Kodashima S, Abe H, Ushiku T, Yamamichi N, Koike K, Fujishiro M. Magnifying endoscopy with narrow-band imaging is useful in differentiating gastric cancer from matched adenoma in white light imaging. *Sci Rep.* 2022;12:8349.
36. Ohki D, Yamamichi N, Sakaguchi Y, Takahashi Y, Kageyama-Yahara N, Yamamichi M, Takeuchi C, Tsuji Y, Sakai Y, Sakurai K, Tomida S, Koike K, Fujishiro M. Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2. *Cancer Med.* 2022;11:5066.
37. Hisada H, Tamura N, Tsuji Y, Nagao S, Fukagawa K, Miura Y, Mizutani H, Ohki D, Yakabi S, Minatsuki C, Takahashi Y, Sakaguchi Y, Yamamichi N, Fujishiro M. The impact of sarcopenia on adverse events associated with gastric endoscopic submucosal dissection. *Surg Endosc.* 2022;36:6387.
38. Fujimoto A, Saito Y, Abe S, Hoteya S, Nomura K, Yasuda H, Matsuo Y, Uraoka T, Kuribayashi S, Tsuji Y, Ohki D, Maehata T, Kato M, Yahagi N. Clinical usefulness of red dichromatic imaging in hemostatic treatment during endoscopic submucosal dissection: First report from a multicenter, open-label, randomized controlled trial. *Dig Endosc.* 2022;34:379.
39. Ikeyama S, Kanda S, Sakamoto S, Sakoda A, Miura K, Yoneda R, Nogi A, Arijii S, Shimoda M, Ono M, Kanda S, Yokoyama S, Takahashi K, Yokoyama Y, Hattori M. A case of early onset cystinuria in a 4-month-old girl. *CEN Case Rep.* 2022;11:216.

Pathology, Immunology and Microbiology

3. Immunology

Department of Immunology

Professor

Hiroshi Takayanagi, M.D., Ph.D.

Associate Professor

Takeshi Nitta, Ph.D.

Assistant Professor

Noriko Komatsu, Ph.D.; Hiroyuki Takaba, Ph.D.

Homepage <http://www.osteimmunology.com/>

Introduction and Organization

The history of the Department of Immunology, formerly the Department of Serology, dates back to 1918. The department adopted its present name when Dr. Tomio Tada took his position as professor and chair in 1977. Through his innovative research and great contributions to the international community of immunologists, Dr. Tada raised the stature of the department to a world-renowned status. After Dr. Tada's retirement in 1994, Dr. Tadatsugu Taniguchi, presently the project professor of the Department of Molecular Immunology at the Research Center for Advanced Science and Technology, the University of Tokyo, performed cutting-edge, internationally recognized research in the field of immunology especially cytokine systems in the context of the regulation of immunity and oncogenesis. Dr. Taniguchi's major achievements were the discovery of interferon- β and a new family of transcription factors, termed interferon regulatory factors (IRFs).

On May 2012, Dr. Hiroshi Takayanagi started the new laboratory aiming to shed light on two major questions; First, why self-tolerance are broken in autoimmune diseases? Second, what is the immune network among multiple organs including bone and neuron?

Teaching activities

All members of our department take very seriously their responsibilities to teach and train the next

generation of scientists. Undergraduate students of the faculty take part in departmental class work through lectures on immunobiology, immunochemistry and molecular immunology as well as practical training by way of laboratory courses on basic immunology experimental techniques. The education of graduate students is based on weekly seminars where students present the progress of their own research projects, discuss the future directions of their research and the research of others, and are exposed to the latest cutting-edge questions confronting the research field of immunology. We also offer a special training course (called 'free quarter') of basic and advanced biological and immunological techniques to medical students. We are also accepting undergraduate students as Medical Scientist Training Program in faculty of medicine. In fiscal year 2022, special lectures for undergraduate students were given by internationally recognized scientists, Dr. Shimon Sakaguchi (Osaka Univ.), Dr. Hisashi Arase (Osaka Univ.), Dr. Hiroshi Kawamoto (Kyoto Univ.), and Dr. Tadatsugu Taniguchi (The Univ. of Tokyo).

Research activities

We aim to achieve further understanding of the mechanisms controlling the immune system, focusing on the development and function of tissue microenvironments in lymphoid organs, such as bone and thymus, and molecular basis for lymphocyte development and activation. The final goal of our

study is to develop epoch-making strategies for the treatment of immune disorders such as autoimmune diseases and severe infectious diseases.

1) Osteoimmunology

The bone and immune systems share a variety of molecules and interact with each other under physiological and pathological conditions, constituting the “osteoimmune system” which functions as a locomotor organ and a mineral reservoir as well as a primary lymphoid organ (Tsukasaki & Takayanagi, *Nat Rev Immunol.*, 2019). The bone marrow is a primary lymphoid organ that plays a critical role in immune cell development. The crucial stromal cell types that support hematopoietic cell development in the bone marrow have not been clarified. We reported the crucial role of osteoblasts in supporting lymphoid lineage development within the bone marrow micro-environment (Terashima et al., *Immunity*, 2016). The mice genetically ablated for osteoblasts exhibited a marked reduction of the number of common lymphoid progenitor cells in the bone marrow and mature lymphocytes in the periphery. Our results showed that osteoblasts play a pivotal role in maintenance of common lymphoid progenitors through the production of IL-7. Furthermore, using a mouse model of sepsis, we showed that sepsis rapidly ablated osteoblasts, which reduced the common lymphoid progenitor number and thereby resulted in peripheral lymphopenia. This study demonstrates a reciprocal interaction between the immune and bone systems, in which acute inflammation induces a defect in bone cells resulting in lymphopenia-associated immunodeficiency, suggesting that osteoblasts are a potential therapeutic target of the treatment of inflammatory diseases.

Osteoclasts are polynuclear cells derived from the monocyte/macrophage lineage, which are responsible for bone resorption. Aberrant osteoclast function and development is involved in the pathogenesis of several diseases such as the inflammatory bone destruction observed in rheumatoid arthritis as well as post-menopausal osteoporosis and osteopetrosis. Osteoclast development is dependent on TNF family cytokine receptor activator of nuclear factor kappa-B ligand (RANKL). We studied the receptor signal transduction pathway for RANKL and identified nuclear factor of

activated T cells c1 (NFATc1) as a master regulator for osteoclast differentiation (Takayanagi et al., *Dev Cell*, 2002; Asagiri et al., *J. Exp. Med.*, 2005). We also identified an ITAM-harboring co-receptor for RANK (Koga et al., *Nature*, 2004) and the importance of bridging signal cascade between RANK and ITAM *via* Btk for RANK dependent osteoclastogenesis (Shinohara et al., *Cell*, 2008; Shinohara et al., *Bone*, 2014). Our recent proteomic analysis identified multiple target proteins phosphorylated upon differentiation of osteoclasts (Sumiya et al., *Biochem Biophys Res Commun.*, 2015).

Furthermore, we have revealed the roles of Semaphorin4D on osteoblast differentiation (Negishi-Koga et al., *Nature Med.* 2011) and Semaphorin3A on inhibition of bone resorption as well as promotion of bone formation (Hayashi et al., *Nature*, 2012; Hayashi et al., *Cell Metab.*, 2019). We also found that immune complexes in serum activate osteoclastogenesis and cause bone loss through binding to Fc γ receptors (Negishi-Koga et al., *Nat Commun.*, 2015). To understand the precise mechanisms underlying cell fate specification during osteoclast differentiation, we performed single-cell RNA sequencing (scRNA-seq) analysis on the *in vitro* osteoclast culture system, and provided a comprehensive picture of molecular processes underlying osteoclastogenesis (Tsukasaki et al., *Nat Metab.*, 2020, Tsukasaki et al., *Inflamm Regen.*, 2022). We also reported that, using a bone-fracture model in mouse, the cytokine IL-17 promotes bone fracture healing via osteoblastic bone formation and that $\gamma\delta$ T cells are the major source of IL-17 produced in the bone injury site (Ono et al., *Nat Commun.*, 2016). Although it has been known that IL-17 enhances osteoclastic bone resorption in certain pathological situations, our current results clearly show the promoting effect of IL-17 on bone formation,

Most recently, we found that oral bacteria promote the conversion of Foxp3⁺T cells into Th17 cells (exFoxp3Th17 cells) in periodontitis which is one of the most common infectious diseases. exFoxp3Th17 cells were found to be the most potent bone-damaging T cells. Interestingly, these bone-damaging exFoxp3Th17 cells protect against oral bacteria in two different ways. First, they elicit mucosal immune responses mainly by the production of anti-bacterial

products. Second, they inhibit bacterial dissemination by removing the tooth. Thus, exFoxp3Th17 cells play a beneficial role in the host defense against oral bacteria. This investigation highlighted the notion that T-cell-mediated bone damage, which was considered to be an adverse consequence of inflammation, may have developed to contribute to host defense against oral bacteria (Tsukasaki et al., Nat Commun., 2018).

An anti-RANKL neutralizing antibody has been introduced for the treatment of osteoporosis, skeletal-related events by bone metastasis and bone destruction in rheumatoid arthritis. We have demonstrated that oral administration of the novel small-molecule inhibitor against RANKL suppressed bone metastasis using the mouse models, indicating the great efficacy of RANKL inhibition with a small-molecule compound in bone metastasis (Nakai et al., Bone Res., 2019). RANKL is synthesized as membrane-bound molecule, and cleaved into its soluble form by proteases. We have reported that soluble RANKL is dispensable for physiological regulation of bone and immune systems, but has a distinct and pivotal role in the promotion of bone metastasis (Asano et al., Nat Metab., 2019). The RANKL system plays a central role in bone and immune homeostasis, but the source of OPG, the decoy receptor for RANKL, has long been unknown. We generated OPG-floxed mice and showed that locally produced OPG, but not circulating OPG, has a crucial function in the thymus, bone, and intestine (Tsukasaki et al., Cell Rep., 2020). The periosteum, a membranous tissue covering the outer surface of bones, has been considered to be involved only in intramembranous bone formation at the cortex. We revealed that stem cells residing in the periosteum control the homeostasis of growth plate and bone marrow by secreting soluble factor *Ihh*, highlighting the importance of the periosteum as the key player in the osteoimmune system (Tsukasaki et al., Nature Commun., 2022). These findings provided a new paradigm for physiological interaction between bone and immune system.

2) Lymphocyte development and lymphoid tissue microenvironment

Thymus is the primary lymphoid organ that

supports development of useful T cells (positive selection) and eliminates self-reactive T cells (negative selection). The microenvironment of the thymus is mainly composed of thymic epithelial cells that regulate selections of developing T cells.

Recently, we focused on thymic fibroblasts, a stromal cell type with uncharacterized function in the thymus, and established a method to isolate the thymic fibroblast subsets, capsular fibroblasts and medullary fibroblasts. Our results demonstrated that medullary fibroblasts contribute to the induction of T cell self-tolerance by producing a unique set of self-antigens (Nitta et al, Nat Immunol., 2020; Nitta et al, Immunol Rev., 2021; Nitta, Inflamm Regen., 2022). Fibroblasts have been attracting much attention in recent years due to their functional diversity in different organs and their ability to control various biological responses through interactions with immune cells. It is expected that our findings contribute to the elucidation of the functions of various types of fibroblasts in vivo. In addition, we reported that the transcription factor *Sox4* is required for the development of thymic tuft cells, a subset of terminally differentiated medullary thymic epithelial cells (mTECs) (Mino et al, Int Immunol 2022). Our findings suggest that mTECs employ the same transcription programs as peripheral epithelial cells to ‘project’ an immunological self within the thymus for the establishment of central self-tolerance.

We have reported that the genetic variations of human *PSMB11* gene, which encodes $\beta 5t$, a thymus-specific proteasome subunit, affected the MHC class I-bound peptide repertoire in the thymus and positive selection of CD8 T cells (Nitta et al., Sci Immunol., 2017). One of the *PSMB11* polymorphisms, G49S, detected in the Japanese population at a high frequency, was associated with a higher risk of Sjögren’s syndrome. These results suggested that, in addition to the MHC haplotype, genetic variations of proteasome influence T cell repertoire selection and susceptibility to autoimmunity. Elucidation of the principles of T-cell repertoire selection is one of most

important issues in immunology. We have been continuing our research efforts including a recent release of updated protocols for gene transduction method optimized for T-cell repertoire analysis (Muro et al., *Methods Mol Biol.*, 2020).

We have also been studying on thymic development of $\gamma\delta$ T cells. We showed that the $\gamma\delta$ TCR signal mediated by the Syk-PI3K pathway is essential for thymic development of IL-17-producing $\gamma\delta$ T cells (Muro et al., *J Clin Invest.*, 2018). These findings suggest that the Syk-PI3K pathway might be a therapeutic target of inflammatory diseases. Recently, we generated mutant mice lacking all of the Skint family genes (Skint1-11) that encode candidate thymic factors for regulation of $\gamma\delta$ T cell development (Narita et al., *Int Immunol.*, 2018). These mice exhibited a marked reduction of V γ 5V δ 1 $\gamma\delta$ T cells in the thymus and skin, but had normal development of other $\gamma\delta$ T cell subsets and leukocytes. This study indicates an exclusive function of Skint family genes in the development of V γ 5V δ 1 $\gamma\delta$ T cells and provides a useful animal model to analyze the mechanism for thymic education of $\gamma\delta$ T cells.

Much attention has been paid to the development and function of the gut-associated lymphoid tissues (GALTs) and the symbiotic relationship between the gut microbiota and host immune system. We identified a previously unrecognized subset of mesenchymal cells in the subepithelial dome of GALTs (Nagashima et al., *Nat Immunol.*, 2017). These cells expressed high levels of RANKL and directly interacted with the gut epithelium to induce microfold (M) cell differentiation and CCL20 expression. The deletion of RANKL in mesenchymal cells impaired M cell-dependent antigen sampling, which resulted in a reduction in IgA production and a decrease in microbial diversity, indicating that subepithelial RANKL-expressing mesenchymal cells (M cell inducer (MCi) cells) are key players in the maintenance of host-microbe symbiosis. Furthermore, we reported that Col6a1-Cre driver mice are useful to study the function of MCi cells (Nagashima et al., *Biochem Biophys Res Commun.*, 2017). Manipulation of MCi cells may provide a molecular basis for novel treatments of intestinal diseases such as inflammatory bowel disorders and infectious diseases.

We have recently found that protein arginine

methylation, a post-translational modification, is an essential regulator of T cell maintenance. T cell-specific deficiency of the arginine methyltransferase PRMT5 led to a decrease in the number of peripheral CD4, CD8 and regulatory T cells, and an almost complete loss of iNKT cells. PRMT5-mediated arginine methylation was essential for the expression of the cytokine-signal-transducing components, the common cytokine receptor γ -chain (γ c) and JAK3, which are required for the development of iNKT cells and the proliferation and survival of peripheral T cells. PRMT5 induced the arginine methylation of the spliceosomal component SmD3 that promoted the splicing of pre-mRNA encoding γ c and JAK3. In recent years, Jak inhibitors have attracted attention as potential agents for the autoimmune diseases such as rheumatoid arthritis. This study presented an entirely new regulatory mechanism governing γ c family cytokine-Jak3 signaling in T cells (Inoue et al., *Nat Immunol.*, 2018).

3) Mechanism of autoimmune disease

The IL-17 producing helper T cell subset (Th17 cell) plays critical roles in several autoimmune disease models such as collagen induced arthritis (CIA) and experimental encephalomyelitis (EAE). We have identified I κ B ζ as an indispensable transcription factor for Th17 cell differentiation (Okamoto et al., *Nature*, 2010). However, in both RA and EAE models, effector mechanisms of Th17 cells have been unclear. Recently, we identified a subset of Th17 cells that robustly produces IL-17 and RANKL and exacerbates both inflammation and bone destruction in CIA mice. Interestingly these Th17 cells are the progeny of CD4 T cells expressing Foxp3, a master regulator for immunosuppressive Treg cells (Komatsu et al., *Nat Med.*, 2014). We also reported that RANKL produced by synovial fibroblasts is primarily responsible for the formation of bone-destructive osteoclasts in inflammatory arthritis (Danks et al., *Ann Rheum Dis.*, 2016). We identified that the transcription factor ETS1 is critical for polarization of tissue-destructive synovial fibroblasts by upregulating both RANKL and MMP expression (Yan et al., *Nat Immunol.*, 2022). Periarticular bone loss is one of the earliest indices of RA, often preceding the onset of clinical symptoms via largely unknown mechanisms. We found that bone

marrow plasma cells promote periarticular bone loss as RANKL-expressing osteoclast inducer cells (Komatsu et al., *J Clin Invest.*, 2021). These results taken together propose the importance of the immune-fibroblast-bone triad in autoimmune arthritis and suggest that the targeting pathogenic cells and/or molecules could be effective in preventing bone destruction in RA (Komatsu and Takayanagi, *Nat Rev Rheumatol.* 2022).

To elucidate a role of RANKL on T cells, we generated T cell-specific RANKL-deficient mice. These mice were protected from EAE, a mouse model of multiple sclerosis, due to an impairment of infiltration of pathogenic T cells into the central nervous system (CNS). RANKL on T cells stimulates the chemokine production by astrocytes, leading to the chronic inflammation in the CNS. Pharmacological inhibition of RANKL prevented the development of EAE, indicating that RANKL is a potential therapeutic target for treatment of multiple sclerosis (Guerrini et al., *Immunity*, 2015).

We have also been studying the mechanism of T cell tolerance induction, because a breakdown of T cell tolerance induces autoimmune diseases. Self-tolerance of T cells is primarily established during their development in the thymic medulla, where mTECs ectopically express a variety of tissue-restricted antigens (TRAs) and thereby TRA-reactive immature T cells are deleted. It has been known that expression of a set of TRAs is regulated by the transcriptional regulator Aire, although how the remaining TRAs are regulated has been unclear. We identified a novel key transcription factor *Fezf2*, which is highly expressed in mTECs and controls the expression of a large fraction of Aire-independent TRAs (Takaba et al., *Cell*, 2015). Mice lacking *Fezf2* in mTECs exhibited severe autoimmune disorders in peripheral organs, and the spectrum of autoimmunity in *Fezf2*-deficient mice differed from that in Aire-deficient mice. These results indicate that two independent factors, *Fezf2* and Aire, play non-redundant and mutually complementary roles in the TRA expression to ensure T cell tolerance induction. In addition, we identified *Chd4* as chromatin remodeler interacting with *Fezf2*. *Chd4* works with not only *Fezf2* but Aire to promote promiscuous TRA expression in mTECs, mediating

central immune tolerance (Tomofuji et al., *Nat Immunol.*, 2020). Thus, these studies represented important advance in our understanding of the mechanisms underlying the immune tolerance and autoimmune diseases.

References

1. Nitta et al., Fibroblasts as a source of self-antigens for central immune tolerance. *Nat Immunol.*, 21: 1172–1180. (2020)
2. Nitta et al., The fibroblast: an emerging key player in thymic T cell selection. *Immunol Rev*, 302: 68-85. (2021)
3. Mino et al., The Transcription Factor Sox4 is Required for Thymic Tuft Cell Development. *Int Immunol.*, 34: 45-52. (2022)
4. Yan M et al., ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts. *Nat Immunol.* 23(9):1330-1341. (2022)
5. Komatsu et al., Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis. *J Clin Invest.*, 131: e143060. (2021)
6. Komatsu N and Takayanagi H Mechanisms of joint destruction in rheumatoid arthritis —immune system—fibroblast—bone interactions *Nat Rev Rheumatol.* 18(7):415-429. (2022)
7. Tomofuji et al., Chd4 choreographs self-antigen expression for central immune tolerance. *Nat Immunol.*, 21: 892–901. (2020)
8. Nitta, Mesenchymal stromal cells in the thymus. *Inflamm Regen.*, 42:33. (2022)
9. Tsukasaki et al., Periosteal stem cells control growth plate stem cells during postnatal skeletal growth. *Nature Communications* 13:4166. (2022)
10. Tsukasaki et al., Osteoclast biology in the single-cell era. *Inflamm Regen.*, 42:27. (2022)

Radiology and Biomedical Engineering

1. Radiology

Department of Radiology

Professor

Osamu Abe, M.D., Ph.D.

Associate Professor

Hideomi Yamashita, M.D., Ph.D., Hidemasa Takao, M.D., Ph.D.,
Takeyuki Watadani, M.D., Ph.D.

Lecturer

Shouhei Hanaoka, M.D., Ph.D., Shiori Amemiya, M.D., Ph.D., Atsuto Katano, M.D., Ph.D.

Project Lecturer

Mami Ogita, M.D., Ph.D., Eisuke Shibata, M.D., Ph.D.

Assistant Professor

Nawa Yobu, Ph.D., Koichiro Yasaka, M.D., Ph.D., Yusuke Watanabe, M.D., Ph.D., Yudai Nakai, M.D., Ph.D., Takatoshi Kubo, M.D., Ph.D., Ryo Kurokawa, M.D., Ph.D., Masafumi Kaiume, M.D., Ph.D., Subaru Sawayanagi, M.D., Yosuke Miki, M.D., Ph.D., Ryu Miyagawa, Ph.D.

Project Assistant Professor

Shohei Inui, M.D., Ph.D., Saori Koshino, M.D., Takeshi Ohta, R.T., Ph.D., Hisaichi Shibata, Ph.D., Tomomi Takenaga, R.T., Ph.D., Yuki Nozawa, M.Sc.

Homepage <http://www.ut-radiology.umin.jp/>

Introduction and Organization

Department of Radiology was established in 1932. Radiology covers three major fields that are, Diagnostic Radiology (imaging and intervention), Radiation Oncology (radiotherapy), and Nuclear Medicine. The clinical, educational and research activities of our department are being carried out in cooperation with Department of Radiology in The Research Institute of Medical Science, which has three (1 associate professor, 1 lecturer, and 2 assistant professor) positions. In addition, Department of Radiology mainly takes care of radiation protection and radiation safety in the hospital.

Clinical activities

Clinical services on Diagnostic Radiology, Nuclear Medicine, and Radiation Oncology are provided in the Radiology Center in cooperation with radiology technologists and nurses.

In the section of Diagnostic Radiology, all CT and MRI examinations are monitored and reported by diagnostic radiologists. Diagnostic radiologists, gastroenterologists, cardiologists, and neurosurgeons mainly perform interventional procedures.

In the section of Nuclear Medicine, two cyclotrons and several remote or processor-controlled automated devices are installed, which facilitate standardized procedures in the PET tracer production and the implementation of GMP in

PET-related work. There are two SPECT rooms and two PET rooms. These nuclear imaging procedures are chiefly performed and reported by diagnostic radiologists and cardiologists.

Each year, over 700 new patients receive radiation therapy in the Radiation Oncology section. Highly accurate 3D radiation therapy is the most outstanding feature. Stereotactic radiation therapy for small lung or liver tumors has been carried out.

In the 9th floor of the Inpatient Building A, there are 12 beds in the Radiology ward, which are usually used for oncology patients receiving radiation therapy and chemotherapy. Some of them are sometimes used for patients receiving invasive diagnostic procedures such as interventional radiology (IVR), angiography and myelography. There are two special beds for radionuclide (RN) therapy in the same floor. In addition, four beds are allotted to terminal care ward located in the 14th floor.

Education

Lectures are given to the fourth-, fifth- and sixth-year students to provide fundamental knowledge of diagnostic radiology, radiation oncology, and nuclear medicine. Professor, associate professors and lecturers as well as specialists assigned as part time lecturers take part in the education. A series of lectures about fundamentals of radiology and related sciences are given to the fourth-year students. As bed-side-learning (Clinical Clerkship, CC) curriculum, small groups of the sixth-year students are taking part in mini-lectures and practice to learn basics of diagnostic radiology, advanced medical techniques of Radiation Oncology and Nuclear Medicine. They will learn detailed principles of image constructions in various kinds of imaging modalities and technology in radiation therapy against cancer. Postgraduate students are also welcome to each of subspecialties of radiology according to their interests.

Research

Research activities in our department include clinical research, animal experiments, and develop-

ment of instruments as well as computer-based new technology including artificial intelligence. Diagnostic Radiology group in the department promotes research activities aiming at efficacy improvement of diagnostic imaging and expansion of its application. Multi-row detector helical computed tomography (MDCT) enables us to take tomographic images in a three- or four-dimensional (3D, 4D) fashion. Using the data acquired by MDCT, various kinds of diseases in almost all parts of the body, from cerebral to musculoskeletal diseases, can be displayed in 3D or time-resolved 3D images. New 3D software developed in our departments is now widely used in the field of the gastrointestinal tract, lung, and central nervous system. In addition, we have opened a new laboratory section named Image Computing and Analysis Laboratory with invitation of experts of engineering. This section will contribute to development of novel software including convolutional neural network to abstract clinically useful information from the 3D imaging data more sophisticatedly. In the field of magnetic resonance (MR) imaging, structural and functional MRI, perfusion and diffusion imaging are the researches of interest. These techniques are aggressively applied to the investigation of vascular and neoplastic diseases of the brain.

Radiation oncology group promotes research projects in two major fields; one is physical engineering such as the optimization of dose distribution in the radiation therapy (RT) and the other is reduction of injuries due to radiation exposure in vitro and in vivo. This group pushes forward studies mainly on a brain tumor, head and neck cancer, esophageal cancer, uterine cervical cancer, prostate cancer in conformity with recent EBM in the clinical study, and is active in studies of the physical engineering traditionally and plays a main role in the highly precise radiation therapy of our country until now. With the purpose of achieving precise external irradiation, a new linear accelerator with multileaf collimator systems was developed and installed, which is utilized mainly for non-coplanar radiation therapy in many patients, especially with brain tumor or head and neck tumor. Dynamic conical conformal radiotherapy for

metastatic brain tumors using the accelerator is under evaluation. In addition to gamma knife radiosurgery, this new accelerator based stereotactic radiotherapy for brain diseases has been undergone, and stereotactic radiotherapy (SRT) for body tumors, such as head and neck cancer, prostate cancer, rectal cancer and lung cancer, has been investigated in combination with intensity modulation radiation therapy (IMRT) for the reduction of the adverse radiation damage. A new technology to track mobile tumors, represented by lung tumors, is under investigation in collaboration with accelerator makers.

Nuclear Medicine group promotes clinical research on functional imaging by the application of radioisotope-labeled tracer technology, combined with molecular biology. In particular, emission tomography (PET and SPECT) is applied for the evaluation of cerebral blood flow and metabolism in patients with dementia, epilepsy, and cerebrovascular diseases. Cerebral blood flow, glucose metabolism, and neural synaptic functions are measured for the understanding of normal and pathophysiological states of CNS disorders, using a variety of positron-emitter radiotracer, such as [F-18] FDG,. The study of dementia using SPECT and the standard brain atlas has made it possible to categorize the type of dementia. Evaluation of dopaminergic function by SPECT is very important in the differential diagnosis of Parkinsonism. Cardiac PET and SPECT are also active fields. Myocardial viability, vascular reserve, and sympathetic nerve denervation in the ischemic heart disease are evaluated with [F-18] FDG, Tl-201 and [I-123] MIBG. Higher brain functions such as reading, speech, and thinking have been studied with PET by comparing blood flow and receptor binding potential (BP) under various tasks and at rest. For the precise localization of activated brain function, computer processing and reconstruction of composite images of function and anatomy is an essential subject for investigation. At present, whole body FDG-PET is one of the most effective tool for exploring metastatic lesions of cancer patients. Combination display of SPECT/PET with CT/MRI would be a routine job and anatomo-functional

images would play an important role in the clinical management of the patients.

Conclusion

Diagnostic radiology, radiotherapy and nuclear medicine are the three pillars that support radiology. Mutual cooperation among these three fields, which are divided by modality, is the basis for comprehensive diagnostic imaging and multidisciplinary treatment, and our department has been working vigorously toward its realization. In the future, there is a strong need to train more field-oriented radiologists who have cross-cutting knowledge, experience, and research achievements in each field.

Publications

One hundred and twenty-six, 137, and 83 English original articles have been published from our department in 2022, 2021, and 2020. respectively. Please refer to our homepage, <http://www.ut-radiology.umin.jp/publication/2022.html>.

Radiology and Biomedical Engineering

2. Biomedical Engineering

Department of System Physiology

Professor (Concurrent)

Kiyoshi Miyagawa, M.D., Ph.D.

Associate Professor

Kimiko Yamamoto, M.D., Ph.D.

Homepage https://square.umin.ac.jp/bme/research_Eng.html

Introduction and Organization

Our department originated from the department of Basic Medical Science, the Institute of Medical Electronics, established in 1961. In 1997, as a result of the shift to the chair system of the Graduate School of Medicine, the Institute was replaced with three departments of Biomedical Engineering: System Physiology, Bioimaging and Biomagnetics, and Biosystem Construction and Control. The Department of System Physiology consists of a Professor (concurrent) and an Associate Professor.

Teaching activities

We give lectures of “Early Exposure to Medicine” for first year students, “Basic Principles of Biomedical Engineering” for second and third year students, “Introduction to Biomedical Engineering” for postgraduate students, “Introduction to Medical Science: Mechanobiology” for master’s students, in the faculty of Medicine, and “Principles of Medicine” for postgraduate students in the faculty of Engineering. We offer practical training of biomedical engineering research to third- and fourth-year students of undergraduate medical school. A weekly seminar is held in our laboratory bringing together staff and research fellows to discuss journal articles and give updates on experiments. Our aim is to enhance the research skills of students.

Research activities

This laboratory has been pursuing the study of

biomechanics dealing with mechanical phenomena in the human body, especially focusing on cellular sensing and response mechanisms to mechanical stimuli. The main theme of our work is the relationships between shear stress or cyclic strain, which are hemodynamic forces generated by blood flow, and their target cells, vascular endothelial cells (ECs). This would be of benefit not only to understanding blood flow-mediated regulation of vascular functions but also to the elucidation of clinically important problems such as angiogenesis, vascular remodeling, atherogenesis, and development of cerebral aneurysm which occur in a blood flow-dependent manner.

Original biomedical engineering methods have been applied, in which cultured ECs are exposed to controlled levels of shear stress or cyclic strain in a fluid–dynamic flow apparatus and whose responses are analyzed at the cellular and molecular levels. Microcirculatory hemodynamics and oxygen transport of genetically modified mice are studied by employing opto-electronics technology. The results of these experiments are listed below.

1. Cell responses to hemodynamic forces
2. Hemodynamic force-mediated gene regulation
3. Hemodynamic force-induced cell differentiation
4. Mechanosensing and mechanotransduction
5. Shear stress-induced mitochondria oxidative Phosphorylation
6. Hemodynamic force-induced changes in plasma membrane cholesterol levels

1. Cell responses to hemodynamic forces

Our studies have demonstrated that ECs have functional responses to hemodynamic forces, shear stress and cyclic strain. When a cultured EC monolayer was partially denuded, surrounding cells migrated and proliferated in the denuded area, and covered the denuded area. Shear stress enhanced the regenerative functions of ECs. Shear stress increased the production of nitric oxide, a potent vasodilator, in ECs in a dose-dependent manner. Shear stress also increased the expression of thrombomodulin, an antithrombotic molecule, in ECs. In contrast, it decreased the expression of vascular cell adhesion, which leads to the inhibition of leukocyte adhesion to vascular cell adhesion molecule-1 (VCAM-1). It was shown that shear stress increases the levels of adrenomedullin and C-type natriuretic peptide mRNA which have vasodilating effects in addition to nitric oxide, and that it also augmented the expression of lectin like low density lipoprotein receptor (LOX-1) at the protein and mRNA level.

2. Hemodynamic force-mediated gene regulation

We have demonstrated that shear stress regulates endothelial gene expression transcriptionally and/or posttranscriptionally. Shear stress downregulates VCAM-1 gene transcription via the double AP-1 binding element (TGACTCA) in the promoter which functions as a shear stress-responsive element. Shear stress has also been shown to increase the expression level of granulocyte/macrophage-colony stimulating factor (GM-CSF) via mRNA stabilization. Differential display and DNA microarray analysis showed that around 600 known and unknown transcripts were up- or down-regulated in human umbilical vein ECs exposed to a shear stress. From these shear stress-responsive genes, a cDNA encoding an unknown G-protein coupled receptor was cloned. We showed that the transcription factor SP1 is involved in the shear stress-induced down-regulation of P2X4 (an ATP-gated cation channel) gene expression in ECs. We also revealed that endothelial genes are differentially regulated by laminar and turbulent shear stress. Laminar shear stress decreases the gene expression of urokinase plasminogen activator (uPA), which plays a role in fibrinolysis and vascular remodeling, via both GATA6-mediated down-regulation of gene

transcription and an acceleration of mRNA degradation, while turbulent shear stress increases the uPA gene expression through mRNA stabilization. We demonstrated that shear stress up-regulates the gene expression of plasminogen activator inhibitor-1 (PAI-1) through activation of transcription factors Sp-1 and Ets-1 in human hepatocytes. We developed a compliant tube-type flow-loading device that allows simultaneous application of physiological levels of shear stress and cyclic strain to cultured cells and observed that the response of endothelial genes to shear stress or cyclic strain depends on whether the two forces are applied separately or together.

3. Hemodynamic force-induced cell differentiation

We have revealed that endothelial progenitor cells (EPCs) circulating in human peripheral blood proliferate and differentiate into mature ECs in response to shear stress, thereby forming tube-like structures in collagen gel. Moreover, we revealed that shear stress increased the gene expression of the arterial EC marker ephrinB2 in EPCs, while it decreased the gene expression of the venous EC marker EphB4, suggesting that shear stress affects arterial-venous differentiation of EPCs.

Embryonic stem (ES) cells have the potential to differentiate into every cell type in the body, and attracting interest as a promising source of cells for use in regenerative medicine. Embryonic cells are exposed to fluid-mechanical forces, including shear stress and the cyclic strain generated by beating heart during the process of embryonic development. We found that shear stress induces the differentiation of murine ES cells into vascular EC lineage in vitro; cyclic strain induces the differentiation into vascular smooth muscle cell (SMC) lineage. Differentiation into the EC lineage and differentiation into SMC lineage are mediated by ligand-independent phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor (PDGFR), respectively. Moreover, our study has shown that shear stress increases expression of ephrinB2 in murine ES cells via the VEGF-Notch signaling pathways, suggesting that shear stress can also affect the arterial-venous differentiation of ES cells. Based on these findings, in a collaborative study, a new hybrid type of artificial blood vessel, in which ES cells were cultured

on the surface of polymer tubes and exposed to pulsatile shear stress and cyclic strain, was developed.

4. Mechanosensing and mechanotransduction

We were the first to show that Ca^{2+} signaling plays an important role in the mechanism by which ECs recognize the shear stress signal and transmit it into the cell interior. Strong shearing forces induced by dragging ECs with a balloon causes an increase in cytoplasmic Ca^{2+} concentrations. A relatively weak shearing force like shear stress generated by fluid flow needs the presence of extracellular ATP to induce Ca^{2+} response, and at several hundred nanomolar of ATP, intracellular Ca^{2+} concentrations increase in a shear stress-dependent manner. Generally, flow-induced Ca^{2+} responses are initiated at a locus at the cell edge and propagate throughout the entire cell in the form of a Ca^{2+} wave. The initiation locus corresponded precisely to caveolae rich cell edges. We found that a subtype of ATP-gated cation channel, the P2X4 receptor, is expressed in human vascular ECs and that P2X4 receptors play a crucial role in the shear stress-dependent Ca^{2+} response. Endogenously released ATP by shear stress is involved in the P2X4-mediated Ca^{2+} responses. We produced *P2X4*-deficient mice and observed that the P2X4-deficient mice have impaired flow-dependent control of vascular tone and remodeling, indicating that shear stress signal transduction via P2X4 plays a critical role in the regulation of circulatory functions.

Our study revealed that cell surface ATP synthase localized in caveolae/lipid rafts are involved in the shear-stress-induced ATP release by ECs. Recently, we demonstrate that the cellular mitochondria play a critical role in this process. Cultured human pulmonary artery ECs were exposed to controlled levels of shear stress in a flow-loading device and the changes in the mitochondrial ATP levels were examined by real-time imaging using a fluorescence resonance energy transfer-based ATP biosensor. Immediately upon the exposure of the cells to flow, the mitochondrial ATP levels increased, which was both reversible and dependent on the shear stress intensity. Inhibitors of the mitochondrial electron transport chain and ATP synthase, as well as knockdown of caveolin-1, a major structural protein of the caveolae, abolished the shear-stress-induced mitochondrial ATP generation, resulting

in the loss of the ATP release and influx of Ca^{2+} into the cells. These results suggest the novel role of the mitochondria in transducing the shear stress into ATP generation: the ATP generation leads to ATP release in the caveolae, triggering purinergic Ca^{2+} signaling. Thus, exposure of ECs to shear stress seems to activate mitochondrial ATP generation through caveola- or caveolin-1- mediated mechanisms.

Moreover, we report that the plasma membrane itself differentiates between shear stress and stretch by undergoing transitions in its lipid phases. Shear stress decreased the lipid order of human pulmonary artery EC plasma membranes, thereby causing a transition from the liquid-ordered phase to the liquid-disordered phase in some areas, along with an increase in membrane fluidity. In contrast, uniaxial stretching and hypotonic swelling increased the membrane lipid order and decreased membrane fluidity. A similar increase in lipid order occurred when the artificial lipid bilayer membranes of giant unilamellar vesicles were stimulated by shear stress by using a flow-loading apparatus or stretched by hypotonic swelling, indicating that mechanical force-mediated responses of lipid membranes are physical phenomena. The cholesterol content of EC plasma membranes significantly decreased in response to shear stress but clearly increased in response to stretch. Blocking these changes in the membrane lipid order by depleting membrane cholesterol with methyl- β -cyclodextrin or by adding cholesterol resulted in a marked inhibition of the EC response specific to shear stress and stretch, i.e., phosphorylation of VEGFR2 and phosphorylation of PDGFR, respectively. These findings indicate that EC plasma membranes differently respond to shear stress and stretch by changing their lipid order, fluidity, and cholesterol content in opposite directions and that these changes in membrane physical properties are involved in the mechanosensing mechanisms and the mechanotransduction that activates membrane receptors specific to each force.

5. Shear stress-induced mitochondria oxidative phosphorylation

Vascular endothelial cells (ECs) sense and respond to hemodynamic shear stress, which is critical for circulatory homeostasis and the pathophysiology of vascular diseases. The

mechanisms of shear stress mechanotransduction, however, remain elusive. We previously demonstrated a direct role of mitochondria in the purinergic signaling of shear stress: shear stress increases mitochondrial ATP production, triggering ATP release and Ca^{2+} signaling via EC purinoceptors. Here, we showed that shear stress rapidly decreases cholesterol in the plasma membrane, thereby activating mitochondrial ATP production. Imaging using D4 mutant-derived cholesterol biosensors showed that the application of shear stress to cultured ECs markedly decreased cholesterol levels in both the outer and inner plasma membrane bilayers. Flow cytometry showed that the cholesterol levels in the outer bilayer began to decrease within 3 min after the onset of shear stress, reached a minimum (around 60% of the control level) at 10 min, and plateaued thereafter. After the shear stress ceased, the decreased cholesterol levels returned to those seen in the control. A biochemical analysis showed that shear stress caused both the efflux and the internalization of plasma membrane cholesterol. ATP biosensor imaging demonstrated that shear stress significantly increased mitochondrial ATP production. Similarly, the treatment of cells with methyl- β -cyclodextrin (M β CD), a membrane-cholesterol-depleting agent, increased mitochondrial ATP production. The addition of cholesterol to cells inhibited the increasing effects of both shear stress and M β CD on mitochondrial ATP production in a dose-dependent manner. These findings indicate that plasma membrane cholesterol dynamics are closely coupled to mitochondrial oxidative phosphorylation in ECs.

6. Hemodynamic force-induced changes in plasma membrane cholesterol levels

Vascular endothelial cells (ECs) sense and respond to hemodynamic shear stress, which is critical for circulatory homeostasis and the pathophysiology of vascular diseases. The mechanisms of shear stress mechanotransduction, however, remain elusive. We previously demonstrated a direct role of mitochondria in the purinergic signaling of shear stress: shear stress increases mitochondrial ATP production, triggering ATP release and Ca^{2+} signaling via EC purinoceptors. Here, we showed that shear stress rapidly

decreases cholesterol in the plasma membrane, thereby activating mitochondrial ATP production. Imaging using D4 mutant-derived cholesterol biosensors showed that the application of shear stress to cultured ECs markedly decreased cholesterol levels in both the outer and inner plasma membrane bilayers. Flow cytometry showed that the cholesterol levels in the outer bilayer decreased rapidly after the onset of shear stress, reached a minimum (around 60% of the control level) at 10 min, and plateaued thereafter. After the shear stress ceased, the decreased cholesterol levels returned to those seen in the control. A biochemical analysis showed that shear stress caused both the efflux and the internalization of plasma membrane cholesterol. ATP biosensor imaging demonstrated that shear stress significantly increased mitochondrial ATP production. Similarly, the treatment of cells with methyl- β -cyclodextrin (M β CD), a membrane-cholesterol-depleting agent, increased mitochondrial ATP production. The addition of cholesterol to cells inhibited the increasing effects of both shear stress and M β CD on mitochondrial ATP production in a dose-dependent manner. These findings indicate that plasma membrane cholesterol dynamics are closely coupled to mitochondrial oxidative phosphorylation in ECs.

References

1. J. Ando and K. Yamamoto. Hemodynamic forces, endothelial mechanotransduction, and vascular diseases. *Magn. Reson. Med. Sci.*, 21(2), 258-266 (2022).
2. I. Ono, Y. Abekura, A. Kawashima, M. Oka, A. Okada, S. Hara, S. Miyamoto, H. Kataoka, A. Ishii, K. Yamamoto, T. Aoki, Endothelial Cell Malfunction in Unruptured Intracranial Aneurysm Lesions Revealed Using a 3D-Casted Mold, *J. Neuropathol. Exp. Neurol.* 82(1), 49-56 (2022).
3. K. Yoshida, S. Tanihara, Y. Miyashita, K. Obayashi, M. Ito, K. Yamamoto, T. Imai, and I. Matsuoka, P2X4 receptor stimulation enhances MrgprB2-mediated mast cell activation and pseudoallergic reactions in mice. *Sci. Rep.*, 12, Article number: 18613 (2022).
4. K. Obayashi, K. Yoshida, M. Ito, T. Mori, K. Yamamoto, T. Imai, I. Matsuoka, Synergistic

cytokine production by ATP and PGE2 via P2X4 and EP3 receptors in mouse bone marrow-derived mast cells. *Cells*. 11 (4), 616 (2022).

Department of Chemical Biology and Molecular Imaging

Professor

Yasuteru Urano, Ph.D.

Associate Professor

Ryosuke Kojima, Ph.D.

Assistant Professor

Kyohhei Fujita, Ph.D.

Webpage <http://cbmi.m.u-tokyo.ac.jp/>

Introduction and Organization

The Laboratory of Chemical Biology and Molecular Imaging is one of the laboratories in the department of Radiology and Biomedical Engineering. Our laboratory is located in the annex of the medical building 3. Our lab members consist of 2 postdoctoral researcher, 7 PhD students, 4 master course students, 1 undergraduate student, and 2 guest researchers, as of FY2022.

Teaching activities

As for under-graduate education, our laboratory takes part in medical engineering lectures for the 3rd year medical students. As for PhD course education, our laboratory delivers the lecture of fluorescence imaging for both master and doctor course students.

Research activities

In our laboratory, we conduct research aimed at developing various fluorescence imaging probes and their biological and medical applications. In fiscal year 2022, we reported on the development of methods for quantifying intracellular pH by fluorescent lifetime imaging, a Raman probe that can be activated by red light, and a fluorescent probe that can visualize thymoma and thymic carcinoma, etc.

Details are as follows.

Intracellular organelles such as endosomes and lysosomes strictly regulate their pH levels. Disruptions of this balance correlate with diseases such as cancer and Alzheimer's, hence accurate quantification and understanding of its dynamics and control mechanisms are vital. Existing fluorescent probes that enable monitoring of intracellular pH often change their ON/OFF fluorescence in response to pH changes. However, the intensities of these signals are directly influenced by the amount of probe, which is a drawback for the precise detection of intracellular pH. We developed a novel method to quantify intracellular pH by fluorescent lifetime imaging, focusing on the fact that fluorescence lifetime is not affected by the amount of probe. Specifically, we developed a probe, m-DiMeNAF488, which has a large fluorescence lifetime change, 4.38 ns for the protonated form and 0.58 ns for the deprotonated, indicating a pKa of 4.58 (optimal to visualize intracellular acidic organelles around pH5). Using this, we successfully captured the acidification of phagosomes during phagocytosis in real time (Publication 1).

Photoactivatable fluorescent probes are useful for pulse labeling and tracking various biomolecules and cells, but because fluorescence has a broad spectral width, there is a limit to the multiplicity when distinguishing different samples in multiple colors. We

focused on Raman imaging with excellent multiplex detection capabilities and developed an activatable Raman probe that can photoactivate Raman signals. Specifically, we designed and developed a new Raman probe, 9CN-diMeJTeP, which induces a strong Raman signal by pre-resonance Raman due to a significant redshift of the absorption wavelength associated with photooxidation. We achieved photoactivation of its Raman signal by irradiating red light under a microscope (Publication 2, collaborative research with Prof. Mayuko Kamaya @ Tokyo Institute of Technology, Prof. Yasuyuki Ozeki, Faculty of Engineering, The University of Tokyo).

In recent years, thoracoscopic and robotic surgeries have become possible for the treatment of thymomas and thymic carcinoma. The ability to accurately distinguish major areas is important for improving treatment outcomes. We examined the discrimination ability of the green fluorescent probe gGlu-HMRG, which can monitor the activity of γ -glutamyltransferase (GGT) known to be highly expressed in multiple types of cancer, for thymomas and thymic carcinoma. Imaging was conducted in a comparative manner between major areas and surrounding normal tissues in 22 cases of clinical specimens of thymomas and thymic carcinoma. It was found that thymomas and thymic cancers could be visualized with a sensitivity of 77.3% and specificity of 100%. These results suggest that gGlu-HMRG could be useful for accurately removing the major areas without leaving any residual tissue in thoracoscopic surgery, etc. (Publication 3)

In addition, we conducted and presented several joint research projects with researchers from within and outside the university (Publications 4-7).

References

- (1) Koda, K.; Keller, S.; Kojima, R.; Kamiya, M.; Urano, Y. Measuring the PH of Acidic Vesicles in Live Cells with an Optimized Fluorescence Lifetime Imaging Probe. *Anal. Chem.* 2022, 94, 11264–11271.
- (2) Kawatani, M.; Spratt, S. J.; Fujioka, H.; Shou, J.; Misawa, Y.; Kojima, R.; Urano, Y.; Ozeki, Y.; Kamiya, M. 9-Cyano-10-Telluriumpyronin Derivatives as Red-Light-Activatable Raman Probes. *Chem. Asian J.* 2023, 18, e202201086.
- (3) Yoshida, D.; Kamiya, M.; Kawashima, S.; Yoshioka, T.; Hino, H.; Abe, A.; Fujita, K.; Kojima, R.; Shinozaki-Ushiku, A.; Urano, Y.; Nakajima, J. Rapid Imaging of Thymoma and Thymic Carcinoma with a Fluorogenic Probe Targeting γ -Glutamyltranspeptidase. *Sci. Rep.* 2023, 13, 3757.
- (4) Tsuyama, Y.; Xu, B.; Hattori, K.; Baek, S.; Yoshioka, Y. A 50 Mm Acoustic Resonator Microchannel Enables Focusing 100 Nm Polystyrene Beads and Sub-Micron Bioparticles. *Sens. Actuators B Chem.* 2023, 376, 132918.
- (5) Hirata, H.; Kamohara, A.; Murayama, M.; Nishioka, K.; Honda, H.; Urano, Y.; Soejima, H.; Oki, S.; Kukita, T.; Kawano, S.; Mawatari, M.; Kukita, A. A Novel Role of Helix-Loop-Helix Transcriptional Factor Bhlhe40 in Osteoclast Activation. *J. Cell. Physiol.* 2022, 237, 3912–3926.
- (6) Tang, X.; Nishimura, A.; Ariyoshi, K.; Nishiyama, K.; Kato, Y.; Vasileva, E. A.; Mishchenko, N. P.; Fedoreyev, S. A.; Stonik, V. A.; Kim, H.-K.; Han, J.; Kanda, Y.; Umezawa, K.; Urano, Y.; Akaike, T.; Nishida, M. Echinochrome Prevents Sulfide Catabolism-Associated Chronic Heart Failure after Myocardial Infarction in Mice. *Mar. Drugs* 2023, 21, 52.
- (7) Hattori, K.; Goda, Y.; Yamashita, M.; Yoshioka, Y.; Kojima, R.; Ota, S. Droplet Array-Based Platform for Parallel Optical Analysis of Dynamic Extracellular Vesicle Secretion from Single Cells. *Anal. Chem.* 2022, 94, 11209–11215.

Department of Biosystem Construction & Control

Lecturer

Takashi Isoyama, Ph.D.

※The following information is the same as that of the previous year for certain reasons.

Homepage http://www.bme.gr.jp/bme_E/

Introduction and Organization

As the first research institute for medical engineering in Japan, Institute of Medical Electronics was established in 1963. Department of Clinical Medicine in the Institute of Medical Electronics was started in 1964 for research and development of advanced diagnostic and therapeutic medical engineering technologies. To date, medical engineering has grown up not only to a very important academic discipline but also to a very important means for clinical medicine. With the structural reformation of Faculty of Medicine, Institute of Medical Electronics has been shifted to Graduate School of Medicine, and Department of Clinical Medicine in the Institute of Medical Electronics has been reformed to the present department since April 1, 1997.

The current members include a lecturer, one graduate student, a senior technical specialist, and a project academic support staff.

Since our research covers wide area of interdisciplinary and comprehensive research fields based on the advanced medical and engineering technologies, we are cooperating with various laboratories.

Teaching activities

We take a part in systematic lectures for the 3rd year medical students. We also provide practice in the “free quarter” course for the 2nd year medical students. In systematic lectures, we teach an introduction of the advanced diagnostic and therapeutic medical

engineering technologies. The lectures for artificial organ technologies are included.

For post-graduate education, we provide lectures for the master course students, and we take a part in series of lectures for the doctor course students. For the master course students, we offer lectures on artificial organ technologies. For the doctor course students, we offer lectures on advanced medical engineering technologies.

The educational practice of the post-graduate students is performed mainly by on-the-job training method in the daily research works. Through the development and animal experiments of the artificial hearts, research strategy, methods of in-vitro, ex-vivo and in-vivo studies, design and fabrication techniques, machining technique, pre-operative management, anesthesia, surgery, post-operative management, measurement, data processing, ethical factor, and other important knowledge, techniques and experiences are acquired. In the practice, we give the master course students several assignments from the field of the artificial organs as a subject of their research. The doctor course students have to find the subject of their research by themselves. The research subject of the doctor course students is not limited to the field of the artificial organs but is found from the wide area of advanced medical and engineering technologies.

Students must attend research and development meeting. They can learn how to perform the research work and how to report it through the meeting.

The education to train the leaders of medical

engineers and clinical engineers is another important role of our laboratory.

Research activities

Our research field covers advanced diagnostic and therapeutic medical engineering technologies for clinical medicine. The main subjects are artificial organs (artificial hearts, assist circulations, artificial lungs, artificial valves, tissue engineered artificial organs, regenerative artificial organs, etc.). Especially, the artificial heart is our world famous research project having a long history since 1959. Concerning the artificial heart, almost all the researches and developments for driving mechanisms, energy converters, blood pumps, biomaterials, power transmissions, measurement techniques, control methods, anatomical fitting, blood compatibility, tissue compatibility, computational fluid dynamics (CFD) analysis, physiology, pathology, and so on, have been studied. All the stuffs and students are in part participating in the artificial heart project. In 1995, we succeeded to survive a goat for 532 days with the paracorporeal total artificial heart (TAH) with no anticoagulant, which is still the longest surviving record of TAH animals in the world.

Our artificial heart research at present is to develop a totally implantable TAH with high performance, good anatomical fitting, high durability, high reliability, high efficiency, good controllability, and excellent biological compatibility, which can be implanted in the body of small stature like Japanese. To meet the purpose, we had been developing the TAH using undulation pumps, named undulation pump TAH (UPTAH). The undulation pump is our original blood pump invented in 1992. The UPTAH revealed to have an excellent performance and the goat whose heart was replaced with the UPTAH survived for 153 days. However, the UPTAH had a problem in the durability of the complex drive shaft mechanism. To improve the problem of the UPTAH, a new blood pump, named the helical flow pump (HFP), was invented in our laboratory in 2005. The HFP is a novel blood pump having a hydrodynamic levitating impeller, which promises high durability. The animal experiment of the helical flow TAH (HFTAH) had started in 2011. The HFTAH could be implanted in the goat

successfully with good anatomical fitting. To date, the goat whose heart was replaced with the HFTAH survived for 100 days. We are expecting to develop an ideal TAH that surpass the outcome of the heart transplantation with combination of the technologies of the physiological control and hybrid materials described later.

How to control the output of a TAH is primary interest. We have developed our original physiological control method of the TAH, named 1/R control. The 1/R control was developed with a conductance (1/R: reciprocal of a resistance) parallel circuit model. With the 1/R control, the particular problems of a TAH such as venous hypertension, slight anemia, low thyroid hormone level and so on, were not observed and the output changed in accordance with a metabolic demand of the animal.

The problem of the 1/R control was a mismatching of the time constants between the control systems of the device and the body. As a consequence, the 1/R control occasionally diverged in the animal experiment of the UPTAH and HFTAH. To improve the problem of instability in the 1/R control, a new control method based on the fluctuation of arterial and venous pressures (named ΔP control) was developed by reforming the 1/R control function. At present, ΔP control is tested with the animal experiment.

On the other hand, the 1/R control was applied to the UPTAH and HFTAH to perform a physiological study with a nonpulsatile TAH by changing the drive mode from pulsatile to nonpulsatile in a single goat. The result showed that, for a period of several weeks, the 1/R control could be promising not only with a pulsatile flow, but also with a nonpulsatile flow. The general conditions and organ functions were not changed by the application of the nonpulsatile flow. The cardiac output and the arterial pressure changed with the condition of the goat in the pulsatile and also nonpulsatile flow, which seemed almost identical. However, under the physiological atrial pressure, the sucking effect of atria was more significant in the nonpulsatile flow than the pulsatile flow. Therefore, the nonpulsatile TAH with the 1/R control was considered to be inadequate, unless some pulsatility would be introduced to avoid the sucking effect for ensuring sufficient inflow condition.

Concerning the materials, we have been developing a

new method to develop hybrid materials. In general, it is not easy to develop mechanical parts for complex artificial organs such as artificial hearts from the components of living tissue because these components have insufficient strength and durability, even though they have excellent tissue compatibility. To overcome these problems, an insert molding method, which is commonly used for resin molding in the industrial field, was introduced. In this method, the mold, in which an artificial material was inserted, was implanted in the animal, and the tissue grew into the mold to make a hybrid material. The method was first applied to the Jellyfish valve that was originally a polymer valve for the artificial hearts. The hybrid Jellyfish valve demonstrated a good result. Then, we started to develop the hybrid conduit of the inflow cannula for the left ventricular assist device (LVAD). The conduit is inserted into the apex of the left ventricle where the thrombus often formed. In this method, the mold in which the core of the conduit was inserted was implanted under the skin of a goat. After several months, the hybrid conduit was extirpated, and then freeze-dried, sterilized and used. The experiment of the LVAD using the hybrid conduit is going on with a goat. This hybrid technique will be an important technology for developing the next generation artificial organs.

A project of the novel gas-exchange system for bridging to lung transplantation has been performed in an AMED project. The device consists of a blood pump, an oxygenator, a drive and control unit, and a battery unit. To realize several-months support, the left side blood pump of helical flow TAH has been employed. This system is expected to offer more opportunities and safer surgical interventions to those who are waiting for lung transplants. In case of high afterload, the sequential flow pump (SFP) would be applied. The SFP in which fluid is given centrifugal force sequentially twice in a pump was invented in our laboratory in 2013. This sequential pressurization mechanism enables high-pressure output without high impeller speed, which can reduce the sheer stress of the blood. To realize integration of the pump with the artificial lung, inlet and outlet ports are located at lateral side and center of the pump, respectively, which is the reverse configuration of conventional centrifugal pumps.

References

1. Yusuke INOUE, Ayaka TASHIRO, Yukino KAWASE, Takashi ISOYAMA, Itsuro SAITO, Toshiya ONO, Shintaro HARA, Kohei ISHII, Terumi YURIMOTO, Yasuyuki SHIRAISHI, Akihiro YAMADA, Tomoyuki YAMBE, Yusuke ABE, Optimum Sterilization Methods of Biocompatible Hybrid Material for Artificial Organs. *Advanced Biomedical Engineering* 9: 2020 83-92,2020

Division of Integrative Genomics

Professor

Katsutoshi Oda, M.D., Ph.D.

Associate Professor

Aya Ushiku, M.D., Ph.D.

Organization

The division of Integrative Genomics was established in January 2020 to comprehensively promote genomic research both clinically and basically. The activity of this division is linked to the Department of Clinical Genomics and Genomic Research Support Center, as well as the Department of Next-Generation Precision Medicine Development Laboratory. We focus on both basic research and translational research in the field of genomics (especially genomic medicine in cancer).

Activities

Teaching activities

We teach the 3rd year medical students (M1) about genomics, genomic medicine, and genetic counseling as part of “General Pathology” and “Medical Engineering Lectures”. For M4 medical students who come to the Department of Clinical Genomics for a one-month rotation in fiscal year, we give lectures and opportunities to participate in genetic counseling and molecular tumor board (Expert Panels) under collaboration with “Next-Generation Precision Medicine Development Laboratory”, “Department of Pathology”, “Department of Clinical Laboratory”, and many other related clinical departments. As for PhD students, our laboratory take part in the lecture of “Clinical Oncology”.

Basic Research

- (1) Genome-wide analysis of cancer
 - a. Whole-genome sequencing, whole-exome sequencing, Comprehensive Genomic Profiling

- b. Multi-omics (Copy Number Variation Analysis, RNA-sequencing, Methylation Array, etc)
- c. Liquid biopsy (with circulating tumor cells, cell-free tumor DNA, DNA from ascites, etc)
- d. Analysis of hereditary cancer syndromes (Genetic testing and NGS-based comprehensive analysis)

(2) Development of a novel NGS-based cancer genomic profiling panel (Todai OncoPanel2)

- a. Analysis of quality of DNA and RNA from FFPE (formalin-fixed paraffin-embedded) specimens.
- b. Prospective analysis of various cancers for clinical application.
- c. Evaluation of microsatellite instability and genomic instability

(3) Exploration of biomarkers for molecular-targeted drugs

- a. Evaluation of homologous recombination deficiency by using mutational signatures
- b. Biomarkers for immune checkpoint inhibitors
- c. Classification by expression signature
- d. Drug sensitivity screening by using patient-derived models

Translational Research

(1) Todai OncoPanel and Genomic Medicine in Cancer

Trial of a multiplex genomic testing by "Todai OncoPanel" for Geneprofiling of malignant solid tumors as Advanced Medical Care Category B was performed in 200 cancer patients (from 2018 to 2020).

UMIN000033647

Todai OncoPanel (TOP) has been originally established at the University of Tokyo (by Professor Hiroyuki Mano (currently Director of National Cancer Center Research Institute) and Professor Hiroyuki Aburatani et al), which is composed of DNA panel (version 3: 464 genes) and RNA panel (version 4: 463 genes). We reported the usefulness of TOP panel, especially in detecting gene fusions, including *ALK*, *ROS1*, and *NTRK*.

(2) Investigator-Initiated Clinical Trial using a PARP inhibitor, entitled “A multi-center, phase II study of Olaparib maintenance therapy in patients with high-grade ovarian cancer, combined with translational research by integrated genome-wide analysis”

This study assesses the efficacy of olaparib maintenance monotherapy in high-grade and stage IIIC/IV ovarian cancer patients (including patients with primary peritoneal and / or fallopian tube cancer) with “BRCA-related biomarker” that is predicted by whole-exome sequencing of fresh-frozen tumor samples.

(3) Enrollment to the prospective trial of patient-proposed healthcare services with multiple targeted agent based on the result of gene profiling by multigene panel test. (BELIEVE) : jRCTs031190104

Clinical activities are described in the section of “Department of Clinical Genomics”.

Publications

1. Tanaka M, Shinozaki-Ushiku A, Kunita A, Yasunaga Y, Akamatsu N, Hasegawa K, Ushiku T: High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma. *Pathol Int*. 2022 Aug;72(8):411-418.
2. Kage H, Kohsaka S, Tatsuno K, Ueno T, Ikegami M, Zokumasu K, Shinozaki-Ushiku A, Nagai S, Aburatani H, Mano H, Oda K: Tumor mutational burden measurement using comprehensive genomic profiling assay. *Jpn J Clin Oncol*. 2022 Aug 5;52(8):925-929.
3. Taguchi A, Rokutan H, Oda K, Tanikawa M, Tanimoto S, Sone K, Mori M, Tsuruga T, Kohsaka S, Tatsuno K, Shinozaki-Ushiku A, Miyagawa K, Mano H, Aburatani H, Ushiku T, Osuga Y: Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma. *BMC Med Genomics*. 2022 Mar 7;15(1):51.
4. Ando T, Kage H, Shinozaki-Ushiku A, Tatsuno K, Tsutsumi S, Nagayama K, Nakajima J, Kohsaka S, Miyagawa K, Aburatani H, Mano H, Nagase T: Composite Clonal Analysis Reveals Transition of NSCLC Subtypes Through Accumulation of Gene Mutations: A Case Report. *JTO Clin Res Rep*. 2022 Jan 10;3(2):100277.
5. Tian D, Shiiya H, Sato M, Shinozaki-Ushiku A, Yan HJ, Nakajima J: Pathological tumor long-to-short axis ratio as a prognostic factor in patients with thymic epithelial tumors. *Thorac Cancer*. 2022 Sep;13(17):2489-2498.
6. Kume A, Shinozaki-Ushiku A, Kunita A, Kondo A, Ushiku T: Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization. *Am J Surg Pathol*. 2022 Oct 1;46(10):1386-1396.
7. Tian D, Shiiya H, Takahashi M, Terasaki Y, Urushiyama H, Shinozaki-Ushiku A, Yan HJ, Sato M, Nakajima J: Noninvasive monitoring of allograft rejection in a rat lung transplant model: Application of machine learning-based 18F-fluorodeoxyglucose positron emission tomography radiomics. *J Heart Lung Transplant*. 2022 Jun;41(6):722-731.
8. Nakazaki K, Yoshida M, Masamoto Y, Shinozaki-Ushiku A, Ikemura M, Hisamoto T, Yasunaga M, Sato S, Kurokawa M: Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. *Int J Hematol*. 2022 Sep;116(3):446-452.
9. Sone K, Kukita A, Masui Y, Yamada D, Shinozaki-Ushiku A, Kawata A, Taguchi A, Miyamoto Y, Tanikawa M, Iriyama T, Mori-

- Uchino M, Tsuruga T, Osuga Y: Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report. *Mol Clin Oncol*. 2022 Mar;16(3):63.
10. Takano H, Yasunaga M, Yamazaki I, Nishikawa M, Masamoto Y, Shinozaki-Ushiku A, Kawakami M, Yatomi Y, Kurokawa M: Degenerated mitochondria in leukemic blast appeared as granules on May-Grunwald-Giemsa staining. *Ann Hematol*. 2022 May;101(5):1135-1136.
 11. Tanaka R, Kaburaki T, Taoka K, Karakawa A, Tsuji H, Nishikawa M, Yatomi Y, Shinozaki-Ushiku A, Ushiku T, Araki F: More Accurate Diagnosis of Vitreoretinal Lymphoma Using a Combination of Diagnostic Test Results: A Prospective Observational Study. *Ocul Immunol Inflamm*. 2022 Aug;30(6):1354-1360.
 12. Shiiya H, Sato M, Shinozaki-Ushiku A, Konoeda C, Kitano K, Nakajima J: Exacerbation of Secondary Pulmonary Hypertension by Flat Chest after Lung Transplantation. *Ann Thorac Cardiovasc Surg*. 2022 Aug 20;28(4):298-301.
 13. Toyohara Y, Sone K, Noda K, Yoshida K, Kurokawa R, Tanishima T, Kato S, Inui S, Nakai Y, Ishida M, Gono W, Tanimoto S, Takahashi Y, Inoue F, Kukita A, Kawata Y, Taguchi A, Furusawa A, Miyamoto Y, Tsukazaki T, Tanikawa M, Iriyama T, Mori-Uchino M, Tsuruga T, Oda K, Yasugi T, Takechi K, Abe O, Osuga Y. Development of a deep learning method for improving diagnostic accuracy for uterine sarcoma cases. *Sci Rep* 12:19612, 2022.
 14. Kukita A, Sone K, Kaneko S, Kawakami E, Oki S, Kojima M, Wada M, Toyohara Y, Takahashi Y, Inoue F, Tanimoto S, Taguchi A, Fukuda T, Miyamoto Y, Tanikawa M, Mori-Uchino M, Tsuruga T, Iriyama T, Matsumoto Y, Nagasaka K, Wada-Hiraike O, Oda K, Hamamoto R, Osuga Y. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells. *Cancers (Basel)*. 2022. Oct 31;14(21):5367.
 15. Honjoh H, Tanikawa M, Wada-Hiraike O, Oda K, Inaba H, Kukita A, Kawata Y, Kusakabe M, Tsuchimochi S, Taguchi A, Miyamoto Y, Sone K, Tsuruga T, Mori-Uchino M, Matsumoto Y, Osuga Y. MED1, a novel binding partner of BRCA1, regulates homologous recombination and R-loop processing. *Sci Rep* 2022 12:17140.
 16. Ishizaka A, Taguchi A, Tsuruga T, Maruyama M, Kawata A, Miyamoto Y, Tanikawa M, Ikemura M, Sone K, Mori M, Koga K, Ushiku T, Oda K, Osuga Y. Endometrial cancer with concomitant endometriosis is highly associated with ovarian endometrioid carcinoma: a retrospective cohort study. *BMC Womens Health* 2022, 22:332.
 17. Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O'Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM, Bookman MA. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. *Lancet Oncol* 2022, 23:e374-e384.
 18. Kobayashi Y, Masuda K, Hirasawa A, Takehara K, Tsuda H, Watanabe Y, Oda K, Nagase S, Mandai M, Okamoto A, Yaegashi N, Mikami M, Enomoto T, Aoki D, Katabuchi H. Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO). *J Gynecol Oncol* 2022, 33:e61.
 19. Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T. Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). *J Gynecol Oncol* 2022, 33:e55.
 20. Yoshimoto D, Taguchi A, Tanikawa M, Sone K, Shimoi T, Tsuruga T, Oda K, Osuga Y. Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: A case enrolled in the BELIEVE trial. *J Obstet Gynaecol Res* 2022, 48:2010-2014.
 21. Tojima Y, Taguchi A, Mori M, Nara K, Miyamoto Y, Tanikawa M, Sone K, Tsuruga T, Yamamoto T, Oda K, Suzuki H, Osuga Y. Effect

of primary prophylaxis with pegfilgrastim in endometrial cancer patients treated with doxorubicin and cisplatin. *Taiwan J Obstet Gynecol* 2022, 61:265-269.

22. Minamoto A, Yamada T, Shimada S, Kinoshita I, Aoki Y, Oda K, Ueki A, Higashigawa S, Morikawa M, Sato Y, Hirasawa A, Ogawa M, Kondo T, Yoshioka M, Kanai M, Muto M, Kosugi S. Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey. *J Hum Genet* 2022, 67:557-563.
23. Inoue F, Sone K, Toyohara Y, Tanimoto S, Takahashi Y, Kusakabe M, Kukita A, Honjoh H, Nishijima A, Taguchi A, Miyamoto Y, Tanikawa M, Iriyama T, Uchino MM, Tsuruga T, Wada-Hiraike O, Oda K, Osuga Y. Histone arginine methyltransferase CARM1 selective inhibitor TP-064 induces apoptosis in endometrial cancer. *Biochem Biophys Res Commun* 2022, 601:123-128.
24. Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. *Commun Biol* 2022, 5:39.

Neuroscience

1. Basic Neuroscience

Department of Neuropathology

Professor

Takeshi Iwatsubo, M.D., Ph.D.

Lecturer

Tomoki Kuwahara, Ph.D.

Associate

Kaoru Yamada, Ph.D.

Kenichiro Sato, M.D., Ph.D.

Homepage <http://www.neuropathology.m.u-tokyo.ac.jp/>

Dr. Iwatsubo's research group has been pursuing the pathogenesis of Alzheimer's disease (AD) and related neurodegenerative conditions (especially, dementia with Lewy bodies; DLB) by multi-disciplinary approaches, based on histopathology and protein biochemistry of postmortem human brains. They then extended the knowledge derived from the human studies in a way to establish cellular models and to elucidate the key steps in the pathological cascade of neurodegeneration. Thus, Dr. Iwatsubo's group has been addressing the pathogenesis of neurodegenerative disorders from the downstream (i.e., analysis of aggregated proteins) as well as from the upstream (i.e., pathogenic effects of pathogenic genes), covering a number of crucial proteins/genes related to AD and DLB, i.e., β -amyloid (including its binding protein CLAC), presenilin/ γ -secretase and α -synuclein. In this way Dr. Iwatsubo's group has contributed much to the widely accepted notion that abnormal misfolding of brain proteins is the common cause of a variety of neurodegenerative disorders including AD. Furthermore, Dr. Iwatsubo's group is currently working hard to translate the basic findings into the clinical application of mechanism-based, disease-modifying therapies for AD through the world-wide ADNI project, in which Dr. Iwatsubo serves as the PI of Japanese ADNI.

1. Research on β -amyloid and presenilins

Using C-terminal specific monoclonal antibodies that discriminate amyloid β peptides ($A\beta$) ending at 40th or 42nd residues ($A\beta_{40}$ and $A\beta_{42}$, respectively), Dr. Iwatsubo has performed a systematic immuno-histochemical studies on autopsied brain tissues from patients with AD, Down syndrome and familial AD, and demonstrated that $A\beta_{42}$, that most readily form amyloid fibrils in vitro, is the initially and predominantly deposited species in human cerebral β -amyloidosis (Iwatsubo et al. Neuron 1994, Ann Neurol 1995). Dr. Iwatsubo's group then established cellular models expressing mutant forms of presenilin (PS) genes linked to familial AD (FAD), and using their original highly-sensitive ELISA quantitation system, his group has clearly shown that an increase in the production of $A\beta_{42}$ is the pathogenic mechanism leading to FAD (Tomita et al. Proc Natl Acad Sci USA, 1997). These findings have provided a firm basis for the currently prevailing β -amyloid hypothesis. They then focused on the mechanisms of γ -secretase complex that cleaves the C terminus of $A\beta$, and set out to cell biological studies using RNA interference on the formation and function of the γ -secretase complex harboring PS as the catalytic center, associated with three additional membrane proteins. They demonstrated that APH-1 and Nicastrin serve as the "stabilizing" co-factor of PS, whereas PEN-2 is the component that confers proteolytic activity to this complex. They also showed that PS,

APH-1, nicastrin and PEN-2 are the essential set of proteins that comprise the γ -secretase complex (Takasugi et al. *Nature*, 2003). This study is highlighted as a milestone work that elucidated the mechanistic roles of protein cofactors in the formation and function of γ -secretase (see reviews; Iwatsubo *Mol Psychiatr*, 2004; *Curr Opin Neurobiol*, 2004). His group has established an elegant strategy to analyze the structure-function relationship within the catalytic structure of γ -secretase complex by cysteine chemistry, and demonstrated that γ -secretase harbors a water-permeable catalytic pore (Sato et al. *J Neurosci*, 2006), and that substrate proteins enter the catalytic pore through the lateral gate located at the C terminal side of PS (Sato et al. *J Neurosci*, 2008). Thus, Dr. Iwatsubo's group started from an elegant immuno-histochemical analysis of A β deposits in AD brains and extended it to a contemporary molecular/cellular biology of PS, that proved to play a key role in "intramembrane proteolysis".

2. Identification and characterization of α -synuclein as a major component of Lewy bodies.

Using cortical Lewy bodies purified from postmortem brains of patients with dementia with Lewy bodies (DLB) by his original method (Iwatsubo et al. *Am J Pathol* 1996) as immunogens, Dr. Iwatsubo's group, in collaboration with Drs. Virginia Lee and John Trojanowski at Univ. Penn, performed an extensive immunochemical search for components of Lewy bodies. They have demonstrated by raising a specific monoclonal antibody that α -synuclein, that proved to be a product of pathogenic gene for familial form of Parkinson's disease, is one of the major constituent of Lewy bodies in sporadic Parkinson's disease and DLB (Baba et al. *Am J Pathol* 1998). His group then purified aggregated α -synuclein from DLB cortices using fine biochemical techniques, purified it to near homogeneity, and demonstrated using mass spectrometry and specific antibodies that α -synuclein deposited in synucleinopathy lesions is highly phosphorylated at a specific serine residue (Fujiwara et al. *Nature Cell Biol* 2002). This finding led to a range of studies focusing on the role of synuclein phosphorylation in neurodegeneration. Also, the phospho-specific α -synuclein antibody is widely used as the most sensitive marker for α -synucleinopathy

lesions, and has characterized a wide spectrum of α -synuclein pathologies in neurodegenerative disorders.

3. Identification of a non-A β Alzheimer amyloid plaque component CLAC, and its precursor CLAC-P

The major component of Alzheimer's amyloid plaques is A β , although there are a number of non-A β components that potentially affect fibrillization and degradation of amyloid deposits. Among these, there has been an enigmatic "missing piece" protein of molecular masses of 50/100 kDa. Dr. Iwatsubo's group raised a monoclonal antibody against amyloid fraction that recognizes this protein, and using this antibody as a probe, they conducted a thorough biochemical purification of these antigens and finally cloned a cDNA coding for the precursor of this protein. This protein turned out to be a novel class of membrane-bound collagen, which was named CLAC (collagen-like Alzheimer amyloid plaque component) and its precursor CLAC-P (Hashimoto et al. *EMBO J* 2002). This finding had an immense impact both on fields of AD research as well as on general biology as a first discovery of neuron-specific collagen harboring a unique membrane-spanning structure. CLAC has been highlighted as a protein that may affect fibrillization of A β and contribute to amyloid plaque formation. Indeed, he has recently shown that CLAC-positive senile plaques constitute a unique subset of plaques distinct from the classical, β -sheet-rich amyloid deposits, underscoring the pathobiological role of CLAC in amyloid formation, and that CLAC inhibits fibrillization of A β in vitro. Knockout mice studies have confirmed the role of CLAC in neuromuscular development (Munezane et al. *Cell Reports*, 2019).

4. Glymphatic system and tau clearance

Accumulation of tau has been implicated in various neurodegenerative diseases termed tauopathies. Tau is a microtubule-associated protein but is also actively released into the extracellular fluids including brain interstitial fluid and cerebrospinal fluid (CSF). However, it remained elusive whether clearance of extracellular tau impacts tau-associated neurodegeneration. We showed that aquaporin-4 (AQP4), a major driver of the glymphatic clearance system, facilitates the elimination of

extracellular tau from brain to CSF and subsequently to deep cervical lymph nodes. Strikingly, deletion of AQP4 not only elevated tau in CSF but also markedly exacerbated phosphorylated tau deposition and associated neurodegeneration in the brains of transgenic mice expressing P301S mutant tau. We thus identified the clearance pathway of extracellular tau in the central nervous system, suggesting that glymphatic clearance of extracellular tau is a novel regulatory mechanism whose impairment contributes to tau aggregation and neurodegeneration.

5. Japanese ADNI and development of disease-modifying therapies against AD

Basic studies on the pathomechanism of AD have boosted the development of mechanism-based drugs for AD, whereas the bottleneck has been the lack of surrogate biomarkers that represent the progression of AD pathology and are useful in the clinical trial of disease-modifying drugs. In close collaboration with Drs. Mike Weiner and Ron Petersen of US-ADNI, Dr. Iwatsubo has initiated the Japanese ADNI as the principal investigator on 2006, recruiting 38 clinical sites nationwide, and preparing all the infrastructures required for the large-scale clinical study. The J-ADNI group recruit 537 individuals in total, and all the data derived from the J-ADNI study have been made in public from the National Bioscience Database Center for research use. Recently, the J-ADNI group has demonstrated the similarity between MCI due to AD in Asian and Caucasian populations by comparing the clinical and biomarker features of J-ADNI and ADNI participants, supporting the feasibility of global clinical trials of disease-modifying therapies for AD. Recently, his group is leading the “Japanese Trial-Ready cohort for prevention of AD (J-TRC). These efforts have led to the successful development of anti-amyloid antibody therapies against AD in 2023.

References

- 1) An H, Litscher G, Watanabe N, Wei W, Hashimoto T, Iwatsubo T, Buchman VL, Shelkovernikova T: ALS-linked cytoplasmic FUS assemblies are compositionally different from physiological stress granules and sequester hnRNPA3, a novel modifier of FUS toxicity. *Neurobiol Dis* 162:105585, 2022
- 2) Kazawa K, Akishita M, Ikeda M, Iwatsubo T, Ishii S: Experts' perception of support for people with dementia and their families during the COVID-19 pandemic. *Geriatr Gerontol Int* 22: 26-31, 2022
- 3) Rotstein A, Levine SZ, Samara M, Yoshida K, Goldberg Y, Cipriani A, Iwatsubo T, Leucht S, Furawaka TA: Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil. *Eur Neuropsychopharmacol* 57:50-58, 2022
- 4) Levine SZ, Goldberg Y, Yoshida K, Efthimiou O, Samara M, Cipriani A, Iwatsubo T, Leucht S, Furawaka TA: Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. *J Psychiatr Res* 148:159-164, 2022
- 5) Ishida K, Yamada K, Nishiyama R, Hashimoto T, Nishida I, Abe Y, Yasui M, Iwatsubo T: Glymphatic system clears extracellular tau and protect from tau aggregation and neurodegeneration. *J Exp Med* 219:e20211275, 2022
- 6) Kaneshiro N, Komai M, Imaoka R, Ikeda A, Kamikubo Y, Hashimoto T, Iwatsubo T, Sakurai T, Uehara T, Takasugi N: Lipid flippase dysfunction as a novel therapeutic target for endosomal anomalies in Alzheimer's disease. *iScience* 25: 103869, 2022
- 7) Haeberlein SB, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A: Two randomized phase 3 studies to evaluate aducanumab in early Alzheimer disease. *J Prev Alzheimers Dis* 9:197-210, 2022
- 8) Tsujikawa K, Hamanaka K, Riku Y, Hattori Y, Hara N, Iguchi Y, Ishigaki S, Hashizume A, Miyatake S, Mitsunashi S, Miyazaki Y, Kataoka M, Jiayi L, Yasui K, Kuru S, Koike H, Kobayashi K, Sahara N, Ozaki N, Yoshida M, Kakita A,

- Saito Y, Iwasaki Y, Miyashita A, Iwatsubo T, Ikeuchi T, Miyata T, Sobue G, Matsumoto N, Sahashi K, Katsuno M: Actin-1 binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. *Sci Adv* 8:eabm5029, 2022
- 9) Sato K, Niimi Y, Mano T, Iwata A, Iwatsubo T: Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database. *Biosci Trends* 16:151-157, 2022
 - 10) Sato K, Niimi Y, Mano T, Iwata A, Iwatsubo T: Automated evaluation of conventional clock-drawing test using deep neural network: potential as a mass screening tool to detect individuals with cognitive decline. *Front Neurol* 13:896403, 2022
 - 11) Kishino Y, Matsukawa K, Matsumoto T, Wakabayashi T, Nonaka T, Kametani F, Hasegawa M, Hashimoto T, Iwatsubo T: Casein kinase 1 δ/ϵ phosphorylates fused in sarcoma (FUS) and ameliorates FUS-mediated neurodegeneration. *J Biol Chem* 298: 102191, 2022
 - 12) Poulakis K, Pereira JB, Muehlboeck J-S, Wahlund L-O, Smedby Ö, Volpe G, Masters CL, Ames D, Niimi Y, Iwatsubo T, Ferreira D, Westman E: Stage vs. Subtype hypothesis in Alzheimer's disease: a multi-cohort and longitudinal Bayesian clustering study. *Nat Commun* 13:4566, 2022
 - 13) Kasuga K, Kikuchi M, Tsukie T, Suzuki K, Ihara R, Iwata A, Hara N, Miyashita A, Kuwano R, Iwatsubo T, Ikeuchi T: Characterization of ATN profile classified using two different N markers in CSF. *BMJ Neurol Open* 4:e000321, 2022
 - 14) Sato K, Niimi Y, Iwatsubo T, Ishii S: Change in long-term care service usage in Japan following the COVID-19 pandemic: a survey using a nationwide statistical summary in 2018–2021. *Geriatr Gerontol Int* 22:803-809, 2022
 - 15) de Erausquin GA, Snyder HM, Brugha TS, Seshadri S, Carrillo M, Sagar R, Huang Y, Newton C, Tartaglia C, Teunissen C, Håkanson K, Akinyemi R, Prasad K, D'Avossa G, Gonzalez-Aleman G, Hosseini A, Vavougiou GD, Sachdev P, Bankart J, Ole Mors NP, Lipton R, Katz M, Fox PT, Katshu MZ, Iyengar MS, Weinstein G, Sohrabi HR, Jenkins R, Stein DJ, Hugon J, Mavreas V, Blangero J, Cruchaga C, Krishna M, Wadood O, Becerra R, Zwir I, Longstreth WT, Kroenenberg G, Edison P, Mukaetova-Ladinska E, Staufenberg E, Figueredo-Aguilar M, Yécora A, Vaca F, Zamponi HP, Lo Re V, Majid A, Sundarakumar J, Gonzalez HM, Geerlings MI, Skoog I, Salmoiraghi A, Boneschi FM, Patel VN, Santos JM, Arroyo GR, Moreno AC, Felix P, Gallo C, Arai H, Yamada M, Iwatsubo T, Sharma M, Chakraborty N, Ferreccio C, Akena D, Brayne C, Maestre G, Blangero SW, Brusco LI, Siddarth P, Hughes TM, Zuñiga AR, Kambeitz J, Laza AR, Allen N, Panos S, Merrill D, Ibáñez A, Tsuang D, Valishvili N, Shrestha S, Wang S, Padma V, Anstey KJ, Ravindranath V, Blennow K, Mullins P, Łojek E, Pria A, Mosley TH, Gowland PG, Girard TD, Bowtell R, Vahidy FS: Chronic neuropsychiatric sequelae of SARS-CoV2: Protocol 1 and methods from the Alzheimer's Association Global Consortium. submitted to *Alzheimers Dementia: Translational Research & Clinical Interventions* 8:e12348, 2022
 - 16) Yoshida K, Seo M, Yan L, Sahker E, Cipriani A, Leucht S, Iwatsubo T, Efthimiou O, Furukawa TA: Personalized prediction of Alzheimer's disease and its treatment effects by donepezil: an individual participant data meta-analysis of eight randomized controlled trials. *J Alz Dis* 89:1143-1157, 2022

Department of Neurochemistry

Professor and Head

Haruhiko Bito, M.D., Ph.D.

Lecturer

Hajime Fujii, Ph.D.

Assistant Professor

Ryang Kim, Ph.D., Keisuke Ota, Ph.D.

Homepage <http://www.neurochem.m.u-tokyo.ac.jp/Homepage.html>

Introduction and Organization

Our Department's primary goal is to elucidate the basic signal transduction mechanisms which mediate key processes underlying various brain functions, such as learning, memory or emotion. A fundamental question is how an ensemble behavior of 10~100 billion neurons can possibly give rise to a coherent and integrated "brain" that controls the whole human organism for a period of more than eighty years. Our central nervous system is physically wired and organized based on evolutionary and developmental principles that are primarily encoded into the genome and that are highly conserved in mammals from rodents to primates. This neural network, however, is able to recognize and memorize external and internal events as they occur. And furthermore, brain function, especially human's, stands out by its intrinsic capacity to extract patterns and rules from these events, and to consciously associate them with abstract meaning and affective valence, while also unconsciously facilitating coordinated body responses.

Neurochemistry once used to be a relatively dull discipline consisting of analyzing substances that form the brain. However, it has recently become a field of excitement where we are now (almost) able to measure changes in cellular messengers or modifications in signaling molecules in critical parts of the neurons such as the dendritic spines or the axon terminals, as the neurons summate synaptic potentials or fire action potentials.

What are the precise nature and the whole spectrum of the molecular changes in the neurons that undergo heavy or patterned electrical activity? What are the molecular rules that govern these local and global changes, both electrical and chemical? How are these events, in turn, converted into more profound modifications of the synaptic wiring mechanisms? And finally do these alterations genuinely underlie certain kinds of information processing and storage?

To address these issues, this Department currently focuses its resources into two basic aims:

- 1) Molecular investigation (including identification, characterization and real-time visualization) of signaling molecules involved in calcium-dependent synaptic modification, especially during signaling from synapse-to-nucleus, and back from nucleus-to-synapses.
- 2) Understanding molecular mechanisms controlling cytoskeletal dynamics and remodeling on both sides of the synapses, in the dendritic spines and in axon terminals.

Following the retirement of Professor Tatsuya Haga (who became the President of Life Sciences Institute at the Faculty of Science at Gakushuin University) in March 2001, and the departure of Associate Professor David Saffen to initially University of Minnesota and then to Ohio State University in August 2001, Associate Professor Haruhiko Bito was appointed as Head of Department since January 2003. The Department is located on the 6th floor, in the West

wing of the third building of the Medical School. The Department currently enrolls one professor, one lecturer, two assistant professors, two postdoctoral scholars, one technical staff, seven Ph.D. graduate students, one research student, one technical assistant and three administrative assistants.

Teaching activities

The Department's teaching activities include:

- 1) Introductory Neuroscience coursework provided to pre-medical students in the Komaba campus (one hour);
- 2) Neurochemistry lectures to medical students as part of the "Biochemistry- Molecular Biology- Nutrition" core curriculum (two hours);
- 3) Introductory Molecular and Cellular Neuroscience, and Basic Neurochemistry lectures to first-year master degree students (three hours);
- 4) Organization of the lecture course: "Basic Neuroscience" (Molecular and Cellular Neuroscience) (a lecture series with fifteen lectures from outstanding neuroscientists from all over Japan).

Additionally, Neurochemistry Seminars are frequently and regularly organized that enables direct exposure of Ph.D. graduate students and postdocs to both young promising researchers and established investigators from all over the world.

Research activities

The Department of Neurochemistry currently focuses its resources into two core projects:

- 1) Molecular investigation (including identification, characterization and real-time visualization) of signaling molecules involved in calcium-dependent synaptic modification, especially during signaling from synapse-to-nucleus, and back from nucleus-to-synapses.

Changes in efficacy of synaptic transmission have been shown to strongly correlate with functional plasticity of many brain circuits including the hippocampus, the amygdala, the striatum, the neocortex, the cerebellum or the spinal cord. An early phase of long-term synaptic plasticity is induced by virtue of specific post- and/or presynaptic modifications of the biochemical machinery dedicated to

synaptic release and neurotransmitter recognition. It then is expressed by bistable mechanisms that are strongly governed and dictated by the pattern of synaptic calcium influxes experienced during the initial conditioning period. While the molecular identity of the involved synaptic proteins is now (almost) being solved (or is becoming much less controversial than before), several essential questions remain unanswered.

The "Old" question was: What are the molecular determinants that enable these plastic changes to be induced and maintained locally? Yet, related issues of critical importance that still remain wide open questions are:

- 1) What are the full-range of calcium-triggered molecular signaling cascades which are activated at and near the potentiated/depressed synapses? And how do they influence plasticity per se?
- 2) What is the contribution of activity-dependent gene expression in prolongation and consolidation of such synapse-restricted changes?

In order to begin to address these issues, we have been investigating in particular the role of several calcium-calmodulin dependent protein kinases.

We previously showed the critical importance of a CaMKK/CaMKIV cascade in triggering synaptically-stimulated nuclear CREB phosphorylation in hippocampal neurons. The extreme biochemical efficacy and the relative poor frequency-dependence of this signaling cascade, in combination with the robust correlation between prolonged pCREB response and downstream gene expression led us to propose that CaMKK/CaMKIV/pCREB cascade was likely to act as a critical temporal integrator for activity-dependent gene expression in excitatory neurons (Bito et al., Cell, 1996; Bito et al., Curr. Opin. Neurobiol., 1997; Bito, Cell Calcium, 1998). This hypothesis has now been critically tested in various brain systems and indeed pCREB immunofluorescence is now considered as a universal marker for integrated synaptic activity that is more sensitive than that of c-Fos (Nonaka, J. Neurosci. 2009). The critical function of CaMKK/CaMKIV/pCREB cascade in the expression of long-term synaptic plasticity was also validated in long-term potentiation in the hippocampus (Redondo et al., J Neurosci. 2010). Furthermore, CaMKIV-KO, CaMKK-KO and

CaMKIV-dominant negative transgenic studies by many laboratories have confirmed the critical role for CaMKIV as synaptic activity-triggered CREB kinase.

We subsequently also showed that CaMKIV in the cerebellar granule cells played a critical role in tuning the pCREB response necessary for depolarization-mediated neuronal survival, and that in fact CaMKIV stability was actively maintained by depolarization. Loss of depolarizing signal led to a caspase-mediated proteolytic degradation of CaMKIV. This in turn severely impaired CREB phosphorylation, facilitating apoptosis, and conversely rescuing pCREB by overexpressing an active form of CaMKIV was sufficient to prevent apoptosis (See et al., *FASEB J.*, 2001). Consistent with our observation that subtle CREB regulation may underlie the neuronal cell survival, CREB-dependent gene expression mechanisms, especially CBP regulation, have actually been proposed to be affected in one way or another in many neurodegenerative disorders such as hereditary polyglutamine diseases. We thus speculated that if CREB-opathies (or various defects in CREB-mediated gene activation mechanisms) were critical determinants in exacerbating neurodegeneration, certain disease forms may actually accompany deficit in CaMKIV/pCREB signaling (Bito and Takemoto-Kimura, *Cell Calcium* 2003). We also identified kinase/phosphatase signaling responsible for activity-dependent nuclear trafficking of CRTC1, a key cofactor of CREB, and demonstrated its roles in CREB-dependent transcription and contextual fear memory in amygdala (Nonaka et al., *Neuron* 2014).

To elucidate the significance of the genes regulated downstream of CREB during learning and memory, we set out to uncover the most elementary regulatory element required and sufficient to trigger robust activity-dependent gene induction of the immediate early gene *Arc*, whose expression in many brain areas have been invariably associated with key cognitive activities mediated by these areas. We discovered a fundamentally novel synaptic activity-responsive element (SARE) which was present as a distal regulatory promoter element and was conserved across most mammalian species (Kawashima et al., *PNAS* 2009; Kim et al., *Nature* 2010; Inoue et al., *Commun. Integr. Biol.* 2010). Surprisingly, SARE contained juxtaposed binding elements for all three

activity-regulated transcription factors, CREB, MEF2 and SRF. The identification of SARE enables us to build reporter virus and mouse lines that are expected to be useful to map the extent of neuronal circuit activation during various kinds of cognitive activities (Kawashima et al., *Nat. Methods* 2013). In addition to the transcriptional regulation, we are currently investigating about the physiological function and its molecular mechanism of *Arc*, which is thought to be a key player that contributes activity dependent neuronal plasticity at post synaptic sites (Okuno et al., *Cell* 2012).

One parallel branch of CaMK signaling that has not been widely studied is the CaMKK/CaMKI pathway. During the search for potential CaMKIV-like CREB regulatory kinases (CLICKs) (Ohmae et al., *J. Biol. Chem.* 2006), we identified a novel CaMKI isoform that contained a C-terminal CAAX lipid modification motif (Takemoto-Kimura et al., *J. Biol. Chem.*, 2003; Takemoto-Kimura et al., *Neuron* 2007). This novel membrane-bound CaMK (CLICK-III/CaMKI γ) is most expressed in the central nucleus of the amygdala and in the ventral medial hypothalamus, while also being present at a much weaker amount in most central neurons. Biochemical and cell biological studies indicated a critical role for lipidification of this kinase to be properly sorted into specific lipid-restricted membrane microdomains. The function played by this lipidified, membrane-inserted CaMK in circuitry formation and maturation was scrutinized using RNA interference. Along with the identification of the critical lipid-modifying enzyme that controls lipid-anchoring of this kinase, we discovered a novel activity-regulated mechanism whereby CLICK-III/CaMKI γ is actively sorted into dendritic lipid rafts, where it specifically regulates Rac-mediated actin remodeling that is required for BDNF-stimulated dendritogenesis (Takemoto-Kimura et al., *Neuron*, 2007; Takemoto-Kimura et al. *Eur. J. Neurosci.* 2010). Similar studies in axonal growth also suggest the active contribution of CaMKK cascade in this process (Ageta-Ishihara et al., *J. Neurosci.* 2009; Takemoto-Kimura et al., *Eur. J. Neurosci.* 2010). Using a membrane-tethered genetically encoded calcium indicator, we successfully recorded spontaneous regenerative calcium transients (SRCaTs) in developing mouse excitatory cortical neurons and discovered that

L-type VGCCs play critical roles in neural development and corticogenesis (Kamijo et al., J. Neurosci. 2018).

How do these multiple Ca^{2+} -dependent signaling molecules process each pattern of intracellular Ca^{2+} dynamics to induce a cellular response? Recently, we have developed a method named dFOMA (dual FRET imaging with optical manipulation) to simultaneously measure activities of two distinct signaling molecules in living neurons. Applying originally developed FRET probes to dFOMA method enabled us to measure activities of CaMKII, calcineurin and Ca^{2+} , when a neuron received various frequencies of synaptic inputs. These experiments provided evidence that CaMKII α and calcineurin are fine-tuned to unique bandwidths and compute input variables in an asymmetric manner (Fujii et al., Cell Reports 2013; Fujii et al., Neurosci Res. 2022). We also applied the CaMKII FRET probe to elucidate the molecular mechanisms of intellectual disability caused by CAMK2A mutations and found a candidate therapeutic (Fujii et al., Front. Mol. Neurosci. 2022).

In line with the visualization of neuronal activity and Ca^{2+} signaling, we have developed R-CaMP2, a red genetically-encoded Ca^{2+} indicator that has single-action-potential sensitivity based on rational design that takes advantage of our long-standing effort and knowledge about CaMKK-CaMKIV signaling. By combining R-CaMP2 with green Ca^{2+} indicator G-CaMP, distinct activity patterns between excitatory and inhibitory neurons in somatosensory cortex was revealed (Inoue et al., Nat. Methods 2015). Furthermore, we have advanced our visualization probe technology to developed ultra-fast, ultra-sensitive Ca^{2+} indicators XCaMP-B/G/Y/R, which allowed imaging in blue, green, yellow, and red, and simultaneously tracked activities of high-frequency firing parvalbumin (PV)-positive cells, as well as activities of three different neuronal cell types (excitatory pyramidal cells, PV-positive and somatostatin (SST)-positive cells) (Inoue et al., Cell, 2019). We also developed knock-in mice expressing these novel Ca^{2+} indicators (Sakamoto et al., Cell Reports Methods 2022; Sakamoto et al., STAR Protocol, 2022).

One further important topic that we have been focusing for a number of years is the role of gene

expression in prolongation / consolidation of synapse-specific local changes. Neurons undergoing various stimulus patterns have been followed up in time and the amount of newly synthesized proteins and the local distribution of induced gene products have been monitored. Using state-of-the-art multi-wavelength fluorescence imaging techniques, we are now quantitatively assessing how local distribution of these newly synthesized gene products affect synaptic protein complexes (Okuno and Bito, AfCS/Nature Mol. Pages 2006).

2) Understanding molecular mechanisms controlling cytoskeletal dynamics and remodeling on both sides of the synapses, in the dendritic spines and in axon terminals.

Both synaptic maturation and synaptic plasticity have been shown to include a morphological component that is directed by the dynamics of actin cytoskeleton, a major cytoskeletal component both in the dendritic spines and at the very proximity of boutons in the axon terminals. Few studies in the past, however, had directly addressed what molecular determinants regulate actin dynamics in living central neurons undergoing synaptic activity. This was in part because actin filament assembly and disassembly were classically studied mostly at the moving edges of lamellipodia of large growth cones in large-size neurons from either mollusc or peripheral nerve cells. Such visualization turned out to be much more difficult in seemingly far less mobile spine structures tightly apposed to presynaptic active zones.

We (and others) used GFP-actin imaging to try to understand how neuronal actin cytoskeleton in hippocampal neurons was organized and reorganized by exposure to synaptic activity. In our dissociated culture system, virtually all spines contained a high amount of GFP-actin and most of them with few exceptions were apposed to FM4-64-positive active presynaptic termini. In these cultures, increases in synaptic glutamatergic transmission by repeated bursts of high-frequency synaptic activity clearly induced several distinct kinds of activity-dependent actin mobilization, including a slow but sustained synaptic delivery of GFP-actin in a non-negligible number of activated spines and a massive but transient enhancement in cortical actin at the somatic periphery.

The former was entirely dependent on NMDA-dependent Ca^{2+} -influx while the latter was likely to be mediated at least in part by L-type voltage-gated Ca^{2+} channel activity. Thus, distinct patterns and sources of Ca^{2+} influx were likely to trigger a complex spatially segregated patterns of actin cytoskeletal reorganization, with variable impact on either neuronal morphology and/or synaptic protein assembly (Furuyashiki et al., PNAS, 2002).

Similar studies are now ongoing in cerebellar Purkinje neurons, where spinogenesis is also subject to complex regulation during development, and where calcium dynamics is key to pre- and postsynaptic plasticity.

What are the key signaling pathways controlling actin dynamics in central neurons? We were especially keen to resolve the contribution of the small GTPase Rho and its downstream effectors, initially in the context of developmentally regulated neuronal morphogenesis. We first established in a model cell line N1E-115 that neurite retraction was directly linked to Rho/ROCK activity (Hirose et al., J. Cell Biol., 1998). We subsequently revealed that in central neurons, in addition to its essential role in regulating growth cone motility, Rho/ROCK activity in fact acted as a negative gate that tightly controls the timing with which the first processes are initiated out from the round cell soma (Bito et al., Neuron, 2000). Disruption of Rho/ROCK activity was sufficient to immediately initiate neuritogenesis. This indicated that endogenous Rho activators, by titrating ROCK activity, continuously antagonized process/ branch formation and that local gradient of Rho activators might play a crucial role in shaping the timing and the extent of process formation (Bito, J. Biochem., 2003). Consistent with this idea, we found that in cerebellar granule cells, a chemokine SDF-1 α released from the pia mater was likely to be a predominant Rho activator via stimulation of a cognate and specific GPCR CXCR4 (Arakawa et al., J. Cell Biol., 2003). While a true gradient in SDF-1 α still remains to be demonstrated in vivo, it is intriguing to note that most active axonal process formation and elongation actually occur in the inner zone of EGL that is opposite and most distant from the interface with the pia mater (Bito, J. Biochem., 2003). Most strikingly, we demonstrated that axon elongation could actively

occur in an intermediate Rho activity range that enables ROCK to be weakened enough while allowing another Rho effector mDial1 to actively mediate its effect on actin nucleation and polymerization (Arakawa et al., J. Cell Biol. 2003).

Whether similar or distinct mechanisms also operate during spinogenesis and spine maturation remains to be determined, though a role for Rho and ROCK has already been postulated in control of spine complexity and spine stability. However, multiple small GTPase signaling cascades clearly seem to contribute together, in a tightly coordinated manner, to spine regulation, since many distinct classes of GEFs and GAPs have now been shown to be localized in the dendritic spines. We ourselves initially reported the first two direct examples for PSD localization for such Rho small GTPases interacting proteins, Citron (Furuyashiki et al., J. Neurosci., 1999) and Cupidin/Homer2 (Shiraishi et al., J. Neurosci., 1999).

In an attempt to pin down molecular mechanisms that link PSD complexes and spine formation, we quantitatively examined the effect of deleting the binding capacity of single PDZ domains of PSD-95, one by one, and in combination, by structure-based amino acid replacements rather than domain deletion. Such a second-generation structure-function relation study surprisingly revealed that a quantitative binding between PSD-95 and synGAP tightly controlled the degree of PSD protein clustering in a manner that was inversely correlated with the distance from the spine head to the shaft. Thus, these results suggest the existence of a tight coordination between the state of PSD complex and the morphogenetic activity of each spine (Nonaka et al. J. Neurosci., 2006).

In parallel with this work, we and others determined that protein-protein interaction was key to determining the physical distance between the synaptic vesicles in the active zone and the voltage-gated calcium channels in its vicinity, the opening of which triggers their release (Kiyonaka et al., Nat. Neurosci. 2007).

Publications by lab members (January 2022- December 2022)

1. Hashizume R, Fujii H, Mehta S, Ota K, Qian Y, Zhu W, Drobizhev M, Nasu Y, Zhang J, Bito H,

- Campbell RE. A genetically encoded far-red fluorescent calcium ion biosensor derived from a biliverdin-binding protein. *Protein Sci.* 31(10), e4440, 2022 doi: 10.1002/pro.4440.
2. Fujii H, Kidokoro H, Kondo Y, Kawaguchi M, Horigane SI, Natsume J, Takemoto-Kimura S, Bito H. Förster resonance energy transfer-based kinase mutation phenotyping reveals an aberrant facilitation of Ca^{2+} /calmodulin-dependent $\text{CaMKII}\alpha$ activity in de novo mutations related to intellectual disability. *Front Mol Neurosci.* 15, 970031, 2022, doi: 10.3389/fnmol.2022.970031.
 3. Manita S, Shigetomi E, Bito H, Koizumi S, Kitamura K. In Vivo Wide-Field and Two-Photon Calcium Imaging from a Mouse using a Large Cranial Window. *J Vis Exp.* (186), e64224, 2022, doi: 10.3791/64224.
 4. Ago K, Nagoshi N, Imaizumi K, Kitagawa T, Kawai M, Kajikawa K, Shibata R, Kamata Y, Kojima K, Shinozaki M, Kondo T, Iwano S, Miyawaki A, Ohtsuka M, Bito H, Kobayashi K, Shibata S, Shindo T, Kohyama J, Matsumoto M, Nakamura M, Okano H. A non-invasive system to monitor in vivo neural graft activity after spinal cord injury. *Commun Biol.* 5(1):803, 2022, doi: 10.1038/s42003-022-03736-8.
 5. Sakamoto M, Ota K, Kondo Y, Okamura M, Fujii H, Bito H. In utero electroporation and cranial window implantation for in vivo wide-field two-photon calcium imaging using G-CaMP9a transgenic mice. *STAR Protoc.* 3(2):101421, 2022, doi: 10.1016/j.xpro.2022.101421.
 6. Sakamoto M, Inoue M, Takeuchi A, Kobari S, Yokoyama T, Horigane SI, Takemoto-Kimura S, Abe M, Sakimura K, Kano M, Kitamura K, Fujii H, Bito H.
 - A Flp-dependent G-CaMP9a transgenic mouse for neuronal imaging in vivo. *Cell Rep Methods.* 2(2):100168, 2022, doi: 10.1016/j.crmeth.2022.100168.
 7. Fujii H, Bito H., Deciphering Ca^{2+} -controlled biochemical computation governing neural circuit dynamics via multiplex imaging. *Neurosci Res.* 179:79-90, 2022, doi: 10.1016/j.neures.2022.04.004.
 8. Wang C, Horigane SI, Wakamori M, Ueda S, Kawabata T, Fujii H, Kushima I, Kimura H, Ishizuka K, Nakamura Y, Iwayama Y, Ikeda M, Iwata N, Okada T, Aleksic B, Mori D, Yoshida T, Bito H, Yoshikawa T, Takemoto-Kimura S, Ozaki N. Identification of ultra-rare disruptive variants in voltage-gated calcium channel-encoding genes in Japanese samples of schizophrenia and autism spectrum disorder. *Transl Psychiatry.* 12(1):84, 2022, doi: 10.1038/s41398-022-01851-y.
 9. Goto F, Kiyama Y, Ogawa I, Okuno H, Ichise T, Ichise H, Anai M, Kodama T, Yoshida N, Bito H, Manabe T. Gastrin-releasing peptide regulates fear learning under stressed conditions via activation of the amygdalostriatal transition area. *Mol Psychiatry.* 27(3):1694-1703, 2022, doi: 10.1038/s41380-021-01408-3.

Neuroscience

2. Integrative Medical Neuroscience

Department of Child Neuropsychiatry

Associate Professor

Yukiko Kano, M.D., Ph.D.

Homepage <http://childpsy.umin.jp/>

Introduction and Organization

Recently, mental problems of child and adolescent or problems of mental development are continuously increasing, and serious deficiency of specialists such as child psychiatrists and necessity of their development are emphasized. Especially, as Japan falls far behind other nations in research and education system of child psychiatry, development of specialists who can promote research by themselves and improve quality of diagnosis and treatment based on their own research are strongly demanded. In response to these needs, Department of Child Neuropsychiatry, Graduate School of Medicine was established in April 2010. This is believed to be the first Japanese department which works as an actual department of child psychiatry managed by child psychiatrist. Based on experience of clinical-based research as well as medical care and training of clinicians for decades in child psychiatry division of Department of Neuropsychiatry and Department of Child Psychiatry since April 2005, we are developing new activities. Professors are administrating Department of Child Psychiatry, the University Hospital also, and trying to utilize its clinical activities for research more effectively.

Teaching activities

In the year of 2022, we had 6 graduate students (1 in master course and 5 in doctor course). In addition to research training, educational program including case conference was implemented with further improvement.

Research activities

Main subjects of our research are Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), Tourette syndrome which is a severe and chronic tic disorder, and child & adolescent obsessive-compulsive disorder (OCD). We are trying to combine scientific analysis of objective mental and behavioral indicators with neuropsychological, brain-imaging, and genetic studies into comprehensive and multidimensional approach to problems in development of brain and mind. We are applying this comprehensive approach to intervention studies including pharmacotherapy.

Major research projects with full or preliminary performance in 2022 are as follows:

- **Epidemiological, behavior phenotype, neuropsychological, and treatment study of Tourette syndrome (chronic tic disorder with multiple motor tics and one or more vocal tics) and child & adolescent OCD**

We are evaluating tics, obsessive-compulsive symptoms, and premonitory urges in Tourette syndrome and child & adolescent OCD to examine their relationship to each other, as well as investigating situation and needs for treatment and support to improve them.

We are following a clinical cohort of patients with Tourette syndrome and are also investigating the impact of the COVID-19 pandemic. We are examining the neuropsychology of Tourette syndrome and the effectiveness of the Comprehensive Behavioral Intervention for Tics (CBIT). We have developed internet-based psychoeducational materials that will

lead to CBIT, and have begun investigating their effectiveness. We are also trying to develop an objective assessment of tics.

Multi-institutional collaborative study about treatment-refractory Tourette syndrome in which severe tics persist even after adulthood are conducted with multidisciplinary professionals including neurosurgeons who perform deep brain stimulation.

We are also continuing to analyze the findings of our survey of tics and related behaviors in community preschoolers.

• **Brain-imaging study of ASD, ADHD and Tourette syndrome by structural-MRI, functional-MRI and near-infrared spectroscopy (NIRS)**

We continue to examine morphological and functional brain imaging in adults with ASD.

• **Development of predictor of parent training for ADHD**

We are examining what aspects of children with ADHD and their caregivers are affected by parent training. In addition to focusing on the relationship between parent training and attachment, we also aim to examine the relationship between brain function as measured by fMRI and these factors.

• **Effectiveness of psychological support for ASD**

We are examining effectiveness of early intervention for autistic preschoolers in terms of their communication behaviors and parental stress. We are also examining support for their transition from kindergarten and preschool to elementary school. Furthermore, effectiveness of a program of group cognitive behavior therapy for adults with high-functioning ASD is investigated in a randomized control trial.

• **Investigation on clinical evaluation and psychological education for adults with developmental disorders**

We are collecting and analyzing data obtained through “inpatient assessment on developmental disorders” program, in which adult patients with suspected developmental disorders undergo detailed clinical assessment, including symptoms of ASD and ADHD, and receive psychoeducation based on this

assessment.

References

1. Kuroda M, Kawakubo Y, Kamio Y, Yamasue H, Kono T, Nonaka M, Matsuda N, Kataoka M, Wakabayashi A, Yokoyama K, Kano Y, Kuwabara H. Preliminary efficacy of cognitive-behavioral therapy on emotion regulation in adults with autism spectrum disorder, A pilot randomized waitlist-controlled study. *PLoS One*, 17(11): e0277398, 2022.
2. Tanaka M, Kanehara A, Morishima R, Yousuke Kumakura Y, Okouchi N, Nakajima N, Hamada J, Ogawa T, Tamune H, Nakahara M, Jinde S, Kano Y, Kasai K. Educational challenges for 22q11.2 deletion syndrome in Japan: Findings from a mixed methods survey. *J Appl Res Intellect Disabil*, 36(3): 558-570, 2023.
3. Ishikawa N, Ishizuka Y, Kano Y, Iida J, Yamamoto J. Exploring factors of successful transition to elementary school among children with autism spectrum disorder in Japan: a focus group study, *International Journal of Developmental Disabilities*, 1-10, 2022.
4. Suzuki A, Yamaguchi R, Kim L, Kawahara T, Ishii-Takahashi A. Effectiveness of mock scanners and preparation programs for successful magnetic resonance imaging: a systematic review and meta-analysis. *Pediatr Radiol*, 53(1): 142-158, 2023.

Neuroscience

3. Clinical Neuroscience

Department of Neuropsychiatry

Professor

Kiyoto Kasai, M.D., Ph.D.

Associate Professor

Seiichiro Jinde, M.D., Ph.D.

Shuntaro Ando, M.D., Ph.D.

Lecturer

Shinsuke Kondo, M.D., Ph.D.

Eisuke Sakakibara, M.D., Ph.D.

Research Associate

Kayo Ichihashi, M.D.

Shinya Fujikawa, M.D., Ph.D.

Shintaro Kawakami, M.D., Ph.D.

Daisuke Koshiyama, M.D., Ph.D.

Tempei Ikegame, M.D., Ph.D.

Susumu Morita, M.D., Ph.D.

Mao Fujioka, M.D., Ph.D.

Taku Kiuchi, M.D., Ph.D.

Hiroshi Azuma, M.D.

Homepage <http://npsy.umin.jp/>

Introduction and Organization

The Department of Neuropsychiatry is the oldest department of psychiatry in Japan which was established in 1886. "Anti-Psychiatry" movement in the last 3 decades had brought highly negative impacts on the progress of all aspects of our activities. However, in 1994, our department has been normalized and restarted to play a leading role in psychiatry in Japan. Since 2005, we have launched the new department of child neuropsychiatry to focus on basic and clinical neuroscience in the developmental disorders including autism spectrum disorder (ASD). Dr. Kiyoto Kasai has been serving as a professor since 2008. Now the Department of Neuropsychiatry is dedicated to high quality clinical services, excellent training, education for students and innovative research.

Clinical activities

For our clinical services, we have more than 15 staff psychiatrists, 5 clinical psychologists and 2 psy-

chiatric social workers. In 2022, approximately 680 new patients visited our outpatient clinic, and the total visits per day were about 100.

In our inpatient wards, the secluded ward has 27 beds including 3 seclusion rooms, as well as 21 beds for the open general ward. Approximately 319 patients with various psychiatric disorders were admitted in 2022. Recently, the number of inpatients who were referred from the emergency unit is increasing. Mean hospitalization is 30 day long, and the age of patients is from teenager to senior. Most of the patients are schizophrenia, mood disorder and the psychosis based on the somatic diseases. Modified electro-convulsive therapy was performed for approximately 300 patients per year.

We established the day care unit for outpatients with schizophrenia in 1974, and the patients are engaged in rehabilitation and re-work programs.

Education

For psychiatric residents, we have provided: 1) clinical meetings on patients (every morning); 2) case

conferences on inpatients (every week); 3) a series of lectures by teaching staffs on various aspects of psychiatry. For undergraduates, we have provided neuropsychiatry comprehensive lectures (for 2nd year students), and clinical clerkship (for 3rd year students). For postgraduate, currently more than 10 neuropsychiatry Ph.D. students are studying.

Research

Our mission in research is to clarify the pathophysiology of the mental illness to develop better treatment approach.

1) Neuroimaging

Our research plays a leading role in psychiatric neuroimaging in Japan and aims at multi-modality neuroimaging (structural and functional MRI, MR spectroscopy, EEG, MEG, near-infrared spectroscopy (NIRS)) in schizophrenia, mood disorders and autism spectrum disorders.

2) Molecular/cellular neuroscience

The goal of the molecular/cellular neuroscience group is to build causal bridges among the molecular, cellular, neural systems, and behavior on the rodent model of neuropsychiatric disorders. We employ integrated multidisciplinary techniques including genetics, cell biology, biochemistry, histology, electrophysiology, imaging, and behavioral analysis for elucidating molecular pathophysiology of rodent models of neuropsychiatric disorder. We have focused on schizophrenia and hippocampal neuronal circuits.

3) Genetic and Epidemiology research

The Genetic Research Group of the department is investigating genetic as well as environmental mechanism of psychiatric disorders. A major focus of the studies is exploration of susceptibility genes of the disorders including schizophrenia, autism, their spectrum disorders and anxiety disorder (mainly panic disorder).

Publications

1. Furukawa Y, Oguro S, Obata S, Hamza T, Ostinelli Edoardo G, Kasai K: Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: a systematic review and dose-effect meta-analysis. *Psychiatry and Clinical Neurosciences*. 2022; 76(9):416-422.
2. Furukawa Y, Hamza T, Cipriani A, Furukawa TA, Salanti G, Ostinelli EG. Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis. *Br J Psychiatry*. 2022; 221(2):440-447.
3. Kirihaara K, Fujioka M, Suga M, Kondo S, Ichihashi K, Koshiyama D, Morita K, Ikegame T, Tada M, Araki T, Jinde S, Taniguchi K, Hosokawa T, Sugishita K, Dogan S, Marumo K, Itokawa M, Kasai K: Betaine supplementation improves positive symptoms in schizophrenia. *Schizophrenia Research*. 2022. PMID: 36401992
4. Koshiyama D, Miyakoshi M, Tanaka-Koshiyama K, Sprock J, Light GA. High-power Gamma related Delta Phase Alteration in Schizophrenia Patients at Rest. *Psychiatry Clin Neurosci* 76: 179-186, 2022.
5. Sakakibara E. On the nature, pathology, and etiology of delusions: comments on Miyazono's delusions and beliefs. *Asian Journal of Philosophy* 1(1) 32.
6. Yamagishi M, Satomura Y, Sakurada H, Kanehara A, Sakakibara E, Okada N, Koike S, Yagishita S, Ichihashi K, Kondo S, Jinde S, Fukuda M, Kasai K: Retrospective Chart Review-based Assessment Scale for Adverse Childhood Events and Experiences. *Psychiatry and Clinical Neurosciences Reports* 1: e58, 2022.
7. Usui K, Kirihaara K, Tada M, Fujioka M, Koshiyama D, Tani M, Tsuchiya M, Morita S, Kawakami S, Kanehara A, Morita K, Satomura Y, Koike S, Suga M, Araki T, Kasai K: The association between clinical symptoms and later subjective quality of life in individuals with ultra-high risk for psychosis and recent-onset psychotic disorder: A longitudinal investigation. *Psychiatry Clin Neurosci*. 2022. PMID: 35352436
8. Usui K, Kirihaara K, Tada M, Fujioka M, Koshiyama D, Tani M, Tsuchiya M, Morita S, Kawakami S, Kanehara A, Morita K, Satomura Y,

- Koike S, Suga M, Araki T, Kasai K: The association between clinical symptoms and later subjective quality of life in individuals with ultra-high risk for psychosis and recent-onset psychotic disorder: A longitudinal investigation. *Psychiatry Clin Neurosci*. 2022. PMID: 35352436
9. Kiyono T, Ando S, Morishima R, Fujikawa S, Kanata S, Morimoto Y, Endo K, Yamasaki S, Usami S, Hiraiwa-Hasegawa M, Nishida A, Kasai K: Sex-based differences in the longitudinal association between autistic traits and positive psychotic experiences in adolescents: A population-based cohort study. *Schizophrenia Research*. 2022; 246:1-6.
 10. Morishima R, Koike H, Kanehara A, Usui K, Okada N, Ando S, Kasai K: Implementation of online classes during national school closure due to COVID-19 and mental health symptoms of adolescents: A cross-sectional survey of 5000 students. *Psychiatry and Clinical Neurosciences Reports*. 2022.
 11. Nagaoka D, Tomoshige N, Ando S, Morita M, Kiyono T, Kanata S, Fujikawa S, Endo K, Yamasaki S, Fukuda M, Nishida A, Hiraiwa-Hasegawa M, Kasai K: Being praised for prosocial behaviors longitudinally reduces depressive symptoms in early adolescents: A population-based cohort study. *Front Psychiatry*, 2022; 13:865907.
 12. Morishima R, Usami S, Ando S, Kiyono T, Morita M, Fujikawa S, Araki T, Kasai K: Trajectory and course of problematic alcohol use after the Great East Japan Earthquake: Eight-year follow-up of Higashi-Matsushima cohort study. *Alcoholism: Clinical and Experimental Research*. 2022; 46(4):570-580.
 13. Ichihashi K, Kyou Y, Hasegawa N, Yasui-Furukori N, Shimizu Y, Hori H, Hashimoto N, Ide K, Imamura Y, Yamada H, Ochi S, Iga J, Takaesu Y, Ohi K, Tsuboi T, Iida H, Yamagata H, Hishimoto A, Horai T, Usami M, Makinodan M, Nagasawa T, Komatsu H, Kido M, Muraoka H, Atake K, Takeshima M, Kubota C, Inagaki T, Tamai S, Kishimoto T, Furihata R, Matsumoto J, Miura K, Inada K, Watanabe K, Kasai K, Hashimoto R: The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project. *Asian Journal of Psychiatry*. 2022; 69:103007.
 14. Kanehara A, Koike H, Fujieda Y, Yajima S, Kabumoto A, Kumakura Y, Morita K, Miyamoto Y, Nochi M, Kasai K: Culture-dependent and universal constructs and promoting factors for the process of personal recovery in users of mental health services: Qualitative findings from Japan. *BMC Psychiatry*. 2022; 22(1):105.
 15. Morishima R, Kumakura K, Usami S, Kanehara A, Tanaka M, Okochi N, Nakajima N, Hamada J, Ogawa T, Ando S, Tamune H, Nakahara M, Jinde S, Kano Y, Tanaka K, Hirata Y, Oka A, Kasai K: Medical, welfare, and educational challenges and psychological distress in parents caring for an individual with 22q11.2 deletion syndrome: A cross-sectional survey in Japan. *American Journal of Medical Genetics Part A*. 2022; 188(1):37-45.
 16. Koike S, Sakakibara E, Satomura Y, Sakurada H, Yamagishi M, Matsuoka J, Okada N, Kasai K: Shared functional impairment in the prefrontal cortex affects symptom severity across psychiatric disorders. *Psychol Med* 2022; 52(13): 2661-70.
 17. Kasai K, Kumagaya S, Takahashi Y, Sawai Y, Uno A, Kumakura Y, Yamagishi M, Kanehara A, Morita K, Tada M, Satomura Y, Okada N, Koike S, Yagishita S: "World-Informed" neuroscience for diversity and inclusion: An organizational change in cognitive sciences. *Clin EEG Neurosci*. 2022. PMID: 35695218.
 18. Kasai K, Yagishita S, Tanaka SC, Koike S, Murai T, Nishida A, Yamasaki S, Ando S, Kawakami N, Kanehara A, Morita K, Kumakura Y, Takahashi Y, Sawai Y, Uno A, Sakakibara E, Okada N, Okamoto Y, Nochi M, Kumagaya SI, Fukuda M: Personalized values in life as point of interaction with the world: Developmental/neurobehavioral basis and implications for psychiatry. *Psychiatry Clin Neurosci Rep* 1: e12, 2022.
 19. Koike S, Uematsu A, Sasabayashi D, Maikusa N, Takahashi T, Ohi K, Nakajima S, Noda Y, Hirano Y: Recent advances and future directions of brain

MRI studies in schizophrenia through the life course: Toward elucidating brain pathology and developing clinical tools. *Magn Reson Med Sci* 2022;21(4):539-52.

20. Koshiyama D, Miura K, Nemoto K, Okada N, Matsumoto J, Fukunaga M, Hashimoto R. Neuroimaging studies within Cognitive Genetics Collaborative Research Organization aiming to replicate and extend works of ENIGMA. *Hum Brain Mapp* 43:182–193, 2022.

Department of Neurology

Professor

Tatsushi Toda, M.D., Ph.D.

Associate Professor

Wataru Satake, M.D., Ph.D.

Lecturer

Masashi Hamada, M.D., Ph.D.

Akatsuki Kubota, M.D., Ph.D.

Associate

Meiko Maeda, M.D., Ph.D., Takashi Matsukawa, M.D., Ph.D.,

Satoshi Kodama, M.D., Ph.D., Toshiyuki Kakumoto M.D., Ph.D., Atsushi Sudo M.D., Ph.D.

Homepage <http://www.utokyo-neurology.org>

Introduction and Organization

The Department of Neurology was established by the founder Professor Yasuo Toyokura in 1964 as one Department in the Brain Research Institute. The Department of Neurology was succeeded by Professors Toru Mannen, Ichiro Kanazawa, and Shoji Tsuji. The organization of the Brain Research Institute was reorganized as the Division of Neuroscience of the Graduate School of Medicine in 1997.

Clinical activities

We offer clinical services in the field of Neurology. We are putting our effort to provide the patients with highly advanced clinical practice as well as on clinical activities connected to postgraduate education of Neurology.

We have outpatient clinics covering the broad fields of Neurology. Furthermore, we also provide clinics specialized to movement disorders and dementia (Dementia center).

In the in-patient ward, we offer programs for postgraduate education including the program for the first stage postgraduate education. We also offer the excellent training program with the goal to get the

board of Neurologist. In 2005, we initiated deep brain stimulation for the treatment of movement disorders in cooperation with Department of Neurosurgery.

Teaching activities

As for under-graduate education, our Department takes a part in lectures of Neurology for the 4th and 5th grade medical students, and clinical clerkship for the 5th grade medical students.

In the clinical clerkship we include small group lectures including neurophysiology, and stroke care. We are also putting our effort for Free Quarters where we offer various opportunities for medical students to be involved in research activities, and 2-3 medical students are conducting their research activities in the laboratories.

In postgraduate education we offer the integrated program including Neurology as the part of the program of Internal Medicine.

Regarding training for board-certified neurologists, we offer the excellent program including patients' care, training in Neurophysiology and Neuropathology, consultation for Neurology and supervising of junior trainees. This program is integrated with

clinical practice at the affiliated hospitals where rich experience is obtained for numerous cases in Clinical Neurology.

In Graduate School, we offer highly advanced research activities based on the interest of graduate students.

Research activities

Our research field covers broad fields related to neurological diseases, with the goals to elucidate the mechanisms of neurological diseases, and to eventually develop new therapeutic strategies. Our research activities include molecular genetics, developmental biology, cell biology, pharmacology, pathology, and physiology. We aim to integrate these broad research fields to better contribute to clinical neurology.

In the development of molecular therapeutics that ameliorate α -dystroglycan (α -DG)-associated diseases, we identified the glycan unit ribitol 5-phosphate (Rbo5P) in α -DG and showed that enzyme activities of α -DG-associated diseases are involved in the synthesis of tandem Rbo5P. We also found that FKTN and FKRP can transfer GroP to O-mannosyl glycans by using CDP-glycerol (CDP-Gro) as a donor substrate. The analysis of mouse models of α -DG-associated diseases indicated that spatiotemporal persistence of functionally glycosylated α -DG may be crucial for brain development. These findings provide insight into pathogenesis and therapeutic strategies in α -DG-associated diseases. In addition, a First In Human clinical trial of a novel antisense nucleic acid NS-035 in Fukuyama-type congenital muscular dystrophy, which is common in Japan due to dystroglycanopathy is currently underway. (Toda, T., Kanagawa, M., Kobayashi, K., Sudo, A., Fujino, G., Kitamura, A., Takahashi, A.)

We perform case-control association studies in Parkinson disease (PD) employing whole-exome sequence analysis to discover rare PD susceptibility variants. Employing a novel bioinformatics approach using GWAS loci in PD along with in vitro functional studies and MPTP mouse model analysis, we identified a novel drug candidate for the prevention of neurodegeneration in PD. We also identified genetic factors responsible for the individual difference of the

effects of zonisamide by using GWAS and transcriptome analysis. (Toda, T., Satake, W., Uenaka, T., Cha, P.C., Fujino, G., Naito, T.)

In the field of molecular genetics, we have developed the Genomic Medicine Research Support Center, and introduced next-generation sequencers to conduct comprehensive genome analyses to elucidate molecular bases of various neurological diseases. Regarding monogenic neurologic diseases, we conduct pedigree analyses in various neurological diseases including epilepsy, multiple system atrophy, amyotrophic lateral sclerosis, hereditary spastic paraplegia, spinocerebellar atrophy, and adrenoleukodystrophy. As for sporadic neurologic diseases, we perform case-control association studies in multiple system atrophy and amyotrophic lateral sclerosis to identify genetic factors underlying these diseases. On the basis of the findings that mutations in *COQ2* are associated with familial as well as sporadic multiple system atrophy, we are conducting an investigator-initiated clinical trial using coenzyme Q10 for patients with multiple system atrophy. Genetic study on benign adult familial myoclonus epilepsy (BAFME), neuronal intranuclear inclusion disease (NIID), oculopharyngeal myopathy with leukoencephalopathy (OPML), and oculopharyngodistal myopathy type 1 (OPDM1) are performed, which have been revealed to be caused by expansions of noncoding repeats at our department. We reported safety and efficacy of hematopoietic stem cell transplantation for adolescent/adulthood-onset cerebral form/cerebello-brainstem form of adrenoleukodystrophy. We are now studying a biomarker for adrenoleukodystrophy. (Toda, T., Tsuji, S., Mitsui, J., Ishiura, H., Matsukawa, T., Naruse, H., Kakumoto, T., Nagasako, Y., Hao, A., Shinmi, J., Mitsue, A., Mitsutake, A., Yamaguchi, N., Almansour, M. A., Porto, K. J. L., Orimo, K.)

The human neurophysiology section specializes in studying the physiology of the human motor and sensory systems in awake healthy volunteers and the pathophysiology of neurological disorders using several non-invasive physiological methods, such as TMS, EEG, MEG, fMRI, NIRS and EOG. Our final goal is to devise new therapeutic techniques for intractable neurological disorders. To this end, the work extends from the study of spinal systems to basal

ganglia and cerebral cortex. We are interested in mismatch negativity changes in ataxic syndrome as well as basalganglia disorders and entrainment of neuronal oscillation by peripheral nerve stimulation, sensor-oriented and sensor-free motion measurements in Parkinson disease, network analysis in patient with epilepsy using MEG, fMRI of spinal cord and neuronal excitability changes in dystonic patients. (Hamada, M., Shiota, Y., Kodama, S., Kainaga M, Seto E, Katsuse K, Tokimura R, and Miyano R.)

In the field of neuromuscular diseases, we provide pathological diagnosis of biopsied materials from patients with myopathy or neuropathy. We also provide autoantibody testing for anti-ganglioside antibodies, and muscle specific antibodies. In research field, using biopsied muscles and collected serum samples, we have been studying the mechanisms of inflammatory myopathies from the view points of pathological changes, myositis specific autoantibodies, serum cytokines, and expression profiling of muscle samples. Our aim is to increase understanding of the etiology and pathogenesis of neuromuscular diseases. (Shimizu, J., Kubota A., Maeda M., Kitamura A.).

In the biochemistry laboratory, autopsy brain analysis of Alzheimer's disease and Lewy body disease was performed, and a new gene involvement was discovered. Chronic cerebral hypoperfusion model mouse was created and its characteristics were analyzed, the technology was applied to analyze amyloid β metabolism under chronic hypoperfusion. On the other hand, we analyzed J-ADNI cohort data. Comparison with US-ADNI data revealed compatibility between the two cohorts. The influence of sex difference and education level, and the influence of serum calcium level was discovered. We analyzed the database of adverse drug reactions to COVID-19 vaccine and dementia drugs. Other activities include development of new imaging techniques using Raman microspectroscopy. We recently invented a novel high-sensitivity lipid imaging methodology using delipidation technique for sample preconditioning before Raman observation, which successfully determined spatial distribution of minor lipid species in porcine nerve and muscle tissues. We also developed a new optical sensor chip detecting biomarkers for Alzheimer's disease using nanoimprint lithography (NIL)-based two-dimensional

photonic crystal (2D-PhC), which achieved the sensitivity surpassing ELISA. We newly developed a detection device for our sensor chip, realizing automated, high-throughput measurement. (Yu Nagashima, Ryo Ohtomo, Tatsuo Mano, Taro Bannai, Takeyuki Tsuchida, Kensuke Hamada, Kagari Mano, Gaku Ohtomo, Kenichiro Sato, Masanori Kurihara)

Neuroimmunology section is focused on understanding inflammatory disease of the CNS: namely multiple Sclerosis and neuromyelitis optica. Through application of both conventional and more contemporary immunological methods (FACS, ELISA, cell culture and NGS analysis), we aim to reveal disease-specific patho-mechanisms for better diagnosis and treatment of immune-mediated CNS inflammation. (Sakuishi K, Koguchi A, and Kawasaki R)

Publication

1. Kubota A, Shimizu J, Unuma A, Maeda M, Shiota Y, Kadoya M, Uchio N, Sakiyama Y, Arai N, Shiio Y, Uesaka Y, Hashida H, Iwata NK, Goto J, Nakashima R, Mimori T, Toda T. Alanine transaminase is predominantly increased in the active phase of anti-HMGCR myopathy. *Neuromuscul Disord*. 2022 Jan;32(1):25-32. doi: 10.1016/j.nmd.2021.10.007.
2. Sato K, Iwata A, Kurihara M, Mano T, Toda T. Stress cardiomyopathy (Takotsubo syndrome) in patients who received adrenergic agonist drugs: A pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) database. *J Cardiol*. 2022 Jan; 79(1):36-41. doi: 10.1016/j.jjcc.2021.08.019.
3. Kono M, Komai T, Yuki H, Hanata N, Kakumoto T, Kubota A, Hashimoto Maeda M, Toda T, Shoda H, Fujio K. Anti-Ku antibody-positive myositis presenting as a wide range of axial myopathies and myocarditis: A case report and review of the literature. *Mod Rheumatol Case Rep*. 2022 Jan 7;6(1):64-68. doi: 10.1093/mrcr/rxab024.
4. Aizawa H, Kato H, Oba K, Kawahara T, Okubo Y, Saito T, Naito M, Urushitani M, Tamaoka A, Nakamagoe K, Ishii K, Kanda T, Katsuno M, Atsuta N, Maeda Y, Nagai M, Nishiyama K, Ishiura H, Toda T, Kawata A, Abe K, Yabe I,

- Takahashi-Iwata I, Sasaki H, Warita H, Aoki M, Sobue G, Mizusawa H, Matsuyama Y, Haga T, Kwak S. Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. *J Neurol*. 2022 Feb;269(2):885-896. doi: 10.1007/s00415-021-10670-y.
5. Kubota A, Ishiura H, Porto KJL, Tanaka M, Mitsui J, Unuma A, Maki H, Komuro I, Tsuji S, Shimizu J, Toda T. DMD exon 2 duplication due to a complex genomic rearrangement is associated with a somatic mosaicism. *Neuromuscul Disord*. 2022 Mar;32(3):263-269. doi: 10.1016/j.nmd.2021.12.004.
 6. Ueda M, Katsuse K, Kakumoto T, Kobayashi S, Ishiura H, Mitsui J, Toda T. A Case of Copper Deficiency in Wilson's Disease with a Normal Zinc Value. *Internal med.*. 2022 Apr.1; 62(7): 1073-1076. doi:10.2169/internalmedicine.9366-22.
 7. Koto S, Chihara N, Akatani R, Nakano H, Hara A, Sekiguchi K, Matsumoto R, Toda T. Transcription Factor c-Maf Promotes Immunoregulation of Programmed Cell Death 1–Expressed CD8⁺ T Cells in Multiple Sclerosis. *Neurol - Neuroimmunol Neuroinflamm*. 2022 Apr.5;9(4): e1166. doi: 10.1212/nxi.0000000000001166
 8. Tokuoka H, Imae R, Nakashima H, Many H, Masuda C, Hoshino S, Kobayashi K, Lefebvre DJ, Matsumoto R, Okada T, Endo T, Kanagawa M, Toda T. CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model. *Nat Commun*. 2022 Apr 14;13(1): 1847. doi: 10.1038/s41467-022-29473-4.
 9. Akamatsu M, Yamashita T, Teramoto S, Huang Z, Lynch J, Toda T, Niu L, Kwak S. Testing of the therapeutic efficacy and safety of AMPA receptor RNA aptamers in an ALS mouse model. *Life Sci Alliance*. 2022 Jan 12;5(4):e202101193. doi: 10.26508/lsa.202101193.
 10. Kitagawa K, Arima H, Yamamoto Y, Ueda S, Rakugi H, Kohro T, Yonemoto K, Matsumoto M, Saruta T, Shimada K; Recurrent Stroke Prevention Clinical Outcome (RESPECT) Study Group. Intensive or standard blood pressure control in patients with a history of ischemic stroke: RESPECT post hoc analysis. *Hypertens Res*. 2022 Apr;45(4):591-601. doi: 10.1038/s41440-022-00862-y
 11. Yamaguchi N, Matsuda S, Matsumoto J, Ugawa Y, Shimizu J, Toda T, Sonoo M, Yoshizawa T. Rippling Muscle Disease with Irregular Toe Jerks and Anti-acetylcholine Receptor Antibodies: Remission after Extended Thymectomy. *Intern Med*. 2022 May 1;61(9):1439-1442. doi: 10.2169/internalmedicine.8146-21.
 12. Naito T, Satake W, Cha PC, Kobayashi K, Murata M, Toda T. Comparative whole transcriptome analysis of Parkinson's disease focusing on the efficacy of zonisamide. *J Neurol Neurosurg Psychiatry*. 2022 May;93(5):509-512. doi: 10.1136/jnnp-2021-328742.
 13. Egawa N, Izumi Y, Suzuki H, Tsuge I, Fujita K, Shimano H, Izumikawa K, Takahashi N, Tsukita K, Enami T, Nakamura M, Watanabe A, Naitoh M, Suzuki S, Seki T, Kobayashi K, Toda T, Kaji R, Takahashi R, Inoue H. TDP-43 regulates cholesterol biosynthesis by inhibiting sterol regulatory element-binding protein 2. *Sci Rep*. 2022 May 14; 12(1) :7988. doi:10.1038/s41598-022-12133-4.
 14. Tokimura R, Hashimoto M, Mitsutake A, Sakai S, Suzuki F, Sugawara K, Fujimoto C, Ishiura H, Toda T. Isolated Paravermal Hyperintensities in Neuronal Intranuclear Inclusion Disease. *Neurology*. 2022 May 31;98(22) :938-939. doi:10.1212/WNL.0000000000200590
 15. Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y, Sakaguchi S, Nokihara H, Kanai K, Tsunemi T, Hattori N, Hatanaka Y, Sonoo M, Atsuta N, Sobue G, Shimizu T, Shibuya K, Ikeda K, Kano O, Nishinaka K, Kojima Y, Oda M, Komai K, Kikuchi H, Kohara N, Urushitani M, Nakayama Y, Ito H, Nagai M, Nishiyama K, Kuzume D, Shimohama S, Shimohata T, Abe K, Ishihara T, Onodera O, Iose S, Araki N, Morita M, Noda K, Toda T, Maruyama H, Furuya H, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators. Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. *JAMA Neurol*. 2022 Jun 1; 79(6):

- 575-583. doi: 10.1001/jamaneurol.2022.0901.
16. Itamiya T, Komai T, Kanda H, Nagafuchi Y, Chang H, Shibata S, Ishiura H, Shoda H, Toda T, Fujio K. Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation. *Clin Rheumatol*. 2022July1; 41(7): 2233-2237 . doi:10.1007/s10067-022-06130-1.
 17. Kurihara M, Sugiyama Y, Tanaka M, Sato K, Mitsutake A, Ishiura H, Kubota A, Kaori K, Hayashi T, Iwata A, Shimizu J, Murayama K, Tsuji S, Toda T. Diagnostic Values of Venous Peak Lactate, Lactate-to-pyruvate Ratio, and Fold Increase in Lactate from Baseline in Aerobic Exercise Tests in Patients with Mitochondrial Diseases, *Intern Med*. 2022July1; 61(13): 1939-1946 . doi:10.2169/internalmedicine.8629-21.
 18. Kikkawa Y, Matsunuma M, Kan R, Yamada Y, Hamada K, Nomizu M, Negishi Y, Nagamori S, Toda T, Tanaka M, Kanagawa M. Laminin $\alpha 5$ _CD239_Spectrin is a candidate association that compensates the linkage between the basement membrane and cytoskeleton in skeletal muscle fibers. *Matrix Biol Plus*. 2022Aug;15: 100118-100118. doi:10.1016/j.mbpplus.2022.100118.
 19. Uchigami H, Sato K, Samejima N, Watanabe A, Kuwana N, Tsuchida T, Toda T, Saito M. Preoperative factors associated with shunt responsiveness in patients with idiopathic normal-pressure hydrocephalus. *Clinical Neurol Neurosurg*. 2022 Aug28;222:107425-107425. doi:10.1016/j.clineuro.2022.107425.
 20. Harada R, Taniguchi-Ikeda M, Nagasaka M, Nishii T, Inui A, Yamamoto T, Morioka I, Kuroda R, Iijima K, Nozu K, Sakai Y, Toda T. Assessment of the upper limb muscles in patients with Fukuyama muscular dystrophy: Noninvasive assessment using visual ultrasound muscle analysis and shear wave elastography, *Neuromuscul Disord*. 2022 Sep;32(9):754-762. doi:10.1016/j.nmd.2022.05.004.
 21. Katsuse K, Kenichiro Sato K, Nobuyuki Tanaka N, Idai Uchida I, Tatsushi Toda T, Takashi Mikata T, Yasufumi Motoyoshi Y. Predicting the CTG Repeat Size from a Single Spirometry Test Performed at Any Time during the Disease Course of Myotonic Dystrophy Type 1. *Intern Med*. 2022;61(15): 281-2286. doi.org/10.2169/internalmedicine.8633-21.
 22. Sekiya H, Suji A, Hashimoto Y, Takata M, Koga S, Nishida K, Futamura N, Kawamoto M, Kohara N, Dickson DW, Kowa H, Toda T. Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson's disease. *Acta Neuropathol Commun*. 2022Sep.06;10(1): 133-133. doi:10.1186/s40478-022-01440-6
 23. Bujo S, Amiya E, Hashimoto-Maeda M, Ishida J, Hatano M, Ishizuka M, Uehara M, Oshima T, Kojima T, Nakanishi K, Daimon M, Shimizu J, Toda T, Komuro I. The effect of immunosuppressive therapy on cardiac involvements in anti-mitochondrial antibody-positive myositis. *ESC Heart Fail*. 2022Sep.06; 9(6): 4112-4119. doi:10.1002/ehf2.14138.
 24. Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Trial of Antisense Oligonucleotide Tofersen for *SOD1* ALS. *N Engl J Med*. 2022 Sep 22; 387 (12):1099-1110. doi: 10.1056/NEJMoa2204705.
 25. Hara R, Mano T, Yano S, Toda T. Isolated Abducens Nerve Palsy Caused by Anterior Inferior Cerebellar Artery Compression. *Intern Med*. 2022.Oct1;61(19)2991-2992. doi: 10.2169/internalmedicine.9294-21.
 26. Seki Y, Yamada T, Kiyosue A, Kimura K, Uehara M, Hatano M, Sasako T, Shiota Y, Sudo A, Ishiura H, Toda T, Yamauchi T, Komuro I. Asymptomatic myocardial infarction in a patient with myotonic dystrophy type 1. *J Cardiology Cases*. 2022 Oct;26(4):248-251. doi:10.1016/j.jccase.2022.05.004.
 27. Ando T, Riku Y, Akagi A, Miyahara H, Hirano M, Ikeda T, Yabata H, Koizumi R, Oba C, Morozumi S, Yasui K, Goto A, Katayama T, Sakakibara S, Aiba I, Sakai M, Konagaya M, Mori K, Ito Y, Yuasa H, Nomura M, Porto KJL, Mitsui J, Tsuji S,

- Mimuro M, Hashizume Y, Katsuno M, Iwasaki Y, Yoshida M. Multiple system atrophy variant with severe hippocampal pathology. *Brain Pathol.* 2022 Jan;32(1):e13002. doi: 10.1111/bpa.13002.
28. Koh K, Tsuchiya M, Ishiura H, Shimazaki H, Nakamura T, Hara H, Suzuyama K, Takahashi M, Tsuji S, Takiyama Y; Japan Spastic Paraplegia Research Consortium. Chédiak-Higashi syndrome presenting as a hereditary spastic paraplegia. *J Hum Genet.* 2022 Feb;67(2):119-121. doi: 10.1038/s10038-021-00977-z.
 29. Kokubo Y, Morimoto S, Sasaki R, Hasegawa M, Ishiura H, Tsuji S, Yoshida M, Yamazoe N, Miyazaki M, Kuzuhara S. An immigrant family with Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. *Neurol Sci.* 2022 Feb;43(2):1423-1425. doi: 10.1007/s10072-021-05737-7.
 30. Almansour A, Ishiura H, Mitsui J, Matsukawa T, Matsukawa MK, Shimizu H, Sugiyama A, Toda T, Tsuji S. Frequency of FMR1 Premutation Alleles in Patients with Undiagnosed Cerebellar Ataxia and Multiple System Atrophy in the Japanese Population. *Cerebellum.* 2022 Dec;21(6):954-962. doi: 10.1007/s12311-021-01329-5.
 31. Hasuike Y, Tanaka H, Gall-Duncan T, Mehkary M, Nakatani K, Pearson CE, Tsuji S, Mochizuki H, Nakamori M. CAG repeat-binding small molecule improves motor coordination impairment in a mouse model of Dentatorubral-pallidoluysian atrophy. *Neurobiol Dis.* 2022 Feb;163:105604. doi: 10.1016/j.nbd.2021.105604.
 32. Taniguchi T, Ando M, Okamoto Y, Yoshimura A, Higuchi Y, Hashiguchi A, Matsuda N, Yamamoto M, Dohi E, Takahashi M, Yoshino M, Nomura T, Matsushima M, Yabe I, Sanpei Y, Ishiura H, Mitsui J, Nakagawa M, Tsuji S, Takashima H. Elderly patients with suspected Charcot-Marie-Tooth disease should be tested for the TTR gene for effective treatments. *J Hum Genet.* 2022 Jun;67(6):353-362. doi: 10.1038/s10038-021-01005-w.
 33. Ikenaga C, Date H, Kanagawa M, Mitsui J, Ishiura H, Yoshimura J, Pinal-Fernandez I, Mammen AL, Lloyd TE, Tsuji S, Shimizu J, Toda T, Goto J. Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis. *Ann Neurol.* 2022 Mar;91(3):317-328. doi: 10.1002/ana.26304.
 34. Kodama S, Jo T, Yasunaga H, Michihata N, Matsui H, Kumazawa R, Shiota Y, Fushimi K, Toda T, Hamada M. Outcomes of gastrointestinal cancer surgeries in Parkinson's disease patients: A nationwide study. *Parkinsonism Relat Disord.* 2022 Mar; 96:45-49. doi: 10.1016/j.parkreldis.2022.02.002.
 35. Ando M, Higuchi Y, Okamoto Y, Yuan J, Yoshimura A, Takei J, Taniguchi T, Hiramatsu Y, Sakiyama Y, Hashiguchi A, Matsuura E, Nakagawa H, Sonoda K, Yamashita T, Tamura A, Terasawa H, Mitsui J, Ishiura H, Tsuji S, Takashima H. An NEFH founder mutation causes broad phenotypic spectrum in multiple Japanese families. *J Hum Genet.* 2022 Jul;67(7):399-403. doi: 10.1038/s10038-022-01019-y.
 36. Hata T, Nan H, Koh K, Ishiura H, Tsuji S, Takiyama Y. A clinical and genetic study of SPG31 in Japan. *J Hum Genet.* 2022 Jul;67(7):421-425. doi: 10.1038/s10038-022-01021-4.
 37. Hiramatsu Y, Okamoto Y, Yoshimura A, Yuan JH, Ando M, Higuchi Y, Hashiguchi A, Matsuura E, Nozaki F, Kumada T, Murayama K, Suzuki M, Yamamoto Y, Matsui N, Miyazaki Y, Yamaguchi M, Suzuki Y, Mitsui J, Ishiura H, Tanaka M, Morishita S, Nishino I, Tsuji S, Takashima H. Complex hereditary peripheral neuropathies caused by novel variants in mitochondrial-related nuclear genes. *J Neurol.* 2022 Aug;269(8):4129-4140. doi: 10.1007/s00415-022-11026-w.
 38. Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, Palma JA, Meissner WG, Krismer F, Berg D, Cortelli P, Freeman R, Halliday G, Höglinger G, Lang A, Ling H, Litvan I, Low P, Miki Y, Panicker J, Pillecchia MT, Quinn N, Sakakibara R, Stamelou M, Tolosa E, Tsuji S, Warner T, Poewe W, Kaufmann H. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. *Mov Disord.* 2022 Jun;37(6):1131-1148. doi: 10.1002/mds.29005.
 39. Ando M, Higuchi Y, Yuan JH, Yoshimura A, Kitao R, Morimoto T, Taniguchi T, Takeuchi M, Takei J, Hiramatsu Y, Sakiyama Y, Hashiguchi A, Okamoto Y, Mitsui J, Ishiura H, Tsuji S,

- Takashima H. Novel de novo POLR3B mutations responsible for demyelinating Charcot-Marie-Tooth disease in Japan. *Ann Clin Transl Neurol*. 2022 May;9(5): 747-755. doi: 10.1002/acn3.51555.
40. Teranishi Y, Miyawaki S, Nakatomi H, Ohara K, Hongo H, Dofuku S, Okano A, Takayanagi S, Ota T, Yoshimura J, Qu W, Mitsui J, Morishita S, Tsuji S, Saito N. Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype-phenotype correlation with targeted deep sequencing. *Sci Rep*. 2022 Jun 9;12(1):9543. doi: 10.1038/s41598-022-13580-9.
 41. Ando M, Higuchi Y, Yuan J, Yoshimura A, Taniguchi T, Kojima F, Noguchi Y, Hobara T, Takeuchi M, Takei J, Hiramatsu Y, Sakiyama Y, Hashiguchi A, Okamoto Y, Mitsui J, Ishiura H, Tsuji S, Takashima H. Comprehensive Genetic Analyses of Inherited Peripheral Neuropathies in Japan: Making Early Diagnosis Possible. *Biomedicines*. 2022 Jun 29;10(7):1546. doi: 10.3390/biomedicines10071546.
 42. Hongo H, Miyawaki S, Teranishi Y, Mitsui J, Katoh H, Komura D, Tsubota K, Matsukawa T, Watanabe M, Kurita M, Yoshimura J, Dofuku S, Ohara K, Ishigami D, Okano A, Kato M, Hakuno F, Takahashi A, Kunita A, Ishiura H, Shin M, Nakatomi H, Nagao T, Goto H, Takahashi SI, Ushiku T, Ishikawa S, Okazaki M, Morishita S, Tsuji S, Saito N. Somatic GJA4 gain-of-function mutation in orbital cavernous venous malformations. *Angiogenesis*. 2023 Feb;26(1): 37-52. doi: 10.1007/s10456-022-09846-5.
 43. Yuan JH, Higuchi Y, Ando M, Matsuura E, Hashiguchi A, Yoshimura A, Nakamura T, Sakiyama Y, Mitsui J, Ishiura H, Tsuji S, Takashima H. Multi-type RFC1 repeat expansions as the most common cause of hereditary sensory and autonomic neuropathy. *Front Neurol*. 2022 Aug 17;13:986504. doi: 10.3389/fneur.2022.986504.
 44. Matsukawa T, Porto KJL, Mitsui J, Chikada A, Ishiura H, Takahashi Y, Nakamoto FK, Seki T, Shiio Y, Toda T, Tsuji S. Clinical and Genetic Features of Multiplex Families with Multiple System Atrophy and Parkinson's Disease. *Cerebellum*. 2022 Sep 13. doi: 10.1007/s12311-022-01426-z. Online ahead of print.
 45. Sasaki R, Morimoto S, Ozawa F, Okano H, Yoshida M, Ishiura H, Tsuji S, Kuzuhara S, Kokubo Y. APOE Alleles With Tau and A β Pathology in Patients With Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex in the Kii Peninsula. *Neurology*. 2022 Nov 29;99(22): e2437-e2442. doi: 10.1212/WNL.0000000000201156.
 46. Hama Y, Date H, Fujimoto A, Matsui A, Ishiura H, Mitsui J, Yamamoto T, Tsuji S, Mizusawa H, Takahashi Y. A Novel de novo KIF1A Mutation in a Patient with Ataxia, Intellectual Disability and Mild Foot Deformity. *Cerebellum*. 2022 Oct 13. doi: 10.1007/s12311-022-01489-y.
 47. Kobayashi R, Naruse H, Kawakatsu S, Iseki C, Suzuki Y, Koyama S, Morioka D, Ishiura H, Mitsui J, Ohta Y, Tsuji S, Toda T, Otani K. Valosin-containing protein Asp395Gly mutation in a patient with frontotemporal dementia: a case report. *BMC Neurol*. 2022 Nov 3;22(1):406. doi: 10.1186/s12883-022-02951-4.
 48. Sakai Y, Miyawaki S, Teranishi Y, Okano A, Ohara K, Hongo H, Ishigami D, Shimada D, Mitsui J, Nakatomi H, Saito N. NF2 Alteration/22q Loss Is Associated with Recurrence in WHO Grade 1 Sphenoid Wing Meningiomas. *Cancers (Basel)*. 2022 Jun 29; 14(13):3183. doi: 10.3390/cancers14133183.
 49. Ishigami D, Koizumi S, Miyawaki S, Hongo H, Teranishi Y, Mitsui J, Saito N. Symptomatic and Stenotic Developmental Venous Anomaly with Pontine Capillary Telangiectasia: A Case Report with Genetic Considerations. *NMC Case Rep J*. 2022 May 31;9:139-144. doi: 10.2176/jns-nmc.2022-0022.
 50. Teranishi Y, Okano A, Miyawaki S, Ohara K, Ishigami D, Hongo H, Dofuku S, Takami H, Mitsui J, Ikemura M, Komura D, Katoh H, Ushiku T, Ishikawa S, Shin M, Nakatomi H, Saito N. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. *Acta Neuropathol Commun*. 2022 May 15;10(1):76. doi: 10.1186/s40478-022-01377-w.
 51. Oike R, Inoue Y, Mitsui J, Ota Y. A case of

- idiopathic normal pressure hydrocephalus with fragile X-associated tremor/ataxia syndrome. *Clin Neurol Neurosurg.* 2022 Jul;218:107278. doi: 10.1016/j.clineuro.2022.107278.
52. Yagi H, Takiguchi H, Takeda N, Inuzuka R, Taniguchi Y, Porto KJ, Ishiura H, Mitsui J, Morita H, Komuro I. Family with congenital contractural arachnodactyly due to a novel multiexon deletion of the FBN2 gene. *Clin Case Rep.* 2022 Feb 9;10(2):e05335. doi: 10.1002/ccr3.5335.
 53. Enomoto Y, Yokoi T, Tsurusaki Y, Murakami H, Tominaga M, Minatogawa M, Abe-Hatano C, Kuroda Y, Ohashi I, Ida K, Shiiya S, Kumaki T, Naruto T, Mitsui J, Harada N, Kido Y, Kurosawa K. Divergent variant patterns among 19 patients with Rubinstein-Taybi syndrome uncovered by comprehensive genetic analysis including whole genome sequencing. *Clin Genet.* 2022 Mar;101(3):335-345. doi: 10.1111/cge.14103.
 54. Hatano K, Date H, Ishiura H, Matsukawa T, Tanaka M, Mitsui J, Goto J, Yoshimura J, Doi K, Morishita S, Tsuji S. Expression profile analysis in cells overexpressing DRPLA cDNA to explore the roles of DRPLA as a transcriptional coregulator. *Neurol Clin Neurosci.* 2022 Jul;10(4):210-217. doi: 10.1111/ncn3.12607.
 55. Yamakawa K, Nishijima H, Kubota A, Naruse H, Baba S, Fujimaki Y, Kondo K, Toda T, Yamasoba T. Clinical and electrophysiological findings of facial palsy in a case of hereditary gelsolin amyloidosis. *Auris Nasus Larynx.* 2023 Apr; 50(2): 305-308. doi: 10.1016/j.anl.2022.02.003.
 56. Shirota Y, Otsuka J, Toda T, Hamada M. Neurophysiological differentiation of upper motor neuron damage in neurodegenerative disorders. *Clin Neurophysiol Pract.* 2022 Sep 23;7:273-278. doi: 10.1016/j.cnp.2022.09.002.
 57. Mooney RA, Ni Z, Shirota Y, Chen R, Ugawa Y, Celnik PA. Age-related strengthening of cerebello-cortical motor circuits. *Neurobiol Aging.* 2022 Oct; 118: 9-12. doi: 10.1016/j.neurobiolaging.2022.04.016.
 58. Kuroda N, Kubota T, Horinouchi T, Ikegaya N, Kitazawa Y, Kodama S, Kuramochi I, Matsubara T, Nagino N, Neshige S, Soga T, Takayama Y, Sone D; IMPACT-J EPILEPSY (In-depth Multicenter analysis during Pandemic of Covid19 Throughout Japan for Epilepsy practice) study group; Kanemoto K, Ikeda A, Terada K, Goji H, Ohara S, Hagiwara K, Kamada T, Iida K, Ishikawa N, Shiraishi H, Iwata O, Sugano H, Iimura Y, Higashi T, Hosoyama H, Hanaya R, Shimotake A, Kikuchi T, Yoshida T, Shigeto H, Yokoyama J, Mukaino T, Kato M, Sekimoto M, Mizobuchi M, Aburakawa Y, Iwasaki M, Nakagawa E, Iwata T, Tokumoto K, Nishida T, Takahashi Y, Kikuchi K, Matsuura R, Hamano SI, Fujimoto A, Enoki H, Tomoto K, Watanabe M, Takubo Y, Fukuchi T, Nakamoto H, Kubota Y, Kunii N, Shirota Y, Ishikawa E, Nakasato N, Maehara T, Inaji M, Takagi S, Enokizono T, Masuda Y, Hayashi T. Impact of COVID-19 pandemic on epilepsy care in Japan: A national-level multicenter retrospective cohort study. *Epilepsia Open.* 2022 May 28;7(3):431-41. doi: 10.1002/epi4.12616.
 59. Kuroda N, Akatsu N, Hatano K, Ikegaya N, Katsuse K, Kodama S, Takayama Y, Fujimoto A. Causal relationship between stress and sleep quality and the validity of telemedicine during the COVID-19 lockdown. *Epilepsy Behav.* 2022 Jan; 126: 108481. doi: 10.1016/j.yebeh.2021.108481.
 60. Kubota T, Kuroda N, Horinouchi T, Ikegaya N, Kitazawa Y, Kodama S, Kuramochi I, Matsubara T, Nagino N, Neshige S, Soga T, Takayama Y, Sone D. Barriers to telemedicine among physicians in epilepsy care during the COVID-19 pandemic: A national-level cross-sectional survey in Japan. *Epilepsy Behav.* 2022 Jan;126:108487. doi: 10.1016/j.yebeh.2021.108487.

Department of Neurosurgery

Professor

Nobuhito Saito, M.D., Ph.D.

Lecturer

Shota Tanaka, M.D., Ph.D. Naoto Kunii, M.D., Ph.D.

Satoru Miyawaki, M.D., Ph.D.

Specially Appointed Lecturer

Shunsaku Takayanagi, M.D., Ph.D.

Assistant Professor

Shunsaku Takayanagi, M.D., Ph.D. Hirokazu Takami, M.D., Ph.D.

Seijiro Shimada, M.D., Ph.D. Naoyuki Shono, M.D., Ph.D.

Satoshi Koizumi, M.D. Hirotaka Hasegawa, M.D., Ph.D.

Satoshi Kiyofuji, M.D., Ph.D. Taijun Hana, M.D., Ph.D.

Hiroki Hongo, M.D., Ph.D. Yuki Shinya, M.D.

Motoyuki Umekawa, M.D.

Specially Appointed Associate Professor at Medical Information Engineering

Taichi Kin, M.D., Ph.D.

Homepage <http://www.m.u-tokyo.ac.jp/neurosurg/>

Introduction and Organization

The Department of Neurosurgery at the University of Tokyo Hospital consists of 14 staff neurosurgeons, who participate in the three major academic activities: patient care, research, and education. The staffs include a professor/chairman, three lecturers, ten assistant professors and one project associate professor at Medical Information Technology.

Clinical ward for neurosurgery in our university hospital was founded in 1951 as the first neurosurgical clinic in Japan. Dr. Keiji Sano, as the founding professor, established the Department of Neurosurgery in 1962. Dr. Kintomo Takakura and Dr. Takaaki Kirino served as the second and the third professor, respectively. The incumbent professor, Dr. Nobuhito

Saito, has been serving as the fourth professor since 2006.

Our department provides expertise for patients with brain tumor, cerebrovascular disease, spinal disease, functional disorder, head trauma, etc.

Clinical activities

General outpatient clinic including new patient clinic is open every weekday and subspecialty clinic is open three days a week (Monday and Friday). The latter is open for patients with brain tumor, pituitary disease, spinal disease, cerebrovascular disease, endovascular intervention, epilepsy, and gamma knife treatment. From April 2022 to March 2023, 18,537 patients were treated at the outpatient clinics.

The neurosurgery ward has approximately 40 beds on the seventh floor of the hospital building opened in September 2001. In 2022, 947 patients were admitted to the neurosurgery ward. 449 surgical procedures and 205 gamma knife procedures were performed in 2022. Our practice covers a wide variety of neurosurgical diseases including malignant and benign brain tumors, hemorrhagic and thromboembolic cerebrovascular diseases, spinal disorders, pediatric diseases, epilepsy, pain and movement disorders.

Intraoperative functional monitoring in brain tumor surgery and pre- and intra-operative functional mapping in epilepsy surgery are frequently used to preserve brain function as much as possible. Endoscopic endonasal surgery is also frequently utilized as a minimally invasive therapeutic option for skull base lesions. State-of-the-art techniques including intra-operative computer-aided navigation and intravascular procedures help our continuous effort to increase the safety of surgical treatment. Some endovascular procedures are performed in our hybrid operating room with the cooperation of the operation department and the anesthesiology doctors.

Our department is affiliated with 32 neurosurgical institutions in and around the city of Tokyo including 10 university medical centers, where our residents and students are exposed to various clinical experiences. Surgical case volume in all hospitals exceeds 11,500 cases.

Teaching activities

Medical students take lectures of clinical neurosurgery in their second year. Clinical case studies and bedside teaching are scheduled in the third and fourth years. The lecturers introduce general neurosurgery as well as the state-of-art neurosurgical practice to the students. At the bedside teaching and clinical clerkship, they are offered opportunities to learn clinical management of neurosurgical patients in the hands-on style, and also are exposed to practice in various subspecialties in neurosurgery through special seminars given by experts in the fields.

We accepted 6 in 2021, 12 in 2022, and 4 in 2023 in our neurosurgical residency program. These residents are trained in the university hospital and affiliated hospitals to experience every aspect of neurosurgical

practice for five years on average. Our residency training is finalized after the sixth year, when the finishing residents serve as senior residents at the university hospital for 6 months. Academic training is provided through numerous intramural clinical and research conferences, journal clubs, seminars as well as quarterly regional meetings of the Japan Neurosurgical Society. After or during residency training, our residents can choose to be admitted into the Ph.D. course at the Graduate School of Medicine, the University of Tokyo, to be involved in advanced basic research activities for 4 years. Upon completion of training, our graduates stay in the department to be associates in our university hospital or become clinical staffs in our affiliated hospitals.

Research activities

Clinical research in the last few years have mainly focused on treatments of acoustic neurinoma, techniques of skull base surgery, treatments of malignant brain tumors, epilepsy surgery, and stereotactic radiosurgery. The results were presented at domestic as well as international meetings including Annual Meetings of the Japan Neurosurgical Society and Annual Meetings of American Association of Neurological Surgeons.

Our department has maintained prominent basic research activities as well. The fields of our current research are as follows:

1) Pathogenesis of cerebral ischemia and neuronal regeneration after ischemic brain damage

One of the major topics in recent basic science is to regenerate the brain with endogenous neural progenitors. Our laboratory has started basic research to regenerate neurons in vivo following ischemic insult. We have demonstrated that the 40% of the lost neurons could be regenerated by administration of growth factors. We also succeeded in regeneration of striatal neurons. Molecular mechanisms of adult neurogenesis are currently investigated using various models to enhance post-ischemic regeneration. By extending the research into primate model, we are pursuing clinical application in the future.

2) Genetic analyses of cerebrovascular diseases and benign brain tumors

We are conducting genetic analysis research for cerebrovascular diseases and benign brain tumors with the aim of identifying molecular markers with high clinical significance and elucidating the pathogenic mechanism.

Specially, genes such as *RNF213* in moyamoya disease, *NF2* in meningioma and schwannoma, *CCM* in cerebral cavernous malformation were analyzed. In addition, comprehensive genetic analyses, including analysis of whole exome sequences, were performed to identify novel disease-related genes..

In the field of cerebrovascular disease, analysis of the *RNF213* gene revealed that *RNF213* variant is associated with not only moyamoya disease but also various intracranial artery stenosis. Furthermore, genome wide association study of intracranial artery stenosis was performed, and disease related gene polymorphisms were clarified. In addition, we have identified disease-related gene in venous malformations that occur in the head and conducting functional analysis.

In the field of benign brain tumors, we improved the diagnostic rate of somatic mosaics of neurofibromatosis type 2 (NF2) by analyzing DNA from various tissues and reveals the phenotypic characteristics of NF2 somatic mosaics. In the genetic analysis of meningioma, we revealed the association between genetic variants, pathological diagnosis, and anatomical site. We are now conducting research to clarify the characteristic of the changes in gene background during the recurrence of meningiomas.

3) Development of new therapeutic modalities for malignant brain tumors

Genotyping is now widely accepted as an essential component of pathological diagnosis in glioma. We have been routinely analysing surgically resected tumor specimens in a semi-prospective fashion. The genetic analyses include sequencing of *IDH1/2* and histone 3-coding genes, as well as loss of heterozygosity analysis of 1p, 19q, and 10q, and methylation analysis of *MGMT* promotor. We optimize therapy based upon the results of the above genetic analyses. In addition, we have been searching for novel biomarkers and therapeutic targets using comprehensive

genetic and epigenetic analyses with whole exome sequencing, RNA sequencing, and methylation analysis. The current focus of our genome study is on spinal astrocytoma and ependymoma. Our particular interest also lies in heterogeneity and malignant progression of glioma, especially from immune-oncological perspectives.

To develop a novel strategy for the treatment of glioma, we isolate brain tumor initiating cells, which are supposed to be responsible for resistance to conventional therapies, from surgical specimens, and utilize them in many aspects of our studies.

Furthermore, we are at the frontier in the field of pediatric brain tumor research, especially on CNS germ cell tumors. We have been publishing important articles regarding basic, translational and clinical research. Multi-omics genomic investigation into the pathogenesis and clinical trials are ongoing.

We have been collaborating with a basic research lab in our university and developing novel fluorescence probes specifically detecting glioma with a hope that fluorescence-guided surgery may result in greater extent of resection.

4) Development and evaluation of function-preserving and less invasive treatment of intractable epilepsy

We have been promoting the research on development, evaluation and standardization of the novel treatment for intractable epilepsy. Particularly, in order to improve the outcome of epilepsy surgery for MRI-negative cases, we are seeking to increase the accuracy of localizing epileptic focus using intracranial electrodes. In addition to the state-of-art technologies such as time-frequency analysis and cortico-cortical evoked potentials, we are developing next-generation intracranial electrodes and accelerating research to identify epileptogenic network. At the same time, we aim to evaluate the effectiveness of function-preserving procedures such as multiple hippocampal transection, which has been originally developed in Japan. Also, as the first facility to introduce vagus nerve stimulation (VNS) therapy in Japan, we are participating in an international collaborative research on the verification of the effectiveness of VNS in the real world.

5) Research on brain function using non-invasive and invasive techniques

We have been studying human brain function using not only non-invasive techniques such as fMRI, MEG, NIRS but also electrocorticography (ECoG) obtained by intracranial electrodes implanted in epilepsy patients. The latter is our markedly advantageous feature that enables us to extract brain information with much higher spatial resolution and SN ratio. We aim to understand brain mechanisms as complicated network systems and to improve the reliability of non-invasive techniques. Since ECoG is a strong candidate for a decoding source of brain-computer interface (BCI), we are planning to expand the research on this field to clinical implementation of BCI for communication and motor control in cooperation with other brain research laboratories and engineering laboratories.

6) Clinical applications of the functional brain imaging and operative simulation using three-dimensional computer graphics for neurosurgery

Our department intensively utilizes various kinds of functional and metabolic imaging modalities including magnetoencephalography, functional MRI, and diffusion tensor imaging-based tractography for presurgical brain mapping. Combining the results of the multi-modalities enables to visualize all cortical and subcortical networks of the motor, language and other cognitive functions in each patient. Furthermore, we succeeded to import the combined information into a neuronavigation system (functional neuronavigation), which quickly and accurately indicates the eloquent brain areas. We could develop virtual reality operative simulation using multi-modal fusion three-dimensional computer graphics. Then, it was possible to precisely examine surgical strategy.

7) Gamma knife radiosurgery

Gamma knife is a kind of devices for stereotactic radiosurgery in which high doses of radiation are delivered at one session and has been widely accepted as one of treatment options for various intracranial disorders such as brain tumors, vascular disorders and functional disorders. The first gamma knife in Japan was introduced at our department and diverse clinical results have been published. Recently, less invasive treatment has taking on an added significance in the field of neurosurgery as well. Therefore, appropriate combination of radical surgery and radiosurgery is

necessary to manage difficult-to-treat lesions such as skull base tumors and deeply seated cerebral arteriovenous malformations, and thus gamma knife radiosurgery would play a more important role in neurosurgery. Further, technological progress has refined treatment as an example of integration of diffusion tensor tractography which was firstly attempted at our department. Such technological progresses might contribute to better outcomes of gamma knife radiosurgery in the future.

References (2022)

1. Amemiya S., Takao H., Watanabe Y., Takei N., Ueyama T., Kato S., Miyawaki S., Koizumi S., Abe O., Saito N. Reliability and Sensitivity to Longitudinal CBF Changes in Steno-Occlusive Diseases: ASL Versus (123) I-IMP-SPECT. **J Magn Reson Imaging** 55(6):1723-1732, 2022 doi: 10.1002/jmri.27996
2. Amemiya S., Watanabe Y., Takei N., Ueyama T., Miyawaki S., Koizumi S., Kato S., Takao H., Abe O., Saito N. Arterial Transit Time-Based Multidelay Combination Strategy Improves Arterial Spin Labeling Cerebral Blood Flow Measurement Accuracy in Severe Steno-Occlusive Diseases. **J Magn Reson Imaging** 55(1):178-187, 2022 doi: 10.1002/jmri.27823
3. Amemiya S., Takao H., Watanabe Y., Miyawaki S., Koizumi S., Saito N., Abe O. Reliability and sensitivity to altered hemodynamics measured with resting-state fMRI metrics: Comparison with (123)I-IMP SPECT. **Neuroimage** 263:119654, 2022 doi: 10.1016/j.neuroimage.2022.119654
4. Fukui A., Muragaki Y., Saito T., Nitta M., Tsuzuki S., Asano H., Kawamata T. Impact of awake mapping on overall survival and extent of resection in patients with adult diffuse gliomas within or near eloquent areas: a retrospective propensity score-matched analysis of awake craniotomy vs. general anesthesia. **Acta Neurochir (Wien)** 164(2):395-404, 2022 doi: 10.1007/s00701-021-04999-6
5. Hasegawa H., Saito N. [Surgical Site Infection Following Craniotomies]. **No Shinkei Geka** 50(5):1008-1016, 2022 doi: 10.11477/mf.1436204660

6. Hasegawa H., Shin M., Kawagishi J., Jokura H., Hasegawa T., Kato T., Kawashima M., Shinya Y., Kenai H., Kawabe T., Sato M., Serizawa T., Nagano O., Aoyagi K., Kondoh T., Yamamoto M., Onoue S., Nakazaki K., Iwai Y., Yamanaka K., Hasegawa S., Kashiwabara K., Saito N. A Practical Grading Scale for Predicting Outcomes of Radiosurgery for Dural Arteriovenous Fistulas: JLGK 1802 Study. **Journal of stroke** 24(2):278-287, 2022 doi: 10.5853/jos.2021.03594
7. Hasegawa H., Shin M., Niwa R., Koizumi S., Yoshimoto S., Shono N., Shinya Y., Takami H., Tanaka S., Umekawa M., Amemiya S., Kin T., Saito N. Revisitation of imaging features of skull base chondrosarcoma in comparison to chordoma. **J Neurooncol** 159(3):581-590, 2022 doi: 10.1007/s11060-022-04097-2
8. Hirano Y., Shinya Y., Aono T., Hasegawa H., Kawashima M., Shin M., Takami H., Takayanagi S., Umekawa M., Ikemura M., Ushiku T., Taoka K., Tanaka S., Saito N. The Role of Stereotactic Frame-Based Biopsy for Brainstem Tumors in the Era of Molecular-Based Diagnosis and Treatment Decisions. **Current oncology (Toronto, Ont)** 29(7):4558-4565, 2022 doi: 10.3390/curroncol 29070360
9. Hirata T., Miyawaki S., Koizumi S., Teranishi Y., Ishikawa O., Saito N. Spontaneous regression of a symptomatic developmental venous anomaly with capillary stain. **Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences** 28(3):257-261, 2022 doi: 10.1177/15910199211032470
10. Hongo H., Teranishi Y., Miyawaki S., Saito N. [Molecular Pathogenesis of Cerebral Cavernous Malformations]. **No Shinkei Geka** 50(1):206-215, 2022 doi: 10.11477/mf.1436204545
11. Ishigami D., Koizumi S., Miyawaki S., Hongo H., Teranishi Y., Mitsui J., Saito N. Symptomatic and Stenotic Developmental Venous Anomaly with Pontine Capillary Telangiectasia: A Case Report with Genetic Considerations. **NMC case report journal** 9:139-144, 2022 doi: 10.2176/jns-nmc. 2022-0022
12. Ishigami D., Miyawaki S., Imai H., Shimizu M., Hongo H., Dofuku S., Ohara K., Teranishi Y., Shimada D., Koizumi S., Ono H., Hirano Y., Segawa M., Nakatomi H., Saito N. Correction to: RNF213 p.Arg4810Lys Heterozygosity in Moyamoya Disease Indicates Early Onset and Bilateral Cerebrovascular Events. **Translational stroke research** 13(4):652, 2022 doi: 10.1007/s12975-021-00971-9
13. Ishigami D., Miyawaki S., Imai H., Shimizu M., Hongo H., Dofuku S., Ohara K., Teranishi Y., Shimada D., Koizumi S., Ono H., Hirano Y., Segawa M., Nakatomi H., Saito N. RNF213 p.Arg4810Lys Heterozygosity in Moyamoya Disease Indicates Early Onset and Bilateral Cerebrovascular Events. **Translational stroke research** 13(3):410-419, 2022 doi: 10.1007/s12975-021-00956-8
14. Kawamura S., Koizumi S., Umekawa M., Miyawaki S., Kinoshita O., Ono M., Saito N. Long-Term Benefit of Mechanical Thrombectomy for Acute Ischemic Stroke in Patients with a Left Ventricular Assist Device: A Single-Center Retrospective Study. **World Neurosurg** 165: e331-e336, 2022 doi: 10.1016/j.wneu.2022.06.046
15. Kawanishi A., Umekawa M., Miyawaki S., Fujitani S., Ishizawa T., Ushiku T., Hongo H., Teranishi Y., Shojima M., Shin M., Hasegawa K., Saito N. Long-term progression-free survival achieved in the skull base metastasis of gastrointestinal stromal tumor with introduction of tyrosine kinase inhibitor: illustrative case. **Journal of neurosurgery Case lessons** 3(16), 2022 doi: 10.3171/case2257
16. Kawashima M., Shin M., Jokura H., Hasegawa T., Yamanaka K., Yamamoto M., Matsunaga S., Akabane A., Yomo S., Onoue S., Kondoh T., Hasegawa H., Shinya Y., Saito N. Outcomes of Gamma Knife radiosurgery for skull base chondrosarcomas: a multi-institutional retrospective study. **J Neurosurg**:1-8, 2022 doi: 10.3171/2022.1.jns212703
17. Kiyofuji S., Shin M., Kondo K., Kin T., Uchida T., Saito N. Endoscopic Transnasal Resection of Trigeminal Schwannoma. **Journal of neurological surgery Part B, Skull base** 83(Suppl 3):e637-e638, 2022 doi: 10.1055/s-0041-1727122

18. Koike T., Tanaka S., Kin T., Suzuki Y., Takayanagi S., Takami H., Kugasawa K., Nambu S., Omura T., Yamazawa E., Kushihara Y., Furuta Y., Niwa R., Sato K., Uchida T., Takeda Y., Kiyofuji S., Saito T., Oyama H., Saito N. Accurate Preoperative Identification of Motor Speech Area as Termination of Arcuate Fasciculus Depicted by Q-Ball Imaging Tractography. **World Neurosurg** 164:e764-e771, 2022 doi: 10.1016/j.wneu.2022.05.041
19. Koizumi S., Shojima M., Shinya Y., Ishikawa O., Hasegawa H., Miyawaki S., Nakatomi H., Saito N. Risk Factors of Brain Arteriovenous Malformation Embolization as Adjunctive Therapy: Single-Center 10-Year Experience. **World Neurosurg** 167:e1448-e1454, 2022 doi: 10.1016/j.wneu.2022.09.069
20. Miyawaki S., Hongo H., Teranishi Y., Saito N. [Genetic Factors of Intracranial Artery Stenosis and Potential for Personalized Medicine]. **No Shinkei Geka** 50(1): 222-233, 2022 doi: 10.11477/mf.1436204547
21. Miyawaki S., Teranishi Y., Saito N. [Molecular Biological Background of Neurofibromatosis Type 2]. **No Shinkei Geka** 50(3):572-577, 2022 doi: 10.11477/mf.1436204589
22. Nagata K., Kunii N., Shimada S., Fujitani S., Takasago M., Saito N. Spatiotemporal target selection for intracranial neural decoding of abstract and concrete semantics. **Cereb Cortex** 32(24):5544-5554, 2022 doi: 10.1093/cercor/bhac034
23. Nakamura Y., Umekawa M., Shinya Y., Hasegawa H., Shin M., Katano A., Shinozaki-Ushiku A., Kondo K., Saito N. Stereotactic radiosurgery for skull base adenoid cystic carcinoma: A report of two cases. **Surg Neurol Int** 13:509, 2022 doi: 10.25259/sni_675_2022
24. Nejo T., Takayanagi S., Tanaka S., Shinozaki-Ushiku A., Kohsaka S., Nagata K., Yokoyama M., Sora S., Ushiku T., Mukasa A., Aburatani H., Mano H., Saito N. Primary Intracranial Spindle Cell Sarcoma, DICER1-Mutant, with MDM2 Amplification Diagnosed on the Basis of Extensive Molecular Profiling. **Clinical medicine insights Case reports** 15:11795476221131189, 2022 doi: 10.1177/11795476221131189
25. Okano A., Miyawaki S., Teranishi Y., Ohara K., Hongo H., Sakai Y., Ishigami D., Nakatomi H., Saito N. Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review. **Neurol Med Chir (Tokyo)** 62(8):347-360, 2022 doi: 10.2176/jns-nmc.2022-0114
26. Otsuka N., Yajima H., Miyawaki S., Koizumi S., Kiyofuji S., Hongo H., Teranishi Y., Kin T., Saito N. Case Report: "Clipping" an Internal Carotid Artery Aneurysm With a Duplicated Middle Cerebral Artery and the Anterior Choroidal Artery Arising From the Dome. **Frontiers in neurology** 13:845296, 2022 doi: 10.3389/fneur.2022.845296
27. Oya S., Yoshida S., Saito A., Shojima M., Yoshikawa G., Ota T., Ono H., Kurita H., Kohyama S., Miyawaki S., Koizumi S., Saito N., Matsui T. The optimal management of ruptured basilar artery dissecting aneurysms: a case series and scoping review. **Neurosurg Rev** 45(5):3427-3436, 2022 doi: 10.1007/s10143-022-01857-6
28. Sakai Y., Miyawaki S., Teranishi Y., Okano A., Ohara K., Hongo H., Ishigami D., Shimada D., Mitsui J., Nakatomi H., Saito N. NF2 Alteration/22q Loss Is Associated with Recurrence in WHO Grade 1 Sphenoid Wing Meningiomas. **Cancers** 14(13), 2022 doi: 10.3390/cancers14133183
29. Sasaki T., Uematsu Y., Fukai J., Tanaka S., Mukasa A., Saito N., Narita Y., Nakao N. Prognostic Factors and Histopathological Features of Pediatric Intracranial Ependymomas: Nationwide Brain Tumor Registry-based Study of Japan. **Neurol Med Chir (Tokyo)** 62(7):322-327, 2022 doi: 10.2176/jns-nmc.2022-0027
30. Sato D., Takayanagi S., Takami H., Iwamoto T., Nomura M., Nambu S., Ikemura M., Tanaka S., Saito N. Novel case of primary intracranial solitary plasmacytoma presenting with significant intratumoral hemorrhage. **Surg Neurol Int** 13:157, 2022 doi: 10.25259/sni_66_2022
31. Satomi K., Takami H., Fukushima S., Yamashita S., Matsushita Y., Nakazato Y., Suzuki T., Tanaka S., Mukasa A., Saito N., Kanamori M., Kumabe T., Tominaga T., Kobayashi K., Nagane M., Iuchi T.,

- Yoshimoto K., Tamura K., Maehara T., Sakai K., Sugiyama K., Yokogami K., Takeshima H., Nonaka M., Asai A., Ushijima T., Matsutani M., Nishikawa R., Ichimura K. 12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors. **Neuro Oncol** 24(5):834-846, 2022 doi: 10.1093/neuonc/noab246
32. Serizawa T*, Tanaka S*, Higuchi Y, Saito N. Radiosurgery for malignant tumors. Youmans Neurologic Surgery, Eighth edition. Winn HR (ed), Philadelphia, Elsevier, 2022. (* Equal contribution)
 33. Shinya Y., Hasegawa H., Shin M., Kawashima M., Koga T., Hanakita S., Katano A., Sugiyama T., Nozawa Y., Saito N. High Dose Radiosurgery Targeting the Primary Tumor Sites Contributes to Survival in Patients With Skull Base Chordoma. **Int J Radiat Oncol Biol Phys** 113(3):582-587, 2022 doi: 10.1016/j.ijrobp.2022.02.024
 34. Shinya Y., Hasegawa H., Shin M., Kawashima M., Koizumi S., Katano A., Suzuki Y., Kashiwabara K., Saito N. Stereotactic Radiosurgery Provides Long-Term Safety for Patients With Arteriovenous Malformations in the Diencephalon and Brainstem: The Optimal Dose Selection and Long-Term Outcomes. **Neurosurgery** 91(3):485-495, 2022 doi: 10.1227/neu.0000000000002064
 35. Shinya Y., Shin M., Hasegawa H., Koizumi S., Kin T., Kondo K., Saito N. Endoscopic endonasal transpetroclival approach for recurrent bilateral petroclival meningioma. **Neurosurgical focus: Video** 6(2): V7, 2022 doi: 10.3171/2022.1.focvid21229
 36. Shono N., Igarashi T., Kin T., Saito T., Saito N. Threshold field painting saves the time for segmentation of minute arteries. **Int J Comput Assist Radiol Surg** 17(11):2121-2130, 2022 doi: 10.1007/s11548-022-02682-4
 37. Takami H., Elzawahry A., Mamatjan Y., Fukushima S., Fukuoka K., Suzuki T., Yanagisawa T., Matsushita Y., Nakamura T., Satomi K., Tanaka S., Mukasa A., Saito N., Kanamori M., Kumabe T., Tominaga T., Kobayashi K., Nagane M., Iuchi T., Tamura K., Maehara T., Sugiyama K., Yoshimoto K., Sakai K., Nonaka M., Asai A., Yokogami K., Takeshima H., Narita Y., Shibui S., Nakazato Y., Hama N., Totoki Y., Kato M., Shibata T., Nishikawa R., Matsutani M., Ichimura K. Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts. **Neuro Oncol** 24(8): 1246-1258, 2022 doi: 10.1093/neuonc/noac021
 38. Takami H., Graffeo C. S., Perry A., Giannini C., Nakazato Y., Saito N., Matsutani M., Nishikawa R., Ichimura K., Daniels D. J. Roles of Tumor Markers in Central Nervous System Germ Cell Tumors Revisited with Histopathology-Proven Cases in a Large International Cohort. **Cancers** 14(4), 2022 doi: 10.3390/cancers14040979
 39. Takami H., Takayanagi S., Tanaka S., Saito N. [Evolving Exploration of the Pathogenesis of CNS Germ Cell Tumors with Regard to Precision Medicine]. **No Shinkei Geka** 50(1):39-50, 2022 doi: 10.11477/mf.1436204530
 40. Takayanagi S., Takami H., Tanaka S., Saito N. [Hemangioblastoma and von Hippel-Lindau Disease]. **No Shinkei Geka** 50(1):101-110, 2022 doi: 10.11477/mf.1436204535
 41. Takeda Y., Hasegawa H., Kin T., Shinya Y., Kawashima M., Furuta Y., Suzuki Y., Sekine T., Saito N. Hemodynamic changes during the obliteration process for cerebral arteriovenous malformations after radiosurgery. **Neurosurg Focus** 53(1):E7, 2022 doi: 10.3171/2022.4.focus2214
 42. Tanabe R., Miyazono K., Todo T., Saito N., Iwata C., Komuro A., Sakai S., Raja E., Koinuma D., Morikawa M., Westermarck B., Heldin C. H. PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma-initiating cell properties via DNA methyltransferase 3A. **Molecular oncology** 16(1): 269-288, 2022 doi: 10.1002/1878-0261.13051
 43. Tanaka S., Takayanagi S., Takami H., Saito N. [Molecularly Targeted Therapy for Craniopharyngioma]. **No Shinkei Geka** 50(1): 171-178, 2022 doi: 10.11477/mf.1436204542
 44. Teranishi Y., Hongou H., Miyawaki S., Saito N. [Solitary fibrous tumor/hemangiopericytoma]. **No Shinkei Geka** 50(1):141-149, 2022 doi: 10.11477/mf.1436204539

45. Teranishi Y., Miyawaki S., Nakatomi H., Ohara K., Hongo H., Dofuku S., Okano A., Takayanagi S., Ota T., Yoshimura J., Qu W., Mitsui J., Morishita S., Tsuji S., Saito N. Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype-phenotype correlation with targeted deep sequencing. **Sci Rep** 12(1):9543, 2022 doi: 10.1038/s41598-022-13580-9
46. Teranishi Y., Okano A., Miyawaki S., Ohara K., Ishigami D., Hongo H., Dofuku S., Takami H., Mitsui J., Ikemura M., Komura D., Katoh H., Ushiku T., Ishikawa S., Shin M., Nakatomi H., Saito N. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. **Acta neuropathologica communications** 10(1):76, 2022 doi: 10.1186/s40478-022-01377-w
47. Tsuchiya T., Miyawaki S., Shinya Y., Teranishi Y., Tomioka A., Yamazawa S., Shin M., Saito N. Intracranial ancient schwannoma originating from vestibular nerve: A case report and review of the literature. **Surg Neurol Int** 13:143, 2022 doi: 10.25259/sni_71_2022
48. Tsuchiya T., Takami H., Yoshimoto S., Nambu S., Takayanagi S., Tanaka S., Saito N. Chronological Progression and Management of Syringobulbia Caused by Spinal Hemangioblastoma: A Case Series and Review of the Literature. **World Neurosurg** 167:e127-e136, 2022 doi: 10.1016/j.wneu.2022.07.118
49. Tsunoda S., Inoue T., Ohwaki K., Akabane A., Saito N. Comparison of postoperative temporalis muscle atrophy between the muscle-preserving pterional approach and the mini-pterional approach in the treatment of unruptured intracranial aneurysms. **Neurosurg Rev** 45(1): 507-515, 2022 doi:10.1007/s10143-021-01558-6
50. Tsunoda S., Inoue T., Takeuchi N., Akabane A., Saito N. Direct Clipping of Paraclinoid Aneurysm in Conjunction with Extradural Anterior Clinoidectomy: Technical Nuance and Functional Outcome. **Journal of neurological surgery Part B, Skull base** 83(5):505-514, 2022 doi: 10.1055/s-0041-1730351
51. Tsunoda S., Inoue T., Segawa M., Kawashima M., Akabane A., Saito N. Superficial temporal artery lengthening technique to prevent postoperative wound complications in direct revascularization to the anterior cerebral artery for Moyamoya disease. **Acta Neurochir (Wien)** 164(7):1845-1854, 2022 doi: 10.1007/s00701-022-05180-3
52. Umekawa M., Hasegawa H., Takeda Y., Shinya Y., Kin T., Koizumi S., Saito N. Brain Arteriovenous Malformation: How to Measure Hemodynamics and What It Tells Us? **World Neurosurg** 167:252-254, 2022 doi: 10.1016/j.wneu.2022.08.040
53. Umekawa M., Koizumi S., Ohara K., Ishigami D., Miyawaki S., Saito N. Distal radial artery approach is safe and effective for cerebral angiography and neuroendovascular treatment: A single-center experience with ultrasonographic measurement. **Interventional neuroradiology: journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences**: 15910199221135308, 2022 doi: 10.1177/15910199221135308
54. Umekawa M., Shinya Y., Hasegawa H., Kawashima M., Shin M., Katano A., Minamitani M., Kashio A., Kondo K., Saito N. Stereotactic radiosurgery ensures an effective and safe long-term control of Koos grade IV vestibular schwannomas: a single-center, retrospective, cohort study. **J Neurooncol** 159(1):201-209, 2022 doi: 10.1007/s11060-022-04058-9
55. Umekawa M., Shinya Y., Hasegawa H., Shin M., Kawashima M., Katano A., Saito N. Long-term outcomes of stereotactic radiosurgery for skull base tumors involving the cavernous sinus. **J Neurooncol** 156(2):377-386, 2022 doi: 10.1007/s11060-021-03921-5
56. Yajima H., Koizumi S., Miyawaki S., Saito N. Mechanical Thrombectomy for M1 Subocclusive Thrombus With Lateral Lenticulostriate Artery Occlusion: A Case Report and Literature Review. **Frontiers in neurology** 13:828245, 2022 doi: 10.3389/fneur.2022.828245
57. Yajima H., Miyawaki S., Koizumi S., Kiyofuji S., Hongo H., Segawa M., Kin T., Nakatomi H., Saito N. Development of a sigmoid sinus dural arteriovenous fistula secondary to sigmoid sinus thrombosis after resection of a foramen magnum meningioma: illustrative case. **Journal of neurosurgery Case lessons** 4(5), 2022 doi:

10.3171/case22253

58. Yamazawa E., Takahashi S., Shin M., Tanaka S., Takahashi W., Nakamoto T., Suzuki Y., Takami H., Saito N. MRI-Based Radiomics Differentiates Skull Base Chordoma and Chondrosarcoma: A Preliminary Study. **Cancers** 14(13), 2022 doi: 10.3390/cancers14133264

Social Medicine

1. Occupational, Environmental and Preventive Medicine

Department of Preventive Medicine

Professor

Shumpei Ishikawa, M.D., Ph.D.

Associate Professor

Hiroto Katoh, M.D., Ph.D.

Assistant Professor

Daisuke Komura, M.D., Ph.D.

Miwako Kakiuchi, M.D., Ph.D.

Homepage <https://plaza.umin.ac.jp/prm/>

Introduction and Organization

Department of Preventive Medicine is the oldest laboratory in the University of Tokyo, established by Masanori Ogata in 1885. Ever since, for more than 130 years, the laboratory has been a hub to important research leading to disease prevention and developed and produced core human resources in public health administration. The philosophy of the Department to Preventive Medicine has not changed throughout its history, but its focus of research has changed from time to time, like infectious diseases and occupational health to name a few, to meet the expectations of the society. Eventually, in response to the completion of the Human Genome Project and the recent advancement in molecular biology, the laboratory had changed its name to the Department of Molecular Preventive Medicine. Under Professor Koji Matsushima, the 8th director of the laboratory, research was actively conducted to clarify inflammation/immune phenomenon with focus on cytokines in disease background, and its clinical application for secondary/tertiary prevention. In December 2018, Professor Shumpei Ishikawa became the 9th director, and in April 2019, he changed the name of the department back to Preventive Medicine.

Currently, our lab includes (besides the professor, the associate professor, and the assistant professors) 10 students (1 are from outside of the University of Tokyo), 2 technical staffs, 6 technical assistants, 1 project

researcher, 1 visiting researchers, 1 research student, 1 academic support staff, and 1 project specialist. Also, three collaborative researchers from private companies have joined our laboratory.

Teaching activities

We give “Preventive Medicine” lecture course to third-year undergraduate students in the school of medicine, practical courses to fifth-year undergraduate students, “Introduction to Preventive Medicine” in medical science master’s program, and “Surviving Cancer in Asia,” a doctoral program common course in medicine.

In the “Preventive Medicine” lecture course, specific emphases are on alteration of the disease pattern associated with social change, basic concepts of occupational and mental health, and information science as a key to the understanding of genome and abundant bio/health data, which is a basis of disease predisposition.

In the practical course for fifth-year undergraduate students, three staff members are in charge of environmental microbiology measurement, cancer genome data analysis, and medical image analysis. In the environmental microbiological measurement, students collect samples from various environments and analyze the distribution of microorganisms in the samples using a long-read sequencer. In cancer genome

data analysis, students use publicly available single-cell transcriptome data and analyze them from their own unique perspectives to make sense of the cancer microenvironment, etc. In medical image analysis, students classify histopathological images using deep learning and analyze and discuss the impact of various techniques to improve its accuracy.

Research activities

In Department of Preventive Medicine, we conduct research based on genome science and information science to explore the appropriate points of intervention for various health issues, in particular, cancer prevention and treatment. Cancer and inflammation/immune diseases are complex systems comprised of numerous types of cells. We aim to elucidate the dynamics of such complex systems by collecting extensive data at genome-level, as well as to explore specific phenomena which may serve as intervenable preventive/therapeutic targets, and to evaluate their significance in the related diseases. In addition, we are developing bioinformatics technology to extract essential information from massive and multi-dimensional biological data, e.g., genome sequence and images, for human interpretation by techniques such as dimensionality reduction and visualization.

Our current primary focus areas of research are as follow:

1. Immune Repertoire Analysis to Reveal Internal/External Immune Environment Profiles in Individuals

Antigen receptor genes of human lymphocyte undergo somatic hypermutation to acquire extensive diversity. The entire set of antigen receptors in lymphocyte population is called immune repertoire, and its profiling in individuals has now become possible thanks to the advancement in genome analysis technology such as next-generation sequencing (NGS). Immune repertoires are considered to reflect immune history affected by external factors, e.g., pathogens and foods that the individual has encountered, and by internal factors, e.g., self-antigens and cancer antigens. In the department of Preventive Medicine, we are trying to develop a method to extract not only current

disease conditions but also other relevant health information, such as past disease history and lifestyles, by analyzing immune repertoires. In particular, in immune repertoire analysis using gastric cancer and gastric mucosa tissues, we combine the results with cancer genome and microbiome analyses to decipher immune history with regard to cancer antigens and *H. pylori* in its entirety, and revealed that the sulfated glycosaminoglycans are major and functional B cell antigens in human cancers. We also use information analysis technique such as deep learning to analyze information related to cancer prevention and treatment. We are also synthesizing antibodies from this immune repertoire data to develop antibody drugs against cancer.

2. Cancer Genome Analysis to Explore Carcinogenic Factors and Point of Intervention

We are combining human clinical cancer tissues with NGS to achieve a comprehensive understanding of the cancer genome. Whole cancer genome sequencing will provide numerous information, such as the driver genes, which would serve direct therapeutic targets, and the genetic background of an individual related to carcinogenic predispositions. It also enables mutation signature analysis to reveal environmental factors which are also possible carcinogenic predispositions. The obtained information is processed as a whole by the combination of bioinformatics and experimental validation to explore the appropriate points of intervention for cancer prevention and treatment, which are crucial for health in our country. We have identified RHOA driver mutation in diffuse-type gastric adenocarcinoma by cancer genome sequencing. In addition, we performed trans-ethnic genome analysis of gastric cancer and showed the existence of East Asian-specific gastric cancer induced by alcohol drinking and smoking. Currently, we are regarding cancer tissues as a whole using clinical cancer tissues and patient-derived xenografts (PDX), by applying genomics point of view, i.e., single-cell analysis, to cancer cells, immune cells, and vascular stroma cells that comprise cancer tissue, to elucidate carcinogenic and progression factors and points of intervention from higher dimensions.

3. Contribution to Elimination of Medical Care Disparities by Histopathological Image Analysis

As the volume of available biomedical information is growing rapidly, technology to extract essential abstract information by compressing dimensions of an enormous amount of biological data is extremely important in our society. In the department of Preventive Medicine, deep neural network is applied to extract essential information (deep texture) of cancer from cancer histopathological images. Our goal is to develop tools to achieve a uniform pathological diagnosis and to help eliminate regional medical care disparities. We developed Luigi, a content-based image retrieval system for cancer histopathological images, and made it available to pathologists and researchers in Web (<https://luigi-pathology.com/>) and smartphone application. The database in Luigi contains histopathological images and their deep texture from more than 7,000 cases of 32 cancer types in The Cancer Genome Atlas. By uploading images, histopathological similar cases in the database are presented. Currently, we're trying to expand the Luigi database by collaborating with various hospitals. We also focus on the development of contents which would seamlessly connect routine lab tests performed in small clinics and cancer genome medicine given in large core hospitals by integrated analysis of histopathological information and cancer genome information.

Publications

1. Mita, H., Katoh, H., Komura, D., Kakiuchi, M., Abe, H., Rokutan, H., Yagi, K., Nomura, S., Ushiku, T., Seto, Y., Ishikawa, S., 2022. Aberrant Cadherin11 Expression Predicts Distant Metastasis of Gastric Cancer. **Pathology - Research and Practice** 154294.
2. Matsubara, D., Yoshimoto, T., Akolekar, N., Totsuka, T., Amano, Y., Kihara, A., Miura, T., Isagawa, Y., Sakuma, Y., Ishikawa, S., Ushiku, T., Fukayama, M., Niki, T., 2022. Genetic and phenotypic determinants of morphologies in 3-dimensional cultures and xenografts of lung tumor cell lines. **Cancer Science** cas.15702.
3. Furuya, G., Katoh, H., Atsumi, S., Hashimoto, I., Komura, D., Hatanaka, R., Senga, S., Hayashi, S., Akita, S., Matsumura, H., Miura, A., Mita, H., Nakakido, M., Nagatoishi, S., Sugiyama, A., Suzuki, R., Konishi, H., Yamamoto, A., Abe, H., Hiraoka, N., Aoki, K., Kato, Y., Seto, Y., Yoshimura, C., Miyadera, K., Tsumoto, K., Ushiku, T., Ishikawa, S., 2022. Nucleic acid-triggered tumoral immunity propagates pH-selective therapeutic antibodies through tumor-driven epitope spreading. **Cancer Science** cas.15596.
4. Kaneko, Y., Yamatsugu, K., Yamashita, T., Takahashi, K., Tanaka, T., Aki, S., Tatsumi, T., Kawamura, T., Miura, M., Ishii, M., Ohkubo, K., Osawa, T., Kodama, T., Ishikawa, S., Tsukagoshi, M., Chansler, M., Sugiyama, A., Kanai, M., Katoh, H., 2022. Pathological complete remission of relapsed tumor by photo-activating antibody-mimetic drug conjugate treatment. **Cancer Science** cas.15565.
6. Hongo, H., Miyawaki, S., Teranishi, Y., Mitsui, J., Katoh, H., Komura, D., Tsubota, K., Matsukawa, T., Watanabe, M., Kurita, M., Yoshimura, J., Dofuku, S., Ohara, K., Ishigami, D., Okano, A., Kato, M., Hakuno, F., Takahashi, A., Kunita, A., Ishiura, H., Shin, M., Nakatomi, H., Nagao, T., Goto, H., Takahashi, S.-I., Ushiku, T., Ishikawa, S., Okazaki, M., Morishita, S., Tsuji, S., Saito, N., 2022. Somatic GJA4 gain-of-function mutation in orbital cavernous venous malformations. **Angiogenesis** 26, 37-52.
7. Tanaka, M., Kunita, A., Yamagishi, M., Katoh, H., Ishikawa, S., Yamamoto, H., Abe, J., Arita, J., Hasegawa, K., Shibata, T., Ushiku, T., 2022. KRAS mutation in intrahepatic cholangiocarcinoma: linkage with metastasis-free survival and reduced E-cadherin expression. **Liver International** liv.15366.
8. Liu, B., Katoh, H., Komura, D., Yamamoto, A., Ochi, M., Onoyama, T., Abe, H., Ushiku, T., Seto, Y., Suo, J., Ishikawa, S., 2022. Functional genomics screening identifies aspartyl-tRNA synthetase as a novel prognostic marker and a therapeutic target for gastric cancers. **The Journal of Pathology** path.5980.
9. Onoyama, T., Ishikawa, S., Isomoto, H., 2022. Gastric cancer and genomics: review of literature. **J Gastroenterol.** 57, 505-516.
10. Tsubosaka, A., Komura, D., Katoh, H., Kakiuchi,

- M., Onoyama, T., Yamamoto, A., Abe, H., Seto, Y., Ushiku, T., Ishikawa, S., 2022. Single-Cell Transcriptome Analyses Reveal the Cell Diversity and Developmental Features of Human Gastric and Metaplastic Mucosa. **bioRxiv**.
11. Teranishi, Y., Okano, A., Miyawaki, S., Ohara, K., Ishigami, D., Hongo, H., Dofuku, S., Takami, H., Mitsui, J., Ikemura, M., Komura, D., Katoh, H., Ushiku, T., Ishikawa, S., Shin, M., Nakatomi, H., Saito, N., 2022. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. **acta neuropathol commun** 10, 76.
 12. Komura, D., Onoyama, T., Shinbo, K., Odaka, H., Hayakawa, M., Ochi, M., Herdiantoputri, R., Sakamoto, K., Katoh, H., Ikeda, T., Ushiku, T., Ishikawa, S., 2022. Beyond pathologist-level annotation of large-scale cancer histology for semantic segmentation using immuno-fluorescence restaining. **bioRxiv**.
 13. Yamatsugu, K., Katoh, H., Yamashita, T., Takahashi, K., Aki, S., Tatsumi, T., Kaneko, Y., Kawamura, T., Miura, M., Ishii, M., Ohkubo, K., Osawa, T., Kodama, T., Ishikawa, S., Kanai, M., Sugiyama, A., 2022. Antibody mimetic drug conjugate manufactured by high-yield *Escherichia coli* expression and non-covalent binding system. **Protein Expression and Purification** 192, 106043.
 14. Yasuda, T., Lee, H.S., Nam, S.Y., Katoh, H., Ishibashi, Y., Yamagata Murayama, S., Matsui, H., Masuda, H., Rimbara, E., Sakurazawa, N., Suzuki, H., Yoshida, H., Seto, Y., Ishikawa, S., Jeon, S.W., Nakamura, M., Nomura, S., 2022. Non-*Helicobacter pylori* *Helicobacter* (NHPH) positive gastric cancer. **Sci Rep** 12, 4811.
 15. Komura, D., Kawabe, A., Fukuta, K., Sano, K., Umezaki, T., Koda, H., Suzuki, R., Tominaga, K., Ochi, M., Konishi, H., Masakado, F., Saito, N., Sato, Y., Onoyama, T., Nishida, S., Furuya, G., Katoh, H., Yamashita, H., Kakimi, K., Seto, Y., Ushiku, T., Fukayama, M., Ishikawa, S., 2022. Universal encoding of pan-cancer histology by deep texture representations. **Cell Reports** 38, 110424.
 16. Zhang, M., Sugita, I., Komura, D., Katoh, H., Shimada, S., Inazawa, J., Tanaka, S., Ishikawa, S., 2022. Genomic landscape of a mouse model of diffuse-type gastric adenocarcinoma. **Gastric Cancer** 25, 83–95.
 17. Sugita, I., Matsuyama, S., Dobashi, H., Komura, D., Ishikawa, S., 2022. Viola: a structural variant signature extractor with user-defined classifications. **Bioinformatics** 38, 540–542.

Department of Public Health/ Department of Health Policy

Professor

Takahiro Higashi, M.D., Ph.D.

(From September 1, 2022)

Associate Professor

Haruhiko Inada, M.D., Ph.D., M.P.H.

(From February 1, 2023)

Research Associate

Atsushi Miyawaki, M.D., Ph.D.

(From September 1, 2022 [Project Research Associate, from April 1 to August 31, 2022])

Homepage <https://publichealth.m.u-tokyo.ac.jp/>

Introduction and Organization

Modern concepts of public health originated in the Industrial Revolution era in the UK, and since then developed in Western countries. In Japan, these concepts became important and popular in the 1880s, when the Japan Non-governmental Association for Hygiene (a synonym of public health in that age) was established to fight against repeated outbreaks of cholera in Japan.

Public health departments in medical schools in Japan were introduced after the World War II, following the model of the U.S. systems for public health and medical education. The Department of Public Health was established in 1947, in Faculty of Medicine, the University of Tokyo. In 1995, the Department became a part of Division of Social Medicine, Graduate School of Medicine, as the result of the shift to a graduate school system in the University of Tokyo. In 2007, School of Public Health was established in the University of Tokyo, and the Department became a part of School of Public Health (Department of Health Policy) and remained being a part of Division of Social Medicine (Department of Public Health).

The objectives of the Department are both education and research of public health. The Department trains graduate and undergraduate students through lectures, seminars, field practice, and laboratory work in public health and occupational medicine, for the degrees of Medical Doctor (MD), Master of Public Health (MPH), and Doctor of Medical Sciences (equivalent to PhD). The Department has conducted research on a wide variety for public health issues, including health policy and economics, occupational medicine, clinical epidemiology, health services research, and so on. In addition, the staff members of the Department have offered public and occupational health services to the governments, industries, and local communities.

In the academic year of 2020, the Department consists of 3 faculty members above listed, 1 project researchers (part-time), 2 supporting staff members, 4 graduate students (3 in PhD program, 1 in professional degree course), and 12 part-time lecturers.

Teaching activities

1) Undergraduate Program (Medical School)

Education in public health in the School of Medicine

is offered for M2 (4th year), M3 (5th year) and M4 (6th year) students. In the Autumn term of the fourth year in School of Medicine (M2), students are provided with the following lectures; general public health, epidemiology, health and labor administration, health policy studies, health economics, cost-effectiveness, human ecology, lifestyle disease control, exercise and dietary nutrition, infectious disease and tuberculosis control, disaster medicine, maternal and child health, cancer control, ICD and statistics, clinical epidemiology, mental health, global health, and environmental medicine. Similarly, in the sixth year (M4), an intensive course of public health (e.g., more advanced public health topics, nutritional epidemiology, health services research for older persons, healthcare policy, and cancer control from the patients' perspective) is provided. All the above lectures are given by faculty members and outside visiting lectures including health practitioners.

Field practice and laboratory work in public health is due in the summer term of the fifth year (M3), which is jointly provided by Department of Preventive Medicine and the other departments related to public health fields. On average seven to eight students (small group) are assigned to one special topic group with a tutor (faculty member or part-time lecturer; we had 14 groups this year). Each group conducts field practice, review work, or laboratory work, and writes a report in the style of original or review paper.

In addition to the core curriculum mentioned above, we accepted students from the School of Medicine within the Clinical Researcher Development Program.

2) MPH Program

Various courses are given by those departments affiliated with School of Public Health. Among them, our Department offers three courses; "Health Policy (cancelled due to instructor's schedule)", "Public Health Preparedness", and "Public Health Practice (cancelled due to instructor's schedule)".

3) PhD Program

The Department offers special lectures, seminars, field practice, and laboratory work on public health and occupational medicine to graduate students. In these training, special emphasis has been placed on the following points: (1) how to conduct epidemiological

studies, (2) how to use epidemiological and statistical methods, (3) how to use economic concepts and methods in the health fields, (4) how to establish the collaboration with health professionals in the various fields, and (5) how to read and write original papers.

Research activities

1) Health policy and economics

Our research activities focus on the topics of health care system and economics in general. We have performed and published those studies related to supply and demand sides of health services in Japan; such as supply and distribution of physicians, access to health care, cost studies of outpatient and inpatient services, and the efficiency and equity issues of the Japan's health insurance system as well as universal health coverage system. We also conduct research on quality of care and social determinants of health using information such as cancer registries and medical records. These studies have been published in health policy and health services research journals. We have continued a collaborative study on UHC systems both in developed and developing countries, since such a system involves health, behavioral, social, and economic factors, and would inevitably be an important health policy issue.

2) Occupational health

We have carried on a longitudinal study on life-style, socio-economic status, occupational stress, and health status of workers in various occupational settings for the purpose of preventing occupational and life-style diseases.

3) Others

Other research activities include, (1) evaluation of disaster preparedness in local communities and healthcare facilities, (2) study on risk communication in public health emergencies, (3) epidemiological study on those children with cerebral palsy, and (4) various public health issues due to the pandemic of COVID-19.

References

(Original Article)

1. Yamamoto S, Sakakibara N, Hirano H, Morizane

- C, Honma Y, Hijioka S, Okusaka T, Higashi T, Kawai A. The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan. *Scientific Reports* 2022 12, Article number: 17601.
2. Ishii T, Watanabe T, Higashi T. Differences in the performance of adjuvant chemotherapy between hemodialysis and non-hemodialysis patients. *Cancer Medicine*. 2023 Feb;12(4):4033-4041. doi: 10.1002/cam4.5258. Epub 2022 Sep 21.
3. Ren N, Nishimura K, Higashi T, Iihara K. Associations Between Adherence to Evidence-Based, Stroke Quality Indicators and Outcomes of Acute Reperfusion Therapy. *Stroke* 2022 Nov;53(11):3359-3368.
4. Okuyama A, Watabe M, Makoshi R, Takahashi H, Tsukada Y, Higashi T. Impact of the COVID-19 pandemic on the diagnosis of cancer in Japan: analysis of hospital-based cancer registries. *Jpn J Clin Oncol*. 2022 Oct 6;52(10):1215-1224. doi: 10.1093/jjco/hyae129.
5. Ishii T, Watanabe T, Higashi T. Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines. *Cancer Med*. 2023 Jan;12(1):122-130. doi: 10.1002/cam4.4929. Epub 2022 Jun 11.
6. Higashi T. Cancer epidemiology and treatment patterns for older persons in Japan: a review of nationwide data and statistics. *Jpn J Clin Oncol*. 2022 Apr 6;52(4):303-312.
7. Kanehara R, Goto A, Watanabe T, Inoue K, Taguri M, Kobayashi S, Imai K, Saito E, Katanoda K, Iwasaki M, Ohashi K, Noda M, Higashi T. Association between diabetes and adjuvant chemotherapy implementation in patients with stage III colorectal cancer. *J Diabetes Investig*. 2022 Oct;13(10):1771-1778. doi: 10.1111/jdi.13837. Epub 2022 Jun 4.
8. Watanabe T, Sugiyama T, Imai K, Higashi T. How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan. *Cancer Science*, 09 March 2022; DOI: 10.1111/cas.15322
9. Ishii T, Nakano E, Watanabe T, Higashi T. Cardiac function checkup during trastuzumab therapy among patients with breast cancer. *Clinical Breast Cancer*, 19 January 2022; <https://doi.org/10.1016/j.clbc.2022.01.005>
10. Kurogi A, Onozuka D, Hagihara A, Nishimura K, Kada A, Hasegawa M, Higashi T, Kitazono T, Ohta T, Sakai N, Arai H, Miyamoto S, Sakamoto T, Iihara K, the J-ASPECT Study Collaborators. Influence of hospital capabilities and prehospital time on outcomes of thrombectomy for stroke in Japan from 2013 to 2016. *Scientific Reports* 12, Article number: 3252 (2022), 28 February 2022; <https://doi.org/10.1038/s41598-022-06074-1>
11. Miyawaki A. Full-time work rates of physicians with physician spouses vs nonphysician spouses in Japan. *JAMA Network Open*. 2022 Nov 1; 5(11):e2242143. doi: 10.1001/jamanetworkopen.2022.42143.
12. Sano K, Miyawaki A, Abe K, Jin X, Watanabe T, Tamiya N, Kobayashi Y. Effects of cost sharing on long-term care service utilization among home-dwelling older adults in Japan. *Health Policy*. 2022 Dec;126(12):1310-1316. doi: 10.1016/j.healthpol.2022.10.002. Epub 2022 Oct 6.
13. Miyawaki A, Ikesu R, Tokuda Y, Goto R, Kobayashi Y, Sano K, Tsugawa Y. Prevalence and changes of low-value care at acute care hospitals: a multicentre observational study in Japan. *BMJ Open*. 2022; 12(9): e063171. <https://bmjopen.bmj.com/content/12/9/e063171>
14. Taniguchi Y, Miyawaki A, Tsugawa Y, Murayama H, Tamiya N, Tabuchi T. Family caregiving and changes in mental health status in Japan during the COVID-19 pandemic. *Archives of Gerontology and Geriatrics*. 2022 Jan;98:104531. <https://doi.org/10.1016/j.archger.2021.104531>
15. Taniguchi Y, Kuno T, Komiyama J, Adomi M, Suzuki T, Abe T, Ishimaru M, Miyawaki A, Saito M, Ohbe H, Miyamoto Y, Imai S, Kamio T, Tamiya N, Iwagami M. Comparison of patient characteristics and in-hospital mortality between patients with COVID-19 in 2020 and those with influenza in 2017–2020: a multicenter, retrospective cohort study in Japan. *The Lancet Regional Health - Western Pacific*. 2022 Mar;20: 100365. doi: 10.1016/j.lanwpc.2021.100365
16. Adomi M, Kuno T, Komiyama J, Taniguchi Y, Abe T, Miyawaki A, Imai S, Morita K, Saito M,

- Ohbe H, Kamio T, Tamiya N, Iwagami M. Association between pre-admission anticoagulation and in-hospital death, venous thromboembolism, and major bleeding among hospitalized COVID-19 patients in Japan. *Pharmacoepidemiol Drug Saf.* 2022 Apr 7;31(6): 680–8. <https://doi.org/10.1002/pds.5433>
17. Yanagisawa-Sugita A, Sugiyama T, Ihana-Sugiyama N, Tanaka H, Imai K, Ueki K, Ohsugi M, Tamiya N, Kobayashi Y. Incidence of interventions for diabetic retinopathy and serious lower-limb complications and its related factors in patients with type 2 diabetes using a real-world large claims database. *Diabetology International* 13 (3): 548-560, 2022. (doi.org/10.1007/s13340-021-00566-7)
 18. Iba A, Tomio J, Abe K, Sugiyama T, Kobayashi Y. Hospitalizations for ambulatory care sensitive conditions in a large city of Japan: a descriptive analysis using claims data. *Journal of General Internal Medicine* 37 (15): 3917-3924, 2022. ([doi: 10.1007/s11606-022-07713-z](https://doi.org/10.1007/s11606-022-07713-z))
 19. Maeda E, Jwa SC, Kumazawa Y, Saito K, Iba A, Yanagisawa-Sugita A, Kuwahara A, Saito H, Terada Y, Fukuda T, Ishihara O, Kobayashi Y. Out-of-pocket payment and patients' treatment choice for assisted reproductive technology by household income: a conjoint analysis using an online social research panel in Japan. *BMC Health Services Research* 22: 1093, 2022. doi.org/10.1186/s12913-022-08474-5
 20. Zaitzu M, Takeuchi T, Zaitzu M, Tonooka A, Uekusa T, Miyake Y, Kobayashi Y, Kobashi G, Kawachi I. Occupational disparities in tumor grade and cytosolic HMGB1 expression in renal cell cancer. *Journal of Occupational Health* 64: e12340, 2022. [doi:10.1002/1348-9585.12340](https://doi.org/10.1002/1348-9585.12340)
 21. 力武諒子、渡邊ともね、山元遥子、市瀬雄一、新野真理子、松木明、太田将仁、坂根純奈、伊藤ゆり、東 尚弘、若尾文彦：がん診療連携拠点病院等の指定要件に関する調査 厚生 の 指 標 2022 年 6 月 号 (第 69 巻 第 6 号) Page15-21
 22. 力武 諒子、渡邊 ともね、山元 遥子、市瀬 雄一、新野 真理子、松木 明、太田 将仁、坂根 純奈、伊藤 ゆり、東 尚弘、若尾 文彦：がん診療連携拠点病院等の指定要件関連の詳細に 関する実態 病院 81 巻 5 号 (2022 年 5 月) Page436-441
 23. 前田恵理、石原 理、左 勝則、李 廷秀、小林 廉毅. 韓国における人工授精および生殖補助医療の公費負担状況—保険適用の背景と影響に関する訪問調査. *公衆衛生* 86(1): 84-90, 2022.
- (Others)**
24. 東 尚弘 医療の質を評価して改善することの社会的意義 *medicina* 59 巻 11 号 Page1818-1821 (2022.10)
 25. 東 尚弘、中山 富雄 がん検診の質の考え方 *medicina* 59 巻 11 号 Page1966-1969 (2022.10)
 26. Miyawaki A, Tsugawa Y. Health and public health implications of COVID-19 in Asian countries. *Asian Economic Policy Review*. 2022; 17(1):18–36. <https://doi.org/10.1111/aepr.12358>
 27. Miyawaki A, Tsugawa Y. Why do homeless women in New York state experience fewer hospital revisits after childbirth than housed women? *BMJ Qual Saf.* 2022;31(4):243–6. [doi: 10.1136/bmjqs-2021-013746](https://doi.org/10.1136/bmjqs-2021-013746)
 28. Evans, C.E.L., Miyawaki, A., & Mizdrak, A. Evaluation of interventions, programmes and policies in food environments; pp 277-291; in *Textbook of Transforming Food Environments*; CRC Press; Boca Raton, FL, US; 2022; Evans, C.E.L. ed.; 1st edition. <http://dx.doi.org/10.1201/9781003043720-19>
 29. 宮脇敦士：アメリカ医療保障制度に関する調査研究報告書【2021 年度版】特集 COVID-19 の感染状況と対策 (pp 7-25) 医療経済研究機構, 2022<https://www.ihep.jp/publications/report/>
 30. 小林廉毅 (談). 原因分析でプロセス解明し紛争防止や質向上に貢献 (産科医療補償制度の現状と役割). *週刊社会保障* 76 (3152): 47-49, 2022.
 31. 小林廉毅. 公衆衛生学の基盤：統計と調査 (第 80 回日本公衆衛生学会総会学会長講演). *公衆衛生情報* 51 (12): 4-5, 2022.
 32. 宮脇敦士：医師との結婚で女性医師のフルタイム勤務率低下 *Medical Tribune* 2022 年 12 月 1 号 Vol55 No.23 (2 面「医師のキャリア」).
 33. 東尚弘. 地域におけるがん医療の課題と展望：均てん化は進んだか？ 第 60 回日本癌治療学会学術集会シンポジウム 2022 年 10 月 20 日

-
34. 高山智子、市瀬雄一、渡邊ともね、東尚弘、
がん診療連携拠点病院がん相談支援センター
の利用状況と医療の質との関連に関する研究、
一般口頭、第 81 回日本公衆衛生学会総会
2022 年 10 月 7-9 日
 35. 市瀬雄一、渡邊ともね、角和珠妃、山元遥子、
新野真理子、東尚弘、経口抗がん薬服用患者
を対象とした服薬管理に関する理解度調査、
一般口頭、第 81 回日本公衆衛生学会総会
2022 年 10 月 7-9 日
 36. 東 尚弘、インターネット調査の回答の正確
性に関する一考察、一般口頭、第 32 回 日本
疫学会学術総会 2022 年 1 月 26-28 日
 37. 太田将仁、伊藤ゆり、渡邊ともね、市瀬雄一、
山元遥子、力武諒子、松木明、新野真理子、
坂根純奈、東尚弘、若尾文彦、院内がん登録・
DPC・現況報告からみるがん診療連携拠点病
院における標準治療実施の現状、一般口頭、
第 32 回 日本疫学会学術総会 2022 年 1 月
26-28 日

Social Medicine

2. Forensic Medicine, and Medical Informatics and Economics

Department of Forensic Medicine

Professor

Hirotarō Iwase, M.D., Ph.D.

Associate Professor

Yohsuke Makino, M.D., Ph.D.

Assistant Professor

Suguru Torimitsu, M.D., Ph.D., Rutsuko Yamaguchi, M.P.H., M.D., Ph.D.

Project Assistant Professor

Go Inokuchi, M.D., Ph.D., Ayumi Motomura, M.D., Ph.D., Fumiko Chiba, M.D., Ph.D.

Shigeki Tsuneya, M.D., Ph.D.

Homepage <http://ut-forensic.jp/>

Introduction and Organization

Associate Professor Kuniyoshi Katayama lectured “judicial medicine” in the University of Tokyo since 1881 before our department was founded as the first department of forensic medicine in Japan in 1889. He renamed “judicial medicine” to “forensic medicine” in 1891 since the department should cover legislation as well as general forensic practices. Dr. Katayama became the first professor of forensic medicine in Japan.

The 2nd Professor Sadanori Mita also founded the serological department (Department of Immunology at present). He studied the antigen-antibody reaction and discovered complement fixation reaction.

The 3rd Professor Tanemoto Furuhashi was very famous for ABO blood group genetics, and also contributed to the development of criminology. He autopsied several cases of historical crimes.

The 4th Professor Shokichi Ueno discovered a complex complement. He helped foundation of national police academy for death investigators.

The 5th Professor Toshiyuki Miki could not perform autopsy for four years due to the University of Tokyo strike. However, he left many achievements in the field of blood typing and paternity examination.

The 6th Professor Ikuo Ishiyama encouraged forensic pathology. He also introduced DNA fingerprinting and PCR technique in the forensic practices.

The 7th Professor Takehiko Takatori studied the biochemical changes of the lipid in cadavers. He dissected five victims of sarin subway attacks in Tokyo and identified sarin in tissue by a sophisticated method.

The 8th Professor Ken-ichi Yoshida studied the molecular mechanism of ischemic heart disease and sudden cardiac death.

Hirotarō Iwase has been directing our department since 2014 as the 9th Professor. In order to reconstruct the field of forensic medicine as the attractive one, six sections (forensic pathology, clinical forensic medicine, forensic toxicology, forensic radiology, forensic odontology, forensic genetics) have started in cooperation with Chiba University. We are preparing to teach practice and research for the future forensic pathologists.

Postmortem examination

The determination of precise cause of death is one of the most important practices at our department. We perform medico-legal autopsies for around 150

criminal cases in eastern part of Tokyo every year. We also perform post-mortem CT at the request of police.

In medico-legal autopsy, we usually examine various tests such as the pathological, alcohol, toxicological, and blood type tests. Finally, forensic pathologists in our department diagnose the cause of death. Expert opinions express the cause of death and forensic judgment for each case.

It should be noted that this year that pandemic of the new coronavirus (SARS-CoV-2) continued. Infection control in dissection was still a hot topic, but with the introduction of the laminar-flow autopsy table following the seismic retrofitting carried out in 2019, it has become possible to accept SARS-CoV-2-infected bodies. In 2020, we have newly introduced our own real-time PCR system in our laboratory, conducting a SARS-CoV-2 PCR test in all cases. Last year, we had several COVID-19 cases, and autopsies were performed with PAPRs (powered air-purifying respirators).

Education

As for under-graduate education, our department provides lectures for the 4th year medical students, Free Quarter training course for the 2nd-4th year medical students, and Elective Clerkship learning for the 6th year medical students.

The lectures consist of forensic pathology, clinical forensic medicine, forensic toxicology, forensic radiology, forensic odontology and forensic genetics. In the Free Quarter training course, students experience laboratory practices (toxicology and histology) or research. In the Elective Clerkship learning, each student experiences the process from autopsy to presentation of expert opinion.

In addition, students of school of public health and (undergraduate & graduate) law school are provided with somewhat practical lectures with exercises. We have provided opportunity for PhD students of School of Health Science, and master course of Medical Science.

Research

In cooperation with other universities including Chiba University, Tokyo Medical and Dental University, and International University of Health and

Welfare, researches in 6 sections (forensic pathology, clinical forensic medicine, forensic toxicology, forensic radiology, forensic odontology and forensic genetics) have proceeded.

1. Forensic Pathology

We conduct research aimed at improving the accuracy of cause-of-death diagnosis and epidemiological studies related to cause-of-death investigation. For example, we are trying angiographic 3D-CT and vascular endoscopy in the search for coronary arteries and cerebral basilar arteries. We are also conducting research on diatoms in order to improve the diagnosis of drowning. Additionally, we are trying to conduct a comparative study of the cause-of-death investigation systems in Tokyo and Chiba prefectures.

2. Clinical Forensic Medicine

Clinical forensic medicine is an academic field that collaborates with various clinical departments to examine a living body that may have been subjected to some form of invasion to determine whether or not an invasion has occurred, and to devise measures to prevent accidents based on information obtained from the accumulation of cause-of-death information. Currently, in collaboration with pediatricians, we are conducting research on the accumulation and analysis of pediatric deaths and their application to prevention. As part of this effort, the Chiba Prefecture Child Death Review (CDR) Study Group has been established in cooperation with Chiba University. In addition, we are also conducting research on bone strength to gain knowledge that will be useful in the evaluation of abuse.

3. Forensic Toxicology

Using LC/MS/MS, LC/QTOF-MS, etc., we are conducting research on detection methods targeting a large number of drugs, including cyanide compounds and dangerous drugs. Animal studies on postmortem drug redistribution had also been conducted. In collaboration with the National Research Institute of Police Science and others, we are also conducting epidemiological studies on drug detection in traffic accident fatalities.

4. Forensic Odontology

Studies are being conducted to examine the usefulness of drug analysis, DNA testing, CT testing, etc., from teeth and palatine and mandible bones for age estimation and other utilities.

5. Forensic Genetics

We are trying research to search for disease genes in cases of sudden death. We are also conducting research on the detection of novel coronavirus genes in cadavers.

6. Forensic Radiology

Using 3D-CT, we are studying the possibility of estimating the stature, sex, and age of the deceased based on bone length and morphology. We are also conducting research on the benefits and risks of postmortem imaging to determine the cause of death. In collaboration with the other universities, we are also studying the characteristics of postmortem CT in COVID-19 deaths.

Publications

- Chiba F, Inokuchi G, Hoshioka Y, Sakuma A, Makino Y, Torimitsu S, Yamaguchi R, Saitoh H, Kono M, Iwase H. Age estimation by evaluation of osteophytes in thoracic and lumbar vertebrae using postmortem CT images in a modern Japanese population. *Int J Leg Med.* 2022;136: 261-267.
- Nariai M, Abe H, Hoshioka Y, Makino Y, Iwase H. Biomarker profiling of postmortem blood for diabetes mellitus and discussion of possible applications of metabolomics for forensic casework. *Int J Legal Med.* 2022; 136(4): 1075-1090.
- Akutsu T, Saito H, Watanabe K, Toyomane K, Yamagishi T, Iwase H. Evaluation and simultaneous determination of rectal mucosa markers by multiplex reverse transcription-PCR for biological evidence of sexual assault with anal penetration. *Foresic Sci Int Genet.* 2022; 59: 102712.
- Nagasawa S, Mori A, Hirata Y, Motomura A, Ishii N, Okaba K, Horioka K, Makino Y, Nakajima M, Torimitsu S, Yamaguchi R, Inokuchi G, Chiba F, Hoshioka Y, Saito N, Yoshida M, Yajima D, Akitomi S, Iwase I, Saitoh H. SmartAmp method can rapidly detect SARS-CoV-2 in dead bodies. *Forensic science international.* 2022; 331: 111168-111168.
- Kazuta M, Hajime U, Makino Y, Minegishi S, Iwase H, Sakurada K. A post-mortem computed tomography imaging method for predicting the anteroposterior and superoinferior positions of the Japanese adult eyeball in the orbit. *Forensic Imaging.* 2022; 29: 200504.
- Makino Y, Unuma K, Nolte KB, Adolphi NL. Accuracy of forensic pathologists in incorporating post-mortem CT (PMCT) in forensic death investigation. *J Forensic Sci.* 2022; 67: 2351-2359.
- Wen S, Unuma K, Makino Y, Mori H, Uemura K. Fatal consequence after MiraDry® treatment: Necrotizing fasciitis complicated with streptococcal toxic shock syndrome. *Leg Med (Tokyo).* 2022; 58:102095.
- Torimitsu S, Yajima D, Inokuchi G, Makino Y, Motomura A, Chiba F, Yamaguchi R, Hoshioka Y, Tsuneya S, Iwase H. Electrolyte analysis of pleural effusion for discrimination between seawater and freshwater drowning in decomposed bodies. *J Forensic Leg Med.* 2022; 90: 102389.
- Torimitsu S, Saka K, Noritake K, Namera A, Makino Y, Yamaguchi R, Iwase H. Detection of lisdexamfetamine and its metabolite d-amphetamine in urine and gastric contents collected from a cadaver at forensic autopsy. *Forensic Toxicol.* 2022; Online ahead of print.
- Inokuchi G, Chiba F, Hoshioka Y, Saito N, Yoshida M, Nagasawa S, Yamagishi Y, Makino Y, Torimitsu S, Yamaguchi R, Tsuneya S, Inoue H, Motomura A, Yajima D, Iwase H. Methamphetamine-related forensic autopsy cases in a Japanese prefecture over a 7-year period: characteristics of deaths and blood concentrations. *Legal medicine.* 2022; 60: 102181-102181.
- Saito N, Hashimoto T, Endo M, Inokuchi G, Shimojo N, Iwase H. Ealy involvement of the child protection team in a tertiary care hospital for detection of child maltreatment. *Chiba Medical J.* 2022; 98E: 59-67.

12. Yamaguchi R, Makino Y, Torimitsu S, Chiba F, Kihara Y, Iwase H. Fatal bilateral pneumothoraces after electropuncture treatment: A case report and literature review. *J Forensic Sci.* 2022; 67(1): 377-383.
13. Yamaguchi R, Makino Y, Inokuchi G, Ishihara K, Torimitsu S, Chiba F, Hoshioka Y, Urabe S, Oya Y, Motomura A, Yajima D, Iwase H. Trend and characteristics in health care related deaths investigated through medico-legal autopsies after system changes in Japan. *J Law Med.* 2022; 29(2): 509-521
14. Yamagishi Y, Nagasawa S, Iwase H, Ogra, Y. Evaluation of post-mortem interaction between hemoglobin and oxime-type carbamate pesticides. *Chem. Res. Toxicol.* 2022; 35: 1110-1116.
15. Yamagishi Y, Nagasawa S, Iwase H, Ogra, Y. Post-mortem interaction between methidathion and human serum albumin in blood. *J. Toxicol Sci.* 2022; 47: 139-146.
16. Okaba K, Motomura A, Horioka K, Inokuchi G, Chiba F, Hoshioka Y, Saito N, Makino Y, Torimitsu S, Yamaguchi R, Tsuneya S, Yajima D, Iwase H. Prevalence of blood-borne infections in forensic samples: Epidemiology in areas of Chiba, Japan. *Journal of Forensic and Legal Medicine.* 2022; 90: 102396.
17. Urabe S, Kurahashi H, Inokuchi G, Chiba F, Motomura A, Hoshioka Y, Torimitsu S, Yamaguchi R, Tsuneya S, Iwase H. Carrion flies (Insecta: Diptera) found on human cadavers in Chiba prefecture, Honshu, Japan, with the first record of *Fannia prisca* from a human corpse. *Journal of Forensic Sciences.* 2022; 67(6): 2469-2478.
18. Tsuneya S, Nakajima M, Makino Y, Torimitsu S, Yamaguchi R, Iwase H. The effect of ethanol or long-time reaction on the diatom test in water samples using sodium hypochlorite. *Leg Med (Tokyo).* 2022; 57: 102054.
19. Hirata Y, Inokuchi Go, Tsuneya S, Hoshioka Y, Chiba F, Yoshida M, Makino Y, Iwase H. A case of fatal fulminant fat embolism syndrome following multiple fractures resulting from a fall. *J Forensic Sci.* 2022; 67(5): 2115-2121.
20. Saka K, Kudo K, Namera A, Fujii Y, Noritake K, Torimitsu S, Makino Y, Iwase H. Simple and simultaneous quantification of cyanide, ethanol, and 1-propanol in blood by headspace GC-MS/NPD with Deans switch dual detector system. *Sci Justice.* 2022; 62: 193-202.

Department of Biomedical Informatics

Professor

Kazuhiko Ohe, M.D.,Ph.D.

Associate Professor

Kayo Waki, M.D.,Ph.D. Yoshimasa Kawazoe, M.D.,Ph.D.

Takeshi Imai, Ph.D.

Lecturer

Shinichiro Yokota, PHN,RN,Ph.D., Hidenao Atarashi BMET, Ph.D.

Homepage <http://www.m.u-tokyo.ac.jp/medinfo/>

Introduction and Organization

We aim to transform medical care and contribute to society by applying the following methods to clinical medicine and medical management; development of basic methods that can be applied to medical information systems in the interdisciplinary field between medicine and informatics, development and construction of basic information environments related to medical information, practical research on medical information systems, and knowledge in these areas.

Keywords for the fields covers medical information system, next-generation electronic medical records, medical information network, virtual medical information environment, computer representation and standardization of medical concepts, medical knowledge engineering, hospital information epidemiology, evaluation of medical quality, clinical information engineering, privacy protection and encryption, Information security, medical analysis, hospital management analysis, medical safety management. The professor concurrently supervise as the director of the Department of Planning and Information Management at the University of Tokyo Hospital, which is united with this department.

The Department of Planning and Information Management is a place where the medical information

system is used to analyze information related to the future plan of the University Hospital.

Our department began in 1983 when the Department of Central Information of the University of Tokyo Hospital, as the National University Hospitals, was formally established, and the medical informatics doctoral course was established in the Graduate School of Basic Medicine I of the Graduate School of Medicine, the University of Tokyo at that time. The first professor was Shigekoto Kaihara (deceased) who established medical informatics in Japan, and the current professor is the second generation. In 1997, when the University of Tokyo became a graduate school, it became the current Department of Social Medicine, Medical Information Economics, and the one professor and one associate professor, who belonged to the Department of Central Information of the University of Tokyo Hospital, moved to full-time staffs of the graduate school.

Teaching activities

In 2022, the faculty composition, including the hospital staff, is 1 professor (Ohe), 1 associate professor (Waki), 2 lecturers (Atarashi, Yokota), 2 assistant professor (specially appointed lecturer (hospital)). (Doi, Ida), 4 assistant professors (Nagae,

Mori, Seki), and 2 special assistant professors (Miyake, Kubota). In addition to these, Associate Professor 1 (Disease and Biotechnology Center) (Imai) and Specially Appointed Associate Professor 1 (Endowed Department of Medical AI Development) (Kawazoe) are also in charge of this course. In the doctoral course of medicine, we educate graduate students in medical informatics, and in the public health medicine major (professional master's course), we are in charge of medical information systems (medical information system lecture 15 units 2 credits, practical training 30 units 1 credit), every year About 10 students are taking elective courses.

The lecture course is 1) Overview of information technology infrastructure and systems related to medical computerization policies in Japan and overseas, 2) Hospital information systems, electronic medical record systems, and standardization of medical information. 3) Security management of medical personal data and information networks. 4) Medical information database—National DB and Sentinel DB, 5) Mobile IT medical care, lifestyle disease management and IT, 6) Knowledge and information handling in medical care, language processing, 7) Open data handling and discussion. was the content.

Practical training consists of 1) data creation, conversion, and Internet basic technical training, 2) database design and database operation: learning a series of basic operations of relational databases based on medical sample data. Acquire the basic technology of data interconversion. 3) Learn to convert data into standardized code. 4) Create a database, extract and convert data suitable for a given task by creating a program, and conduct research.

It is also a health and medical informatics cooperative course for the Department of Health Science and Nursing, and is in charge of the health science and nursing doctoral course (three years). If desired, we also accept students in the master's course of medical science, and are mainly in charge of Associate Professor Takeshi Imai (Center for Disease Biotechnology), who is also in charge of the department. In the master's program in medical science, Imai was in charge of one lecture on medical informatics and clinical medical ontology. Our department has an educational system that allows

students to obtain degrees such as Doctor of Medicine, Master of Public Health Medicine, Doctor of Health Science, and Master of Medical Science. There was 1 master of medical science and 1 master of public health medicine. At the Faculty of Medicine, staffs were in charge of 5 lectures on medical informatics in M2.

In the Ministry of Education, Culture, Sports, Science and Technology's medical data human resource development project "Development Project of Medical Real World Data Utilization Human Resource" adopted in 2019, the first batch of students will be accepted from May 2020. Assistant professors were in charge, and lectures and practical training were mainly held on Saturdays as adult education courses. Details are available at <https://www.med-rwd.jp/>.

Research activities

Main research areas: 1) Applied research on hospital information systems and medical information systemization represented by electronic medical records, 2) New medical knowledge extraction and medical economics targeting electronic medical records and hospital information system databases 3) Standardization of descriptions of clinical medical terminology and concepts and research on structured knowledge representation methods 4) Basic research on information systems for clinical research 5) Personal information protection and security in medical information systems 6) Research on lifestyle-related disease management using mobile devices. Representative research themes are as follows.

Research and development of a standardization platform for medical information and its utilization, automatic information collection of hospital wards using FHIR standard specifications, basic research on medical text analysis for natural language processing, research on fall risk prediction model and evaluation for inpatients, AI-based automatic finding classification of renal pathological images, development of clinical support systems based on clinical guidelines, e-Phenotyping, etc. In addition, we are carrying out many industry-university collaborative researches with clinical research on

lifestyle-related diseases and self-management of health using mobile devices such as smartphones as the main research theme.

As social activities, the Ministry of Health, Labor and Welfare's study group on various medical information policies (Medical Information Standardization Committee, ICD Special Committee), the Japanese Association of Medical Sciences Terminology Management Committee, the Social Insurance Medical Fee Payment Fund Standard Injury Name Master Review Committee, International Several staff members play important roles in WG2 of the Organization for Standardization ISO/TC215 (Medical Information Standardization Committee), the Ministry of Health, Labor and Welfare/PMDA medical information database infrastructure development project MID-NET, and research on the utilization of the national health insurance claim database NDB.

References

1. Kawazoe Y, Shimamoto K, Yamaguchi R, Nakamura I, Yoneda K, Shinohara E, Shintani-Domoto Y, Ushiku T, Tsukamoto T, Ohe K. Computational Pipeline for Glomerular Segmentation and Association of the Quantified Regions with Prognosis of Kidney Function in IgA Nephropathy. *Diagnostics*. 2022;12(12): 2955.
2. Takeuchi A, Yokota S, Tomotaki A, Fukahori H, Shimpuku Y, Yoshinaga N. Relationship between Research Activities and Individual Factors among Japanese Nursing Researchers during the COVID-19 Pandemic. *PLOS ONE*. 2022;17(8): e0271001.
3. Hayakawa J, Seki T, Kawazoe Y, Ohe K. Pathway Importance by Graph Convolutional Network and Shapley Additive Explanations in Gene Expression Phenotype of Diffuse Large B-cell Lymphoma. *PLOS ONE*. 2022;17(6): e0269570.
4. Masukawa K, Aoyama M, Yokota S, Nakamura J, Ishida R, Nakayama M, Miyashita M. Machine Learning Models to Detect Social Distress, Spiritual Pain, and Severe Physical Psychological Symptoms in Terminally Ill Patients with Cancer from Unstructured Text Data in Electronic Medical Records. *Palliative Medicine*. 2022;36(8): 1207-1216.
5. Tomotaki A, Iwamoto T, Yokota S. Research Types and New Trends on the Omaha System Published in English and Japanese from 2012 to 2019: A Scoping Review. *CIN: Computers, Informatics, Nursing*. 2022;40(8): 531-537.
6. Kawai Y, Waki K, Yamaguchi S, Shibuta T, Miyake K, Kimura S, Toyooka T, Nakajima R, Uneda K, Wakui H, Tamura K, Nangaku M, Ohe K. The Use of Information and Communication Technology-Based Self-management System DialBeticsLite in Treating Abdominal Obesity in Japanese Office Workers: Prospective Single-Arm Pilot Intervention Study. *JMIR Diabetes*. 2022; 7(4): e40366.
7. Kondo M, Okitsu T, Waki K, Yamauchi T, Nangaku M, Ohe K. Effect of Information and Communication Technology-Based Self-management System DialBeticsLite on Treating Abdominal Obesity in the Specific Health Guidance in Japan: Randomized Controlled Trial. *JMIR Formative Research*. 2022;6(3): e33852.
8. Kurasawa H, Waki K, Chiba A, Seki T, Hayashi K, Fujino A, Haga T, Noguchi A, Ohe K. Treatment Discontinuation Prediction in Patients With Diabetes Using a Ranking Model: Machine Learning Model Development. *JMIR Bioinform Biotech*. 2022;3(1): e37951.
9. Sankoda A, Waki K, Yamaguchi S, Mieno M, Nangaku M, Yamaguchi T, Ohe K. Effect of Digital Health Among People With Type 2 Diabetes Mellitus During the COVID-19 Pandemic in Japan. *Journal of Diabetes Science and Technology*. 2022;16(1): 256-258.

Internal Medicine

1. Medicine I

Department of Cardiovascular Medicine

Professor

Issei Komuro, M.D., Ph.D.

Associate Professor

Hatano Masaru, M.D., Ph.D. (Advanced Medical Center for Heart Failure)

Lecturer

Hiroyuki Morita, M.D., Ph.D. Hiroshi Akazawa, M.D., Ph.D.

Eiki Takimoto, M.D., Ph.D.

Hospital Lecturer

Norifumi Takeda, M.D., Ph.D. Satoshi Kodera, M.D., Ph.D.

Homepage <https://cardiovasc.m.u-tokyo.ac.jp/>

Introduction and Organization

The Department of Cardiovascular Medicine was established in 1998 by regrouping cardiologists of five previous internal medical departments. After Yoshio Yazaki, the first professor, and Ryoza Nagai, the second professor, the present professor Issei Komuro was elected in August, 2012. Our department comprises one professor, one associate professor, 3 lecturers, 2 hospital lecturers, 16 research assistants, 7 staff members, and 41 graduate school students.

Clinical activities

The Department of Cardiovascular Medicine is actively involved in clinical medicine, basic research and teaching. Not only do we have the most advanced equipment and facilities (e.g., 24-hour cardiac care unit), but our personnel are also highly trained to be knowledgeable and experts in modern methods of diagnosis and treatment. Especially, we make a special effort to treat patients with severe heart failures. As a teaching and research hospital, we also emphasize the development and integration of new treatment methods if they may be beneficial to patients.

In 2022, a total of 1,777 patients were newly admitted to our hospital ward of 57 beds. The average duration of hospitalization was 11.2 days.

Because we are an authorized facility for heart transplantation, the use of left ventricular assist device in cases of severe heart failure has been increasing. In 2006, the first patient with heart failure from our department underwent a heart transplant procedure at the Department of Cardiovascular Surgery. In 2022, 18 patients underwent heart transplant (total 189 cases). In March 2014, our facility was also authorized to perform lung transplantation. Coronary angiography was performed in 1,864 patients, of which 417 patients underwent percutaneous coronary interventions. CT coronary angiography and cardiovascular MRI were performed in 636 and 176 patients, respectively. With regard to arrhythmias, there were 257 cases of catheter ablation, 99 cases of implantation or replacement of pacemakers and other specialized pacemaker devices, including 13 cases of implantation or replacement of implantable cardioverter-defibrillator and 7 cases of implantation or replacement of a cardiac resynchronization device.

Out-patient clinics are available as a specialized

department and as part of the Department of Medicine. Out-patient clinics are open in the mornings and afternoons from Monday to Friday, and approximately 182.5 patients visited each day. The disease profile includes ischemic heart disease, heart failure, arrhythmia, hypertension and peripheral artery disease. There are special outpatient clinics for advanced heart failure, ischemic heart disease, pulmonary hypertension, congenital heart disease, valvular heart disease, arrhythmia, Marfan syndrome, myocarditis, cardiac amyloidosis, onco-cardiology, and cardiac rehabilitation. The department is also focused on acute cases of coronary heart disease and aortic disease, as emergent catheterization is available on a 24-hour basis.

Education

We have a particular interest in teaching not only medical students but also residents, who are important for the future of cardiovascular medicine. The courses available at the medical school include clinical lectures and clinical clerkships. In clinical clerkship, three students are placed under the guidance of one research associate, which enables teaching in small groups. Specialized groups provide practical lectures. Residents are educated through specialized group conferences, grand rounds, and clinical conferences.

Research activities

From a research perspective, our interests include all fields of cardiovascular medicine, ranging from molecular biology to clinical research, including genomics. Importantly, our research interests are aimed at facilitating new diagnostic and treatment methods for cardiovascular diseases. Our areas of interest include the following:

1. Cardiac hypertrophy and heart failure: multiomics analyses of pathogenic mechanisms and development of novel therapies (e.g., gene therapy)
2. Interplay between organs, cells, and molecules in chronic inflammation
3. Genetic analysis of inherited cardiomyopathy
4. Experiments on pathophysiology of cardiomyopathy using human iPS cells
5. Investigation of disease pathophysiology and development of novel therapies (severe heart failure, cardiac transplantation, congenital heart disease, etc.)
6. New treatments for structural heart disease
7. Diagnosis and treatment of Marfan syndrome and adult congenital heart disease
8. New treatments for pulmonary hypertension
9. New treatments for congenital heart disease
10. Aerobic threshold and cardiac rehabilitation
11. Imaging techniques (echocardiography, MRI, CT, and SPECT) in cardiovascular diseases
12. Epidemiology and prevention of cardiovascular disease
13. Artificial Intelligence in Cardiology

Publications (2022)

1. Adachi Y, Ueda K, Nomura S, Ito K, Katoh M, Katagiri M, Yamada S, Hashimoto M, Zhai B, Numata G, Otani A, Hinata M, Hiraike Y, Waki H, Takeda N, Morita H, Ushiku T, Yamauchi T, Takimoto E and Komuro I. Beiging of perivascular adipose tissue regulates its inflammation and vascular remodeling. *Nat Commun* 13:5117, 2022.
2. Bujo S, Amiya E, Maeda MH, Ishida J, Hatano M, Ishizuka M, Uehara M, Oshima T, Kojima T, Nakanishi K, Daimon M, Shimizu J, Toda T and Komuro I. The effect of immunosuppressive therapy on cardiac involvements in anti-mitochondrial antibody-positive myositis. *ESC Heart Fail* 9:4112-4119, 2022.
3. Fukui A, Kaneko H, Okada A, Yano Y, Itoh H, Matsuoka S, Morita K, Kiriyama H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Nishiyama A, Node K, Yokoo T, Nangaku M, Yasunaga H and Komuro I. Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database. *Nephrol Dial Transplant* 37:1691-1699, 2022.
4. Ieki H, Ito K, Saji M, Kawakami R, Nagatomo Y, Takada K, Kariyasu T, Machida H, Koyama S, Yoshida H, Kurosawa R, Matsunaga H, Miyazawa K, Ozaki K, Onouchi Y, Katsushika S, Matsuoka R, Shinohara H, Yamaguchi T, Kodera S, Higashikuni Y, Fujiu K, Akazawa H, Iguchi N, Isobe M, Yoshikawa T and Komuro I. Deep

- learning-based age estimation from chest X-rays indicates cardiovascular prognosis. *Commun Med (Lond)* 2:159, 2022.
5. Itoh H, Kaneko H, Okada A, Suzuki Y, Fujiu K, Matsuoka S, Michihata N, Jo T, Nakanishi K, Takeda N, Morita H, Node K, Di Tullio MR, Homma S, Yasunaga H and Komuro I. Age-Specific Relation of Cardiovascular Health Metrics With Incident Cardiovascular Disease. *Am J Cardiol* 177:34-39, 2022.
 6. Kamon T, Kaneko H, Itoh H, Okada A, Matsuoka S, Kiriya H, Fujiu K, Morita K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Node K, Yasunaga H and Komuro I. Sex Difference in the Association between Lipid Profile and Incident Cardiovascular Disease among Young Adults. *J Atheroscler Thromb* 29:1475-1486, 2022.
 7. Kaneko H, Yano Y, Lee HH, Lee H, Okada A, Itoh H, Morita K, Fukui A, Fujiu K, Suzuki Y, Matsuoka S, Nakamura S, Michihata N, Jo T, Takeda N, Morita H, Yokoo T, Nishiyama A, Node K, Viera AJ, Muntner P, Oparil S, Kim HC, Yasunaga H and Komuro I. Medication-Naïve Blood Pressure and Incident Cancers: Analysis of 2 Nationwide Population-Based Databases. *Am J Hypertens* 35:731-739, 2022.
 8. Kaneko H, Yano Y, Suzuki Y, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Node K, Viera AJ, Lima JAC, Oparil S, Lam CSP, Carey RM, Yasunaga H and Komuro I. Reduction in blood pressure for elevated blood pressure/stage 1 hypertension according to the American College of Cardiology/American Heart Association guideline and cardiovascular outcomes. *Eur J Prev Cardiol* 29:1921-1929, 2022.
 9. Ko T, Nomura S, Yamada S, Fujita K, Fujita T, Satoh M, Oka C, Katoh M, Ito M, Katagiri M, Sassa T, Zhang B, Hatsuse S, Yamada T, Harada M, Toko H, Amiya E, Hatano M, Kinoshita O, Nawata K, Abe H, Ushiku T, Ono M, Ikeuchi M, Morita H, Aburatani H and Komuro I. Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF-beta-IGFBP7 axis. *Nat Commun* 13:3275, 2022.
 10. Matsuoka S, Kaneko H, Kamon T, Suzuki Y, Yano Y, Okada A, Itoh H, Morita K, Fukui A, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Yokoo T, Nishiyama A, Node K, Yasunaga H and Komuro I. Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline. *J Atheroscler Thromb* 29:1487-1498, 2022.
 11. Matsuoka S, Kaneko H, Okada A, Morita K, Itoh H, Michihata N, Jo T, Takeda N, Morita H, Fujiu K, Nakamura S, Node K, Yasunaga H and Komuro I. Age Modified Relationship Between Modifiable Risk Factors and the Risk of Atrial Fibrillation. *Circ Arrhythm Electrophysiol* 15:e010409, 2022.
 12. Nakanishi K, Daimon M, Yoshida Y, Ishiwata J, Sawada N, Hirokawa M, Kaneko H, Nakao T, Mizuno Y, Morita H, Di Tullio MR, Homma S and Komuro I. Blood pressure categorization and subclinical left ventricular dysfunction in antihypertensive medication-naïve subjects. *ESC Heart Fail* 9:1766-1774, 2022.
 13. Nakayama A, Morita H, Sato T, Kawahara T, Takeda N, Kato S, Itoh H and Komuro I. Small Dense Low-Density Lipoprotein Cholesterol is a Potential Marker for Predicting Laser Treatment for Retinopathy in Diabetic Patients. *J Atheroscler Thromb* 29:678-691, 2022.
 14. Numata G, Takimoto E, Kariya T, Adachi Y, Tokiwa H, Toyoda M, Mafune R, Saito Y, Nakamura S, Ueda K, Ikeda Y and Komuro I. A pacing-controlled protocol for frequency-diastolic relations distinguishes diastolic dysfunction specific to a mouse HFpEF model. *Am J Physiol Heart Circ Physiol* 323:H523-H527, 2022.
 15. Suzuki Y, Kaneko H, Okada A, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Node K, Nangaku M, Yasunaga H and Komuro I. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors. *Kidney Int* 102:1147-1153, 2022.
 16. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Ueno K, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yokota I, Node K, Yasunaga H and Komuro I. Dose-dependent relationship of blood pressure and glycaemic status with risk of aortic dissection and aneurysm. *Eur J Prev Cardiol* 29:2338-2346, 2022.
 17. Suzuki Y, Kaneko H, Yano Y, Okada A, Matsuoka

- S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Node K, Yasunaga H and Komuro I. Reduction in blood pressure for people with isolated diastolic hypertension and cardiovascular outcomes. *Eur J Prev Cardiol* 30:928-934, 2023.
18. Tsuji M, Kakuda N, Bujo C, Ishida J, Amiya E, Hatano M, Shimada A, Imai H, Shimada S, Kinoshita O, Yamauchi H, Ono M and Komuro I. Sarcopenia and risk of infection in adult heart transplant recipients in Japan. *ESC Heart Fail* 9:1413-1423, 2022.
19. Ueno K, Kamiya K, Kaneko H, Okada A, Itoh H, Fujiu K, Takeda N, Morita H, Michihata N, Jo T, Yasunaga H and Komuro I. Acute-Phase Initiation of Cardiac Rehabilitation for Short-Term Improvement in Activities of Daily Living in Patients Hospitalized for Acute Heart Failure. *J Cardiovasc Dev Dis* 9, 2022.
20. Ueno K, Kaneko H, Kamiya K, Itoh H, Okada A, Suzuki Y, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Ako J, Yasunaga H and Komuro I. Clinical utility of simple subjective gait speed for the risk stratification of heart failure in a primary prevention setting. *Sci Rep* 12:11641, 2022.
21. Yoshida Y, Nakanishi K, Daimon M, Hirose K, Ishiwata J, Kaneko H, Nakao T, Mizuno Y, Morita H, Di Tullio MR, Homma S and Komuro I. Aortic valve sclerosis and subclinical LV dysfunction in the general population with normal LV geometry. *Eur J Prev Cardiol*, 2022.

Department of Respiratory Medicine

Professor

Takahide Nagase, M.D.,Ph.D.

Lecturer

Goh Tanaka, M.D.,Ph.D., Akihisa Mitani, M.D.,Ph.D.

Assistant Professor

Masanori Kawakami, M.D.,Ph.D., Hirokazu Urushiyama, M.D.,Ph.D.

Satoshi Noguchi, M.D.,Ph.D., Keita Maemura, M.D., Ph.D.

Yu Mikami, M.D., Ph.D., Kosuke Makita, M.D.,Ph.D.

Takahiro Ando, M.D., Ph.D. Kensuke Fukuda, M.D., Ph.D.

Homepage <http://kokyuki.umin.jp/>

Introduction and Organization

The staff of the Department of Respiratory Medicine, Graduate School of Medicine, University of Tokyo, consists of 1 professor, 2 lecturers, and 8 assistant professors. At The University of Tokyo, affiliated hospitals and other institutions, approximately 70 members belong to the Department. At the University of Tokyo Hospital, 24 physicians belong to the Department.

Mortality from respiratory diseases such as primary lung cancer and COPD is expected to continue to increase, advancement of respiratory medicine research is necessary. We conduct basic and clinical research for a wide variety of respiratory disorders including primary lung cancer, COPD, asthma and interstitial lung diseases. We have focused on molecular mechanisms underlying the pathogenesis of lung disorders. Our research goal is to develop novel diagnostic and therapeutic modalities for better management of these pulmonary diseases.

Clinical activities

The Department of Respiratory Medicine is responsible for out-patient care as well as care of in-patients (35 patients on average) on the 13th floor of the hospital ward A at the University of Tokyo Hospital. We have two teams consisting of junior residents, two fellows, and an experienced attending.

In-patients are mostly admitted for primary lung cancer. Other diseases include respiratory infections, interstitial pneumonia, and COPD. Many patients with primary lung cancer also have co-existing interstitial pneumonia or COPD. There are many emergency visits and admissions from pneumonia, respiratory failure due to exacerbation of COPD or interstitial pneumonia, progression of lung cancer, etc. In cases of severe respiratory failure such as severe pneumonia and ARDS, we provide ventilatory support in collaboration with the ICU staff.

A specialized clinical conference for respiratory disease has been held once a week since the late 1990s, where staff from our department, Department of Thoracic Surgery, and Department of Radiology join and discuss together to determine the best diagnostic

and therapeutic approach to individual patients. This conference has been highly appreciated as a prototype of Cancer Board of the University of Tokyo Hospital, and, is now held as Respiratory Cancer Board. This conference is still one of the most frequently held Cancer Board at our hospital. Our department contributes to the pre- and post-surgical evaluation of respiratory functions, and also provides consultation on respiratory problems from almost every department at our hospital.

Together with the Department of Infectious Disease, we are responsible for taking care of COVID patients and infection control measures. We supervise the clinical teams that take care of inpatients with moderate COVID-19, make decisions on PCR testing and infection prevention practices, and run the fever clinic for patients who visit our hospital on a regular basis.

At present, primary lung cancer is the leading cause of cancer death, and is one of the major medical and social problem to be overcome. Recently, the remarkable effectiveness of molecular-targeted therapies in primary lung cancer attracted much attention in both basic science and clinical practice. Pneumonia is the 3rd leading cause of all deaths when combined with aspiration pneumonia, and COPD is also a major cause of death. No effective therapeutic modalities are currently available for many respiratory diseases. For example, mortality of acute respiratory distress syndrome (ARDS) is extremely high despite intensive care using currently available tools. Idiopathic pulmonary fibrosis is a progressive and fatal inflammatory and fibrotic disorder of the lung parenchyma, and only a few medications are currently available to treat the disease. Our focus is to develop a novel and potential therapeutic approach to these diseases.

Total numbers of in-patients in 2022

1. Primary lung cancer	383
2. Abnormal lung shadows	37
3. Interstitial pneumonia	40
4. Respiratory infections	36
5. Non-tuberculous mycobacterial infections	9
6. Other cancers	18

7. Pneumothorax	5
8. COPD	8
9. Others	26

A weekly chart round and professor's round are scheduled every Tuesday afternoon.

A specialized clinical conference for patients with respiratory diseases is held as Respiratory Cancer Board every Thursday evening, together with thoracic surgeons and radiologists. At this conference, radiological diagnosis, indication of CT-guided biopsy and thoracoscopic biopsy, and treatment strategies not only about thoracic malignancies but also other respiratory diseases are discussed, making it possible to give the best care to every patient.

Teaching activities

For medical school education, our department takes part in systematic lectures and specific learning for diagnosis and treatment of respiratory diseases for the 4th year medical students, clinical clerkship for 5th year medical students, and clinical lectures for 5th and 6th year medical students. During elective clerkship for 5th year students, students visit and learn from one of several leading affiliated hospitals in Tokyo.

During systematic lectures, the concept, pathogenesis, pathology, diagnosis, and treatment of common respiratory diseases are comprehensively presented. During clinical lectures, we present clinical cases of important diseases such as primary lung cancer and pneumothorax, and discuss several important points on the diagnostic evaluation and treatment in collaboration with the Faculty of the Department of Thoracic Surgery. Recent major advances in the relevant fields are also reviewed.

During clinical clerkship, each student, as a member of medical care team, has opportunities to experience the daily clinical care with residents and fellows as well as with the faculty. Each student learns how to perform a medical interview, perform physical exams and make plans for diagnosis and treatment. Respiratory specialists provide lecture on chest X-ray as an essential element in clinical clerkship, which is highly popular among the students. Elective clerkship during the 5th year of the educational program is

designed to facilitate the exposure to a wide range of clinical practice both at The University of Tokyo Hospital and at one of the affiliated hospitals for two weeks each (although COVID-19 pandemic made the latter unavailable in 2021). Several lectures on respiratory diseases are also provided.

As for post-graduate education, respiratory physicians (fellows and one attending) assemble a team with residents, and provide medical care for patients with various respiratory diseases. Under these process, residents acquire knowledge and skills required for diagnosis and treatment of respiratory diseases. Seminars on important themes such as medical treatment of lung cancer, diagnostic chest imaging, etc. are held at regular intervals.

Research

Our department conduct basic and clinical research for various respiratory disorders including primary lung cancer, COPD, asthma, interstitial pneumonia, and respiratory infection. Epidemiological, clinical, cellular, and molecular techniques are utilized for the elucidation of pathogenic mechanisms and for the development of novel diagnostic and therapeutic modalities in respiratory medicine. Postgraduate students as well as faculty members study genetic and epigenetic alterations in lung cancer, cell biology using airway epithelial cells, fibroblast and smooth muscle cells, both in collaboration with the Faculty of the Department of Thoracic Surgery. Genetically engineered mice are also used as disease models. These results have been presented and published in scientific meetings and peer-reviewed journals. Our main research projects are as follows.

- Search for diseases-susceptibility genes and elucidation of their pathophysiological roles in respiratory diseases
- Analysis of disease-models using genetically engineered mice
- Analysis of DNA methylation, histone modification and miRNA in lung cancer
- Search for previously unidentified oncogenic driver mutations in lung cancer and elucidation of resistant mechanisms to molecular-targeted drugs
- Analysis of functional alterations of airway epithelial cells and fibroblasts in relation to tissue repair and remodeling, e.g., epithelial-mesenchymal transition, and the roles of various cytokines and chemokines, in asthma and COPD
- Detection of small airway disease using impulse oscillometry and its clinical application
- Search for predictive factors for responses to chemotherapy in malignancy including lung cancer
- Epidemiological study of respiratory diseases, using Diagnosis Procedure Combination database.

Takahide Nagase is a GOLD Assembly member.

References

1. Ando T, Kage H, Shinozaki-Ushiku A, Tatsuno K, Tsutsumi S, Nagayama K, Nakajima J, Kohsaka S, Miyagawa K, Aburatani H, Mano H, Nagase T. Composite Clonal Analysis Reveals Transition of NSCLC Subtypes Through Accumulation of Gene Mutations: A Case Report JTO Clin Res Rep. 2022 Jan 10;3(2):100277.
2. Oki R, Hirakawa Y, Oda Y, Nakamura M, Honda K, Abe H, Domoto Y, Miyashita N, Nagase T, Nangaku M. Renal-limited ANCA-associated vasculitis during erlotinib treatment for lung carcinoma. CEN Case Rep 2022; 11: 67-72.
3. Murata M, Nakagawa N, Kawasaki T, Yasuo S, Yoshida T, Ando K, Okamori S, Okada Y. Adverse events during intrahospital transport of critically ill patients: A systematic review and meta-analysis. Am J Emerg Med. 2022 Feb;52: 13-19.
4. Mitani A, Hamada K, Yoshikawa N, Morita Y, Horie T, Inoue Y, Saito M, Ishii T, Sunohara M, Takahashi R, Emoto N, Nishimoto N, Murano Y, Okazaki S, Tateishi S, Yao A, Shimura T, Kurano M, Yatomi Y, Yanagimoto S. Epidemiological study using igm and igg antibody titers against sars-cov-2 in the university of apan, apan (ut-cats). J Infect Chemother 2021;27:1342-1349.
5. Amano Y, Kage H, Tanaka G, Sato Y, Tanaka M, Nagase T. Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib

- Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report. *Case Rep Oncol* 2022;15: 338-344.
6. Kawasaki T, Nakagawa N, Murata M, Yasuo S, Yoshida T, Ando K, Okamori S, Okada Y. Diagnostic accuracy of urinary antigen tests for legionellosis: A systematic review and meta-analysis. *Respir Investig.* 2022 Mar;60(2):205-214.
 7. Awano N, Jo T, Izumo T, Inomata M, Morita K, Matsui H, Fushimi K, Urushiyama H, Nagase T, Yasunaga H. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study. *J Intensive Care.* 2022 Mar 9;10(1):14.
 8. Miyamoto S, Yamazaki T, Shimizu K, Matsubara T, Kage H, Watanabe K, Kobo H, Matsuyama Y, Rodin G, Yoshiuchi K. Brief, anualized and semistructured individual psychotherapy programme for patients with advanced cancer in Japan: study protocol for Managing Cancer and Living Meaningfully (CALM) phase 2 trial. *BMJ Open* 2022;12:e056136
 9. Tian D, Shiiya H, Takahashi M, Terasaki Y, Urushiyama H, Shinozaki-Ushiku A, Yan HJ, Sato M, Nakajima J. Noninvasive monitoring of allograft rejection in a rat lung transplant model: Application of machine learning-based 18F-fluorodeoxyglucose positron emission tomography radiomics. *J Heart Lung Transplant.* 2022 Jun;41(6):722-731.
 10. Kato T, Radicioni G, Papanikolas MJ, Stoychev GV, Markovetz MR, Aoki K, Porterfield M, Okuda K, Barbosa Cardenas SM, Gilmore RC, Morrison CB, Ehre C, Burns KA, White KK, Brennan TA, Goodell HP, Thacker H, Loznevt HT, Forsberg LJ, Nagase T, Rubinstein M, Randell SH, Tiemeyer M, Hill DB, Kesimer M, O'Neal WK, Ballard ST, Freeman R, Button B, Boucher RC. Mucus concentration-dependent biophysical abnormalities unify submucosal gland and superficial airway dysfunction in cystic fibrosis. *Sci Adv* 2022;8:eabm9718.
 11. Abe M, Mitani A, Zong L, Zhang CD, Hoshi K, Yanagimoto S. High frequency and long duration of toothbrushing can potentially reduce the risk of common systemic diseases in late adolescence. *Spec Care Dentist* 2022 May; 42(3): 317-318.
 12. Roszik J, Lee JJ, Wu YH, Liu X, Kawakami M, Kurie JM, Belouali A, Boca SM, Gupta S, Beckman RA, Madhavan S, Dmitrovsky E. Real-World Studies Link Nonsteroidal Anti-inflammatory Drug Use to Improved Overall Lung Cancer Survival. *Cancer Res Commun.* 2022 Jul;2(7):590-601.
 13. Tanosaki T, Mikami Y, Shindou H, Suzuki T, Hashidate-Yoshida T, Hosoki K, Kagawa S, Miyata J, Kabata H, Masaki K, Hamamoto R, Kage H, Miyashita N, Makita K, Matsuzaki H, Suzuki Y, Mitani A, Nagase T, Shimizu T, Fukunaga K. Lysophosphatidylcholine Acyltransferase 1 Deficiency Promotes Pulmonary Emphysema via Apoptosis of Alveolar Epithelial Cells. *Inflammation* 2022;45:1765-1779
 14. Nakagawa N, Kawakami M. Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. *Front Oncol.* 2022 Aug 12;12:952393.
 15. Kage H, Kohsaka S, Tatsuno K, Ueno T, Ikegami M, Zokumasu K, Shinozaki-Ushiku A, Nagai S, Aburatani H, Mano H, Oda K. Tumor mutational burden measurement using comprehensive genomic profiling assay. *Jpn J Clin Oncol* 2022; 52:925-929.
 16. Urushiyama H, Jo T, Hasegawa W, Yokoyama A, Ando T, Sakamoto Y, Kumazawa R, Uda K, Michihata N, Awano N, Hiroki M, Fushimi K, Yasunaga H, Nagase T. Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan. *ERJ Open Res.* 2022 Nov 28;8(4):00209-2022.
 17. Miyakawa K, Miyashita N, Horie M, Terasaki Y, Tanaka H, Urushiyama H, Fukuda K, Okabe Y, Ishii T, Kuwahara N, Suzuki HI, Nagase T, Saito A. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer. *Cancer Sci* 2022; 113(11): 3932-46.
 18. Imai M, Nakamura Y, Sunami K, Kage H, Komine K, Koyama T, Amano T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Bando H, Makiyama A, Suzuki T, Hirata M,

- Kohsaka S, Tsuchihara K, Naito Y, Yoshino T. Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors. *Cancer Sci* 2022; 113:3646-3656.
19. Sunami K, Naito Y, Komine K, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, Saigusa Y, Yoshino T. Chronological improvement in precision oncology implementation in Japan. *Cancer Sci* 2022;113:3995-4000.
20. Chen Z, Zheng L, Chen Y, Liu X, Kawakami M, Mustachio LM, Roszik J, Ferry-Galow KV, Parchment RE, Liu X, Andresson T, Duncan G, Kurie JM, Rodriguez-Canales J, Liu X, Dmitrovsky E. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3 ζ protein and represses lung cancer metastasis. *Cancer Biol Ther*. 2022 Dec 31;23(1):265-280.
21. Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shirota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, Yoshino T. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. *JAMA Netw Open* 2022;5:e2245081.
22. Tamiya H, Mitani A, Abe T, Nagase Y, Suzuki H, Jo T, Tanaka G, Nagase T. Association between Inhalation Instruction Method in Community Pharmacies and Inhaler Device Handling Error in Patients with Obstructive Lung Disease: An Evaluation of the Impact of Practical Demonstration by Pharmacists. *Biol Pharm Bull*. 2022;45(12):1764

Department of Gastroenterology

Professor

Mitsuhiro Fujishiro, M.D., Ph.D.

Lecturer

Ryosuke Tateishi, M.D., Ph.D.,

Yoku Hayakawa, M.D., Ph.D.,

Assistant Professor

Yotaro Kudo, M.D., Ph.D.,

Keisuke Yamamoto, M.D., Ph.D.

Naminatsu Takahara, M.D., Ph.D.,

Koji Miyabayashi, M.D., Ph.D.,

Ryota Takahashi, M.D., Ph.D.

Tatsuya Minami, M.D., Ph.D.,

Tsuyoshi Hamada, M.D., Ph.D.,

Takahiro Kishikawa, M.D., Ph.D.,

Nobumi Suzuki, M.D., Ph.D.,

Takuma Nakatsuka, M.D., Ph.D.,

Tomotaka Saito, M.D., Ph.D.,

Yoshiki Sakaguchi, M.D., Ph.D.,

Yu Takahashi, M.D., Ph.D.,

Rei Ishibashi, M.D., Ph.D.,

Sozabuto Ihara, M.D., Ph.D.,

Ryunosuke Hakuta, M.D., Ph.D.,

Tatsuya Sato, M.D., Ph.D.,

Tomoharu Yamada, M.D., Ph.D.,

Ken Kurokawa, M.D., Ph.D.,

Tatsunori Suzuki, M.D., Ph.D.

Homepage <http://gastro.m.u-tokyo.ac.jp/>

Introduction and Organization

The Department of Gastroenterology was established through a reorganization of the Graduate School of Medicine and that of the Division of Internal Medicine of The University of Tokyo Hospital in 1998. The department is responsible for clinical services, education, and research activities in the liver, pancreato-biliary, and gastrointestinal tract. It comprises a professor, two lecturers, 20 assistant professors, 11 fellows, 56 graduates, and other visiting researchers including students from abroad as of March 2023. Some others are under a temporary transfer inside and outside the country. The North and South wings on the 11th floor of Ward A have provided core hospital rooms for the department. Laboratories of the department are scattered on each floor, mainly of Clinical Research Center.

Clinical activities

The Department of Gastroenterology owns 81 inpatient beds in charge. By using these beds, we saw total 26,120 inpatients with 2,607 new inpatients in an average hospital stay of 9.0 days in the fiscal year of 2022. Resident, junior and senior staff members bear the responsibility for the medical management of each inpatient in collaboration with subspecialty groups concerned. We saw total 62,726 outpatients with 1,716 new outpatients (2.7%) in the fiscal year of 2022. Specialty and subspecialty clinical conferences are held on Monday evening.

The number of treatments for hepatocellular carcinoma, represented by percutaneous radiofrequency ablation, nearly 200 cases per year, is showing one of the greatest achievements in the field. The number of cases undergoing radiofrequency ablation for metastatic liver

tumors is also increasing recent years. In addition, we are making efforts to develop an innovation for daily clinical activities. For example, fibrosis progression in chronic liver disease is conventionally assessed by liver biopsy. Recently we can evaluate the stage of liver fibrosis by FibroScan®, newly developed equipment that measures liver stiffness by ultrasound, which is useful for evaluating increasing non-alcoholic steatohepatitis patients. In addition, nearly 100% cure for HCV hepatitis can be achieved by using oral antiviral agents instead of IFN therapy. This will be especially beneficial for elderly patients and advanced fibrotic patients.

We perform about 1,000 cases of endoscopic ultrasonography (EUS) and endoscopic retrograde cholangiopancreatography (ERCP), the standard endoscopic procedures for biliary and pancreatic diseases, annually. We have evaluated over 3,000 pancreatic cystic neoplasms, and also performed various endoscopic treatments such as endoscopic extraction of bile duct stones in over 1,500 cases and biliary drainage with metal stents for malignant biliary strictures in over 1,200 cases, too. We have contributed to development and reported clinical studies on endoscopic papillary balloon dilation (EPBD) and papillary large balloon dilation (EPLBD) for the treatment of bile duct stones, and covered metal stents for malignant as well as benign biliary strictures. Our expertise includes advanced endoscopic treatment for patients who are difficult to manage by standard treatment, such as ERCP using a balloon endoscope and transluminal drainage, EUS-guided stone extraction in cases with surgically altered anatomy, endotherapy for pancreatic stone and stricture. In cases with pancreatic and biliary tract cancer, we have investigating new chemotherapeutic regimens and recently introduced preoperative chemotherapy for resectable pancreatic cancer. Comprehensive genome profiling is performed using tumor specimens collected by EUS-FNA to facilitate individualized treatment. The number of cases of intractable diseases such as primary sclerosing cholangitis and IgG4-related diseases, is one of the highest in Japan.

In the gastrointestinal field, ESD (endoscopic submucosal dissection) is performed as a curative endoscopic treatment for neoplasms in the esophagus, stomach, or colon (approximately 500 patients a year).

Collaborative endoscopic surgery with other departments is actively performed: 1) ESD for superficial pharyngeal cancer is often performed in cooperation with the department of otorhinolaryngology; 2) ESD for duodenal epithelial tumor with the support of the Department of Gastrointestinal Surgery, 3) as for Non-exposed endoscopic wall-inversion surgery (NEWS), which was developed with the Department of Gastrointestinal Surgery, its clinical indication has been now expanded from the resection of GIST to the treatment of gastric cancer. In 2021, ‘Endoscopic full-thickness resection for submucosal tumor’ has been approved as a highly challenging novel medical technology with the support of the Department of Gastrointestinal Surgery. Our challenge to novel endoscopic procedures continues. Double-balloon endoscopy (DBE) and capsule endoscopy (CE) enabled the examination of whole small intestines (approximately 90 cases in 2022). Especially in inflammatory bowel disease (IBD) patients, we perform the examination using an optimal method including DBE, CE, and MR enterography. In severe IBD cases, we conduct the combination therapy of conventional immunosuppressive drugs and the latest biologics to increase QOL and achieve mucosal healing and prevention of relapse. About 400 metal stent placements for malignant gastrointestinal obstruction have been performed at our facility. All those interventions are performed by the members of our department, who are specially trained for each technique. In addition, for the management of inoperative malignancies, we effectively combine the interventional treatments with various chemotherapy regimens including immuno-checkpoint inhibitor. Aiming at personalized medicine based on genetic information, we are also actively conducting cancer multi-gene panel testing.

On an outpatient basis, the number of performed ultrasonography, gastroduodenal endoscopy, and colonoscopy is 12,500 patients, 10,000 patients, and 5,500 patients per year, respectively. In the endoscopy examinations, we diagnose approximately 380 cases of esophageal cancer, 550 cases of gastric cancer, and 700 cases of colorectal tumor annually. We perform various basic studies using these resected tissues to feed the new finding back to actual clinical activities.

Teaching activities

The undergraduate medical students regularly take the clinical lectures of the staff in our department. Several courses of practical teaching are also provided for the students. Particularly, in the Clinical Clerkship program during the fifth grade, each student joins in the medical treatment of inward patients as a member of the clinical team in our hospital. At the end of the period, the students make a summary presentation of the patients and also outline the articles from the world's leading medical journals.

The residents of internal medicine participate in the training of our department for 1-4 months in the first year. They learn the knowledge of therapeutics and diagnostics in gastroenterology as well as general internal medicine. Our department deals with the training curriculum as a medical specialist of internal medicine. The residents in the course are supported to experience some diseases in the gastrointestinal field. The residents who major in gastroenterology as a subspecialty take the expert training of gastroenterology in the affiliated hospitals for several years.

The students of the Department of Gastroenterology in the Graduate School of Medicine perform a high standard of medical research in the basic or clinical field for four years.

Research activities

Both basic and clinical researchers are equally encouraged on the condition that the results may eventually contribute to the cure of gastroenterological disorders. The themes of our recent basic researches include the study on carcinogenesis in gastroenterological neoplasms, mechanism of viral hepatitis infection, the pathogenesis of metabolic liver diseases, liver regeneration, liver fibrosis, pathogenesis of *Helicobacter pylori* infection, molecular characterization of gastrointestinal morphology, establishing new animal models, tracing cell differentiation, and stem cell biology for various diseases in our area. Using new concepts such as transparent organs, genomic and epigenomic profiling of clinical samples, organoids, or liquid biopsy, we perform various experiments to translate the basic results into clinics eventually.

Various clinical activities are recorded in database and analyzed. Studies oriented toward evidence-based medicine are highly appreciated. Recent studies include multicenter study to investigate radiofrequency ablation for liver metastasis of colorectal cancer, the impact of metabolic factors in hepatocarcinogenesis and studies using nationwide registry for liver diseases. We have also designed many clinical trials as follows; Effects of various drug treatments on advanced hepatocellular carcinoma, SNPs analyses for antiviral treatment for hepatitis C, new chemotherapeutic regimens for advanced pancreatic cancer or biliary tract cancer, balloon endoscope-assisted ERCP for surgically altered anatomy, the efficacy of polyglycolic acid sheets for artificial endoscopic ulcers, development of AI for assisted endoscopic diagnosis, and personalized salvage therapy of *Helicobacter* infection.

Our department always tries to show the newest and highest-level clinical activities, based on the various data of many patients, especially those suffering from malignant diseases. Furthermore, we aim to find the new aspects of diseases and create a new strategy against them, which is based on clinical, basic, and epidemiological studies in our area. And in collaboration with Faculty of engineering, we are actively promoting projects to advance new medical materials and therapeutic devices through medical-engineering collaboration.

Selected References

1. Arai J, Niikura R, Hayakawa Y, Aoki T, Yamada A, Kawai T, Fujishiro M. OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer. *Gut*. 2022;71(5):1043-1044.
2. Hirose T, Kakushima N, Fujishiro M. Sudden Chest Pain During Vomiting After Drinking. *Gastroenterology*. 2022;162(4):e5-e6.
3. Fujishiro M, Matsumoto T. History of endoscopes: Contribution of the Japan Gastroenterological Endoscopy Society. *Dig Endosc*. 2022;34 Suppl 2:13-14.
4. Kogure H, Nakai Y, Fujishiro M. How to not get lost in the labyrinth during device-assisted enteroscopy endoscopic retrograde cholangio-pancreatography. *Dig Endosc*. 2022;34(1):85-86.

5. Kato H, Tateishi K, Fujiwara H, Nakatsuka T, Yamamoto K, Kudo Y, Hayakawa Y, Nakagawa H, Tanaka Y, Ijichi H, Otsuka M, Iwadate D, Oyama H, Kanai S, Noguchi K, Suzuki T, Sato T, Hakuta R, Ishigaki K, Saito K, Saito T, Takahara N, Kishikawa T, Hamada T, Takahashi R, Miyabayashi K, Mizuno S, Kogure H, Nakai Y, Hirata Y, Toyoda A, Ichikawa K, Qu W, Morishita S, Arita J, Tanaka M, Ushiku T, Hasegawa K, Fujishiro M, Koike K. MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages. *Gastroenterology*. 2022; 162(4):1272-1287.
6. Hisada H, Tamura N, Tsuji Y, Nagao S, Fukagawa K, Miura Y, Mizutani H, Ohki D, Yakabi S, Minatsuki C, Takahashi Y, Sakaguchi Y, Yamamichi N, Fujishiro M. The impact of sarcopenia on adverse events associated with gastric endoscopic submucosal dissection. *Surg Endosc*. 2022;36(9):6387-6395.
7. Arai J, Aoki T, Sato M, Niikura R, Suzuki N, Ishibashi R, Tsuji Y, Yamada A, Hirata Y, Ushiku T, Hayakawa Y, Fujishiro M. Machine learning-based personalized prediction of gastric cancer incidence using the endoscopic and histologic findings at the initial endoscopy. *Gastrointest Endosc*. 2022; 95(5):864-872.
8. Takeuchi C, Sato J, Yamashita S, Sasaki A, Akahane T, Aoki R, Yamamichi M, Liu YY, Ito M, Furuta T, Nakajima S, Sakaguchi Y, Takahashi Y, Tsuji Y, Niimi K, Tomida S, Fujishiro M, Yamamichi N, Ushijima T. Autoimmune gastritis induces aberrant DNA methylation reflecting its carcinogenic potential. *J Gastroenterol*. 2022; 57(3):144-155.
9. Takahashi Y, Yamamichi N, Kubota D, Shimamoto T, Nagao S, Sakuma N, Sakaguchi Y, Yakabi S, Tsuji Y, Wada R, Mitsushima T, Ichinose M, Fujishiro M.
10. Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study. *Gastric Cancer*. 2022;25(3):481-489. Emura F, Chandrasekar VT, Hassan C, Armstrong D, Messmann H, Arantes V, Araya R, Barrera-Leon O, Bergman JJGHM, Bandhari P, Bourke MJ, Cerisoli C, Chiu PW, Desai M, Dinis-Ribeiro M, Falk GW, Fujishiro M, Gaddam S, Goda K, Gross S, Haidry R, Ho L, Iyer PG, Kashin S, Kothari S, Lee YY, Matsuda K, Neuhaus H, Oyama T, Ragunath K, Repici A, Shaheen N, Singh R, Sobrino-Cossio S, Wang KK, Waxman I, Sharma P. Rio de Janeiro Global Consensus on Landmarks, Definitions, and Classifications in Barrett's Esophagus: World Endoscopy Organization Delphi Study. *Gastroenterology*. 2022;163(1):84-96
11. Kawamura S, Matsushita Y, Kurosaki S, Tange M, Fujiwara N, Hayata Y, Hayakawa Y, Suzuki N, Hata M, Tsuboi M, Kishikawa T, Kinoshita H, Nakatsuka T, Sato M, Kudo Y, Hoshida Y, Umemura A, Eguchi A, Ikenoue T, Hirata Y, Uesugi M, Tateishi R, Tateishi K, Fujishiro M, Koike K, Nakagawa H. Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. *J Clin Invest*. 2022;132(11):e151895.
12. Iida T, Mizutani Y, Esaki N, Ponik SM, Burkel BM, Weng L, Kuwata K, Masamune A, Ishihara S, Haga H, Kataoka K, Mii S, Shiraki Y, Ishikawa T, Ohno E, Kawashima H, Hirooka Y, Fujishiro M, Takahashi M, Enomoto A. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics. *Oncogene*. 2022;41(19):2764-2777.
13. Ohki D, Yamamichi N, Sakaguchi Y, Takahashi Y, Kageyama-Yahara N, Yamamichi M, Takeuchi C, Tsuji Y, Sakai Y, Sakurai K, Tomida S, Koike K, Fujishiro M. Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2. *Cancer Med*. 2022;11(24):5066-5078.
14. Suzuki T, Masugi Y, Inoue Y, Hamada T, Tanaka M, Takamatsu M, Arita J, Kato T, Kawaguchi Y, Kunita A, Nakai Y, Nakano Y, Ono Y, Sasahira N, Takeda T, Tateishi K, Uemura S, Koike K, Ushiku T, Takeuchi K, Sakamoto M, Hasegawa K, Kitago M, Takahashi Y, Fujishiro M; GTK Pancreatic Cancer Study Group in Japan. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. *Cancer Sci*. 2022;113(9):3097-3109.
15. Fukumoto T, Minami T, Moriyama M, Yamada T, Wake T, Kinoshita MN, Fujiwara N, Nakagomi R,

- Nakatsuka T, Sato M, Enooku K, Nakagawa H, Fujishiro M, Shiina S, Koike K, Tateishi R. Improved prognosis of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antivirals. *Hepatol Commun*. 2022;6(9):2496-2512.
16. Sugano K, Spechler SJ, El-Omar EM, McColl KEL, Takubo K, Gotoda T, Fujishiro M, Iijima K, Inoue H, Kawai T, Kinoshita Y, Miwa H, Mukaisho KI, Murakami K, Seto Y, Tajiri H, Bhatia S, Choi MG, Fitzgerald RC, Fock KM, Goh KL, Ho KY, Mahachai V, O'Donovan M, Odze R, Peek R, Rugge M, Sharma P, Sollano JD, Vieth M, Wu J, Wu MS, Zou D, Kaminishi M, Malfertheiner P. Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. *Gut*. 2022;71(8):1488-1514.
17. Yamamoto K, Iwadate D, Kato H, Nakai Y, Tateishi K, Fujishiro M. Targeting autophagy as a therapeutic strategy against pancreatic cancer. *J Gastroenterol*. 2022;57(9):603-618.
18. Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, Miyata H, Izumi N, Kudo M, Koike K. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). *J Gastroenterol*. 2022;57(8):587-597.
19. Kakushima N, Fujishiro M, Chan SM, Cortas GA, Dinis-Ribeiro M, Gonzalez R, Kodashima S, Lee SY, Linghu E, Mabe K, Pan W, Parra-Blanco A, Pioche M, Rollan A, Sumiyama K, Tanimoto M; World Endoscopy Organization Stomach and Duodenal Diseases Committee. Proposal of minimum elements for screening and diagnosis of gastric cancer by an international Delphi consensus. *DEN Open*. 2022;2(1):e97.
20. Yamamoto H, Yano T, Araki A, Esaki M, Ohtsuka K, Ohmiya N, Oka S, Nakase H, Bamba S, Hirai F, Hosoe N, Matsuda T, Mitsui K, Watanabe K, Ogata H, Katsuki S, Matsumoto T, Fujishiro M, Fujimoto K, Inoue H. Guidelines for endoscopic balloon dilation in treating Crohn's disease-associated small intestinal strictures (supplement to the Clinical Practice Guidelines for Enteroscopy). *Dig Endosc*. 2022;34(7):1278-1296.
21. Kubota D, Takahashi Y, Yamamichi N, Matsui M, Shimamoto T, Minatsuki C, Nakagawa H, Mizutani S, Tsuji Y, Sakaguchi Y, Tamura N, Yakabi S, Ohki D, Mizutani H, Niimi K, Wada R, Fujishiro M. Analysis of Barrett's Esophagus and Its Risk Factors: A Cross-Sectional Study of 10,122 Subjects at a Japanese Health Examination Center. *Digestion*. 2022;103(6):411-420.
22. Hisada H, Tsuji Y, Obata M, Cho R, Nagao S, Miura Y, Mizutani H, Ohki D, Yakabi S, Takahashi Y, Sakaguchi Y, Kakushima N, Yamamichi N, Fujishiro M. The impact of sarcopenia on short- and long-term outcomes of endoscopic submucosal dissection for early gastric cancer. *J Gastroenterol*. 2022;57(12):952-961.
23. Nakagawa K, Sho M, Fujishiro M, Kakushima N, Horimatsu T, Okada KI, Iguchi M, Uraoka T, Kato M, Yamamoto Y, Aoyama T, Akahori T, Eguchi H, Kanaji S, Kanetaka K, Kuroda S, Nagakawa Y, Nunobe S, Higuchi R, Fujii T, Yamashita H, Yamada S, Narita Y, Honma Y, Muro K, Ushiku T, Ejima Y, Yamaue H, Kodera Y. Clinical practice guidelines for duodenal cancer 2021. *J Gastroenterol*. 2022;57(12):927-941.
24. Shibata C, Otsuka M, Seimiya T, Kishikawa T, Ishigaki K, Fujishiro M. Lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia via specific integrins. *Clin Transl Med*. 2022;12(11):e1089.
25. Seimiya T, Otsuka M, Fujishiro M. Roles of circular RNAs in the pathogenesis and treatment of pancreatic cancer. *Front Cell Dev Biol*. 2022 Nov 17;10:1023332.
26. Shibata C, Otsuka M, Seimiya T, Ishigaki K, Miyakawa Y, Kishikawa T, Fujishiro M. Smaller extracellular vesicles are released from pancreatic cancer cells by the alteration of the lipid composition under low glucose conditions. *Biochem Biophys Res Commun*. 2022;637:314-321.

Internal Medicine

2. Medicine II

Department of Nephrology and Endocrinology

Professor

Masaomi Nangaku, M.D., Ph.D.

Associate Professor

Noriko Makita, M.D., Ph.D.

Hiroshi Nishi, M.D., Ph.D.

Lecturer

Motonobu Nakamura, M.D., Ph.D.

Yoshifumi Hamasaki, M.D., Ph.D.

Hospital Lecturer

Nobuaki Ito, M.D., Ph.D.

Imari Mimura, M.D., Ph.D.

Associate

Katsunori Manaka, M.D., Ph.D.,

Junichiro Satoh, M.D., Ph.D.,

Maki Takeuchi, M.D., Ph.D.,

Ryo Matsuura, M.D., Ph.D.,

Hajime Kato, M.D., Ph.D.,

Yosuke Hirakawa, M.D., Ph.D.,

Yoichiro Ikeda, M.D., Ph.D.;

Mai Sugahara, M.D., Ph.D.,

Shinji Tanaka, M.D., Ph.D.,

Official website <http://www.todai-jinnai.com>

Introduction and Organization

The Department of Nephrology and Endocrinology is one of the major divisions in the Department of Internal Medicine of the University of Tokyo, which covers nephrology, hypertension, and endocrinology, and also renal diseases associated with diabetes mellitus, cardiovascular diseases, collagen diseases and so on. Usually we have up to 25 inpatients in the hospital. The Professor and each member of the staff have an active responsibility for all clinical activities. Each member has an office and a research laboratory. In our department, almost all members support the clinical works of our residents. We are intimately

working together in all clinical activities under the supervision of the professor, the associate professors, and the lecturers.

Clinical activities

The residents are in charge of up to 25 patients of our department and supervised by associates and faculty staffs. We have clinical conferences to discuss the diagnosis and treatment of our patients with all members of the staff. Particularly difficult cases are further discussed with guest specialists from outside.

Nephritis should be morphologically diagnosed by renal biopsy and the optimal treatment should be

chosen for each patient. In our department, renal biopsy is actively performed to give the real benefits of treatment to the patients. We also treat diabetic patients with proteinuria and end-stage renal failure. Each staff of our department also works at the hemodialysis unit, thus we can manage patients in every stage of renal diseases. In collaboration with Department of Urology, we are conducting renal transplantation and promoting peritoneal dialysis.

In the endocrine unit there is a variety of patients having disorders in thyroid, parathyroid, pituitary, adrenal and gonadal glands. It is also our specialty to diagnose and treat secondary hypertension caused by primary aldosteronism, Cushing's syndrome, pheochromocytoma, renal artery stenosis and so on. We often have consultation from other departments concerning disorders of water and mineral metabolism.

Education

We have responsibility for educating undergraduates, graduate students and residents. Our staffs take part in several lectures for undergraduate and graduate students. In addition, our members are actively involved in clinical clerkship for undergraduate students, and other clinical practice. Particularly, we have put emphasis on participation of the students in clinical practice including medical investigations, diagnosis, and treatment. In the wards, we are also educating residents during daily clinical works and periodical lectures concerning kidney and endocrine diseases. Our department also participates in Metabolism Research Course for educating young clinical researchers and fellows in collaboration with Department of Diabetes and Metabolic Diseases, Department of Cardiology, and Department of Geriatric Medicine.

Research

In our department there are more than 30 students of the graduate school. We have research conferences to discuss the results of the research with the Professor and faculty members. As you see in the references below, our research topics are various and cover every field of nephrology, hypertension and endocrinology. We are also actively collaborating with scientists outside the department and outside the University

including foreign countries. Achievements of our researches are published in the world's leading journals of nephrology, hypertension and endocrinology.

1. Investigation of mechanism and development of treatment of chronic kidney diseases: from the viewpoints of hypoxia, oxidative stress, epigenetics, carbonyl stress and endoplasmic reticulum stress.
2. Investigation of causes of atypical hemolytic-uremic syndrome.
3. Roles of renal proximal tubule transport in the regulation of plasma volume and blood pressure.
4. Physiological and pathological significance of Na-HCO₃ cotransporter NBCe1.
5. Molecular mechanism of G protein-coupled receptor (GPCR)-mediated signal transduction, and development of a new drug and strategy targeting GPCR.
6. Investigation on pathogenesis of disorders and treatments of mineral and bone metabolism

Department of Hemodialysis & Apheresis

Introduction and Organization

Hemodialysis and related blood purification therapy had been individually performed in their respective departments. However, all the departments' apparatus and human resources were centralized to form the Department of Hemodialysis and Center for Hemodialysis in 2000 at the University Hospital. The Center for Hemodialysis was further renovated and started operations in Fall of 2006.

This new Center for Hemodialysis is equipped with one pressure control unit in addition to 12 hemodialysis machines under a state-of-the-art hemodialysis control system. Our concept of a hemodialysis controlling system is a hub to transfer all digital and analog data from patients and to monitor machines, including blood purification machines, to the host computer in our hospital, centralizing all data and administering medical coding and billing robustly. Blood purification machines in the ICU can be monitored seamlessly under the cloud system of our hospital. Blood purification machines are selected uniformly to secure patients' safety while avoiding

human error and increasing the overall educational quality of staff members.

Clinical activities

1. Start of maintenance hemodialysis therapy for end-stage renal disease (ESRD).
2. Regular hemodialysis therapy for hospitalized ESRD patients. Please note that our center does not accept holiday dialysis.
3. Emergency hemodialysis and hemodiafiltration for ICU patients.
4. Plasma exchange for neurodegenerative diseases, SLE, TTP, TMA, and pre/post-liver transplant patients.
5. DFPP for collagenous diseases, MG, HCV, and dermatological disorders.
6. LDL apheresis for nephrotic syndrome and ASO patients.
7. White blood cell elimination therapy for ulcerative colitis and rheumatological arthritis.
8. Cell-free and concentrated ascites reinfusion therapy (CART) for refractory ascites.
9. Induction and maintenance of peritoneal dialysis for ESRD.

Education

1. A systematic review course for M2 students, which covers clinical features, diagnosis, and evidence-based therapeutic strategies for acute and chronic renal failure including diabetic nephropathy.
2. Technical development course for medical engineers and nurses.
3. Tutorial course for clinical fellows applying to the speciality of blood purification therapy.
4. Exposure in hemodialysis & apheresis course to second year residents on request.
5. Our state-of-the-art blood purification protocols are summarized in Japanese handbook in 2010 [Apheresis Pocket Manual] and 2011 [CRRT Pocket Manual]. "Apheresis Pocket Manual" has been translated into Chinese and English, and those translated versions have helped a number of non-Japanese-speaking people to learn how to perform apheresis.
6. Our department takes main part in Critical Care Nephrology Course for educating young clinical researchers and fellows in collaboration with

Department of Critical Care Medicine.

Research

1. Prognostic analysis for post-liver transplant patients who received plasma exchange therapy.
2. Development and application of a non-invasive pulse hemoglobin meter.
3. Genome wide association study for Nephrotic syndrome and those functional analyses.
4. Association between factors at the initiation of renal replacement therapy and prognosis.
5. Elucidation of basic mechanisms in cardio-renal syndrome and intervention.
6. Pathophysiology of acute kidney injury and its applicability for renal regenerative study.
7. AKI biomarkers and their clinical significance in ICU/CCU.
8. Renal biomarker to determine clinical action ability in CKD and type-2 DN.

Publications

- (1) Oki R, Hamasaki Y, Komaru Y, Miyamoto Y, Matsuura R, Akari S, Nakamura T, Murase T, Doi K, Nangaku M. Plasma xanthine oxidoreductase is associated with carotid atherosclerosis in stable kidney transplant recipients. *Nephrology (Carlton)*. 2022 Apr;27(4):363-370.
- (2) Sakashita M, Nangaku M. Multi-omics studies reveal genes critical for AKI and ferroptosis. *Kidney Int*. 2022 Apr;101(4):665-667.
- (3) Ishii T, Tanaka T, Nangaku M. Is HIF activation Janus faced? The therapeutic effects of the HIF-2 α inhibitor. *Kidney Int*. 2022 May;101(5):866-869.
- (4) Inoue R, Nishi H, Osaka M, Yoshida M, Nangaku M. Neutrophil Protein Kinase R Mediates Endothelial Adhesion and Migration by the Promotion of Neutrophil Actin Polymerization. *J Immunol*. 2022 May 1;208(9):2173-2183.
- (5) Sasaki Y, Higashijima Y, Suehiro JI, Sugawara T, Oguri-Nakamura E, Fukuhara S, Nagai N, Hirakawa Y, Wada Y, Nangaku M, Kanki Y. Lysine demethylase 2B regulates angiogenesis via Jumonji C dependent suppression of angiogenic transcription factors. *Biochem Biophys Res Commun*. 2022 May 21;605:16-23.
- (6) Kurata Y, Nangaku M. Dapagliflozin for the

- treatment of chronic kidney disease. *Expert Rev Endocrinol Metab.* 2022 Jul;17(4):275-291.
- (7) Hasegawa S, Nangaku M. Whole-Kidney Three-Dimensional Staining with CUBIC. *J Vis Exp.* 2022 Jul 18;(185).
 - (8) Hasegawa S, Nangaku M. Anti-aging mechanism of calorie restriction in humans. *Kidney Int.* 2022 Aug;102(2):223-225.
 - (9) Hidaka N, Koga M, Kimura S, Hoshino Y, Kato H, Kinoshita Y, Makita N, Nangaku M, Horiguchi K, Furukawa Y, Ohnaka K, Inagaki K, Nakagawa A, Suzuki A, Takeuchi Y, Fukumoto S, Nakatani F, Ito N. Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance. *J Bone Miner Res.* 2022 Aug;37(8):1479-1488.
 - (10) Matsuura R, Honda K, Oki R, Hamasaki Y, Doi K, Nangaku M. Screening and Management for Intracranial Aneurysms in Japanese Patients With ADPKD. *Kidney Int Rep.* 2022 Jun 1;7(8):1893-1896.
 - (11) Maruno S, Tanaka T, Nangaku M. Exploring molecular targets in diabetic kidney disease. *Kidney Res Clin Pract.* 2022 Sep;41(Suppl 2): S33-S45.
 - (12) Tanemoto F, Nangaku M, Mimura I. Epigenetic memory contributing to the pathogenesis of AKI-to-CKD transition. *Front Mol Biosci.* 2022 Sep 21;9:1003227.
 - (13) Hirakawa Y, Yoshioka K, Kojima K, Yamashita Y, Shibahara T, Wada T, Nangaku M, Inagi R. Potential progression biomarkers of diabetic kidney disease determined using comprehensive machine learning analysis of non-targeted metabolomics. *Sci Rep.* 2022 Sep 29;12(1): 16287.
 - (14) Hanafusa N, Tu C, McCullough K, Bieber B, Pisoni RL, Robinson BM, Hasegawa T, Nangaku M. An investigation into possible sex differences in Association of Haemoglobin with survival among Haemodialysis patients in the J-DOPPS cohort. *Nephrology (Carlton).* 2022 Oct;27(10): 795-803.
 - (15) Nakamura M, Nangaku M. Snapshots of nascent RNA can validate different nephron segment responses in acute kidney injury: a step toward clinically useful biomarkers? *Kidney Int.* 2022 Oct;102(4):678-680.
 - (16) Nakamura M, Satoh N, Horita S, Nangaku M. Insulin-induced mTOR signaling and gluconeogenesis in renal proximal tubules: A mini-review of current evidence and therapeutic potential. *Front Pharmacol.* 2022 Oct 10;13: 1015204.
 - (17) Oki R, Hamasaki Y, Tsuji S, Suzuki K, Tsuneishi S, Imafuku M, Komaru Y, Miyamoto Y, Matsuura R, Doi K, Nangaku M. Clinical frailty assessment might be associated with mortality in incident dialysis patients. *Sci Rep.* 2022 Oct 21;12(1): 17651.
 - (18) Makita N, Sato J, Manaka K, Akahane K, Ito T, Yamazaki H, Mizoguchi A, Hikima Y, Horikoshi H, Nangaku M, Iiri T. Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies. *JCI Insight.* 2022 Oct 24;7(20): e156742.
 - (19) Xia Y, Coates PT, Nangaku M. How does diabetes cause susceptibility to COVID-19 in the kidney: new clues provided by organoids. *Kidney Int.* 2022 Nov;102(5):951-953.
 - (20) Sugahara M, Tanaka T, Nangaku M. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors. *Pharmacol Ther.* 2022 Nov;239:108272.
 - (21) Nakai K, Manaka K, Sato J, Takeuchi M, Yamazaki Y, Sasano H, Tsurutani Y, Saito J, Nishikawa T, Iiri T, Nangaku M, Makita N. Aldosterone-Producing Adenomas of Increased Size Are Associated With Higher Steroidogenic Activity. *J Clin Endocrinol Metab.* 2022 Nov 23; 107(11):3045-3054.
 - (22) Kato H, Hoshino Y, Hidaka N, Ito N, Makita N, Nangaku M, Inoue K. Machine Learning-Based Prediction of Elevated PTH Levels Among the US General Population. *J Clin Endocrinol Metab.* 2022 Nov 25;107(12):3222-3230.
 - (23) Nangaku M, Akizawa T, Nagakubo T, Yonekawa T, Kimura T, Endo Y, Cobitz A. Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. *Ther Apher Dial.* 2022 Dec;

26(6):1065-1078.

- (24) Ishii T, Mimura I, Nagaoka K, Naito A, Sugasawa T, Kuroda R, Yamada D, Kanki Y, Kume H, Ushiku T, Kakimi K, Tanaka T, Nangaku M. Effect of M2-like macrophages of the injured-kidney cortex on kidney cancer progression. *Cell Death Discov.* 2022 Dec 5;8(1):480.
- (25) Doi K, Kimura H, Kim SH, Kaneda S, Wada T, Tanaka T, Shimizu A, Sano T, Chikamori M, Shinohara M, Matsunaga YT, Nangaku M, Fujii T. Enhanced podocyte differentiation and changing drug toxicity sensitivity through pressure-controlled mechanical filtration stress on a glomerulus-on-a-chip. *Lab Chip.* 2023 Jan 31;23(3):437-450.
- (26) Sugawara Y, Hirakawa Y, Nagasu H, Narita A, Katayama A, Wada J, Shimizu M, Wada T, Kitamura H, Nakano T, Yokoi H, Yanagita M, Goto S, Narita I, Koshihara S, Tamiya G, Nangaku M, Yamamoto M, Kashihara N. Genome-wide association study of the risk of chronic kidney disease and kidney-related traits in the Japanese population: J-Kidney-Biobank. *J Hum Genet.* 2023 Feb;68(2):55-64.
- (27) Sakashita M, Nangaku M. Ferumoxytol: an emerging therapeutic for iron deficiency anemia. *Expert Opin Pharmacother.* 2023 Feb;24(2):171-175.
- (28) Matsumura M, Okada A, Yokoyama H, Sekiguchi M, Shimizu A, Tanaka T, Nangaku M, Takano H. Usefulness of gallium-67 scintigraphy for evaluating the histopathological activity in interstitial nephritis. *Clin Exp Nephrol.* 2023 Mar;27(3):251-261.
- (29) Kato H, Miyazaki H, Kimura T, Hoshino Y, Hidaka N, Koga M, Nangaku M, Makita N, Ito N. Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia. *Bone Rep.* 2023 Feb 2;18:101659.

Department of Diabetes and Metabolic Diseases

Professor

Toshimasa Yamauchi, M.D., Ph.D.

Associate Professor

Masato Iwabu, M.D., Ph.D. (until April 2022)

Nobuhiro Shojima, M.D., Ph.D. (since July 2022)

Lecturer

Nobuhiro Shojima, M.D., Ph.D. (until June 2022)

Masaki Igarashi, M.D., Ph.D. (since Sep 2022)

Project Lecturer

Tomohisa Aoyama, M.D., Ph.D.

Assistant Professor

Satoru Takase, M.D., Ph.D. (until Mar 2023),

Mikio Takanashi, M.D., Ph.D.

Masaki Igarashi, M.D., Ph.D. (until Aug 2022),

Yoshitaka Sakurai, M.D., Ph.D.

Takayoshi Sasako, M.D. Ph.D. (until Jan 2023),

Gotaro Toda, M.D., Ph.D.,

Masakazu Aihara, M.D., Ph.D.

Yuka Kobayashi, M.D., Ph.D. (until Mar 2023)

URL <http://dm.umin.jp/>

Introduction and Organization

In 1998 the Department of Internal Medicine at the University of Tokyo was reorganized to the more functional units based on clinical specialties. The physicians specialized in diabetes and metabolic diseases from 3 former departments of Internal Medicine were unified to the Department of Metabolic Diseases. The Department of Diabetes and Metabolic Diseases is one of the major divisions in the Department of Internal Medicine at the University of Tokyo, and covers diabetes mellitus and metabolic diseases including obesity disease and dyslipidemia.

Under the supervision and direction of the previous professors Dr. Satoshi Kimura (1998-2003), Dr. Toshiro Fujita (2003), Takashi Kadowaki (2003-2018)

and current professor Dr. Toshimasa Yamauchi (2018-present), we have been providing a wide-ranged clinical, teaching and research activities. Currently, we hold beds mainly on the 12th floor of the North Wing Ward A of the University of Tokyo Hospital. Besides the staffs listed above, our division holds faculties in branches, for example, Department of Clinical Nutrition Therapy (Associate Professor: Dr. Naoto Kubota), Laboratory for Advanced Research on Pathophysiology of Metabolic Diseases (Project Associate Professor: Dr. Miki Okada-Iwabu, , Department of Healthcare Information Management (Associate Professor: Dr. Kayo Waki, Project Assistant Professor: Dr. Kana Miyake), Department of Clinical Laboratory (Associate Professor: Dr. Makoto Kurano), Division for Health Service Promotion, The

University of Tokyo (Assistant Professor: Dr. Sachiko Okazaki) and Center for Epidemiology and Preventive Medicine (Project Assistant Professor: Dr. Yukari Masuda). With all these staffs, we actively instruct and teach the residents and medical school students; annual evaluation of the teaching skill by the students always rates our department within the three places of the top. In addition, there are 14 students of Graduate School in our division. With all these 59 members, we enthusiastically work on the research activities, which lead to the outstanding contributions in the field of metabolism.

Clinical activities

Based on the update clinical evidences and with the experienced skills, we provide patient-centered medical services in the highest quality. We have outpatient clinics from Monday through Friday, and have been following approximately 227 new patients this year (total 33,412 patients per year). On the inpatient ward, we not only take care of around 18 patients in our division as mentioned above, but also provide a sophisticated management to all patients suffering from metabolic diseases, especially diabetes mellitus. Diabetes mellitus, metabolic syndrome, dyslipidemia and obesity disease are becoming more prevalent in Japan, and lead to complications including nephropathy, retinopathy, neuropathy and cardiovascular diseases. Thus, in collaboration with other departments, we optimize the treatment of each patient.

We provide the educational classes to the patients every weekday in the inpatient ward, and also give lectures twice a week in the outpatient unit. In addition, in collaboration with ancillary staffs of our hospital, we provide patients well-reasoned instructions regarding nutritional management, excise therapy and medical therapy.

The weekly official activities of our department consist of the pre-round case conference and the Ward Round by the Professor on Monday. We also hold a weekly case conference by the consultation group staffs.

Teaching activities

As for medical student education, our department

takes a part in systemic lectures for the 4th year medical students, bed-side learning and clinical clerkship for the 5th year medical students, and clinical lectures for the 6th year medical students.

In systemic lectures, comprehensive presentation for the understanding of basic knowledge about the concept, pathogenesis, diagnosis and treatment of common metabolic diseases is performed.

In clinical lectures, we present clinical cases of important diseases such as diabetes mellitus, and try to discuss with the students several points for planning the diagnosis and treatment in collaboration with the faculties of the Departments of Nephrology, Cardiology, and Ophthalmology.

During the period of clinical clerkship, the students have opportunities to experience the daily clinical care with junior and senior residents as well as with the Faculty members. Each student can learn how to do history taking, perform physical examinations and make the actual plans for the diagnosis and treatment. In addition, we arrange the program so that the students can experience the clinical practice and learn the disease itself more profoundly. One faculty and one senior-resident always instruct one student. Especially, Diabetes Clinical Seminar and oral examination that lead to profound understandings of the metabolic diseases are regularly provided by the Professor.

As for the post-graduate education, attending doctor (staff) and senior resident instruct the junior residents. We provide advanced teaching through the seminars and grand conference.

Research activities

There are several laboratories in our departments; collaborating with each other or with other departments, we focus on the molecular mechanisms of the metabolic diseases and the establishment of the novel therapeutics.

1) Molecular mechanisms of type 2 diabetes

We have been attempting to elucidate the mechanisms underlying the development of type 2 diabetes at the molecular and genetic levels. To this end, in collaboration with RIKEN and several cohorts, we explored the comprehensive catalog of genomic

variations to identify variations conferring susceptibility to type 2 diabetes in the Japanese population. We are also exploring the signal transduction pathways and physiological roles of insulin and adipokines in various tissues and the mechanisms of insulin secretion under the normal or pathological conditions, such as diabetes and obesity disease, using a number of transgenic and knockout animal models, in parallel with information obtained by whole-genome analysis of human patients. In particular, we are interested in the physiological and pathophysiological functions of adipokines secreted by adipocytes, including adiponectin, and the signal transduction pathway of adiponectin through the receptors, AdipoR1 and AdipoR2, that we discovered and characterized. We have also identified “AdipoRon” as an adiponectin receptor agonist, which will contribute to the development and optimization of AdipoR-targeted therapeutics. In addition, we have been successfully unraveling the molecular mechanisms of β cell proliferation and inter-tissue communication of glucose metabolism in obesity disease and type 2 diabetes. Recently, we are investigating brown and white adipocyte-specific transcriptional and epigenetic regulations in obesity. We believe that these findings and research activities will lead to novel therapeutic strategies for diabetes and the metabolic syndrome.

2) Pathophysiological roles of lipid storage and atherosclerosis

Our aim is to clarify the significance of metabolic risk factors in the onset and development of atherosclerosis. We are currently investigating the pathophysiological roles of lipid storage in obesity disease, fatty liver, diabetes, hyperlipidemia and atherosclerosis using strategies of molecular biology and genetic engineering techniques. Utilizing the animal models of lipid disorders and molecular biological technique, we are analyzing the roles of lipid transporters, nuclear receptors and the anti-oxidative proteins on the lipid disorders and atherosclerosis. We are currently interested in the cholesterol and lipid absorption from the intestine and lipid handling in the cells.

3) Clinical trials and epidemiological studies

We are conducting clinical trials and epidemiological

studies including “Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3)” follow-up study, “Japan Diabetes comprehensive database project based on an Advanced electronic Medical record System (J-DREAMS)”, database project on obesity (J-ORBIT), National Database project, systematic reviews and meta-analyses with a focus on important issues such as metabolic syndrome. We investigated anti-aging effect of Nicotinamide mononucleotide on muscle function, association between tear and blood glucose concentrations and investigator initiated clinical trials targeting for a new class of anti-diabetic agents.

References

1. Adachi Y, Ueda K, Nomura S, Ito K, Katoh M, Katagiri M, Yamada S, Hashimoto M, Zhai B, Numata G, Otani A, Hinata M, Hiraike Y, Waki H, Takeda N, Morita H, Ushiku T, Yamauchi T, Takimoto E, Komuro I. Beiging of perivascular adipose tissue regulates its inflammation and vascular remodeling. *Nat Commun.* 13:5117, 2022
2. Bouchi R, Sugiyama T, Goto A, Imai K, Ihana-Sugiyama N, Ohsugi M, Yamauchi T, Kadowaki T, Ueki K. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. *J Diabetes Investig.* 13:280-291, 2022
3. Hiraike Y, Tsutsumi S, Wada T, Oguchi M, Saito K, Nakamura M, Ota S, Koebis M, Nakao H, Aiba A, Nagano G, Ohno H, Oki K, Yoneda M, Kadowaki T, Aburatani H*, Waki H*, Yamauchi T*. NFIA determines the cis-effect of genetic variation on *Ucp1* expression in murine thermogenic adipocytes. *iScience.* 25:104729, 2022.
4. Igarashi M†*, Nakagawa-Nagahama Y†, Miura M†, Kashiwabara K, Yaku K, Sawada M, Sekine R, Fukamizu Y, Sato T, Sakurai T, Sato J, Ino K, Kubota N, Nakagawa T, Kadowaki T, Yamauchi T*: Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. *npj Aging* 8(1) 5,

2022 (†共同第一著者、*共同責任著者)

5. Iwabu M, Okada-Iwabu M, Kadowaki T, Yamauchi T. Elucidating exercise-induced skeletal muscle signaling pathways and applying relevant findings to preemptive therapy for lifestyle-related diseases. *Endocrine J.* 69:1-8, 2022
6. Iwamoto M, Kubota T, Sakurai Y, Wada N, Shioda S, Yamauchi T, Kadowaki T, Kubota N. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes. *Pharmacol Res Perspect.* 10: e00971, 2022
7. Jinnouchi T, Sakurai Y, Miyoshi K, Koizumi C, Waki H, Kubota N, Yamauchi T. A Case of Chronic Intestinal Pseudo-obstruction with Mitochondrial Diseases. *Intern Med.* 2022 Feb 15;61(4):469-474.
8. Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. *Lancet Diabetes Endocrinol.* 10:193-206, 2022
9. Klonoff DC, Wang J, Rodbard D, Kohn MA, Li C, Liepmann D, Kerr D, Ahn D, Peters AL, Umpierrez GE, Seley JJ, Xu NY, Nguyen KT, Simonson G, Agus MSD, Al-Sofiani ME, Armaiz-Pena G, Bailey TS, Basu A, Battelino T, Bekele SY, Benhamou PY, Bequette BW, Blevins T, Breton MD, Castle JR, Chase JG, Chen KY, Choudhary P, Clements MA, Close KL, Cook CB, Danne T, Doyle FJ 3rd, Drincic A, Dungan KM, Edelman SV, Ejskjaer N, Espinoza JC, Fleming GA, Forlenza GP, Freckmann G, Galindo RJ, Gomez AM, Gutow HA, Heinemann L, Hirsch IB, Hoang TD, Hovorka R, Jendle JH, Ji L, Joshi SR, Joubert M, Koliwad SK, Lal RA, Lansang MC, Lee WA, Leelarathna L, Leiter LA, Lind M, Litchman ML, Mader JK, Mahoney KM, Mankovsky B, Masharani U, Mathioudakis NN, Mayorov A, Messler J, Miller JD, Mohan V, Nichols JH, Nørgaard K, O'Neal DN, Pasquel FJ, Philis-Tsimikas A, Pieber T, Phillip M, Polonsky WH, Pop-Busui R, Rayman G, Rhee EJ, Russell SJ, Shah VN, Sherr JL, Sode K, Spanakis EK, Wake DJ, Waki K, Wallia A, Weinberg ME, Wolpert H, Wright EE, Zilbermint M, Kovatchev B. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. *J Diabetes Sci Technol.* 2022 Mar 29;19322968221085273. doi: 10.1177/19322968221085273. Epub ahead of print. PMID: 35348391
10. Kondo M, Okitsu T, Waki K, Yamauchi T, Nangaku M, Ohe K. Effect of Information and Communication Technology-Based Self-management System DialBeticsLite on Treating Abdominal Obesity in the Specific Health Guidance in Japan: Randomized Controlled Trial. *JMIR Form Res.* 6: e33852, 2022
11. Kurakawa KI, Okada A, Bessho K, Jo T, Ono S, Michihata N, Kumazawa R, Matsui H, Fushimi K, Yamaguchi S, Yamauchi T, Nangaku M, Kadowaki T, Yasunaga H. Major complications after percutaneous biopsy of native or transplanted liver in pediatric patients: a nationwide inpatient database study in Japan. *BMC Gastroenterol.* 22:395, 2022
12. Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, Yu GZ, Rüeger S, Speidel L, Kim YJ, Horikoshi M, Mercader JM, Taliun D, Moon S, Kwak SH, Robertson NR, Rayner NW, Loh M, Kim BJ, Chiou J, Miguel-Escalada I, Della Briotta Parolo P, Lin K, Bragg F, Preuss MH, Takeuchi F, Nano J, Guo X, Lamri A, Nakatochi M, Scott RA, Lee JJ, Huerta-Chagoya A, Graff M, Chai JF, Parra EJ, Yao J, Bielak LF, Tabara Y, Hai Y, Steinthorsdottir V, Cook JP, Kals M, Grarup N, Schmidt EM, Pan I, Sofer T, Wuttke M, Sarnowski C, Gieger C, Noursome D, Trompet S, Long J, Sun M, Tong L, Chen WM, Ahmad M, Noordam R, Lim VJY, Tam CHT, Joo YY, Chen CH, Raffield LM, Lecoeur C, Prins BP, Nicolas A, Yanek LR, Chen G, Jensen RA, Tajuddin S, Kabagambe EK, An P, Xiang AH, Choi HS, Cade BE, Tan J, Flanagan J, Abaitua F, Adair LS, Adeyemo A, Aguilar-Salinas CA, Akiyama M, Anand SS, Bertoni A, Bian Z,

- Bork-Jensen J, Brandslund I, Brody JA, Brummett CM, Buchanan TA, Canouil M, Chan JCN, Chang LC, Chee ML, Chen J, Chen SH, Chen YT, Chen Z, Chuang LM, Cushman M, Das SK, de Silva HJ, Dedoussis G, Dimitrov L, Doumatey AP, Du S, Duan Q, Eckardt KU, Emery LS, Evans DS, Evans MK, Fischer K, Floyd JS, Ford I, Fornage M, Franco OH, Frayling TM, Freedman BI, Fuchsberger C, Genter P, Gerstein HC, Giedraitis V, González-Villalpando C, González-Villalpando ME, Goodarzi MO, Gordon-Larsen P, Gorkin D, Gross M, Guo Y, Hackinger S, Han S, Hattersley AT, Herder C, Howard AG, Hsueh W, Huang M, Huang W, Hung YJ, Hwang MY, Hwu CM, Ichihara S, Ikram MA, Ingelsson M, Islam MT, Isono M, Jang HM, Jasmine F, Jiang G, Jonas JB, Jørgensen ME, Jørgensen T, Kamatani Y, Kandeel FR, Kasturiratne A, Katsuya T, Kaur V, Kawaguchi T, Keaton JM, Kho AN, Khor CC, Kibriya MG, Kim DH, Kohara K, Kriebel J, Kronenberg F, Kuusisto J, Läll K, Lange LA, Lee MS, Lee NR, Leong A, Li L, Li Y, Li-Gao R, Ligthart S, Lindgren CM, Linneberg A, Liu CT, Liu J, Locke AE, Louie T, Luan J, Luk AO, Luo X, Lv J, Lyssenko V, Mamakou V, Mani KR, Meitinger T, Metspalu A, Morris AD, Nadkarni GN, Nadler JL, Nalls MA, Nayak U, Nongmaithem SS, Ntalla I, Okada Y, Orozco L, Patel SR, Pereira MA, Peters A, Pirie FJ, Porneala B, Prasad G, Preissl S, Rasmussen-Torvik LJ, Reiner AP, Roden M, Rohde R, Roll K, Sabanayagam C, Sander M, Sadow K, Sattar N, Schönherr S, Schurmann C, Shahriar M, Shi J, Shin DM, Shriner D, Smith JA, So WY, Stančáková A, Stilp AM, Strauch K, Suzuki K, Takahashi A, Taylor KD, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tomlinson B, Torres JM, Tsai FJ, Tuomilehto J, Tusie-Luna T, Udler MS, Valladares-Salgado A, van Dam RM, van Klinken JB, Varma R, Vujkovic M, Wachter-Rodarte N, Wheeler E, Whitsel EA, Wickremasinghe AR, van Dijk KW, Witte DR, Yajnik CS, Yamamoto K, Yamauchi T, Yengo L, Yoon K, Yu C, Yuan JM, Yusuf S, Zhang L, Zheng W; FinnGen; eMERGE Consortium, Raffel LJ, Igase M, Ipp E, Redline S, Cho YS, Lind L, Province MA, Hanis CL, Peyser PA, Ingelsson E, Zonderman AB, Psaty BM, Wang YX, Rotimi CN, Becker DM, Matsuda F, Liu Y, Zeggini E, Yokota M, Rich SS, Kooperberg C, Pankow JS, Engert JC, Chen YI, Froguel P, Wilson JG, Sheu WHH, Kardia SLR, Wu JY, Hayes MG, Ma RCW, Wong TY, Groop L, Mook-Kanamori DO, Chandak GR, Collins FS, Bharadwaj D, Paré G, Sale MM, Ahsan H, Motala AA, Shu XO, Park KS, Jukema JW, Cruz M, McKean-Cowdin R, Grallert H, Cheng CY, Bottinger EP, Dehghan A, Tai ES, Dupuis J, Kato N, Laakso M, Köttgen A, Koh WP, Palmer CNA, Liu S, Abecasis G, Kooner JS, Loos RJF, North KE, Haiman CA, Florez JC, Saleheen D, Hansen T, Pedersen O, Mägi R, Langenberg C, Wareham NJ, Maeda S, Kadowaki T, Lee J, Millwood IY, Walters RG, Stefansson K, Myers SR, Ferrer J, Gaulton KJ, Meigs JB, Mohlke KL, Gloyn AL, Bowden DW, Below JE, Chambers JC, Sim X, Boehnke M, Rotter JI, McCarthy MI, Morris AP. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nat Genet.* 54:560-572, 2022
13. Matsuoka S, Kaneko H, Okada A, Fukui A, Yano Y, Itoh H, Morita K, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Nakamura S, Nishiyama A, Yokoo T, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Association between proteinuria and incident colorectal cancer: analysis of a nationwide population-based database. *BMJ Open.* 12: e056250, 2022
 14. Oe M, Fukuda M, Ohashi Y, Shimojima Y, Tsuruoka K, Qin Q, Yamauchi T, Sanada H. Evaluation of foot ulcer incidence in diabetic patients at a diabetic foot ulcer prevention clinic over a 10-year period. *Wound Repair Regen.* 30:546-552, 2022
 15. Ogawa W, Araki E, Ishigaki Y, Hirota Y, Maegawa H, Yamauchi T, Yorifuji T, Katagiri H. New classification and diagnostic criteria for insulin resistance syndrome. *Endocr J.* 69:107-113, 2022
 16. Okada A, Hashimoto Y, Goto T, Yamaguchi S, Ono S, Ikeda Kurakawa K, Nangaku M, Yamauchi T, Yasunaga H, Kadowaki T. A

- Machine Learning-Based Predictive Model to Identify Patients Who Failed to Attend a Follow-up Visit for Diabetes Care After Recommendations from a National Screening Program. *Diabetes Care*. 45:1346-1354, 2022
17. Okada A, Yamana H, Yamaguchi S, Kurakawa KI, Michihata N, Matsui H, Fushimi K, Nangaku M, Yamauchi T, Yasunaga H, Kadowaki T. Effect of Branched-Chain Amino Acid Infusion on In-Hospital Mortality of Patients With Hepatic Encephalopathy and End-Stage Kidney Disease: A Retrospective Cohort Study Using a National Inpatient Database. *J Ren Nutr*. 32: 432-440, 2022
 18. Okada A, Yamaguchi S, Jo T, Yokota I, Ono S, Ikeda Kurakawa K, Nangaku M, Yamauchi T, Kadowaki T. Impact of body mass index on in-hospital mortality in older patients hospitalized for bacterial pneumonia with non-dialysis-dependent chronic kidney disease. *BMC Geriatr*. 22:950,2022
 19. Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. *Int J Mol Sci*. 2021 Apr 16;22(8):4156.
 20. Sankoda A, Waki K, Yamaguchi S, Mieno M, Nangaku M, Yamauchi T, Ohe K. Effect of Digital Health Among People With Type 2 Diabetes Mellitus During the COVID-19 Pandemic in Japan. *J Diabetes Sci Technol*. 16:256-258, 2022
 21. Sasaki A, Yokote K, Naitoh T, Fujikura J, Hayashi K, Hirota Y, Inagaki N, Ishigaki Y, Kasama K, Kikkawa E, Koyama H, Masuzaki H, Miyatsuka T, Nozaki T, Ogawa W, Ohta M, Okazumi S, Shimabukuro M, Shimomura I, Nishizawa H, Saiki A, Seki Y, Shojima N, Tsujino M, Ugi S, Watada H, Yamauchi T, Yamaguchi T, Ueki K, Kadowaki T, Tatsuno I; Correction to: Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity. *Diabetol Int*.13:33-34, 2022
 22. Sasako T, Kadowaki H, Fujiwara T, Kodera S, Komuro I, Kadowaki T, Yamauchi T. Severe aortic stenosis during leptin replacement therapy in a patient with generalized lipodystrophy-associated progeroid syndrome due to an LMNA variant: A case report. *J Diabetes Investig* 13: 1636-1638, 2022.
 23. Sasako T, Yamauchi T. Addressing screams for evidence on renoprotection by GLP-1 receptor agonists. *Kidney Int*, 101(2), 222-224, 2022.
 24. Sasako T, Umehara T, Soeda K, Kaneko K, Suzuki M, Kobayashi N, Okazaki Y, Tamura-Nakano M, Chiba T, Accili D, Kahn CR, Noda T, Asahara H, Yamauchi T, Kadowaki T, Ueki K. Deletion of skeletal muscle Akt1/2 causes osteosarcopenia and reduces lifespan in mice. *Nat Commun* 13: 5655, 2022.
 25. Sasako T, Yamauchi T* Addressing screams for evidence on renoprotection by GLP-1 receptor agonists. *Kidney Int* 101:222-224,2022
 26. Seki Y, Yamada T, Kiyosue A, Kimura K, Uehara M, Hatano M, Sasako T, Shirota Y, Sudo A, Ishiura H, Toda T, Yamauchi T, Komuro I. Asymptomatic myocardial infarction in a patient with myotonic dystrophy type 1. *J Cardiol Cases* 26(4): 248-251, 2022.
 27. Suzuki Y, Kaneko H, Okada A, Itoh H, Morita K, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K, Matsunaga A, Ako J, Fukui A, Nishiyama A, Yokoo T, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database. *Am J Nephrol*. 53:240-248, 2022
 28. Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K, Matsunaga A, Ako J, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset. *Am J Nephrol*. 9:1-9, 2022
 29. Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Yano Y, Kamiya K, Matsunaga A, Ako J, Fukui A, Yokoo T, Nishiyama A, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Risk for Proteinuria in Newly Defined Hypertensive People Based on the 2017

American College of Cardiology/American Heart Association Blood Pressure Guideline .Am J Cardiol.168:83-89, 2022

30. Suzuki Y, Kaneko H, Okada A, Matsuoka S, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Node K, Yamauchi T, Yasunaga H, Komuro I. Prediabetes in Young Adults and Its Association With Cardiovascular Health Metrics in the Progression to Diabetes. *J Clin Endocrinol Metab.* 107:1843-1853, 2022
31. Tian J, Chung HK, Moon JS, Nga HT, Lee HY, Kim JT, Chang JY, Kang SG, Ryu D, Che X, Choi JY, Tsukasaki M, Sasako T, Lee SH, Shong M, Yi HS: Skeletal muscle mitoribosomal defects are linked to low bone mass caused by bone marrow inflammation in male mice. *J Cachexia Sarcopenia Muscle* 13: 1785-1799, 2022
32. Yamaguchi S, Okada A, Sunaga S, Ikeda Kurakawa K, Yamauchi T, Nangaku M, Kadowaki T. Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. *BMJ Open.* 2: e060390, 2022

Department of Hematology and Oncology

Professor

Mineo Kurokawa, M.D., Ph.D.

Lecturer

Yosuke Masamoto, M.D., Ph.D.,

Ken Morita, M.D., Ph.D

Assistant Professor

Kazuki Taoka, M.D., Ph.D.,

Hiroaki Maki, M.D., Ph.D.

Akira Honda, M.D., Ph.D.,

Arika Shimura, M.D., Ph.D.

Megumi Yasunaga, M.D., Ph.D.,

Hideaki Mizuno, M.D., Ph.D.

Akira Chiba, M.D., Ph.D.

Homepage <http://www.u-tokyo-hemat.com/>

Introduction and Organization

The Department of Hematology and Oncology is responsible for clinical activities in outpatient as well as inpatient clinics of hematological disorders, research activities for hematology/oncology, and education of undergraduate as well as graduate students. We are also engaged in continuous education of post-graduate doctors who develop into sophisticated hematologists of eminent distinction. These activities are performed by the united efforts of all members who belong to the department. Dr. Mineo Kurokawa was assigned as Professor of the Department of Hematology and Oncology in 2005. Other staff of our department consists of 2 lecturers and 7 assistant professors.

Clinical activities

On the average, 50-70 patients with hematological diseases are treated in the ward. Clinical facilities include patient rooms with high-efficiency particulate air filtration and filtrated water supply. Patients who are eligible for the treatment with high-grade infection prophylaxis are admitted to the facilities. Patient care is provided by team management. That is, three doctors

(a junior resident, a senior resident, and an assistant professor) are assigned to a single patient. Since clinical issues are highly related to hematopoietic stem cell transplantation especially for patients with hematological diseases, a substantial portion of our clinical conferences are shared with staff members of the Department of Cell Therapy and Transplantation Medicine and the Department of Pediatrics (Hematology/Oncology). Many problems arising in daily clinical practice are discussed in the morning clinical conference held thrice a week. Diagnostic and therapeutic issues as well as pathological aspects of indicative and/or educational cases are discussed in clinical conferences held twice a month.

Outpatient clinical services are provided from Monday to Friday in the morning and afternoon using three booths. Approximately 70-80 patients visit our outpatient clinic every weekday. One of our ultimate goals in the clinical activities is to cure patients with hematological malignancies.

We perform various kinds of genetic or molecular tests to detect, characterize, and monitor neoplastic cells and their results are used in the diagnosis and treatment.

Here we introduce technical aspects on the treatment strategy:

1. High dose chemotherapy with autologous stem cell transplant: High-dose chemotherapy is administered for the treatment of hematological neoplasms and solid tumors. For the autologous stem cell support, peripheral blood stem cell is usually selected as a source of stem cells. Recently, we are actively performing autologous transplantation as a treatment for CNS malignant lymphoma, which is considered intractable, to improve the prognosis.
2. Allogeneic hematopoietic stem cell transplant: Bone marrow cells are harvested from healthy donors by operation under general anesthesia and immediately infused to a recipient. Peripheral blood stem cells (PBSCs) are harvested from healthy donors by leukapheresis using an automated continuous flow blood cell separator. PBSCs are immediately infused to a recipient or preserved in liquid nitrogen in cooperation with the Department of Transfusion Medicine. Allogeneic transplant with non-myeloablative conditioning (also referred to as reduced-intensity stem cell transplant (RIST)) is commonly performed for elderly patients and patients with impaired organ function. HLA-haploidentical hematopoietic stem cell transplantation is also ready to be performed to patients if necessary. Allogeneic hematopoietic stem cell transplant for the elderly is performed under the admission of Patient Relations and Clinical Ethics Center. Cord blood cells are also used as a source of hematopoietic stem cells.
3. CAR-T Cell Therapy: T cells that are collected from the patients are genetically treated in the lab to produce special receptors called chimeric antigen receptors, or CARs. These CARs allow the T cells to recognize an antigen at the surface of lymphoma cells and activate T cells' ability to kill these tumor cells. By collaborating with the Department of Cell Therapy and Transplantation Medicine, the Department of Pediatrics (Hematology/Oncology), and the Cell Processing Center, we have installed a capacity to perform this most advanced and promising cancer treatment for patients with hematologic malignancies, and actively recruiting patients.

Teaching activities

A lecture course on etiology, pathogenesis, clinical and laboratory features, differential diagnosis, therapy and prognosis for all hematological diseases is provided for the second-grade medical students. The course contents include:

1. Mechanisms of hematopoiesis, transplantation medicine and cell therapy
2. Acute leukemia and myeloproliferative disorders
3. Bone marrow failure syndrome (aplastic anemia and myelodysplastic syndrome)
4. Lymphoma and myeloma
5. Hemostasis and thrombosis
6. Hemolytic anemia and anemia of various causes

Clinical clerkships on diagnostic and therapeutic issues and arts are given for the third-grade medical students on a man-to-man basis with a senior faculty member who is erudite both in general internal medicine and in hematology and oncology. During the course, students are required to learn the basic techniques of medical interview and physical examination, interpretation of laboratory tests, and practical medical procedures.

Undergraduate students are educated to become independent researchers both in basic and clinical research.

Education of clinical fellows to train hematologists is also provided. They are trained to achieve knowledge and techniques necessary for hematologists in our hospital and encouraged to present clinical studies at academic meetings.

Research activities

The major research projects are as follow: (1) molecular mechanisms of hematopoietic neoplasms, (2) hematopoietic transcription factors, (3) signal transduction in hematopoietic cells, (4) chromosomal and genomic approaches to leukemogenesis, (5) generation of murine models for leukemias, (6) reprogramming of leukemic cells into iPS cells, and functional analysis using iPS cells, (7) regulation of hematopoiesis. (8) genetic and pathological mechanism of Erdheim-Chester disease. Translational research to develop novel methods for diagnosis and treatment based on basic research is also performed. Every effort has been made to achieve the highest quality in both

clinical and basic medical research. The ultimate aims of our research are the application of epoch-making discoveries in research fields to the clinical hematology and oncology. Representative publications from our departments published in the past year are listed in the reference.

References

1. Yokomizo T, Ideue T, Morino-Koga S, Tham CY, Sato T, Takeda N, Kubota Y, Kurokawa M, Komatsu N, Ogawa M, Araki K, Osato M, Suda T. Independent origins of fetal liver haematopoietic stem and progenitor cells. *Nature*. 2022 Sep; 609(7928):779-784.
2. Oyama T, Taoka K, Chiba A, Matsuda K, Maki H, Masamoto Y, Kurokawa M. Bing-Neel Syndrome Successfully Treated with Tirabrutinib. *Intern Med*. 2022 Dec 1;61(23):3575-3579.
3. Masamoto Y, Shimura A, Kurokawa M. Reduced bendamustine for elderly patients with follicular lymphoma. *Ann Hematol*. 2022 Mar;101(3):713-715.
4. Nakazaki K, Yoshida M, Masamoto Y, Shinozaki-Ushiku A, Ikemura M, Hisamoto T, Yasunaga M, Sato S, Kurokawa M. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. *Int J Hematol*. 2022 Sep;116(3):446-452.
5. Miyauchi M, Sasaki K, Kagoya Y, Taoka K, Masamoto Y, Yamazaki S, Arai S, Mizuno H, Kurokawa M. CAMK2G is identified as a novel therapeutic target for myelofibrosis. *Blood Adv*. 2022 Mar 8;6(5):1585-1597.
6. Takano H, Yasunaga M, Yamazaki I, Nishikawa M, Masamoto Y, Shinozaki-Ushiku A, Kawakami M, Yatomi Y, Kurokawa M. Degenerated mitochondria in leukemic blast appeared as granules on May-Grunwald-Giemsa staining. *Ann Hematol*. 2022 May;101(5):1135-1136.
7. Shull LC, Lencer ES, Kim HM, Goyama S, Kurokawa M, Costello JC, Jones K, Artinger KB. PRDM paralogs antagonistically balance Wnt/ β -catenin activity during craniofacial chondrocyte differentiation. *Development*. 2022 Feb 15;149(4):dev200082.
8. Masamoto Y, Shimura A, Honda A, Taoka K, Maki H, Kurokawa M. Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma. *Ann Hematol*. 2023 Jan; 102(1):243-244.
9. Shiroshta K, Kobayashi H, Watanuki S, Karigane D, Sorimachi Y, Fujita S, Tamaki S, Haraguchi M, Itokawa N, Aoyoama K, Koide S, Masamoto Y, Kobayashi K, Nakamura-Ishizu A, Kurokawa M, Iwama A, Okamoto S, Kataoka K, Takubo K. A culture platform to study quiescent hematopoietic stem cells following genome editing. *Cell Rep Methods*. 2022 Dec 5;2(12):100354.
10. Higo T, Suzuki Y, Sato M, Koya J, Mizuno H, Miyauchi M, Masamoto Y, Kataoka K, Sumitomo Y, Tsuruta-Kishino T, Sato T, Kurokawa M. Heterozygous Dnmt3a R878C induces expansion of quiescent hematopoietic stem cell pool. *Exp Hematol*. 2022 May;109:45-54.
11. Murakami D, Maki H, Matsuda K, Masamoto Y, Suzuki F, Amemiya S, Osawa K, Hinata M, Ikemura M, Ushiku T, Kurokawa M. Cerebral toxoplasmosis complicating lymphoplasmacytic lymphoma in partial remission. *J Infect Chemother*. 2022 Feb;28(2):279-282.
12. Ogawa E, Edamitsu T, Ohmori H, Kohu K, Kurokawa M, Kiyonari H, Satake M, Okuyama R. Transcription Factors Runx1 and Runx3 Suppress Keratin Expression in Undifferentiated Keratinocytes. *Int J Mol Sci*. 2022 Sep 2;23(17):10039.
13. Kurihara Y, Mizuno H, Honda A, Shimura A, Fujioka Y, Maki H, Kurokawa M. CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. *J Cell Mol Med*. 2022 Feb;26(3):950-952.
14. Hayashida H, Honda A, Hino T, Mizuno H, Toyama K, Kurokawa M. A case of thymoma showing significant tumor reduction after anti-thymocyte globulin. *Gen Thorac Cardiovasc Surg*.

- 2022 Jan;70(1):96-99.
15. Oyama T, Matsuda K, Honda A, Maki H, Masamoto Y, Murakami D, Toya T, Sakurai M, Kataoka K, Doki N, Kurokawa M. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis. *Int J Hematol.* 2023 Feb; 117(2):260-268.
 16. Murakami D, Matsuda K, Honda A, Masamoto Y, Kurokawa M. Severe infections and renal dysfunction during immunosuppressive therapy with cyclosporine A for aplastic anemia. *Int J Hematol.* 2022 Oct;116(4):482-488.
 17. Fukui Y, Honda A, Takano H, Obo T, Mizuno H, Masamoto Y, Kurokawa M. Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma. *J Clin Exp Hematop.* 2022 Dec 28;62(4):217-221.
 18. Masamoto Y, Taoka K, Maki H, Kurokawa M. Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab. *Ann Hematol.* 2022 Dec;101(12):2795-2797.
 19. Ebisawa K, Masamoto Y, Yagi K, Kurokawa M. A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate. *Ann Hematol.* 2022 Nov; 101(11):2551-2552.
 20. Hino T, Honda A, Shimura A, Masamoto Y, Kurokawa M. R-GCD regimen in elderly patients with relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma: a retrospective single-center analysis. *Int J Hematol.* 2022 Feb; 115(2):296-297.
 21. Ebisawa K, Honda A, Chiba A, Masamoto Y, Okazaki H, Kurokawa M. High D-index during mobilization predicts poor mobilization of CD34+ cells after anti-lymphoma salvage chemotherapy. *J Clin Apher.* 2022 Feb;37(1):4-12.
 22. Kato K, Yabe H, Shimozawa N, Adachi S, Kurokawa M, Hashii Y, Sato A, Yoshida N, Kaga M, Onodera O, Kato S, Atsuta Y, Morio T. Stem cell transplantation for pediatric patients with adrenoleukodystrophy: A nationwide retrospective analysis in Japan. *Pediatr Transplant.* 2022 Feb; 26(1):e14125.
 23. Mizuta S, Ugai T, Kato H, Doki N, Ota S, Kawakita T, Katayama Y, Kurokawa M, Nakamae H, Yano S, Nawa Y, Kanda Y, Fukuda T, Atsuta Y, Kako S. Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. *Int J Hematol.* 2022 Sep;116(3):393-400.
 24. Matsuda K, Jo T, Shimura A, Honda A, Taoka K, Masamoto Y, Matsui H, Fushimi K, Yasunaga H, Kurokawa M. Risk of febrile neutropenia in very elderly patients aged ≥ 80 years receiving their first cycle of R-CHOP regimen: a nationwide real-world study in Japan. *Br J Haematol.* 2022 May; 197(3):e37-e41.
 25. Yoshida M, Matsuda K, Endo K, Honda A, Maki H, Taoka K, Masamoto Y, Wakimoto Y, Jubishi D, Moriya K, Kurokawa M. Toxic shock like syndrome caused by *Streptococcus agalactiae* bacteremia during treatment for multiple myeloma. *J Infect Chemother.* 2023 Apr;29(4):407-409.
 26. Oyama T, Matsuda K, Honda A, Yasunaga M, Nakazaki K, Maki H, Masamoto Y, Kurokawa M. Long-term follow-up of central nervous system relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. *Leuk Lymphoma.* 2022 Dec;63(14): 3497-3500.
 27. Sato M, Yasunaga M, Ohzu M, Toyama K, Nakazaki K, Nakahara F, Kubo T, Okura N, Abe O, Kurokawa M. Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive angiography: a case report. *Ann Hematol.* 2022 May;101(5): 1153-1155.
 28. Ito Y, Honda A, Kurokawa M. Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: a meta-analysis. *Blood Adv.* 2022 Mar 8;6(5):1499-1511.
 29. Matsuda K, Oyama T, Maki H, Nakazaki K, Yasunaga M, Honda A, Masamoto Y, Kurokawa M.

- Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia. *Intern Med.* 2023 Aug 1;62(15):2181-2185.
30. Oyama T, Taoka K, Chiba A, Masamoto Y, Ikemura M, Honda A, Maki H, Kurokawa M. Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion. *Int J Hematol.* 2023 Mar; 117(3):463-467.
31. Ito Y, Honda A, Kurokawa M. COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis. *Clin Lymphoma Myeloma Leuk.* 2022 Aug;22(8):e691-e707.
32. Miyashita H, Taoka K, Kume A, Ushiku A, Ushiku T, Toyama K, Kurokawa M. Clinical usefulness of a novel classification of T cell distribution patterns in the tumor microenvironment of follicular lymphoma to detect transformation. *Ann Hematol.* 2022 Nov;101(11):2477-2483.
33. Murayama R, Oyama H, Abe-Doi M, Masamoto Y, Kashiwabara K, Tobe H, Komiyama C, Sanada H, Kurokawa M. Safety verification of a new peripheral intravenous catheter placed in the upper arm vein for administration of drugs with high irritant potential. *Drug Discov Ther.* 2022 Jul 20; 16(3):128-134.
34. Yoshida M, Morita K, Fukushima H, Jona M, Nishikawa M, Yatomi Y, Kishino Y, Iwasaki A, Ushiku T, Imadome KI, Honda A, Maki H, Kurokawa M. Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma. *Int J Hematol.* 2023 May;117(5):769-773.
35. Sato M, Honda A, Maki H, Toyama K, Yamaguchi R, Ikeda M, Moriya K, Kurokawa M. Successful treatment of pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa* after allogeneic hematopoietic stem cell transplantation with colistin and amikacin inhalation therapy. *J Infect Chemother.* 2022 Jan;28(1):91-94.

Department of Allergy and Rheumatology

Professor

Keishi Fujio, M.D., Ph.D. (Rheumatology)

Associate Professor

Hirofumi Shoda, M.D., Ph.D. (Rheumatology)

Lecturer

Hiroaki Harada, M.D., Ph.D. (Allergology)

Hospital Lecturer

Haruka Tsuchiya, M.D., Ph.D. (Rheumatology)

Yumi Tsuchida, M.D., Ph.D. (Rheumatology)

Research Associate

Toshihiko Komai, M.D., Ph.D. (Rheumatology)

Toshiaki Shimizu, M.D., Ph.D. (Rheumatology)

Bunki Natsumoto, M.D., Ph.D. (Rheumatology)

Masanori Kono, M.D., Ph.D. (Rheumatology)

Project Associate professor

Tomohisa Okamura, M.D., Ph.D. (Rheumatology)

Project Research Associate

Yasuo Nagafuchi, M.D., Ph.D. (Rheumatology)

Mineto Ohta, M.D., Ph.D. (Rheumatology)

Homepage <http://www.m.u-tokyo.ac.jp/mcm/>

Introduction and Organization

The Department of Allergy and Rheumatology presently consists of 15 staffs mentioned above, who preside over 3 medical staff, 18 graduate students for "Doctor of Medical Science". The outpatient facilities are situated on the 2nd floor of the Outpatient Clinic. The inpatient facility is mainly located on the 14th floor of the Hospital Ward A. The physician's office is situated in the East Hospital Ward and the research rooms are located in the East Hospital Ward, the

Central Ward, Molecular Life Innovation Ward, and the Clinical Research Center A.

Education

In regard to undergraduate education, the Department is in charge of internal medicine diagnosis and systemic lectures for M2 students and clinical lectures and bedside education for M3 and M4 students in cooperation with other departments of internal medicine. The systemic lectures and clinical lectures

cover clinical immunology, connective tissue diseases and allergy. Bedside education provides students with a good opportunity to learn patient care as well as practical knowledge through numerous seminars.

For postgraduate education, internal medicine trainees are accepted on rotation basis and trained as internist. Our department accepts students for "Doctor of Medical Science". Our 4-year education covers clinical immunology, molecular immunology, rheumatology and allergology.

Medical Care

General and special outpatient clinics are opened from Monday to Friday. Special outpatients clinics include clinics for rheumatoid arthritis, connective tissue diseases, bronchial asthma, allergy, and kidney disorders. For inpatients, there are presently 25 to 30 beds. Every week on Monday afternoon the charts are rounded and on Tuesday afternoon the professor makes his rounds. To achieve the highest quality of medical care, clinical conferences are held. Majority of patients in the ward are suffered from connective tissue diseases and usually exhibit multiple organ involvements. Therefore, a careful, well-rounded approach to each patient as a whole is required rather than a limited special approach to a single organ system.

Research

The Department consists of some laboratories in which clinical and basic studies are carried out concerning mainly rheumatology and allergology. Recently the mainstream of research has employed various techniques of molecular biology and cellular immunology. The principal research topics are listed below.

1. Functional genomics in autoimmune diseases, such as systemic lupus erythematosus, and its clinical application to precision medicine.
2. Analysis of newly identified autoimmune-associated T cell subset and its roles in autoimmune diseases.
3. Analysis of T cell and B cell repertoires in autoimmune diseases.
4. Analysis of synovial tissues in rheumatoid arthritis.
5. Analysis of mice models of immune-related diseases.
6. Analysis of autoimmune disease-specific iPS cells
7. Investigation of biomarkers in autoimmune disease.

Publications

1. Distinct transcriptome architectures underlying lupus establishment and exacerbation. Nakano M, Ota M, Takeshima Y, Iwasaki Y, Hatano H, Nagafuchi Y, Itamiya T, Maeda J, Yoshida R, Yamada S, Nishiwaki A, Takahashi H, Takahashi H, Akutsu Y, Kusuda T, Suetsugu H, Liu L, Kim K, Yin X, Bang SY, Cui Y, Lee HS, Shoda H, Zhang X, Bae SC, Terao C, Yamamoto K, Okamura T, Ishigaki K, Fujio K. **Cell**. 2022 Sep 1;185(18):3375-3389.e21.
2. Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K, Amariuta T, Too CL, Laufer VA, Scott IC, Viatte S, Takahashi M, Ohmura K, Murasawa A, Hashimoto M, Ito H, Hammoudeh M, Emadi SA, Masri BK, Halabi H, Badsha H, Uthman IW, Wu X, Lin L, Li T, Plant D, Barton A, Orozco G, Verstappen SMM, Bowes J, MacGregor AJ, Honda S, Koido M, Tomizuka K, Kamatani Y, Tanaka H, Tanaka E, Suzuki A, Maeda Y, Yamamoto K, Miyawaki S, Xie G, Zhang J, Amos CI, Keystone E, Wolbink G, van der Horst-Bruinsma I, Cui J, Liao KP, Carroll RJ, Lee HS, Bang SY, Siminovitch KA, de Vries N, Alfredsson L, Rantapää-Dahlqvist S, Karlson EW, Bae SC, Kimberly RP, Edberg JC, Mariette X, Huizinga T, Dieudé P, Schneider M, Kerick M, Denny JC; BioBank Japan Project; Matsuda K, Matsuo K, Mimori T, Matsuda F, Fujio K, Tanaka Y, Kumanogoh A, Traylor M, Lewis CM, Eyre S, Xu H, Saxena R, Arayssi T, Kochi Y, Ikari K, Harigai M, Gregersen PK, Yamamoto K, Louis Bridges S Jr, Padyukov L, Martin J, Klareskog L, Okada Y, Raychaudhuri S. **Nat Genet**. 2022 Nov;54(11):1640-1651.
3. Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus.

- Takeshima Y, Iwasaki Y, Nakano M, Narushima Y, Ota M, Nagafuchi Y, Sumitomo S, Okamura T, Elkon K, Ishigaki K, Suzuki A, Kochi Y, Yamamoto K, Fujio K. **Ann Rheum Dis.** 2022 Jun;81(6):845-853.
4. Entering the era of precision medicine through multiomics approach. Fujio K. **Inflamm Regen.** 2022 Sep 9;42(1):42.
 5. Jaccoud's Arthropathy in Systemic Lupus Erythematosus. Izuka S, Natsumoto B, Shoda H, Fujio K. **Intern Med.** 2023 Mar 1;62(5):809-810.
 6. Significance of the multiomics approach to elucidate disease mechanisms in humans. Fujio K. **Inflamm Regen.** 2022 Nov 4;42(1):41.
 7. Emerging role of leptin in joint inflammation and destruction. Tsuchiya H, Fujio K. **Immunol Med.** 2022 Mar;45(1):27-34.
 8. ANCA-associated vasculitis with protein-losing enteropathy is characterized by hypocomplementemia. Goto M, Tsuchida Y, Terada K, Takahashi H, Sugimori Y, Komai T, Iwasaki Y, Shoda H, Fujio K. **Rheumatol Int.** 2022 Oct; 42(10):1863-1872.
 9. The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis. Kobayashi S, Nagafuchi Y, Shoda H, Fujio K. **Front Immunol.** 2022 May 24;13:900638.
 10. Self-limited Polymyalgia Rheumatica-like Syndrome Following mRNA-1273 SARS-CoV-2 Vaccination. Izuka S, Komai T, Natsumoto B, Shoda H, Fujio K. **Intern Med.** 2022 Mar 15; 61(6):903-906.
 11. Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases. Ono M, Matsumoto K, Boku N, Fujii N, Tsuchida Y, Furui T, Harada M, Kanda Y, Kawai A, Miyachi M, Murashima A, Nakayama R, Nishiyama H, Shimizu C, Sugiyama K, Takai Y, Fujio K, Morishige KI, Osuga Y, Suzuki N. **Int J Clin Oncol.** 2022 Feb;27(2):301-309.
 12. Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation. Itamiya T, Komai T, Kanda H, Nagafuchi Y, Chang H, Shibata S, Ishiura H, Shoda H, Toda T, Fujio K. **Clin Rheumatol.** 2022 Jul;41(7):2233-2237.
 13. The differential diagnosis of IgG4-related disease based on machine learning. Yamamoto M, Nojima M, Kamekura R, Kuribara-Souta A, Uehara M, Yamazaki H, Yoshikawa N, Aochi S, Mizushima I, Watanabe T, Nishiwaki A, Komai T, Shoda H, Kitagori K, Yoshifuji H, Hamano H, Kawano M, Takano KI, Fujio K, Tanaka H. **Arthritis Res Ther.** 2022 Mar 19;24(1):71.
 14. Anti-Ku antibody-positive myositis presenting as a wide range of axial myopathies and myocarditis: A case report and review of the literature. Kono M, Komai T, Yuki H, Hanata N, Kakumoto T, Kubota A, Hashimoto Maeda M, Toda T, Shoda H, Fujio K. **Mod Rheumatol Case Rep.** 2022 Jan 7;6(1):64-68.
 15. The transcription factor Sox4 is required for thymic tuft cell development. Mino N, Muro R, Ota A, Nitta S, Lefebvre V, Nitta T, Fujio K, Takayanagi H. **Int Immunol.** 2022 Jan 1;34(1): 45-52.
 16. Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy. Izuka S, Komai T, Shoda H, Fujio K. **Rheumatol Int.** 2023 Feb;43(2): 335-343. doi: 10.1007/s00296-022-05214-0.
 17. Splicing QTL analysis focusing on coding sequences reveals mechanisms for disease susceptibility loci. Yamaguchi K, Ishigaki K, Suzuki A, Tsuchida Y, Tsuchiya H, Sumitomo S, Nagafuchi Y, Miya F, Tsunoda T, Shoda H, Fujio K, Yamamoto K, Kochi Y. **Nat Commun.** 2022 Aug 24;13(1):4659.
 18. AFF3, a susceptibility factor for autoimmune diseases, is a molecular facilitator of immunoglobulin class switch recombination. Tsukumo SI, Subramani PG, Seija N, Tabata M, Maekawa Y, Mori Y, Ishifune C, Itoh Y, Ota M, Fujio K, Di Noia JM, Yasutomo K. **Sci Adv.** 2022 Aug 26;8(34):eabq0008.
 19. A diagnostic score for eosinophilic granulomatosis with polyangiitis among eosinophilic disorders. Takahashi H, Komai T, Setoguchi K, Shoda H, Fujio K. **Allergol Int.** 2023 Apr;72(2): 316-323.

20. Control of naive and effector CD4 T cell receptor repertoires by rheumatoid-arthritis-risk HLA alleles. Nagafuchi Y, Ota M, Hatano H, Inoue M, Kobayashi S, Okubo M, Sugimori Y, Nakano M, Yamada S, Yoshida R, Tsuchida Y, Iwasaki Y, Shoda H, Okada Y, Yamamoto K, Ishigaki K, Okamura T, Fujio K. **J Autoimmun.** 2022 Dec; 133:102907.
21. A nationwide questionnaire survey on the prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis in Japan. Matsubara Y, Nakamura Y, Tamura N, Kameda H, Otomo K, Kishimoto M, Kadono Y, Tsuji S, Atsumi T, Matsuno H, Takagi M, Kobayashi S, Fujio K, Nishimoto N, Okamoto N, Nakajima A, Matsui K, Yamamura M, Nakashima Y, Kawakami A, Mori M, Tomita T. **Mod Rheumatol.** 2022 Aug 20;32(5):960-967.
22. Serum extracellular traps associate with the activation of myeloid cells in SLE patients with the low level of anti-DNA antibodies. Hanata N, Ota M, Tsuchida Y, Nagafuchi Y, Okamura T, Shoda H, Fujio K. **Sci Rep.** 2022 Nov 1;12(1): 18397.
23. Dysregulation of the gene signature of effector regulatory T cells in the early phase of systemic sclerosis. Kobayashi S, Nagafuchi Y, Okubo M, Sugimori Y, Hatano H, Yamada S, Nakano M, Yoshida R, Takeshima Y, Ota M, Tsuchida Y, Iwasaki Y, Setoguchi K, Kubo K, Okamura T, Yamamoto K, Shoda H, Fujio K. **Rheumatology (Oxford).** 2022 Oct 6;61(10):4163-4174.
24. The possible effects of the Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 on the practice of fertility preservation in female cancer patients in Japan. Kunitomi C, Harada M, Sanada Y, Kusamoto A, Takai Y, Furui T, Kitagawa Y, Yamada M, Watanabe C, Tsugawa K, Nishiyama H, Hosoi H, Miyachi M, Sugiyama K, Maeda Y, Kawai A, Hamatani T, Fujio K, Suzuki N, Osuga Y. **Reprod Med Biol.** 2022 Mar 21;21(1):e12453.
25. Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Tanaka Y, Yamaguchi A, Miyamoto T, Tanimura K, Iwai H, Kaneko Y, Takeuchi T, Amano K, Iwamoto N, Kawakami A, Murakami M, Nishimoto N, Atsumi T, Sumida T, Ohmura K, Mimori T, Yamanaka H, Fujio K, Fujino Y, Saito K, Nakano K, Hirata S, Nakayamada S. **Rheumatology (Oxford).** 2022 Nov 2;61(11): 4273-4285.
26. Autotaxin is a potential link between genetic risk factors and immunological disturbances of plasmacytoid dendritic cells in systematic lupus erythematosus. Tsuchida Y, Shoda H, Nakano M, Ota M, Okamura T, Yamamoto K, Kurano M, Yatomi Y, Fujio K, Sawada T. **Lupus.** 2022 Nov; 31(13):1578-1585.
27. Transcriptome analysis of immune cells from Behçet's syndrome patients: the importance of IL-17-producing cells and antigen-presenting cells in the pathogenesis of Behçet's syndrome. Okubo M, Sumitomo S, Tsuchida Y, Nagafuchi Y, Takeshima Y, Yanaoka H, Shirai H, Kobayashi S, Sugimori Y, Maeda J, Hatano H, Iwasaki Y, Shoda H, Okamura T, Yamamoto K, Ota M, Fujio K. **Arthritis Res Ther.** 2022 Aug 8;24(1):186.
28. Predominant mesangial IgM, C3, and λ light chain depositions and interstitial nephritis in a patient with overlap syndrome and positivity for anti-mitochondrial M2 antibody: a case report. Yamada S, Kanda H, Abe H, Domoto YS, Yoshida R, Harada H, Kubo K, Ushiku T, Fujio K. **Mod Rheumatol Case Rep.** 2022 Jan 7; 6(1):124-127.
29. Rheumatoid arthritis in a patient with compound heterozygous variants in the COL11A2 gene and progressive hearing loss: A case report. Tsuchida Y, Nagafuchi Y, Uehara T, Suzuki H, Yamada M, Kono M, Hatano H, Shoda H, Fujio K, Kosaki K. **Medicine (Baltimore).** 2022 Feb 18;101(7): e28828.

Department of Infectious Diseases (Internal Medicine)

Professor

Takeya Tsutsumi, M.D., Ph.D.

Associate Professor

Shu Okugawa, M.D., Ph.D.

Assistant Professor

Koh Okamoto, M.D., Ph.D. Daisuke Jubishi, M.D., Ph.D. Hideki Hashimoto, M.D., Ph.D.

Homepage <https://plaza.umin.ac.jp/utid/index.html>

Introduction and Organization

The Department of Infectious Diseases has been one of the leading academic organizations specialized for internal medicine, in particular, infectious disease medicine in Japan since 1998, when the Departments of Internal Medicine, established in 1890, were rearranged into new ones according to subspecialty of internal medicine. Our department has been chiefly engaged in clinical, educational and research activities for infectious diseases including bacterial, fungal and viral infections of all organs including HIV infection, tuberculosis and viral hepatitis. Our department is located on 13th floor of the University of Tokyo Hospital Building and has well-furnished research laboratories including P-2 class laboratory, and computer rooms as own properties. In clinical and research activities, we are collaborating with the Department of Infection Control and Prevention. One professor, one associate professor, three assistant professors, some residents and full-time staff members are all performing their own duties in clinical, educational and research activities.

Clinical activities

We have hospital beds on the 13th floor of the Ward A of University of Tokyo Hospital. Diseases include

HIV infection, viral hepatitis, pneumonia, drug-resistant bacteria infections or tuberculosis, EBV infection, CMV infection, parasite infection, sexual transmitted infection, *etc.* Every effort is made to give patients the best care and best quality of life. Assistant associates and residents take care of inpatients. The case presentation by residents is held every day. Weekly clinical conference is held to discuss all cases, in particular, those with clinical problems difficult to be solved. Consultations are very frequent from other departments on the management of infectious diseases. The general diagnostic, therapeutic plans and decisions for each patient are given at the Professor's round.

Our department offers out-patient care everyday on infectious diseases and general medicine. We are also engaged in infection control and prevention of emerging infectious diseases with the department of infection control and prevention.

Teaching activities

Our department takes a part in clinical lectures and bed-side learning (clinical clerkship) of the internal medicine for undergraduate medical students according to the educational programs of the University of Tokyo. For the fourth year medical

students, six lectures of infectious diseases are given. In addition, principles of medical diagnosis are taught at the bedside. During the clinical clerkship for fifth and sixth year students, our associates teach them on man-to man basis the basic way of thinking for correct diagnosis and therapy, the techniques of interrogation and physical examination, the way for interpretations of laboratory tests and other medical examinations, and the basic medical procedures on each case. The education of junior residents and fellows is performed as described in "Clinical Activities".

Research activities

Both clinical and basic research are necessary to improve the diagnosis and treatment to infectious diseases. The members of our department are doing best to obtain new findings using highly sophisticated methodologies. A intramural research conference is held, in which some members present their annual research progresses to be discussed by all the department staff. In addition, each laboratory holds its own conference and/or journal club on a weekly or bi-weekly basis.

The research field covers wide areas of infectious diseases including HIV infection, viral hepatitis and hepatocarcinogenesis, and bacterial infection. Also, various emerging and re-emerging infectious diseases are covered. Following themes are currently being investigated in the department.

- 1) Establishment of effective therapy for HCV and HBV infection: we have made a great contribution in the establishment of the guideline for treatment of hepatitis viral infection in Japan.
- 2) Establishment of effective therapy for HIV infection: we have made a great contribution in the establishment of the guideline for treatment of HIV infection in Japan.
- 3) Epidemiological study of infectious diseases by various pathogens.
- 4) Elucidation of the mechanism of hepatocarcinogenesis in hepatitis viral infection: the direct involvement of both HBV and HCV in hepatocarcinogenesis has been demonstrated using our transgenic mouse systems.
- 5) Pathogenesis of *Escherichia coli* infection.
- 6) Pathogenesis of *Clostridioides difficile* infection
- 7) Establishment of effective therapy for HCV/HIV co-infection: we have made a great contribution in the establishment of the guideline for treatment of HCV/HIV co-infection in Japan.
- 8) Clinical research on COVID-19.

Publications

1. Takashita E, Yamayoshi S, Halfmann P, Wilson N, Ries H, Richardson A, Bobholz M, Vuyk W, Maddox R, Baker DA, Friedrich TC, O'Connor DH, Uraki R, Ito M, Sakai-Tagawa Y, Adachi E, Saito M, Koga M, Tsutsumi T, Iwatsuki-Horimoto K, Kiso M, Yotsuyanagi H, Watanabe S, Hasegawa H, Imai M, Kawaoka Y. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6. *N Engl J Med.* 2022;387: 2094.
2. Adachi E, Saito M, Koga M, Tsutsumi T, Yotsuyanagi H. Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS. *Intern Med.* 2022;61:3459
3. Yamaoka Y, Sasai M, Suehiro Y, Hashimoto S, Goto A, Yamamoto N, Suzuki N, Higaki S, Fujii I, Suzuki C, Matsumoto T, Hoshida T, Koga M, Tsutsumi T, Lim LA, Matsubara Y, Tomochika S, Yoshida S, Hazama S, Yotsuyanagi H, Nagano H, Sakaida I, Takami T, Yamasaki T. Comparison of two primer-probe sets of *Fusobacterium nucleatum* using droplet digital polymerase chain reaction for the detection of colorectal neoplasia from faecal samples. *Ann Clin Biochem.* 2022; 59:396.
4. Nagai H, Saito M, Adachi E, Sakai-Tagawa Y, Yamayoshi S, Kiso M, Kawamata T, Koga M, Kawaoka Y, Tsutsumi T, Yotsuyanagi H. Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy. *Jpn J Infect Dis.* 2022;75: 608.
5. Mizutani T, Ishizaka A, Koga M, Tsutsumi T, Yotsuyanagi H. Role of Microbiota in Viral Infections and Pathological Progression. *Viruses.* 2022;14:950.

6. Halfmann PJ, Kuroda M, Armbrust T, Theiler J, Balaram A, Moreno GK, Accola MA, Iwatsuki-Horimoto K, Valdez R, Stoneman E, Braun K, Yamayoshi S, Somsen E, Baczenas JJ, Mitamura K, Hagihara M, Adachi E, Koga M, McLaughlin M, Rehrauer W, Imai M, Yamamoto S, Tsutsumi T, Saito M, Friedrich TC, O'Connor SL, O'Connor DH, Gordon A, Korber B, Kawaoka Y. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. *Sci Transl Med*. 2022;14:eabm4908.
7. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. *Nature*. 2022;607:119.
8. Adachi E, Nagai E, Saito M, Isobe M, Konuma T, Koga M, Tsutsumi T, Nannya Y, Yotsuyanagi H. Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. *J Infect Chemother*. 2022;28:1015.
9. Mizutani T, Ishizaka A, Koga M, Ikeuchi K, Saito M, Adachi E, Yamayoshi S, Iwatsuki-Horimoto K, Yasuhara A, Kiyono H, Matano T, Suzuki Y, Tsutsumi T, Kawaoka Y, Yotsuyanagi H. Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization. *Microbiol Spectr*. 2022;10:e0168921.
10. Adachi E, Saito M, Nagai H, Ikeuchi K, Koga M, Tsutsumi T, Yotsuyanagi H. Transient depletion of T cells during COVID-19 and seasonal influenza in people living with HIV. *J Med Virol*. 2022;94:1789
11. Koga M, Senkoji T, Kubota M, Ishizaka A, Mizutani T, Sedohara A, Ikeuchi K, Kikuchi T, Adachi E, Saito M, Koibuchi T, Hosomichi K, Ohashi J, Kawana- Tachikawa A, Matano T, Tsutsumi T (corresponding author), Yotsuyanagi H. Predictors associated with a better response to the Japanese aluminum-free hepatitis A vaccine, Aimugen®, for people living with HIV. *Hepatology*. 2022;52:227
12. Ikeuchi K, Okushin K, Saito M, Adachi E, Tsutsumi T, Takura T, Yotsuyanagi H. Prevalence of HIV infection among non-elderly individuals with hepatitis C in Japan: a population-based cohort study using a health insurance claim data. *BMC Infect Dis*. 2022;22:167.
13. Sekiba K, Otsuka M, Funato K, Miyakawa Y, Tanaka E, Seimiya T, Yamagami M, Tsutsumi T, Okushin K, Miyakawa K, Ryo A, Koike K. HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA. *J Hepatology*. 2022;76:53.
14. Kurano M, Okamoto K, Jubishi D, Hashimoto H, Sakai E, Saigusa D, Kano K, Aoki J, Harada S, Okugawa S, Doi K, Moriya K, Yatomi Y. Dynamic modulations of sphingolipids and glycerophospholipids in COVID-19. *Clin Transl Med*. 2022;12:e1069.
15. Kurano M, Jubishi D, Okamoto K, Hashimoto H, Sakai E, Morita Y, Saigusa D, Kano K, Aoki J, Harada S, Okugawa S, Doi K, Moriya K, Yatomi Y. Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries. *J Biomed Sci*. 2022;29:94.
16. Yamaguchi R, Yamamoto T, Okamoto K, Tatsuno K, Ikeda M, Tanaka T, Wakabayashi Y, Sato T, Okugawa S, Moriya K, Suzuki H. Prospective audit and feedback implementation by a multidisciplinary antimicrobial stewardship team shortens the time to de-escalation of anti-MRSA agents. *PLoS One*. 2022;17:e0271812.
17. Yamamoto S, Ikeda M, Ohama Y, Sunouchi T, Hoshino Y, Ito H, Yamashita M, Kanno Y, Okamoto K, Yamagoe S, Miyazaki Y, Okugawa S, Fujishiro J, Moriya K. *Aureobasidium melanigenum* catheter-related bloodstream

- infection: a case report. *BMC Infect Dis.* 2022; 22:335.
18. Ito H, Okamoto K, Ariyoshi T, Yamamoto S, Yamashita M, Kanno Y, Ikeda M, Okugawa S, Moriya K. *Neisseria meningitidis* serogroup W135 in a traveler visiting Japan from Argentina, 2019. *J Infect Chemother.* 2022;28:1180.
 19. Jubishi D, Okamoto K, Hamada K, Ishii T, Hashimoto H, Shinohara T, Yamashita M, Wakimoto Y, Otani A, Hisasue N, Ikeda M, Harada S, Okugawa S, Moriya K, Yanagimoto S. The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study. *Hum Vaccin Immunother.* 2022;18:2048559.
 20. Kitaura S, Okamoto K, Wakabayashi Y, Okada Y, Okazaki A, Ikeda M, Okugawa S, Fujimoto F, Bujo C, Minatsuki S, Tsushima K, Chikamatsu K, Mitarai S, Moriya K. A Cold-Blooded Tiptoe: Nonresolving Cellulitis in an Immuno-compromised Patient. *Open Forum Infect Dis.* 2022;9:ofac074.
 21. Jin C, Wakimoto Y, Ikeda M, Ohama Y, Ri M, Yamashita H, Ohtani A, Yamashita M, Shinohara T, Jubishi D, Kanno Y, Okamoto K, Higurashi Y, Harada S, Okugawa S, Seto Y, Moriya K. Human abdominal abscess caused by *Necropsobacter rosorum* and tips for its identification: A case report. *J Infect Chemother.* 2022;28:833.
 22. Morita Y, Kurano M, Jubishi D, Ikeda M, Okamoto K, Tanaka M, Harada S, Okugawa S, Moriya K, Yatomi Y. Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries. *Int J Infect Dis.* 2022;117:302.
 23. Yamashita M, Ikeda M, Kato I, Ohama Y, Ando M, Ikemura M, Jubishi D, Kanno Y, Okamoto K, Umeyama T, Nakamura S, Miyazaki Y, Okugawa S, Moriya K. Protothecosis in the mucosa of the pharynx mimicking pharyngeal cancer in an immunocompetent individual: a case report. *Ann Clin Microbiol Antimicrob.* 2022;21:5.
 24. Yamaguchi R, Okamoto K, Yamamoto T, Harada S, Tanaka T, Suzuki H, Moriya K. Impact of targeted intervention using a collaborative approach for oral third-generation cephalosporins: An interrupted time-series analysis. *Antimicrob Steward Healthc Epidemiol.* 2022;2:e115.
 25. Shimura T, Kurano M, Okamoto K, Jubishi D, Hashimoto H, Kano K, Igarashi K, Shimamoto S, Aoki J, Moriya K, Yatomi Y. Decrease in serum levels of autotaxin in COVID-19 patients. *Ann Med.* 2022;54:3189.
 26. Kitaura S, Jindai K, Okamoto K. Japan perspective on antimicrobial stewardship and solid organ transplantation. *Transpl Infect Dis.* 2022;24:e13939.
 27. Kanematsu A, Okamoto K, Nakagawa N, Sonoda H, Moriya K. Identification of *Odoribacter splanchnicus* bacteremia using MALDI-TOF mass spectrometry and 16S rRNA sequencing: A case report. *Anaerobe.* 2022;78:102663.
 28. Ohama Y, Nomura Y, Mizoguchi M, Higurashi Y, Okamoto K, Harada S. Accurate Identification of *Klebsiella variicola* by MALDI-TOF Mass Spectrometry in Clinical Microbiology Laboratories. *Microbiol Spectr.* 2022;10:e0284422.
 29. Kurano M, Ohmiya H, Kishi Y, Okada J, Nakano Y, Yokoyama R, Qian C, Xia F, He F, Zheng L, Yu Y, Jubishi D, Okamoto K, Moriya K, Kodama T, Yatomi Y. Measurement of SARS-CoV-2 Antibody Titers Improves the Prediction Accuracy of COVID-19 Maximum Severity by Machine Learning in Non-Vaccinated Patients. *Front Immunol.* 2022;13:811952.
 30. Beppu H, Fukuda T, Kawanishi T, Yasui F, Toda M, Kimura H, Nakamura Y, Nakamura Y, Kojima K, Ogawa H, Ishiwatari A, Kamei Y, Ogawa T, Abe Y, Endo M, Hanawa T, Mizobuchi R, Sugita C, Okamoto K, Hatakeyama S, Yamada T, Kohara M, Wakai S. Hemodialysis patients with coronavirus disease 2019: reduced antibody response. *Clin Exp Nephrol.* 2022;26:170.
 31. Kato S, Nakano Y, Nakano Y, Okamoto K, Takasugi N, Hidaka M, Sekiguchi M, Hiwatari M, Kurano M, Kato M. COVID-19 in an adolescent with aplastic anemia undergoing immunosuppressive therapy: A case report and

- details of antibody testing for SARS-CoV-2. *Pediatr Blood Cancer*. 2022 ;69:e29332.
32. Okamoto K, Yamada N, Suzuki T, Muramatsu T, Uemura H, Gatanaga H, Kato T, Hatakeyama S. Emergence of Hepatitis C Virus Genotype 2c Infection Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Tokyo, Japan. *Sex Transm Dis*. 2022;49:e29.
 33. Nakamura K, Kawakami T, Naraba H, Motoki M, Ikechi D, Nakano H, Mochizuki M, Takahashi Y, Hashimoto H. Impact of oligomeric enteral nutrition with low-molecular-weight whey peptides on diarrhea in critical care nutrition. *J Clin Biochem Nutr*. 2022;71:255.
 34. Yamakawa K, Yamamoto R, Terayama T, Hashimoto H, Ishihara T, Ishimaru G, Imura H, Okano H, Narita C, Mayumi T, Yasuda H, Yamada K, Yamada H, Kawasaki T, Shime N, Doi K, Egi M, Ogura H, Aihara M, Kushimoto S, Nishida O; Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J-SSCG 2020), the COVID-19 Task Force. Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022). *Acute Med Surg*. 2022;9:e789.
 35. Yoshida H, Motohashi T, De Bus L, De Waele J, Takaba A, Kuriyama A, Kobayashi A, Tanaka C, Hashi H, Hashimoto H, Nashiki H, Shibata M, Kanamoto M, Inoue M, Hashimoto S, Katayama S, Fujiwara S, Kameda S, Shindo S, Suzuki T, Komuro T, Kawagishi T, Kawano Y, Fujita Y, Kida Y, Hara Y, Fujitani S; DIANA Study Japanese group. Use of broad-spectrum antimicrobials for more than 72 h and the detection of multidrug-resistant bacteria in Japanese intensive care units: a multicenter retrospective cohort study. *Antimicrob Resist Infect Control*. 2022;11:119.
 36. Nakano H, Hashimoto H, Mochizuki M, Naraba H, Takahashi Y, Sonoo T, Nakamura K. Evaluation of Intravascular Volume Using the Internal Jugular Vein Cardiac Collapse Index in the Emergency Department: A Preliminary Prospective Observational Study. *Ultrasound Med Biol*. 2022;48:1169.
 37. Kanda N, Nakano H, Naraba H, Kawasaki A, Ohno N, Yoshikawa Y, Sakuramoto H, Takahashi Y, Sonoo T, Hashimoto H, Nakamura K. The efficacy and safety of nurse-initiated sedation management in an intensive care unit: A two-phase prospective study in Japan. *Jpn J Nurs Sci*. 2022;19:e12486.
 38. Ikechi D, Hashimoto H, Nakano H, Nakamura K. A Case of Suspected COVID-19 Vaccine-related Thrombophlebitis. *Intern Med*. 2022;61:1631.
 39. Naraba H, Goto T, Tokuda M, Sonoo T, Nakano H, Takahashi Y, Hashimoto H, Nakamura K. Accuracy and Stability of a Subcutaneous Flash Glucose Monitoring System in Critically Ill Patients. *J Diabetes Sci Technol*. 2022;16:1128.
 40. Yoshida M, Matsuda K, Endo K, Honda A, Maki H, Taoka K, Masamoto Y, Wakimoto Y, Jubishi D, Moriya K, Kurokawa M. Toxic shock like syndrome caused by *Streptococcus agalactiae* bacteremia during treatment for multiple myeloma. *J Infect Chemother*. 2023;29:407.
 41. Okuda M, Sakai-Tagawa Y, Koga M, Koibuchi T, Kikuchi T, Adachi E, Ahyoung Lim L, Yamamoto S, Yotsuyanagi H, Negishi K, Jubishi D, Yamayoshi S, Kawaoka Y. Immunological Correlates of Prevention of the Onset of Seasonal H3N2 Influenza. *J Infect Dis*. 2022;226:1800.
 42. Kurano M, Morita Y, Nakano Y, Yokoyama R, Shimura T, Qian C, Xia F, He F, Zheng L, Ohmiya H, Kishi Y, Okada J, Yoshikawa N, Nakajima K, Nagura Y, Okazaki H, Jubishi D, Moriya K, Seto Y, Yasui F, Kohara M, Wakui M, Kawamura T, Kodama T, Yatomi Y. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers. *Int Immunopharmacol*. 2022;103:108491.
 43. Yoshimura J, Yamakawa K, Ohta Y, Nakamura K, Hashimoto H, Kawada M, Takahashi H, Yamagiwa T, Kodate A, Miyamoto K, Fujimi S, Morimoto T. Effect of Gram Stain-Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated Pneumonia:

The GRACE-VAP Randomized Clinical Trial. JAMA Netw Open. 2022;5:e226136.

44. Kanda N, Hashimoto H, Suzuki T, Nakamura K. Performance of the new FilmArray Blood Culture Identification 2 panel and its potential impact on clinical use in patients with Gram-negative bacteremia. J Infect Chemother. 2022;28:1037.

Department of Stress Science and Psychosomatic Medicine

Associate Professor

Kazuhiro Yoshiuchi, M.D., Ph.D.

Associate

Makoto Otani, M.D., Ph.D.

Research Associate

Tadahiro Yamazaki, M.D.

Homepage <https://plaza.umin.ac.jp/~psmut/>

Introduction and Organization

The Department of Stress Science and Psychosomatic Medicine is one of 11 divisions of the Department of Internal Medicine, the University of Tokyo. It covers eating disorder, panic disorder, and various psychosomatic diseases such as chronic headache, irritable bowel syndrome, functional dyspepsia, hypertension, diabetes mellitus, and hyperthyroidism. Our teaching staff consists of one associate professor, one associate, one research associate, and 5 adjunct professors, and other members are 2 senior residents, 13 graduate students, and 5 researchers.

Clinical activities

Our department is responsible for both outpatient clinic and inpatient ward. The ward is managed as a part of the Division of General Internal Medicine, and senior residents, an associate, and the associate professor attend it every day and provide close side-by-side instruction to junior residents. The weekly professor's round is scheduled on Thursday morning. During 2022 April to 2023 March, overall 2,464 patients (89 individuals) were admitted to the ward, most of whom were eating disorder patients. Outpatient clinic is attended on every morning and afternoon in three consultation rooms by approximate-

ly fifteen physicians. During 2022 April to 2023 March, the numbers of the new outpatients and of the overall outpatients in our department were 149 and 4,807, respectively.

Teaching activities

We are giving 6 methodical lectures on psychosomatic medicine for fourth grade medical students, 'clinical clerkship' for fifth grade students lasting two weeks, 'advanced clinical clerkship' for 3 to 4 fifth grade students lasting 4 weeks each, and clinical lectures on psychosomatic diseases in cardiology for fifth grade students and on eating disorders for sixth grade students. We are trying to teach them not only basic knowledge of specific diseases, ways of physical examination, or interpretation of laboratory data, but also relevant ways of clinical interview, doctor-patient relationship building, and behavior modification.

As for education for junior residents, our senior residents and an associate provide one-on-one instruction. In addition, they can learn how to present the history of newly-admitted patients at the weekly professor's round from our teaching staff.

Research activities

Targeting stress-related diseases such as not only

those covered by our department but also other lifestyle-related disease, and cancers, we are investigating their pathophysiology and psychopathology through assessing bio-psycho-behavioral time-series data, various questionnaire data, and autonomic nervous function. We are also actively conducting basic as well as clinical research on eating-related substances.

Some representative research methods are as follows:

- 1) Ecological momentary assessment (EMA): Investigation on neurobehavioral basis of stress-related diseases such as tension-type headache, eating disorders, insomnia, and panic disorder using portable computers for real-time assessment of subjective symptoms in combination with ambulatory monitors such as electrocardiogram and actigraphy.
- 2) Neuroendocrinological and neuroimmunological studies in anorexia nervosa patients: multi-disciplinary investigation on energy metabolism during a refeeding phase; changes in various substances such as neuropeptides before and after treatment; relationship between bone metabolism and various makers; and exploration of biomarkers for evaluating treatment efficacy.
- 3) Psycho-oncology: Development of a new questionnaire for evaluating depressive mood in cancer patients.

Thirteen graduate students and 5 researchers actively conducted their researches along with our teaching staff. We have been also collaborating with many scientists belonging to other departments either in Japan or abroad. Research conferences are held once a month, where one of the graduate students presents his/her research for open discussion by all the members of our department.

References

1. Takeuchi H, Suwa K, Kishi A, Nakamura T, Yoshiuchi K, Yamamoto Y. The effects of objective push-type sleep feedback on habitual sleep behavior and momentary symptoms in daily life: mobile health intervention trial using a healthcare IoT system. *JMIR mHealth and uHealth* 2022;10(10):e39150
2. Yokomichi N, Maeda I, Morita T, Yoshiuchi K, Ogawa S, Hisanaga T, Sakashita A, Nakahara R, Kaneishi K, Iwase S. Association of antipsychotic dose with survival of advanced cancer patients with delirium *Journal of Pain and Symptom Management. J Pain Symptom Manage* 2022;64(1):28–36
3. Matsumoto Y, Umemura S, Okizaki A, Fujisawa D, Kobayashi N, Tanaka Y, Sasaki C, Shimizu K, Ogawa A, Kinoshita H, Uchitomi Y, Yoshiuchi K, Matsuyama Y, Motira T, Goto K, Ohe Y. Early specialized palliative care for patients with metastatic lung cancer receiving chemotherapy: A feasibility study of a nurse-led screening-triggered program. *Jap J Clin Oncol* 2022;52: 375-382
4. Yoshikawa E, Fujisawa D, Hisamura K, Murakami Y, Okuyama T, Yoshiuchi K. The potential role of peer support interventions in treating depressive symptoms in cancer patients. *J Nippon Med Sch* 2022;89:16-23
5. Inoue S, Maeda I, Ogawa A, Yoshiuchi K, Terada S, Yamada N. Safety and effectiveness of perospirone in comparison to risperidone for treatment of delirium in patients with advanced cancer: A multicenter prospective observational study in real-world psycho-oncology settings. *Acta Medica Okayama* 2022;76(2):195-202
6. Kurisu K, Fujimori M, Harashima S, Akechi T, Matsuda T, Saika K, Yoshiuchi K, Miyashiro I, Uchitomi Y. Suicide, other externally caused injuries, and cardiovascular disease within two years after cancer diagnosis: a nationwide population-based study in Japan (J-SUPPORT 1902). *Cancer Med.* 2023;12(3):3442-3451
7. Kurisu K, Hashimoto M, Ishizawa T, Shibayama O, Inada S, Fujisawa D, Inoguchi H, Shimoda H, Inoue S, Ogawa A, Akechi T, Shimizu K, Uchitomi Y, Matsuyama Y, Yoshiuchi K. Development of computer adaptive testing for measuring depression in patients with cancer. *Sci Rep.* 2022;12(1):8247
8. Miyamoto S, Yamazaki T, Shimizu K, Matsubara T, Kage H, Watanabe K, Kobo H, Matsuyama Y, Rodin G, Yoshiuchi K. Brief, manualised and semistructured individual psychotherapy

programme for patients with advanced cancer in Japan: study protocol for Managing Cancer and Living Meaningfully (CALM) phase 2 trial. *BMJ Open*. 2022;12(3):e056136

9. Kurisu K, Matsuoka M, Sato K, Hattori A, Yamanaka Y, Nohara N, Otani M, Yoshiuchi K. Increased prevalence of eating disorders in Japan since the start of the COVID-19 pandemic. *Eating and Weight Disorders* 2022;27:2251–2255
10. Sakamoto R, Ohtake Y, Kataoka Y, Matsuda Y, Hata T, Otonari J, Yamane A, Matsuoka H, Yoshiuchi K. The efficacy of acceptance & commitment therapy for type 2 diabetes: a systematic review and meta-analysis. *J Diabetes Investig* 2022;13(2):262–270
11. Kurisu K, Inada S, Maeda I, Ogawa A, Iwase S, Akechi T, Motita T, Oyamada S, Yamaguchi T, Imai K, Nakahara R, Kaneishi K, Nakajima N, Sumitani M, Yoshiuchi K*. A decision tree prediction model for a short-term outcome of delirium in patients with advanced cancer receiving pharmacological interventions: a secondary analysis of a multicenter and prospective observational study (Phase-R). *Palliat Support Care* 2022;20(2):153-158

Internal Medicine

3. Clinical Laboratory Medicine and Pathology

Department of Transfusion Medicine

Professor

Hitoshi Okazaki, M.D., Ph.D.

Lecturer

Toshiyuki Ikeda, M.D., Ph.D.

Research Associate

Toshiya Hino, M.D., Ph.D., Takahiro Hongo, M.D., Ph.D.

Homepage <http://square.umin.ac.jp/traf-tky/>

Introduction and Organization

The Transfusion Medicine service was established in 1949, as an internal provisional measure, and officially established in 1966. In 1984, Professor Hiroshi Toyama assumed as the first Professor of the department. Professor Toyama greatly contributed to the field of transfusion medicine, especially by publishing “Transfusion Medicine” (actually in its 3rd edition), which is the bible of transfusion medicine in Japan. Other great contributions from the department are as follows. Dr. Kazuo Okochi, ex-lecturer of the department, is the pioneer in the field of transfusion-associated hepatitis research, ex-Professor Takeo Juji clarified the mechanisms of transfusion-associated graft-versus-host disease (TA-GVHD), a serious post-transfusion complication, and ex-Professor Yoichi Shibata contributed enormously to the field of platelet immunology. In 1997, the Department of Transfusion Medicine was established as a chair of the Division of Internal Medicine of the Graduate School of Medical Sciences, the University of Tokyo.

Actually, the department is composed of 6 medical doctors (4 full-time, and 2 partial-time), 10 laboratory technicians, 2-3 nurses and 1 office assistant.

Clinical activities

The main activity of the department of Transfusion

Medicine is the control, preservation, and provision of safe blood products and their derivatives (including albumin). The control of all blood products in the hospital is centralized to the department, which, in addition, provides information and orientation related to blood transfusion. Transfusion-related laboratory tests and tests for transfusion-transmitted infectious diseases are routine practices of the department, which also actively takes part in the diagnosis, prevention and treatment of adverse reactions and post-transfusion complications. Collection, preservation and provision of autologous blood are also important functions of the department, where the outpatient clinic for autologous blood was established by ex-Professor Koki Takahashi in January 2006. At the outpatient clinic, the first established in Japan, the transfusionist gives consultation to the patients, prepares the adequate blood collection schedule, takes the informed consent, and performs the blood collection, according to the surgeons' needs. Additionally, collection and preservation of peripheral blood stem cells are also performed.

The main activities are as follows:

- I Control and preservation of blood products and its derivatives;
- II. Laboratory tests
 - 1) Blood typing and histocompatibility testing;
 - 2) Detection of anti-erythrocyte, anti-leukocyte

- and anti-platelet antibodies;
- 3) Detection of HBV antigens and antibodies, HCV, HAV, HTLV and HIV antibodies;
- 4) HLA typing for hematopoietic stem cell transplantation and organ transplantation;

III. Clinical work

- 1) Pre-operative autologous blood collection and preservation;
- 2) Collection and preservation of peripheral blood stem cells for transplantation;

Teaching activities

Sixth-grade medical students are provided with practical courses focusing on clinical practice of blood transfusion and laboratory tests. Courses are given in small groups of 6 students each, in a total of 18 groups per year. The course lasts 5 days/week, including the following subjects;

- 1) Visit to the laboratories of the department to understand the routine of a laboratory;
- 2) Introduction to the blood group types (red cells, platelets, leukocytes) and their importance in transfusion medicine and in transplantation (bone marrow and organ);
- 3) Methodology of blood typing and compatibility testing for transfusion;
- 4) Methodology for screening of irregular antibodies, and their importance in transfusion practice;
- 5) Introduction to the post-transfusional complications, their etiology, prevention and treatment.
- 6) Introduction to the preventive measures of blood borne viral transmission, especially focusing on the NAT test and the look-back survey.
- 7) Acquisition of informed consents related to blood transfusion, using the role playing method.
- 8) The indications and techniques of autologous blood collection and preservation;
- 9) The techniques for peripheral blood stem cells (PBSCs) collection and preservation, as well as their clinical application;
- 10) The recent advances in the field of blood transfusion, including the “Blood Law”, and the recently revised “Indications of blood products” and “The principles of transfusion practice”.
- 11) One-day visit to the Japanese Red Cross Blood Center, to learn the general process of blood

donation and transfusion, including the types of blood products, and their indications.

Research activities

Research on red cells, leukocytes, and platelets, the post-transfusional complications, transplantation immunology, immunotherapy, and stem cell biology are the main themes of the department. Typing of blood cells is performed by serological and DNA-based methods. The HLA typing, which was introduced by ex-Professor Takeo Juji, one of the pioneers of this field, is an essential test for hematopoietic stem cell and organ transplantations, and still continues as one of the most important research fields of the department. The mixed-passive hemagglutination (MPHA) method, the most popular methodology for platelet serology in Japan, was developed by ex-Professor Yoichi Shibata and its applicability is now extended for granulocyte as well as endothelial cell serology. Transplantation immunology, including stem cell biology is also an important subject. Also, development of new materials for medical use is also being researched. Recently, the risk factors of the detrimental effects of autologous blood donation, especially focusing on the noninvasive measurement of circulating blood volume, are being investigated. Following are the main themes.

- 1. Detection of platelet alloantigens and antibodies and their role in the transfusion practice.
- 2. Diagnosis and prevention of post-transfusional complications and thrombocytopenic purpura of the newborn.
- 3. Clinical application of refrigerated and frozen-stored blood for autologous transfusion in surgical patients, and the improvement of the preservation methods.
- 4. Study on the effect of pre-storage leukoreduction of autologous blood for the prevention of possible adverse effects.
- 5. Development of a new methodology for platelet cross-match.
- 6. HLA and HPA genotyping.
- 7. Development of a new methodology for evaluation of platelet function.
- 8. Ex-vivo expansion of hematopoietic stem cells and their clinical application.

9. Pathophysiology of TRALI and TACO.
10. Study on the risk factors of autologous blood donation.
11. Study on the correlation between the results obtained by conventional coagulation tests and the measurement results of thromboelastograms.

4. Ikeda T, Terada R, Nagura Y, Okazaki H
High-dose intravenous iron supplementation after preoperative autologous blood donation is useful to prevent post-donation/preoperative anemia Transfus Apher Sci. 2022 Jun;61(3):103348.

References

1. Summary" by Cardigan, Rebecca; New, Helen; Estcourt, Lise; Zhiburt, Eugene; Dubey, Rounak; Bengtsson, Jesper; Jöud, Magnus; Castillo, Carlos; Cid, Joan; Lozano, Miquel; Gounder, Dhana; Flanagan, Peter; Morley, Sarah; Clarke, Gwen; Devine, Dana; Hindawi, Salwa; Al Otaibi, Aqeel; Bub, Carolina; Kutner, Jose; Ikeda, Toshiyuki; Goto, Naoko; Okazaki, Hitoshi; Fontaine , Magali; Pasion, Jeremiah; Song, Linda; Latham, Tom; Kerkhoffs, Jean-Louis; De Haas, Masja; Zwaginga, Jaap Jan; Gathof, Birgit; Ommer, Katharina; Pirenne, France; Raba, Michel; François, Anne; Daly, James; Powley, Tanya ; Dunbar, Nancy, International Forum on Policies and Practice for Transfusion of ABO and RhD Non-identical Platelets: Vox Sang 2022 Jan;117(1):136-144.
2. Kazutoshi Ebisawa, Akira Honda, Arika Chiba, Yosuke Masamoto, Hitoshi Okazaki. and Mineo Kurokawa
High D-index during mobilization predicted lower collection of CD34+ cells after anti-lymphoma salvage chemotherapy J Clin Apher 2022 Feb;37(1):4-12.
3. Makoto Kurano , Yoshifumi Morita, Yuki Nakano, Rin Yokoyama, Takuya Shimura , Chungeng Qian , Fuzhen Xia , Fan He, Liang Zheng , Hiroko Ohmiya, Yoshiro Kishi, Jun Okada, Naoyuki Yoshikawa, Kazuki Nakajima, Yutaka Nagura, Hitoshi Okazaki, Daisuke Jubishi, Kyoji Moriya, Yasuyuki Seto, Fumihiko Yasui, Michinori Kohara, Masatoshi Wakui, Takeshi Kawamura, Tatsuhiko Kodama, Yutaka Yatomi
Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers Int Immunopharmacol 2022 Feb;103:108491.

Reproductive, Developmental and Aging Sciences

1. Obstetrics and Gynecology

Department of Reproductive Endocrinology

Professors

Yutaka Osuga

Homepage http://www.h.u-tokyo.ac.jp/patient/depts/a_joseika02/index.html
#reproduction
<https://www.gynecology-htu.jp/>

Organization

The Department of Reproductive Endocrinology is organized by Assistant Professors Takeshi Nagamatsu. All the staff members are taking part in both clinical and research activities. For the clinical aspect, we are engaged with in-patient and out-patient care including the activities in the delivery units.

Activities

In clinical section, we have an out-patient clinic for infertility, gynecological endocrine diseases, genetic counseling and assisted reproductive technologies (ART).

We have a highly organized infertility clinic, where every patient is systemically examined and after diagnosis of underlying infertility factor (s) appropriate treatment is performed following our protocol. Once it turns out that higher level of treatment is necessary, ART is applied to such cases. We have been engaged in *in vitro* fertilization and embryo transfer (IVF-ET) as a main axis of ART for twenty years. Conventional IVF-ET is mainly indicated to cases with tubal factor, mild male factor, immunological factor or of unexplained infertility factor. In case of severe male factor or other fertilization disorder intracytoplasmic sperm injection (ICSI) is performed. Now we have about 220 OPU cycles of IVF-ET every year, which conventional IVF-ET and ICSI share almost equally. The clinical pregnancy rate of conventional IVF-ET is around 30% per embryo transfer cycle, which is

comparable with that of ICSI. Other ART techniques such as embryo cryopreservation and assisted hatching are also performed.

In basic research section, a couple of projects as follows are under way, some of which have already yielded interesting findings; 1) the mechanism of folliculogenesis and follicular apoptosis in the ovary, 2) the functions of gynecologic hormones such as gonadotropins and ovarian steroids, 3) the analysis / etiology of endometriosis, adenomyosis and fibroma and so on.

References published in 2022

1. Hosoya S, Piedvache A, Nakamura A, Nasu R, Hine M, Itoi S, Yokomizo R, Umezawa A, Hiraie O, Koga K, Osuga Y, Narumi S, Morisaki N. Prolongation of the Menstrual Cycle After Receipt of the Primary Series and Booster Doses of mRNA Coronavirus Disease 2019 (COVID-19) Vaccination. *Obstet Gynecol.* 2023 Dec 14.
2. Hiratsuka D, Omura E, Ishizawa C, Iida R, Fukui Y, Hiraoka T, Akaeda S, Matsuo M, Harada M, Wada-Hiraie O, Osuga Y, Hirota Y. Pregnancy is associated with reduced progression of symptomatic adenomyosis: a retrospective pilot study. *BMC Pregnancy Childbirth.* 2023 Sep 4;23(1):634.
3. Hiraie O, Koga K, Taniguchi F, Harada T, Takeshita T, Shiota M, Osuga Y. A nationwide survey of the use of the laparoscopic power

- morcellator.; Laparoscopic power morcellator Research Committee in Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy (JSGOE). *J Obstet Gynaecol Res.* 2023 Feb;49(2):682-690
4. Uehara M, Hiraie O, Hirano M, Harada M, Koga K, Yoshimura N, Tanaka S, Osuga Y. Evaluation of atherosclerosis-related biomarkers during perimenopause: A prospective cohort study in women with endometriosis. *J Obstet Gynaecol Res.* 2022 Dec;48(12):3160-3170
 5. Harada T, Taniguchi F, Kitajima M, Kitawaki J, Koga K, Momoeda M, Mori T, Murakami T, Narahara H, Osuga Y, Yamaguchi K. Clinical practice guidelines for endometriosis in Japan (The 3rd edition). *J Obstet Gynaecol Res.* 2022 Dec;48(12):2993-3044.
 6. Maeda E, Hiraie O, Sugimori H, Kinoshita A, Hirao M, Nomura K, Osuga Y. Working conditions contribute to fertility-related quality of life: a cross-sectional study in Japan. *Reprod Biomed Online.* 2022 Dec;45(6):1285-1295.
 7. Ishizawa C, Hirota Y, Iida R, Kaku T, Hirata T, Fukui Y, Omura E, Akaeda S, Hiraoka T, Matsuo M, Osuga Y. Levonorgestrel-Releasing Intrauterine System Improves Menorrhagia-Related Quality of Life in Patients with Symptomatic Adenomyosis. *Reprod Sci.* 2023 Mar;30(3):966-973. doi: 10.1007/s43032-022-01077-9. Epub 2022 Sep 7. PMID: 36071343
 8. Uehara M, Wada-Hiraie O, Koga K, Yamamoto N, Hirano M, Harada M, Hirota Y, Osuga Y. Prediction of the final menstrual period in women taking Dienogest using estradiol and follicle-stimulating hormone values: a case-control study. *Endocr J.* 2022 Dec 28;69(12):1437-1445.
 9. Iwata M, Oikawa Y, Shimizu Y, Sakashita N, Shoji A, Igarashi A, Osuga Y. Efficacy of Low-Dose Estrogen-Progestins and Progestins in Japanese Women with Dysmenorrhea: A Systematic Review and Network Meta-analysis. *Adv Ther.* 2022 Nov;39(11):4892-4909.
 10. Yamada M, Ishikawa T, Iwasa T, Oishi H, Osuka S, Oka K, Ono S, Ono M, Orisaka M, Kanasaki H, Kawano Y, Kawamura K, Kishi H, Kimura F, Kuroda S, Kuwahara A, Kobayashi H, Komiya A, Saito H, Sato K, Sato S, Shiraishi K, Shirasawa H, Suzuki T, Takai Y, Takae S, Takahashi T, Takiuchi T, Tachibana M, Tamura I, Tamura H, Jwa SC, Baba T, Harada M, Hirata T, Fukui A, Fukuda Y, Fukuhara S, Maruyama T, Yumura Y, Yoshino O, Hirota Y, Tsujimura A, Kuji N, Osuga Y. Guidelines for Reproductive Medicine in Japan. *Reprod Med Biol.* 2022 Aug 24;21(1)
 11. Nagashima N, Hirata T, Arakawa T, Neriishi K, Sun H, Harada M, Hirota Y, Koga K, Wada-Hiraie O, Osuga Y. Long-term conservative management of symptomatic bladder endometriosis: A case series of 17 patients. *Taiwan J Obstet Gynecol.* 2022 Jul;61(4):606-611.
 12. Takahashi H, Tanaka H, Osuga Y, Miura K, Saito S, Sato S, Sugawara J, Ide S, Koh I, Yamauchi K, Okuyama A, Okuno K, Kuwata T, Fujieda S, Ikeda T. Retained products of conception (RPOC) following delivery without placenta previa: Which patients with RPOC show postpartum hemorrhage? *Placenta.* 2022 Jun 24;124:12-17.
 13. Uehara M, Wada-Hiraie O, Hirano M, Koga K, Yoshimura N, Tanaka S, Osuga Y. Relationship between bone mineral density and ovarian function and thyroid function in perimenopausal women with endometriosis: a prospective study. *BMC Womens Health.* 2022 Apr 27;22(1):134.
 14. Wada-Hiraie O, Yamada S, Osuga Y. An extremely rare case of pituitary functioning gonadotroph microadenoma accompanied by ovarian hyperstimulation syndrome in a woman of reproductive age. *F S Rep.* 2022 Feb 3;3(1):79-83.
 15. Katagiri Y, Jwa SC, Kuwahara A, Iwasa T, Ono M, Kato K, Kishi H, Kuwabara Y, Harada M, Hamatani T, Osuga Y. Assisted reproductive technology in Japan: A summary report for 2019 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology. *Reprod Med Biol.* 2021 Dec 14;21(1)
 16. Kunitomi C, Harada M, Sanada Y, Kusamoto A, Takai Y, Furui T, Kitagawa Y, Yamada M, Watanabe C, Tsugawa K, Nishiyama H, Hosoi H, Miyachi M, Sugiyama K, Maeda Y, Kawai A, Hamatani T, Fujio K, Suzuki N, Osuga Y. The possible effects of the Japan Society of Clinical

- Oncology Clinical Practice Guidelines 2017 on the practice of fertility preservation in female cancer patients in Japan. *Reprod Med Biol*. 2022 Mar 21;21(1):e12453.
17. Ono M, Matsumoto K, Boku N, Fujii N, Tsuchida Y, Furui T, Harada M, Kanda Y, Kawai A, Miyachi M, Murashima A, Nakayama R, Nishiyama H, Shimizu C, Sugiyama K, Takai Y, Fujio K, Morishige KI, Osuga Y, Suzuki N. Correction to: Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases. *Int J Clin Oncol*. 2022 Apr;27(4):825-826.
 18. Tozawa A, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Harada M, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Suzuki N, Osuga Y. Correction to: Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2. *Int J Clin Oncol*. 2022 Mar;27(3):635-637.
 19. Tozawa A, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Harada M, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Suzuki N, Osuga Y. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2. *Int J Clin Oncol*. 2022 Feb;27(2):281-300.
 20. Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Tozawa A, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Osuga Y, Suzuki N. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1. *Int J Clin Oncol*. 2022 Feb;27(2):265-280.
 21. Kuji S, Harada M, Yoshioka N, Kajiyama H, Satoh T, Mikami M, Shozu M, Enomoto T, Osuga Y, Suzuki N. Survival and reproductive outcomes after fertility-sparing surgery performed for borderline epithelial ovarian tumor in Japanese adolescents and young adults: Results of a retrospective nationwide study. *J Obstet Gynaecol Res*. 2022 Mar;48(3):806-816.
 22. Harada T, Osuga Y, Suzuki Y, Fujisawa M, Fukui M, Kitawaki J. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuporelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. *Fertil Steril*. 2022 Mar;117(3):583-592.
 23. Ono M, Matsumoto K, Boku N, Fujii N, Tsuchida Y, Furui T, Harada M, Kanda Y, Kawai A, Miyachi M, Murashima A, Nakayama R, Nishiyama H, Shimizu C, Sugiyama K, Takai Y, Fujio K, Morishige KI, Osuga Y, Suzuki N. Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases. *Int J Clin Oncol*. 2022 Feb;27(2):301-309.

Department of Gynecologic Oncology

Associate Professor

Yutaka Osuga, Yasushi Hirota

Homepage <https://www.gynecology-htu.jp/>

Organization

The Department of Gynecologic Oncology is organized by one professor and one associate professors, being directed practically by Professor Yutaka Osuga, the Department of Obstetrics and Gynecology. The staff members are taking part in clinical and research activities as well as teaching activities.

Activities

In the clinical activities, more than 150 patients with gynecological cancer and more than one thousand patients with benign gynecological diseases are treated in our department every year. Appropriate combinations of surgical treatment, chemotherapy and radiotherapy have been chosen according to the patients' conditions, and favorable clinical outcomes have been achieved. Minimally-invasive surgery is frequently employed in the treatment of benign and gynecological tumors and genital organ malformation. We take charge of more than 400 cases of endoscopic gynecological surgery including robotically-assisted laparoscopic surgery annually. We also employ the clinical trials of JCOG (Japan Clinical Oncology Group) and JGOG (Japanese Gynecologic Oncology Group) as well as the single-institution clinical trials. Advanced treatment performed in our department is as follows:

- (1) Cancer genomic medicine (Genetic tests of the hereditary gynecologic cancers)
- (2) Radical trachelectomy for women of childbearing age with early cervical cancer

- (3) Laparoscopic sacralcolpopexy for pelvic organ prolapse
- (4) Adenomyomectomy

Based on our knowledge and experience in this field, we also perform clinical, translational and basic research energetically. Our department focuses on the pathogenesis and the pathophysiology of malignant gynecological diseases such as cervical, endometrial and ovarian cancers, and benign diseases such as endometriosis and adenomyosis. Our ongoing projects are as follows:

- (1) Establishment of new therapeutic approach targeting histone modification enzymes in gynecological malignancies
- (2) Search for epigenomic biomarkers using deep learning in gynecological malignancies
- (3) Development of an automated hysteroscopic diagnosis system for gynecological diseases using deep learning
- (4) Control mechanism of genome stability in gynecological malignancies
- (5) Search for novel biomarkers using germline and somatic variants in gynecological cancers
- (6) Genomic approach to elucidate the pathogenesis and pathophysiology of endometriosis and adenomyosis
- (7) Immunological aspects in the pathophysiology of endometriosis

References published in 2022

1. Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology

- Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases. Ono M, Matsumoto K, Boku N, Fujii N, Tsuchida Y, Furui T, Harada M, Kanda Y, Kawai A, Miyachi M, Murashima A, Nakayama R, Nishiyama H, Shimizu C, Sugiyama K, Takai Y, Fujio K, Morishige KI, Osuga Y, Suzuki N. *Int J Clin Oncol*. 2022 Feb;27(2):301-309.
2. Histone arginine methyltransferase CARM1 selective inhibitor TP-064 induces apoptosis in endometrial cancer. Inoue F, Sone K, Toyohara Y, Tanimoto S, Takahashi Y, Kusakabe M, Kukita A, Honjoh H, Nishijima A, Taguchi A, Miyamoto Y, Tanikawa M, Iriyama T, Uchino MM, Tsuruga T, Wada-Hiraike O, Oda K, Osuga Y. *Biochem Biophys Res Commun*. 2022 Apr 23; 601:123-128.
 3. MED1, a novel binding partner of BRCA1, regulates homologous recombination and R-loop processing. Honjoh H, Tanikawa M, Wada-Hiraike O, Oda K, Inaba H, Kukita A, Kawata Y, Kusakabe M, Tsuchimochi S, Taguchi A, Miyamoto Y, Sone K, Tsuruga T, Mori-Uchino M, Matsumoto Y, Osuga Y. *Sci Rep*. 2022 Oct 13;12(1):17140.
 4. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R. *Commun Biol*. 2022 Jan 11;5(1):39.
 5. Development of a deep learning method for improving diagnostic accuracy for uterine sarcoma cases. Toyohara Y, Sone K, Noda K, Yoshida K, Kurokawa R, Tanishima T, Kato S, Inui S, Nakai Y, Ishida M, Gonoi W, Tanimoto S, Takahashi Y, Inoue F, Kukita A, Kawata Y, Taguchi A, Furusawa A, Miyamoto Y, Tsukazaki T, Tanikawa M, Iriyama T, Mori-Uchino M, Tsuruga T, Oda K, Yasugi T, Takechi K, Abe O, Osuga Y. *Sci Rep*. 2022 Nov 16;12(1):19612.
 6. Effect of primary prophylaxis with pegfilgrastim in endometrial cancer patients treated with doxorubicin and cisplatin. Tojima Y, Taguchi A, Mori M, Nara K, Miyamoto Y, Tanikawa M, Sone K, Tsuruga T, Yamamoto T, Oda K, Suzuki H, Osuga Y. *Taiwan J Obstet Gynecol*. 2022 Mar;61(2):265-269.
 7. Suspicious Positive Peritoneal Cytology (Class III) in Endometrial Cancer Does Not Affect Prognosis. Sone K, Suzuki E, Taguchi A, Honjoh H, Nishijima A, Eguchi S, Miyamoto Y, Iriyama T, Mori M, Osuga Y. *J Clin Med*. 2022 Nov 3;11(21):6527.
 8. Manual vacuum aspiration (women's MVA) for endometrial biopsy for patients with suspected endometrial malignancies. Saito E, Matsumoto Y, Nitta S, Fujino S, Tsuruga T, Mori-Uchino M, Iwase H, Kasamatsu T, Kugu K, Osuga Y. *J Obstet Gynaecol Res*. 2022 Nov;48(11):2896-2902.
 9. Cells with stem-like properties are associated with the development of HPV18-positive cervical cancer. Kusakabe M, Taguchi A, Tanikawa M, Wagatsuma R, Yamazaki M, Tsuchimochi S, Toyohara Y, Kawata A, Baba S, Ueno T, Sone K, Mori-Uchino M, Ikemura M, Matsunaga H, Nagamatsu T, Wada-Hiraike O, Kawazu M, Ushiku T, Takeyama H, Oda K, Kawana K, Mano H, Osuga Y. *Cancer Sci*. 2023 Mar;114(3): 885-895.
 10. Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma. Taguchi A, Rokutan H, Oda K, Tanikawa M, Tanimoto S, Sone K, Mori M, Tsuruga T, Kohsaka S, Tatsuno K, Shinozaki-Ushiku A, Miyagawa K, Mano H, Aburatani H, Ushiku T, Osuga Y. *BMC Med Genomics*. 2022 Mar 7;15(1):51.
 11. Prognosis of high-risk human papillomavirus-related cervical lesions: A hidden Markov model analysis of a single-center cohort in Japan. Ikesu R, Taguchi A, Hara K, Kawana K, Tsuruga T, Tomio J, Osuga Y. *Cancer Med*. 2022 Feb;11(3): 664-675.
 12. Endometrial cancer with concomitant endometriosis is highly associated with ovarian endometrioid carcinoma: a retrospective cohort study. Ishizaka A, Taguchi A, Tsuruga T, Maruyama M, Kawata A, Miyamoto Y, Tanikawa M, Ikemura M, Sone K, Mori M, Koga

- K, Ushiku T, Oda K, Osuga Y. *BMC Womens Health*. 2022 Aug 5;22(1):332.
13. Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report. Sone K, Kukita A, Masui Y, Yamada D, Shinozaki-Ushiku A, Kawata A, Taguchi A, Miyamoto Y, Tanikawa M, Iriyama T, Mori-Uchino M, Tsuruga T, Osuga Y. *Mol Clin Oncol*. 2022 Mar; 16(3):63.
 14. Transiently elevated D-dimer levels post-concentrated ascites reinfusion therapy cannot be used to predict deep vein thrombosis-pulmonary embolism. Sone K, Taguchi A, Kawata A, Eguchi S, Miyamoto Y, Tanikawa M, Uchino-Mori M, Iriyama T, Tsuruga T, Osuga Y. *J Obstet Gynaecol Res*. 2022 Mar;48(3):817-823.
 15. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells. Kukita A, Sone K, Kaneko S, Kawakami E, Oki S, Kojima M, Wada M, Toyohara Y, Takahashi Y, Inoue F, Tanimoto S, Taguchi A, Fukuda T, Miyamoto Y, Tanikawa M, Mori-Uchino M, Tsuruga T, Iriyama T, Matsumoto Y, Nagasaka K, Wada-Hiraike O, Oda K, Hamamoto R, Osuga Y. *Cancers (Basel)*. 2022 Oct 31;14(21):5367.
 16. Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: A case enrolled in the BELIEVE trial. Yoshimoto D, Taguchi A, Tanikawa M, Sone K, Shimoi T, Tsuruga T, Oda K, Osuga Y. *J Obstet Gynaecol Res*. 2022 Jul;48(7):2010-2014.

Department of Perinatal Medicine

Professor

Osuga Yutaka

Homepage <https://www.obstetrics-htu.jp/english/>

Organization

The Department of Perinatal Medicine is organized by one professor and one associate professor, being directed practically by Professor Tomoyuki Fujii, the chairman of the Department of Obstetrics and Gynecology. All the staff members take part in both clinical and research activities, as well as teaching activities, with about 20 associates of the University of Tokyo Hospital. From the clinical aspect, they are engaged with in-patient and out-patient care including the activities in the delivery units.

Activities

Clinical service for perinatology in the University of Tokyo Hospital consists of out-patient clinic and the delivery unit. [See Delivery Unit of the University of Tokyo Hospital]

With the advance of the techniques for prenatal diagnosis of pathological pregnancies and congenital malformations, the area of fetal medicine is spreading. Intensive scrutiny using ultrasonography makes it possible to clarify background causes of fetal growth restriction. New techniques for genetic analysis have been introduced into prenatal diagnosis. The perinatologists and medical engineering team in our department are working on clinical research to clarify the pathoetiology of preterm birth and preeclampsia. Perineal ultrasound is a new approach for assessing labor progress. Using this technique, our challenge is to establish novel clinical approach for precise and objective evaluation of labor progression which can contribute to safer labor management. Pregnancy complicated with adenomyosis is associated with variety of adverse perinatal events, such as second trimester miscarriage, preeclampsia, and placental

malposition. Our mission is to establish optimal clinical management which improves perinatal outcomes for both the mother and the neonate.

Recurrent pregnancy loss (RPL) is a condition in which a woman has two or more clinical pregnancy losses. Our department has been providing a “special clinic for RPL”. About 150 new couples with RPL visit us every year. Underlying causes of RPL are identified by screening tests. Anatomical, chromosomal, hormonal, biological, and autoimmune factors can trigger RPL. For RPL women with autoimmune factors, especially with antiphospholipid antibodies, anti-coagulation therapy using heparin and low dose aspirin is performed. For low risk group, low dose aspirin is administered. Causative factor is not detectable in half of the women with RPL. Supportive care rather than pharmacological intervention is important for those women. In our clinic, mental stress in RPL women is evaluated using K6 scale. We are investigating the relationship between their mental status and the outcome in the subsequent pregnancy.

After a renewal of the inpatient's wards for obstetrics and NICU/GCU/PICU in 2019, the new perinatal medical center restarted as one of the largest facility in Japan and is accommodated with full capacity to treat with all maternal and fetal diseases. We are proud to provide advanced medical care for every patient.

References published in 2022

1. Iriyama T, Sayama S, Osuga Y. Role of adenosine signaling in preeclampsia. *J Obstet Gynaecol Res.* 2022 Jan;48(1):49-57.

2. Nakanishi M, Iriyama T, Sayama S, Hanaoka S, Toshimitsu M, Seyama T, Sone K, Kumasawa K, Nagamatsu T, Osuga Y. Pregnancy-induced hemorrhagic degeneration of adenomyosis. *J Obstet Gynaecol Res.* 2022 May;48(5):1265-1270.
3. Mimura N, Nagamatsu T, Morita K, Taguchi A, Toya T, Kumasawa K, Iriyama T, Kawana K, Inoue N, Fujii T, Osuga Y. Suppression of human trophoblast syncytialization by human cytomegalovirus infection. *Placenta.* 2022 Jan; 117:200-208.
4. Kasuya M, Akiba N, Iriyama T, Sayama S, Kubota K, Toshimitsu M, Seyama T, Sone K, Kumasawa K, Nagamatsu T, Fujii T, Osuga Y. The impact of fetal growth restriction in diagnosing preeclampsia on the severity of maternal features. *J Obstet Gynaecol Res.* 2022 Apr;48(4):912-919.
5. Kato K, Nagamatsu T, Yamaguchi S, Ichinose M, Sayama S, Toshimitsu M, Seyama T, Kumasawa K, Iriyama T, Osuga Y. Changes in fetal presentation in the preterm period and the prediction of non-cephalic delivery. *J Matern Fetal Neonatal Med.* 2023 Dec;36(1):2141564.
6. Sayama S, Iriyama T, Nakayama T, Seyama T, Sone K, Kumasawa K, Nagamatsu T, Suzuki K, Fujii T, Osuga Y. Prenatal diagnosis of pyriform sinus fistula using ultrasonography by detecting the communication to the pharynx. *Taiwan J Obstet Gynecol.* 2022 Mar;61(2):385-387.
7. Katoh Y, Iriyama T, Yano E, Sayama S, Seyama T, Kotajima-Murakami H, Sato A, Sakuma H, Iguchi Y, Yoshikawa M, Inaoka N, Ichinose M, Toshimitsu M, Sone K, Kumasawa K, Nagamatsu T, Ikeda K, Osuga Y. Increased production of inflammatory cytokines and activation of microglia in the fetal brain of preeclamptic mice induced by angiotensin II. *J Reprod Immunol.* 2022 Dec;154:103752.
8. Yoshikawa M, Seyama T, Iriyama T, Sayama S, Fujii T, Toshimitsu M, Nakaya M, Kurokawa R, Shibata E, Watadani T, Kumasawa K, Nagamatsu T, Koga K, Osuga Y. A Case of Preeclampsia with Uterine Necrosis after Uterine Artery Embolization for Postpartum Hemorrhage. *Case Rep Obstet Gynecol.* 2022 May 17;2022: 2859766.
9. Yano E, Iriyama T, Hanaoka S, Sayama S, Ichinose M, Toshimitsu M, Seyama T, Sone K, Kumasawa K, Nagamatsu T, Kobayashi K, Fujii T, Osuga Y. Anatomical identification of ischial spines applicable to intrapartum transperineal ultrasound based on magnetic resonance imaging of pregnant women. *J Matern Fetal Neonatal Med.* 2022 Dec;35(25):9736-9741.
10. Ichinose M, Iriyama T, Sayama S, Toshimitsu M, Seyama T, Sone K, Kumasawa K, Nagamatsu T, Hanaoka S, Osuga Y. Postpartum degeneration of adenomyosis with diffuse cyst-like changes and localized hemorrhage detected by sequential magnetic resonance imaging. *J Obstet Gynaecol Res.* 2022 Nov;48(11):2973-2978.
11. Yano E, Iriyama T, Sayama S, Ariyosi Y, Akiba N, Ichinose M, Toshimitsu M, Seyama T, Sone K, Kumasawa K, Nagamatsu T, Nakayama T, Kobayashi K, Osuga Y. The head direction to the angle of progression ratio: a quantitative parameter for intrapartum evaluation of cephalic malposition. *Am J Obstet Gynecol MFM.* 2023 Jan;5(1):100755.
12. Sayama S, Iriyama T, Takeda N, Yamauchi H, Toshimitsu M, Seyama T, Sone K, Kumasawa K, Nagamatsu T, Fujii T, Osuga Y. Proposed Management Policy for Pregnant Women with Loeys-Dietz Syndrome Following Prophylactic Aortic Root Replacement Based on Experience from a Tertiary Care Center. *Int Heart J.* 2022; 63(1):176-179.

Department of Molecular and Cellular Reproductive Medicine

Professor

Yutaka Osuga

Associate Professor

Osamu Hiraike

Homepage <https://www.gynecology-htu.jp/>

Organization

The Department of Molecular and Cellular Reproductive Medicine is organized by one professor and one associate professor.

Activities

Our department mainly aims to investigate the reproductive endocrinology, and molecular biological methods are utilized to accomplish this purpose. Basic researches are currently performed and we report many interesting findings annually. We specifically focus on the role of inflammation and transcription machinery in these issues. Senescence and aging process are also extensively investigated.

- 1) The mechanism of folliculogenesis, follicular atresia and intrafollicular microenvironment in the ovary.
- 2) The physiological functions of sex steroid hormones and gonadotropins.
- 3) The molecular mechanisms of endometriosis.
- 4) The molecular mechanisms of uterine fibroid and adenomyosis.
- 5) The effects of aging and cellular senescence on the reproductive system.

In clinical section, we have an out-patient clinic for infertility, gynecological endocrine disorders and genetic counseling. We also perform minimally invasive surgery for benign gynecological diseases including endometriosis, uterine fibroid, adenomyosis,

infertility, and pelvic organ prolapse. More than 90% of surgery cases for benign gynecological disorders are operated using endoscope, and we deal with more than 400 cases annually.

In accordance with the notion of life stage specific approaches, we also manage patients complaining primary/secondary amenorrhea, infertility, dysmenorrhea, heavy menstrual bleeding, and climacterium. Osteoporosis in their 10's to 20's and perimenopausal age could be a heavy burden for patients and we have already established the primary care system for these women. Numerous number of female athletes refer to our clinic as well.

References published in 2022

1. Elsherbini M, Koga K, Maki E, Kumasawa K, Satake E, Taguchi A, Makabe T, Takeuchi A, Izumi G, Takamura M, Harada M, Hirata T, Hirota Y, Wada-Hiraike O, Osuga Y. Impact of Chronic Exposure to Endometriosis on Perinatal Outcomes: Establishment of a Mouse Model. *Biomedicine*. 2022 Oct 19;10(10):2627.
2. Elsherbini M, Koga K, Hiraoka T, Kumasawa K, Maki E, Satake E, Taguchi A, Makabe T, Takeuchi A, Izumi G, Takamura M, Harada M, Hirata T, Hirota Y, Wada-Hiraike O, Osuga Y. Establishment of a novel mouse model of adenomyosis suitable for longitudinal and quantitative analysis and perinatal outcome studies. *Sci Rep*. 2022 Oct 20;12(1)

3. Koike H, Harada M, Kusamoto A, Kunitomi C, Xu Z, Tanaka T, Urata Y, Nose E, Takahashi N, Wada-Hiraike O, Hirota Y, Koga K, Osuga Y. Notch Signaling Induced by Endoplasmic Reticulum Stress Regulates Cumulus-Oocyte Complex Expansion in Polycystic Ovary Syndrome. *Biomolecules*. 2022 Jul 27;12(8):1037.
4. Sun H, Hirata T, Koga K, Arakawa T, Nagashima N, Neriishi K, Elsherbini M, Maki E, Izumi G, Harada M, Hirota Y, Wada-Hiraike O, Osuga Y. Elevated phosphorylation of estrogen receptor α at serine-118 in ovarian endometrioma. *F S Sci*. 2022 Nov;3(4):401-409.
5. Hiratsuka D, Aikawa S, Hirota Y, Fukui Y, Akaeda S, Hiraoka T, Matsuo M, Osuga Y. DNA Methylation and Histone Modification Are the Possible Regulators of Preimplantation Blastocyst Activation in Mice. *Reprod Sci*. 2023 Feb;30(2):494-525.
6. Hirakawa T, Yotsumoto F, Shirasu N, Kiyoshima C, Urushiyama D, Yoshikawa K, Miyata K, Kurakazu M, Koga KA, Aoki M, Nabeshima K, Koga KS, Osuga Y, Komatsu H, Taniguchi F, Harada T, Yasunaga S, Miyamoto S. Trophic and immunomodulatory effects of adipose tissue derived stem cells in a preclinical murine model of endometriosis. *Sci Rep*. 2022 May 16;12(1):8031.
7. Aikawa S, Hirota Y, Fukui Y, Ishizawa C, Iida R, Kaku T, Hirata T, Akaeda S, Hiraoka T, Matsuo M, Osuga Y. A gene network of uterine luminal epithelium organizes mouse blastocyst implantation. *Reprod Med Biol*. 2022 Jan 5;21(1):
8. Hiraoka T, Hirota Y, Aikawa S, Iida R, Ishizawa C, Kaku T, Hirata T, Fukui Y, Akaeda S, Matsuo M, Shimizu-Hirota R, Takeda N, Osuga Y. Constant Activation of STAT3 Contributes to the Development of Adenomyosis in Females. *Endocrinology*. 2022 May 1;163(5)
9. Fukui Y, Hirota Y, Aikawa S, Ishizawa C, Iida R, Kaku T, Hirata T, Akaeda S, Hiraoka T, Matsuo M, Osuga Y. Uterine Receptivity is Reflected by LIF Expression in the Cervix. *Reprod Sci*. 2022 May;29(5):1457-1462.

Reproductive, Developmental and Aging Sciences

2. Pediatric Sciences

Department of Pediatrics, Department of Developmental Pediatrics

Professor

Motohiro Kato, M.D., Ph.D.

Naoto Takahashi, M.D., Ph.D. (Department of Pediatric and Neonatal Intensive Care Unit)

Associate Professor

Yutaka Harita, M.D., Ph.D., Hikoro Matsui M.D., Ph.D.

Lecturer

Ryo Inuzuka, M.D., Ph.D., Shoichiro Kanda, M.D.,Ph.D., Kohei Kashima, M.D.,Ph.D.
(Department of Maternal, Fetal and Neonatal Medicine)

Project Lecturer

Atsushi Sato, M.D.,Ph.D., Yuko Kajiho, M.D.,Ph.D., Akiko Kinumaki, M.D.,Ph.D.

Research Associate

Mami Kobayashi, M.D., Takako Matsuoka, M.D.,Ph.D., Shunpei Uchino, M.D.,Ph.D.,
Hiroshi Terashima, M.D., Takanobu Inoue, M.D.,Ph.D., Hitomi Masuda, M.D.,
Yoshihiko Shitara, M.D., Takeo Mukai, M.D.,Ph.D., Atsushi Ito, M.D.,Ph.D.,
Kentaro Watanabe, M.D.,Ph.D., Yu Tanaka, M.D.,Ph.D., Takuya Oshima, M.D.,
Hiroshi Muto, M.D., Mieko Maezawa, M.D., Kazuhiro Shiraga, M.D.,
Kenichiro Hayashi, M.D., Masahiro Sekiguchi, M.D., Ph.D., Hiroyuki Tanaka, M.D., Ph.D.,
Yu Kakimoto, M.D., Hidetoshi Ohta, M.D., Moe Hidaka, M.D., Kaname Uchida, M.D.,
Koji Hirohata, M.D., Yosuke Ogawa, M.D., Hisataka Nozawa, M.D., Yuriko Katayama,
M.D., Koichi Takamizawa, M.D., Kaname Sato, M.D., Kyosuke Ibi, M.D., Natsuho Adachi,
M.D., Hiroki Kitaoka M.D., Ayumi Kunikata, M.D., Shutaro Inoue, M.D., Yui Ozawa, M.D.,
Marina Tanaka, M.D., Kumiko Uryu, M.D., Rumi Taniguchi, M.D., Yukiko Kuroda, M.D.,
Akiko Shibata, M.D., Miyuki Ota M.D., Etsushi Toyofuku, M.D., Satoko Kobayashi, M.D.,
Ayami Sato, M.D., Keiko Watanabe, M.D.

(As of March 31, 2023)

Homepage <http://square.umin.ac.jp/ped/>

Introduction and Organization

The Department of Pediatrics and the Department of Developmental Pediatrics are sub-divisions of the Reproductive, Developmental and Aging Medicines, at the Graduate School of Medicine at The University of Tokyo. Our staff consists of 2 professors, 2 associate professors, 3 lecturers, 3 project lecturers, 34 research associates on March 31, 2023.

Our outpatient services are housed on the second floor of the outpatient clinic building, while inpatient care is offered at the Pediatric Medical Center located in the inpatient building. Our administrative offices are located at the second floor of the East Research Building. Additionally, our laboratories are situated on the seventh floor of the Clinical Research Center and on the second and third floors of the East Research Building.

Our departments are dedicated to providing high-quality clinical care, teaching, and research in pediatrics and developmental pediatrics. We continually strive to improve our services and offerings to meet the evolving needs of our patients, their families, and the broader community. Our ultimate aim is to become a leading center for pediatric and developmental medical care, not only in Tokyo but also on a global scale.

Clinical activities

Our outpatient pediatric clinics provide care across a broad spectrum of pediatric disorders, including but not limited to hematology/oncology, cardiology, neurology, nephrology, endocrinology, and neonatology. Moreover, patients with conditions related to genetics, pulmonology, and allergology/immunology are attended to by part-time physicians specializing in each field. Additionally, we maintain continuity of care post-discharge through our outpatient clinics, coordinating care that aligns with the specific needs of patients and their families through partnerships with local medical institutions.

We operate specialized clinics covering all fields of pediatric disorders. Pediatric and neonatal patients are admitted to the Pediatric Medical Center where they receive targeted treatments. Since June 2019, we have intensified our focus on critical care, culminating in the establishment of the section for Pediatric and

Perinatal Intensive Care. This includes a Neonatal Intensive Care Unit (NICU) with 21 beds and a Pediatric Intensive Care Unit (PICU) with 12 beds, serving as one of the tertiary centers for pediatric emergencies in the eastern part of Tokyo. Our PICU delivers state-of-the-art monitoring and comprehensive care for children suffering from critical illnesses or injuries, and those with complex medical conditions.

In our NICU and Growing Care Unit (GCU), which has 36 beds, we care for high-risk infants, including premature babies weighing under 500 grams and newborns requiring invasive interventions for congenital disorders. We offer high-quality, specialized medical care as a leading perinatal center in Tokyo, involving multi-disciplinary collaboration with obstetricians, pediatric cardiologists, cardiac surgeons, pediatric surgeons, ophthalmologists, neurosurgeons, among others. Our approach also incorporates family-centered care through coordination with co-medical staff.

In the general ward of the Pediatric Medical Center, we provide comprehensive care for children suffering from a wide range of conditions including hematological/oncological disorders, cardiac conditions, neuromuscular issues, immunological diseases, renal and urinary tract diseases, endocrinological conditions, metabolic disorders, and psychosomatic diseases. This is done in collaboration with related departments. Additionally, our hospital has received accreditation as a provider of chimeric antigen receptor T-cell therapy.

We offer a comprehensive package of support services. These include subsidized housing through McDonald House, an on-site school to help young patients continue their education, and a variety of additional services such as psychosocial support for families, translation services, and volunteer groups.

Teaching activities

M2 students are given pediatric systematic lectures covering each specialty area. M3 students undergo a 2-week participatory ward training (M3 Clinical Clerkship). During the training period, students are assigned to each clinical team and are in charge of

inpatients, taking their medical history, examining them, recording their admission records, and observing various specialized examinations. During the internship in the pediatric ward, the students will do cruises in pediatric neurology, nephrology, transfusion, endocrinology, neonatology, hematology/oncology, cardiology, emergency resuscitation, and others. On Tuesdays, the students will be exposed to and discuss pediatric cases as a whole through online rounds of chart rounds. During the second week of the internship, each student will present their assigned cases to foster experience in presentation skills and question and answer sessions. The M4 clinical clerkship is a one-month program that provides highly specialized training that cannot be experienced in the two-week ward training. Pediatrics with a focus on the typical development of healthy children. The professor or associate professor conducts an examination on the last day. In addition, students are provided with online learning content through the pediatrics educational website.

Research activities

Our research divisions focus on nephrology, hematology/oncology, neurology, cardiology, endocrinology/metabolism, immunology/allergy, and neonatology. We also operate interdisciplinary research groups that focus on areas like cell biology, genetic molecular biology, and epidemiology. The highlights of our research activities over the past year are as follows:

Hematology/Oncology group:

Our division has performed whole-genome sequencing (WGS), whole-exome sequencing (WES), and RNA-sequencing to characterize the genetic landscapes of several pediatric cancers, including leukemia, brain tumors, and soft tissue sarcomas.

Nephrology group:

Our aim is to reveal the molecular mechanism of pediatric kidney diseases. We identified novel causative mutations on several proteinuric diseases including pediatric nephrotic syndrome and congenital anomalies of the kidney and urinary tract. We are also developing a novel urinary test using urinary extracellular vesicles.

Endocrinology and Metabolism group:

We are analyzing genes and mechanisms involved in endocrinology and metabolic diseases. We analyze the molecular biological mechanisms using model animals and iPS cells. We are also studying pathways in growth plate cartilage in relation to pediatric growth and development, including single-cell RNA analysis using mouse and human specimens.

Cardiology group:

To reveal the molecular mechanism of cardiomyopathy, we performed genome-wide association studies and generated an animal model for cardiomyopathy. Additionally, we perform hemodynamic analysis for patients with congenital heart disease using clinical imaging modalities.

Neurology Group:

After a clinical trial of valganciclovir for congenital cytomegalovirus infection has shown therapeutic efficacy for recovering hearing difficulty, we continue to follow up on hearing and psychomotor development.

Neonatology group:

Epigenetic changes in cord blood and postnatal peripheral blood of preterm and SGA infants are investigated using epigenome-wide methylation analysis. The influence of gut microbiome on neonatal immune function and nutritional status is also investigated. Cytokine profiles have been investigated in order to elucidate pathophysiology of several diseases in perinatal period. Molecular mechanism of neonatal immune tolerance is also an important research topic in the group.

PICU group:

The Pediatric Intensive Care Unit (PICU) Group promotes research originating from clinical practice. The group conducts research directly related to understanding, evaluating, and treating pathological conditions in clinical practice, including biological response research using bedside physiological data, such as heart rate variability analysis, quantification of nerve reflexes, evaluation of cerebral blood flow regulation, and pulse wave analysis; medical safety research using DWH; development of new diagnostic equipment and evaluation systems using AI; and development of novel bedside digital fundoscope. We are conducting research directly related to the understanding, evaluation, and treatment of pathological conditions in clinical practice.

Selected References

1. Takizawa K, Ueda K, Sekiguchi M, Nakano E, Nishimura T, Kajiho Y, Kanda S, Miura K, Hattori M, Hashimoto J, Hamasaki Y, Hisano M, Omori T, Okamoto T, Kitayama H, Fujita N, Kuramochi H, Ichiki T, Oka A, Harita Y. Urinary extracellular vesicles signature for diagnosis of kidney disease. *iScience*. 25(11): 105416, 2022
2. Nakamura M, Kanda S, Kajiho Y, Hinata M, Tomonaga K, Fujishiro J, Harita Y. A case of right hypodysplastic kidney and ectopic ureter associated with bicornuate uterus in a prepubertal girl. *CEN Case Rep*. 12(1):122-129, 2023
3. Miura K, Kaneko N, Hashimoto T, Ishizuka K, Shirai Y, Hisano M, Chikamoto H, Akioka Y, Kanda S, Harita Y, Yamamoto T, Hattori M. Precise clinicopathologic findings for application of genetic testing in pediatric kidney transplant recipients with focal segmental glomerulosclerosis/steroid-resistant nephrotic syndrome. *Pediatr Nephrol*. 38(2):417-429, 2023
4. Critical brainstem encephalitis/encephalopathy in a child with COVID-19. Kunikata A, Hayashi K, Kinumaki A, Akatsuka Y, Shimoda K, Kato M, Matsui H. *Pediatr Int*. 64 : e15353, 2022
5. Circulating nephrin autoantibodies and posttransplant recurrence of primary focal segmental glomerulosclerosis. Hattori M, Shirai Y, Kanda S, Ishizuka K, Kaneko N, Ando T, Eguchi M, Miura K. *Am J Transplant*. 2022 Oct; 22(10):2478-2480. doi: 10.1111/ajt.17077.
6. Urinary extracellular vesicles signature for diagnosis of kidney disease. Takizawa K, Ueda K, Sekiguchi M, Nakano E, Nishimura T, Kajiho Y, Kanda S, Miura K, Hattori M, Hashimoto J, Hamasaki Y, Hisano M, Omori T, Okamoto T, Kitayama H, Fujita N, Kuramochi H, Ichiki T, Oka A, Harita Y. *iScience*. 2022 Nov 8;25(11): 105416. doi: 10.1016/j.isci.2022.105416.
7. Ibi K, Takahashi N. Assisted reproductive technology and neonatal intensive care unit: A retrospective observational study from a single center. *J Obstet Gynaecol Res*. 2023 Jan;49(1): 273-279. doi: 10.1111/jog.15478. Epub 2022 Oct 25.
8. Takahashi N, Shoji H, Arai H, Tanaka K, Kakiuchi S, Yoda H, Shimizu T. Effect of biotin supplementation in infant formula: A multi-center study in Japan. *Pediatr Int*. 2023 Jan; 65(1):e15359. doi: 10.1111/ped.15359.
9. Morioka I, Kakei Y, Omori T, Nozu K, Fujioka K, Takahashi N, Yoshikawa T, Moriuchi H, Ito Y, Oka A; Japanese Congenital
10. Cytomegalovirus Study Group. Oral Valganciclovir Therapy in Infants Aged ≤ 2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan. *J Clin Med*. 2022 Jun 21; 11(13):3582. doi: 10.3390/jcm11133582.
11. Inuzuka R, Nii M, Inai K, Shimada E, Shinohara T, Kogiso T, Ono H, Otsuki SI,
12. Kurita Y, Takeda A, Hirono K, Takei K, Yasukohchi S, Yoshikawa T, Furutani Y, Shinozaki T, Matsuyama Y, Senzaki H, Tokushige K, Nakanishi T. Predictors of liver cirrhosis and hepatocellular carcinoma among perioperative survivors of the Fontan operation. *Heart*. 2023 Jan 27;109(4):276-282.
13. Dimopoulos K, Constantine A, Clift P, Condliffe R, Moledina S, Jansen K, Inuzuka R, Veldtman GR, Cua CL, Tay ELW, Opatowsky AR, Giannakoulas G, Alonso-Gonzalez R, Cordina R, Capone G, Namuyonga J, Scott CH, D'Alto M, Gamero FJ, Chicoine B, Gu H, Limsuwan A, Majekodunmi T, Budts W, Coghlan G, Broberg CS; for Down Syndrome International (DSi). Cardiovascular Complications of Down Syndrome: Scoping Review and Expert Consensus. *Circulation*. 2023 Jan 31;147(5):425-441.
14. Omori A, Inuzuka R, Matsui H, Hirata Y. Aortic and bronchial perforation caused by a vascular clip 3 years after its placement. *Eur J Cardiothorac Surg*. 2022 Sep 2;62(4):ezac457.
15. Watanabe K, Kimura S, Seki M, Isobe T, Kubota Y, Sekiguchi M et al. Identification of the ultrahigh-risk subgroup in neuroblastoma cases through DNA methylation analysis and its treatment exploiting cancer metabolism. *Oncogene*. 2022;41:4994-5007.
16. Isobe T, Takagi M, Sato-Otsubo A, Nishimura A, Nagae G, Yamagishi C et al. Multi-omics

analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia. *Nature communications*. 2022;13:4501.

17. Hiwatari M, Seki M, Matsuno R, Yoshida K, Nagasawa T, Sato-Otsubo A et al. Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma. *Oncogene*. 2022;41:2789-97.

Department of Pediatric Surgery

Professor

Jun Fujishiro, M.D., Ph.D.

Lecturer

Mariko Yoshida, M.D., Ph.D. Shinya Takazawa, M.D., Ph.D.

Research Associate

Kenichiro Konishi, M.D, Ph.D Toshiko Takezoe, M.D., Ph.D. Keisuke Suzuki, M.D., Ph.D. Tomohiro Sunouchi, M.D Akinori Ichinose, M.D. Takashi Tsutsuno, M.D.

Homepage pedsurg.umin.jp/

History and organization

In 1951, a pediatric surgical team was established in the Department of Second Surgery. Subsequently, in 1961, a pediatric surgical research team, which would eventually research diaphragmatic hernia, was established, with a chief, Dr. Ishida, appointed by Professor Kimoto.

In 1971, the department was authorized to be the first clinical Department of Pediatric Surgery at a national university.

A pediatric intensive care unit was founded by Prof. Ishida in 1973, and the construction of a ward capable of accommodating mainly pediatric surgical patients was completed.

Assistant Prof. Saito assumed office as the first director of this clinical department.

Dr. Sumio Saito became a professor of pediatric surgery in 1983. Professor Saito has enthusiastically performed clinical studies on operation techniques and the use of biliary atresia.

Dr. Toshio Nakajo took office as a professor in 1985. Prof. Nakajo has developed original operative procedures, such as a radical operation for umbilical hernia, and an anti-reflex valve for biliary atresia. These original operative procedures have since been inherited by other pediatric surgeons as Nakajo methods.

Our department was authorized as the Department of

Pediatric Surgery of Kyusyu University by the Ministry of Education in 1989.

Dr. Yoshiaki Tsuchida assumed the role of Professor in 1990 and published many highly regarded articles, mainly concerning neuroblastoma and Wilm's tumor, based on his research and clinical work.

In 1995, the department was reorganized as the Department of Reproductive, Developmental and Aging Science, Pediatric Science and Pediatric Surgery, due to a university policy for the graduate school.

In 1997, Dr. Kohei Hashizume became a professor in the Department of Pediatric Surgery. He started performing living-related partial liver transplantation (LRPLT) for children with Professor Makuuchi in the Department of Second Surgery.

Dr. Tadashi Iwanaka became the sixth professor in August 2006. He engaged in clinical and research activity on pediatric minimally invasive surgery, and retired in 2015. In 2016, Associate Prof. Jun Fujishiro became a chief of the department of pediatric surgery of Tokyo University. In 2019, Dr. Fujishiro promoted to a professor from an associate professor.

The present staff includes one professor and chief, two lecturers, four research associates and nine graduate students. More than 20 members of our department shoulder the clinical work as pediatric surgeons.

Clinical activities

Staff members higher than the level of research associate take charge of the outpatient clinic from Monday through Friday. The pediatric surgical outpatient clinic takes place in the same location as the pediatric outpatient clinic, and we closely cooperate with pediatricians to diagnose and treat patients. We also have specialized outpatient clinics, liver and biliary tract clinics, a tumor clinic, and a spina bifida clinic. Recently, a second-opinion clinic opened to provide careful detailed explanations, and this has received a favorable reception.

Our ward was transferred to the hospital's second floor of B wing from the second floor of south of the A wing on January 2018. Other pediatric surgical patients also are admitted to this ward. We have seven beds in the ward, and about 300 patients a year are hospitalized within it. Most operation cases are inguinal hernia, but we manage other cases such as respiratory surgery disease, neonatal digestive organ obstructions, infant malignant tumors such as Wilms' tumor and neuroblastoma, biliary tract diseases such as biliary tract dilatation and biliary atresia, respiratory anomalies such as tracheal stenosis and lung cysts, gastrointestinal anomalies, and urological disorders including hydronephrosis and vesicoureteral reflux.

We work with other pediatric surgery teams at other institutions who perform endoscopic surgery (laparoscopic surgery/thoracoscopic surgery). We have developed an endoscopic surgery technique for pediatric diseases not covered by insurance, for cases requiring advanced medical care. Furthermore, we surgically manage seriously ill, mentally and physically handicapped infants, as well as patients with intractable nervous system diseases, to improve their quality of life, and we cooperate with pediatricians (neonatologists) to treat patients with prenatal diagnoses.

Education

We expose first and second year students to our daily clinical work, as well as to our research work, during the "Free Quarter" and "Research Lab Visit" courses. These students are guided to be concerned with clinical areas, and are in charge of parts of various

research projects. The students hold a results announcement party at the end of training. For M2 students, general pediatric surgery and neonatal surgery instruction is provided by the associate professor and the lecturer.

An education program is also provided for M3 and M4 students for five days.

The bedside education of pediatric surgery consists of participation in clinical conferences, attendance at operations, and small group lectures concerning neonatal surgery; pediatric surgical oncology; pediatric hepatobiliary surgery; and pediatric emergency medicine, which includes the practice of performing cardiac massage and intra-tracheal intubation using mannequins for practice.

Additionally, we take charge of the core surgical curriculum during the "super-rotation" postgraduate training. We offer a program in which each resident can learn basic knowledge about pediatric surgical disease and surgery and hemodynamic and respiratory evaluation, as well as basic surgical techniques and patient management strategies.

Research activities

There are two pillars of the research projects in our group recently. One is the elucidation of the course and the development of new therapy of pediatric surgical disease using proteome analysis. The other is the clinical research using NCD (National Clinical Database). The results of these studies has been already announced in some articles.

We concentrate power on the study for the pathophysiology of biliary atresia and approach it from many aspects including an animal model, disease-specific iPS cells, and the search of the biomarkers.

In addition, We now goes a research of the organ regeneration using in-body tissue architecture and start diaphragm and the trachea and gastrointestinal reproduction from bio-sheet or bio-tube technology.

References

- 1) Yamaguchi K, Horie C, Takane K, Ikenoue T, Nakagawa S, Isobe Y, Ota Y, Ushiku T, Tanaka M, Fujishiro J, Hoshino N, Arisue A, Nishizuka S, Aikou S, Shida D, Furukawa Y.

- Identification of odontogenic ameloblast associated as a novel target gene of the Wnt/ β -catenin signaling pathway.
Cancer Sci. 2022; 00: 1- 13. doi:10.1111/cas.15657
- 2) Sukezaki A, Kato S, Makise N, Watadani T, Fujishiro J.
Pseudotumoral cystitis mimicking malignancy in a child.
Pediatr Int. 2022; 64(1):e15160. doi:10.1111/ped.15160. PMID: 35616154
 - 3) Sakaguchi H, Konishi K, Yasuda R, Sasaki H, Yoshimaru K, Tainaka T, Fukahori S, Sanada Y, Iwama I, Shoji H, Kinoshita M, Matsuura T, Fujishiro J, Uchida H, Nio M, Yamashita Y, Mizuochi T.
Serum matrix metalloproteinase-7 in biliary atresia: a Japanese multicenter study
Hepatol Res. 2022; ;52(5):479-487. doi: 10.1111/hepr.13753. PMID: 35106887
 - 4) Kawano T, Souzaki R, Sumida W, Ishimaru T, Fujishiro J, Hishiki T, Kinoshita Y, Kawashima H, Uchida H, Tajiri T, Yoneda A, Oue T, Kuroda T, Koshinaga T, Hiyama E, Nio M, Inomata Y, Taguchi T, Ieiri S.
Laparoscopic approach for abdominal neuroblastoma in Japan: results from nationwide multicenter survey.
Surg Endosc. 2022; 36(5): 3028-3038. doi: 10.1007/s00464-021-08599-4. PMID: 34143289
 - 5) Yamamoto S, Ikeda M, Ohama Y, Sunouchi T, Hoshino Y, Ito H, Yamashita M, Kanno Y, Okamoto K, Yamagoe S, Miyazaki Y, Okugawa S, Fujishiro J, Moriya K.
Aureobasidium melanigenum catheter-related bloodstream infection: a case report.
BMC Infect Dis. 2022; 22(1):335. doi: 10.1186/s12879-022-07310-9. PMID: 35382751
 - 6) Omata K, Yoshida M, Suzuki K, Kawashima H, Fujishiro J.
Ectopic gallbladder with congenital biliary dilatation: a pediatric case report.
Surg Case Rep. 2022; 8(1):51. doi: 10.1186/s40792-022-01401-0. PMID: 35347468
 - 7) Li Y, Watanabe E, Kawashima Y, Plichta DR, Wang Z, Ujike M, Ang QY, Wu R, Furuichi M, Takeshita K, Yoshida K, Nishiyama K, Kearney SM, Suda W, Hattori M, Sasajima S, Matsunaga T, Zhang X, Watanabe K, Fujishiro J, Norman JM, Olle B, Matsuyama S, Namkoong H, Uwamino Y, Ishii M, Fukunaga K, Hasegawa N, Ohara O, Xavier RJ, Atarashi K, Honda K.
Identification of trypsin-degrading commensals in the large intestine.
Nature. 2022 Sep; 609(7927): 582-589. doi: 10.1038/s41586-022-05181-3. Epub 2022 Sep 7. PMID: 36071157
 - 8) Watanabe E, Ota H, Takasugi N, Hiwatari M, Fujishiro J
A school-aged case of intratumor bleeding of an adrenal neuroblastoma rescued by transcatheter atrial embolization.
Pediatr Int. 2022 Jan;64(1):e14987. doi: 10.1111/ped.14987. PMID: 35312221
 - 9) Fujiogi M, Konishi T, Michihata N, Hashimoto Y, Matsui H, Ishimaru T, Fushimi K, Yasunaga H, Fujishiro J.
Perioperative outcomes of thyroid cancer surgery in children and adults: a nationwide inpatient database study in Japan.
Ann Clin Epidemiol 2022, <https://doi.org/10.37737/ace.23004>
 - 10) Misako Nakamura , Shoichiro Kanda , Yuko Kajiho , Munetoshi Hinata , Kotaro Tomonaga , Jun Fujishiro , Yutaka Harita
A case of right hypodysplastic kidney and ectopic ureter associated with bicornuate uterus in a prepubertal girl
CEN Case Rep,. 2023 Feb;12(1):122-129. doi: 10.1007/s13730-022-00730-1.
 - 11) Ishimaru T, Fujiogi M, Michihata N, Konishi T, Morita K, Matsui H, Uda K, Fushimi K, Kawashima H, Fujishiro J, Yasunaga H
Perioperative outcomes of laparoscopically assisted anorectoplasty versus conventional procedures for anorectal malformation: a retrospective nationwide database study.
Pediatr Surg Int. 2022;38(12):1785-1791. doi: 10.1007/s00383-022-05234-8. PMID: 36102983
 - 12) Asai A, Wu JF, Wang KS, Yamataka A, Nio M, Su DJ, Short C, Tsuboi K, Ochi T, Sasaki H, Okubo R, Yodoshi T, Konishi K, Rogers ME, Tiao GM
The Outcome of Patients With Cystic Biliary

- Atresia With Intact Proximal Hepatic Ducts Following Hepatic-Cyst-Jejunostomy.
J Pediatr Gastroenterol Nutr. 2022 Aug 1;75(2): 131-137.
- 13) Konishi KI, Suzuki K, Komura M, Kudo H, Ishimaru T, Sugiyama M, Komuro H, Iwanaka T, Fujishiro J.
Endoscopic nasobiliary drainage tube insertion for treatment of afferent loop obstruction in a pregnant woman after Kasai portoenterostomy.
J Pediatr Surg Case Rep. Volume 78, March 2022, 102194.
 - 14) Sakaguchi H, Konishi KI, Yasuda R, Sasaki H, Yoshimaru K, Tainaka T, Fukahori S, Sanada Y, Iwama I, Shoji H, Kinoshita M, Matsuura T, Fujishiro J, Uchida H, Nio M, Yamashita Y, Mizuochi T.
Serum matrix metalloproteinase-7 in biliary atresia: A Japanese multicenter study.
Hepatol Res. 2022 Feb 1.
 - 15) Morita K, Fujiogi M, Michihata N, Matsui H, Fushimi K, Yasunaga H, Fujishiro J.
Oral Antibiotics and Organ Space Infection after Appendectomy and Intravenous Antibiotics Therapy for Complicated Appendicitis in Children.
Eur J Pediatr Surg. 2022 Dec 28. doi: 10.1055/a-1958-7915. PMID: 36220134
 - 16) Marques Marinho M, Oikawa R, Hayashi K, Takazawa S, Harada K, Mitsuishi M.
Design and validation of looping assistance methods in robotic-assisted neonatal surgical suturing in a chest model
Int J Med Robot. 2022 Oct 27;e2476. doi: 10.1002/rcs.2476.
 - 17) Hayashi K, Mori M, Sanmoto Y, Oiki H, Ishimaru T, Arakawa Y, Koh K, Kawashima H.
Relationship between the timing of chemotherapy and surgical complications following surgical biopsy in children with malignant solid tumors
Pediatr Blood Cancer. 2023 Jan;70(1):e30030. doi: 10.1002/pbc.30030.
 - 18) Naohiro Takamoto, Shinya Takazawa, Yuki Yoshida, Tamotus Sasaki, Akira Nishi
Examination of the effectiveness of bedside nasojejunal tube placement using a portable imaging device with a flat panel detector

Reproductive, Developmental and Aging Sciences

3. Aging Sciences

Department of Geriatric Medicine

Department of Aging Research

Professor

Masahiro Akishita, MD, PhD.

Associate Professor

Sumito Ogawa, MD, PhD.

Lecturer

Taro Kojima, MD, PhD.

Masaki Ishii, MD, PhD.

Kotaro Azuma, MD, PhD.

Research Associate

Mitsutaka Yakabe, MD, PhD.

Michiko Nanao, MD, PhD.

Yoko Yamada, MD, PhD.

Tatsuya Hosoi, MD, PhD.

Homepage <https://www.h.u-tokyo.ac.jp/english/centers-services/clinical-divisions/geriatric-medicine/index.html> (English)
<http://geriatrics.umin.jp/> (Japanese)

Introduction and Organization

The Department of Geriatric Medicine was established in 1962, as the first geriatric department in Japan.

Since older adult patients tend to have multiple organ disorders, these patients should be taken cared as a whole from multiple points of view. In addition, symptoms, signs and responses to the treatment in the older adult patients could be quite different from the younger counterparts. Specific knowledge on the physiological and metabolic changes with aging is necessary when these older adult patients are treated. Quality of life of the patients is another point of view which should be emphasized. The department belongs to the division of Internal Medicine. The staff includes one professor, one associate professor, three lecturers, and four assistant professors.

Our sub-specialty includes pneumology, cardiology, neurology, hematology, endocrinology, and bone metabolism, besides geriatrics. The main objective of

our research is to elucidate the pathophysiology of aging process and to understand older adult patients from viewpoints of basic aging science using molecular biology technique and clinical aspects using the recent advancement of technology and geriatric assessment.

Clinical activities

The Department of Geriatric Medicine specialized in the diagnosis and treatment of dementia, frailty, geriatric syndrome and polypharmacy in older adults. We provide Comprehensive Geriatric Assessment (CGA) and manages multiple diseases in older patients who have physical and/or mental disabilities. The Department of Geriatric Medicine belongs to Internal Medicine. In the outpatient setting, we accept patients every day in the three outpatient wards (#207, #208, and #209). We also provide specialized outpatient treatment on dementia, frailty and sarcopenia, osteoporosis, chronic obstructive pulmonary disease

(COPD), and sleep apnea. As a 'second opinion outpatient clinic', we accept consultation on polypharmacy. Since 2003, we provide 'women's general outpatient clinic' by female physicians for treatment of gender sensitive conditions. In the inpatient setting, we have our proper wards in the 13th floor of our hospital, and generally accept approximately 10 patients who are treated by junior, senior, and chief residents of our staff. Older patients often suffer from a variety of diseases and clinical problems. To deal with them, our department forms multi-disciplinary teams composed of geriatricians and related specialists such as psychologists and pharmacists to provide comprehensive medical care.

Education

Clinical education is provided for fifth- and sixth-year medical students on a man-to-man basis with a faculty staff member. During the period, the student studies one or two cases, through which the student learns the techniques of interrogation and physical examination, interpretation of laboratory tests, and actual medical procedures. Interpretation of the results of geriatric assessment is studied through lectures in a case-oriented manner with an emphasis placed on the multidisciplinary basis of geriatric patients.

Research

The purpose of our study is to fulfill the society where older adult people enjoy healthy independent life. We are engaged in studies on various topics including epidemiological studies, clinical studies, and basic molecular studies to contribute to our research aim. Our main research themes are as follows.

- 1) Research on the molecular mechanism of vascular calcification
- 2) Regulation of vascular function by sex hormone
- 3) Molecular biology for the control of aging: Association of vascular and neuronal senescence and the role of Sirt1
- 4) Molecular biology and treatment of sarcopenia
- 5) Multicenter-investigation of the optimal treatment strategy for hypertension or lipid disorder in the older adult patients
- 6) Clinical study on metabolic syndrome in the older adult patients
- 7) Research on the appearance of patients with cognitive impairment; Development of AI model which detects cognitive impairment from the facial expression
- 8) Research on appropriate healthcare for the older adult patients including pharmacotherapy
- 9) Expression and regulation of nuclear receptors in osteoblast and osteoclast
- 10) Molecular mechanism under the treatment of osteoporosis
- 11) Genetic analysis of osteoporosis and osteoarthritis
- 12) Identification and functional analysis of the target gene networks associated with hormone responsiveness in prostate and breast cancers
- 13) Roles of nuclear receptors in age-related diseases and cancers
- 14) Molecular mechanism of vitamin K function and its roles in aging
- 15) Novel roles of antimicrobial peptide, defensin
- 16) Adrenomedullin and airway hyperresponsiveness
- 17) Klotho protein and vitamin D in lung
- 18) Clinical investigation of sleep-related breathing disorder
- 19) Observational study on medical treatment/care provided in the end-of-life stage of life
- 20) Observational study on the outcome of frail patients
- 21) Clinical study on the relationship between
- 22) metabolic diseases and pulmonary aging

Publications (Original Articles)

1. Akashi S, Oguri M, Ikeno E, Manita M, Taura J, Watanabe S, Hayashi T, Akao M, Okumura K, Akishita M, Yamashita T. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial. *JAMA Netw Open*. 2022;5:e2228500.
2. Akishita M, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T, Koretsune Y, Okumura K, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Teramukai S, Kimura T, Morishima Y, Takita A, Yamashita T. Frailty

- and outcomes in older adults with non-valvular atrial fibrillation from the ANAFIE registry. *Arch Gerontol Geriatr*. 2022;101:104661.
3. **Azuma K, Osuka Y, Kojima N, Sasai H, Kim H, Inoue S.** Association of Vitamin K Insufficiency as Evaluated by Serum Undercarboxylated Osteocalcin With Frailty in Community-Dwelling Older Adults. *Front Aging*. 2022;3:865178. doi: 10.3389/fragi.2022.865178.
 4. **Chen LK, Iijima K, Shimada H, Arai H.** Community re-designs for healthy longevity: Japan and Taiwan examples. *Arch Gerontol Geriatr*. 2022 23;104875, doi: 10.1016/j.archger.2022.104875.
 5. **Fujikawa H, Son D, Aoki T, Kondo K, Takemura Y, Saito M, Den N, Eto M.** Translating and validating a Japanese version of the instrument for patient assessment of medical professionalism (J-IPAMP): a cross-sectional survey. *BMC Med Edu*. 2022;22:641. doi: 10.1186/s12909-022-03699-8.
 6. **Fujikawa H, Son D, Aoki T, Eto M.** Association between patient care ownership and personal or environmental factors among medical trainees: a multicenter cross-sectional study. *BMC Med Edu*. 2022;22:666. doi: 10.1186/s12909-022-03730-y.
 7. **Fujikawa H, Eto M.** What Is the Optimal Amount of Supervision to Induce Residents to Develop Patient Care Ownership? *Acad Med*. 2022;97:1578. doi: 10.1097/ACM.0000000000004927.
 8. **Fujikawa H, Mitsuyama T, Son D, Izumiya M, Eto M.** Development and Validation of a Performance Assessment Checklist Scale for Vaccine Administration. *Int Med*. 2022. doi: 10.2169/internalmedicine.9268-21.
 9. **Hattori Y, Hamada S, Yamanaka T, Kidana K, Iwagami M, Sakata N, Tamiya N, Kojima T, Ogawa S, Akishita M.** Drug prescribing changes in the last year of life among homebound older adults: national retrospective cohort study. *BMJ Support Palliat Care*. 2022. Jul 13: bmjspcare-2022-003639. doi: 10.1136/spcare-2022-003639. Epub ahead of print. PMID: 35831182.
 10. **Hattori Y, Hamada S, Ishizaki T, Sakata N, Iwagami M, Tamiya N, Akishita M, Yamanaka T.** National trends in gastrostomy in older adults between 2014 and 2019 in Japan. *Geriatr Gerontol Int*. 2022;22(8):648-652.
 11. **Hidaka R, Masuda Y, Ogawa K, Tanaka T, Kanazawa M, Suzuki K, Stading M, Iijima K, Matsuo K.** Impact of oral frailty prevention program with textured lunch gatherings on attitude and behavior towards eating habits and improving oral frailty: The Comprehensive Awareness Modification of Mouth, Chewing And Meal (CAMCAM) program. *Preprint from Research Square*, 02 Mar 2023, doi: 10.21203/rs.3.rs-2604863/v1 PPR: PPR624235
 12. **Hosoi T, Yakabe M, Sasakawa H, Sasako T, Ueki K, Kato S, Tokuoka SM, Oda Y, Abe M, Matsumoto T, Akishita M, Ogawa S.** Sarcopenia phenotype and impaired muscle function in male mice with fast-twitch muscle-specific knockout of the androgen receptor. *Proc Natl Acad Sci USA*. 2023;120(4):e2218032120.
 13. **Hosoi T, Yamana H, Tamiya H, Matsui H, Fushimi K, Akishita M, Yasunaga H, Ogawa S.** Association between comprehensive geriatric assessment and polypharmacy at discharge in patients with ischaemic stroke: a nationwide retrospective cohort study. *EClinicalMedicine* 50: 101528,2022
 14. **Ide H, Akehi Y, Fukuhara S, Ohira S, Ogawa S, Kataoka T, Kumagai H, Kobayashi K, Komiya A, Shigehara K, Syuto T, Soh J, Tanabe M, Taniguchi H, Chiba K, Matsushita K, Mitsui Y, Yoneyama T, Shirakawa T, Fujii Y, Kumano H, Ueshiba H, Amano T, Sasaki H, Maeda S, Mizokami A, Suzuki K, Horie S.** Summary of the Clinical Practice Manual for Late-Onset Hypogonadism. *Int J Urol* 2023. doi: 10.1111/iju.15160. Online ahead of print.
 15. **Iki M, Fujimori K, Nakatoh S, Tamaki J, Ishii S, Okimoto N, Ogawa S.** Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study. *Osteoporosis Int*. 33:1097-1108,2022
 16. **Iki M, Fujimori K, Nakatoh S, Tamaki J, Ishii S, Okimoto N, Kamiya K, Ogawa S.** Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: a

- nationwide health insurance claims database study in Japan. *Bone* 160:116396,2022
17. Iki M, Fujimoto K, Nakatoh S, Tamaki J, Ishii S, Okimoto N, Kamiya K, Ogawa S. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: a nationwide health insurance claims database study in Japan. *Bone* 166:116605,2023
 18. Imoto S, Suzukawa M, Takeda K, Motohashi T, Nagase M, Enomoto Y, Kawasaki Y, Nakano E, Watanabe M, Shimada M, Takada K, Watanabe S, Nagase T, Ohta K, Teruya K, Nagai H. Evaluation of tuberculosis diagnostic biomarkers in immunocompromised hosts based on cytokine levels in QuantiFERON-TB Gold Plus. *Tuberculosis (Edinb)*. 2022;136:102242.
 19. Imoto S, Suzukawa M, Takada K, Watanabe S, Igarashi S, Kitani M, Nagase T, Ohta K. Immunoglobulin A promotes IL-6 and IL-8 production, proliferation, and migration by the human bronchial smooth muscle cells. *Cell Immunol*. 2022;381:104612.
 20. Ishii M, Yamaguchi Y, Hamaya H, Iwata Y, Takada K, Ogawa S, Imura M, Akishita M. Influence of oral health on frailty in patients with type 2 diabetics aged 75 years or older. *BMC Geriatr*. 22:145,2022
 21. Iwasaki M, Ohara Y, Motokawa K, Hayakawa M, Shirobe M, Edahiro A, Watanabe Y, Awata S, Okamura T, Inagaki H, Sakuma N, Obuchi S, Kawai H, Ejiri M, Ito K, Fujiwara Y, Kitamura A, Nofuji Y, Abe T, Iijima K, Tanaka T, Son BK, Shinkai S, Hirano H. Population-based reference values for tongue pressure in Japanese older adults: a pooled analysis with over 5,000 participants. *J Prosthodont Res*. 2023;67(1):62-69, doi:10.2186/jpr.JPR_D_21_00272.
 22. Kasajima M, Kusaka S, Matsui H, Tanaka T, Son BK, Iijima K, Goda K, Kitsuregawa M, Eggleston K, Bhattacharya J, Hashimoto H. Frailty and dementia in Japan's ageing population: projected needs and economic costs of care. *The Lancet public health*. 2022;7(5):e458-e468, doi: 10.1016/S2468-2667(22)00044-5.
 23. Kasajima M, Eggleston K, Kusaka S, Matsui H, Tanaka T, Son BK, Iijima K, Goda K, Kitsuregawa M, Bhattacharya J, Hashimoto H. Projecting prevalence of frailty and dementia and the economic cost of care in Japan from 2016 to 2043: a microsimulation modelling study. *Lancet Public Health*. 2022 May;7(5):e458-e468, doi: 10.1016/S2468-2667(22)00044-5.
 24. Kobayashi A, Azuma K, Takeiwa T, Kitami T, Horie K, Ikeda K, Inoue S. A FRET-based respirasome assembly screen identifies spleen tyrosine kinase as a target to improve muscle mitochondrial respiration and exercise performance in mice. *Nat Commun*. 2023;14(1):312. doi: 10.1038/s41467-023-35865-x.
 25. Kojima T, Hamaya H, Ishii S, Hattori Y, Akishita M. Association of disability level with polypharmacy and potentially inappropriate medication in community dwelling older people. *Arch Gerontol Geriatr*. 2023 Mar;106:104873.
 26. Konno D, Ikegaya Y, Sasaki T. Weak representation of awake/sleep states by local field potentials in aged mice. *Sci Rep*. 12:7766, 2022
 27. Lyu W, Tanaka T, Son BK, Yoshizawa Y, Akishita M, Iijima K. Associations of nutrition-related, physical, social factors and their combinations with sarcopenia in community-dwelling older adults: Kashiwa Cohort Study. *Nutrients*. 2022; 14(17): 3544. doi: 10.3390/nu14173544.
 28. Lyu W, Tanaka T, Son BK, Akishita M, Iijima K. Associations of multi-faceted factors and their combinations with frailty in Japanese community-dwelling older adults: Kashiwa cohort study. *Arch Gerontol Geriatr*. 2022;102:104734. doi: 10.1016/j.archger.2022.104734.
 29. Mizumoto J, Son D, Izumiya M, Horita S, Eto M. Experience of residents learning about social determinants of health and an assessment tool: Mixed-methods research. *J Gen Med*. 2022;00:1-8. doi: 10.1002/jgf2.559.
 30. Mizumoto J, Mitsuyama T, Kumagaya S, Eto M, Izumiya M, Horita S. Primary care nurses during the coronavirus disaster and their struggle: Qualitative research. *J Gen Fam Med*. 2022. doi: 10.1002/jgf2.566.
 31. Mizumoto J, Mitsuyama T, Kondo S, Izumiya M, Horita S, Eto M. Defining the observable processes of patient care related to social

- determinants of health. *Med Educ*. 2022 Aug 11. doi: 10.1111/medu.14915.
32. Mori H, Izumiya M, Hayashi M, Eto M. Current perception of social accountability of medical schools in Japan: A qualitative content analysis. *Med Teach*. 2022;Nov2:1-8.
 33. Mori T, Wakabayashi H, Kishima M, Itoda M, Fujishima I, Kunieda K, Ohno T, Shigematsu T, Oshima F, Ogawa N, Nishioka S, Momosaki R, Shimizu A, Saito Y, Yamada M, Ogawa S. Association between inflammation and functional outcome in patients with sarcopenic dysphagia. *J Nutr Health Aging* 26:400-406,2022
 34. Moritoyo T, Nishimura N, Hasegawa K, Ishii S, Kirihara K, Takata M, Kishi SA, Umeda-Kameyama Y, Kawarasaki S, Ihara R, Sakanaka C, Wakabayashi Y, Niizuma K, Tominaga T, Yamazaki T, Hasumi K. A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triphenyl phenol. *Br J Clin Pharmacol*. 2022 Dec 23. doi: 10.1111/bcp.15651. Online ahead of print.
 35. Nagatani M, Tanaka T, Son BK, Kawamura J, Tagomori J, Hirano H, Shirobe M, Iijima K. Oral Frailty as a Risk Factor for Mild Cognitive Impairment in Community-Dwelling Older Adults: Secondary Analysis of the Kashiwa Study Data. *Exp Gerontol*. 2023;172:112075. doi:10.1016/j.exger.2022.112075
 36. Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, Iki M. Association of pharmacotherapy with the second hip fracture incidence in women: a retrospective analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan. *Geriatr. Gerontol. Int*. 22:930-937,2022
 37. Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, Iki M. Association between pharmacotherapy and secondary hip fracture in a real-world setting: a nationwide database study. *J Bone Miner Metab*. 41:248-257,2023
 38. Nishimoto M, Tanaka T, Hirano H, Watanabe Y, Oharav Y, Shirobe M, Iijima K. Severe periodontitis increases the risk of oral frailty: A six-year follow-up study from Kashiwa cohort study. *Geriatrics (Basel)*. 2023;8(1):25. doi: 10.3390/geriatrics8010025.
 39. Nishioka S, Fujishima I, Kishima M, Ohno T, Shimizu A, Shigematsu T, Itoda M, Wakabayashi H, Kunieda K, Ohshima F, Ogawa S, Fukuma K, Ogawa N, Kayashita J, Yamada M, Mori T, Onizuka S. Association of existence of sarcopenia and poor recovery of swallowing function in post-stroke patients with severe deglutition disorder: A multicenter cohort study. *Nutrients* 14:4115,2022
 40. Nishita Y, Makizako H, Jeong S, Otsuka, R, Kim H, Obuchi S, Fujiwara Y, Ohara Y, Awata S, Yamada M, Iijima K, Shimada H, Suzuki T. Temporal trends in cognitive function among community-dwelling older adults in Japan: Findings from the ILSA-J integrated cohort study. *Arch Gerontol Geriatr*. 2022 Sep-Oct;102:104718, doi: 10.1016/j.archger.2022.104718.
 41. Nomura K, Ebihara S, Ikebata Y, Umegaki H, Ooi K, Ogawa S, Katsuya T, Kobayashi Y, Sakurai T, Miyao M, Yamaguchi K, Akishita M, The Japan Geriatrics Society Geriatric Medical Practice Committee. Japan Geriatrics Society “Statement for the Use of Telemedicine in Geriatric Care-Telemedicine as a Complement to In-person Medical Practice”: Geriatric Medical Practice Committee consensus statement. *Geriatr. Gerontol. Int*. 22:913-916,2022
 42. Sakai K, Nakayama E, Yoneoka D, Sakata N, Iijima K, Tanaka T, Hayashi K, Sakuma K, Hoshino E. Association of Oral Function and Dysphagia with Frailty and Sarcopenia in Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis. *Cells*. 2022 Jul 14; 11(14):2199, doi: 10.3390/cells11142199.
 43. Sato S, Miyazaki S, Tamaki A, Yoshimura Y, Arai H, Fujiwara D, Katsura H, Kawagoshi A, Kozu R, Maeda K, Ogawa S, Ueki J, Wakabayashi H. Respiratory sarcopenia: A position paper by four professional organizations. *Geriatr. Gerontol. Int*. 23:5-15,2023
 44. Son BK, Imoto T, Inoue T, Nishimura T, Lyu W, Tanaka T, Iijima K. Different reversibility of skeletal muscle mass and strength in elderly Japanese women after the first wave of COVID-19. *JCSM rapid communication* 2023 Feb 27. DOI:10.1002/rco2.73. Online ahead of print

45. **Son BK, Imoto T, Inoue T, Nishimura T, Tanaka T, Iijima K.** Social detachment influenced muscle mass and strength during the COVID-19 pandemic in Japanese community-dwelling older women *J Frailty Aging* 2022;11(2):231-235. doi:10.14283/jfa.2022.4
46. **Sun Y, Iwagami M, Sakata N, Ito T, Inokuchi R, Uda K, Hamada S, Ishimaru M, Komiyama J, Kuroda N, Yoshie S, Ishizaki T, Iijima K, Tamiya N.** Development and validation of a risk score to predict the frequent emergency house calls among older people who receive regular home visits. *BMC Primary Care*. 2022;5:23(132).
47. **Suzuki Y, Shiraishi N, Komiya H, Sakakibara M, Akishita M, Kuzuya M.** Potentially inappropriate medications increase while prevalence of polypharmacy/hyperpolypharmacy decreases in Japan: A comparison of nationwide prescribing data. *Arch Gerontol Geriatr*. 2022;102:104733.
48. **Takahashi K, Tanaka T, Yoshizawa Y, Fujisaki-Sueda-Sakai M, Son BK, Iijima K.** Lower urinary tract symptoms and functional ability in older adults: A community-based cross-sectional study. *BMC open* 2022; 12(4): e054530. doi: 10.1136/bmjopen-2021-054530.
49. **Takase M, Takahashi K, Ogino R, Nitani R, Tanaka T, Saisho S, Goto J, Iijima K.** Functional capacity in community-dwelling older adults maintained by a higher friend network than family network: Implications from a two-year longitudinal study. *BMC Res Notes*, 2022 Oct 11;15(1):319, doi: 10.1186/s13104-022-06216-8.
50. **Tamaki J, Ogawa S, Fujimori K, Ishii S, Nakatoh S, Okimoto N, Kamiya K, Iki M.** Hip and vertebral fracture risk after initiating anti-diabetic drugs in Japanese elderly: a nationwide study. *J Bone Miner Metab*. 41:29-40,2023
51. **Tanaka T, Yoshizawa Y, Sugaya K, Yoshida M, Son BK, Lyu W, Tsushita K, Iijima K.** Predictive validity of the Questionnaire for Medical Checkup of Old-Old for functional disability: using the National Health Insurance Database System. *Geriatr Gerontol Int*. 2023. doi: 10.1111/ggi.14533.
52. **Tanaka T, Son BK, Iijima K.** Poor health behaviors among housebound Japanese community-dwelling older adults due to prolonged self-restraint during the first COVID-19 pandemic: A cross-sectional survey. *J Frailty Aging* 2023;12(1):86-90. doi: 10.14283/jfa.2022.20.
53. **Tanaka T, Son BK, Lyu W, Iijima K.** The impact of social engagement on the development of sarcopenia among community-dwelling older adults: A Kashiwa cohort study. *Geriatr Gerontol Int* 2022;22(5):384-391. doi: 10.1111/ggi.14372.
54. **Wakabayashi H, Kishima M, Itoda M, Fujishima I, Kunieda K, Ohno T, Shigematsu T, Oshima F, Mori T, Ogawa N, Nishioka S, Momosaki R, Yamada M, Ogawa S.** Prevalence of hoarseness and its association with severity of dysphagia in patients with sarcopenic dysphagia. *J Nutr Health Aging* 26:266-271,2022
55. **Watanabe S, Kobayashi K, Suzukawa M, Igarashi S, Takada K, Imoto S, Kitani M, Fukami T, Nagase T, Ohta K.** Identification of ANXA2 on epithelial cells as a new receptor for secretory IgA using immunoprecipitation and mass spectrometry. *Clin Exp Immunol*. 2022;208(3): 351-360
56. **Yamamoto K, Akasaka H, Yasunobe Y, Shimizu A, Nomoto K, Nagai K, Umegaki H, Akasaki Y, Kojima T, Kozaki K, Kuzuya M, Ohishi M, Akishita M, Takami Y, Rakugi H; Cherry Study Group.** Clinical characteristics of older adults with hypertension and unrecognized cognitive impairment. *Hypertens Res*. 2022;45(4):612-619.
57. **Yamamoto T, Tanaka T, Hirano H, Mochida Y, Iijima K.** Model to Predict Oral Frailty Based on Questionnaire: A Cross-Sectional Study. *Int J Environ Res Public Health*. 2022 Oct 14;19(20): 13244, doi: 10.3390/ijerph192013244.
58. **Yamanaka T, Kidana K, Yamaguchi Y, Hirahara S, Hirakawa Y, Mizuki M, Arai H, Akishita M, Miura H.** Palliative home care for older patients with respiratory disease in Japan: Practices and opinions of physicians. *Geriatr Gerontol Int*. 2022;22(11):943-949.
59. **Yakabe M, Hosoi T, Sasakawa H, Akishita M, Ogawa S.** Kampo formula Hochu-ekki-to (Bu-Zhong-Yi-Qi-Tang, TJ-41) ameliorates muscle atrophy by modulating atrogenes and AMPK in vivo and in vitro. *BMC Complement Med Ther*. 22:341,2022

60. **Yakabe M, Shibasaki K, Hosoi T, Matsumoto S, Hoshi K, Akishita M, Ogawa S.** Validation of the questionnaire for medical checkup of old-old (QMCOO) score cutoff to diagnose frailty. *BMC Geriatr.* 23:157,2023
61. **Yakabe M, Shibasaki K, Hosoi T, Matsumoto S, Hoshi K, Akishita M, Ogawa S.** Effectiveness of the questionnaire for medical checkup of old-old (QMCOO) to diagnose frailty in community-dwelling elderly adults. *Geriatr. Gerontol. Int.* 22: 127-131,2022
62. **Yoshizawa Y, Tanaka T, Takahashi K, Fujisaki M, Son BK, Iijima K.** Impact of Health Literacy on the Progression of Frailty after 4 Years among Community-Dwelling Older Adults. *Int J Environ Res Public Health.* 2022;19(1):394.

Surgical Sciences

1. Surgery

Department of Thoracic Surgery

Professor

Nakajima, Jun

Associate Professor

Sato, Masaaki

Lecturer

Konoeda, Chihiro

Assistant Professor

Nagano, Masaaki

Nakao, Keita

Cong, Yue

Yamaya, Takafumi

Homepage <http://cts.m.u-tokyo.ac.jp/>

History

Study on thoracic surgery has begun since 1916 when symposium on lung surgery was held at annual meeting of Japan Surgical Society. Clinical and basic research of the thoracic surgery have been performed since the prewar era at the Second department of Surgery in this university. Professor Tsuduki, Masao adopted the modified Coryllos's thoracoplasty for the treatment of the pulmonary tuberculosis in 1934. In 1942, they initiated thoracoscopy for the treatment of the tuberculosis in our country. Before the World War II, thoracic surgery had been performed under spontaneous breathing. Since 1950 safer anesthesia with endotracheal intubation has been started in this university.

After the successful application of the antituberculosis drugs, surgical treatment of the thoracic malignant neoplasms was the major concern of the thoracic surgery. Case reports on surgical therapy for lung cancer has been present since 1920's in our country. In 1950, successful right pneumonectomy for the primary lung cancer in this university was reported. Surgical therapy for the

mediastinal tumor was also begun in 1950. In 1954, thymectomy through median sternotomy has begun in our department.

The Department of Cardiothoracic Surgery, The University of Tokyo, was established on December 15, 1964, as the first department of this field along with the cardiovascular surgery in the Japanese national universities. It has played an internationally leading role and contributed to development of the field in our country.

Professors and Chairs in the history of the department are as follows: Kimoto, Seiji (1964.12.15 ~ 1968.3.31), Saigusa, Masahiro (1968.4.1 ~ 1981.3.31), Asano, Ken-ichi (1981.4.1 ~ 1986.3.31), Furuse, Akira (1986.4.1 ~ 1997.3.31) and Takamoto, Shinichi (1997.6.1 ~ 2009.3.31).

The Department of Cardiothoracic Surgery has been divided into two departments, Department of Cardiovascular Surgery and Department of Thoracic Surgery in 1995. The mission of the Department of Thoracic Surgery is to cure the patients with diseases of the thoracic organs through clinical works, basic and clinical research, and education of the medical

students, postgraduates, and the surgical residents in our university.

Nakajima, Jun has taken over the mission of the department of thoracic surgery as an independent department for the first time since April 2011 until the end of March, 2023.

Clinical activities

Five staffs (Nakajima J, Sato M, Konoeda C, Nagano M, and Nakao K), who are certificated as members of the Japanese Board of General Thoracic Surgery, are in charge of the Department of Thoracic Surgery, University of Tokyo Hospital. They specialize in surgical treatment for diseases of the respiratory and the mediastinal organs and the chest wall, except for diseases of the esophagus and mammary glands.

Lung cancer is the leading cause of cancer death in our country: In 2020, Ministry of Health, Labour and Welfare documented that number of deaths from malignant neoplasms was approximately 390 thousand out of 1.37 million total deaths in Japan. Of them, 76 thousand people were killed by malignant tracheal / pulmonary neoplasms. Surgical therapy for non-small cell lung cancer (NSCLC) is thus the most important issue in our department. By the practice of treatment based on EBM, we perform basic training of thoracic surgery for medical school students, graduate students and clinical residents, as well as doing the professional education for training physicians who wish to become board-certified thoracic surgeons.

We have performed video-assisted thoracoscopy for the diagnosis and treatment of the thoracic disease with less surgical invasiveness since 1992 for safer treatment of older patients with cardiovascular and/or respiratory complications. We currently conduct a standard surgery for clinical stage I non-small cell lung cancer (NSCLC), that is, lobectomy and lymphadenectomy through thoracoscopy: Since 2015, more than 90% of patients with NSCLC has undergone thoracoscopic surgery in our department. Research on less-invasiveness, oncological advantage of the thoracoscopic surgery is thus actively done. Robot-assisted lobectomy/segmentectomy with Da Vinci has applied to lung cancer patients since January 2021.

Pulmonary metastasis represents far advanced malignant neoplasms of extrathoracic organs. Pulmonary resection is an option for the treatment of pulmonary metastasis. We actively perform pulmonary resection through thoracoscopy on patients with pulmonary metastasis who are eligible for surgical therapy through thoracoscopy

Thymic epithelial neoplasms, such as thymoma and thymic carcinoma, show broad spectrum in the degree of malignancy. They also associated with paraneoplastic syndromes, such as the myasthenia gravis and the pure red cell aplasia. Although they are relatively rare diseases, we sought to establish the strategies on diagnosis and treatment of these diseases, which are still yet to be determined, from our clinical experiences of more than 200 cases with the diseases in our department. We are now actively participating a multiinstitutional study on malignant thymic epithelial neoplasms database led by Japanese Association for research on the thymus (JART).

Our hospital has been certified as a lung transplant centers since March 2014. We have started to register patients who are eligible for lung transplantation. We successfully performed the first case in Tokyo of living donor lung transplantation in April 2015: The patients had suffered from the interstitial pneumonia. In July 2015, we also succeeded in performing brain-dead donor bilateral lung transplantation on a patient who had suffered from the pulmonary hypertension. We have performed 135 lung transplants (including 26 living related donor lung transplantations) to date.

Academic education

Medical students in the fifth grade have three-week program on the clinical training of the thoracic and the cardiovascular surgery. They are also able to participate the clinical clerkship of the thoracic surgery, an elective course for 4 weeks. We also conduct a further research training for medical students who like to study thoracic surgery. The Department of Thoracic Surgery also offers the 4-year postgraduate program for qualified surgeons who are willing to specialize in the thoracic surgery. We have a training program for surgeons who wish to be a board-certified thoracic surgeon after 4-year residency.

Current research

Main subjects of current research at present include basic and clinical studies on the malignant neoplasms in the thorax including lung cancer and thymic tumors, and transplantation of the thoracic organs. The following items are the major themes under research in our department:

- (1) Minimally invasive surgeries for thoracic malignant neoplasms.
- (2) Navigation techniques for finding out small pulmonary lesions through thoracoscopy.
- (3) Imaging analysis of lung adenocarcinoma
- (4) Global analysis of oncogenes and suppressor genes associated with lung cancer.
- (5) Application of new fluorescent agents for diagnosis of lung cancer.
- (6) Immunotherapy for lung cancer.
- (7) Analysis on mechanisms of acute or chronic rejection of the allogeneic lung after allogeneic transplantation.
- (8) Long-term digital monitoring of post-lung transplant patients
- (9) Research on extracorporeal membranous oxygenation for bridge use to lung transplantation

Selected publications (2022)

1. Ijiri N, Sato M, Konoeda C, Nagayama K, Nakajima J. Basiliximab for early perioperative transplant-associated thrombotic microangiopathy after lung transplantation: a case report. *Surg Case Rep.* 2022;8(1):187.
2. Kawashima S, Yoshida D, Yoshioka T, Ogasawara A, Fujita K, Yanagiya M, et al. Rapid imaging of lung cancer using a red fluorescent probe to detect dipeptidyl peptidase 4 and puromycin-sensitive aminopeptidase activities. *Sci Rep.* 2022;12(1):9100.
3. Morota M, Nagano M, Ijiri N, Yoshiyasu N, Shinohara Y, Nobori Y, et al. Effect of intraoperative needle biopsy on the survival of nonsmall cell lung cancer patients: a propensity score matching analysis. *Surg Today.* 2022; 52(10):1497-503.
4. Nagano M, Sato M, Yanagiya M, Nakao K, Konoeda C, Kitano K, et al. Number of dye

- marks required in virtual-assisted lung mapping. *Gen Thorac Cardiovasc Surg.* 2023;71(5):313-20.
5. Sato M, Kobayashi M, Sakamoto J, Fukai R, Takizawa H, Shinohara S, et al. The role of virtual-assisted lung mapping 2.0 combining microcoils and dye marks in deep lung resection. *J Thorac Cardiovasc Surg.* 2022;164(1):243-51. e5.
6. Shiiya H, Sato M, Shinozaki-Ushiku A, Konoeda C, Kitano K, Nakajima J. Exacerbation of Secondary Pulmonary Hypertension by Flat Chest after Lung Transplantation. *Ann Thorac Cardiovasc Surg.* 2022;28(4):298-301.
7. Shinohara Y, Yamamoto K, Ito M, Sakata M, Koizumi S, Hashisako M, et al. Development and validation of the Japanese version of the uMARS (user version of the mobile app rating system). *Int J Med Inform.* 2022;165:104809.
8. Sun C, Anraku M, Kawahara T, Karasaki T, Kitano K, Nagayama K, et al. Respiratory strength and pectoralis muscle mass as measures of sarcopenia: Relation to outcomes in resected non-small cell lung cancer. *J Thorac Cardiovasc Surg.* 2022;163(3):779-87.e2.
9. Sun C, Anraku M, Kawahara T, Karasaki T, Konoeda C, Kitano K, et al. Combination of Skeletal Muscle Mass and Density Predicts Postoperative Complications and Survival of Patients With Non-Small Cell Lung Cancer. *Ann Surg Oncol.* 2022;29(3):1816-24.
10. Tian D, Shiiya H, Sato M, Shinozaki-Ushiku A, Yan HJ, Nakajima J. Pathological tumor long-to-short axis ratio as a prognostic factor in patients with thymic epithelial tumors. *Thorac Cancer.* 2022;13(17):2489-98.
11. Tian D, Shiiya H, Takahashi M, Terasaki Y, Urushiyama H, Shinozaki-Ushiku A, et al. Noninvasive monitoring of allograft rejection in a rat lung transplant model: Application of machine learning-based (18)F-fluorodeoxyglucose positron emission tomography radiomics. *J Heart Lung Transplant.* 2022;41(6):722-31.
12. Tian D, Yan HJ, Shiiya H, Sato M, Shinozaki-Ushiku A, Nakajima J. Machine learning-based radiomic computed tomography phenotyping of thymic epithelial tumors: Predicting pathological and survival outcomes. *J Thorac Cardiovasc Surg.*

- 2023;165(2):502-16.e9.
13. Yamaguchi H, Sato M, Yamamoto K, Shinohara K, Yanagiya M, Hashisako M, et al. Availability of virtual-assisted lung mapping affects procedure selection for early-stage lung cancer: a web-based cross-sectional study. *Eur J Cardiothorac Surg.* 2022;63(1).
14. Yamaguchi H, Sato M, Yamamoto K, Ueda K, Date H, Chen-Yoshikawa T, et al. Virtual-assisted lung mapping in sublobar resection of small pulmonary nodules, long-term results. *Eur J Cardiothorac Surg.* 2022;61(4):761-8.
15. Yanagiya M, Sato M, Ijiri N, Kobayashi K, Nagano M, Konoeda C, et al. Virtual-assisted lung mapping using dual staining with indocyanine green and indigo carmine enhanced marking detectability. *J Thorac Dis.* 2022;14(4):1061-9.
16. Yoshiyasu N, Sato M, Yamaguchi H, Nakajima J. Risk Factors for Invisible Intraoperative Markings After Virtual-Assisted Lung Mapping. *Ann Thorac Surg.* 2022;114(5):1903-10.
17. Yoshiyasu N, Sato M, Yasui T, Takami M, Kawahara T, Konoeda C, et al. Thoracic mediastinal-occupying ratio predicts recovery and prognosis after lung transplantation. *Interact Cardiovasc Thorac Surg.* 2022;35(3).
18. Ando T, Kage H, Shinozaki-Ushiku A, Tatsuno K, Tsutsumi S, Nagayama K, et al. Composite Clonal Analysis Reveals Transition of NSCLC Subtypes Through Accumulation of Gene Mutations: A Case Report. *JTO Clin Res Rep.* 2022;3(2):100277.
19. Hanabusa Y, Kubo T, Watadani T, Nagano M, Nakajima J, Abe O. Successful transcatheter arterial embolization for a massive hemothorax caused by acupuncture. *Radiol Case Rep.* 2022;17(9):3107-10.
20. Kuriki Y, Yoshioka T, Kamiya M, Komatsu T, Takamaru H, Fujita K, et al. Development of a fluorescent probe library enabling efficient screening of tumour-imaging probes based on discovery of biomarker enzymatic activities. *Chem Sci.* 2022;13(16):4474-81.
21. Kuroda H, Koyama S, Mun M, Nakajima J, Funai K, Yoshino I, et al. Survival Outcomes of Complete Pulmonary Metastasectomy for Head and Neck Squamous Cell Carcinomas. *Cancer Manag Res.* 2022;14:3095-103.
22. Sato C, Kubo T, Shibata E, Yanagiya M, Nakajima J, Abe O. Successful transcatheter embolization of an unruptured idiopathic peripheral pulmonary artery aneurysm. *Radiol Case Rep.* 2023;18(1):8-10.
23. Sun C, Anraku M, Nakajima J. ASO Author Reflections: An Evolving Skeletal Muscle Profiling-Towards Precise Host Phenotype and Prognostic Stratification in Non-small Cell Lung Cancer. *Ann Surg Oncol.* 2022;29(3):1825-6.
24. Sun C, Nagaoka K, Kobayashi Y, Maejima K, Nakagawa H, Nakajima J, et al. Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors. *Int J Cancer.* 2023;152(7):1463-75.

Department of Cardiac Surgery

Professor

Minoru Ono, M.D., Ph.D.

Associate Professor

Yasutaka Hirata, M.D., Ph.D.

Lecturer

Haruo Yamauchi, M.D., Ph.D., Osamu Kinoshita, M.D., Ph.D.,

Mitsutoshi Kimura, M.D., Ph.D.

Associate

Shogo Shimada, M.D., Ph.D., Masahiko Ando, M.D., Ph.D., Hyoe Komae, M.D., Ph.D.,

Tomoyuki Iwase, M.D., Ph.D., Miyuki Shibata, M.D., Ph.D., Takayuki Gyoten, M.D.,

Kazuki Yakuwa, M.D.

Homepage <http://cts.m.u-tokyo.ac.jp/>

Introduction and Organization

Cardiac surgery in the Department was initiated by Dr. Seiji Kimoto, who performed ligation of patent ductus arteriosus in June, aortic arch aneurysm resection in July and first-in-Japan Blalock-Taussig operation for Tetralogy of Fallot in October in 1951. He also started implantation of alcohol-preserved aortic homograft for abdominal aortic aneurysm in 1952, and closed commissurotomy for mitral valve stenosis in 1954. The first open heart surgery (atrial septal defect closure) was performed in 1955, using selective brain perfusion cooling method that was developed in the Department.

Establishment of Department of Thoracic Surgery in the University of Tokyo Hospital was approved by the government first in Japan December 15, 1964. Under the leadership of Professor Kimoto excellent research works were created especially on pacemaker and artificial heart, and many opinion leaders were produced. Dr. Masahiro Saigusa, the second Professor, endeavored to make open heart surgery safer by introducing new- generation heart-lung machines to the Department. Dr. Kenichi Asano, the third

Professor, started posterior-leaflet preserving mitral valve replacement first in Japan. He also dramatically improved surgical results of Tetralogy of Fallot. Dr. Akira Furuse, the fourth Professor, modernized management of extremely busy clinical works. During this time, the Department was divided into two Divisions, Cardiovascular and General thoracic, due to the University policy of Graduate-school.

Dr. Shinichi Takamoto assumed the fifth Professor in June 1997. He rearranged clinical teams into three groups (adult cardiac disease, thoracic aortic disease and congenital heart disease) to adapt the rapid progress of cardiovascular surgery.

Dr. Minoru Ono was elected as the sixth Professor in November 2009. Advanced Heart Failure Center was open on the 5th Floor of Hospital Building B, January 2018 to cope with an increasing number of patients who require ventricular assist device and heart transplantation treatment. Present staffs are one Chief Professor, one Associate Professor and three Lecturer and seven Associates.

Clinical Activities

Clinical conference starts at 7:15 am in weekdays. Regular surgery is scheduled on every weekday. Adult patients are hospitalized in the South Wing of 5th floor, and pediatric patients in the South Wing of 2nd floor. Clinics are open Monday through Friday for the follow-up visit as well as for patient referral.

Case volume in recent years has been over 400, which is one of the highest in Japan. We are leading in Japan by showing excellent surgical results. There are 10 Board-certified cardiovascular surgeons, each of whom has his own subspecialty among adult cardiac, thoracic aortic or congenital heart disease. We are famous for off-pump coronary artery bypass surgery, mitral valve plasty, heart transplantation, ventricular assist device implantation, aortic valve sparing root replacement, arch replacement, treatment of extended thoracic aortic aneurysm and repair of complex congenital heart diseases, such as Jatene, Fontan and Norwood operations. Transcatheter aortic valve replacement was initiated in 2015. Many high-risk very old patients with aortic valve stenosis were successfully treated.

The University of Tokyo Tissue Bank was founded in 1997, based on the Department of Cardiovascular Surgery. The Bank has been actively promoting procurement, preservation and shipping of human valve and blood vessel allograft in Japan. We take the lead in surgical treatment using allograft for severe active endocarditis or infection of aortic aneurysm or vascular prosthesis. Surgical treatment using allograft was approved for health insurance coverage by the Government in 2018. As of March 2023, 197 cases of heart transplantation including 15 pediatric patients and 413 cases of ventricular assist device (VAD) implantation including 274 implantable continuous-flow VADs were performed in The University Hospital with excellent long-term survival.

Teaching Activities

We have the chair of systematic review of cardiovascular surgery in the spring term at the 2nd grade of medical course. We expose the students to daily clinical works as well as research works during the course of “Free Quarter” and “Research Lab Visit”, which are scheduled in the summer and spring

vacations at 1st and 2nd grade. Joint lectures with the Cardiology Department are scheduled 3rd through 4th grades. Each student is assigned one or two cardiovascular surgical cases in the Regular Clinical Clerkship, in which he/she is required to learn preoperative patient evaluation and management, surgical treatment and postoperative care, based on participatory practice. There are also fifteen small key-lectures on cardiovascular surgery. Hands-on practice is provided during the Advanced Clinical Clerkship one-month course in the last months of 3rd grade.

We take charge in core surgical curriculum in the “Super-rotation” postgraduate training. We offer a program in which each resident can learn basic knowledge of cardiovascular disease and surgery, and hemodynamic and respiratory evaluation as well as basic surgical techniques and patient management. Residents who take the course of cardiovascular surgery are required three-year general surgical training for General Surgery Board certification. We have well-developed specialty/subspecialty training programs to allow the residents to pass Cardiovascular Board Examination by 9-10th postgraduate year.

Research Activities

In order to achieve excellent clinical results and to seek for new possibilities of surgical treatments, it is essential for cardiothoracic surgical department of the University to have active research programs in clinical and basic subjects. The Cardiothoracic Department of the University of Tokyo has created highly active research programs in the every field of cardiothoracic surgery, played an internationally leading role and contributed to its development. A research meeting is held once a month on a research project for every member of the department to understand and to make free thorough discussions of the subject.

Basic and/or clinical research activities are focused on 1) establishment of recovery and weaning protocols of left ventricular assist device, 2) basic and clinical research on cryopreserved allograft, 3) application of regenerative medicine to end-stage heart failure, 4) analysis of cardiomyocytes matured and differentiated from iPS cells, 5) mechanism analysis of right heart failure and development of

effective pharmacological and mechanical therapy, 6) development of versatile suture device, 7) clinical research to test the safety and efficacy of artificial pancreas during open heart surgery.

References

- Ikeda N, Yamamoto H, Taketomi A, Hibi T, Ono M, Niikura N, Sugitani I, Isozumi U, Miyata H, Nagano H, Unno M, Kitagawa Y, Mori M. The impact of COVID-19 on surgical procedures in Japan: analysis of data from the National Clinical Database. *Surg Today*. 2022 Jan; 52(1): 22-35. PMID: 34783905.
- Aoyama G, Zhao L, Zhao S, Xue X, Zhong Y, Yamauchi H, Tsukihara H, Maeda E, Ino K, Tomii N, Takagi S, Sakuma I, Ono M, Sakaguchi T. Automatic Aortic Valve Cusps Segmentation from CT Images Based on the Cascading Multiple Deep Neural Networks. *J Imaging*. 2022 Jan 14;8(1):11. PMID: 35049852.
- Terakawa K, Yamauchi H, Lee Y, Ono M. A Novel Knitted Polytetrafluoroethylene Patch for Cardiovascular Surgery. *Int Heart J*. 2022;63(1): 122-130. PMID: 35095061.
- Ando M, Yamauchi H, Gyoten T, Komae H, Hoshino Y, Itoda Y, Shimada S, Kimura M, Kinoshita O, Ono M. Association between left ventricular ejection fraction and mortality after Bentall procedure. *Heart Vessels*. 2022 Aug; 37(8):1462-1469. PMID: 35124729.
- Tsuji M, Kakuda N, Bujo C, Ishida J, Amiya E, Hatano M, Shimada A, Imai H, Shimada S, Kinoshita O, Yamauchi H, Ono M, Komuro I. Sarcopenia and risk of infection in adult heart transplant recipients in Japan. *ESC Heart Fail*. 2022 Apr; 9(2): 1413-1423. PMID: 35146960.
- Myers PO, Dayan V, Szeto WY, Thourani VH, Malaisrie SC, Moon MR, Prager RL, Ono M, Okita Y, Freemantle N, Milojevic M. Joint surgical associations (EACTS, LACES, ASCVTS, AATS, and STS) position statement regarding the VARC-3 definitions for aortic valve clinical research. *J Thorac Cardiovasc Surg*. 2022 May; 163(5): 1792-1794. PMID: 35307218.
- Kida K, Kanaki T, Gao S, Hatanaka D, Iwakami M, Liu S, Horikawa M, Ono M, Chang D. A Novel 3D Culture System Using a Chitin-Based Polysaccharide Material Produces High-Quality Allogeneic Human UCMSCs with Dispersed Sphere Morphology. *Cells*. 2022 Mar 15;11(6): 995. PMID: 35326446.
- Sato T, Kobayashi Y, Nagai T, Nakatani T, Kobashigawa J, Saiki Y, Ono M, Wakasa S, Anzai T. Long-term preservation of functional capacity and quality of life in advanced heart failure patients with bridge to transplant therapy: A report from Japanese nationwide multicenter registry. *Int J Cardiol*. 2022 Jun 1; 356: 66-72. PMID: 35337935.
- Kuramitsu K, Yamanaga S, Osawa R, Hibi T, Yoshikawa M, Toyoda M, Shimata K, Yosuke E, Ono M, Kenmochi T, Sogawa H, Natori Y, Yano H, Chen-Yoshikawa T, Yoshida K, Fukumoto T, Yuzawa K, Egawa H. Impact of COVID-19 on the Living Donor Liver and Kidney Transplantation Programs in Japan in 2020. *Transpl Infect Dis*. 2022 Jun;24(3):e13845. PMID: 35505462.
- Gyoten T, Amiya E, Kinoshita O, Tsuji M, Kimura M, Hatano M, Ono M. Myocardial recovery evaluation from ventricular assist device in patients with dilated cardiomyopathy. *ESC Heart Fail*. 2022 Aug;9(4):2491-2499. PMID: 35535672.
- Narita K, Amiya E, Hatano M, Ishida J, Minatsuki S, Tsuji M, Bujo C, Kakuda N, Isotani Y, Ono M, Komuro I. Determining the factors for interhospital transfer in advanced heart failure cases. *Int J Cardiol Heart Vasc*. 2022 May 14; 40:101035. doi: 10.1016/j.ijcha.2022.101035. PMID: 35601528.
- Kumamaru H, Kakeji Y, Fushimi K, Ishikawa KB, Yamamoto H, Hashimoto H, Ono M, Iwanaka T, Marubashi S, Gotoh M, Seto Y, Kitagawa Y, Miyata H. Cost of postoperative complications of lower anterior resection for rectal cancer: a nationwide registry study of 15, 187 patients. *Surg Today*. 2022 Dec;52(12): 1766-1774. PMID: 35608708.
- Hayward C, Adachi I, Baudart S, Davis E, Feller ED, Kinugawa K, Klein L, Li S, Lorts A, Mahr C, Mathew J, Morshuis M, Müller M, Ono M, Pagani FD, Pappalardo F, Rich J, Robson D,

- Rosenthal DN, Saeed D, Salerno C, Sauer AJ, Schlöglhofer T, Tops L, VanderPluym C. Global best practices consensus: Long-term management of patients with hybrid centrifugal flow left ventricular assist device support. *J Thorac Cardiovasc Surg*. 2022 Oct;164(4):1120-1137.e2. PMID: 35624053.
14. Ko T, Nomura S, Yamada S, Fujita K, Fujita T, Satoh M, Oka C, Katoh M, Ito M, Katagiri M, Sassa T, Zhang B, Hatsuse S, Yamada T, Harada M, Toko H, Amiya E, Hatano M, Kinoshita O, Nawata K, Abe H, Ushiku T, Ono M, Ikeuchi M, Morita H, Aburatani H, Komuro I. Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF- β -IGFBP7 axis. *Nat Commun*. 2022 Jun 7;13(1):3275. PMID: 35672400.
 15. Kawamura S, Koizumi S, Umekawa M, Miyawaki S, Kinoshita O, Ono M, Saito N. Long-term benefit of mechanical thrombectomy for acute ischemic stroke in patients with left ventricular assist device: a single-center retrospective study. *World Neurosurg*. 2022 Sep;165: e331-e336. PMID: 35718273.
 16. Kakuda N, Amiya E, Hatano M, Tsuji M, Bujo C, Ishida J, Yagi H, Saito A, Narita K, Isotani Y, Fujita K, Ando M, Shimada S, Kinoshita O, Ono M, Komuro I. Residual Pulmonary Vascular Resistance Increase Under Left Ventricular Assist Device Support Predicts Long-Term Cardiac Function After Heart Transplantation. *Front Cardiovasc Med*. 2022 Jun 1;9:904350. doi: 10.3389/fcvm.2022.904350. PMID: 35722119; PMCID: PMC9198244.
 17. Ono M. Continuous-flow left ventricular assist device treatment for arrhythmogenic right ventricular cardiomyopathy complicated by advanced biventricular failure - University of Tokyo experiences. *Front Cardiovasc Med*. 2022 Oct 5;9:1023191. PMID: 36277799.
 18. Yoshioka D, Toda K, Ono M, Fukushima N, Shiose A, Saiki Y, Usui A, Wakasa S, Niinami H, Matsumiya G, Arai H, Sawa Y, Miyagawa S; Japanese HeartMateII Investigators. Effect of Diabetes Mellitus on Outcomes in Patients With Left Ventricular Assist Device - Analysis of Data From a Japanese National Database. *Circ J*. 2022 Nov 25; 86(12): 1950-1958. PMID: 35786688.
 19. Gyoten T, Amiya E, Ono M. Surgical Interventions for Late Aortic Valve Regurgitation Associated with Continuous Flow-Left Ventricular Assist Device Therapy: Experience Gained and Lessons Learned. *Life (Basel)*. 2022 Dec 29;13(1):94. PMID: 36676043.
 20. Karigyo C, Fonseca J, Andrade A, Ono M. A Cooperative Environment for Ventricular Assist Device Development and Application: The Japanese Experience. *Braz J Cardiovasc Surg*. 2022 Dec 1;37(6):959-960. PMID: 36441959.
 21. Ono M. Durable Ventricular Assist Device for Bridge to Transplantation. In: Fukushima PN, editor. *Heart Transplantation*. London: IntechOpen; 2022 [cited 2022 Feb 05]. doi:10.5772/intechopen.102467
 22. Nakamura M, Yaku H, Ako J, Arai H, Asai T, , Ono M, Shiomi H, Tanemoto K; Japanese Circulation Society Joint Working Group. JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. *Circ J*. 2022 Feb 25;86(3):477-588. PMID: 35095031.
 23. Ono M, Yamaguchi O, Ohtani T, Kinugawa K, Saiki Y, Sawa Y, Shiose A, Tsutsui H, Fukushima N, Matsumiya G, Yanase M; JCS/JSCVS/JATS/ JSVS Joint Working Group. 2021 Guideline on Implantable Left Ventricular Assist Device for Patients With Advanced Heart Failure. *Circ J*. 2022 May 25;86(6):1024-1058. PMID: 35387921.
 24. Hatano M, Jimba T, Fujiwara T, Tsuji M, Bujo C, Ishida J, Amiya E, Kinoshita O, Ono M. Late-onset right ventricular failure after continuous-flow left ventricular assist device implantation: case presentation and review of the literature. *J Cardiol*. 2022 Aug;80(2):110-115. PMID: 34974940.
 25. Kunibe Y, Ando M, Komae H, Shimada S, Kinoshita O, Yamauchi H, Ono M. Perigraft seroma after total aortic arch replacement using Triplex graft. *Gen Thorac Cardiovasc Surg*. 2022 Jul;70(7):668-672. PMID: 35349036.
 26. Tsuji S, Shimada S, Itoda Y, Yamauchi H, Ono M. Aortic valve replacement of a quadricuspid aortic valve with right coronary artery ostium

adjacent to one of the commissures. J
Cardiothorac Surg. 2022 Jun 7;17(1):146. PMID:
35672828.

Department of Gastrointestinal Surgery

Professor

Yasuyuki Seto M.D., Ph.D.

Associate Professor

Sachiyo Nomura M.D., Ph.D.

Susumu Aikou M.D., Ph.D.(The Institute of Medical Science)

Lecturer

Koichi Yagi M.D., Ph.D.

Associates

Shoh Yajima M.D. Ph.D.

Masayuki Urabe M.D., Ph.D.

Yoshiyuki Miwa M.D. Ph.D

Asami Okamoto M.D., Ph.D.

Shuichiro Oya M.D. Ph.D

Homepage <http://gibes.m.u-tokyo.ac.jp/>

General Affairs:

Since 1997, the former Third Department of Surgery, which was located in a branch hospital of the University of Tokyo, has been divided into two departments, the Department of Gastrointestinal Surgery and the Department of Metabolic Care and Endocrine Surgery, in line with the integration of the main and branch hospitals. Department of Metabolic Care and Endocrine Surgery has been renamed Breast and Endocrine Surgery in April 2017. Under the supports by the Social Medical Corporation Sosaikoseikai, the Social Medical Corporation Kawakita Medical Foundation and RIZAP Group Inc., Bariatric & Metabolic care (social cooperation program) was newly established in April 2017.

With the prolongation of life expectancy, there are increasing numbers of multi-morbid patients requiring multi-organ treatment, as well as a greater need for multidisciplinary approaches to the patients. Our fundamental principles of patient treatment are

comprehensive patient care which includes pre-, peri-, and postoperative management of the diseases as well as patient care over long-term postoperative periods which often extend to the terminal stage. We believe that patient care encompassing the entire lifespan provides a wealth of valuable information concerning the appropriateness of current treatment strategy, the establishment of new surgical designs, the development of new basic research activities which can much contribute to clinical fields, and indications of desirable modes of terminal care.

Fostering good surgeons as well as scientists who meet both clinical and academic needs has always been the guiding principle of our department.

Educational Activities:

The new system of clinical clerkship for medical students has begun from 2013. During those periods, the students are educated strictly and gently by staffs. Clinical exercises, e.g., blood sampling, injection, and

ligation, etc., are performed. They can attend the operations as an assistant.

They learn general patient care which encompasses not only perioperative management of diseases but also non-surgical management of postoperative disorders and terminal care. Our educational system provides medical students with a great deal of practical information from the medical point of view as well as better opportunities to ponder the implications of life and death.

For the medical students, the clinical clerkship lectures are held two or three times a week. The experts (from outside hospital) other than the staff give special unique and informative lectures, which are popular among the students.

Intern doctors rotate every three or one and half months. After completion of their initial training program, they go into a further exclusive clinical training program for several consecutive years and become a chief resident.

Research Activities:

Our goal is to cure the cancer patients by much better surgery. The development of better surgical methods has the highest priority. Better surgery means radicality of the cancer control, minimal invasiveness, and good QOL after surgery. Recently, transmediastinal (non-transthoracic) radical esophagectomy with extended lymphadenectomy has been applied, which shows less pulmonary complications, shorter postoperative hospital stay and better QOL after surgery. To develop this surgical procedure, we and other surgeons sharing same will established the Japanese Society for Nontransthoracic Radical Esophagectomy in 2016. New methods of endoscopic/laparoscopic full-thickness resection, non-exposed endoscopic wall-inversion surgery (NEWS) has been developed for submucosal gastric tumor as a collaboration of endoscopy and laparoscopy, and now NEWS is applied for some gastric cancer. Elimination of the pulmonary complications after esophagectomy and the detection of minute metastasis for the establishment of better surgery are also our important targets.

Another main research activities of the department of Gastrointestinal Surgery has been focused on

diagnosis and therapy for gastrointestinal diseases and clinical and basic research for gastrointestinal carcinogenesis from the view point of "Surgery and Inflammation". The department's research activities have focused on a wide spectrum of research topics, ranging from basic research topics to clinical ones. Our research activities have been well organized and ultimately achieved by maintaining a close connection between hospital and laboratory activities. Our medical staffs make every effort to promote the research activities and obtain successful results.

Clinical Activities:

We have outpatient clinics from Monday through Friday. We have specialized divisions for outpatient management of esophageal, gastric diseases. The ward is divided into two subgroups, and each of them has one medical staff for supervision, one assistant supervisor, one chief resident, and one or two junior residents in rotation. They are on duty for daily patient care under the supervision of medical staffs. Ordinary, each subgroup takes care of 15-25 patients.

The weekly official activities of our department are Ward Rounds by the Professor on Monday. We have post- and preoperative case conferences on Wednesday, Thursday, and Friday morning, respectively, and a journal club on Monday. We also have a specialized upper gastrointestinal case conference on Wednesday evening. Further, cancer board is held bi-weekly, where the radiologists and endoscopists as well as surgeons attend together and have discussions frankly.

Generally, elective surgery is scheduled on Tuesday, Wednesday and Thursday. The statistics shows 80 gastric and 70 esophageal cancer surgeries are performed a year, respectively. Hernia surgery is also performed. Laparoscopic sleeve gastrectomy for morbid obesity has started in June 2016, and the number of cases is steadily increasing. All residents and medical personnel work with high motivation for the good of the patients.

References

1. Itamoto K, Kumamaru H, Aikou S, Yagi K, Yamashita H, Nomura S, Miyata H, Kuroda S, Fujiwara T, Endo S, Kitagawa Y, Kakeji Y, Seto Y. No association between hospital volume and

- short term outcomes of some common surgeries: a retrospective cohort study based on a Japanese nationwide database. *Surg Today* 52(6): 941-952, 2022
2. Iwata R, Shiomi S, Aikou S, Yagi K, Yamashita H, Seto Y. Optimal settings of near-infrared fluorescence imaging with indocyanine green for intraoperative detection of lymph node metastasis in esophageal cancer. *Gen Thorac Cardiovasc Sur* 70(10): 924-929, 2022
 3. Konishi K, Fujiogi M, Michihata N, Kumazawa R, Ohbe H, Matsui H, Fushimi K, Ogita M, Tanabe M, Seto Y, Yasunaga H. Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan. *Breast cancer* 29: 688-697, 2022
 4. Konishi K, Fujiogi M, Michihata N, Matsui H, Tanabe M, Seto Y, Yasunaga H. Association between body mass index and incidence of breast cancer in premenopausal women: A Japanese nationwide database study. *Breast Cancer Res and Treat* 194: 315-325, 2022
 5. Konishi K, Fujiogi M, Michihata N, Morita K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Association of operative day of the week with the length of stay and total hospitalization costs in patients with partial mastectomy: a nationwide database study in Japan. *JMAJ* 5: 319-327, 2022
 6. Konishi K, Fujiogi M, Michihata N, Niwa T, Morita K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Impact of body mass index on short-term outcomes after differentiated thyroid cancer surgery: a nationwide inpatient database study in Japan. *Eur Thyroid J* 11(1): e210081, 2022
 7. Konishi K, Fujiogi M, Sato A, N Michihata N, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Short-Term outcomes following breast cancer surgery with and without neoadjuvant chemotherapy: a nationwide administrative database study in Japan. *Ann Surg Oncol* 29: 3000-3010, 2022
 8. Konishi K, Fujiogi M, Sato A, N Michihata N, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. ASO visual abstract: short-term outcomes following breast cancer surgery with and without neoadjuvant chemotherapy: a nationwide administrative database study in Japan. *Ann Surg Oncol* 29: 3013, 2022
 9. Konishi K, Fujiogi M, Tanabe M, Seto Y, Yasunaga H. ASO author reflections: neoadjuvant chemotherapy does not affect short-term outcomes after breast cancer surgery. *Ann Surg Oncol* 29: 3011-3012, 2022
 10. Konishi K, Goto T, Fujiogi M, Michihata N, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. New machine learning scoring system for predicting postoperative mortality in gastroduodenal ulcer perforation: A study using a Japanese nationwide inpatient database. *Surgery* 171(4): 1036-1042, 2022
 11. Konishi T, Fujiogi M, Michihata N, Ohbe H, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer. *Jpn J Clin Oncol* 52: 1115-1123, 2022
 12. Konishi T, Fujiogi M, Shigemi D, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Risk factors for postoperative bleeding following breast cancer surgery: A nationwide database study of 477, 108 cases in Japan. *World J Surg* 46: 3062-3071, 2022
 13. Konishi T, Fujiogi M, Shigemi D, Nishioka K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Surgical and obstetric outcomes of breast cancer surgery during pregnancy: a nationwide database study in Japan. *Breast Cancer Res and Treat* 195: 289-299, 2022
 14. Konishi T, Takamoto T, Fujiogi M, Hashimoto Y, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Laparoscopic versus open distal pancreatectomy with or without splenectomy: A propensity score analysis in Japan. *Int J Surg* 104: 106765, 2022
 15. Konishi T, Tanabe M, Michihata N, Matsui H, Nishioka K, Fushimi K, , Seto Y, Yasunaga H. Risk factors for arm lymphedema following breast cancer surgery: a Japanese nationwide database study of 84, 022 patients. *Breast cancer* 30: 36-45, 2022

16. Konishi T, Yoshimoto T, M Fujiogi, H Yamana, Tanabe M, Seto Y, Yasunaga H. Validity of operative information in Japanese administrative data: a chart review-based analysis of 1221 cases at a single institution. *Surg Today* 52;1484-1490, 2022
17. Niwa T, Konishi T, Sasahara A, Sato A, Morizono A, Harada M, Nishioka K, Fukuoka O, Makise N, Saito Y, Ando M, Yoshimoto T, Shikama T, Yamashita S, Tanabe M, Seto Y. Subcutaneous axillary primary epithelioid hemangioendothelioma: report of a rare case. *Surg Case Rep* 9;8(1): 166, 2022
18. Okamoto A, Aikou S, Iwata R, Oya S, Kawasaki K, Okumura Y, Yagi K, Yamashita H, Nomura S, Seto Y. The type of gastrectomy affects skeletal muscle loss and the long-term outcomes of elderly patients with gastric cancer: a retrospective study using computed tomography images. *Surg Today* 52(5): 812-821, 2022
19. Saito N, Sato Y, Abe H, Wada I, Kobayashi Y, Nagaoka K, Kushihara Y, Ushiku T, Seto Y, Kakimi K. Selection of RNA-based evaluation methods for tumor microenvironment by comparing with histochemical and flow cytometric analyses in gastric cancer. *Scientific Reports* 20;12(1): 8576, 2022
20. Shiomi S, Yajima S, Yoshimura S, Urabe M, Ri M, Okumura Y, Yagi K, Aikou S, Nomura S, Seto Y. Optimal criteria for predicting lymph node metastasis in esophageal squamous cell carcinoma by anatomical location using pre-operative computed tomography: a retrospective cohort study. *Surg Today* 52(8): 1185-1193, 2022
21. Sugawara K, Yagi K, Aikou S, Yamashita H, Seto Y. Impacts of complications after esophageal cancer surgery on health-related quality of life and nutritional status. *Gen Thorac Cardiovasc Surg.* doi: 10.1007/s11748-022-01846-y, 2022
22. Sugawara K, Yagi K, Okumura Y, Aikou S, Yamashita H, Seto Y. Survival Prediction Capabilities of Preoperative Inflammatory and Nutritional Status in Esophageal Squamous Cell Carcinoma Patients. *World J Surg* 46(3): 639-647, 2022
23. Sugawara K, Yamashita H, Urabe M, Okumura Y, Yagi K, Aikou S, Seto Y. Combining nutritional status with TNM stage: a physiological update on gastric cancer staging for improving prognostic accuracy in elderly patients. *Int J Clin Oncol* 27(12): 1849-1858, 2022
24. Toriumi T, Yagi K, Ri M, Yajima S, Okumura Y, Aikou S, Yamashita H, Nomura S, Seto Y. Lymphatic invasion is a prognostic factor of pathological N0 esophageal squamous cell carcinoma *Dis Esophagus* 35(7): doab087.doi: 10.1093/dote/doab087, 2022
25. Urabe M, Yagi K, Shiomi S, Toriumi T, Okumura Y, Seto Y. Implications of liver-directed therapy for postoperative hepatic metastasis from esophageal cancer. *J Chest Surg* 55(5): 397-404, 2022
26. Yasuda T, Lee HS, Nam SY, Katoh H, Ishibashi Y, Yamagata Murayama S, Matsui H, Masuda H, Rimbara E, Sakurazawa N, Suzuki H, Yoshida H, Seto Y, Ishikawa S, Jeon SW, Nakamura M, Nomura S. Non-Helicobacter pylori Helicobacter (NHPH) positive gastric cancer. *Sci Rep* 12(1): 4811.doi: 10.1038/s41598-022-08962-y, 2022
27. Zhang CD, Takeshima H, Sekine S, Yamashita S, Liu YY, Hattori N, Abe H, Yamashita H, Fukuda M, Imamura Y, Ushiku T, Katai H, Makino H, Watanabe M, Seto Y, Ushijima T. Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation. *Gastric Cancer* 25(2): 336-345, 2022
28. Zhang CD, Yamashita H, Okumura Y, Yagi K, Aikou S, Seto Y. Signature and Prediction of Perigastric Lymph Node Metastasis in Patients with Gastric Cancer and Total Gastrectomy: Is Total Gastrectomy Always Necessary? . *Cancers (Basel)* 14(14): 3409. doi: 10.3390/cancers14143409, 2022

Hepato-biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division

Professor and Chairman

Kiyoshi Hasegawa, M.D., Ph.D.

Associate Professor

Nobuhisa Akamatsu, M.D., Ph.D.

Lecturers

Junichi Kaneko, M.D., Ph.D.

Yoshikuni Kawaguchi, M.D., Ph.D.

Homepages <http://www.u-tokyo-hbp-transplant-surgery.jp/>

Introduction and Organization

The Hepato-Biliary-Pancreatic (HBP) Surgery Division, Artificial Organ and Liver Transplantation Division, Department of Surgery is originated from Second Department of Surgery (2nd Dept of Surg), which was established in 1893. This department has a history of over 130 years and has made tremendous contribution to the Japanese surgical advancement, such as the foundation of Japanese Surgical Society. As departments in the style of graduate school have been increasingly founded in The University of Tokyo, and organ-specific medication has been progressively recommended, 2nd Dept of Surg has been replaced to HBP Surg Division since June 1st, 1998.

Clinical Activities

Our division deals with patients with HBP malignancies, benign diseases and end stage liver disease. We specialize in hepatectomies for hepatocellular carcinoma and colorectal metastasis. Laparoscopic or robotic Whipple's procedure has started recent year. Living donor liver transplantation achieved international renown. Now we are ranked in

the top three high volume centers in Japan including deceased donor liver transplantation. Roughly 500 patients undergo surgery every year. Elective operations are carried out on Monday, Wednesday and Friday. The perioperative management is strictly controlled, with nearly zero mortality. Adjuvant chemotherapy is performed in a style of prospective clinical trials.

Education

Education for medical students includes systematic lectures of surgery for M2 (senior year) students, and clinical lectures and bed-side practice for M3 and final-year students, in accordance with other surgical and non-surgical departments. Since 2013, The Clinical Clerkship, more practical medical training had started. In our division, students actively participate the surgical activities.

Clinical Clerkship is designed to consist of 2 parts; 2 weeks clinical practice in the University of Tokyo and 1 week practice in other hospitals. Medical students are expected to join the surgical team and the surgical operations. They can learn about preoperative examinations & care of the patients, informed

consents, diagnosis, presentation at the conferences, operative procedures, and postoperative managements. They also are expected to submit a report on a theme of specific surgical topics.

Research

We have published papers mainly on HBP Surgery and liver transplantation. The ongoing topics involve clinical application of ICG fluorescence imaging enabling visualization of biological structures (biliary trees, hepatic tumors, hepatic segmental boundaries, etc.), prospective clinical trials of adjuvant chemotherapy for hepatocellular carcinoma, metastatic colorectal cancer, neoadjuvant chemotherapy for borderline resectable pancreatic cancer, utility of contrast-enhanced intraoperative ultrasonography, pre operative navigation for hepatic surgery, and clinical application of artificial intelligence and synthetic blood vessel graft.

Publications (2022)

1. Kokudo T, Kokudo N, Hasegawa K. Oncological benefit of anatomic resection for patients with hepatocellular carcinoma. *Surg Today*. 2022 Dec 7. Online ahead of print.
2. Ishizawa T, Akamatsu N, Kaneko J, Arita J, Hasegawa K. Closure and anastomosis of the pancreas using a four-needle three-loop suture device. *Glob Health Med*. 2022 Aug 31;4(4):225-229.
3. Hakoda H, Kiritani S, Kokudo T, Yoshimura K, Iwano T, Tanimoto M, Ishizawa T, Arita J, Akamatsu N, Kaneko J, Takeda S, Hasegawa K. Probe electrospray ionization mass spectrometry-based rapid diagnosis of liver tumors. *J Gastroenterol Hepatol*. 2022 Nov;37(11):2182-2188.
4. Kokudo T, Ishizawa T, Nagata R, Ichida A, Mihara Y, Kawaguchi Y, Akamatsu N, Kaneko J, Arita J, Kokudo N, Hasegawa K. Optimal tumor numbers in surgical candidates for multiple hepatocellular carcinomas. *Surgery*. 2022 Oct; 172(4):1174-1178.
5. Bae SK, Arita J, Akamatsu N, Maki H, Nishioka Y, Kawahara T, Miyata A, Kokudo T, Nagata R, Mihara Y, Ichida A, Inagaki Y, Kawaguchi Y, Ishizawa T, Kaneko J, Tamura S, Tanaka Y, Moriya K, Hasegawa K. The impact of the covalently closed circular DNA level on recurrence of hepatocellular carcinoma after initial hepatectomy: an analysis of patients with resolved hepatitis B virus infection. *HPB (Oxford)*. 2022 Oct;24(10):1780-1788.
6. Kazami Y, Arita J, Nishioka Y, Kawaguchi Y, Ichida A, Ishizawa T, Akamatsu N, Kaneko J, Nakai Y, Koike K, Hasegawa K. Preoperative Predictive Features of Invasive Carcinoma Among Intraductal Papillary Mucinous Neoplasm of the Pancreas. *Pancreas*. 2022 Jul 1; 51(6):642-648.
7. Maki H, Hasegawa K. Advances in the surgical treatment of liver cancer. *Biosci Trends*. 2022 Jul 20;16(3):178-188.
8. Kiritani S, Kaneko J, Arita J, Ishizawa T, Akamatsu N, Hasegawa K. Radical Antegrade Modular Pancreatosplenectomy for Left-Sided Pancreatic Ductal Adenocarcinoma May Reduce the Local Recurrence Rate. *Dig Surg*. 2022; 39(4):191-200.
9. Takahashi R, Akamatsu N, Nakazawa A, Nagata R, Ichida A, Kawaguchi Y, Ishizawa T, Kaneko J, Arita J, Hasegawa K. Effect of the response to preoperative treatment for hepatorenal syndrome on the outcome of recipients of living-donor liver transplantation. *J Hepatobiliary Pancreat Sci*. 2022 Jul;29(7):798-809.
10. Arita J, Ichida A, Nagata R, Mihara Y, Kawaguchi Y, Ishizawa T, Akamatsu N, Kaneko J, Hasegawa K. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors. *J Hepatobiliary Pancreat Sci*. 2022 Jul;29(7):732-740.
11. Watanabe G, Mise Y, Oba M, Saiura A, Inoue Y, Takahashi Y, Kishi Y, Suyama K, Takayama T, Noie T, Nishioka Y, Akamatsu N, Arita J, Kokudo N, Hasegawa K. A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial. *HPB (Oxford)*. 2022 Aug;24(8):1245-1251.

12. Matsumura M, Hasegawa K, Oba M, Yamaguchi K, Uetake H, Yoshino T, Morita S, Takahashi K, Unno M, Shimada Y, Muro K, Matsushashi N, Mori M, Baba H, Shimada M, Mise Y, Kawaguchi Y, Kagimura T, Ishigure K, Saiura A, Sugihara K, Kokudo N. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. *Langenbecks Arch Surg.* 2022 Jun;407(4):1345-1356.
13. Ichida A, Akamatsu N, Nagata R, Mihara Y, Kawaguchi Y, Bae SK, Ishizawa T, Kaneko J, Arita J, Hasegawa K. Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases. *Anticancer Res.* 2022 Feb;42(2):1161-1167.
14. Kawaguchi Y, Fuks D, Vauthey JN, Kokudo N, Gayet B, Hasegawa K. A novel simple three-level liver resection classification without compromising the performance to predict surgical and postoperative outcomes. *Eur J Surg Oncol.* 2022 Jan;48(1):305-306.
15. Kazami Y, Kaneko J, Keshwani D, Takahashi R, Kawaguchi Y, Ichida A, Ishizawa T, Akamatsu N, Arita J, Hasegawa K. Artificial intelligence enhances the accuracy of portal and hepatic vein extraction in computed tomography for virtual hepatectomy. *J Hepatobiliary Pancreat Sci.* 2022 Mar;29(3):359-368.
16. Watanabe G, Kawaguchi Y, Ichida A, Ishizawa T, Akamatsu N, Kaneko J, Arita J, Hasegawa K. Understanding conditional cumulative incidence of complications following liver resection to optimize hospital stay. *HPB (Oxford).* 2022 Feb;24(2):226-233.
17. Okada Y, Kawaguchi Y, Matsumura M, Matsubara S, Nakai Y, Ichida A, Ishizawa T, Akamatsu N, Kaneko J, Arita J, Koike K, Hasegawa K. A safe sequential treatment approach for patients who have acute cholecystitis with severe inflammation: Transmural gallbladder drainage followed by laparoscopic cholecystectomy under the guidance of fluorescence imaging. *Asian J Endosc Surg.* 2022 Jan;15(1):230-234.
18. Ishizawa T, McCulloch P, Stassen L, van den Bos J, Regimbeau JM, Dembinski J, Schneider-Koriath S, Boni L, Aoki T, Nishino H, Hasegawa K, Sekine Y, Chen- Yoshikawa T, Yeung T, Berber E, Kahramangil B, Bouvet M, Diana M, Kokudo N, Dip F, White K, Rosenthal RJ. Assessing the development status of intraoperative fluorescence imaging for anatomy visualisation, using the IDEAL framework. *BMJ Surg Interv Health Technol.* 2022 Nov 4;4(1):e000156.
19. Karako K, Mihara Y, Arita J, Ichida A, Bae SK, Kawaguchi Y, Ishizawa T, Akamatsu N, Kaneko J, Hasegawa K, Chen Y. Automated liver tumor detection in abdominal ultrasonography with a modified faster region-based convolutional neural networks (Faster R-CNN) architecture. *Hepatobiliary Surg Nutr.* 2022 Oct;11(5):675-683.
20. Kiritani S, Arita J, Mihara Y, Nagata R, Ichida A, Kawaguchi Y, Ishizawa T, Akamatsu N, Kaneko J, Hasegawa K. Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm. *Surgery.* 2023 Feb;173(2):365-372.

Department of Urology

Professor

Haruki Kume, M.D., Ph.D.

Assistant Professor

Daisuke Yamada, M.D., Ph.D., Yusuke Sato, M.D., Ph.D.,

Yuta Yamada, M.D., Ph.D., Yoshiyuki Akiyama, M.D., Ph.D.,

Satoru Taguchi, M.D., Ph.D.

Associate

Kenji Yoda, M.D., Kanae Yoshida, M.D., Yoichi Fujii, M.D., Ph.D.,

Daiji Watanabe, M.D., Shintaro Takahashi, M.D., Norihide Shirakawa, M.D.,

Hayato Hoshina, M.D., Kenichi Hashimoto, Ph.D.

Homepage <http://www.h.u-tokyo.ac.jp/urology/>

Introduction and Organization

Urology is a special field of clinical medicine covering the diseases of the adrenal gland, the kidney, the urinary tract and the male genital system by means of a surgical procedure as well as an approach of internal medicine. In addition, urology encompasses pediatric urology, neurourology, female urology, renal transplantation, renal vascular surgery, endocrine surgery and geriatric urology. For this reason, urology requires the scientific background of oncology, nephrology, endocrinology, andrology, immunology, pediatrics, histology, microbiology, neurology and gerontology. Now we have commenced to utilize cellular and molecular biology to develop the research in urology. It is expected for our department to devote to the scientific progress in the frontier of urology.

In recent years, we have been taking international leadership in applying the new and minimally invasive treatment modalities. They are exemplified by endoscopic management of the diseases in the upper urinary tract, ESWL or laser lithotripsy for urolithiasis, hyperthermic and laser therapies for BPH, and minimum incision endoscopic or laparoscopic adrenalectomy, nephrectomy, and robot-assisted

prostatectomy substituting open procedures.

Clinical activities

There are 44 beds in the ward (8th floor of the central-ward-building). The professor, associate professors, lecturers and associates are involved in in-patient and out-patient cares and teaching of the students as well as research activities. Clinical visiting professors are mainly engaged in the teaching. The residents take care of all the patients on 24-hour a day basis. Associate staff members team up with the residents on a man-to-man basis. Elective operations are performed on every weekday (from Monday to Friday). 1753 operations were performed in 2022. The numbers of main operations are adrenalectomy 12, nephrectomy 20, partial nephrectomy 71, nephroureterectomy 14, radical cystectomy 18, radical prostatectomy 121, transurethral resection of the bladder tumor (TUR-Bt) 190, transurethral resection of the prostate (TUR-P) 9, and robot-assisted surgeries 204 (radical prostatectomy 121, partial nephrectomy 59, radical cystectomy 17, pyeloplasty 7).

At the weekly professor's round on Wednesday, data of all in patients are presented and appropriate

treatment strategies are recommended for them. On Wednesday evening, a clinical conference is held for discussing cases with difficult problems in detail and the best treatment is chosen for each case.

In out-patient clinic, services are provided from Monday to Friday. Patients assigned to specialized services as renal tumor, adrenal surgery, bladder cancer, prostate cancer, andrology, neurourology, urolithiasis, kidney transplantation, second opinion, pediatric urology and female urology receive sophisticated care on the particular day of the week.

The total number of out-patients was 26,296 patient-days from January 2022 to December 2022.

Teaching activities

Systematic urological lectures are provided for second year medical students. Both clinical lectures and bed side teaching are scheduled for third and fourth year medical students. Thirteen times of systematic lectures are performed by professor, associate professors and instructors concerning their specialties.

Bed side teaching is concentrated on practical care of the patients. Teachers give lectures mainly regarding pre- and post-operative management, indication of operation, surgical anatomy and surgical techniques.

Research activities

There are 9 research themes for research as below. The basic principles for research are program in surgical techniques and therapy for incurable diseases, which include advanced cancer, renal insufficiency, sexual dysfunction, and interstitial cystitis. We have published approximately 50 English papers every year.

Renal tumor

Urolithiasis

Kidney Transplantation

Prostate diseases

New surgical technique

Urinary disturbance/ Female Urology

Andrology

Virology

References

1. Takayama T, Sugihara T, Kameda T, Yamazaki M, Komatsubara M, Kamei J, Fujisaki A, Ando S, Fujimura T. Treatment outcome of radium-223 treatment for castration-resistant prostate cancer and bone metastases at a single university hospital. *Int J Radiat Res*, 20(1), 75-81,2022.1.
2. Jimba M, Matsuzawa Y, Suzuki M, Kitamura T, Carandang RR, Sieber NL. Risk of increasing the sudden diagnosis of AIDS in Japan during and after COVID-19 outbreak. *JMA J*, 5(1), 104-106, 2022.1.
3. Zaitzu M, Takeuchi T, Zaitzu M, Tonooka A, Uekusa T, Miyake Y, Kobayashi Y, Kobashi G, Kawachi I. Occupational disparities in tumor grade and cytosolic HMGB1 expression in renal cell cancer. *J Occup Health*, 64(1), e12340,2022.1.
4. Oshina T, Taguchi S, Miyakawa J, Akiyama Y, Sato Y, Kawai T, Fukuhara H, Nakagawa T, Kume H. Clinicopathological features and oncological outcomes of urothelial carcinoma involving the ureterovesical junction. *Jpn J Clin Oncol*, 52(1), 65-72,2022.1.
5. Hagiwara K, Sakamoto A, Sasaki K, Kanatani A, Kimura M, Kaneko T, Takahashi S, Yamada Y, Nakagawa T. Higher serum alkaline phosphatase value indicates the need for bone mineral density testing in non-metastatic prostate cancer patients undergoing androgen deprivation therapy. *Jpn J Clin Oncol*, 52(1), 73-80,2022.1.
6. Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Hara I, Kawamura N, Inoue M, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Egawa S, Kakehi Y, Sugimoto M. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study. *Int J Clin Oncol*, 27(1), 194-201,2022.1.
7. Kinjo M, Tanba M, Masuda K, Nakamura Y, Tanbo M, Fukuhara H. Comparison of effectiveness between modified transvaginal mesh surgery and vaginal pessary treatment in

- patients with symptomatic pelvic organ prolapse. *Low Urin Tract Symptoms*, 14(1), 64-71,2022.1.
8. Sasaki T, Ebara S, Tatenuma T, Ikehata Y, Nakayama A, Kato D, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Kitamura H, Saito K, Koie T, Koga F, Urakami S, Inoue T. Prognostic differences among Grade Group 4 subgroups in robotic-assisted radical prostatectomy. *BJUI Compass*, 3(5), 392-399, 2022.1.
 9. Kinoshita Y, Katano S, Nishida S, Shimizu T, Fujimura T, Kume H, Iwami D. Creatinine reduction ratio on postoperative day 2 predicts long-term outcomes after living donor kidney transplantation. *Int J Urol*, 29(2), 114-120,2022. 2.
 10. Kubo T, Takayama T, Fujisaki A, Nakamura S, Teratani T, Sata N, Kitayama J, Nakai H, Iwami D, Fujimura T. Novel high-quality and reality biomaterial as a kidney surgery simulation model. *PLoS ONE*, 17(2), e0263179,2022.2.
 11. Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Takahashi S, Kume H. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis. *J Immunother Cancer*, 10(2), e003965,2022.2.
 12. Matsunaga A, Yoshida M, Shinoda Y, Sato Y, Kamei J, Niimi A, Fujimura T, Kume H, Igawa Y. Effectiveness of ultrasound-guided pelvic floor muscle training in improving prolonged urinary incontinence after robot-assisted radical prostatectomy. *Drug Discov Ther*, 16(1), 37-42, 2022.2.
 13. Takeuchi T, Hattori-Kato M, Okuno Y, Zaitzu M, Azuma T. Genome-Wide Association Study Adjusted for Occupational and Environmental Factors for Bladder Cancer Susceptibility. *Genes (Basel)*, 13(2), 448,2022.2.
 14. Shin Kumagai, Osamu Muraki, Yasukuni Yoshimura. Evaluation of the effect of levator ani muscle contraction on post-prostatectomy urinary incontinence using cine MRI. *Neurourol Urodyn*, 41(2), 616-625,2022.2.
 15. Yokomizo A, Yonese J, Egawa S, Fukuhara H, Uemura H, Nishimura K, Nagata M, Saito A, Lee T, Yamaguchi S, Nonomura N. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan. *Int J Clin Oncol*, 27(2), 418-426,2022.2.
 16. Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Takehi Y, Sugimoto M. Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer; results from a prospective cohort in the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study. *Urol Oncol*, 40(2), 56.e.9-e15,2022.2.
 17. Mizuno T, Satho N, Horita S, Tsukada H, Takagi M, Sato Y, Kume H, Nangaku M, Nakamura M. Oxidized alkyl phospholipids stimulate sodium transport in proximal tubules via a non-genomic PPAR γ -dependent pathway. *J Biol Chem*, 298 (3) , 101681,2022.3.
 18. Ando S, Kamei J, Yamazaki M, Sugihara T, Kameda T, Fujisaki A, Kurokawa S, Takayama T, Fujimura T. Longer preserved urethral length in robot-assisted radical prostatectomy significantly contributes to post-operative urinary continence recovery. *BJUI Compass*, 3(2), 184-190,2022.3.
 19. Takayama T, Kameda T, Nakano K. Female-only Ureteral Stent Placement and Replacement Technique Using Pig-tail Straightener. *Dokkyo Medical Journal*, 1(1), 81-83,2022.3.
 20. Nagamoto S, Urakami S, Oka S, Ogawa K, Kono K, Sakaguchi K, Kinowaki K, Yamada D, Kume H. Impact of the neutrophil-to-lymphocyte ratio as a surgical prognostic factor in renal cell carcinoma with inferior vena cava tumor thrombus. *Asian J Surg*, 46(1), 192-200,2022.3.
 21. Makino K, Sato Y, Takenaka K, Yamashita H, Akiyama Y, Yamada Y, Nakamura M, Kawai T, Yamada D, Suzuki M, Kume H. Cumulative incidence and clinical risk factors of radiation

- cystitis after radiotherapy for prostate cancer. *Urol Int*, Online ahead of print, 2022.3.
22. Yoshida, S., Matsushima, H., & Fujii, Y. Classification of oligometastatic prostate cancer with additional consideration for hormone sensitivity. *World journal of urology*, 40(3), 871-873, 2022.3.
 23. Akiyama Y, Niimi A, Igawa Y, Nomiya A, Yamada Y, Sato Y, Kawai T, Yamada D, Kume H, Homma Y. Cystectomy for patients with Hunner-type interstitial cystitis at a tertiary referral center in Japan. *Low Urin Tract Symptoms*, 14(2), 102-108, 2022.3.
 24. Mochida Y, Ochiai K, Nagase T, Nonomura K, Akimoto Y, Fukuhara H, Sakai T, Matsumura G, Yamaguchi Y, Nagase M. Piezo2 expression and its alteration by mechanical forces in mouse mesangial cells and renin-producing cells. *Sci Rep*, 12(1), 4197, 2022.3.
 25. Nagamoto S, Urakami S, Oka S, Ogawa K, Kono K, Sakaguchi K, Kinowaki K, Yamada D, Kume H. Impact of the neutrophil-to-lymphocyte ratio as a surgical prognostic factor in renal cell carcinoma with inferior-vena-cava tumor thrombus. *Asian J Surg*, 46(1), 192-200, 2022.3.
 26. Kaneko T, Yanagida K, Matsui K, Kimura M, Yamada Y, Ishii K, Kurozumi T, Suzuki T, Watanabe Y, Kawano H, Sakamoto T, Nakagawa T. Incidence of genitourinary injuries in pelvic fractures: a 12-year single-center retrospective study. *Neurourol Urodyn*, 41(4), 1025-1030, 2022.4.
 27. Kinoshita Y, Shirakawa K, Sano M, Yokoo T, Kume H, Kobayashi E. Development of a novel porcine ischemia/reperfusion model inducing different ischemia times in bilateral kidneys—effects of hydrogen gas inhalation. *Transl Androl Urol*, 11(4), 430-438, 2022.4.
 28. Kamei J, Fujisaki A, Saito K, Sugihara T, Ando S, Miyagawa T, Takayama T, Fujimura T. Less invasive and equivalent short-term outcomes with simultaneous en bloc robot-assisted radical cystectomy and laparoscopic nephroureterectomy: Comparison with conventional open radical cystectomy and nephroureterectomy. *Asian J Endosc Surg*, 15(2), 255-260, 2022.4.
 29. Ando S, Nakamura S, Hyuga T, Tanabe K, Nakai H, Fujimura T. Indigo Carmine Dye-Assisted Lymphatic-Sparing Microsurgical Subinguinal Varicocelelectomy Among Children and Adolescents. *Indian J Surg*, published online, 2022.4.
 30. Shishido T, Okegawa T, Hayashi K, Masuda K, Taguchi S, Nakamura Y, Tambo M, Fukuhara H. Laparoscopic retroperitoneal lymph node dissection versus open retroperitoneal lymph node dissection for testicular cancer: A comparison of clinical and perioperative outcomes. *Asian J Urol*, 9(2), 119-124, 2022.4.
 31. Kato T, Hiramasa H, Mitsuzuka K, Maruyama S, Sasaki H, Saito T, Matsumoto R, Sakamoto S, Sakai Y, Fukuhara H, Naya Y, Tsukino H, Hara I, Ogawa O, Hashine K, Fumimasa F, Yokomizo A, Tohi Y, Takehi Y, Sugimoto M. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN. *Prostate Cancer Prostatic Dis*, 25(4), 666-671, 2022.4.
 32. Nomura Y, Okada Y, Nakagawa C, Kurokawa I, Shigeta M, Fujisawa H, Yoshimura Y. Magnetic resonance imaging evaluation of the effectiveness of FemiCushion in pelvic organ prolapse. *J Obstet Gynaecol Res*, 48(5), 1255-1264, 2022.5.
 33. Kamasako T, Kaga K, Inoue K, Hariyama M, Yamanishi T. Supervised machine learning algorithm identified KRT20, BATF and TP63 as biologically relevant biomarkers for bladder biopsy specimens from interstitial cystitis/bladder pain syndrome patients. *Int J Urol*, 29(5), 406-412, 2022.5.
 34. Nakamura Y, Taguchi S, Kinjo M, Tambo M, Okegawa T, Fukuhara H. Adrenal metastasis in nivolumab-treated renal cell carcinoma: a unique entity as a sanctuary site. *Urol Int*, 29(6), 597-599, 2022.6.
 35. Teshima T, Kobayashi Y, Kawai T, Kushihara Y, Nagaoka K, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Tanaka N, Tsunoda T, Kume H, Kakimi K. Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma. *Oncol Lett*, 24(2), 265, 2022.6.

36. Kinjo M, Masuda K, Nakamura Y, Taguchi S, Tambo M, Fukuhara H. Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder? *Int Urogynecol J*, Online ahead of print,2022.6.
37. Kobayashi K, Matsuyama H, Kawai T, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Kume H, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Azuma H, Inoue K, Mitsui T, Kawakita M, Oyama C, Mizokami A, Shinohara N, Kuroiwa H. Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study). *Urol Int*, 29(7), 632-638,2022.7.
38. Kurokawa S, Kamei J, Sakata K, Sugihara T, Fujisaki A, Ando S, Takayama T, Fujimura T. The cutoff value of transitional zone index predicting the efficacy of dutasteride on subjective symptoms in patients with benign prostate hyperplasia. *LUTS*, 14(4), 261-266,2022.7.
39. Kimura N, Yamada Y, Takeshima Y, Otsuka M, Akamatsu N, Hakozaiki Y, Miyakawa J, Sato Y, Akiyama Y, Yamada D, Fujimura T, Kume H. The 'prostate-muscle index': a simple pelvic cavity measurement predicting estimated blood loss and console time in robot-assisted radical prostatectomy. *Sci Rep*, 12(1), 11945,2022.7.
40. Kimura N, Takayama K, Yamada Y, Kume H, Fujimura T, Inoue S. Ribonuclease H2 Subunit A Preserves Genomic Integrity and Promotes Prostate Cancer Progression. *Cancer Res Commun*, 2(8), 870–883,2022.8.
41. Yamanaka T, Takemura K, Hayashida M, Suyama K, Urakami S, Miura Y. Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective study. *Reserch square*, 0.21203/rs.3.rs-1947367, 1-8,202.8.
42. Kaga K, Yamanishi T, Shibata C, Kamasako T, Kaga M, Fuse M. The efficacy of compression stocking on patients with nocturia: sundrome patients -arm pilot study. *Cureus*, 14(8), e28603, 2022.8.
43. Hakozaiki Y, Yamada Y, Kawai T, Nakamura M, Takeshima Y, Iwaki T, Teshima T, Kinoshita Y, Fujii Y, Akiyama Y, Sato Y, Yamada D, Suzuki M, Kashiwagi-Hakozaiki M, Ushiku T, Kume H. Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer. *Sci Rep*, 12(1), 16202,2022.9.
44. Nakamura M, Kameyama S, Ambe Y, Teshima T, Izumi T, Tsuru I, Inoue Y, Yoshimatsu T, Inatsu H, Amakawa R, Kusakabe M, Morikawa T, Shiga Y. Predictive factors for postoperative renal function after off-clamp, non-renorrhaphy partial nephrectomy. *Transl Androl Urol*, 11(9), 1226-1233,2022.9.
45. Takada I, Hidano S, Takahashi S, Ogawa H, Tsuchiya M, Yokoyama A, Sato S, Ochi H, Nakagawa T, Kobayashi T, Nakagawa S, Makishima M Authors equally contributed. Transcriptional coregulator Ess2 controls survival of post-thymic CD4+ T cells through the Myc and IL-7 signaling pathways. *J Biol Chem*, 298(9), 102342,2022.9.
46. Takada I, Hidano S, Takahashi S, Yanaka K, Ogawa H, Tsuchiya M, Yokoyama A, Sato S, Ochi H, Nakagawa T, Kobayashi T, Nakagawa S, Makishima M. Ess2 controls survival of post-thymic CD4+ T cells through the Myc and IL-7 signaling pathways. *J Biol Chem*, 298(9), 102342,2022.9.
47. Azuma T, Kano M, Iwata S, Honda S, Miyoshi Y, Nishiguchi J. Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. *PLoS One*, 17(9),2022.9.
48. Tohi Y, Kato T, Miyakawa J, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Matsumura M, Yokomizo A, Kinoshita H, Hara I, Kawamura N, Hashimoto K, Inoue M, Teishima J, Kanno H, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Takehi Y, Sugimoto M. Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study. *Jpn J Clin Oncol*, 52(9), 1056-1061,2022.9.
49. Yamazaki M, Takayama T, Fujita A, Kikuchi T, Kamimura T, Myoga H, Mayumi S, Yazaki K, Katano S, Komatsubara M, Kamei J, Sugihara T, Ando S, Fujimura T. 3D printed kidney model could be an important educational tool for

- residents. *Asian J Endosc Surg*, Online ahead of print,2022.10.
50. Cheng F, Watton PN, Pederzani G, Kurobe M, Takaoka E, Chapple C, Birder L, Yoshimura N, Robertson AM. A constrained mixture-micturition-growth (CMMG) model of the urinary bladder: Application to partial bladder outlet obstruction (BOO). *J Mech Behav Biomed Mater*, 134,2022.10.
 51. Takeshima Y, Yamada Y, Takemura K, Kimura N, Hakozaiki Y, Miyakawa J, Taguchi S, Akiyama Y, Sato Y, Kawai T, Yamada D, Fujimura T, Kume H. The association between the parameters of uroflowmetry and lower urinary tract symptoms in prostate cancer patients after robot-assisted radical prostatectomy. *PLoS ONE*, 17(10),2022. 10.
 52. Yamada Y, Taguchi S, Kume H. Surgical tolerability and frailty in elderly patients undergoing robot-assisted radical prostatectomy: A narrative review. *Cancers* 2022, 14(20), 5061, 2022.10.
 53. Nakamura M, Yamada Y, Sato Y, Honda K, Yamada D, Kawai T, Akiyama Y, Suzuki M, Kume H. Preservation of pelvic floor muscles contributes to early continence recovery after robot-assisted radical prostatectomy. *PLoS One*, 17(10),2022.10.
 54. Zhou J, Koizumi N, Nishiyama Y, Kogiso K, Ishikawa T, Kobayashi K, Watanabe Y, Fujibayashi T, Yamada M, Matsuyama M, Tsukihara H, Tsumura R, Yoshinaka K, Matsumoto N, Ogawa M, Miyazaki H, Numata K, Nagaoka H, Iwai T, Iijima H. A VS ultrasound diagnostic system with kidney image evaluation functions. *Int J Comput Assist Radiol Surg*, online ahead of print,2022.10.
 55. Kato D, Ebara S, Tatenuma T, Sasaki T, Ikehata Y, Nakayama A, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Inoue T, Kitamura H, Saito K, Koga F, Urakami S, Koie T. Short-term oncological and surgical outcomes of robot-assisted radical prostatectomy: A retrospective multicenter cohort study in Japan (the MSUG94 group). *Asian J Endosc Surg*, 15(4), 745-752, 2022.10.
 56. Kawase M, Ebara S, Tatenuma T, Sasaki T, Ikehata Y, Nakayama A, Toide M, Yoneda T, Sakaguchi K, Ishihara T, Teishima J, Makiyama K, Inoue T, Kitamura H, Saito K, Koga F, Urakami S, Koie T. A Nomogram for Predicting Prostate Cancer with Lymph Node Involvement in Robot-Assisted Radical Prostatectomy Era: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group). *Diagnostics (Basel)*, 12(10), 2545,2022.10.
 57. Namiki S, Kawase M, Ebara S, Tatenuma T, Sasaki T, Ikehata Y, Nakayama A, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Inoue T, Kitamura H, Saito K, Koga F, Urakami S, Koie T. Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group). *Cancers (Basel)*, 14(23), 5803,2022.11.
 58. Watanabe M, Taguchi S, Machida H, Tambo M, Takeshita Y, Kariyasu H, Fukushima K, Shimizu Y, Okegawa T, Fukuhara H, Yokoyama K. Clinical validity of non-contrast-enhanced VI-RADS: Prospective study using 3-T MRI with high gradient magnetic field. *European Radiology* 2022, 32(11), 7513-7521,2022.11.
 59. Sugimoto K, Taguchi S, Kishitani K, Kawai T, Masuda K, Nakamura Y, Kinjo M, Tambo M, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Fukuhara H, Kume H. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma. *BMC Urol*, 22(1), 177,2022.11.
 60. Kato T, Yokomizo A, Matsumoto R, Tohi Y, Miyakawa J, Mitsuzuka K, Sasaki H, Inokuchi J, Matsumura M, Sakamoto S, Kinoshita H, Fukuhara H, Kamiya N, Kimura R, Nitta M, Okuno H, Akakura K, Kakehi Y, Sugimoto M. Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study. *Int J Urol*, 29(11), 1271-1278,2022.11.

61. Watanabe M, Taguchi S, Machida H, Tambo M, Takeshita Y, Kariyasu T, Fukushima K, Shimizu Y, Okegawa T, Fukuhara H, Yokoyama K. Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field. *Eur Radiol*, 32(11), 7513-7521,2022.11.
62. Kurokawa r, Kato S, Koyama H, Ishida M, Kurokawa M, Kuroda R, Ushiku T, Kume H, Abe O. Osteolytic or mixed bone metastasis is not uncommon in patients with high-risk prostate cancer. *European Journal of Radiology* 2022, 157, 110595,2022.12.
63. Suzuki M, Yamamoto M, Shiratori T, Naito A, Nakamura M. Evaluation of trends in prescription drugs for overactive bladder in Japanese patients. *International Journal of Urology*, Online ahead of print,2022.12.
64. Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Yoshida K, Yamamoto S, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Matsumoto A, Uemura Y, Akiyama Y, Yamada, Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Ishikawa A, Tanaka Y, Nagase Y, Fujimura T, Fukuhara H, Takahashi S, Kume H. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020). *Int J Urol*, 29(12), 1462-1469,2022.12.
65. Sugihara T, Kamei J, Yasunaga H, Sasabuchi Y, Fujimura T. Prescription of Choreito, a Japanese Kampo Medicine, with Antimicrobials for Treatment of Acute Cystitis: A Retrospective Cohort Study. *Antibiotics (Basel)*, 11(12), 1840, 2022.12
66. Kitamura T, Suzuki M, Shigehara K, Fukuda K, Matsuyama T, Kume H. Prevalence of human papillomavirus types 16/18 and effect of vaccination among Japanese female general citizens in the vaccine crisis era. *Viruses*
67. Suzuki M, Shiratori T, Naito A. Relevant predisposing factors for voiding in a sitting position among Japanese male adult patients. *Continence*

Department of Surgical Oncology

Professor

Soichiro Ishihara, M.D., Ph.D.

Associate Professor

Hiroaki Nozawa, M.D., Ph.D.

Lecturer

Kazuhito Sasaki, M.D., Ph.D., Koji Murono, M.D.

Assistant Professor

Shigenobu Emoto, M.D., Ph.D., Hiroyuki Matsuzaki, M.D., Ph.D.,

Yuichiro Yokoyama, M.D., Ph.D., Shinya Abe, M.D., Ph.D., Yuzo Nagai, M.D., Ph.D.,

Yuichiro Yoshioka, M.D., Ph.D., Takahide Shinagawa, M.D., Ph.D.,

Hirofumi Sonoda, M.D., Pharm.D., Ph.D., Yoko Yamamoto, Ph.D.

Homepage <http://all-1su.umin.jp/>

Introduction and Organization

In 1995, a new system for postgraduate education was introduced. The First Department of Surgery was reorganized to form the Department of Surgical Oncology and the Department of Vascular Surgery. The staff of the Department of Surgical Oncology consists of one Professor, one Associate Professor, two Lecturers and nine Assistant Professors. The outpatient office is located on the third floor of the Outpatient Building. The ward is situated on the eighth floor of the Ward Building. The administrative office and research laboratories are located in the Administration and Research Building. Current activities of the Department of Surgical Oncology in clinical practice, education, and research are summarized as follows.

Clinical activities

The Department of Surgical Oncology provides comprehensive evaluation, diagnosis, treatment and management for adult patients with both general and oncologic surgical problems, in the ambulatory as well as inpatient setting. In particular, we are trying to

identify the best way to treat each patient with the least surgical stress by minimally invasive surgery such as laparoscopic surgery and robotic surgery (da Vinci Surgical System), and preoperative chemoradiotherapy for rectal cancer. The department is also well known for its innovative therapy for inflammatory bowel disease. Department specialists have expertise in biological cancer immunotherapy, chemotherapy for a variety of malignancies, and radiotherapy for rectal cancer. The outpatient clinic is open from Monday through Friday, and twenty-four-hour consultation is available for urgent or emergency problems.

The outpatient clinic is specialized in the lower GI tract. The Department was responsible for 505 surgically treated inpatients in the year of 2022. On Monday, Wednesday and Friday mornings, pre- and post-surgery conferences are held, and the Director's Round takes place after the conference every Wednesday. Operating days are Monday, Tuesday and Thursday. In addition to the clinical conferences, research conferences are held every Monday morning. Each research unit holds its own conference every week. Over 1200 colonoscopies are performed for a year. The newest technologies are introduced for

diagnosis and treatment of colon and rectal cancer and long-term surveillances for inflammatory bowel disease are performed.

Teaching activities

The Department of Surgical Oncology also offers a fellowship in surgical oncology for well-qualified surgeons who have completed their training in general surgery and wish to further specialize in surgical oncology. The Department of Surgical Oncology has a Surgical Oncology Training Program and provides broad reaching experience in technical aspects of diagnosis, treatment and management for adult patients with both surgical and oncologic problems, development of surgical judgment, and increasing knowledge about routine and complex conditions. In addition, the dedicated staff allows multiple opportunities for academic development both along clinical and basic scientific lines.

In the undergraduate education program, our department plays a role in the systemic lecture and in the clinical introduction lecture for the 2nd year medical students. We offer the clinical lectures and the bedside learning program for 3rd year medical students, in cooperation with other departments of surgery. In the systemic lectures on surgery, various fields were covered such as surgical oncology and immunology, injury, somatic reaction to surgery, infectious diseases, shock, pre- and post-surgical management and nutrition. In the clinical lectures, we presented many diseases such as colon cancer, colonic polyp, colonic polyposis and inflammatory bowel disease. In the postgraduate education program, new residents are trained to become qualified surgeons. In addition to pre- and post-surgery clinical conferences, the residents are expected to attend research conferences and seminars, which are held periodically. They are also asked to present cases at clinical meetings, which are held locally such as the local meeting of the Japanese Society of Gastroenterology.

Research activities

We apply the techniques used in molecular and cellular biology to our research. The following are the major themes under research.

1) Preoperative radiotherapy in lower rectal cancer

- 2) Cancer surveillance in ulcerative colitis
- 3) Carcinogenesis in ulcerative colitis
- 4) Laparoscopically assisted colon surgery
- 5) Local immunity in colorectal cancer
- 6) Genetic analysis of colorectal cancer and adenoma
- 7) Prognostic factor of early colorectal cancer
- 8) Surveillance program following colectomy for colorectal cancer
- 9) Analysis of factors associated with conversion surgery in initially unresectable/metastatic colorectal cancer
- 10) Cancer Immunotherapy targeting to the tumor vessels
- 11) Autophagy in Oncology
- 12) Lipid metabolism in carcinogenesis and tumor progression
- 13) Pathological studies in obstructive colorectal cancer
- 14) Genetic analysis on sensitivity to chemotherapeutic agents
- 15) Hemostasis and fibrinolysis in Oncology
- 16) Intraabdominal chemotherapy for peritoneal metastasis of gastric cancer
- 17) Pharmacokinetics in intraperitoneal chemotherapy
- 18) Clinical trials of chemotherapeutic drugs in metastatic colorectal cancer (single- or multi-institutional)
- 19) Single nucleotide polymorphisms (SNPs) in inflammatory bowel disease
- 20) Anatomy of vessels feeding the colon and rectum
- 21) High Frequency Ultrasonography (HIFU) for solid cancer
- 22) Quantitative analysis of intraperitoneal cancer cells in peritonitis carcinomatosis
- 23) Immunomodulation in chemoradiotherapy for locally advanced rectal cancer
- 24) Robot assisted laparoscopic colorectal surgery
- 25) Postoperative defecation function, urinary function, and sexual function after rectal cancer surgery
- 26) Application of 3D images and 3D printers in colorectal surgery
- 27) Navigation surgery
- 28) AI endoscopic diagnosis
- 29) AI pathological diagnosis
- 30) Microbiome in colorectal cancer

References

1. Murono K, Nozawa H, Kawai K, Sasaki K, Emoto S, Kishikawa J, et al. Vascular anatomy of the splenic flexure: a review of the literature. *Surg Today*. 2022;52(5):727-735.
2. Tachikawa Y, Kawai K, Ozaki K, Nozawa H, Sasaki K, Murono K, Emoto S, et al. CD133(+)HIF-1 α (-) Expression After Chemo-radiotherapy Predicts Poor Prognosis in Rectal Cancer. *Anticancer Res*. 2022;42(4):2033-2043.
3. Nagata H, Kawai K, Oba K, Nozawa H, Yamauchi S, Sugihara K, Ishihara S. Laparoscopic Colectomy: A Risk Factor for Postoperative Peritoneal Metastasis. *Clin Colorectal Cancer*. 2022;21(3):e205-e212
4. Okamoto K, Nozawa H, Emoto S, Murono K, Sasaki K, Ishihara S. Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer. *Oncology*. 2022;100(11):576-582. F
5. Sonoda H, Kitamura C, Kano K, Anzai H, Nagai Y, Abe S, et al. Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer. *Anticancer Res*. 2022; 42(5): 2461-2468.
6. Noguchi T, Ando T, Emoto S, Nozawa H, Kawai K, Sasaki K, et al. Artificial Intelligence Program to Predict p53 Mutations in Ulcerative Colitis-Associated Cancer or Dysplasia. *Inflamm Bowel Dis*. 2022 1;28(7):1072-1080
7. Okamoto K, Nozawa H, Sasaki K, Murono K, Emoto S, Ishihara S. Diverting ileostomy is a risk factor for renal impairment during CAPOX therapy. *Int J Clin Oncol*. 2022;27(10):1616-1623.
8. Komatsu K, Emoto S, Abe S, Nozawa H, Kawai K, Sasaki K, Murono K, Ishihara S. Perineal Approach, the Closest Approach to the Pelvic Floor, in Perineal Hernia Repair After Abdominoperineal Resection. *Dis Colon Rectum*. 2022 1;65(9):e907.
9. Okada M, Kawai K, Sasaki K, Nozawa H, Kaneko M, Murono K, et al. Intervention Strategies to Reduce Surgical Site Infection Rates in Patients Undergoing Rectal Cancer Surgery. *In Vivo*. 2022; 36(1):439-445.
10. Nozawa H, Kawai K, Sasaki K, Emoto S, Abe S, Sonoda H, et al. Predictive factors of survival of colorectal cancer patients after para-aortic lymph node metastasis. *Int J Clin Oncol*. 2022; 27(3): 520-527
11. Lim S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, et al. Low Expression of SNAI1 in Lymph Node Metastasis Indicates Delayed Recurrence of Colonic Cancer. *Anticancer Res*. 2022; 42(12):5927-5935.
12. Yokoyama Y, Emoto S, Nozawa H, Kawai K, Sasaki K, Murono K, Ishibashi R, Koike K, Ishihara S. Laparoscopic resection after self-expanding stent insertion for obstructive left-sided colorectal cancer: Clinicopathological features and outcomes. *Scand J Surg*. 2022; 111(2): 1457496922109 6191.
13. Matsunaga K, Sasaki K, Nozawa H, Kawai K, Murono K, Emoto S, et al. Clinicopathological Characteristics of Anastomotic Recurrence After Curative Resection for Colorectal Cancer: Comparison with Non-Anastomotic Local Recurrences. *Dis Colon Rectum*. 2022
14. Ozaki K, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Abe H, Ushiku T, Ishihara S. Impact of the viability assessment of lateral lymph node metastasis in rectal cancer after neoadjuvant chemoradiotherapy. *Int J Colorectal Dis*. 2022; 37(2):467-473.
15. Kawai K, Nozawa H, Sasaki K, Murono K, Ishihara S. Hazard function analysis for development of second primary colorectal cancer after surgery for primary colorectal cancer. *J Gastroenterol Hepatol*. 2022; 37(1):56-62.
16. Nozawa H, Hata K, Sasaki K, Murono K, Kawai K, Emoto S, Ishihara S. Laparoscopic vs open restorative proctectomy after total abdominal colectomy for ulcerative colitis or familial adenomatous polyposis. *Langenbecks Arch Surg*. 2022; 407(4):1605-1612.
17. Murai S, Kawai K, Sonoda H, Nozawa H, Sasaki K, Murono K, et al. Computed tomographic colonography versus double-contrast barium enema for the preoperative evaluation of rectal cancer. *Surg Today*. 2022; 52(5):755-762.
18. Okamoto K, Nozawa H, Sonoda H, Kaneko M, Ishihara S. Combinatory anti-tumor activities of 1,4-bis[2-(dimethylamino) ethylamino]-5,8-

- dihydroxyanthracene-9,10-dione (AQ4) and temsirolimus against colorectal cancer cells. *J Cancer Res Clin Oncol*. 2023;149(8):4689-4699.
19. Kasuga S, Anzai H, Makise N, Sonoda H, Nagai Y, Abe S, et al. Giant filiform polyposis with high-grade dysplasia: A case report and review of the literature. *Ann Med Surg (Lond)*. 2022 2;82:104433.
 20. Emoto S, Hata K, Nozawa H, Kawai K, Tanaka T, Nishikawa T, et al. Risk factors for non-reaching of ileal pouch to the anus in laparoscopic restorative proctocolectomy with handsewn anastomosis for ulcerative colitis. *Intest Res*. 2022;20(3):313-320.
 21. Abe S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, et al. Preoperative sarcopenia is a poor prognostic factor in lower rectal cancer patients undergoing neoadjuvant chemoradiotherapy: a retrospective study. *Int J Clin Oncol*. 2022;27(1):141-153.
 22. Sasaki K, Nozawa H, Kawai K, Murono K, Emoto S, Kishikawa J, et al. Risk of extracolonic malignancies and metachronous rectal cancer after colectomy and ileorectal anastomosis in familial adenomatous polyposis. *Asian J Surg*. 2022; 45(1): 396-400.
 23. Abe S, Nozawa H, Kawai K, Sasaki K, Murono K, Emoto S, et al. Poor nutrition and sarcopenia are related to systemic inflammatory response in patients with rectal cancer undergoing preoperative chemoradiotherapy. *Int J Colorectal Dis*. 2022;37(1):189-200.
 24. Lim S, Nagai Y, Nozawa H, Kawai K, Sasaki K, Murono K, et al. Surgical outcomes of robotic, laparoscopic, and open low anterior resection after preoperative chemoradiotherapy for patients with advanced lower rectal cancer. *Surg Today*. 2023;53(1):109-115.
 25. Nozawa H, Kawasaki A, Hayashi C, Kawai K, Sasaki K, Murono K, Emoto S, Ishihara S. Impact of COVID-19 Outbreak on Stoma Surgery and Stoma Clinic Service: A Retrospective Study at a Single Japanese Referral Hospital. *Int J Clin Pract*. 2022 4;2022: 4789775.
 26. Ochiai K, Kobayashi E, Sasaki K, Nozawa H, Kawai K, Murono K, Sakuma I, Ishihara S. Stereotactic navigation using registration based on intra-abdominal landmarks in robotic-assisted lateral pelvic lymph node dissection. *Tech Coloproctol*. 2022; 26(9): 735-743.
 27. Abe S, Nozawa H, Sasaki K, Murono K, Emoto S, Yokoyama Y, et al. Sarcopenia is Associated With Oncological Prognosis and the Incidence of Secondary Cancer in Patients With Middle/Lower Rectal Cancer. *Clin Colorectal Cancer*. 2023; 22(1):143-152.
 28. Nozawa H, Okamoto K, Kawai K, Sasaki K, Emoto S, Murono K, Sonoda H, Ishihara S. Anatomical features of inferior mesenteric and left colic arteries and surgery in colorectal cancer patients with persistent descending mesocolon. *ANZ J Surg*. 2022; 92(7-8):1760-1765.
 29. Taira T, Nozawa H, Kawai K, Sasaki K, Murono K, Emoto S, et al. Prognoses in Pathologically Confirmed T1 Lower Rectal Cancer Patients with or without Preoperative Therapy: An Analysis Using the Surveillance, Epidemiology, and End Results Database. *Oncology*. 2022; 100(2): 82-88.
 30. Emoto S, Yokoyama Y, Nozawa H, Kawai K, Sasaki K, Murono K, et al. Preoperative diagnosis of obstructive colitis in colorectal cancer patients who underwent self-expandable metallic stent insertion as a bridge to surgery. *Asian J Surg*. 2022;45(12):2700-2705.
 31. Chen Z, Sasaki K, Murono K, Kawai K, Nozawa H, Kobayashi H, Ishihara S, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Oncologic Status of Obturator Lymph Node Metastases in Locally Advanced Low Rectal Cancer: A Japanese Multi-Institutional Study of 3487 Patients. *Ann Surg Oncol*. 2022
 32. Abe H, Yasunaga Y, Yamazawa S, Nakai Y, Gono W, Nishioka Y, Murono K, Sasaki K, Arita J, Kawai K, Nozawa H, Hasegawa K, Ishihara S, Ushiku T. Histological growth patterns of colorectal cancer liver metastases: a strong prognostic marker associated with invasive patterns of the primary tumor and p53 alteration. *Hum Pathol*. 2022; 123:74-83.
 33. Abe S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, et al. Clinical impact of primary tumor sidedness and sex on unresectable

- post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study. *BMC Cancer*. 2022 2;22(1):486.
34. Fukui R, Nozawa H, Sakamoto A, Sasaki K, Murono K, Emoto S, Ishihara S. Temporal changes in functional outcomes of stapled and hand-sewn ileal pouch-anal anastomosis for ulcerative colitis and familial adenomatous polyposis. *Colorectal Dis*. 2023; 25(3):396-403.
 35. Murai S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, et al. Determination of the positional relationship of the second Houston valve and peritoneal reflection using computed tomographic colonography and magnetic resonance imaging. *Surg Today*. 2023; 53(5): 614-620.
 36. Hojo D, Murono K, Nozawa H, Kawai K, Hata K, Tanaka T, Oba K, Ishihara S. Improvement in Surgical Outcomes Using 3-Dimensional Printed Models for Lateral Pelvic Lymph Node Dissection in Rectal Cancer. *Dis Colon Rectum*. 2022 1; 65(4):566-573.
 37. Kawazu M, Ueno T, Saeki K, Sax N, Togashi Y, Kanaseki T, Chida K, Kishigami F, Sato K, Kojima S, Otsuka M, Kawazoe A, Nishinakamura H, Yuka M, Yamamoto Y, Yamashita K, Inoue S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H. HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. *Gastroenterology*. 2022; 162(3): 799-812.
 38. Yamada K, Saiki Y, Komori K, Shiomi A, Ueno M, Ito M, Hida K, Yamamoto S, Shiozawa M, Ishihara S, Kanemitsu Y, Ueno H, Kinjo T, Maeda K, Kawamura J, Fujita F, Takahashi K, Mizushima T, Shimada Y, Sasaki S, Sunami E, Ishida F, Hirata K, Ohnuma S, Funahashi K, Watanabe J, Kinugasa Y, Yamaguchi S, Hashiguchi Y, Ikeda M, Sudo T, Komatsu Y, Koda K, Sakamoto K, Okajima M, Ishida H, Hisamatsu Y, Masuda T, Mori S, Minami K, Hasegawa S, Endo S, Iwashita A, Hamada M, Ajioka Y, Usuku K, Ikeda T, Sugihara K. Characteristics of anal canal cancer in Japan. *Cancer Med*. 2022; 11(14): 2735-2743.
 39. Uranbileg B, Kurano M, Kano K, Sakai E, Arita J, Hasegawa K, Nishikawa T, Ishihara S, Yamashita H, Seto Y, Ikeda H, Aoki J, Yatomi Y. Sphingosine 1-phosphate lyase facilitates cancer progression through converting sphingolipids to glycerophospholipids. *Clin Transl Med*. 2022; 12(9):e1056.
 40. Kishigami F, Tanaka Y, Yamamoto Y, Ueno T, Kojima S, Sato K, Inoue S, Sugaya S, Ishihara S, Mano H, Kawazu M. Exploration of predictive biomarkers for postoperative recurrence of stage II/III colorectal cancer using genomic sequencing. *Cancer Med*. 2022; 11(18):3457-3470.
 41. Fujiyoshi K, Sudo T, Fujita F, Chino A, Akagi K, Takao A, Yamada M, Tanakaya K, Ishida H, Komori K, Ishihara S, Miguchi M, Hirata K, Miyakura Y, Ishikawa T, Yamaguchi T, Tomita N, Ajioka Y, Sugihara K. Correction to: Risk of first onset of colorectal cancer associated with alcohol consumption in Lynch syndrome: a multicenter cohort study. *Int J Clin Oncol*. 2022; 27(6):1060.
 42. Watanabe J, Kanemitsu Y, Suwa H, Kakeji Y, Ishihara S, Shinto E, Ozawa H, Suto T, Kawamura J, Fujita F, Itabashi M, Ohue M, Ike H, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. A multicenter cohort study on mapping of lymph node metastasis for splenic flexural colon cancer. *Ann Gastroenterol Surg*. 2022 18;7(2):265-271.
 43. Fujiyoshi K, Sudo T, Fujita F, Chino A, Akagi K, Takao A, Yamada M, Tanakaya K, Ishida H, Komori K, Ishihara S, Miguchi M, Hirata K, Miyakura Y, Ishikawa T, Yamaguchi T, Tomita N, Ajioka Y, Sugihara K. Risk of first onset of colorectal cancer associated with alcohol consumption in Lynch syndrome: a multicenter cohort study. *Int J Clin Oncol*. 2022; 27(6): 1051-1059.

Department of Vascular Surgery

Associate Professor and Chief of Vascular Surgery

Katsuyuki Hoshina, M.D., Ph.D.

Lecturer

Toshio Takayama, M.D., Ph.D.

Assistant Professor

Ryosuke Taniguchi, M.D., Ph.D., Takuro Shirasu, M.D., Ph.D.,

Masaru Kimura, M.D., Ph.D., Kazuhiro Miyahara, M.D., Ph.D.

Homepage <https://vascular-1su.jp/>

Introduction and Organization

In 1995, a new system for postgraduate education was introduced. The First Department of Surgery was reorganized to form the Department of Vascular Surgery and the Department of Surgical Oncology. The staff of the Department of Vascular Surgery consists of one Associate Professor, one Lecturer, and four Assistant Professors. The outpatient office is located on the third floor of the Outpatient Building. The ward is situated on the eighth floor of the Ward Building. The administrative office and research laboratories are located in the Administration and Research Building. Current activities of the Department of Vascular Surgery in clinical practice, education, and research are summarized as follows.

Clinical activities

The Department of Vascular Surgery has an extensive clinical program in both primary and tertiary care for vascular problems, and manages patients with peripheral arterial occlusion, abdominal and thoraco-abdominal aortic aneurysms, peripheral aneurysm, visceral arterial occlusion, carotid artery disease and common disorders of the venous circulation such as varicose veins and venous leg ulcers. State-of-the-art techniques of percutaneous transluminal angioplasty, angioscopy and intraoperative ultrasonography are available for the treatment of peripheral arterial

disease. And endovascular aneurysm repair was also available for the treatment of abdominal aortic aneurysm. The outpatient clinic is open from Monday through Friday, and twenty-four-hour consultation is available for urgent or emergency problems.

Included in the department is the non-invasive Clinical Vascular Laboratory, which sees over 500 patients per year, with broad reaching expertise in peripheral vascular diagnostic modalities. Also the department has an active angiography program, which encompasses all aspects of diagnostic and therapeutic intervention in over 500 patients per year and a full range of other support and collaborative services.

On Monday, Wednesday and Friday mornings, pre- and post-surgery conferences are held. Operating days are Monday, Tuesday and Thursday. The vascular clinical conference is held every Tuesday evening.

Teaching activities

The operative procedure should be the basics of surgery. In 2017, the Japanese Board of Cardiovascular Surgery announced that 30 hours of Off JT experience will be required for new cardiovascular specialist applicants. Responding to this announcement and taking into consideration the social request for change in recent years, The Japanese Society for Vascular Surgery created the Off JT working group to create a new framework for Off JT.

Thus far, there has not been a versatile Off JT system that can be used in any institution with young surgeons. Therefore, in our department, we aimed to develop a simple and inexpensive Off JT system that can be used at any institution with medical students and young surgeons. We developed a new Off JT system that is simple and inexpensive and can be used at any institution with medical students and young surgeons. The effectiveness and appropriateness of this system were confirmed by the learning curve, analysis of the balance of the anastomosis, and scoring by the trainers. In addition, we demonstrated the relationships among time, performance, and skill. We will set this system as one of the educational methods for surgeons.

The Department of Vascular Surgery also offers a fellowship in vascular surgery for well-qualified surgeons who have completed their training in general surgery and wish to further specialize in vascular surgery. The Department of Vascular Surgery has a Vascular Surgery Training Program and provides broad reaching experience in technical aspects of vascular surgery, development of surgical judgment, and increasing knowledge about routine and complex conditions. In addition, the dedicated staff offers multiple opportunities for academic development both along clinical and basic scientific lines.

In the undergraduate education program, the Department of Vascular Surgery plays a role in the systemic and clinical lectures and the bedside learning program for 3rd year medical students, in cooperation with other departments of surgery. In the postgraduate education program, new residents are trained to become qualified surgeons in our department. The Department of Vascular Surgery is involved with the education program of the post-graduate education meeting, which is held monthly. In addition to pre- and post-surgery clinical conferences, the residents are expected to attend research conferences and seminars, which are held periodically.

Research activities

The Department of Vascular Surgery includes major research laboratories for academic development both along clinical and basic scientific lines. The clinical vascular laboratories are approaching completely non-

invasive testing for vascular disorders, analyzing essential physiologic information about the specific problems being addressed. The basic vascular laboratories are actively performing research on endothelial biology, the mechanism of intimal hyperplasia, microcirculation, application of gene therapy to vascular surgery and vascular prosthesis development. Vascular research meeting is held every month on Saturday morning. The following are the major themes under research.

- 1) Navigation system for less invasive vascular surgery
- 2) Pathophysiology of the development of the aneurysm
- 3) Pathophysiology of stent restenosis
- 4) Analyzing the intercellular transmission of the growth signal in the vascular smooth muscle cells
- 5) Tissue oxygen dynamics assessed by near infrared spectroscopy
- 6) Genome wide-association studies for arteriosclerosis.
- 7) Pharmacological analysis of microcirculation in in-vivo model
- 8) Mechanism of arteriogenesis in ischemic limb.
- 9) Development of a new drug delivery system for therapeutic angiogenesis
- 10) Hemodynamic analysis after endovascular aneurysm repair
- 11) Introduction of gene into vascular wall cells by electroporation
- 12) Application of nano technology for in-vivo gene transfer to vascular wall cells
- 13) Basic research for arterialization of artificial organ
- 14) Development of a new method for evaluation of limb ischemia
- 15) Development of a new machine for auto-evaluation of in-vivo endothelial function
- 16) Creating strategy for diagnosis of acute aortic syndrome.
- 17) Analysis of ambulatory system and muscle mechanics in claudicants with peripheral artery disease.
- 18) Modeling of saccular aneurysm with the computational simulation.
- 19) Development of hemostatic agent using Tetra-PEG hydrogel.

- 20) Prediction of dilated morphology of aortic aneurysm by airbag simulation.
- 21) Quantification of hand movements during suture using Leap Motion and its clinical feedback.
- 22) Study of intimal hyperplasia using aorta-inferior vena cava fistula model.

References

- 1: Okata S, Hoshina K, Hanada K, Kamata H, Fujisawa A, Yoshikawa Y, Sakai T. Hemostatic Capability of a Novel Tetra-Polyethylene Glycol Hydrogel. *Ann Vasc Surg.* 2022 Aug;84:398-404. doi: 10.1016/j.avsg.2022.01.016. Epub 2022 Mar 4. PMID: 35257910.
- 2: Tsuyuki S, Hoshina K, Miyahara K, Suhara M, Matsukura M, Isaji T, Takayama T. Motion analysis of suturing technique with Leap Motion ControllerTM. *Proof of concept. Sci Prog.* 2022 Apr Jun;105(2):368-504221103777. doi:10.1177/00368504221103777. PMID:35635261; PMCID: PMC10450291.
- 3: Hanada K, Hoshina K, Tsuyuki S, Miyahara K, Suhara M, Matsukura M, Isaji T, Takayama T. Ten-Hour Simulation Training Improved the Suturing Performance of Medical Students. *Ann Vasc Surg.* 2022 Aug;84:163-168. doi:10.1016/j.avsg.2021.12.076. Epub 2022 Jan 5. PMID: 34995745.
- 4: Ueda Y, Asamoto M, Kariya T, Akai T, Hoshina K, Uchida K. Ventricular fibrillation during carotid endarterectomy and bailout stenting: a case report. *JAClinRep.* 2022 Mar 31;8(1):26. doi:10.1186/s40981-022-00517-4. PMID:35357630; PMCID: PMC8971334.
- 5: Fujinami T, Ashikaga T, Hoshina K, Sasaoka T, Kurihara K, Yoshikawa S, Inagaki H, Sasano T. β -Blockers Reduced the Target Lesion Revascularization After Percutaneous Coronary Intervention Using an Everolimus-eluting Stent. *In Vivo.* 2022 Jan-Feb;36(1):416-423. doi: 10.21873/in vivo.12719. PMID: 34972743; PMCID: PMC8765150.
- 6: Matsubara K, Fukuhara N, Hoshina K, Miyahara K, Suhara M, Taniguchi R, Matsukura M, Takayama T. Specific Features of Patients Under 40 Years Old With Small-to-Medium-Sized Arterial Deterioration. *Front Surg.* 2022 Feb 24;9:808383. doi:10.3389/fsurg.2022.808383. PMID:35284485; PMCID: PMC8907261.
- 7: Shirasu T, Hoshina K, Deguchi JO. Audit and Feedback for Sustained Improvement of Overall Surgical Outcomes after Abdominal Aortic Aneurysms. *Eur J Vasc Endovasc Surg.* 2022 Jul;64(1):137. doi: 10.1016/j.ejvs.2022.04.043. Epub 2022 May 16. PMID: 35589090.
- 8: Taniguchi R, Ohashi Y, Lee JS, Hu H, Gonzalez L, Zhang W, Langford J, Matsubara Y, Yatsula B, Tellides G, Fahmy TM, Hoshina K, Dardik A. Endothelial Cell TGF- β (Transforming Growth Factor-Beta) Signaling Regulates Venous Adaptive Remodeling to Improve Arteriovenous Fistula Patency. *Arterioscler Thromb Vasc Biol.* 2022 Jul;42(7):868-883. doi: 10.1161/ATVBAHA.122.317676. Epub 2022 May 5. PMID: 35510552; PMCID: PMC9233042.
- 9: Tsuyuki S, Miyahara K, Hoshina K, Kawahara T, Suhara M, Mochizuki Y, Taniguchi R, Takayama T. Motion capture device reveals a quick learning curve in vascular anastomosis training. *Surg Today.* 2023 Jul 19. doi:10.1007/s00595-023-02726-5. Epub ahead of print. PMID: 37466703.
- 10: Endo T, Miyahara K, Shirasu T, Mochizuki Y, Taniguchi R, Takayama T, Hoshina K. Risk Factors for Incisional Hernia After Open Abdominal Aortic Aneurysm Repair. *In Vivo.* 2023 Nov-Dec;37(6):2803-2807. doi: 10.21873/in vivo.13393. PMID:37905664; PMCID: PMC10621461.

Department of Breast and Endocrine Surgery

Professor

Yasuyuki Seto M.D., Ph.D.

Associate Professor

Masahiko Tanabe M.D., Ph.D.

Lecturer

Kotoe Nishioka M.D., Ph.D.

Associates

Ayaka Sato M.D., Ph.D.

Asako Sasahara M.D., Ph.D.

Arisa Morizono M.D., Ph.D.

Satoshi Yamashita M.D., Ph.D.

Homepage

Organization

Our section is staffed by one professor, associate professor, lecturer, and four associates. Official activities of our units are run on the same schedule as the Department of Gastrointestinal Surgery.

Clinical Activities

We started our activities in this area in 1987, and our department was established with the reconstruction of our hospital structure in 1997. This is a result of the growth of demand nationally and internationally. It is caused by not only treatment for the malignant disease but also functional one or giving more attention to the quality of life.

Professional skills and broader knowledge of the endocrine system are required for this area. Diseases we treat at our department are breast, thyroid, and parathyroid. In addition to treatment for malignant cases of these diseases, we perform surgical procedures as well as systemic therapy. We co-work with the department of internal endocrine medicine and have about 250 surgical procedures annually.

In breast surgery, more than half of mammary

cancer patients undergo breast-preserving surgery. In addition, sentinel node navigation surgery has been adopted, resulting in better postoperative life quality. Reconstruction surgery for breast cancer is likely to provide much better QOL. In this field, we have collaborated with the Department of Plastic Surgery. Chemotherapy, hormone therapy, and molecular targeting therapy play essential roles in breast cancer treatment. We have accumulated a lot of experience and achievement in this field.

Our clinical themes are 1) establishment of safe procedures for endocrine surgery without complications; 2) diagnosis and treatment of micro-breast lesions under ultrasonographic guides; 3) preoperative diagnosis for thyroid neoplasms and breast tumors.

Research Activities

We investigate broad areas of breast cancer, thyroid disease, and parathyroid disease. Most of our studies are performed with other good institutions.

1) Hereditary Breast and Ovarian Cancer syndrome

- 2) Precision medicine based on Todai OncoPanel
- 3) Clinical significance of Ki67 in the area of early breast cancer.
- 4) Clinical evaluation for the developing drugs in breast and thyroid cancer.
- 5) Studies in the area of sentinel node biopsy in breast cancer.
- 6) Studies about the management of the toxic effects of chemotherapies.
- 7) Cover makeup studies for cancer patients.
- 8) Epigenetic changes critical for breast cancer development.
- 9) Cancer stem cells in breast cancer.
- 10) Quantification of HER2 expression using Digital PCR.
- 11) Development of molecular target drugs in the area of TGF beta
- 12) Analysis of MED12 mutation and TERT promoter mutation in breast fibroadenoma and phyllodes tumor.
- 13) Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
- 14) Epidemiological study using nationwide databases to resolve clinical questions

Publications

1. Konishi T, Fujiogi M, Shigemi D, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Risk Factors for Postoperative Bleeding Following Breast Cancer Surgery: A Nationwide Database Study of 477,108 Cases in Japan *World J Surg.* 2022 Dec;46(12):3062-3071.
2. Niwa T, Konishi T, Sasahara A, Sato A, Morizono A, Harada M, Nishioka K, Fukuoka O, Makise N, Saito Y, Ando M, Yoshimoto T, Shikama T, Yamashita S, Tanabe M, Seto Y. Subcutaneous axillary primary epithelioid hemangioendothelioma: report of a rare case. *Surg Case Rep.* 2022 Sep 9;8(1):166.
3. Konishi T, Goto T, Fujiogi M, Michihata N, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. New machine learning scoring system for predicting postoperative mortality in gastroduodenal ulcer perforation: A study using a Japanese nationwide inpatient database. *Surgery.* 2022 Apr;171(4):1036-1042.
4. Konishi T, Fujiogi M, Michihata N, Morita K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Association of Operative Day of the Week with the Length of Stay and Total Hospitalization Costs in Patients with Partial Mastectomy: A Nationwide Database Study in Japan. *JMA J.* 2022 Jul 15;5(3):319-327.
5. Konishi T, Fujiogi M, Shigemi D, Nishioka K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Surgical and obstetric outcomes of breast cancer surgery during pregnancy: a nationwide database study in Japan. *Breast Cancer Res Treat.* 2022 Oct;195(3):289-299.
6. Konishi T, Takamoto T, Fujiogi M, Hashimoto Y, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Laparoscopic versus open distal pancreatectomy with or without splenectomy: A propensity score analysis in Japan. *Int J Surg.* 2022 Aug;104:106765.
7. Konishi T, Fujiogi M, Michihata N, Ohbe H, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer. *Jpn J Clin Oncol.* 2022 Oct 6;52(10):1115-1123.
8. Konishi T, Fujiogi M, Michihata N, Matsui H, Tanabe M, Seto Y, Yasunaga H. Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study. *Breast Cancer Res Treat.* 2022 Jul;194(2):315-325.
9. Konishi T, Yoshimoto T, Fujiogi M, Yamana H, Tanabe M, Seto Y, Yasunaga H. Validity of operative information in Japanese administrative data: a chart review-based analysis of 1221 cases at a single institution. *Surg Today.* 2022 Oct;52(10):1484-1490.
10. Konishi T, Fujiogi M, Michihata N, Kumazawa R, Ohbe H, Matsui H, Fushimi K, Ogita M, Tanabe M, Seto Y, Yasunaga H. Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan. *Breast Cancer.* 2022 Jul;29(4):688-697.
11. Konishi T, Fujiogi M, Tanabe M, Seto Y,

-
- Yasunaga H. ASO Author Reflections: Neoadjuvant Chemotherapy Does Not Affect Short-Term Outcomes After Breast Cancer Surgery. *Ann Surg Oncol.* 2022 May;29(5):3011-3012.
12. Konishi T, Fujiogi M, Sato A, Michihata N, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Short-Term Outcomes Following Breast Cancer Surgery With and Without Neoadjuvant Chemotherapy: A Nationwide Administrative Database Study in Japan. *Ann Surg Oncol.* 2022 May;29(5):3000-3010.
13. Konishi T, Fujiogi M, Michihata N, Niwa T, Morita K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Impact of body mass index on short-term outcomes after differentiated thyroid cancer surgery: a nationwide inpatient database study in Japan. *Eur Thyroid J.* 2022 Jan 1;11(1):e210081.

Surgical Sciences

2. Sensory and Motor System Medicine

Department of Dermatology

Professor

Shinichi Sato, M.D., Ph.D.

Associate Professor

Sayaka Shibata, M.D., PhD.

Lecturer

Ayumi Yoshizaki, M.D., Ph.D.

Takuya Miyagawa, M.D., Ph.D.

Daisuke Yamada, M.D., Ph.D.

Hayakazu Sumida, M.D., Ph.D.

Takashi Yamashita, M.D., Ph.D.

Hospital Lecturer

Tomomi Miyake, M.D.

Asako Yoshizaki, M.D., Ph.D.

Associate

Shunsuke Miura, M.D., Ph.D.

Jun Omatsu, M.D., Ph.D.

Takemichi Fukazawa, M.D., Ph.D.

Satoshi Toyama, M.D., Ph.D.

Hikari Boki, M.D., Ph.D.

Satoshi Ebata, M.D., Ph.D.

Ai Kuzumi, M.D., Ph.D.

Website <https://dermatology.m.u-tokyo.ac.jp/>

Introduction and Organization

The Department of dermatology celebrated its 100th anniversary in 1990. Originally it was founded as the Department of Dermatology and Urology, which also encompassed venereology. In 1946, the Department of Dermatology was separated from that of Urology. Regarding venereology, sexually transmitted diseases only related to skin manifestations are now dealt with in our department.

As of March 2023, the professor, one associate professor, five lecturers, two hospital lecturers and seven associates take part in inpatient and outpatient cares as well as research and teaching activities. Fifty-two doctors who basically belong to our department are currently out in affiliated hospitals mainly engaged in clinical works there. Additionally, three staff members are abroad at present, mainly involved

in advanced research activities in cell biology and molecular biology.

Clinical Activities

In the outpatient clinic we see around 200 patients a day. Incisional and excisional biopsies are frequently performed under local anesthesia at the outpatient operation facilities belonging to our department. Clinical and histological discussions by all staff members including Professor and Associate Professors are held regularly, which always gives us invaluable lessons.

Concerning the inpatient clinic, there are about ten staff members under the supervision of the ward-chief. Surgical operations such as removal of malignancies and skin grafting that require general anesthesia are also performed weekly in the central surgical facilities.

Education

We have twenty dermatologists who are studying in the postgraduate course under the guidance of staff members of our department.

In addition to series of lectures, clinical education is provided for fifth- and sixth- grade medical students, which aims at giving a general introduction for how to make dermatological approaches for diagnosis and treatment, with a stress on learning how to observe and describe a variety of skin eruptions. Actually the students are supposed to see patients in outpatient clinic every day for an entire week, as well as to participate in the inpatient clinic.

Research

Each specialized outpatient service reflects its own research field in a disease-oriented manner. However, those specialized groups performing their own clinical and research activities are never exclusive, and there are increasing communications with other departments such as internal medicine and blood transfusion service as well as intergroup communications. Recent advanced techniques in cellular, molecular biology and our newly established laboratories, will enable us to organize optimal research conditions.

Publications

1. Akatsuka T, Omatsu J, Miyagawa T, Omori I, Kawashima H, Oshima N, Sato S. Congenital midline sinus of the upper lip: Evaluating the use of ultrasonography. *Skin Health Dis.* 2022 Oct 1;3(1):e170.
2. Sumida H, Asano Y, Shimizu J, Sato S. Edema localized to the lips as a novel manifestation of myositis. *Int J Rheum Dis.* 2023 Apr;26(4):789-792. doi: 10.1111/1756-185X.14543. Epub 2022 Dec 23.
3. Mizuno Y, Shibata S, Ito Y, Taira H, Sugimoto E, Awaji K, Sato S. Interleukin-26-DNA complexes promote inflammation and dermal-epidermal separation in a modified human cryosection model of bullous pemphigoid. *Front Immunol.* 2022 Oct 10;13:1013382.
4. Oka K, Miyagawa T, Suga H, Miyagaki T, Mizuno Y, Kamijo H, Hisamoto T, Omori I, Boki H, Oka T, Takahashi-Shishido N, Sugaya M, Sato S. Increased expression of squamous cell carcinoma antigen 1 and 2 in mycosis fungoides and Sézary syndrome. *Eur J Dermatol.* 2022 Jul 1;32(4):464-470.
5. Yoshizaki A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Sato S. Involvement of B cells in the development of systemic sclerosis. *Front Immunol.* 2022 Jul 28;13:938785.
6. Ebata S, Yoshizaki-Ogawa A, Sato S, Yoshizaki A. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. *J Clin Med.* 2022 Aug 8;11(15):4631.
7. Norimatsu Y, Yoshizaki A, Yamada T, Akiyama Y, Toyama S, Sato S. Pemphigus vulgaris with advanced hypopharyngeal and gastric cancer following SARS-CoV-2 vaccination. *J Dermatol.* 2023 Feb;50(2):e74-e75.
8. Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A. Involvement of Molecular Mechanisms between T/B Cells and IL-23: From Palmoplantar Pustulosis to Autoimmune Diseases. *Int J Mol Sci.* 2022 Jul 27;23(15):8261.
9. Mizuno Y, Shibata S, Miyagaki T, Ito Y, Taira H, Omori I, Hisamoto T, Oka K, Matsuda KM, Boki H, Takahashi-Shishido N, Sugaya M, Sato S. Serum cell-free DNA as a new biomarker in cutaneous T-cell lymphoma. *J Dermatol.* 2022 Nov;49(11):1124-1130.
10. Sakakibara M, Sumida H, Yanagida K, Miyasato S, Nakamura M, Sato S. Bitter taste receptor T2R38 is expressed on skin-infiltrating lymphocytes and regulates lymphocyte migration. *Sci Rep.* 2022 Jul 11;12(1):11790.
11. Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A. Pharmacotherapy of Itch-Antihistamines and Histamine Receptors as G Protein-Coupled Receptors. *Int J Mol Sci.* 2022 Jun 13;23(12):6579.
12. Kawanabe R, Yoshizaki A, Matsuda KM, Kotani H, Hisamoto T, Norimatsu Y, Kuzumi A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Sato S. Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-

- CD20 Monoclonal Antibody Administration. *Life* (Basel). 2022 Apr 27;12(5):646.
13. Matsuda KM, Yoshizaki A, Yamaguchi K, Fukuda E, Okumura T, Ogawa K, Ono C, Norimatsu Y, Kotani H, Hisamoto T, Kawanabe R, Kuzumi A, Fukasawa T, Ebata S, Miyagawa T, Yoshizaki-Ogawa A, Goshima N, Sato S. Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status. *Front Immunol*. 2022 May 4;13:893086.
 14. Ebata S, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Yoshihide A, Yoshizaki A, Sato S. Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial. *Rheumatology (Oxford)*. 2022 Nov 2;61(11):4364-4373.
 15. Urano-Takaoka M, Sumida H, Miyagawa T, Awaji K, Nagai K, Omatsu J, Miyake T, Sato S. Serum Cytokeratin 18 as a Metastatic and Therapeutic Marker for Extramammary Paget's Disease. *Acta Derm Venereol*. 2022 Jan 26;102:adv00636.
 16. Kuzumi A, Yoshizaki A, Chiba K, Mitsuo S, Matsuda KM, Norimatsu Y, Nagai K, Omatsu J, Miyake T, Sato S. Genital necrosis with cutaneous thrombosis after COVID-19 mRNA vaccination. *J Eur Acad Dermatol Venereol*. 2022 Mar;36(3):e185-e186.
 17. Ikawa T, Ichimura Y, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y. The Contribution of LIGHT (TNFSF14) to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts. *J Invest Dermatol*. 2022 Jun;142(6):1541-1551.e3.
 18. Boki H, Kimura T, Miyagaki T, Suga H, Blauvelt A, Okochi H, Sugaya M, Sato S. Lymphatic Dysfunction Exacerbates Cutaneous Tumorigenesis and Psoriasis-Like Skin Inflammation through Accumulation of Inflammatory Cytokines. *J Invest Dermatol*. 2022 Jun;142(6):1692-1702.e3.
 19. Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. *J Dermatol*. 2022 Jan;49(1):179-183.

Department of Plastic and Reconstructive Surgery

Professor

Mutsumi Okazaki, M.D.

Associate Professor

Shimpei Miyamoto, M.D.

Lecturer

Masakazu Kurita, M.D.

Project Lecturer

Yoko Tomioka, M.D.

Associate

Koji Kanayama, M.D., Kou Fujisawa, M.D., Jun Oba, M.D.,

Hitomi Matsutani, M.D., Rui Yang, M.D., Kurita Daichi M.D.

Homepage <https://plastic.m.u-tokyo.ac.jp/english/>

Organization

The present faculty of the Department of Plastic and Reconstructive Surgery consists of 1 professor, 1 associate professor, 1 project lecturer, 1 project lecturer, 6 associates, 3 physicians, and 5 residents. There are about 100 doctors in the department, but most are serving in rotation at affiliated hospitals.

The outpatient clinic is located on the 3rd floor of the outpatients building, while there are wards with about 16 available beds on the 10th floor in the New Ward. Our faculty room is located in the Medical Laboratory Building and laboratory rooms in the East Laboratory Building.

The present status of the educational, research and clinical activities of the department is as follows.

Clinical Activities

The outpatient clinic is opened every morning from Monday to Friday. There are several specialized clinics for facial paralysis, breast reconstruction, head

and neck reconstruction, congenital anomalies, vascular malformations, critical limb ischemia, lymphedema, keloid, abdominal hernia, and cosmetic surgery including cosmetic dermatology. Over 1,000 new patients visited our department, including about 800 patients in emergency. About 1,400 surgeries were performed. Each week, preoperative and postoperative conferences that all members of the department should attend are held on Tuesday and Wednesday evening respectively.

Teaching Activities

In regard to pregraduate education, the department has the duty of lecturing to 2nd and 4th year medical students, and also of instructing 4th medical students in bed side practice. The subjects taken up in the lectures include general concepts of plastic surgery, wound healing, congenital malformations, skin grafts and flaps, microsurgery, head and neck reconstruction, hand surgery, craniomaxillofacial surgery, burn and trauma, cosmetic surgery, and regenerative medicine.

In the bed side practice the students have the opportunity of seeing various diseases and disorders in the field of plastic surgery and attending inpatients and surgical operations and clinical lectures by faculty members. For graduate school students, microsurgical training program is undertaken in the laboratory room. In the postgraduate course, after completing the 6-year training program, a trainee can sit for the board examination of the Japan Society of Plastic and Reconstructive Surgery.

Research Activities

Basic and clinical researches are performed in groups. The major research subjects are as follows:

- 1) Blink examination for appropriate closing-eye function in patients with facial paralysis.
- 2) Studies on monitoring tissue circulation using flexible optical probe.
- 3) ICG examination for evaluating blood and lymph flow.
- 4) In vivo reprogramming of wound-resident cells generates skin epithelial tissue
- 5) Clinical studies on fat regeneration using suctioned fat tissue and adipose stromal progenitor cells.
- 6) Studies on hair regrowth using epidermal stem cells, dermal papilla cells and dermal sheath cells.
- 7) Basic studies on free tissue transfer using microsurgery.

References (2022)

1. Tomioka Y, Sekino M, Gu J, Kurita M, Yamashita S, Miyamoto S, Iida T, Kanayama K, Yoshimura K, Nakagawa M, Akazawa S, Kagaya Y, Tanaka K, Sunaga Y, Ueda K, Kawahara T, Tahara Y, Okazaki M. Wearable, wireless, multi-sensor device for monitoring tissue circulation after free-tissue transplantation: a multicentre clinical trial. *Sci Rep*. 2022 Oct 3;12(1):16532.
2. Shiraishi M, Kurita M, Narushima M, Banda CH, Okazaki M. Formation of bilateral arteriovenous malformations. *J Vasc Surg Cases Innov Tech*. 2022 Jul 2;8(3):441-442.
3. Dai M, Yamashita S, Okazaki M, Kimori K, Sanada H, Sugama J. Real-time image-sharing to educate a patient with lymphoedema on self-care: a case study. *Br J Nurs*. 2022 Aug 11;31(15):S22-S29.
4. Hongo H, Miyawaki S, Teranishi Y, Mitsui J, Katoh H, Komura D, Tsubota K, Matsukawa T, Watanabe M, Kurita M, Yoshimura J, Dofuku S, Ohara K, Ishigami D, Okano A, Kato M, Hakuno F, Takahashi A, Kunita A, Ishiura H, Shin M, Nakatomi H, Nagao T, Goto H, Takahashi SI, Ushiku T, Ishikawa S, Okazaki M, Morishita S, Tsuji S, Saito N. Somatic GJA4 gain-of-function mutation in orbital cavernous venous malformations. *Angiogenesis*. 2023 Feb;26(1):37-52.
5. Tanaka K, Okazaki M. Basic Concept of Skull Base Reconstructive Surgery. *No Shinkei Geka*. 2022 May;50(3):586-594.
6. Tanaka K, Suesada N, Homma T, Mori H, Tsutsumi T, Asakage T, Okazaki M. Muscle-penetration method: Cable nerve grafting with well vascularized surrounding tissue and shortest graft length. *J Plast Reconstr Aesthet Surg*. 2022 Jul;75(7):2387-2440.
7. Miyamoto S, Fukunaga Y, Arikawa M, Fujisawa K, Okazaki M. Crescent-shaped skin paddle for a fibular flap: Avoiding skin grafting at the donor site. *Head Neck*. 2022 Jul;44(7):1742-1746.
8. Tanaka K, Suesada N, Homma T, Hidaka T, Mori H, Okazaki M, Sugawara T, Tsutsumi T, Asakage T. Early postoperative complications and their measures after skull base reconstruction: A study from the standpoint of plastic and reconstructive surgeons. *Auris Nasus Larynx*. 2022 Oct;49(5):845-855.
9. Numahata T, Kitamura Y, Okazaki M. Successful Repair of a Forehead Depression Deformation due to En Coup de Sabre Using Costal Cartilage Transplantation. *J Craniofac Surg*. 2022 Sep 1;33(6):e585-e586.
10. Du Z, Shen Q, Mito D, Kato M, Okazaki M, Kurita M. Optimized 3D-printed template design for production of silicone skin chambers. *J Dermatol Sci*. 2022 Jan;105(1):55-57.
11. Hidaka T, Ogawa K, Tomioka Y, Yoshii K, Okazaki M. The Impact of Brow-Lift on Eyelid Closure in Patients with Facial Paralysis. *Facial*

- Plast Surg Aesthet Med. 2022 Sep-Oct;24(5): 385-390.
12. Yamashita S, Kitamura Y, Fujisawa K, Mito D, Tomioka Y, Kurita M, Miyamoto S, Iida T, Okazaki M. Microsurgical Lymphovenous Anastomosis for Pelvic Lymphoceles after Gynecological Cancer Surgery. *J Plast Reconstr Aesthet Surg*. 2022 Mar;75(3):1142-1149.
 13. Ogawa K, Okazaki M, Mori H, Hidaka T, Tomioka Y, Tanaka K, Uemura N, Akiyama M. Comparative Blink Analysis in Patients With Established Facial Paralysis Using High-Speed Video Analysis. *J Craniofac Surg*. 2022 May 1;33(3):797-802.
 14. Hidaka T, Ogawa K, Tomioka Y, Yoshii K, Tomio J, Okazaki M. Change in Eyelid Closure in Spontaneous Blinking After Static Eyelid Reconstruction Surgery for Patients With Facial Paralysis. *Ann Plast Surg*. 2022 Mar 1;88(3):303-307.
 15. Tanaka K, Suesada N, Homma T, Mori H, Sugawara T, Tsutsumi T, Asakage T, Okazaki M. The different concepts of surgical managements between anterior and lateral skull base reconstructions based on surgical purposes. *Auris Nasus Larynx*. 2022 Apr;49(2):271-278.
 16. Kanayama K, Kato H, Mori M, Takahi F, Nakatsukasa S, Okazaki M. Optimal choice of punch size for follicular unit excision: A comparative study of 153 Asian patients. *J Cosmet Dermatol*. 2022 Jun; 21(6):2668-2670.
 17. Tanaka K, Suesada N, Homma T, Mori H, Okazaki M. Reliability of Temporal Vascular Anastomosis and Techniques for Better Outcomes. *J Reconstr Microsurg*. 2022 Jan;38(1): 41-46.

Department of Oral-Maxillofacial Surgery

Professor

Kazuto Hoshi, M.D., Ph.D.

Associate Professor

Hideto Saijo, D.D.S., Ph.D.

Masashi Shiiba, D.D.S., Ph.D.

Lecturer

Toru Ogasawara, D.D.S., Ph.D.

Kazumi Ohkubo, D.D.S., Ph.D.

Hideyuki Suenaga, D.D.S., Ph.D.

Masanobu Abe, D.D.S., Ph.D.

Associate

Natsuko Uchino, D.D.S., Ph.D.

Asako Taniguchi, D.D.S., Ph.D.

Rika Narita, D.D.S., Ph.D.

Yoko Uchida, D.D.S., Ph.D.

Kenichi Kumagai, D.D.S., Ph.D.

Miki Kashiwagi, D.D.S., Ph.D.

Yusuke Tsuda, M.D., Ph.D.

Ryo Maruoka, D.D.S., Ph.D.

Homepage <http://plaza.umin.ac.jp/%7Eoralsurg/>

Introduction and Organization

Department of Oral and Maxillofacial Surgery, commenced by Dr. Hisashi Ishihara in 1900, is one of the oldest departments in Graduate School of Medicine, the University of Tokyo. This department consists of wide variety of specialists, such as oral surgeons, orthodontists and prosthodontists. We handle all diseases in the oral-maxillofacial region, such as congenital anomalies, jaw deformities, benign and malignant tumors, trauma and inflammation. In particular, we have established and practiced medical system for cleft lip and palate since around 2000. In November 2016, we established the Cleft Lip and Palate Center, which we become the center for oral surgeons, orthodontists, and others. Specialists such as prosthodontists, otolaryngologists, anesthesiologists, obstetricians, pediatricians, pediatric surgeons, speech therapists, nurses, dental hygienists, and

dental technicians form a team to deal with illnesses from all directions and provide multidisciplinary treatment. Dental care for the patients who have systemic disorders or under medical control is another field of our department. Multidisciplinary treatment teamed by these specialists is characteristic and has performed excellent results in clinical works. In research fields, all staffs participate in the clinical and basic research to support the treatment scientifically and to develop new treatment protocols, and we have mainly performed the experimental studies on the regenerative abilities of tissues such as bone, periosteum, cartilage, perichondrium, vessels, nerve, and skin. At present, we are focusing on tissue engineering in research works especially in bone, cartilage and vessels. The Department of Tissue Engineering was established at the University of Tokyo Hospital in October 2001, and at present Professor Kazuto Hoshi of our department is concurrently serving as its director.

The Department of Oral and Maxillofacial Surgery has Cartilage and Bone Regenerative Medicine and a Tissue Engineering Department, where assistant professors, and graduate students are conducting basic research on regenerative medicine in the maxillofacial region.

Clinical activities

In the outpatient clinic, we have 12 dental treatment booths, one operation room and one speech therapy room. Average number of patients treated at outpatient clinic is approximately 100 per day.

Our department has two sections mainly; one is oral and maxillofacial surgery and another is dental and orthodontic dentistry.

In outward dispensary, oral surgery section performs dental surgeries such as extraction of impacted teeth, amputation of infected dental root and gingivoplasty in the operation room. Patients who had been performed surgical treatment are also followed up after release from the hospital.

Dentistry and orthodontic dentistry performs facial growth control and tooth movements for patients with congenital orofacial anomalies such as cleft lip and palate, jaw deformities and other congenital deformities. Speech therapy for the patients with cleft lip and palate is also performed by speech therapists in our department.

Special section for patients of congenital deformities is on Monday afternoon examined by plastic surgeon, oral and maxillofacial surgeons, orthodontists. We also have special sections for patients with oral cancer and temporomandibular joint disorder.

In the ward, we have approximately 400 new inpatients and surgical treatment is performed on approximately 300 cases per year. The main surgical treatments are chiloplasty and palatoplasty for cleft lip and palate patients, bone grafting in alveolar cleft, orthognatic surgery of orofacial deformities, fixation of orofacial fractures, resection of malignant tumors combined with reconstruction surgery.

Peculiarity of our treatment strategy is team approach that consists of oral and maxillofacial surgeons, orthodontists and prosthodontists. In our department, patients with congenital dento-facial

deformity are treated by utilizing several techniques such as distraction technique, autologous bone graft technique, and the original artificial bone graft technique in addition to orthognatic surgery. The original bone graft is made from patient's three dimensional images of CT data and this technique is now applied for patients.

Education

Teaching activities are divided into two parts; for undergraduate medical students and for postgraduate dental students. For undergraduate students, we make 5 systematic lectures in their second year of specialized course, and one lecture and one week bedside learning in final year. Through these curriculums, we demonstrate the characteristics and treatments of the diseases in oral-maxillofacial region. Teaching is focused on following points; congenital anomalies such as cleft lip and palate and branchial arch syndromes, dentofacial deformities caused by developmental and acquired problems, surgical resection and functional reconstruction of benign and malignant tumors, temporomandibular joint disorders, inflammation and maxillofacial trauma. Minimum dental knowledge concerning jaw movement, tooth pain, periodontal disease, malocclusion and dental restorations are instructed.

For postgraduate dental students, we have two-year-resident course. This course aims to train for a wide range of dental treatments and to learn about medical cares. Various specialists instruct dental treatments for them in outpatient clinic. Dental caries treatments, periodontal cares and applications of dentures are instructed. Tooth extractions and orthodontic treatment are instructed by oral surgeons and orthodontists. Medical cares in the ward are taught by medical doctors and oral surgeons.

After two-year residential course, research training at postgraduate school is positively recommended. Our aim for education of clinician is to raise up specialists mastered both clinic and research skills.

Research

Our research project consists of clinic and basic sections. Each research themes are closely related on the aim of clinical improvement.

The main projects are as follows.

Clinical research:

1. Treatment of facial deformities and malocclusion in patients with cleft lip/ palate
2. Research on facial growth in patients with craniofacial anomalies
3. Reconstruction of oral and maxillofacial area by custom-made artificial bone (CT bone) (clinical trial)
4. Transplantation of implant-type tissue-engineered cartilage for cleft lip-nose patients
5. QOL study of oral health care system in preparative cancer patients
6. Overcoming eating loss (eat-loss)
7. The association between oral disorders and systemic diseases
8. Development of surgical assisted systems using artificial intelligence, computer vision, and augmented reality
9. Research on the treatment of temporo-mandibular joint disorder using autologous adipose-derived mesenchymal stem cells

Basic and experimental research:

1. Regeneration of bone and cartilage with tissue-engineering approach
2. Molecular biology of cartilage repair and its application to cartilage regenerative medicine
3. Development of novel scaffolds for cartilage and bone regeneration
4. In vivo evaluation of tissue-engineered cartilage and bone
5. Study on the control of mesenchymal cell differentiation
6. Elucidation of epigenetic abnormalities in oral cancers and oral premalignant lesions
7. Functional analysis of microRNAs in human dental pulp stem cells
8. Study on the cleft lip and osteonecrosis of the jaw using animal models
9. Elucidation of mechanisms of tissue repair by adipose-derived stem cells and macrophages
10. Analysis of regulatory mechanisms of bone using a reconstitution system of the cellular network in bone metabolism

Publication

(Original articles, Case report)

1. Fan M, Arai M, Tawada A, Chiba T, Fukushima R, Uzawa K, Shiiba M, Kato N, Tanzawa H, Takiguchi Y. Contrasting functions of the epithelial stromal interaction 1 gene, in human oral and lung squamous cell cancers. *Oncol Rep.* 2022 Jan;47(1):5. doi: 10.3892/or.2021.8216. PMID: 34738627 [peer-reviewed journal]
2. Osaki J, Yamazaki S, Hikita A, Hoshi K. Hematopoietic progenitor cells specifically induce a unique immune response in dental pulp under conditions of systemic inflammation. *Heliyon.* 2022 Feb 5;8(2):e08904. doi:10.1016/j.heliyon.2022.e08904. PMID: 35198771; PMCID: PMC8842015.
3. Ma Q, Kobayashi E, Fan B, Hara K, Nakagawa K, Masamune K, Sakuma I, Suenaga H. Machine-learning-based approach for predicting postoperative skeletal changes for orthognathic surgical planning. *Int J Med Robot.* 2022 Feb 7; e2379. doi: 10.1002/rcs.2379. [peer-reviewed journal]
4. Komatsu M, Saito K, Miyamoto I, Koike K, Iyoda M, Nakashima D, Kasamatsu A, Shiiba M, Tanzawa H, Uzawa K. Aberrant GIMAP2 expression affects oral squamous cell carcinoma progression by promoting cell cycle and inhibiting apoptosis. *Oncol Lett.* 2022 Feb; 23(2): 49. doi:10.3892/ol.2021.13167. PMID: 34992682 [peer-reviewed journal]
5. Koichiro Sato, Kazutoshi Nakaoka, Haruna Yabe, Takanori Eguchi, Kenichi Kumagai, Go Arai, Yumi Ito, Yoshiki Hamada. Epstein-Barr-virus-infected Plasma Cells Infiltrating Plasma Cell Mucositis of the Oral Cavity and Larynx, *Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology* (in press) [peer-reviewed journal]
6. Kawakami H, Nishizawa S, Hikita A, Hoshi K. Histochemical and Morphometrical Analyses of Scarless Wound Healing in Mouse Fetal Model. *Tokai J Exp Clin Med,* 2021 Apr 20; 46(1):33-43. PMID: 33835474 [peer-reviewed journal]
7. Uzieliene I, Bagdonas E, Hoshi K, Sakamoto T, Hikita A, Tachtamisevaite Z, Rakauskiene G,

- Kvederas G, Mobasher A, Bernotiene E. Different phenotypes and chondrogenic responses of human menstrual blood and bone marrow mesenchymal stem cells to activin A and TGF- β 3. *Stem Cell Res Ther*, 2021 Apr 29; 12(1):251. doi: 10.1186/s13287-021-02286-w, PMID: 33926568, Free PMC article [peer-reviewed journal]
8. Tonosaki K, Yonenaga K, Ono S, Itai S, Oyama S, Mizuno T, Watanabe R, Hoshi K. Correction to: Swallowing evaluation by the Kuchikara Taberu Balance Chart and videoendoscopic examination reveals that respiratory conditions, chewing, and position are strongly related to dysphagia. *Odontology*, 2021 Apr; 109(2):453-454. doi: 10.1007/s10266-020-00575-z, PMID: 33346895, No abstract available [peer-reviewed journal] Ono S, Ishimaru M, Ida Y, Yamana H, Ono Y, Hoshi K, Yasunaga H. Validity of diagnoses and procedures in Japanese dental claims data. *BMC Health Serv Res*, 2021 Oct 18; 21(1):1116. doi: 10.1186/s12913-021-07135-3, PMID: 34663302, Free PMC article [peer-reviewed journal]
 9. Kanda K, Asawa Y, Inaki R, Fujihara Y, Hoshi K, Hikita A. Requirement of direct contact between chondrocytes and macrophages for the maturation of regenerative cartilage. *Sci Rep*, 2021 Nov 18; 11(1):22476. doi: 10.1038/s41598-021-01437-6, PMID: 34795319, Free PMC article [peer-reviewed journal]
 10. Shimizu R, Asawa Y, Komura M, Hoshi K, Hikita A. Superior stemness of a rapidly growing subgroup of isolated human auricular chondrocytes and the potential for use in cartilage regenerative therapy. *Regen Ther*, 2022 Jan 4; 19: 47-57. doi: 10.1016/j.reth.2021.12.005, eCollection 2022 Mar, PMID: 35059479, Free PMC article [peer-reviewed journal]
 11. Yonenaga K, Itai S, Hoshi K. Implications for clinical dental practice during the coronavirus disease pandemic: A scoping review. *J Prosthodont Res*, 2022 Jan 11; 66(1): 6-11. doi:10.2186/jpr. JPR_D_21_00064, Epub 2021 Oct 26, PMID: 34707074, Review
 12. Kanda K, Asawa Y, Inaki R, Fujihara Y, Hoshi K, Hikita A. Author Correction: Requirement of direct contact between chondrocytes and macrophages for the maturation of regenerative cartilage. *Sci Rep*. 2022 Jan 13; 12(1):967. doi: 10.1038/s41598-021-03460-z, PMID: 35027564, Free PMC article, No abstract available
 13. Miyamoto Y, Kubota K, Asawa Y, Hoshi K, Hikita A. Publisher Correction. M1-like macrophage contributes to chondrogenesis in vitro. *Sci Rep*, 2022 Feb 22; 12(1):3298. doi: 10.1038/s41598-022-07417-8, PMID: 35194120, Free PMC article, No abstract available.
 14. Ning FL, Lyu J, Pei JP, Gu WJ, Zhang NN, Cao SY, Zeng YJ, Abe M, Nishiyama K, Zhang CD. The burden and trend of gastric cancer and possible risk factors in five Asian countries from 1990 to 2019. *Sci Rep*, 2022 Apr 8; 12(1):5980. doi: 10.1038/s41598-022-10014-4, PMID: 35395871, PMCID: PMC8993926 [peer-reviewed journal]
 15. Ma Q, Kobayashi E, Fan B, Hara K, Nakagawa K, Masamune K, Sakuma I, Suenaga H. Machine-learning-based approach for predicting postoperative skeletal changes for orthognathic surgical planning. *Int J Med Robot*, 2022 Jun; 18(3):e2379. doi: 10.1002/rcs.2379 [peer-reviewed journal]
 16. Kanazawa S, Okada H, Riu D, Mabuchi Y, Akazawa C, Iwata J, Hoshi K, Hikita A. Hematopoietic-mesenchymal signals regulate the properties of mesenchymal stem cells. *Int J Mol Sci*, 2022 Jul 26; 23(15):8238. doi: 10.3390/ijms23158238, PMID: 35897814, Free PMC article
 17. Fujihara Y, Mori Y, Saijo H, Abe T, Susami T, Haga N, Hoshi K. Long-term dental outcomes in patients with fibrodysplasia ossificans progressiva: a report of three cases of tooth extraction. *Quintessence Int*, 2022 Aug 17; 53(8):712-720. doi: 10.3290/j.qi.b3094989, PMID: 35674162
 18. Tonosaki K, Yonenaga K, Itai S, Oyama S, Mizuno T, Ono S, Watanabe R, Hoshi K. Complete lateral positioning enabled feeding in a patient with aspiration pneumonia. *Tokai J Exp Clin Med*, 2022 Sep 20; 47(3):105-108. PMID: 36073279

19. Tsuji N, Sakamoto T, Hoshi K, Hikita A. Spatiotemporal analysis of osteoblast morphology and wnt signal-induced osteoblast reactivation during bone modeling in vitro. *JBMR Plus*, 2022 Oct 21; 6(11):e10689. doi: 10.1002/jbm4.10689, eCollection 2022 Nov, PMID: 36398107, Free PMC article
20. Kato H, Koga M, Kinoshita Y, Hidaka N, Hoshino Y, Takashi Y, Arai M, Kobayashi H, Katsura M, Nakamoto Y, Makise N, Ushiku T, Hoshi K, Nangaku M, Makita N, Fukumoto S, Ito N. Utility of multimodality approach including systemic FGF23 venous sampling in localizing phosphaturic mesenchymal tumors. *J Endocr Soc*, 2022 Nov 24; 7(2):bvac181. doi: 10.1210/jendso/bvac181, eCollection 2022 Dec 15, PMID: 36540156, Free PMC article
21. Kato H, Okawa R, Ogasawara T, Hoshino Y, Hidaka N, Koga M, Kinoshita Y, Kobayashi H, Taniguchi Y, Fukumoto S, Nangaku M, Makita N, Hoshi K, Nakano K, Ito N. Effect of conventional treatment on dental complications and ectopic ossifications among 30 adults with XLH. *J Clin Endocrinol Metab*, 2022 Dec 16: dgac732. doi: 10.1210/clinem/dgac732, Epub ahead of print, PMID: 36524341 【peer-reviewed journal】

(Review articles)

1. Abe M, Mitani A, Yao A, Hoshi K, Yanagimoto S. Systemic Disorders Closely Associated with Malocclusion in Late Adolescence: A Review and Perspective. *Int J Environ Res Public Health*. 19(6): 3401, 2022. <https://doi.org/10.3390/ijerph19063401> Published 14 March, 2022 【peer-reviewed journal】
2. Abe M, Mitani A, Yao A, Zong L, Zhang CD, Hoshi K, Yanagimoto S. Oral Health in Japan: State-of-the-Art and Perspectives. *Int J Environ Res Public Health*. 2022 Jul 6;19(14): 8232. doi:10.3390/ijerph19148232.PMID: 35886083 Free PMC article. 【peer-reviewed journal】

Department of Orthopaedic Surgery

Professor

Sakae Tanaka, M.D., Ph.D.

Associate Professors

Taku Saito, M.D., Ph.D.

Yasushi Oshima, M.D., Ph.D.

Lecturers

Shuji Taketomi, M.D., Ph.D.

Takumi Matsumoto, M.D., Ph.D.

Hiroshi Kobayashi, M.D., Ph.D.

Specially Appointed Lecturer

Ryota Yamagami, M.D.

Associates

So Kato, M.D., Ph.D.

Hideki Nakamoto, M.D., Ph.D.

Tomofumi Kage, M.D., Ph.D.

Kenta Makabe, M.D., Ph.D.

Hisatoshi Ishikura, M.D., Ph.D.

Junya Miyahara, M.D., Ph.D.

Takafumi Miyake, M.D.

Naoto Kaminaga, M.D., Ph.D.

Yudai Kumanomidoh, M.D.

Kazuhiro Kohata, M.D., Ph.D.

Koichi Okajima, M.D.

Hiroyasu Kodama, M.D.

Takahiro Sasaki, M.D.

Homepage <http://www.u-tokyo-ortho.jp/>

Introduction and Organization

In 1906 our department was established as the first educational institute of orthopedic surgery in Japan, by the first professor Yoshinori Tashiro who had learned orthopedic surgery in Germany and Austria.

Initially, the department treated patients with infectious disorders and congenital malformations, such as poliomyelitis, tuberculosis of the spine, congenital clubfoot and hip dislocation. The number of outpatients visiting our department in 1910 was estimated to be no more than 3.3% of that of the two surgical departments in the University of Tokyo Hospital.

The number and characteristics of the patients, however, have changed dramatically in these 100 years. This is because our department addressed the acute needs of society from the beginning. Prof. Tashiro believed that trauma should be treated by orthopedists, so he provided his pupils with this training. Since 1950's, the department has increasingly been involved in the treatment of traffic and industrial accident victims. Prof. Tashiro and his successor professor Kenji Takagi devoted themselves to the establishment of an institute for children with disabilities. The arthroscopy was developed by Prof. Takagi, and is now considered to represent a breakthrough in the development of minimally invasive surgery. We have recently been

conducting many studies related to the ossification of spinal ligaments (OPLL), rheumatoid arthritis, biomechanics, and the degenerative skeletal disorders such as osteoporosis and osteoarthritis in response to the progressive aging of our society.

Our department is now adept in the entire field of medical science and medical practice related to the human locomotor system, the importance of which is now clearly recognized not only in Japan, but also all over the world. To meet the expanding needs of society, we have been conducting the teaching, clinical, and research activities described below.

Faculty members of the department are one professor, two associate professors, three lecturers, one specially appointed lecture, 13 associates, four medical staff members, and 12 senior residents.

Teaching activities

As for undergraduate education, our department provides a comprehensive series of lectures, physical assessment classes and problem-based learning (PBL) program to 4th year medical students, clinical clerkship programs to 5th year students and elective clinical clerkship programs to 6th year medical students.

A comprehensive series of lectures provides basic knowledge of the physiology, pathology, diagnosis and treatment of various musculoskeletal disorders. Twelve consecutive lectures in total cover a whole field of orthopaedics: basic science, pediatric disorders, rheumatic diseases, metabolic bone diseases, musculoskeletal neoplasm, trauma and regional disorders of the musculoskeletal system (spine, shoulder, elbow, hand, hip, knee, ankle and foot). In the physical assessment classes, we have provided physical diagnostic maneuvers and the radiological assessment of a variety of musculoskeletal diseases. PBL has been introduced to a small group of students to learn medical humanity and to develop a practical methodology to resolve clinical problems.

During the 3-week period of clinical clerkship program, students have opportunities to join one of clinical teams and experience patient care and orthopaedic practice with residents and faculty members. We have developed an original text for the students to learn on-site orthopedics effectively. They are encouraged to participate in clinical conferences

and surgeries. They are also required to submit reports on the cases they are involved in. They learn how to conduct a medical interview, check physical findings and draw up actual plans for a diagnosis and treatment including surgery.

Elective clinical clerkship provides 4 weeks of more intensive exposure to the clinical practice. The students are attached to a clinical team and are involved in most of the clinical activities performed by the team.

For postgraduate education, junior residents join our department for 1-8 months. In 11 doctors-in-training completed our program during this fiscal year. Since the training period is short, they are encouraged to experience emergency cases as often as possible to learn primary care. For senior residents, 1-year clinical programs were conducted in corporation with our affiliated hospitals. A postgraduate seminar and a basic research conference are held weekly.

Including the postgraduate training, an eight-year course has been adopted with clinical and research training taking place either in the University of Tokyo Hospital or in our 40 affiliated hospitals.

Clinical activities

We have the outpatient clinic open from Monday through Friday, with specialized divisions for spine, hip, rheumatoid arthritis, tumor, scoliosis, limb reconstruction and bone lengthening, knee, hand, elbow, shoulder, sports, peripheral nerves, bone systemic disorders, and foot. A total of 34,337 patients visited the outpatient clinic in fiscal 2022.

The ward has approximately 60 to 70 beds available and is divided into the subgroups above. The members are on duty for daily patient care under the supervision of faculty members. The weekly official activities of our department include ward rounds by the professor on Thursday. Post- and preoperative case conferences are held on Monday evening, Wednesday evening and Thursday morning.

1,345 operations were performed in fiscal 2022. These include 303 spine surgeries, 58 surgeries for rheumatoid arthritis patients, 128 hip surgeries, 264 knee surgeries (including 36 computer-assisted ACL reconstructions, 152 computer-assisted TKA/UKA, 255 hand surgeries, 43 foot and ankle surgeries, 36 pediatric surgeries, 134 surgeries for bone and soft

tissue tumor, and 106 trauma surgeries.

The main disorders of cervical spine surgery were myelopathy due to spondylosis or OPLL. We successfully adopted double-door open laminoplasty by splitting the spinal processes for most of these cases. This procedure was invented and developed in our department and is now used nationwide. Difficult operations such as subluxation of the cervical spine due to rheumatoid arthritis, Down's syndrome or cerebral palsy were treated using a navigation system that has been officially approved as a high-level advanced medical treatment.

The spine group is now converting open surgeries to minimum invasive surgeries using endoscopic technique. In 2012, the cervical microendoscopic Interlaminar decompression through a midline approach (CMID) was developed, and has been yielding favorable results in selected patients with cervical myelopathy.

The scoliosis group used the navigation system especially for patients with complex deformity. In addition to the conventional correction surgery, growth-assist techniques such as dual growing rods are utilized.

Main operations performed by the rheumatoid arthritis clinic group were total joint arthroplasty. They are using image-free navigation system in total knee arthroplasty operation, which is useful for the accurate placement of the implants.

The hip surgery group treated mainly acetabular dysplasia and osteoarthritis of the hip joint. They performed not only total hip replacements, but also several osteotomies including rotational acetabular osteotomy (RAO). The RAO was originated and established in our department. They conducted a clinical trial for a new artificial hip joint using the MPC polymer in collaboration with the Department of Materials Engineering in Tokyo University.

The knee clinic group developed a new anterior cruciate ligament reconstruction technique using the navigation system based on intraoperative three-dimensional fluoroscopic image to realize ideal graft placement.

The peripheral nerve clinic group has developed "costal nerve transfer to the musculocutaneous nerve" for brachial plexus injury.

The tumor group managed multidisciplinary treat-

ment for musculoskeletal sarcoma including chemotherapy, limb sparing surgery and radiotherapy in cooperation with other departments.

Limb reconstruction operations using external fixators included non-union, leg lengthening and deformity correction. One of the main interests of this group is the development of a system to analyze the mechanical properties of a skeletal system. During this period of analysis, the mechanical properties of the fracture site in vivo are to be evaluated by monitoring the motion of a dynamic pin clamp during simulated walking.

Research activities

Our research activities cover the full range of the musculoskeletal system medicine, using the in-depth sciences of biology and technology. Especially in the field of molecular biology of bone and cartilage metabolism, we are regarded as being on the leading edge in the world. Basic research is performed under the supervision of the faculty staff members. Five endowment departments take an active role in research activities in close collaboration with our department. They deal with regenerative medicine, clinical research, and material engineering.

As for research of bone resorption, we have been researching and released some important reports about bone metabolism, especially in differentiation, activation and apoptosis of osteoclast. Recently we have been getting achievement in the new research topics such as "Osteoimmunology", a new research field studying on signaling cross-talk between bone metabolism and immunology, or "Epigenetics", new research concept in spotlight using comprehensive analysis technique.

As for research of cartilage, we have researched molecular biology of cartilage with the students of the graduate school and the members of Bone and Cartilage Regenerative Medicine. Our research activities cover the generation and differentiation of chondrocytes, the joint formation, the degeneration of joint cartilage, and the regenerative methods.

Our clinical groups also take part in many multicenter clinical studies conducted by Japan Musculoskeletal Oncology Group (JMOG), National Database of Rheumatic Diseases by iR-net in Japan

(NinJa), and other multicenter groups. In 2017, the NPO Tokyo University Spine Group was established, proactively registering all spine surgeries at affiliated facilities and sharing surgical outcomes. As of August 2023, 32,440 spine surgeries have been registered.

References

- Doi T, Horii C, Tozawa K, Nakarai H, Sasaki K, Yoshida Y, Ito Y, Ohtomo N, Sakamoto R, Nakajima K, Nagata K, Okamoto N, Nakamoto H, Kato S, Taniguchi Y, Matsubayashi Y, Tanaka S, Oshima Y. Noninvasive Skin Autofluorescence of Advanced Glycation End Products for Detecting Ossification of the Posterior Longitudinal Ligament in the Thoracic Spine. *Spine (Phila Pa 1976)*. 2022 Nov 4. Online ahead of print.
- Tozawa K, Matsubayashi Y, Kato S, Doi T, Taniguchi Y, Kumanomido Y, Higashikawa A, Yoshida Y, Kawamura N, Sasaki K, Azuma S, Yu J, Hara N, Iizuka M, Ono T, Fukushima M, Takeshita Y, Tanaka S, Oshima Y. Surgical outcomes between posterior decompression alone and posterior decompression with fusion surgery among patients with Meyerding grade 2 degenerative spondylolisthesis: a multicenter cohort study. *BMC Musculoskelet Disord*. 2022 Oct 8;23(1):902.
- Sakamoto R, Nakamoto H, Yoshida Y, Ohtomo N, Nagata K, Kato S, Doi T, Matsubayashi Y, Taniguchi Y, Tanaka S, Oshima Y. Does T1 slope minus cervical lordosis mismatch affect surgical outcomes of cervical laminoplasty in the absence of preoperative severe kyphosis? *BMC Musculoskelet Disord*. 2022 Aug 25;23(1):810.
- Tachibana N, Chijimatsu R, Okada H, Oichi T, Taniguchi Y, Maenohara Y, Miyahara J, Ishikura H, Iwanaga Y, Arino Y, Nagata K, Nakamoto H, Kato S, Doi T, Matsubayashi Y, Oshima Y, Terashima A, Omata Y, Yano F, Maeda S, Ikegawa S, Seki M, Suzuki Y, Tanaka S, Saito T. RSPO2 defines a distinct undifferentiated progenitor in the tendon/ligament and suppresses ectopic ossification. *Sci Adv*. 2022 Aug 19;8(33):eabn2138.
- Nakajima K, Osada T, Ogawa A, Tanaka M, Oka S, Kamagata K, Aoki S, Oshima Y, Tanaka S, Konishi S. A causal role of anterior prefrontal-putamen circuit for response inhibition revealed by transcranial ultrasound stimulation in humans. *Cell Rep*. 2022 Aug 16;40(7):111197.
- Nagata K, Tozawa K, Miyahara J, Ito Y, Nakamoto H, Nakajima K, Kato S, Doi T, Taniguchi Y, Matsubayashi Y, Tanaka S, Oshima Y. Association Between Preoperative Neuropathic Pain and Patient Reported Outcome Measures After Cervical Spinal Cord Decompression Surgery. *Global Spine J*. 2022 Jun 17. Online ahead of print.
- Oshima M, Tani S, Yamada T, Ohe T, Iwai H, Oshima Y, Inanami H. Limitations of minimally invasive posterior cervical foraminotomy-a decompression method of posteriorly shifting the nerve root-in cases of large anterior osteophytes in cervical radiculopathy: A retrospective multicenter cohort study. *J Orthop Sci*. 2022 Jul 8. Online ahead of print.
- Nagata K, Miyahara J, Nakamoto H, Kawamura N, Takeshita Y, Higashikawa A, Ono T, Fukushima M, Okazaki R, Hara N, Kato S, Doi T, Taniguchi Y, Matsubayashi Y, Tanaka S, Oshima Y. Effect of diabetes on patient-reported outcome measures at one year after laminoplasty for cervical spondylotic myelopathy. *Sci Rep*. 2022 Jun 11;12(1):9684.
- Kato S, Nakamoto H, Matsubayashi Y, Taniguchi Y, Doi T, Yoshida Y, Higashikawa A, Takeshita Y, Fukushima M, Ono T, Hara N, Okazaki R, Iwai H, Oshima M, Sugita S, Hirai S, Masuda K, Tanaka S, Oshima Y; University of Tokyo Spine Group. Postoperative outcomes after degenerative lumbar spine surgery in rheumatoid arthritis patients -a propensity score-matched analysis. *BMC Musculoskelet Disord*. 2022 Apr 22;23(1):380.
- Nagata K, Yamada K, Shinozaki T, Miyazaki T, Tokimura F, Tajiri Y, Matsumoto T, Yamakawa K, Oka H, Higashikawa A, Sato T, Kawano K, Karita T, Koyama T, Hozumi T, Abe H, Hodohara M, Kohata K, Toyonaga M, Oshima Y, Tanaka S,

- Okazaki H; OSSI investigators. Effect of Antimicrobial Prophylaxis Duration on Health Care-Associated Infections After Clean Orthopedic Surgery: A Cluster Randomized Trial. *JAMA Netw Open*. 2022 Apr 1;5(4):e226095.
11. Tachibana N, Doi T, Nakajima K, Nakamoto H, Miyahara J, Nagata K, Nakarai H, Tozawa K, Ohtomo N, Sakamoto R, Kato S, Taniguchi Y, Matsubayashi Y, Tanaka S, Oshima Y. Does Surgical Treatment Affect the Degree of Anxiety or Depression in Patients With Degenerative Cervical Myelopathy? *Global Spine J*. 2022 Mar 29. Online ahead of print.
 12. Doi T, Ohashi S, Ohtomo N, Tozawa K, Nakarai H, Yoshida Y, Ito Y, Sakamoto R, Nakajima K, Nagata K, Okamoto N, Nakamoto H, Kato S, Taniguchi Y, Matsubayashi Y, Tanaka S, Oshima Y. Evaluation of bone strength using finite-element analysis in patients with ossification of the posterior longitudinal ligament. *Spine J*. 2022 Aug; 22(8): 1399-1407.
 13. Miyahara J, Yoshida Y, Nishizawa M, Nakarai H, Kumanomido Y, Tozawa K, Yamato Y, Iizuka M, Yu J, Sasaki K, Oshima M, Kato S, Doi T, Taniguchi Y, Matsubayashi Y, Higashikawa A, Takeshita Y, Ono T, Hara N, Azuma S, Kawamura N, Tanaka S, Oshima Y. Treatment of restenosis after lumbar decompression surgery: decompression versus decompression and fusion. *J Neurosurg Spine*. 2022 Jan 7;36(6):892-899.
 14. Okamoto N, Kato S, Doi T, Nakamoto H, Matsubayashi Y, Taniguchi Y, Inanami H, Higashikawa A, Kawamura N, Hara N, Azuma S, Takeshita Y, Ono T, Fukushima M, Tanaka S, Oshima Y. Influence of Perioperative Antithrombic Agent Discontinuation in Elective Posterior Spinal Surgery: A Propensity-Score-Matched Analysis. *World Neurosurg*. 2022 Feb;158:e362-e368.
 15. Nakarai H, Kato S, Kawamura N, Higashikawa A, Takeshita Y, Fukushima M, Ono T, Hara N, Azuma S, Tanaka S, Oshima Y. Minimal clinically important difference in patients who underwent decompression alone for lumbar degenerative disease. *Spine J*. 2022 Apr;22(4):549-560.
 16. Tozawa K, Matsubayashi Y, Kato S, Doi T, Taniguchi Y, Kumanomido Y, Higashikawa A, Yoshida Y, Kawamura N, Sasaki K, Azuma S, Yu J, Hara N, Iizuka M, Ono T, Fukushima M, Takeshita Y, Tanaka S, Oshima Y. Surgical outcomes between posterior decompression alone and posterior decompression with fusion surgery among patients with Meyerding grade 2 degenerative spondylolisthesis: a multicenter cohort study. *BMC Musculoskelet Disord*. 2022 Oct 8;23(1):902.
 17. Takei S, Torii S, Taketomi S, Iwanuma S, Tojima M, Otomo M, Iizuka S, Tanaka S. Is Increased Kicking Leg Iliopsoas Muscle Tightness a Predictive Factor for Developing Spondylolysis in Adolescent Male Soccer Players? *Clin J Sport Med*. 2022 Mar 1;32(2):e165-e171.
 18. Kage T, Inui H, Tomita T, Yamazaki T, Taketomi S, Yamagami R, Kono K, Kawaguchi K, Takagi K, Sameshima S, Tanaka S. The Association between In Vivo Knee Kinematics and Patient-Reported Outcomes during Squatting in Bicruciate-Stabilized Total Knee Arthroplasty. *J Knee Surg*. 2022 Oct;35(12):1342-1348.
 19. Inui H, Yamagami R, Kono K, Kawaguchi K, Sameshima S, Kage T, Tanaka T, Taketomi S, Tanaka S. Comparison of the joint laxity of total knee arthroplasty evaluated by the distraction force and the varus-valgus force. *Knee*. 2022 Jan;34:98-107.
 20. Kono K, Inui H, Tomita T, Yamazaki T, Taketomi S, Yamagami R, Kawaguchi K, Kage T, Arakawa T, Tanaka S. Effect of weight-bearing in bicruciate-retaining total knee arthroplasty during high-flexion activities. *Clin Biomech (Bristol, Avon)*. 2022 Feb;92:105569.
 21. Takei S, Taketomi S, Torii S, Tojima M, Kaneoka K, Tanaka S. Characteristics of the Kicking Motion in Adolescent Male Soccer Players Who Develop Osgood-Schlatter Disease: A Prospective Study. *Orthop J Sports Med*. 2022 Mar 14; 10(3): 23259671221083567.

22. Yamagami R, Inui H, Taketomi S, Kono K, Kawaguchi K, Sameshima S, Kage T, Tanaka S. Proximal tibial morphology is associated with risk of trauma to the posteromedial structures during tibial bone resection reproducing the anatomical posterior tibial slope in bicruciate-retaining total knee arthroplasty. *Knee*. 2022 Jun;36:1-8.
23. Kawaguchi K, Taketomi S, Mizutani Y, Inui H, Yamagami R, Kono K, Kage T, Takei S, Fujiwara S, Ogata T, Tanaka S. Dynamic Postural Stability Is Decreased During the Single-Leg Drop Landing Task in Male Collegiate Soccer Players With Chronic Ankle Instability. *Orthop J Sports Med*. 2022 Jul 25;10(7):23259671221107343.
24. Kono K, Inui H, Kage T, Tomita T, Yamazaki T, Taketomi S, Yamagami R, Kawaguchi K, Tanaka S. Femoral rollback at high-flexion during squatting is related to the improvement of sports activities after bicruciate-stabilized total knee arthroplasty: an observational study. *BMC Musculoskelet Disord*. 2022 May 26;23(1):496.
25. Takagi K, Taketomi S, Inui H, Yamagami R, Kawaguchi K, Sameshima S, Kage T, Tahara K, Tanaka S. The effects of initial graft tension on femorotibial relationship following anatomical rectangular tunnel anterior cruciate ligament reconstruction using bone-patellar tendon-bone graft. *Knee*. 2022 Aug;37:112-120.
26. Nakahira Y, Taketomi S, Kawaguchi K, Mizutani Y, Hasegawa M, Ito C, Uchiyama E, Ikegami Y, Fujiwara S, Yamamoto K, Nakamura Y, Tanaka S, Ogata T. Kinematic Differences Between the Dominant and Nondominant Legs During a Single-Leg Drop Vertical Jump in Female Soccer Players. *Am J Sports Med*. 2022 Aug;50(10):2817-2823.
27. Taketomi S, Inui H, Yamagami R, Nakazato K, Kawaguchi K, Kono K, Sameshima S, Kage T, Tanaka S. Lateral posterior tibial slope does not affect femoral but does affect tibial tunnel widening following anatomic anterior cruciate ligament reconstruction using a Bone-Patellar Tendon-Bone graft. *Asia Pac J Sports Med Arthrosc Rehabil Technol*. 2022 Oct 5;30:25-31.
28. Sameshima S, Inui H, Taketomi S, Yamagami R, Kono K, Kawaguchi K, Kage T, Tanaka S. The intraoperative gap differences due to joint distraction force differences in total knee arthroplasty are affected by preoperative lower limb alignment and body mass index. *Clin Biomech (Bristol, Avon)*. 2022 Oct;99:105765.
29. Kage T, Inui H, Tomita T, Yamazaki T, Taketomi S, Yamagami R, Kono K, Kawaguchi K, Murakami R, Arakawa T, Tanaka S. In vivo kinematic comparison of medial pivot total knee arthroplasty in weight-bearing and non-weight-bearing deep knee bending. *Clin Biomech (Bristol, Avon)*. 2022 Oct;99:105762.
30. Kage T, Taketomi S, Tomita T, Yamazaki T, Inui H, Yamagami R, Kono K, Kawaguchi K, Sameshima S, Arakawa T, Tanaka S. Anterior cruciate ligament-deficient knee induces a posterior location of the femur in the medial compartment during squatting. *J Orthop Res*. Dec 20. Online ahead of print.
31. Yamagami R, Inui H, Taketomi S, Kono K, Kawaguchi K, Sameshima S, Kage T, Arakawa T, Tanaka S. Intraoperative femoral rotational kinematics are similar in varus and valgus knees during medial pivot total knee arthroplasty. *Clin Biomech (Bristol, Avon)*. Dec 9. Online ahead of print.
32. Matsumoto T, Takeda R, Maenohara Y, Chang SH, Omata Y, Takuo J, Tanaka S. Comparison between suture and staple fixations as internal fixation techniques for Akin osteotomy. *Foot Ankle Surg*. 2022 Jan;28(1):100-106.
33. Matsumoto T, Takeda R, Kasai T, Chang SH, Izawa N, Hirose J, Takuo J, Tanaka S. Clinical Outcomes After First Metatarsophalangeal Joint Arthrodesis by Flat Cut Joint Preparation With Individual Adjustment for Sagittal Alignment. *J Foot Ankle Surg*. 2022 Jan-Feb;61(1):60-66.
34. Matsumoto T, Higuchi J, Maenohara Y, Chang SH, Iidaka T, Horii C, Oka H, Muraki S, Hashizume H, Yamada H, Yoshida M, Nakamura K, Tanaka S, Yoshimura N. The discrepancy between

- radiographically-assessed and self-recognized hallux valgus in a large population-based cohort. *BMC Musculoskelet Disord*. 2022 Jan 4;23(1):31.
35. Takeda R, Matsumoto T, Maenohara Y, Omata Y, Inui H, Nagase Y, Nishikawa T, Tanaka S. Increasing trend of radiographic features of knee osteoarthritis in rheumatoid arthritis patients before total knee arthroplasty. *Sci Rep*. 2022 Jun 21;12(1):10452.
 36. Zhang L, Michihata N, Matsui H, Fushimi K, Yasunaga H, Tsuda Y, Tanaka S, Kobayashi H. Preoperative arterial embolization and wound complications after resection of malignant bone tumor in the pelvis: a nationwide database study. *Jpn J Clin Oncol*. 2022 Oct 6;52(10):1176-1182.
 37. Miyamoto K, Kobayashi H, Zhang L, Tsuda Y, Makise N, Yasunaga Y, Ikemura M, Nakai Y, Shibata E, Ushiku T, Tanaka S. Atypical Neurofibromatous Neoplasm with Uncertain Biologic Potential in the Posterior Mediastinum of a Young Patient with Neurofibromatosis Type 1: A Case Report. *Case Rep Oncol*. 2022 Nov 8; 15(3): 988-994.
 38. Hirai T, Kobayashi H, Kobayashi E, Saito M, Akiyama T, Kikuta K, Nakai T, Endo M, Tsukamoto S, Hakozaiki M, Takenaka S, Nishimura S, Kawashima H, Tanzawa Y, Kawano H, Tanaka S. Dedifferentiation in low-grade osteosarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. *Int J Clin Oncol*. 2022 Nov; 27(11): 1758-1766.
 39. Kobayashi H, Zhang L, Hirai T, Tsuda Y, Ikegami M, Tanaka S. Clinical characteristics of undifferentiated pleomorphic sarcoma of bone and the impact of adjuvant chemotherapy on the affected patients: a population-based cohort study. *Jpn J Clin Oncol*. 2022 May 31;52(6):589-598.
 40. Kobayashi H, Zhang L, Hirai T, Tsuda Y, Ikegami M, Tanaka S. Role of adjuvant chemotherapy in patients with localized, undifferentiated pleomorphic sarcoma of soft tissue: a population-based cohort study. *Int J Clin Oncol*. 2022 Apr; 27(4):802-810.
 41. Takamiya A, Ishibashi Y, Makise N, Hirata M, Ushiku T, Tanaka S, Kobayashi H. Imaging characteristics of NTRK-rearranged spindle cell neoplasm of the soft tissue: A case report. *J Orthop Sci*. 2022 Jan 13. Online ahead of print.
 42. Kobayashi H, Zhang L, Hirai T, Tsuda Y, Ikegami M, Tanaka S. Comparison of clinical features and outcomes of patients with leiomyosarcoma of bone and soft tissue: a population-based cohort study. *Jpn J Clin Oncol*. 2022 Feb 5;52(2):143-150.
 43. Kobayashi H, Okuma T, Okajima K, Ishibashi Y, Zhang L, Hirai T, Ohki T, Ikegami M, Sawada R, Shinoda Y, Akiyama T, Goto T, Tanaka S. Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin. *J Orthop Sci*. 2022 Jan;27(1):222-228.
 44. Kato H, Koga M, Kinoshita Y, Hidaka N, Hoshino Y, Takashi Y, Arai M, Kobayashi H, Katsura M, Nakamoto Y, Makise N, Ushiku T, Hoshi K, Nangaku M, Makita N, Fukumoto S, Ito N. Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors. *J Endocr Soc*. 2022 Nov 24;7(2):bvac181.
 45. Kato H, Okawa R, Ogasawara T, Hoshino Y, Hidaka N, Koga M, Kinoshita Y, Kobayashi H, Taniguchi Y, Fukumoto S, Nangaku M, Makita N, Hoshi K, Nakano K, Ito N. Effect of Conventional Treatment on Dental Complications and Ectopic Ossifications Among 30 Adults With XLH. *J Clin Endocrinol Metab*. 2022 Dec 16. 17;108(6):1405-1414. Online ahead of print.
 46. Hoshino Y, Hidaka N, Kato H, Koga M, Taniguchi Y, Kobayashi H, Nangaku M, Makita N, Ito N. Incidence of ossification of the spinal ligaments in acromegaly patients. *Bone Rep*. 2022 Oct 17; 17:101628.
 47. Kawai A, Narahara H, Takahashi S, Nakamura T, Kobayashi H, Megumi Y, Matsuoka T, Kobayashi E. Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study.

- BMC Cancer. 2022 May 11;22(1):528.
48. Tabata J, Nakaoku T, Araki M, Yoshino R, Kohsaka S, Otsuka A, Ikegami M, Ui A, Kanno SI, Miyoshi K, Matsumoto S, Sagae Y, Yasui A, Sekijima M, Mano H, Okuno Y, Okamoto A, Kohno T. Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis. *Cancer Res.* 2022 Oct 17;82(20):3751-3762.
 49. Kage H, Kohsaka S, Tatsuno K, Ueno T, Ikegami M, Zokumasu K, Shinozaki-Ushiku A, Nagai S, Aburatani H, Mano H, Oda K. Tumor mutational burden measurement using comprehensive genomic profiling assay. *Jpn J Clin Oncol.* 2022 Aug 5;52(8):925-929. doi: 10.1093/jjco/hyac063. Erratum in: *Jpn J Clin Oncol.* 2022 Nov 3;52(11):1358.
 50. Ikeuchi H, Hirose T, Ikegami M, Takamochi K, Suzuki K, Mano H, Kohsaka S. Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model. *Oncogene.* 2022 Apr;41(17):2470-2479. doi: 10.1038/s41388-022-02263-4. Epub 2022 Mar 19.
 51. Ishikura H, Nakamura M, Nakamura S, Tanaka T, Kawano H, Tanaka S. Relationship between the Accuracy of the Acetabular Cup Angle and BMI in Posterolateral Total Hip Arthroplasty with CT-Based Navigation. *Medicina (Kaunas).* 2022 Jun 27;58(7):856.
 52. Tanaka T, Moro T, Asai S, Hashikura K, Ishikura H, Tanaka S. Comparison between cup implantations during total hip arthroplasty with or without a history of rotational acetabular osteotomy. *Arch Orthop Trauma Surg.* 2022 Nov;142(11):3539-3547.
 53. Ishikura H, Nakamura M, Oka H, Yonezawa K, Hidaka R, Tanaka T, Kawano H, Tanaka S. A new classification system for evaluating fatty infiltration of the gluteus minimus in hip osteoarthritis using plain computed tomography. *J Orthop Sci.* 2022 Jul;27(4):792-797.
 54. Kaneko T, Horiuchi K, Chijimatsu R, Mori D, Nagata K, Omata Y, Yano F, Inui H, Moro T, Tanaka S, Saito T. Regulation of osteoarthritis development by ADAM17/Tace in articular cartilage. *J Bone Miner Metab.* 2022 Mar;40(2):196-207.
 55. Kaneko T, Nakamura S, Hayakawa K, Tokimura F, Miyazaki T. Clinical and radiological outcomes of total hip arthroplasty in octogenarian patients using a three-dimensional porous titanium cup: a retrospective analysis in Japanese patients. *Eur J Orthop Surg Traumatol.* 2022 Nov 22. Online ahead of print.
 56. Miyake T, Uehara K, Kohata K, Miura T, Ohe T, Tanaka S, Morizaki Y. New body surface indexes for germinal matrix: DIP joint extension boundary line and dorsal distal interphalangeal crease. *J Orthop Sci.* 2022 Sep 15. Online ahead of print.
 57. Tani S, Okada H, Onodera S, Chijimatsu R, Seki M, Suzuki Y, Xin X, Rowe DW, Saito T, Tanaka S, Chung UI, Ohba S, Hojo H. Stem cell-based modeling and single-cell multiomics reveal gene-regulatory mechanisms underlying human skeletal development. *Cell Rep.* 2023 Apr 25;42(4):112276.
 58. Tonak HA, Aydin Y, Ozcanyuz B, Ozcanli H, Uehara K, Morizaki Y. Psychometric Properties of the Turkish Version of the JHand for the Patient-Oriented Outcome Measure for Patients with Hand and Elbow Disorders. *Eval Health Prof.* 2022 Dec 12. Online ahead of print.
 59. Matsubara T, Soma K, Yamada I, Fujita H, Yoshitani J, Oka H, Okada H, Tanaka S. Offset nail fixation for intertrochanteric fractures improves reduction and lag screw position. *PLoS One.* 2022 Nov 16;17(11):e0276903.
 60. Kurashige T, Nakagawa T, Matsubara T, Kobayashi M. Modified paratricipital approach without mobilization of the ulnar nerve prevents postoperative ulnar neuropathy in distal humerus fractures. *J Orthop Sci.* 2023 Sep;28(5):1113-1117.
 61. Hojo H, Saito T, He X, Guo Q, Onodera S, Azuma T, Koebis M, Nakao K, Aiba A, Seki M, Suzuki Y, Okada H, Tanaka S, Chung UI, McMahon AP, Ohba S. Runx2 regulates chromatin accessibility to

- direct the osteoblast program at neonatal stages. *Cell Rep.* 2022 Sep 6;40(10):111315.
62. Omata Y, Okada H, Uebe S, Izawa N, Ekici AB, Sarter K, Saito T, Schett G, Tanaka S, Zaiss MM. Interspecies Single-Cell RNA-Seq Analysis Reveals the Novel Trajectory of Osteoclast Differentiation and Therapeutic Targets. *JBMR Plus.* 2022 May 16;6(7):e10631.
63. Chijimatsu R, Takeda T, Tsuji S, Sasaki K, Kato K, Kojima R, Michihata N, Tsubaki T, Matui A, Watanabe M, Tanaka S, Saito T. Development of hydroxyapatite-coated nonwovens for efficient isolation of somatic stem cells from adipose tissues. *Regen Ther.* 2022 Jun 8;21:52-61.
64. Saito T. The superficial zone of articular cartilage. *Inflamm Regen.* 2022 May 2;42(1):14.
65. Yano F, Takeda T, Kurokawa T, Tsubaki T, Chijimatsu R, Inoue K, Tsuji S, Tanaka S, Saito T. Effects of conditioned medium obtained from human adipose-derived stem cells on skin inflammation. *Regen Ther.* 2022 Apr 16;20:72-77.
66. Kato H, Ansh AJ, Lester ER, Kinoshita Y, Hidaka N, Hoshino Y, Koga M, Taniguchi Y, Uchida T, Yamaguchi H, Niida Y, Nakazato M, Nangaku M, Makita N, Takamura T, Saito T, Braddock DT, Ito N. Identification of ENPP1 Haploinsufficiency in Patients With Diffuse Idiopathic Skeletal Hyperostosis and Early-Onset Osteoporosis. *J Bone Miner Res.* 2022 Jun;37(6):1125-1135.
67. Watanabe H, Okada H, Hirose J, Omata Y, Matsumoto T, Matsumoto M, Nakamura M, Saito T, Miyamoto T, Tanaka S. Transcription Factor Hematopoietically Expressed Homeobox Protein (Hhex) Negatively Regulates Osteoclast Differentiation by Controlling Cyclin-Dependent Kinase Inhibitors. *JBMR Plus.* 2022 Feb 14; 6(4): e10608.

Department of Ophthalmology

Professor

Makoto Aihara, M.D., Ph.D.

Associate Professor

Megumi Honjo, M.D., Ph.D., Ryo Obata, M.D., Ph.D., Takashi Miyai, M.D., Ph.D.

Lecturer

Hitomi Saito, M.D., Ph.D., Hiromasa Sawamura, M.D., Ph.D., Rei Sakata, M.D., Ph.D.,
Rie Tanaka, M.D., Ph.D.

Research Associate

Takashi Ueta, M.D., Ph.D., Keiko Azuma, M.D., Ph.D., Tetsuya Toyono, M.D., Ph.D.,
Taku Toyama, M.D., Ph.D., Yukako Taketani, M.D., Ph.D., Sugimoto Koichiro, M.D.,
Ishiyama Yukako, M.D., Kohdai Kitamoto, M.D., Ph.D., Arai Takahiro, M.D.,
Ono Takashi, M.D., Ph.D., Aoki Shuichiro, M.D., Aoyama Yurika, M.D., Shu Kanhou, M.D.

Homepage <https://www.todaiganka.jp>

Introduction and Organization

The Department of Ophthalmology, University of Tokyo School of Medicine, was founded in 1889. Since then, the department has contributed to Japanese ophthalmology not only by educating many eminent ophthalmologists in Japan but also by producing significant basic research in ophthalmology.

The department has been active in collaboration with ophthalmologists around the world, sponsoring international ophthalmological meetings, educating fellows from foreign countries, and sending our staff and fellows abroad.

Clinical activities

Altogether, approximately 2900 new outpatients are seen every year in our hospital, which has a total of 27 beds. Residents work in the ambulatory section and take care of inpatients. Special services are provided in units devoted to ophthalmic subspecialties such as cornea, glaucoma, retina, uveitis, neuro-ophthalmology, orthoptics, diabetic retinopathy, and genetic

and color blindness problems. The staff members supervise the ambulatory and special services depending on each one's specialty.

Most of the inpatients suffer from cataract, glaucoma, corneal diseases, retinal detachment, diabetic retinopathy, age-related macular degeneration, uveitis, ptosis, dry eye and strabismus. Surgeries are performed in the operating theater of the hospital under operating microscopes. Approximately 8610 cases underwent operations in our department. Surgeries can be monitored by TV system, which is mounted on operating microscopes. Since multiple observers can watch the same images and share findings, this system has great potential in training and promoting discussion.

Education

As an undergraduate course, we give lectures on corneal physiology, corneal diseases, and corneal transplantation. In addition, we are engaged in practical training for medical students on ophthalmological examinations at the outpatient clinic. As a

postgraduate course, we give lectures on topics concerning corneal transplantation, corneal diseases and new medical therapies.

Research

Research topics in our department cover a variety of fields in ophthalmology; e.g. ocular pharmacology in glaucoma, lipid mediators in ocular diseases, regenerative medicine in the cornea and retina, aqueous humor dynamics, immunology and molecular biology. Special laboratories for physiology, pharmacology and genetic engineering have been established. Specific fields of research in our department are as follows.

1. Lipid mediators in ocular diseases
2. Clinical investigation of normal tension glaucoma
3. Drug development in IOP reduction of glaucoma
4. Screening method of glaucoma
5. Pathophysiology and molecular mechanisms of diabetic retinopathy
6. Relationship between visual function and quality of life in patient with low vision
7. Investigation of molecular mechanisms of retinal arteritis and phlebitis
8. Investigation of gene mutations in primary vitreoretinal lymphoma and development of new treatment
9. Study of mechanisms involving disease-specific HLA in Behcet's disease
10. Analysis of structure-function relationships in macular diseases
11. Molecular analysis of corneal neovascularization
12. Gene therapy for corneal dystrophies
13. Analysis of Meibomian gland with Mibography
14. Analysis of safety of topical eye drops using human corneal epithelial cell sheets
15. Clinical trial of corneal crosslinking for keratoconus and keratoectasia
16. Ophthalmic examination of patients with congenital insensitivity to pain with anhydrosis
17. Assessment of higher visual functions by fMRI
18. Relevance between ophthalmic diseases and cortical functions

Publications

1. Liu Y, Yamagishi R, Honjo M, Kurano M, Yatomi Y, Igarashi K, Aihara M. Role of Autotaxin in High Glucose-Induced Human ARPE-19 Cells. *Int J Mol Sci.* 2022 Aug 16; 23(16):9181.
2. Fujishiro T, Honjo M, Kawasaki H, Aihara M. Visual cortex damage in a ferret model of ocular hypertension. *Jpn J Ophthalmol.* 2022 Mar;66(2): 205-212.
3. Ono T, Iwasaki T, Terada Y, Miyai T, Mori Y, Nejima R, Honma T, Aihara M, Miyata K. Corneal Toxicity After Stinging by a Sea Anemone, *Anthopleura uchidai*: A Case Report With Confirmation by In Vitro Study. *Cornea.* 2022 Aug 1;41(8):1035-1037.
4. Suzuki T, Obata R, Inoue T, Ueta Y, Azuma K, Tate H, Kitamoto K, Otaki C, Hashimoto Y, Aihara M, Tachi N. Intravenous lipo-prostaglandin E1 administration for patients with acute central retinal artery occlusion. *BMJ Open Ophthalmol.* 2022 May;7(1):e001014.
5. Nemoto H, Honjo M, Okamoto M, Sugimoto K, Aihara M. Potential Mechanisms of Intraocular Pressure Reduction by Micropulse Transscleral Cyclophotocoagulation in Rabbit Eyes. *Invest Ophthalmol Vis Sci.* 2022 Jun 1;63(6):3.
6. Azuma K, Koumura T, Iwamoto R, Matsuoka M, Terauchi R, Yasuda S, Shiraya T, Watanabe S, Aihara M, Imai H, Ueta T. Mitochondrial glutathione peroxidase 4 is indispensable for photoreceptor development and survival in mice. *J Biol Chem.* 2022 Apr;298(4):101824.
7. Fujita A, Hashimoto Y, Matsui H, Yasunaga H, Aihara M. Recent Trends in Treatment and Associated Costs of Primary Angle-Closure Glaucoma: A Retrospective Cohort Study. *Ophthalmol Glaucoma.* 2022 Oct 15:S2589-4196(22)00201-0.
8. Hashimoto Y, Okada A, Matsui H, Yasunaga H, Aihara M, Obata R. Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan. *Jpn J Ophthalmol.* 2022 Dec 12:1-10.
9. Chen LW, Ono T, Hashimoto Y, Tsuneya M, Abe Y, Omoto T, Taketani Y, Toyono T, Aihara

- M, Miyai T. Regular and irregular astigmatism of bullous keratopathy using Fourier harmonic analysis with anterior segment optical coherence tomography. *Sci Rep*. 2022 Oct 25;12(1):17865.
10. Tsuneya M, Chen LW, Ono T, Hashimoto Y, Kitamoto K, Taketani Y, Toyono T, Aihara M, Miyai T. UbiA prenyltransferase domain-containing protein 1 (UBIAD1) variant c.695 A > G identified in a multigenerational Japanese family with Schnyder corneal dystrophy. *Jpn J Ophthalmol*. 2022 Nov 11.
 11. Sakata R, Fujishiro T, Saito H, Nakamura N, Honjo M, Shirato S, Miyamoto E, Yamada Y, Aihara M. Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma. *J Ocul Pharmacol Ther*. 2022 Oct 31.
 12. Aoyama Y, Sakata R, Fujishiro T, Honjo M, Shirato S, Aihara M. Changes in corneal endothelial cell density after initial Ex-PRESS drainage device implantation and its relating factors over 3 years. *Eye (Lond)*. 2022 Jan 10.
 13. Asahina Y, Hashimoto H, Aihara M, Noie T, Morikawa T. Impact of Neoadjuvant Chemotherapy on SATB2 Expression in Colorectal Carcinomas: SATB2 Positivity is Preserved in Most Cases, but Down-Expressed in Effective Cases of Chemotherapy. *Int J Surg Pathol*. 2022 Mar 27;10668969221088881.
 14. Akiyama K, Ono T, Ishii H, Chen LW, Kitamoto K, Toyono T, Yoshida J, Aihara M, Miyai T. Impact of rigid gas-permeable contact lens on keratometric indices and corneal thickness of keratoconus eyes examined with anterior segment optical coherence tomography. *PLoS One*. 2022 Jul 8;17(7):e0270519.
 15. Hashimoto Y, Yamana H, Iwagami M, Ono S, Takeuchi Y, Michihata N, Uemura K, Yasunaga H, Aihara M, Kaburaki T. Ocular Adverse Events after Coronavirus Disease 2019 mRNA Vaccination: Matched Cohort and Self-Controlled Case Series Studies Using a Large Database. *Ophthalmology*. 2022 Oct 26:S0161-6420(22)00832-6.
 16. Azuma K, Nomura Y, Kitamoto K, Hashimoto Y, Fujino R, Ueda K, Inoue T, Obata R. Locational agreement of near-infrared autofluorescence with choroidal vascular hyperpermeability in central serous chorioretinopathy. *Retina*. 2022 Nov 1; 42(11):2203-2209.
 17. Shirahama S, Tanaka R, Kaburaki T. Anterior Uveitis Associated with Human Herpesvirus 7 Infection Diagnosed by Multiplex Polymerase Chain Reaction Assay: A Case Report. *Ocul Immunol Inflamm*. 2022 Feb 24;1-3.
 18. Ishii H, Yoshida J, Toyono T, Yamagami S, Usui T, Miyai T. Three-year results of accelerated transepithelial cross-linking (30 mW/cm² × 3 min) for keratoconus: a prospective study. *BMJ Open Ophthalmol*. 2022 Feb 8;7(1):e000827.
 19. Shiraya T, Araki F, Nakagawa S, Ueta T, Totsuka K, Abe H, Naito Y, Toyama T, Sugimoto K, Kato S. Differential gene expression analysis using RNA sequencing: retinal pigment epithelial cells after exposure to continuous-wave and subthreshold micropulse laser. *Jpn J Ophthalmol*. 2022 Sep;66(5):487-497.
 20. Shiraya T, Araki F, Nakagawa S, Ueta T, Totsuka K, Abe H, Naito Y, Toyama T, Sugimoto K, Kato S. Differential gene expression analysis using RNA sequencing: retinal pigment epithelial cells after exposure to continuous-wave and subthreshold micropulse laser. *Jpn J Ophthalmol*. 2022 Sep;66(5):487-497.
 21. Toyama T, Kawai H, Hashimoto Y, Azuma K, Shiraya T, Numaga J, Obuchi S, Ueta T; OTASSHA Study Group. Macular and peripapillary retinal nerve fiber layer thinning in eyes with prediabetes in the elderly population: OTASSHA study. *Graefes Arch Clin Exp Ophthalmol*. 2022 Dec 1.
 22. Wang Y, Toyama T, Hashimoto Y, Kawai H, Azuma K, Shiraya T, Kato S, Watanabe Y, Hirano H, Fujiwara Y, Ihara K, Kim H, Numaga J, Obuchi S, Ueta T. ASSOCIATION OF PREDIABETES WITH RETINAL MICROVASCULATURE ON SWEEP-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN THE ELDERLY: OTASSHA Study. *Retina*. 2022 Jun 1;42(6):1130-1136.
 23. Aoki S, Imaizumi H. Simultaneous development of full-thickness macular hole and neovascular

age-related macular degeneration. *Am J Ophthalmol Case Rep.* 2022 Jan 22;25:101325.

24. Ozawa R, Azuma K, Nomura Y, Murata H, Asaoka R, Kitamoto K, Ueda K, Inoue T, Obata R. Association between retinal sensitivity and the presence of quiescent choroidal neovascularization in pachychoroid diseases. *PLoS One.* 2022 Jul 26;17(7):e0271543.

Department of Otorhinolaryngology and Head & Neck Surgery

Professor

Tatsuya Yamasoba, M.D., Ph.D.

Associate Professor

Kenji Kondo, M.D., Ph.D.

Akinori Kashio, M.D., Ph.D.

Rumi Ueha, M.D., Ph.D. (Swallowing Center)

Lecturer

Shu Kikuta, M.D., Ph.D.

Yuki Saito, M.D., Ph.D.

Chisato Fujimoto, M.D., Ph.D.

Research Associate

Osamu Fukuoka, M.D.

Hironobu Nishijima, M.D., Ph.D.

Makoto Kinoshita, M.D., Ph.D.

Ryoji Kagoya, M.D., Ph.D.

Takao Goto, M.D.

Kenya Kobayashi, M.D., Ph.D.

Taku Sato, M.D.

Shinji Urata, M.D., Ph.D.

Teru Kamogashira, M.D., Ph.D.

Hajime Koyama, M.D., Ph.D.

Kei Ogawa, M.D., Ph.D.

Homepage <http://utokyo-ent.org/>

Introduction and Organization

The Department of Otorhinolaryngology was founded in 1899 by Prof. Waichiro Okada who studied in Germany. This is the first department of otorhinolaryngology of the national university in Japan. Our department covers all otorhinolaryngological diseases and associated systemic diseases, and has specialized clinics in middle ear and inner ear diseases, hearing impaired infant and children, adult and elderly patients, facial palsy, vertigo and balance disorders, olfactory disorders and paranasal diseases, voice and speech disorders, swallowing and airway disorders, aphasia, central auditory disorders and head & neck

cancers.

A professor, associate professors, lecturers (assistant professors) and associates participate in surgery, out-patient and in-patient care as well as research and educational activities. Moreover 8 Japanese graduate students and two Chinese foreign graduate students participate in basic research.

Weekly preoperative and postoperative conferences are held to discuss surgical cases in detail. Special lectures on leading research activities are presented by invited guests on a regular basis. A weekly journal club is held to introduce current research papers.

Clinical activities

In the out-patient clinic, general and special services are provided to approximately 150 out-patients on a daily basis in all areas of otorhinolaryngology and related specialties, and approximately 300 new patients visit monthly.

In the inpatient hospital, 33 beds are prepared for patients under the supervision of lecturers and senior residents from each subspecialty group including head & neck surgery, middle ear surgery and cochlear implant surgery; voice and swallowing surgery, and paranasal surgery and other minor surgery. Preoperative and postoperative problems are checked and discussed by each group, the professor's and associate professor's rounds. Approximately 700 operations are performed annually.

Cochlear implant surgery over 400 cases has been performed for infants, children and adult patients with profound hearing loss and is very successful to provide new hearing. Head and neck surgery is performed to extirpate malignant tumor with neighboring tissues and reconstruct upper respiratory and swallowing functions at one stage operation cooperating with plastic surgeons. Reconstructive surgery of microtia and atresia to reconstruct external ear is routinely performed with plastic surgeons.

Auditory brainstem response is routinely examined in order to diagnose peripheral and central deafness in neonates, infants and children.

Treatment of acoustic tumor using an γ -knife and auditory brainstem implant are performed in consultation with neurosurgeons.

Teaching activities

Serial lectures on otolaryngology head and neck surgery, and special lectures on its current topics are provided to the fourth year and the fifth/sixth year of medical students, respectively.

Clinical training is provided for the sixth year class of medical students on a one-to-one basis with staff doctors. They are requested to write reports on a clinical case or a clinical problem. The students participate to see surgery, special clinics and clinical examinations such as otoscope, fiberscope, pure-tone audiometry, auditory brainstem response, and caloric test. Interview with patient is encouraged. They are

questioned on many aspects of clinical problems in seminars by professor and associate professors.

Research activities

Clinical and basic research activities are highly encouraged. Clinical research, which is supervised by senior doctors, is very actively pursued even by young residents. Case reports presentation and writing skills are regarded as important experience in order to develop young doctors' research activity and investigate important findings in patients. The clinical research is related to ear surgery, neurotology, audiology, head and neck surgery, laryngology, bronchoesophagology and rhinology and is related to case research, clinical statistics and clinical electrophysiology. Basic research is also encouraged to solve essence of clinical problems and to elucidate basic phenomena or anatomical and cellular structures. Our research topics cover:

- 1) Morphology and neurophysiology of the inner ear focusing on sensory neural deafness
- 2) Speech perception and language development in deaf children
- 3) Liquid biopsy of perilymph via round window membrane
- 4) Prediction of hearing outcome in tympanoplasty using machine learning
- 5) Analysis of balance disorders using vestibular function tests
- 6) Development of novel examination methods for balance disorders
- 7) Development of novel therapeutic methods for balance disorders by galvanic vestibular stimulation
- 8) Predicting and elucidating the pathogenesis of vestibular disorders using machine learning
- 9) Elucidation of the pathogenesis of vestibular migraine
- 10) Development of novel therapeutic methods for persistent postural-perceptual dizziness
- 11) Elucidation of the mechanism of postural control in patients with vestibulopathy using mathematical models
- 12) Hair cell physiology and pathology and introduction of hair cell regeneration in the

auditory and vestibular end organ

- 13) Clinical neurophysiology of the facial nerves focusing on degeneration and regeneration in patients
- 14) Analyses of development, regeneration and aging in olfactory neural system
- 15) Pathophysiology of olfactory dysfunction
- 16) Computer fluid dynamics of intranasal airflow
- 17) Metabolic conversion of odorant molecules by nasal mucus
- 18) Analysis of eosinophilic chronic sinusitis using human samples and animal models
- 19) Swallowing impairment in patients with lung transplants
- 20) Swallowing mechanisms using pathological and electrophysiological analysis and VR system
- 21) Evaluation of swallowing physiology with pharyngo-esophageal high-resolution manometry
- 22) Esophageal Motility in Neuromuscular Disorders
- 23) Esophageal Motility in systemic sclerosis
- 24) Gene expression analysis of recurrent respiratory papillomatosis
- 25) Kinetics of vocal cord movement using high-speed video system
- 26) Histochemical, molecular biological, and genome analysis of head and neck cancer

Various clinical and basic research is conducted by staffs, residents, and graduate students as well as doctors at affiliated hospitals.

References

1. Abe C, Katayama C, Ohbayashi K, Horii K, Ogawa B, Fujimoto C, Iwasaki Y, Nin F, Morita H. Galvanic vestibular stimulation-induced activation of C1 neurons in medulla oblongata protects against acute lung injury. *Am J Physiol Regul Integr Comp Physiol*. Epub 2022.
2. Akashi K, Sakai T, Fukuoka O, Saito Y, Yoshida M, Ando M, Ito T, Murakami Y, Yamasoba T. Usefulness of circulating tumor DNA by targeting human papilloma virus-derived sequences as a biomarker in p16-positive oropharyngeal cancer. *Sci Rep*.12(1):572.2022.
3. Baba S, Kondo K, Yoshitomi A, Taniguchi K, Nakaya M, Yamasoba T. Efficacy of High-Dose Corticosteroid Therapy in Acute Stage Severe Facial Palsy in Children. *Otol Neurotol*. Epub 2022.
4. Cao X, Maruyama J, Zhou H, Fu Y, Kerwin L, Powers C, Sattler RA, Manning JT, Singh A, Lim R, Healy LD, Johnson S, Paz Cabral E, Li D, Lu L, Ledesma A, Lee D, Richards S, Rivero-Nava L, Li Y, Shen W, Stegman K, Blair B, Urata S, Kishimoto-Urata M, Ko J, Du N, Morais K, Lawrence K, Rivera I, Pai CI, Bresson D, Brunswick M, Zhang Y, Ji H, Paessler S, Allen RD. Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies. *Sci Rep*.12(1):15517.2022.
5. Dy AES, Kashio A, Fujimoto C, Kinoshita M, Kikkawa YS, Hoshi Y, Igarashi K, Uranaka T, Iwasaki S, Yamasoba T. Vestibular Imaging and Function in Patients With Inner Ear Malformation Presenting With Profound Hearing Loss. *OTO Open*.6(3):2473974X221128912.2022.
6. Gao Y, Kamogashira T, Fujimoto C, Iwasaki S, Yamasoba T. Beneficial effects of time-restricted feeding on gentamicin cytotoxicity in mouse cochlea and vestibular organs. *Laryngoscope Investig Otolaryngol*.7(2):530-9.2022.
7. Gao Y, Kamogashira T, Fujimoto C, Iwasaki S, Yamasoba T. Effects of pyrroloquinoline quinone on noise-induced and age-related hearing loss in mice. *Sci Rep*.12(1):15911.2022.
8. Gao Y, Kamogashira T, Fujimoto C, Iwasaki S, Yamasoba T. Pyrroloquinoline quinone (PQQ) protects mitochondrial function of HEI-OC1 cells under premature senescence. *NPJ Aging*.8(1):3.2022.
9. Han B, Kikuta S, Kamogashira T, Kondo K, Yamasoba T. Sleep deprivation induces delayed regeneration of olfactory sensory neurons following injury. *Front Neurosci*. 16: 1029279. 2022.
10. Hasegawa H, Shinya Y, Ono M, Kikuta S, Kondo K, Saito N. Kashime: A Novel Knotless Surgical Suture to Simplify Dural Stitches in Endoscopic Transnasal Surgery. *Oper Neurosurg (Hagerstown)*. Epub 2022.
11. Ijichi C, Kondo K, Kobayashi M, Shirasawa A, Shimbo K, Nakata K, Maruyama Y, Ihara Y, Kawato Y, Mannen T. Lipocalin 15 in the olfactory

- mucus is a biomarker for Bowman's gland activity. *Sci Rep-Uk*.12(1):9984.2022.
12. Ijichi C, Wakabayashi H, Sugiyama S, Hayashi K, Ihara Y, Nishijima H, Touhara K, Kondo K. Odorant metabolism of the olfactory cleft mucus in idiopathic olfactory impairment patients and healthy volunteers. *Int Forum Allergy Rhinol*. 12(3):293-301.2022.
 13. Imamura Y, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ota I, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Yokota T, Okano S, Tanaka K, Onoe T, Ariizumi Y, Homma A. Systemic therapy for salivary gland malignancy: current status and future perspectives. *Jpn J Clin Oncol*.52(4):293-302.2022.
 14. Ishii R, Ohkoshi A, Kiyota N, Matsuura K, Yasuda K, Imamura Y, Saito Y, Homma A, Japan Clinical Oncology Group H, Neck Cancer Study G. Management of elderly patients with head and neck cancer. *Jpn J Clin Oncol*.52(4):313-21.2022.
 15. Iwasaki S, Kamogashira T, Fujimoto C, Kabaya K, Kinoshita M, Yamasoba T. The Role of Neck Input in Producing Corrective Saccades in the Head Impulse Test. *Front Neurol*.13:881411.2022.
 16. Kagoya R, Iwanami T, Mochizuki M, Kondo K, Ito K. Case report: Unilateral transnasal endoscopic marsupialization of nasopalatine duct cyst. *Front Surg*.9:978915.2022.
 17. Kagoya R, Toma-Hirano M, Yamagishi J, Matsumoto N, Kondo K, Ito K. Immunological status of the olfactory bulb in a murine model of Toll-like receptor 3-mediated upper respiratory tract inflammation. *J Neuroinflammation*. 19(1): 13.2022.
 18. Kamei R, Urata S, Maruoka H, Okabe S. In vivo Chronic Two-Photon Imaging of Microglia in the Mouse Hippocampus. *J Vis Exp*. (185)2022.
 19. Kamogashira T, Funayama H, Asakura S, Ishimoto S. Vestibular Neuritis Following COVID-19 Vaccination: A Retrospective Study. *Cureus*.14(4):e24277.2022.
 20. Kanemoto K, Kashio A, Ogata E, Akamatsu Y, Koyama H, Uranaka T, Hoshi Y, Iwasaki S, Yamasoba T. Cochlear Implantation in Patients with Mitochondrial Gene Mutation: Decline in Speech Perception in Retrospective Long-Term Follow-Up Study. *Life (Basel)*.12(4)2022.
 21. Kaneoka A, Ueha R, Nagatomo M, Matsunaga A, Umezaki S, Inokuchi H, Ogata T. Esophageal Speech for a Patient with Amyotrophic Lateral Sclerosis Who Underwent a Central-part Laryngectomy to Prevent Aspiration: A Case Report. *Prog Rehabil Med*.7:20220064.2022.
 22. Kashio A, Yamada C, Yasuhara K, Kamogashira T, Someya S, Yamasoba T. Taurine, Coenzyme Q(10), and Hydrogen Water Prevents Germanium Dioxide-Induced Mitochondrial Dysfunction and Associated Sensorineural Hearing Loss in mouse. *Hearing research*. Epub 2022..
 23. Kawaguchi A, Shin M, Hasegawa H, Shinya Y, Shojima M, Kondo K. Endoscopic Extended Transclival Approach for Lower Clival Meningioma. *World Neurosurg*.164:117.2022.
 24. Kawakita D, Nagao T, Takahashi H, Kano S, Honma Y, Hirai H, Saigusa N, Akazawa K, Tani K, Ojiri H, Tsukahara K, Ozawa H, Okami K, Kondo T, Togashi T, Fushimi C, Shimura T, Shimizu A, Okamoto I, Okada T, Imanishi Y, Watanabe Y, Otsuka K, Sakai A, Ebisumoto K, Sato Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Ando M, Matsuki T, Nakaguro M, Sato Y, Urano M, Utsumi Y, Kohsaka S, Saotome T, Tada Y. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. *Ther Adv Med Oncol*.14:17588359221119538.2022.
 25. Kikuta S, Han B, Yoshihara S, Nishijima H, Kondo K, Yamasoba T. High CT Attenuation Values Relative to the Brainstem Predict Fungal Hyphae Within the Sinus. *Frontiers in Surgery*. 92022.
 26. Kishimoto-Urata M, Urata S, Fujimoto C, Yamasoba T. Role of Oxidative Stress and Antioxidants in Acquired Inner Ear Disorders. *Antioxidants (Basel)*.11(8)2022.
 27. Kishimoto-Urata M, Urata S, Kagoya R, Imamura F, Nagayama S, Reyna RA, Maruyama J, Yamasoba T, Kondo K, Hasegawa-Ishii S, Paessler S. Prolonged and extended impacts of SARS-CoV-2 on the olfactory neurocircuit. *Sci Rep*.12(1):5728.2022.
 28. Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, Mitani H, Iwae S, Fujimoto Y, Onozawa Y, Hanai N, Ogawa T, Hara H, Monden N, Shimura E, Minami S, Fujii T, Tanaka K,

- Homma A, Yoshimoto S, Oridate N, Omori K, Ueda T, Okami K, Ota I, Shiga K, Sugasawa M, Asakage T, Saito Y, Murono S, Nishimura Y, Nakamura K, Hayashi R, Head, Neck Cancer Study Group of the Japan Clinical Oncology G. Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial. *J Clin Oncol*. 40(18):1980-90.2022.
29. Kobayashi K, Ikeda A, Matsumoto Y, Matsumura S, Omura G, Eguchi K, Sakai A, Ito A, Matsumoto F, Yoshimoto S. Surgical technique for super-selective neck dissection under local anesthesia in recurrent head and neck cancer. *Head Neck*.44(8): 1991-4.2022.
 30. Koda K, Katoh M, Yasuhara K. Management of anaplastic thyroid cancer and proposed treatment guidelines-A 5-year case series study. *Cancer Rep (Hoboken)*.5(11):e1727.2022.
 31. Koda K, Yasuhara K. Diagnosis and Treatment of an Infected Supraorbital Ethmoid Cell Cyst. *Archives of Clinical and Medical Case Reports*. 6:199-2022022.
 32. Koda K, Yasuhara K, Sugasawa S, Nagano G, Katoh M, Kakigi A. Observational study of inner ear contrast magnetic resonance images of endolymphatic hydrops to differentiate between definite and probable Menière's disease. *Otolaryngology Case Reports*.24:100460.2022.
 33. Koda K, Yasuhara K, Sugasawa S, Nagano G, Katoh M, Kakigi A. Assessing the usefulness of inner ear contrast-enhanced magnetic resonance imaging and pure-tone audiometry in estimating the prognostic value of hearing improvement in patients with definite Meniere's disease. *Eur Arch Otorhinolaryngol*. Epub 2022.
 34. Kohsaka S, Tada Y, Ando M, Nakaguro M, Shirai Y, Ueno T, Kojima S, Hirai H, Saigusa N, Kano S, Tsukahara K, Togashi T, Ozawa H, Kondo T, Okami K, Takahashi H, Kawakita D, Fushimi C, Suzuki T, Shimizu A, Okamoto I, Okada T, Sato Y, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Urano M, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Shimura T, Nagao T, Mano H. Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling. *NPJ Precis Oncol*.6(1):82.2022.
 35. Koyama H, Kashio A, Uranaka T, Matsumoto Y, Yamasoba T. Application of Machine Learning to Predict Hearing Outcomes of Tympanoplasty. *Laryngoscope*. Epub 2022.
 36. Koyama H , Yamasoba T. Vestibular dysfunction after cochlear implantation in children. *ENT & Audiology News* 31:38-39. 2022.
 37. Maruyama J, Reyna RA, Kishimoto-Urata M, Urata S, Manning JT, Harsell N, Cook R, Huang C, Nikolich-Zugich J, Makishima T, Paessler S. CD4 T-cell depletion prevents Lassa fever associated hearing loss in the mouse model. *PLoS Pathog*.18(5):e1010557.2022.
 38. Masuda H, Ueha R, Sato T, Goto T, Koyama M, Yamauchi A, Kaneoka A, Suzuki S, Yamasoba T. Risk Factors for Aspiration Pneumonia After Receiving Liquid-Thickening Recommendations. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*.167(1):125-32.2022.
 39. Matsumoto N, Kashio A, Yoshida M, Kondo K, Miyamoto S, Okazaki M, Ikemura M, Ushiku T, Yamasoba T. Cholesterol granuloma in facial nerve canal presenting with facial nerve paralysis. *Auris Nasus Larynx*. Epub 2022.
 40. Miura K, Kawakita D, Oze I, Suzuki M, Sugasawa M, Endo K, Sakashita T, Ohba S, Suzuki M, Shiotani A, Kohno N, Maruo T, Suzuki C, Iki T, Hiwatashi N, Matsumoto F, Kobayashi K, Toyoda M, Hanyu K, Koide Y, Murakami Y, Hasegawa Y. Predictive factors for false negatives following sentinel lymph node biopsy in early oral cavity cancer. *Sci Rep*.12(1):6917.2022.
 41. Miyazaki T, Chen S, Florinas S, Igarashi K, Matsumoto Y, Yamasoba T, Xu ZQ, Wu H, Gao C, Kataoka K, Christie RJ, Cabral H. A Hoechst Reporter Enables Visualization of Drug Engagement In Vitro and In Vivo: Toward Safe and Effective Nanodrug Delivery. *ACS nano*. 16(8):12290-304.2022.
 42. Mori A, Takeda H, Kobayashi M, Misawa T, Watanabe R, Abe S, Kumakawa K, Nishio S, Usami S, Yamasoba T. Successful cochlear implantation in a patient with Epstein syndrome during long-term follow-up. *Auris Nasus Larynx*.

- 49(2):308-12.2022.
43. Nishijima H, Zunitch MJ, Yoshida M, Kondo K, Yamasoba T, Schwob JE, Holbrook EH. Rapid fluorescent vital imaging of olfactory epithelium. *iScience*.25(5):104222.2022.
44. Nishio SY, Moteki H, Miyagawa M, Yamasoba T, Kashio A, Iwasaki S, Takahashi M, Naito Y, Fujiwara K, Sugaya A, Takahashi H, Kitaoka K, Usami SI. Etiology of hearing loss affects auditory skill development and vocabulary development in pediatric cochlear implantation cases. *Acta Otolaryngol*.142(3-4):308-15.2022.
45. Niwa T, Konishi T, Sasahara A, Sato A, Morizono A, Harada M, Nishioka K, Fukuoka O, Makise N, Saito Y, Ando M, Yoshimoto T, Shikama T, Yamashita S, Tanabe M, Seto Y. Subcutaneous axillary primary epithelioid hemangioendothelioma: report of a rare case. *Surg Case Rep*.8(1):166.2022.
46. Nomura T, Horikoshi T, Kitano Y, Yamada M, Kondo K, Kikuchi S. Postoperative functional evaluation of obstructive sleep apnea syndrome by computational fluid dynamics. *Indian J Otolaryngol Head Neck Surg*.74(Suppl 3):5044-51.2022.
47. Nomura T, Sasaki A, Fujimoto M, Mano M, Suda N, Kondo K. Effects of jaw movement in bimaxillary orthognathic surgery on the upper airway: Computational fluid dynamics analysis. *Orthod Craniofac Res*. Epub 2022.
48. Ogawa G, Kagoya R, Mochiki M, Ito K. A Case of Mumps Presenting With Unilateral Submandibular Sialadenitis and Laryngeal Edema. *Cureus*.14(9):e29290.2022.
49. Omura K, Han B, Nishijima H, Aoki S, Ebihara T, Kondo K, Otori N, Kojima H, Yamasoba T, Kikuta S. Heterogeneous distribution of mature olfactory sensory neurons in human olfactory epithelium. *Int Forum Allergy Rhinol*.12(3):266-77.2022.
50. Patel ZM, Holbrook EH, Turner JH, Adappa ND, Albers MW, Altundag A, Appenzeller S, Costanzo RM, Croy I, Davis GE, Dehgani-Mobaraki P, Doty RL, Duffy VB, Goldstein BJ, Gudis DA, Haehner A, Higgins TS, Hopkins C, Huart C, Hummel T, Jitaroon K, Kern RC, Khanwalkar AR, Kobayashi M, Kondo K, Lane AP, Lechner M, Leopold DA, Levy JM, Marmura MJ, Mclelland L, Miwa T, Moberg PJ, Mueller CA, Nigwekar SU, O'brien EK, Paunescu TG, Pellegrino R, Philpott C, Pinto JM, Reiter ER, Roalf DR, Rowan NR, Schlosser RJ, Schwob J, Seiden AM, Smith TL, Soler ZM, Sowerby L, Tan BK, Thamboo A, Wrobel B, Yan CH. International consensus statement on allergy and rhinology: Olfaction. *Int Forum Allergy Rhinol*.12(4):327-680.2022.
51. Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwarra M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T, Nagao T. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy. *Front Oncol*.11:779882.2022.
52. Saito Y, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ota I, Yokota T, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Okano S, Imamura Y, Ariizumi Y, Hayashi R. Human papillomavirus-related oropharyngeal carcinoma. *Jpn J Clin Oncol*. 52(7): 700-6.2022.
53. Saito Y, Yoshimoto S, Kitayama M, Hayashi T, Yamamura K, Kobayashi K, Fukuoka O, Nibu KI, Yamasoba T. Elective neck dissection for T3-T4N0 laryngeal carcinoma: evidence from Japan's National Head and Neck Cancer Registry. *Int J Clin Oncol*. Epub 2022.
54. Sakai T, Saito Y, Tateishi Y, Yamazawa S, Fukuoka O, Kobayashi K, Omura G, Akashi K, Yoshida M, Ando M, Ebihara Y, Yamasoba T. Tumor-stroma ratio can predict lymph-node metastasis in cT1/2N0 oral tongue squamous cell carcinoma independent of tumor budding grade. *Int J Clin Oncol*.27(12):1818-27.2022.
55. Sakata A, Kashio A, Koyama H, Uranaka T, Iwasaki S, Fujimoto C, Kinoshita M, Yamasoba T. Long-Term Progression and Rapid Decline in Hearing Loss in Patients with a Point Mutation at Nucleotide 3243 of the Mitochondrial DNA. *Life (Basel)*.12(4)2022.

56. Shinya Y, Shin M, Hasegawa H, Koizumi S, Kin T, Kondo K, Saito N. Endoscopic endonasal transpetroclival approach for recurrent bilateral petroclival meningioma. *Neurosurg Focus Video*. 6(2):V7.2022.
57. Sugaya T, Ueha R, Sato T, Goto T, Yamauchi A, Yamasoba T. Safety of surgical tracheostomy under continued antithrombotic therapy: A retrospective cohort study. *Clin Otolaryngol*. 47(1):88-93.2022.
58. Sugito R, Yamauchi A, Sato T, Goto T, Ueha R, Nito T, Yamasoba T. Sex-and Age-Based Etiological Analysis of 2901 Patients With Dysphonia in a Japanese Tertiary Medical Institute. *Journal of voice : official journal of the Voice Foundation*. Epub 2022.
59. Suto A, Ueha R, Ogura T, Maeda E, Tatebayashi M, Shimada D, Koyama M, Sato T, Goto T, Yamauchi A, Yamasoba T. Swallowing computed tomography and virtual reality as novel imaging modalities for the diagnosis of clicking larynx: Two case reports. *Auris Nasus Larynx*. Epub 2022.
60. Suzuki N, Katoh M, Koda K, Kuriyama M, Nagano G, Yasuhara K. Idiopathic common carotid artery laceration: A case report. *Clin Case Rep*.10(11):e6551.2022.
61. Takeuchi M, Ahn J, Lee K, Takaki K, Ifukube T, Yabu K-I, Takamichi S, Ueha R, Sekino M. Hands-Free Wearable Electrolarynx using Linear Predictive Coding Residual Waves and Listening Evaluation. *Advanced Biomedical Engineering*. 11:68-75.2022.
62. Tokimura R, Hashimoto Maeda M, Mitsutake A, Sakai S, Suzuki F, Sugawara K, Fujimoto C, Ishiura H, Toda T. Isolated Paravermal Hyperintensities in Neuronal Intranuclear Inclusion Disease. *Neurology*.98(22):938-9.2022.
63. Tsunoda K, Nagai R, Kobayashi R, Takazawa M, Wasano K, Kondo K. Tone Enhancement Electro-Fiberscope Combined with Strobe Light Source and Re-analysis Past Images-Tone Enhancement Dynamic Stroboscope. *Laryngoscope*. 132(11): 2206-8.2022.
64. Uchida Y, Nishita Y, Otsuka R, Sugiura S, Sone M, Yamasoba T, Kato T, Iwata K, Nakamura A. Aging Brain and Hearing: A Mini-Review. *Front Aging Neurosci*.13:791604.2022.
65. Ueha R, Ito T, Furukawa R, Kitabatake M, Oujii-Sageshima N, Ueha S, Koyama M, Uranaka T, Kondo K, Yamasoba T. Oral SARS-CoV-2 Inoculation Causes Nasal Viral Infection Leading to Olfactory Bulb Infection: An Experimental Study. *Front Cell Infect Microbiol*. 12:924725. 2022.
66. Ueha R, Ito T, Ueha S, Furukawa R, Kitabatake M, Oujii-Sageshima N, Uranaka T, Tanaka H, Nishijima H, Kondo K, Yamasoba T. Evidence for the spread of SARS-CoV-2 and olfactory cell lineage impairment in close-contact infection Syrian hamster models. *Front Cell Infect Microbiol*.12:1019723.2022.
67. Umekawa M, Shinya Y, Hasegawa H, Kawashima M, Shin M, Katano A, Minamitani M, Kashio A, Kondo K, Saito N. Stereotactic radiosurgery ensures an effective and safe long-term control of Koos grade IV vestibular schwannomas: a single-center, retrospective, cohort study. *J Neurooncol*. 159(1):201-9.2022.
68. Urata S, Okabe S. Three-dimensional mouse cochlea imaging based on the modified Sca/eS using confocal microscopy. *Anat Sci Int*. 2023.
69. Yamakawa K, Nishijima H, Kubota A, Naruse H, Baba S, Fujimaki Y, Kondo K, Toda T, Yamasoba T. Clinical and electrophysiological findings of facial palsy in a case of hereditary gelsolin amyloidosis. *Auris Nasus Larynx*. Epub 2022.

Department of Rehabilitation Medicine

Professor

Toru Ogata, M.D.

※The following information is the same as that of the previous year for certain reasons.

Homepage <http://todaireh.umin.ne.jp>

Introduction and Organization

The Department of Rehabilitation Medicine was established by Ministry of Education, Culture, Sports, Science and Technology in April 2001. It is one of the newest fields in Graduate School of Medicine, the University of Tokyo. It belongs to the Sensory and Motor System Science Course of the Surgical Science Division. Current authorized staff is only one professor.

This department derives from the establishment of the physical therapy room in the central diagnostic and therapeutic sections in order to develop the clinical practice of rehabilitation medicine in 1963. The chair of professor was set up as a full-time director of the central rehabilitation service in 1984, but the formal title remained a physical therapy department.

Rehabilitation medicine is a newly established clinical section which was born in development of the modern principle of the medical health service by which it came to value the enhancement of not only adding years of patient's life but also adding life to the years. Regardless of the rapid expansion of needs, acknowledgment of rehabilitation medicine was delayed in the frame of the old-fashioned clinical departments. In our country, it was 1996 when the rehabilitation specialty was authorized as formal clinical practice by the former Ministry of Health and Welfare.

On the other hand, it was positioned as an assistance instructor in the sensory and motor system medicine department with shifting to the graduate

school course systems since 1995 to 97 in the University of Tokyo. Finally, the rehabilitation medicine field was installed in the sensory and motor system medicine department by a budget step of 2001. We have accepted the graduate school student formally since fiscal year 2001. However, the arrangement of additional teaching staff is not still materialized. Therefore, the staff of the graduate school is only one professor. Twenty students have entered the graduate school by 2020, and fifteen of them were granted Ph.D.

Clinical activities

The professor serves as a director of Rehabilitation Center, the University of Tokyo Hospital. The Rehabilitation Center and the Department of Rehabilitation Medicine are united and engage in clinical practice. We have at present no charged ward, and treat about 4,700 new referrals annually from almost all the departments of the university hospital. We always take charge of 250-300 patients corresponding about 25-30% of the whole number of inpatients. We also see 15 people per day at the outpatient rehabilitation setting. The numerical ratio of outpatient is being reduced in order to give priority to the clinical service corresponding to needs expansion of service to inpatients.

Teaching activities

We have provided several clinical curriculums on

rehabilitation medicine for 4th, 5th, and 6th year medical students since 1973. The systematic lecture series for 4th year medical students (M2) include the subjects on rehabilitation for disorders such as cerebrovascular disturbances, respiratory disorders, neuromuscular diseases, bone and joint diseases, and pediatric disorders as well as on outline of rehabilitation, and amputation/prostheses. We have provided a clinical practice in small group, so-called clinical clerkship for 5th and 6th year students from Wednesday to Friday every week. They experience a few patients and learn how to take a patients' history, physical findings, functional evaluation, and how to plan rehabilitation programs. We have introduced a few of elective students for elective clinical clerkship to our collaborating hospitals with specialized rehabilitation ward.

In addition, we have provided the training of students including physical therapy, occupational therapy, and speech therapy. Twenty students or more come and stay at the university hospital annually as a long-term clerkship from several PT/OT/ST training schools.

Research activities

Our research activities are growing up. In 2006, the Rehabilitation Center moved to the new building and a research laboratory was provided for the first time. As the motion analysis system was partially renewed, we are planning our researches mainly in the field of musculoskeletal disabilities. In addition, we are planning collaborating researches with other departments in our hospital, other faculties in our university, and institutions outside the University of Tokyo. The ongoing projects are as follows.

- 1) 3D Motion analysis of patients with musculoskeletal disorders
- 2) Prognostic evaluation of patients with metastatic bone tumors
- 3) Rehabilitation and long-term outcome in patients with skeletal dysplasias
- 4) Pathology and treatment for patients with congenital limb deficiencies
- 5) Analysis of rehabilitation outcome using DPC data

References

1. Goto M, Haga N, Takedani H: Physical activity and its related factors in Japanese people with haemophilia. *Haemophilia* 25: e267-e273, 2019
2. Mano H, Fujiwara S, Haga N: Body knowledge in children with congenital lower limb deficiency. *Pediatr Int* 61(2): 158-165, 2019
3. Matsushita M, Kitoh H, Mishima K, Yamashita S, Haga N, Fujiwara S, Ozono K, Kubota T, Kitaoka T, Ishiguro N: Physical, mental and social problems of adolescent and adult patients with achondroplasia. *Calc Tissue Int* 104(4): 364-372, 2019
4. Nakahara Y, Kitoh H, Nakashima Y, Toguchida J, Haga N: The longitudinal study of activities of daily living and quality of life in Japanese patients with fibrodysplasia ossificans progressiva. *Disabil Rehabil* 41(6): 699-704, 2019
5. Taya M, Amiya E*, Hatano M, Maki H, Hosoya Y, Ishida J, Bujo C, Tsuji M, Konishi Y, Yokota K, Haga N, Komuro I: Inspiratory muscle training for advanced heart failure with lamin-related muscular dystrophy. *J Cardiol Cases* 2019, jccase 20(6): 232-234, 2019.9
6. Yamoto K, Saitsu H, Nishimura G, Kosaki R, Takayama S, Haga N, Tonoki H, Okumura A, Horii E, Okamoto N, Suzumura H, Ikegawa S, Kato F, Fujisawa Y, Nagata E, Takada S, Fukami M, Ogata T: Comprehensive clinical and molecular studies in split hand/foot malformation: identification of two plausible candidate genes (LRP6 and UBA2). *Eur J Hum Genet* 27: 1845-1857, 2019
7. Yoshida M, Matsunaga A, Igawa Y, Fujimura T, Shinoda Y, Aizawa N, Sato Y, Kamei J, Kume H, Homma Y, Haga N, Sanada H*: May preoperative ultrasound-guided pelvic floor muscle training promote early recovery of urinary continence after robot-assisted radical prostatectomy? *Neurourol Urodyn* 38(1): 158-164, 2019
8. Ogura K, Uehara K, Akiyama T, Shinoda Y, Iwata S, Tsukushi S, Kobayashi E, Hirose T, Yonemoto T, Endo M, Tanzawa Y, Nakatani F, Kawano H, Tanaka S, Kawai A: Development of a patient-oriented disease specific outcome measure of health-related quality of life (HRQOL) for

- musculoskeletal oncology patients. *J Orthop Sci* 24(3): 539-547, 2019
9. Fujimura T, Igawa Y, Aizawa N, Niimi A, Yamada Y, Sugihara T, Kamei J, Sato Y, Matsunaga A, Yoshida M, Shinoda Y, Fukuhara H, Nakagawa T, Homma Y, Kume H: Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot-assisted radical prostatectomy. *Neurourol Urodyn* 38(4): 1067-1075, 2019
 10. Shinoda Y, Sawada R, Yoshikawa F, Oki T, Hirai T, Kobayashi H, Matsudaira K, Oka H, Tanaka S, Kawano H, Haga N: Factors related to the quality of life in patients with bone metastases. *Clin Exp Metastasis* 36(5): 441-448, 2019
 11. Shinoda Y, Kobayashi H, Kaneko M, Ohashi S, Bessho M, Hayashi N, Oka H, Imanishi J, Sawada R, Ogura K, Tanaka S, Haga N, Kawano H: Prediction of the pathological fracture risk during stance and fall-loading configurations for metastases in the proximal femur, using a computed tomography-based finite element method. *J Orthop Sci* 24(6): 1074-1080, 2019
 12. Morita K, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Azechi H, Okada N, Koshiyama D, Shiino T, Fukunaga M, Watanabe Y, Ikeda M, Kasai K, Hashimoto R: Eye - movement characteristics of schizophrenia and their association with cortical thickness. *Psychiatry Clin. Neurosci.* 73: 508–9, 2019
 13. Morita K, Miura K, Kasai K, Hashimoto R: Eye movement characteristics in schizophrenia: A recent update with clinical implications. *Neuropsychopharmacol Rep.* Epub ahead of print, 2019
 14. Morita K, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Azechi H, Okada N, Koshiyama D, Ikeda M, Kasai K, Hashimoto R: Eye movement abnormalities and their association with cognitive impairments in schizophrenia. *Schizophr. Res.* 209: 255–62, 2019

Surgical Sciences

3. Vital Care Medicine

Department of Anesthesiology

Professor

Kanji Uchida, M.D., Ph.D.

Associate Professor

Masahiko Sumitani, M.D., Ph.D.

Project Associate Professor

Maiko Hasegawa, M.D., Ph.D.

Lecturer

Nobuko Ito, M.D., Ph.D., Masahiko Bougaki, M.D., Ph.D., Yoshiteru Mori, M.D.,
Gaku Kawamura, M.D., Ph.D., Taro Kariya, M.D., Ph.D.,
Masaaki Asamoto, M.D., Ph.D., Michiko Ushio, M.D.

Project Lecturer

Takuma Hiraiwa, M.D.

Associate

Yosuke Imai, M.D., Ph.D., Ken Kuwajima, M.D., Ph.D., Yuho Tamai, M.D.,
Ayako Hirai, M.D., Yoko Hoshino, M.D., Kazuhito Mietani, M.D., Ph.D.,
Yuko Araki, M.D., Takamitsu Ikeda, M.D., Ph.D., Reo Inoue, M.D., Ph.D.,
Masaki Iwakiri, M.D., Yuji Ueda, M.D., Miyako Nagaya, M.D.,
Tomoaki Nakamura, M.D., Kenji Watanabe, M.D., Yoshika Sudo, M.D.,
Ryosuke Doi, M.D., Kento Omi, M.D., Junko Tsukamoto, M.D.,
Yuki Odawara, M.D., Gen Kawashima, M.D., Chiharu Kushida, M.D.,
Yaeko Yokoshima, M.D.

Homepage <https://www.ut-anes.org/>

Introduction and Organization

The Department of Anesthesiology was established in 1952 and is the oldest department of anesthesiology in Japan. As of March 1, 2023, the Department of Anesthesiology consists of Professor Kanji Uchida; Associate Professor Masahiko Sumitani; Project Associate Professor Maiko Hasegawa; Lecturers Nobuko Ito, Masahiko Bougaki, Yoshiteru Mori, Gaku Kawamura, Taro Kariya, Masaaki Asamoto, Michiko Ushio; Project Lecturer Takuma Hiraiwa; 22

Associates, 11 anesthesiology residents, and 7 graduate students. The outpatient clinic is located on the 2nd floor of Outpatient Clinic Building and the 3rd floor of Central Clinical Service Building 2, the inpatient units are located on the 9th floor south of Inpatient Building A, and the offices and laboratories are located on Clinical Research Building East, Central Building South, and the 4th floor of Clinical Research Building A. The current activities of our department in clinic, education, and research are

described below.

Clinical activities

Department of Anesthesiology is in charge of anesthesia and perioperative management for patients undergoing surgery, acute and chronic pain treatment, and palliative care for cancer patients, of the University of Tokyo Hospital. The number of surgeries at the University of Tokyo Hospital increased as a result of the doubling of the number of operating rooms to 23 when the Central Clinical Service Building 2 became operational in January 2007, and the annual number of surgical cases reached 11,323 (8,831 managed by the anesthesiologists) in FY2019. In FY2020, the number of cases decreased due to the impact of the COVID-19 pandemic. However, from FY2021, there has been a recovery trend, and in FY2022 (Apr 2022 – Mar 2023), the total number of surgeries reached 11,460 cases, with 8,408 cases managed by the anesthesiologists, returning to the pre-COVID levels. The number of surgeries for patients with many complications and elderly patients has been increasing every year, and in addition, heart, liver, and lung transplants from brain-dead donors have been performed.

Because many patients with severe and complicated conditions, both surgically and medically, are treated at the University of Tokyo Hospital, we routinely provide anesthesia for patients with many preoperative comorbidities, including transplant recipients with end-stage organ failure. We contribute to a good postoperative recovery by performing a careful preoperative assessment, optimizing the patient's condition preoperatively, and performing appropriate intraoperative anesthetic management. In the operating rooms, we are also well-prepared to respond quickly to medical or surgical emergencies that may occur during surgery.

For preoperative patients, we provide outpatient and inpatient preoperative consultation service every weekday for more detailed preoperative evaluation for complicated cases, and took care of 1,378 preoperative patients in FY2022. We have actively engaged in the Perioperative Management Center Program and are designing and implementing a system for more efficient and appropriate

perioperative patient management. Starting from FY2022, we significantly expanded the preoperative evaluations by anesthesiologists in the outpatient basis. This expansion includes 4,810 outpatient preoperative evaluation visits (in addition to 193 consultations for oral care) and 1,099 evaluations for inpatients, all conducted in the outpatient booths, which marks a significant shift from predominantly conducting preoperative evaluations on the inpatient wards. As for postoperative care, we are in charge of postoperative intensive patient care in the ICU2 in cooperation with the Department of Acute Medicine, contributing to safe postoperative management and recovery. The number of postoperative intensive care patients taken care of by the staff members of our department was 1,119 in FY2022.

We have also established an obstetric anesthesia team to improve the safety and comfort of perinatal care. The obstetric anesthesia outpatient clinic is opened once or twice a week to evaluate the anesthetic risk of pregnant women, and the number of visitors in FY2022 was 315. The number of neuraxial labor analgesia was 321 in FY2022.

As an outpatient clinic, the Pain Relief Center (Pain Clinic) is open every weekday. For patients with various pain disorders (including those hospitalized in other departments), we focus on not only the sensory factors of pain but also the biopsychosocial factors, and conduct multidisciplinary pain evaluation and treatment, including neurological, neuropsychiatric and psychiatric evaluations, in cooperation with multiple departments. The number of outpatients in FY2022 was 4,994, of which 258 were first-time patients. The number of active beds was 1, and the number of inpatients was 11. There were 137 requests for pain consultation for inpatients in FY2022.

In close collaboration with our department, the Department of Pain and Palliative Medicine provides multidisciplinary palliative care by the palliative care team, and is also in charge of the outpatient cancer treatment pain clinic for chronic pain associated with cancer treatment and the second opinion clinic for cancer pain in the supportive care phase to the advanced stage, in accordance with the characteristics of the University of Tokyo Hospital as a cancer treatment institution.

Education

We give lectures for fourth-year medical students and provide clinical education (Clinical Clerkship) for fifth and sixth-year medical students on a person-to-person basis with our faculty staff members. The lectures of the FY2022 were: History and mechanisms of anesthesia, Inhalational anesthesia, Intravenous anesthesia, Regional and local anesthesia, Preoperative evaluation, Management of the cardiovascular system in anesthesia, Intraoperative monitoring, Airway management in anesthesia, Postoperative management, and Pain clinic.

The major content of the Clinical Clerkship consists of (1) surgical anesthesia clerkship, (2) pain clinic clerkship, and (3) short lectures. In the surgical anesthesia clerkship, students participate in preoperative examinations, planning of anesthesia management, and onsite anesthesia management to learn the basic knowledge of examination and testing techniques as well as physiology and pharmacology necessary for perioperative management in a clinical setting. Pain clinic clerkship aims to deepen understanding of the causes of various intractable pains and therapeutic methods focusing on pharmacotherapy, nerve block therapy, exercise therapy, and cognitive-behavioral therapy. The short lectures cover seven topics: General anesthesiology, Airway maintenance and intubation, Central venous access placement, Subarachnoid spinal anesthesia, Peripheral nerve block, Postoperative ICU management, and Pain clinic. Practical training using a simulator is also provided for tracheal intubation, central venous puncture, and subarachnoid spinal anesthesia. As a summary of the Clinical Clerkship education, we ask the students to submit reports on anesthesia cases and reports on anesthetics and cardiovascular drugs, with presentations and discussions on the contents.

For post-graduate education, we accepted a total of 111 junior residents of PGY1 and 2 from the General Education Center as rotators (1-2 months for each rotator) in FY2022. The training includes anesthesia management, preoperative and intraoperative management, and basic skills and knowledge in emergency and resuscitation settings. For the 11 anesthesiology residents of PGY3+, faculty staffs

teach and supervise daily clinical anesthesia, postoperative ICU care, obstetric anesthesia, and pain clinic. The anesthesiology residents are encouraged to give presentations at scientific meetings, including the Japanese Society of Anesthesiologists (JSA) annual meetings, and publish papers. Anesthesiology residents achieve JSA board certification by the end of the training. In addition, journal clubs and case studies are organized to cultivate a professional attitude in residents and develop their competency to perform care and research as independent anesthesiologists.

Research

Our department has seven research groups. The research fields include respiratory, cardiovascular, pain, nervous, and immune systems.

Our ongoing and recent major research subjects are:

- A role of cytokine signaling in acute lung injury;
- Transpulmonary pressure during mechanical ventilation;
- Exploring risk factors of perioperative exacerbation of interstitial lung disease;
- Modification of immune system by anesthesia;
- Apoptotic signal transduction induced by sepsis or ischemia-reperfusion injury;
- A role of lipid mediators in the formation of hyperalgesia;
- A role of spinal microglial cells in the development of inflammation-mediated neuropathic pain;
- Cognitive-behavioral therapy on chronic pain;
- Analysis of electroencephalography during general anesthesia;
- Exploring relationship between postoperative delirium and blood-brain barrier dysfunction;
- Clinical significance of fatty acid metabolites in general anesthesia;
- Retrospective analyses on perioperative management of left ventricular assisting device implantation or heart transplantation;
- Physiology and molecular biology of left/right heart failure of animal models;
- Invention and validation of new anesthetic procedures with emerging technologies;

- Epidemiological survey and outcome study with large administrative database.

Publications

1. Ando M, Sumitani M, Fuyuki M, Abe H, Shinoda Y, Matsubayashi Y, et al. Imaging features inferring symptom onset due to spinal metastasis progression: a preliminary study. *Ann Palliat Med*. 2022;11(7):2247-56.
2. Asahara M, Ito N, Hoshino Y, Sasaki T, Yokomizo T, Nakamura M, et al. Role of leukotriene B4 (LTB4)-LTB4 receptor 1 signaling in post-incisional nociceptive sensitization and local inflammation in mice. *PLoS ONE*. 2022; 17(10): e0276135.
3. Edamura T, Sumitani M, Hayakawa K, Inoue R, Abe H, Tsuchida R, et al. Different profiles of the triad of lysophosphatidylcholine, lysophosphatidic acid, and autotaxin in patients with neuropathic pain diseases: a preliminary observational study. *Pain Ther*. 2022;11(4):1439-49.
4. Hoshino Y, Okuno T, Saigusa D, Kano K, Yamamoto S, Shindou H, et al. Lysophosphatidic acid receptor_{1/3} antagonist inhibits the activation of satellite glial cells and reduces acute nociceptive responses. *FASEB J*. 2022;36(4): e22236.
5. Kasahara S, Takahashi N, Matsudaira K, Oka H, Takatsuki K, Yabuki S. Psychometric properties of the multidimensional pain inventory: Japanese language version (MPI-J). *Pain Physician*. 2022; 25(1):E105-E112.
6. Kasahara S, Matsudaira K, Sato N, Niwa SI. Attention - deficit/hyperactivity disorder and centralized pain: A review of the case of John F. Kennedy. *Clin Case Rep*. 2022;10(10):e6422.
7. Kasahara S, Takao C, Matsudaira K, Sato N, Tu TTH, Niwa SI, et al. Case report: Treatment of persistent atypical odontalgia with attention deficit hyperactivity disorder and autism spectrum disorder with risperidone and atomoxetine. *Front Pain Res (Lausanne)*. 2022;3:926946.
8. Mietani K, Hasegawa-Moriyama M, Inoue R, Ogata T, Shimojo N, Kurano M, et al. Serum levels of apolipoprotein A-I and E are associated with postoperative delirium: A post hoc analysis. *Medicine (Baltimore)*. 2022;101(30):e29906.
9. Mietani K, Hasegawa-Moriyama M, Yagi K, Inoue R, Ogata T, Kurano M, et al. Preoperative detection of serum phosphorylated neurofilament heavy chain subunit predicts postoperative delirium: a prospective observational study. *J Gerontol Geriatr*. 2022;70(3):1-9.
10. Mietani K, Hasegawa-Moriyama M, Yagi K, Inoue R, Ogata T, Shimojo N, et al. Elevation of serum plasminogen activator inhibitor-1 predicts postoperative delirium independent of neural damage: a sequential analysis. *Sci Rep*. 2022; 12(1):17091.
11. Saita K, Sumitani M, Nishizawa D, Tamura T, Ikeda K, Wakai K, et al. Genetic polymorphism of pleiotrophin is associated with pain experience in Japanese adults: Case-control study. *Medicine (Baltimore)*. 2022;101(37):e30580.
12. Ueda Y, Asamoto M, Kariya T, Akai T, Hoshina K, Uchida K. Ventricular fibrillation during carotid endarterectomy and bailout stenting: a case report. *JA Clin*. 2022;8(1).
13. Uranbileg B, Kurano M, Sumitani M, Ito N, Kano K, Aoki J, et al. Lysophosphatidic acids in cerebrospinal fluids: potential biomarkers and therapeutic targets for neuropathic pain. *Medical Mass Spectrometry*. 2022;6(2):85-92.
14. Ushio M, Uchida K. The quest for meticulous patient care, even in the challenging COVID-19 era, is a trait inherited by professional anesthesiologists. *J Anesth*. 2022;36(6):669-70.

Department of Emergency and Critical Care Medicine

Professor

Kent Doi, M.D.

Lecturer

Takehiro Matsubara, M.D.

Project Lecturer

Miyuki Yamamoto, M.D.

Research Associate

Toshifumi Asada, M.D., Hitomi Nakamura, M.D. Jinsuke Mizuno, M.D.

Atsushi Shimada, M.D. Yuko Sato, M.D. Eri Endo, M.D.

Keiko Gyoten, M.D. Hiromi Matsuda, M.D. Tomohiko Shirokoshi, M.D.

Project Research Associate

Mio Shikama, M.D.

Homepage <http://uteccm.umin.jp/>

Introduction and Organization

Department of Emergency and Critical Care Medicine was established in 1965, as the emergency service within the Central Clinical Service Facilities of the University of Tokyo Hospital and at the same time as the intensive care service for in-hospital patients, it became a tertiary emergency care and critical care center in the metropolitan Tokyo and also became the principal teaching facility of the University of Tokyo. It is a designated Level I Trauma Center, and also the home of one of the newest Life Flight aeromedical services in the country.

The Emergency Center sees approximately 17,000 patients per year. It contains major trauma and cardiac resuscitation rooms complete with STAT X-ray and full monitoring and resuscitation equipment. There are 9 treatment spaces including space for orthopedics, gynecology, and Ophthalmology-ENT evaluations. 10 overnight-stay monitored beds, X-ray, rapid spiral

CT, ultrasound, angiography and STAT Lab are located adjacent to the Emergency Center.

In September, 2001, the University of Tokyo Hospital opened the In-patient Ward A and our department has necessarily extended services for management of critical patients, in the new Critical Care Center now containing adult ICU/CCU of 16 beds in ICU1, 18 beds in ICU2 and 6 beds in Emergency ICU.

The Emergency Care Center and the Critical Care Center see an excellent mix of multiple trauma, high-acuity medical, surgical, pediatric, and gynecologic patients. The Life Flight service provides another opportunity for exposure to critically ill patients. Consult services are available from all of the clinical departments of the Medical School. The university of Tokyo hospital was officially designated as emergency medical care center in December 2010.

Clinical activities

Our clinical activities are divided into three categories as follows:

1) Emergency medicine

Our department is responsible for not only tertiary emergency but also primary and secondary emergency care on 24-hour-a-day basis.

The new ER, four times the size of the previous ER was built in November, 2006. The facility has 5 consultation rooms, 4 specialized consultation rooms for dentistry, ophthalmology, otorhinolaryngology and gynecology, 3 resuscitation bays, and 4 observation beds.

2) Intensive care

Staff members specialized in internal medicine, cardiovascular medicine, orthopedic surgery, surgery, neurosurgery or anesthesiology create “the semi-closed ICU” model. We are responsible for the entire care of the critically ill patients (i.e. patients with respiratory insufficiency such as ARDS, acute kidney injury, sepsis, MOF, shock), post-operative patients, and tertiary emergency patients, placing an emphasis on evidence-based medical therapy.

3) Risk management

It is split into two categories – in-hospital and out of hospital disasters. In regard to in-hospital risk management, including “code blue emergency”, we are responsible for patient safety on 24-hour/365-day basis. And in regard to out of hospital risk management, our hospital has been authorized by the Tokyo Metropolitan Government as a disaster base hospital, and also the Government has requested the formation of Disaster Medical Assistant Team (DMAT). We have oxygen and medical suction equipment on the passageways in the ER in case of treating the large number of disaster patients.

Teaching activities

In the systematic lectures of M2, the latest findings related to the field of emergency medicine, such as general emergency medicine, basics of initial emergency care, cardiopulmonary resuscitation, initial trauma care, and disaster medicine, are lectured and introduced.

In M3, students are in charge of general medicine

and participate in actual practice of emergency general medicine in the emergency department, and in M4, students practice emergency and intensive care medicine and receive lectures on disaster medicine in addition to practical training on critical care in the intensive care unit.

Since 2004, post-graduate clinical training has become mandatory and all residents are required to receive training in the emergency department. In accordance with the training guidelines of the Ministry of Health, Labour and Welfare, residents learn and practice comprehensive emergency medicine that covers primary to tertiary care in the emergency department. In addition, initial clinical trainees are also assigned to the intensive care unit, where they are educated to understand intensive care from the viewpoint of pathophysiology and internal medicine.

In 2006, we started the second semester of clinical training, and are educating the residents in applied crisis medicine such as initial trauma care, cardiopulmonary resuscitation, multiple organ failure, shock, and mechanical assistance for various organ failures, etc.

Research activities

Our clinical studies revealed that organ network disruption could be observed by network analysis with clinical parameters and new biomarkers of ICU patients.

References

1. Abe M, Shiga H, Tatsumi H, Endo Y, Kikuchi Y, Suzuki Y, Doi K, Nakada TA, aagafuchi H, Hattori N, Hirohashi N, Moriguchi T, Yamaga O, Nishida O. Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes. *Ren Replace Ther.* 2022; 8(1):58.
2. Kurano M, Jubishi D, Okamoto K, Hashimoto H, Sakai E, Morita Y, Saigusa D, Kano K, Aoki J, Harada S, Okugawa S, Doi K, Moriya K, Yatomi Y. Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries. *J Biomed Sci.* 2022 Nov 10;29(1):94.
3. Kurano M, Okamoto K, Jubishi D, Hashimoto H, Sakai E, Saigusa D, Kano K, Aoki J, Harada S,

- Okugawa S, Doi K, Moriya K, Yatomi Y. Dynamic modulations of sphingolipids and glycerophospholipids in COVID-19. *Clin Transl Med*. 2022 Oct;12(10):e1069.
4. Matsuura R, Honda K, Oki R, Hamasaki Y, Doi K, Nangaku M. Screening and Management for Intracranial Aneurysms in Japanese Patients With ADPKD. *Kidney Int Rep*. 2022 Jun 1;7(8):1893-1896.
 5. Yamamoto M, Watanabe Y, Doi K. Reddish-purple effluent fluid induced by hydroxocobalamin in continuous renal replacement therapy. *Acute Med Surg*. 2022 Jul 25;9(1):e773.
 6. Ohashi-Fukuda N, Fukuda T, Doi K. Association between time to advanced airway management and survival during pediatric out-of-hospital cardiac arrest. *Resusc Plus*. 2022 Jun 24;11:100260.
 7. Miyamoto Y, Iwagami M, Aso S, Uda K, Fushimi K, Hamasaki Y, Nangaku M, Yasunaga H, Doi K. Postoperative outcomes of cancer surgery in patients with and without kidney failure with dialysis therapy: a matched-pair cohort study. *Clin Kidney J*. 2022 Jan 13;15(6):1137-1143.
 8. Agarwal R, Hauske SJ, Wheeler DC, Doi K, Elsaesser A, Ritter I, Steubl D, Wanner C. Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals. *Diabetes Obes Metab*. 2022 Jul;24(7):1390-1393.

Health Sciences and Nursing

1. Health Sciences

Department of Mental Health

Professor

Daisuke Nishi, M.D., Ph.D.

Lecturer

Natsu Sasaki, M.D., Ph.D.

Homepage <https://mhpn.m.u-tokyo.ac.jp/>

Introduction and Organization

The department was firstly established as Department of Fourth Clinical Medical Nursing in School of Health Care and Nursing in 1957. When the School of Health Care and Nursing was reorganized as the School of Health Sciences in 1965, the department was renamed Department of Mental Health. In 1992, as School of Health Sciences became The School of Health Science and Nursing, Department of Mental Health became Department of Mental Health and Psychiatric Nursing. As the result of the shift to the chair system of the Graduate School of Medicine in 1996, two departments were established, Department of Mental Health and Department of Psychiatric Nursing. Faculty, staff, and students of two departments have been working cooperatively ever since. Since 2007, Department of Mental Health became a part of School of Public Health, with a perspective of “public mental health.”

The department currently has faculty members introduced above, an associate professor, a project lecturer, a research associate, part-time lecturers, a technical specialist, visiting research fellows, 5 doctoral course students, 6 master course students, and secretaries.

The department has two major objectives: one is to teach mental health to undergraduate and graduate students in order to produce global leaders in research and practice in this field. The other is to conduct cutting-edge research in the fields of mental health.

All of the activities of the department are conducted in collaboration with staff members in the departments, other departments within the University of Tokyo, and

institutions within and outside Japan.

Teaching activities

The department is responsible for giving lectures on mental health; mental disorders; clinical and health psychology; and psychometry and behavior evaluation to undergraduate students. Other than lectures, the department provides students opportunities to experience mental health activities in relevant mental health settings.

The department provides graduate courses on mental health I and II, featuring epidemiology and practice in mental health and occupational mental health, respectively. The department also provided a 1.5 hour seminar every Wednesday evening for 20 weeks in each semester (40 weeks per year) for graduate students and research students, with presentations of research plans and progress, and literature review by graduate students, as well as presentation of and lectures by guest speakers.

Research activities

The department conducts research on mental health epidemiology, perinatal mental health, traumatic stress and resilience, and mental health in the workplace. In the field of mental health epidemiology, we are in charge of the survey in Japan of a large-scale international collaborative study (the World Mental Health Survey), which is being conducted under the initiative of Harvard University. In perinatal mental health, we are working with companies to prevent perinatal depression. For traumatic stress, we are

working to evaluate the effectiveness of trauma-informed care and to promote its implementation. For mental health in the workplace, we are developing programs to prevent depression in the workforce. In addition, we are working on suicide prevention, disaster mental health, and international mental health in collaboration with researchers from domestic and international institutions and universities. Many of these studies are conducted in collaboration with researchers from domestic and international institutions and universities.

References

1. Nishi D. Desire for Shorter Life Expectancy From a Mental Health Perspective. *J Epidemiol.* released online September 30. Epub ahead of print.
2. Nishi D, Imamura K, Watanabe K, Obikane E, Sasaki N, Yasuma N, Sekiya Y, Matsuyama Y, Kawakami N. The preventive effect of internet-based cognitive behavioral therapy for prevention of depression during pregnancy and in the postpartum period (iPDP): a large scale randomized controlled trial. *Psychiatry Clin Neurosci.* 2022 Nov;76(11):570-578. Epub 2022 Sep16.
3. Shiba K, Daoud A, Kino S, Nishi D, Kondo K, Kawachi I. Uncovering heterogeneous associations of disaster-related traumatic experiences with subsequent mental health problems: A machine learning approach. *Psychiatry Clin Neurosci.* 2022 Apr;76(4):97-105.
4. Tsuno K, Okawa S, Matsushima M, Nishi D, Arakawa Y, Tabuchi T. The effect of social restrictions, loss of social support, and loss of maternal autonomy on postpartum depression in 1 to 12-months postpartum women during the COVID-19 pandemic. *J Affect Disord.* 2022 Jun 15; 307:206-214.
5. Obikane E (*), Sasaki N (*), Imamura K, Nozawa K, Vedanthan R, Cuijpers P, Shimazu T, Kamada M, Kawakami N, Nishi D. Usefulness of Implementation Outcome Scales for Digital Mental Health (iOSDMH): Experiences from Six Randomized Controlled Trials. *International Journal of Environmental Research and Public Health.* 2022; 19(23) (*) These authors contributed equally to this work.
6. Sasaki N, Ikeda M, Nishi D. Long-term influence of unintended pregnancy on psychological distress: a large sample retrospective cross-sectional study. *Archives of women's mental health.* 2022:1-9.
7. Sasaki N, Imamura K, Watanabe K, Hidaka Y, Ando E, Eguchi H, Inoue A, Tsuno K, Komase Y, Iida M, Otsuka Y, Sakuraya A, Asai Y, Iwanaga M, Kobayashi Y, Inoue R, Shimazu A, Tsutsumi A, Kawakami N. The impact of workplace psychosocial factors on menstrual disorders and infertility: a protocol for a systematic review and meta-analysis. *Systematic reviews.* 2022;11(1): 195.
8. Sasaki N, Kuroda R, Tsuno K, Imamura K, Kawakami N. COVID-19 vaccination did not improve employee mental health: A prospective study in an early phase of vaccination in Japan. *Neuropsychopharmacol Rep.* 2022;42(2):230-2.
9. Sasaki N, Kuroda R, Tsuno K, Imamura K, Kawakami N. The effect of job strain and worksite social support on reported adverse reactions of COVID-19 vaccine: A prospective study of employees in Japan. *Journal of occupational health.* 2022;64(1): e12356.
10. Sasaki N, Tabuchi T, Okubo R, Ishimaru T, Kataoka M, Nishi D. Temporary employment and suicidal ideation in COVID-19 pandemic in Japan: A cross-sectional nationwide survey. *Journal of occupational health.* 2022;64(1): e12319.
11. Hidaka Y, Kawakami N, Watanabe K, and Nishi D. The association between premenstrual syndrome before pregnancy and antenatal depression: A cross-sectional study with pre-recorded information. *Psychiatry and Clinical Neurosciences Reports* 2022, 1(3), p.e27.
12. Imamura K, Sasaki N, Sekiya Y, Watanabe K, Sakuraya A, Matsuyama Y, Nishi D, Kawakami N. The Effect of the Imacoco Care Psychoeducation Website on Improving Psychological Distress Among Workers During the COVID-19 Pandemic: Randomized

- Controlled Trial. *JMIR Form Res.* 2022 Mar 10; 6(3): e33883.
13. Iida M, Watanabe K, Yeo SA, Yasuma N, Nishi D, & Kawakami N. Association of Personal Values in Adolescence with Subjective Health Status, Meaning in Life, and Life Satisfaction in Adulthood: A Cross-sectional Study with Retrospective Recall. *Japanese Psychological Research.* 2022.
 14. Kessler, R. C., Kazdin, A. E., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Altwajri, Y. A., Andrade, L. H., Benjet, C., Bharat, C., Borges, G., Bruffaerts, R., Bunting, B., Caldas de Almeida, J. M., Cardoso, G., Chiu, W. T., Cía, A., Ciutan, M., Degenhardt, L., de Girolamo, G., de Jonge, P., de Vries, Y. A., Florescu, S., Gureje, O., Haro, J. M., Harris, M. G., Hu, C., Karam, A. N., Karam, E. G., Karam, G., Kawakami, N., Kiejna, A., Kovess-Masfety, V., Lee, S., Makanjuola, V., McGrath, J. J., Medina-Mora, M. E., Moskalewicz, J., Navarro-Mateu, F., Nierenberg, A. A., Nishi, D., Ojagbemi, A., Oladeji, B. D., O'Neill, S., Posada-Villa, J., Puac-Polanco, V., Rapsey, C., Ruscio, A. M., Sampson, N. A., Scott, K. M., Slade, T., Stagnaro, J. C., Stein, D. J., Tachimori, H., ten Have, M., Torres, Y., Viana, M. C., Vigo, D. V., Williams, D. R., Wojtyniak, B., Xavier, M., Zarkov, Z., Ziobrowski, H. N., and the WHO WMH survey collaborators. Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. *World Psychiatry.* 2022 Jun;21(2):272-286.
 15. Hazumi M, Okazaki E, Usuda K, Kataoka M, Nishi D. Relationship between attitudes toward COVID-19 infection, depression and anxiety: a cross-sectional survey in Japan. *BMC Psychiatry.* 2022;22(1):798. Published 2022 Dec 19.
 16. Hazumi M, Usuda K, Okazaki E, Kataoka M, Nishi D. Differences in the Course of Depression and Anxiety after COVID-19 Infection between Recovered Patients with and without a Psychiatric History: A Cross-Sectional Study. *Int J Environ Res Public Health.* 2022 Sep 8;19(18): 11316.
 17. Sasaki N, Inoue A, Asaoka H, Sekiya Y, Nishi D, Tsutsumi A, Imamura K. The Survey Measure of Psychological Safety and Its Association with Mental Health and Job Performance: A Validation Study and Cross-Sectional Analysis. *Int J Environ Res Public Health.* 2022 Aug 11;19(16): 9879.
 18. Sasaki N, Akiyama H, Kawakami N, Nishi D. Preconception menstrual cycle disorder and antenatal depression: A cross-sectional study with pre-recorded information. *J Psychosom Obstet Gynaecol.* 43(4):411-418, 2022.10.
 19. Carrozzino D, Christensen KS, Patierno C, Woźniewicz A, Møller SB, Arendt ITP, Zhang Y, Yuan Y, Sasaki N, Nishi D, Berrocal Montiel C, Ceccatelli S, Mansueto G, Cosci F. Cross-cultural validity of the WHO-5 Well-Being Index and Euthymia Scale: A clinimetric analysis. *J Affect Disord.* 2022 Aug 15; 311:276-283. Epub 2022 May 21.
 20. Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, Akhondzadeh S, Benedetti F, Caneo C, Cramer H, Cribb L, de Manincor M, Dean O, Deslandes AC, Freeman MP, Gangadhar B, Harvey BH, Kasper S, Lake J, Lopresti A, Lu L, Metri NJ, Mischoulon D, Ng CH, Nishi D, Rahimi R, Seedat S, Sinclair J, Su KP, Zhang ZJ, Berk M. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytochemicals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. *World J Biol Psychiatry.* 2022 Jul;23(6):424-455. Epub 2022 Mar 21.
 21. Bruffaerts R, Harris MG, Kazdin AE, Vigo DV, Sampson NA, Chiu WT, Al-Hamzawi A, Alonso J, Altwajri YA, Andrade L, Benjet C, de Girolamo G, Florescu S, Haro JM, Hu CY, Karam A, Karam EG, Kovess-Masfety V, Lee S, McGrath JJ, Navarro-Mateu F, Nishi D, O'Neill S, Posada-Villa J, Scott KM, Have MT, Torres Y, Wojtyniak B, Xavier M, Zarkov Z, Kessler RC; WHO World Mental Health Survey Collaborators. Perceived helpfulness of treatment for social anxiety disorder: findings from the WHO World Mental Health Surveys. *Soc Psychiatry Psychiatr*

- Epidemiol. 2022 Oct;57(10):2079-2095. Epub 2022 Mar 9.
22. Kataoka M, Kotake R, Asaoka H, Miyamoto Y, Nishi D. Reliability and Validity of the Japanese Version of the Attitudes Related to Trauma-Informed Care (ARTIC-10) Scale. *J Trauma Nurs.* 2022 Nov-Dec 01;29(6):312-318.
 23. Asaoka H, Koido Y, Kawashima Y, Ikeda M, Miyamoto Y, Nishi D. Association between clinical decision for patients with COVID-19 and post-traumatic stress symptoms among healthcare professionals during the COVID-19 andemic. *Environmental and Occupational Health Practice.* 2022; 4(1)
 24. Asaoka H, Sasaki N, Imamura K, Kuroda R, Tsuno K, Kawakami N. Effects of workplace measures against COVID-19 on psychological distress of full-time employees: A 12-month prospective study in the COVID-19 pandemic. *Scand J Work Environ Health.* 2022;48(6):468-478.
 25. Obikane E, Watanabe K, Nishi D, Kawakami N. Adverse childhood experiences and personal values in adolescence: a cross-sectional study using community adult samples in Japan. *Pediatr Int.* 2023 Jan;65(1): e15370. Epub ahead of print.
 26. Kataoka M, Hazumi M, Usuda K, Emi Okazaki E, Nishi D. Association of preexisting psychiatric disorders with post-COVID-19 prevalence: a cross-sectional study. *Scientific reports*, 2023 Jan, 13(1)
 27. Iwanaga M, Nishi D, Obikane E, Kawakami N. Age of victimization and moderating role of social support for the relationship between school-age bullying and life satisfaction in middle-age. *Scand J Public Health.* 2023 Feb 2;14034948221148788. Online ahead of print.
 28. Obikane E, Nishi D, Ozaki A, Shinozaki T, Kawakami N, Tabuchi T. Association between Poverty and Refraining from Seeking Medical Care during the COVID-19 Pandemic in Japan: A Prospective Cohort Study. *Int J Environ Res Public Health.* 2023 Feb 2;20(3):2682.
 29. Kazdin, A. E., Wu, C.-S., Hwang, I., Puac-Polanco, V., Sampson, N. A., Al-Hamzawi, A., Alonso, J., Andrade, L. H., Benjet, C., Caldas-de-Almeida, J.-M., de Girolamo, G., de Jonge, P., Florescu, S., Gureje, O., Haro, J. M., Harris, M. G., Karam, E. G., Karam, G., Kovess-Masfety, V., Lee, S., McGrath, J. J., Navarro-Mateu, F., Nishi, D., Oladeji, B. D., Posada-Villa, J., Stein, D. J., Üstün, T. B., Vigo, D. V., Zarkov, Z., Zaslavsky, A. M., Kessler, R. C., and the WHO World Mental Health Survey collaborators. (2021). "Antidepressant use in low- middle- and high-income countries: a World Mental Health Surveys report." *Psychological Medicine* 2023 Mar; 53(4): 1583-1591.

Department of Biostatistics/ Epidemiology and Preventive Health Sciences

Professor

Yutaka Matsuyama, Ph.D.

Associate Professor

Koji Oba, Ph.D.

Assistant Professor

Yasuhiro Hagiwara, Ph.D., M.P.H.

Homepage <http://www.epistat.m.u-tokyo.ac.jp/en/>

Introduction and Organization

The Department of Epidemiology and Biostatistics evolved from the Department of Epidemiology in 1992. Since then, we have been responsible for providing educational courses on methodology of epidemiologic research and biostatistics to undergraduate students. We belong to Graduate School of Medicine as Departments of Biostatistics/ Epidemiology and Preventive Health Sciences, providing education for undergraduate as well as graduate-school students and consultation to clinical researchers.

Unfortunately, education programs for biostatistics and epidemiological methodology are not sufficient in Japanese universities and graduate schools compared to the situation in the US and European countries. Nevertheless, the necessity for collaboration among biostatisticians and clinical researchers/ epidemiologists has been claimed in recent years. Hence, the central missions of our educational courses are devoted to provide students expert knowledge and extensive experience in biostatistics and epidemiology to take part in clinical/ epidemiological research as biostatisticians or methodologists. We do not only focus on practical

aspects on statistical analysis in medical research but also place emphasis on the methodological principles of biostatistics/epidemiology.

Our main research area is the development of methodology for clinical/epidemiological research. Of course, it requires keeping in touch with real clinical/epidemiological problems. So, another indispensable research area is a support for real-world clinical and epidemiological studies including clinical trials. To achieve these requirements simultaneously, a non-profit organization the Japan Clinical Research Support Unit was established in 2001 by the former faculty members in our department. This organization J-CRSU had provided research support and coordination in design, data management, and statistical analysis in many projects inside/outside the university. Our experience in J-CRSU is the basis of our supportive activities for clinical research that we work through today.

Teaching activities

- Undergraduate Courses
 - 1) Epidemiology (2 credits)
 - 2) Biostatistics (2 credits; named “Statistics” in medical doctor course)

- 3) Applied Mathematics (2 credits)
 - 4) Biostatistics Practice (1 credit)
 - 5) Practical Examples in Clinical and Epidemiologic Research (1 credit)
 - 6) Medical Data Analysis, and its Practice (1 credit each)
 - 7) Theoretical Epidemiology (2 credits)
- School of Public Health (Graduate School)
 - 1) Statistical Analysis of Medical Research (2 credits)
 - 2) Practice of Biostatistics (2 credits)
 - 3) Design of Medical Research (2 credits)
 - Doctoral Courses (Graduate School)
 - 1) Biostatistics (4 credits)
 - 2) Epidemiology and Preventive Health Sciences (4 credits)
 - 3) Introduction to Medical Statistics (2 credits; for the School of Medicine)

The faculty of the department had provided lectures in a series of educational courses organized by “The Clinical Bioinformatics Research Unit” in 2002-2007.

Research activities

1. Methodology for designing and analyzing clinical trials:
 - Interim analysis
 - Adaptive designs
 - Multiplicity
 - Data management of large-scale multicenter clinical trials
2. Methodology of Biostatistics and theoretical epidemiology:
 - Analysis of longitudinal (time-to-event and/or repeated measures) data
 - Analysis of missing/incomplete data
 - Causal inference
 - Semiparametric modeling
3. International collaboration of individual-level meta-analysis on gastric cancer
4. Coordination and data analysis of collaborative epidemiological/clinical research:
 - Japan Arteriosclerosis Longitudinal Study

- Japan Diabetes Collaborative Study
 - Chronic Kidney Disease Japan Cohort
5. Validity/reliability studies of QOL questionnaires and other rating scales
 6. Pharmacoeconomic assessment of medical technology

We had been supporting some of the above collaborative clinical/epidemiologic studies, which aims to support investigator- initiated studies and to provide education to researchers and support staffs. Currently, we are officially conducting a consultation for design and analysis of clinical trials assisted by the Clinical Research Promotion Center of the University of Tokyo Hospital.

The University of Tokyo participated in "Support Program for Biostatisticians," an industry-government-academia collaborative project launched by the Japan Agency for Medical Research and Development (AMED) in FY2016, and has been participating in its successor, "Promotion Program for Biostatisticians," since FY2021 (principal investigator: Professor Matsuyama). Both projects are aimed at fostering biostatisticians at clinical research institutes and research centers in Japan, and are designed and implemented for master course and one-year post-graduate education/training programs. Our department is also officially participating in these programs, and will provide more and more educational/practical supports to future biostatisticians on the basis of our rich experience in biostatistical education and support in variety of research.

References

1. Takeuchi Y, Iwagami M, Ono S, Michihata N, Uemura K, Yasunaga H. A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan. *Vaccine*. 2022;40;7622–7630.
2. Kikawa Y, Hagiwara Y, Fujisawa T, Araki K, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Toyama T, Aihara T, Mukai H, Taira N. Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of

- Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy. *PLoS One*. 2022;17:e0278344.
3. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Okiyama N, Kodera M, Hasegawa M, Sato S. Safety and efficacy of rituximab in systemic sclerosis (DESIREs): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. *Lancet Rheumatol*. 2022;4:e546–e555.
 4. Oba K, Kagiwada Y, Kamada M, Miki R, Kondo Y, Kamakura T, Yamagami T, Fujita T, Tsuchida Y. Evaluating the feasibility of a remote-based training program supported by information and communications technology in the older adults living at home. *BMC Geriatr*. 2022;22:574.
 5. Watanabe J, Maeda H, Nagasaka T, Yokota M, Hirata K, Akazawa N, Kagawa Y, Yamada T, Shiozawa M, Ando T, Kato T, Mishima H, Sakamoto J, Oba K, Nagata N. Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. *Int J Cancer*. 2022;151:2172–2181.
 6. Nagata H, Kawai K, Oba K, Nozawa H, Yamauchi S, Sugihara K, Ishihara S. Laparoscopic colectomy: a risk factor for postoperative peritoneal metastasis. *Clin Colorectal Cancer*. 2022;21:e205–e212.
 7. Kemmochi M, Nawa Y, Ohno S, Sawashita Y, Terada H, Oba K. Analysis of the radial and ulnar arteries using ultrasound and a vascular visualization device in children. *Paediatr Anaesth*. 2022;32:747–753.
 8. Sawamoto R, Oba K, Matsuyama Y. Bayesian adaptive randomization design incorporating propensity score-matched historical controls. *Pharm Stat*. 2022;21:1074–1089.
 9. Ebata S, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Yoshihide A, Yoshizaki A, Sato S. Predictors of rituximab effect on modified rodnan skin score in systemic sclerosis: a machine learning analysis of the DESIREs trial. *Rheumatology (Oxford)*. 2022;61:4364–4373.
 10. Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S. Increased red blood cell distribution width in the first year after diagnosis predicts worsening of systemic sclerosis-associated interstitial lung disease at 5 years: a pilot study. *Diagnostics (Basel)*. 2021;11:2274.
 11. Hagiwara Y, Shiroiwa T. Estimating value-based price and quantifying uncertainty around it in health technology assessment: frequentist and Bayesian approaches. *Med Decis Making*. 2022;42:672–683.
 12. Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, incidence rate and risk factors of medication-related osteonecrosis of the jaw (MRONJ) in patients with osteoporosis and cancer: a nationwide population-based study in Japan. *J Oral Maxillofac Surg*. 2021;80:714–727.
 13. Matsumoto H, Igarashi A, Hagiwara Y, Yamamoto-Mitani N. Relational Design for Dementia and Job Significance (ReDeSign): study protocol for a randomized controlled trial of an online dementia training for retail workers. *Contemp Clin Trials Commun*. 2022;26:100896.
 14. Abe S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Kishikawa J, Ishii H, Yokoyama Y, Nagai Y, Anzai H, Sonoda H, Oba K, Ishihara S. Preoperative sarcopenia is a poor prognostic factor in lower rectal cancer patients undergoing neoadjuvant chemoradiotherapy: a retrospective study. *Int J Clin Oncol*. 2022;27:141–153.
 15. Machida H, Matsuo K, Oba K, Aoki D, Enomoto T, Okamoto A, Katabuchi H, Nagase S, Mandai M, Yaegashi N, Yamagami W, Mikami M. Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study. *J Gynecol Oncol*. 2022;33:e3.
- (Only main publications)

Department of Biomedical Ethics & Department of Health Promotion Sciences

Professor

Akira Akabayashi, M.D., Ph.D.

Associate Professor

Yoshiyuki Takimoto, M.D., Ph.D.

Lecturer

Eisuke Nakazawa, Ph.D.

Research Associate

Makoto Udagawa, MA

Homepage <http://www.ethps.m.u-tokyo.ac.jp/>

Introduction and Organization

The former Department of Health Administration was established in 1967 and Dr. Tsuneo Tanaka became its first professor in 1974. He devoted himself to the development of the community health care system in Japan and published numerous papers concerning the social theory of health administration and data management systems for community health care. He also contributed to the establishment of the School of Health Sciences. In 1985, Dr. Atsuki Gunji became the second professor of the department. During Dr. Gunji's tenure, two major research projects were undertaken. One was "The effects of physical activity and inactivity on health." From 1990, a 20-day bed rest human experimental study was conducted every year in the context of an international cooperative research project that was supported by government grants. The other project concerned health care systems, especially health care economics and the quality of hospital care.

In 1996, the Department of Health Administration developed into two departments: the Department of Health Economics and the Department of Health

Promotion Sciences. Both were established as departments of the Graduate School of Medicine. In 1998, Dr. Yasuki Kobayashi became the professor of the Department of Health Economics. He conducted research into health care delivery systems in Japan. In 2001, he moved to the Department of Public Health. From 1996 to 2002, Dr. Kiyoshi Kawakubo took charge of the Department of Health Promotion Sciences as the associate professor.

In June 2002, Dr. Akira Akabayashi became professor of the Department of Health Economics. Professor Akabayashi's area of research is biomedical ethics. In April 2003, the Department of Health Economics was restructured and named the Department of Biomedical Ethics. From 2007, Dr. Jung Su Lee became the associate professor and took charge of the Department of Health Promotion Sciences. In 2017, Dr. Yoshiyuki Takimoto acceded to the chair of the Department of Health Promotion Sciences. In 2019, the Department of Health Promotion Sciences was consolidated into the Department of Biomedical Ethics.

Staff members of the department include a

professor, an associate professor, a lecturer, an associate, and a technical specialist. All five members, two project researchers, twelve lecturers from other organizations, and ten visiting researchers contribute to department teaching and research activities.

We have six department graduate students. Four of them are doctoral program students.

In this annual report, the organization and teaching activities are reviewed followed by an explanation of research activities.

Teaching activities

Our departments highly prioritize the teaching and guidance of graduate students and their research activities. Eighteen bachelor theses, twenty-two master theses, and eleven doctoral dissertations were completed between April 2004 and March 2020. Our department's staff members are also responsible for the following undergraduate and graduate courses.

Undergraduate Courses

Required courses

- 1) Introduction to Biomedical Ethics (Lecture)
- 2) Biomedical Ethics I (2 credits, lecture)
- 3) Theory and Science of Health Behavior (2 credits, lecture)
- 4) Seminar in Public Health Science II (2 credits, seminar)
- 5) First-Year Seminar for Natural Science Students (2 credits, seminar)

Elective courses

- 6) Integrated Lecture of Clinical Medicine (Lecture)
- 7) Integrated Lecture of Clinical Medicine, Biomedical ethics (Lecture)
- 8) Integrated Lecture of Clinical Medicine, Biomedical ethics and Geriatric Medicine (Lecture)
- 9) Social Medicine (Lecture)
- 10) Biomedical Ethics II (2 credits, lecture)
- 11) Clinical Ethics (2 credits, lecture)
- 12) Public Health Ethics (2 credits, lecture)

Graduate Courses

- 1) Biomedical Ethics I
- 2) Biomedical Ethics II

In addition to these courses, the department operates lectures, practical training, and joint seminars for research guidance on a regular basis.

Graduate level courses in Biomedical Ethics focus on the analytical study of ethical theories and on the review of several empirical studies within the field and its related areas.

Research activities

The Department of Biomedical Ethics is interested in the current topics of health care ethics. We are currently conducting studies in the fields of biomedical ethics, research ethics and clinical ethics. Methodology is two-folded—theoretical and empirical. While conducting theoretical research on ethics and philosophy of health care, we also have adopted a descriptive approach.

We have recently established The University of Tokyo Center for Biomedical Ethics and Law (CBEL)—a new interdisciplinary and international education research center aimed to address bioethical issues relevant to Japan and the international community. Our center will form an international network by establishing partnerships with research centers overseas (GABEX: Global Alliance of Biomedical Ethics Centers Project). Through these efforts, we will foster the next generation of bioethics experts in policy-making, research, and clinical medicine who are capable of providing international leadership in the future (<http://www.cbhel.jp/>).

Specific research topics include:

- 1) Study of methods for promoting social consensus on topics related to advanced medical technology
- 2) Study of the function and responsibilities of ethics committees in Japan
- 3) Acceptability of advance directives in Japanese society
- 4) Development of evaluative methods for bio-medical ethics education
- 5) Ethical and psychosocial aspects of living related organ transplantation
- 6) Publication of a medical ethics case book for Japan
- 7) Comparative study of clinical ethics in the Asian region

- 8) Historical analyses for the term “bioethics” in the Japanese context

References

1. Akabayashi A, Nakazawa E, Ino H. Could artificial intelligence hijack author contributions? *Nature*. 2022; 606(7915):653. doi: 10.1038/d41586-022-01697-w.
2. Arai N, Takimoto Y, Nakazawa E, Ishimura T, Yokoyama N, Hara M, Ozeki-Hayashi R, Akabayashi A. Psychosocial and ethical behaviors and attitudes of health care professionals in the clinical setting of living kidney donors: A qualitative study. *Transplant Proc*. 2022 Sep; 54(7):1750-1758. doi: 10.1016/j.transproceed.2022.04.026.
3. Dowa Y, Takimoto Y, Kawai M, Shiihara T. Hospital Ethics Committees in Japan: Current Status From an Exploratory Survey 2012-2015. *Am J Prev Med Public Health*. 2022; 8(5): 1-6.
4. Ino H, Nakazawa E. Over-the-counter drug misuse and dependence: Public health ethics' foray into fight against the codeine crisis. *Pharmacy*. 2022; 10(6):155. doi: 10.3390/pharmacy10060155.
5. Kato H, Nakazawa E, Mori K, Akabayashi A. Disclosure of spousal death to patients with dementia: Attitude and actual behavior of care managers. *Eur J Investig Health Psychol Educ*. 2023; 13(2):419-428. doi: 10.3390/ejihpe13020031.
6. Komada MT, Lee JS, Watanabe E, Nakazawa E, Mori K, Akabayashi A. Factors of influenza vaccine inoculation and non-inoculation behavior of community-dwelling residents in Japan: Suggestions for vaccine policy and public health ethics after COVID-19. *Vaccine X*. 2023 Apr; 13:100245. doi: 10.1016/j.jvacx.2022.100245.
7. Kono M, Arai N, Takimoto Y. Identifying practical clinical problems in active euthanasia: A systematic literature review of the findings in countries where euthanasia is legal. *Palliat Support Care*. 2023 Jan 9:1-9. doi: 10.1017/S1478951522001699.
8. Miwa E, Shoji E, Nakazawa E, Akabayashi A. Family care relationships in reproductive justice. *Women*. 2022; 2(4):339-345. doi: 10.3390/women2040031.
9. Mori T, Deasy Y, Mori K, Nakazawa E, Akabayashi A. An exploratory quantitative study of factors associated with dissatisfaction with Japanese healthcare among highly skilled foreign professionals living in Japan. *BioMed*. 2022; 2(4):431-441. doi: 10.3390/biomed2040034.
10. Muraoka K, Takimoto Y, Nakazawa E, Tsuji T, Liu M. Stroke survivors' experiences and needs during the decision-making process considering rehabilitation options: A pilot descriptive study in Japan. *Prog Rehabil Med*. 2022 May 13; 7: 20220024. doi: 10.2490/prm.20220024.
11. Nagai H, Nakazawa E, Akabayashi A. The creation of the Belmont Report and its effect on ethical principles: a historical study. *Monash Bioeth Rev*. 2022 Dec; 40(2):157-170. doi: 10.1007/s40592-022-00165-5.
12. Oikawa M, Takimoto Y, Akabayashi A. Attitudes of the public toward consent for biobank research in Japan. *Biopreserv Biobank*. 2022 Dec 19. doi: 10.1089/bio.2022.0041.
13. Ozeki-Hayashi R, Nakazawa E, Truog R, Akabayashi A. Initiation and withdrawal of invasive ventilation for patients with amyotrophic lateral sclerosis: A narrative literature review. *J*. 2022; 5(3):402-409. doi: 10.3390/j5030027.
14. Sato H, Fujita M, Tsuchiya A, Hatta T, Mori K, Nakazawa E, Takimoto Y, Akabayashi A. Disclosing a diagnosis of autism spectrum disorder without intellectual disability to pediatric patients in Japan in early diagnostic stages and associated factors: a cross-sectional study. *Biopsychosoc Med*. 2022 Aug 20; 16(1):18. doi: 10.1186/s13030-022-00247-0.
15. Takahashi S, Nakazawa E, Ichinohe S, Akabayashi A, Akabayashi A. Wearable technology for monitoring respiratory rate and SpO2 of COVID-19 Patients: A systematic review. *Diagnostics (Basel)*. 2022 Oct 21; 12(10): 2563. doi: 10.3390/diagnostics12102563.
16. Takeshita K, Nagao N, Kaneda H, Miura Y, Kinjo T, Takimoto Y. Report on the establishment of the consortium for hospital ethics committees in Japan and the first collaboration conference of

- hospital ethics committees. *Asian Bioeth Rev.* 2022 Sep 6; 14(4):307-316. doi: 10.1007/s41649-022-00219-0.
17. Takimoto Y. Indications for involuntary hospitalization for refusal of treatment in severe anorexia nervosa: a survey of physicians and mental health care review board members in Japan. *J Eat Disord.* 2022 Nov 21; 10(1):176. doi: 10.1186/s40337-022-00703-w.
 18. Takimoto Y. International comparison of physicians' attitudes toward refusal of treatment by patients with anorexia nervosa: a case-based vignette study. *J Eat Disord.* 2022 Jun 23; 10(1): 86. doi: 10.1186/s40337-022-00613-x.
 19. Takimoto Y. Key components of the mental capacity assessment of patients with anorexia nervosa: a study of three countries. *J Eat Disord.* 2022 Jul 26; 10(1):110. doi: 10.1186/s40337-022-00633-7.
 20. Takimoto Y, Nabeshima T. Ethical healthcare attitudes of Japanese citizens and physicians: Patient-centered or family-centered? *AJOB Empir Bioeth.* 2022 Dec 28; 1-10. doi: 10.1080/23294515.2022.2160511.
 21. Takimoto, Y, Shimanouchi, A. Ethics Guideline Development for Neuroscience Research involving Patients with Mental Illness in Japan. *Asian Bioeth Rev.* 2023 Feb. <https://doi.org/10.1007/s41649-023-00240-x>.
 22. Takimoto Y, Udagawa M. Development and evaluation of remote supervision in clinical ethics consultation training. *Clin Ethics.* 2022. doi: 10.1177/14777509221144568.
 23. Udagawa M, Takimoto Y. Practical training using immersive roleplay and an intensive course on clinical ethics consultation in Japan. *BMC Med Ethics.* 2022 Nov 24; 23(1):118. doi: 10.1186/s12910-022-00861-1.
 24. Urade M, Fujita M, Tsuchiya A, Mori K, Nakazawa E, Takimoto Y, Akabayashi A. Facts and recommendations regarding when medical institutions report potential abuse to child guidance centers: A cross-sectional study. *Pediatr Rep.* 2022 Nov 2; 14(4):479-490. doi: 10.3390/pediatric14040056.

Health Sciences and Nursing

2. Preventive and Administrative Nursing

Department of Nursing Administration / Advanced Clinical Nursing

Associate Professor

Aya Kitamura, Ph.D., R.N.

Assistant Professor

Naoko Ichikawa, Ph.D., R.N.

Ryohei Kida, Ph.D., R.N.

Tamaki Isobe, Ph.D., R.N.

Homepage <http://nurs-adm.umin.jp/>

Introduction and Organization

The Department of Nursing Administration / Advanced Clinical Nursing has 60 years of history and tradition. It was first established in 1954 as the Department of Fundamental Nursing at the School of Health Care and Nursing. The School of Health Care and Nursing was composed of two basic medical departments and six nursing departments. When it was reorganized as the School of Health Sciences in 1965, only one nursing department remained. Renamed the Department of Nursing, it was responsible for nursing education. In 1992, the School of Health Sciences became the School of Health Sciences and Nursing, and two new departments of nursing were established; the Department of Nursing then became the Department of Fundamental Nursing. As a result of the shift to the chair of the Graduate School of Medicine in 1996, two departments were established: the Department of Nursing Administration and the Department of Advanced Clinical Nursing. Our department is responsible for undergraduate fundamental nursing education.

Teaching activities

Undergraduate Courses

In the undergraduate program, our department oversees lectures and clinical practicums for Introduction to Nursing Science, Fundamental Nursing I, Fundamental Nursing II, Basic Nursing Skills, and Nursing Administration.

Introduction to Nursing Science (1 credit, lecture)

In this course, students learn nursing concepts, functions, theories, targets, and the practical side of nursing through lectures, discussions, and inter-professional education.

Theory and Methodology of Nursing I (2 credits, lecture)

This course provides knowledge and nursing skills for understanding patients and providing care. Students learn about the nursing process and skills necessary for knowing and caring for patients, which are essential for providing appropriate nursing care.

Theory and Methodology of Nursing II (2 credits, elective course, lecture)

This course offers perspectives on the basic nursing skills and nursing organization management through a

series of critique of scientific articles and discussions.

Basic Nursing Skills (2 credits, lecture)

This course covers the basics of assessing clients' health, including physical examination skills and practices in fundamental nursing skills, which are essential for providing nursing care with physiological and psychosocial integrity. Students learn about the nursing process through case discussions.

Practicum: Basic Nursing Skills (2 credits, practicum)

Under instructors' supervision, students have the opportunity to apply their fundamental knowledge and nursing skills in a variety of settings. Students will assess clients' health and needs by applying the nursing process.

Nursing Administration (1 credit, lecture)

This course introduces students to the roles of nurse administrators/managers in all types of healthcare settings, such as institutions, organizations, and communities as well as political settings. Students will learn the fundamental theories and practices of nursing administration/management by analyzing current issues in healthcare and nursing.

Practicum: Nursing Administration (1 credit, practicum)

Students participate in a nursing administrative practicum in units or divisions in hospitals. They will learn about care delivery systems, such as staffing and patient classification systems, nursing informatics, and budgetary issues (e.g., cost effectiveness and quality improvement).

Graduate Courses

In the graduate program, our department oversees lectures and seminars for Nursing Administration and Advanced Clinical Nursing.

Advanced Clinical Nursing I (2 credits)

During this course, students acquire the necessary knowledge and perspectives to conduct research that focuses on advanced nursing technologies or organizations through discussion and a critical analysis of relevant advanced nursing professions or organization

management theories, the environment surrounding nursing science and nursing practice, and political decision making.

Seminar

We have an accredited departmental seminar where members discuss their own research project plans.

Research activities

Our research scope is wide, ranging from individual nursing care technologies to the care-related environment and the systems and organizations that support the nursing profession. We aim to elucidate the mechanisms underlying them and relationships to patient outcomes, thereby creating technologies and systems that maximize the full power of nursing.

Area of Nursing Administration

In the area of nursing administration, we are working to elucidate the complex phenomena of organizations and workers from various perspectives, such as research to improve the job psychological state of working nurses, research to contribute to nursing policies, and research on future career development, to realize a society in which the sustainability of nursing organizations can be achieved. Studies on the job psychological state of nurses cover topics related to factors and outcomes related to nurses' intention to continue working, such as organizational commitment, work engagement, and sense of personal-job fit. Research contributing to nursing policy includes support for potential nurses to return to work, appropriate work environment management, including working hours, education of nursing managers and outcomes, and clinical implementation of evidence-based practice. In the area of research on future career development, we are conducting research on the employability of nurses.

Area of Advanced Clinical Nursing

In the area of advanced clinical nursing, research is being conducted to develop new nursing techniques, aiming at visualization of nursing techniques and clarifying the mechanisms that provide the basis for care. Specifically, they visualize care effects using

echo, thermography, and pressure sensors and develop care methods suitable for the target population. In addition, they are working to generate evidence for new nursing techniques based on fundamental research, including animal experiments.

Our main research themes

- Developing and verifying novel nursing technologies and devices
- Developing and verifying novel services systems
- Nursing administration skills, including the ability to mobilize individuals and groups to achieve missions and goals
- Organizational dynamics and diversity
- Career development support and empowerment for nurses
- Quality of health care and nursing, including investigating the relationship among structures, processes, and outcomes

References

1. Kida R. & Takemura Y. Working conditions and fatigue in Japanese shift work nurses: A cross-sectional survey. *Asian Nursing Research*. 2022; 16(2), 80-86.
2. Susuki T, Kida R, Takemura Y, Ichikawa N, Kunie K, & Koyanagi H. Work-related communication mediates the relationship between perceived diversity climate and psychological empowerment among part-time nurses: a cross-sectional study. *Journal of Nursing Management*, 2022; 30(2)
3. Sawada S, Takemura Y, Isobe T, Koyanagi H, & Kida R. Perceived Impact of nurse turnover on the organization: A Delphi study on managers of nursing. *Journal of Nursing Management*. 2022. 30(7)
4. Kida R, Takemura Y, Inoue M, Ichikawa N & Koyanagi H. Nursing Management for the Temporary Lodging Facilities in Japan in the Early Stages of the COVID-19 Pandemic: A Multiple-Case Study. *Japan Journal of Nursing Science*. 20(1)
5. Sugama J, Ishibasi M, Ota E, Kamakura Y, Saitoh E, Sanada H, Nakayama T, Nomura T, Yamada M, Nakagami G, Sato N, Shibata S, Hase T, Fukada J, Miki T, Arita M, Urai T, Okawa Y, Kitamura A, Dai M, Takahashi T, Tamai N, Tobita I, Noguchi H, Matsumoto M, Miura Y, Mukai K, Mugita Y, Yoshida M, Kurachi M, Shirasaka T, Yamane Y. Japanese clinical practice guidelines for aspiration and pharyngeal residual assessment during eating and swallowing for nursing care. *Japan Journal of Nursing Science*. 2022:e12496.
6. Takemura Y, Inoue M, Ichikawa N, Kida R, Koyanagi H, Ikezaki S, and Ikeda M. Key Strategies for Managing Nursing Care under the COVID-19 Pandemic: A Multiple Case Study of Nursing Directors. *Journal of Nursing Management*. 2022. 30(8).
7. Takizawa C, Minematsu T, Nakagami G, Kitamura A, Koudounas S, Kunimitsu M, Sanada H. Expression levels of NPPB, ITGB6, CPNE4, EML5, and ITSN1 in fresh exudates swabbed from critically colonized and infected full-thickness wounds in rats. *International Wound Journal*. 2022.
8. The Fact-finding Committee of the Japanese Society of Pressure Ulcers, Konya C, Takeuchi Y, Nakagami G, Kitamura A, Morita K, Ishizawa M, Abe Y, Higuchi H, Mizuki T, Motegi S, Shoji S, Shimada K, Tanaka K, Kawakami S, & Sanada H. Nationwide time-series surveys of pressure ulcer prevalence in Japan. *Journal of Wound Care*. 2022; 31(Sup12):S40-S47.

Department of Family Nursing

Professor

Mari Ikeda, Ph.D., R.N., P.H.N., C.C.P.

Lecturer

Sachiko Kita, Ph.D., R.M.W, R.N., P.H.N.

Assistant Professor

Mayumi Morisaki, Ph.D., R.N., P.H.N.

Homepage <http://www.fn.m.u-tokyo.ac.jp/>

Introduction and Organization

This department was established in 1992. Three faculty members currently serve the department: a professor, a lecturer, and an assistant professor. Enrolled at present are 1 doctoral student, and 1 administrative staff.

Education

1. Graduate Courses, School of Health Sciences and Nursing (credit hours)
 - Advanced Family Nursing I (2)
 - Advanced Family Nursing II (2)
 - Laboratory and/or Field Work on Family Nursing (16)
 - Practicum in Translational Research Nursing (2)
2. Undergraduate Courses for Students in the School of Integrated Health Sciences (credit hours)
 - Family Health (2)
 - Health Communication (1)
3. Undergraduate Courses for Nursing Students in the School of Integrated Health Sciences (credit hours)
 - Pediatric and Child Health Nursing (4)
 - Clinical Practicum in Pediatric and Child Health Nursing (2)
 - Integrated Clinical Practicum in Nursing (1)

Research

Our department research family with health problems, developmental task or encounter with

changes in the community to which the family belongs. We aim to reveal the fluctuation that have occurred in the family system and create family support. Our on-going, specific research theme include the following:

1. Mental health and childcare Support during family formation;
2. Development and dissemination of nursing care focusing on attachment styles;
3. Family violence and gender-based violence
4. QOL for cancer patients and their families;
5. Development of a Pediatric Quality of Life (QOL) Inventory for children with chronic illness and their parents;
6. Lifetime support for survivors of childhood cancer and their families: treatment and care in their late effects, special needs education, and working;
7. Transitional care for children, adolescent and young adult with childhood-onset chronic diseases;
8. Research about prevention of deterioration of postpartum depression, child abuse and neglect;
9. Support for bereavement from family members.

Regarding the "Development and dissemination of nursing care focusing on attachment style," we have been disseminating the Attachment Style Interview (ASI) developed by Professor Bifulco in the UK which is translated into Japanese version as ASI-J. We also

completed a translated version of the ASI-J for children between 2019 and 2021, and conducting its reliability and validity studies. Currently, we are conducting online training of the ASI-J for researchers, clinical practitioners, and graduate students.

Regarding research on family violence, we have developed a scale to measure family poly-victimization which means the co-occurrence of different types of violence, such as intimate partner violence, child abuse and elder abuse. In addition, we have developed a Training program for Child Abuse Prevention for citizens (TCAP-C) and tested the effectiveness. Since 2017, we have been conducting an international collaboration study with international scholars from eleven countries, to identify trauma recovery pathways after gender-based violence.

Studies focusing on transition such as “Transitional care for children, adolescent and young adult with childhood-onset chronic diseases” in patients with child chronic diseases has been conducted since 2016. We established a transition outpatient clinic in the University of Tokyo Hospital in June 2016 and have been providing transitional cares for patients with congenital heart disease, epilepsy, chromosomal abnormality, hematologic disease, and endocrine disease in the clinic. We also developed the tool “My Health Passport” in order for patients to summarize the information about their disease and share their experiences with others (e.g., friends and coworkers) and established evidence of its effectiveness. We collaborate with the evidence-based clinic, with regard to research, practice and graduate education.

In addition, we hold bimonthly family nursing research seminar, whereby deeper understanding of family nursing practice and research are promoted. In this we aim to enhance the quality of clinical practice and research in family nursing and contribute to the establishment of the science of family nursing.

Publications

1. Tobe H, Sakka M, Kita S, Ikeda M, Kamibepu K. The Efficacy of a Resilience-Enhancement Program for Mothers Based on Emotion Regulation: A Randomized Controlled Trial in Japan. *International Journal of Environmental Research and Public Health*. 2022; 19(22):14953. <http://doi.org/10.3390/ijerph192214953>
2. Sasaki N, Ikeda M, Nishi D. Long-term influence of unintended pregnancy on psychological distress: a large sample retrospective cross-sectional study. *Archives of Women's Mental Health*. 2022 Dec; 25(6): 1119-1127. DOI: 10.1007/s00737-022-01273-1
3. Kita S, Kamibappu K, Saint Arnault D. “Knitting together the lines broken apart”: Recovery process to integration among Japanese survivors of intimate partner violence. *International Journal of Environmental Research and Public Health*. 2022; 30; 19(19): 12504.
4. Takemura Y, Inoue M, Ichikawa N, Kida R, Koyanagi H, Ikezaki S, Ikeda M. Key strategies for managing nursing care under the COVID-19 pandemic: A multiple-case study of nursing directors. *Journal of Nursing Management*. 2022 Nov; 30(8): 4042-4053. <http://doi.org/10.1111/jonm.13844>
5. Koutra K, Burns C, Sinko L, Kita S, Bilgin H, Saint Arnault D. Trauma recovery rubric: A mixed-method analysis of trauma recovery pathways in four countries. *International Journal of Environmental Research and Public Health*. 2022; 19(16).
6. Iwasaki T, Kou A, Harasawa N, Morishita-Kawahara M, Yamagata C, Moriya H, Ikeda M, Nagae H. Exploring the Attitudes and Needs of Advance Care Planning Practice Among the Working Generation. *Tokyo Women's Medical University Journal*. 2022; 6. <https://doi.org/10.24488/twmuj.2022004>
7. Kita S, Zeynep O, Saint Arnault D. Initial testing of components of the Cultural Determinants of Trauma Recovery (CDTR) Theory among American Gender-Based Violence survivors: Structural equation modeling. *Journal of Advanced Nursing*, 2022; 79(4) : 1476-1492.
8. Muramoto M, Kita S, Tobe H, Ikeda M, Kamibepu K. The association between self-compassion in the postnatal period and difficult experiences with COVID-19 pandemic-related changes during pregnancy: An observational study for women at 1 month postnatal in Japan. *Japan Journal of Nursing Science*, 2022; e12494.
9. Morisaki-Nakamura M, Suzuki S, Kobayashi A,

-
- Kita S, Sato I, Iwasaki M, Hirata Y, Sato A, Oka A, Kamibeppu K. Efficacy of a Transitional Support Program Among Adolescent Patients With Childhood-Onset Chronic Diseases: A Randomized Controlled Trial. *Frontiers in Pediatrics*. 2022.
10. Sato I, Soejima T, Ikeda M, Kobayashi K, Setoyama A, Kamibeppu K. Reliability and validity of the Japanese version of the Pediatric Quality of Life Inventory Infant Scales. *Journal of Patient-Reported Outcomes*, 2022;6(10).
 11. Hayakawa A, Sato I, Kamibeppu K, Ishida Y, Inoue M, Sato A, Shiohara M, Yabe H, Koike K, Adachi S, Atsuta Y, Yamashita T, Kanda Y, Okamoto S. Impact of chronic GVHD on QOL assessed using visual analogue scale in survivors after pediatric HSCT and those depending on QOL raters: a cross-sectional observational study in Japan. *International Journal of Hematology*. 2022; 115(1):123-128.

Department of Community Health Nursing / Public Health Nursing

Associate Professor

Kyoko Yoshioka-Maeda, Ph.D., R.N., P.H.N.

Assistant Professor

Chikako Honda, Ph.D., R.N., P.H.N.

Hiroshige Matsumoto, Ph.D., R.N., P.H.N.

Homepage <https://chiikikango.m.u-tokyo.ac.jp/>

Introduction and Organization

The Department of Community Health Nursing was established in June 1992. The educational program for the public health nurse license has been established in the master's program of the graduate school since 2014. Our department is also in charge of this program.

Teaching activities

Our department aims to educate public health nurses with a research mindset and researchers with a public health nurse mindset. In the undergraduate program, we teach basic methods and theories of health promotion for individuals, families, and specific populations living in the community. The titles are as follows: Home Health Nursing, Community Health Nursing, Home Health Nursing Practice. There is a total of four credits of lecture and two credits of practicum.

In the graduate program, we teach about the advanced methods and theories in community health nursing and public health nursing. The titles are as follows: Advanced Community Health Nursing I, II, Advanced Community Health Nursing Seminar I, II and Practice I, II. There are a total of 12 credits: 4 credits of lecture

and 8 credits of exercises and practical training.

We also offer an additional nine types of lecture/practical training as a part of the education program for public health nurse licenses. The titles are as follows: Skills for Public Health Nursing I, II, Public Health Nursing I, II, III, IV, Public Administration for Nurses, Public Health Nursing Practice I, II. There are 13 credits of lecture and five credits of practicum.

We also supervise undergraduate/graduate students with their thesis.

Research activities

We conduct research to improve health and quality of life by understanding the nursing needs of people living in the community and those receiving care at home on an individual basis, as well as the needs of families, groups, and the community as a whole. In an aging society with a declining birth rate, it is important to support the independence of the older adults and prevent the need for nursing care. In addition, we aim to create community care systems that enable people with physical and mental disabilities to live well in their own familiar communities. It is also essential to support children throughout the community so that they can grow and develop healthily. Our research we are engaged in

contributes to the creation of a society that is conducive to a comfortable living environment, addressing the evolving needs of society and the times.

Our research is supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, and other foundations.

Ongoing research projects in our department are listed below.

1. Improving public health nursing practice and building care systems

- Algorithms and evaluation methods for public health nursing activities using information and communication technology
- Comprehensive community care systems

2. Development, evaluation and dissemination of programs to solve health problems at different stages of life

- Programs to protect the health of community residents
- Injury prevention for infants and toddlers
- Dementia education programs in the community

3. Study on the development of professional competencies and skills of public health nurses

- Policy making and project development by public health nurses
- Elucidation of skills and tacit knowledge of public health nurses

4. Cutting-edge issues that do not fit into conventional frameworks

- VR-based home visit learning materials for nursing students

5. The "Zero Missed Hip Dislocations in Infants" Project

To achieve our goal of preventing missed hip dislocation in newborns and infants, we're working together with experts in nursing, medicine, and engineering. Our goal is to develop a screening system that can be used by public health nurses and midwives

during their visits to newborns. We are also focusing on developing a comprehensive community-based approach to early treatment of this condition.

References

1. Yoshioka-Maeda, K., Katayama, T., Shiomi, M., Hosoya, N., Fujii, H., & Mayama, T. (2022). Feasibility of an educational program for public health nurses to promote local healthcare planning: protocol for a pilot randomized controlled trial. *Pilot and Feasibility Studies*, 8(1), 92.
2. Yoshioka-Maeda, K., Fujii, H., Kageyama, M., & Takamura, S. (2022). Factors of parental preparation of children with mental illnesses for their independent living after their own death. *Healthcare*, 10(12), 2360.
3. Yoshioka-Maeda, K., Honda, C., Sumikawa, Y., Okamoto, Y., Shimada, M., Fujii, H., ... & Otsuki, M. (2022). Developing a virtual reality simulation program for improving nursing students' clinical reasoning skills in home settings: A protocol paper. *Nursing Reports*, 12(4), 968-979.
4. Honda, C., Yoshioka-Maeda, K., Fujii, H., Iwasaki-Motegi, R., & Yamamoto-Mitani, N. (2022). Evaluation of infant injury prevention education provided during antenatal classes after two years: A pilot prospective cohort study. *International journal of environmental research and public health*, 19(12), 7195.
5. Matsumoto, H., Igarashi, A., Sakka, M., Takaoka, M., Kugai, H., Ito, K., & Yamamoto-Mitani, N. (2022). A two-step model for encouraging the general public to exhibit helping behaviors toward people living with dementia. *Innovation in Aging*, 6(3), igac023.
6. Matsumoto, H., Hagiwara, Y., Yamamoto-Mitani, N., & Igarashi, A. (2022). A randomized control trial for redesign: a dementia-friendly mobile microlearning training for store workers in Japan. *The Gerontologist*, gnac182.
7. Yokobori, H., Iwasaki-Motegi, R., Naruse, T., & Yamamoto-Mitani, N. (2022). Public health nurses' activities toward child abuse prevention before childbirth in Japan. *Public health nursing*, 39(6), 1346-1354.

Health Sciences and Nursing

3. Clinical Nursing

Department of Gerontological Home Care and Long-term Care Nursing/Palliative Care Nursing

Professor

Noriko Yamamoto-Mitani, Ph.D., R.N.

Associate Professor

Ayumi Igarashi, Ph.D., R.N.

Assistant Professor

Mariko Sakka, Ph.D., R.N.

Yuka Sumikawa, Ph.D., R.N.

Homepage <https://longtermcare.m.u-tokyo.ac.jp/en/home-en/>

Introduction and Organization

The Department of Adult Health Nursing/ Palliative Care Nursing has almost 50 years of history and tradition. Originally, the department was started as the *Department of Adult Health* in 1965 and it underwent several re-organizations. The current structure with two sub-divisions of *Adult Health Nursing* and *Palliative Care Nursing* was started in 2006. Further, *Adult Health Nursing* was renamed to *Gerontological Home Care and Long-term Care Nursing* in 2016. Noriko Yamamoto-Mitani has been responsible for administration as a department chair since 2012.

Education

In the undergraduate program, our department is in charge of the lectures and clinical practicums for *adult health nursing*. In graduate education, we aim to educate students into independent researchers and competent clinicians who effectively use research. For this purpose, we respect each student's research interest that they derived from their clinical experiences. Students complete their master's thesis or doctoral dissertation by developing a research

question from their own scientific interests regarding nursing practice for older people or adults in the chronic stage.

In education, we emphasize the critical thinking process as a researcher who conducts unique and original research: from cultivating perspectives as a researcher to coming up with original research topics, developing research topics into unique research questions/ hypotheses, choosing appropriate research methods, and developing valid research protocols.

Research

In research, we aim to contribute to the development of nursing science and improvement in the quality of nursing practice through collaborative research with clinicians. Specifically, we aim to develop new nursing knowledge grounded on Japanese culture, as needed in tomorrow's aged society. Faculty members conduct studies on various topics in the field of adult and gerontological nursing.

Regarding methods, besides conventional statistical methods, we often utilize qualitative methods to understand the experiences of individual patients and/or nurses and to conceptualize and theorize them.

1) Quality assurance and improvement for long-term care for older people

The goal of long-term care nursing is to allow older adults to live as high-quality lives as possible, even with diseases/disabilities; the paradigm of long-term care is different from that of acute care which typically aims to have the patients recover promptly from disease conditions. There has not been enough attention to long-term care nursing in today's healthcare practice; there has been little research on quality assurance and improvement in the long-term care field in Japan. In this department, we have been conducting multiple studies on long-term care in facilities and homecare nurse agencies regarding care quality assurance and improvement.

First, we attempt to develop intervention models to improve care quality in close collaboration with clinicians, including nurses and care workers. We aim to develop sustainable systems to improve their daily care practice, collaborating with nurses at long-term care facilities and homecare nurse agencies.

Second, we develop indicators to assess the quality of long-term care, including home care nursing. We have been developing them as a part of the overall assessment system needed for long-term care nursing.

Quality assurance and improvement for long-term care facilities and home-care nurse agencies grow in importance, given the educational opportunities for healthcare providers working at long-term care facilities and homecare nurse agencies are limited compared to those working at critical hospitals.

2) Establishing a case study method to develop nursing science from clinical sites

We attempt to develop a new research method that clinicians could use to conduct effective case studies. Although case study has been used for a long time, it has not had a standardized method. We aim to develop a protocol for conducting a case study that contributes to developing nursing science.

3) Establishment of support systems for older people in the integrated community care

In the Japanese aged society, establishing a local structure supporting the life of older people in the community is an urgent need. In collaboration with different stakeholders, we strive to create programs

that aim to build a dementia-friendly community (DFC). As part of this effort, we developed and evaluated a dementia awareness program for local residents that uses virtual reality (VR) technology to provide a first-person experience from the perspective of a person with dementia. As a next step, we are expanding the scope of the program from local residents to nurses working at healthcare institutions, nursing students, and children, and are modifying and evaluating the program to suit each target group.

4) Creating a workplace that supports care-work balance

In a super-aging society, the number of people caring for family members while working is increasing. Therefore, we are working on the development of e-learning programs to create a workplace that supports the balance between nursing care provision and work. Through e-learning, we are developing content that allows students to learn not only about nursing care, but also about how to respond as colleagues and superiors, and how to create a workplace. In the next fiscal year, we plan to intervene through an e-learning program developed as workplace training for companies and local governments and evaluate its effect.

5) Examination of care provision systems for the future spread of infectious diseases such as COVID-19

The COVID-19 pandemic has had many effects on nursing, medical, and long-term care systems worldwide. We conduct research from the following two perspectives, targeting Japan and overseas. The first perspective is to grasp the actual situation of COVID-19 response in long-term care facilities worldwide. The second perspective is to examine the support systems and issues of home-visit nursing stations and public health centers for COVID-19 home care patients in Japan. In order to prepare for the next infectious disease crisis, we aim to grasp the actual situation of the care system during the spread of emerging infectious diseases and propose countermeasures.

We also conduct studies on a range of topics in nursing of chronic conditions, from preventive to end-of-life phase. We have been conducting studies

which are expected to allow us to understand the state of individuals who require nursing in those periods and investigate effective and efficient nursing care for such individuals.

Publications

1. Matsumoto H, Igarashi A, Hagiwara Y, Yamamoto-Mitani N. Relational Design for Dementia and Job Significance (ReDeSign): Study protocol for a randomized controlled trial of an online dementia training for retail workers. *Contemp Clin Trials Commun*. 2022 Jan 21; 26:100896. doi: 10.1016/j.conctc.2022.100896.
2. Yokobori H, Iwasaki-Motegi R, Naruse T, Yamamoto-Mitani N. Public Health Nurses' Activities toward Child Abuse Prevention before Childbirth in Japan. *Public Health Nurs*. 2022; 39(6):1346- 1354. doi: 10.1111/phn.13122
3. Sari DW, Noguchi-Watanabe M, Sasaki S, Yamamoto-Mitani N. Dietary Patterns of 479 Indonesian Adults and Their Associations with Sodium and Potassium Intakes Estimated by Two 24-h Urine Collections. *Nutrients*. 2022; 15; 14(14):2905. doi: 10.3390/nu14142905
4. Honda C, Yoshioka-Maeda K, Fujii H, Iwasaki-Motegi R, Yamamoto-Mitani N. Evaluation of Infant Injury Prevention Education Provided during Antenatal Classes after Two Years: A Pilot Prospective Cohort Study. *Int J Environ Res Public Health*. 2022; 11;19(12):7195. doi: 10.3390/ijerph19127195
5. Iwasaki-Motegi R, Yoshioka-Maeda K, Honda C, Yamamoto-Mitani N. Prefectural public health nurses' support in human resource development of municipal public health nurses in Japan. *Nihon Koshu Eisei Zasshi*. 2022; 15;69(6):417-423. doi: 10.11236/jph.21-078
6. Ho LYW, Kwong EWY, Song MS, Kawakami A, Boo S, Lai CKY, Yamamoto-Mitani N. Decisionmaking preferences on end-of-life care for older people: Exploration and comparison of Japan, the Hong Kong SAR and South Korea in East Asia. *J Clin Nurs*. 2022; 31(23-24):3498-3509. doi: 10.1111/jocn.16178
7. Matsumoto H, Hagiwara Y, Yamamoto-Mitani N, Igarashi A. A randomized control trial for ReDeSign: A dementia-friendly mobile microlearning training for store workers in Japan. *Gerontologist*. 2022; doi: 10.1093/geront/gnac182
8. Yoshioka-Maeda K, Honda C, Sumikawa Y, Okamoto Y, Shimada M, Fujii H, Iwasaki-Motegi R, Miura T, Otsuki M. Developing a Virtual Reality Simulation Program for Improving Nursing 3 Students' Clinical Reasoning Skills in Home Settings: A Protocol Paper. *Nurs Rep*. 2022. 12(4): 968-979. doi: 10.3390/nursrep12040093.
9. Eltaybani S, Yasaka T, Fukui C, Inagaki A, Takaoka M, Suzuki H, Maruyama M, Igarashi A, Noguchi-Watanabe M, Sakka M, Weller C, Yamamoto-Mitani N. Family-oriented interventions in long-term care residential facilities for older people: A scoping review of the characteristics and outcomes. *Nurs Forum*. 2022; 57(5):800-818. doi:10.1111/nuf.12768
10. Naruse T, Kynoch K, Sumikawa Y, Ramis MA, Tuckett AG. Effectiveness of social activity interventions on sleep among older people: a systematic review protocol. *JBIE Evid Synth*. 2022. 18(0): 1-6. doi: 10.11124/JBIES-21-00231
11. Eltaybani S, Suzuki H, Igarashi A, Sakka M, Amamiya Y, Yamamoto-Mitani N. Long-term care facilities' response to the COVID-19 pandemic: A protocol of a cross-sectional, multi-site, international survey. *Nurs Open*. 2022; 9(5):2506-2517. doi:10.1002/nop2.1264
12. Eltaybani S, Kiyomi K, Kato R, Inagaki A, Shinohara M, Yamamoto-Mitani N. Effectiveness of home visit nursing for older people on patient-related clinical outcomes: an umbrella review protocol. *JBIE Evid Synth*. 2022;20(8): 2071-2078. Published 2022 Aug 1. doi:10.11124/JBIES-21-00343.
13. Masuda A, Sakka M, Kitamura S, Igarashi A, Noguchi-Watanabe M, Araki A, Yamamoto-Mitani N. Collaborative visits by hospital specialist nurses with homecare nurses: A nationwide, cross-sectional, web-based survey. *Journal of International Nursing Research*. 2 (2023), No. 1 pp. e2021-0011-e2021-0011. doi: 10.53044/jinr.2021-0011.
14. Matsumoto H, Igarashi A, Sakka M, Takaoka M, Kugai H, Ito K, Yamamoto-Mitani N. A two-step

model for encouraging the general public to exhibit helping behaviors towards people living with dementia. *Innov Aging*. 2022. doi: 10.1093/geroni/igac023

15. Iwasaki-Motegi R, Yoshioka-Maeda K, Honda C, Yamamoto-Mitani N. Prefectural public health nurses' support in human resource development of municipal public health nurses in Japan. *Nihon Koshu Eisei Zasshi*. 2022. doi: 10.11236/jph.21-078.

Department of Midwifery and Women's Health

Professor

Megumi Haruna, Ph.D., R.N.M.

Lecturer

Kaori Yonezawa, Ph.D., R.N.M.

Assistant Professor

Emi Sasagawa, Ph.D., R.N.M.

Assistant Professor

Yuriko Usui, Ph.D., R.N.M.

Homepage <http://midwifery.m.u-tokyo.ac.jp/>

Introduction and Organization

The Department of Midwifery and Women's Health was established in 2002.

It has 4 faculty members introduced above, 1 JSPS postdoctoral fellowship for overseas researcher, 17 graduate students (8 in master's courses, 9 in doctoral courses), and 10 visiting researchers.

Teaching activities

We have graduate and undergraduate courses.

1. Graduate Courses, School of Health Sciences and Nursing
 - 1) Advanced Midwifery and Women's Health I (2 credits, lectures)
 - 2) Advanced Midwifery and Women's Health II (2 credits, lectures)
2. Graduate Courses, School of Health Sciences and Nursing for midwifery
 - 1) Midwifery I (2 credits, lectures)
 - 2) Midwifery II (2 credits, lectures)
 - 3) Midwifery III (2 credits, lectures)
 - 4) Midwifery IV (2 credits, lectures)

- 5) Midwifery V (2 credits, lectures)
- 6) Midwifery VI (1 credit, lectures)
- 7) Clinical Practicum of Administration for Midwifery (1 credit, practices)
- 8) Clinical Practicum in Midwifery I (2 credits, practices)
- 9) Clinical Practicum in Midwifery II (8 credits, practices)

3. Undergraduate Courses of Nursing, School of Health Sciences and Nursing
 - 1) Maternal-Newborn Nursing (2 credits, lectures)
 - 2) First AID course (1 credit, lecture)
 - 3) Clinical Practicum in Maternal-Newborn Nursing (2 credits, practices)

Research activities

Our research activities encompass the field of maternal and child health emphasizing on the promotion of women's health and quality of life at every stage of life.

We aim to conduct the following research projects:

1. Creating evidence of health guidance during pregnancy
 - 1) Healthy lifestyle: Adequate maternal nutrition,

weight management, exercise, physical activity, sleep, and mental health are needed to ensure a healthy lifestyle among pregnant women.

We aim to conduct the Japan Pregnancy, Eating, Activity, Cohort Study (J-PEACH study) to provide evidence for appropriate health guidance. It investigates maternal body weight, glucose and lipid metabolite biomarkers, nutritional intakes, and physical activities to optimize weight management and a healthy lifestyle during pregnancy to prevent adverse perinatal outcomes including low birth weight.

2. Development of a support system for reliable childbirth

1) Midwifery care for positive childbirth experiences

This study evaluates the care provided by midwife-led system and in-hospital midwifery clinic with the aim of building a positive and efficient midwifery care for a positive birth experience for the mother.

2) “Fear of childbirth” and psychosocial factors among pregnant Japanese women

This study aims to identify the psychosocial risk factors of intense fear of childbirth.

3) Development of assessment methods of birth canal using transperineal ultrasonography

This study aims to develop the objective assessment methods of birth canal and the association of birth canal and delivery mode using transperineal ultrasonography.

4) Development of the strategy for safe delivery in El Salvador

To reduce the maternal mortality ratio in El Salvador, a program for humanized childbirth based on scientific evidence that leads to maternal safety and comfort during childbirth is developed.

5) Evaluation of learning efficacy of Virtual Reality on midwifery education

Collaborative research between the University of the Sunshine Coast, Queensland, Australia and the Waikato Institute of Technology, New Zealand is conducted to create and evaluate educational content related to midwifery using virtual reality technology. Furthermore, a 360°

camera is being used to create teaching materials and to study its effectiveness in midwifery education.

6) Development and effectiveness of an online Japanese version of mindfulness-based childbirth and parenting program

This study aims to develop a short online Japanese version of the Mindfulness-Based Childbirth and Parenting (MBCP) program and to investigate the program’s effectiveness on women’s prenatal mental health.

3. Development of a support system for postpartum body management

1) Pelvic floor disorders among postpartum women

This study evaluates the effect of pelvic floor muscle training in prevention of postpartum pelvic floor disorders (e.g., urinary incontinence). Furthermore, this study aims to develop and implement a pelvic floor muscle training program.

4. Development of a support system for women’s health

1) Health Support for working mothers and women

This study investigates the cadences of daily life and conditions of sleep such as excessive daytime sleepiness and other related factors among working mothers. Furthermore, it also explores factors associated with work engagement among working pregnant women.

2) Support for breastfeeding mothers and babies

This study aims to develop the Japanese version of the Infant Breastfeeding Assessment Tool (IBFAT), to assess the instinctive feeding behavioral reflexes of newborns, and explore factors affecting the IBFAT.

5. Creating evidence of health guidance for neonatal skin care

1) Development of an effective skin care intervention to prevent neonatal skin problems.

This study investigates the effect of following a moisturizing skincare routine on improving skin barrier functions among healthy neonates. Moreover, we will investigate the relationship between newborns’ skin problems and allergies

(i.e., food allergy or atopic dermatitis).

2) Effect of skincare on skin barrier function and normal bacterial flora

This study investigates the effect of skin care, including bathing, on infants' skin. It focuses on skin barrier function and normal bacterial flora as a skin condition.

Publications

1. Yonezawa K, Haruna M, Ohya Y. Impact of skin conditions of infants on their mothers' quality of life. *Journal of Neonatal Nursing*, 2022; 28(3): 188-191 <https://doi.org/10.1016/j.jnn.2021.10.012>
2. Yonezawa K, Haruna M, Ohya Y, Yamamoto-Hanada K. Exacerbation and severity of allergic symptoms during pregnancy and their impact on mental health. *International Journal of Women's Dermatology*. 2022; 8(1): e002. <https://doi.org/10.1097/JW9.0000000000000002>
3. Matsubara M, Haruna M, Yonezawa K, Yokoyama M, Tahara-Sasagawa E, Hikita N, Nakamura Y, Mizuno Y, Sanada H, Tamai N, Abe M, Kashiwabara K. Development and validation of an infant facial skin assessment tool: a prospective observational study. *BMC pediatrics*, 2022; 22(1): 614. <https://doi-org.utokyo.idm.oclc.org/10.1186/s12887-022-03691-7>
4. Yokoyama M, Yonezawa K, Matsubara M, Hikita N, Sasagawa E, Haruna M. The factors related to recovery time of diaper dermatitis in infants: A prospective observational study. *Japan journal of nursing science: JJNS*, 2022; 19(4): e12492. <https://doi-org.utokyo.idm.oclc.org/10.1111/jjns.12492>
5. Shiraishi M, Matsuzaki M, Haruna M. Association between perception of pre-pregnancy body weight and nutritional status during pregnancy: A cross-sectional study. *Asia Pacific journal of clinical nutrition*, 2022; 31(4): 692-700. [https://doi-org.utokyo.idm.oclc.org/10.6133/apjcn.202212_31\(4\).0012](https://doi-org.utokyo.idm.oclc.org/10.6133/apjcn.202212_31(4).0012)
6. Inuzuka Y, Yamamoto-Hanada K, Akaishi R, Haruna M, Matsubara M, Saito-Abe M, Sago H, Ohya Y. Dissemination of atopic dermatitis and food allergy information to pregnant women in an online childbirth preparation class. *The journal of allergy and clinical immunology. Global*, 2022; 1(1): 24-26. doi.org/10.1016/j.jacig.2021.12.004.
7. Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Carlsen KCL, Skjerven HO, Reh binder EM, Lowe AJ, Dissanayake E, Shimojo N, Yonezawa K, Ohya Y, Yamamoto-Hanada K, Morita K, Axon E, Cork M, Cooke A, Van Vogt E, Schmitt J, ... Boyle RJ. Skin care interventions in infants for preventing eczema and food allergy. *The Cochrane database of systematic reviews*, 2022; 11(11): CD013534. <https://doi-org.utokyo.idm.oclc.org/10.1002/14651858.CD013534.pub3>
8. Shinohara E, Ohashi Y, Hada A, Usui Y. Effects of 1-day e-learning education on perinatal psychological support skills among midwives and perinatal healthcare workers in Japan: a randomised controlled study. *BMC psychology*, 2022; 10(1): 133. <https://doi-org.utokyo.idm.oclc.org/10.1186/s40359-022-00832-6>
9. Suzuki D, Ohashi Y, Shinohara E, Usui Y, Yamada F, Yamaji N, Sasayama K, Suzuki H, Nieva RF Jr, da Silva Lopes K, Miyazawa J, Hase M, Kabashima M, Ota E. The Current Concept of Paternal Bonding: A Systematic Scoping Review. *Healthcare (Basel, Switzerland)*, 2022; 10(11): 2265. <https://doi-org.utokyo.idm.oclc.org/10.3390/healthcare10112265>
10. Sugawara C, Yamana H, Sasagawa E, Yonezawa K, Hikita N, Morita K, Matsui H, Yasunaga H, Haruna M. Factors Associated with Surgical Treatment in Postpartum Women with Mastitis or Breast Abscess: A Retrospective Cohort Study. *Breastfeed Med*. 2022; 17(3): 233-238. doi:10.1089/bfm.2021.0244.
11. Murakami M, Yonezawa K, Shimizu S, Haruna M, Sasagawa E, Usui Y. Newborn-oriented and environmental factors for newborns' skin barrier functions. *Jpn J Nurs Sci*. 2022; 19(2): e12457. doi: 10.1111/jjns.12457.
12. Kaori Yonezawa, Tomomi Tose, Megumi Haruna, Emi Sasagawa, Yuriko Usui. Impact of the COVID-19 Pandemic on the Childcare of Mothers with infants under one year old COVID-19. *Japan journal of nursing science*:

JJNS, 2022; 42: 346-355. <https://doi.org/10.5630/jans.42.346> (in Japanese)

13. Shinohara E, Tahara-Sasagawa E, Chizuko Ushioda, Kaoru Tsurumi, Yuko Imamura, Kumiko Adachi. Literature Review on Maternal and Child Health Care for Foreign Residents in Japan. The Journal of Japanese Midwives' Association, 2022; 76(1): 51-56. (in Japanese)

Department of Psychiatric Nursing

Professor

Daisuke Nishi, M.D., Ph.D.

Associate Professor

Yuki Miyamoto, R.N., P.H.N., P.S.W., Ph.D.

Project Research Associate

Utako Sawada, R.N., Ph.D.

Homepage [http:// plaza.umin.ac.jp/heart/](http://plaza.umin.ac.jp/heart/)

Introduction and Organization

Our department was firstly established as Department of Fourth Clinical Medical Nursing in School of Health Care and Nursing in 1957. When the School of Health Care and Nursing was reorganized as the School of Health Sciences in 1965, the department was renamed Department of Mental Health. In 1992, as School of Health Sciences became The School of Health Science and Nursing, Department of Mental Health became Department of Mental Health and Psychiatric Nursing. As the result of the shift to the chair system of the Graduate School of Medicine in 1996, two departments were established, Department of Mental Health and Department of Psychiatric Nursing. Faculty, staff, and students of two departments have been working cooperatively ever since.

Our department currently has two faculty members introduced above, a project research associate, part-time lecturers, visiting research fellows, 4 doctoral course students, 4 master course students, and research associates.

Our department's mission comprises two elements. One is to provide education and research training in mental health and psychiatric nursing to undergraduate and graduate students in order to prepare students to assume leadership roles in nursing clinical practice, administration, teaching, and research in this field. The other is to conduct clinical research in the fields of psychiatric nursing and

advance knowledge and theory through research.

All activities of our department are conducted in collaboration with staff members in the Department of Mental Health.

Education

Our department is responsible for giving lectures on psychiatric nursing to undergraduate students. Other than lectures, our department provides students opportunities to practice psychiatric nursing activities in several relevant facilities.

Our department is also obliged to educate graduate students in master and doctor programs in psychiatric nursing. To accomplish this objective, our department has a specialized lecture course on psychiatric nursing, and seminars on mental health and psychiatric nursing for graduate students. These activities are conducted and supervised by the faculty. In collaboration with the department of mental health, we also have the department seminar every Wednesday evening, where members provide the actual plans for their own research and discuss the topic.

We also have a variety of study clubs. We have psychiatric nursing study club, study group for multi-level analysis, qualitative research study group, and so on.

Research

Our research field covers mental health and psychiatric nursing. Our department has many research projects across diverse fields as follows: study of self-management in mental health; recovery in people with mental health difficulties; community support system for the people with mental health needs; peer support; stigma; social inclusion; mental health in people with substance use disorder or physical diseases; mental health in nurses or other workers; disaster mental health nursing; trauma-informed care, and reducing the use of seclusion and restraint. We are conducting studies in collaboration with researchers in other institutions and universities.

One of our research topics is "recovery," a concept that has proximity and overlap with quality of life among people who have experienced mental health difficulties. Recovery is a dynamic concept that includes restoring life, which means developing the individuals' aspirations for their life and getting back the life they want to live. In Japan, mental health care is changing and will increasingly need to emphasize the quality of life and recovery of those who have experienced mental health difficulties.

Some examples of our research work on recovery include (1) Accumulating the narratives of people who have experienced mental illness. (2) Developing patient-reported outcome measures that people with mental disorders feel are relevant to their lives. (3) Developing practices that enhance the well-being of people with and without mental disorders. We are also involved in a range of other projects.

It is necessary to pursue research involving people who have experience of mental health difficulties. We are co-producing research with people who have experienced mental health difficulties (patient and public involvement in designing and conducting research). There is a need to share the premise that any person's thoughts and opinions are important and valuable. We aim to improve mental health and medical welfare and to contribute to the realization of a society in which individuals feel that they are respected as they are.

Publications

1. Iiyama S, Izutsu T, Miyamoto Y, Benavidez JRM, Tsutsumi A. Effectiveness of Psychological First Aid e-Orientation among the General Population in Muntinlupa, the Philippines. *International Journal of Environmental Research and Public Health*. 2023;20(2):983. doi:10.3390/ijerph20020983
2. Yamaguchi S, Abe M, Kawaguchi T, Igarashi M, Shiozawa T, Ogawa M, Yasuma N, Sato S, Miyamoto Y, Fujii C. Multiple stakeholders' perspectives on patient and public involvement in community mental health services research: a qualitative analysis. *HealthExpect*. 2022; 25: 1844- 1860. doi:10.1111/hex.13529
3. Chiba R, Funakoshi A, Miyamoto Y. The Preliminary Efficacy of a Program to Facilitate Benefit Finding for People with Mental Illness: A Pilot Randomized Controlled Trial in Japan. *Healthcare*. 2022; 10(8):1491. PMID: 36011148. doi:10.3390/healthcare10081491
4. Hazumi M, Okazaki E, Usuda K, Kataoka M, Nishi D. Relationship between attitudes toward COVID-19 infection, depression and anxiety: a cross-sectional survey in Japan. *BMC Psychiatry*. 2022;22(1):798. Published 2022 Dec 19. doi: 10.1186/s12888-022-04474-1
5. Mascayano F, van der Ven E, Moro MF, Schilling S, Alarcón S, Barathie JA, Alnasser L, Asaoka H, Ayinde O, Balalian AA, Basagoitia A, Brittain K, Dohrenwend B, Durand-Arias S, Eskin M, Fernández-Jiménez E, Freytes M, Giménez L, Gisle L, Hoek HW, Jaldo R, Lindert J, Maldonado H, Martínez -Alés G, Martínez -Viciano C, Mediavilla R, McCormack C, Myer L, Narvaez J, Nishi D, Ouali U, Puac-Polanco V, Ramírez J, Restrepo-Henao A, Rivera -Segarra E, Rodríguez AM, Saab D, Seblova D, Tenorio A, Valeri L, Alvarado R, Susser E, On behalf of the HEROES group. The impact of the COVID-19 pandemic on the mental health of healthcare workers: study protocol for the COVID-19 HEalth caRe wOrkErS (HEROES) study. *Social Psychiatry and Psychiatric Epidemiology*. 2022 Mar;57(3):633-645.
6. Harris MG, Kazdin AE, Munthali RJ, Vigo DV, Hwang I, Sampson NA, Al-Hamzawi A, Alonso J,

- Andrade LH, Borges G, Bunting B, Florescu S, Gureje O, Karam EG, Lee S, Navarro-Mateu F, Nishi D, Rapsey C, Scott KM, Stagnaro JC, Viana MC, Wojtyniak B, Xavier M, Kessler RC. Perceived helpfulness of service sectors used for mental and substance use disorders: Findings from the WHO World Mental Health Surveys. *Int J Ment Health Syst.* 29;16(1), 2022
7. Shiba K, Daoud A, Kino S, Nishi D, Kondo K, Kawachi I. Uncovering heterogeneous associations of disaster-related traumatic experiences with subsequent mental health problems: A machine learning approach. *Psychiatry Clin Neurosci.* 2022 Apr;76(4):97-105.
 8. Kazdin, A. E., Wu, C.-S., Hwang, I., Puac-Polanco, V., Sampson, N. A., Al-Hamzawi, A., Alonso, J., Andrade, L. H., Benjet, C., Caldas-de-Almeida, J.-M., de Girolamo, G., de Jonge, P., Florescu, S., Gureje, O., Haro, J. M., Harris, M. G., Karam, E. G., Karam, G., Kovess-Masfety, V., Lee, S., McGrath, J. J., Navarro-Mateu, F., Nishi, D., Oladeji, B. D., Posada-Villa, J., Stein, D. J., Üstün, T. B., Vigo, D. V., Zarkov, Z., Zaslavsky, A. M., Kessler, R. C., and the WHO World Mental Health Survey collaborators. (2021). "Antidepressant use in low- middle- and high-income countries: a World Mental Health Surveys report." *Psychological Medicine* [Epub ahead of print]
 9. Tsuno K, Okawa S, Matsushima M, Nishi D, Arakawa Y, Tabuchi T. The effect of social restrictions, loss of social support, and loss of maternal autonomy on postpartum depression in 1 to 12-months postpartum women during the COVID-19 pandemic. *J Affect Disord.* 2022 Jun 15;307:206-214. doi: 10.1016/j.jad.2022.03.056.
 10. Kessler, R. C., Kazdin, A. E., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Altwaijri, Y. A., Andrade, L. H., Benjet, C., Bharat, C., Borges, G., Bruffaerts, R., Bunting, B., Caldas de Almeida, J. M., Cardoso, G., Chiu, W. T., Cía, A., Ciutan, M., Degenhardt, L., de Girolamo, G., de Jonge, P., de Vries, Y. A., Florescu, S., Gureje, O., Haro, J. M., Harris, M. G., Hu, C., Karam, A. N., Karam, E. G., Karam, G., Kawakami, N., Kiejna, A., Kovess-Masfety, V., Lee, S., Makanjuola, V., McGrath, J. J., Medina-Mora, M. E., Moskalewicz, J., Navarro-Mateu, F., Nierenberg, A. A., Nishi, D., Ojagbemi, A., Oladeji, B. D., O'Neill, S., Posada-Villa, J., Puac-Polanco, V., Rapsey, C., Ruscio, A. M., Sampson, N. A., Scott, K. M., Slade, T., Stagnaro, J. C., Stein, D. J., Tachimori, H., ten Have, M., Torres, Y., Viana, M. C., Vigo, D. V., Williams, D. R., Wojtyniak, B., Xavier, M., Zarkov, Z., Ziobrowski, H. N., and the WHO WMH survey collaborators. (In Press). Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. *World Psychiatry.* 2022 Jun;21(2):272-286.
 11. Nishi D. Desire for Shorter Life Expectancy From a Mental Health Perspective. *J Epidemiol.* 2022 Sep 30. doi: 10.2188/jea.JE20220197. Epub ahead of print. PMID: 36184557.
 12. Nishi D, Imamura K, Watanabe K, Obikane E, Sasaki N, Yasuma N, Sekiya Y, Matsuyama Y, Kawakami N. The preventive effect of internet-based cognitive behavioral therapy for prevention of depression during pregnancy and in the postpartum period (iPDP): a large scale randomized controlled trial. *Psychiatry Clin Neurosci.* 2022 Nov;76(11):570-578. doi: 10.1111/pcn.13458. Epub 2022 Sep16. PMID: 36114656.
 13. Hazumi M, Usuda K, Okazaki E, Kataoka M, Nishi D. Differences in the Course of Depression and Anxiety after COVID-19 Infection between Recovered Patients with and without a Psychiatric History: A Cross-Sectional Study. *Int J Environ Res Public Health.* 2022 Sep 8; 19(18):11316. doi: 10.3390/ijerph191811316. PMID: 36141588; PMCID: PMC9517442.
 14. Obikane E, Watanabe K, Nishi D, Kawakami N. Adverse childhood experiences and personal values in adolescence: a cross-sectional study using community adult samples in Japan. *Pediatr Int.* 2022 Sep 27:e15370. doi: 10.1111/ped.15370. Epub ahead of print. PMID: 36165851.
 15. Sasaki N, Inoue A, Asaoka H, Sekiya Y, Nishi D, Tsutsumi A, Imamura K. The Survey Measure of Psychological Safety and Its Association with Mental Health and Job Performance: A Validation Study and Cross-Sectional Analysis. *Int J*

- Environ Res Public Health. 2022 Aug 11;19(16):9879. doi: 10.3390/ijerph19169879. PMID: 36011522; PMCID: PMC9407795.
16. Carrozzino D, Christensen KS, Patierno C, Woźniewicz A, Møller SB, Arendt ITP, Zhang Y, Yuan Y, Sasaki N, Nishi D, Berrocal Montiel C, Ceccatelli S, Mansueto G, Cosci F. Cross-cultural validity of the WHO-5 Well-Being Index and Euthymia Scale: A clinimetric analysis. *J Affect Disord*. 2022 Aug 15;311:276-283. doi: 10.1016/j.jad.2022.05.111. Epub 2022 May 21. PMID: 35609763.
 17. Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, Akhondzadeh S, Benedetti F, Caneco C, Cramer H, Cribb L, de Manincor M, Dean O, Deslandes AC, Freeman MP, Gangadhar B, Harvey BH, Kasper S, Lake J, Lopresti A, Lu L, Metri NJ, Mischoulon D, Ng CH, Nishi D, Rahimi R, Seedat S, Sinclair J, Su KP, Zhang ZJ, Berk M. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytochemicals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. *World J Biol Psychiatry*. 2022 Jul;23(6):424-455. doi: 10.1080/15622975.2021.2013041. Epub 2022 Mar 21. PMID: 35311615.
 18. Bruffaerts R, Harris MG, Kazdin AE, Vigo DV, Sampson NA, Chiu WT, Al-Hamzawi A, Alonso J, Altwaijri YA, Andrade L, Benjet C, de Girolamo G, Florescu S, Haro JM, Hu CY, Karam A, Karam EG, Kovess-Masfety V, Lee S, McGrath JJ, Navarro-Mateu F, Nishi D, O'Neill S, Posada-Villa J, Scott KM, Have MT, Torres Y, Wojtyniak B, Xavier M, Zarkov Z, Kessler RC; WHO World Mental Health Survey Collaborators. Perceived helpfulness of treatment for social anxiety disorder: findings from the WHO World Mental Health Surveys. *Soc Psychiatry Psychiatr Epidemiol*. 2022 Oct;57(10):2079-2095. doi: 10.1007/s00127-022-02249-3. Epub 2022 Mar 9. PMID: 35262761; PMCID: PMC9458773.
 19. Kataoka M, Kotake R, Asaoka H, Miyamoto Y, Nishi D. Reliability and Validity of the Japanese Version of the Attitudes Related to Trauma-Informed Care (ARTIC-10) Scale. *J Trauma Nurs*. 2022 Nov-Dec 01;29(6):312-318. doi: 10.1097/JTN.0000000000000684. PMID: 36350170; PMCID: PMC9653105.
 20. Asaoka H, Koido Y, Kawashima Y, Ikeda M, Miyamoto Y, Nishi D. Association between clinical decision for patients with COVID-19 and post-traumatic stress symptoms among healthcare professionals during the COVID-19 pandemic. *Environmental and Occupational Health Practice*. in press. doi:10.1539/eohp.2022-0018-OA
 21. Asaoka H, Sasaki N, Imamura K, Kuroda R, Tsuno K, Kawakami N. Effects of workplace measures against COVID-19 on psychological distress of full-time employees: A 12-month prospective study in the COVID-19 pandemic. *Scand J Work Environ Health*. 2022 May 16:4030. doi: 10.5271/sjweh.4030.
 22. Nozawa K, Ishii A, Asaoka H, Iwanaga M, Kumakura Y, Oyabu Y, Shinozaki T, Imamura K, Kawakami N, Miyamoto Y. Effectiveness of an Online Peer Gatekeeper Training Program for Postsecondary Students on Suicide Prevention in Japan: Protocol for a Randomized Controlled Trial. *JMIR Res Protoc*. 2022 Apr 26;11(4):e34832. doi: 10.2196/34832.
 23. Iida M, Sasaki N, Imamura K, Kuroda R, Tsuno K, Kawakami N. COVID-19-Related Workplace Bullying and Customer Harassment Among Healthcare Workers Over the Time of the COVID-19 Outbreak: A Eight-Month Panel Study of Full-Time Employees in Japan. *J Occup Environ Med*. 2022 May 1;64(5):e300-e305. doi: 10.1097/JOM.0000000000002511. Epub 2022 Feb 9. PMID: 35143454.
 24. Yasuma N, Shiozawa T, Ogawa M, Abe M, Igarashi M, Kawaguchi T, Sato S, Nishi D, Kawakami N, Yamaguchi S, Fujii C. What outcomes in community mental health research are important to caregivers of people with schizophrenia? An exploratory qualitative analysis of an online survey. *Neuropsychopharmacol Rep*. 2022 Oct 10. doi: 10.1002/npr2.12295. Epub ahead of print. PMID: 36217559.
 25. Takano A, Miyamoto Y, Shinozaki T, Matsumoto T, Kawakami N. Effects of a web-based relapse prevention program on abstinence: Secondary subgroup analysis of a pilot randomized

- controlled trial. *Neuropsychopharmacol Rep.* 2022 Sep;42(3):362-367. doi: 10.1002/npr2.12272. Epub 2022 Jun 11. PMID: 35689457; PMCID: PMC9515705.
26. de Vries YA, Al-Hamzawi A, Alonso J, Andrade LH, Benjet C, Bruffaerts R, Bunting B, de Girolamo G, Florescu S, Gureje O, Haro JM, Karam A, Karam EG, Kawakami N, Kovess-Masfety V, Lee S, Mneimneh Z, Navarro-Mateu F, Ojagbemi A, Posada-Villa J, Scott K, Stagnaro JC, Torres Y, Xavier M, Zarkov ZN, Kessler RC, de Jonge P; WHO World Mental Health Survey collaborators. Transdiagnostic development of internalizing psychopathology throughout the life course up to age 45: a World Mental Health Surveys report. *Psychol Med.* 2022 Aug;52(11): 2134-2143. doi: 10.1017/S0033291720004031. Epub 2020 Nov 10. PMID: 33168122; PMCID: PMC9367642.
 27. Tsuji R, Nishi D, Sasaki N, Akiyama H, Kuroda R, Tsuno K, Imamura K, Kawakami N. Association between meal frequency with others and psychological distress during the COVID-19 pandemic: A cross-sectional study. *Psychiatry and Clinical Neurosciences Reports.* 2022;1(4): e61.
 28. Obikane E(*), Sasaki N(*), Imamura K, Nozawa K, Vedanthan R, Cuijpers P, Shimazu T, Kamada M, Kawakami N, Nishi D. Usefulness of Implementation Outcome Scales for Digital Mental Health (iOSDMH): Experiences from Six Randomized Controlled Trials. *International Journal of Environmental Research and Public Health.* 2022; 19(23) doi: <https://doi.org/10.3390/ijerph192315792>.
(*) These authors contributed equally to this work.
 29. Sasaki N, Ikeda M, Nishi D. Long-term influence of unintended pregnancy on psychological distress: a large sample retrospective cross-sectional study. *Archives of women's mental health.* 2022;1-9. doi: 10.1007/s00737-022-01273-1
 30. Sasaki N, Imamura K, Watanabe K, Hidaka Y, Ando E, Eguchi H, Inoue A, Tsuno K, Komase Y, Iida M, Otsuka Y, Sakuraya A, Asai Y, Iwanaga M, Kobayashi Y, Inoue R, Shimazu A, Tsutsumi A, Kawakami N. The impact of workplace psychosocial factors on menstrual disorders and infertility: a protocol for a systematic review and meta-analysis. *Systematic reviews.* 2022;11(1): 195.
 31. Sasaki N, Tabuchi T, Okubo R, Ishimaru T, Kataoka M, Nishi D. Temporary employment and suicidal ideation in COVID-19 pandemic in Japan: A cross-sectional nationwide survey. *Journal of occupational health.* 2022;64(1): e12319.
 32. Hidaka Y, Kawakami N, Watanabe K, and Nishi D. 2022. The association between premenstrual syndrome before pregnancy and antenatal depression: A cross-sectional study with pre-recorded information. *Psychiatry and Clinical Neurosciences Reports*, 1(3), p.e27.
 33. Imamura K, Sasaki N, Sekiya Y, Watanabe K, Sakuraya A, Matsuyama Y, Nishi D, Kawakami N. The Effect of the Imacoco Care Psychoeducation Website on Improving Psychological Distress Among Workers During the COVID-19 Pandemic: Randomized Controlled Trial. *JMIR Form Res.* 2022 Mar 10;6(3):e33883. doi: 10.2196/33883. PMID: 35133972.
 34. Iida M, Watanabe K, Yeo SA, Yasuma N, Nishi D. & Kawakami N. Association of Personal Values in Adolescence with Subjective Health Status, Meaning in Life, and Life Satisfaction in Adulthood: A Cross-sectional Study with Retrospective Recall. *Japanese Psychological Research.* 2022. doi: 10.1111/jpr.12444

Department of Gerontological Nursing / Wound Care Management

Professor

Gojiro Nakagami, Ph.D., R.N.

Assistant Professor

Mari Abe, Ph.D., R.N., Toshiaki Takahashi, Ph.D., R.N., Yuko Mugita, Ph.D., R.N.

Homepage <http://www.rounenkango.m.u-tokyo.ac.jp/index-e.html>

Introduction and Organization

The Department of Gerontological Nursing was established in June 2003, followed by the establishment of the Department of Wound Care Management in April 2006. We have been promoting the education of undergraduate and graduate students, clinical activities in hospitals relating to pressure injuries and diabetic foot, and research activities on the topics of gerontological nursing, wound care management, and nursing science and engineering.

Our department has established several departments: Department of Life Support Technology (Molten), Department of Advanced Skin Care (Miss Paris), Department of Advanced Nursing Technology, Department of Skincare Science, and Department of Imaging Nursing Science. We have been promoting collaborative research among government, industry and academia, as well as integrating multiple disciplines across campus.

In April 2017, the Global Nursing Research Center (GNRC) was established with the aim to create a transdisciplinary research and educational environment that fosters young researchers in nursing science in order to promote care innovation. Professor Sanada, former head of the department, served as the first director of the center until March 2022, and faculty staff members in our department have been involved in the Division of Care Innovation in GNRC as a

concurrent position.

The former head of the department, Professor Hiromi Sanada (currently Professor Emerita of the University of Tokyo) retired in March 2022, and Professor Gojiro Nakagami took over as the new head of this department in April 2022. Gerontological Nursing and Wound Care Management is currently headed by one professor and assisted by three assistant professors, a project academic specialist, an assistant clerk, seven part-time lecturers for undergraduate courses, and seven part-time lecturers for graduate courses. The student body consists of five doctoral course students and five master's course students. Our mission statement is "We wish to create a society that respects the beauty of aging and recognizes it as to be a joyful process in life."

Teaching activities

1. Undergraduate course

For undergraduate education, our department takes part in lectures of Health Support Practice, Overview of Clinical Medicine, and Observation of Human Anatomy, as well as lectures, exercises, and clinical practice about gerontological nursing and nursing science and engineering.

1) Health Support Practicum (W in 2nd yr; 1 credit)

Nursing is a science of searching for ways to support health and the achievement of self-actualization, and it is practiced in various social situations, including hospitals, healthcare centers or medical facilities. The aim of this practicum is for students to understand the variety and wide potential of nursing, and to learn the methods and practices for health support through experiential learning of various types of nursing from the earliest stages of their nursing course. In 2022, we conducted an onsite and online practicum and the program included themes related to:

- a) Policy creation for solving problems confronted in nursing
- b) Health support service
- c) Nursing-based hospital management
- d) Development of medical devices for supporting patients' lives.

2) Overview of Clinical Medicine (S1 in 3rd yr; 2 credits)

The aim of this series of lectures is to learn the basic knowledge and thought processes for understanding clinical medicine, and to learn the pharmaceuticals required for nursing practice. The main content themes in the 2022 session included:

- a) Introduction to surgical treatment
- b) Introduction to radiology
- c) Surgical anesthesia
- d) Perioperative management
- e) Clinical conditions
- f) Natural history and treatment of diseases
- g) Nursing pharmaceuticals

The above lectures were provided through cooperation from the departments at The University of Tokyo Hospital.

3) Observation of Human Anatomy (A1 in 3rd yr; 1 credit)

The aim of this series of lectures is to gain a deeper understanding of life and learn about human anatomy through a careful examination of “death” and “disease,” as conceptual opposites of “life” and “health.” The main themes in the 2022 curriculum included:

- a) Introduction to anatomical pathology
- b) Case studies
- c) Introduction to anatomicopathological research
- d) Anatomy using ultrasound equipment

- e) Visit to specimen room

4) Gerontological Nursing (A2 in 3rd yr; 2 credits)

A series of lectures with the aim of understanding the physical, psychological, and social characteristics of the elderly population; to learn fundamental theories of gerontological nursing; and to promote an understanding of the ailments and conditions required to provide proper care to the elderly. The main themes covered in the 2022 session were as follows:

- a) Practical simulation for gerontological nursing
- b) Physical, psychological, and social characteristics of the elderly from a nursing standpoint
- c) Geriatric syndrome and nursing (i.e., dementia, walking disability, pressure injury, incontinence)
- d) Age-related changes in the physiological system
- e) Aging and dementia
- f) Aging and osteoporosis
- g) Aging and renal function, hypertension, and stroke
- h) Aging and cardiovascular disorders
- i) Aging and respiratory disorders
- j) Pharmacological management of the elderly
- k) Use of ultrasonography in nursing
- l) Nutritional management for the elderly
- m) Relationship-building and communication skills with the elderly

A portion of the above lectures was provided through cooperation from the Department of Geriatric Medicine and other departments at The University of Tokyo Hospital.

5) Clinical Practicum in Gerontological Nursing (A1 in 4th yr; 2 credits)

The aim of this practicum is to gain the holistic understanding of the elderly, learn the perspective and role functions of nursing for the elderly, and be able to think about the issues and future of gerontological nursing. In 2022, the practice was conducted online and consisted mainly of online interviews and activities with senior volunteers, case scenario exercises, lectures on multidisciplinary cooperation in each geriatric care setting (hospital, geriatric health care facility, and home), remote observation of actual geriatric nursing care, practice ultrasound techniques that can be utilized in geriatric nursing, and gathering information and experience with the latest equipment and systems in nursing, caregiving, and healthcare.

2. Graduate course

1) Gerontological Nursing I (S1; 2 credits)

The main theme of Gerontological Nursing I in 2022 was to understand the latest research related to the care of elderly persons and to discuss future perspectives in gerontological nursing from three viewpoints: basic biology, engineering, and clinical nursing research. Recent research papers were selected from these three fields and critically evaluated.

2) Gerontological Nursing II (A1; 2 credits)

Gerontological Nursing II provided lectures regarding recent topics around gerontological medicine and nursing from broad viewpoints, including biological, individual, and social aspects, by part-time lecturers and specialists from each research field. The aim of this course was to understand and learn scientific ways of thinking about gerontological considerations of the future Japanese community. The main titles in 2022 were as follows:

- a) Prevention of catheter failure using echo
- b) Nursing care innovation
- c) Biological nursing: skin blotting
- d) Nursing science and engineering for innovation of care in the super-aging society
- e) Care of cancer patients undergoing chemotherapy: Appearance care from the perspective of skin care
- f) Clinical issues and research findings in the community as a dermatology practitioner
- g) Clinical issues from a plastic surgery perspective with a focus on visiting physicians, and the latest wound care methods

3) Wound Care Management I (S2; 2 credits)

The main purpose of Wound Care Management I in 2022 was to learn and deepen understanding of the basic knowledge required to carry out wound nursing research, as well as to develop a broad interest in new knowledge and acquire an attitude and methodology for self-study. The topics were as follows:

- a) Prediction and prevention of wounds
- b) Assessment of wounds
- c) Treatment and care of wounds
- d) Institutions and policies related to wound care and management

4) Wound Care Management II (A2; 2 credits)

Wound management includes the prediction and prevention of wound development, wound assessment, treatment, and care (including excretory care), requiring a wide range of knowledge from nurses engaged in wound management. Therefore, research in wound care nursing requires a multidisciplinary approach that integrates different fields of nursing science and engineering. In this special lecture, students will learn the latest knowledge necessary for wound management, including basic research and practice, and will acquire scientific thinking ability and skills in wound nursing through discussions and exercises. Lectures, exercises, and discussions were held on (1) wound and skin assessment using equipment, and (2) pressure management and pressure injury prevention utilizing robotics technology.

5) Master's theses

The following research themes were submitted in 2022:

- “Development of e-learning and pelvic floor muscle contraction automatic evaluation algorithm for pelvic floor muscle training biofeedback using self-performed ultrasound”
- “Development of a skin temperature estimation system for a prediction method of pressure injury occurrence based on continuous body sensor data”
- “Development and evaluation of a rapid skin taurine measurement device using skin blotting for the early detection of dehydration”

6) Doctoral theses

The following research themes were submitted in 2022:

- “The effectiveness of local low-frequency vibration on wound healing of full-thickness wounds in a hyperglycemic rat model”
- “Predictive factors and characteristics of infusion site induration and subcutaneous edema among of the patients under outpatient chemotherapy” (in Japanese)
- “Identification of itch-prone skin in dry skin-derived pruritus by detection of NGF/SEMA3A ratio”(in Japanese)

Research activities

1. Activity policy

Our gerontological nursing research focuses on those suffering from geriatric syndromes, such as pressure injuries, incontinence, malnutrition, pain, dysphagia and dementia. Our wound care management research focuses on pressure injuries, diabetic foot ulcers, and skin tears.

The majority of our clinical research has been conducted at The University of Tokyo Hospital. We regularly participate in pressure injury multi-disciplinary team rounds.

Regarding international activities, our department has been promoting collaborative research with researchers in universities around the world. Our counterparts include Curtin University (Australia) University of Nottingham, and Universitas Muhammadiyah Pontianak in 2022.

2. Research fields and themes in 2022

1) Basic experimental studies:

- Evaluation of wound condition using exudates
- Skin blotting for analyzing dehydration
- Cutaneous wound healing and diabetes mellitus
- Investigation of the effect of cellular senescence on wound healing
- Development of a novel method for controlling wound infection focusing on gene expression of bacteria and hosts

2) Nursing engineering:

- Sensing of the treatment environment and development of AI-based prediction models
- Non-invasive detection of tissue injury and pre-injury status using ultrasonography and thermography
- Development of apps using communication robots for the elderly
- Development of an absorbent pad for the prevention of incontinence-associated dermatitis
- Development of an educational system for new visiting nurses using XR technology

3) Clinical studies:

- Novel assessment technologies for pressure injuries
- Establishment of an automated pelvic floor muscle contraction evaluation method using ultrasonography
- Establishment of a novel assessment method for

constipation using ultrasonography

- Implementation of ultrasonography-based peripheral venous catheter placement techniques
- Survey of the skin condition of wheelchair basketball athletes
- Survey on the relationship between the microbiota in the bed environment and the development of pressure injury infections
- Survey of the effectiveness of biofilm removal on wound healing
- Evaluation of the effectiveness of nurses who completed advanced nursing procedure training
- Development of a tele-nursing system and clinical evaluation of its effectiveness

Several awards were given for our research in 2022, as follows:

Presentations

- The 52nd Japanese Society for Wound Healing Research Encouragement Award (November 2022). Haba D, Qin Q, Minematsu T, Sanada H, Nakagami G. Verification of the effect of local low-frequency vibration stimulation on glucose metabolism and vasodilatation/neogenesis to promote healing of full-thickness wound in diabetic rats. (in Japanese)
- The Japanese Society of Physical Therapy 6th Symposium of Young Researchers Network Data Analysis Award (July 2022). Haba D, Qin Q, Nakagami G. New treatment strategy for diabetic foot ulcer based on promotion of glucose metabolism by local low-frequency vibration. (in Japanese)
- 31st Annual Meeting of the Japanese Society for Wound, Ostomy and Incontinence Management, Best Presentation Award, English Session (June 2022). Haba D, Nakagami G, Qin Q, Minematsu T, Sanada H. Local low-frequency vibration promotes wound healing of a full-thickness wound in the diabetic rat.

Papers

- 42nd Japan Academy of Nursing Science Academic Paper Award for Excellence (December 2022). Abe-Doi M, Murayama R, Kawamoto A, Komiyama C, Doorenbos A, Sanada H. Damage to subcutaneous tissue at the catheterization site during chemotherapy: A prospective observational

- study using ultrasonography. *Japan Journal of Nursing Science*. 2021;e12436.
- The 10th Society of Nursing Science and Technology Conference Award (October 2022). Higashimura S, Tamai N, Nakagami G, Tobe H, Sanada H. A pilot epidemiological study on chronic dehydration of older adults in a home care setting. *Journal of Nursing Science and Engineering*. 2022;9:123-135.
 - The 10th Society of Nursing Science and Engineering Incentive Award (October 2022). Matsumoto M, Ishibashi K, Kitamura A, Tamai N, Miura Y, Takahashi T, Higashimura S, Nakagami G, Sanada H. An AI-based evaluation method of fecal retention for rectal echocardiographic videos taken by home care nurses. *Journal of the Society of Nursing Science and Technology. Journal of Nursing Science and Engineering*. 2021;9:34-46. (in Japanese)
 - The 10th Society of Nursing Science and Technology Incentive Award (October 2022). Koudounas S, Minematsu T, Mugita Y, Tomida S, Nakai A, Nakagami G, Sanada H. Inhibiting effect of synthetic urine on the growth and mobility of *Pseudomonas aeruginosa*, *Escherichia coli*, *Proteus mirabilis* and *Klebsiella pneumoniae* shifts to a promoting effect during culture. *Journal of Nursing Science and Engineering*. 2021;8:220-229.
 - Ohura Award of the Japanese Decubitus Ulcer Society (August 2022). Takizawa C, Kitamura A, Nakagami G, Matsumoto M, Hayashi C, Kawasaki A, Sanada H. The relationship between the temperature distribution detected by thermography and suspected deep tissue injuries. *Japanese Journal of Pressure Ulcers*. 2022;24(1):14-28.
 - Ohura Award of the Japanese Decubitus Ulcer Society (August 2022). Nakagami G, Yokota S, Kitamura A, Takahashi T, Morita K, Noguchi H, Ohe K, Sanada H. Supervised machine learning-based prediction for in-hospital pressure injury development using electronic health records: A retrospective observational cohort study in a university hospital in Japan. *International Journal of Nursing Studies*. 2021;119:103932.

References

Original Papers

1. Higashimura S, Tamai N, Nakagami G, Tobe H, Sanada H. A pilot epidemiological study on chronic dehydration of older adults in home care setting. *Journal of Nursing Science and Engineering*. 2022;9:123-135.
2. Matsumoto M, Misawa N, Tsuda M, Manabe N, Kessoku T, Tamai N, Kawamoto A, Sugama J, Tanaka AH, Haruma K, Sanada H, Nakajima A. Expert consensus document: diagnosis for chronic constipation with faecal retention in the rectum using ultrasonography. *Diagnostics*. 2022; 12(2):300.
3. Takahashi T, Nakagami G, Murayama R, Abe-Doi M, Matsumoto M, Sanada H. Automatic vein measurement by ultrasonography to prevent peripheral intravenous catheter failure for clinical practice using artificial intelligence: development and evaluation study of an automatic detection method based on deep learning. *BMJ open*. 2022; 12(e051466).
4. Higashimura S, Nakagami G, Sanada H. Effectiveness of new pelvic floor exercises on urinary incontinence in older women with cognitive impairment: A pilot study at long-term care facilities. *Journal of Society of Nursing Practice*. 2022;34(1):26-39.
5. Nitta S, Maeda T, Koudounas S, Minematsu T, Weller C, Sanada H. Which objective itch-assessment tools are applicable to patients with cognitive impairments? A scoping review. *International Journal of Older People Nursing*. 2022:e12458.
6. Tanabe H, Oosawa K, Miura M, Mizuno S, Yokota T, Ueda T, Zushi Y, Nagata M, Murayama R, Abe-Doi M, Sanada H. Effect of a thin-tipped short bevel needle for peripheral intravenous access on the compressive deformation and displacement of the vein: a preclinical study. *Journal of Vascular Access*. 2022: 11297298221075169.
7. Shintani Y, Murayama R, Abe-Doi M, Sanada H. Incidence, causes, and timing of peripheral intravenous catheter failure related to insertion timing in the treatment cycle in patients with

- hematological malignancies: a prospective descriptive study. *Japan Journal of Nursing Science*. 2022:e12484.
8. Sugama J, Ishibasi M, Ota E, Kamakura Y, Saitoh E, Sanada H, Nakayama T, Nomura T, Yamada M, Nakagami G, Sato N, Shibata S, Hase T, Fukada J, Miki T, Arita M, Urai T, Okawa Y, Kitamura A, Dai M, Takahashi T, Tamai N, Tobita I, Noguchi H, Matsumoto M, Miura Y, Mukai K, Mugita Y, Yoshida M, Kurachi M, Shirasaka T, Yamane Y. Japanese clinical practice guidelines for aspiration and pharyngeal residual assessment during eating and swallowing for nursing care. *Japan Journal of Nursing Science*. 2022:e12496.
 9. Murayama R, Oyama H, Abe-Doi M, Masamoto Y, Kashiwabara K, Tobe H, Komiyama C, Sanada H, Kurokawa M. Safety verification of a new peripheral intravenous catheter placed in the upper arm vein for administration of drugs with high irritant potential. *Drug Discoveries & Therapeutics*. 2022;16(3):128-134.
 10. Minematsu T, Tomida S, Tobe H, Koudaunas S, Nakagami G, Sanada H. Evaluation of liquid-less biofilm staining on wound blotting samples. *Journal of Nursing Science and Engineering*. 2022;9:222-228.
 11. Shimura T, Nakagami G, Ogawa R, Ono S, Takahashi T, Nagata M, Kashiwabara K, Sugama J, Sanada H, Oe M. Incidence of and risk factors for self-load-related and medical device-related pressure injuries in critically ill patients: a prospective observational cohort study. *Wound Repair and Regeneration*. 2022;30(4):453-467.
 12. Takizawa C, Kitamura A, Nakagami G, Matsumoto M, Hayashi C, Kawasaki A, Sanada H. The relationship between the temperature distribution detected by thermography and suspected deep tissue injuries. *Japanese Journal of Pressure Ulcers*. 2022;24(1):14-28.
 13. Qin Q, Nakagami G, Ohashi Y, Dai M, Sanada H, Oe M. Development of a self-monitoring tool for diabetic foot prevention using smartphone-based thermography: Plantar thermal pattern changes and usability in the home environment. *Drug discoveries & therapeutics*. 2022;16(4):169-176.
 14. Oe M, Fukuda M, Ohashi Y, Shimojima Y, Tsuruoka K, Qin Q, Yamauchi T, Sanada H. Evaluation of foot ulcer incidence in diabetic patients at a diabetic foot ulcer prevention clinic over a 10-year period. *Wound repair and regeneration*. 2022;30(5):546-552.
 15. Astrada A, Nakagami G, Fajrianita I, Matsumoto M, Kawamoto A, Jais S, Sanada H. Ultrasonographic features of diabetic foot osteomyelitis: a case series. *Journal of Wound Care*. 2022;31(9):748-754.
 16. Tsuruoka K, Oe M, Minematsu T, Tomida S, Ohashi Y, Shimojima Y, Qin Q, Abe M, Yamauchi T, Sanada H. Association between elevated skin temperature of the foot callus and inflammatory marker in people with diabetes. *Journal of Japanese Society of Wound, Ostomy and Continence Management*. 2022;23(3):261-268.
 17. Iwahira Y, Nakagami G, Sanada H. Risk factors for capsular contracture after breast reconstruction with tissue expanders and silicone implants in nonirradiated patients: A retrospective observational cohort study. *Medicine (Baltimore)*. 2022;101(48):e31837.
 18. Fact-finding Committee of the Japanese Society of Pressure Ulcers; Konya C, Takeuchi Y, Nakagami G, Kitamura A, Morita K, Ishizawa M, Abe Y, Higuchi H, Mizuki T, Motegi S, Shoji S, Shimada K, Tanaka K, Kawakami S, Sanada H. Nationwide time-series surveys of pressure ulcer prevalence in Japan. *Journal of Wound Care*. 2022;31(Sup12): S40-S47.

International Health

1. International Social Medicine

Department of Global Health Policy

Professor

Masahiro Hashizume, MD, PhD

Associate Professor

Chris Fook Sheng Ng, PhD

Assistant Professor

Paul Lester Chua, PhD

Project Assistant Professor

Shuhei Nomura, PhD

Homepage <http://www.ghp.m.u-tokyo.ac.jp>

Introduction and Organization

As of March 2023 the department, headed by Professor Masahiro Hashizume, included the following staff complement; one associate professor (Chris Fook Sheng Ng); one assistant professor (Paul Lester Chua); one project assistant professors (Shuhei Nomura); 14 post-doctoral fellows; 9 adjunct lecturers; 9 doctoral students; and 6 master's students.

The priority areas of research are:

- Health impacts of climate, climate change and air pollution.
- Health outcome research (mortality, morbidity and disability; health service research; health technology assessment and cost-effectiveness; disease modeling; and comparative risk factor analysis);
- Health system performance assessment, including the analysis of health system inputs, outputs, and impact;
- Health and foreign policy (e.g. global health architecture and governance, the G7 and global health, donor commitments, and innovations in global health).

Finally, the fundamental role of the department is to produce the next generations of leaders in global health.

Education

All lectures in the department are conducted in English, to ensure that student writing and presentation skills are held to an international standard.

Master's program

The Master's program is a demanding, interdisciplinary program emphasizing student-directed learning, problem-solving, and the acquisition of fundamental public health skills required for global health practices (health policy, statistics, epidemiology, and social sciences). Students are required to complete a minimum of 30 course credits and a master's thesis. Beyond the program and concentration requirements, students are encouraged to consult with faculty advisers to choose elective courses best suited to their needs.

PhD program

The PhD program is designed to train the next generation of leaders in global health. PhD students are required to complete a minimum of 24-course credits

and a doctoral thesis which needs to be published in a peer-reviewed journal. PhD students without MPH degrees should take the lectures to acquire fundamental public health skills such as health policy, biostatistics and epidemiology.

Global Health Policy I and II

This course introduces the principles and theories of global health problems, as well as practical applications of quantitative methods (demography, statistics, epidemiology and econometrics) to analyze and interpret issues and challenges for policy.

The followings are the topics covered in the academic year 2022:

- Global environmental change and health
- Health impact assessments in environmental health
- Evidence synthesis for global health research
- Temperature and mortality
- Overview of global burden of disease
- Innovations in maternal and child health
- Planetary health
- Equity in health and universal health coverage assessment
- Data and epidemiological methods for environmental health research
- Air pollution and health
- Comparative risk assessment
- Cancer epidemiology and prevention GHP
- Infectious disease surveillance system
- Projections of climate change-related health impacts
- Environment and child health
- Japan's Global Health Diplomacy in the era of COVID-19 and beyond

GHP seminar

Every Tuesday, 13:00-15:00

1) Journal club

Students present a summary of research articles from the major medical, social science, economics journals, which are relevant to global health policy. The major objective is to share knowledge, evoke debates and facilitate discussions.

2) Research seminar

A guest speaker or a master or doctoral student presents his/her research. There is a 15-minute presentation followed by a 30-minute discussion.

Research

Projections of excess mortality due to climate change - a multi-country environmental epidemiology study. Grant-in-Aid for Scientific Research (B) (Japan Society for the Promotion of Science) PI: Masahiro Hashizume

Climate Change and Human Health in Asia: Current Impacts, Future Risks, and Health Benefits of Mitigation Policies. E-Asia as part of Strategic International Collaborative Research Program (Japan Science and Technology Agency) PI: Masahiro Hashizume.

Human resource development and the development of infectious disease epidemiological methods for the expansion of infectious disease surveillance systems, including COVID-19. Health and Labour Science Research (Ministry of Health, Labour and Welfare) PI: Masahiro Hashizume.

Analysis of climate influences on medical conditions and diseases. Bilateral Collaborations (South Africa) (Japan Society for the Promotion of Science) Japanese PI: Masahiro Hashizume.

Use of burden of disease for health care research in the with/post-COVID-19 era and empirical analysis. Grant-in-Aid for Scientific Research (B) (Japan Society for the Promotion of Science) PI: Shuhei Nomura.

Selected Publications

1. Vicedo-Cabrera AM, Tobias A, Jaakkola JJK, Honda Y, Hashizume M, Guo Y, Schwartz J, Zanobetti A, Bell ML, Armstrong B, Katsouyanni K, Haines A, Ebi KL, Gasparrini A. Global mortality burden attributable to non-optimal temperatures. *Lancet*. 2022 Mar 19;399(10330):1113.
2. Madaniyazi L, Tobias A, Kim Y, Chung Y, Armstrong B, Hashizume M. Assessing

- seasonality and the role of its potential drivers in environmental epidemiology: a tutorial. *Int J Epidemiol.* 2022 Oct 13;51(5):1677-1686.
3. He C, Kim H, Hashizume M, Lee W, Honda Y, Kim SE, Kinney PL, Schneider A, Zhang Y, Zhu Y, Zhou L, Chen R, Kan H. The effects of night-time warming on mortality burden under future climate change scenarios: a modelling study. *Lancet Planet Health.* 2022 Aug;6(8):e648-e657.
 4. Roy A, Alam MA, Kim Y, Hashizume M. Association between daily ambient temperature and drug overdose in Tokyo: a time-series study. *Environ Health Prev Med.* 2022;27:36.
 5. Nsashiya RS, Rahman MM, Ndam LM, Hashizume M. Exploiting the Bayesian approach to derive counts of married women of reproductive age across Cameroon for healthcare planning, 2000-2030. *Sci Rep.* 2022 Oct 27;12(1):18075.
 6. Nishikawa H, Seposo XT, Madaniyazi L, Kim Y, Tobias A, Yamagami M, Kim SE, Takami A, Sugata S, Honda Y, Ueda K, Hashizume M, Ng CFS. Long-term trends in mortality risk associated with short-term exposure to air pollution in 10 Japanese cities between 1977 and 2015. *Environ Res.* 2022 Dec 20;219:115108.
 7. Pan R, Honda Y, Minakuchi E, Kim SE, Hashizume M, Kim Y. Ambient temperature and external causes of death in Japan from 1979 to 2015: a time-stratified case-crossover analysis. *Environ Health Perspect.* 2022 Apr;130(4):47004.
 8. Chua PLC, Ng CFS, Madaniyazi L, Seposo X, Salazar MA, Huber V, Hashizume M. Projecting temperature-attributable mortality and hospital admissions due to enteric infections in the Philippines. *Environ Health Perspect.* 2022 Feb;130(2):27011.
 9. Chua PLC, Ng CFS, Tobias A, Seposo XT, Hashizume M. Associations between ambient temperature and enteric infections by pathogen: a systematic review and meta-analysis. *Lancet Planetary Health.* 2022 Mar;6(3):e202-e218.
 10. Madaniyazi L, Jung CR, Ng CFS, Seposo X, Hashizume M, Nakayama SF, Japan Environment and Children's Study Group. Early life exposure to indoor air pollutants and the risk of neuro-developmental delays: The Japan environment and children's study. *Environ Int.* 2022 Jan;158:107004.
 11. Madaniyazi L, Armstrong B, Chung Y, Ng CFS, Seposo X, Kim Y, Tobias A, Guo Y, Sera F, Honda Y, Gasparrini A, Hashizume M. Multi-country Multi-city (MCC) Collaborative Research Network. Seasonal variation in mortality and the role of temperature: a multi-country multi-city study. *Int J Epidemiol.* 2022 Feb 18;51(1):122-133.
 12. Zhou L, He C, Kim H, Honda Y, Lee W, Hashizume M, Chen R, Kan H. The burden of heat-related stroke mortality under climate change scenarios in 22 East Asian cities. *Environ Int.* 2022 Dec;170:107602.
 13. Nomura S, Eguchi A, Tanoue Y, Yoneoka D, Kawashima T, Suzuki M, Hashizume M. Excess deaths from COVID-19 in Japan and 47 prefectures from January through June 2021. *Public Health.* 2022; 203: 15-8.
 14. Nomura S, Eguchi A, Ghaznavi C, Tanoue Y, Kawashima T, Yoneoka D, Yamasaki L, Suzuki M, Hashizume M. Excess deaths from non-COVID-19-related causes in Japan and 47 prefectures from January 2020 through May 2021 by place of death. *SSM Popul Health.* 2022 Sep;19:101196.
 15. Lwin KS, Ghaznavi C, Win KL, Gilmour S, Hashizume M, Nomura S. Myanmar's coup risks a flood of vaccine-preventable disease. *J Glob Health.* 2022 Sep 3;12:03060.

Department of Community and Global Health

Professor, Academic Leader

Masamine Jimba, MD, PhD, MPH

Lecturer

Akira Shibamura, PhD

Assistant Professors

Junko Kiriya, PhD, Ken Ing Cherng Ong, PhD

Website: <http://www.ich.m.u-tokyo.ac.jp>

Introduction and Organization

The Department of Community and Global Health (formerly Department of International Community Health) has been headed by four professors since 1993: Professors Gen Ohi (1993-1996), Som-Arch Wongkhomthong (1996-1999), Susumu Wakai (1999-2006), and Masamine Jimba (2006-present).

The mission of the department is to seek equity and social justice in health within and across nations. To achieve this, we aim toward:

1. Investigating how to improve health status of the most vulnerable people, in particular, in low- and middle-income countries
2. Undertaking research on the influence of globalization on health and social development
3. Investigating mechanisms to reduce health and development inequalities between and within nations

Our research focuses on how to promote community-based activities and how to link a bottom-up approach to national and international policies. As of March 2023, the members of the department include the department chair and professor, 1 lecturer, 2 assistant professors, 3 secretaries, 11 visiting lecturers, 12 doctoral students, 13 master's degree students, and 43 visiting scientists. More than half of the students in this department are international

students.

International Cooperation Activities

As Regional Vice-President for Northern Part of Western Pacific of International Union for Health Promotion and Education, Professor Jimba contributed to enhancing health promotion at the global and regional level. Moreover, as the Immediate-Past President of Asia-Pacific Academic Consortium for Public Health, Professor Jimba took a leading role in improving public health research and practices in the region.

Education

The main objectives of our teaching activities are the following two:

- 1) To train competent researchers who understand and complement the wise activities of practitioners in the field.
- 2) To train practitioners who can also wisely carry out research in the field.

The postgraduate curriculum is composed mainly of community and global health advanced courses, exercises and practical work. All curricula focus on community health. Our main educational activities other than the curriculum include technical assistance

in writing Master's and doctoral theses. We always encourage students to publish their theses in international journals. In addition, we urge students to gain experiences in the field and learn about real global health from their experiences.

Because we have many international students, all lectures, practices, and discussions are carried out in English. For those who do not have health/medical background, we provide a wide variety of curricula from basics to advanced level.

We also provide training run by JICA and lectures at other universities to young leaders from overseas.

Research

The major objectives of our research activities are the following two:

- 1) To promote research which has a significant impact on international and local societies
- 2) To promote research which contributes to endogenous development

We aim to demonstrate research findings based on community-based data directly collected from the field. Therefore, we consider fieldwork very important. At the same time, our department aims to contribute to policy making and promoting actions for better health by making the most of community-based research. We carry out research by working in collaboration with different research institutes, international organizations, JICA, NGOs, and universities in low- and middle-income countries. We conduct research mainly in low- and middle-income countries, but we are also involved in research in Japan.

The major directions of current research have encompassed 1) health, nutrition, and development, 2) health, human rights and human security, 3) ecological approach in infectious disease control, 4) health promotion, 5) disaster and health, 6) human resources for health worldwide, and 7) maternal and child health.

Our research has been conducted in various countries, including Nepal, Myanmar, Thailand, Viet Nam, Lao PDR, Cambodia, Indonesia, Ghana, Uganda, Malawi, and Zambia.

Publications

1. Do AD, Pham TTP, Nguyen CQ, Hoang DV, Fukunaga A, Stickley A, Yazawa A, Phan DC, Hachiya M, Jimba M, Huynh DV, Le HX, Do HT, Mizoue T, Inoue Y. Individual-level social capital is associated with depressive symptoms among middle-aged community dwellers in rural Vietnam: a cross-sectional study. *BMJ Open*. 2022 Dec 6;12(12):e064998.
2. Fujii D, Fujimura MS, Ong KIC, Jimba M. Cutting the Chain of Discrimination during COVID-19 Pandemic by Health Literacy. *JMA J*. 2022 Oct 17;5(4):535-538.
3. Nishikawa M, Yamanaka M, Shibamura A, Kiriya J, Jimba M. Cross-Cultural Information for Japanese Nurses at an International Hospital: A Controlled Before-After Intervention Study. *Int J Environ Res Public Health*. 2022 Oct 7; 19(19):12829.
4. Sarhan MBA, Fujiya R, Shibamura A, Giacaman R, Kiriya J, Kitamura A, Jimba M. Health literacy as a key to improving weight status among Palestinian adolescents living in chronic conflict conditions: a cross-sectional study. *BMJ Open*. 2022 Sep 16;12(9):e061169.
5. Kunieda MK, Manzo ML, Subramanian SV, Jimba M. Individual- and Neighborhood-Level Factors of Measles Vaccination Coverage in Niamey, Niger: A Multilevel Analysis. *Vaccines (Basel)*. 2022 Sep 10;10(9):1513.
6. Koto-Shimada K, Fujita N, Matsuoka S, Jimba M, Touch S, Zwi AB. Medium-term outcomes of a program to upgrade the nursing faculty in Cambodia: A qualitative study. *Nurse Educ Today*. 2022 Sep;116:105438.
7. Hartwig L, Namukose V, Kiriya J, Onyancha C, Shibamura A, Jimba M. The effectiveness of a behavioral science and design intervention for family savings on use of maternal health services and male involvement: study protocol for a randomized controlled trial. *BMC Public Health*. 2022 Aug 19;22(1):1579.
8. Fujimura MS, Conkle J, Van Wyk M, Jimba M. Nutritional status of children under 5 years old in Namibia: adjusting for poor quality child anthropometry. *J Nutr Sci*. 2022 Aug 15;11:e66.

9. Ith S, Yi S, Tuot S, Yem S, Chhoun P, Jimba M, Shibanuma A. Gender-based violence and depressive symptoms among female entertainment workers in Cambodia: A cross-sectional study. *PLOS Glob Public Health*. 2022 Aug 3; 2(8):e0000873.
10. Shinejil U, Kiriya J, Shibanuma A, Miller R, Avirmed D, Jimba M. Association between Robson classification groups and cesarean delivery: a longitudinal analysis in Mongolia. *AJOG Glob Rep*. 2022 Jul 17;2(3):100071.
11. Carandang RR, Sakamoto JL, Kunieda MK, Shibanuma A, Yarotskaya E, Basargina M, Jimba M. Effects of the maternal and child health handbook and other home-based records on mothers' non-health outcomes: a systematic review. *BMJ Open*. 2022 Jun 21;12(6):e058155.
12. Nanishi K, Okawa S, Hongo H, Shibanuma A, Abe SK, Tabuchi T. Influence of the COVID-19 pandemic on breastfeeding support for healthy mothers and the association between compliance with WHO recommendations for breastfeeding support and exclusive breastfeeding in Japan. *PeerJ*. 2022 May 19;10:e13347.
13. Choi S, Kiriya J, Shibanuma A, Jimba M. Mediating role of social capital in the association between socioeconomic status and childcare practices in rural Malawi: a cross-sectional study. *BMJ Open*. 2022 May 9;12(5):e054134.
14. Osawa E, Okuda H, Koto-Shimada K, Shibanuma A, Saito T. The Environment Encouraging COVID-19 Response at Public Health Centers and Future Challenges in Japan. *Int J Environ Res Public Health*. 2022 Mar 11;19(6):3343.
15. Arita K, Shibanuma A, Carandang RR, Jimba M. Competence in Daily Activities and Mental Well-Being among Technical Intern Trainees in Japan: A Cross-Sectional Study. *Int J Environ Res Public Health*. 2022 Mar 8;19(6):3189.
16. Sakamoto JL, Carandang RR, Kharel M, Shibanuma A, Yarotskaya E, Basargina M, Jimba M. Effects of mHealth on the psychosocial health of pregnant women and mothers: a systematic review. *BMJ Open*. 2022 Feb 15;12(2):e056807.
17. Jimba M, Suzuki M, Kitamura T, Carandang RR, Sieber NL. Risk of Increasing the Sudden Diagnosis of AIDS in Japan during and after the COVID-19 Outbreak. *JMA J*. 2022 Jan 17;5(1): 104-106. doi: 10.31662/jmaj.2021-0174. Epub 2021 Dec 24.
18. Junaedi A, Ong KIC, Rachmatullah F, Shibanuma A, Kiriya J, Jimba M. Factors influencing physical distancing compliance among young adults during COVID-19 pandemic in Indonesia: A photovoice mixed methods study. *PLOS Glob Public Health*. 2022 Jan 13;2(1):e0000035.
19. Miller R, Arita K, Igarashi NH, Fujii D, Yumino A, Jimba M. Social support as a bridge: A rapid realist review of migrant inclusion in the Japanese response to the COVID-19 pandemic. *J Migr Health*. 2022;6:100135.
20. Takeuchi H, Takanashi S, Hasan SMT, Hore SK, Yeasmin S, Ahmad SM, Alam MJ, Jimba M, Khan MA, Iwata T. Anti-Ascaris IgE as a Risk Factor for Asthma Symptoms among 5-Year-Old Children in Rural Bangladesh with Even Decreased Ascaris Infection Prevalence. *Int Arch Allergy Immunol*. 2022;183(6):662-672.
21. Kharel M, Sakamoto JL, Carandang RR, Ulambayar S, Shibanuma A, Yarotskaya E, Basargina M, Jimba M. Impact of COVID-19 pandemic lockdown on movement behaviours of children and adolescents: a systematic review. *BMJ Glob Health*. 2022 Jan;7(1):e007190.

International Health

2. International Biomedical Sciences

Department of Human Genetics

Professor

Akihiro Fujimoto, Ph.D.

Associate Professor

Motoko Unoki, PhD.

Homepage <http://www.humgenet.m.u-tokyo.ac.jp/index.en.html>

Introduction and Organization

The Department of Human Genetics was established in 1992. Currently, the department has 1 professor, 5 graduate student, and 1 undergraduate students. We also accept a few graduate students from other Universities for their PhD studies.

Teaching activities

For students at the Graduate School of International Health, courses that cover basic principles as well as the clinical application of human genetics are provided.

As to undergraduate students, a series of lectures is given to each of the sophomore (Human Genetics I, compulsory) and junior (Human Genetics II, elective) classes at the School of Health Sciences. A series of lectures is also provided to the first year (M0) students at the School of Medicine (compulsory).

Research activities

Human Genetics is a field focusing on the diversity of the human genome, and can include studies into the molecular mechanisms of genetics, evolutionary history of homo sapiens, cancer genome, as well as susceptibility genes for common and rare diseases. The findings of such genetic studies have proven useful in many applications, from supporting clinical diagnosis of diseases to drug development and therapy. Recent advancements in genomic analyses have allowed us to obtain enormous amounts of genetic and transcriptomic data. Such data will continue to grow in size and utilization in society, reflecting the

increasing importance of the field of human genetics.

Our department dives headlong into analyses of genomic, transcriptomic and epigenomic data to evaluate diversity in the human genome, as well as identifying variants and elucidating their functional importance and potential therapeutic applications. Our approach is holistic, focusing not only on data analysis, but also on practical experiments to reach our goal of uncovering new knowledge.

References

1. Yagasaki K, et al. Practical forensic use of kinship determination using high-density SNP profiling based on a microarray platform, focusing on low-quantity DNA. **Forensic Sci Int Genet.** 2022 Nov;61:102752
2. Kiyose H, et al. Comprehensive analysis of full-length transcripts reveals novel splicing abnormalities and oncogenic transcripts in liver cancer. **PLoS Genet.** 2022 Aug 4; 18(8): e1010342
3. Sano Y, et al. Likely pathogenic structural variants in genetically unsolved patients with retinitis pigmentosa revealed by long-read sequencing. **J Med Genet.** 2022 Nov;59(11): 1133-1138
4. Unoki M, Sasaki H: The UHRF protein family in epigenetics, development, and carcinogenesis (Review). **Proceedings of the Japanese Academy, Ser. B, Physical and Biological Science** 98(8): 401-415, 2022

Department of Developmental Medical Sciences

Professor

Meng Ling Moi, Ph.D.

Assistant Professor

Misao Himeno, Ph.D.

Ryuji Majima, Ph.D.

Homepage <http://www.sih.m.u-tokyo.ac.jp/departments-en/>

Introduction and Organization

The Department of Maternal and Child Health was founded in 1966 as the first department that is dedicated to maternal and child health in Japan. With the subsequent expansion of research activities and the foundation of the Graduate School of Medicine, the department was renamed in 1998 as the Department of Developmental Medical Sciences. Of date, the department has been involved in basic science research and studies for the advancement of the physical and mental health of mothers and children. Basic science research includes those on the infection, immunity and metabolism, nervous and endocrine systems, whereas the epidemiologic studies deal with development, mother-to-child relationship, vaccination and health promotion. In 2021, under the new head of department and new staff members, the department has entered a new era, with emphasis than on pathogenesis, prevention and treatment of viral infections, child development specific conditions (congenital and acquired), from the standpoints of international health science, virology, immunology and neuroscience, with research and education goals for the development of measures that contributes to the improvement of maternal-child health and public health.

At present, our department consists of one professor, two assistant professors, two technical specialists, one secretary, eighteen invited lecturers, ten visiting researchers, and ten graduate students (including six overseas student), one undergraduate student and four

research students.

Our department offers courses to both undergraduate and postgraduate students, have weekly departmental meetings and individual research groups, communicate with collaborators inside or outside the University of Tokyo, and have seminars and meetings with researchers invited from abroad.

Currently, we are collaborating with academia and private research institutions from the Asia-Pacific regions, including China, Thailand, Viet Nam, Malaysia, Myanmar, Indonesia, Bangladesh, Sri Lanka and Australia, and the United States in research for the advancement of global maternal and children health. Our department are actively involved in the education and research with early and mid-career professionals, with aims of contributing to the upbringing of global leaders with competencies and skills to contribute to the fields of medical research and public health.

Teaching activities

1. Undergraduate course, Faculty of Medicine, School of Integrated Health Sciences
 - 1) Infectious diseases
 - 2) Immunity and defense mechanism
 - 3) Human growth and development
 - 4) Topics in life and environmental sciences
 - 5) Maternal and child health
 - 6) School health
 - 7) International health

- 8) Experiments in life sciences
- 9) Exercises in life sciences
- 10) Introduction to general health science

2. Graduate course, the Graduate School of Medicine, School of International Health

In addition to lectures and laboratory courses by our own staff, special lectures are given by experts both inside and outside the University.

Research activities

- (1) Mosquito-borne virus cohort studies in Vietnam, Thailand, Malaysia, the Philippines, Indonesia and Myanmar, our department conducts and research on viral and host-immunological factors that affects outbreaks.
- (2) Investigates the immunology and pathogenesis of flaviviral infections by developing biological relevant in-vitro and in-vivo models. In collaboration with academic and industrial counterparts, our department also conducts studies on the development of diagnostics, vaccines and therapeutics for emerging and re-emerging infectious diseases including dengue, Zika, Chikungunya, Japanese encephalitis viruses.
- (3) Determination of the mechanisms of cross-reactive immunity during dengue, Zika, Japanese encephalitis and flavivirus secondary infection, with aims to determine the mechanisms behind pre-existing immunity in protection or pathogenesis and influences viral evolution during infection. This knowledge is critical for developing and deploying flavivirus vaccines and anti-viral therapeutics in an increasingly flavivirus-experienced world.
- (4) Clinical, genetic and pathologic studies of acute encephalopathy: Acute necrotizing encephalopathy, acute encephalopathy with biphasic seizures and late reduced diffusion, acute encephalitis with refractory, repetitive partial seizures, and clinically mild encephalitis/encephalopathy with a reversible splenic lesion.
- (5) Pharmacological studies on the pathogenesis and treatment of developmental disorders, such as autism spectrum disorder and attention deficit/hyperactivity disorder, using genetically engineered animals.
- (6) Molecular pathologic and translational studies on childhood intractable epilepsy and developmental disorders, such as CDKL5 deficiency disorder, using genetically engineered animals.
- (7) Studies on the nutrition, immunity, brain and epigenetics of human fetuses and neonates.
- (8) International studies on the maternal and child health.
- (9) Studies on the virulence, drug resistance and vaccines of herpesviruses and poxviruses.
- (10) Molecular epidemiology of pediatric viral infections, in particular gastrointestinal diseases (rotavirus, norovirus, sapovirus and bocavirus), respiratory infections (influenza, RS virus and rhinovirus), exanthematous diseases (rubella) and HIV infection.

References

1. Mao ZQ, Minakawa N, Moi ML. Novel Antiviral Efficacy of *Hedyotis diffusa* and *Artemisia capillaris* Extracts against Dengue Virus, Japanese Encephalitis Virus, and Zika Virus Infection and Immunoregulatory Cytokine Signatures. *Plants* (Basel). 2022 Sep 30;11(19):2589. doi: 10.3390/plants11192589.
2. Himeno M, Chen SW, Kido T. Co-culture Model for Hepatitis B Virus Infection Using iPSC-Derived Liver Progenitor Cells and Liver Sinusoidal Endothelial Cells. *Methods Mol Biol*. 2022; 2544:107-117.
3. Nwe KM, Ngwe Tun MM, Myat TW, Sheng Ng CF, Htun MM, Lin H, et al. Acute-phase Serum Cytokine Levels and Correlation with Clinical Outcomes in Children and Adults with Primary and Secondary Dengue Virus Infection in Myanmar between 2017 and 2019. *Pathogens*, 2022; 10.3390/pathogens11050558
4. Takemura T, Nguyen CT, Pham HC, Nguyen TT, Hoang VMP, Nguyen LKH, et al. The 2017 Dengue virus 1 outbreak in northern Vietnam was caused by a locally circulating virus group. *Trop Med Health*, 2022; 10.1186/s41182-021-00386-0
5. Sasaki T, Moi ML, Saito K, Isawa H, Takasaki T, Sawabe K. *Aedes albopictus* Strain and Dengue Virus Serotype in the Dengue Fever Outbreaks in

- Japan: Implications of Wolbachia Infection. *Jpn J Infect Dis*, 2022 ; 10.7883/yoken.JJID.2021.376
6. Satoh K, Takahashi K, Noguchi K, Kobayashi Y, Majima R, Iwase Y, et al. Characterization of the Second Apoptosis Inhibitor Encoded by Guinea Pig Cytomegalovirus. *J Virol*. 2022 Dec 21; 96(24):e0162222.
 7. He T, Edwards TC, Majima R, Jung E, Kankanala J, Xie J et al. Repurposing N-hydroxy thienopyrimidine-2,4-diones (HtPD) as inhibitors of human cytomegalovirus pUL89 endonuclease: Synthesis and biological characterization. *Bioorg Chem*. 2022 Dec;129:106198.
 7. Takahashi S, Takeguchi R, Tanaka R, Fukuoka M, Koike T, Ohtani H, et al. CDKL5 deficiency causes epileptic seizures independent of cellular mosaicism. *J Neurol Sci*. 2022 Dec 15;443: 120498.
 8. Moi ML. [Dengue amidst COVID-19: challenges & control measures for the double burden]. *Uirusu*, 2021; 10.2222/jsv.71.1
 9. Kouji Y, Himeno M, Mori Y, Nakano Y, Saijou E, Tanimizu N et al. Development of human iPSC-derived quiescent hepatic stellate cell-like cells for drug discovery and in vitro disease modeling. *Stem Cell Reports*. 2021 Dec 14;16(12):3050-3063.
 10. Shibata A, Kasai M, Hoshino A, Mizuguchi M. Association of IL-1B rs16944 Polymorphism With Acute Encephalopathy With Biphasic Seizures and Late Reduced Diffusion Is Opposite to That of Febrile Seizures. *Front Neurol*. 2022 May 30;13:891721.
 11. Shibamura M, Yamada S, Yoshikawa T, Inagaki T, Nguyen PHA, Fujii H, et al. Longitudinal Trends of Prevalence of Neutralizing Antibody against Human Cytomegalovirus over the Past 30 Years in Japanese Women. *Jpn J Infect Dis*. 2022 Sep 22; 75(5):496-503.
 12. Kasai M, Omae Y, Khor SS, Shibata A, Hoshino A, Mizuguchi M et al. Protective association of HLA-DPB1*04:01:01 with acute encephalopathy with biphasic seizures and late reduced diffusion identified by HLA imputation. *Genes Immun*. 2022 Jun;23(3-4):123-128.
 13. Kasai M, Omae Y, Kawai Y, Shibata A, Hoshino A, Mizuguchi M, et al. GWAS identifies candidate susceptibility loci and microRNA biomarkers for acute encephalopathy with biphasic seizures and late reduced diffusion. *Sci Rep*. 2022 Jan 25; 12(1):1332.
 14. Nguyen PHA, Yamada S, Harada S, Fukushi S, Mizuguchi M, Saijo M. Virulence of Herpes Simplex Virus 1 Harboring a UAG Stop Codon between the First and Second Initiation Codon in the Thymidine Kinase Gene. *Jpn J Infect Dis*. 2022 Jul 22;75(4):368-373.

Department of Human Ecology

Professor

Masahiro UMEZAKI, Ph.D.

Associate Professor

Shoko KONISHI, Ph.D.

Research Associates

Lena TAKAYASU, Ph.D.

Yuki MIZUNO, Ph.D.

Homepage: <http://www.humeco.m.u-tokyo.ac.jp/en/>

Introduction and Organization

The Department of Human Ecology was founded when Kenji Uraguchi was appointed Professor of the Human Ecology Department on April 1, 1965. Following Professor Uraguchi's retirement on March 31, 1966, Professor Haruo Katsunuma (also appointed Professor of the Public Health Department, School of Medicine) became a joint Professor of the Human Ecology Department. Tsuguyoshi Suzuki was appointed as an Associate Professor and worked in the Department until August 31, 1971, when he was transferred to the Faculty of Medicine, Tohoku University, as a Professor. After Professor Katsunuma left the Department on March 31, 1972, Professor Akira Koizumi became the head of the Human Ecology Department on April 1, 1972. Professor Koizumi was transferred to the Public Health Program, School of Medicine, on March 31, 1976, and Associate Professor Shosuke Suzuki served as a department head from April 1, 1976, to April 15, 1979.

Tsuguyoshi Suzuki was appointed Professor of the Human Ecology Program on April 16, 1979. He founded the theoretical framework of the current human ecology curriculum, which is based on studying the mechanisms by which humans adapt to the environment. After Associate Professor Shosuke Suzuki was transferred to the Faculty of Medicine, Gunma University, as Professor on July 31, 1981, Ryutaro Ohtsuka was appointed Associate Professor on September 1, 1981. Associate

Professor Ohtsuka established a methodology for collecting quantitative information on demography, nutrition, and subsistence, targeting small-scale populations based on extensive fieldwork, the methodology of which continues to be utilized by current department members. Following the retirement of Professor Tsuguyoshi Suzuki on March 31, 1992, Ryutaro Ohtsuka was appointed professor on April 1, 1992.

Chiho Watanabe was appointed as an Associate Professor in December 1997. He expanded methodologies that examine relations between the environment and health by utilizing various tools, such as measuring biomarkers in biological specimens collected in the field and animal experiments. Professor Ohtsuka retired on March 31, 2005, and Chiho Watanabe was appointed as a Professor on April 1, 2005. Masahiro Umezaki was appointed as an Associate Professor in August 2005. While relying on quantitative research based on fieldwork, he has also been exploring new research topics, including the application of spatial information sciences on health sciences, the roles of gut microbiota in human nutrition, mitigation/alleviation strategies of depopulation and aging in human populations, and medical anthropology. Professor Chiho Watanabe was transferred from the University of Tokyo to the National Institute of Environmental Studies on April 1, 2017. Masahiro Umezaki was appointed Professor as of January 1, 2018. Shoko Konishi was appointed Associate Professor as of June 1, 2018. Dr. Konishi has been studying the

associations between fecundity, fertility, and environmental factors from the perspectives of population studies, environmental sciences, anthropology, and sociology.

In the fiscal year 2022, the Department had four faculty members: Professor Umezaki and Drs. Konishi, Takayasu, and Mizuno. The Department also had 14 visiting lecturers for both graduate or undergraduate courses. Professor Umezaki held additional roles in the Earth Observation Data Integration and Fusion Research Initiative (EDITORIA) at the University of Tokyo. Professor Umezaki and Dr. Konishi joined the UTokyo Center for Climate Solutions (UTCCS).

Teaching activities

This Department is one of six in the School of International Health. Human Ecology Special Lecture I focuses on the basic components of human ecology, such as demography, nutrition, and environment, and introduces the notion of human ecosystems and low fertility in Japan. Human Ecology Special Lecture II emphasizes recent topics and ongoing research in human ecology and related areas. With these graduate student classes, we attempt to describe human ecology as a basic component of international health and providing current issues and the approaches used in this field. The graduate course lectures are provided in English.

The Department oversees a part of the School of Integrated Health Sciences, providing undergraduate course lectures on human ecology, environment and health, demography, international health, and medical anthropology. We are also responsible for organizing pharmacology, toxicology, physiology, and environmental and human engineering. We focus on introducing global-scale issues, such as population explosion, food security, and environmental issues, regarding problems faced by the Asia-Pacific region (including Japan). We also explore the relationship between human activities and environmental chemical contamination.

Research activities

Human ecology investigates the human population in the context of their respective ecologies and the global context. Mostly, our research tackles tasks in the field of human environmental health and/or population ecology, but with a more comprehensive and broader context.

Therefore, we must adopt different approaches, including fieldwork, experimentation, and geographic information system (GIS)/global positioning system (GPS) analyses. Our study fields include Asian-Oceanian (including Japan) rural and urban communities, focusing on population, nutrition, growth, the environment, and sustainability. Experimental studies have been conducted on the effects of perinatal exposure to heavy metals, emphasizing the factors that modify these effects. Almost all our studies require a transdisciplinary approach. We collaborate with various local and international research institutes. The following is a list of the major activities conducted in the past year:

1. Adaptation to low-protein diet

The inconsistency between the protein-deficient diets of Papua New Guinea highlanders and their muscular physique is well known. Moreover, although their protein intake is less than biologically adequate, disorders related to protein deficiency have rarely been reported. We speculate that the population has adapted to a low-protein diet by utilizing air nitrogen fixed by intestinal bacteria and/or by intensive “recycling” of the urea that passes into the gastrointestinal tract. Recent advances in sequencing techniques have enabled us to examine the adaptation of this population to a low-protein diet in a more direct way. We evaluated the gut microbiota of healthy individuals in four Papua New Guinea communities with varying degrees of protein deficiency. The association between the gut microbiota and variations in protein intake and nutritional biomarkers was investigated. Shotgun metagenomic analysis further demonstrated that some genes related to nitrogen fixation and urease were enriched in Papua New Guinea communities compared with other countries. Gnotobiotic animal experiments have revealed different nutritional responses to a low-protein diet depending on the type of gut microbiota transplanted.

2. Adaptive strategy to aging and depopulation

Japan is experiencing post-demographic transition (i.e., low fertility, aging, and population decrease). Targeting Japanese rural communities, the frontrunners of this global issue, we conducted population projections and studies on their food habits, nutritional intake, and subjective perceptions of health. We also

conducted a study to identify mitigation and alleviation strategies for aging and depopulation that have been formulated in local communities.

A case study in Nagasaki city, focusing on the residential zones on a steep slope and residents' aging, suggested that older people lived on steep slopes and without direct roadway access.

3. Nutrition and eating behaviors

Follow-up surveys have been conducted in a village in West Java, Indonesia. In the survey in 2022, the impact of covid-19 epidemics on the survival strategies of the villagers was investigated.

We also performed animal experiments to elucidate the determinants of eating behavior. Our experiment revealed that mice preferred a high-fat diet to a high-carbohydrate diet after the consumption of soluble fiber for a certain period.

4. Interdisciplinary Investigation on the Technology, the Environment, and Fertility (IITEF)

Japan has the highest number of assisted reproductive technologies in the world. Our ongoing project is to test the hypothesis that exposure to technology and environmental chemicals is linked to increased infertility in the country. A total of 198 male participants were recruited from two hospitals in Tokyo and Tsukuba in 2020 and 2021. We ran preliminary measurement of urinary isoflavone and paraben concentrations.

Additionally, the IITEF project administered a large-scale online questionnaire survey targeting 8,000 men living across Japan. The participants were males aged 20 to 54 years who responded to questions on socioeconomic status and sexual behavior. The findings have been published as a scientific paper.

5. Iodine intake, thyroid function, and reproductive health

We utilized menstrual cycle data and biological specimens (urine and serum) to analyze the associations between iodine intake, thyroid function, and menstrual cycle characteristics. As a biomarker of iodine intake, we measured iodine concentration in urine using inductively coupled plasma mass spectrometry (ICP-MS). Serum levels of thyroid stimulating hormone, thyroxine, triiodothyronine, anti-

thyroglobulin antibody, and anti-TPO antibody were quantified at a clinical laboratory center. Menstrual cycle characteristics were obtained from self-recorded diary of menstrual bleeding for five consecutive months and self-reported questionnaires. The results suggest that even within clinical normal range thyroid-related biomarkers are associated with menstrual cycle variation.

5. Health transition in Lao People's Democratic Republic

The diet in northern Laos has been characterized by consumption of large amounts of rice with dishes made of wild plants. Wild plants with bitter taste and astringency, which are supposed to contain more phytochemicals, are preferred over domesticated vegetables. Phytochemicals are suspected to play a role in nutritional adaptation of local people through their interactions with intestinal bacteria. As people have gradually been involved in the market economy, their diet has changed toward more consumption of animal meat and oil, and less consumption of wild plants and consequently phytochemicals. Our research project investigated the potential health impacts of such dietary changes in Oudomxay Province, northern Laos. The questionnaire survey and biological sample collection were conducted in three communities with different degrees of integration into the market economy. By evaluating oxidative stress, chronic inflammation, and gut microbiota composition in the three communities, we sought to clarify a biological link between dietary transition and recent emergence of noncommunicable diseases in rural Laos. To examine phytochemical intake from wild plants, we have conducted quantitative dietary surveys, as well as identified species of wild edible plants and assessed their phytochemicals.

6. Potential fetal microbiome transfer from intrauterine exposure

Mounting evidence shows that bacteria in fertilization products (analyzed using DNA-based technologies) challenges the sterile womb hypothesis. We conducted cultivation-based and 16S rRNA sequence analyses using a mouse model of mid- and late gestation, which suggested the presence of bacteria in fetal, placental, and uterine tissues. This low-

abundance fetal microbiome appears to be volatile and transient in nature, contrasting the relatively stable bacterial composition that matures during infancy. The similarity between the bacterial compositions of maternal and fetal tissues suggests vertical transmission, which has also been previously described in other animals and germ-free animal models. The existence of this fetal microbiome is hypothesized to be associated with immunocompetence in mothers and the development of immunity in fetuses. We have published a review article on fetal microbiomes.

7. Mouse gut microbiome transitions

The gut microbiome and aging have been discussed based on the average flora of people of different ages. Few studies have been conducted on the microbiome of the same individual over a long period of time. We conducted experiments on mice from shortly after birth to just before death to determine the changes in the gut microbiome related to pregnancy and lifespan. There are certain phylogenetic trends in bacteria that persist in the gut for long periods, and these persistent microbes are thought to relate strongly to host homeostasis.

8. Determinants of chronic inflammation in rural population in Japan

Chronic inflammation is linked to various noncommunicable diseases and controlling it can improve health among older people. Various factors (e.g., age, diet, chemical exposure, etc.) have been reported as associated with chronic inflammation, but a complete picture of the determinants of chronic inflammation has not yet been clarified. We conducted a study to assess chronic inflammation and investigate its determinants among residents in rural areas in Japan (Ojika city, Nagasaki; Suzu city, Ishikawa), where the population aging rate is high. Nutrient intake was assessed using a food frequency questionnaire, and several biomarkers were measured to assess chronic inflammation and trace element exposure.

theory regarding the foetal microbiome. *Crit Review Microbiol*, 2022;48(5), 611–623.

2. Furuhashi, H., Takayasu, L., Isshi, K., Hara, Y., Ono, S., Kato, M., ... & Suda, W. Effect of storage temperature and flash-freezing on salivary microbiota profiles based on 16S rRNA — targeted sequencing. *European Journal of Oral Sciences*, 2022;130(2), e12852.
3. Kibe, M., Tomita, S., & Umezaki, M. Divergence in nutritional intake and physical activity patterns among households in a village of ethnic minorities in northern Laos at the initial stage of health transition. *Hum Ecol*, 2022;50(2), 287–305.
4. Konishi, S., & Mizuno, Y. Pre-Conceptional Anti-Thyroid Antibodies and Thyroid Function in Association with Natural Conception Rates. *IJERPH*, 2022;19(20), 13177.
5. Konishi, S., Moriki, Y., Kariya, F., & Akagawa, M. Casual sex and sexlessness in Japan: a cross-sectional study. *Sexes*, 2022;3(2), 254–266.
6. Konishi, S., Umezaki, M., & Suzuki, S. Perceived health, fertility, and social network of middle-aged and older women in Japan. *Jpn J Health Hum Ecology*, 2022;88(1), 15–22.
7. Kosaka, S., Nakao, R., Goto, C., Umezaki, M., & Ohnishi, M. Food store accessibility affects nutritional intake through shopping frequency and food intake in middle-aged to older adults in rural Nagasaki, Japan. *Am J Hum Biol*, 2022;34(6), e23725.
8. Masuda, M., Natsuhara, K., Sueyoshi, S., Odani, S., Yagyu, F., Tadokoro, K., ... & Umezaki, M. Association between the dietary inflammatory index and disability in Japanese older people. *Public Health Nutr*, 2022;25(11), 3137–3145.
9. Mizuno, Y., Masuoka, H., Kibe, M., Kosaka, S., Natsuhara, K., Hirayama, K., ... & Umezaki, M. Impact of modernization on urinary concentrations of arsenic, cadmium, lead, and selenium in rural residents of Northern Laos. *Am J Hum Biol*, 2022;34(4), e23685.

References

1. Cariño III, R., Takayasu, L., Suda, W., Masuoka, H., Hirayama, K., Konishi, S., & Umezaki, M. The search for aliens within us: a review of evidence and

Department of Biomedical Chemistry

Professor

Tomoyoshi Nozaki, Ph.D., MD

Associate Professor

Yoh-ichi Watanabe, Ph.D.

Assistant Professor

Jeelani Ghulam, Ph.D., Santos Herbert Jimenez, Ph.D.

※The following information is the same as that of the previous year for certain reasons.

Homepage <http://www.biomedchem.m.u-tokyo.ac.jp/>

Introduction and Organization

Aim of our department is to contribute to global health and welfare from basic research. Our department, formerly named Biochemistry and Nutrition was renamed on April 1st, 1996 to The Department of Biomedical Chemistry as newly affiliating with Biomedical Science Division of International Health, Graduate School of Medicine, The University of Tokyo. Former Prof. Kiyoshi Kita (Professor Emeritus) has been retired in March 2016, and Dr. Tomoyoshi Nozaki, National Institute of Infectious Diseases, has been assigned as a new professor in October, 2016, and became a full-time processor in August, 2017.

Teaching activities

Teaching activities in our department cover a broad spectrum of biochemistry-oriented life sciences from premise to frontiers and in either conceptual or experimental point of view

Graduate Course: Biomedical Chemistry I, II

This course is comprised of lectures and seminars to provide basic concepts and newer vistas for understanding biomedical chemistry with special reference

to biochemistry and molecular biology. These include the structure and function of biomolecules, metabolism, its regulation, and underlying mechanism at either molecular, cellular and systemic level.

Undergraduate Course: Basic Life Science, Life Science and Genome Science I & II, Nutrition, Laboratory Practice for Life Science I & II, Seminar in Environmental and Human Life Sciences, Microbiology II (Parasitology).

Research activities

Our major research interests include virulence mechanisms and metabolism of protozoa, particularly *Plasmodium* spp. causing malaria and *Entamoeba histolytica* causing amebic dysentery. We mainly focus on vesicular trafficking, phagocytosis, autophagy, proteases, amino acid metabolisms, RNA maturation, translation, drug development, and organellogenesis. Our research approaches are very robust, and include biochemistry, molecular and cell biology, live imaging, multi-omics including metabolomics, and reverse genetics. Our present research themes include:

- Molecular elucidation of pathogenesis of parasites
- Biochemical and biological analyses of metabolism and organelles unique to parasites

- Analysis of vesicular traffic, protein secretion, and phagocytosis/trogocytosis in parasites
- Genome wide analysis and comparison of parasite strains
- Drug discovery and development against protozoan infections such as malaria and amebiasis
- Elucidation of divergence of RNA maturation and translation

References

1. Iwasaki, A., Ohtomo, K., Kurisawa, N., Shiota, I., Rahmawati, Y., Jeelani, G., Nozaki, T., Suenaga, K. Isolation, structure determination and total synthesis of Hoshinoamide C, an anti-parasitic lipopeptide from the marine cyanobacterium *Caldora penicillata*. *J Nat Prod.* 84:126-135, 2021. doi: 10.1021/acs.jnatprod.0c01209.
2. Pramisandi, A., Kurnia, K., Chrisnayanti, E., Bernawati, P., Dobashi, K., Mori, M., Mahsunah, A. H., Nonaka, K., Matsumoto, A., Kristiningrum, Hidayati, D. N., Dewi, D., Prabandari, E. E., Amalia, E., Nurkanto, A., Inaoka, D. K., Waluyo, D., Kita, K., Nozaki, T., Ōmura, S., Shiomi, K. Gentisyl alcohol and homogentisic acid: *Plasmodium falciparum* dihydroorotate dehydrogenase inhibitors isolated from fungi. *J. Gen. Appl. Microbiol.*, 67, 114-117, 2021. doi 10.2323/jgam.2020.08.004
3. Taku, I., Hirai, T., Makiuchi, T., Shinzawa, N., Iwanaga, S., Annoura, T., Nagamune, K., Nozaki, T., Saito-Nakano, Y. Rab5b-associated Arf1 GTPase regulates export of N-myristoylated adenylate kinase 2 from the endoplasmic reticulum in *Plasmodium falciparum*. *Front Cell Inf Microbiol* 10:610200, 2021. doi: 10.3389/fcimb.2020.610200..
4. Saito-Nakano, Y., Wahyuni, R., Nakada-Tsukui, K., Tomii, K., Mitra, B. N., Nozaki, T. Rab7D small GTPase is involved in phago-, trogocytosis and cytoskeletal reorganization in the enteric protozoan *Entamoeba histolytica*. *Cell. Microbiol.* 232, e13267, 2021. doi.org/10.1111/cmi.13267
5. Jeelani, G., Nozaki, T. Eukaryotic translation initiation factor 5A and its hypusination play an important role in proliferation and potentially in differentiation of the human enteric protozoan parasite *Entamoeba histolytica*. *PLoS Pathog.*, 17(2):e1008909, 2021. doi: 10.1371/journal.ppat.1008909.
6. Nurkanto, A., Jeelani, G., Santos, H. J., Mori, M., Annoura, T., Tozawa, Y., Shiomi, K., Nozaki, T. Characterization of *Plasmodium falciparum* pantothenate kinase and identification of its inhibitors from microbial natural products. *Front Cell Inf Microbiol.* 11:639065, 2021. doi: 10.3389/fcimb.2021.639065
7. Watanabe, N., Nakada-Tsukui, K., and Nozaki, T. Diversity of phosphoinositide binding proteins in *Entamoeba histolytica*. *Parasitol Int (review)* 83: 102367, 2021. doi: 10.1016/j.parint.2021.102367.
8. Das, K., Watanabe, N., and Nozaki, T. Two StAR-related lipid transfer proteins play specific roles in endocytosis, exocytosis, and motility in the parasitic protist *Entamoeba histolytica*. *PLoS Pathog*, 17(4): e1009551, 2021. doi: 10.1371/journal.ppat.1009551.
9. Das, K., Sardar, S., Ghosal, A., Saito-Nakano, Y., Dutta, S., Nozaki, T., Ganguly, S. Multilocus sequence typing (MLST) of *Entamoeba histolytica* identifies a genetic marker associated with disease outcomes. *Parasitol Int* 83:102370, 2021. doi: 10.1016/j.parint.2021.102370..
10. Santos, H. J. and Nozaki, T. Interorganellar communication and membrane contact sites in protozoan parasites. *Parasitol Int (review)* 83: 102372, 2021. doi: 10.1016/j.parint.2021.102372
11. Hartuti, E. D., Sakura, T., Tagod, M. S. O., Yoshida, E., Wang, X., Mochizuki, K., Acharjee, R., Matsuo, Y., Tokumasu, T., Mori, M., Waluyo, D., Shiomi, K., Nozaki, T., Hamano, S., Shiba, T., Kita, K., Inaoka, D., K. Identification of 3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives as novel selective inhibitors of *Plasmodium falciparum* dihydro-orotate dehydrogenase. *Int J Mol Sci* 22:7236, 2021. doi: 10.3390/ijms22137236.
12. Takahashi, H., Iwasaki, A., Kurisawa, N., Suzuki, R., Jeelani, G., Matsubara, T., Sato, T., Nozaki, T., Suenaga, K. Motobamide, an antitrypanosomal cyclic peptide from the marine cyanobacterium *Leptolyngbya* sp. *J Nat Prod.* 84:1649-1655, 2021. doi: 10.1021/acs.jnatprod.1c00234.

13. Kurisawa, N., Otomo, K., Iwasaki, A., Jeelani, G., Nozaki, T., and Suenaga, K. Isolation and total synthesis of Kinenzoline, an antitrypanosomal linear depsipeptide isolated from a marine *Salileptolyngbya* sp. cyanobacterium. *J Org Chem*, 86(18):12528-12536, 2021. doi: 10.1021/acs.joc.1c00817.
14. Acharjee, R. Talaam, K. K., Hartuti, E. D., Matsuo, Y., Sakura, T., Gloria, B. M., Hidano, S., Kido, Y., Mori, M., Shiomi, K., Sekijima, M., Nozaki, T., Umeda, K., Nishikawa, Y., Hamano, S., Kita, K., Inaoka, D. K. Biochemical studies of mitochondrial malate:quinone oxidoreductase from *Toxoplasma gondii*. *Int J Mol Sci*. 22(15): 7830, 2021. doi: 10.3390/ijms22157830
15. Waluyo D, Prabandari EE, Pramisandi A, Hidayati DN, Chrisnayanti E, Puspitasari DJ, Dewi D, Suryani, Kristiningrum, Oktaviani AN, Afrianti KR, Nonaka K, Matsumoto A, Tokiwa T, Adipratiwi N, Ariyani T, Hartuti ED, Putri TZ, Rahmawati Y, Inaoka DK, Miyazaki Y, Sakura T, Nurlaila N, Siska E, Kurnia K, Bernawati P, Melinda M, Mahsunah AH, Nugroho NB, Mori M, Dobashi K, Yamashita M, Nurkanto A, Watanabe A, Shiomi K, Wibowo AE, Nozaki T. Exploring natural microbial resources for the discovery of anti-malarial compounds. *Parasitol Int*. 85:102432. doi: 10.1016/j.parint.2021.102432.
16. Ebihara, A., Iwasaki, A., Miura, Y., Jeelani, G., Nozaki, T., Suenaga, K. Isolation and total synthesis of Bromoiesol sulfates, anti-trypanosomal arylethers from a *Salileptolyngbya* sp. marine cyanobacterium. *J. Org. Chem*. 86(17):11763-11770, 2021. doi: 10.1021/acs.joc.1c01214.
17. Iwasaki, A., Teranuma, K., Kurisawa, N., Rahmawati, Y., Jeelani, G., Nozaki, T., Gerwick, W., Suenaga, K. First total synthesis and structure activity relationship of Iheyamide A, an anti-trypanosomal linear peptide isolated from a *Dapis* sp. marine cyanobacterium. *J. Nat. Prod*. 84(9):2587-2593, 2021. doi: 10.1021/acs.jnatprod.1c00792.
18. Nakada-Tsukui, K. and Nozaki, T. Trogocytosis in unicellular eukaryotes. Special Issue: New phase of phagocytosis and a bite of trogocytosis. *Cells*. 10(11), 2975, 2021. doi.org/10.3390/cells10112975
19. Bharadwaj, R., Tushar, Ahmad, A., Inampudi, K., Nozaki, T.*, Somlata*. An atypical EhGEF regulates phagocytosis in *Entamoeba histolytica* through EhRho1. *PLoS Pathog* 17(11):e1010030. (*double correspondence) doi: 10.1371/journal.ppat.1010030.
20. Peng, R., Yoshinari, S., Kawano-Sugaya, T., Jeelani, G., Nozaki, T. tRNA splicing in the unicellular parasitic amoebozoan: identification and functional characterization of divergent 3'-phosphate tRNA ligase from *Entamoeba histolytica*. *Front Cell Inf Microbiol*, section Parasite and Host, 11:746261, 2021. doi: 10.3389/fcimb.2021.746261.

School of Public Health

1. Epidemiology and Health Sciences

Department of Social and Preventive Epidemiology

Professor

Satoshi Sasaki, M.D., Ph.D.

Associate

Kentaro Murakami, Ph.D.

Homepage <http://www.nutrep.m.u-tokyo.ac.jp/>

Introduction and Organization

The Department of Social and Preventive Epidemiology is a new department which was established at the same time of the establishment of the School of Public Health, the University of Tokyo (April 2007).

Epidemiology is a study of quantitatively assessing health status and disease development in populations and statistically analyzing the relationship of risk factors with the development of certain disease. In addition to traditional risk factors including alcohol drinking, smoking, nutrition, and physical activity, gene and factors controlling gene and socioeconomic factors are also important topics in epidemiologic research. Epidemiologic data are needed for conducting the assessment of certain treatment including medicine and estimating situation of disease development.

Epidemiology not only provides research methodology in the field of public health but also is considered a practical study for public health and thus a central field of health science. However, both education and research systems have long been insufficient in Japan. Social and preventive epidemiology is a study of epidemiologically clarifying the relationship between various phenomena in human society (including individual lifestyle) and certain disease.

The Department of Social and Preventive Epidemiology particularly focuses on nutrition, which is essential for individual and population health, as a main research topic and epidemiologically researches

various issues related to nutrition (nutritional epidemiology), playing a central role in this research field in Japan.

The Department currently consists of one professor and one associate.

Teaching activities

We have the following two lectures in the School of Public Health.

Epidemiological research and practice
Practice and assessment in public health

Both are strongly associated with practical tasks in public health field, aiming at giving students opportunities for acquiring abilities of conducting public health activities and tasks based on theory of epidemiology.

We have also several lectures for students in other schools.

Research activities

Our main topic is basic research for development and application of research methodology in the field of nutritional epidemiology. Based on this basic research, we also conduct a wide range of epidemiologic research for investigating the relationship of nutrition with health and disease. As a characteristic of this research field, we conduct many multi-center studies with various kinds of disease.

Another characteristic is collection of research findings (scientific papers) derived from epidemiologic research all over the world on the association of nutrition with health and disease, which is applied for health control through nutrition improvement and disease control.

References

1. Murakami K, Shinozaki N, Livingstone MBE, Fujiwara A, Asakura K, Masayasu S, Sasaki S. Characterisation of breakfast, lunch, dinner, and snacks in the Japanese context: an exploratory cross-sectional analysis. *Public Health Nutr* 2022; 25(3): 689-701.
2. Yoshii Y, Murakami K, Asakura K, Masayasu S, Sasaki S. A longer time spent at childcare is associated with lower diet quality among children aged 5-6 years, but not those aged 1.5-2 and 3-4 years: Dietary Observation and Nutrient intake for Good health Research in Japanese young children (DONGuRI) study. *Public Health Nutr* 2022; 25(3): 657-69.
3. Miyake Y, Tanaka K, Okubo H, Sasaki S, Tokinobu A, Arakawa M. Maternal metal intake during pregnancy and childhood behavioral problems in Japan: the Kyushu Okinawa Maternal and Child Health Study. *Nutr Neurosci* 2022; 25(8): 1641-9.
4. Murakami K, Livingstone B, Masayasu S, Sasaki S. Eating patterns in a nationwide sample of Japanese aged 1-79 years from MINNADE study: eating frequency, clock time for eating, time spent on eating and variability of eating patterns *Public Health Nutr* 2022; 25(6): 1515-27.
5. Omura Y, Murakami K, Matoba K, Nishimura R, Sasaki S. Effects of individualized dietary advice compared with conventional dietary advice for adults with type 2 diabetes: A randomized controlled trial. *Nutr Metab Cardiovasc Dis* 2022; 32(4): 1035-44.
6. Murakami K, Shinozaki N, Yuan X, Tajima R, Matsumoto M, Masayasu S, Sasaki S. Food Choice Values and Food Literacy in a Nationwide Sample of Japanese Adults: Associations with Sex, Age, and Body Mass Index. *Nutrients* 2022; 14(9): 1899.
7. Sugimoto M, Murakami K, Sasaki S. Temporal patterns of sleep and eating among children during school closure in Japan due to COVID-19 pandemic: associations with lifestyle behaviours and dietary intake. *Public Health Nutr* 2022; : Online ahead of print.
8. Shinozaki N, Murakami M, Asakura K, Masayasu S, Sasaki S. Development of a Digital Photographic Food Atlas as a Portion Size Estimation Aid in Japan. *Nutrients* 2022; 14(11): 2218.
9. Fujiwara A, Murakami K, Suga H, Sasaki S, Three-Generation Study of Women on Diets and Health Study Group. Cross-Sectional Associations of Intakes of Starch and Sugars with Depressive Symptoms in Young and Middle-Aged Japanese Women: Three-Generation Study of Women on Diets and Health. *Nutrients* 2022; 14(12): 2400.
10. Sugimoto M, Temme EHM, Biesbroek S, Kanellopoulos A, Okubo H, Fujiwara S, Asakura K, Masayasu S, Sasaki S, Van't Veer P. Exploring culturally acceptable, nutritious, affordable, and low climatic impact diet for Japanese diets: Proof of concept of applying a new modelling approach using Data Envelopment Analysis. *British Journal of Nutrition* 2022; 128(12): 2438-52.
11. Miyake Y, Tanaka K, Okubo H, Sasaki S, Arakawa M. Tryptophan intake is related to a lower prevalence of depressive symptoms during pregnancy in Japan: baseline data from the Kyushu Okinawa Maternal and Child Health Study. *Eur J Nutr* 2022; 61(8): 4215-22.
12. Miyake Y, Tanaka K, Okubo H, Sasaki S, Arakawa M. Maternal calcium intake during pregnancy and childhood blood pressure: the Kyushu Okinawa Maternal and Child Health Study. *Ann Epidemiol* 2022; 73: 17-21.
13. Murakami K, Shinozaki N, Kimoto N, Masayasu S, Sasaki S. Relative Validity of Food Intake in Each Meal Type and Overall Food Intake Derived Using the Meal-Based Diet History Questionnaire against the 4-Day Weighed Dietary Record in Japanese Adults. *Nutrients* 2022; 14(15): 3193.
14. Sari DW, Noguchi-Watanabe M, Sasaki S, Yamamoto-Mitani N. Dietary Patterns of 479 Indonesian Adults and Their Associations with Sodium and Potassium Intakes Estimated by Two 24-h Urine Collections. *Nutrients* 2022; 14(14):

2905.

15. Fujiwara A, Omura Y, Oono F, Sugimoto M, Sasaki S, Takimoto H. A Scoping Review of Epidemiological Studies on Intake of Sugars in Geographically Dispersed Asian Countries: Comparison of Dietary Assessment Methodology. *Adv Nutr* 2022; 13(5): 1947-73.
16. Murakami K, Shinozaki N, Kimoto N, Masayasu S, Sasaki S. Relative Validity of the Meal-Based Diet History Questionnaire for Estimating Nutrient Intake among Japanese Women and Men aged 30-76 Years. *Nutrients* 2022; 14(20): 4270.
17. Higashi J, Asakura K, Mori S, Sasaki S, Nishiwaki Y. Guardianship dietary and other behavioural factors associated with skipping breakfast in Japanese primary school children: A child-guardian dyad study. *Asia Pac J Clin Nutr* 2022; 31(4): 701-12.
18. Nguyen MQ, Miyake Y, Tanaka K, Hasuo S, Takahashi K, Nakamura Y, Okubo H, Sasaki S, Arakawa M. Maternal Consumption of Dairy Products during Pregnancy Is Associated with Decreased Risk of Emotional Problems in 5-Year-Olds: The Kyushu Okinawa Maternal and Child Health Study. *Nutrients* 2022; 14(22): 4713.
19. Shinozaki N, Murakami K. Accuracy of estimates of serving size using digitally displayed food photographs among Japanese adults. *J Nutr Sci* 2022; 11(24): e105.

Department of Clinical Epidemiology and Health Economics

Professor

Hideo Yasunaga, MD, PhD.

Assistant Professor

Hiroki Matsui, MPH.

Homepage <http://www.heer.m.u-tokyo.ac.jp/>

Introduction and Organization

The Department of Clinical Epidemiology and Health Economics was established in April 2007, as a part of Master of Public Health (MPH) program under the new School of Public Health (SPH). The Department is also affiliated with the Division of Social Medicine for doctoral education.

The mission of the Department is two folds; to help health professionals obtain scientifically sound basis and skills for evidence-based practice, and to empirically evaluate the clinical practice, health care system/policy for further improvement of the quality of health care. For this purpose, the Department puts a unique emphasis on quantitative analytic methods and inter-disciplinary theories across clinical epidemiology, health service research, health economics and health policy.

Teaching activities

Under the MPH program, the Department is responsible for 6 courses, one on introduction to clinical medicine for non-MD students, two on clinical epidemiology, two on health economics, and one on healthcare organization management.

The lecture course on clinical epidemiology provides a quick review on elementary to intermediate levels of epidemiology such as research design, bias and error,

and causal inference.

Health economics course provides an intermediate level of micro-economics and health economics theories of consumer choice, insurance, and human capital, and enhances discussion to apply these theories to behaviors of providers and consumers. The 3-day intensive course offers students an opportunity for hands-on training of actual cost-effectiveness analysis of health care and technologies.

Research activities

Current activities in this Department cover a broad range of health services research, including clinical epidemiological studies, economic evaluation of health technology and health policy, quality of life research, and hospital administration and quality assurance.

The Department also contributes to clinical and health service research using a large claim database based on the Japanese original patient classification system, Diagnosis Procedure Combination (DPC). DPC database allows a unique and detailed analysis on the process of care in acute care hospitals in this country. DPC database also provides resource diagnosis in hospital levels as well as regional levels, when combined with other public data sources such as the Patient Survey, and Hospital Census.

References

1. Abe H, Sumitani M, Matsui H, Inoue R, Fushimi K, Uchida K, Yasunaga H. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: a nationwide retrospective cohort study in Japan. *Pharmacotherapy*. 2022;42(3):241-249.
2. Abe H, Sumitani M, Matsui H, Inoue R, Konishi M, Fushimi K, Uchida K, Yasunaga H. Gabapentinoid use is associated with reduced occurrence of hyperactive delirium in older cancer patients undergoing chemotherapy: a nationwide retrospective cohort study in Japan. *Anesthesia & Analgesia*. 2022;135(2):362-369.
3. Aso S, Matsui H, Fushimi K, Yasunaga H. Effect of Dobutamine on Patients with Septic Shock: A Retrospective Nationwide Study. *Annals of Clinical Epidemiology*. 2022;4(2):41-48.
4. Awano N, Jo T, Izumo T, Inomata M, Morita K, Matsui H, Fushimi K, Urushiyama H, Nagase T, Yasunaga H. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: A nationwide observational study. *Journal of Intensive Care*. 2022;10(1):14.
5. Chinen T, Sasabuchi Y, Matsui H, Yamaguchi H, Yasunaga H. Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: A retrospective cohort study. *BMC Cancer*. 2022;22(1):460.
6. Fujita A, Hashimoto Y, Matsui H, Yasunaga H, Aihara M. Recent trends in glaucoma surgery: a nationwide database study in Japan, 2011-2019. *Japanese Journal of Ophthalmology*. 2022;66(2):183-192.
7. Fujita A, Hashimoto Y, Okada A, Obata R, Aihara M, Matsui H, Yasunaga H. Association Between Proteinuria and Retinal Vein Occlusion in Individuals with Preserved Renal Function: A Retrospective Cohort Study. *Acta Ophthalmologica*. 2022;100(7):e1510-e1517.
8. Fukui R, Kaneko H, Okada A, Yano Y, Itoh H, Matsuoka S, Morita K, Kiriya H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Nishiyama A, Node K, Yokoo T, Nangaku M, Yasunaga H, Komuro I. Semiquantitative assessed proteinuria and risk of heart failure: Analysis of a nationwide epidemiological database. *Nephrology Dialysis Transplantation*. 2022;37(9):1691-1699.
9. Furuya H, Nakajima M, Ikeda K, Nakamura K, Ohbe H, Aso S, Kumazawa R, Iwamoto T, Iwata A, Furuta S, Matsui H, Fushimi K, Yasunaga H, Nakajima H. Prognosis and treatment of myositis-associated severe interstitial lung disease. *Arthritis Care & Research*. 2022;74(3):478-483.
10. Fuseda Y, Michihata N, Kumazawa R, Fushimi K, Yasunaga H. Annual Trend in Lumbar Puncture for Infants Younger Than 3 Months Hospitalized with Suspected Serious Bacterial Infection: A Nationwide Inpatient Database Study. *Pediatric Infectious Disease Journal*. 2022;41(8):631-635.
11. Hamada S, Nakajima M, Kaszynski RH, Otaka S, Goto H, Matui H, Fushimi K, Yamaguchi Y, Yasunaga H. Association between adjunct clindamycin and in-hospital mortality in patients with necrotizing soft tissue infection due to group A *Streptococcus*: A nationwide cohort study. *European Journal of Clinical Microbiology & Infectious Diseases*. 2022;41(2):263-270.
12. Hashimoto Y, Kaneko H, Okada A, Matsui H, Yasunaga H, Aihara M, Obata R. Association between retinal vein occlusion and Life's Simple 7 cardiovascular health metrics: A large claims database study. *Ophthalmology Retina*. 2022;6(8):684-692.
13. Hashimoto Y, Matsui H, Michihata N, Ishimaru M, Yasunaga H, Aihara M, Kaburaki T. Incidence of sympathetic ophthalmia after inciting events: a national database study in Japan. *Ophthalmology*. 2022;129(3):344-352.
14. Hashimoto Y, Michihata N, Yamana H, Shigemi D, Morita K, Matsui H, Yasunaga H, Aihara M. Safety of topical ophthalmic antibiotics in pregnant women with hordeola, chalazia, blepharitis, or bacterial conjunctivitis: propensity score analyses. *EYE*. 2022 ;36(5):1066-1073.
15. Hashimoto Y, Yamana H, Michihata N, Shigemi D, Ishimaru M, Matsui H, Yasunaga H, Aihara M. Eye drops for dry eye disease during pregnancy and adverse neonatal outcomes: high-

- dimensional propensity score analyses. *Ophthalmic Epidemiology*. 2022;29(4):384-393.
16. Hirano T, Nakajima M, Ohbe H, Kaszynski RH, Iwasaki Y, Arakawa Y, Sasabuchi Y, Fushimi K, Matsui H, Yasunaga H. Corticosteroid use with extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest: A nationwide observational study. *Resuscitation Plus*. 2022;12: 100308.
 17. Hirano Y, Kaneko H, Konishi T, Itoh H, Matsuda S, Kawakubo H, Uda K, Matsui H, Fushimi K, Daiko H, Itano O, Yasunaga H, Kitagawa Y. Short-Term Outcomes of Epidural Analgesia in Minimally Invasive Esophagectomy for Esophageal Cancer: Nationwide Inpatient Data Study in Japan. *Annals of Surgical Oncology*. 2022;29(13):8225-8234.
 18. Hirose N, Morita K, Matsui H, Fushimi K, Yasunaga H. Association between nurse aide staffing and patient mortality after major cancer surgeries in acute care settings: A retrospective cohort study using a national inpatient database. *Nursing and Health Sciences*. 2022;24(1):283-292.
 19. Hirose N, Morita K, Matsui H, Fushimi K, Yasunaga H. Dose-response association between nurse staffing and patient outcomes following major cancer surgeries using a nationwide inpatient database in Japan. *Journal of Clinical Nursing*. 2022;31(17-18):2562-2573.
 20. Honda A, Michihata N, Iizuka Y, Uda K, Morita K, Mieda T, Takasawa E, Ishiwata S, Tajika T, Matsui H, Fushimi K, Yasunaga H, Chikuda H. Risk factors for severe lower extremity ischemia following venoarterial extracorporeal membrane oxygenation: An analysis using a nationwide inpatient database. *Trauma Surgery & Acute Care Open*. 2022;7:e000776.
 21. Hosoi T, Yamana H, Tamiya H, Matsui H, Fushimi K, Akishita M, Yasunaga H, Ogawa S. Association between comprehensive geriatric assessment and polypharmacy at discharge in patients with ischaemic stroke: a nationwide retrospective cohort study. *eClinicalMedicine*. 2022;50:101528.
 22. Inooka Y, Yamana H, Shinoda Y, Inokuchi H, Matsui H, Fushimi K, Yasunaga H, Haga N. Predictive factors for oral intake recovery after acute stroke: analysis of a Japanese nationwide inpatient database. *Dysphagia* 2022;37(6):1623-1632.
 23. Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, incidence rate and risk factors of medication-related osteonecrosis of the jaw (MRONJ) in patients with osteoporosis and cancer: a nationwide population-based study in Japan. *Journal of Oral and Maxillofacial Surgery*. 2022;80(4):714-727.
 24. Ishimaru T, Fujiogi M, Michihata N, Konishi T, Morita K, Matsui H, Uda K, Fushimi K, Kawashima H, Fujishiro J, Yasunaga H. Perioperative Outcomes of Laparoscopically Assisted Anorectoplasty versus Conventional Procedures for Anorectal Malformation: A Retrospective Nationwide Database Study. *Pediatric Surgery International*. 2022;38(12): 1785-1791.
 25. Itoh H, Kaneko H, Okada A, Suzuki Y, Fujiu K, Matsuoka S, Michihata N, Jo T, Nakanishi K, Takeda N, Morita H, Node K, Di Tullio MR, Homma S, Yasunaga H, Komuro I. Age-Specific Relation of Cardiovascular Health Metrics With Incident Cardiovascular Disease. *American Journal of Cardiology*. 2022;177:34-39.
 26. Iwasaki Y, Ohbe H, Shigemi D, Fushimi K, Yasunaga H. Effect of antithrombin III among patients with disseminated intravascular coagulation in obstetrics: a nationwide observational study in Japan. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2022;129(5):805-811.
 27. Kamijo K, Nakajima M, Shigemi D, Kaszynski RH, Ohbe H, Goto T, Sasabuchi Y, Fushimi K, Matsui H, Yasunaga H. Resuscitative endovascular balloon occlusion of the aorta for life-threatening postpartum hemorrhage: A nationwide observational study in Japan. *The Journal of Trauma and Acute Care Surgery*. 2022; 93(3):418-423.
 28. Kamon T, Kaneko H, Itoh H, Okada A, Matsuoka S, Kiriyaama H, Fujiu K, Morita K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Node K, Yasunaga H, Komuro I. Sex difference in the association between lipid profile and incident

- cardiovascular disease among young adults. *Journal of Atherosclerosis and Thrombosis*. 2022; 29(10):1475-1486.
29. Kaneko H, Suzuki Y, Ueno K, Okada A, Fujiu K, Matsuoka S, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Node K, Yasunaga H, Komuro I. Association of Life's Simple 7 with incident cardiovascular disease in 53,974 patients with cancer. *European Journal of Preventive Cardiology*. 2022;29(18):2324-2332.
 30. Kaneko H, Yano Y, Lee HH, Lee H, Okada A, Itoh H, Morita K, Fukui A, Fujiu K, Suzuki Y, Matsuoka S, Nakamura S, Michihata N, Jo T, Takeda N, Morita H, Yokoo T, Nishiyama A, Node K, Viera AJ, Muntner P, Oparil S, Kim HC, Yasunaga H, Komuro I. Medication-Na⁺ve Blood Pressure and Incident Cancers: Analysis of Two Nationwide Population-Based Databases. *American Journal of Hypertension*. 2022;35(8): 731-739.
 31. Kaneko H, Yano Y, Suzuki Y, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Node K, Viera AJ, Lima JAC, Oparil S, Lam CSP, Carey RM, Yasunaga H, Komuro I. Reduction in blood pressure for elevated blood pressure/ stage 1 hypertension according to the ACC/AHA guideline and cardiovascular outcomes. *European Journal of Preventive Cardiology*. 2022;29(14):1921-1929.
 32. Karakawa R, Konishi T, Yoshimatsu H, Fuse Y, Hashimoto Y, Matsui H, Fushimi K, Yano T, Yasunaga H. Comparison of short-term outcomes between pedicled- and free-flap autologous breast reconstruction. *Breast Cancer*. 2022;29(6):1067-1075.
 33. Kodama S, Jo T, Yasunaga H, Michihata N, Matsui H, Kumazawa R, Shirota Y, Fushimi K, Toda T, Hamada M. Outcomes of gastrointestinal cancer surgeries in Parkinson's disease patients: a nationwide study. *Parkinsonism and Related Disorders*. 2022;96:45-49.
 34. Konishi T, Fujiogi M, Michihata N, Kumazawa R, Ohbe H, Matsui H, Fushimi K, Ogita M, Tanabe M, Seto Y, Yasunaga H. Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan. *Breast Cancer*. 2022;29(4):688-697.
 35. Konishi T, Fujiogi M, Michihata N, Matsui H, Tanabe M, Seto Y, Yasunaga H. Association between body mass index and incidence of breast cancer in premenopausal women: A Japanese nationwide database study. *Breast Cancer Research and Treatment*. 2022;194(2):315-325.
 36. Konishi T, Fujiogi M, Michihata N, Morita K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Association of operative day of the week with length of stay and total hospitalization costs in patients with partial mastectomy: a nationwide database study in Japan. *JMA Journal*. 2022;5(3):319-327.
 37. Konishi T, Fujiogi M, Michihata N, Ohbe H, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer. *Japanese Journal of Clinical Oncology*. 2022; 52(10):1115-1123.
 38. Konishi T, Fujiogi M, Sato A, Michihata N, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Short-term outcomes following breast cancer surgery with and without neoadjuvant chemotherapy: a nationwide administrative database study in Japan. *Annals of Surgical Oncology*. 2022;29(5):3000-3010.
 39. Konishi T, Fujiogi M, Shigemi D, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Risk factors for postoperative bleeding following breast cancer surgery: a nationwide database study of 477,108 cases in Japan. *World Journal of Surgery*. 2022;46(12):3062-3071.
 40. Konishi T, Fujiogi M, Shigemi D, Nishioka K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Surgical and obstetric outcomes of breast cancer surgery during pregnancy: A nationwide database study in Japan. *Breast Cancer Research and Treatment*. 2022;195(3): 289-299.
 41. Konishi T, Goto T, Fujiogi M, Michihata N, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. New machine learning scoring system for predicting postoperative mortality in gastroduodenal ulcer perforation: A

- study using a Japanese nationwide inpatient database. *Surgery*. 2022;171(4):1036-1042.
42. Konishi T, Sakata A, Inokuchi H, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Treatments and outcomes of adult parapharyngeal and retropharyngeal abscess: 1,882 cases from a Japanese nationwide database. *American Journal of Otolaryngology*. 2022;44(2):103770.
 43. Konishi T, Takamoto T, Fujiogi M, Hashimoto Y, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Laparoscopic versus open distal pancreatectomy with or without splenectomy: A propensity score analysis in Japan. *International Journal of Surgery*. 2022;104:106765.
 44. Konishi T, Yoshimoto T, Fujiogi M, Yamana H, Tanabe M, Seto Y, Yasunaga H. Validity of operative information in Japanese administrative data: a chart review-based analysis of 1221 cases at a single institution. *Surgery Today*. 2022; 52(10):1484-1490.
 45. Kumazawa R, Jo T, Matsui H, Fushimi K, Yasunaga H. Direct oral anticoagulants versus warfarin for secondary prevention of cerebral infarction and bleeding in older adults with atrial fibrillation. *Journal of the American Geriatrics Society*. 2022;70(7):2029-2039.
 46. Kurakawa KI, Okada A, Bessho K, Jo T, Ono S, Michihata N, Kumazawa R, Matsui H, Fushimi K, Yamaguchi S, Yamauchi T, Nangaku M, Kadowaki T, Yasunaga H. Major complications after percutaneous biopsy of native or transplanted liver in pediatric patients: A nationwide inpatient database study in Japan. *BMC Gastroenterology*. 2022;22(1):395.
 47. Kutsuna S, Ohbe H, Matsui H, Yasunaga H. Effectiveness of fluoroquinolone antimicrobials in addition to tetracyclines for Japanese Spotted Fever: A retrospective analysis using a national inpatient database. *International Journal of Infectious Diseases*. 2022;123:70-75.
 48. Kutsuna S, Ohbe H, Matsui H, Yasunaga H.. Delayed Tetracycline Initiation Increases Mortality Risk in Patients With Japanese Spotted Fever: Retrospective Analysis Using a National Inpatient Database. *Open Forum Infectious Diseases*. 2022;9(11):ofac573.
 49. Matsuda K, Jo T, Matsui H, Fushimi K, Yasunaga H, Sugimoto K. Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia. *Blood Cancer Journal*. 2022;12(12):167.
 50. Matsuda K, Jo T, Shimura A, Honda A, Taoka K, Masamoto Y, Matsui H, Fushimi K, Yasunaga H, Kurokawa M. Risk of febrile neutropenia in very elderly patients aged ≥ 80 years receiving their first cycle of R-CHOP regimen: a nationwide real-world study in Japan. *British Journal of Haematology*. 2022;197(3):e37-e41.
 51. Matsui H, Yamana H, Fushimi K, Yasunaga H. Development of deep learning models for predicting in-hospital mortality using an administrative claims database. *JMIR Medical Informatics*. 2022;10(2):e27936.
 52. Matsuoka S, Kaneko H, Kamon T, Suzuki Y, Yano Y, Okada A, Itoh H, Morita K, Fukui A, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Yokoo T, Nishiyama A, Node K, Yasunaga H, Komuro I. Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline. *Journal of Atherosclerosis and Thrombosis*. 2022;29(10): 1487-1498.
 53. Matsuoka S, Kaneko H, Okada A, Fukui A, Yano Y, Itoh H, Morita K, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Nakamura S, Nishiyama A, Yokoo T, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Association between Proteinuria and Incident Colorectal Cancer: Analysis of a Nationwide Population-Based Database. *BMJ Open*. 2022;12(4): e056250.
 54. Matsuoka S, Kaneko H, Okada A, Itoh H, Suzuki Y, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Node K, Yasunaga H, Komuro I. Association of retinal atherosclerosis assessed using Keith-Wagener-Barker system with incident heart failure and other atherosclerotic cardiovascular disease: Analysis of 319,501 individuals from the general population. *Atherosclerosis*. 2022;348:68-74.
 55. Matsuoka S, Kaneko H, Okada A, Morita K, Itoh H, Michihata N, Jo T, Takeda N, Morita H, Fujiu

- K, Nakamura S, Node K, Yasunaga H, Komuro I. Age Modified Relationship between Modifiable Risk Factors and the Risk of Atrial Fibrillation. *Circulation: Arrhythmia and Electrophysiology*. 2022;15(1):e010409.
56. Michihata N, Shigemi D, Yamana H, Matsui H, Jo T, Yasunaga H. Safety of Japanese Herbal Kampo Medicines for the Treatment of Depression During Pregnancy. *International Journal of Gynecology and Obstetrics*. 2022;159(3):865-869.
57. Michihata N, Suzuki T, Honda A, Oka I, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H. Clinical features of Kawasaki disease with atlantoaxial rotatory fixation. *Pediatric Infectious Disease Journal*. 2022;41(8):626-630.
58. Michihata N, Suzuki T, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease. *European Journal of Pediatrics*. 2022;181(10):3607-3615.
59. Miyachi H, Konishi T, Kumazawa R, Matsui H, Shimizu S, Fushimi K, Matsui H, Yasunaga H. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. *Journal of the American Academy of Dermatology*. 2022;86(6):1266-1274.
60. Miyachi H, Konishi T, Shigemi D, Matsui H, Shimizu S, Fushimi K, Matsue H, Yasunaga H. Association between psoriasis and short-term outcomes of acute myocardial infarction: a matched-pair cohort study using a nationwide inpatient database in Japan. *JAAD International*. 2022;8:21-30.
61. Miyakawa T, Michihata N, Morita K, Matsui H, Honda M, Yasunaga H. Ambient temperature and hospital admissions for acute cholecystitis: A nationwide inpatient database study in Japan. *HPB*. 2022;24(3):398-403.
62. Miyamoto Y, Iwagami M, Aso S, Uda K, Fushimi K, Hamasaki Y, Nangaku M, Yasunaga H, Doi K. Postoperative outcomes of cancer surgery in patients with and without kidney failure with dialysis therapy: A matched-pair cohort study. *Clinical Kidney Journal* 2022;15(6):1137-1143.
63. Miyamoto Y, Matsuyama T, Goto T, Ohbe H, Kitamura T, Yasunaga H, Ohta B. Association between age and neurological outcomes in out-of-hospital cardiac arrest patients resuscitated with extracorporeal cardiopulmonary resuscitation: a nationwide multicentre observational study. *European Heart Journal: Acute Cardiovascular Care*. 2022;11(1):35-42.
64. Mizuno S, Ono S, Takano A, Yasunaga H, Iwase H. Dental characteristics associated with methamphetamine use: Analysis using forensic autopsy data. *BMC Oral Health*. 2022;22(1):141.
65. Nagata S, Ohbe H, Jo T, Matsui H, Fushimi K, Yasunaga H. Glucocorticoids and rates of biphasic reactions in patients with adrenaline-treated anaphylaxis: A propensity score matching analysis. *International Archives of Allergy and Immunology*. 2022;183(9):939-945.
66. Nakamura K, Ohbe H, Uda K, Matsui H, Yasunaga H. Effectiveness of early rehabilitation following aortic surgery: a nationwide inpatient database study. *Gen Thorac Cardiovasc Surg*. 2022;70(8):721-729.
67. Nishimoto Y, Ohbe H, Matsui H, Nakajima M, Sasabuchi Y, Goto T, Morita K, Fushimi K, Sato Y, Yasunaga H. Predictive ability of the sequential organ failure assessment score for in-hospital mortality in patients with cardiac critical illness: a nationwide observational study. *EHJ Acute Cardiovascular Care*. 2022;11(4):312-321.
68. Ogasawara H, Obe H, Yasunaga H. Oral food challenge management in Japan: A retrospective analysis of health insurance claims data. *Clinical & Experimental Allergy*. 2022;52(7):898-900.
69. Ogawa Y, Yamana H, Noda T, Kishimoto M, Yoshihara S, Kanaoka K, Matsui H, Fushimi K, Yasunaga H, Kawaguchi M, Imamura T. Severe complications after general anesthesia versus sedation during pediatric diagnostic cardiac catheterization for ventricular septal defect. *Journal of Clinical Medicine*. 2022;11(17):5165.
70. Ohbe H, Goto T, Matsui H, Fushimi K, Yasunaga H. Associations of government-issued ICU admission criteria with clinical practices, outcomes, and ICU bed occupancy. *Annals of the*

- American Thoracic Society. 2022;19(6):1013-1021.
71. Ohbe H, Goto T, Nakamura K, Matsui H, Yasunaga H. Development and validation of early prediction models for new-onset functional impairment at hospital discharge of ICU admission. *Intensive Care Medicine*. 2022;48(6): 679-689.
 72. Ohbe H, Matsui H, Kumazawa R, Yasunaga H. Intensive care unit versus high dependency care unit admission after emergency surgery: a nationwide in-patient registry study. *British Journal of Anaesthesia*. 2022;129(4):527-535.
 73. Ohbe H, Matsui H, Kumazawa R, Yasunaga H. Postoperative intensive care unit admission following major elective surgery: a nationwide inpatient database study. *European Journal of Anaesthesiology*. 2022;39(5):436-444.
 74. Ohbe H, Matsui H, Yasunaga H. ICU versus high-dependency care unit for patients with acute myocardial infarction: a nationwide propensity score-matched cohort study. *Critical Care Medicine*. 2022;50(6):977-985.
 75. Ohbe H, Sasabuchi Y, Kumazawa R, Matsui H, Yasunaga H. Intensive care unit occupancy in Japan, 2015-2018: a nationwide inpatient database study. *Journal of Epidemiology*. 2022; 32(12):535-542.
 76. Ohbe H, Sasabuchi Y, Matsui H, Yasunaga H. Impact of the COVID-19 pandemic on critical care utilization in Japan: a nationwide inpatient database study. *Journal of Intensive Care*. 2022; 10(1):51.
 77. Ohbe H, Tagami T, Ogura T, Matsui H, Yasunaga H. Low-flow duration and outcomes of extracorporeal cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: a nationwide inpatient database study. *Critical Care Medicine*. 2022;50(12):1768-1777.
 78. Ohbe H, Tagami T, Uda K, Matsui H, Yasunaga H. Incidence and outcomes of in-hospital cardiac arrest in Japan 2011-2017: a nationwide inpatient database study. *Journal of Intensive Care*. 2022; 10(1):10.
 79. Ohisa K, Yamana H, Morita K, Matsui H, Fushimi K, Yasunaga H. Association between subcutaneous steroid injection for extravasation of vesicant anticancer drugs and skin ulcers requiring surgery. *European Journal of Oncology Nursing*. 2022;58:102119.
 80. Okada A, Hashimoto Y, Goto T, Yamaguchi S, Ono S, Ikeda Kurakawa K, Nangaku M, Yamauchi T, Yasunaga H, Kadowaki T. A machine learning-based predictive model to identify patients who failed to attend a follow-up visit for diabetes care after recommendations from a national screening program. *Diabetes Care*. 2022;45(6):1346-1354.
 81. Okada A, Yamana H, Yamaguchi S, Kurakawa K, Michihata N, Matsui H, Fushimi K, Nangaku M, Yamauchi T, Yasunaga H, Kadowaki T. Effect of branched-chain amino acid infusion on in-hospital mortality of patients with hepatic encephalopathy and endstage kidney disease: a retrospective cohort study using a national inpatient database. *Journal of Renal Nutrition*. 2022;32(4):432-440.
 82. Okada A, Yasunaga H. Prevalence of non-communicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. *JMA Journal*. 2022;5(2):190-198.
 83. Okubo Y, Nishi A, Uda K, Miyairi I, Michihata N, Kumazawa R, Matsui H, Fushimi K, Yasunaga H. Financial Incentives for Infection Prevention and Antimicrobial Stewardship to Reduce Antibiotic Use: A Japan's Nationwide Observational Study. *Journal of Hospital Infection*. 2022;131:89-98.
 84. Ono S, Ishimaru M, Yokota I, Konishi T, Okada A, Ono Y, Matsui H, Itai S, Yonenaga K, Tonosaki K, Watanabe R, Hoshi K, Yasunaga H. Risk of post-extraction bleeding with direct oral anticoagulant compared with warfarin: Retrospective cohort study using large scale claims data in Japan. *Thrombosis Research*. 2022;222:24-30.
 85. Sakakibara K, Shigemi D, Toriumi R, Ota A, Michihata N, Yasunaga H. Emergency Visits and Hospitalization after Message Chat, Voice Call, or Video Call for Telehealth in Obstetrics and Gynecology: A Cross-Sectional Study Using Telehealth Service User Data in Japan. *J Med Internet Res*. 2022;24(9):e35643.
 86. Sakamoto T, Fujiogi M, Ishimaru M, Matsui H,

- Fushimi K, Yasunaga H. Comparison of postoperative infection after emergency inguinal hernia surgery with enterectomy between mesh repair and non-mesh repair: a national database analysis. *Hernia*. 2022;26(1):217-223.
87. Sato M, Yamana H, Ono S, Ishimaru M, Matsui H, Yasunaga H. Trends in prophylactic antibiotic use for tooth extraction from 2015 to 2018 in Japan: an analysis using a health insurance claims database. *Journal of Infection and Chemotherapy*. 2022;28(4):504-509.
88. Seike Y, Matsuda H, Shimizu H, Ishimaru S, Hoshina K, Michihata N, Yasunaga H, Komori K; Japanese Committee for Stentgraft Management (JACSM). Nationwide analysis of the association between persistent type II endoleak and late outcomes of endovascular abdominal aortic aneurysm repair in Japan: Propensity-matched analysis. *Circulation* 2022;145(14):1056-1066.
89. Shibahashi K, Konishi T, Ohbe H, Yasunaga H. Cost-effectiveness analysis of termination-of-resuscitation rules for patients with out-of-hospital cardiac arrest. *Resuscitation*. 2022;180:45-51.
90. Shibahashi K, Ohbe H, Yasunaga H. Association between intensive care unit admission practices and outcomes in patients with isolated traumatic subarachnoid hemorrhage: A nationwide inpatient database analysis in Japan. *Neurocritical Care*. 2022;37(2):497-505.
91. Shibahashi K, Ohbe H, Yasunaga H. Urban-rural inequalities in care and outcomes of severe traumatic brain injury: A nationwide inpatient database analysis in Japan. *World Neurosurgery*. 2022;163:e628-e634.
92. Shibahashi K, Ohbe H, Yasunaga H. Adjuvant oral tranexamic acid and reoperation after burr-hole surgery in patients with chronic subdural hematoma: Propensity score-matched analysis using a nationwide inpatient database. *Journal of Neurosurgery*. 2022;138(2):430-436.
93. Shigemi D, Tabuchi T, Okawa S, Yasunaga H. Association between health literacy and COVID-19 prevention behaviors among pregnant and postpartum women. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2022;35(25):9971-9977.
94. Sugawara C, Yamana H, Sasagawa E, Yonezawa K, Hikita N, Morita K, Matsui H, Yasunaga H, Haruna M. Factors associated with surgical treatment in postpartum women with mastitis or breast abscess: A retrospective cohort study. *Breastfeeding Medicine*. 2022;17(3):233-238.
95. Sugihara T, Kamei J, Yasunaga H, Sasabuchi Y, Fujimura T. Prescription of Choreito, a Japanese Kampo medicine, with antimicrobials for treatment of acute cystitis: a retrospective cohort study. *Antibiotics*. 2022;11:1840.
96. Suzuki J, Sasabuchi Y, Hatakeyama S, Matsui H, Sasahara T, Morisawa Y, Yamada T, Fushimi K, Yasunaga H. Additional effect of azithromycin over β -lactam alone for severe community-acquired pneumonia-associated acute respiratory distress syndrome: a retrospective cohort study. *Pneumonia*. 2022 ;14(1):1.
97. Suzuki T, Michihata N, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H. Low- versus high-concentration intravenous immunoglobulin for children with Kawasaki disease in the acute phase. *International Journal of Rheumatic Diseases*. 2022;25(5):576-583.
98. Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K, Matsunaga A, Ako J, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Impact of Glucose Tolerance on Incident Proteinuria in Prediabetes: Analysis of a Nationwide Population-Based Dataset. *American Journal of Nephrology*. 2022;53(4):307-315.
99. Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Yano Y, Kamiya K, Matsunaga A, Ako J, Fukui A, Yokoo T, Nishiyama A, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Risk for Proteinuria in Newly Defined Hypertensive People Based on the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. *American Journal of Cardiology*. 2022;168:83-89.
100. Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I. Comparison of cardiovascular outcomes between SGLT2

- inhibitors in diabetes mellitus. *Cardiovascular Diabetology*. 2022;21(1):67.
101. Suzuki Y, Kaneko H, Okada A, Itoh H, Morita K, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K, Matsunaga A, Ako J, Fukui A, Nishiyama A, Yokoo T, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database. *American Journal of Nephrology*. 2022;53(2-3): 240-248.
 102. Suzuki Y, Kaneko H, Okada A, Matsuoka S, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Node K, Yamauchi T, Yasunaga H, Komuro I. Prediabetes in Young Adults and Its Association with Cardiovascular Health Metrics in the Progression to Diabetes. *Journal of Clinical Endocrinology & Metabolism*. 2022;107(7): 1843-1853.
 103. Suzuki Y, Kaneko H, Okada A, Nangaku M, Yasunaga H, Komuro I. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors. *Kidney International*. 2022;102(5):1147-1153.
 104. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I. Glycemic status and the association of change in blood pressure with incident cardiovascular disease. *American Heart Journal*. 2022;254:48-56.
 105. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Matsunaga A, Node K, McEvoy JW, Lam CSP, Oparil S, Yasunaga H, Komuro I. Association of Cardiovascular Health Metrics with Risk of Transition to Hypertension in Non-Hypertensive Young Adults. *American Journal of Hypertension*. 2022;35(10):858-866.
 106. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, Fujiu K, Yamaguchi S, Michihata N, Jo T, Takeda N, Morita H, Node K, Kim HC, Viera AJ, Oparil S, Yasunaga H, Komuro I. Age-Dependent Relationship of Hypertension Subtypes with Incident Heart Failure. *JAHA*. 2022;11(9):e025406.
 107. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Ueno K, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yokota I, Node K, Yasunaga H, Komuro I. Dose-dependent relationship of blood pressure and glycemic status with risk of aortic dissection and aneurysm. *European Journal of Preventive Cardiology*. 2022;29(18):2338-2346.
 108. Suzuki Y, Kaneko H, Okada A, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Nangaku M, Yasunaga H, Komuro I. Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer. *American Journal of Nephrology*. 2022;53(10):753-760.
 109. Tagami T, Yamakawa K, Endo A, Hayakawa M, Ogura T, Hirayama A, Yasunaga H. Japanese Multicenter Research of COVID-19 by Assembling Real-world Data: A Study Protocol. *ACE*. 2022;4(3): 92-100.
 110. Taguchi R, Shigemi D, Yasunaga H. Trends in antihypertensive prescription for pregnant women with hypertension and their peripartum outcomes before and after label and guideline revisions in Japan. *Hypertension Research*. 2022; 45(11):1823-1831.
 111. Tahara S, Hattori Y, Aso S, Uda K, Kumazawa R, Matsui H, Fushimi K, Yasunaga H, Morita A. Trends in Surgical Procedures for Spontaneous Intracerebral Hemorrhage in Japan. *Journal of Stroke and Cerebrovascular Diseases*. 2022; 31(9):106664.
 112. Takeuchi Y, Iwagami M, Ono S, Michihata N, Uemura K, Yasunaga H. A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan. *Vaccine*. 2022;40(52):7622-7630.
 113. Uemura K, et al. Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data. *Vaccine*. 2022; 40(52):7622-7630.
 114. Ueno K, Kamiya K, Kaneko H, Okada A, Itoh H, Fujiu K, Takeda N, Morita H, Michihata N, Jo T, Yasunaga H, Komuro I. Acute-phase initiation of

- cardiac rehabilitation for improvement in activities of daily living in patients hospitalized for acute heart failure. *Journal of Cardiovascular Development and Disease*. 2022;9(4):97.
115. Ueno K, Kaneko H, Kamiya K, Itoh H, Okada A, Suzuki Y, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Ako J, Node K, Yamauchi T, Yasunaga H, Komuro I. Relationship of normal-weight central obesity with the risk for heart failure and atrial fibrillation: Analysis of a nationwide health check-up and claims database. *European Heart Journal Open*. 2022;2(3):oeac026.
 116. Ueno K, Kaneko H, Kamiya K, Itoh H, Okada A, Suzuki Y, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Ako J, Yasunaga H, Komuro I. Clinical utility of simple subjective gait speed for the risk stratification of heart failure in a primary prevention setting. *Scientific Reports*. 2022;12(1):11641.
 117. Urushiyama H, Jo T, Hasegawa W, Yokoyama A, Ando T, Sakamoto Y, Kumazawa R, Uda K, Michihata N, Awano N, Hiroki M, Fushimi K, Yasunaga H, Nagase T. Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: A national database study in Japan. *ERJ Open Research*. 2022;8(4):00209-2022.
 118. Wada Y, Takahashi H, Matsui H, Yasunaga H, Fujiwara H, Sasabuchi Y. Adhesion barriers and intraperitoneal or uterine infections after cesarean section: A retrospective cohort study. *Surgery*. 2022;172(6):1722-1727.
 119. Yamamoto M, Yasunaga H, Kakinoki R, Tsubokawa N, Morita A, Tanaka K, Sakai A, Kurahashi T, Hirata H; CeCORD J study Group. The CeCORD-J study on collagenase injection versus aponeurotomy for Dupuytren's contracture compared by hand function and cost effectiveness. *Scientific Reports*. 2022;12(1):9094.
 120. Yamamoto R, Kaito D, Homma K, Endo A, Tagami T, Suzuki M, Umetani N, Yagi M, Nashiki E, Suhara T, Nagata H, Kabata H, Fukunaga K, Yamakawa K, Hayakawa M, Ogura T, Hirayama A, Yasunaga H, Sasaki J; J-RECOVER study group. Early intubation and decreased in-hospital mortality in patients with coronavirus disease 2019. *Crit Care*. 2022;26(1):124.
 121. Yamana H, Sasabuchi Y, Matsui H, Michihata N, Jo T, Yasunaga H. Maoto plus neuraminidase inhibitor versus neuraminidase inhibitor alone for reducing hospitalisation in older adults with seasonal influenza. *Annals of Clinical Epidemiology*. 2022;4:120-128
 122. Yamana H, Tsuchiya A, Horiguchi H, Morita S, Kuroki T, Nakai K, Nishimura H, Jo T, Fushimi K, Yasunaga H. Validity of a model using routinely collected data for identifying infections following gastric, colorectal, and liver cancer surgeries. *Pharmacoepidemiology and Drug Safety*. 2022;31(4):452-460.
 123. Yamazaki R, Ohbe H, Matsuda Y, Kito S, Shigeta M, Morita K, Matsui H, Fushimi K, Yasunaga H. Early electroconvulsive therapy in patients with bipolar depression: a propensity score-matched analysis using a nationwide inpatient database. *Journal of Affective Disorders*. 2022;312:245-251.
 124. Zhang L, Michihata N, Matsui H, Fushimi K, Yasunaga H, Tsuda Y, Tanaka S, Kobayashi H. Preoperative Arterial Embolization and Wound Complications After Resection of Malignant Bone Tumor in the Pelvis: A Nationwide Database Study. *Japanese Journal of Clinical Oncology*. 2022;52(10):1176-1182.

Department of Health Communication

Professor

Takahiro Kiuchi, M.D., Ph.D.

Associate Professor

Tsuyoshi Okuhara, Ph.D., MPH

Homepage <http://www.umin.ac.jp/hc/>

Introduction and Organization

The Department of Health Communication was established as a part of the newly developed School of Public Health (professional graduate school) in April 2007, which was derived from the University Hospital Medical Information Network (UMIN) Center. It consists of two faculty members: a professor and an associate professor.

Health communication is a major discipline in school of public health, especially in the US, and there are many graduate programs and research centers for health communication. On the other hand, there have been few such departments in Japan, although the importance of the health communication discipline has gradually been recognized among the academic society as well as among general public. Our department was established one of the few departments specialized in health communication in Japan.

Teaching Activities

The Department of Health Communication, within the School of Public Health, is a professional graduate program that aims to foster the development of medical and public health professionals as well as researchers. We strive to make the most of our professional activities and experience at UMIN Center. We provide lectures and practical instruction in the program. The following is the current curriculum:

[Health Communication Lectures]

1. Introduction to health communication
2. Evaluation and research in health communication
3. Media and communication (1): Television
4. Media and communication (2): News paper
5. Media and communication (3): Internet
6. Improving communication based on empirical research
7. Patient and public education
8. Communication with foreign patients
9. Communication for behavioral changes
10. Entertainment education
11. Visual communication
12. Communicating for policy and advocacy
13. Communication in group and organization
14. Group discussion

[Health Communication Practice]

1. Health writing (1) Creating a document to support patients and families.
2. Health writing (2) Creating a document to encourage behavior change
3. MBTI (Myers-Briggs Type Indicator) (1)(2)(3)
4. Mass communication: Media doctor
5. Coaching
6. Health writing (3) Presentation and discussion

[Medical research and CDISC standards]

1. Introduction to data management in clinical research
2. Introduction to CDISC standards

3. Standardization of case report form – CDASH
4. Data and metadata – Define.xml
5. Standardization of dataset for analysis – AdaM
6. Electronic application by CDISC standards
7. Standardization of data format – SDTM

In the undergraduate program, we present lectures entitled “Medical Literature Informatics” and “health communication.”

Research Activities

(1) Research related to UMIN activities

The research that continues from the UMIN center is characterized by the following.

■ A focus on health informatics and communication
The Department of Health Communication is the only research institute in Japan that carries out health informatics and communication-related research, addressing areas such as the Internet and satellite communications.

■ Targeting health information science, not health-care information practice

Currently, main topics of the research at most medical informatics programs in Japan focus on information for healthcare practice, such as hospital information systems, electronic medical record systems, tele-medicine, and electronic billing systems. In contrast, the Department of Health Communication has focused on information systems for medical science, such as medical literature databases, data registries for clinical studies, and information systems for medical education.

Most systems developed at the UMIN Center have been subjects for research. In particular, we published and reported systems utilizing advanced technologies and having scientifically meaningful concepts at academic conferences.

■ Information Systems for Clinical Epidemiologic Studies

We have developed and applied information systems for clinical epidemiological studies. Recently, we have

focused on research in electronic formats and standardization that are related to clinical research, such as the Clinical Data Interchange Standards Consortium (CDISC). We utilized the achievements attained by the medical research data center at the UMIN.

■ Research Regarding the Security of an Information Network

The study addresses a Virtual Private Network (VPN), and secure transactions with electronic mail (encryption), which have been also utilized for system management at the UMIN Center.

(2) Research on health communication

Currently, “health communication” is becoming an important concept in the distribution of clinical results for the improvement of population-based clinical outcomes. We have conducted health communication research focusing on knowledge and skills in “informatics” and “communication.” The following are current research topics at the Department of Health Communication.

■ Research on communication to support behavioral change of healthcare consumers

Communication that is easy for patients and citizens to understand and that supports more appropriate decision-making and behavioral change by patients and citizens is the foundation of effective medical care and public health. We are developing and evaluating messages that support behavioral change of healthcare consumers.

■ Research on Media

Mass media and social media have a social influence; however, their quality of information varies. We analyze the health care information distributed by mass media and social media, and examine the impact of media information on health care consumers..

■ Research on Patient-Professional Relationship and Communication

Communication between patients and health care professionals is the foundation of effective health care. We investigate the relationship of patient and provider

characteristics with their communication behaviors, and impacts of the communication on patient outcomes.

■ Research on Health Literacy

The increase in media reports and the rapid expansion of the Internet have rendered various sources of health information more available to the general public. Thus, skills in understanding and applying information about health issues may have a substantial impact on health behaviors and health outcomes. These skills have recently been conceptualized as health literacy. We investigate its relationship with patient and provider communication, and patient health behaviors and outcomes.

References

1. Furukawa E, Okuhara T, Okada H, Shirabe R, Yokota R, Iye R, Kiuchi T. Translation, cross-cultural adaptation, and validation of the Japanese version of The Patient Education Materials Assessment Tool (PEMAT). *International Journal of Environmental Research and Public Health* 2022;19:15763.
2. Kato M, Ishikawa H, Kiuchi T, Akiyama M, Kawamura Y, Okuhara T, Ono N, Miyawaki R. Patterns of Alcohol and alcohol-flavoured non-alcoholic beverage advertisements Over Japanese free-to-air television networks. *BMC Public Health* 2022; 22:1864.
3. Yokota R, Okuhara T, Okada H, Goto E, Sakakibara K, Kiuchi T. Associations between Stigma, Cognitive Appraisals, Coping Strategies and Stress Responses among Japanese Women Undergoing Infertility Treatment. *Healthcare* 2022;10(10):1907.
4. Yokota R, Okuhara T, Okada H, Goto E, Sakakibara K, Kiuchi T. Association between Stigma and Anxiety, Depression, and Psychological Distress among Japanese Women Undergoing Infertility Treatment. *Healthcare* 2022;10:1300.
5. Goto E, Ishikawa H, Okuhara T, Okada H, Tsunazumi A, Kagawa Y, Fujino Y, Kiuchi T. Associations between job and workplace factors, health and physical factors, personal factors, and presenteeism among general employees in Japan: A longitudinal study. *Journal of Occupational Health* 2022;e12344.
6. Okuhara T, Okada H, Goto E, Tsunazumi A, Kagawa Y, Kiuchi T. Encouragement of cervical cancer screening via an evolutionary theoretical approach: a randomized controlled study in Japan. *Preventive Medicine Reports*. 2022;27:101818.
7. Okuhara T, Okada H, Goto E, Tsunazumi A, Kagawa Y, Kiuchi T. Encouraging HPV Vaccination via an Evolutionary Theoretical Approach: A Randomized Controlled Study in Japan. *Vaccines* 2022;10(5):701.
8. Yokota R, Okada H, Okuhara T, Goto E, Furukawa E, Shirabe R, Sakakibara K, Kiuchi T. Development of the Japanese version of the Infertility Stigma Scale: Examination of its reliability and validity. *Healthcare* 2022;10(3): 505.
9. Okuhara T, Okada H, Goto E, Tsunazumi A, Kagawa Y, Kiuchi T. Encouraging COVID-19 vaccination via an evolutionary theoretical approach: a randomized controlled study in Japan. *Patient Education and Counseling*. 2022;S0738-3991(22)00085-4.
10. Iye R, Okuhara T, Okada H, Goto E, Furukawa E, Kiuchi T. The Effect of Exposure to “Exemption” Video Advertisements for Functional Foods: A Randomized Control Study in Japan. *Healthcare* 2022;10:2.
11. Miyaji T, Kiuchi T, Yamaguchi T. Institutional Change in Clinical Trials through the COVID-19 Pandemic. *Journal of the Society for Clinical Trial Management* 2022;2(1):1-4.

School of Public Health

2. Behavioral Health Sciences

Departments of Health and Social Behavior & Health Education and Health Sociology

Professor in health and social behavior

Hideki Hashimoto, M.D., D.PH.

Lecturer

Daisuke Takagi, Ph. D. (health and social behavior)

Masamitsu Kamada, Ph. D.(health education and health sociology)

Research Associate

Asuka Kato, MPH, Ph.D. (health and social behavior)

Homepage <http://webpark1166.sakura.ne.jp/>

Introduction and Organization

The department originated as one of the first departments dedicated to health education and behavioral science in Japan, led by former Prof. Emeritus Tadao Miyasaka, who had double degrees of M.D. from the University of Tokyo and MPH in health education from Harvard School of Public Health in 1950s. He was succeeded by a sociologist, former Prof. Kyoichi Sonoda who founded the first health sociology department affiliated with the medical school in Japan. Since then, the program has been leading research focusing on socio-behavioral aspects of health in this country. The legend was extended by former Prof. Chieko Kawada who raised academic and practical attention on the concept of empowerment and adult pedagogy in health education. Since 1997, the department was further evolved by Prof. Ichiro Kai who integrated diverse health and social science disciplines into social gerontology program, and by Associate Prof. Yoshihiko Yamazaki who led sociological research projects on salutogenesis, social stigma, power, and agency in health settings. The

departments were reorganized under the newly established School of Public Health since 2007. In 2012, the Department of Social Gerontology has been renamed as the Department of Health and Social Behavior to apply a life-course perspective to a wider range of social conditions and human well-being.

The new department intends to further integrate health science (medicine and public health) and social science (economics, sociology, and psychology) to reveal a causal mechanism linking social structure and individual health for realizing health equity as a fundamental goal to human security.

Teaching activities

The departments offer four courses in the master degree program for public health, and seven courses in the undergraduate program for the Integrated Health Sciences track.

1. Graduate Courses, School of Public Health

- 1) Health and Society I & II: The course was considerably renewed to focus on inequity, discrimination, social exclusion, and

sociopolitical activities to overcome these challenges through community building. The renewed course invites adjunctive lecturers specialized in ageism, gender discrimination, child poverty, and foreign residents in Japan, each focusing a specific topic of social determinants of health. Class II offers more practical topics to make change in social problems through advocacy, social business, and community management, through small group work and student presentation of small projects.

- 2) Health Education: The course provides basic knowledge on relevant behavioral theories for health promotion and behavioral modification, followed by case method learning on health educational intervention in community, school, and work places. The case discussion was facilitated by invited lecturers to reach practical lessons for effective communication.
 - 3) Health Sociology: Sociology in medicine and sociology applied to health issues are treated in the systemic course of lectures, covering social model of health, medical gaze and socialization of health professionals, phenomenology of chronic illness, and culture and health.
 - 4) Comparative health systems in Asia: Started in 2020, jointly offered by Prof. Soonman Kwon in Seoul National University. The course provides basic frame/theory for comparative analysis of health systems and offers specific country cases for in-class discussion.
2. Undergraduate Courses, School of Integrated Health Sciences
- 1) Introduction to social survey and practice; Provides introductory lecture on sampling, psychometrics, design of social survey and questionnaires. Students are asked to conduct a mini social survey within class on the theme they choose as relevant in their class experience.
 - 2) Health and Society (former Health sociology); Lecture series on social model of health generation, social relationship and health, chronic illness experience, and social stigma.
 - 3) Health education
Case scenario based practicum and lectures on health promotion intervention in clinical, school,

and worksite settings.

- 4) Social security and welfare program: Lecture series on the history and the current systems of health care security and welfare policies in this country.
- 5) Integrated Lectures of Public Health Sciences I (jointly offered by the faculty of Health Sciences)
- 6) Scientific writing
- 7) Critical reading/writing of epidemiological studies
- 8) Integrated Practicum of Public Health Sciences II (jointly offered with Department of Medical Ethics).

Research activities

The Department has contributed to an ongoing research of socioeconomic status and health/functions among elderly population in the collaboration with the School of Economics of the University of Tokyo and the Research Institute of Economic, Industry, and Technology. The Japanese Study of Ageing and Retirement (J-STAR) is a sister study with the U.S. Health and Retirement Study, Study of Health, Ageing, and Retirement in Europe (SHARE), England Longitudinal Survey of Ageing (ELSA), and their global sisters in Asian countries. The scope of JSTAR is diverse; contribution of health for successful ageing, social economic conditions and access to health care, household economy and its impact on life styles such as eating habits and nutrition, impact of retirement onto cognitive function, etc..

Since 2010, the Department has launched another panel study of younger generation, the Japanese study of Stratification, Health, Income, and Neighborhood (J-SHINE) in collaboration with researcher groups on neuroscience, economics, sociology, and social psychology. The aim of this comprehensive panel study is to identify a mechanism how socio-economic environments get to “under-skin” to cause social gradient of health across socio-economic positions. In the year of 2011, the JSHINE conducted a supplemental survey to respondent’s spouse and children. Main and supplement surveys were followed in 2012 and 2013, respectively. Obtained panel data are made open to a broader range of researchers under

the data-control committee, to share analytic scheme and to enhance inter-disciplinary studies so as to better identify common factors as well as unique factors affecting health inequality in Japanese context. Following third follow-up for children conducted in 2015-2016, and third follow-up of respondent adults in 2017. Facing the COVID-19 pandemic since early 2020, JSHINE project conducted an additional survey in 2020 December to evaluate the social, psychological, and economic impact incurred by the pandemic and related social restriction policies.

Dr. Takagi, in collaboration with Niigata University, is conducting a longitudinal social epidemiological survey of community-dwelling older adults in Myanmar and Malaysia. In these countries that have distinctive stage of economic development, culture, and ageing rate, this study aims at verifying applicability of the existing social models of health and building new theories based on each country's context. A probability proportionate sampling of sites and selection of local investigators have been completed in 2017, and interview surveys is underway in 2020 before COVID-19 and political difficulty started. Dr. Takagi also conducted in collaboration with a municipal government in Chiba Prefecture a survey targeting regional crime prevalence and the preventive effect through social network structure by using sociometric measurement of social network in a community.

Dr. Kamada, in collaboration with Tokyo Medical University, Harvard University, and Unnan Municipality authority has been conducting a community-based intervention program to enhance exercise habits. He is also actively engaged in developing a gamification program through smartphone to enhance walking habits among the community, of which results are to be published. Dr. Kamada most recently works to develop an application software to objectively obtain daily step counts of iPhone users that would make a technical innovation to facilitate social epidemiology of physical activities in fields.

Prof. Hashimoto has been engaged in a joint project with the Tokyo Metropolitan Government on the information management in the field of welfare programs to tackle child maltreatment since 2020. In the last year, a summary report for standardization

information systems, e-learning system to facilitate effective case recording, and risk prediction models for recurrent case of maltreatment were submitted to the government as project outputs as of March 2023.

Other Social activities

Dr. Kato has been leading the research on social and internalized stigma among the people living with diabetes, of which contribution is extended to enhance advocacy activities in the related academic and subspecialty societies.

Publications

Peer reviewed journals

1. Sasaki Y, Shobugawa Y, Nozaki I, Takagi D, Nagamine Y, Funato M, Chihara Y, Shirakura Y, Lwin KT, Zin PE, Bo TZ, Sone T, Win HH. Association between Happiness and Economic Status among Older Adults in Two Myanmar Regions. *Int J Environ Res Public Health*. 2022 Mar 9;19(6):3216. doi: 10.3390/ijerph19063216.
2. Takagi D, Kondo N, Tsuji T, Kondo K. Parks/sports facilities in local communities and the onset of functional disability among older adults in Japan: The J-shaped spatial spillover effects. *Health Place*. 2022 May;75:102801. doi:10.1016/j.healthplace.2022.102801.
3. Haseda M, Takagi D, Stickley A, Kondo K, Kondo N. Effectiveness of a community organizing intervention on mortality and its equity among older residents in Japan: A JAGES quasi-experimental study. *Health Place*. 2022 Mar;74:102764. doi:10.1016/j.healthplace.2022.102764.
4. Kitagishi T, Takagi D. Information and communication technology, educational attainment, and disparity in health information from one's personal social network: The J-SHINE 2017 cross-sectional study. *PLoS One*. 2022 Sep 28; 17(9):e0275285. doi:10.1371/journal.pone.0275285.
5. Tsuji T, Takagi D, Kondo N, Maruyama Y, Ide K, Lingling, Wang H, Kondo K. [Promoting community gathering places "Kayoinoba" for healthy aging reduce health inequalities among communities: An eight-year ecological study].

- Nihon Kosshu Eisei Zasshi. 2022 May 24; 69(5):383-393. Japanese. doi:10.11236/jph.21-120. Epub 2022 Mar 16. PMID: 35296594.
6. Kamada M, Hayashi H, Shiba K, Taguri M, Kondo N, Lee IM, Kawachi I. Large-Scale Fandom-based Gamification Intervention to Increase Physical Activity: A Quasi-experimental Study. *Med Sci Sports Exerc.* 2022 Jan 1;54(1):181-188. doi: 10.1249/MSS.0000000000002770.
7. Hatakeyama N, Kamada M, Kondo N. Parental Working Hours and Children's Sedentary Time: A Cross-sectional Analysis of the J-SHINE. *J Epidemiol.* 2022 Jan 5;32(1):4-11. doi: 10.2188/jea.JE20200170. Epub 2021 Mar 4.
8. Gomi T, Kitayuguchi J, Okuyama K, Kamada M, Inoue S, Kamioka H, Mutoh Y. Relationship Between Neighborhood Food Environment and Diet Variety in Japanese Rural Community-dwelling Elderly: A Cross-sectional Study. *J Epidemiol.* 2022 Jun 5;32(6):290-297. doi: 10.2188/jea.JE20200415. Epub 2021 Jun 22.
9. Abe T, Kitayuguchi J, Fukushima N, Kamada M, Okada S, Ueta K, Tanaka C, Mutoh Y. Fundamental movement skills in preschoolers before and during the COVID-19 pandemic in Japan: a serial cross-sectional study. *Environ Health Prev Med.* 2022;27(0):26. doi: 10.1265/ehpm.22-00049.
10. Oba K, Kagiwada Y, Kamada M, Miki R, Kondo Y, Kamakura T, Yamagami T, Fujita T, Tsuchida Y. Evaluating the feasibility of a remote-based training program supported by information and communications technology in the older adults living at home. *BMC Geriatr.* 2022 Jul 13; 22(1):574. doi: 10.1186/s12877-022-03273-3.
11. Amagasa S, Kamada M, Bauman AE, Miyachi M, Inoue S. Evaluation of pre-Games effects of the Tokyo 2020 Olympic Games on Japanese population-level physical activity: a time-series analysis. *Int J Behav Nutr Phys Act.* 2022 Aug 6; 19(1):96. doi: 10.1186/s12966-022-01332-x.
12. Watanabe H, Anezaki H, Kazawa K, Tamaki Y, Hashimoto H, Moriyama M. Long-term effectiveness of a disease management program to prevent diabetic nephropathy: a propensity score matching analysis using administrative data in Japan. *BMC Endocr Disord.* 2022 May 20;22(1):135. doi: 10.1186/s12902-022-01040-4.
13. Hashimoto A, Kawaguchi H, Hashimoto H. Contribution of the Technical Efficiency of Public Health Programs to National Trends and Regional Disparities in Unintentional Childhood Injury in Japan. *Front Public Health.* 2022 Jul 12;10:913875. doi:10.3389/fpubh.2022.913875.
14. Kasajima M, Eggleston K, Kusaka S, Matsui H, Tanaka T, Son BK, Iijima K, Goda K, Kitsuregawa M, Bhattacharya J, Hashimoto H. Projecting prevalence of frailty and dementia and the economic cost of care in Japan from 2016 to 2043: a microsimulation modelling study. *Lancet Public Health.* 2022 May;7(5):e458-e468. doi: 10.1016/S2468-2667(22)00044-5.
15. Kim H, Jeon B, Frisina Doetter L, Tamiya N, Hashimoto H. Same same but different? Comparing institutional performance in the long-term care systems of Japan and South Korea. *Social Policy & Administration.* 2022; 56(1), 148-162. <https://doi.org/10.1111/spol.12761>
16. Kumamaru H, Kakeji Y, Fushimi K, Ishikawa KB, Yamamoto H, Hashimoto H, Ono M, Iwanaka T, Marubashi S, Gotoh M, Seto Y, Kitagawa Y, Miyata H. Cost of postoperative complications of lower anterior resection for rectal cancer: a nationwide registry study of 15,187 patients. *Surg Today.* 2022 May 24. doi: 10.1007/s00595-022-02523-6.
17. Nozaki, I., Shobugawa, Y., Sasaki, Y., Takagi, D., Nagamine, Y., Zin, P. E., Bo, T. Z., Nyunt, T. W., Oo, M. Z., Lwin, K. T., & Win, H. H. Unmet needs for hypertension diagnosis among older adults in Myanmar: Secondary analysis of a multistage sampling study. *Health Research Policy and Systems.* 2022 November 29; 20:114. <https://doi.org/10.1186/s12961-022-00918-y>.
18. Obikane E, Sasaki N, Imamura K, Nozawa K, Vedanthan R, Cuijpers P, Shimazu T, Kamada M, Kawakami N, Nishi D. Usefulness of Implementation Outcome Scales for Digital Mental Health (iOSDMH): experiences from six randomized controlled trials. *Int J Environ Res Public Health.* 19:15792, 2022. <https://doi.org/10.3390/ijerph192315792>.

-
19. Murphy J, Milton K, Mclaughlin M, Shilton T, McLoughlin G, Reece LJ, Mair JL, Direito A, Kariippanon KE, Mackenzie KJ, Mavilidi MF, Shellington EM, Kamada M, Heron L, Jauregui E, Abdeta C, Pina I, Pinto R, Sutherland R. Advocating for implementation of the Global Action Plan on Physical Activity: challenges and support requirements. *J Phys Act Health*. 20(1): 10-19, 2023. <https://doi.org/10.1123/jpah.2022-0357>.

Book chapter

1. Takagi, D. (2022). AI-powered recommendations and social relationships. In Y. Sato, Y. Inaba, & Y. Fujiwara (Eds.), *How will AI change society?* (pp. 61-89) The University of Tokyo Press. (Japanese)

School of Public Health

3. Health Services Sciences

Department of Clinical Information Engineering

Professor

Hiroshi Oyama, M.D., Ph.D.

Assistant professor

Kelssy Hitomi dos Santos Kawata, Ph.D.

Homepage: https://webpark1893.sakura.ne.jp/wp/home/cie_en/

Introduction and Organization

Information engineering significantly impacts computer hardware, software, and data processing. It is a discipline that seeks objective data and emphasizes the conception of new data transfer methods, storage, processing, and input/output. It also targets research on developing computer devices and systems.

Reviewing the history of the application of computers in medicine, calculating machines for supporting scientists and technologists first appeared in the 1950s. In the 1960s, computers were used for accounting and various statistics. The personal computer appeared in the 1980s and was adopted for personal use in many professions. The systematization of large hospitals, such as university hospitals, pushed ahead rapidly.

In the 1990s, the computer began to help human thinking, such as in presentations, design, and discovery. When computers became connected through the internet, the distribution of information became very easy and rapid, both within organizations and internationally.

In 2003, a high-quality, "finished" sequence of the human genome was completed. At the dawn of the twenty-first century, bioinformatics appeared as a new discipline, one that uses applied mathematics, informatics, statistics, computer science, and biochemistry to solve biological problems. In medicine, advanced information technologies have been applied to health information infrastructures, electrical clinical

guidelines, and knowledge navigation systems.

In response to the needs of the time, the Department of Clinical Information Engineering (CIE) was established at the School of Public Health in April 2007. Its predecessor was the clinical information engineering division of clinical bioinformatics, using Special Coordination Funds for Promoting Science and Technology from Japan's Ministry of Education, Culture, Sports, Science, and Technology.

Teaching activities

The Department of Clinical Information Engineering aims to nurture talented people with special knowledge and skills at an international level to apply advanced information technologies to practical projects in clinical medicine and the health sciences. It offers courses on information system design, development methodology, evaluation, and project management in biomedicine, health care, and public health in the School of Public Health, and data mining and virtual reality for clinical decision-making in social medicine.

Famous visiting lecturers and researchers from the National Cancer Center and other universities have given lectures here, furthering our hope of becoming a world leader in this field.

The education of graduate students is based on weekly conferences at which the students present their research projects' progress and discuss their future directions.

Research activities

Our research covers biomedical computer applications focusing on data (collection, analysis, and representation). It constitutes a combination of information science, computer science, and clinical science designed to assist in managing and processing data, information, and knowledge to support the practice and delivery of clinical care. Our laboratory is engaged in the following research activities:

A) Computer Graphics & Virtual Reality (VR) for Medical Science: Our research has three goals: to improve the living conditions of in-patients with limited physical activity by providing virtual experiences, to develop new diagnostic methods using medical imaging, and to develop a surgical edutainment and preoperative surgical planning support system in virtual space.

The advantages of simulating surgical procedures using VR techniques include (1) practicing the surgical procedure and image-based training; (2) planning the surgical procedure for individual patients preoperatively using VR images modeled from the patient's preoperative computed tomography (CT) or magnetic resonance (MR) images, in collaboration with the Department of Neurosurgery; (3) allowing supervisors to evaluate a procedure objectively; and (4) helping patients and their families to better understand the surgical procedure before and after the operation.

B) Social Information Engineering for Public Health (Public Health Informatics): Our laboratory researches new tools and methodologies for applying information, computer science, and technology to public health practice, research, and learning. We are studying differences in the computerization of public health in the US and Japan.

2. Koike, T., Tanaka, S., Kin, T., Suzuki, Y., Takayanagi, S., Takami, H., ... Oyama, H. & Saito, N. (2022). Accurate Preoperative Identification of Motor Speech Area as Termination of Arcuate Fasciculus Depicted by Q-Ball Imaging Tractography. *World Neurosurgery*, 164, e764-e7
3. Nagayo, Y., Saito, T., & Oyama, H. (2022). Augmented reality self-training system for suturing in open surgery: A randomized controlled trial. *International Journal of Surgery*, 106650.

References

1. Lem, W. G., dos Santos Kawata, K. H., Kobayashi, T., & Oyama, H. (2023). Public Stigma Related to People With Mental Health Conditions Among Japanese Company Employees. *Journal of Clinical Medicine Research*, 15(3), 139-147.

Department of Global Environmental Health

Associate Professor

Yoonhee Kim, Ph.D.

Homepage <https://sites.google.com/m.u-tokyo.ac.jp/envhealth/>

Introduction and Organization

The Department of Global Environmental Health (GEH) started under the School of Public Health (SPH), Graduate School of Medicine, in April 2018 and has contributed to the master's program (MPH). It has been affiliated with the School of International Health (SIH), Graduate School of Medicine since July 2018 as an Associate Department, accepting master's and doctoral students.

The GEH aims:

1. To study relationships between environmental exposure and human health
2. To produce well-educated professionals with the academic knowledge and ability to undertake environmental epidemiological research

Education

This department provides two postgraduate courses at SPH: 1) Environmental Health and 2) Methods for Environmental Health Research. The former is an introductory course in environmental epidemiology that introduces basic concepts and methods to assess a potential relationship between environmental stressors and health outcomes at both individual and population levels. It provides state-of-the-art scientific knowledge and interpretation for health risk/impact assessment in environmental health perspectives. The latter is an advanced course dealing with statistical and epidemiological methodologies in environmental epidemiology that provides the theory and practice of a specific method to estimate the short-term effects of

environmental risk factors on human health.

Journal Club

GEH has participated in a biweekly conference call with multiple schools/institutes* to read and discuss articles in environmental epidemiology.

*Seoul National University, Korea Advanced Institute of Science & Technology (KAIST), National Institute for Environmental Studies, University of Tsukuba, Kyoto University, and Nagasaki University

GEH R Seminar

Every other Tuesday, 11:00-12:30

Graduate students present fundamental knowledge and skills of R language and its applications, particularly for time-series regression analysis and spatial analysis, that they learned from R textbooks and/or research articles in environmental epidemiology. Sharing the basic and advanced methodologies and discussion helps students develop their capacity to implement research projects.

All course lectures, thesis advising, and discussions in seminars are carried out in English.

Research

Our research interests particularly focus on climate change and air pollution in human populations in the field of environmental epidemiology. We address the scientific questions of how they link, quantify the health risks of a specific environmental factor, and further investigate social determinants that could potentially modify the exposure-response relationships.

Our research collaborations include:

1. Global perspectives of seasonal variability of suicide and the short-term associations between suicide and ambient temperature and air pollution using a large-scale daily time-series database across 26 countries, as a part of the Multi-Country Multi-City (MCC) Collaborative Research Network
2. Health risk assessment of climate change and air pollution in Asian countries, including Japan, South Korea, China, Lao PDR, and Thailand.
3. Nationwide studies on the short-term associations between suicide and ambient temperature and air pollution in Finland
4. Establishment of an early warning system for malaria incidence in southern Africa
- temperature-related mortality. *Scientific Reports* 2022;12:5178.
6. Madaniyazi L, Armstrong B, Chung Y, Ng CFS, Seposo X, Kim Y et al. Seasonal variation in mortality and the role of temperature: a multi-country multi-city study. *International Journal of Epidemiology* 2022;51(1):122-133.

Publications

1. Madaniyazi L, Tobias A, Kim Y, Chung Y, Armstrong B, Hashizume M. Assessing seasonality and the role of its potential drivers in environmental epidemiology: a tutorial. *International Journal of Epidemiology* 2022; 51(5):1677-1686.
2. Roy A, Alam MA, Kim Y, Hashizume M. Association between daily ambient temperature and drug overdose in Tokyo: A time-series study. *Environmental Health and Preventive Medicine* 2022;27:36.
3. Pan R, Honda Y, Minakuchi E, Kim SE, Hashizume M, Kim Y. Ambient temperature and external causes of death in Japan from 1979 to 2015: A time-stratified case-crossover analysis. *Environmental Health Perspectives* 2022;130(4): 047004.
4. Kawano A, Kim Y, Meas M, Sokal-Gutierrez K. Association between satellite-detected tropospheric nitrogen dioxide and acute respiratory infections in children under age five in Senegal: Spatio-temporal analysis. *BMC Public Health* 2022;22:178.
5. Mistry MN, Schneider, R, Masselot P, Royé D, Armstrong B, and MCC Collaborative Research Network. Comparison of weather station and climate reanalysis data for modelling

Endowed Department

Department of Artificial Intelligence in Healthcare

Project Associate Professor

Yoshimasa Kawazoe, M.D., Ph.D.

Project Research Associate

Emiko Shinohara, Ph.D.

Project Research Associate

Mai Hirabayashi, Ph.D.

Project Research Associate

Daisaku Shibata, Ph.D.

Project Researcher

Kiminori Shimamoto, M.E.

Homepage <https://ai-health.m.u-tokyo.ac.jp/>

Introduction and Organization

Practical applications based on the development of AI technology call for a fundamental transformation of the industrial structure. The global spread of COVID-19 has significantly changed the way medical care, economy, and society operate. To maintain and further develop the quality of the Japanese society, which some consider to be in decline because of the falling birth rate, rational and efficient social management based on information and communications technology (ICT) as well as artificial intelligence (AI), become indispensable. This course was established in 2018 at the University of Tokyo Hospital Department of Planning, Information and Management (Graduate School of Medicine Department of Biomedical Informatics) as a collaborative course, to explore the form of new medical services while promoting the development of underlying technologies, such as, ICT and AI. The objective has been to contribute to human resource development by forming a support base for

researchers involved in this field, and to develop joint research beyond the boundaries of faculties and universities to contribute to the development of medical care.

Teaching activities

We have promoted activities to train researchers as well as students in this area inside and outside the university. In 2022, we were in charge of the medical informatics course at the University of Tokyo Faculty of Medicine designed for 4th-year students. We have also taught courses to Graduate School of Medicine School of Public Health professional master's degree students and have contributed to courses on medical RWD human resources development projects for working adults. The courses have focused on AI-related technologies in medical informatics. We have provided research guidance to doctoral students of the Graduate School of Medicine Department of Biomedical Informatics as well as Reproductive, Developmental and Aging Sciences; research

guidance was provided at the individual level.

Research activities

Development of natural language processing technique for medical treatment

Symptoms and clinical findings, the relationship between these and treatment actions are freely described in the medical records of patients, unlike the test values. The structuring and analysis of such textual information are expected to contribute to new clinical medical discoveries and medical safety. The development of a natural language processing technique for structuring text information requires an annotated text corpus with an annotated target text and specific information on the subject of interest (symptoms, findings, etc.). In this course, we plan to target case reports of intractable diseases designated by the Ministry of Health, Labor and Welfare with the aim of developing a case report corpus that consistently and comprehensively annotates expressions that indicate the clinical condition of patients and the treatments that have been performed. By using the annotated information, we aim to extract information, such as the name of the patient's disease, the presence (or absence) of the kind of symptoms, the location of the symptoms, whether they are mild or severe, whether they are related to the treatment performed, the outcome at discharge, etc., from the text for subsequent analysis. We are also developing a machine learning model that accurately reproduces the annotated information. The natural language processing technique we are planning on developing will be able to create text for the clinical fields of medical records, structuring the details of the data.

Application of natural language processing technology

By analyzing electronic medical chart records using computers, we anticipate uncovering new insights into medicine and healthcare. These charts capture a variety of data, of which the freely written text holds significant information. Nevertheless, this textual data has historically posed technical challenges for computerized analysis. Supported by the Japan Science and Technology Agency (JST), this course highlights our use of natural language processing

technology, co-developed with our research partners. Our goal is to further research into unveiling new therapeutic effects from diverse electronic medical chart data. Our studies have already demonstrated the ability to accurately identify known adverse events from chemotherapy within these texts. Moving forward, our research endeavors will focus on discovering novel therapeutic benefits of combined drug treatments, striving to enhance the safety of patient care.

Social activities

1. Gave lectures at various seminars, describing ICT related issues in the medical field utilizing AI.
2. Participated in the HL7-FHIR (Fast Healthcare Interoperability Resources) implementation study working group established under the Japan Association of Medical Informatics Research Group "Academic Research Group for Next Generation Healthcare Record System," and studied the details necessary for proceeding with the implementation of HL7-FHIR in Japan.
3. Involved in the discussions of the collection of clinical information and the construction of information systems as a member of the Designated Core Hospitals for Cancer Genomic Medicine Working Group (RPWG).
4. Promoted the standardization of disease names registered in electronic medical records under the standard disease name master working group.

References

1. Kage H, Shinozaki-Ushiku A, Ishigaki K, Sato Y, Tanabe M, Tanaka S, Tanikawa M, Watanabe K, Kato S, Akagi K, Uchino K, Mitani K, Takahashi S, Miura Y, Ikeda S, Kojima Y, Watanabe K, Mochizuki H, Yamaguchi H, Kawazoe Y, Kashiwabara K, Kohsaka S, Tatsuno K, Ushiku T, Ohe K, Yatomi Y, Seto Y, Aburatani H, Mano H, Miyagawa K, Oda K. Clinical utility of Today OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan. *Cancer Sci.* 2023 Jan 5. doi: 10.1111/cas.15717.
2. Kawazoe Y, Shimamoto K, Yamaguchi R, Nakamura I, Yoneda K, Shinohara E, Shintani-Domoto Y, Ushiku T, Tsukamoto T, Ohe K.

Computational Pipeline for Glomerular Segmentation and Association of the Quantified Regions with Prognosis of Kidney Function in IgA Nephropathy. *Diagnostics*. 2022;12(12): 2955.

3. Shinohara E, Shibata D, Kawazoe Y. Development of comprehensive annotation criteria for patients' states from clinical texts. *J Biomed Inform*. 2022 Oct;134:104200.
4. Kawazoe Y, Shimamoto K, Shibata D, Shinohara E, Kawaguchi H, Yamamoto T. Impact of a Clinical Text-Based Fall Prediction Model on Preventing Extended Hospital Stays for Elderly Inpatients: Model Development and Performance Evaluation. *JMIR Med Inform*. 2022;10(7): e37913.
5. Hayakawa J, Seki T, Kawazoe Y, Ohe K. Pathway importance by graph convolutional network and Shapley additive explanations in gene expression phenotype of diffuse large B-cell lymphoma. *PLoS One*. 2022 Jun 24;17(6):e0269570.
6. Nishimura R, Miyabe Hirabayashi M, Yoshino T. Baseless-Rumor Alert Bot to Promote Reliability of Information. *IPSJ Journal*. 2022;30(1):2-14.

Department of medical research and the management of musculoskeletal pain

Professor

Koh Matsudaira, M.D,Ph.D.

Associate Professor

Hiroyuki Oka, M.D,Ph.D.

Homepage http://www.h.u-tokyo.ac.jp/research/center22/contribute/undouki_toutu.html

Introduction and Organization

The department of medical research and the management of musculoskeletal pain was established at the 22nd Century Medical and Research Centre thanks to donations from ippon Zoki Pharmaceutical Co., Ltd., AYUMI Pharmaceutical Corporation, ONO PHARMACEUTICAL CO., LTD., Chugai Pharmaceutical Co., Ltd., SOMPO Holdings, Inc., NuVasive Japan Co., Ltd., Promotion of Practical Use of AI Medical Diagnosis Support Equipment, MS&AD InterRisk Research & Consulting, Inc, Inotech Co., Ltd., The Association for Preventive Medicine in Japan, DeNA Co., Ltd., Ibuki LLC. The department is a collaboration among the Department of Orthopaedics, the Department of Rehabilitation Medicine. Currently, our aims are to design an algorithm for diagnosing and treating most types of musculoskeletal pain that do not have established treatment guidelines and to elucidate evidence for the possibility of developing causal therapies.

In the “Comprehensive Survey of Living Conditions” and the “Survey on the Status of Occurrence of Diseases at Work,” which were published by the Health, Labour, and Welfare Ministry, the issues affecting the locomotive apparatus over the years, particularly low back pain and joint pain, have been ranked as the top complaints among citizens and as a cause of absence from work. Musculoskeletal pain,

mainly low back pain and joint pain, is an issue with a high complaint rate that causes tremendous social loss.

The course on medical research and the management of musculoskeletal pain was made available to provide more knowledge on highly prevalent musculoskeletal pain and to become a core programme in leading multidisciplinary clinical research.

To achieve these goals, we will closely collaborate with the Department of Orthopaedics, Department of Spinal Surgery, Department of Rehabilitation. On the basis of an extensive epidemiological survey, we will identify risk factors that contribute to determining the therapeutic strategy for treating musculoskeletal pain as well as the prognosis. In addition, on the basis of these determined risk factors, we will develop and propose diagnostic tools/algorithms as well as prevention and treatment programmes. Then we will collect and analyse clinical data and systematise the diagnosis, prevention, and treatment of chronic pain – mainly musculoskeletal pain.

Research activities

We will explore the risk factors that contribute to determining the therapeutic strategy for treating musculoskeletal pain and the prognosis.

Prospects for future research

1) Systematization of chronic pain, mainly motor organ pain (collection and analysis of clinical data)

A manual that can realize back pain prevention in the field of industrial health, treatment and work balance support for workers who have diseases that cause motor pain, such as cancer patients, support for balancing chronic pain and work/reducing health costs.

2) Development of diagnostic tools and treatment programs for musculoskeletal pain

Development of back pain preventive exercise, development of sensor for presenting posture to prevent back pain, development of quantitative evaluation system for knee osteoarthritis X-ray based on a large database, clinical information, and medical images of musculoskeletal diseases. Developed a system that predicts sarcopenia and muscle weakness with high accuracy by using medical equipment (non-invasive and simple ultrasound and artificial intelligence), spinal canal and paraspinal muscle of lumbar spine for quantitative evaluation of fatty degeneration in humans (joint research with Dr. Jeremy Fairbank, University of Oxford).

3) Fostering clinicians who are familiar with musculoskeletal pain assessment and treatment, and enlightening the general public with evidence-based knowledge about musculoskeletal pain

References

1. Arita S, Ishimoto Y, Hashizume H, Nagata K, Muraki S, **Oka H**, Takami M, Tsutsui S, Iwasaki H, Yukawa Y, Akune T, Kawaguchi H, Tanaka S, Nakamura K, Yoshida M, Yoshimura N, Yamada H; Consortium. Is radiographic lumbar spinal stenosis associated with the quality of life?: The Wakayama Spine Study. *PLoS One*. 2022 Feb 17; 17(2):e0263930. doi: 10.1371/journal.pone.0263930. PMID: 35176078; PMCID: PMC8853503.
2. Teraguchi M, Hashizume H, **Oka H**, Cheung JPY, Samartzis D, Tamai H, Muraki S, Akune T, Tanaka S, Yoshida M, Yoshimura N, Yamada H. Detailed Subphenotyping of Lumbar Modic Changes and Their Association with Low Back Pain in a Large Population-Based Study: The Wakayama Spine Study. *Pain Ther*. 2022 Mar; 11(1):57-71. doi: 10.1007/s40122-021-00337-x. Epub 2021 Nov 15. PMID: 34782999; PMCID: PMC8861214.
3. Nishizawa A, Katsuhira J, Watanabe M, Fujii T, Yoshimoto T, **Oka H**, Matsudaira K. Relationship between the locomotive syndrome and kinetic and kinematic parameters during static standing and level walking. *Gait Posture*. 2022 Mar; 93:146-152. doi: 10.1016/j.gaitpost.2022.01.017. Epub 2022 Jan 22. PMID: 35151196.
4. Tamai H, Teraguchi M, Hashizume H, **Oka H**, Cheung JPY, Samartzis D, Muraki S, Akune T, Kawaguchi H, Nakamura K, Tanaka S, Yoshida M, Yoshimura N, Yamada H. A Prospective, 3-year Longitudinal Study of Modic Changes of the Lumbar Spine in a Population-based Cohort: The Wakayama Spine Study. *Spine (Phila Pa 1976)*. 2022 Mar 15;47(6):490-497. doi: 10.1097/BRS.0000000000004301. PMID: 35213525.
5. Horii C, Iidaka T, Muraki S, **Oka H**, Asai Y, Tsutsui S, Hashizume H, Yamada H, Yoshida M, Kawaguchi H, Nakamura K, Akune T, Oshima Y, Tanaka S, Yoshimura N. The cumulative incidence of and risk factors for morphometric severe vertebral fractures in Japanese men and women: the ROAD study third and fourth surveys. *Osteoporos Int*. 2022 Apr;33(4):889-899. doi: 10.1007/s00198-021-06143-7. Epub 2021 Nov 19. PMID: 34797391.
6. Osuka Y, Okubo Y, Nofuji Y, Sasai H, Seino S, Maruo K, Fujiwara Y, **Oka H**, Shinkai S, Lord SR, Kim H. Modifiable intrinsic factors related to occupational falls in older workers. *Geriatr Gerontol Int*. 2022 Apr;22(4):338-343. doi: 10.1111/ggi.14370. Epub 2022 Mar 9. PMID: 35266260.
7. Nagata K, Yamada K, Shinozaki T, Miyazaki T, Tokimura F, Tajiri Y, Matsumoto T, Yamakawa K, **Oka H**, Higashikawa A, Sato T, Kawano K, Karita T, Koyama T, Hozumi T, Abe H, Hodohara M, Kohata K, Toyonaga M, Oshima Y, Tanaka S, Okazaki H; OSSI investigators. Effect of Antimicrobial Prophylaxis Duration on Health Care-Associated Infections After Clean Orthopedic Surgery: A Cluster Randomized Trial.

- JAMA Netw Open. 2022 Apr 1;5(4):e226095. doi: 10.1001/jamanetworkopen.2022.6095. PMID: 35412627; PMCID: PMC9006110.
8. Murata S, Iwasaki H, **Oka H**, Hashizume H, Yukawa Y, Minamide A, Tsutsui S, Takami M, Nagata K, Taiji R, Kozaki T, Yamada H. A novel technique using ultrasonography in upper airway management after anterior cervical decompression and fusion. *BMC Med Imaging*. 2022 Apr 12;22(1):67. doi: 10.1186/s12880-022-00792-8. PMID: 35413818; PMCID: PMC9004088.
 9. Yamada K, Fujii T, Kubota Y, Wakaizumi K, **Oka H**, Matsudaira K. Negative effect of anger on chronic pain intensity is modified by multiple mood states other than anger: A large population-based cross-sectional study in Japan. *Mod Rheumatol*. 2022 Apr 18;32(3):650-657. doi: 10.1093/mr/roab035. PMID: 34910207.
 10. Itoh N, Mishima H, Yoshida Y, Yoshida M, **Oka H**, Matsudaira K. Evaluation of the Effect of Patient Education and Strengthening Exercise Therapy Using a Mobile Messaging App on Work Productivity in Japanese Patients With Chronic Low Back Pain: Open-Label, Randomized, Parallel-Group Trial. *JMIR Mhealth Uhealth*. 2022 May 16;10(5):e35867. doi: 10.2196/35867. PMID: 35576560; PMCID: PMC9152720.
 11. Matsudaira K, **Oka H**, Yoshimoto T. Changing concepts in approaches to occupational low back pain. *Ind Health*. 2022 Jun 1;60(3):197-200. doi: 10.2486/indhealth.60_300. Epub 2022 Apr 15. PMID: 35431293; PMCID: PMC9171122.
 12. Yoshimura N, Iidaka T, Horii C, Mure K, Muraki S, **Oka H**, Kawaguchi H, Akune T, Ishibashi H, Ohe T, Hashizume H, Yamada H, Yoshida M, Nakamura K, Tanaka S. Epidemiology of locomotive syndrome using updated clinical decision limits: 6-year follow-ups of the ROAD study. *J Bone Miner Metab*. 2022 Jul;40(4):623-635. doi: 10.1007/s00774-022-01324-8. Epub 2022 May 10. Erratum in: *J Bone Miner Metab*. 2022 Jun 14;: PMID: 35536512.
 13. Yoshimoto T, Yamada K, Fujii T, Kawamata K, Kasahara S, **Oka H**, Matsudaira K. Validity and Reliability of the Japanese Version of the Örebro Musculoskeletal Pain Screening Questionnaire-Short Form for Chronic Low Back Pain. *Pain Physician*. 2022 Jul;25(4):E681-E688. PMID: 35793192.
 14. Harada T, Hashizume H, Taniguchi T, Iidaka T, Asai Y, **Oka H**, Muraki S, Akune T, Kawaguchi H, Nakamura K, Yoshida M, Tanaka S, Yoshimura N, Yamada H. Association between acetabular dysplasia and sagittal spino-pelvic alignment in a population-based cohort in Japan. *Sci Rep*. 2022 Jul 25;12(1):12686. doi: 10.1038/s41598-022-16865-1. PMID: 35879394; PMCID: PMC9314415.
 15. Yoshimura N, Iidaka T, Horii C, Mure K, Muraki S, **Oka H**, Kawaguchi H, Akune T, Ishibashi H, Ohe T, Hashizume H, Yamada H, Yoshida M, Nakamura K, Tanaka S. Correction to: Epidemiology of locomotive syndrome using updated clinical decision limits: 6-year follow-ups of the ROAD study. *J Bone Miner Metab*. 2022 Sep;40(5):872. doi: 10.1007/s00774-022-01349-z. Erratum for: *J Bone Miner Metab*. 2022 Jul;40(4):623-635. PMID: 35699791.
 16. Yoshimura N, Iidaka T, Horii C, Muraki S, **Oka H**, Kawaguchi H, Nakamura K, Akune T, Tanaka S. Trends in osteoporosis prevalence over a 10-year period in Japan: the ROAD study 2005-2015. *J Bone Miner Metab*. 2022 Sep; 40(5):829-838. doi: 10.1007/s00774-022-01352-4. Epub 2022 Aug 29. PMID: 36038673.
 17. Tonosu J, **Oka H**, Watanabe K, Abe H, Higashikawa A, Kawai T, Yamada K, Nakarai H, Tanaka S, Matsudaira K. Relationship Between Sacroiliac Joint-related Pain and Spinopelvic Mobility. *Spine (Phila Pa 1976)*. 2022 Sep 15; 47(18):E582-E586. doi: 10.1097/BRS.0000000000004390. Epub 2022 Jun 29. PMID: 35793690.
 18. Kozaki T, Hashizume H, Taniguchi T, Nishiyama D, Iwasaki H, Tsutsui S, Takami M, Nagata K, Fukui D, Yamanaka M, Tamai H, Taiji R, Murata S, **Oka H**, Yamada H. S2 alar-iliac screw loosening as a preventive factor for hip joint osteoarthritis after adult spinal deformity surgery: a case-control study. *Eur Spine J*. 2022 Nov; 31(11):3081-3088. doi: 10.1007/s00586-022-07344-2. Epub 2022 Aug 23. PMID: 35999305.
 19. Matsubara T, Soma K, Yamada I, Fujita H, Yoshitani J, **Oka H**, Okada H, Tanaka S. Offset nail fixation for intertrochanteric fractures

improves reduction and lag screw position. PLoS One. 2022 Nov 16;17(11):e0276903. doi: 10.1371/journal.pone.0276903. PMID: 36383515; PMC 9668128.

Department of Osteoimmunology

Project Associate Professor

Kazuo Okamoto, Ph.D.

Project Assistant Professor

Masayuki Tsukasaki, Ph.D.

Homepage <http://www.osteoimmunology.com/kifu/index.html>

Introduction and Organization

Bone is a key component of the skeletal-locomotor system and serves as a calcium reservoir regulated by the endocrine system in vertebrates. Bone also acts as the “primary lymphoid organ” that harbors and mobilizes hematopoietic stem cells (HSCs) and immune progenitor cells. Furthermore, the bone and immune systems are closely related through a number of shared regulatory molecules including cytokines, receptors and signaling molecules. Osteoimmunology is an interdisciplinary research field that investigates the shared mechanisms and crosstalks between the bone and the immune systems. Studies on bone destruction associated rheumatoid arthritis (RA) have highlighted regulation of bone by the immune cells and promoted this field. As seen in the clinical benefits of anti-TNF antibody, anti-IL-6 antibody and CTLA4-Ig on inflammation and osteoclast differentiation for the treatment of RA, the osteoimmunological insight is now of growing importance in clinical applications. It is necessary to comprehensively understand the interplay between bone and immune systems for elucidation of the molecular mechanisms underlying the pathogenesis of various bone diseases (osteoporosis, osteoarthritis, periodontal disease etc.) and immune diseases (autoimmune diseases, infectious diseases etc.).

Osteoimmunology is now emphasized by not only the academic but also clinical sides, and the international competition has intensified in both basic and pharmaceutical researches. This department was founded as a new department focusing on the osteo-

immunology in May 2016. The second term started in May 2019, and was temporarily suspended in June 2022. Subsequently, the third phase started in November 2022, with support from AYUMI Pharmaceutical Corporation, ELECOM, JCR Pharmaceuticals, Kondo Cotton Spinning, MIKIHOUSE, MITSUI FUDOSAN, Meiji, Noevir, TAKENAKA, TENNENBUTSU IKAGAKU KENKYU ZAIDAN and Yakult. We aim to understand the mechanisms underlying the pathogenesis of various skeletal and immune diseases, and to provide the molecular basis for novel drug discovery in the field.

Teaching activities

As for under-graduate education, our department takes a part in systemic lectures. We train post-doctoral fellows, graduate and post-graduate students in Department of Immunology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo.

Research activities

By extending the concept of osteoimmunology to various skeletal and immune diseases, we aim to comprehensively elucidate the crosstalks between the bone and immune systems involved in the pathogenesis of the diseases, and provide the molecular basis for novel therapeutic strategies. Our achievement would help to improve the welfare and raise the level of medical treatment in the world.

Main research achievements

RANKL in bone, immunity and cancer

Bone is a dynamic organ that continuously undergoes a process involving resorption and formation (bone remodeling), which are mediated by osteoclasts and osteoblasts, respectively. An imbalance of bone resorption and formation is often central to metabolic bone diseases, including bone destruction in RA, postmenopausal osteoporosis, bone tumors and osteopetrosis. Osteoclasts are large, multinucleated cells formed by the fusion of precursor cells of monocyte/macrophage lineage. Mature osteoclasts degrade bone matrix proteins by secreting proteolytic enzymes and decalcify the inorganic components of bone by releasing hydrochloric acid. RANKL is an essential cytokine for osteoclast differentiation. RANKL, which are produced by the supporting mesenchymal cells including osteoblasts, osteocytes and synovial fibroblasts, binds to its receptor RANK expressed on osteoclast precursor cells. Mice with a disruption of either *Rank* or *Rankl* exhibit severe osteopetrosis accompanied by a tooth eruption defect resulting from a complete lack of osteoclasts. Mutations in the *RANK* and *RANKL* genes have been identified in human patients with bone disorders such as autosomal recessive osteopetrosis. These genetic findings clearly demonstrate that RANK/RANKL signaling is essential for osteoclastogenesis *in vivo*. We aim to elucidate the molecular mechanism underlying RANKL-induced osteoclast differentiation, in order to develop the novel therapeutic strategies for the treatment of various bone diseases such as RA and osteoporosis (Tsukasaki et al, *J Bone Miner Res*, 2016; Okamoto et al, *Physiol Rev*, 2017). Recently, we have elucidated the mechanism of osteoclastogenesis at the single cell level by single-cell RNA sequencing analysis. Osteoclast differentiation pathway can be divided into multi stages, and we identified a number of genes that determine each differentiation stage. We found that the transcriptional regulator *Cited2* regulates the terminal differentiation step by promoting cell cycle arrest. The single-cell analysis data covering all pathways of osteoclast differentiation would be a useful resource for the development of therapeutic treatments targeting osteoclasts (Tsukasaki et al, *Nat Metab*, 2020).

RANKL plays crucial roles in not only osteoclast differentiation but also the immune system, including lymph node development, thymic epithelial cell differentiation and M cell differentiation in gut. Thus, RANKL is one of the most important factors explicitly linking the skeletal and immune systems. RANKL is synthesized as a membrane-bound molecule, which is cleaved into the soluble form by proteases. Both forms function as agonistic ligands for RANK. However, the functional difference between the membrane-bound and soluble forms of RANKL had been poorly understood *in vivo*. Thus, we tried to elucidate the physiological and pathological significances of soluble RANKL by generating mice that selectively lack soluble RANKL. Soluble RANKL-deficient mice did not show any discernible osteopetrotic phenotype. In addition, soluble RANKL made no contribution to ovariectomy-induced osteoporosis. Thus, membrane-bound RANKL mainly functions in osteoclast differentiation *in vivo*. Furthermore, unlike RANKL-null mice, soluble RANKL-deficient mice had normal development of the immune organs, including lymph node development, thymic medullary epithelial cell differentiation and M cell differentiation. Collectively, we demonstrated that soluble RANKL is dispensable for physiological regulation of bone and immune systems (Asano et al, *Nat Metab*, 2019).

RANKL also deeply contributes to the pathogenesis of bone metastasis. In bone, tumor cells induce the RANKL expression in osteoblasts through the production of PTHrP and IL-6. RANKL promotes osteoclastic bone resorption, which provides space for tumor expansion and releases certain growth factors from the degraded bone matrices to stimulate tumor growth, forming a vicious cycle. In addition, RANK is expressed at high levels on many different epithelial tumor cells that preferentially metastasize to bone. RANKL acts directly on RANK-expressing tumor cells to increase tumor migration to bone. Notably, soluble RANKL contributes to bone metastasis by exerting a chemotactic activity in tumor cells expressing RANK. Soluble RANKL deficiency in mice markedly suppressed the metastasis of murine melanoma cell line B16F10 and breast cancer cell line EO771, both of which express RANK, to bone (Asano et al, *Nat Metab*, 2019; Okamoto, *J Bone*

Miner Metab, 2021). Interestingly, the recent human study indicates that breast cancer patients with high levels of serum RANKL had an increased risk of developing bone metastases. Thus, to measure the serum RANKL level may help identify the patients who have a high risk of development of bone metastasis.

In rheumatoid arthritis, synovial fibroblasts act as the main source of RANKL that induces osteoclastic bone resorption in joints. Recent single cell analyses have shown that synovial fibroblasts could be classified into two subsets, inflammation type and tissue-destructive type. By analyzing the mechanism of transcriptional regulation of RANKL, we revealed that transcriptional factor ETS1 drives the polarization toward tissue-destructive fibroblasts in rheumatoid arthritis (Yan et al, *Nat Immunol*, 2022).

The RANKL decoy receptor osteoprotegerin (OPG) regulates bone metabolism and the immune organ development as an inhibitor of RANKL signal. OPG is a soluble protein, which also circulates in the blood. By analyzing osteoblast-specific, thymic epithelial cell-specific and intestinal epithelial cell-specific OPG-deficient mice, we showed that bone metabolism, thymic epithelial cell differentiation and M cell differentiation is controlled by OPG locally produced in bone, thymus and intestine, respectively, but not by circulating OPG. The findings further revealed the importance of local regulation of the RANKL/RANK system (Tsukasaki et al, *Cell Rep*, 2020).

Recently, a fully human anti-RANKL neutralizing antibody has been introduced for the treatment of osteoporosis and skeletal-related events by bone tumors. We have evaluated the efficacy of the novel small molecule inhibitor against RANKL signaling using mouse disease models (Guerrini et al, *Immunity*, 2015). Using the mouse models of bone metastasis, we have demonstrated that oral administration of the small-molecule RANKL inhibitor against RANKL suppressed the metastasis of human breast cancer cell line and murine melanoma cell line to bone (Nakai et al, *Bone Res*, 2019).

Roles of T cells in bone destruction associated with inflammation

The bone destruction in RA is the result of the enhanced osteoclast activity due to the inflammatory

responses triggered by the activation of pathogenic helper T cells. We previously reported using a mouse model of autoimmune arthritis that a subset of Foxp3⁺ T cells loses Foxp3 expression under arthritic conditions and converts into IL-17-producing T cells (called exFoxp3Th17 cells). exFoxp3Th17 cells display a greater capacity for inducing both synovitis and osteoclastic bone resorption (Komatsu et al, *Nat Med*, 2014). The conversion of Foxp3⁺ T cells into effector T cells has also been observed in various diseases such as diabetes and multiple sclerosis. We have recently demonstrated that exFoxp3Th17 cells also act as osteoclastogenic T cells in alveolar bone destruction in periodontitis. exFoxp3Th17 cells accumulate in periodontitis tissues in response to oral bacteria, and stimulate mesenchymal cells including osteoblastic cells and periodontal ligament cells to induce RANKL. We found that exFoxp3Th17 cells protect against bacteria by evoking mucosal immune responses as well as removing the tooth (Tsukasaki et al, *Nat Commun*, 2018). Our findings introduce a new concept that bone destruction contributes to the host defense against oral bacteria in periodontitis.

In recent years, Jak inhibitors have attracted attention as potential agents for the autoimmune diseases such as rheumatoid arthritis. We have recently found that protein arginine methylation, a post-translational modification, is critically involved in the regulation of the Jak signaling pathway. T cell-specific deficiency of the arginine methyltransferase PRMT5 led to a decrease in the number of peripheral CD4, CD8 and regulatory T cells, and an almost complete loss of iNKT cells. PRMT5-mediated arginine methylation was essential for the expression of the cytokine-signal-transducing components, the common cytokine receptor γ -chain (γ_c) and JAK3, which are required for the development of iNKT cells and the proliferation and survival of peripheral T cells. PRMT5 induced the arginine methylation of the spliceosomal component SmD3 that promoted the splicing of pre-mRNA encoding γ_c and JAK3 (Inoue et al, *Nature Immunol*, 2018). This study presented a novel regulatory mechanism governing γ_c family cytokine-Jak3 signaling in T cells.

Immune regulation by osteoblast in the bone marrow

HSCs have the capacity to differentiate into all immune cells, and their activities require extrinsic signals from the microenvironments (niches) in the bone marrow. Various cell types including CXCL12-abundant reticular (CAR) cells, leptin receptor-expressing perivascular stromal cells, Nestin⁺ perivascular cells and neural cells have been shown to be important for HSC maintenance. Although osteoblasts were first reported to function as the HSC niche in the early 2000s, the significance of the osteoblastic niche had remained unclear. In order to clarify the role of osteoblasts in the hematopoiesis in the bone marrow, we generated an inducible deletion system of osteoblasts in adult mice. We found that inducible ablation of osteoblast had no effect on the HSCs but reduced the number of both common lymphoid progenitors in the bone marrow and lymphocytes in the periphery. Osteoblast-derived IL-7 is required for development of common lymphoid progenitors in the bone marrow (Terashima et al, *Immunity*, 2016). Moreover, we showed that sepsis reduces the osteoblast number, which induces lymphopenia through IL-7 downregulation. Our study identified a novel mechanism by which bone cells regulate the immune system.

References

1. Yan M, Komatsu N, Muro R, Huynh NC, Tomofuji Y, Okada Y, Suzuki HI, Takaba H, Kitazawa R, Kitazawa S, Pluemsakunthai W, Mitsui Y, Satoh T, Okamura T, Nitta T, Im SH, Kim CJ, Kollias G, Tanaka S, Okamoto K, Tsukasaki M, Takayanagi H. ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts. *Nat Immunol.* 23:1330-1341, 2022
2. Ono T, Denda R, Tsukahara Y, Nakamura T, Okamoto K, Takayanagi H, Nakashima T. Simultaneous augmentation of muscle and bone by locomimeticism through calcium-PGC-1 β signaling. *Bone Res.* 10:52, 2022
3. Tsukasaki M, Komatsu N, Negishi-Koga T, Huynh NC, Muro R, Ando Y, Seki Y, Terashima A, Pluemsakunthai W, Nitta T, Nakamura T, Nakashima T, Ohba S, Akiyama H, Okamoto K, Baron R, Takayanagi H. Periosteal stem cells control growth plate stem cells during postnatal skeletal growth. *Nat Commun.* 13: 4166, 2022
4. Tsukasaki M, Takayanagi H. Osteoclast biology in the single-cell era. *Inflamm Regen.* 42: 27, 2022

Department of Computational Diagnostic Radiology and Preventive Medicine

Project Professor

Naoto Hayashi, M.D.,Ph.D.

Project Associate Professor

Takeharu Yoshikawa, M.D.,Ph.D.

Project Research Associate

Kensuke Asaba, M.D.,Ph.D., Katsuhiko Koyama, M.D., Ph.D., Takayuki Fujiwara, M.D., Ph.D., Takahiro Nakao, M.D., Ph.D., Kanna Fujita, M.D., Ph.D., Mai Shimbo, M.D., Ph.D.
Saori Koshino, M.D., Ph.D.

Project researcher

Masaya Akiyama, M.S., Alam Md Ashraful, Ph.D., Yukihiro Nomura, Ph.D., R.T.

Homepage <http://www.ut-radiology.umin.jp/division/cdrpm.html>

Introduction and Organization

The Department of Computational Diagnostic Radiology and Preventive Medicine (CDRPM) was established in May 2005. It is under the supervision of the Department of Radiology.

The aim of our research project is as follows: (1) to create a large database of health screening clinical data including medical images, (2) to develop methods to analyze large volumes of medical images and to search for algorithms to detect subtle abnormal findings in these images, and (3) to evaluate the clinical usefulness of such image processing methods and to apply the system in clinical settings.

The department comprises twelve professors and three project researchers, along with a medical staff of approximately 70 employees in the health-screening center.

Clinical Activities

CDRPM is responsible for the clinical activities in the CDRPM Health Screening Center. The following diagnostic imaging modalities are installed to facilitate high level of diagnostic accuracy: positron emission computed tomography (PET), 3-tesla magnetic resonance imaging (3T-MRI) system, multi-detector CT (MDCT), ultrasound imaging system, and digital mammography.

Teaching Activities

At present, CDRPM does not accept students. However, CDRPM participates in the education of students and residents in the Department of Radiology. CDRPM endeavors to help students whose research themes include image analysis such as computer-assisted detection, or epidemiologic studies employing health-screening data.

Research Activities

1) Health screening database

We have developed a unique health screening information system to facilitate daily management of the health screening activities and to input health screening data. This information system is still under constant revision. The medical images acquired in the health screenings are stored in the hospital picture archiving and communication system (PACS) for clinical use. Medical images used solely for research purposes are stored in an independent PACS installed inside the CDRPM department.

2) Image processing software development

We have structured an integrated software developing system to facilitate the production of image processing software. The system is divided into the clinical part and the research part, with the data in the latter being anonymized. The clinical part consists of case entry for software development, and clinical application of the developed software. The research part consists of an interface to obtain images of the representative cases to develop the software, and an interface to test the developed software with the accumulated cases.

3) Clinical evaluation, application of software, and epidemiological studies

Researches based on the health-screening database are carried out in collaboration with other researchers of various specialties. Images are analyzed using the developed software.

References

- 1) Takahashi M, Takenaga T, Nomura Y, Hanakoka S, Hayashi N, Nemoto M, Nakao T, Miki S, Yoshikawa T, Kobayashi T, Abe S. Automated volume measurement of abdominal adipose tissue from entire abdominal cavity in dixon MR images using deep learning. *Radiol Phys Technol*. 2023;16(1):28-38. doi:10.1007/s12194-022-00687-x.
- 2) Ishii S, Hatano M, Maki H, Minatsuki S, Saito A, Yagi H, Shimbo M, Soma K, Numata G, Fujiwara T, Takeda N, Komura I. Prognostic value of follow-up vasoreactivity test in pulmonary arterial hypertension. *J Cardiol*. 2023. doi: 10.1016/j.jjcc.2023.01.005.
- 3) Kikuchi T, Hanaoka S, Nakao T, Nomura Y, Yoshikawa T, Alam A, Mori H, Hayashi N. Significance of FDG-PET standardized uptake values in predicting thyroid disease. *European Thyroid Journal*. 2023;12(1):e220165. doi: 10.1530/ETJ-22-0165.
- 4) Yoshikawa T, Miki S, Nakao T, Koshino S, Hayashi N, Abe O. Axillary lymphadenopathy after pfizer-BioNTech and moderna COVID-19 vaccination: MRI evaluation. *Radiology*. 2023; 306(1):270-278. doi: 10.1148/radiol.220814.
- 5) Sasako T, Kadowaki H, Fujiwara T, et al. Severe aortic stenosis during leptin replacement therapy in a patient with generalized lipodystrophy-associated progeroid syndrome due to an LMNA variant: A case report. *J Diabetes Investig*. 2022;13(9):1636-1638. doi: 10.1111/jdi.13827.
- 6) Shibata H, Hanaoka S, Nomura Y, Nakao T, Takenaga T, Hayashi N, Abe O. On the simulation of ultra-sparse-view and ultra-low-dose computed tomography with maximum a posteriori reconstruction using a progressive flow-based deep generative model. *Tomography (Ann Arbor)*. 2022;8(5):2129-2152. doi: 10.3390/tomography8050179.
- 7) Shimbo M, Hatano M, Ishii S, et al. Renal replacement therapy as a therapeutic option for right heart failure in severe pulmonary arterial hypertension. *ESC Heart Fail*. 2022;9(4):2728-2731. doi: 10.1002/ehf2.13945.
- 8) Nakao T, Hanaoka S, Nomura Y, Hayashi N, Abe O. Anomaly detection in chest 18F-FDG PET/CT by bayesian deep learning. *Jpn J Radiol*. 2022; 40(7):730-739. doi: 10.1007/s11604-022-01249-2.
- 9) Hoshiai S, Hanaoka S, Masumoto T, Nomura Y, et al. Effectiveness of temporal subtraction computed tomography images using deep learning in detecting vertebral bone metastases. *Eur J Radiol*. 2022;154:110445. doi: 10.1016/j.ejrad.2022.110445.
- 10) Itai S, Tonosaki K, Ono S, Watanabe R, Koshino S, et al. The inhibitory effect of catechin on the growth of oral bacteria in vitro and halitosis in a clinical setting. . 2022:in press.

-
- 11) Nakayama A, Kodera S, Morita H, Fujiwara T, Takeda N, Komuro I. Cost-effectiveness of management for hospitalized patients; gender difference between female and male cardiologists. *International Heart Journal*. 2022;63(2):264-270. doi: 10.1536/ihj.21-451.
 - 12) Yoshikawa M, Asaba K, Nakayama T. Estimating causal effects of genetically predicted type 2 diabetes on COVID-19 in the east asian population. *Front Endocrinol*. 2022;13. doi: 10.3389/fendo.2022.1014882.
 - 13) Shimbo M, Amiya E, Komuro I. Telemonitoring during exercise training in cardiac telerehabilitation: A review. *Rev. Cardiovasc. Med*. 2023;. ;24(4). doi: 10.31083/j.rcm2404104.

Department of Cell Therapy in Regenerative Medicine

Specially Appointed Associate Professor

Dehua Chang, M.D., Ph.D.

Researcher and Associate

Zhu Shuoji (Ph.D. Student), Shentu Yunchao, Tajima Michiko, Kobayashi Masaki,
Katsuhiko Kida

Administrative Assistant

Noriko Kajiwara

Department Outline

The Department of Cell Therapy in Regenerative Medicine was established in 2021 to promote practical technologies for regenerative medicine, such as developing the mass culture of 3D mesenchymal stem cells (MSCs) and diagnostic imaging related to MSCs. MSCs are stem cells derived from the mesoderm, a type of somatic stem cell, and can differentiate into bone, cartilage, cardiomyocytes, etc. MSC culture methods are classified into two types: adhesive cells (2D) and floating cells (3D). The advancement and application of regenerative medicine necessitate a stem cell culture method that facilitates faster proliferation, enhanced stemness, and improved functionality. Our department aims to develop technology for the mass culture of high-quality MSCs using Cellhesion®, a scaffold material developed by Nissan Chemical Corporation. Recently, cell quality evaluation has become necessary to ensure reproducibility, reliability, and accuracy in drug discovery research using cultured cells. MSCs express marker genes, such as CD105, CD73, CD90, etc. However, since it is impossible to determine the quality of MSCs, such as whether they are increasing cells or not, even if these markers are expressed, it is essential to have a method to evaluate the quality of MSCs. In addition, because MSCs vary among tissues of origin, donors, and other factors, even MSCs with a

low number of passages may not increase and cannot be passaged. At present, it is left to the operator to decide at what stage to discontinue the culture. Our department will use Nikon Corporation's cell imaging technology to evaluate cell quality during MSC 3D mass culture.

Research Content

Nissan Chemical Corporation has pioneered in regenerative medicine by developing the scaffold material Cellhesion® for cultivating UCMSCs, demonstrating approximately seven times the anti-inflammatory efficacy compared to traditional 2D cultivated cells, showcasing substantial potential for treating various diseases. In this study, we conducted a comprehensive assessment of the proliferative capacity of UCMSCs cultivated in both 2D and 3D environments, accompanied by an analysis and evaluation of secretion factors related to angiogenic factors, angiogenesis, cell migration, self-replication capacity, and multi-differentiation ability of UCMSCs in vitro study.

The 3D-cultured UCMSCs maintain their inherent characteristics as mesenchymal stem cells and preserve their potential to differentiate into bone, cartilage, and adipose tissues. Comparative studies have shown that 3D culture enhances cell proliferation and increases the

secretion of vascular growth factors like HGF, VEGF, IL-6, and IL-8 compared to 2D culture. In 3D culture, there was a considerable increase in angiogenesis, total extension, and branching points compared to 2D culture, as shown by in vitro angiogenesis assays.

It has been observed that UCMSCs when cultivated in a 3D environment using Cellhesion® material, maintain their undifferentiated and migratory capacities. Additionally, they exhibit noteworthy and enhanced cellular activity, which is not attainable through 2D cultivation. Therefore, it is highly likely that the use of Cellhesion® material can provide significant potential and opportunities for advancements in regenerative medicine and cellular therapy.

Future Outlook

We aim to evaluate the anti-inflammatory and angiogenic effects of 3D-cultured MSCs optimized for large-scale cultivation. In future studies, we plan to assess the effectiveness of administering supernatants that contain 3D cultured MSCs and angiogenic factors in vivo models of knee osteoarthritis and lower limb ischemia. We aim to explore their potential benefits in promoting vascular regeneration and reducing inflammation. Our goal is to assess the efficacy of these treatments while ensuring that 3D-cultured MSCs are safe and reliable.

References

1. Liu G, David BT, Trawczynski M, Fessler RG. Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. *Stem Cell Rev Rep*. 2020; 16(1):3-32.
2. Zucchelli E, Birchall M, Bulstrode NW, Ferretti P. Modeling Normal and Pathological Ear Cartilage *In vitro* Using Somatic Stem Cells in Three-Dimensional Culture. *Front Cell Dev Biol*. 2020 Jul 28; 8:666. doi: 10.3389/fcell.2020.00666. PMID: 32850801; PMCID: PMC7402373.
3. Lechanteur C, Briquet A, Giet O, Delloye O, Baudoux E, Beguin Y. Clinical-scale expansion of mesenchymal stromal cells: a large banking experience. *J Transl Med*. 2016 May 20;14(1):145. doi: 10.1186/s12967-016-0892-y. PMID: 27207011; PMCID: PMC4875672.
4. Eun Seo Kim, Katsuhiko Kida, Jongsoo Mok, et al. Cellhesion VP enhances the immunomodulating potential of human mesenchymal stem cell-derived extracellular vesicles. *Biomaterials*, 2021 Volume 271: 120742.DOI: 10.1016/j.biomaterials.2021.120742.
5. Li-Tzu Wang, Chiao-Hsuan Ting, Men-Luh Yen, Ko-Jiunn Liu, Huey-Kang Sytwu, Kenneth K Wu, B Linju Yen. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials. *J Biomed Sci*. 2016 Nov 4; 23(1):76.
6. Katsuda T, Kosaka N, Takeshita F, Ochiya T. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. *Proteomics*. 2013 May; 13 (10-11): 1637-1653.
7. Lechanteur C, Briquet A, Giet O, Delloye O, Baudoux E, Beguin Y. Clinical-scale expansion of mesenchymal stromal cells: a large banking experience. *J Transl Med*. 2016 May 20;14(1):145. doi: 10.1186/s12967-016-0892-y. PMID: 27207011; PMCID: PMC4875672.
8. Levenberg S, Burdick JA, Kraehenbuehl T, et al. Neurotrophin-Induced Differentiation of Human Embryonic Stem Cells on Three-Dimensional Polymeric Scaffolds. *Tissue Eng* 2005; 11:506–512.
9. Dominici M, Blanc KL, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; 8:315–317.
10. Kida K, Kanaki T, Gao S, et al. A Novel 3D Culture System Using a Chitin-Based Polysaccharide Material Produces High-Quality Allogeneic Human UCMSCs with Dispersed Sphere Morphology. *Cells* 2022; 11:995.
11. Cesarz Z, Tamama K. Spheroid Culture of Mesenchymal Stem Cells. *Stem Cells Int* 2016; 2016:9176357.

Department of Home Care Medicine

Project Associate Professor

Takashi Yamanaka, M.D., Ph.D.

Project Lecturer

Jiro Okochi, M.D., Ph.D.

Project Research Associate

Kiwami Kidana, M.D., Ph.D., Shota Hamada, R.Ph., Dr.P.H.

Project Researcher

Shigemasa Katayama, M.D., Ph.D., Tatsuya Kurokawa, M.D., Ph.D.,
Maiko Mizuki, MPH.

Homepage <http://chcm.umin.jp/>

Introduction and Organization

Department of Home Care Medicine was established in 2018 at the 22nd Century Medical and Research Center in the University of Tokyo Hospital based upon contributions by Mr. Kazuteru Noguchi, JSH Co., Ltd., Japan Home Medical Care Inc., Towa Pharmaceutical Co. Ltd., Sawai Pharmaceutical Co. Ltd., and Ain Pharmaciez. Our department collaborates with Department of Geriatric Medicine. We have taken over educational activities and research activities from Center for Home Care Medicine, Faculty of Medicine. With the increase in the elderly population, home care medicine is more needed compared with the past. We teach home care medicine to medical students and trainee doctors along with studying the topics of home care medicine to systematize it.

Education

Clinical education of home care medicine is provided for fifth and sixth year medical students. We create a personalized mandatory program of home care medicine and give an orientation of the program. Then medical students learn about home care medicine with

physicians, nurses, medical social workers or care managers in the community.

We also create a program of home care medicine for trainee doctors who wish to learn about it.

Research

The main themes of our study were as follows.

- 1) Educational program development of home care medicine and studying the educational effectiveness of the program
- 2) Building a case registry system of home medical care
- 3) Follow-up study on QOL or prognosis of patients who receive home medical care and their care givers
- 4) Drug treatment in home medical care
- 5) Skills of medical therapeutics and care in home care medicine

Publications

1. Kuroda N, Iwagami M, Hamada S, Komiyama J, Mori T, Tamiya N. Associations of polypharmacy and drugs with sedative or anticholinergic

properties with the risk of long-term care needs certification among older adults in Japan: A population-based, nested case-control study. *Geriatr Gerontol Int.* 2022;22(7):497-504.

2. Hattori Y, Hamada S, Ishizaki T, Sakata N, Iwagami M, Tamiya N, Akishita M, Yamanaka T. National trends in gastrostomy in older adults between 2014 and 2019 in Japan. *Geriatr Gerontol Int.* 2022;22(8):648-652.
3. Yamanaka T, Kidana K, Mizuki M, Hattori Y, Hamada S, Akishita M. Sex differences in places of home care. *Geriatr Gerontol Int.* 2022;22(9): 813-814.
4. Yamanaka T, Kidana K, Yamaguchi Y, Hirahara S, Hirakawa Y, Mizuki M, Arai H, Akishita M, Miura H. Palliative home care for older patients with respiratory disease in Japan: Practices and opinions of physicians. *Geriatr Gerontol Int.* 2022;22(11):943-949.
5. Hattori Y, Hamada S, Yamanaka T, Kidana K, Iwagami M, Sakata N, Tamiya N, Kojima T, Ogawa S, Akishita M. Drug prescribing changes in the last year of life among homebound older adults: national retrospective cohort study. *BMJ Support Palliat Care.* 2022:bmjspcare-2022-003639.
6. Yamaguchi Y, Saif-Ur-Rahman KM, Nomura M, Ohta H, Hirakawa Y, Yamanaka T, Hirahara S, Miura H. Opioid Prescription Method for Breathlessness Due to Non-Cancer Chronic Respiratory Diseases: A Systematic Review. *Int J Environ Res Public Health.* 2022;19(8):4907.
7. Sun Y, Iwagami M, Sakata N, Ito T, Inokuchi R, Uda K, Hamada S, Ishimaru M, Komiyama J, Kuroda N, Yoshie S, Ishizaki T, Iijima K, Tamiya N. Development and validation of a risk score to predict the frequent emergency house calls among older people who receive regular home visits. *BMC Prim Care.* 2022;23(1):132.
8. Tsuchiya-Ito R, Hamada S, Slaug B, Ninomiya A, Uda K, Ishibashi T. Implementation and costs of housing adaptations among older adults with different functional limitations in Japan. *BMC Geriatr.* 2022;22(1):444.

Department of Therapeutic Strategy for Heart Failure

Research Associate Professor

Eisuke Amiya, M.D., Ph.D (2021/11/1-)

Research Assistant Professor

Seitaro Nomura, M.D., Ph.D(-2023/3/31)

Toshiyuki Ko, M.D., Ph.D (2021/11/1-)

Genri Numata, M.D., Ph.D(2023/4/1-)

Project Researcher

Naoko Kato, Ph.D

Homepage <http://plaza.umin.ac.jp/~heart-f/>

Introduction and Organization

The Department of Therapeutic Strategy for Heart Failure (TSHF) in the University of Tokyo Hospital was established by the support of the Department of Cardiac Surgery and the Department of Cardiovascular Medicine of the University of Tokyo Hospital in May 2008. The purpose to establish the department of TSHF is to promote surgical and medical innovative treatment for end-stage heart failure in the University of Tokyo Hospital, which includes heart transplant, pediatric heart transplant, ventricular assist device, and regenerative therapy. The Department has been also supported by eight companies.

Recently, right heart failure (RHF) gains recognition as well as left heart failure (LHF). RHF developed after left ventricular assist device (LVAD) is a critical issue which remains to be elucidated. Pulmonary hypertension (PH) is also an important cause of RHF. Now a lot of patients with severe PH are referred to our hospital because the University of Tokyo Hospital has been approved as a lung transplantation center since 2014. We pursue optimal treatment strategy for not

only LHF but also RHF.

Clinical Activities

1. Heart Transplant (HTx)

Patients who performed heart transplant in our hospital or in abroad transferred from our hospital are followed up once a month in the out-patient clinic, and undergo repeated myocardial biopsy regularly. When some symptom or findings which suggest rejection are detected, patients will undergo to intensify immunosuppressive regimen in-hospital treatment.

2. Ventricular Assist Device (VAD) Therapy

We recently implant not only extracorporeal pulsatile but also implantable ventricular assist device (VAD). All candidates fell into end-stage heart failure before VAD implantation, and a significant number of them were rescued with heart transplantation or bridge to recovery. We implant centrifugal VAD (EVAHEART, HVAD and HeartMate3) or axial VAD (HeartMate II and Jarvik 2000) considering patients' physics and clinical status). We also started the "Destination

therapy”, which means the implantation of VAD without heart transplantation.

3. Treatment of PH

Although pulmonary arterial hypertension (PAH) was a disease of poor prognosis, the treatment outcome of PAH significantly improved in this decade attributed to a number of newly approved drugs. Now we can use ten agents for PAH including oral, inhaled, subcutaneous and intravenous drugs. Combination therapy of these drugs is increasingly prevalent for the management of PAH. We join the nationwide PH registry to establish optimal treatment strategy for PAH.

Teaching Activities

We have the chair of systematic review of cardiovascular surgery in the spring term at the 2nd grade of medical course. We also take charge in clinical practice on diagnosis of cardiovascular disease in the autumn term at the 2nd grade. We expose the students to daily clinical works as well as research works during the course of “Free Quarter” and “Research Lab Visit”, which are scheduled in the summer and spring vacations at 1st and 2nd grade. Joint lectures with the Cardiology Department are scheduled 3rd through 4th grades. Each student is assigned one or two cardiovascular surgical cases in the Bed Side Learning, in which he/she is required to learn preoperative patient evaluation and management, surgical treatment and postoperative care, based on participatory practice. There are also twelve small key-lectures on cardiovascular surgery. Hands-on practice is provided during the “Clinical clerkship” one-month course in the last months of 3rd grade.

We take charge in core surgical curriculum in the “Super-rotation” postgraduate training. We offer a program in which each resident can learn basic knowledge of cardiovascular disease and surgery, and hemodynamic and respiratory evaluation as well as basic surgical techniques and patient management. Residents who take the course of cardiovascular surgery are required three-year general surgical training for General Surgery Board certification. We have well-developed specialty/ subspecialty training programs to allow the residents to pass Cardiovascular Board Examination by 10th postgraduate year.

Research Activities

In order to achieve excellent clinical results and to seek for new possibilities of surgical treatments for heart failure, it is essential for our department of the University to have active research programs in clinical and basic subjects related to assisted circulations and heart transplantation. We created highly active research programs in every field of medical and surgical heart failure treatment, and played an internationally leading role and contributed to its development. A research meeting is held every Saturday on a research project with Department of Cardiothoracic Surgery.

Basic and/or clinical research activities are focused on 1) development of new driving method of rotary blood pump, 2) basic and clinical research on regenerative therapy, 3) establishment of social support system for patients with implantable LVAD.

References

- 1: Gyoten T, Amiya E, Ono M. Surgical Interventions for Late Aortic Valve Regurgitation Associated with Continuous Flow-Left Ventricular Assist Device Therapy: Experience Gained and Lessons Learned. *Life (Basel)*. 2022 Dec 29;13(1):94.
- 2: Gyoten T, Amiya E, Kinoshita O, Tsuji M, Kimura M, Hatano M, Ono M. Clinical outcomes of continuous flow left ventricular assist device therapy as bridge to transplant strategy in muscular dystrophy: a single-center study. *Gen Thorac Cardiovasc Surg*. 2023 Jun;71(6):347-353.
- 3: Tsuji M, Kakuda N, Bujo C, Saito A, Ishida J, Amiya E, Hatano M, Shimada A, Imai H, Kimura M, Ando M, Kinoshita O, Yamauchi H, Komuro I, Ono M. Prophylactic negative pressure wound therapy is not effective for preventing driveline infection following left ventricular assist device implantation. *Artif Organs*. 2023 Mar;47(3):566-573.
- 4: Isotani Y, Amiya E, Ishida J, Komuro I. Summation of Precordial R Wave Amplitudes, a Clinical Parameter for Detecting Early TTR Amyloidosis Cardiac Involvement. *J Cardiovasc Dev Dis*. 2022 Oct 11;9(10):348.
- 5: Bujo S, Amiya E, Maeda MH, Ishida J, Hatano M, Ishizuka M, Uehara M, Oshima T, Kojima T,

- Nakanishi K, Daimon M, Shimizu J, Toda T, Komuro I. The effect of immunosuppressive therapy on cardiac involvements in anti-mitochondrial antibody-positive myositis. *ESC Heart Fail*. 2022 Dec;9(6):4112-4119.
- 6: Ishizuka M, Uehara M, Katagiri M, Ishida J, Kojima T, Amiya E, Komuro I. Successful treatment of recurrent cardiac sarcoidosis with the combination of corticosteroid and methotrexate monitored by 18F-fluoro-2-deoxyglucose positron emission tomography: case series. *Eur Heart J Case Rep*. 2022 Aug 12;6(8):ytac334.
- 7: Amiya E, Morita H. Simple Way of Identifying High-Risk Group of Heart Failure in Hypertrophic Cardiomyopathy in the Japanese Population. *Circ J*. 2022 Nov 25;86(12):1941-1942.
- 8: Kakuda N, Amiya E, Hatano M, Tsuji M, Bujo C, Ishida J, Yagi H, Saito A, Narita K, Isotani Y, Fujita K, Ando M, Shimada S, Kinoshita O, Ono M, Komuro I. Residual Pulmonary Vascular Resistance Increase Under Left Ventricular Assist Device Support Predicts Long-Term Cardiac Function After Heart Transplantation. *Front Cardiovasc Med*. 2022 Jun 1;9:904350.
- 9: Ko T, Nomura S, Yamada S, Fujita K, Fujita T, Satoh M, Oka C, Katoh M, Ito M, Katagiri M, Sassa T, Zhang B, Hatsuse S, Yamada T, Harada M, Toko H, Amiya E, Hatano M, Kinoshita O, Nawata K, Abe H, Ushiku T, Ono M, Ikeuchi M, Morita H, Aburatani H, Komuro I. Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF- β -IGFBP7 axis. *Nat Commun*. 2022 Jun 7;13(1):3275.
- 10: Narita K, Amiya E, Hatano M, Ishida J, Minatsuki S, Tsuji M, Bujo C, Kakuda N, Isotani Y, Ono M, Komuro I. Determining the factors for interhospital transfer in advanced heart failure cases. *Int J Cardiol Heart Vasc*. 2022 May 14;40:101035.
- 11: Yagi H, Takeda N, Amiya E, Akiyama N, Chang H, Ishiura H, Sato J, Akazawa H, Morita H, Komuro I. Nonsyndromic arteriopathy and aortopathy and vascular Ehlers-Danlos syndrome causing COL3A1 variants. *Am J Med Genet A*. 2022 Sep;188(9):2777-2782.
- 12: Gyoten T, Amiya E, Kinoshita O, Tsuji M, Kimura M, Hatano M, Ono M. Myocardial recovery evaluation from ventricular assist device in patients with dilated cardiomyopathy. *ESC Heart Fail*. 2022 Aug;9(4):2491-2499.
- 13: Shimbo M, Hatano M, Ishii S, Saito A, Yagi H, Minatsuki S, Maki H, Amiya E, Takeda N, Komuro I. Renal replacement therapy as a therapeutic option for right heart failure in severe pulmonary arterial hypertension. *ESC Heart Fail*. 2022 Aug;9(4):2728-2731.
- 14: Amiya E. Social Inequalities in Non-ischemic Cardiomyopathies. *Front Cardiovasc Med*. 2022 Mar 7;9:831918. doi: 10.3389/fcvm.2022.831918.
- 15: Isotani Y, Amiya E, Ishida J, Ishizuka M, Hatano M, Nakanishi K, Daimon M, Komuro I. Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias. *Oxf Med Case Reports*. 2022 Feb 19;2022(2):omac007.
- 16: Tsuji M, Kakuda N, Bujo C, Ishida J, Amiya E, Hatano M, Shimada A, Imai H, Shimada S, Kinoshita O, Yamauchi H, Ono M, Komuro I. Sarcopenia and risk of infection in adult heart transplant recipients in Japan. *ESC Heart Fail*. 2022 Apr;9(2):1413-1423.
- 17: Hatano M, Jimba T, Fujiwara T, Tsuji M, Bujo C, Ishida J, Amiya E, Kinoshita O, Ono M. Late-onset right ventricular failure after continuous-flow left ventricular assist device implantation: case presentation and review of the literature. *J Cardiol*. 2022 Aug;80(2):110-115.
- 18: Shoji S, Kuno T, Kohsaka S, Amiya E, Asleh R, Alvarez P, Kampaktsis P, Staffa SJ, Zurakowski D, Doulamis I, Briasoulis A. Incidence and long-term outcome of heart transplantation patients who develop postoperative renal failure requiring dialysis. *J Heart Lung Transplant*. 2022 Mar;41(3):356-364.
- 19: Sugihara T, Nakaoka Y, Uchida HA, Yoshifuji H, Maejima Y, Watanabe Y, Amiya E, Tanemoto K, Miyata T, Umezawa N, Manabe Y, Ishizaki J, Shirai T, Nagafuchi H, Hasegawa H, Miyamae T, Niuro H, Ito S, Ishii T, Isobe M, Harigai M. Establishing clinical remission criteria and the framework of a treat-to-target algorithm for Takayasu arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health,

Labour and Welfare for intractable vasculitis.
Mod Rheumatol. 2022 Aug 20;32(5):930-937.

- 20: Narita K, Amiya E. Social and environmental risks as contributors to the clonal course of heart failure. Heart Fail Rev. 2022 Jul;27(4):1001-1016.

Department of Biostatistics and Bioinformatics

Project Professor

Daisuke Koide, R.Ph., HIM, Ph.D.

Project Lecturer

Shogo Nomura, Ph.D.

Project Assistant Professor

Shotaro Aso, MD, Ph.D .

Homepage <http://biostatistics.m.u-tokyo.ac.jp/>

Introduction and Organization

Biostatistics is an applied statistics in the fields of medical and health sciences and contributes to these fields through developments of statistical methodologies for clinical trials and epidemiological researches. Biostatisticians who work at an organization for conducting and coordinating clinical researches (e.g., academic research organization) in hospitals and institutions are few in Japan. To this end, the Japan funding agency, Agency for Medical Research and Development (AMED), started the Support Program for Biostatisticians from 2016.

The AMED selected the Graduate School of the University of Tokyo and the Graduate school of the Kyoto University, as 2 centers for training biostatisticians, which function as core facilities, respectively. Each graduate school establishes a new biostatistics course, forms a training center upon collaboration with a hospital, and performs on-the-job training.

This program improves the environment that leads to higher quality in clinical research and trials, with the collaboration of industry, academia, and the government, based upon the donations from drug companies and national research funding. Collaborative projects of industry, academia, and the government through the flow of funds in this program, are the first of their kind in Japan.

On March 1, 2017, the Department of Biostatistics

and Bioinformation was established in the Graduate School of Medicine. In the Graduate School of Interdisciplinary Information Studies in the University of Tokyo, the Biostatistics and Bioinformatics course also started on April 1, 2018. This course provides specialized education to acquire not only statistical methodologies, but also practical skills (e.g., design and analysis of clinical research, programming, reporting) for conducting clinical research. We train biostatisticians with high communication skill and ethics that can promote high quality research in collaboration with health care professionals by teaching and on-the-job -training (OJT). AMED has renewed this project for more 5years since FY2021.

Teaching activities

1) Education in the Biostatistics and Bioinformatics course

In the Biostatistics and Bioinformatics course, through the following teachings, we educate a wide range of knowledge and skills required to biostatisticians. Its curriculum is made up of 28 subjects including 42 credits. For students who have taken over 38 credits, we issue a certificate along with the Master degree.

Biostatistics

Statistical inference, categorical data analysis,

survival analysis, longitudinal data analysis, Bayesian statistics, multiple comparison procedure, multivariate analysis, causal inference, missing data analysis, stochastic process and time series analysis, pharmacometrics, statistical programming, genomic data analysis

Clinical research and epidemiology

Clinical trial methodology, design and analysis of epidemiological research, research ethics and guidelines, medical research and CDISC standards, general clinical medicine, regulatory science, medical writing, medical technology evaluation exercises

In addition, the students receive the OJT at University of Tokyo Hospital and the National Cancer Center. The OJT programs are developed by the biostatisticians of each institution. In the first year of master's program, the students learn the basic practice of biostatistician through the training at the University of Tokyo Hospital. In the second year, at the National Cancer Research Center, students receive advanced training in how to plan the design and analysis of clinical researches.

2) Seminars and symposiums for the healthcare professionals and biostatisticians

We give seminars about clinical trial methodologies and biostatistics for physician, nurse, clinical research coordinator, monitor, and other healthcare professionals. We also hold symposia for biostatisticians in academia and pharmaceutical companies in order to share and discuss the “state-of-the-arts” of statistical methodologies.

Research activities

In the department of biostatistics and bioinformatics, the main research areas are as follows:

1) Statistical methodology and design of clinical trials and epidemiology

We study on the statistical methodologies and design for streamlining clinical trial and estimating treatment effect precisely. The research area includes Bayesian design in oncology, clinical trial design using biomarkers, adaptive design, study on the use of

Bayesian statistics in clinical trials, causal inference, and multiple comparison method.

2) Epidemiological methodology

Epidemiology deals with health or disease related incidence quantitatively in large populations, evaluates cause and effective factors, and ultimately finds the measures of prevention. It starts from epidemics (such as infectious diseases) and now its focus is on lifestyle related diseases, such as cardiovascular disorders. Also, several kinds of medical databases are developed rapidly in Japan. It is important to conduct epidemiological, pharmacoepidemiological and clinical epidemiological studies using such databases.

3) Pharmacoepidemiology

Pharmacoepidemiology is a study to investigate drug use and its effects in a population. We are engaged in research on effectiveness, risk, and cost using data obtained from hospital information system and electronic medical record.

4) Clinical Epidemiology

Clinical epidemiology is the application of the principles and methods of epidemiology to conduct clinical research studies focusing on prevention, diagnosis, prognosis, and treatment of disease. As the basic science of Evidence-based Medicine, the importance of clinical epidemiology has been increasing.

5) Medical informatics

Medical informatics is a science of studying how to use data, information and knowledge in the all medical fields, such as clinical, medical studies, education and government. Recently, the area of medical informatics is much expanding because of the progress of genomic studies or bioinformatics, and introduction of new technologies, such as virtual reality and artificial intelligence (AI).

6) Algebraic statistics

The focus of research is on developing and applying methods of algebraic statistics to specific statistical problems. In statistical inference, the computation of complicated integrals or summation sometimes makes the problem intractable. When a statistical model

has algebraic structure, techniques from algebraic statistics are useful. I currently work on the topics related to Groebner basis theory and the holonomic gradient method.

References

1. Facile R, Muhlbradt EE, Gong M, Li Q, Popat V, P?avy F, Cornet R, Ruan Y, Koide D, Saito TI, Hume S, Rockhold F, Bao W, Dubman S, Jauregui Wurst B. Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey. *JMIR Med Inform.* 2022 Jan 27;10(1):e30363. doi: 10.2196/30363. PMID: 35084343; PMCID: PMC8832264.
2. Nishikawa A, Yoshinaga E, Nakamura M, Suzuki M, Kido K, Tsujimoto N, Ishii T, Koide D. Validation Study of Algorithms to Identify Malignant Tumors and Serious Infections in a Japanese Administrative Healthcare Database. *Annals of Clinical Epidemiology.* 4(1): 20-31. 2022. Doi: <https://doi.org/10.37737/ace.22004>
3. Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J, Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology G. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. *Lancet.* 2023. 401(10372): 195-203.
4. Nakamura Y, Okamoto W, Denda T, Nishina T, Komatsu Y, Yuki S, Yasui H, Esaki T, Sunakawa Y, Ueno M, Shinozaki E, Matsushashi N, Ohta T, Kato K, Ohtsubo K, Bando H, Hara H, Satoh T, Yamazaki K, Yamamoto Y, Okano N, Terazawa T, Kato T, Oki E, Tsuji A, Horita Y, Hamamoto Y, Kawazoe A, Nakajima H, Nomura S, Mitani R, Yuasa M, Akagi K and Yoshino T. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. *JCO Precis Oncol.* 2022. 6: e2100383.
5. Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J and Japan Clinical Oncology G. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2022. 8(10): 1447-1455.
6. Terashima T, Morizane C, Ushima M, Shiba S, Takahashi H, Ikeda M, Mizuno N, Tsuji K, Yasui K, Azemoto N, Satake H, Nomura S, Yachida S, Sugano K and Furuse J. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. *Jpn J Clin Oncol.* 2022. 52(10): 1105-1114.
7. Niguma K, Mamishin K, Naito Y, Nomura S, Wakabayashi M, Kusuha S, Funasaka C, Nakao T, Fukasawa Y, Kondoh C, Harano K, Kogawa T, Matsubara N, Hosono A, Onishi T, Kawasaki T and Mukohara T. Impact of Older Age and Medico-social Factors on the Decision to Offer Adjuvant Chemotherapy to Patients With Breast Cancer. *Anticancer Res.* 2022. 42(7): 3743-3751.
8. Hasegawa H, Tsukada Y, Wakabayashi M, Nomura S, Sasaki T, Nishizawa Y, Ikeda K, Takeshita N, Teramura K and Ito M. Impact of near-infrared fluorescence imaging with indocyanine green on structural sequelae of anastomotic leakage after laparoscopic intersphincteric resection of malignant rectal tumors. *Tech Coloproctol.* 2022. 26(7): 561-570.
9. Kojima T, Kato K, Hara H, Takahashi S, Muro K, Nishina T, Wakabayashi M, Nomura S, Sato A, Ohtsu A and Doi T. Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303). *Esophagus.* 2022. 19(4): 702-710.
10. Aso S, Ono S, Michihata N, Uemura K, Yasunaga H. Effectiveness of vaccination on influenza-related critical illnesses in the elderly population. *J Infect Chemother.* 2023;S1341-321X(23)00037-5.

Department of Advanced Cardiology

Project Associate Professor

Katsuhito Fujiu, M.D., Ph.D.

Project Lecturer

Hidehiro Kaneko, M.D., Ph.D.

Project Assistant Professor

Ying Chen, M.D., Ph.D.

Homepage <https://cardiovasc.m.u-tokyo.ac.jp/>

Introduction and Organization

This course is an endowed chair established on April 1, 2018, under the donations of Medtronic Japan Co., Ltd., St. Jude Medical Co., Ltd., Boston Scientific Japan Co., Ltd., Fukuda Denshi Tokyo Central Sales Co., Ltd and SIMPLEX QUANTUM Co., Ltd.

In conjunction with the department of cardiovascular medicine, this course develops leading-edge medical care. It elucidates the pathogenesis of unresolved heart failure and cardiovascular disease and analyzes the pathological condition using cultured cells, experimental animals, and patient specimens. By clarifying the new disease pathogenesis mechanism and pathogenesis mechanism, it aims at elucidating the fundamental pathophysiology of cardiovascular disease and developing development prevention methods, new diagnostic methods, and new therapeutic methods.

Teaching activities

The above research results are presented at the university and academic conferences, the importance of this field is well known and widely presented by dissertation. Also, we are actively engaged in outreach activities for society.

Research activities

The heart and blood vessels maintain homeostasis in cooperation with organs throughout the body. The failure of this cooperation is considered to cause the onset of heart failure and sudden death. The therapy that improved cardiovascular death prognosis is a drug that acts on the whole body, not on the heart alone, except for cardiac resynchronization therapy and implantable defibrillator. From this point of view, as a research to improve the prognosis of cardiovascular death, we will proceed with the investigation, considering that poor coordination among multiple organs is involved in the onset of heart disease. Furthermore, about half of the cells that make up the heart are cardiomyocytes. In contrast, the other half are non-cardiomyocytes. In this study, we focus on non-cardiomyocytes and how non-cardiomyocytes interact with cardiomyocytes. The aim is to find new therapeutic targets for heart disease by clarifying whether it is acting, maintaining homeostasis of the heart, and elucidating the pathogenesis of heart failure that is its failure.

Furthermore, the relationship between the heart and the brain has been examined in detail as a study of inter-organ cooperation.

References

1. Age Modified Relationship Between Modifiable Risk Factors and the Risk of Atrial Fibrillation. Matsuoka S, Kaneko H, Okada A, Morita K, Itoh H, Michihata N, Jo T, Takeda N, Morita H, Fujiu K, Nakamura S, Node K, Yasunaga H, Komuro I. *Circ Arrhythm Electrophysiol*. 2022 Jan;15(1): e010409. doi: 10.1161/CIRCEP.121.010409.
2. Nerve-macrophage interactions in cardiovascular disease. Fujiu K, Manabe I. *Int Immunol*. 2022 Jan 22; 34(2): 81-95. doi: 10.1093/intimm/dxab 036.
3. Deep learning model to detect significant aortic regurgitation using electrocardiography. Sawano S, Kodera S, Katsushika S, Nakamoto M, Ninomiya K, Shinohara H, Higashikuni Y, Nakanishi K, Nakao T, Seki T, Takeda N, Fujiu K, Daimon M, Akazawa H, Morita H, Komuro I. *J Cardiol*. 2022 Mar;79(3):334-341. doi: 10.1016/j. jjcc.2021.08.029.
4. Acute-Phase Initiation of Cardiac Rehabilitation for Short-Term Improvement in Activities of Daily Living in Patients Hospitalized for Acute Heart Failure. Ueno K, Kamiya K, Kaneko H, Okada A, Itoh H, Fujiu K, Takeda N, Morita H, Michihata N, Jo T, Yasunaga H, Komuro I. *J Cardiovasc Dev Dis*. 2022 Mar 25;9(4):97. doi: 10.3390/jcdd9040097.
5. Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database. Suzuki Y, Kaneko H, Okada A, Itoh H, Morita K, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K, Matsunaga A, Ako J, Fukui A, Nishiyama A, Yokoo T, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. *Am J Nephrol*. 2022; 53(2-3): 240-248. doi: 10.1159/000522147. <2022.4>
6. Risk for Proteinuria in Newly Defined Hypertensive People Based on the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Yano Y, Kamiya K, Matsunaga A, Ako J, Fukui A, Yokoo T, Nishiyama A, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. *Am J Cardiol*. 2022 Apr 1;168:83-89. doi: 10.1016/j. amjcard.2021.12.023.
7. Association between proteinuria and incident colorectal cancer: analysis of a nationwide population-based database. Matsuoka S, Kaneko H, Okada A, Fukui A, Yano Y, Itoh H, Morita K, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Nakamura S, Nishiyama A, Yokoo T, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. *BMJ Open*. 2022 Apr 4;12(4):e056250. doi: 10.1136/bmjopen-2021-056250.
8. Relationship of normal-weight central obesity with the risk for heart failure and atrial fibrillation: analysis of a nationwide health check-up and claims database. Ueno K, Kaneko H, Kamiya K, Itoh H, Okada A, Suzuki Y, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Ako J, Node K, Yamauchi T, Yasunaga H, Komuro I. *Eur Heart J Open*. 2022 Apr 13; 2(3): oeac026. doi: 10.1093/ehjopen/oeac 026.
9. Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset. Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K, Matsunaga A, Ako J, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. *Am J Nephrol*. 2022; 53(4): 307-315. doi: 10.1159/ 000522280. <2022.5>
10. Prediction of Atrial Fibrillation Being Asymptomatic at First Onset by Cardiac Pacing. Matsubara TJ, Fujiu K, Kodera S, Kani K, Goto K, Shimizu Y, Oguri G, Hasumi E, Kojima T, Komuro I. *Int Heart J*. 2022;63(3):486-491. doi: 10.1536/ihj.21-594. <2022.5>
11. Association of retinal atherosclerosis assessed using Keith-Wagener-Barker system with incident heart failure and other atherosclerotic cardiovascular disease: Analysis of 319,501 individuals from the general population. Matsuoka S, Kaneko H, Okada A, Itoh H, Suzuki Y, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Node K, Yasunaga H, Komuro I. *Atherosclerosis*. 2022 May; 348: 68-74. doi: 10.1016/j.atherosclerosis.2022.02.024.

12. Age-Dependent Relationship of Hypertension Subtypes With Incident Heart Failure. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, Fujiu K, Yamaguchi S, Michihata N, Jo T, Takeda N, Morita H, Node K, Kim HC, Viera AJ, Oparil S, Yasunaga H, Komuro I. *J Am Heart Assoc*. 2022 May 3;11(9):e025406. doi: 10.1161/JAHA.121.025406.
13. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I. *Cardiovasc Diabetol*. 2022 May 18;21(1):67. doi: 10.1186/s12933-022-01508-6.
14. Prediabetes in Young Adults and Its Association With Cardiovascular Health Metrics in the Progression to Diabetes. Suzuki Y, Kaneko H, Okada A, Matsuoka S, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Node K, Yamauchi T, Yasunaga H, Komuro I. *J Clin Endocrinol Metab*. 2022 Jun 16;107(7):1843-1853. doi: 10.1210/clinem/dgac247.
15. Clinical utility of simple subjective gait speed for the risk stratification of heart failure in a primary prevention setting. Ueno K, Kaneko H, Kamiya K, Itoh H, Okada A, Suzuki Y, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Ako J, Yasunaga H, Komuro I. *Sci Rep*. 2022 Jul 8; 12(1):11641. doi: 10.1038/s41598-022-13752-7.
16. Medication-Naïve Blood Pressure and Incident Cancers: Analysis of 2 Nationwide Population-Based Databases. Kaneko H, Yano Y, Lee HH, Lee H, Okada A, Itoh H, Morita K, Fukui A, Fujiu K, Suzuki Y, Matsuoka S, Nakamura S, Michihata N, Jo T, Takeda N, Morita H, Yokoo T, Nishiyama A, Node K, Viera AJ, Muntner P, Oparil S, Kim HC, Yasunaga H, Komuro I. *Am J Hypertens*. 2022 Aug 1;35(8): 731-739. doi: 10.1093/ajh/hpac054.
17. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial. Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. *JAMA Cardiol*. 2022 Aug 1;7(8): 787-794. doi: 10.1001/jamacardio.2022.1561.
18. Effectiveness and Approach of Rehabilitation in Patients With Acute Heart Failure: A Review. Ueno K, Kaneko H, Itoh H, Takeda N, Morita H, Fujiu K, Kamiya K, Komuro I. *Korean Circ J*. 2022 Aug;52(8):576-592. doi: 10.4070/kcj.2022.0181.
19. Cholecystitis and Cholangitis during Continuous Renal Replacement Therapy in a Patient with Retroperitoneal Hemorrhage Requiring Large Amounts of Contrast Medium for the Assessment and Intervention. Goto K, Shimizu Y, Kojima T, Takeda N, Fujiu K, Komuro I. *Intern Med*. 2022 Aug 15; 61(16): 2533-2537. doi: 10.2169/internalmedicine.8518-21.
20. Age-Specific Relation of Cardiovascular Health Metrics With Incident Cardiovascular Disease. Itoh H, Kaneko H, Okada A, Suzuki Y, Fujiu K, Matsuoka S, Michihata N, Jo T, Nakanishi K, Takeda N, Morita H, Node K, Di Tullio MR, Homma S, Yasunaga H, Komuro I. *Am J Cardiol*. 2022 Aug 15;177:34-39. doi: 10.1016/j.amjcard.2022.04.046.
21. Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database. Fukui A, Kaneko H, Okada A, Yano Y, Itoh H, Matsuoka S, Morita K, Kiriya H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Nishiyama A, Node K, Yokoo T, Nangaku M, Yasunaga H, Komuro I. *Nephrol Dial Transplant*. 2022 Aug 22;37(9):1691-1699. doi: 10.1093/ndt/gfab248.
22. Non-Cardiac Organs Metamorphose Heart.
23. Oshima T, Fujiu K. *Int Heart J*. 2022;63(5): 795-797. doi: 10.1536/ihj.22-403. <2022.9>
24. Automatic Detection of Left Ventricular Dilatation and Hypertrophy from Electrocardiograms Using Deep Learning. Kokubo T, Koder S, Sawano S, Katsushika S, Nakamoto M, Takeuchi H, Kimura N, Shinohara H, Matsuoka R, Nakanishi K, Nakao T, Higashikuni Y, Takeda N, Fujiu K, Daimon M, Akazawa H, Morita H, Matsuyama Y, Komuro I. *Int Heart J*. 2022 Sep 30;63(5):939-947. doi: 10.1536/ihj.22-132.

25. Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline. Matsuoka S, Kaneko H, Kamon T, Suzuki Y, Yano Y, Okada A, Itoh H, Morita K, Fukui A, [Fujiu K](#), Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Yokoo T, Nishiyama A, Node K, Yasunaga H, Komuro I. *J Atheroscler Thromb*. 2022 Oct 1; 29(10):1487-1498. doi: 10.5551/jat.63262.
26. Sex Difference in the Association between Lipid Profile and Incident Cardiovascular Disease among Young Adults. Kamon T, Kaneko H, Itoh H, Okada A, Matsuoka S, Kiriyaama H, [Fujiu K](#), Morita K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Node K, Yasunaga H, Komuro I. *J Atheroscler Thromb*. 2022 Oct 1;29(10):1475-1486. doi: 10.5551/jat.63166.
27. Association of Cardiovascular Health Metrics With Risk of Transition to Hypertension in Non-Hypertensive Young Adults. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, [Fujiu K](#), Michihata N, Jo T, Takeda N, Morita H, Matsunaga A, Node K, McEvoy JW, Lam CSP, Oparil S, Yasunaga H, Komuro I. *Am J Hypertens*. 2022 Oct 3; 35(10):858-866. doi: 10.1093/ajh/hpac057.
28. Reduction in blood pressure for elevated blood pressure/stage 1 hypertension according to the American College of Cardiology/American Heart Association guideline and cardiovascular outcomes. Kaneko H, Yano Y, Suzuki Y, Okada A, Itoh H, Matsuoka S, [Fujiu K](#), Michihata N, Jo T, Takeda N, Morita H, Node K, Viera AJ, Lima JAC, Oparil S, Lam CSP, Carey RM, Yasunaga H, Komuro I. *Eur J Prev Cardiol*. 2022 Oct 20; 29(14):1921-1929. doi: 10.1093/eurjpc/zwac193.
29. Age prediction from coronary angiography using a deep neural network: Age as a potential label to extract prognosis-related imaging features. Sawano S, Kodera S, Sato M, Katsushika S, Sukeda I, Takeuchi H, Shinohara H, Kobayashi A, Takiguchi H, Hirose K, Kamon T, Saito A, Kiriyaama H, Miura M, Minatsuki S, Kikuchi H, Higashikuni Y, Takeda N, [Fujiu K](#), Ando J, Akazawa H, Morita H, Komuro I. *PLoS One*. 2022 Oct 27; 17(10):e0276928. doi: 10.1371/journal.pone.0276928. eCollection 2022.
30. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors.
31. Suzuki Y, Kaneko H, Okada A, Matsuoka S, [Fujiu K](#), Michihata N, Jo T, Takeda N, Morita H, Node K, Nangaku M, Yasunaga H, Komuro I. *Kidney Int*. 2022 Nov; 102(5):1147-1153. doi: 10.1016/j.kint.2022.05.031. Epub 2022 Aug 9.
32. Is Continuous Monitoring for Arrhythmia Advantageous in Low-Risk Groups? Matsubara TJ, [Fujiu K](#). *JACC Asia*. 2022 Nov 1;2(6):747-749. doi:10.1016/j.jacasi.2022.09.004. eCollection 2022 Nov.
33. Threshold of BMI for the Development of Hypertension among Japanese Adults. Suzuki Y, Kaneko H, Yano Y, Okada A, Hashimoto Y, Itoh H, Matsuoka S, Yokota I, [Fujiu K](#), Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I. *J Nutr*. 2022 Nov;152(11):2565-2571. doi: 10.1093/jn/nxac192. Epub 2022 Aug 30.
34. Glycemic status and the association of change in blood pressure with incident cardiovascular disease. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, [Fujiu K](#), Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I. *Am Heart J*. 2022 Dec;254:48-56. doi: 10.1016/j.ahj.2022.07.005. Epub 2022 Jul 22.
35. Deep learning-based age estimation from chest X-rays indicates cardiovascular prognosis. Ieki H, Ito K, Saji M, Kawakami R, Nagatomo Y, Takada K, Kariyasu T, Machida H, Koyama S, Yoshida H, Kurosawa R, Matsunaga H, Miyazawa K, Ozaki K, Onouchi Y, Katsushika S, Matsuoka R, Shinohara H, Yamaguchi T, Kodera S, Higashikuni Y, [Fujiu K](#), Akazawa H, Iguchi N, Isobe M, Yoshikawa T, Komuro I. *Commun Med (Lond)*. 2022 Dec 9; 2(1):159. doi: 10.1038/s43856-022-00220-6.
36. Association of Life's Simple 7 with incident cardiovascular disease in 53 974 patients with cancer. Kaneko H, Suzuki Y, Ueno K, Okada A, [Fujiu K](#), Matsuoka S, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Node K, Yasunaga H, Komuro I. *Eur J Prev Cardiol*. 2022 Dec 21;

-
- 29(18):2324-2332. doi: 10.1093/eurjpc/zwac195.
37. Dose-dependent relationship of blood pressure and glycaemic status with risk of aortic dissection and aneurysm. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Ueno K, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yokota I, Node K, Yasunaga H, Komuro I. Eur J Prev Cardiol. 2022 Dec 21;29(18):2338-2346. doi: 10.1093/eurjpc/zwac205.
38. Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer. Suzuki Y, Kaneko H, Okada A, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Nangaku M, Yasunaga H, Komuro I. Am J Nephrol. 2022;53(10):753-760. doi: 10.1159/000527703. Epub 2022 Dec 21. < 2023.1 >

Laboratory for Advanced Research on Pathophysiology of Metabolic Diseases

Project Associate Professor

Miki Okada-Iwabu, Ph.D.

Introduction and Organization

Laboratory for Advanced Research on Pathophysiology of Metabolic Diseases was launched in 2017 to promote cutting-edge research aimed at unraveling the underlying pathophysiology of diabetes and related metabolic diseases thereby contributing to the development of effective preventive measures against these diseases.

“Individuals at risk of diabetes”, i.e., those strongly suspected of having diabetes and those in whom the possibility of diabetes cannot be denied, are currently estimated to account for 28.5% of males and 21.4% of females in Japan, thus making it an urgent task not only for metabolic science but for society at large to fully elucidate the underlying pathophysiology of diabetes. Diabetes is defined as a hyperglycemic condition resulting from decreased secretion and/or action of insulin from the pancreas and encompasses a wide disease spectrum from such rare conditions as mitochondrial diabetes and lipotrophic diabetes to diabetes mellitus as a common disease. Diabetes occurs not only through genetic susceptibility to the disease but due to disorderly living habits, such as overeating, lack of physical activity and obesity. Therefore, the Laboratory is intended to promote wide-ranging research into human tissues from patients with diabetes mellitus as a common disease but from those with rare forms of diabetes by drawing on state-of-the-art genomic, epigenomic, metabolomic, metagenomic and iPS-cell technologies and to bring resulting research insights to bear on the development of innovative

diagnostic, preventive and therapeutic modalities for diabetes.

Within the research milieu that the Laboratory offers, therefore, the research currently being promoted is expected to lead to the elucidation of the pathophysiology of diabetes and related metabolic diseases, where rare disease-derived tissue- and iPS cell-based investigations are expected to provide invaluable insights into the pathophysiology of diabetes as a common disease. Thus, the Laboratory is devoted to promoting relevant research leading to the development of innovative diagnostic, preventive and therapeutic modalities, thereby contributing to the effective prevention and treatment of diabetes.

Teaching activities

Working in collaboration with its closely related Laboratory, Departments of Diabetes and Metabolic Disease, Division of Nephrology and Endocrinology, the Laboratory aims to foster internationally-oriented young talents in both an academic and social sense with the focus on graduate students, through the Laboratory’s mentoring program for academic dissertations and conference presentations to develop and enhance their science capabilities and skills.

The Laboratory has also had an active role in the clinical researcher development program by the University of Tokyo, the main aim of which is to impart not only the importance of clinical research but the rudiments of clinical thinking to medical students and clinical researchers in training. As part of Metabolism

Research Course on the clinical researcher development program, the Course holds up and pursues, as its research theme, exploration of key molecules involved in the onset/progression of obesity/ type 2 diabetes, given that radical preventive/therapeutic modalities remain yet to be established for the so-called lifestyle-related diseases, which include the metabolic syndrome, type 2 diabetes, obesity, dementia, and frailty, as well as for age-related diseases, all of which are known to occur and progress through interactions between individuals' genetic and environmental factors. Thus, the aim of the program is to explore these key molecules by drawing on the analysis of integrated genomic, epigenomic, transcriptomic, metabolomic and clinical data.

Metabolism Research Course is widely open to medical students and clinicians in training alike to provide support not only for designated themes but for themes of interest to course participants and to foster an infrastructure/environment that would facilitate the presentation of research results at conferences in Japan and overseas as well as their publication as peer-reviewed papers in a timely fashion.

Research activities

Diabetes occurs due not only to genetic factors but to the influence of environmental factors, such as overeating, lack of physical activity, and obesity. Therefore, while diabetes represents a disease condition with a wide spectrum from inherited rare forms of diabetes to diabetes as a common disease, its pathophysiology remains yet to be fully elucidated.

The Laboratory thus focuses on the analysis of the physiological functions of organs and systems that play a key role in the onset of diabetes, i.e., pancreatic endocrine cells, liver, adipose tissue, skeletal muscle, nervous system, immune system and intestinal tract, as well as diseases resulting from disruption of their functions by drawing fully on state-of-the-art omic (genomic, epigenomic, metabolomic, and metagenomic) and iPS-cell technologies and genetic cell and animal engineering.

Research themes also being pursued at the Laboratory include the onset/progression of chronic diseases associated with aging and rare diseases, such as mitochondrial diabetes and lipotrophic diabetes, to

facilitate the development of innovative diagnostic, preventive and therapeutic modalities for these diseases, based on resulting research findings and insights.

References

1. Iwabu M, Okada-Iwabu M, Kadowaki T, Elucidating exercise-induced skeletal muscle signaling pathways and applying relevant findings to preemptive therapy for lifestyle-related diseases., *Endocr J.*, 69:1-8, 2022

Department of Advanced Clinical Science and Therapeutics

Project Associate Professor

Mutsuo Harada, M.D., Ph.D.

Project Assistant Professor

Masamichi Ito, M.D., Ph.D.

Project Researcher

Yusuke Adachi, M.D., Ph.D.

Project Academic Support Staff

Kanako Ikeya,

Yuko Ishiyama

Homepage <http://square.umin.ac.jp/sentan/>

Introduction and Organization

The Department of Advanced Clinical Science and Therapeutics, established at the University of Tokyo in 2004, aims to develop new clinical strategies and therapy in cardiovascular medicine and other areas. The laboratory location was moved to the brand new research building called Clinical Research Center-A in January 2020. This department hopes to develop not only basic research, but also applications to devise new clinical strategies.

Research activities

Followings are our recent basic and clinical research activities.

- New strategies to regulate acute/chronic myocarditis.
- New strategies to regulate acute myocardial infarction and ischemia/reperfusion injury.
- New strategies to regulate atherosclerosis and aneurism.
- New strategies to regulate systolic/diastolic heart failure.
- New strategies to regulate cardio-kidney syndrome.

- Development of gene therapies with AAV vectors (anti-inflammation etc.).
- Development of new growth factor treatments (hepatocyte growth factor, etc.).
- Development of new anti-adhesion molecule treatments (anti-inflammation, etc.).
- Development of new anti-extracellular treatments (anti-inflammation, anti-oxidation, etc.).
- Development of new chemical compounds (anti-inflammation, anti-coagulation, etc.).
- Development of drug screening for heart failure using iPS cell-derived cardiomyocytes.
- Expanding the use of foods and natural extracts.
- Expanding the application of existing drugs and devices.
- Analysis of angiogenesis using in situ hybridization.

References

1. Katagiri M, Yamada S, Katoh M, Ko T, Ito M, Komuro I. Heart Failure Pathogenesis Elucidation and New Treatment Method Development. JMA J. 2022 Oct 17;5(4):399-406.

- doi:10.31662/jmaj.2022-0106. Epub 2022 Aug 1.
2. Ko T, Nomura S, Yamada S, Fujita K, Fujita T, Satoh M, Oka C, Katoh M, Ito M, Katagiri M, Sassa T, Zhang B, Hatsuse S, Yamada T, Harada M, Toko H, Amiya E, Hatano M, Kinoshita O, Nawata K, Abe H, Ushiku T, Ono M, Ikeuchi M, Morita H, Aburatani H, Komuro I. Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF- β -IGFBP7 axis. *Nat Commun.* 2022 Jun 7;13(1):3275. doi: 10.1038/s41467-022-30630-y.
 3. Miura K, Matsuura K, Yamasaki Itoyama Y, Sasaki D, Takada T, Furutani Y, Hayama E, Ito M, Nomura S, Morita H, Toyoda M, Umezawa A, Onoue K, Saito Y, Aburatani H, Nakanishi T, Hagiwara N, Komuro I, Shimizu T. Functional Evaluation of Human Bioengineered Cardiac Tissue Using iPS Cells Derived from a Patient with Lamin Variant Dilated Cardiomyopathy. *Int Heart J.* 2022;63(2):338-346. doi: 10.1536/ihj.21-790.
 4. Adachi Y, Ueda K, Nomura S, Ito K, Katoh M, Katagiri M, Yamada S, Hashimoto M, Zhai B, Numata G, Otani A, Hinata M, Hiraike Y, Waki H, Takeda N, Morita H, Ushiku T, Yamauchi T, Takimoto E, Komuro I. Beiging of perivascular adipose tissue regulates its inflammation and vascular remodeling. *Nat Commun.* 2022 Sep7; 13(1):5117. doi:10.1038/s41467-022-32658-6. PMID: 36071032.
 5. Liu PY, Fukuma N, Hiroi Y, Kunita A, Tokiwa H, Ueda K, Kariya T, Numata G, Adachi Y, Tajima M, Toyoda M, Li Y, Noma K, Harada M, Toko H, Ushiku T, Kanai Y, Takimoto E, Liao JK, Komuro I. Tie2-Cre-Induced Inactivation of Non-Nuclear Estrogen Receptor- α Signaling Abrogates Estrogen Protection Against Vascular Injury. *JACC Basic Transl Sci.* 2022 Nov 16;8(1):55-67. doi: 10.1016/j.jacbts.2022.07.001. eCollection 2023 Jan. PMID: 36777173.

Department of Comprehensive Radiation Oncology

Project Professor

Keiichi Nakagawa, MD, Ph.D

Project Research Associate

Masanari Minamitani, MD, Ph.D

Homepage <http://www.u-tokyo-rad.jp/staff/shuyougakukouza.html>

Introduction and Organization

The endowed chair was launched on April 1, 2021. At the time of its establishment, there were two members: project professor Nakagawa and project associate Ozaki. Due to Ozaki's appointment at Hirosaki University, on April 1, 2022, Minamitani joined as a project associate.

The purpose of the establishment of this course is to: From the standpoint of clinical radiation oncology and medical physics, (1) promote the development of radiation therapy technology, (2) train medical physicists with science and engineering backgrounds and promote the precision of radiation therapy, (3) improve the public's literacy about cancer in general with a focus on radiation therapy (including medical physics and the effects of radiation on the human body), and (4) "cancer education" described in the Course of Study for junior high and high schools in particular. We are supporting the promotion of the four of them. We have received support from Elekta K.K. and Chiyoda Technol Corporation.

Nakagawa is the former head of the Radiation Therapy Division. While researching the development of radiation therapy equipment and clinical applications, he felt the importance of specialists in medical physics. Currently, medical physicists are working at relatively large hospitals that perform radiation therapy, but the development of bases for medical physicists has not progressed. One of the primary goals of this course is to contribute to the

further development of medical physics through the improvement of image quality related to radiation therapy, the analysis of big data in the field of radiation therapy, and the development of human resources in collaboration with the Radiation Therapy Division.

In addition, Nakagawa was involved in the launch of the Basic Act on Cancer Control enacted in 2006 and served as a member of the Council for the Promotion of Cancer Control for ten years. It has aimed to improve public cancer education and Japanese people's health literacy by doing so. Improving health literacy using cancer teaching materials leads to various benefits in society, such as cancer prevention and early detection, patient-centered decision-making when selecting treatment methods, balancing cancer treatment and work, and social understanding of the effects of radiation on the human body. Our second goal is to become a base for these issues.

Clinical activities

Two LINACs, one Tomotherapy, one iridium brachytherapy device, one gamma knife for stereotactic irradiation of the head, one CT imaging device dedicated to treatment planning, and treatment planning devices are equipped in the Department of Radiation Oncology. The primary purpose of this course is not clinical. Still, we assist in medical treatment while examining cases with doctors in the treatment department as appropriate.

In addition, feedback on issues recognized in

clinical practice is received and linked to technological development.

Education

This course provides graduate school education to students from the Graduate School of Medicine, Faculty of Medicine, the University of Tokyo. The Department also collaborates with the Graduate Schools of Science and Engineering and accepts students from science and engineering backgrounds who wish to become medical physicists and research students conducting medical physics research.

While there were no admissions of students aspiring to be medical physicists in 2022, we are expanding the educational structure in preparation for accepting students from 2023 onwards. Additionally, six students from the Department of Radiology and Biomedical Engineering are affiliated with the radiation therapy department, and guidance has been provided for tasks such as thesis writing.

Research

Following the purpose of this course, we conduct research on medical physics and cancer education. In medical physics, we are developing new high-precision radiation therapy technologies by researching "image-guided radiation irradiation methods" using images related to radiation therapy and research on image processing utilizing artificial intelligence and analysis of big data related to radiation therapy in collaboration with related clinical departments.

For example, in the study on image quality improvement, we presented a survey on improving the image quality of MVCT using deep learning.

Megavoltage computed tomography (MVCT) is used in helical Tomotherapy for image-guided radiotherapy (IGRT). For precise registration based on image guidance, the quality of MVCT images must be ensured. However, the image quality of MVCT is considerably lower than that of kilovoltage CT (kVCT) and thereby limits the accuracy of IGRT. We developed a deep-learning based model to improve the image quality of MVCT. The image quality of the improved MVCT image was quantitatively evaluated by several image quality indices. As a clinical benefit, it was observed by medical doctors that the improved images

enhanced the precision of contouring. Furthermore, we found that our deep-learning based model enables the improvement of the image quality of MVCT while reducing metal artifacts, which often appear in kVCT [4].

In school education for cancer, we have been continuously conducting joint research with the Japan Cancer Society since last year. Cancer education has also been implemented in 25 junior high schools in Shinagawa and Shibuya wards of Tokyo, as well as in Hachioji and Hino cities, reaching approximately 2,500 participants. We have also contributed articles to domestic journals about the potential of cancer education in school settings [8,9]. Minamitani has given presentations about cancer education at health education seminars conducted by the Tokyo Metropolitan Board of Education.

For adult cancer education, within the Corporate Action to Promote Cancer Control, a commissioned project by the Ministry of Health, Labour, and Welfare chaired by Nakagawa, both Nakagawa and Minamiya have provided lectures to corporations both online and offline. Plans are in place to investigate whether such adult cancer education leads to proper preventive actions against cancer and an increase in cancer screening rates. We developed a scale to measure cancer knowledge and literacy in Japanese people, the Japanese Cancer Intelligence Quotient (JCIQ) [7].

Furthermore, in February 2022, a joint research project themed "Awareness of cancer in small and medium-sized enterprises and the employment status of cancer patients" began in collaboration with Dai-ichi Life Insurance Company. The research is based on insurance contract data from Dai-ichi Life, analyzing trends in "awareness of cancer" and "employment status of cancer patients" in small and medium-sized enterprises, in collaboration with Tokyo University Hospital. The results aim to contribute to creating a work environment where individuals can work with peace of mind even after being diagnosed with cancer. As a result, it was reported in an international journal that the interest of business owners in small and medium-sized enterprises in cancer measures is related to the implementation of cancer screenings and support systems in the company [6].

Additionally, in collaboration with MTI Ltd., a large-scale web survey was conducted using the female health management app "LunaLuna" to gather information from LunaLuna users about radiation therapy and cervical cancer. The results of this survey are planned to be submitted to an international journal in 2023.

As mentioned above, our department conducts extensive research activities in both medical physics and cancer education. Coupled with talent development, we look forward to further progress in the next fiscal year.

Publications

- 1: Enomoto A, Fukasawa T, Terunuma H, Nakagawa K, Yoshizaki A, Sato S, Miyagawa K. Decrease in MAP3Ks expression enhances the cell death caused by hyperthermia *Int J Hyperthermia*. 2022;39(1):200-208.
- 2: Atsuto Katano, Masanari Minamitani, Keiichi Nakagawa, Hideomi Yamashita. The Spontaneous Remission of Recurrent Lymph Node Metastatic Prostate Cancer With Lowering Serum Prostate-Specific Antigen Level. *Cureus* 14(5): e25333
- 3: Motoyuki Umekawa, Yuki Shinya, Hirota Hasegawa, Mariko Kawashima, Masahiro Shin, Atsuto Katano, Masanari Minamitani, Akinori Kashio, Kenji Kondo & Nobuhito Saito. Stereotactic radiosurgery ensures an effective and safe long-term control of Koos grade IV vestibular schwannomas: a single-center, retrospective, cohort study. *Journal of Neuro-Oncology*. 2022; 159:201–209
- 4: Ozaki S, Kaji S, Nawa K, Imae T, Aoki A, Nakamoto T, Ohta T, Nozawa Y, Yamashita H, Haga A, Nakagawa K. Training of deep cross-modality conversion models with a small dataset, and their application in megavoltage CT to kilovoltage CT conversion *Med Phys* 2022;49(6):3769-3782.
- 5: Katano A, Minamitani M, Yamashita H, Nakagawa K. Delayed Onset of Pleural Effusion After Thoracic Radiation Therapy for Hodgkin Lymphoma: A Case Report With Over 30-Year Follow-Up. *Cureus*.14(7):e27138
- 6: Masanari Minamitani, Masayuki Tatemichi, Tomoya Mukai, Atsuto Katano, Keiichi Nakagawa. Effect of employers' concerns about cancer countermeasures on the implementation of cancer screening and support for balancing cancer treatment and work in small and medium-sized Japanese enterprises. *J Occup Health*. 2022;64:e12352.
- 7: Masanari Minamitani, Tomoya Mukai, Hideomi Yamashita, Atsuto Katano, Mitsunori Miyashita, and Keiichi Nakagawa. Development of Japanese Cancer Intelligence Quotient to Measure Cancer Literacy and Knowledge among Japanese Layperson. *JMA J*. 2022;5(4):446-457.
- 8: Masanari Minamitani and Keiichi Nakagawa. Cancer Education in school. The Animation on Radiotherapy. *School Health*, 2022, 353.
- 9: Masanari Minamitani and Keiichi Nakagawa. Cancer Education Possibility performed in science class. *Science Education*. 2022; 71:729-732.

Department of Immunotherapeutics

Project Professor

Kazuhiro Kakimi, M.D.,Ph.D.

Project Lecturer

Koji Nagaoka, Ph.D.

Project Researcher

Yukari Kobayashi

Technical Assistant

Yaeko Furuhashi, Yukiko Konakai

Homepage <https://immunotherapy-uth.jp/>

Introduction and Organization

The Department of Immunotherapeutics is located within the 22nd Century Medical and Research Center, established in 2004 within the University of Tokyo Hospital as a base for industry-academia collaboration and as an organization promoting translational research. It was established to conduct clinical research and clarify the role of this treatment technology in cancer treatment.

In May 2019, MEDINET Co., Ltd. completed the endowed courses for three periods of 15 years, and from June, Takara Bio Co., Ltd. made a new start as endowed courses. The laboratory location has also moved from the Central Clinical Building II to the Molecular Life Innovation Building. We conduct several joint programs with many clinical departments and engage in research on tumor immunology by analyzing the obtained clinical specimens with cutting-edge technology.

Our goal is to build a system that integrates a huge amount of clinical data and provides optimal treatment for each patient. In particular, we are focusing on identifying neoantigens based on patient genome information and developing TCR-T cell therapy using neoantigen-specific TCRs.

Teaching activities

Graduate students from the department of Neurosurgery, Gastroesophageal Surgery, Respiratory Surgery, and Urology joined our team for research. We collected surgically resected tumors from each clinical department, cultured tumor-infiltrating lymphocytes, extracted DNA/RNA from the tumors, and performed NGS analysis. We are studying the effects of the intratumoral immune environment on anti-tumor immune responses

In the laboratory, in addition to basic immunoassay techniques using cell culture and flow cytometry, they have mastered the handling of bioinformatics tools necessary for genome analysis.

Graduate students who are actually in charge of outpatient care or endoscopies in their respective clinical departments, or with the help of colleagues, build cooperation with medical offices and affiliated hospitals, collect specimens, and conduct research. I believe that this experience will help them develop new treatment methods and tackle unknown issues when they become future clinical practice leaders.

Three graduate students who published papers on research using valuable specimens before and after treatment with immune checkpoint inhibitors,

searching for biomarkers that predict postoperative prognosis, and researching neoantigen immunotherapy using mouse models, successfully obtained a Ph.D. degree.

Research activities

Immune checkpoint inhibitors have been approved for various cancer types, but many patients still do not respond to these therapies or become resistant to them after therapeutic effects have been shown. In order to rationally judge the indications of immune checkpoint inhibitors and clarify the points of resistance to treatment, we will clarify the molecular mechanisms that determine the responsiveness to immune checkpoint inhibitors in individual patients.

Accumulated clinical experience defines responsiveness to immune checkpoint inhibitors, including tumor-specific factors, tumor microenvironment, host-related factors, and dynamic changes associated with treatment. Furthermore, high-dimensional analysis at the single-cell level becomes possible, and it is possible and necessary to comprehensively integrate detailed and enormous information for predicting efficacy and searching for the key to overcoming treatment resistance.

We have studied current tumor immunology based on detailed observations, accumulating hypotheses and their verification. On the other hand, in genomic analysis, comprehensive information is searched for answers without being bound by preconceptions using bioinformatics and computer science. To have confidence in evaluating the anti-tumor immune response, we should integrate conventional immunology and genomic immunology. Therefore, tumor immunology research conducted in our department focuses on integrative analysis as cancer immunogenomics.

NGS has allowed it to analyze neoantigens generated from genomic abnormalities in individual patients, enabling the development of cancer immunotherapy targeting neoantigens.

Neoantigens are predicted based on genomic information of individual patients by the high binding ability to MHC molecules. Then, they are validated for their reactivity to tumor-specific T cells.

Therefore, we constructed an innovative neoantigen analysis platform that combines a neoantigen prediction system and immunogenicity verification using tumor-specific TCR-expressing cells. Our goal is to realize TCR-T cell therapy targeting neoantigens.

Publication List

1. Ishii T, Mimura I, Nagaoka K, Naito A, Sugasawa T, Kuroda R, Yamada D, Kanki Y, Kume H, Ushiku T, Kakimi K, Tanaka T, Nangaku M. Effect of M2-like macrophages of the injured-kidney cortex on kidney cancer progression. *Cell Death Discov.* 2022 Dec 5;8(1):480. doi: 10.1038/s41420-022-01255-3. PMID: 36470862; PMCID: PMC9722672.
2. Sun C, Nagaoka K, Kobayashi Y, Maejima K, Nakagawa H, Nakajima J, Kakimi K. Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors. *Int J Cancer.* 2023 Apr 1;152(7):1463-1475. doi: 10.1002/ijc.34382. Epub 2022 Dec 13. PMID: 36451303.
3. Teshima T, Kobayashi Y, Kawai T, Kushihiro Y, Nagaoka K, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Tanaka N, Tsunoda T, Kume H, Kakimi K. Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma. *Oncol Lett.* 2022 Jun 16;24(2):265. doi: 10.3892/ol.2022.13384. PMID: 35765279; PMCID: PMC9219027.
4. Miyamoto A, Honjo T, Masui M, Kinoshita R, Kumon H, Kakimi K, Futami J. Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading. *Front Oncol.* 2022 May 4;12:869393. doi: 10.3389/fonc.2022.869393. PMID: 35600379; PMCID: PMC9115381.
5. Saito N, Sato Y, Abe H, Wada I, Kobayashi Y, Nagaoka K, Kushihiro Y, Ushiku T, Seto Y, Kakimi K. Selection of RNA-based evaluation methods for tumor microenvironment by comparing with histochemical and flow cytometric analyses in gastric cancer. *Sci Rep.* 2022 May 20;12(1):8576. doi:10.1038/s41598-022-12610-w. PMID: 35595859.

-
6. Sato S, Matsushita H, Shintani D, Kobayashi Y, Fujieda N, Yabuno A, Nishikawa T, Fujiwara K, Kakimi K, Hasegawa K. Association between effector-type regulatory T cells and immune checkpoint expression on CD8⁺ T cells in malignant ascites from epithelial ovarian cancer. *BMC Cancer*. 2022 Apr 21;22(1):437. doi: 10.1186/s12885-022-09534-z. PMID: 35449092; PMCID: PMC9026673.

Social Cooperation Program

Department of Medical Information Engineering

Project Associate Professor

Taichi Kin, M.D.,Ph.D.

Project Research Associate

Toki Saito, Ph.D.

Homepage <https://medicalinfo-engineering.org>

Introduction and Organization

Department of Medical Information Engineering was launched on November 2021, through the financial support of SoftBank corporation, with assistance by the Department of Neurosurgery. Two faculty staffs, Taichi Kin as the Specially Appointed Associate Professor and Toki Saito as the Specially Appointed Assistant Professor started the research project.

The Department of Medical Information Engineering aims at research and development of medical data processing such as medical images by making full use of information and communication technology, artificial intelligence technology, anonymous processing technology, and cloud technology. Specifically, this includes medical image processing technologies such as tissue segmentation, annotation, and virtual reality surgical simulation, and anonymization, information and communication technologies of medical image data.

Teaching activities

Department of Medical Information Engineering was involved in the education through research activities of graduate students of the Graduate School of Medicine.

Research activities

Our research covers the biomedical computer applications that focus on medical data such as

medical imaging. Our laboratory is engaged in the following research activities:

- 1) medical image processing
3D reconstruction, segmentation, registration, rendering, fluid dynamics
- 2) virtual reality surgical simulation
tissue deformation, using surgical instruments
- 3) surgical support system
surgical navigation, XR technology
- 4) information and communication technology
block chain, anonymization, cloud technology

References

1. Satoshi Kiyofuji, Taichi Kin, Toki Saito, Tsukasa Koike, Yasuhiro Takeda, Tatsuya Uchida, Katsuya Sato, Ryoko Niwa, Yasuyuki Furuta, Nobuhito Saito. Invention of Online Interactive Three-dimensional Neurosurgery Simulator with Audiovisual Capture for Tactile Feedback. *Oper Neurosurg.* 24(2): 194-200, 2022.
2. Tsukasa Koike, Shota Tanaka, Taichi Kin, Yuichi Suzuki, Shunsaku Takayanagi, Hirokazu Takami, Kazuha Kugasawa, Shohei Nambu, Takaki Omura Erika Yamazawa Yoshihiro Kushihiro, Yasuyuki Furuta, Ryoko Niwa, Katsuya Sato, Tatsuya Uchida, Yasuhiro Takeda, Satoshi Kiyofuji, Toki Saito, Hiroshi Oyama, Nobuhito Saito. Accurate Preoperative Identification of Motor Speech Area as Termination of Arcuate Fasciculus Depicted by Q-Ball Imaging

- Tractography. *World Neurosurg* 164: e764-e771, 2022.
3. Yuki Shinya, Masahiro Shin, Hirotaka Hasegawa, Satoshi Koizumi, Taichi Kin, Kenji Kondo, Nobuhito Saito. Endoscopic endonasal transpetroclival approach for recurrent bilateral petroclival meningioma. *Neurosurg Focus Video* 6(2): v7, 2022.
4. Hirotaka Hasegawa, Masahiro Shin, Ryoko Niwa, Satoshi Koizumi, Shoko Yoshimoto, Naoyuki Shono, Yuki Shinya, Hirokazu Takami, Shota Tanaka, Umekawa Motoyuki, Shiori Amemiya, Taichi Kin, Nobuhito Saito. Revisitation of imaging features of skull base chondrosarcoma in comparison to chordoma. *J Neurooncol* 159(3): 581-590, 2022.
5. Takeda Yasuhiro, Hasegawa Hirotaka, Kin Taichi, Shinya Yuki, Kawashima Mariko, Furuta Yasuyuki, Suzuki Yuichi, Sekine Tetsuro, Saito Nobuhito. Hemodynamic changes during the obliteration process for cerebralarteriovenous malformations after radiosurgery. *Neurosurg Focus* 53(1): E7, 2022.
6. Nozomi Otsuka, Hirohisa Yajima, Satoru Miyawaki, Satoshi Koizumi, Satoshi Kiyofuji, Hiroki Hongo, Yu Teranishi, Taichi Kin, Nobuhito Saito. Case Report: "Clipping" an Internal Carotid Artery Aneurysm With a Duplicated Middle Cerebral Artery and the Anterior Choroidal Artery Arising From the Dome. *Front Neurol* 13: 845296, 2022.
7. Yuki Shinya, Masahiro Shin, Hirotaka Hasegawa, Satoshi Koizumi, Taichi Kin, Kenji Kondo, Nobuhito Saito. Endoscopic endonasal transpetroclival approach for recurrent bilateral petroclival meningioma. *Neurosurg Focus Video* 6(2): V7, 2022.
8. Takeo Igarashi, Tsukasa Koike, Taichi Kin. Interactive Deformable Image Registration with Dual Cursor. DOI: 10.2312/pg.20221241. *Pacific Graphics* 2022.
9. Shono Naoyuki, Igarashi Takeo, Kin Taichi, Toki Saito, Nobuhito Saito. Threshold field painting saves the time for segmentation of minute arteries. *Int J Comput Assist Radiol Surg*. 17(11): 2121-2130, 2022.
10. Ding Xia, Xi Yang, Oliver van Kaick, Taichi Kin, Takeo Igarashi. Data-driven Multi-Modal Partial Medical Image Preregistration by Template Space Patch Mapping. *MICCAI* 2022, 259-268.
11. Hirohisa Yajima, Satoru Miyawaki, Satoshi Koizumi, Satoshi Kiyofuji, Hiroki Hongo, Masafumi Segawa, Taichi Kin, Hirofumi Nakatomi, Nobuhito Saito. Development of a sigmoid sinus dural arteriovenous fistula secondary to sigmoid sinus thrombosis after resection of a foramen magnum meningioma: illustrative case. *J Neurosurg Case Lessons* 4(5): CASE22253, 2022.
12. Kiyofuji Satoshi, Shin Masahiro, Kondo Kenji, Kin Taichi, Uchida Tatsuya, Saito Nobuhito. Endoscopic Transnasal Resection of Trigeminal Schwannoma. *J Neurol Surg B Skull Base* 83(Suppl 3): e637-e638, 2022.

Health Economy and Society Policy

Project Professor

Tomoyuki Takura, Ph.D, MEng.

Project Lecturer

Sayaka Horiuchi, MPH, MD

Homepage <http://plaza.umin.ac.jp/hehp/>

Introduction and Organization

Health Economy and Society policy is a donated fund course established in 22nd Century Medical and Research Center in February 2017, which is donated by 10 companies, Development Bank of Japan Inc., Chugai Pharmaceutical Co., Ltd., Baxter Limited, Nihon Medi-Physics Co., Ltd., Medibrain Corporation, Asahi Kasei Medical Co., Ltd., NIPRO Corporation, Toray Medical Co., Ltd., JMS Co., Ltd., and Terumo Corporation, and is cooperating with Department of Cardiac Surgery, Division of Nephrology and Endocrinology, and Department of Clinical Epidemiology & Health Economics as cooperating course.

The social structure has been changing over recent years and it can be assumed that policies related to the medical system and medical industry are at a crossroads in Japan and may undergo dramatic changes in the future. Our department was established to discuss future healthcare systems (medical practices and systems, economy and industry), particularly in terms of theory construction and validation studies pertaining to the "evaluation of the value of the healthcare field" and other topics. Concretely, we promote theoretical and methodological research on health technology assessment, cost effectiveness analysis, and the healthcare industry structure, and aim to evaluate the value of healthcare technologies and healthcare systems.

Education

We also promote manpower training programs (Program for "The movements of medical value": 18 times in total) in health technology assessment with collaboration departments, which is an extension course. This program includes healthcare economics (pharmaceutical affairs system, financial and insurance system, hospital accounting, cost-effectiveness evaluation, microeconomics) and data science (medical big data, bayesian statistics, markov chain monte carlo method, software analysis) and research ethics.

Research activities

We are engaging in the following research in order to promote rational and evidence-based medical resource investment, to support medical practice, and to promote advances in medical technology.

- 1) The evaluation of the cost effectiveness of various therapies, including (but not limited to) VAD therapy for severe heart failure, hemodialysis therapy for end-stage renal failure and radiological diagnostics.
- 2) A study of the socioeconomic impact of chronic pain and health behavior (adherence) on the disease burden and the financial burden (including international comparison).
- 3) Testing and developing methods for evaluating labor productivity (e.g., the productivity of cardiology doctors) by applying data envelopment analysis (DEA) techniques.

Moreover, we are also working on a project to develop a forecasting model for health technology assessment (HTA) and disease prevention that makes use of big data and AI as data science. We have also started a study that applies computational finance to forecast the market value of research and development projects.

References

1. Tomoyuki Takura, Kosaku Nitta, Ken Tsuchiya, Hideki Kawanishi. Long-Term Effects of Contrast Media Exposure on Renal Failure Progression: A Retrospective Cohort Study. *BMC Nephrology*. 24, 135. 2023.
2. Tomoyuki Takura, Minoru Ono, Junya Ako, Yuji Ikari, Koichi Toda, Yoshiki Sawa; ETICA Study Investigators. Clinical and Economic Evaluation of Impella Treatment for Fulminant Myocarditis - A Preliminary Retrospective Cohort Study in Japan. *Circ J*. 2022; 87(5):610-618. doi: 10.1253/circj.CJ-22-0439.
3. Hiroki Sugimori, Maki Hirao, Ataru Igarashi, Hiroshi Yatsushashi, Shunya Ikeda, Naohiko Masaki, Hiroshi Yotsuyanagi, Takeshi Yoda, Takeshi Odajima, Tomoyuki Takura, Tomohiro Hirao. Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan. *Sci Rep*. 12(1):17139. 2022. doi: 10.1038/s41598-022-21470-3.
4. Tetsuya Shiina, Keiko Goto-Hirano, Tomoyuki Takura, Hiroyuki Daida. Cost-effectiveness of follow-up invasive coronary angiography after percutaneous coronary stenting: a real-world observational cohort study in Japan. *BMJ Open*. 12(8):e061617. 2022. doi: 10.1136/bmjopen-2022-061617.
5. Tomoyuki Takura, Sayaka Horiuchi. Cost-effectiveness analysis of infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study. *Journal of Cardiology*. 80(2):172-178. doi: 10.1016/j.jjcc.2022.03.005. 2022.
6. Tomoyuki Takura, Hiroko Miura. Socioeconomic Determinants of Universal Health Coverage in the Asian Region. *Int. J. Environ. Res. Public Health*. 2022; 19(4):2376. <https://doi.org/10.3390/ijerph19042376>.
7. Tomoyuki Takura, Tomoko Koike, Yoko Matsuo, Asuko Sekimoto, Masami Mutou. Proxy Responses Regarding Quality of Life of Terminal Lung Cancer Patients: preliminary results from a prospective observational study. *BMJ Open*. 12(2):e048232. doi: 10.1136/bmjopen-2020-048232. 2022.
8. Kazuhiko Ikeuchi, Kazuya Okushin, Makoto Saito¹, Eisuke Adachi¹, Takeya Tsutsumi, Tomoyuki Takura, Hiroshi Yotsuyanagi. Prevalence of HIV infection among non-elderly individuals with hepatitis C in Japan: A population-based cohort study using a health insurance claim data. *BMC Infectious Diseases*. 22(1):167. doi: 10.1186/s12879-022-07152-5.2022.
9. Yasunori Suematsu, Shin-ichiro Miura, Akira Minei, Yoko Sumita, Koshiro Kanaoka, Michikazu Nakai, Hisatomi Arima, Koshi Nakamura, Tomoyuki Takura, Kazunori Shimada, Hirokazu Shiraishi, Nagaharu Fukuma, Yusuke Ohya, Shigeru Makita. Study Protocol of Cardiac Rehabilitation for Acute Myocardial Infarction From the JROAD/JROAD-DPC Database — JROAD-CR —. The JROAD-CR Investigators. *Circulation Reports*. 5 (2): 62-65. 2023.
10. JCS/JACR 2021 Guideline on Rehabilitation in Patients With Cardiovascular Disease. Shigeru Makita, Takanori Yasu, Yoshihiro J Akashi, Hitoshi Adachi, Hideo Izawa, Shunichi Ishihara, Yoshitaka Iso, Hideo Ohuchi, Kazuto Omiya, Yusuke Ohya 0, Koichi Okita, Yutaka Kimura, Akira Koike, Masahiro Kohzuki, Shinji Koba, Masataka Sata, Kazunori Shimada, Tomoki Shimokawa, Hirokazu Shiraishi, Naokata Sumitomo 0, Tetsuya Takahashi, Tomoyuki Takura, Hiroyuki Tsutsui, Masatoshi Nagayama, Emiko Hasegawa, Yoshihiro Fukumoto, Yutaka Furukawa, Shin-Ichiro Miura, Satoshi Yasuda, Sumio Yamada 0, Yuichiro Yamada, Dai Yumino, Toshiko Yoshida, Takuji Adachi, Toshimi Ikegame, Kazuhiro P Izawa, Takeshi Ishida, Neiko Ozasa, Naohiko Osada, Hiroaki Obata 0, Naoya Kakutani, Yusuke Kasahara, Masaaki Kato, Kentaro Kamiya, Shintaro Kinugawa, Yuji Kono, Yasuyuki Kobayashi, Teruyuki Koyama, Kazuhiro Sase,

Shinji Sato 0, Tatsuhiko Shibata, Norio Suzuki, Daisuke Tamaki, Minako Yamaoka-Tojo, Michio Nakanishi, Eisaku Nakane, Mari Nishizaki, Taiki Higo, Kanta Fujimi, Tasuku Honda, Yasuharu Matsumoto, Noriko Matsumoto, Ikuko Miyawaki, Makoto Murata, Shusuke Yagi, Masanobu Yanase 0, Midori Yamada, Miho Yokoyama, Noboru Watanabe, Haruki Ito, Takeshi Kimura, Syunei Kyo, Yoichi Goto, Ryuji Nohara, Ken-Ichi Hirata ; Japanese Circulation Society/the Japanese Association of Cardiac Rehabilitation Joint Working Group. *Circ J.* 2022 Dec 9. doi: 10.1253/circj.CJ-22-0234. Online ahead of print.

11. Tomoyuki Takura, Issei Komuro, Minoru Ono. Trends in the cost-effectiveness level of percutaneous coronary intervention: Macro socioeconomic analysis and health technology assessment. *J Cardiol.* 2022;81(4):356-363. Sep 28;S0914-5087(22)00243-X. doi: 10.1016/j.jjcc.2022.09.011. Online ahead of print.
12. Tomoyuki Takura. "Socio-Economic Considerations of Universal Health Coverage: Focus on the Concept of Health Care Value and Medical Treatment Price". *Health Insurance*. London, IntechOpen; 1-34. 2022 (DOI: 10.5772/intechopen.104798)

Department of Healthcare Quality Assessment

Project Professor

Hiroaki Miyata, PhD

Project Associate Professor

Hiraku Kumamaru, MD, ScD, Hiroyuki Yamamoto, MD, PhD, MPH

Project Assistant Professor

Naoaki Ichihara, MD, PhD, MPH

Project Researcher

Shun Kosaka, MD, PhD, Shiori Nishimura, PhD, Hisateru Tachimori, PhD,
Ryo Nakamaru, MD, PhD, Shiyori Usune

Visiting Researcher

Arata Takahashi, HIM, PhD, Hideki Endo, MD, Chieko Fujimura, Satoshi Shoji, MD, PhD
Shinya Hirakawa, PhD, Naoko Kinukawa, PhD, Daisuke Shinjo, PhD

Clerical Staff (Secretary)

Takayo Nakamura, Yuko Miyashiro

Website <http://hqa.umin.jp/>

Introduction and Organization

The Department of Healthcare Quality Assessment (HQA) was established in 2006, and now work in collaboration with the Departments of Cardiovascular Surgery, Health and Social Behavior, and Pediatric Surgery. It conducts collaborative research with National Clinical Database (NCD), Nipro Corporation, Johnson and Johnson K.K, and Intuitive Surgical Sàrl.

The objective of providing healthcare is to provide high quality healthcare services to all patients. Institute of Medicine states that health care reform should focus on improving the patients' health as well as health care values that they think are important. "Quality improvement initiative," therefore, needs to adjust the healthcare systems to accommodate the fee-for-service perspectives while improving the clinical environment for both patients and providers.

Research

Department of Healthcare Quality Assessment (HQA) has been actively collaborating with healthcare professionals and various clinical committees as they play key roles in the quality improvement initiatives in the field. In such positive environment driven by the patient-centered philosophy, the patients receive more satisfying care, physicians are rewarded for their excellence, and healthcare costs are sustained. To accomplish these goals, there are 3 principles that navigate us through the journey: (a) the topmost value should always be on that of patients, (b) all medical practices should be organized around medical conditions as well as the care cycles of the patients, and (c) the results---risk-adjusted outcomes and medical costs spent---must be scientifically measured and evaluated.

In April 2010, the Japan Society of Surgery and 10 related surgical societies founded the National

Clinical Database (NCD), which is an all-Japan endeavor that aims to build a large-scale, comprehensive clinical registry that utilize the “big data” to improve the quality of surgery as well as advance surgical sciences in Japan. HQA has been playing important academic roles in the project since its birth. The actual data entry started from January 1st, 2011, and since then NCD has been collecting data on more than 95% of all surgical operations across Japan in collaboration with the clinical societies. NCD is also connected with the participating societies’ board of certification systems, which makes it unique among other large-scale clinical registries in the world. Today, more than 5,400 hospitals and clinics are participating in NCD with the accumulated data of 20 million cases (approximately 2 million each year).

HQA has developed risk models for different groups of surgical procedures that help us develop several practical tools aimed for medical professionals in the joint research activity with Japan Cardiovascular Surgery Database (JCVSD). One of those tools is JapanSCORE, which allows users to calculate a patient’s post-operative risk of mortality and morbidities. Another tool called RiskCalculator returns a medical professional the calculated risk of mortality and morbidity in a real-time manner after s/he inputs a minimum number of pre-operative risk information. Both tools can be used in medical team meetings as well as in sessions with patients to reach better informed consent. Just like JCVSD’s JapanSCORE and RiskCalculator, feedback tools based on the NCD data have been provided to different subspecialty surgical areas including the gastroenterological surgery and thoracic surgery. All of these activities help Japan’s healthcare quality initiatives in various places, and HQA is proud take part in it.

Since 2014, HQA has been participating in the post marketing surveillance studies based on NCD, in collaboration with PMDA (Pharmaceuticals and Medical Devices Agency), Academic societies and device manufacturers. Also, starting in 2017, HQA has led a new initiative at NCD of collecting diagnosis procedure combination data and insurance claims data from participating facilities. Data on the use of medical products as well as on billings from

these data are being used to supplement the clinical information collected in the registries for conducting clinical and health services research.

Future Directions

Clinical databases like NCD are the core components of quality improvement initiatives across the multiple subspecialties. HQA supports NCD’s systematic data collection, data management, practical analyses, and the development of useful feedback systems. Recently, non-surgical fields such as clinical oncology are also joining NCD and this trend has become stronger. Our benchmarking projects backed up by NCD’s big data will keep driving the quality improvement activities in many healthcare fields.

Increasing numbers of clinical research output has been coming out of the detailed analyses on NCD data in collaboration with each specialty field. Besides professional societies, medical device firms have started the operation of their post-marketing surveillance studies in collaboration with NCD. Working with NCD, the industry, PMDA, and the related medical societies, HQA helps the project move forward through academic support. Furthermore, HQA has been involved in international collaborative research work with database activities such as American College of Surgeon’s NSQIP and Asian Cardiac Database while contributing to the quality improvement activities in different regions of the world.

Publications

1. Kumamaru H, Kakeji Y, Fushimi K, Ishikawa KB, Yamamoto H, Hashimoto H, Ono M, Iwanaka T, Marubashi S, Gotoh M, Seto Y, Kitagawa Y, Miyata H. Cost of postoperative complications of lower anterior resection for rectal cancer: a nationwide registry study of 15,187 patients. *Surg Today*. 2022; 52 (12): 1766–74.
2. Shoji S, Kohsaka S, Kumamaru H, Yamaji K, Nishimura S, Ishii H, Amano T, Fushimi K, Miyata H, Ikari Y. Cost reduction associated with transradial access in percutaneous coronary intervention: A report from a Japanese

- nationwide registry. *Lancet Reg Heal - West Pacific*. 2022; 28: 100555.
3. Higuchi R, Kumamaru H, Kohsaka S, Saji M, Takamisawa I, Nanasato M, Shimokawa T, Shimizu H, Takayama M. Outcome of Nonagenarians Undergoing Transfemoral Transcatheter Aortic Valve Replacement: A Nationwide Registry Analysis From Japan. *JACC Asia*. 2022; 2 (7): 856–64.
 4. Hoshino N, Endo H, Hida K, Kumamaru H, Hasegawa H, Ishigame T, Kitagawa Y, Kakeji Y, Miyata H, Sakai Y. Laparoscopic Surgery for Acute Diffuse Peritonitis Due to Gastrointestinal Perforation: A Nationwide Epidemiologic Study Using the National Clinical Database. *Ann Gastroenterol Surg*. 20211213th ed. 2022; 6 (3): 430–44.
 5. Ichinose J, Yamamoto H, Aokage K, Kondo H, Sato Y, Suzuki K, Chida M. Real-world perioperative outcomes of segmentectomy versus lobectomy for early-stage lung cancer: a propensity score-matched analysis. *Eur J cardio-thoracic Surg Off J Eur Assoc Cardio-thoracic Surg*. 2022; 63 (1).
 6. Kaibori M, Ichihara N, Miyata H, Kakeji Y, Nanashima A, Kitagawa Y, Yamaue H, Yamamoto M, Endo I. Surgical outcomes of laparoscopic versus open repeat liver resection for liver cancers: A report from a nationwide surgical database in Japan. *J Hepatobiliary Pancreat Sci*. 2022; 29 (8): 833–42.
 7. Kofunato Y, Takahashi A, Gotoh M, Kakeji Y, Seto Y, Konno H, Kumamaru H, Miyata H, Marubashi S. Geriatric Risk Prediction Models for Major Gastroenterological Surgery Using the National Clinical Database in Japan: A Multicenter Prospective Cohort Study. *Ann Surg*. 20201015th ed. 2022; 275 (6): 1112–20.
 8. Kono E, Isozumi U, Nomura S, Okoshi K, Yamamoto H, Miyata H, Yasufuku I, Maeda H, Sakamoto J, Uchiyama K, Kakeji Y, Yoshida K, Kitagawa Y. Surgical Experience Disparity Between Male and Female Surgeons in Japan. *JAMA Surg*. 2022; 157 (9): e222938.
 9. Okamura A, Yamamoto H, Watanabe M, Miyata H, Kanaji S, Kamiya K, Kakeji Y, Doki Y, Kitagawa Y. Association Between Preoperative HbA1c Levels and Complications after Esophagectomy: Analysis of 15,801 Esophagectomies From the National Clinical Database in Japan. *Ann Surg*. 2022; 276 (5): e393–9.
 10. Nishimura S, Kumamaru H, Shoji S, Nakatani E, Yamamoto H, Ichihara N, Miyachi Y, Sandhu AT, Heidenreich PA, Yamauchi K, Watanabe M, Miyata H, Kohsaka S. Assessment of coding-based frailty algorithms for long-term outcome prediction among older people in community settings: A cohort study from the Shizuoka Kokuho Database. *Age and Ageing*. 2020; 51(3): 1–9.
 11. Ikeda N, Yamamoto H, Taketomi A, Hibi T, Ono M, Niikura N, Sugitani I, Isozumi U, Miyata H, Nagano H, Unno M, Kitagawa Y, Mori M. The impact of COVID-19 on surgical procedures in Japan: analysis of data from the National Clinical Database. *Surg Today*. 2022; 52 (1): 22-35.
 12. Sato Y, Yamamoto H, Ikeda N, Konishi H, Endo S, Okada Y, Kondo H, Shintani Y, Toyooka S, Nakamura H, Hoshikawa Y, Chen-Yoshikawa TF, Yoshino I, Kakizoe T, Chida M. The impact of COVID-19 on thoracic surgical procedures in Japan: Analysis of data from the National Clinical Database. *Lung Cancer*. 2022; 172: 127-35.
 13. Okoshi K, Endo H, Nomura S, Kono E, Fujita Y, Yasufuku I, Hida K, Yamamoto H, Miyata H, Yoshida K, Kakeji Y, Kitagawa Y. Comparison of short term surgical outcomes of male and female gastrointestinal surgeons in Japan: retrospective cohort study. *BMJ*. 2022; 378: e070568.

Laboratory for Cryo-Electron Microscopy

Project Associate Professor

Chieko Saito, Ph.D.

Project Assistant Professor

Fabian Eisenstein, Ph.D.

Homepage

Introduction and Organization

The Laboratory of Cryo-Electron Microscopy was established in April 2022 to promote the analysis of biological specimens using cryo-electron microscopy in cooperation with JEOL Ltd. The duration of the laboratory is four years (April 1, 2022 - March 31, 2026).

This laboratory aims to promote the use of cryo-electron microscopy in society and to advance cryo-electron microscopy as a research platform, and to foster human resources who will play a role in this effort. We will conduct research on sample preparation methods, high-speed imaging methods, and three-dimensional structural analysis methods to obtain high-resolution images for single-particle analysis and tomographic analysis. In addition, by providing educational support for lectures on the principles of cryo-electron microscopy and practical training, sample preparation, and three-dimensional structural analysis methods, we aim to develop human resources capable of promoting structural analysis of biological specimens through cryo-electron microscopy.

The current members of the laboratory for Cryo-Electron Microscopy are: Project Associate Professor (Chieko Saito, appointed in November 2022), Project Assistant Professor (Fabian Eisenstein, appointed in January 2023), and Technical Assistant (Toshie Furuya, appointed in August 2022).

Clinical activities

No special note.

Teaching activities

To solve technical problems necessary to apply cryo-electron microscopy to life science research, drug discovery, etc., and to conduct joint research with various researchers who need this technique. We will also develop human resources capable of promoting such research.

In FY2022, we cooperated in the planning and implementation of a technical course on cryo-electron microscopy, which was conducted jointly with Structural Biology Laboratory (Kikkawa Lab.), Laboratory of Advanced Structure Laboratory (Danev Lab.), and other laboratories in UTokyo (Kurumizaka Lab and Nureki Lab). In addition, students from the World INovative Graduate Study Program for Life Science and Technology (WINGS-LST) program were accepted to the above training sessions, which were conducted as an experimental training course.

Research activities

In FY2022, we conducted collaborative research with WINGS-LST program students (Graduate School of Engineering), with the University of Tokyo Hospital (Department of Cardiovascular Medicine), and with the Department of Molecular

Biology, Division of Molecular Cell Biology, Graduate School of Medicine.

With the start of the second phase of the Japan Agency for Medical Research and Development's Platform for Advanced Technology Basis for Supporting Innovative Drug Discovery and Life Science Research (AMED BINDS) in April 2022, we supported in the consulting and the management of these facilities. In addition, we supported the start-up of two cryo-EM facilities (CRYO ARM™ 300 II (JEM-3300) and CRYO ARM™ 200 (JEM-Z200), manufactured by JEOL) installed at the Kashiwa 2 campus.

References

1. Tomoko Ohshima, Hayashi Yamamoto, Yuriko Sakamaki, Chieko Saito, Noboru Mizushima. NCOA4 drives ferritin phase separation to facilitate macroferritinophagy and micro-ferritinophagy. *Journal of Cell Biology*, 221(10) e202203102 (2022).
2. Satoru Takahashi, Chieko Saito, Ikuko Koyama-Honda, Noboru Mizushima. Quantitative 3D correlative light and electron microscopy of organelle association during autophagy. *Cell Structure and Function*, v47(2) 89-99 (2022)

Department of Cellular and Tissue Communications

Project Professor

Jun K. YAMASHITA, M.D.,Ph.D.

Project Assistant Professor

Tomohiro Minakawa, Ph.D.

Homepage <https://www.m.u-tokyo.ac.jp/english/departments/units.html>

Introduction and Organization

The Department of Cellular and Tissue Communications was established on July 1, 2022, with Takara Bio Inc. as the investor and the Department of Cardiac Surgery (Prof. Minoru Ono) as the collaborating department. The main purpose of this department is to elucidate new actions and roles of extracellular vesicles (EVs) in diseases, which have been recently highlighted as a new type of intercellular communication, and to develop new next-generation therapies using EVs. One Project Professor and one Project assistant professor have been appointed, and Dr. Yamashita and Dr. Minagawa have been appointed to these positions respectively.

The details of the reason for the establishment, significance, and research content are as follows.

The purpose of this department is to develop research on novel cellular and tissue communications focusing on a new biological phenomenon called “phenotypic synchronization of cells (PSyC)” via extracellular vesicles (EVs), which has recently been discovered and reported in Japan, to elucidate new pathological conditions and to develop new therapeutic methods using EVs. EVs are considered to be involved in various biological phenomena and pathological conditions by delivering various molecules in various forms, and are an important new research target in medical biology. Entering this research field based on the world's first discovery of the unique function of EVs (PSyC) would contribute to the University for securing its leading position in EV research and EV

treatment. The establishment of this department will benefit for academic, research, and social activities.

The focus of this course is to explore the possibility of pathological analysis and therapeutic application based on basic research on the PSyC phenomenon. We also aim to develop human resources who will pioneer and develop new research areas based on the research content of this course.

[Research Contents]

1) Phenotypic Synchronization of Cells (PSyC): Using cells that can mark EVs, we would like to conducting real-time monitoring with high spatial-temporal resolution to elucidate the actual mode of EV exchange, the signaling molecules in EVs and their mechanisms of action.

(2) Significance of PSyC and EVs in pathological conditions: PSyC is considered to be involved not only in synchronization of differentiation, but also broadly in homeostasis, aging, and regeneration processes. The physiological and pathophysiological significance of PSyC will be clarified.

3) Therapeutic application of PSyC and EVs: Development of next-generation novel therapies utilizing cellular and tissue communications and PSyC with EVs. Explore the possibilities of anti-aging and rejuvenation therapies through cardiac regeneration, anti-atherosclerosis, and improvement of vascular function.

The following are assumed to be possible,

- EV is an area that has recently been highlighted and the research is progressing rapidly, but the "synchronization of cellular phenotypes" is a unique

discovery that was reported for the first time. Furthermore, the new roles and significance of EVs will be clarified by analysis of the latest technologies such as real-time monitoring, opening up a new academic field centered on cellular and tissue communications.

- The analysis of pathological conditions from a different perspective, including communication with EVs, will lead to a new understanding of diseases and the development of new treatment methods.
- By being the first to launch EV therapies supported by scientific findings, we can lead the development of new EV therapies worldwide.
- The potential for the development of completely new therapies such as anti-aging and rejuvenation therapies can also be expected.
- The company can expect to commercialize EVs through its investors and develop the application of therapeutics and other industrialization.

The research targets of cellular and tissue communications and cell differentiation are related to stem cell biology and developmental biology. And those of heart failure, atherosclerosis, tissue aging, are related to cardiovascular medicine and surgery, which may be the initial therapeutic targets for heart and blood vessels. The research targets centered on EV-mediated PSyC are highly unique, but the results can be linked to various related fields and have high potential for development. Thus, this course is a new research field that has not existed at the University of Tokyo before, and it can lead to new interactions, research linkages, and industry-academia collaborations.

Research activities

The following is an overview of our research to date. Drs. Yamashita and Minagawa, members of our faculty, discovered and reported the PSyC phenomenon (Minakawa, *J Extracell Vesicles*, 2021). Yamashita and colleagues have been conducting basic research on cardiovascular cell differentiation using pluripotent stem cells and its application to regenerative medicine and other fields. With the differentiation of pluripotent stem cells into cardiovascular cells as the basis and core of their research, they have conducted a series of wide-ranging research activities, including basic research on

various types of differentiation, induction of cardiovascular cells from human pluripotent stem cells, application of 3D organization to cardiac regeneration therapy and creation of new disease models, and commercialization of these products.

- (1) Cardiovascular cell differentiation of pluripotent stem cells and application to regenerative medicine: We have conducted original and advanced research on cardiovascular cell differentiation and regeneration using pluripotent stem cells (ES cells and iPS cells). Using Flk1-positive cells as common progenitors in mouse ES cells, we have established a new experimental system that allows us to investigate the differentiation mechanism of cardiovascular cells systematically (*Nature*, 2000). We are the first to identify cardiac progenitor cells (FCV cells) that differentiate into cardiomyocytes at high rates (*FASEB J*, 2005) and to successfully differentiate iPS cells into cardiovascular cells (*Circulation*, 2008; Best Paper Award in the Basic Science category of the same journal). Based on these achievements, we have analyzed the vascular differentiation mechanism of stem cells (*Blood*, 2009; *J Cell Biol*, 2010; *Blood*, 2011 (front cover); *Stem Cells*, 2012a), developed cell therapy using cardiac tissue sheets (*Stem Cells*, 2012b). We have developed novel methods for induction of cardiac/endothelial cell differentiation and purification of human iPS cells (*PLoS One*, 2011a, 2011b, 2017, 2020), and technologies for cardiac tissue formation from iPS cells, including simple multiple layering of cell sheets using gelatin hydrogel (*Sci Rep*, 2014, 2015, 2016). The application of these technologies to cardiac regenerative medicine is underway (in collaboration with the Department of Cardiac Surgery of University of Tokyo and Kyoto University, and iHeart Japan, Inc.)
- (2) Development and application of novel pathological models: We developed the world's first model for a lethal arrhythmia, Torsade de Pointes (TdP), using iPS cell-derived mini 3D tissue (Kawatou, *Nat Commun*, 2017). The model will be further developed for application to drug safety studies and in vitro disease reproduction and therapeutic research.
- (3) Pioneering new EV biology & medicine: The discovery of EV-induced cellular phenotypic synchronization (Minakawa, *J Extracell Vesicles*, 2021) will bring a new research field to the EV world. EVs, together with real-time monitoring, will elucidate

a variety of new functions of EVs. We will also investigate the application of EVs to novel cardiac regeneration therapies based on their currently discovered ability to induce myocardial differentiation.

(4) Regeneration of human hearts: We would like to making it possible to regenerate human hearts by enabling the proliferation of human cardiomyocytes and the conversion of cardiac progenitor cells into stem cells. We are currently analyzing the regulatory mechanism of human cardiomyocyte proliferation using various bioinformatics methods and our university's supercomputer.

(5) AMPK-based anti-aging and rejuvenation strategies: Metformin, an AMPK activator, is a potential longevity drug that can extend lifespan, and undifferentiated transcription factors used to induce iPS cells have also been suggested to have lifespan-extending effects. AMPK activation, which serves as a link between these factors, has been shown to induce naïve conversion of pluripotent stem cells (Liu, iScience, 2021). A similar mechanism has been found to operate in human cells (Yang, BioRxiv, 2022).

(6) Applications of Bioinformatics to pluripotent stem cells. Development of a new cytotoxicity detection system: We are developing a new cytotoxicity detection system using the pluripotent stem cells with their broad gene expression potential due to their pluripotency and low genomic modification (Yamane, iScience, 2022; Mori, BMC Bioinformatics, 2023). (in collaboration with Dr. Wataru Fujibuchi).

With these studies as a background, we have been working mainly on (3), (4), (5), and (6) since our appointment in FY2022.

References

[Papers]

1. Yamane J, Wada T, Otsuki H, Inomata K, Suzuki M, Hisaki T, Sekine S, Kouzuki H, Kobayashi K, Sone H, Yamashita JK, Osawa M, Saito MK, Fujibuchi W. StemPanTox: A fast and wide-target drug assessment system for tailor-made safety evaluations using personalized iPS cells. iScience. 6;25:104538, 2022.
2. 大塚 悟史、中尾 洋一: 春ウコンに含まれるアストロサイト分化誘導促進物質の同定, 化学と生物, 61:6-8, 2023

[Awards]

皆川朋皓, 第 28 回 (令和 4 年度) 日本炎症・再生医学会奨励賞 2022.7.7

[Lectures]

1. 山下潤. 幹細胞と組織工学による組織機能の構成的再現. 第 43 回日本炎症再生医学会シンポジウム, 2022.7.6.
2. 皆川朋皓, 山下潤. 近接する細胞へのエクソソーム・細胞外小胞送達による細胞形質同調. 第 43 回 日本炎症・再生医学会, 2022.7.7
3. 山下潤. 細胞外小胞の新しい機能と可能性ー細胞形質を制御するー. 第 81 回日本癌学会学術集会・共催セミナー, 2022.9.30.
4. Yamashita JK. Cardiovascular regeneration with human iPS cell-derived heart tissue. Symposium on Medical Exchange of Shanghai University and the University of Tokyo, 2022.11.17.
5. Kawatou M, Minatoya K, Ashihara T, Yamashita JK. Human iPS cell-engineered heart tissue to reproduce ventricular fibrillation in vitro. 第 87 回日本循環器学会学術集会, 2023.3.11.
6. 山下潤. 再生医療への幹細胞/ティッシュエンジニアリング融合技術の役割と新展開. 第 22 回日本再生医療学会総会シンポジウム, 2023.3.24.
7. 山下潤. 血管内塞栓を形成しない安全な基材による新しい効率的心筋前駆細胞移植法の開発. 第 22 回日本再生医療学会総会, 2023.3.25.
8. 皆川朋皓, 山下潤. 隣接細胞間における小胞動態のライブイメージング. 生物物理学会中部支部講演会, 2023.3.31.

Department of Next Generation Locomotive Imaging System

Project Associate Professor

Toru Doi, M.D., Ph.D.

Project Assistant Professor

Nozomu Ohtomo, M.D.

Introduction and Organization

The Department of Next Generation Locomotive Imaging System is established to develop new imaging system for scoliosis deformity in April 2020, which is fully funded by ZOZO Corporation. Screening examinations of scoliosis include the forward bending test and Moiré tomography. However, screening tests such as the forward bending test are not considered accurate enough to detect scoliosis and Moiré tomography is no longer manufactured and cannot be used for school screening examinations. Moreover, radiographic examinations for diagnosing scoliosis requires radiation exposure. Therefore, it is necessary to develop a new screening tool for detecting scoliosis. We aimed to develop a new screening tool for detecting scoliosis using a 3-dimension (3D) measurement bodysuit (ZOZOSUIT®).

Research activities

Our research aim is to develop a new screening imaging system for detecting scoliosis, using a unique 3D body measurement suit (ZOZOSUIT®), which was developed by ZOZO Co.. The development of this new-generation imaging system may detect scoliosis deformity without radiation exposure.

Patients with scoliosis or suspected scoliosis, non-scoliosis patients, and healthy volunteers were enrolled. They were divided into Non-Scoliosis and Scoliosis groups. The Scoliosis group was further subdivided into Mild-, Moderate-, and Severe-Scoliosis groups. Patients' characteristics and Z

values, which were calculated by a 3D virtual human body model created by ZOZOSUIT® to evaluate trunk asymmetry caused by scoliosis, were compared between the Non-Scoliosis and Scoliosis groups or among the Non-, Mild-, Moderate- and Severe-Scoliosis groups. Finally, the optimal cutoff of the Z value was determined to detect moderate to severe scoliosis using receiver operating characteristics (ROC) curve analysis. A total of 101 patients were included in this study. The Non-Scoliosis group included 47 patients, and the Scoliosis group included 54 patients, with 11, 31, and 12 patients in the Mild-, Moderate-, and Severe-Scoliosis groups, respectively. The Scoliosis group showed a significantly higher Z value than the Non-Scoliosis group. The Moderate- or Severe-Scoliosis group had a significantly higher Z value than the Non- or Mild-Scoliosis group. The ROC curve analysis revealed that the optimal cutoff of the Z value was 19.9 mm (sensitivity, 95.3%; specificity, 58.6%). A novel scoliosis screening method using ZOZOSUIT® may be useful for detecting moderate to severe scoliosis.

References

1. Treatment of restenosis after lumbar decompression surgery: decompression versus decompression and fusion.
Junya Miyahara, Yuichi Yoshida, Mitsuhiro Nishizawa, Hiroyuki Nakarai, Yudai Kumanomido, Keiichiro Tozawa, Yukimasa Yamato, Masaaki

Iizuka, Jim Yu, Katsuyuki Sasaki, Masahito Oshina, So Kato, **Toru Doi**, Yuki Taniguchi, Yoshitaka Matsubayashi, Akiro Higashikawa, Yujiro Takeshita, Takashi Ono, Nobuhiro Hara, Seiichi Azuma, Naohiro Kawamura, Sakae Tanaka, Yasushi Oshima.

Journal of Neurosurgery Spine 2022 Jan 7:1-8.

2. Evaluation of bone strength using finite-element analysis in patients with ossification of the posterior longitudinal ligament.

Toru Doi, Satoru Ohashi, Nozomu Ohtomo, Keiichiro Tozawa, Hiroyuki Nakarai, Yuichi Yoshida, Yusuke Ito, Ryuji Sakamoto, Koji Nakajima, Kosei Nagata, Naoki Okamoto, Hideki Nakamoto, So Kato, Yuki Taniguchi, Yoshitaka Matsubayashi, Sakae Tanaka, Yasushi Oshima.

Spine Journal 2022 Mar 4:S1529-9430(22)00094-8.

3. Does surgical treatment affect the degree of anxiety or depression in patients with degenerative cervical myelopathy?

Naohiro Tachibana, **Toru Doi**, Koji Nakajima, Hideki Nakamoto, Junya Mihayahra, Kosei Nagata, Hiroyuki Nakarai, Keiichiro Tozawa, Nozomu Ohtomo, Ryuji Sakamoto, So Kato, Yuki Taniguchi, Yoshitaka Matsubayashi, Sakae Tanaka, Yasushi Oshima

Global Spine Journal. 2022 Mar 29;21925682-221088549.

Department of Next-Generation Endoscopic Computer Vision

Project Associate Professor

Yosuke Tsuji, M.D., Ph.D.

Project Research Associate

Hiroya Mizutani, M.D., Ph.D., Tomonori Aoki, M.D., Ph.D.

Introduction and Organization

This Social Cooperative Chair was launched in January 2023 with the investment of AI Medical Services, Inc. As an affiliated chair of the University of Tokyo Graduate School of Medicine, it is also supported by the Department of Gastroenterology (Prof. Mitsuhiro Fujishiro).

The main research project of the department is the use of AI in gastrointestinal endoscopy. As a result of the introduction of the option of endoscopy in population-based gastric cancer screening (a public medical service aiming at reducing mortality from gastric cancer) from 2016, the number of endoscopic examinations has dramatically increased, and the increased workload on physicians and the risk of missing gastric cancer have become major issues. At the same time, since endoscopy is an examination method that depends on the skill of the physician, the difference in skill is also an issue. Recently, many attempts to apply the latest AI technologies such as Deep Learning to the medical field have been reported, and there are high expectations for the application of AI in the field of endoscopy. The purpose of our department is to conduct research and development for the utilization of AI in endoscopy and evaluate the results in clinical practice.

Clinical activities

Our department is not directly involved in the clinical practice. Dr. Tsuji (Project Associate Professor) is the head of the Gastrointestinal Tract Group in the Department of Gastroenterology at the University of

Tokyo Hospital, where he manages the treatment of the gastrointestinal tract. Together with Drs. Hiroya Mizutani, and Tomonori Aoki (Project Research Associate), who also belong to the Gastrointestinal Tract Group of the Department of Gastroenterology at the University of Tokyo Hospital, he is involved in many diagnoses and treatments using gastrointestinal endoscopy.

Teaching activities

Our department is not directly involved in education. Dr. Tsuji (Project Associate Professor) is in charge of a lecture on "Non-neoplastic Bowel Disease" in the organized course "Gastroenterology" for the second-year medical students in the Department of Internal Medicine, School of Medicine, the University of Tokyo.

Research activities

Our department will conduct research, development, and clinical evaluation of software programs that assist physicians in diagnosis using the latest image analysis technology. Specifically, the following two points will be the main focus of the research:

- (1) We will develop AI equipped with endoscopists' knowledge to improve the quality of endoscopic diagnosis by equalizing the endoscopic diagnosis and reducing missed diagnoses.
- (2) To establish next-generation endoscopic diagnosis and treatment methods using AI, we will acquire, process, and classify data based on actual clinical

experience. We will resolve issues related to the small number of data on rare cases, annotation cost, etc., which are challenges in the social implementation of endoscopic AI, from the perspective of image analysis technology.

To develop an endoscopic diagnosis support AI, a large amount of high-quality "training data," i.e., a large number of high-quality endoscopic images and videos of diseases, is first required. In addition, information such as the location of the disease, the extent of the disease, and the final diagnosis must be linked to the image data. For this reason, we are building a system for training AI by accumulating a large number of endoscopic images as high-quality video data in collaboration with the University of Tokyo and other facilities. After accumulating a certain number of data, we will develop an AI to support disease detection and differential diagnosis and conduct necessary trials to verify the effectiveness of the AI and to introduce it into actual clinical practice in the future.

References

1. Nagao S, Tani Y, Shibata J, Tsuji Y, Tada T, Ishihara R, Fujishiro M. Implementation of artificial intelligence in upper gastrointestinal endoscopy. *DEN Open*. 2022 Mar 15;2(1):e72.
2. Ochiai K, Tada T, Shibata J, Nagao S, Tsuji Y, Fujishiro M, Ishihara S. Artificial Intelligence in Colonoscopy: Exploring Computer-aided Detection Systems Stomach and Intestine 2022, 57(10):1298-1304
3. Kubota D, Tsuji Y, Mizutani H, Nagao S, Fujishiro M. An unexpected adverse event of endoscopic ultrasonography: acute aortic dissection. *Gastrointest Endosc*. 2022 Nov;96(5): 866-867.
4. Hisada H, Tsuji Y, Obata M, Cho R, Nagao S, Miura Y, Mizutani H, Ohki D, Yakabi S, Takahashi Y, Sakaguchi Y, Kakushima N, Yamamichi N, Fujishiro M. The impact of sarcopenia on short- and long-term outcomes of endoscopic submucosal dissection for early gastric cancer. *J Gastroenterol*. 2022 Dec;57(12): 952-961

Next-Generation Precision Medicine Development Laboratory

Project Associate Professor

Hiddenori Kage, M.D., Ph.D.

Project Lecturer

Akiko Kunita, Ph.D.

Introduction and Organization

In June 2019, The University of Tokyo, National Cancer Center Japan, and Konica Minolta, Inc. agreed to develop Todai OncoPanel (TOP), a next-generation comprehensive cancer genomic panel (CGP). TOP was initially developed by Professor Aburatani, The University Tokyo Research Center for Advanced Science and Technology and Hiroyuki Mano, former professor at The University of Tokyo and current Head of Cell Informatics, at National Cancer Center Japan. The research collaboration combines the knowledge of Ambry Genetics Corporation, a Konica Minolta company, and its global gene diagnostic technology, with the TOP technology to reinforce the informatics foundation technology of the TOP and develop a next-generation CGP. The Department of Next-Generation Precision Medicine Development Laboratory was established in April 2021 as a Social Collaboration Department within 22nd Century Medical and Research Center of The University of Tokyo Hospital, collaborating with Konica Minolta, Inc.

Clinical activities

As a Social Collaboration Department within 22nd Century Medical and Research Center, we do not directly engage in clinical activities. Dr. Kage is involved in cancer genomic medicine at The University of Tokyo Hospital through oversight of the Expert

Panel.

Teaching activities

As a Social Collaboration Department within 22nd Century Medical and Research Center, we do not directly engage in teaching activities. When M4 medical students came to the Department of Clinical Genomics for a one-month rotation in fiscal year 2022, Dr. Kage gave lectures and participated in Expert Panels with the students.

Research activities

TOP can detect a large number of gene mutations with its DNA panel and gene fusions with its RNA panel. At the Department of Next-Generation Precision Medicine Development Laboratory, we focus on (1) optimization of pathological specimens for CGP tests and (2) evaluation of TOP through Advance Medicare Care B.

(1) Best tissue processing practices for CGP tests with RNA panel

Background: Formalin-fixed, paraffin-embedded (FFPE) samples are valuable resources routinely used for pathology and clinical CGP tests. However, they also represent a multistage process that is not standardized, especially for RNA sequencing. Because pre-analytical sample processing ultimately affects the sequencing accuracy, its optimization is essential.

Therefore, we evaluated the effects of fixative concentrations, fixation time, and tissue size on DNA/RNA quality.

Methods: Pig livers were removed within 30 min of sacrifice. Equally sized tissues (2 mm/ 12 mm/ 50 mm thickness) were fixed in neutral-buffered formalin (10% or 20% NBF) for one (24 h), three (72 h), and seven days (168 h). FFPE blocks were prepared, and DNA and RNA were extracted from each 10 mm section using spin columns. The DNA/RNA quality was evaluated using fluorescence-based quantification and fragment size distribution (DIN for DNA/DV200 for RNA).

Results: DNA integrity was best for samples fixed in 10% NBF for one day. The RNA integrity remained unchanged irrespective of the NBF concentration. For RNA, the best fixation duration was one day. Increased degradation was observed in both DNA and RNA extracted from samples fixed for three and seven days versus those fixed for one day. Regarding tissue size in fixation, DNA yield per tissue area and the integrity were best extracted from small (2 mm thickness) tissues and had a great influence over the integrity. Conversely, RNA yield per tissue area and the integrity were best when extracted from large (50 mm thickness) tissues and had the minimal impact on the integrity.

Conclusions: Effects of the fixation methods varied between DNA and RNA. For the best tissue processing practices, fixation in 10% NBF for one day was suitable for DNA and RNA. Large tissues should be sliced into thin sections for effective fixation.

(2) Evaluation of TOP through Advance Medicare Care B

Background: Comprehensive cancer genome profiling (CGP) has been nationally reimbursed in Japan since June 2019. Less than 10% of the patients have been reported to undergo recommended treatment. Todai OncoPanel (TOP) is a dual DNA-RNA panel as well as a paired tumor-normal matched test.

Methods: Two hundred patients underwent Todai OncoPanel as part of Advanced Medical Care B with approval by the Ministry of Health, Labour and Welfare between September 2018 and December 2019. Tests were performed in patients with cancers without standard treatment or when patients had already undergone standard treatment.

Results: Data from DNA and RNA panels were analyzed in 198 and 191 patients, respectively. The percentage of patients who were given therapeutic or diagnostic recommendations was 61% (120/198). One hundred and four samples (53%) harbored gene alterations that were detected with the DNA panel and had potential treatment implications, and 14 samples (7%) had a high tumor mutational burden. Twenty-two samples (11.1%) harbored 30 fusion transcripts or MET exon 14 skipping that were detected by the RNA panel. Of those thirty transcripts, six had treatment implications and four had diagnostic implications. Thirteen patients (7%) were found to have pathogenic or likely pathogenic germline variants and genetic counseling was recommended. Overall, 12 patients (6%) received recommended treatment.

Conclusions: Patients benefited from both TOP DNA and RNA panels while following the same indication as the approved CGP tests.

Publications

1. Ando T, Kage H, Shinozaki-Ushiku A, Tatsuno K, Tsutsumi S, Nagayama K, Nakajima J, Kohsaka S, Miyagawa K, Aburatani H, Mano H, Nagase T. Composite Clonal Analysis Reveals Transition of NSCLC Subtypes Through Accumulation of Gene Mutations: A Case Report. *JTO Clin Res Rep* 2022;3:100277. PMID: 35199052
2. Miyamoto S, Yamazaki T, Shimizu K, Matsubara T, Kage H, Watanabe K, Kobo H, Matsuyama Y, Rodin G, Yoshiuchi K. Brief, manualised and semistructured individual psychotherapy programme for patients with advanced cancer in Japan: study protocol for Managing Cancer and Living Meaningfully (CALM) phase 2 trial. *BMJ Open* 2022;12:e056136. PMID: 35277407
3. Tanosaki T, Mikami Y, Shindou H, Suzuki T, Hashidate-Yoshida T, Hosoki K, Kagawa S, Miyata J, Kabata H, Masaki K, Hamamoto R, Kage H, Miyashita N, Makita K, Matsuzaki H, Suzuki Y, Mitani A, Nagase T, Shimizu T, Fukunaga K. Lysophosphatidylcholine Acyltransferase 1 Deficiency Promotes Pulmonary Emphysema via Apoptosis of Alveolar Epithelial Cells. *Inflammation* 2022;45:1765-1779. PMID: 35338433

4. Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shiota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, Yoshino T. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. *JAMA Netw Open* 2022;5:e2245081. PMID: 36469316
5. Mizuno S, Ikegami M, Koyama T, Sunami K, Ogata D, Kage H, Yanagaki M, Ikeuchi H, Ueno T, Tanikawa M, Oda K, Osuga Y, Mano H, Kohsaka S. High-throughput functional evaluation of MAP2K1 variants in cancer. *Mol Cancer Ther* 2022;22:227-239 PMID: 36442478
6. Sunami K, Naito Y, Komine K, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, Saigusa Y, Yoshino T. Chronological improvement in precision oncology implementation in Japan. *Cancer Sci*. 2022;113: 3995-4000. PMID: 35976133
7. Imai M, Nakamura Y, Sunami K, Kage H, Komine K, Koyama T, Amano T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Bando H, Makiyama A, Suzuki T, Hirata M, Kohsaka S, Tsuchihara K, Naito Y, Yoshino T. Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors. *Cancer Sci*. 2022;113: 3646-3656 PMID: 35876224
8. Kage H, Kohsaka S, Tatsuno K, Ueno T, Ikegami M, Zokumasu K, Shinozaki-Ushiku A, Nagai S, Aburatani H, Mano H, Oda K. Tumor mutational burden measurement using comprehensive genomic profiling assay. *Jpn J Clin Oncol* 2022; 52:917-921. PMID: 35482395
9. Tanosaki T, Mikami Y, Shindou H, Suzuki T, Hashidate-Yoshida T, Hosoki K, Kagawa S, Miyata J, Kabata H, Masaki K, Hamamoto R, Kage H, Miyashita N, Makita K, Matsuzaki H, Suzuki Y, Mitani A, Nagase T, Shimizu T, Fukunaga K. Lysophosphatidylcholine Acyltransferase 1 Deficiency Promotes Pulmonary Emphysema via Apoptosis of Alveolar Epithelial Cells. *Inflammation* 2022;45:1765-1779. PMID: 35338433
10. Kume A, Shinozaki-Ushiku A, Kunita A, Kondo A, Ushiku T: Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization. *Am J Surg Pathol* 2022. PMID:35605962
11. Suzuki T, Masugi Y, Inoue Y, Hamada T, Tanaka M, Takamatsu M, Arita J, Kato T, Kawaguchi Y, Kunita A, Nakai Y, Nakano Y, Ono Y, Sasahira N, Takeda T, Tateishi K, Uemura S, Koike K, Ushiku T, Takeuchi K, Sakamoto M, Hasegawa K, Kitago M, Takahashi Y, Fujishiro M, Japan GTKPCSGi: KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. *Cancer Sci* 2022. PMID: 35567350
12. Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, Abe J, Arita J, Hasegawa K, Shibata T, Ushiku T: KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression. *Liver Int* 2022, 42:2329-40. PMID:35833881
13. Tanaka M, Shinozaki-Ushiku A, Kunita A, Yasunaga Y, Akamatsu N, Hasegawa K, Ushiku T: High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma. *Pathol Int* 2022, 72: 411-8. PMID:35698921

Department of Tissue Stem Cells and Life Dentistry

Project Professor

Makoto Komura, M.D., Ph.D.

Project Lecturer

Yukiyo Asawa, D.V.M., Ph.D.

Homepage <http://plaza.umin.ac.jp/~tsc-lds/manage.html>

Introduction and Organization

A social cooperation course, The Department of Tissue Stem Cells and Life Dentistry was a collaborative department established in the department of tissue engineering, the University of Tokyo Hospital on November 19, 2018.

The research is currently based in University of Tokyo Hospital Tissue Engineering Department, Department of Oral and Maxillofacial Surgery, and Department of Pediatric Surgery.

The goal of our department is to succeed in translational research, from basic to clinical with the promotion of technology development on tissue organ regeneration, funded by Sheep Medical Co., Ltd. (formerly Dental Assist Co., Ltd.).

Major research projects include: research to elucidate self-renewal mechanisms using template-encapsulated tissue bodies (bio sheet/ bio tube) for trachea, gingiva and cornea regeneration, development of pulp stem cell culture methods, research on humoral factors in dental pulp culture supernatant fluid, establishment of techniques to induce bone differentiation in human umbilical cord, and analysis of oral microflora.

In 2022, the department is currently headed by a Project Professor, was assisted by a Project Lecturer.

Teaching activities

We shared the appeal of basic research to undergraduates through laboratory tours.

With the cooperation of Department of Pediatric Surgery, we are preparing to give lectures to master and Ph.D. students. On January 17, 2023, We gave a lecture on "Pediatric Surgery and Regenerative Medicine" in the Department of Reproductive, Developmental and Aging Sciences.

We also gave research guidance to master and Ph.D. students majoring in pediatric surgery and oral and maxillofacial surgery through practical training and exercises.

Research activities

In our study, we use somatic stem cell that exists in bio tissue, and we try to stimulate the somatic cell. By using dental pulp-derived stem cell, cartilage stem cell, and umbilical cord-derived stem cell, we are working to make up for the functional and structural defects. The target organs for this specific reproductions are, bone, cartilage, skin and muscle (including gingiva).

The following are the research topics of our department in 2020:

- Self-regeneration mechanism identification of skin mold encapsulation tissue
 - Structure analysis of skin-encapsulated tissue
 - Construction of regeneration model using skin-encapsulated tissue
 - Factor examination of regeneration model
- Development of dental pulp stem cell culture method

- Development of human dental pulp stem cell culture method
- Analysis on human dental pulp cell
- Development of mouse dental pulp stem cell culture method
- Analysis on mouse dental pulp cell
- Evaluation of mouse dental pulp cell differentiation
- Proliferation of cartilage stem cell
 - Construction of tracheal cartilage anastomosis site evaluation model
 - Technical development of strengthened tracheal anastomosis site
 - Dynamic measurement of tracheal anastomosis site
 - Functional evaluation of human ES cell
- Bone differentiation culture technique of human umbilical cord
 - Development of umbilical cord cell culture method while maintaining undifferentiated form
 - Development of bone differentiation induction method
- Analysis of oral microflora
 - Identification of bacteria with anti-inflammatory properties.
 - Anti-inflammatory action of bacteria against periodontopathic bacteria.

Komura, H., Kumagai, K., Seto, I., Abe, T., Hikita, A., Komura, M., Hoshi, K. Evaluation of cellular characteristics and bone differentiation potential of dental pulp cells derived from human permanent and wisdom teeth.

- 2: The 21st Annual Meeting of the Japanese Society for Regenerative Medicine. SP-19-6 March 19, 2022. Komura, H., Suzuki, K., Asawa, Y., Kanazawa, S., Shiraishi, K., Nakayama, Y., Komura, M. Skin regeneration by subcutaneously implanted periapical encapsulated tissue body (bio sheet).
- 3: The 76th Annual Meeting of the Japanese Society of Oral Medicine. April 21-23, 2022. Harada, T., Shiraishi, K., Asawa, Y., Abe, T., Komura, M., Hoshi, K. Basic study on mouse dental pulp cells for the development of bone regeneration technology.
- 4: The 76th Annual Meeting of the Japanese Society of Oral Medicine. April 21-23, 2022. Shiraishi, K., Harada, T., Kawakami, H., Kumagai, K., Abe, M., Asawa, Y., Komura, M., Hoshi, K. Characterization of dental pulp cells derived from human permanent teeth and evaluation of bone differentiation potential for development of bone regeneration therapy.

References

- 1: Shimizu R, Asawa Y, Komura M, Hoshi K, Hikita A. Superior stemness of a rapidly growing subgroup of isolated human auricular chondrocytes and the potential for use in cartilage regenerative therapy. *Regen Ther.* 2022 Jan 4;19: 47-57.
- 2: Yokote F, Yamauchi Y, Komura H, Tanuma T, Sakao Y, Kawamura M, Komura M. A novel method of tracheal anastomosis healing using a single submucosal injection of basic fibroblast growth factor: initial report. *Eur J Cardiothorac Surg.* 2022 Mar 24;61(4):917-924.

Conference Presentations

- 1: The 21st Annual Meeting of the Japanese Society for Regenerative Medicine. SP-13-2 March 17, 2022. Asawa, Y., Shiraishi, K., Nishida, T.,

Department of Digital Mental Health

Project Professor

Norito Kawakami, M.D., Ph.D.

Project Associate Professor

Kotaro Imamura, Ph.D.

Project Lecturer

Asuka Sakuraya, Ph.D.

Homepage <https://dmh.m.u-tokyo.ac.jp/>

Introduction and Organization

The Department of Digital Mental Health was established in June 2022 as a social cooperation program in collaboration with the Graduate School of Medicine, The University of Tokyo and 15 companies. We conduct basic and applied research on digital mental health (DMH) technology and services, such as measuring mental health and developing intervention programs to maintain and promote mental health. We contribute to society by disseminating research findings for mental health and also contribute to medical education based on these findings. We mainly research how to apply digital health technology to mental health promotion in the workplace and health and productivity management systems. The Department of Digital Mental Health is the world's first department established in a university to apply DMH technology in the occupational mental health field. From our activity, the following results will be expected;

- 1) Innovative digital mental health solutions applying artificial intelligence (AI) and simulation models will be developed and widely disseminated to individuals, companies, and organizations to promote people's mental health.
- 2) Scientific evidence about the accuracy of measurement methods and effectiveness of intervention programs will be accumulated, and evidence-based services applying DMH

technologies will be established.

- 3) Strategies for the dissemination and implementation of evidence-based DMH services will be developed, and a framework for their quality assurance will be proposed to society.

Research activities

Mental health is an important issue for individuals, companies, organizations, and society. In particular, mental health became a major public health challenge during the COVID-19 pandemic. In the post-pandemic society, it will be important to develop DMH technology to support mental health in the workplace and community using digital tools. The main research topics are as follows:

- 1) Applying digital technologies such as AI and simulation models to promote DMH, and developing a fully automated and tailored stress management program guided by AI.
- 2) Evaluating the effectiveness of evidence-based DMH measurement and intervention programs using gold-standard methodology such as randomized controlled trials.
- 3) Developing effective strategies for the dissemination and implementation of evidence-based DMH measurement and intervention programs to individuals, companies/organizations, and municipalities. We also research quality assurance frameworks for DMH services.

In addition to this, we will conduct extensive research on mental health in the digital society and "Society 5.0."

References

1. Fukasawa M, Umeda M, Akiyama T, Horikoshi N, Yasumura S, Yabe H, Suzuki Y, Bromet EJ, Kawakami N. Worry about Radiation and Its Risk Factors Five to Ten Years after the Fukushima Nuclear Power Plant Disaster. *Int J Environ Res Public Health*. 2022 Dec 16;19(24):16943. doi: 10.3390/ijerph192416943. PMID: 36554824; PMCID: PMC9778659.
2. Yasuma N, Shiozawa T, Ogawa M, Abe M, Igarashi M, Kawaguchi T, Sato S, Nishi D, Kawakami N, Yamaguchi S, Fujii C. What outcomes in community mental health research are important to caregivers of people with schizophrenia? An exploratory qualitative analysis of an online survey. *Neuropsychopharmacol Rep*. 2022 Dec;42(4):526-531. doi: 10.1002/npr2.12295. Epub 2022 Oct 10. PMID: 36217559; PMCID: PMC9773637.
3. Sasaki N, Akiyama H, Kawakami N, Nishi D. Preconception menstrual cycle disorder and antenatal depression: a cross-sectional study with prerecorded information. *J Psychosom Obstet Gynaecol*. 2022 Dec;43(4):411-418. doi: 10.1080/0167482X.2021.2010699. Epub 2021 Dec 9. PMID: 34882063.
4. Obikane E, Sasaki N, Imamura K, Nozawa K, Vedanthan R, Cuijpers P, Shimazu T, Kamada M, Kawakami N, Nishi D. Usefulness of Implementation Outcome Scales for Digital Mental Health (iOSDMH): Experiences from Six Randomized Controlled Trials. *Int J Environ Res Public Health*. 2022 Nov 27;19(23):15792.
5. Tsuji R, Nishi D, Sasaki N, Akiyama H, Kuroda R, Tsuno K, Imamura K, Kawakami N. Association between meal frequency with others and psychological distress during the COVID-19 pandemic: A cross-sectional study. *Psychiatry Clin Neurosci Rep*. 2022 e61. <https://doi.org/10.1002/pcn5.61>
6. Sugiura K, Morita Y, Kawakami N, Kayama M. How Do Psychiatrists in Japan Choose Involuntary Admission, and What Do They Think of Supported Decision Making? A Thematic Analysis of Peer to Peer Interviews. *Community Ment Health J*. 2022 Nov 3. doi: 10.1007/s10597-022-01046-1. Epub ahead of print. PMID: 36327042.
7. Komase Y, Akiyama H, Kawakami N. Effects of the Collective Gratitude on Work Engagement: A Multilevel Cross-sectional Study. *J Occup Environ Med*. 2022 Nov 1;64(11):e729-e735. doi: 10.1097/JOM.0000000000002683. Epub 2022 Aug 20. PMID: 35993606.
8. Tsuno K, Kawakami N, Tsutsumi A, Shimazu A, Inoue A, Odagiri Y, Shimomitsu T. Victimization and witnessing of workplace bullying and physician-diagnosed physical and mental health and organizational outcomes: A cross-sectional study. *PLoS One*. 2022 Oct 26;17(10):e0265863. doi: 10.1371/journal.pone.0265863. PMID: 36288324; PMCID: PMC9603991.
9. Yasuma N, Imamura K, Watanabe K, Iida M, Takano A. Adolescent cannabis use and the later onset of bipolar disorder: protocol for a systematic review and meta-analysis of prospective cohort studies. *Neuropsychopharmacol Rep*. 2022 Oct 25.
10. Obikane E, Watanabe K, Nishi D, Kawakami N. Adverse childhood experiences and personal values in adolescence: a cross-sectional study using community adult samples in Japan. *Pediatr Int*. 2022 Sep 27:e15370. doi: 10.1111/ped.15370. Epub ahead of print. PMID: 36165851.
11. Kuribayashi K, Takano A, Inagaki A, Imamura K, Kawakami N. Effect of stress management based on cognitive-behavioural therapy on nurses as a universal prevention in the workplace: a systematic review and meta-analysis protocol. *BMJ Open*. 2022 Sep 19;12(9):e062516.
12. Nishi D, Imamura K, Watanabe K, Obikane E, Sasaki N, Yasuma N, Sekiya Y, Matsuyama Y, Kawakami N. The preventive effect of internet-based cognitive behavioral therapy for prevention of depression during pregnancy and in the postpartum period (iPDP): a large scale randomized controlled trial. *Psychiatry Clin Neurosci*. 2022 Aug 12.
13. Sasaki N, Imamura K, Watanabe K, Hidaka Y,

- Ando E, Eguchi H, Inoue A, Tsuno K, Komase Y, Iida M, Otsuka Y, Sakuraya A, Asai Y, Iwanaga M, Kobayashi Y, Inoue R, Shimazu A, Tsutsumi A, Kawakami N. The impact of workplace psychosocial factors on menstrual disorders and infertility: a protocol for a systematic review and meta-analysis. *Syst Rev*. 2022 Sep 7;11(1):195.
14. Sasaki N, Inoue A, Asaoka H, Sekiya Y, Nishi D, Tsutsumi A, Imamura K. The Survey Measure of Psychological Safety and Its Association with Mental Health and Job Performance: A Validation Study and Cross-Sectional Analysis. *Int J Environ Res Public Health*. 2022 Aug 11;19(16):9879.
 15. Sasaki N, Kuroda R, Tsuno K, Imamura K, Kawakami N. COVID-19 vaccination did not improve employee mental health: A prospective study in an early phase of vaccination in Japan. *Neuropsychopharmacol Rep*. 2022 Jun;42(2):230-232.
 16. Kawakami N, Kim Y, Saito M, Fujishiro S. People's worry about long-term impact of COVID-19 pandemic on mental health. *Asian J Psychiatr*. 2022 Sep;75:103196. doi: 10.1016/j.ajp.2022.103196. Epub 2022 Jun 24. PMID: 35816936; PMCID: PMC9232257.
 17. Takano A, Miyamoto Y, Shinozaki T, Matsumoto T, Kawakami N. Effects of a web-based relapse prevention program on abstinence: Secondary subgroup analysis of a pilot randomized controlled trial. *Neuropsychopharmacol Rep*. 2022 Sep;42(3):362-367. doi: 10.1002/npr2.12272. Epub 2022 Jun 11. PMID: 35689457; PMCID: PMC9515705.
 18. Kessler RC, Kazdin AE, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Altwaijri YA, Andrade LH, Benjet C, Bharat C, Borges G, Bruffaerts R, Bunting B, de Almeida JMC, Cardoso G, Chiu WT, Cía A, Ciutan M, Degenhardt L, de Girolamo G, de Jonge P, de Vries YA, Florescu S, Gureje O, Haro JM, Harris MG, Hu C, Karam AN, Karam EG, Karam G, Kawakami N, Kiejna A, Kovess-Masfety V, Lee S, Makanjuola V, McGrath JJ, Medina-Mora ME, Moskalewicz J, Navarro-Mateu F, Nierenberg AA, Nishi D, Ojagbemi A, Oladeji BD, O'Neill S, Posada-Villa J, Puac-Polanco V, Rapsey C, Ruscio AM, Sampson NA, Scott KM, Slade T, Stagnaro JC, Stein DJ, Tachimori H, Ten Have M, Torres Y, Viana MC, Vigo DV, Williams DR, Wojtyniak B, Xavier M, Zarkov Z, Ziobrowski HN; WHO World Mental Health Survey collaborators. Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. *World Psychiatry*. 2022 Jun;21(2):272-286. doi: 10.1002/wps.20971. PMID: 35524618; PMCID: PMC9077614.
 19. Eiko Ozasa, Asuka Sakuraya, Yasuto Sato, Sachiko Takehara, Noriko Kojimahara. How Doctors in Charge of Medical Education Recognize and Use Clinical Practice Guidelines in Education: A Cross-Sectional Study. *Tokyo Women's Medical University Journal* <https://doi.org/10.24488/twmuj>.
 20. Yang CC, Watanabe K, Kawakami N. The Associations Between Job Strain, Workplace PERMA Profiler, and Work Engagement. *J Occup Environ Med*. 2022 May 1;64(5):409-415. doi: 10.1097/JOM.0000000000002455. Epub 2021 Dec 6. PMID: 34873133.

Department of Prevention of Diabetes and Lifestyle-Related Diseases

Project Associate Professor

Satoko Yamaguchi, M.D., Ph.D.

Project Lecturer

Akira Okada, M.D., Ph.D.

Homepage <https://plaza.umin.ac.jp/prev/>

Introduction and Organization

The Department of Prevention of Diabetes and Lifestyle-Related Diseases is a Social Cooperation Program founded in April 2018, which is sponsored by Asahi Mutual Life Insurance Company and is cooperating with the Department of Nephrology and Endocrinology (Professor Masaomi Nangaku) and Department of Diabetes and Metabolic Diseases (Professor Toshimasa Yamauchi).

The objective of our department is to undertake research on preventing onset and progression of diabetes and other lifestyle-related diseases, through analyses of big data including medical databases and usage of information and communication technology (ICT), thereby making a contribution to improving health of people in Japan.

Lifestyle-related diseases including diabetes account for approximately 30% of medical expenses and 60% of deaths. Moreover, Japan is facing an unprecedented super aged society with aging rate of 28.1% in 2018, and an increasing number of people require long-term care due to conditions caused by lifestyle-related diseases. Analyzing factors associated with onset and progression of lifestyle-related diseases is expected to contribute to preventing lifestyle-related diseases and conditions caused by them, decreasing the number of people requiring long-term care, as well as optimizing

medical expenses.

Our department intends to conduct multidirectional analyses of big data including medical databases and construct models predicting progression of lifestyle-related diseases.

We are receiving four collaborative researchers from Asahi Mutual Life Insurance Company.

Research activities

The members of our department are working on the following research topics.

1) Research on long-term care

An increasing number of people require long-term care in recent years, and as of 2022, approximately 6.9 million people have been certified as being in need for long-term care in Japan. However, factors and diseases leading to conditions requiring long-term care remain largely unknown. In order to identify factors predicting conditions requiring long-term care, we obtained and have analyzed anonymized data of Comprehensive Survey of Living Conditions, a nationwide survey containing household situation and health-related questions, from Ministry of Health, Labor and Welfare.

2) Research on discontinuation of physician visit in people with diabetes

Discontinuation of diabetes care is associated with increased rate of complications and mortality. We analyzed JMDC database and showed that guideline-recommended practices within the first month of physician consultation for diabetes care can decrease subsequent discontinuation of physician visits in patients with newly diagnosed diabetes.

Additionally, we developed a machine-learning model for predicting people's failure to attend a follow-up visit for diabetes care after recommendations from a national screening program.

3) Research on impact of the COVID-19 pandemic on healthcare service use and health check-ups

The COVID-19 pandemic disrupted healthcare service and health check-ups globally, especially at its beginning. We investigated the impact of pandemic on healthcare service use by analysing hospital-based claims database.

In addition, we investigated the impact of pandemic on health check-ups by conducting a nationwide survey targeting health check-up facilities, in collaboration with Japan Society of Ningen Dock.

This work was supported by MHLW Special Research (Program Grant Number JPMH20CA2046) and Research on Emerging and Re-emerging Infectious Diseases and Immunization (Program Grant Number JPMH21HA2011).

4) Research on bleeding complications after liver biopsy and kidney biopsy in pediatric patients

Little has been reported about bleeding complications after liver or kidney biopsy in pediatric patients. Using a nationwide inpatient database, we investigated major complications after liver biopsy or kidney biopsy in pediatric patients.

We performed research using DPC database and JMDC database in collaboration with the Department of Clinical Epidemiology and Health Economics (Professor Hideo Yasunaga) and medical information database of the University of Tokyo Hospital in collaboration with the Department of Biomedical Informatics (Professor Kazuhiko Ohe).

In addition to moving these projects forward, we plan to take on new projects using databases in the future.

References

1. Okada A, Yamana H, Yamaguchi S, Kurakawa KI, Michihata N, Matsui H, Fushimi K, Nangaku M, Yamauchi T, Yasunaga H, Kadowaki T. Effect of Branched-Chain Amino Acid Infusion on In-Hospital Mortality of Patients With Hepatic Encephalopathy and End-Stage Kidney Disease: A Retrospective Cohort Study Using a National Inpatient Database. *J Ren Nutr.* 2022;32(4):432-440.
2. Okada A, Hashimoto Y, Goto T, Yamaguchi S, Ono S, Ikeda Kurakawa K, Nangaku M, Yamauchi T, Yasunaga H, Kadowaki T. A Machine Learning-Based Predictive Model to Identify Patients Who Failed to Attend a Follow-up Visit for Diabetes Care After Recommendations From a National Screening Program. *Diabetes Care.* 2022;45(6):1346-1354.
3. Yamaguchi S, Okada A, Sunaga S, Ikeda Kurakawa K, Yamauchi T, Nangaku M, Kadowaki T. Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. *BMJ Open.* 2022;12(4):e060390.
4. Kurakawa KI, Okada A, Bessho K, Jo T, Ono S, Michihata N, Kumazawa R, Matsui H, Fushimi K, Yamaguchi S, Yamauchi T, Nangaku M, Kadowaki T, Yasunaga H. Major complications after percutaneous biopsy of native or transplanted liver in pediatric patients: a nationwide inpatient database study in Japan. *BMC Gastroenterol.* 2022;22(1):395.
5. Okada A, Yamaguchi S, Jo T, Yokota I, Ono S, Ikeda Kurakawa K, Nangaku M, Yamauchi T, Kadowaki T. Impact of body mass index on in-hospital mortality in older patients hospitalized for bacterial pneumonia with non-dialysis-dependent chronic kidney disease. *BMC Geriatr.* 2022;22(1):950.
6. Okada A, Yamada G, Kimura T, Hagiwara Y, Yamaguchi S, Kurakawa KI, Nangaku M, Yamauchi T, Matsuyama Y, Kadowaki T. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities. *J Diabetes Investig.* 2022.

7. Okada A, Ikeda Kurakawa K, Harita Y, Shimizu A, Yamaguchi S, Aso S, Ono S, Hashimoto Y, Kumazawa R, Michihata N, Jo T, Matsui H, Fushimi K, Nangaku M, Yamauchi T, Yasunaga H, Kadowaki T. Comparison of bleeding complications after pediatric kidney biopsy between intravenous sedation and general anesthesia: a nationwide cohort study. *BMC Pediatr.* 2023;23(1):33.

Department of Pain and Palliative Medical Sciences

Project Associate Professor

Maiko Hasegawa-Moriyama, M.D., Ph.D.

Project Assistant Professor

Kirio Kawai, M.D

Homepage N/A

History and outline of organization

About a half of the cancer patients die by cancer though of the recent innovations of anti-cancer treatments. It mainly depends on the efficacy of the first-line strategies whether cancer is curable or not. Almost all the cancer patients whose initial treatment was unsuccessful die after the distressing struggle against their disease within several years. It is clear for such patients that both sufficient anti-cancer treatments and appropriate approaches to improve their quality of life (QOL) are simultaneously indispensable.

However, in our nation, most attention has been entirely paid to the improvement of cure rate and survival time of cancer patients. On the other hand, we have to consider that their QOL is scarcely concentrated until quite recently.

Palliative care means the combination of active therapeutic approach and total human care for the patients no matter which their cancer does or does not respond to anti-cancer treatments. Pain relief, other symptom management, psychological, social and spiritual cares are as a top priority for these patients. It is also emphasized that palliative care is necessary to be applied in the cancer treatment even for patients in early stage of their diseases as well as the progressive or terminal phase of their clinical courses.

In Department of Pain and Palliative Medicine Science, The University of Tokyo Hospital, we participate in pain and palliative care team and takes a leading role not only to control physical symptoms of cancer

patients but also to care for the mental and social support at the same time, and to improve the overall QOL of patients.

Palliative care is described clearly in the law "Cancer Control Act" approved by the National Diet on June 2006 that "The medical treatment to aim at relieving many kinds of pain and problems of cancer patients is applicable from the early course of the illness".

However, it is possible that the use of analgesic, especially opioids are not sufficient for cancer pain in Japan. Therefore, this department work on development and distribution of pain screening tool and educational program. According to our recent study, the nationwide adequacy of opioid availability was approximately 75%, and the largest gaps in adequacy between prefectures were more than 65%, suggesting that opioid might not be adequately prescribed nationwide.

Therefore, we analyze the correlation between cancer pain severity and opioid availability using medical big data to reduce this regional disparity.

Based on these background and purpose, the department was founded in May, 2021.

Consultation

In The University of Tokyo Hospital, we pain and palliative care team are composed of many kinds of specialists containing three full-time staff doctors, two full-time doctors, and two certificated cancer and hospice care nurses who take an initiative in this

multidisciplinary team. We visit to bedsides, consultation rooms and everywhere in the hospital, and offer palliative care to cancer patients who have received cancer care in cooperation with patients' attending doctors, ward staff, therapists of rehabilitation, social workers and every kind of professionals.

Education

In the Department of Pain and Palliative Medicine, junior residents of the first and second year can learn the basic knowledge and practice of palliative care by selecting an optional subject for one, two, four or eight months. And then they can participate in the pain and palliative care team and attend the daily team-conference on weekdays.

Educational

- In the intensive course for the first-year residents, we prepare lectures about:
 - # pain management
 - # diagnoses and management of delirium
 - # Introduction of guidelines in the field of palliative medicine and their use
 - # Basic medication for palliative care
 - # Spirituality and whole person care for Japanese patients facing death

Daily and weekly schedule

- Conference: Monday-Friday (every weekday); 9:00-10:30am
- Consultation: Monday-Friday (every weekday); from the end of morning conference, up to the completion of all the requested consulting of the day.
- The cancer registry: They input data in the ward round with the HIS (Hospital information system) terminal on each floor.

Research

The clinical information accumulated from the palliative care consultation and anesthesia for patients undergoing cancer surgery is input to the concise database simultaneously and utilized for various kinds of clinical researches to submit to the international medical journal.

To date, we the Department of Palliative Medical Sciences have contributed to the progress of following

fields of investigations.

- ① Opioid availability for the palliative care of patients with advanced cancer is increasing globally. However, opioid consumption in Japan is still extremely low compared with that in other countries. We investigated the current situation of pain control and opioid consumption in patients with advanced cancer by a nationwide questionnaire survey in Japan. Caregivers from 2000 comprehensive support centres nationwide answered the web-based questionnaire survey asking for details about their assigned patients who died of end-stage cancer. The survey included the questionnaire of pain intensity and opioid prescription.
- ② In clinical situation, the use of opioids frequently induce delirium. As a result, the use of opioids can be avoided although pain control is not sufficient. Therefore, we investigate the methods for diagnostic tool for delirium and its mechanisms.

Publications

1. Abe H, Sumitani M, Matsui H, Inoue R, Konishi M, Fushimi K, Uchida K, Yasunaga H. Gabapentinoid use is associated with reduced incidence of hyperactive delirium in elderly cancer patients undergoing chemotherapy: a nationwide retrospective cohort study in Japan. *Anesthesia & Analgesia* 2022; 135: 362-9
2. Mietani K, Hasegawa-Moriyama M, Yagi K, Inoue R, Ogata T, Kurano M, Shimojo N, Seto Y, Sumitani M, Uchida K. Preoperative detection of serum phosphorylated neurofilament heavy chain subunit predicts postoperative delirium: A prospective observational study. *J Gerontol Geriatr* 2022; 70: 169-77
3. Ando M, Sumitani M, Fuyuki M, Abe H, Shinoda Y, Matsubayashi Y, Oshima Y, Inoue R, Tsuchida R, Uchida K. Imaging features inferring symptom onset due to spinal metastasis progression: A preliminary study. *Ann Palliat Med* 2022; 11: 2247-56
4. Abe H, Sumitani M, Matsui H, Inoue R, Fushimi K, Uchida K, Yasunaga H. Use of naldemedine is associated with reduced incidence of hyperactive

- delirium in cancer patients with opioid-induced constipation: a nationwide retrospective cohort study in Japan. *Pharmacotherapy: Journal of Human Pharmacology and Drug Therapy* 2022; 42: 241-9
5. Inoue R, Sumitani M, Otake Y, Ohya R, Tsuchida R, Konishi M, Abe H, Uchida K. Augmented reality-supported exercise therapy system improves physical frailty and musculoskeletal pain: a preliminary feasibility study. *J Muscle Health* 2022; 4: 1013
 6. Kurisu K, Inada S, Maeda I, Ogawa A, Iwase S, Akechi T, Morita T, Imai K, Nakahara R, Kaneishi K, Nakajima N, Sumitani M, Yoshiuchi K. Decision tree prediction model for outcome of pharmacological treatment of delirium in advanced cancer patients: Pharmacological adult study of safety and efficacy in real world (Phase-R). *Palliat Support Care* 2022; 20: 153-8
 7. Saita K, Sumitani M, Nishizawa D, Tamura T, Ikeda K, Wakai K, Sudo Y, Abe H, Otonari J, Takeuchi K, Hishida A, Tanaka K, Shimanoe C, Takezaki T, Ibusuki R, Oze I, Ito H, Ozaki E, Matsui D, Nakamura Y, Kusakabe M, Suzuki S, Nakagawa-Senda H, Arisawa K, Katsuura-Kamano S, Kuriki K, Kita Y. Genetic polymorphism of pleiotrophin is associated with pain experience in Japanese adults: case-control study. *Medince (Baltimore)* 2022; 101: e30580
 8. Mietani K, Hasegawa-Moriyama M, Inoue R, Ogata T, Shimojo N, Kurano M, Yatomi Y, Uchida K, Sumitani M. Serum levels of apolipoprotein A-1 and E are associated with postoperative delirium: A post-hoc analysis. *Medince (Baltimore)* 2022; 101: e29906
 9. Hao X, Zhou Y, Ling Y, Feng Z, Miyoshi H, Sumitani M, Chan KY, Park HJ, Rao Y. Effects of high-dose opioid analgesia on survival, pain relief, quality of life and adverse drug reactions in cancer and neuropathic pain patients: a retrospective cohort study in real-world clinical practice. *Ann Transl Med* 2022; 10: 998
 10. Edamura T, Sumitani M, Hayakawa K, Inoue R, Abe H, Tsuchida R, Chikuda H, Ogata T, Kurano M, Aoki J, Yatomi Y, Uchida K. Different profiles of the triad of lysophosphatidylcholine, lysophosphatidic acid and autotaxin in patients with neuropathic pain diseases: a preliminary observational study. *Pain and Therapy* 2022; 11: 1439-49
 11. Mietani M, Hasegawa-Moriyama M, Yagi K, Inoue R, Ogata T, Shimojo N, Seto Y, Uchida K, Sumitani M. Elevation of serum plasminogen activator inhibitor-1 predicts postoperative delirium independent of neural damage: A sequential analysis. *Scientific Reports* 2022; 12: 17091
 12. Abe H, Inoue R, Tsuchida R, Ando M, Saita K, Konishi M, Edamura T, Ogawa A, Matsuoka Y, Sumitani M. Efficacy of treatments for pain and numbness in cancer survivors: a systematic review and meta-analysis. *Ann Palliat Med* 2022; 11: 1439-49
- (And, 9 Japanese articles)*

Department of Innovative Dementia Prevention

Project Associate Professor

Tomoko Wakabayashi, Ph.D.

Homepage <http://www.neuropathology.m.u-tokyo.ac.jp>

Introduction and Organization

Department of Innovative Dementia Prevention was launched on July 2017, through the financial support of Kobayashi Pharmaceuticals, with assistance by the Department of Neuropathology. Two faculty staffs, Tadafumi Hashimoto as the Project Associate Professor and Ryoko Ihara as the Project Assistant Professor started the research projects, with Dr. Daisuke Izawa of Kobayashi as a collaborative researcher. From January 2019, Dr. Tomoko Wakabayashi joined in the department in the replacement of Dr. Ryoko Ihara, and Dr. Yutaro Ito of Kobayashi also joined in the research project in the replacement of Dr. Izawa. Dr. Hashimoto has moved out in September 2021, and Dr. Wakabayashi has taken up the Project Associate Professor in December 2021.

The aged society in Japan urges us to challenge the dementing disorders including Alzheimer's disease (AD), although there have emerged no effective therapeutic strategies against AD based on its pathomechanism. Our laboratory will conduct basic research on the molecular mechanism of dementia and development of clinical measures for evaluation of efficacies of the therapeutic drugs in parallel, aiming at identifying the novel targets for prevention and early treatment of dementia and establish methods to prevent or delay the progression of dementia by drugs and functional foods. We also will be actively involved in the education and outreach activities of basic and clinical research on AD and dementia.

Education

Department of Innovative Dementia Prevention was involved in the education through research activities of graduate students of the Graduate School of Medicine and medical student belonging to the Medical Scientist Training Program.

Research

Department of Innovative Dementia Prevention is conducting research in the following four directions, based on the amyloid hypothesis of AD, toward the goal of developing strategies for prevention of dementia and AD.

① Molecular mechanism of A β dynamics in the brain Amyloid β peptide (A β), a causative protein for AD, is produced from the amyloid precursor protein (APP) through two-step proteolysis by β - and γ -secretases, and then secreted into the extracellular space. Once released outside the neurons, A β is readily cleared by proteolytic degradation or transported outside the brains. However, A β that escaped from the clearance starts to aggregate and deposit forming amyloid fibrils. Thus, the elucidation of the A β dynamics in the brain, comprised of the elementary processes of "production", "secretion", "aggregation" and "deposition", is vital to the clarification of the pathogenic mechanism of AD as well as development of therapeutic and prevention strategies against AD. However, to quantitatively analyze each of the process, there is a compelling need for accurate quantitation of A β that is present at picomolar levels in brains.

We have adopted the microdialysis technique using

dialysis membrane of ~1,000 kDa cut-off that enables the recovery of brain interstitial fluids and quantitation of the levels, rates of production and clearance of A β in the hippocampus and other parts of the brains (Yamamoto K, et al., *Cell Rep.*, 2015). In combination with the in vivo seeding experiments injecting aggregation seeds for A β and evaluate the following A β deposition (Hori Y, et al., *J. Biol. Chem.*, 2015), we have identified a >200 kDa high molecular weight (HMW) A β oligomer species in the soluble fractions of brains of APP transgenic mice and AD brains (Hashimoto T, Soc for Neuroscience meeting 2017), and found that oligomeric structure of HMW A β is essential for the induction of β -amyloidosis. We also found that the level of HMW A β oligomers in the brains of amyloid angiopathy-rich AD cases were significantly higher than those of amyloid angiopathy-minimal AD cases, injection of HMW A β oligomers into cerebrospinal fluid from a cisterna magna induced CAA in the perivascular space, suggesting that seed-competent HMW A β oligomers may accumulate in the amyloid angiopathy in the brains of AD patients. We also generated a novel method for purification of HMW A β oligomers using an adeno-associated virus encoding BRI-3xFLAG-A β 1-42. Using these techniques, we will further identify A β species that are involved in the A β dynamics in the brain, including those specifically involved in deposition or toxicity of A β .

② Elucidation of the role of apolipoprotein E (apoE) in the pathogenesis of AD, and development of method of AD prevention targeting apoE

Apolipoprotein E (apoE) is produced by astrocytes and comprises the major lipoprotein in the central nervous system. Human APOE gene has three genetic polymorphisms (ϵ 2, ϵ 3, ϵ 4), resulting in the production of three protein isoforms (apoE2, apoE3, apoE4) harboring different amino acids at two critical residues at positions 112 and 158. The allele frequency of ApoE ϵ 4 allele is ~8-10% in normal population, whereas it is elevated to >30-40% in AD. Thus, ApoE ϵ 4 is a strong genetic risk factor of AD, although the mechanism whereby ApoE ϵ 4 accelerates AD pathophysiology has remained elusive, without any effective therapeutic strategies targeting apoE.

We have created a series of bigenic mice by crossing

knock-in (KI) mice expressing human apoE2, E3 or E4 with APP transgenic mice, and we are currently trying to examine how each human isoform of apoE influences on A β dynamics in the brain. This will lead us to the intervention into the effect of apoE isoforms on A β , toward the goal of AD prevention. We have found a significant decrease in A β deposition in the brains of human apoE3 KI/APP transgenic mice. Using in vivo seeding technique, we have also found that apoE3 suppressed the deposition of A β compared with murine apoE, and that apoE4 was less able to suppress the A β deposition compared to apoE3. We further found that deletion of the APOE gene in APP tg mice markedly reduced A β deposition, and that no A β deposition was induced by in vivo seeding experiment in the brain of APPtg/apoE KO mice. Furthermore HMW A β oligomers were associated with apoE in the brain. These data suggested that apoE is an essential factor for A β deposition (Hashimoto T, Soc for Neuroscience meeting 2021). In vivo microdialysis experiments, we found that the A β levels in the interstitial fluids of human apoE3 KI/APP transgenic mice are similar to those in APP transgenic mice by method. We also have established a method to monitor the interaction between A β and apoE using a bi-molecular complementation assay. We will use this unique assay system to identify small molecule drugs that modulate the interaction of apoE and A β .

③ Establishment of a novel AD model using three-dimensional culture system for the development of prevention methods targeting brain A β metabolism.

To overcome the lack of experimental paradigms for the evaluation of aggregation and deposition in vitro, we adopted 3-dimensional culture system using Matrigel for the neuronal differentiation of human ReNcell-VM neuronal precursor cells, to observe the process of A β deposition and A β -dependent neurotoxicity reminiscent to that in AD brains. In 2018, we found the phosphorylation of tau by the overproduction of E22G mutant A β in the ReNcell-VM neurons. We will use this system for the development of anti-dementia drugs targeting A β production and deposition.

④ Clinical studies on the clinical and cognitive measures in the early stages of AD.

We have set out to the systematic analysis of the clinical data on the natural course of the early stage of AD derived from Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI), with a special focus on the preclinical AD stage, where elderly individuals are clinically and cognitively normal but positive for amyloid biomarkers. We have found that preclinical AD individuals lack learning effects in the cognitive tests, e.g., MMSE and logical memory, presumably representing subtle cognitive deficits. We also aim at international harmonization and comparison of the evaluation of cognitive decline, using US-ADNI database and other international datasets.

⑤ Molecular mechanisms linking type II diabetes mellitus and Alzheimer's disease

A number of epidemiological studies have reported that type 2 diabetes increases the risk of developing Alzheimer's disease (AD). Studies using human autopsy brains, imaging analysis, and mouse models suggest that insulin resistance, a central pathology of diabetes, may be correlated with amyloid accumulation. In addition, analysis of Alzheimer's patient brains has shown that insulin signaling may be impaired in AD brains, suggesting that insulin resistance may be a common pathology in both diseases. Therefore, we are investigating the effects of metabolic abnormalities such as diabetes or of genetic suppression of insulin signaling on the formation of amyloid pathology and its molecular mechanisms.

In order to elucidate the molecular mechanisms linking type 2 diabetes and AD, especially the effects on amyloid pathogenesis, we have been conducting analyses using APP Tg mice (A7), a mouse model of Alzheimer's disease. In APP Tg mice, which were fed a high-fat diet (HFD) from 3 months of age and developed a diabetic-like condition, there was a decrease in brain responsiveness to insulin stimulation in addition to systemic insulin resistance. In this mouse, the amount of A β in the brain increased significantly with age compared to the normal diet group, and the accumulation of amyloid plaques was also accelerated at 15 months of age. In vivo kinetic analysis showed that this might be partly due to a decrease in A β clearance in the brain caused by HFD feeding.

We then analyzed the contribution of IRS-1 and IRS-2, substrates of insulin and IGF-1 receptors, to brain

signaling activity and found that IRS-2 is mainly involved in brain insulin signaling. While loss of IRS-1 did not affect the pathology of the APP Tg mouse brain, IRS-2 deficiency markedly suppressed amyloid accumulation in the brain, even though it triggered systemic insulin resistance and led to diabetes. By contrast, amyloid accumulation was accelerated when IRS-2-deficient APP Tg mice were fed with HFD. This suggests that upstream factors, such as stress associated with metabolic overload, rather than decreased insulin signaling, may be responsible for accelerated amyloid accumulation.

One of the factors contributing to insulin resistance is endoplasmic reticulum (ER) stress, which is altered by metabolic stress. In HFD-fed and genetically obese animals, ER stress in liver and adipose tissue is increased and unfolded protein response (UPR) signaling is elevated. Inhibiting ER stress has been shown to improve insulin resistance. It has also been reported that ER stress is elevated in the brains of Alzheimer's disease patients, suggesting that it may be an aggravating factor in both diseases. Therefore, the chemical chaperone TUDCA was administered to the periphery or brain of aging or HFD-fed APP Tg mice with metabolic abnormalities to analyze the effects of reduced endoplasmic reticulum stress on A β accumulation. The results showed that administration of TUDCA to the periphery, but not to the brain, markedly suppressed amyloid accumulation in the brain. This suggests that stress and inflammation induced in peripheral tissues due to metabolic abnormalities may directly regulate brain pathology.

On the other hand, the mechanism by which IRS-2 deficiency exerts a protective effect on A β accumulation has not yet been elucidated. We analyzed mRNA expression in APP Tg mouse brains lacking IRS-2 and found that the expression of ECM-related genes was upregulated. Among these genes, collagen VI and thrombospondin-1 and -4 were shown to suppress amyloid fibril formation of A β by *in vitro* assay. These results indicate that inhibition of insulin signaling may suppress amyloid accumulation by upregulating the expression of multiple ECMs in the brain and inhibiting A β fibrillation.

References

1. Kishino Y, Matsukawa K, Matsumoto T, Miyazaki R, Wakabayashi T, Nonaka T, Kametani F, Hasegawa M, Hashimoto T, Iwatsubo T. Casein kinase 1 δ/ϵ phosphorylates fused in sarcoma (FUS) and ameliorates FUS-mediated neurodegeneration. *J Biol Chem* 2022; 298:102191
2. Kaneshiro N, Komai M, Imaoka R, Ikeda A, Kamikubo Y, Saito T, Saido TC, Tomita T, Hashimoto T, Iwatsubo T, Sakurai T, Uehara T, Takasugi N. Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer's disease. *iScience* 2022;25:103869
3. Ishida K, Yamada K, Nishiyama R, Hashimoto T, Nishida I, Abe Y, Yasui M, Iwatsubo T. Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration. *J Exp Med* 2022; 219:e20211275
4. An H, Litscher G, Watanabe N, Wei W, Hashimoto T, Iwatsubo T, Buchman VL, Shelkovnikova TA. ALS-linked cytoplasmic FUS assemblies are compositionally different from physiological stress granules and sequester hnRNPA3, a novel modifier of FUS toxicity. *Neurobiol Dis* 2022; 162:105585

Department of Precision Medicine Neurology

Project Associate Professor

Jun Mitsui, M.D., Ph.D.

Project Research Associate

Niroya Naruse, M.D., Ph.D.

Introduction and Organization

The Department of Precision Medicine Neurology was established on September 1, 2022, with the aim of applying state-of-the-art genome sequencing technology to elucidate the molecular mechanisms, and to develop novel therapies that can intervene against the molecular mechanisms of neurological diseases.

Clinical activities

Specialized outpatient clinics for multiple system atrophy are provided in collaboration with the Department of Neurology. The outpatient clinic provides consultations, second opinions, and patient registration for patients with multiple system atrophy. In the ward, we provide consultation for the examination and treatment of patients with multiple system atrophy in cooperation with the Department of Neurology. Clinical sequencing is performed after consultation for the diagnosis of hereditary neurological diseases.

Teaching activities

As for under-graduate education, we provides lectures on genetic research and therapeutic development for neurological diseases. In postgraduate education, we collaborates with the Department of Neurology to provide education on the genetic diseases to residents. Regarding graduate education, we promotes a wide range of research according to the wishes of graduate students.

Research activities

Multiple system atrophy is a neurodegenerative disease that causes a variety of symptoms, including autonomic nervous system disturbances, cerebellar ataxia, and parkinsonism. It is an intractable disease for which effective treatments are lacking, although there are drugs that alleviate several symptoms. We are conducting basic research on multiple system atrophy and its treatment to overcome this disease.

In previous studies, we identified patients with biallelic variants in the COQ2 gene in multiplex families (Mitsui J, et al. *N Engl J Med.* 2013;369:233-44). It has been shown that coenzyme Q10 level in cerebellar tissue is decreased in patients with familial multiple system atrophy who have biallelic COQ2 variants (Mitsui J, et al. *N Engl J Med.* 2013; 369:233-44), and that coenzyme Q10 administration improves the rate of cerebral oxygen metabolism (Mitsui J, et al. *Cerebellum.* 2017;16(3):664-672).

Furthermore, the carrier frequency of the COQ2 variant is higher in patients with sporadic multiple system atrophy (Porto KJ, et al. *J Neurol Sci.* 2021; 429:117623), and blood coenzyme Q10 level is decreased even in patients without COQ2 variants (Mitsui J, et al. *JAMA Neurol.* 2016;73(8):977-80). Based on these results, we believe that coenzyme Q10 supplementation may be an effective treatment for this disease.

First, an investigator-initiated Phase 1 trial (UMIN000016695) was conducted to investigate

safety and pharmacokinetics of coenzyme q10 (Mitsui J, et al. *Neurol Clin Neurosci.* 2022;10(1):14-24). A multicenter, investigator-initiated Phase 2 trial (UMIN000031771) was subsequently conducted to explore whether coenzyme Q10 is effective against symptom progression in multiple system atrophy. Based on the results, a Phase 3 trial is currently being planned.

The Multiple System Atrophy Registry has been established and is being operated to assist in patient recruitment in clinical trials and to obtain natural history of multiple system atrophy (<https://msajp.org/>).

Other than the COQ2 gene, we have reported that GBA1 variants were associated with multiple system atrophy (Mitsui J, et al. *Ann Clin Transl Neurol.* 2015; 2(4):417-26).

References

1. Ando T, Riku Y, Akagi A, Miyahara H, Hirano M, Ikeda T, Yabata H, Koizumi R, Oba C, Morozumi S, Yasui K, Goto A, Katayama T, Sakakibara S, Aiba I, Sakai M, Konagaya M, Mori K, Ito Y, Yuasa H, Nomura M, Porto KJL, Mitsui J, Tsuji S, Mimuro M, Hashizume Y, Katsuno M, Iwasaki Y, Yoshida M. Multiple system atrophy variant with severe hippocampal pathology. *Brain Pathol.* 2022 Jan;32(1):e13002.
2. Almansour A, Ishiura H, Mitsui J, Matsukawa T, Matsukawa MK, Shimizu H, Sugiyama A, Toda T, Tsuji S. Frequency of FMR1 Premutation Alleles in Patients with Undiagnosed Cerebellar Ataxia and Multiple System Atrophy in the Japanese Population. *Cerebellum.* 2022 Dec;21(6):954-962.
3. Enomoto Y, Yokoi T, Tsurusaki Y, Murakami H, Tominaga M, Minatogawa M, Abe-Hatano C, Kuroda Y, Ohashi I, Ida K, Shiiya S, Kumaki T, Naruto T, Mitsui J, Harada N, Kido Y, Kurosawa K. Divergent variant patterns among 19 patients with Rubinstein-Taybi syndrome uncovered by comprehensive genetic analysis including whole genome sequencing. *Clin Genet.* 2022 Mar; 101(3):335-345.
4. Taniguchi T, Ando M, Okamoto Y, Yoshimura A, Higuchi Y, Hashiguchi A, Matsuda N, Yamamoto M, Dohi E, Takahashi M, Yoshino M, Nomura T, Matsushima M, Yabe I, Sanpei Y, Ishiura H, Mitsui J, Nakagawa M, Tsuji S, Takashima H. Elderly patients with suspected Charcot-Marie-Tooth disease should be tested for the TTR gene for effective treatments. *J Hum Genet.* 2022 Jun; 67(6):353-362.
5. Ikenaga C, Date H, Kanagawa M, Mitsui J, Ishiura H, Yoshimura J, Pinal-Fernandez I, Mammen AL, Lloyd TE, Tsuji S, Shimizu J, Toda T, Goto J. *Ann Neurol.* 2022 Mar;91(3):317-328.
6. Ando M, Higuchi Y, Okamoto Y, Yuan J, Yoshimura A, Takei J, Taniguchi T, Hiramatsu Y, Sakiyama Y, Hashiguchi A, Matsuura E, Nakagawa H, Sonoda K, Yamashita T, Tamura A, Terasawa H, Mitsui J, Ishiura H, Tsuji S, Takashima H. An NEFH founder mutation causes broad phenotypic spectrum in multiple Japanese families. *J Hum Genet.* 2022 Jul;67(7):399-403.
7. Kubota A, Ishiura H, Porto KJL, Tanaka M, Mitsui J, Unuma A, Maki H, Komuro I, Tsuji S, Shimizu J, Toda T. DMD exon 2 duplication due to a complex genomic rearrangement is associated with a somatic mosaicism. *Neuromuscul Disord.* 2022 Mar;32(3):263-269.
8. Yagi H, Takiguchi H, Takeda N, Inuzuka R, Taniguchi Y, Porto KJ, Ishiura H, Mitsui J, Morita H, Komuro I. Family with congenital contractural arachnodactyly due to a novel multiexon deletion of the FBN2 gene. *Clin Case Rep.* 2022 Feb 9;10(2):e05335.
9. Hiramatsu Y, Okamoto Y, Yoshimura A, Yuan JH, Ando M, Higuchi Y, Hashiguchi A, Matsuura E, Nozaki F, Kumada T, Murayama K, Suzuki M, Yamamoto Y, Matsui N, Miyazaki Y, Yamaguchi M, Suzuki Y, Mitsui J, Ishiura H, Tanaka M, Morishita S, Nishino I, Tsuji S, Takashima H. Complex hereditary peripheral neuropathies caused by novel variants in mitochondrial-related nuclear genes. *Neurol.* 2022 Aug;269(8):4129-4140.
10. Yamakawa K, Nishijima H, Kubota A, Naruse H, Baba S, Fujimaki Y, Kondo K, Toda T, Yamasoba T. Clinical and electrophysiological findings of facial palsy in a case of hereditary gelsolin

- amyloidosis. *Auris Nasus Larynx*. 2023 Apr; 50(2):305-308.
11. Ando M, Higuchi Y, Yuan JH, Yoshimura A, Kitao R, Morimoto T, Taniguchi T, Takeuchi M, Takei J, Hiramatsu Y, Sakiyama Y, Hashiguchi A, Okamoto Y, Mitsui J, Ishiura H, Tsuji S, Takashima H. Novel de novo POLR3B mutations responsible for demyelinating Charcot-Marie-Tooth disease in Japan. *Ann Clin Transl Neurol*. 2022 May;9(5):747-755.
 12. Oike R, Inoue Y, Mitsui J, Ota Y. A case of idiopathic normal pressure hydrocephalus with fragile X-associated tremor/ataxia syndrome. *Clin Neurol Neurosurg*. 2022 Jul;218:107278.
 13. Teranishi Y, Okano A, Miyawaki S, Ohara K, Ishigami D, Hongo H, Dofuku S, Takami H, Mitsui J, Ikemura M, Komura D, Katoh H, Ushiku T, Ishikawa S, Shin M, Nakatomi H, Saito N. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. *Acta Neuropathol Commun*. 2022 May 15;10(1):76.
 14. Mochizuki H, Aoki M, Ikenaka K, Inoue H, Iwatsubo T, Ugawa Y, Okazawa H, Ono K, Onodera O, Kitagawa K, Saito Y, Shimohata T, Takahashi R, Toda T, Nakahara J, Matsumoto R, Mizusawa H, Mitsui J, Murayama S, Katsuno M; Future Vision Committee of Japanese Society of Neurology; Aoki Y, Ishiura H, Izumi Y, Koike H, Shimada H, Takahashi Y, Tokuda T, Nakajima H, Hatano T, Misawa S, Watanabe H. Recommendations (Proposal) for promoting research for overcoming neurological diseases 2020. *Rinsho Shinkeigaku*. 2022 Jun 24;62(6):429-442.
 15. Mochizuki H, Aoki M, Ikenaka K, Inoue H, Iwatsubo T, Ugawa Y, Okazawa H, Ono K, Onodera O, Kitagawa K, Saito Y, Shimohata T, Takahashi R, Toda T, Nakahara J, Matsumoto R, Mizusawa H, Mitsui J, Murayama S, Katsuno M; Future Vision Committee of Japanese Society of Neurology; Aoki Y, Ishiura H, Izumi Y, Koike H, Shimada H, Takahashi Y, Tokuda T, Nakajima H, Hatano T, Misawa S, Watanabe H. Recommendations (Proposal) for promoting research for overcoming neurological diseases 2020. *Rinsho Shinkeigaku*. 2022 Jun 24;62(6):443-457.
 16. Teranishi Y, Miyawaki S, Nakatomi H, Ohara K, Hongo H, Dofuku S, Okano A, Takayanagi S, Ota T, Yoshimura J, Qu W, Mitsui J, Morishita S, Tsuji S, Saito N. Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype-phenotype correlation with targeted deep sequencing. *Sci Rep*. 2022 Jun 9; 12(1):9543.
 17. Ishigami D, Koizumi S, Miyawaki S, Hongo H, Teranishi Y, Mitsui J, Saito N. Symptomatic and Stenotic Developmental Venous Anomaly with Pontine Capillary Telangiectasia: A Case Report with Genetic Considerations. *NMC Case Rep J*. 2022 May 31;9:139-144.
 18. Sakai Y, Miyawaki S, Teranishi Y, Okano A, Ohara K, Hongo H, Ishigami D, Shimada D, Mitsui J, Nakatomi H, Saito N. NF2 Alteration/22q Loss Is Associated with Recurrence in WHO Grade 1 Sphenoid Wing Meningiomas. *Cancers (Basel)*. 2022 Jun 29; 14(13):3183.
 19. Ando M, Higuchi Y, Yuan J, Yoshimura A, Taniguchi T, Kojima F, Noguchi Y, Hobara T, Takeuchi M, Takei J, Hiramatsu Y, Sakiyama Y, Hashiguchi A, Okamoto Y, Mitsui J, Ishiura H, Tsuji S, Takashima H. Comprehensive Genetic Analyses of Inherited Peripheral Neuropathies in Japan: Making Early Diagnosis Possible. *Biomedicines*. 2022 Jun 29;10(7):1546.
 20. Yuan JH, Higuchi Y, Ando M, Matsuura E, Hashiguchi A, Yoshimura A, Nakamura T, Sakiyama Y, Mitsui J, Ishiura H, Tsuji S, Takashima H. Multi-type RFC1 repeat expansions as the most common cause of hereditary sensory and autonomic neuropathy. *Front Neurol*. 2022 Aug 17;13:986504.
 21. Matsukawa T, Porto KJL, Mitsui J, Chikada A, Ishiura H, Takahashi Y, Nakamoto FK, Seki T, Shiio Y, Toda T, Tsuji S. Clinical and Genetic Features of Multiplex Families with Multiple System Atrophy and Parkinson's Disease. *Cerebellum*. 2022 Sep 13. doi: 10.1007/s12311-022-01426-z.
 22. Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P,

- Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. *N Engl J Med*. 2022 Sep 22;387(12):1099-1110.
23. Hama Y, Date H, Fujimoto A, Matsui A, Ishiura H, Mitsui J, Yamamoto T, Tsuji S, Mizusawa H, Takahashi Y. A Novel de novo KIF1A Mutation in a Patient with Ataxia, Intellectual Disability and Mild Foot Deformity. *Cerebellum*. 2022 Oct 13. doi: 10.1007/s12311-022-01489-y.
24. Kobayashi R, Naruse H, Kawakatsu S, Iseki C, Suzuki Y, Koyama S, Morioka D, Ishiura H, Mitsui J, Ohta Y, Tsuji S, Toda T, Otani K. Valosin-containing protein Asp395Gly mutation in a patient with frontotemporal dementia: a case report. *BMC Neurol*. 2022 Nov 3;22(1):406.

Department of Health Services Research

Project Associate Professor

Taisuke Jo, M.D., Ph.D.

Project Lecturer/Project Assistant Professor

Hayato Yamana, M.D., PhD.

Project Assistant Professor

Nobuaki Michihata, M.D., PhD.

Homepage <http://webpark1902.sakura.ne.jp/wp/>

Introduction and Organization

The Department of Health Services Research (HSR), a Social Cooperation Program, was founded by Professor Hideo Yasunaga, Department of Clinical Epidemiology & Health Economics with the support of Professor Takahide Nagase, Department of Respiratory Medicine in April 2016. The program was funded by Tsumura & Co., Tokyo, Japan.

The objective of the Department of HSR was to convey and develop HSR, which encompasses clinical medicine, clinical epidemiology and health economics, to pursue the maintenance of health services particularly in the ageing society in Japan. Education and training of personnel to cultivate human resources such as researchers and analysts in HSR is another important mission of this program.

The founding staff members were Taisuke Jo (Project Associate Professor), Nobuaki Michihata (Project Assistant Professor) and Yusuke Sasabuchi (Project Assistant Professor). Hayato Yamana (Project Assistant Professor) started to take part in this program in April 2018 with two other staff members, Taisuke Jo and Nobuaki Michihata. Hayato Yamana was promoted to Project Lecturer in 2021 and resigned at the end of November 2022.

Teaching activities

All the members of HSR participated in the lectures of Clinical Epidemiology, a curriculum of School of Public Health (SPH) in The University of Tokyo. The members also contributed to the education and training of individual students of SPH as well as students of the Graduate School of Medicine, The University of Tokyo.

Taisuke Jo (Project Associate Professor) participated in the series of clinical lectures in Respiratory Medicine for students of Faculty of Medicine, The University of Tokyo.

Research activities

Health Services Research covers a broad cross-disciplinary field involving studies of structures, processes and outcomes assessment in clinical epidemiology and health services, studies evaluating the quality of health care and analysis of health economics, finance and allocation of medical resources. Utilizing large databases, the members of HSR were working to address the following issue.

- 1) Clinical and epidemiological research questions related to various diseases, including respiratory disease.
- 2) Outcomes and cost-effectiveness in both western medicine and eastern medicine in Japan.

3) Impact of super-ageing society on population dynamics and demand for health services.

4) Efficient distribution of medical staff, medical institutions, and armamentariums.

The following are the examples of studies conducted in 2022. More than 72 articles were published.

1) Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study

Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is the leading cause of death among patients with IPF. However, there is no established treatment for this condition. Hence, we aimed to investigate the effectiveness and safety of recombinant human soluble thrombomodulin (rTM) for the treatment of AE-IPF. **Methods:** Data were retrospectively collected from the Japanese Diagnosis Procedure Combination database from 1 January 2014 to 31 March 2018. We identified adult patients with IPF who received high-dose methylprednisolone (mPSL) therapy and mechanical ventilation upon admission. Eligible patients ($n = 2814$) were divided into those receiving high-dose mPSL alone (mPSL alone group, $n = 2602$) and rTM combined with high-dose mPSL (rTM group, $n = 212$). A stabilised inverse probability of treatment weighting (IPTW) using propensity scores was performed to compare outcomes between the two groups. The primary outcome was in-hospital mortality, and the secondary outcomes were 14- and 28-day mortality, bleeding events and length of hospital stay. **Results:** The in-hospital mortality rates of the mPSL alone and rTM groups were 75.9% and 76.9%, respectively. The results did not significantly differ between the two groups after performing a stabilised IPTW. The odds ratio of the rTM group compared to the mPSL alone group was 1.15 (95% confidence interval: 0.71–1.84; $p = 0.57$). Moreover, the secondary outcomes did not differ significantly between the two groups. **Conclusions:** In patients with AE-IPF who developed severe respiratory failure, rTM in addition to high-dose mPSL was not associated with a better outcome.

2) Safety of topical ophthalmic antibiotics in pregnant women with hordeola, chalazia, blepharitis, or bacterial conjunctivitis: propensity score analyses

Objective: To investigate the association between exposure to topical ophthalmic antibiotics during pregnancy and adverse neonatal outcomes. **Methods:** In this retrospective cohort study, we identified pregnant women with hordeola, chalazia, blepharitis, or bacterial conjunctivitis from 2005 to 2018 using the Japanese Medical Data Centre Claims Database. From the eligible women, we extracted women who were dispensed no topical antibiotics during the first trimester (non-antibiotic group), women who were dispensed topical fluoroquinolones alone at least once (fluoroquinolone alone group), and women who were dispensed any single type of antibiotic (single-antibiotic group). We compared the frequency of congenital anomalies (CA), preterm birth (PB), low birth weight (LBW), and the composite outcome of these three between the fluoroquinolone and nonantibiotic groups and between the single-antibiotic and non-antibiotic groups, using propensity score adjustment. **Results:** A total of 891 eligible women were identified. In the fluoroquinolone ($n = 409$) and non-antibiotic ($n = 309$) groups, CA occurred in 6.8% and 6.8%, PB in 2.4% and 3.2%, LBW in 2.9% and 3.2%, and the composite outcome in 10.5% and 11.3%, respectively. Analysis using propensity score adjustment showed no significant difference between the groups in the frequency of CA (adjusted odds ratio, 1.15; 95% confidence interval, 0.61–2.18), PB (0.80; 0.30–2.17), LBW (1.08; 0.45–2.63), or the composite outcome (1.12; 0.67–1.87). Comparison of the single-antibiotic and non-antibiotic groups showed similar results. **Conclusions:** Topical ophthalmic antibiotics for hordeola, chalazia, blepharitis, or bacterial conjunctivitis during the first trimester were not associated with increased adverse neonatal outcomes.

3) Association between comprehensive geriatric assessment and polypharmacy at discharge in patients with ischaemic stroke: A nationwide, retrospective, cohort study

Background Polypharmacy and its adverse drug events are a major healthcare challenge related to falls, hospitalisations and mortality. Comprehensive

geriatric assessment (CGA) may contribute to polypharmacy improvement, however, there is no clear evidence so far.

Methods Using a national inpatient database in Japan from April 1, 2014 to March 31, 2018, we investigated the association between CGA and polypharmacy. We identified patients aged ≥ 65 years admitted for ischaemic stroke who could receive oral medications. Propensity score matching was conducted for patients with and without CGA during hospitalisation. The outcomes were polypharmacy (defined as use of five or more types of oral medications) at discharge, the number of medication types prescribed at discharge, and the difference between the numbers of medication types prescribed on admission and at discharge.

Findings A total of 162,443 patients were analysed, of whom 39,356 (24.2%) received CGA, and propensity score matching identified 39,349 pairs. Compared with non-CGA group, the CGA group had a significantly lower proportion of polypharmacy at discharge (34.3% vs. 32.9%, $p < 0.001$) and a smaller number of medication types prescribed at discharge (3.84 vs. 3.76, $p < 0.001$).

Interpretation This study shows the clear evidence that there is a positive relationship between CGA and a reduction in the number of medications in older inpatients with ischaemic stroke.

The members of HSR are further mounting an effort to accomplish the task in cooperation with the Department of Clinical Epidemiology & Health Economics and the Department of Respiratory Medicine.

References

(Due to space constraints, only a portion of the publications is listed below.)

- 1: Isogai T, Saad AM, Michihata N, Ahuja KR, Shekhar S, Abdelfattah OM, Kaur M, Gad MM, Svensson LG, Kapadia SR. Association of hospital procedural volume with incidence and outcomes of surgical bailout in patients undergoing transcatheter aortic valve replacement. *Catheter Cardiovasc Interv.* 2022;99:160-168.
- 2: Matsuoka S, Kaneko H, Okada A, Morita K, Itoh H, Michihata N, Jo T, Takeda N, Morita H, Fujiu K, Nakamura S, Node K, Yasunaga H, Komuro I. Age Modified Relationship Between Modifiable Risk Factors and the Risk of Atrial Fibrillation. *Circ Arrhythm Electrophysiol.* 2022;15:e010409.
- 3: Konishi T, Fujiogi M, Michihata N, Niwa T, Morita K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Impact of body mass index on short-term outcomes after differentiated thyroid cancer surgery: a nationwide inpatient database study in Japan. *Eur Thyroid J.* 2022;11:e210081.
- 4: Suzuki Y, Kaneko H, Okada A, Itoh H, Morita K, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K, Matsunaga A, Ako J, Fukui A, Nishiyama A, Yokoo T, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database. *Am J Nephrol.* 2022;53:240-248.
- 5: Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K, Matsunaga A, Ako J, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset. *Am J Nephrol.* 2022;53(4):307-315.
- 6: Nagata S, Ohbe H, Jo T, Matsui H, Fushimi K, Yasunaga H. Glucocorticoids and Rates of Biphasic Reactions in Patients with Adrenaline-Treated Anaphylaxis: A Propensity Score Matching Analysis. *Int Arch Allergy Immunol.* 2022;183:939-945.
- 7: Tamiya H, Mitani A, Abe T, Nagase Y, Suzuki H, Jo T, Tanaka G, Nagase T. Association between Inhalation Instruction Method in Community Pharmacies and Inhaler Device Handling Error in Patients with Obstructive Lung Disease: An Evaluation of the Impact of Practical Demonstration by Pharmacists. *Biol Pharm Bull.* 2022; 45(12):1764-1771.
- 8: Suzuki Y, Kaneko H, Okada A, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Nangaku M, Yasunaga H, Komuro I. Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer. *Am J Nephrol.* 2022;53:753-760.
- 9: Nomura O, Michihata N, Kaneko K, Yoshikawa T,

- Ishiguro A; Japan Pediatric Society Steering Committee for Board Examinations. Research Publication Experience as a Requirement for Board Examination Acceptance to Promote Scholarly Activities of Pediatric Residents. *JMA J.* 2022;5:93-98.
- 10: Matsui H, Yamana H, Fushimi K, Yasunaga H. Development of Deep Learning Models for Predicting In-Hospital Mortality Using an Administrative Claims Database: Retrospective Cohort Study. *JMIR Med Inform.* 2022;10: e27936.
 - 11: Miyakawa T, Michihata N, Morita K, Matsui H, Honda M, Yasunaga H. Ambient temperature and hospital admissions for acute cholecystitis: a nationwide inpatient database study in Japan. *HPB (Oxford).* 2022;24:398-403.
 - 12: Hashimoto Y, Matsui H, Michihata N, Ishimaru M, Yasunaga H, Aihara M, Kaburaki T. Incidence of Sympathetic Ophthalmia after Inciting Events: A National Database Study in Japan. *Ophthalmology.* 2022;129:344-352.
 - 13: Sugawara C, Yamana H, Sasagawa E, Yonezawa K, Hikita N, Morita K, Matsui H, Yasunaga H, Haruna M. Factors Associated with Surgical Treatment in Postpartum Women with Mastitis or Breast Abscess: A Retrospective Cohort Study. *Breastfeed Med.* 2022;17:233-238.
 - 14: Kodama S, Jo T, Yasunaga H, Michihata N, Matsui H, Kumazawa R, Shiota Y, Fushimi K, Toda T, Hamada M. Outcomes of gastrointestinal cancer surgeries in Parkinson's disease patients: A nationwide study. *Parkinsonism Relat Disord.* 2022;96:45-49.
 - 15: Awano N, Jo T, Izumo T, Inomata M, Morita K, Matsui H, Fushimi K, Urushiyama H, Nagase T, Yasunaga H. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study. *J Intensive Care.* 2022;10:14.
 - 16: Ueno K, Kamiya K, Kaneko H, Okada A, Itoh H, Fujii K, Takeda N, Morita H, Michihata N, Jo T, Yasunaga H, Komuro I. Acute-Phase Initiation of Cardiac Rehabilitation for Short-Term Improvement in Activities of Daily Living in Patients Hospitalized for Acute Heart Failure. *J Cardiovasc Dev Dis.* 2022;9:97.
 - 17: Konishi T, Goto T, Fujiogi M, Michihata N, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. New machine learning scoring system for predicting postoperative mortality in gastroduodenal ulcer perforation: A study using a Japanese nationwide inpatient database. *Surgery.* 2022;171:1036-1042.
 - 18: Yamana H, Tsuchiya A, Horiguchi H, Morita S, Kuroki T, Nakai K, Nishimura H, Jo T, Fushimi K, Yasunaga H. Validity of a model using routinely collected data for identifying infections following gastric, colon, and liver cancer surgeries. *Pharmacoepidemiol Drug Saf.* 2022; 31:452-460.
 - 19: Sato M, Yamana H, Ono S, Ishimaru M, Matsui H, Yasunaga H. Trends in prophylactic antibiotic use for tooth extraction from 2015 to 2018 in Japan: An analysis using a health insurance claims database. *J Infect Chemother.* 2022;28: 504-509
 - 20: Suzuki Y, Kaneko H, Okada A, Itoh H, Fujii K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Yano Y, Kamiya K, Matsunaga A, Ako J, Fukui A, Yokoo T, Nishiyama A, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Risk for Proteinuria in Newly Defined Hypertensive People Based on the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. *Am J Cardiol.* 2022;168:83-89.
 - 21: Matsuoka S, Kaneko H, Okada A, Fukui A, Yano Y, Itoh H, Morita K, Fujii K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Nakamura S, Nishiyama A, Yokoo T, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I. Association between proteinuria and incident colorectal cancer: analysis of a nationwide population-based database. *BMJ Open.* 2022;12:e056250.
 - 22: Seike Y, Matsuda H, Shimizu H, Ishimaru S, Hoshina K, Michihata N, Yasunaga H, Komori K; Japanese Committee for Stentgraft Management (JACSM)*. Nationwide Analysis of Persistent Type II Endoleak and Late Outcomes of Endovascular Abdominal Aortic Aneurysm Repair in Japan: A Propensity-Matched Analysis. *Circulation.* 2022;145:1056-1066.
 - 23: Honda A, Michihata N, Iizuka Y, Uda K, Morita

- K, Mieda T, Takasawa E, Ishiwata S, Tajika T, Matsui H, Fushimi K, Yasunaga H, Chikuda H. Risk factors for severe lower extremity ischemia following venoarterial extracorporeal membrane oxygenation: an analysis using a nationwide inpatient database. *Trauma Surg Acute Care Open*. 2022;7:e000776
- 24: Hashimoto Y, Michihata N, Yamana H, Shigemi D, Morita K, Matsui H, Yasunaga H, Aihara M. Safety of topical ophthalmic antibiotics in pregnant women with hordeola, chalazia, blepharitis, or bacterial conjunctivitis: propensity score analyses. *Eye (Lond)*. 2022;36:1066-1073.
 - 25: Yoshii K, Michihata N, Hirasawa K, Nagata S, Morisaki N. Secular trends in early motor development between 1980 and 2010 in Japan. *Arch Dis Child*. 2022 May;107(5):468-473.
 - 26: Matsuda K, Jo T, Shimura A, Honda A, Taoka K, Masamoto Y, Matsui H, Fushimi K, Yasunaga H, Kurokawa M. Risk of febrile neutropenia in very elderly patients aged ≥ 80 years receiving their first cycle of R-CHOP regimen: a nationwide real-world study in Japan. *Br J Haematol*. 2022;197:e37-e41.
 - 27: Konishi T, Fujiogi M, Sato A, Michihata N, Kumazawa R, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Short-Term Outcomes Following Breast Cancer Surgery With and Without Neoadjuvant Chemotherapy: A Nationwide Administrative Database Study in Japan. *Ann Surg Oncol*. 2022;29:3000-3010.
 - 28: Suzuki T, Michihata N, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H. Low- versus high-concentration intravenous immunoglobulin for children with Kawasaki disease in the acute phase. *Int J Rheum Dis*. 2022;25:576-583
 - 29: Matsuoka S, Kaneko H, Okada A, Itoh H, Suzuki Y, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Node K, Yasunaga H, Komuro I. Association of retinal atherosclerosis assessed using Keith-Wagener-Barker system with incident heart failure and other atherosclerotic cardiovascular disease: Analysis of 319,501 individuals from the general population. *Atherosclerosis*. 2022;348:68-74.
 - 30: Ueno K, Kaneko H, Kamiya K, Itoh H, Okada A, Suzuki Y, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Ako J, Node K, Yamauchi T, Yasunaga H, Komuro I. Relationship of normal-weight central obesity with the risk for heart failure and atrial fibrillation: analysis of a nationwide health check-up and claims database. *Eur Heart J Open*. 2022;2:oeac026
 - 31: Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, Fujiu K, Yamaguchi S, Michihata N, Jo T, Takeda N, Morita H, Node K, Kim HC, Viera AJ, Oparil S, Yasunaga H, Komuro I. Age-Dependent Relationship of Hypertension Subtypes With Incident Heart Failure. *J Am Heart Assoc*. 2022;11:e025406.
 - 32: Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. *Cardiovasc Diabetol*. 2022;21:67.
 - 33: Ohisa K, Yamana H, Morita K, Matsui H, Fushimi K, Yasunaga H. Association between subcutaneous steroid injection for extravasation of vesicant anticancer drugs and skin ulcers requiring surgery. *Eur J Oncol Nurs*. 2022;58:102119.
 - 34: Suzuki Y, Kaneko H, Okada A, Matsuoka S, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Node K, Yamauchi T, Yasunaga H, Komuro I. Prediabetes in Young Adults and Its Association With Cardiovascular Health Metrics in the Progression to Diabetes. *J Clin Endocrinol Metab*. 2022;107:1843-1853.
 - 35: Okada A, Yamana H, Yamaguchi S, Kurakawa KI, Michihata N, Matsui H, Fushimi K, Nangaku M, Yamauchi T, Yasunaga H, Kadowaki T. Effect of Branched-Chain Amino Acid Infusion on In-Hospital Mortality of Patients With Hepatic Encephalopathy and End-Stage Kidney Disease: A Retrospective Cohort Study Using a National Inpatient Database. *J Ren Nutr*. 2022;32:432-440.
 - 36: Konishi T, Fujiogi M, Michihata N, Kumazawa R, Ohbe H, Matsui H, Fushimi K, Ogita M, Tanabe M, Seto Y, Yasunaga H. Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in

- Japan. Breast Cancer. 2022;29:688-697
- 37: Kumazawa R, Jo T, Matsui H, Fushimi K, Yasunaga H. Direct oral anticoagulants versus warfarin for secondary prevention of cerebral infarction and bleeding in older adults with atrial fibrillation. *J Am Geriatr Soc.* 2022;70:2029-2039.
 - 38: Konishi T, Fujiogi M, Michihata N, Matsui H, Tanabe M, Seto Y, Yasunaga H. Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study. *Breast Cancer Res Treat.* 2022;194:315-325
 - 39: Ueno K, Kaneko H, Kamiya K, Itoh H, Okada A, Suzuki Y, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Ako J, Yasunaga H, Komuro I. Clinical utility of simple subjective gait speed for the risk stratification of heart failure in a primary prevention setting. *Sci Rep.* 2022;12:11641.
 - 40: Konishi T, Fujiogi M, Michihata N, Morita K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Association of Operative Day of the Week with the Length of Stay and Total Hospitalization Costs in Patients with Partial Mastectomy: A Nationwide Database Study in Japan. *JMA J.* 2022;5:319-327.
 - 41: Hashimoto Y, Yamana H, Michihata N, Shigemi D, Ishimaru M, Matsui H, Yasunaga H, Aihara M. Eye drops for dry eye disease during pregnancy and adverse neonatal outcomes: high-dimensional propensity score analyses. *Ophthalmic Epidemiol.* 2022;29:384-393.
 - 42: Kaneko H, Yano Y, Lee HH, Lee H, Okada A, Itoh H, Morita K, Fukui A, Fujiu K, Suzuki Y, Matsuoka S, Nakamura S, Michihata N, Jo T, Takeda N, Morita H, Yokoo T, Nishiyama A, Node K, Viera AJ, Muntner P, Oparil S, Kim HC, Yasunaga H, Komuro I. Medication-Naïve Blood Pressure and Incident Cancers: Analysis of 2 Nationwide Population-Based Databases. *Am J Hypertens.* 2022;35:731-739.
 - 43: Fuseda Y, Michihata N, Kumazawa R, Fushimi K, Yasunaga H. Annual Trend in Lumbar Puncture for Infants Younger Than 3 Months Hospitalized With Suspected Serious Bacterial Infection: A Nationwide Inpatient Database Study. *Pediatr Infect Dis J.* 2022;41:631-635.
 - 44: Michihata N, Suzuki T, Honda A, Oka I, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H. Clinical Features of Kawasaki Disease With Atlantoaxial Rotatory Fixation. *Pediatr Infect Dis J.* 2022;41:626-630.
 - 45: Hosoi T, Yamana H, Tamiya H, Matsui H, Fushimi K, Akishita M, Yasunaga H, Ogawa S. Association between comprehensive geriatric assessment and polypharmacy at discharge in patients with ischaemic stroke: A nationwide, retrospective, cohort study. *EClinicalMedicine.* 2022;50:101528
 - 46: Itoh H, Kaneko H, Okada A, Suzuki Y, Fujiu K, Matsuoka S, Michihata N, Jo T, Nakanishi K, Takeda N, Morita H, Node K, Di Tullio MR, Homma S, Yasunaga H, Komuro I. Age-Specific Relation of Cardiovascular Health Metrics With Incident Cardiovascular Disease. *Am J Cardiol.* 2022;177:34-39.
 - 47: Fukui A, Kaneko H, Okada A, Yano Y, Itoh H, Matsuoka S, Morita K, Kiriya H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Nishiyama A, Node K, Yokoo T, Nangaku M, Yasunaga H, Komuro I. Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database. *Nephrol Dial Transplant.* 2022;37:1691-1699
 - 48: Kurakawa KI, Okada A, Bessho K, Jo T, Ono S, Michihata N, Kumazawa R, Matsui H, Fushimi K, Yamaguchi S, Yamauchi T, Nangaku M, Kadowaki T, Yasunaga H. Major complications after percutaneous biopsy of native or transplanted liver in pediatric patients: a nationwide inpatient database study in Japan. *BMC Gastroenterol.* 2022;22:395.
 - 49: Honda A, Iizuka Y, Michihata N, Uda K, Mieda T, Takasawa E, Ishiwata S, Kakuta Y, Tomomatsu Y, Ito S, Inomata K, Matsui H, Fushimi K, Yasunaga H, Chikuda H. Effect of Intraoperative Tranexamic Acid on Perioperative Major Hemorrhage Requiring Transfusion in Patients Undergoing Elective Spine Surgery: A Propensity Score-Matched Analysis Using a National Inpatient Database. *Global Spine J.* 2022: 21925682221123317.

Division of Chronic Kidney Disease (CKD) Pathophysiology

Division Chief (Professor)

Reiko Inagi, Ph.D.

Assistant Professor

Sho Hasegawa, M.D., Ph.D.

PhD Students

Haruki Ouchi, M.D. (Division of Nephrology and Endocrinology)

Yuto Takenaka, M.D. (Division of Nephrology and Endocrinology)

Chigusa Kitayama, M.D. (Division of Nephrology and Endocrinology)

Li Qi, M.D. (Division of Nephrology and Endocrinology)

Visiting Reseracher

Kamolwan Pakchotanon, M.D. (2022 September – 2023 February)

Lab Technician

Ikumi Okuaki, B.S.

Keiko Miyamoto, B.S.

Homepage <http://www.todai-ckd.com>

Introduction and Organization

In Japan, more than 13 million people suffer from chronic kidney disease (CKD), or roughly one in every eight adults. Why has the number of CKD patients increased so remarkably? One major cause is the sharp increase in the number of people with diabetic nephropathy, which is a complication of diabetes; since 1998, this has been the most important cause among diseases which require incipient dialysis in Japan. Additional causes include the aging of society and other social factors. The kidney is called a silent organ, and CKD progresses without subjective symptoms. It is now evident, however, that asymptomatic CKD which progresses over time carries a number of risks.

One risk is the possible progression of CKD to

end-stage renal disease (ESRD), which requires renal replacement therapy. A second risk is the development and progression of lifestyle-related diseases, such as heart attack and arteriosclerosis. The kidneys work closely with the heart and other organs, and a decrease in renal function causes dysfunction of the heart and blood vessels. This adverse impact of the progression of CKD on other organs underlines the importance of the kidneys in maintaining general health. Further, many researchers have also focused on the vicious spiral of aging and CKD: aging worsens the progression of CKD, while CKD accelerates aging. With our modern lifestyles and the super-aging society, CKD cannot be separated from lifestyle-related diseases, and senility cannot be separated from CKD.

Creating a healthy, long-lived society full of energy

and vigor requires that the quality of life (QOL) of the elderly be improved. In turn, total medical expenditures will also be decreased. These are important issues requiring urgent solutions. Against this background, the Division of CKD Pathophysiology was newly established in November 2013 with support from Kyowa Hakko Kirin Co., Ltd. The aim of the Division is to aid and support the CKD control and the creation of a healthy and long-lived society. The Division takes an innovative approach to identifying the pathophysiology of CKD and works to develop more effective CKD preventive and therapeutic strategies. Through these research activities, our goal is to contribute to the creation of a healthy, long-lived society in which the elderly can live a happy and independent life.

Major Research Projects

The Division of CKD Pathophysiology works in collaboration with the Division of Nephrology and Endocrinology, a part of The University of Tokyo Graduate School of Medicine (Professor Masaomi Nangaku) to conduct basic and clinical research on CKD pathophysiology, including:

- 1) Identifying the mechanism of destruction of adaptive signals to various stresses (endoplasmic reticulum stress, ischemia, glycation stress, oxidative stress) in CKD; and using the findings obtained to establish new CKD treatment strategies.
- 2) Clarifying the mechanism of functional change in renal erythropoietin (EPO)-producing cells, along with the mechanisms of CKD progression and identification of the mechanism of development and progress of renal anemia.
- 3) Clarifying the impact of kidney aging on CKD progression in super-aging society
- 4) Identifying factors in the exacerbation of CKD in patients with diabetes, and developing diagnostic and therapeutic drugs targeting such factors.
- 5) Pathophysiology of uremic toxins on organ crosstalk and impact of uremia management in CKD
- 6) Identifying a novel renoprotective mechanism based on the molecular inflammatory axis in kidney injury

- 7) Pathophysiological role of organelle stress, organelle crosstalk damage in renal injury

Research Funds (PI)

- Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research
21H02824 (to **Reiko Inagi**, Novel tubular homeostasis mechanism mediated by primary cilia),
21K9439 (to **Reiko Inagi**, Pathophysiological role of organelle contact site in tubular homeostasis),
21K6159 (to **Sho Hasegawa**, Unraveling the role of ER-mitochondria crosstalk in the pathogenesis of diabetic kidney disease),
- Japan Agency for Medical Research and Development (AMED)
CREST 20gm1410005s0101 (to **Reiko Inagi**, Study on understanding of the molecular mechanisms of tissue-specific unfolded protein responses for radical cure of human chronic diseases)
- SENSHIN Medical Research Foundation (to **Reiko Inagi**, Elucidating the Role of plasma exosome on vasoprotection in kidney disease)
- MSD Life Science Foundation, Public Interest Incorporated Foundation, Additional Research Grant (to **Sho Hasegawa**, Pathophysiological role of ER-mitochondria crosstalk in diabetic kidney disease)
- Kowa Life Science Research Foundation (to **Sho Hasegawa**, Elucidating the Role of Neurotransmitters in the Repair Process of Renal Tissue)
- Japan Kidney Foundation, Grant for research in chronic kidney disease (to **Sho Hasegawa**, Comprehensive analysis of the effects of HIF-PH inhibitors on intestinal homeostasis)

Awards

Dr. Sho Hasegawa received the Young Investigator Award from the Japanese Society of Nephrology.

Dr. Sho Hasegawa received the 11th Banyu Medical Award from MSD Life Science Foundation.

References

1. Inoue T, Nakamura Y, Tanaka S, Kohro T, Li LX, Huang L, Yao J, Kawamura S, Inoue R, Nishi H,

- Fukaya D, Uni R, Hasegawa S, Inagi R, Umene R, Wu CH, Ye H, Bajwa A, Rosin DL, Ishihara K, Nangaku M, Wada Y, Okusa MD. Bone marrow stromal cell antigen-1 (CD157) regulated by sphingosine kinase 2 mediates kidney fibrosis. **Front Med (Lausanne)**. 2022 Oct 4;9:993698. doi: 10.3389/fmed.2022.993698. PMID: 36267620; PMCID: PMC9576863.
2. Hirakawa Y, Yoshioka K, Kojima K, Yamashita Y, Shibahara T, Wada T, Nangaku M, Inagi R. Potential progression biomarkers of diabetic kidney disease determined using comprehensive machine learning analysis of non-targeted metabolomics. **Sci Rep**. 2022 Sep 29;12(1):16287. doi: 10.1038/s41598-022-20638-1. PMID: 36175470; PMCID: PMC9523033.
3. Okpechi IG, Caskey FJ, Gaipov A, Tannor EK, Noubiap JJ, Effa E, Ekrikpo UE, Hamonic LN, Ashuntantang G, Bello AK, Donner JA, Figueiredo AE, Inagi R, Madero M, Malik C, Moorthy M, Pecoits-Filho R, Tesar V, Levin A, Jha V. Early Identification of CKD-A Scoping Review of the Global Populations. **Kidney Int Rep**. 2022 Apr 6;7(6):1341-1353. doi: 10.1016/j.ekir.2022.03.031. PMID: 35685314; PMCID: PMC9171699.
4. Inagi R. Organelle Stress and Metabolic Derangement in Kidney Disease. **Int J Mol Sci**. 2022 Feb 2;23(3):1723. doi: 10.3390/ijms23031723. PMID: 35163648; PMCID: PMC8836232.
5. Wu CH, Inoue T, Nakamura Y, Uni R, Hasegawa S, Maekawa H, Sugahara M, Wada Y, Tanaka T, Nangaku M, Inagi R. Activation of $\alpha 7$ nicotinic acetylcholine receptors attenuates monocyte-endothelial adhesion through FUT7 inhibition. **Biochem Biophys Res Commun**. 2022 Jan 29;590:89-96. doi: 10.1016/j.bbrc.2021.12.094. Epub 2021 Dec 27. PMID: 34973535.
6. Yoshioka K, Hirakawa Y, Kurano M, Ube Y, Ono Y, Kojima K, Iwama T, Kano K, Hasegawa S, Inoue T, Shimada T, Aoki J, Yatomi Y, Nangaku M, Inagi R. Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease. **Kidney Int**. 2022 Mar; 101(3):510-526. doi: 10.1016/j.kint.2021.10.039. Epub 2021 Nov 29. PMID: 34856312.
7. Hasegawa S, Inagi R. The subtle long-lasting burden of mitochondrial DNA variants. **Nat Rev Nephrol**. 2022 Jan;18(1):4-5. doi: 10.1038/s41581-021-00500-9. PMID: 34663981.
8. Muso E, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Saito T, Mune M, Sugiyama S, Iino Y, Hirano T, Hattori M, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Oda H, Mori K, Kimura H, Ito O, Nishiyama A, Maruyama S, Inagi R, Fujimoto S, Tsukamoto T, Suzuki Y, Honda H, Babazono T, Tsuruya K, Yuzawa Y. Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function. **Ther Apher Dial**. 2022 Feb;26(1):220-228. doi: 10.1111/1744-9987.13694. _

Department of Retinal Biology and Pathology

Project Professor

Sumiko Watanabe, Ph.D.

Project Assistant Professor

Toshiro Iwagawa, Ph.D

Introduction and Organization

We are focusing on analysis of retinal development and basic mechanisms of retinal degenerative diseases with ultimate goal to elucidate new targets for drug design in ocular diseases. Faculties are Ph.D, basic medical scientists, and graduate students consist of both Ph.D type and MD background students. Our laboratory had been established 2021 July and is supported by Chugai-pharmaceutical co. The basis of our laboratory is Department of Molecular and Developmental Biology, which was in The Institute of Medical Science, University of Tokyo (IMSUT) until 2021. Major members of current laboratory including the faculties were working on molecular basis of retinal development especially focusing on transcriptional mechanisms including epigenetics of retinal development at this laboratory in IMSUT. Recent few years, we had focused on working on retinitis pigmentosa, which is the inherited severe retinal degenerative disease. Analysis of impact of the gene mutations, which was reported from patients genomic analysis, for maintenance of photoreceptor homeostasis was main strategy of our research. However, we had started analysis of roles of inflammation for onset and progression of retinal degeneration. Determination of the cells which contribute to build the inflammatory environment within retina is an important issue to be solved. There are several retinal immunocompetent cells, such as microglia, astrocyte, Mueller glia, and retinal pigment epithelium (RPE), and we have particular interests with the microglia. After starting the

new laboratory in the hospital, we expanded our focus from retina to retina and sclera with particular interest with blood vessels. Therefore, not only retinitis pigmentosa, various vessel related retinal diseases such as ocular complications of diabetic mellitus and aged macular degeneration (AMD) are our research targets. Microglia and inflammatory environment in retina may play pivotal roles for the vessel related retinal degenerative diseases, and we had established several assay systems related to this point both in in vitro and in vivo.

The laboratory also aims to bridge the basic research - and the clinical-team. We have regular discussion of our laboratory members and ophthalmology department clinicians, and exchange knowledge and techniques between two groups. By such efforts, we aim to establish basic/clinical collaborative research group in ophthalmology field.

Teaching activities

The graduate students (2 Ph.D candidates) are clinicians, and have their own project. In 2022, we published 2 papers of the students projects to scientific journals. Group data discussion, laboratory data discussion, journal club, and individual data discussion are regularly hold by onsite as well as online. One of our purposes to establish the lab here from IMSUT is to establish structure of mutual collaboration between clinicians and basic science researchers. For that purpose, we have regular data conference between ophthalmology department and us, and faculties of both

laboratories also have regular meeting to discuss project direction. We also participate to train Ph.D candidate students of the ophthalmology department by teaching principles of experimental techniques and discussing research data. Vice versa, we learnt how to do ophthalmology related several image analyses, such as OCT and fundus photography of the mouse. These techniques help us to expand choice of analyses of disease model mice. In addition, as a hub laboratory in the basic ophthalmology related works, students and young researchers in the University of Tokyo and other universities often visit us to learn techniques and knowledge in this field.

Research activities

Summary of the research: Retinal degeneration mice and human iPS cells are two major models used in our research, and several projects of the retina and cornea are ongoing. Technically, we employ molecular biology, biochemistry, electroretinogram, and several imaging analyses. In addition, the LC-MS based membrane lipid analysis and the proteome in collaboration with the experts are often used. Ophthalmological techniques also facilitate to make our research activities deepen with broad spectrum. We had focused on retinal neurons and microglia, but now include more posterior segment of the eye, such as RPE, choriocapillaris, and choroid. Details of some of specific projects are as follows.

*** Roles of CSF2 as a modulator of inflammation during retinal degeneration**

Colony-stimulating factor 2 (CSF2) is a potent cytokine that stimulates myeloid cells, such as dendritic cells and macrophages. We have been analyzing the roles of microglia in retinal degeneration through the modulation of inflammation in the eye, and examined the roles of CSF2 in this process. Transcripts of both subunits of the CSF2 receptor are expressed in microglia, but no evidence suggesting the involvement of CSF2 in inflammation in the degenerating eye has been reported. We found that *Csf2* transcripts were induced in the early phase of *in vitro* mouse adult retina culture, used as degeneration models, suggesting that CSF2 induction is one of the earliest events occurring in the pathology of retinal degeneration. To examine

the roles of CSF2 in retinal inflammation, we overexpressed CSF2 in retinal explants. Induction of CSF2 activated microglia and Müller glia, and the layer structure of the retina was severely perturbed. C-C motif chemokine ligand 2 (*Ccl2*) and C-X-C motif chemokine ligand 10 (*Cxcl10*), both of which are expressed in activated microglia, were strongly induced by the expression of CSF2 in the retina. However, addition of CSF2 to microglial cell lines MG5 and BV2 did not show apparent effects of CSF2 except weak induction of *Ccl2* transcripts and proliferation, suggesting that CSF2 induced strong inflammation in the context of the retinal environment, probably through editing molecular network of initial phase of degeneration.

***Downregulation of VEGF in the Retinal Pigment Epithelium Followed by Choriocapillaris Atrophy After NaIO3 Treatment in Mice**

Sodium iodate (NaIO3) induces retinal pigment epithelium (RPE) dysfunction, which leads to photoreceptor degeneration. This system is widely used as retinitis pigmentosa model. Previously, we used electron microscopy to show that the administration of NaIO3 resulted in the accumulation of cell debris in the subretinal space, which was thought to be caused by failed phagocytosis in the outer segment of the photoreceptor due to RPE dysfunction. We further analyzed the pathological changes in the retina and choroid of NaIO3-injected mice, and found that the expression of OTX2, an RPE marker, disappeared from central part of the RPE 1 day after NaIO3 administration. Furthermore, fenestrated capillaries (choriocapillaris, CC) adjacent to the RPE could not be identified only 2 days after NaIO3 administration. An examination of the expression of the CC-specific protein plasmalemma vesicle-associated protein (PLVAP), in sections and flat-mount retina/choroid specimens showed destruction of the CC, and complete disappearance of the PLVAP signal 7 days after NaIO3 administration. In contrast, CD31 flat-mount immunohistochemistry of the retina indicated no difference in retinal vessels between NaIO3-treated mice and controls. Electron microscopy showed that the fenestrated capillaries in the kidney and duodenum were morphologically indistinguishable between control and NaIO3-treated mice. We examined

cytokine production in the retina and RPE, and found that the *Vegfa* transcript level in the RPE decreased starting 1 day after NaIO₃ administration. Taken together, these observations show that NaIO₃ reduces the CC in the early stages of the pathology, which is accompanied by a rapid decrease in *Vegfa* expression in the RPE.

A loss of the CC has been reported in various ocular degenerative diseases, mainly based on recent technical development of optical coherence tomography angiography (OCTA). CC flow alterations were shown to be associated with the development and progression of AMD, and retinitis pigmentosa. Our observation of the loss of the CC in the early phase of NaIO₃-induced pathogenesis may contribute to understanding of roles of alteration of CC in pathogenesis of the retinal degenerative diseases.

References

1. Azuma, K., Koumura, T., Iwamoto, R., Matsuoka, M., Terauchi, R., Yasuda, S., Shiraya, T., Watanabe, S., Aihara, M., Imai, H., Ueta, T., Mitochondrial GPx4 is indispensable for photoreceptor development and survival in mice, *JBC*, 2022, 298, 101824
2. Nagata, K., Hishikawa, D., Sagara, H., Saito, M., Watanabe, S., Shimizu, T., Shindou, H. Lysophosphatidylcholine acyltransferase 1 controls mitochondrial reactive oxygen species generation and survival of retinal photoreceptor cells, *JBC*, 2022, 298, 101958
3. Saita, K., Moriuchi, Y., Iwagawa, T., Aihara, M., Takai, Y., Uchida, K., Watanabe, S., Roles of CSF2 as a modulator of inflammation during retinal degeneration, *Cytokine*, 2022 158, 155996

Department of Real-world Evidence

Project Associate Professor

Yusuke Sasabuchi, M.D., M.P.H, Ph.D.

Project Lecturer

Shotaro Aso, M.D., M.P.H, Ph.D.

History and Overview of the Organization

Real-World Data (RWD) refers to patient data collected in daily clinical settings, distinct from the controlled environments of Randomized Controlled Trials (RCTs). This includes data from insurance databases, health check-ups, and electronic medical records. Evidence derived from RWD research is known as Real-World Evidence (RWE). RWD research is rapidly evolving globally. Regulatory authorities in Europe and America have opted to utilize RWE for expanding indications and safety monitoring of pharmaceuticals and medical devices. This has promoted an integrated approach to the utilization of RWD among industry, government, and academia.

In this context, the Department of Real-world Evidence was established in December 2022 as a social collaboration department with funding from DeSC Healthcare Corporation. The department aims to enhance public health and well-being by promoting multidisciplinary research using Japan's RWD to generate RWE and disseminating these findings to society. The collaborating department is the Department of Clinical Epidemiology & Economics (Professor Hideo Yasunaga).

The founding faculty members include Project Associate Professor Yusuke Sasabuchi (appointed December 2022) and Project Lecturer Shotaro Aso (appointed April 2023).

The creation of RWE can enhance daily clinical

practice through updated medical knowledge, improve the efficacy and safety of pharmaceuticals and medical devices, and contribute to their development. RWD research can fill gaps in evidence where RCTs are challenging to implement, thereby contributing to evidence-based medicine. It can also contribute to building a sustainable medical system through health economic policy research. Additionally, the department aims to reflect research outcomes in medical education and train data scientists.

Educations

The Department of Real-world Evidence provides support for lectures and guidance to students specializing in the School of Public Health at the collaborating Department of Clinical Epidemiology & Health Economics, as well as lectures and guidance for students in the Medical Real-World Data Utilization Personnel Training Program.

- For students specializing in the School of Public Health: Support is provided for Clinical Epidemiology & Health Economics exercises including a lecture in Clinical Epidemiology (1 session) by Sasabuchi.
- Sasabuchi and Aso provide guidance to students specializing in the School of Public Health.
- Medical Real-World Data Utilization Personnel Training Program: Introduction to Medical Real-World Data Construction (1 session) Clinical Issue Analysis and Practical Management (4 sessions) Practical Task

Training 2 (task presentation and evaluation)
Guidance for specialized students: Sasabuchi, Aso

- In the Medical Real-World Data Utilization Personnel Training Program, the curriculum includes 'Introduction to Medical Real-World Data Construction' (1 session), 'Clinical Issue Analysis and Practical Management' (4 sessions), and 'Practical Task Training 2' (task presentation and evaluation), with Sasabuchi and Aso providing guidance to specialized students.

Research activities

Two faculty members from the Department of Real-world Evidence directly guide students and researchers in RWD research, thereby fostering their skills as data scientists. The department's research activities focus on pharmacological epidemiology, clinical epidemiology, and health economic policy research. This focus emphasizes utilizing RWD from various sources, including the DeSC database, the national database (NDB), the DPC database, patient registries, and electric medical records. Through these educational and research activities, the department aims to respond to the societal demand for RWD research and RWE utilization, promote research using Japan's RWD, and contribute to overall health improvement.

References

1. Nishimoto Y, Ohbe H, Matsui H, Nakajima M, Sasabuchi Y, Sato Y, Watanabe T, Yamada T, Fukunami M, Yasunaga H. Effectiveness of systemic thrombolysis on clinical outcomes in high-risk pulmonary embolism patients with venoarterial extracorporeal membrane oxygenation: a nationwide inpatient database study. *J Intensive Care*. 2023 Feb 6;11(1):4.
2. Sugihara T, Kamei J, Yasunaga H, Sasabuchi Y, Fujimura T. Prescription of Choreito, a Japanese Kampo Medicine, with Antimicrobials for Treatment of Acute Cystitis: A Retrospective Cohort Study. *Antibiotics (Basel)*. 2022 Dec 18;11(12):1840.
3. Ohbe H, Sasabuchi Y, Matsui H, Yasunaga H. Impact of the COVID-19 pandemic on critical care utilization in Japan: a nationwide inpatient database study. *J Intensive Care*. 2022 Dec 2;10(1):51.
4. Shiotsuka J, Uchino S, Sasabuchi Y, Masuyama T, Lefor AK, Sanui M. Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study. *PLoS One*. 2022 Dec 1;17(12):e0277916.
5. Hayashi K, Sasabuchi Y, Matsui H, Nakajima M, Ohbe H, Fushimi K, Ono K, Yasunaga H. Additive effectiveness of acrylonitrile-co-methallyl sulfonate surface-treated membranes in the treatment of pneumonia: A propensity score-matched retrospective cohort study. *Artif Organs*. 2023 Feb;47(2):408-416.
6. Wada Y, Takahashi H, Matsui H, Yasunaga H, Fujiwara H, Sasabuchi Y. Adhesion barriers and intraperitoneal or uterine infections after cesarean section: A retrospective cohort study. *Surgery*. 2022 Dec;172(6):1722-1727.
7. Shinmoto K, Ohbe H, Nakajima M, Miyamoto Y, Sasabuchi Y, Yasunaga H, Hiraoka E. Outcomes after early versus delayed antibiotic treatment of liver abscess in Japan: A nationwide retrospective cohort study. *J Infect Chemother*. 2023 Jan;29(1):1-6.
8. Ohbe H, Sasabuchi Y, Iwagami M, Ogura T, Ono S, Matsui H, Yasunaga H. Intensive Care Unit versus High-dependency Care Unit for COVID-19 Patients with Invasive Mechanical Ventilation. *Ann Am Thorac Soc*. 2023 Jan;20(1):102-109.

Department of Lipidomics

Professor

Yoshiya Oda, Ph.D.

Assistant Professor

Suzumi M Tokuoka, Ph.D.

Homepage <http://lipidomics.m.u-tokyo.ac.jp/index-e.html>

Introduction and Organization

The Department of Lipidomics was established in April 2011, funded by Shimadzu Corp. and Ono Pharmaceutical Co., Ltd. The objective of the laboratory is to establish and improve mass spectrometry-based lipidomics methodologies, and its application to biomedical studies including basic lipid biology as well as clinical research.

The laboratory was started with three staff scientists, Takao Shimizu (Professor), Yoshihiro Kita (Associate Professor. He moved to Life Science Core Facility in Dec. 2013), and Suzumi Tokuoka (Assistant Professor). In April, 2014, Fuyuki Tokumasu joined as an Associate Professor (he moved to Nagasaki University in April, 2019) and in May 2018, Yoshiya Oda joined as a professor. In 2021, we have three guest researchers and two technical assistants. This year marks the 20th year since the launch of the former donated laboratory for metabolomics.

Teaching activities

The department staffs gave several lectures for undergraduate and graduate students. For undergraduate students, Drs. Shimizu and Kita delivered several lectures on biochemistry. Dr. Kita gave lectures on “Proteome and metabolome” for master’s students and “Principles and Applications of Mass Spectrometry” for doctoral students.

Research activities

Our research interests cover following topics.

Methods for clinical samples

Studies using human specimens are more reflective of human diseases than experimental data using laboratory animals and cell lines. However, lipidomics analysis on human clinical specimens such as blood, urine, feces, and biopsy samples is not always optimized for lipidomics analysis because of the large variability of data depending on individual differences compared to animal experiments. We are developing a technique for handling clinical samples for lipidomics analysis, and are working to create a highly practical lipidomics analysis method. Furthermore, in the clinical field, it is required to measure a large number of samples to take into account individual differences. Therefore, we are developing high-throughput and highly reliable assays and applying them to clinical practice.

Lipid biomarker discovery

Lipid biomarker discovery by liquid chromatography-mass spectrometry-based method requires a high-level integration of chromatography and mass spectrometry, which ensures lipid separation, semi-quantitative detection, and identification. We are collaborating with industries to overcome known difficulties in lipid chromatography, develop differential analyses and feature-extraction methods, and establish an intelligent analytical system linked with lipid database.

Metabolic flux analysis of lipids

A simple lipidomics analysis provides large datasets that describe the amount-based profile of lipidome. However, such a ‘snapshot’ analysis is not sufficient to understand the dynamics of lipid metabolic pathway,

because changes in metabolic flux is not always reflected to static amount of metabolites. To overcome this situation, we are developing a flux-oriented lipidomics analysis using stable-isotope tracers.

Multiplex quantitation strategy for biologically active lipids

Lipid mediators, including prostaglandins, leukotrienes, platelet-activating factor, bile acids and many other bioactive lipid metabolites are attracting great attention as disease-related or physiologically important molecules. Comprehensive analysis of known lipids is a useful, unbiased method in disease mechanism studies, and the lipid profile is a useful parameter that characterizes disease status as well. We have developed an original multiplex quantification method for trace amounts of biologically active lipids using liquid chromatography-tandem mass spectrometry (LC-MS/MS). We are developing more sensitive and rapid methods that cover more lipid mediators, which meet the demands on various large-scale studies and high-throughput screening approaches.

Discovery of novel lipids and their related molecules metabolizing pathways

Although major biosynthetic and catabolic pathways for classical lipid mediators have been well documented so far, there are still possibilities for yet unidentified lipid mediator metabolizing pathways in vivo. We have obtained preliminary data for novel lipid mediator-producing pathway using gene-deficient mice. Using the latest lipidomics techniques to the cell cultures and animal models, we will elucidate a novel lipid mediator related pathway and its biological significance.

Expansion of proteomics based on immune-PCR

Until now, proteomics based on mass spectrometry has been the mainstream method, but quantitative analysis was poor and plasma proteomics could not detect proteins such as cytokines, which are only present in very small amounts. This is why we introduced this method for the first time in Japan. We have already found interesting biomarker candidates in various diseases. We are also trying to integrate lipidomics and proteomics.

Automating Metabolite Analysis and Improving Coverage

Various methods are used to improve the coverage of metabolomics and lipidomics. One such method is gas chromatography (GC), which requires derivatization of the molecule to be analyzed. We are developing protocols to enable various derivatization methods using an automated derivatization system. Although individual molecules cannot be identified, we are investigating the possibility of risk diagnosis based on the profiles of blood components using a Fourier transform infrared spectrophotometer, which is fast, reproducible, and easy to operate. Our goal is to contribute to medical care by incorporating various technologies without limiting measurement methods.

References

1. Hosoi T, Yakabe M, Sasakawa H, Sasako T, Ueki K, Kato S, Tokuoka SM, Oda Y, Abe M, Matsumoto T, Akishita M, Ogawa S. Sarcopenia phenotype and impaired muscle function in male mice with fast-twitch muscle-specific knockout of the androgen receptor. *Proc Natl Acad Sci U S A*. 2023 Jan 24;120(4):e2218032120.
2. Kita Y, Tokuoka SM, Oda Y, Shimizu T. TRACES: A lightweight browser for liquid chromatography–multiple reaction monitoring–mass spectrometry chromatograms. *Metabolites*, 12, 354 (2022) (Published: 15 April 2022).
3. Tokuoka SM, Kita Y, Sato M, Shimizu T, Yatomi Y, Oda Y. Lipid profiles of human serum fractions enhanced with CD9 antibody-immobilized magnetic beads. *Metabolites*, 12, 230 (2022) (Published: 5 March 2022).
4. Hamano F, Tokuoka SM, Ishibashi M, Yokoi Y, Tourlousse DM, Kita Y, Sekiguchi Y, Yasui H, Shimizu T, Oda Y. Multi-omics analysis to generate hypotheses for mild health problems in monkeys. *Metabolites*, 11, 701 (2021) (Published: 13 October 2021).
5. Tokuoka SM, Kita Y, Sato M, Shimizu T, Yatomi Y, Oda Y. Development of Tandem Mass Tag Labeling Method for Lipid Molecules Containing Carboxy and Phosphate Groups, and Their Stability in Human Serum. *Metabolites*. 2020 Dec 30;11(1):19.

6. Tokuoka SM, Yasumoto A, Kita Y, Shimizu T, Yatomi Y, Oda Y. Limitations of deuterium-labeled internal standards for quantitative electrospray ionization mass spectrometry analysis of fatty acid metabolites. *Rapid Commun Mass Spectrom*. 2020 Jul 15;34(13):e8814.
7. Tokuoka SM, Kita Y, Shimizu T, Oda Y. Isobaric mass tagging and triple quadrupole mass spectrometry to determine lipid biomarker candidates for Alzheimer's disease. *PLoS One*. 2019 Dec 10; 14(12):e0226073.
8. Izumi Y, Matsuda F, Hirayama A, Ikeda K, Kita Y, Horie K, Saigusa D, Saito K, Sawada Y, Nakanishi H, Okahashi N, Takahashi M, Nakao M, Hata K, Hoshi Y, Morihara M, Tanabe K, Bamba T, Oda Y. Inter-Laboratory Comparison of Metabolite Measurements for Metabolomics Data Integration. *Metabolites*, 9, 257 (2019) (Published Online:31 October 2019)
9. Tanaka TQ, Tokuoka SM, Nakatani D, Hamano F, Kawazu S, Welles TE, Kita K, Shimizu T, Tokumasu F. Polyunsaturated fatty acids promote *Plasmodium falciparum* gametocytogenesis. *Biol. Open*, 8, bio042259 (2019) (Published Online:20 June 2019)
10. Kohira T, Kita Y, Tokuoka SM, Shiba M, Satake M, Shimizu T. Characterization of supported liquid extraction as a sample pretreatment method for eicosanoids and related metabolites in biological fluids. *J Chrom B*, 1124, 298-307 (2019) (Published Online:12 Jun 2019)
11. Yoshida K, Kita Y, Tokuoka SM, Hamano F, Yamazaki M, Sakimura K, Kano M, Shimizu T. Monoacylglycerol lipase deficiency affects diet-induced obesity, fat absorption, and feeding behavior in CB1 cannabinoid receptor-deficient mice. *FASEB J*, 33, 2484-2497 (2019) (Published Online:30 Jan 2019)
12. Yanagida K, Igarashi H, Yasuda D, Kobayashi D, Ohto-Nakanishi T, Akahoshi N, Sekiba A, Toyoda T, Ishijima T, Nakai Y, Shojima N, Kubota N, Abe K, Kadowaki T, Ishii S, Shimizu T. The $G\alpha_{12/13}$ -coupled receptor, LPA4 limits proper adipose tissue expansion and remodeling in diet-induced obesity. *JCI Insight*, 3, e97293 (2018) (First published December 20, 2018)
13. Kita Y, Shiudou H, Shimizu T. Cytosolic phospholipase A2 and lysophospholipid acyltransferases. *Biochim Biophys Acta*, 1864, 838-845 (2019) (Available online 9 August 2018)
14. Hori T, Okuno T, Hirata K, Yamashita K, Kawano Y, Yamamoto M, Hato M, Nakamura M, Shimizu T, Yokomizo T, Miyano M, Yokoyama S. Na⁺-mimicking ligands stabilize the inactive state of leukotriene B4 receptor BLT1. *Nat Chem Biol*, 14, 262–269 (2018)
15. Valentine WV, Tokuoka SM, Hishikawa D, Kita Y, Shindou H, Shimizu T. Lysophosphatidic acid acyltransferase 3 incorporates docosahexaeneic acid into skeletal muscle cell membranes and is upregulated by PPAR δ activation. *J Lipid Res*, 59, 184-194 (2018)

Department of Preventive Medicine for Locomotive Organ Disorders

Project Professor

Noriko Yoshimura, M.D., Ph.D.

Project Research Associate

Toshiko Iidaka, M.D., Ph.D.

Homepage [http:// www.h.u-tokyo.ac.jp/research/center22/index.html](http://www.h.u-tokyo.ac.jp/research/center22/index.html)

Introduction and Organization

The department of Preventive Medicine for Locomotive Organ Disorders in 22nd Century Medical and Research Center, The University of Tokyo Hospital, on April 1st, 2020, which is a social collaboration department with NIPPON TELEGRAPH AND TELEPHONE CORPORATION (NTT), Suntory Wellness Ltd., ASAHI KASEI PHARMA CORPORATION, and Fujifilm Corporation, and in close collaboration with departments of Orthopaedic Surgery and Rehabilitation Medicine in the hospital. Our department has been established to clarify the epidemiological profiles of locomotive organ disorders, such as, osteoarthritis (OA), osteoporosis (OP) and sarcopenia (SP). Further, we also try to elucidate the frequencied and risk factors for locomotive syndrome, which was defined by the Japanese Orthopaedic Association (JOA) in 2014.

Research activities

Although locomotive organ disorders are major causes of disability and require support, little information is available regarding their epidemiology. The Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) study, which started in 2005-7, is a prospective cohort study that aims to elucidate the environmental and genetic background for bone and joint diseases. It was designed to examine the extent to which risk factors for these diseases are related to clinical features, laboratory and radiographic findings,

bone mass and geometry, lifestyle, nutritional factors, anthropometric and neuromuscular measures, and fall propensity. In addition, the study's aim was also to determine how these diseases affect activities of daily living and quality of life in Japanese men and women.

We have completed the baseline study in 2005-2007, then, 2nd, 3rd, 4th, and 5th follow-ups were completed in 2008-2010, 2012-2013, 2015-2016, and 2018-2019 respectively. We have been conducting the follow-up survey since 2022.

References

1. Vandenput L, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C, Bischoff-Ferrari HA, Biver E, Bruyère O, Cauley JA, Center JR, Chapurlat R, Christiansen C, Cooper C, Crandall CJ, Cummings SR, da Silva JAP, Dawson-Hughes B, Diez-Perez A, Dufour AB, Eisman JA, Elders PJM, Ferrari S, Fujita Y, Fujiwara S, Glüer CC, Goldshtein I, Goltzman D, Gudnason V, Hall J, Hans D, Hoff M, Hollick RJ, Huisman M, Iki M, Ish-Shalom S, Jones G, Karlsson MK, Khosla S, Kiel DP, Koh WP, Koromani F, Kotowicz MA, Kröger H, Kwok T, Lamy O, Langhammer A, Larijani B, Lippuner K, Mellström D, Merlijn T, Nordström A, Nordström P, O'Neill TW, Obermayer-Pietsch B, Ohlsson C, Orwoll ES, Pasco JA, Rivadeneira F, Schei B, Schott AM, Shiroma EJ, Siggeirsdottir K, Simonsick EM,

- Sornay-Rendu E, Sund R, Swart KMA, Szulc P, Tamaki J, Torgerson DJ, van Schoor NM, van Staa TP, Vila J, Wareham NJ, Wright NC, Yoshimura N, Zillikens MC, Zwart M, Harvey NC, Lorentzon M, Leslie WD, Kanis JA: Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. *Osteoporos Int* 33(10): 2103-2136, 2022, doi: 10.1007/s00198-022-06435-6.
2. Yoshimura N, Iidaka T, Horii C, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T, Tanaka S: Trends in osteoporosis prevalence over a 10-year period in Japan: The ROAD study 2005–2015. *J Bone Miner Metab* 40(5): 829-838, 2022, doi: 10.1007/s00774-022-01352-4.
3. Chotiyarnwong P, McCloskey EV, Harvey NC, Lorentzon M, Prieto-Alhambra D, Abrahamsen B, Adachi JD, Borgström F, Bruyere O, Carey JJ, Clark P, Cooper C, Curtis EM, Dennison E, Diaz-Curiel M, Dimai HP, Grigorie D, Hilgsmann M, Khashayar P, Lewiecki EM, Lips P, Lorenc RS, Ortolani S, Papaioannou A, Silverman S, Sosa M, Szulc P, Ward KA, Yoshimura N, Kanis JA: Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. *Arch Osteoporos* 17(1): 87, 2022, doi: 10.1007/s11657-022-01117-6.
4. Teraguchi M, Hashizume H, Oka H, Cheung JPY, Samartzis D, Tamai H, Muraki S, Akune T, Tanaka S, Yoshida M, Yoshimura N, Yamada H: Detailed subphenotyping of lumbar modic changes and their association with low back pain in a large population-based study: The Wakayama Spine Study. *Pain Ther* 11(1): 57-71, 2022, doi: 10.1007/s40122-021-00337-x.
5. Horii C, Iidaka T, Muraki S, Oka H, Asai Y, Tsutsui S, Hashizume H, Yamada H, Yoshida M, Kawaguchi H, Nakamura K, Akune T, Oshima Y, Tanaka S, Yoshimura N: The cumulative incidence of and risk factors for morphometric severe vertebral fractures in Japanese men and women: the ROAD study third and fourth surveys. *Osteoporos Int* 33(4): 889-899, 2022, doi: 10.1007/s00198-021-06143-7.
6. Shoji A, Gao Z, Arai K, Yoshimura N: 30-year trends of hip and vertebral fracture incidence in Japan: a systematic review and meta-analysis. *J Bone Miner Metab* 40(2): 327-336, 2022, doi: 10.1007/s00774-021-01288-1.
7. Asai Y, Tsutsui S, Yoshimura N, Hashizume H, Oka H, Muraki S, Iidaka T, Horii C, Kawaguchi H, Nakamura K, Tanaka S, Yoshida M, Yamada H: Relationship between age-related spinopelvic sagittal alignment and low back pain in adults of population-based cohorts: The ROAD Study. *J Pain Res* 15: 33-38, 2022, doi: 10.2147/JPR.S339712.
8. Matsumoto T, Higuchi J, Maenohara Y, Chang Song Ho, Iidaka T, Horii C, Oka H, Muraki S, Hashizume H, Yamada H, Yoshida M, Nakamura K, Tanaka S, Yoshimura N: The discrepancy between radiographically-assessed and self-recognized hallux valgus in a large population-based cohort. *BMC Musculoskelet Disord* 23(1): 31, 2022, doi: 10.1186/s12891-021-04978-z.
9. Yoshimura N, Iidaka T, Horii C, Mure K, Muraki S, Oka H, Kawaguchi H, Akune T, Ishibashi H, Ohe T, Hashizume H, Yamada H, Yoshida M, Nakamura K, Tanaka S: Epidemiology of locomotive syndrome using updated clinical decision limits: 6-year follow-ups of the ROAD study. *J Bone Miner Metab* 40(4): 623-635, 2022, doi: 10.1007/s00774-022-01324-8.
10. Harada T, Hashizume H, Taniguchi T, Iidaka T, Asai Y, Oka H, Muraki S, Akune T, Kawaguchi H, Nakamura K, Yoshida M, Tanaka S, Yoshimura N, Yamada H: Association between acetabular dysplasia and sagittal spino-pelvic alignment in a population-based cohort in Japan. *Scientific Reports* 12(1): 12686, 2022, doi: 10.1038/s41598-022-16865-1.
11. Arita S, Ishimoto Y, Hashizume H, Nagata K, Muraki S, Oka H, Takami M, Tsutsui S, Iwasaki H, Yukawa Y, Akune T, Kawaguchi H, Tanaka S, Nakamura K, Yoshida M, Yoshimura N, Yamada H; Consortium. Is radiographic lumbar spinal stenosis associated with the quality of life?: The Wakayama Spine Study. *PLoS One* 17(2): e0263930, 2022, doi: 10.1371/journal.pone.0263930.
12. Uehara M, Wada-Hiraike O, Hirano M, Koga K,

- Yoshimura N, Tanaka S, Osuga Y: Relationship between bone mineral density and ovarian function and thyroid function in perimenopausal women with endometriosis: a prospective study. *BMC Womens Health* 22(1):134, 2022, doi: 10.1186/s12905-022-01711-3.
13. Tamai H, Teraguchi M, Hashizume H, Oka H, Cheung JPY, Samartzis D, Muraki S, Akune T, Kawaguchi H, Nakamura K, Tanaka S, Yoshida M, Yoshimura N, Yamada H. A Prospective, 3-year Longitudinal Study of Modic Changes of the Lumbar Spine in a Population-based Cohort: The Wakayama Spine Study. *Spine* 47(6):490-497, 2022, doi: 10.1097/BRS.0000000000004301.
 14. Iidaka T, Horii C, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T, Tanaka S, Yoshimura N. Trends in prevalence of hip osteoarthritis over a 10-year period in Japan: The ROAD study 2005–2015. *Osteoarthr Cartil Open* 4(3):100285, 2022, doi: 10.1016/j.ocarto.2022.100285.
 15. Uehara M, Wada-Hiraike O, Hirano M, Harada M, Koga K, Yoshimura N, Tanaka S, Osuga Y: Evaluation of Atherosclerosis-Related Biomarkers during Perimenopause: A Prospective Cohort Study in Women with Endometriosis. *J Obstet Gynaecol Res* 48(12): 3160-3170, 2022, doi: 10.1111/jog.15447.

University Hospital

Central Clinical Services

Advanced Medical Center for Heart Failure

Director, Associate Professor

Masaru Hatano, M.D., Ph.D.

Vice Director

Masahiko Ando, M.D., Ph.D.

Homepage <https://www.h.u-tokyo.ac.jp/patient/depts/shinfuzen/>

Introduction and Organization

Advanced medical center for heart failure collaborates with a wide range of university hospitals and core regional medical institutions to accept patients who require heart transplantations of ventricular assist device (VAD) implantation. In addition to cardiovascular medicine and cardiovascular surgery, the center provides medical care with a heart team consisting of recipient transplant coordinators, pharmacists, medical engineers and physical therapists. In addition to such medical cooperation efforts, the center is also responsible for training heart failure specialists and other specialized staff by accepting trainees.

Clinical activities

Target diseases include idiopathic cardiomyopathies such as dilated cardiomyopathy and hypertrophic cardiomyopathy, various types of secondary cardiomyopathy, and all causes of heart failure regardless of underlying disease

- Heart transplantation : Performed 213

Heart transplantation to date (as of 25 Dec 2023), the largest number in Japan

- Ventricular Assist Device (VAD): The center can employ all types of VADs approved in Japan, making it possible to choose the most suitable model according to each patient's physical and heart failure condition. It is also recognized as a facility that can perform destination therapy.

- Drug therapy for heart failure: The center has extensive experience in the use of heart failure drugs, including those that have been in recent years.
- Introduction of Vyndaqel for cardiac amyloidosis: The center has been certified to prescribe Vyndaqel by The Japanese Circulation Society and have already gained a significant amount of experience with the drug.
- HeartSeet: The center participates in a post-marketing clinical trial of HeartSeet, a skeletal myoblast sheet to be transplanted onto the surface of the heart.

Teaching and Research activities

In addition to medical care, we accept training in advanced heart failure management from medical facilities nationwide and play an important role in training heart failure specialists and specialized staff. We are also focusing on research and in addition to disseminating many research results, we are promoting translational research that bridges basic research and clinical practice. In addition, while treating a large number of heart failure patients, we are also striving to establish optimal prevention and treatment strategy (precision medicine) that consider individual differences.

References

1. F Fujiwara T, Takeda N, Hara H, Ishii S, Numata G, Tokiwa H, Katoh M, Maemura S, Suzuki T,

- Takiguchi H, Yanase T, Kubota Y, Nomura S, Hatano M, Ueda K, Harada M, Toko H, Takimoto E, Akazawa H, Morita H, Nishimura S, Komuro I. PGC-1 α -mediated angiogenesis prevents pulmonary hypertension in mice. *JCI Insight*. 2023 Sep 8;8(17):e162632.
2. Isotani Y, Amiya E, Hatano M, Kiriyaama H, Uehara M, Ishida J, Tsuji M, Bujo C, Narita K, Ishii S, Kakuda N, Minatsuki S, Yagi H, Saito A, Numata G, Yamada T, Kurihara T, Suzuki T, Komuro I. A new assessment method for right ventricular diastolic function using right heart catheterization by pressure-volume loop. *Physiol Rep*. 2023 Jul;11(13):e15751.
 3. Minatsuki S, Hatano M, Tanikawa I, Hirose K, Saito A, Yagi H, Takeda N, Komuro I. Verification of Optimal Balloon Size in Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. *Cardiovasc Intervent Radiol*. 2023 Jul;46(7):967-969.
 4. Kiriyaama H, Kiyosue A, Minatsuki S, Kawahara T, Katsushika S, Kamon T, Hirose K, Shinohara H, Miura M, Saito A, Kikuchi H, Koderia S, Hatano M, Ando J, Myojo M, Itoh N, Yamamoto K, Ikenouchi H, Takeda N, Komuro I. Potential value of saline-induced Pd/Pa ratio in patients with coronary artery stenosis. *Front Cardiovasc Med*. 2023 Jan 6;9:1001833.
 5. Ishii S, Hatano M, Maki H, Minatsuki S, Saito A, Yagi H, Shimbo M, Soma K, Numata G, Fujiwara T, Takeda N, Komuro I. Prognostic value of follow-up vasoreactivity test in pulmonary arterial hypertension. *J Cardiol*. 2023 Jul;82(1):69-75.
 6. Yamada T, Nomura S, Amiya E, Katoh M, Inoue S, Hatsuse S, Fujita K, Ito M, Fujita T, Bujo C, Tsuji M, Ishida J, Ko T, Yamada S, Katagiri M, Sassa T, Kinoshita O, Nawata K, Tobita T, Satoh M, Ishiwata J, Daimon M, Tatsuno K, Fukuda S, Kashimura T, Minamino T, Hatano M, Ono M, Aburatani H, Komuro I. LMNA Mutations and Right Heart Failure in Patients With Cardiomyopathy and With Left Ventricular Assist Devices. *J Card Fail*. 2023 May;29(5):855-857.
 7. Atsukawa M, Tsubota A, Kondo C, Koyano KS, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, Ikegami T, Nakamuta M, Shigefuku R, Iwasa M, Tanaka Y, Hatano M, Iwakiri K. Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study. *Hepatol Int*. 2023 Feb;17(1):139-149.
 8. Dai Z, Ko T, Fujita K, Nomura S, Uemura Y, Onoue K, Hamano M, Katoh M, Yamada S, Katagiri M, Zhang B, Hatsuse S, Yamada T, Inoue S, Kubota M, Sawami K, Heryed T, Ito M, Amiya E, Hatano M, Takeda N, Morita H, Yamanishi Y, Saito Y, Komuro I. Myocardial DNA Damage Predicts Heart Failure Outcome in Various Underlying Diseases. *JACC Heart Fail*. 2023 Oct 28:S2213-1779(23)00680-7.
 9. Hosokawa K, Abe K, Funakoshi K, Tamura Y, Nakashima N, Todaka K, Taniguchi Y, Inami T, Adachi S, Tsujino I, Yamashita J, Minatsuki S, Ikeda N, Shimokawahara H, Kawakami T, Ogo T, Hatano M, Ogino H, Fukumoto Y, Tanabe N, Matsubara H, Fukuda K, Tatsumi K, Tsutsui H. Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study. *J Thromb Haemost*. 2023 Aug;21(8):2151-2162.
 10. Purevsuren M, Uehara M, Ishizuka M, Suzuki Y, Shimbo M, Kakuda N, Ishii S, Sumida H, Miyazaki M, Yamashita T, Yoshizaki A, Asano Y, Sato S, Hatano M, Komuro I. Native T1 mapping in early diffuse and limited systemic sclerosis, and its association with diastolic function. *J Cardiol*. 2023 Aug;82(2):100-107.
 11. Ishii S, Minatsuki S, Hatano M, Saito A, Yagi H, Shimbo M, Soma K, Fujiwara T, Itoh H, Konoeda C, Sato M, Takeda N, Daimon M, Nakajima J, Komuro I. The ratio of TAPSE to PASP predicts prognosis in lung transplant candidates with pulmonary arterial hypertension. *Sci Rep*. 2023 Mar 7;13(1):3758.
 12. Ishii S, Fujiwara T, Yagi H, Takeda N, Ando M, Yamauchi H, Inuzuka R, Taniguchi Y, Hatano M, Komuro I. A novel pathogenic variant located just upstream of the C-terminal Ser423-X-Ser425 phosphorylation motif in SMAD3 causing Loeys-

- Dietz syndrome. *Mol Genet Genomic Med*. 2023 Dec;11(12):e2257.
13. Yagi H, Amiya E, Uehara M, Minatsuki S, Hatano M, Takeda N, Akazawa H, Komuro I. Coronary Periarteritis and Pericardial Thickening Could Be Predictors for Coronary Artery Events Complicated by IgG4-Related Disease. *CJC Open*. 2023 Mar 17;5(6):480-489.
 14. Tsuji M, Kakuda N, Bujo C, Saito A, Ishida J, Amiya E, Hatano M, Shimada A, Imai H, Kimura M, Ando M, Kinoshita O, Yamauchi H, Komuro I, Ono M. Prophylactic negative pressure wound therapy is not effective for preventing driveline infection following left ventricular assist device implantation. *Artif Organs*. 2023 Mar;47(3):566-573.
 15. Inoue S, Ko T, Nomura S, Yamada T, Zhang B, Dai Z, Jimba T, Katoh M, Ishida J, Amiya E, Hatano M, Takeda N, Morita H, Ono M, Komuro I. Compound Heterozygous Truncating Variants in the *BAG5* Gene As a Cause of Early-Onset Dilated Cardiomyopathy. *Circ Genom Precis Med*. 2023 Dec;16(6):e004282.
 16. Kakuda N, Amiya E, Hatano M, Ishida J, Tsuji M, Bujo C, Yagi H, Fujita K, Ishii S, Isotani Y, Kurihara T, Numata G, Gyoten T, Shimada S, Ando M, Ono M, Komuro I. Effect of renal function under left ventricular assist device support on the cardiac function and clinical events after heart transplantation. *Clin Transplant*. 2023 Dec;37(12):e15107.
 17. Hosokawa K, Watanabe H, Taniguchi Y, Ikeda N, Inami T, Yasuda S, Murohara T, Hatano M, Tamura Y, Yamashita J, Tatsumi K, Tsujino I, Kobayakawa Y, Adachi S, Yaoita N, Minatsuki S, Todaka K, Fukuda K, Tsutsui H, Abe K; KABUKI Investigators. A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial. *Circulation*. 2023 Nov 13.
 18. Gyoten T, Amiya E, Kinoshita O, Tsuji M, Kimura M, Hatano M, Ono M. Clinical outcomes of continuous flow left ventricular assist device therapy as bridge to transplant strategy in muscular dystrophy: a single-center study. *Gen Thorac Cardiovasc Surg*. 2023 Jun;71(6):347-353.
 19. Yanase T, Hatano M, Bujo C, Tsuji M, Ishida J, Amiya E, Okamoto K, Ando M, Shimada S, Kinoshita O, Fukushi S, Yamada S, Ono M, Komuro I. Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia. *Int Heart J*. 2023 Mar 31;64(1):95-99.
 20. Hirose K, Minatsuki S, Saito A, Yagi H, Takeda N, Hatano M, Komuro I. Impact of psychiatric disorders on the hemodynamic and quality of life outcome of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: a retrospective study. *Respir Res*. 2023 Nov 11;24(1):274.
 21. Sawano S, Miura M, Higashikuni Y, Saigusa H, Kodera S, Takeda N, Hatano M, Ando J, Ono M, Komuro I. Clinical valve thrombosis and arterial embolism in a cancer patient after transcatheter aortic valve replacement. *Oxf Med Case Reports*. 2023 Nov 28; 2023(11):omad125. doi: 10.1093/omcr/omad125.
 22. Shindo A, Ueda K, Minatsuki S, Nakayama Y, Hatsuse S, Fujita K, Nomura S, Hatano M, Takeda N, Akazawa H, Komuro I. Novel *AGL* variants in a patient with glycogen storage disease type IIIb and pulmonary hypertension caused by pulmonary veno-occlusive disease: A case report. *Front Genet*. 2023 Mar 23;14:1148067.
 23. Kurihara T, Amiya E, Hatano M, Ishida J, Minatsuki S, Inoue S, Nomura S, Morita H, Komuro I. Multivessel Coronary Artery Dissection in a Patient with Co-Occurrence of Aortic Dissection and Dilated Cardiomyopathy in the Postpartum Period. *Diseases*. 2023 Dec 10;11(4):178.

Department of Clinical Genomics

Director & Professor

Katsutoshi Oda, M.D., Ph.D.

Project Associate Professor

Hidenori Kage, M.D., Ph.D.

Associate Professor

Aya Ushiku, M.D., Ph.D.

Organization

The Department of Clinical Genomics started as a special unit providing clinical genomics services in 2003. The department functions as the core unit to provide genetic counseling services to support an appropriate and efficient application of genetic testing, as well as genomic medicine in cancer. The department also provides a training program for physicians preparing for board-certified clinical geneticists. Many medical staffs with diverse specialties including pediatricians, obstetricians, neurologists, cardiologists, diabetologists and surgeons participate in the activities of the Department.

Activities

Genetic Counseling

The room (Room 200) is specifically allocated in the outpatient clinic. Genetic counseling is performed by a team of board-certified clinical geneticist and certified genetic counselors in cooperation with other clinical departments. All cases are reviewed and discussed at the conference which is held once every month. We also provide support to clinical departments for establishing genetic diagnosis in various types of diseases, including neurological disorder, pediatric and perinatal disorders, Marfan's Syndrome and Hereditary Breast and Ovarian Cancer.

Genomic Medicine in Cancer

We provide cancer genomic profiling (clinical

sequencing) for incurable malignant solid tumors with 12 collaborative hospitals, as a "Cancer Genome Core Hospital". Two types of cancer genomic profiling (OncoGuide™ NCC Oncopanel System, FoundationOne® CDx Cancer Genomic Profiling) were approved by PMDA in June, 2019. FoundationOne® Liquid CDx Cancer Genomic Profiling was also approved in 2021. As well, we provide an original multiplex genome sequencing, named "Todai OncoPanel", which is composed of DNA panel and RNA panel. The Todai Oncopanel was approved as a name of "GenMineTOP" for manufacturing and marketing from the Ministry of Health, Labour and Welfare in 2022. The room (Room 202) is specifically allocated in the outpatient clinic for genomic medicine in cancer (twice weekly).

Publications

1. Tanaka M, Shinozaki-Ushiku A, Kunita A, Yasunaga Y, Akamatsu N, Hasegawa K, Ushiku T: High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma. *Pathol Int.* 2022 Aug;72(8):411-418.
2. Kage H, Kohsaka S, Tatsuno K, Ueno T, Ikegami M, Zokumasu K, Shinozaki-Ushiku A, Nagai S, Aburatani H, Mano H, Oda K: Tumor mutational burden measurement using comprehensive genomic profiling assay. *Jpn J Clin Oncol.* 2022 Aug 5;52(8):925-929.

3. Taguchi A, Rokutan H, Oda K, Tanikawa M, Tanimoto S, Sone K, Mori M, Tsuruga T, Kohsaka S, Tatsuno K, Shinozaki-Ushiku A, Miyagawa K, Mano H, Aburatani H, Ushiku T, Osuga Y: Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma. *BMC Med Genomics*. 2022 Mar 7;15(1):51.
4. Ando T, Kage H, Shinozaki-Ushiku A, Tatsuno K, Tsutsumi S, Nagayama K, Nakajima J, Kohsaka S, Miyagawa K, Aburatani H, Mano H, Nagase T: Composite Clonal Analysis Reveals Transition of NSCLC Subtypes Through Accumulation of Gene Mutations: A Case Report. *JTO Clin Res Rep*. 2022 Jan 10;3(2):100277.
5. Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shiota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, Yoshino T: Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. *JAMA Netw Open*. 2022 Dec 1;5(12):e2245081.
6. Sunami K, Naito Y, Komine K, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, Saigusa Y, Yoshino T: Chronological improvement in precision oncology implementation in Japan. *Cancer Sci*. 2022 Nov;113(11):3995-4000.
7. Imai M, Nakamura Y, Sunami K, Kage H, Komine K, Koyama T, Amano T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Bando H, Makiyama A, Suzuki T, Hirata M, Kohsaka S, Tsuchihara K, Naito Y, Yoshino T: Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors. *Cancer Sci*. 2022 Nov;113(11):3646-3656.
8. Amano Y, Kage H, Tanaka G, Sato Y, Tanaka M, Nagase T: Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report. *Case Rep Oncol*. 2022 Mar 30;15(1):338-344.
9. Yamamoto K, Chang H, Fukushima A: Pregnant women's experiences of non-invasive prenatal testing (NIPT) in Japan: A qualitative study. *J Genet Couns*. 2022 Apr;31(2):338-355.
10. Itamiya T, Komai T, Kanda H, Nagafuchi Y, Chang H, Shibata S, Ishiura H, Shoda H, Toda T, Fujio K: Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation. *Clin Rheumatol*. 2022 Jul;41(7):2233-2237..
11. Yagi H, Takeda N, Amiya E, Akiyama N, Chang H, Ishiura H, Sato J, Akazawa H, Morita H, Komuro I: PNonsyndromic arteriopathy and aortopathy and vascular Ehlers-Danlos syndrome causing COL3A1 variants. *Am J Med Genet A*. 2022 Sep;188(9):2777-2782.
12. Ebihara T, Nagatomo T, Sugiyama Y, Tsuruoka T, Osone Y, Shimura M, Tajika M, Ichimoto K, Naruke Y, Akiyama N, Lim SC, Yatsuka Y, Nitta KR, Kishita Y, Fushimi T, Okazaki A, Ohtake A, Okazaki Y, Murayama K: Severe spinal cord hypoplasia due to a novel ATAD3A compound heterozygous deletion. *Mol Genet Metab Rep*. 2022 Aug 24;33:100912.
13. Ando T, Kage H, Shinozaki-Ushiku A, Tatsuno K, Tsutsumi S, Nagayama K, Nakajima J, Kohsaka S, Miyagawa K, Aburatani H, Mano H, Nagase T. Composite Clonal Analysis Reveals Transition of NSCLC Subtypes Through Accumulation of Gene Mutations: A Case Report. *JTO Clin Res Rep*. 2022 Jan 10;3(2):100277.

Department of Child Psychiatry

Associate Professor

Yukiko Kano, M.D., Ph.D.

Homepage <http://kokoro.umin.jp/>

Introduction and Organization

The Department of Child Psychiatry was established in April 2005 as the clinical counterpart to the Clinical Education Center of Mental Development, both of which are funded by the special grant for faculty development. The major aim of the Clinical Education Center is to train mental health specialists in various fields with a fundamental grounding in child psychiatry and neurosciences. Much of the services provided are based on the 39 years of experience in intervention and treatment for developmentally disabled children established in the former child psychiatry division of Department of Neuropsychiatry. Our department uses a multidisciplinary approach by working in collaboration not only with the Department of Neuropsychiatry, Department of Pediatrics and Graduate School of Education in the University of Tokyo but also several other educational and/or clinical facilities on mental development or developmental disorders. The Department of Child Psychiatry complemented the Clinical Education Center by providing fieldwork for clinical training and offered clinical services to patients with various development problems also.

The Clinical Education Center of Mental Development was closed in March 2010 because of time limit of the fund, and Department of Child Neuropsychiatry, Graduate School of Medicine was established in April 2010. The Department of Child Psychiatry, as the clinical counterpart to the department in graduate school, focuses on clinical activity related to research as well as quality practice of child psychiatry and education of leading child psychiatrists and allied professionals. In addition to professors of the graduate school, 2 psychiatrists and 3 psychologists (2 full-time

ones for a definite term and 1 part-time one) are officially assigned to the Department of Child Psychiatry. One psychiatric social worker works mainly for the Department of Child Psychiatry since 2013 also.

Clinical activities

In the year 2022, 9 psychiatrists and 4 psychologists (full-time and part-time) and 1 psychiatric social worker are in charge of treatment at the Department of Child Psychiatry. Although patients with various disorders are seen, the focus of the department is mainly on patients with developmental disorders. We offer services to patients with a broad range of developmental disorders including Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), Learning Disabilities (LD), Intellectual Disability (ID), tic disorders, and child & adolescent Obsessive-Compulsive Disorders (OCD).

Number of new patients in 2022 was 217, which is not as high as in 2019 before the COVID-19 pandemic, but compared to 173 in 2020, the number of new patients is on a recovery track. Out of 217 patients, children of elementary school age were 80, and children of junior high school age were 30. In other words, children of elementary or junior high school age were more than half of the patients. Number of preschool children was 86, suggesting our response to ongoing needs for early diagnosis and intervention.

The follow-up clinic consisted of general clinic and special clinic (Tic/OCD clinic). At the general clinic, a rigorous diagnosis based on detailed assessment and decision about treatment course are provided for children and adolescents with any kinds of mental problems. After fine adjustment of treatment course

within a given period, the patients are referred to community hospitals/clinics or intervention/education facilities with a detailed report. The special clinic meets a need for high level services and works with research for special diseases.

Services for the general child psychiatry outpatients are provided by psychiatrists in the areas of pharmacotherapy, psychotherapy, psychoeducation and also work closely with the schools and community.

Psychologists have charge of psychological consultation as well as psychological examination. Patients involved in those are mainly individuals with developmental disabilities, and individualized treatment focusing on developmental viewpoint is planned for each. Psychological consultation includes services in the following areas: (1) evaluation of cognitive and behavioral development, (2) individualized treatment of the disabled individual (3) counseling of parents and providing information to the disabled individual's support network (relatives, schools) and environmental coordination. In addition to psychologists, psychiatric social worker participates in actual environmental coordination. Cognitive behavior therapy for obsessive-compulsive symptoms or anxiety is sometimes provided also.

As for intervention for preschool children with ASD, intensive individualized therapy consisting of weekly 10 sessions was provided for children aged 3 years or younger.

Parent-training for parents with ADHD children, which started in 2011, was provided. This program aimed that the parents learn deeper understanding of difficult children and appropriate strategy of coping with them.

In addition to these outpatient services, "inpatient assessment on developmental disorders" program started in 2010. This program is provided in the inpatient ward of neuropsychiatry for adolescents or adults who have mental problems such as depression and wish a detailed examination about possibility of hidden developmental disorders including ASD and ADHD. Based on this assessment, psychoeducation on strategies coping with problems related to developmental disorders is provided to patients and their families.

We also focus on psychiatric liaison activity with other departments in the University hospital,

especially pediatrics.

Furthermore, as a cross-department and cross-divisional activity, Children, AYA and Family centered Mental Care Center was established in January 2022, and we are playing a central role in its practice.

Education

Undergraduates of the University of Tokyo have opportunities to participate in an assessment and diagnosis session at the general first visit outpatient clinic and intervention for preschool children. Graduate students in clinical psychology course from the University of Tokyo participate in intervention for preschoolers also.

One month training course is offered to junior residents especially in pediatric specialty course. This course includes intake interview of first visit patients, attendance for assessment and treatment for follow-up patients, intervention for preschoolers, and the parent-training. Eighteen residents participated in this course. For general psychiatrists including senior residents of the Department of Neuropsychiatry, an inpatient program of assessment about developmental disorders is provided as opportunity to get knowledge and experience of developmental disorders.

Research

We participate in investigation of etiology and development of effective treatment on ASD and ADHD, which are organized in collaboration with the Department of Neuropsychiatry and other research, educational and clinical facilities. In addition, research related specifically to the clinical activities in the Department of Child Psychiatry is currently being investigated.

Clinical evaluation and treatment

Effectiveness study of early intervention for autistic preschoolers is being undertaken. We focused on investigating early intervention including treatment for children and parent support.

We are also considering support for transition from kindergarten/nursery school to elementary school for children with ASD.

Effectiveness of a program of group cognitive

behavior therapy for adults with high-functioning ASD is investigated in a randomized control trial.

We are also analyzing the data obtained from “inpatient assessment on developmental disorders” program.

In order to develop predictor of parent training for ADHD, we are collecting and analyzing data.

The possible relations among clinical characteristics such as tics and obsessive-compulsive symptoms in Tourette syndrome (chronic tic disorder with multiple motor tics and one or more vocal tics) and child & adolescent OCD are being evaluated.

Comprehensive Behavioral Intervention for Tics (CBIT) is provided for children and adolescents with Tourette syndrome, and investigation of its effectiveness is undertaken. We have developed internet-based psychoeducational materials that will lead to CBIT, and have begun investigating their effectiveness. We are also trying to develop an objective assessment of tics.

Multi-institutional collaborative study about treatment-refractory Tourette syndrome in which severe tics persist even after adulthood are conducted with multidisciplinary professionals including neurosurgeons who perform deep brain stimulation.

We are also continuing to analyze the findings of our survey of tics and related behaviors in community preschoolers.

Neuropsychological research

Neuropsychological data on ASD, ADHD and Tourette syndrome are being collected. Analysis of the relations among neuropsychological findings and the clinical evaluation are being conducted.

Neuroimaging

Studies include structural MRI, Near-Infrared Spectroscopy (NIRS) and functional MRI with exploring the pathogenesis of developmental disorders such as ASD and ADHD.

References

1. Kuroda M, Kawakubo Y, Kamio Y, Yamasue H, Kono T, Nonaka M, Matsuda N, Kataoka M, Wakabayashi A, Yokoyama K, Kano Y, Kuwabara H. Preliminary efficacy of cognitive-behavioral therapy on emotion regulation in adults with autism spectrum disorder, A pilot randomized waitlist-controlled study. *PLoS One*, 17(11): e0277398, 2022.
2. Tanaka M, Kanehara A, Morishima R, Yousuke Kumakura Y, Okouchi N, Nakajima N, Hamada J, Ogawa T, Tamune H, Nakahara M, Jinde S, Kano Y, Kasai K. Educational challenges for 22q11.2 deletion syndrome in Japan: Findings from a mixed methods survey. *J Appl Res Intellect Disabil*, 36(3): 558-570, 2023.
3. Ishikawa N, Ishizuka Y, Kano Y, Iida J, Yamamoto J. Exploring factors of successful transition to elementary school among children with autism spectrum disorder in Japan: a focus group study, *International Journal of Developmental Disabilities*, 1-10, 2022.
4. Nogami W, Nakagawa A, Katayama N, Kudo Y, Amano M, Ihara S, Kurata T, Kobayashi Y, Sasaki Y, Ishikawa N, Sato T, Mimura M. Effect of Personality Traits on Sustained Remission Among Patients with Major Depression: A 12-Month Prospective Study. *Neuropsychiatr Dis Treat*, 18: 2771-2781, 2022.
5. Suzuki A, Yamaguchi R, Kim L, Kawahara T, Ishii-Takahashi A. Effectiveness of mock scanners and preparation programs for successful magnetic resonance imaging: a systematic review and meta-analysis. *Pediatr Radiol*, 53(1): 142-158, 2023.

Department of Pain and Palliative Medicine

Associate Professor

Masahiko Sumitani, M.D., Ph.D.

Lecturer

Hiroaki Abe, M.D, Ph.D.

Homepage <https://www.h.u-tokyo.ac.jp/english/centers-services/central-clinical-facilities/department-of-palliative-medicine/index.html>

History and outline of organization

About a half of the cancer patients die by cancer though of the recent innovations of anti-cancer treatments. It mainly depends on the efficacy of the first-line strategies whether cancer is curable or not. Almost all the cancer patients whose initial treatment was unsuccessful die after the distressing struggle against their disease within several years. It is clear for such patients that both sufficient anti-cancer treatments and appropriate approaches to improve their quality of life (QOL) are simultaneously indispensable.

However in our nation, most attention has been entirely paid to the improvement of cure rate and survival time of cancer patients. On the other hand, we have to consider that their QOL is scarcely concentrated until quite recently.

Palliative care means the combination of active therapeutic approach and total human care for the patients no matter which their cancer does or does not respond to anti-cancer treatments. Pain relief, other symptom management, psychological, social and spiritual cares are as a top priority for these patients. It is also emphasized that palliative care is necessary to be applied in the cancer treatment even for patients in early stage of their diseases as well as the progressive or terminal phase of their clinical courses.

In Department of Pain and Palliative Medicine of The University of Tokyo Hospital, we pain and palliative

care team takes a leading role not only to control physical symptoms of cancer patients but also to care for the mental and social support at the same time, and to improve the overall QOL of patients. Moreover, we also promote the education, research and innovation of pain and palliative medicine of our hospital and university.

Palliative care is described clearly in the law "Cancer Control Act" approved by the National Diet on June 2006 that "The medical treatment to aim at relieving many kinds of pain and problems of cancer patients is applicable from the early course of the illness".

Consultation

In The University of Tokyo Hospital, we pain and palliative care team are composed of many kinds of specialists containing three full-time staff doctors, two full-time doctors, and two certificated cancer and hospice care nurses who take an initiative in this multidisciplinary team. We visit to bedsides, consultation rooms and everywhere in the hospital, and offer palliative care to cancer patients who have received cancer care in cooperation with patients' attending doctors, ward staff, therapists of rehabilitation, social workers and every kind of professionals.

The annual number of consultation by our pain and palliative care team is getting increased. In 2019, the numbers achieved to more than total 1000 cases per year and further increased. To date we have become to

collaborate with almost all departments treating cancer in our hospital. These results indicate that the hospital understands the significance of palliative care well and relies on our team.

Education

In the Department of Pain and Palliative Medicine, junior residents of the first and second year can learn the basic knowledge and practice of palliative care by selecting an optional subject for one, two, four or eight months. And then they can participate in the pain and palliative care team and attend the daily team-conference on weekdays.

1) Palliative care training program

The training course (selection) for two months (or * for one month)

- Program to acquire basic knowledge and practice of palliative care for targeting all junior residents. * Only in "Comprehensive Internal Medicine" selection.

The training course (selection) for four or eight months

- Program to acquire basic knowledge, practice, and skills of communication for doctors who need to be clinical oncologists or pain and palliative care specialists.

2) Curriculum

Contents of training

- All junior residents are assigned to the pain and palliative care team. They chiefly participate in palliative care practice as a member of the team.
- In the course for four and eight months, they learn to make palliative care plans for inpatients, discuss palliative care of the cases with patients' attending doctors, ward staff, and execute these palliative care plans.

Goal to attain

- Palliative care for inpatients (around 40 cases a day): They acquire the outline of control of physical and psychiatric symptoms of the patients with common diseases in our country such as digestive cancers. They also learn the outline of spiritual and family care.
- Cancer registry: In The University of Tokyo

Hospital, it is not unusual that the patient whom the pain and palliative care team treats is often in an end stage, and his or her condition changes physically and mentally day by day. Residents should input the clinical data about palliative care of such patients concisely to the database. They acquire the outline of data management of the palliative care connected directly to a clinical research.

- Communicative competence: The clinician often has to break "Bad news" to his patients time after time along the course of their illness. It is very difficult for the clinician to provide the appropriate information about diagnoses, recurrence, progression and prognosis of illness to his patients.

The oncologist has to deal with patients' strong grief and feeling of loss when their illness is obviously progressive as well as has to manage both their accepting realities and expecting hopes. We practice according to the guidelines of communication that is recommended by the Japanese Psycho-Oncology Society.

Educational

- In the intensive course for the first-year residents, we prepare lectures about:
 - # pain management
 - # diagnoses and management of delirium
 - # Introduction of guidelines in the field of palliative medicine and their use
 - # Basic medication for palliative care
 - # Spirituality and whole person care for Japanese patients facing death

Daily and weekly schedule

- Conference: Monday-Friday (every weekday); 9:00-10:30am
- Consultation: Monday-Friday (every weekday); from the end of morning conference, up to the completion of all the requested consulting of the day.
- The cancer registry: They input data in the ward round with the HIS (Hospital information system) terminal on each floor.

The instruction system

- Inpatient care: Residents participate in the consultation team (pain and palliative care team) that contains medical instructors. We pain and palliative care team take charge of about 40-50 inpatients usually.

- Multidisciplinary conference: Psychiatrists, pain clinicians/Anesthesiologists, orthopaedicians, pharmacists, medical social workers and others participate in the daily or weekly conference besides the regular member of the pain and palliative care team. Residents can discuss actively the multidisciplinary palliative care plans which our team should carry out. Participants from each occupation also guide the care plans from their viewpoints of experts.

Research

The clinical information accumulated from the palliative care consultation is input to the concise database simultaneously and utilized for various kinds of clinical researches to submit to the international medical journal such as "International Journal of Radiation Oncology Biology Physics", "Journal of Pain and Symptom Management" and so on.

To date, we the Department of Palliative Medicine have contributed to the progress of following fields of investigations. Please refer to our homepage for results in details and acquisition of the research fund.

- 1) Evaluation and quality assurance of special pain and palliative care team
- 2) Cancer Survivorship
- 3) Investigating cognitive dysfunction induced by pain
- 4) Cancer treatments-induced neurological side effect
- 5) Synergistic influence between sleep disorder and pain
- 6) Assessment of neuropathic pain
- 7) Relationships among our university hospital and local hospitals and clinics
- 8) Palliative care supporting metastatic breast cancer patient
- 9) In palliative medicine field, clinical researches and questionnaires

Publications

1. Abe H, Sumitani M, Matsui H, Inoue R, Konishi M, Fushimi K, Uchida K, Yasunaga H. Gabapentinoid use is associated with reduced incidence of hyperactive delirium in elderly cancer patients undergoing chemotherapy: a nationwide retrospective cohort study in Japan. *Anesthesia & Analgesia* 2022; 135: 362-9
2. Mietani K, Hasegawa-Moriyama M, Yagi K, Inoue R, Ogata T, Kurano M, Shimojo N, Seto Y, Sumitani M, Uchida K. Preoperative detection of serum phosphorylated neurofilament heavy chain subunit predicts postoperative delirium: A prospective observational study. *J Gerontol Geriatr* 2022; 70: 169-77
3. Ando M, Sumitani M, Fuyuki M, Abe H, Shinoda Y, Matsubayashi Y, Oshima Y, Inoue R, Tsuchida R, Uchida K. Imaging features inferring symptom onset due to spinal metastasis progression: A preliminary study. *Ann Palliat Med* 2022; 11: 2247-56
4. Abe H, Sumitani M, Matsui H, Inoue R, Fushimi K, Uchida K, Yasunaga H. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: a nationwide retrospective cohort study in Japan. *Pharmacotherapy: Journal of Human Pharmacology and Drug Therapy* 2022; 42: 241-9
5. Inoue R, Sumitani M, Otake Y, Ohya R, Tsuchida R, Konishi M, Abe H, Uchida K. Augmented reality-supported exercise therapy system improves physical frailty and musculoskeletal pain: a preliminary feasibility study. *J Muscle Health* 2022; 4: 1013
6. Kurisu K, Inada S, Maeda I, Ogawa A, Iwase S, Akechi T, Morita T, Imai K, Nakahara R, Kaneishi K, Nakajima N, Sumitani M, Yoshiuchi K. Decision tree prediction model for outcome of pharmacological treatment of delirium in advanced cancer patients: Pharmacological adult study of safety and efficacy in real world (Phase-R). *Palliat Support Care* 2022; 20: 153-8
7. Saita K, Sumitani M, Nishizawa D, Tamura T, Ikeda K, Wakai K, Sudo Y, Abe H, Otonari J, Takeuchi K, Hishida A, Tanaka K, Shimanoe C, Takezaki T, Ibusuki R, Oze I, Ito H, Ozaki E, Matsui D, Nakamura Y, Kusakabe M, Suzuki S, Nakagawa-Senda H, Arisawa K, Katsuura-Kamano S, Kuriki K, Kita Y. Genetic polymorphism of pleiotrophin is associated with pain experience in Japanese adults: case-control study. *Medicine (Baltimore)* 2022; 101: e30580

8. Mietani K, Hasegawa-Moriyama M, Inoue R, Ogata T, Shimojo N, Kurano M, Yatomi Y, Uchida K, Sumitani M. Serum levels of apolipoprotein A-1 and E are associated with postoperative delirium: A post-hoc analysis. *Medicine (Baltimore)* 2022; 101: e29906
9. Hao X, Zhou Y, Ling Y, Feng Z, Miyoshi H, Sumitani M, Chan KY, Park HJ, Rao Y. Effects of high-dose opioid analgesia on survival, pain relief, quality of life and adverse drug reactions in cancer and neuropathic pain patients: a retrospective cohort study in real-world clinical practice. *Ann Transl Med* 2022; 10: 998
10. Edamura T, Sumitani M, Hayakawa K, Inoue R, Abe H, Tsuchida R, Chikuda H, Ogata T, Kurano M, Aoki J, Yatomi Y, Uchida K. Different profiles of the triad of lysophosphatidylcholine, lysophosphatidic acid and autotaxin in patients with neuropathic pain diseases: a preliminary observational study. *Pain and Therapy* 2022; 11: 1439-49
11. Mietani M, Hasegawa-Moriyama M, Yagi K, Inoue R, Ogata T, Shimojo N, Seto Y, Uchida K, Sumitani M. Elevation of serum plasminogen activator inhibitor-1 predicts postoperative delirium independent of neural damage: A sequential analysis. *Scientific Reports* 2022; 12: 17091
12. Abe H, Inoue R, Tsuchida R, Ando M, Saita K, Konishi M, Edamura T, Ogawa A, Matsuoka Y, Sumitani M. Efficacy of treatments for pain and numbness in cancer survivors: a systematic review and meta-analysis. *Ann Palliat Med* 2022; 11: 1439-49

(And, 9 Japanese articles)

University Hospital

Central Clinical Services

Department of Pharmacy

Professor

Tappei Takada, Ph.D.

Lecturer

Yoshihide Yamanashi, Ph.D., Masashi Honma, Ph.D.

Research Associate

Takahiro Amemiya, Ph.D., Yuki Ikebuchi, Ph.D.,
Hiroshi Miyata, Ph.D., Atsushi Tokuda, M.Sc.,
Yusuke Nagae, M.Sc.

Homepage <http://plaza.umin.ac.jp/~todaiyak/>

Introduction and Organization

We have 8 faculty members, 84 pharmacy staffs, and 8 graduate students and 9 undergraduate students from the faculty of pharmaceutical sciences (as of March 1st, 2023).

Clinical activities

Department of Pharmacy consists of the following six sections:

1) Drug information section

This section offers drug information for questions from medical persons, executes and supports the medicine management to inpatients. In addition, the section prepares materials for pharmaceutical affair committee, where each medicine is discussed whether it should be adopted or deleted. Preparation of several periodicals regarding drug information for clinicians is also included.

2) The dispensing section

After inspecting all prescriptions for contra-indications or improper use, medications are dispensed. Drug information is given to outpatients from this section, using a private room if necessary. The computerized order system is linked with automatic packaging machines for oral medicines, automatic dispensing system and barcode label printer for injection drugs.

3) Pharmaceutical section

This section sterilizes formulations of a pharmaceutical such as injection medicines, instillation medicines and decontaminating chemicals. They prepare capsule medicines, ointment medicines, suppositories, central vein nutrition (IVH) for inpatients and in-home care patients. After strict inspection of prescriptions, they also dispense anti-malignant tumor medicine (database is constructed based on the submitted protocols and patients' information) for all of the administration in the hospital. In order to support advanced medical care, they develop and check formulations (characterization of the uniformity, stability and so on) of the medicine that is quite necessary for certain patients, but is not marketed.

4) Drug matters and drug management section

Drug matter section manages the adoption of medical supplies (in-hospital and out-hospital), periodically reconsiders the adopted medicines, and also manages the accountings of all the medicines and other materials used in our department. This section also takes statistics of every information of drug affairs. Drug management section takes care of supplying and safe-keeping of all the in-hospital medicines (2,724 items), out-patient medicines, anesthetics, muscle relaxation drugs, psychotropic drugs, poison

medicines.

5) Narcotic section

Under the supervision of authorized manager for narcotics (the director of the department of pharmacy), narcotics are properly managed, recorded, reported, inspected and directed. Narcotics are properly arranged and managed at the dispensing section and each medical care section.

6) Ward section

They contribute to the team medical care by providing specialized drug information and sharing them with all the staffs involved in the treatment as follows;

- ① Supporting the proper use of medication by pharmacists stationed at ICU sections.
- ② Arrangement and mixing of injections for patients at the staff station of Hematology and Oncology.
- ③ Investigation of carrying medicines and the adverse effect histories, allergy histories *etc.* at the time of hospitalization. Participation for conferences. Procurement and appraisal of patients' basic information about the disease, compilation of the medicine history. Monitoring of medication guidance and the adverse effect for patients, and compilation of guidance record. Offering the doctor with drug information, prescription design support and detailed contents of medication guidance to each patient.
- ④ Investigation and management of ward stock medicine.
- ⑤ Nutrient support of the patients as a member of NST.
- ⑥ Management of proper use of narcotics as a member of palliative care team.
- ⑦ Management of proper use of antibiotics, rounds of a hospital ward, and training of the staffs as members of ICT and AST.

Statistical Data (fiscal year 2022)

Number of items on in-hospital formulary: 2,724

Number of prescriptions (ps.) filled or preparation (pp.) (annual)

out-patients	:	333,593 ps.
(outside	:	303,334 ps.)
(inside	:	30,259 ps.)

out-patient chemotherapy: 19,940 ps.

in-patients : 233,796 ps.

injection drugs : 194,504 ps.

IVH : 4,529 pp.

chemotherapy : 12,053 pp.

TDM consultations (annual) : 22,000 pp.

Numbers of hospital pharmaceutical cares (annual):
24,027 pp.

Education

The department of pharmacy takes various responsibilities of education with regard to clinical pharmacy, pharmacology, and pharmacokinetics for students and graduate students in the faculty of medicine, in the faculty of pharmacy, and in the school of integrated health sciences. We also have our own half a year post-graduate training course optimized for new pharmacists.

For students in the faculty of medicine, we are in charge of "Pathogenetic and Pathology" as an optional course lecture. We are providing a 3-days practice course as a part of compulsory clinical practice for the M3 or M4 students and teach clinical pharmaceutics and practical knowledge of prescription and risk management to them. For the students in the health sciences and nursing, we are in charge of clinical pharmacokinetics lectures as a part of a compulsory subject, "Pharmacology and Toxicology".

For students in the faculty of pharmacy, we are in charge of lectures for the undergraduate students: "Clinical Pharmacy" (compulsory subject). They are educated for the clinical pharmacology and pharmacokinetics. For the graduate students, we are in charge of "Special Lecture Basic Pharmaceutical Science IV", "Special Lecture Clinical Science", "Advanced Course of Medical Pharmacy" as a cooperator of the Clinical Pharmacokinetics. Recent trends of the medical pharmacy as well as the practical developments and future visions of the department of pharmacy are presented in this lecture. In addition to them, we accept undergraduate and graduate students from the faculty of pharmaceutical sciences and faculty of medicine. They are doing various research activities.

Six year course education system has been launched in the field of pharmaceutical sciences since 2006. In

this system, the clinical training by pharmacists at the hospital is one of the most important curriculums. In 2021, we accepted clinical training students from The University of Tokyo, Tokyo University of Pharmacy and Life Sciences, Showa Pharmaceutical University, Hoshi University, and Musashino University, Tokyo University of Science, Keio University and educated them for 2.5 months. In addition, we have had an original one-year post-graduate training course for pharmacists since long time before starting the 6-year course education system. They learned various practical knowledge and techniques necessary for hospital pharmacists. Such education style is still continuing by shortening the period to half a year. In 2022, 10 pharmacists finished this course.

In addition, we are promoting life-long education of pharmacists in the local area by holding regular technical workshops and seminars.

Research

It is evident that the molecular function of particular element cannot always be assigned to only one function at whole body level, because one to one simple correspondence is not common in our body. It is also true that the understanding of the relationship between drug and its ultimate target is not sufficient to predict the pharmacological/toxicological effects. We need to understand not only the detailed molecular machinery of drug target, but also its environment surrounding the target (ex. other associated proteins, signaling molecules, etc.), where and when it works, and finally how it behaves as functional unit in our body. This is a basic idea trying to understand “living body” as “system”. By further promoting this idea to “system pharmacology”, we will be able to identify a molecular target which is related to the pharmacological/toxicological output in clinical situation or even at early drug development stage. Based on such concept, following projects are now ongoing:

- (1) Chang SJ, Toyoda Y, Kawamura Y, Nakamura T, Nakatochi M, Nakayama A, Liao WT, Shimizu S, Takada T, Takeuchi K, Wakai K, Shi Y, Shinomiya N, Chen CJ, Li C, Okada Y, Ichida K, Matsuo H, for Japan Gout Genomics C. A meta-analysis of genome-wide association studies using Japanese and Taiwanese has revealed novel loci associated with gout susceptibility. *Hum Cell*. 2022;35:767-70.
- (2) Fujii E, Takata T, Yamano H, Honma M, Shimokawa M, Sasaki H, Shikano M. Study on horizon scanning by citation network analysis and text mining: A focus on drug development related to T cell immune response. *Ther Innov Regul Sci*. 2022;56:230-43.
- (3) Kariya Y, Honma M, Tokuda K, Konagaya A, Suzuki H. Utility of constraints reflecting system stability on analyses for biological models. *PLoS Comput Biol*. 2022;18:e1010441.
- (4) Miyata H, Toyoda Y, Takada T, Hiragi T, Kubota Y, Shigesawa R, Koyama R, Ikegaya Y, Suzuki H. Identification of an exporter that regulates vitamin C supply from blood to the brain. *iScience*. 2022;25:103642.
- (5) Nakayama A, Kawamura Y, Toyoda Y, Shimizu S, Kawaguchi M, Aoki Y, Takeuchi K, Okada R, Kubo Y, Imakiire T, Iwasawa S, Nakashima H, Tsunoda M, Ito K, Kumagai H, Takada T, Ichida K, Shinomiya N, Matsuo H. Genetic epidemiological analysis of hypouricaemia from 4993 Japanese on non-functional variants of URAT1/SLC22A12 gene. *Rheumatology (Oxford)*. 2022;61:1276-81.
- (6) Takata T, Sasaki H, Yamano H, Honma M, Shikano M. Study on horizon scanning with a focus on the development of AI-based medical products: Citation network analysis. *Ther Innov Regul Sci*. 2022;56:263-75.
- (7) Tomabeche R, Kishimoto H, Sato T, Saito N, Kiyomiya K, Takada T, Higuchi K, Shirasaka Y, Inoue K. SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1. *PNAS Nexus*. 2022;1:pgac063.
- (8) Toyoda Y, Cho SK, Tasic V, Pavelcova K, Bohata J, Suzuki H, David VA, Yoon J, Pallaiova A, Saligova J, Nousome D, Cachau R, Winkler CA, Takada T, Stiburkova B. Identification of a dysfunctional exon-skipping splice variant in GLUT9/SLC2A9 causal for renal hypouricemia type 2. *Front Genet*. 2022;13:1048330.
- (9) Toyoda Y, Kawamura Y, Nakayama A, Morimoto K, Shimizu S, Tanahashi Y, Tamura T, Kondo T, Kato Y, Ichida K, Suzuki H, Shinomiya N, Kobayashi Y,

Takada T, Matsuo H. OAT10/SLC22A13 acts as a renal urate re-absorber: Clinico-genetic and functional analyses with pharmacological impacts.

Front Pharmacol. 2022;13:842717.

- (10) Toyoda Y, Takada T, Saito H, Hirata H, Ota-Kontani A, Tsuchiya Y, Suzuki H. Identification of inhibitory activities of dietary flavonoids against URAT1, a renal urate re-absorber: In vitro screening and fractional approach focused on Rooibos leaves. **Nutrients.** 2022;14:575.
- (11) Yamanashi Y, Takada T, Tanaka Y, Ogata Y, Toyoda Y, Ito SM, Kitani M, Oshida N, Okada K, Shoda J, Suzuki H. Hepatic Niemann-Pick C1-like 1 exacerbates non-alcoholic fatty liver disease by re-absorbing specific biliary oxysterols. **Biomed Pharmacother.** 2022;156:113877.

Department of Clinical Laboratory

Professor

Yutaka Yatomi, M.D.

Associate Professor

Makoto Kurano, M.D.

Lecturer

Masao Daimon, M.D., Yuichiro Shirota, M.D.

Kosuke Watanabe, M.D., Masaya Sato, M.D.

Associate

Tomoko Nakao, M.D., Masako Nishikawa, M.D,

Hideaki Isago, M.D.

Chief Technologist

Yoshikazu Ono, M.T.

Homepage <http://lab-tky.umin.jp/>

Introduction and Organization

Department of Clinical Laboratory consists of the following sections, and the 3rd - generation Laboratory Automation System is in full operation, and ordering of laboratory tests, the flow of samples, operation of laboratory analyzers, quality control of analysis, and data reporting are all controlled by the Laboratory Automation computer system. This system has greatly improved the quality, safety, and efficiency of the laboratory and contributed to both patients and doctors by providing rapid and high-quality laboratory testing.

The 1st Section

This section deals mainly with the maintenance of laboratory system, blood and urine sampling, and urinalysis. In 2022, 223,213 outpatient blood sampling were performed in this section. Furthermore, 271,757 urine samples were examined.

The 2nd Section

This section deals with clinical biochemistry and immuno-serology tests. In 2022, 5,550,003 serum

enzyme tests (such as AST and ALT), and 566,479 immunological tests were performed.

The 3rd Section

This section deals with laboratory hematology and diabetes-related tests, and gene analysis tests. In 2022, 1,180,677 samples were examined for complete blood cell counts, cell surface marker analysis, prothrombin time, fibrinogen, glucose, and HbA1C tests.

The 4th Section

This section deals with physiological tests, including circulatory, pulmonary, and neuromuscular function ones. In 2022, 44,781 ECG, 19,252 pulmonary function tests, and 12,064 EEG were performed.

The 5th Section

This section deals with ultrasonography. In 2022, 7,163 echocardiography tests, 14,148 abdominal echography tests, and 13,362 other ultrasonography tests were performed.

Teaching activities

Lectures are given to the fourth and sixth grade medical students on clinical laboratory medicine including hematology, chemistry, endocrinology, immunology, bacteriology, cardiology, and pulmonary function. The reversed CPC program is presented to the sixth grade students. Clinical clerkship is provided for the sixth year medical students, in small groups of 6-7 students for one-week duration. Elective clerkship is provided for two sixth year medical students, who selected to join the training on clinical laboratory medicine, for four-week duration. In this course, students learn clinical and practical knowledge and techniques on various laboratory tests. The second, third, and fourth grade medical students can join research activities in our department (Free Quarter course).

Students from professional schools also study laboratory medicine under the guidance of members in Clinical Laboratory Center. As educational facilities for certified clinical laboratory physicians, we have been training up many physicians.

Research activities

The main goal of our research projects is the development of new and useful laboratory tests, and elucidation of pathophysiology of diseases through laboratory tests. The present main areas included are: i) (Patho)physiological roles of lysophospholipid mediators and its application into laboratory medicine, ii) introduction of mass spectrometry into clinical laboratory practice, iii) cancer genomic medicine using next generation sequencing, iv) echocardiographic studies of the pathophysiology of valvular heart disease and the hemodynamics, v) neuroscience research using magnetoencephalography and non-invasive brain stimulation, and vi) promotion of medical-engineering cooperation.

References

- Original article:**
1. Addetia, K., Miyoshi, T., Amuthan, V., Citro, R., Daimon, M., Fajardo, P.G., Kasliwal, R.R., Kirkpatrick, J.N., Monaghan, M.J., Muraru, D., Ogunyankin, K.O., Park, S.W., Ronderos, R.E., Sadeghpour, A., Scalia, G.M., Takeuchi, M., Tsang, W., Tucay, E.S., Tude Rodrigues, A.C., Zhang, Y., Hitschrich, N., Blankenhagen, M., Degel, M., Schreckenber, M., Mor-Avi, V., Asch, F.M., and Lang, R.M. Normal values of left ventricular size and function on 3D echocardiography: Results of the World Alliance of Societies of Echocardiography Study. *J. Am. Soc. Echocardiogr.* 35: 449-459, 2022.
 2. Bujo, S., Amiya, E., Hashimoto Maeda, M., Ishida, J., Hatano, M., Ishizuka, M., Uehara, M., Oshima, T., Kojima, T., Nakanishi, K., Daimon, M., Shimizu, J., Toda, T., and Komuro, I. The effect of immunosuppressive therapy on cardiac involvements in anti-mitochondrial antibody-positive myositis. *ESC Heart Fail.* 9: 4112-4119, 2022.
 3. Chaichum, S., Chiang, S.J., Daimon, M., Chang, S.C., Chan, C.L., Hsu, C.Y., Chen, H.H., and Tseng, C.L. Segmental tissue speckle tracking predicts the stenosis severity in patients with coronary artery disease. *Front. Cardiovasc. Med.* 8: 832096, 2022.
 4. Edamura, T., Sumitani, M., Hayakawa, K., Inoue, R., Abe, H., Tsuchida, R., Chikuda, H., Ogata, T., Kurano, M., Aoki, J., Yatomi, Y., and Uchida, K. Different Profiles of the Triad of Lysophosphatidylcholine, Lysophosphatidic Acid, and Autotaxin in Patients with Neuropathic Pain Diseases: a Preliminary Observational Study. *Pain Ther.* 11: 1439-1449, 2022.
 5. Fujikura, Y., Kimura, K., Yamanouchi, K., Sugihara, H., Hatakeyama, M., Zhuang, H., Daimon, M., Morita, H., Komuro, I., and Oishi, K. A medium-chain triglyceride containing ketogenic diet exacerbates cardiomyopathy in a CRISPR/Cas9 gene-edited rat model with Duchenne muscular dystrophy. *Sci. Rep.* 12: 11580, 2022.
 6. Henry, M.P., Cotella, J., Mor-Avi, V., Addetia, K., Miyoshi, T., Schreckenber, M., Blankenhagen, M., Hitschrich, N., Amuthan, V., Citro, R., Daimon, M., Gutierrez-Fajardo P., Kasliwal, R., Kirkpatrick, J.N., Monaghan, M.J., Muraru, D., Ogunyankin, K.O., Park, S.W., Tude Rodrigues, A.C., Ronderos, R., Sadeghpour, A., Scalia, G., Takeuchi, M., Tsang, W., Tucay, E.S., Zhang, M., Lang, R.M., and Asch, F.M. 3D transthoracic static and dynamic normative values of the mitral valve apparatus: Results from the multicenter World Alliance of Societies of

- Echocardiography Study. *J. Am. Soc. Echocardiogr.* 35: 738-751, 2022.
7. Inoue, S., Nakao, T., Kinoshita, O., Suzuki, H., Yatomi, Y., and Daimon, M. Preoperative diagnosis of acute aortic regurgitation caused by a ruptured anomalous cord in a patient with a bicuspid aortic valve using transesophageal echocardiography. *J. Med. Ultrason.(2001)* 49: 493-494, 2022.
 8. Kaiume, M., Kurokawa, M., Maeda, E., Daimon, M., and Abe, O. Detection of Left Ventricular Dysfunction on Axial Non-Contrast Chest CT. *Eur. J. Radiol.* 150: 110274, 2022.
 9. Kashiwakura, Y., Baatartsogt, N., Yamazaki, S., Nagao, A., Amano, K., Suzuki, N., Matsushita, T., Sawada, A., Higasa, S., Yamasaki, N., Fujii, T., Ogura, T., Takedani, H., Taki, M., Matsumoto, T., Yamanouchi, J., Sakai, M., Nishikawa, M., Yatomi, Y., Yada, K., Nogami, K., Watano, R., Hiramoto, T., Hayakawa, M., Kamoshita, N., Kume, A., Mizukami, H., Ishikawa, S., Sakata, Y., Ohmori, T. The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs. *Mol Ther Methods Clin Dev.* 27: 404-414, 2022.
 10. Kawata, T., Daimon, M., Nakanishi, K., Kimura, K., Sawada, N., Nakao, T., Hirokawa, M., Ishiwata, J., Takeda, N., Yatomi, Y., and Komuro I. Factors influencing inferior vena cava diameter and its respiratory variation: Simultaneous comparison with hemodynamic data. *J. Cardiol.* 79: 642-647, 2022.
 11. Kokubo, T., Kodera, S., Sawano, S., Katsushika, S., Nakamoto, M., Takeuchi, H., Kimura, N., Shinohara, H., Matsuoka, R., Nakanishi, K., Nakao, T., Higashikuni, Y., Takeda, N., Fujiu, K., Daimon, M., Akazawa, H., Morita, H., Matsuyama, Y., and Komuro, I. Automatic Detection of Left Ventricular Dilatation and Hypertrophy from Electrocardiograms using Deep Learning. *Int Heart J.* 63: 939-947, 2022.
 12. Kurano, M., Jubishi, D., Okamoto, K., Hashimoto, H., Sakai, E., Morita, Y., Saigusa, D., Kano, K., Aoki, J., Harada, S., Okugawa, S., Doi, K., Moriya, K., and Yatomi, Y. Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries. *J. Biomed Sci.* 29: 94, 2022.
 13. Kurano, M., Morita, Y., Nakano, Y., Yokoyama, R., Shimura, T., Qian, C., Xia, F., He, F., Zheng, L., Ohmiya, H., Kishi, Y., Okada, J., Yoshikawa, N., Nakajima, K., Nagura, Y., Okazaki, H., Jubishi, D., Moriya, K., Seto, Y., Yasui, F., Kohara, M., Wakui, M., Kawamura, T., Kodama, T., and Yatomi, Y. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers. *Int. Immunopharmacol.* 103: 108491, 2022.
 14. Kurano, M., Ohmiya, H., Kishi, Y., Okada, J., Nakano, Y., Yokoyama, R., Qian, C., Xia, F., He, F., Zheng, L., Yu, Y., Jubishi, D., Okamoto, K., Moriya, K., Kodama, T., and Yatomi, Y. Measurement of SARS-CoV-2 Antibody Titers Improves the Prediction Accuracy of COVID-19 Maximum Severity by Machine Learning in Non-Vaccinated Patients. *Front. Immunol.* 13: 811952, 2022.
 15. Kurano, M., Okamoto, K., Jubishi, D., Hashimoto, H., Sakai, E., Saigusa, D., Kano, K., Aoki, J., Harada, S., Okugawa, S., Doi, K., Moriya, K., and Yatomi Y. Dynamic modulations of sphingolipids and glycerophospholipids in COVID-19. *Clin. Transl. Med.* 12: e1069, 2022.
 16. Kurano, M., Saito, Y., Uranbileg, B., Saigusa, D., Kano, K., Aoki, J., and Yatomi, Y. Modulations of bioactive lipids and their receptors in postmortem Alzheimer's disease brains. *Front. Aging. Neurosci.* 14: 1066578, 2022.
 17. Kurano, M., Sakai, E., and Yatomi, Y. Understanding modulations of lipid mediators in cancer using a murine model of carcinomatous peritonitis. *Cancer Med.* 11: 3491-3507, 2022.
 18. Kurano, M., Tsukamoto, K., Sakai, E., Hara, M., and Yatomi Y. Isoform-Dependent Effects of Apolipoprotein E on Sphingolipid Metabolism in Neural Cells. *J. Alzheimers Dis.* 85: 1529-1544, 2022.
 19. Kurano, M., Tsukamoto, K., Sakai, E., and Yatomi, Y. Differences in the Distribution of Ceramides and Sphingosine among Lipoprotein and Lipoprotein-Depleted Fractions in Patients with Type 2 Diabetes Mellitus. *J. Atheroscler Thromb.* 29: 1727-1758, 2022.

20. Liu, Y., Yamagishi, R., Honjo, M., Kurano, M., Yatomi, Y., Igarashi, K., and Aihara, M. Role of Autotaxin in High Glucose-Induced Human ARPE-19 Cells. *Int. J. Mol. Sci.* 23: 9181, 2022.
21. Liu, M., Honjo, M., Yamagishi, R., Igarashi, N., Nakamura, N., Kurano, M., Yatomi, Y., Igarashi, K., and Aihara, M. Fibrotic Response of Human Trabecular Meshwork Cells to Transforming Growth Factor-Beta 3 and Autotaxin in Aqueous Humor. *Biomolecules.* 12: 1231, 2022.
22. Mietani, K., Hasegawa-Moriyama, M., Inoue, R., Ogata, T., Shimojo, N., Kurano, M., Yatomi, Y., Uchida, K., and Sumitani, M. Serum levels of apolipoprotein A-I and E are associated with postoperative delirium: A post hoc analysis. *Medicine (Baltimore)* 101: e29906, 2022.
23. Mitani, A., Horie, T., Yokoyama, R., Nakano, Y., Hamada, K., Inoue, Y., Saito, M., Ishii, T., Sunohara, M., Takahashi, R., Usui, T., Emoto, N., Nishimoto, N., Murano, Y., Okazaki, S., Tateishi, S., Iwasawa, K., Yao, A., Kurano, M., Yatomi, Y., and Yanagimoto, S. Interpretations of SARS-CoV-2 IgM and IgG antibody titers in the seroepidemiological study of asymptomatic healthy volunteers. *J. Infect. Chemother.* 28: 266-272, 2022.
24. Miyamoto, S., Yamazaki, T., Shimizu, K., Matsubara, T., Kage, H., Watanabe, K., Kobo, H., Matsuyama, Y., Rodin, G., and Yoshiuchi, K. Brief, manualised and semistructured individual psychotherapy programme for patients with advanced cancer in Japan: study protocol for Managing Cancer and Living Meaningfully (CALM) phase 2 trial. *BMJ Open.* 12: e056136, 2022.
25. Morita, Y., Kurano, M., Jubishi, D., Ikeda, M., Okamoto, K., Tanaka, M., Harada, S., Okugawa, S., Moriya, K., Yatomi, Y. Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries. *Int. J. Infect. Dis.* 117: 302-311, 2022.
26. Mukai, Y., Nakanishi, K., Daimon, M., Sawada, N., Hirose, K., Iwama, K., Yamamoto, Y., Yoshida, Y., Ishiwata, J., Koyama, K., Nakao, T., Morita, H., Di Tullio, M.R., Homma, S., and Komuro, I. Association of arterial properties with left ventricular morphology and function in the community. *J. Hypertens.* 40: 2423-2429, 2022.
27. Murakami, K., Tamada, T., Saigusa, D., Miyauchi, E., Nara, M., Ichinose, M., Kurano, M., Yatomi, Y., and Sugiura, H. Urine autotaxin levels reflect the disease activity of sarcoidosis. *Sci. Rep.* 12: 4372, 2022.
28. Nakanishi, K., Daimon, M., Yoshida, Y., Ishiwata, J., Sawada, N., Hirokawa, M., Kaneko, H., Nakao, T., Mizuno, Y., Morita, H., Di Tullio, M.R., Homma, S., and Komuro, I. Blood pressure categorization and subclinical left ventricular dysfunction in antihypertensive medication-naïve subjects. *ESC Heart Fail.* 9: 1766-1774, 2022.
29. Naito, Y., Sunami, K., Kage, H., Komine, K., Amano, T., Imai, M., Koyama, T., Ennishi, D., Kanai, M., Kenmotsu, H., Maeda, T., Morita, S., Sakai, D., Watanabe, K., Shiota, H., Kinoshita, I., Yoshioka, M., Mamesaya, N., Ito, M., Kohsaka, S., Saigusa, Y., Yamamoto, K., Hirata, M., Tsuchihara, K., and Yoshino, T. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. *JAMA Netw Open.* 5: e2245081, 2022.
30. Sato, M., Kobayashi, T., Soroida, Y., Tanaka, T., Nakatsuka, T., Nakagawa, H., Nakamura, A., Kurihara, M., Endo, M., Hikita, H., Sato, M., Gotoh, H., Iwai, T., Tateishi, R., Koike, K., and Yatomi, Y. Development of novel deep multimodal representation learning-based model for the differentiation of liver tumors on B-mode ultrasound images. *J. Gastroenterol Hepatol.* 37: 678-684, Press Release.
31. Shimura, T., Kurano, M., Okamoto, K., Jubishi, D., Hashimoto, H., Kano, K., Igarashi, K., Shimamoto, S., Aoki, J., Moriya, K., and Yatomi, Y. Decrease in serum levels of autotaxin in COVID-19 patients. *Ann. Med.* 54: 3189-3200, 2022.
32. Tada, S., Yasukawa, K., Yatomi, Y., and Uchiki, T. A simple colorimetric assay to determine the concentration and proportion of human mercaptalbumin. *Pract. Lab. Med.* 31: e00281, 2022.
33. Takano, H., Yasunaga, M., Yamazaki, I., Nishikawa, M., Masamoto, Y., Shinozaki-Ushiku, A., Kawakami, M., Yatomi, Y., and Kurokawa, M.

- Degenerated mitochondria in leukemic blast appeared as granules on May-Grunwald-Giemsa staining. *Ann. Hematol.* 101: 1135-1136, 2022.
34. Tokuoka, S.M., Kita, Y., Sato, M., Shimizu, T., Yatomi, Y., and Oda, Y. Lipid Profiles of Human Serum Fractions Enhanced with CD9 Antibody-Immobilized Magnetic Beads. *Metabolites.* 12: 230, 2022.
 35. Tsuchida, Y., Shoda, H., Nakano, M., Ota, M., Okamura, T., Yamamoto, K., Kurano, M., Yatomi, Y., Fujio, K., and Sawada, T. Autotaxin is a potential link between genetic risk factors and immunological disturbances of plasmacytoid dendritic cells in systematic lupus erythematosus. *Lupus.* 31: 1578-1585, 2022.
 36. Uranbileg, B., Kurano, M., Kano, K., Sakai, E., Arita, J., Hasegawa, K., Nishikawa, T., Ishihara, S., Yamashita, H., Seto, Y., Ikeda, H., Aoki, J., and Yatomi Y. Sphingosine 1-phosphate lyase facilitates cancer progression through converting sphingolipids to glycerophospholipids. *Clin. Transl. Med.* 12: e1056, 2022.
 37. Yamamoto, Y., Kiriyaama, H., Daimon, M., Mori, Y., Yamauchi, H., Miura, M., and Komuro, I. Esophageal hematoma associated with trans-esophageal echocardiography during transcatheter aortic valve replacement in an elderly Japanese woman. *J. Med. Ultrason (2001).* 49: 481-483, 202.
 38. Yamamoto, Y., Daimon, M., Nakanishi, K., Nakao, T., Hirokawa, M., Ishiwata, J., Kiriyaama, H., Yoshida, Y., Iwama, K., Hirose, K., Mukai, Y., Takeda, N., Yatomi, Y., and Komuro, I. Incidence of atrial functional tricuspid regurgitation and its correlation with tricuspid valvular deformation in patients with persistent atrial fibrillation. *Front. Cardiovasc. Med.* 9: 1023732, 2022.
 39. rakawa, Y., Kurano, M., Ube, Y., Ono, Y., Kojima, K., Iwama, T., Kano, K., Hasegawa, S., Inoue, T., Shimada, T., Aoki, J., Yatomi, Y., Nangaku, M., and Inagi, R. Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease. *Kidney Int.* 101: 510-526, 2022.

Department of Pathology

Director

Tetsuo Ushiku, M.D., Ph.D. (Professor, Department of Pathology and Diagnostic Pathology)

Deputy Director

Masako Ikemura, M.D., Ph.D. (Lecturer, Office for “Promotion of CPC Education and General Integrative Medicine”)

Aya Shinozaki-Ushiku, M.D., Ph.D. (Associate Professor, Division of Integrative Genomics)

Project Professor

Takeshi Sasaki, M.D., Ph.D. (Next-Generation Pathology Information Networking)

Lecturer

Mariko Tanaka, M.D., Ph.D.

Hiroyuki Abe, M.D., Ph.D. (Department of Pathology and Diagnostic Pathology)

Research Associate

Ryohei Kuroda, M.D., Ph.D., Hirofumi Rokutan, M.D., Ph.D., Masaki Suzuki, Munetoshi Hinata, M.D., Ph.D., Noritaka Kudo (~ Jun 30)

Akiko Iwasaki, M.D., Ph.D., Mayu Hakozaki, M.D., Ph.D., Atsushi Kondo, M.D., Ph.D. (Department of Pathology and Diagnostic Pathology)

Yoichi Yasunaga, M.D., Ph.D. (~Jul 31 Department of Pathology and Diagnostic Pathology, Aug 1~)

Homepage <http://pathol.umin.ac.jp/>

Introduction and Organization

Department of Pathology and Diagnostic Pathology and Department of Pathology of the University of Tokyo Hospital have been organized to function as a unit to perform pathology practice (autopsy, surgical pathology, cytology, molecular testing, etc.) at the University of Tokyo Hospital as well as education and research on human pathology.

We set up Telepathology & Remote Diagnosis Promotion Center (TRDP Center) in 2013. We also started Outpatient Clinic of Pathology to provide detailed information and explanation about pathologic diagnosis to the patients with breast cancer.

In February 2018, the University of Tokyo

Hospital was selected as one of the core hospitals to promote cancer genomic medicine in Japan. From August 2018 to December 2019, the advanced medical care (category B) named ‘Trial of a multiplex genomic testing by "Todai OncoPanel" for Geneprofilng of malignant solid tumors’ was conducted which enrolled 200 patients. In addition, cancer panel testing covered by public health insurance (NCC OncoPanel and FoundationOne CDx) started in November 2019. We serve as members of expert panel to contribute to the promotion of genomic medicine.

Clinical activities

(diagnostic pathology and autopsy)

The annual statistics of the pathology practice in 2022

fiscal year consisted of 17,566 surgical cases, 15,273 cytology, 862 intraoperative histologic diagnosis, 393 intraoperative cytology, 33 autopsy cases (autopsy rate, 8.5%). The numbers of surgical and cytology cases returned to those before COVID-19 pandemic, while the numbers of intraoperative diagnosis and autopsy cases remained small due to the pandemic. Fortunately, there was no need to limit activity in our department.

The following surgical pathology conferences are regularly held; thoracic organs (Drs. Shinozaki-Ushiku, Suzuki and Hinata in charge), liver and pancreato-biliary tract (Drs. Tanaka and Rokutan), liver metastasis (Dr. Abe), and female genital tracts (Drs. Ikemura and Iwasaki), breast (Dr. Ikemura), hematology (Dr. Shinozaki-Ushiku), bone and soft tissues (Drs. Ushiku and Yasunaga), kidney (Drs. Abe and Hinata), and skin (Dr. Tanaka).

We provide FFPE specimens suitable for multiplex genomic testing. We also join clinico-pathologic and genomic conference which is held every week to present histology of the cases and join the discussion. Conventional companion diagnoses using immunohistochemistry and FISH/DISH are also provided.

Our mission is to provide the correct diagnosis as soon as possible. We also perform double check by reviewing the reports and slides of all cases to assure the quality of pathologic diagnosis. Whole slide imaging system have been installed, which enabled us to deposit and review all the biopsy specimens as digital information in daily practice.

We hold autopsy case conferences every Monday. Hospital clinico-pathologic conferences (CPC) are also held every month, in which two cases are discussed. The contents are provided as CPC Digest through the hospital internet.

Teaching activities

The lectures and exercise course of systemic pathology are for the 2nd grade medical students. Clinical Clerkship (CC) courses of autopsy and surgical pathology are for the 3rd and 4th grade medical students. We accepted several medical students in Elective Clerkship course as well as Free Quarter program.

We instructed all clinical residents (junior course)

to submit a report of CPC case as an obligatory requirement of their medical training. We have made out the digest version of CPC slides open in the hospital and started e-learning program for interns to solve the problems in CPC by themselves, thereby facilitating their understanding.

The Department of Pathology accepted four junior residents (total 8 months) in 2022 for their first and second-year program.

Research activities

We are working on the pathologic research projects of neoplastic diseases based on observation obtained from pathologic diagnosis as well as discussion with clinicians at surgical pathology conferences.

To develop AI-based pathology diagnosis system, some projects are currently in progress. Dr. Abe focuses on gastrointestinal tract biopsy diagnosis using machine learning. Dr. Hinata has developed an automatic system to detect immunotherapy-sensitive subtype in gastric cancer using histologic image-based deep learning.

The development of automatic grossing and sectioning system using AI-equipped robot is also in progress as collaborative research with engineering faculty-of the University of Tokyo (Prof. Mamoru Mitsuishi).

We continue the study to investigate the usefulness of post-mortem CT images for hospital autopsy in collaboration with the department of radiology. We obtain post-mortem images with a CT apparatus in the autopsy-assisting CT room and compare the results with those of autopsy to better understand the patients' pathophysiology.

In addition, a lot of collaborative research projects are also being conducted with various departments and laboratories.

References

1. Arai J, Niikura R, Hayakawa Y, Suzuki N, Hirata Y, Ushiku T, Fujishiro M. Clinicopathological Features of Gastric Cancer with Autoimmune Gastritis. *Biomedicines*. 2022;10(4):884.
2. Hakozaiki Y, Yamada Y, Kawai T, Nakamura M, Takeshima Y, Iwaki T, Teshima T, Kinoshita Y, Fujii Y, Akiyama Y, Sato Y, Yamada D, Suzuki

- M, Kashiwagi-Hakozaki M, Ushiku T, Kume H. Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer. *Sci Rep*. 2022;12(1):16202.
3. Hirano Y, Shinya Y, Aono T, Hasegawa H, Kawashima M, Shin M, Takami H, Takayanagi S, Umekawa M, Ikemura M, Ushiku T, Taoka K, Tanaka S, Saito N. The Role of Stereotactic Frame-Based Biopsy for Brainstem Tumors in the Era of Molecular-Based Diagnosis and Treatment Decisions. *Curr Oncol*. 2022;29(7):4558-4565.
 4. Ishizaka A, Taguchi A, Tsuruga T, Maruyama M, Kawata A, Miyamoto Y, Tanikawa M, Ikemura M, Sone K, Mori M, Koga K, Ushiku T, Oda K, Osuga Y. Endometrial cancer with concomitant endometriosis is highly associated with ovarian endometrioid carcinoma: a retrospective cohort study. *BMC Womens Health*. 2022;22(1):332.
 5. Kage H, Kohsaka S, Tatsuno K, Ueno T, Ikegami M, Zokumasu K, Shinozaki-Ushiku A, Nagai S, Aburatani H, Mano H, Oda K. Tumor mutational burden measurement using comprehensive genomic profiling assay. *Jpn J Clin Oncol*. 2022;52(8):917-921.
 6. Kakushima N, Hinata M, Ushiku T. White opaque substance in a non-neoplastic duodenal lesion. *Dig Endosc*. 2022;34(7):1495.
 7. Kato H, Koga M, Kinoshita Y, Hidaka N, Hoshino Y, Takashi Y, Arai M, Kobayashi H, Katsura M, Nakamoto Y, Makise N, Ushiku T, Hoshi K, Nangaku M, Makita N, Fukumoto S, Ito N. Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors. *J Endocr Soc*. 2022;7(2):bvac181.
 8. Kurokawa R, Kato S, Koyama H, Ishida M, Kurokawa M, Kuroda R, Ushiku T, Kume H, Abe O. Osteolytic or mixed bone metastasis is not uncommon in patients with high-risk prostate cancer. *European Journal of Radiology*. 2022;157:110595.
 9. Miyamoto K, Kobayashi H, Zhang L, Tsuda Y, Makise N, Yasunaga Y, Ikemura M, Nakai Y, Shibata E, Ushiku T, Tanaka S. Atypical Neurofibromatous Neoplasm with Uncertain Biologic Potential in the Posterior Mediastinum of a Young Patient with Neurofibromatosis Type 1: A Case Report. *Case Rep Oncol*. 2022;15(3):988-994.
 10. Nakagawa K, Sho M, Fujishiro M, Kakushima N, Horimatsu T, Okada KI, Iguchi M, Uraoka T, Kato M, Yamamoto Y, Aoyama T, Akahori T, Eguchi H, Kanaji S, Kanetaka K, Kuroda S, Nagakawa Y, Nunobe S, Higuchi R, Fujii T, Yamashita H, Yamada S, Narita Y, Honma Y, Muro K, Ushiku T, Ejima Y, Yamaue H, Kodera Y. Clinical practice guidelines for duodenal cancer 2021. *J Gastroenterol*. 2022;57(12):927-941.
 11. Nakazaki K, Yoshida M, Masamoto Y, Shinozaki-Ushiku A, Ikemura M, Hisamoto T, Yasunaga M, Sato S, Kurokawa M. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. *Int J Hematol*. 2022;116(3):446-452.
 12. Nejo T, Takayanagi S, Tanaka S, Shinozaki-Ushiku A, Kohsaka S, Nagata K, Yokoyama M, Sora S, Ushiku T, Mukasa A, Aburatani H, Mano H, Saito N. Primary Intracranial Spindle Cell Sarcoma, DICER1-Mutant, with MDM2 Amplification Diagnosed on the Basis of Extensive Molecular Profiling. *Clin Med Insights Case Rep*. 2022;15:11795476221131189.
 13. Ohki D, Tsuji Y, Tanaka M, Ushiku T, Fujishiro M. A case of a tiny neuroendocrine carcinoma in a large flat-elevated rectal tumor causing multiple liver metastases. *Clin J Gastroenterol*. 2022;15(6):1078-1082.
 14. Sato D, Takayanagi S, Takami H, Iwamoto T, Nomura M, Nambu S, Ikemura M, Tanaka S, Saito N. Novel case of primary intracranial solitary plasmacytoma presenting with significant intratumoral hemorrhage. *Surg Neurol Int*. 2022;13:157.
 15. Shi C, Badgwell BD, Grabsch HI, Gibson MK, Hong SM, Kumarasinghe P, Lam AK, Lauwers G, O'Donovan M, van der Post RS, Tang L, Ushiku T, Vieth M, Selinger CI, Webster F, Nagtegaal ID. Data Set for Reporting Carcinoma of the

- Stomach in Gastrectomy. Arch Pathol Lab Med. 2022;146(9):1072-1083.
16. Suzuki T, Masugi Y, Inoue Y, Hamada T, Tanaka M, Takamatsu M, Arita J, Kato T, Kawaguchi Y, Kunita A, Nakai Y, Nakano Y, Ono Y, Sasahira N, Takeda T, Tateishi K, Uemura S, Koike K, Ushiku T, Takeuchi K, Sakamoto M, Hasegawa K, Kitago M, Takahashi Y, Fujishiro M; GTK Pancreatic Cancer Study Group in Japan. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Cancer Sci. 2022;113(9):3097-3109.
 17. Tamura N, Sakaguchi Y, Furutani W, Matsui M, Nagao S, Sakuma N, Fukagawa K, Miura Y, Mizutani H, Ohki D, Kataoka Y, Saito I, Ono M, Minatsuki C, Tsuji Y, Ono S, Kodashima S, Abe H, Ushiku T, Yamamichi N, Koike K, Fujishiro M. Magnifying endoscopy with narrow-band imaging is useful in differentiating gastric cancer from matched adenoma in white light imaging. Sci Rep. 2022;12:8349.
 18. Tanaka M, Shinozaki-Ushiku A, Kunita A, Yasunaga Y, Akamatsu N, Hasegawa K, Ushiku T. High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma. Pathol Int. 2022;72(8):411-418.
 19. Teranishi Y, Okano A, Miyawaki S, Ohara K, Ishigami D, Hongo H, Dofuku S, Takami H, Mitsui J, Ikemura M, Komura D, Katoh H, Ushiku T, Ishikawa S, Shin M, Nakatomi H, Saito N. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. Acta Neuropathol Commun. 2022;10:76.

Radiology Center

Professor (Director)

Osamu Abe, M.D., Ph.D.

Lecturer (Vice Director)

Wataru Gono, M.D., Ph.D.

Assistant Professor

Go Shirota, M.D., Ph.D.

Chief Technologist (Vice Director)

Hideyuki Iwanaga, R.T.

Homepage <https://www.h.u-tokyo.ac.jp/patient/depts/houshasenbu/>

Introduction and Organization

Radiology Center was established in August 1964 as a part of the Central Clinical Services. Currently, the Department consists of three divisions: Diagnostic Radiology (imaging and intervention), Nuclear Medicine, and Radiotherapy, in addition to Radiation Safety Control Center. The center engages in radiology services such as various imaging examinations, radiotherapy, and radiation safety management.

The members are as follows: Professor Osamu Abe (Director, since Oct. 2016), Wataru Gono (Vice Director/Lecturer), Go Shirota (Assistant Professor), 77 radiology technologists, including Chief Technologist Hideyuki Iwanaga, and one technical specialist in charge of radiation control. In addition to the above, Radiology Center is operated in corporation with the staff radiologists, graduate students, and residents of the Department of Radiology, as well as physicians from other departments, nurses, and clinical engineering technicians of the Department of Clinical Laboratory. In recent years, the number of radiological services has increased, and we are trying to cope with this trend by improving work efficiency, optimizing staffing, and introducing new equipment.

The development of technologies for advancing and improving radiological practice is a cooperative effort

between physicians and radiologists. In addition to the fields of imaging and radiation therapy, the construction of image management systems, image processing, and image transfer systems have become essential themes in recent years. The radiology information system (RIS) and diagnostic reporting systems were digitalized in 1994. And a picture archiving and communication system (PACS, the film-less imaging system) was introduced in the hospital in May 2003. To reduce and equalize the burden of radiologists, we started preparing for the trial introduction of a new high-performance diagnostic interpreting system in 2012 and launched a new PACS system with deep learning-based software in 2023. In the field of radiation safety control, stimulated by the need to evaluate the individual accumulated exposure dose by medical radiation, we have started a working group to solve this problem. We provide the individualized accumulated exposure dose data on RIS. We also work for research on new radiology techniques such as image-guided radiation therapy, CT, MRI, PET, flat panel detector, postmortem imaging, artificial intelligence, etc.

Clinical activities

1) Diagnostic Radiology Section:

The diagnostic radiology section is responsible for

simple radiography (bone, chest, abdomen, head, pediatric, breast, pelvic measurement), various radiography with contrast mediums (gastrointestinal tract, urinary tract), radiography in the operating rooms, radiography in the emergency rooms, outpatient radiography, portable radiography in hospital wards, dental and oral radiography, bone mineral content determination, CT, MRI, angiography and interventional radiology (IVR), image processing and analysis (3D image reconstruction and analysis).

Most examinations are performed in the diagnostic radiology section on the 1st floor of the Central Clinical Services Building 1. Some are performed in the MRI rooms, Surgical Center, Critical Care and Emergency Medical Center/ER, and some other departments in the Central Clinical Services Building 2. The number of examinations, especially CT and MRI, is dramatically increasing. Six multi-slice CT machines (2 x 320-row, 1 x 256-row, 1 x 64-row CT, 2 x 80-row), 7 MRI machines (5 x 3T MRI, 2 x 1.5T MRI), 6 angiography systems (including one hybrid angiography system in the Surgical Center) are in use. From April 2023, Interventional Radiology Computed Tomography (IR-CT) is in operation, enabling to provide more advanced IR procedures.

2) Nuclear Medicine Section:

The nuclear medicine section is responsible for various nuclear medicine examinations (gamma camera, single-photon emission computerized tomography (SPECT), positron emission tomography (PET)), radiopharmaceutical management, production of PET nuclides using accelerators, label synthesis, quality verification, radioactive contaminant management, and internal isotope irradiation therapy.

The nuclear medicine section in Central Clinical Services Building 1 performs various medical services using unsealed radionuclides. Nuclear medicine examinations include conventional scintigraphy (bone, tumor, kidney, thyroid), myocardial SPECT, and brain SPECT. Functional and statistical images using tracer methods are also available. In recent years, the demand for PET examinations has been increasing, especially for ^{18}F -fluorodeoxyglucose-PET (FDG-PET) in cases with malignant tumors. PET examinations using tracers labeled with positron nuclides produced by a small cyclotron are used to

evaluate blood flow and metabolism, receptor imaging, and the presence of amyloid accumulation in the brain. With the opening of the Central Clinical Service Building 2, a PET-CT scanner and a cyclotron were installed. In 2009, we started internal radioisotope therapy for castration-resistant prostate cancer with bone metastasis and radioimmunotherapy for malignant lymphoma.

3) Radiation Oncology Section:

The radiation oncology section is responsible for high-energy radiotherapy, gamma-knife therapy, brachytherapy, and radioisotope (RI) internal therapy. The radiation oncology section is on the third basement floor of Central Clinical Services Building 2 and has dedicated rooms for RI internal therapy on the 9th floor of the Inpatient Building A.

The radiation oncology section has three linear accelerators (LINAC), an iridium brachytherapy machine, a gamma-knife for stereotactic irradiation of the head, and a CT scanner for treatment planning. A treatment planning system is used to perform radiation therapy. All linear accelerators are equipped with a CT imaging function for position matching, enabling highly accurate image-guided radiation therapy. In 2014, one of the linear accelerators was upgraded, and a tomotherapy was introduced. Tomotherapy is a helical intensity-modulated machine dedicated to high-precision radiotherapy for brain and head and neck tumors, whole-body irradiation, and whole-body skin irradiation. The Radiology Information System (RIS), introduced in 2012 from the viewpoint of medical safety, is now in operation to construct a comprehensive management system for cancer treatment. Recently, the gamma-knife system was updated in February 2019, and image-guided radiotherapy is now available in the gamma-knife system.

4) Others:

The radiation control office handles the hospital's management of X-ray generators, radioactive contaminants, radiation education, and health management (glass badge management, etc.). In addition, it conducts management and operation under the Medical Service Law and the Law Concerning Prevention of Radiation Hazards Act on the

Prevention of Hazards to Persons with Disabilities.

Bone mineral densitometry	186	2,808	2,994

Conclusion

In 2002, the diagnostic imaging equipment was fully digitalized, and in the following year, a filmless system was realized by distributing images and diagnostic reports via the hospital information system. The Critical Care and Emergency Medical Center/ER, MRI rooms, and the radiation oncology section were relocated to the Central Clinical Service Building 2 (completed in 2006), and the latest equipment was introduced. In January 2018, when Inpatient Building B started operation, a portable radiography system was established.

As a result of the development of digital technology, diagnostic equipment, image processing technology, diagnostic imaging, and radiotherapy technology have become more sophisticated. Radiology Center will continue to contribute to improving the level of medical care at the University of Tokyo Hospital through improved services to other departments.

Publications

See the corresponding part of the Department of Radiology.

Number of examinations in 2022.4 to 2023.3

	Inpatient	Outpatient	Total
Radiography (plain)	79,572	75,165	154,737
Radiography (enhanced)	4,869	1,089	5,958
Angiography	3,447	23	3,470
Computed tomography	13,578	37,358	50,936
Magnetic resonance imaging	4,678	16,744	24,422
Nuclear medicine	1,312	3,355	4,667
Radiotherapy	3,732	8,078	11,810

Rehabilitation Center

Professor

Toru Ogata, M.D.

Lecturer

Sayaka Fujiwara, M.D.

Research Associate

Haruhi Inokuchi, M.D., Kentaro Morita, M.D.,

Ryoko Sawada, M.D.

※The following information is the same as that of the previous year for certain reasons.

Homepage <http://todaireh.umin.ne.jp>

Introduction and Organization

The physical therapy service started in 1963 at the University of Tokyo Hospital, and then expanded to include occupational therapy and social work section. In 1966 this service was converted to the central rehabilitation service department as a part of the Central Diagnostic and Therapeutic Service Department. The Central Rehabilitation Service became an independent unit in 1970. After the reorganization of the University of Tokyo Hospital according to major organic classification in 1998, outpatient clinic as rehabilitation medicine was installed. The formal title of our unit was changed from the Physical Therapy Department to the Rehabilitation Department by the budget measures in the fiscal year 2001, and we integrated the related personnel categories, which belonged to the orthopedic surgery department and the physical medicine department.

At present our department consists of four sections. Rehabilitation physicians' section includes five full-time doctors and two other part-time doctors. They work chiefly for clinical practice in medical rehabilitation service, but also have to engage in teaching activities for medical students. Nineteen physical therapists are working in the physical therapy section. In the occupational therapy section, six

occupational therapists work for the general rehabilitation service and the other four therapists work for the psychiatric rehabilitation. Four acupuncture therapists perform acupuncture and moxibustion. In the Day-care Unit, clinical psychologists and nurses also work. In 2006, speech therapists who had belonged to other departments in the University of Tokyo Hospital were included in our department. From 2009, a speech therapist added to our department, and now three therapists perform therapy for patients with aphasia, dysarthria, and dysphagia.

Clinical activities

The professor serves as a director of Rehabilitation Center, the University of Tokyo Hospital. The Rehabilitation Center and the Department of Rehabilitation Medicine are united and engage in clinical practice. We have at present no charged ward, and treat about 4,700 new referrals annually from almost all the departments of the university hospital. We always take charge of 250-300 patients corresponding about 25-30% of the whole number of inpatients. We also see 15 people per day at the outpatient rehabilitation setting. The numerical ratio of outpatient is being reduced in order to give priority to the clinical service corresponding to needs expansion of service to inpatients.

Teaching activities

We have provided several clinical curriculums on rehabilitation medicine for 4th, 5th, and 6th year medical students since 1973. The systematic lecture series for 4th year medical students (M2) include the subjects on rehabilitation for disorders such as cerebrovascular disturbances, respiratory disorders, neuromuscular diseases, bone and joint diseases, and pediatric disorders as well as on outline of rehabilitation, and amputation/prostheses. We have provided a clinical practice in small group, so-called clinical clerkship for 5th and 6th year students from Wednesday to Friday every week. They experience a few patients and learn how to take a patients' history, physical findings, functional evaluation, and how to plan rehabilitation programs. We have introduced a few of elective students for elective clinical clerkship to our collaborating hospitals with specialized rehabilitation ward.

In addition, we have provided the training of students including physical therapy, occupational therapy, and speech therapy. Twenty students or more come and stay at the university hospital annually as a long-term clerkship from several PT/OT/ST training schools.

Research activities

Our research activities are growing up. In 2006, the Rehabilitation Center moved to the new building and a research laboratory was provided for the first time. As the motion analysis system was partially renewed, we are planning our researches mainly in the field of musculoskeletal disabilities. In addition, we are planning collaborating researches with other departments in our hospital, other faculties in our university, and institutions outside the University of Tokyo. The ongoing and scheduled projects are as follows.

- 1) 3D Motion analysis of patients with musculoskeletal disorders
- 2) Study on the relationship between sensory deficit and motor control
- 3) Rehabilitation and long-term outcome in patients with skeletal dysplasias
- 4) Pathology and treatment for patients with congenital limb deficiencies
- 5) Analysis of rehabilitation outcome using DPC data

References

1. Kojima T, Ishikawa H, Tanaka S, Haga N, Nishida K, Yukioka M, Hashimoto J, Miyahara H, Niki Y, Kimura T, Oda H, Asai S, Funahashi K, Kojima M, Ishiguro N: Validation and establishing targets for the physician-based clinical scale for foot and ankle surgery in patients with long-standing rheumatoid arthritis based on patient-reported outcomes: Results from a multicenter prospective observational cohort study to evaluate the efficacy of joint surgery in the treat-to-target era. *Mod Rheumatol*, Online ahead of print
2. Mano H, Fujiwara S, Haga N: Body knowledge in children with congenital upper limb deficiency. *Brain Nerve* 72(4): 445-451, 2020
3. Mano H, Fujiwara S, Haga N: Effect of prostheses on children with congenital lower limb deficiencies. *Pediatr Int* 62: 1039-1043, 2020
4. Mano H, Fujiwara S, Takamura K, Kitoh H, Takayama S, Ogata T, Haga N: Treatment approaches for congenital transverse limb deficiency: Data analysis from an epidemiological nation survey in Japan. *J Orthop Sci*, Online ahead of print
5. Matsuoka M, Tsukamoto S, Orihara Y, Kawamura R, Kuratani M, Haga N, Ikebuchi K, Katagiri T: Design of primers for direct sequencing of nine coding exons in the human ACVR1 gene. *Bone* 138: 115469, 2020
6. Matsushita M, Mishima K, Yamashita S, Haga N, Fujiwara S, Ozono K, Kubota T, Kitaoka T, Ishiguro N, Kitoh H: Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta. *J Bone Miner Metabol* 38(1): 109-116, 2020
7. Pignolo RJ, Cheung K, Kile S, Fitzpatrick MA, De Cunto C, Al Mukaddam M, Hsiao EC, Baujat G, Delai P, Eekhoff EMW, Di Rocco M, Grunwald Z, Haga N, Keen R, Levi B, Morhart R, Scott C, Sherman A, Zhang K, Kaplan FS: Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry. *Bone* 134: 115274, 2020

8. Sawada R, Yamana H, Shinoda Y*, Tsuda Y, Matsui H, Fushimi K, Kobayashi H, Matsubayashi Y, Yasunaga H, Tanaka S, Haga N: Predictive factors of 30-day mortality after surgery for spinal metastasis: Analysis of a nationwide database. *J Orthop Sci* S0949-2658(20)30208-6, 2020, Online ahead of print
9. Shinoda Y, Sawada R, Ishibashi Y, Akiyama T, Zhang L, Hirai T, Oka H, Ohki T, Ikegami M, Okajima K, Okuma T, Kobayashi H, Goto T, Haga N, Tanaka S: Prediction of pathological fracture in patients with lower limb bone metastasis using computed tomography imaging. *Clin Exp Metastasis* 37(5): 607-616, 2020
10. Takeda J, Nanatsue K, Yamagishi R, Ito M, Haga N, Hirata H, Ogi T, Ohno K: InMeRF: Prediction of pathogenicity of missense variants by individual modeling for each amino acid substitution. *NAR Genom Bioinform* 2(2):lqaa038,2020
11. Taya M, Hatano M, Saito A, Nitta D, Maki H, Hosoya Y, Minatsuki S, Tsuji M, Sato T, Murakami H, Narita K, Konishi Y, Watanabe S, Yokota K, Haga N, Komuro I: Clinical importance of respiratory muscle fatigue in patients with cardiovascular disease. *Medicine(Baltimore)* 99(34): e21794, 2020
12. Umezaki S, Shinoda Y, Mukasa A, Tanaka S, Takayanagi S, Oka H, Tagawa H, Haga N, Yoshino M: Factors associated with health-related quality of life in patients with malignant glioma: Impact of symptoms and implications for rehabilitation. *Jap J Clin Oncol* 50(9): 990-998, 2020
13. Haga N, Nakashima Y, Kitoh H, Kamizono J, Katagiri T, Saijo H, Tsukamoto S, Shinoda Y, Sawada R, Nakahara Y: Fibrodysplasia ossificans progressiva: review and research activities in Japan. *Pediatr Int* 62: 3-13, 2020

Surgical Center

Professor (Director)

Kazuhiko Fukatsu M.D., Ph.D.

Lecturer

Satoshi Murakoshi, M.D., Ph.D.

Yuhei Saito, Ph.D.

Yuki Taniguchi, M.D., Ph.D.

Ryoji Fukushima, M.D., Ph.D.

Assistant Professor

Ryota Yamagami, M.D.

※The following information is the same as that of the previous year for certain reasons.

Homepage <http://www.h.u-tokyo.ac.jp/patient/depts/syujutsu/index.html>

Introduction and Organization

Uniform management of operating rooms (OR) first began at the University of Tokyo Hospital in July 1955. The office, so called the surgical center, was located at the Old Central Building until December 1987. The center moved to the new Central Clinical Service Building 1 in January 1988, where there are 12 ORs including one bio-clean room. The surgical center became to provide managerial services of the OR to 18 surgical departments after moving into the new office building. The total number of operations remained to be below 6,300 a year between 1999 and 2000 because of the limitation of number of ORs and nurses.

In July 2001, the branch hospital in Mejiro area was merged with the University of Tokyo Hospital in Hongo area, which opened a new Ward A Building in October 2001. After the merger, the number of elective operations markedly increased and became over 7,300. Two additional ORs began to be used tentatively to accommodate an enormous increase in the number of elective operations. The one OR was set up on the ICU/CCU/HCU floor in the new Ward A Building and the other was in the Outpatient Clinic Building. The outpatient OR for orthopedic outpatients was diverted

for the general OR, which was used for the short-stay and day surgery.

Until September 2001, the elective operations had been performed in 9.5 ORs/day on average. After October 2001, 12 ORs/day began to be used. In 2006, the Central Clinical Service Building 2, which had 11 ORs, was completed to solve the shortage of the number of ORs. As a result, the total number of ORs became 23, and then the number of operations has tremendously increased. More recently, “On call PM block time” has been introduced to improve OR utilization. In April 2014, one of the ORs in the Central Clinical Service Building 2 was renovated into a hybrid OR which is equipped with advanced interventional imaging system for the patients undergoing interventional surgical treatment. In August 2020, Day Surgery room was built at ICU-2 area for ophthalmic operation.

A total of 8,485, 9,550, 9,921, 9,944, 10,394, 10,170, 10,752, 11,235, 11,150, 10,960, 11,161, 11,014, 11,124, 11,323, 9,945 (under the circumstance of Covid-19 pandemic) and 11,047 operations were performed in 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020 and 2021 fiscal

year, respectively. The number of operations in 2021 fiscal year counts for approximately 1.8 times comparing to that in 2001.

These days more and more patients undergo endoscopic surgery such as laparoscopy/thoracoscopy assisted operation. There is also an apparent increase in the number of patients who are at high risk with critical morbidity or carrier of the particular types of pathogens such as tuberculosis, MRSA, pseudomonas aeruginosa, HBV, HCV and HIV.

Clinical Activities

All operations of in-patients are performed in 23 ORs and Day Surgery room at the surgical center. Computer system has been utilized to handle the information on operation. In May 1999, the on-line system was introduced to order the elective and urgent/emergent operations through the computer terminal in the wards. The input of postoperative patient information started from March 2000. This system also enabled the medical staff to know the availability of the ORs of the next day. From November in 2000, the medical staff can see the operation schedule through the hospital computer network.

The present status of the operation process began to be seen through the computer monitor from May 1997. The photographs of surgical sites, resected organs and live video image began to be delivered to the clinical departments from February 1997.

Hospital logistics system were totally replaced to improve material flow of hospital in October 2001, when supply processing and distribution (SPD) department was established and started its practice. In the surgical center, this SPD system has been available since September in 2002.

Recently, the number of complicated and long surgical procedures using advanced technology has dramatically increased. In addition, more and more patients tend to undergo surgery using artificial implant, joint prosthesis or intraocular lenses. Those operations include organ transplantation, microvascular surgery, cardiovascular surgery, minimally invasive surgery and navigation-guided orthopedic/neurosurgical surgery and stent grafting for the abdominal or thoracic aortic aneurysms. Organ transplantation and intraoperative three-dimensional echo-guided surgery are also

frequently performed. Minimally invasive surgery is another recent trend of the operation. Those include endovascular treatment for heart anomalies such as ASD and VSD. More recently, the robotic surgery has started at the surgical center.

Healthcare-Associated infections (HAIs) are critical issues in the surgical center. It is essential to educate staffs how to prevent HAIs and occupational infections. As the number of operations associated with emerging or re-emerging infectious diseases such as HIV and tuberculosis has increased, all healthcare staff are required to adhere to the principles of standard and/or transmission-based precautions also in the surgical center.

Teaching Activities

The following lectures or seminar are given to the undergraduate and postgraduate medical students: aseptic techniques, sterilization/disinfection methods, prevention of perioperative infections, humoral and cellular responses to trauma and shock, training of scrubbing and gown techniques. The curriculum is updated each year. Introductory course for disinfection, sterilization and preservation of surgical instruments and medical devices was added in the training courses in 1998, which gained more interest and popularity among many students.

In the surgical center, the innovative surgical instruments and medical devices are introduced to perform highly advanced operations such as in the navigation surgery, transplantation surgery, cardiovascular surgery and robotic surgery. As a result, the education related to the assist for those surgical procedure has become most important activities in the surgical center. The lectures of advanced technologies are in the curriculum for the surgeons, the nursing staff and clinical engineers so that they can understand how to use them in a proper way.

Lectures for the nursing staff consist of a freshman course and an advanced course. The freshman course is a basic training course for scrub nurses and circulating nurses. It consists of lectures of aseptic techniques, decontamination/sterilization methods, prevention of perioperative infections, and on-site training of scrubbing and gown techniques as well as aseptic preparation of surgical instruments in the OR. An

advanced course is prepared to the experienced nurses as well. The purpose of this course is to upgrade their perioperative nursing skills so that they can demonstrate full nursing skills even in the complicated and long operations such as transplant surgery, open-heart surgery neurosurgery and robotic surgery.

There is also a training course to medical engineers and students of biomedical engineers. This training course consists of introduction on the medical devices and electronic instruments, precautions of accidental troubles in handling surgical instruments/medical devices, development of new surgical instruments/medical devices, cardiopulmonary bypass techniques and illumination techniques in the operating fields. The contents of this course are summarized in the manual for the nursing staff and contribute to decrease the frequency of incident associated with surgical instruments and medical devices.

The on-the-job training are given to the non-nursing staff including technical officials and part-time employees since they start their careers at the surgical center. They are given lectures on aseptic techniques, sterilization/disinfection methods, prevention of perioperative infections, and maintenance of reusable surgical instruments such as forceps, scissors and clamps. These subjects are stated and summarized in the manual. Lectures are also given to the senior technical officers and part-time employees to promote their technical knowledge and skills.

- 10) Perioperative infection control and prevention related to the sterilization
- 11) Maintenance of the surgical environment in the OR
- 12) Maintenance and management of surgical equipment
- 13) Nutritional management of perioperative patients
- 14) Others

Research Activities

- 1) Safe surgery and risk management in the OR
- 2) Improvement of cost-effectiveness in the surgical treatment
- 3) Development of central monitoring system using IT technology
- 4) Introduction of robotic surgery
- 5) Efficient use of human resources
- 6) Introduction of advanced surgical procedure including microscopy surgery and laparoscopy
- 7) Management of equipment of endoscopy-assisted surgery
- 8) Centralization of the live video images of the surgical field
- 9) Management of surgical instruments using unique device identification (UDI)

Central Supply Service

Professor

Kazuhiko Fukatsu, M.D., Ph.D.

Lecturer

Satoshi Murakoshi, M.D., Ph.D.

Assistant Professor

Hiroshi Ookawa

※The following information is the same as that of the previous year for certain reasons.

Homepage <http://www.cc.h.u-tokyo.ac.jp/mulins/zairyobu/>

Introduction

Central supply service is an integrated place in the hospital for cleaning and sterilization of previously used devices. All re-usable devices are transported to our division via automated guided vehicle system from surgical center, ward and outpatient clinics. The used instruments are cleaned using standard precautionary procedures, disinfected, reassembled, packaged, and sterilized. The sterilized instruments are then placed at designated sites for use.

One professor and one assistant professor, one nurse, one 8 staff members, and 26 members from external staff sources are the main members of this division.

Facilities

The following facilities are located in an area of 1,077 square meters:

Cleaning equipment: 7 washer disinfectors (WDs), 1 vacuum-ultrasonic cleaning unit, 1 decompression boiling washer

Drying equipment: 5 system drying units.

Sterilizing equipment: 6 autoclaves, 1 hydrogen peroxide plasma sterilizer, 1 hydrogen peroxide sterilizer, 1 low temperature steam formaldehyde sterilizer.

Activities

Used devices are cleaned with automated washer disinfectors and/or manual washing, then packaged carefully into container sets or paper bags. The packaged materials are sterilized with autoclaves, ethylene oxide gas sterilizer or hydrogen peroxide plasma sterilizer according to their characteristics. The cleaning procedure is checked with test device. All sterilization process is recorded and ensured by chemical indicators and biological indicators. Performance validation is also carried out for autoclave sterilization.

The number of devices handled in the central supply service is dramatically increasing with increased number of operations in the surgical centers.

Staffs of central supply service have also worked for re-counting of used surgical devices on surgical center floor since 2011. The work has contributed towards risk management in the hospital.

Staffs also join infection control team round and periodically count device number in each ward for appropriate management of medical devices.

Research activities

To establish more efficient procedures for cleaning, intensive trials have been performed and the data have been presented at academic conferences. Moreover, basic research on host response to surgical

insult is another theme of our division. The research is important for improving outcome of surgical patients and our data have been published as original articles

Department of Endoscopy and Endoscopic Surgery

Associate Professor

Yousuke Nakai, M.D., Ph.D.

Assistant Professor

Naomi Kakushima, M.D., Ph.D.

Homepage <https://www.h.u-tokyo.ac.jp/patient/depts/kougaku/>

Introduction and Organization

Department of Endoscopy and Endoscopic Surgery was established in April 1997. Although the present regular staffs of our department include only two doctors, about 80 doctors from other departments including the department of gastroenterology, gastrointestinal surgery, surgical oncology, respiratory medicine, thoracic surgery, gynecologic oncology and otorhinolaryngology, perform endoscopic procedures.

Clinical activities

Endoscopic procedures, including upper gastrointestinal endoscopy, colonoscopy, bronchoscopy, otorhinolaryngological endoscopy and gynecological endoscopy, are performed from Monday to Friday. Emergency endoscopy is performed in the nighttime or holidays. The numbers of endoscopic procedures in each field are increasing gradually year by year and the total number during 2016 reached to 20,000. In the gastrointestinal tract, image enhanced endoscopy for detailed inspection and therapeutic endoscopy, including endoscopic submucosal dissection for esophageal, gastric and colorectal tumors, are major advanced fields. In addition, endoscopic diagnosis and management of pancreatobiliary diseases is also performed. Our recent clinical activities are

summarized in Table 1.

Another important activity of our department is the disinfection and maintenance of endoscopic apparatuses used in other units including the outpatient clinic, radiotherapy department, surgery department or intensive care units. Endoscopes in our hospital are collected in our department after use and disinfected.

In 2022, due to COVID-19 pandemic, prevention of COVID-19 infection both among patients and staffs has been an important topic. We will provide safe endoscopic procedures by appropriate PPE (personal protective equipment) and the social distance in the endoscopy suite.

Teaching activities

We participate in under-graduate education as a part of systemic lectures and bed-side learning by the department of gastroenterology, surgery and other departments. As for post-graduate education, training opportunities for endoscopy and endoscopic surgery are given to residents or young doctors in a program of each department. We accept foreign doctors to learn advanced endoscopic procedures.

Table1	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
EGD*	11840	11740	11874	11944	11490	11699 (2177)	11226 (2501)	8,906	10232	10239
Colonoscopy	6000	6043	6394	6814	5921	5530 (109)	5675 (329)	4,548	5619	5445
Bronchoscopy	169	218	228	362	350	316	395	300	312	305
ERCP**	912	1035	946	1206	1137	1057	1314	1302	1166	1326
EUS†	763	766	882	1084	1023	923	1059	711	847	993
Enteroscopy	375	396	310	86	304	138	151	74	23	83
Laryngoscopy	128	102	105	125	114	92	102	42	39	99
Colposcopy	404	327	295	417	430	414	392	333	364	451
Total	20591	20627	21034	22038	20769	20169	20314	16226	18602	18941

*Esophagogastroduodenoscopy, **Endoscopic ultrasonography, †Endoscopic retrograde cholangiopancreatography, ‡performed at Center for Epidemiology and Preventive Medicine

Research activities

Our research activities cover a variety of endoscopic fields in cooperation with other departments. In the field of gastrointestinal endoscopy, our department participates in the JED (Japan Endoscopy Project) project endorsed by Japan Gastroenterological Endoscopy Society and contributes to the development of the nationwide endoscopy database.

References

1. Sato T, Yasuda I, Nakai Y; WONDERFUL study group in Japan. The second shot to walled-off necrosis: The sooner the better versus sooner or later DEN Open 2022;3:e182.
2. Nakai Y, Shiomi H, Hamada T, Ota S, Takenaka M, Iwashita T, Sato T, Saito T, Masuda A, Matsubara S, Iwata K, Mukai T, Isayama H, Yasuda I; WONDERFUL study group in Japan. Early versus delayed interventions for necrotizing pancreatitis: A systematic review and meta-analysis. DEN Open 2022;3:e171.
3. Hakuta R, Nakai Y, Oyama H, Noguchi K, Kanai S, Nomura Y, Suzuki T, Ishigaki K, Saito K, Saito T, Hamada T, Takahara N, Mizuno S, Kogure H, Moriya K, Fujishiro M. Increased risk of biliary infection after biliary stent placement in users of proton pump inhibitors. DEN Open 2022;3:e129.
4. Sato T, Saito T, Nakai Y, Fujishiro M. To-and-fro balloon technique for deployment of a lumen-apposing metal stent in highly solid walled-off necrosis of the pancreas. Endoscopy 2022;54:E750-1.
5. Hamada T, Saito T, Noguchi K, Nakai Y, Fujishiro M. The "funitel" technique for endoscopic target biopsy at a biliary bifurcation. Endoscopy 2022;54:E637-8.
6. Fukuda K, Nakai Y, Mizuno S, Sato T, Noguchi K, Kanai S, Suzuki T, Hakuta R, Ishigaki K, Saito K, Saito T, Takahara N, Hamada T, Kogure H, Fujishiro M. Endoscopic Bridge-and-Seal of Bile Leaks Using a Fully Covered Self-Expandable Metallic Stent above the Papilla. J Clin Med. 2022;11:6019.
7. Sato T, Nakai Y, Fujishiro M. Current endoscopic approaches to biliary strictures. Curr Opin Gastroenterol 2022;38:450-60.
8. Kogure H, Nakai Y, Fujishiro M. How should needle tract seeding be addressed in endoscopic ultrasound-guided fine-needle aspiration? Dig Endosc 2022;34:958-9.
9. Yamashita Y, Tachikawa A, Shimokawa T, Yamazaki H, Itonaga M, Sakai Y, Sugiyama H, Nakai Y, Tanaka K, Isayama H, Kitano M. Covered versus uncovered metal stent for endoscopic drainage of a malignant distal biliary obstruction: Meta-analysis. Dig Endosc 2022;34: 938-51.
10. Hamada T, Kogure H, Hakuta R, Nakai Y, Koike K. The "zipline" technique for double-balloon enteroscopy-assisted removal of a migrated stent

- in a peripheral bile duct. *Endoscopy* 2022;54: E353-4.
11. Iwashita T, Ogura T, Ishiwatari H, Nakai Y, Iwata K, Mukai T, Shimizu M, Isayama H, Yasuda I, Itoi T. Utility of dedicated bougie dilator for a 0.018-inch guidewire during EUS-guided biliary drainage: A multi-center retrospective cohort study. *J Hepatobiliary Pancreat Sci.* 2022;29:810-6.
 12. Kato S, Kuwatani M, Onodera M, Kudo T, Sano I, Katanuma A, Uebayashi M, Eto K, Fukasawa M, Hashigo S, Iwashita T, Yoshida M, Taya Y, Kawakami H, Kato H, Nakai Y, Kobashigawa K, Kawahata S, Shinoura S, Ito K, Kubo K, Yamato H, Hara K, Maetani I, Mukai T, Shibukawa G, Itoi T. Risk of Pancreatitis Following Biliary Stenting With/Without Endoscopic Sphincterotomy: A Randomized Controlled Trial. *Clin Gastroenterol Hepatol* 2022;20:1394-1403.
 13. Kitano M, Yoshida M, Ashida R, Kita E, Katanuma A, Itoi T, Mikata R, Nishikawa K, Matsubayashi H, Takayama Y, Kato H, Takenaka M, Ueki T, Kawashima Y, Nakai Y, Hashimoto S, Shigekawa M, Nebiki H, Tsumura H, Okabe Y, Ryozaawa S, Harada Y, Mitoro A, Sasaki T, Yasuda H, Miura N, Ikemoto T, Ozawa E, Shioji K, Yamaguchi A, Okuzono T, Moriyama I, Hisai H, Fujita K, Goto T, Shirahata N, Iwata Y, Okabe Y, Hara K, Hashimoto Y, Kuwatani M, Isayama H, Fujimori N, Masamune A, Hatamaru K, Shimokawa T, Okazaki K, Takeyama Y, Yamaue H; Committee of Clinical Research, Japan Pancreas Society. Needle tract seeding after endoscopic ultrasound-guided tissue acquisition of pancreatic tumors: A nationwide survey in Japan. *Dig Endosc* 2022 May3. Online ahead of print.
 14. Hisada H, Tsuji Y, Obata M, Cho R, Nagao S, Miura Y, Mizutani H, Ohki D, Yakabi S, Takahashi Y, Sakaguchi Y, Kakushima N, Yamamichi N, Fujishiro M. The impact of sarcopenia on short- and long-term outcomes of endoscopic submucosal dissection for early gastric cancer. *J Gastroenterol* 2022;57:952-61.
 15. Kakushima N, Hinata M, Ushiku T. White opaque substance in a non-neoplastic duodenal lesion. *Dig Endosc* 2022;34:1495.
 16. Hisada H, Sakaguchi Y, Oshio K, Mizutani S, Nakagawa H, Sato J, Kubota D, Obata M, Cho R, Nagao S, Miura Y, Mizutani H, Ohki D, Yakabi S, Takahashi Y, Kakushima N, Tsuji Y, Yamamichi N, Fujishiro M. Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future. *Curr Oncol.* 2022;29:4678-88.

Department of Hemodialysis and Apheresis

Professor

Masaomi Nangaku, M.D., Ph.D.

Lecturer

Daisuke Yamada, M.D., Ph.D.

Yoshifumi Hamasaki, M.D., Ph.D.

Introduction and Organization

Hemodialysis and related blood purification therapy had been individually performed in their respective departments. However, all the departments' apparatus and human resources were centralized to form the Department of Hemodialysis and Center for Hemodialysis in 2000 at the University Hospital. The Center for Hemodialysis was further renovated and started operations in Fall of 2006. This new Center for Hemodialysis is equipped with one pressure control unit in addition to 12 hemodialysis machines under a state-of-the-art hemodialysis control system. Our concept of a hemodialysis controlling system is a hub to transfer all digital and analog data from patients and to monitor machines, including blood purification machines, to the host computer in our hospital, centralizing all data and administering medical coding and billing robustly. Blood purification machines in the ICU are also connectable to this system, which was developed collaboratively with Nihon Kohden Corp. Blood purification machines are selected uniformly to secure patients' safety while avoiding human error and increasing the overall educational quality of staff members.

Clinical activities

1. Start of maintenance hemodialysis therapy for end-stage kidney disease (ESKD).
2. Regular hemodialysis therapy for hospitalized

ESKD patients. Please note that our center does not accept holiday dialysis.

3. Emergency hemodialysis and hemodiafiltration for ICU patients.
4. PAD screening using skin reperfusion pressure examination during hemodialysis treatment, and intradialytic exercise to ameliorate frailty and sarcopenia.
5. Plasmapheresis for neurodegenerative diseases, myasthenia gravis, dermatological disorders, waldenstrom macroglobulinemia, collagen diseases, TMA (TTP), and pre/post solid organ transplant patients.
6. Granulocyte and Monocyte Apheresis for inflammatory bowel diseases such as ulcerative colitis.
7. Cell-free and concentrated ascites reinfusion therapy (CART) for refractory ascites.
8. Induction and maintenance of peritoneal dialysis for ESKD.

Teaching activities

1. Tutorial course for clinical fellows applying to the speciality of blood purification therapy.
2. Exposure in hemodialysis & apheresis course to second year residents on request.
3. Our state-of-the-art blood purification protocols are summarized in Japanese handbook in 2010 [Apheresis Pocket Manual] and 2011 [CRRT Pocket Manual]. English and Chinese version of

“Apheresis Pocket Manual” is available for global experts of Apheresis therapy.

4. Critical Care Nephrology Course for educating young clinical researchers and fellows in collaboration with Department of Emergency and Critical Care Medicine.

Research activities

1. Prognostic analysis for post-liver transplant patients received plasma exchange therapy.
2. Identification of prognostic factors including biomarkers in AKI/CKRT patients admitting to ICU/CCU.
3. Associations between factors at the initiation of kidney replacement therapy and prognosis in ESKD patients.
4. Identification of prognostic factors at initiation of peritoneal dialysis (PD), and at the onset of infectious complications in PD patients.
5. Elucidation of basic mechanisms in cardio-renal syndrome and intervention.
6. Pathophysiology of acute kidney injury and its applicability for renal regenerative study.
7. Renal biomarker to determine clinical actionability in CKD and type-2 DN.
8. The potentiality of urine biomarker tests for developing country [JICA-JST: Science and Technology Research Partnership for Sustainable Development].

References

1. Matsuura R, Komaru Y, Miyamoto Y, Yoshida T, Yoshimoto K, Yamashita T, Hamasaki Y, Noiri E, Nangaku M, Doi K. HMGB1 Is a Prognostic Factor for Mortality in Acute Kidney Injury Requiring Renal Replacement Therapy. *Blood Purif.* 2023 Jun 19;1-8.
2. Komaru Y, Isshiki R, Matsuura R, Hamasaki Y, Nangaku M, Doi K. Application of urinary biomarkers for diagnosing acute kidney injury in critically ill patients without baseline renal function data. *J Crit Care.* 2023 Oct;77:154312.
3. Oki R, Hamasaki Y, Tsuji S, Suzuki K, Tsuneishi S, Imafuku M, Komaru Y, Miyamoto Y, Matsuura R, Doi K, Nangaku M. Clinical frailty assessment might be associated with mortality in incident dialysis patients. *Sci Rep.* 2022 Oct 21;12(1):17651.
4. Matsuura R, Honda K, Oki R, Hamasaki Y, Doi K, Nangaku M. Screening and Management for Intracranial Aneurysms in Japanese Patients With ADPKD. *Kidney Int Rep.* 2022 Jun 1;7(8):1893-1896.
5. Miyamoto Y, Iwagami M, Aso S, Uda K, Fushimi K, Hamasaki Y, Nangaku M, Yasunaga H, Doi K. Postoperative outcomes of cancer surgery in patients with and without kidney failure with dialysis therapy: a matched-pair cohort study. *Clin Kidney J.* 2022 Jan 13;15(6):1137-1143.
6. Oki R, Hamasaki Y, Komaru Y, Miyamoto Y, Matsuura R, Akari S, Nakamura T, Murase T, Doi K, Nangaku M. Plasma xanthine oxidoreductase is associated with carotid atherosclerosis in stable kidney transplant recipients. *Nephrology (Carlton).* 2022 Apr;27(4):363-370. Epub 2021 Oct 14.
7. Komai T, Iwasaki Y, Tsuchida Y, Hanata N, Tsuchiya H, Harada H, Hamasaki Y, Nangaku M, Shoda H, Fujio K. Efficacy and safety of plasma exchange in interstitial lung diseases with anti-melanoma differentiation-associated 5 gene antibody positive clinically amyopathic dermatomyositis. *Scand J Rheumatol.* 2021 Dec 13:1-7.
8. Matsuura R, Yamashita T, Hayase N, Hamasaki Y, Noiri E, Numata G, Takimoto E, Nangaku M, Doi K. Preexisting heart failure with reduced ejection fraction attenuates renal fibrosis after ischemia reperfusion via sympathetic activation. *Sci Rep.* 2021 Jul 23;11(1):15091.
9. Tomura M, Hamasaki Y, Komaru Y, Miyamoto Y, Matsuura R, Matsumoto A, Doi K, Kume H, Nangaku M. Prognostic significance of concentric left ventricular hypertrophy at peritoneal dialysis initiation. *BMC Nephrol.* 2021 Apr 16;22(1):135.
10. Kotani A, Oda Y, Hirakawa Y, Nakamura M, Hamasaki Y, Nangaku M. Peritoneal Dialysis-related Peritonitis Caused by Streptococcus oralis. *Intern Med.* 2021 May 22.
11. Oki R, Tsuji S, Hamasaki Y, Komaru Y, Miyamoto Y, Matsuura R, Yamada D, Doi K, Kume H,

- Nangaku M. Time until treatment initiation is associated with catheter survival in peritoneal dialysis-related peritonitis. *Sci Rep*. 2021 Mar 22; 11(1):6547.
12. Oki R, Hamasaki Y, Komaru Y, Miyamoto Y, Matsuura R, Yamada D, Iwagami M, Doi K, Kume H, Nangaku M. Catheter Diversion Procedure With Exit-Site Renewal Promotes Peritoneal Dialysis Catheter Survival. *Kidney Int Rep*. 2020 Dec 7;6(2):325-332.
 13. Matsuura R, Doi K, Hamasaki Y, Nangaku M. RRT Selection for AKI Patients With Critical Illness. *Semin Nephrol*. 2020 Sep;40(5):498-505.
 14. Matsuura R, Hiraishi A, Holzman LB, Hanayama H, Harano K, Nakamura E, Hamasaki Y, Doi K, Nangaku M, Noiri E. SHROOM3, the gene associated with chronic kidney disease, affects the podocyte structure. *Sci Rep*. 2020 Dec 3;10(1): 21103.
 15. Miyamoto Y, Aso S, Iwagami M, Morita K, Fushimi K, Hamasaki Y, Nangaku M, Doi K, Yasunaga H. Expanded Indication for Recombinant Tissue Plasminogen Activator from 3 to 4.5 h after Onset of Stroke in Japan. *J Stroke Cerebrovasc Dis*. 2020 Dec;29(12):105341.
 16. Komaru Y, Doi K, Nangaku M. Urinary Neutrophil Gelatinase-Associated Lipocalin in Critically Ill Patients With Coronavirus Disease 2019. *Crit Care Explor*. 2020 Aug 20;2(8):e0181.
 17. Komaru Y, Yoshida T, Hamasaki Y, Nangaku M, Doi K. Hierarchical Clustering Analysis for Predicting 1-Year Mortality After Starting Hemodialysis. *Kidney Int Rep*. 2020 May 23;5(8): 1188-1195.
 18. Miyamoto Y, Aso S, Iwagami M, Yasunaga H, Matsui H, Fushimi K, Hamasaki Y, Nangaku M, Doi K. Association Between IV Thiamine and Mortality in Patients With Septic Shock: A Nationwide Observational Study. *Crit Care Med*. 2020 Aug;48(8):1135-1139.
 19. Matsuura R, Komaru Y, Miyamoto Y, Yoshida T, Yoshimoto K, Hamasaki Y, Nangaku M, Doi K. Different Biomarker Kinetics in Critically Ill Patients with High Lactate Levels. *Diagnostics (Basel)*. 2020 Jul 4;10(7):454.
 20. Matsuura R, Iwagami M, Moriya H, Ohtake T, Hamasaki Y, Nangaku M, Doi K, Kobayashi S, Noiri E. The Clinical Course of Acute Kidney Disease after Cardiac Surgery: A Retrospective Observational Study. *Sci Rep*. 2020 Apr 16;10(1): 6490.
 21. Komaru Y, Inokuchi R, Iwagami M, Hamasaki Y, Nangaku M, Doi K. Inverse Correlation Between Incidence and Mortality of Acute Kidney Injury in Critically Ill Patients: A Systematic Review. *Shock*. 2020 Sep;54(3):280-284.
 22. Kimura C, Oki R, Hamasaki Y, Nangaku M. An Abscess Developing in an Old Subcutaneous Tunnel after Catheter Diversion. *Intern Med*. 2021 Mar 1;60(5):813-814.
 23. Komaru Y, Doi K, Matsuura R, Yoshida T, Miyamoto Y, Yoshimoto K, Nangaku M. Urinary chloride concentration as a prognostic marker in critically ill patients. *Nephrology (Carlton)*. 2020 May;25(5):384-389.
 24. Matsuura R, Iwagami M, Moriya H, Ohtake T, Hamasaki Y, Nangaku M, Doi K, Kobayashi S, Noiri E. A Simple Scoring Method for Predicting the Low Risk of Persistent Acute Kidney Injury in Critically Ill Adult Patients. *Sci Rep*. 2020 Mar 31; 10(1):5726.
 25. Miyamoto Y, Iwagami M, Aso S, Matsui H, Doi K, Yasunaga H. Pregabalin and injury: A nested case-control and case-crossover study. *Pharmacoepidemiol Drug Saf*. 2020 Feb 21.
 26. Hayase N, Doi K, Hiruma T, Matsuura R, Hamasaki Y, Noiri E, Nangaku M, Morimura N. Recombinant thrombomodulin prevents acute lung injury induced by renal ischemia-reperfusion injury. *Sci Rep*. 2020 Jan 14;10(1):289.
 27. Komaru Y, Inokuchi R, Iwagami M, Matsuura R, Hamasaki Y, Nangaku M, Doi K. Correlation between the Incidence and Attributable Mortality Fraction of Acute Kidney Injury: A Systematic Review. *Blood Purif*. 2020 Jan 22:1-8.

Immune-Mediated Diseases Therapy Center

Professor

Associate Professor

Hiroko Kanda, M.D., Ph.D.

Lecturer

Associate

Homepage <http://www.m.u-tokyo.ac.jp/patients/depts./menekishikkan/>

Introduction and Organization

In many immune diseases, some immune cells and responses are out of control. “Biologics” have been developed as agents that control the cytokines and cell surface molecules. In Japan, TNF inhibitors were introduced for the first time as “biologics” for rheumatoid arthritis (RA) in 2003. The effect of these drugs has been tremendous and has brought about a paradigm shift in RA practice, not only in terms of treatment goals, but also in terms of treatment algorithms, revised classification criteria for diagnosis, and so on. Now, “small-molecule inhibitors” that target specific molecules of intracellular signal transduction events have been added, and these drugs, called “molecular targeted therapies,” are being developed one after another. Currently, “Biologics” include 9 TNF inhibitors, 3 IL-6 inhibitors, 1 CTLA4-Ig, 4 IL-17 inhibitors, 1 IL-12/23 inhibitor, 2 IL-23 inhibitors, 2 alpha 4 integrin inhibitors, 2 IL-5 inhibitors, 1 IL-4/13 inhibitor, 1 anti-IgE antibody, 1 IL-1 inhibitor, 2 B-cell activation inhibitors, 1 type I IFN inhibitor, 2 complement activation inhibitors and 1 nFcR inhibitor, and “small-molecule inhibitors” include 5 JAK inhibitors, 1 TYK2 inhibitor and 1 PDE4 inhibitor, have been approved. Target diseases include not only

immunological diseases such as RA, juvenile idiopathic arthritis, systemic lupus erythematosus, scleroderma, adult-onset Still's disease, vasculitis, spondyloarthritis, psoriasis and psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, neuromyelitis optica, nocturnal paroxysmal hemochromaturia, Castleman's disease, but also autoinflammatory diseases, atopic Dermatitis. Molecularly targeted therapies have shown high efficacy against these diseases and are expected to avoid long-term administration of corticosteroids.

In 2017, with the expansion of molecular targeted agents, the “Immune-mediated Diseases Therapy Center Outpatient Department” was established in the outpatient consultation division. Due to further increases in the number of drugs and indications, the Center was approved as a department of the Graduate School of Medicine of the University of Tokyo in April 2020. At the same time, the “Immune-mediated Diseases Therapy Center” was established on the 12th floor of Inpatient Unit B as an outpatient center to provide intravenous molecular targeted therapy for all patients with immune-mediated diseases in the university of Tokyo hospital. There are eight departments: Allergy and Rheumatology, Dermatology,

Ophthalmology, Orthopaedics surgery and Spinal surgery, Gastroenterology, Colon and Rectal surgery, Neurology, and Hematology. Together with three dedicated nurses and two pharmacists, we are working to make the outpatient clinic a smoother and safer place to provide molecular targeted therapy. In addition, once every two months, the immune-mediated diseases therapy center meeting is held as a forum for information sharing, where new drug regimens are discussed and problems are remedied.

The current number of prescriptions for molecularly targeted agents has more than doubled from 550 in 2017 to 1,300 in 2021, with 65% subcutaneous, 30% intravenous, and 5% oral. As a cross-sectional center, we would like to deepen our cooperation and aim for safer operations in the future.

Clinical activities

We have an outpatient clinic at the “Immune-Mediated Therapy Center” every Monday morning, where we provide consultation services for diagnosis and treatment of immune-mediated diseases, especially those related to molecular targeted therapy. The actual treatment is provided by the attending physician of each department, but as mentioned above, intravenous treatment is centralized at our center.

Teaching activities

As for education for outpatient staff, lectures on each disease are held once a year. When a new drug is introduced, additional lectures related to that drug are given. Medical students are educated through BSL.

Research activities

We aim to conduct research on the efficacy and safety of molecular targeted agents for each immune-mediated disease by searching for biomarkers and analyzing medical information, which will lead to the establishment of precision medicine.

References

1. Saeko Yamada S, [Kanda H](#), Abe H, Domoto YS, Yoshida R, Harada H, Kubo K, Ushiku T, Fujio K. Predominant mesangial IgM, C3, and λ light chain depositions and interstitial nephritis in a patient with overlap syndrome and positivity for anti-mitochondrial M2 antibody: a case report. *Mod Rheumatol Case Rep.* 6: 124-7, 2022
2. Itamiya T, Komai T, [Kanda H](#), Nagafuchi Y, Chang H, Shibata S, Ishiura H, Shoda H, Toda T, Fujio K. Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation. *Clin Rheumatol* 41: 2233-7, 2022
3. Kanda H. Association between bone mineral density and anti-citrullinated protein antibodies in patients with rheumatoid arthritis. *Rheumatology.* 2022; 68: 118-22
4. Kanda H. Cryopyrin-associated periodic syndrome. *Clinical Immunology & Allergology.* 2022; 77: 694-8
5. Kanda H. Vascular diseases associated with rheumatoid arthritis (including vasculitis syndrome and hypersensitivity vasculitis). *Nippon Rinsho.* 2022; 80:603-7
6. Kanda H. How to take physical findings of psoriatic arthritis. *Journal of the Japanese Dermatological association.* 2022; 132: 27-34

Tissue Bank

Director and Associate Professor

Sumihito Tamura, M.D., Ph.D. FACS

Homepage <https://www.h.u-tokyo.ac.jp/english/centers-services/central-clinical-facilities/tissue-bank/index.html>

Introduction and Organization

The tissue bank handles cardiac arrest and brain death donor information on a 24-7-365 basis, and is responsible for the retrieval and cryo-preservation management of homograft cardiac valve and blood vessels. We provide these cryo-preserved vascular tissues to medical organizations nationwide for patients that require vascular tissue transplantation. Additionally, we initiated allograft bone banking program limited to in-house retrieval and supply since 2018. Dissemination and educational activities for the advancement of tissue transplantation and transplantation medicine is our important mission. In this line of effort, starting 2020, our staff now function as in-house organ donor coordinator.

Activities

Tissue retrieval is carried out by a team of surgeons after a transplantation coordinator certified by the Japan Society of Tissue Transplantation (JSTT) explains tissue donation to the donor's family, and obtains their consent. The donated tissue undergoes preservation work in the cleanroom located within the Central Clinical Facilities and is stored under strict round-the-clock online management, so that it may be transplanted to a patient (recipient) who is deemed to necessitate a tissue transplantation. As a rare tissue bank that handles homograft cardiac valves and vascular tissues in Japan, the department is certified by the JSTT and has the largest number of stored tissues in Japan.

Target Diseases

Cardiac valve transplantation:

Infectious endocarditis, prosthetic valve infection, aortic valve periannular abscess, some cases of congenital cardiovascular diseases (hypoplastic left heart syndrome, pulmonary artery/aorta reconstruction, etc.), etc.

Vascular transplantation

vascular prosthesis infection, infected aortic aneurysm, hepatobiliary tract and pancreas diseases, some cases of congenital cardiac diseases.

Characteristics

Excellent resistance to infections: Homograft tissues are cryopreserved in a state in which the cells are alive, and provide higher resistance to infections by bacteria than artificial cardiac valves and vessels.

No need for anticoagulation: It is not always necessary to use coagulants throughout one's life, as in the case of post-replacement of artificial cardiac valves and blood vessels, and it is particularly useful for people who are engaged with strenuous exercise, young children, or women who have a desire to give birth.

Durability: As long as 15 to 20 years. However, re-do operations may be necessary in some cases.

Banking system: In collaboration with other tissue banking facilities in Japan, responds to recovery cases mainly in the Kanto region. Certified cardiac and liver surgeons consists the donor response team. Shipment area covers entire nation.

Honoring the donor: Importance is non-comparable to artificial grafts. Human tissues are recovered from deceased donors. Since donation is rare in Japan, graft

supply remains scarce. We honor donor and family members, who decided to give to others in their final moments. It is our mission to maintain and spread this precious and important therapeutic option in Japan.

Department of Corneal Transplantation

Professor

Makoto Aihara, M.D., Ph.D.

Lecturer

Takashi Miyai, M.D., Ph.D.

※The following information is the same as that of the previous year for certain reasons.

Homepage <http://www.h.u-tokyo.ac.jp/patient/depts/kakumaku.html>

Introduction and Organization

The department of corneal transplantation was established in 1976 as one of clinical sections in the University of Tokyo Hospital. The purpose of the establishment of this section is to carry out and promote corneal transplantation and to perform clinical and basic research in the corneal diseases and corneal transplantation. The section is composed of two members (Professor Makoto Aihara, Lecturer Takashi Miyai).

Clinical activities

The clinical activities of this section include corneal transplantation and outpatient clinics for various corneal diseases as a consulting corneal service. The members are responsible not only for corneal transplantation but also for general ophthalmological practice as a senior staff member of Department of Ophthalmology, University of Tokyo. The corneal service for special cases is held every Monday (PM), Wednesday (AM), Thursday (AM), and Friday (AM). Keratoconus clinic for providing corneal crosslinking surgery, which is a brand-new treatment to halt keratoconus progression, were held in the afternoon of Thursday. Special contact lens clinic for keratoconus and post-keratoplasty eyes were in the afternoon of the second and fourth Thursday. At the corneal service, we

determine indication for corneal transplantation and follow up patients after the surgery. Total 71 corneal surgeries including keratoplasty were performed in 2021. In addition to the full-thickness corneal transplantation (penetrating keratoplasty), we have successfully performed corneal endothelial transplantation for patients with bullous keratopathy, the most common disease of corneal transplantation. Generally, corneal transplantation is performed as emergency operation, because we need to transplant corneas as soon as possible.

The other important activities of the section include mediation of donor eyes to other university hospitals and medical institutes that need donor eyes for corneal transplantation with cooperation of Eyebank. We are also performing corneal transplantation using corneas from American Eyebank as needed.

Followings are our main clinical themes to be pursued to improve the safety and prognosis of corneal transplantation.

- 1) Positive proof that donors were free of such infectious diseases as viral hepatitis, syphilis, AIDS and acute T-cell leukemia to prevent transmission to recipient patients through grafting.
- 2) Postoperative clinical outcomes are evaluated in regenerative medicine for ocular surface reconstruction, such as cultured corneal limbal, oral mucosal and conjunctival epithelial sheet

transplantation on the amniotic membrane, full-thickness corneal transplantation, lamellar keratoplasty, and endothelial keratoplasty.

- 3) Critical factors to affect clinical outcomes are statistically investigated in various kinds of corneal operation technique.

Teaching activities

We give lectures on corneal diseases and corneal transplantation to medical students and practitioners. In addition, we are engaged in practical training for young ophthalmologists on ophthalmological examinations at the outpatient clinic.

Research activities

We are conducting clinical research of postoperative results of DSAEK, clinical results of corneal crosslinking, and clinical research of corneal biometry by using anterior segment OCT.

In addition, we are investigating genetic analysis and genome editing research for corneal dystrophy. And we are also conducting research to elucidate the pathology using corneal transplant specimens.

References

- 1: Yamamoto R, Ono T, Toyono T, Shirakawa R, Noda M, Yoshida J, Miyai T. Assessment of Long-Term Anterior and Posterior Topographic Changes in the Cornea After Ptosis Surgery Using Fourier Harmonic Analysis. *Cornea*. 2021 Apr; 40(4):440-444. doi:10.1097/ICO.0000000000002429. PMID: 33881809.
- 2: Nakagawa S, Ishii H, Takamoto M, Kaburaki T, Ishii K, Miyai T. Diagnosis of cytomegalovirus corneal endotheliitis using surgically removed Descemet's membrane and endothelium despite negative results with aqueous humor PCR: a case report. *BMC Ophthalmol*. 2021 May 1;21(1):194. doi: 10.1186/s12886-021-01962-y. PMID: 33933006; PMCID: PMC8088667.
- 3: Ueda K, Ono T, Toyono T, Yoshida J, Kaburaki T, Miyai T. Descemet stripping endothelial keratoplasty after cytomegalovirus corneal endotheliitis and immunosuppression for Mooren's ulcer. *Am J Ophthalmol Case Rep*. 2021 Apr 14;22:101088. doi:10.1016/j.ajoc.2021.101088. PMID:33937582; PMCID: PMC8079431.
- 4: Omoto T, Agata C, Akiyama R, Kitamoto K, Toyono T, Yoshida J, Yamagami S, Usui T, Miyai T. Iridotrabecular and Iridocorneal Contact Changes after Cataract Surgery and Endothelial Keratoplasty in Bilateral Iridoschisis. *Case Rep Ophthalmol*. 2021 Apr 12;12(1):198-203. doi: 10.1159/000513793. PMID: 33976682; PMCID: PMC8077475.
- 5: Takahashi S, Ono T, Abe K, Mori Y, Nejima R, Iwasaki T, Miyai T, Miyata K. Prognosis and etiology of traumatic and non-traumatic corneal perforations in a tertiary referral hospital: a 30-year retrospective study. *Graefes Arch Clin Exp Ophthalmol*. 2022 Feb;260(2):629-635. doi: 10.1007/s00417-021-05389-5. Epub 2021 Sep 1. PMID: 34468830.
- 6: Ono T, Mori Y, Nejima R, Iwasaki T, Miyai T, Aihara M, Miyata K. Comparison of Corneal Irregularity After Recurrent and Primary Pterygium Surgery Using Fourier Harmonic Analysis. *Transl Vis Sci Technol*. 2021 Sep 1; 10(11):13. doi: 10.1167/tvst.10.11.13. PMID: 34515760; PMCID: PMC8444459.
- 7: Ono T, Mori Y, Nejima R, Iwasaki T, Miyai T, Miyata K. Corneal endothelial cell density and morphology in ophthalmologically healthy young individuals in Japan: An observational study of 16842 eyes. *Sci Rep*. 2021 Sep 14;11(1):18224. doi: 10.1038/s41598-021-97776-5. PMID: 34521951; PMCID: PMC8440503.
- 8: Kamiya K, Ayatsuka Y, Kato Y, Shoji N, Miyai T, Ishii H, Mori Y, Miyata K. Prediction of keratoconus progression using deep learning of anterior segment optical coherence tomography maps. *Ann Transl Med*. 2021 Aug;9(16):1287. doi: 10.21037/atm-21-1772. PMID: 34532424; PMCID: PMC8422102.
- 9: Ono T, Mori Y, Nejima R, Iwasaki T, Miyai T, Ohtani S, Miyata K. Corneal Edema with Anterior Uveitis after Exposure to the Sap of *Euphorbia trigona*: A Case Report. *Case Rep Ophthalmol*. 2021 Aug 6;12(2):699-705. doi: 10.1159/

000517742. PMID: 34594207; PMCID: PMC8436689.
- 10: Miyoshi Y, Ono T, Seki S, Toyono T, Kitamoto K, Hayashi T, Usui T, Aihara M, Miyai T. Corneal Graft Rejection after Descemet's Membrane Endothelial Keratoplasty with Peripheral Anterior Synechiae. *Case Rep Ophthalmol*. 2022 Jan 31;13(1):17-22. doi: 10.1159/000520877. PMID: 35221975; PMCID: PMC8832220.
 - 11: Ishii H, Yoshida J, Toyono T, Yamagami S, Usui T, Miyai T. Three-year results of accelerated transepithelial cross-linking (30 mW/cm² × 3 min) for keratoconus: a prospective study. *BMJ Open Ophthalmol*. 2022 Feb 8;7(1):e000827. doi: 10.1136/bmjophth-2021-000827. PMID: 35224204; PMCID: PMC8830257.
 - 12: Inamochi A, Miyai T, Usui T, Aihara M, Yamagami S. Effects of corneal epithelial superficial keratectomy in patients with focal limbal stem cell disease. *Am J Ophthalmol Case Rep*. 2021 Dec 7;25:101239. doi: 10.1016/j.ajoc.2021.101239. PMID: 34917856; PMCID: PMC8666511.
 - 13: Ono T, Takahashi S, Mori Y, Nejima R, Iwasaki T, Kataoka Y, Miyai T, Miyata K. Severe fishhook-related ocular injury: A case series. *Trauma Case Rep*. 2021 Dec 8;37:100574. doi: 10.1016/j.tcr.2021.100574. PMID: 34917740; PMCID: PMC8666537.
 - 14: Abe K, Miyai T, Toyono T, Aixinjueluo W, Inoue T, Asano S, Ishii H, Yoshida J, Shirakawa R, Usui T. Comparison of efficacy and safety of accelerated trans- epithelial crosslinking for keratoconus patients with corneas thicker and thinner than 380µm. *Curr Eye Res*. 2022 Apr; 47(4):511-516. doi: 10.1080/02713683.2021.2018466. Epub 2021 Dec 27. PMID: 34898348.

Department of Cell Therapy and Transplantation Medicine

Professor

Mineo Kurokawa, M.D., Ph.D. (Hematology-Oncology)

Assistant Professor

Moe Hidaka, M.D., Ph.D. (Pediatrics/Hematology-Oncology)

Junji Tokushige, M.D., Ph.D. (Hematology-Oncology)

Homepage <http://www.h.u-tokyo.ac.jp/mukin/>

Introduction and Organization

The Department of Cell Therapy and Transplantation Medicine was institutionally established in 1995, and was formally organized in 1996. At present, the staff consists of the above-mentioned medical doctors. Clinical facilities include 8 single-patient rooms with high-efficiency particulate air filtration and other high standards. Patients who are eligible for the treatment with high-grade infectious prophylaxis are admitted to the facilities.

Clinical activities

Approximately 1,000 patients have undergone hematopoietic stem cell transplantation (HSCT) in our department since 1995. Allogeneic bone marrow transplantation from donors Japan Marrow Donor Program (JMDP) as well as international bone marrow donor programs, HSCT from HLA-mismatched donors, and donor lymphocyte infusion are available. In 2022, 17 patients (including 2 children) received autologous HSCT and 23 patients (including 5 children) allogeneic HSCT. We cooperate with the members of Department of Hematology and Oncology, Hematology/Oncology group in the Department of Pediatrics, and Department of Transfusion Medicine.

Allogeneic hematopoietic stem cell transplantation: Bone marrow cells are operatively harvested and infused without preservation. For peripheral blood

stem cell transplantation, leukapheresis is performed with the use of an automated continuous flow blood cell separator, and harvested cells are preserved at -196°C in cooperation with Department of Transfusion Medicine. Recently, transplantation after pre-conditioning of reduced intensity (RIST for reduced-intensity HSCT or NST for non-myeloablative HSCT) is commonly performed for the elderly and patients with organ dysfunction. The development of this strategy is expanding the eligibility of transplant recipients.

Some patients cannot get transplantation treatment because they don't have eligible donors with at least a 90% match of HLA. Recently, with the development of new methods of transplantation management, such as immunosuppression, it has become possible to safely carry out transplants from donors with a 50% HLA match (HLA haploidentical transplantation; haplo transplants), and the procedure is expected to spread more widely in the future. The department proactively performs haplo transplants for patients in need to overcome diseases.

Allogeneic HSCT for the elderly and HLA haploidentical transplantation are performed under the admission of Patient Relations and Clinical Ethics Center.

High-dose chemotherapy with or without autologous stem cell support: High-dose chemotherapy is administered according to the malignant disease. For

the autologous stem cell support, peripheral blood stem cell is usually selected as a source of stem cells. Similar procedures used in the allogeneic stem cell harvest are performed for leukapheresis and preservation of autologous stem cell. Malignant lymphomas arising from the central nervous system (brain and spinal cord) are known to be refractory to treatment and have a poor prognosis. Recently, chemotherapy including autologous HSCT has been used to treat this disease with good efficacy. In our department, we are striving to improve the prognosis of patients with CNS malignant lymphoma by providing treatment including autologous transplantation.

CAR-T Cell Therapy: CAR-T cell therapies are customized for each individual patient. They are made by collecting T cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognize and bind to specific proteins, or antigens, on the surface of tumor cells, and allow T cells to exert their ability to kill these tumor cells. By collaborating with the Department of Hematology and Oncology, the Department of Pediatrics (Hematology/Oncology), and the Cell Processing Center, we are performing this most advanced and promising cancer treatment for patients with hematologic malignancies, and actively recruiting patients.

Clinical conference for hematopoietic stem cell transplantation: The conference is held monthly. The members of Department of Hematology and Oncology, Hematology/Oncology group in Department of Pediatrics, and Department of Transfusion Medicine join the conference and discuss on HSCT recipients.

Teaching activities

Together with the members of Department of Hematology and Oncology and Hematology/Oncology group in the Department of Pediatrics, lecture courses on etiology, pathogenesis, clinical and laboratory features, differential diagnosis, therapy and prognosis for all hematological diseases are provided to the second-grade medical students. Clinical clerkship courses are given to the third-grade medical students,

who join the patient care teams consisting of junior and senior medical doctors and learn medical practices and patient management, through playing a role as a junior member of the team, as well as through discussions and presentations. We also provide educational opportunities to continuously develop future specialists on HSCT – Board-certified physicians, hematopoietic cell transplant coordinators, and long-term follow up nurses by the Japan Society for Hematopoietic Cell Transplantation.

Research activities

The major research projects are focused on clinical studies such as development of improved/new methods for hematopoietic stem cell transplantation, immunotherapy for hematopoietic malignancies, and basic studies on hematopoietic stem cells, leukemogenesis and regenerative medicine using hematopoietic cells. In the area of pediatric oncology, we continue the studies on molecular mechanisms of pediatric malignancies such as neuroblastoma, rhabdomyosarcoma, and infant leukemia.

References

1. Oyama T, Matsuda K, Honda A, Maki H, Masamoto Y, Murakami D, Toya T, Sakurai M, Kataoka K, Doki N, Kurokawa M. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis. *Int J Hematol*. 2023 Feb;117(2):260-268.
2. Fukui Y, Honda A, Takano H, Obo T, Mizuno H, Masamoto Y, Kurokawa M. Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma. *J Clin Exp Hematop*. 2022 Dec 28;62(4):217-221.
3. Kato K, Yabe H, Shimozaawa N, Adachi S, Kurokawa M, Hashii Y, Sato A, Yoshida N, Kaga M, Onodera O, Kato S, Atsuta Y, Morio T. Stem cell transplantation for pediatric patients with adrenoleukodystrophy: A nationwide retrospective analysis in Japan. *Pediatr Transplant*. 2022 Feb;26(1):e14125.
4. Mizuta S, Ugai T, Kato H, Doki N, Ota S, Kawakita T, Katayama Y, Kurokawa M, Nakamae H, Yano S, Nawa Y, Kanda Y, Fukuda T, Atsuta Y,

- Kako S. Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. *Int J Hematol*. 2022 Sep; 116(3):393-400.
5. Ito Y, Honda A, Kurokawa M. Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: a meta-analysis. *Blood Adv*. 2022 Mar 8;6(5):1499-1511.
 6. Sato M, Honda A, Maki H, Toyama K, Yamaguchi R, Ikeda M, Moriya K, Kurokawa M. Successful treatment of pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa* after allogeneic hematopoietic stem cell transplantation with colistin and amikacin inhalation therapy. *J Infect Chemother*. 2022 Jan;28(1):91-94.
 7. Kato S, Nakano Y, Okamoto K, Takasugi N, Hidaka M, Sekiguchi M, Hiwatari M, Kurono M, Kato M. COVID-19 in an adolescent with aplastic anemia undergoing immunosuppressive therapy: A case report and details of antibody testing for SARS-CoV-2. *Pediatric Blood Cancer*. 2022 Feb, 69(2):e29332.doi

Clinical Nutrition Center

Head of the Center

Kazuhiko Fukatsu (Professor)

Assistant Head of the Center

Naoto Kubota (Associate Professor) Department of Clinical Nutrition Therapy

Hideaki Ijichi (Lecturer) Division of Dietary Treatment and Nutritional Care

※The following information is the same as that of the previous year for certain reasons.

Homepage <http://www.h.u-tokyo.ac.jp/patient/depts/eiyou/>

Introduction and Organization

In 1922, a stall in the outpatient department of the hospital and hospital ward shop sold milk, baked goods, cider and ice cream. In 1925, a service contract between the hospital and the Kojinkai Foundation resulted in the start of a patient food service. In 1936, a “special therapeutic diet” approach for newborn infants, diabetes, nephropathy in which a physician prescribed the food composition individually for each patient was instituted for the first time in Japan. In 1950, a national-hospital complete food service system was announced, and the nutrient content provided was standardized. The nutrient content provision for patient meals at the time was 2400 kcal/day. In 1952, the inpatient meal service was officially outsourced to a foundation.

In 1957, the first nationwide meeting of national-university-hospital head dietitians was held at the University of Tokyo with the aim of improving patients’ diets.

In 1958, the complete food service was abolished. Implementation of a standard food service and staffing with a dietitian became required conditions, and the food service section was staffed by a part-time section chief and a dietitian. In 1962, a request from the nationwide meeting of national-university-hospital head dietitians, which primarily conducted its activities at the University of Tokyo, was realized, and the managerial dietitian system was established by a partial revision of the Nutritionists Act. In 1972, nutritional

guidance was actively provided to inpatients and outpatients with the aim of obtaining approval to charge fees, and in 1978 a medical diet charge and nutrition guidance charge were established. In 1988, a timely tray service achieved by using hot and cold food-tray carts was instituted in order to dispel the “too early, cold, unappetizing” reputation of hospital meals.

In 1991, the name of the food service section was changed to the “Department of Nutrition Management”, a change that had long been sought by nationwide national-university-hospital managerial dietitian staff members. At the same time, the nutrition sections of the main hospital and branch hospital were consolidated, and the head of the Department of Nutrition Management, who was a managerial dietitian, assumed the section manager post to form a system composed of 5 managerial dietitians at the main hospital and 3 managerial dietitians at the branch hospital.

In 1994, as a result of a partial revision of the National Health Insurance Act, a diet therapy notification system on admission was set up. An on-admission nutrition guidance fee was also established.

In 1998, the first Diet Therapy Exhibit organized by the Department of Nutrition Management was conducted as part of the diabetes week events by the Tokyo Diabetes Association. Since then, Diet Therapy Exhibit has been conducted every year for over 20 years.

In 2001, integration of the branch hospital with the main hospital resulted in an 8-managerial-dietitian system. In 2004, the Department of Nutrition

Management was separated from the medical service division. In 2005, the introduction of the self-pay system for inpatient meals meant that inpatients began to be charged for their meals. During the same year one managerial dietitian (limited-term employment) was added to the staff.

In 2006, charges for the performance of nutrition management were newly established, and that meant providing nutrition management for all patients. The increase in work was accompanied by the addition of one managerial dietitian (limited-term employment) to the staff. Team care was introduced the same year, and in-hospital activity in the form of an all-department nutrition support team (NST) was inaugurated. Each hospital ward was staffed with a physician, managerial dietitian, and nurse in charge of an NST, and whenever necessary members from other fields (pharmacists, medical technologists, physical therapists) joined, and they held a hospital ward meeting once a week. In 2010, an NST committee was created as a result of the establishment of charges for NSTs. The NST director up until that time became a member of the committee and played an active role as the center of in-hospital NST activities. The addition of one managerial dietitian (full time) was approved as a full-time employee to engage in the activities of charges for the NST. In 2011, the inauguration of a nutritional guidance service for recipients of health checkups in the Department of Epidemiology and Preventive Medicine was accompanied by the addition of one managerial dietitian (limited-term employment) to the staff. In 2012, charges for conducting nutrition management were abolished. They were incorporated into the basic hospital-admission fee, and the nutrition management system by physicians, managerial dietitians, and nurses was improved.

In 2013, the Department of Nutrition Management was reorganized as the Department of Clinical Nutrition Therapy. A physician (Professor, the head of the Central Clinical Services Administration) assumed the concurrent post of head of the Department, and the head of the Department of Nutrition Management assumed the post of Assistant Head of the Department; they undertook responsibility for managing the food service, maintaining activities of the NST, and strengthening its functions. In 2014, two physicians, full-time department head (associate professor) and

lecturer, were assigned and improvements were made to NST activities and to the nutrition therapy, education, and research system. As a result of a managerial strategic personnel distribution, 5 new managerial dietitians (full-time) have also been assigned this fiscal year. Along with the increase in work of managerial dietitians for strengthening the nutrition management system and expanding the number of clinical trials in P1 unit, another managerial dietitian (limited-term employment) was added to the staff in May 2015.

Long-coveted introduction of the New Cook Chill System was eventually admitted by the University of Tokyo and the process was started in October 2016. Renovation of the main kitchen was started in June 2017. During the renovation, the makeshift kitchen was placed on the 1st floor (the main kitchen) and the 3rd basement floor (the washing room and the formula room) of the Inpatients Ward A and the menu was restricted for the makeshift kitchen use. In February 2018, the New Cook Chill System in the University of Tokyo Hospital began. The menu was considerably modified for the new cooking system.

In April 2018, a new formula room was launched on the first floor of the Inpatients Ward A for the expansion of Pediatric Medical Center. Monthly issue of diet news for the patients started in June 2018 and Grand Menu for the special admission room was newly set up in January 2019.

In 2019, the University of Tokyo Hospital was recognized as Tokyo Food Hygiene Meister by Tokyo Metropolitan Certification System for Self-Management of Food Hygiene, and also as an Elite Institution of Food Hygiene by Bunkyo-ku.

In April 2020, the department was reorganized to be the Clinical Nutrition Center, composed of the Department of Clinical Nutrition Therapy in charge of nutritional guidance and the Division of Dietary Treatment and Nutritional Care in charge of meal service and nutritional care for inpatients. A professor of the Surgical Center assumed the Head of the Clinical Nutrition Center, and the both sections named a director (physician) and a deputy director (managerial dietitian), respectively. All the other managerial dietitians belong to the Center and engage in the works of both sections.

During the pandemic of COVID-19, the hospital closed the special admission room and the Grand Menu

was stopped in 2021.

Clinical Activities

The Center is proactively conducting nutritional guidance in regard to metabolic diseases, including diabetes, chronic kidney disease, dyslipidemia, and obesity, perioperative guidance, including in regard to postgastrectomy diets, hepatobiliary and pancreatic disease diets, and cardiac disease diets, etc.

In 2021, nutritional guidance of inpatients and outpatients increased upto 3648 instances for inpatients and 6916 instances for outpatients. Nutritional guidance for malignant tumor patients was performed for 822 instances.

The Center is also proactively cooperating with several departments in the hospital. In 2021, perioperative guidance was 91 instances, diabetes and dialysis prevention guidance for outpatients was 141 instances, dietary management with palliative care was 339 instances, nutritional guidance for outpatient chemotherapy was 161 instances, nutritional guidance at the preventive medicine center was 60 instances. In addition, the provision of inpatient nutrition information was 61 instances.

In April 2014, the department started calculating charges for NST and counted 1261 instances in the first fiscal year. In April 2016, dentists joined the NST round and started to calculate the additional charge. After 2020, due to the COVID-19 pandemic, the instances decreased. 260 rounds were performed and 204 instances were calculated in 2021.

In November 2014, a procedure manual of nutritional management was revised and an original two-step nutritional screening by physicians, managerial dietitians, nurses and pharmacists was introduced. In this system, the high-risk patients of malnutrition were weekly screened through the common criteria in our hospital and referred to the NST of each floor (ward NST). In April 2015, alternative initial screening criteria specific for pediatric and pregnant patients were added to the procedure manual of nutritional management, respectively. By 2019, almost all the floor started the ward NST, which indicated raised awareness of nutritional care as a team medicine in our hospital. Then, in 2020, instead of the common screening criteria, each floor started more

specific screening for the ward NST, based on the characteristics of the patients and treatment department.

In 2018, related with the start of surgery for severe obesity patients (sleeve gastrectomy), sleeve diet was newly introduced. In January 2019, ketogenic diet was also introduced in cooperation with Epilepsy Center.

In 2019, in addition to the Tokyo Food Hygiene Meister and Elite Institution of Food Hygiene by Bunkyo-ku, the safe and assured food service in our hospital was evaluated “S” rank (the highest) by the hospital function evaluation.

Educational Activities

The department has accepted managerial dietitian clinical trainees. In 2019, the department accepted 45 trainees from 7 training schools: Ochanomizu University, Tokyo Kasei University, Otsuma Women’s University, Kagawa Education Institute of Nutrition, Jissen Women’s Educational Institute, Japan Women’s University, and Wayo Women’s University.

In 2011, the department began accepting NST trainees. From 1 to 4 or 5 terms are conducted a year (5 days/ week/ term). Participants are mainly managerial dietitians, pharmacists, nurses, medical technologists, and physical therapists, and candidates are trainees whose aim is acquiring the qualifications certified by academic societies or to become a full-time employee to calculate the billing charges for the NST. There were 18 participants in 2019. Due to the COVID-19 pandemic, these programs accepting external trainee were cancelled in 2020-2021.

In 2017, the department was involved in the curriculum of Clinical Clerkship 2, the medical education program of the Faculty of Medicine, the University of Tokyo. 106 medical students at M4 grade participated in the two-day practice course in 2021.

To disseminate NST activities fully in the hospital, the department has organized two NST-related seminars throughout the year: Basic Series for Nutrition Therapy and Clinical Nutrition Seminar. The department has also organized NST Conference and Joint Conference of Team Medicine (JCTM) for case discussions to facilitate cooperation with each floor NST and other medical teams. In 2020, due to the COVID-19 pandemic, all the seminars and JCTM were conducted online and the NST Conference was

adjourned. In 2021, the Center combined the two seminars and restarted with a hybrid style, on-site and online, with total 546 attendee.

In 2015, the department started “Nutritional Management e-learning” for all employee to learn basic knowledge of nutritional management procedure.

In 2016, “The Manual of The Department of Clinical Nutrition Therapy 2015-2016” was published. After that, “The Pocket Manual of The Department of Clinical Nutrition Therapy 2016-2017”, “The Manual of The Department of Clinical Nutrition Therapy 2017-2019”, “Records of the Kitchen Renovation 2016-2018”, “The Pocket Manual of The Department of Clinical Nutrition Therapy 2018-2021”, “Illustrated Tools of Nutritional Guidance 2018-2022” and “New Cook Chill Manual 2018-2022” were published by March 2020.

Research

- Research topic: “Retrospective study using database of patients records who have undergone nutritional guidance”
- Research topic: “Surveillance of nutritional status and its change in pancreatic cancer patients receiving chemotherapy”
- Research topic: “Surveillance of change in body composition by using visceral fat measuring device”
- Research topic: “Roles of microbiome in lifestyle-related diseases” (Joint research)
- Research topic: “Exploratory research in the association of plasma amino acids and the nutrition status of patients with diabetes mellitus and the comorbidities”
- Research topic: “Exploratory research of biomarkers in the blood and body fluid for diabetes mellitus”
- Research topic: “Impact of periodical measurement of serum glycoalbumin on the patients with diabetes mellitus”
- Research topic: “Impact of periodical measurement of diabetes mellitus-related biomarkers in tear fluid”
- Research topic: “Association of food diversity and obesity in patients with diabetes mellitus”
- Research topic: “Evaluation of nutritional guidance on the treatment-naïve patients with high LDL-cholesterolemia”
- Research topic: “Association of initial nutritional condition and prognosis in elderly patients at NST round”
- Research topic: “Assessment of dietary intake of inpatients with diabetes mellitus”
- Research topics: “Correlation research of biomarkers in the blood and body fluid and diabetes mellitus”
- Research topic: “Association of diet and nutritional factors and control of blood sugar and lipid in patients with diabetes mellitus”
- Research topic: “Association of diet and nutritional factors and sarcopenia and frail in elderly patients with diabetes mellitus”
- Research topic: “Association of dietary intake and background dietary habit in inpatients with diabetes mellitus”
- Research topic: “Assessment of dietary intake and bodily characteristics in patients with eating disorder”
- Research topic: “Association of change of dietary intake and weight loss effect in highly obese patients after bariatric surgery”
- Research topic: “Surveillance of nutritional status and its change in patients with severe heart failure”
- Research topic: “Surveillance of nutritional assessment and guidance at the perioperative clinic”

References

<Publications (English)>

1. Nakatsuka T, Tateishi K, Kato H, Fujiwara H, Yamamoto K, Kudo Y, Nakagawa H, Tanaka Y, Ijichi H, Ikenoue T, Ishizawa T, Hasegawa K, Tachibana M, Shinkai Y, Koike K. Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosis. *Cell Death Dis.* 12:99, 2021.
2. Yamazaki T, Inada S, Sawada M, Sekine R, Kubota N, Fukatsu K, Yoshiuchi K. Diets with high carbohydrate contents were associated with refeeding hypophosphatemia: A retrospective study in Japanese inpatients with anorexia nervosa. *Int J Eat Disord.* 54:88-94, 2021.
3. Tanaka Y, Shimanaka Y, Caddeo A, Kubo T, Mao Y, Kubota T, Kubota N, Yamauchi T, Mancina RM, Baselli G, Luukkonen P, Pihlajamäki J, Yki-Järvinen H, Valenti L, Arai H, Romeo S, Kono N. LPIAT1/MBOAT7 depletion increases

- triglyceride synthesis fueled by high phosphatidylinositol turnover. *Gut*. 70:180-193, 2021.
4. Aihara M, Kubota N, Minami T, Shirakawa R, Sakurai Y, Hayashi T, Iwamoto M, Takamoto I, Kubota T, Suzuki R, Usami S, Jinnouchi H, Aihara M, Yamauchi T, Sakata T, Kadowaki T. Association between tear and blood glucose concentrations: Random intercept model adjusted with confounders in tear samples negative for occult blood. *J Diabetes Investig*. 12:266-276, 2021.
 5. Saito K, Nakai Y, Takahara N, Ishigaki K, Suzuki Y, Inokuma A, Noguchi K, Kanai S, Sato T, Hakuta R, Saito T, Hamada T, Mizuno S, Kogure H, Ijichi H, Tateishi K, Koike K. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. *Invest New Drugs*. 39:605-613, 2021.
 6. Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. *Int J Mol Sci*. 22:4156, 2021.
 7. Hamada T, Oyama H, Nakai Y, Tada M, Koh H, Tateishi K, Arita J, Hakuta R, Ijichi H, Ishigaki K, Kawaguchi Y, Kogure H, Mizuno S, Morikawa T, Saito K, Saito T, Sato T, Takagi K, Takahara N, Takahashi R, Tanaka A, Tanaka M, Ushiku T, Hasegawa K, Koike K. ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms. *Cancer Epidemiol Biomarkers Prev*. 30:1020-1028, 2021.
 8. Kubota N, Kubota T, Kadowaki T. Midlobular zone 2 hepatocytes: A gatekeeper of liver homeostasis. *Cell Metab*. 33:855-856, 2021.
 9. Watanabe D, Murakami H, Ohno H, Tanisawa K, Konishi K, Todoroki-Mori K, Tsunematsu Y, Sato M, Ogata Y, Miyoshi N, Kubota N, Kunisawa J, Wakabayashi K, Kubota T, Watanabe K, Miyachi M. Stool pattern is associated with not only the prevalence of tumorigenic bacteria isolated from fecal matter but also plasma and fecal fatty acids in healthy Japanese adults. *BMC Microbiol*. 21: 196, 2021.
 10. Hasegawa Y, Ijichi H, Saito K, Ishigaki K, Takami M, Sekine R, Usami S, Nakai Y, Koike K, Kubota N. Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A prospective cohort study. *Clin Nutr*. 40:4792-4798, 2021.
 11. Watkins A, Fukatsu K, Higashizono K, Watanabe T, Noguchi M, Tominaga E, Murakoshi S, Yasuhara H. Influence of a Low-Carbohydrate High-Fat Diet on Peritoneal Inflammation, Cancer-Associated Lymphocytes, and Survival in a Murine Carcinomatous Peritonitis Model. *JPN J Parenter Enteral Nutr*. 45:1293-1301, 2021.
 12. Hayashi T, Kubota T, Mariko I, Takamoto I, Aihara M, Sakurai Y, Wada N, Miki T, Yamauchi T, Kubota N, Kadowaki T. Lack of Brain Insulin Receptor Substrate-1 Causes Growth Retardation, With Decreased Expression of Growth Hormone-Releasing Hormone in the Hypothalamus. *Diabetes*. 70:1640-1653, 2021.
 13. Furuzono S, Kubota T, Taura J, Konishi M, Naito A, Tsutsui M, Karasawa H, Kubota N, Kadowaki T. A xanthene derivative, DS20060511, attenuates glucose intolerance by inducing skeletal muscle-specific GLUT4 translocation in mice. *Commun Biol*. 4:994, 2021.
 14. Sano M, Takahashi R, Ijichi H, Ishigaki K, Yamada T, Miyabayashi K, Kimura G, Mizuno S, Kato H, Fujiwara H, Nakatsuka T, Tanaka Y, Kim J, Masugi Y, Morishita Y, Tanaka M, Ushiku T, Nakai Y, Tateishi K, Ishii Y, Isayama H, Moses HL, Koike K. Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism. *Gut*. 70:1713-1723, 2021.
 15. Ochiai T, Sano T, Nagayama T, Kubota N, Kadowaki T, Wakabayashi T, Iwatsubo T. Differential involvement of insulin receptor substrate (IRS)-1 and IRS-2 in brain insulin signaling is associated with the effects on amyloid pathology in a mouse model of Alzheimer's disease. *Neurobiol Dis*. 159:105510, 2021.
 16. Ishihama S, Yoshida S, Yoshida T, Mori Y, Ouchi N, Eguchi S, Sakaguchi T, Tsuda T, Kato K, Shimizu Y, Ohashi K, Okumura T, Bando YK, Yagyu H, Wettschureck N, Kubota N, Offermanns S, Kadowaki T, Murohara T, Takefuji M. LPL/AQP7/GPD2 promotes glycerol metabolism

under hypoxia and prevents cardiac dysfunction during ischemia. *FASEB J.* 35:e22048, 2021.

17. Jinnouchi T, Sakurai Y, Miyoshi K, Koizumi C, Waki H, Kubota N, Yamauchi T. Chronic Intestinal Pseudo-obstruction with Mitochondrial Diseases. *Intern Med.* 61:469-474, 2021.
18. Kato H, Tateishi K, Fujiwara H, Nakatsuka T, Yamamoto K, Kudo Y, Hayakawa Y, Nakagawa H, Tanaka Y, Ijichi H, Otsuka M, Iwadate D, Oyama H, Kanai S, Noguchi K, Suzuki T, Sato T, Hakuta R, Ishigaki K, Saito K, Saito T, Takahara N, Kishikawa T, Hamada T, Takahashi R, Miyabayashi K, Mizuno S, Kogure H, Nakai Y, Hirata Y, Toyoda A, Ichikawa K, Qu W, Morishita S, Arita J, Tanaka M, Ushiku T, Hasegawa K, Fujishiro M, Koike K. MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages. *Gastroenterology*. Epub 2021 Dec 22.

Swallowing Center

Director/Associate Professor

Rumi Ueha, M.D., Ph.D.

Vice Director

Haruhi Inokuchi, M.D., Ph.D. (Department of Rehabilitation Medicine)

Asako Kaneoka, SLP., Ph.D. (Rehabilitation Center)

Homepage <http://www.m.u-tokyo.ac.jp/mcm/>

Introduction and Organization

A condition in which there is a problem with swallowing food or drink is called swallowing disorder. In recent years, advances in medical technology have increased the lifesaving rate and aging of society, resulting in an increase in the number of patients with dysphagia among a wide range of age groups caused by congenital diseases, stroke, intractable diseases, malignant tumors, and aging. Since 2009, we have been providing medical care for patients with dysphagia at the University of Tokyo Hospital by organizing the "Swallowing Support Team" with specialists in the field of swallowing. To provide a more specialized and multifaceted treatment for dysphagia in 2021, the Swallowing Center was established.

At the Swallowing Center, the departments of Otolaryngology and Head and Neck Surgery, Rehabilitation Medicine, Oral-Maxillofacial Surgery and Orthodontics, Geriatric Medicine, Pediatrics, Pediatric Surgery, Neurology, Clinical Nutrition, Nursing, and Clinical Laboratory work together as a team of multidisciplinary specialists, including physicians, speech pathologists, nurses, dietitians, pharmacists, and dental hygienists, taking a multifaceted approach to each patient.

The following is a list of departments and divisions that collaborate with the Swallowing Center:

1. Otolaryngology and Head and Neck Surgery
2. Rehabilitation Medicine
3. Oral-Maxillofacial Surgery and Orthodontics
4. Geriatric Medicine

5. Pediatrics
6. Pediatric Surgery
7. Neurology
8. Clinical Nutrition Center
9. Nursing Department
10. Pharmaceutical Department

We also hold a bimonthly meeting of the Swallowing Center to share information and improve problems.

Clinical activities

We have outpatient clinics for patients with dysphagia at the Department of Otorhinolaryngology and Head and Neck Surgery every Tuesday and Thursday morning. For hospitalized patients, we provide more specialized and multifaceted treatment for dysphagia caused by a variety of factors in a wide range of age groups, with physicians and specialists from multiple departments working as a team. A weekly swallowing conference is held on Tuesdays to discuss the various cases with a multidisciplinary team.

We also actively perform surgical treatment for dysphagia (to prevent aspiration or to improve swallowing function) and provide intensive rehabilitation after surgery to improve swallowing function during hospitalization.

The following is a list of swallowing examinations performed in 2022:

- Videofluorographic swallowing study: 683 cases
- Videoendoscopic examination of swallowing: 586 cases
- High-resolution swallowing manometry: 37 cases

- Swallowing computed tomography: 13 cases

Teaching activities

The center emphasizes educational activities on feeding and swallowing throughout the hospital, and actively organizes e-learning and training sessions.

We participate in undergraduate education as part of systemic lectures and bedside learning by the Department of Otolaryngology and Head and Neck Surgery and Rehabilitation Medicine.

Research activities

Our research field covers a variety of topics related to swallowing. Clinical and basic research activities are highly encouraged. Clinical research is related to swallowing dynamics and physiology, laryngology, broncho-esophagology, and rhinology, as well as case research and clinical statistics.

Basic research is also encouraged to solve the essence of clinical problems and to elucidate basic phenomena or anatomical and cellular structures. Our research topics are as follows:

1. Effects of aspiration prevention surgery on patients with severe dysphagia
2. Swallowing mechanisms using pathological and electrophysiological analysis and VR system
3. Esophageal Motility in neuromuscular disorders
4. Esophageal Motility in systemic sclerosis
5. Swallowing impairment in patients with lung transplants
6. Evaluation of swallowing physiology with pharyngo-esophageal high-resolution manometry
7. Regeneration of vocal fold structure and its molecular mechanism
8. Gene expression analysis of recurrent respiratory papillomatosis
9. Research on preventive rehabilitation for dysphagia due to chemoradiotherapy for head and neck cancer
10. Pathophysiology of dysphagia after esophageal cancer surgery
11. Statistical analysis of dysphagia patients using big data
12. Research on the effect of cervical spine surgery on swallowing function

References

1. Sugaya T, Ueha R, Sato T, Goto T, Yamauchi A, Yamasoba T. Safety of surgical tracheostomy under continued antithrombotic therapy. *Clin Otolaryngol*. 47(1):88-93. 2022.
2. Masuda H, Ueha R, Sato T, Goto T, Yamauchi A, Kaneoka A, Suzuki S, Yamasoba T. Risk factors for aspiration pneumonia after receiving liquid thickening recommendations. *Otolaryngol Head Neck Surg*. 67(1):125-132. 2022.
3. Ueha R, Ito T, Furukawa R, Kitabatake M, Ouji-Sageshima N, Ueha S, Koyama M, Uranaka T, Kondo K, Yamasoba T. Oral SARS-CoV-2 inoculation causes nasal viral infection leading to olfactory bulb infection: an experimental study. *Front Cell Infect Microbiol*. 12:924725. 2022.
4. Ueha R, Ito T, Ueha S, Furukawa R, Kitabatake M, Ouji-Sageshima N, Tanaka H, Uranaka T, Kondo K, Yamasoba T. Evidence for the Spread of SARS-CoV-2 and Olfactory Cell Lineage Impairment in Close-Contact Infection Syrian Hamster Models. *Front Cell Infect Microbiol*. 12: 1019723. 2022.
5. Sugito R, Yamauchi A, Sato T, Goto T, Ueha R, Nito T, Yamasoba T. Sex- and age-based etiological analysis of 2901 patients with dysphonia in a Japanese tertiary medical institute. *J Voice*. S0892-1997(22)00236-3. doi: 10.1016/j.jvoice.2022.08.003. 2022
6. Kaneoka A, Ueha R, Nagatomo M, Matsunaga A, Umezaki S, Inokuchi H, Ogata T. Esophageal speech for a patient with Amyotrophic Lateral Sclerosis who underwent a central-part laryngectomy to prevent aspiration: a case report. *Progress in Rehabilitation Medicine*. 7:20220064. doi: 10.2490/prm.20220064. 2022.
7. Koyama S, Mori E, Ueha R. Insight into the mechanisms of olfactory dysfunction by COVID-19. *Auris Nasus Larynx*. doi: 10.1016/j.anl.2022.12.002. 2022.
8. Inooka Y, Yamana H, Shinoda Y, Inokuchi H, Matsui H, Fushimi K, Yasunaga H, Haga N. Predictive factors for oral intake recovery after acute stroke: analysis of a Japanese nationwide inpatient database. *Dysphagia*. 37(6):1623-1632. 2022.

International Medical Center

Director and Associate Professor

Sumihito Tamura, M.D., Ph.D. FACS

Homepage <http://www.h.u-tokyo.ac.jp/english/international-patients/index.html>

Introduction and Organization

The International Medical Center is a Division within the Central Clinical Facilities established to enhance The University of Tokyo Hospital's development as an international medical hub in coordination with the University of Tokyo's significant movement in globalization. Designated management position has been assigned.

Activities and challenges

The University of Tokyo Hospital offers sophisticated surgery and state-of-the-art treatment in variety of fields. One of the roles of the International Medical Center is to establish a system through which we provide medical expertise to patients from overseas. The International Medical Center will cater to the various requirements that must be met when accepting overseas patients, including multilingual support, translation of medical documents, and offering solutions to financial challenges, so that each department can focus solely on providing medical treatment to those patients.

As well as receiving patients, another important aspect is the globalization of clinical education. We hope to establish a system in which non-Japanese doctors accepted for residencies, or those who come to receive cutting-edge medical training can carry out operations, interventions or demonstrations without being hindered by their nationality. Similarly, we hope to establish a system through which overseas doctors can learn new techniques alongside Japanese doctors, and to provide an environment where doctors from various countries can mingle with young doctors working at our hospital, as well as student physicians in participatory clinical training. We have been

actively accepting observership trainees per hospital ruling and advanced clinical trainees granted permission for hands-on clinical experience by the Ministry of Health, Labor and Welfare under the Exceptional Cases of the Medical Practitioners 'Act, Article 17, regarding Advanced Clinical Training of Foreign Medical Practitioners, etc.

Lastly, heightening the capability of physicians and medical staff to cater to international needs is an important factor in globalizing The University of Tokyo Hospital. Starting last year, International Continuous Professional Development Program has been introduced, attracting multiple groups from around the globe for learning experience at the University of Tokyo Hospital. To this end, the International Medical Center will attempt to cultivate personnel by hosting various international exchanges so as to further develop the hospital's capabilities to become an international hub in the field.

Center for Epidemiology and Preventive Medicine

Director & Associate Professor

Nobutake Yamamichi, M.D., Ph.D.

Deputy Director & Assistant Professor

Lumine Matsumoto, M.D., Ph.D.

Associates

Keiko Niimi, M.D., Ph.D., Yukari Masuda, M.D., Ph.D.

Hiroataka Matsuzaki, M.D., Ph.D., Eriko Hasumi, M.D., Ph.D., Chie Buijyo, M.D., Ph.D.,

Takako Nishikawa, M.D., Ph.D., Nobuyuki Sakuma, M.D., Ph.D.,

Homepage: <https://www.todai-yobouigaku-dock.jp/>
<https://www.h.u-tokyo.ac.jp/patient/depts/yobouigaku/>

Introduction and Organization

Following the inauguration of a new Central Clinical Service Building in November 2006 in the University of Tokyo Hospital, the Center for Epidemiology and Preventive Medicine was established on January 1st, 2007, within the Central Clinical Facilities and the relevant regulations were revised. On January 9th, the Working Group for the Establishment of the Center for Epidemiology and Preventive Medicine was organized; on April 1st, Steering Committee for the Establishment of the Center for Epidemiology and Preventive Medicine was organized; on June 4th, the department started offering its services on a trial basis (in-hospital services) and was officially inaugurated in July, starting to provide public services.

The principal objectives of the establishment of the Center for Epidemiology and Preventive Medicine are 1) to scientifically demonstrate the utility and effectiveness of examinations and preventive interventions, 2) to integrate a vast amount of clinical data and health-related information to develop more efficient models for disease management, 3) through 1) and 2), to promote preventive medicine and medicine for health promotion in an effort to contribute to the

improvement of public health, and 4) to train medical personnel who can put above-mentioned 1), 2) and 3) into practice.

In these twelve years since the official opening, our center has increased the number of examinees from ten subjects per day to twelve per day (March 2018). Following the reorganization in April 2018, the Center was transferred to the 15th floor of the inpatient building B in September 2018. As the area for examination was expanded, we have been able to increase the number of examinees to 16 in October 2018, 20 in April 2019, 22 in January 2021, and 25 in October 2022. Most of the examinations except for MRI and CT scan can be performed within our floor, which increased the convenience and comfort for the examinees.

In the administrative organization of the Center for Epidemiology and Preventive Medicine, the Director directly under the head of the hospital is responsible for the entire organization. Examinations in the Department are administered in collaboration with three Central Clinical Facilities (Clinical Laboratory Center, Radiological Center, and Department of Endoscopy and Endoscopic Surgery) and four Clinical

Divisions (Gastroenterology, Breast and Endocrine Surgery, Gynecologic Surgery and Ophthalmology and Vision Collection).

The staff of the Center for Epidemiology and Preventive Medicine is composed of nine physicians. Three of the regular physicians also perform upper gastrointestinal endoscopy and colonoscopy. Our department also has 11 nurses, six assistant clerks, and three medical clerk.

Clinical activities

In addition to basic examinations, we provide ten optional examinations: 1) comprehensive cardiovascular examinations, 2) comprehensive cerebrovascular examinations, 3) checkup for dementia, 4) colorectal cancer screening, 5) uterine cancer screening, 6) breast cancer screening, 7) lung cancer screening, 8) tumor marker diagnosis, 9) estimation of gastric cancer risk, and 10) pancreatic cancer screening. While meeting the needs of examinees, we have increased the number of the optional examinations.

The physicians of our department are responsible for analyzing the results of examinations and performing overall evaluations. We take plenty of time to perform comprehensive medical examinations and instantly write a referral letter to each department in the University of Tokyo Hospital when we find any abnormality through the examinations. Formally, the examinee is notified in writing within approximately three weeks after the examination. We also offer each examinee a free consultation so that we can help him/her understand the results or decide whether to have further detailed examination.

Teaching activities

We started clinical teaching for medical students in April 2017. Following the lecture of preventive medicine, students observe explanations by physicians to the examinees. They learn not only how to apply preventive medicine to practice, but also the manner of physicians to examinees.

Research activities

The University of Tokyo Hospital is expected not only to provide its service of comprehensive medical

examinations but also to promote evidence-based practice and scientific examinations, which is the mission of our department. Academically, we aim to establish a database from clinical data and to promote epidemiological research. This will enable us to prevent disease based on scientific data. We have conducted cross-sectional/longitudinal analysis. We also work in collaboration with other departments in our hospital and other facilities.

Past activities

The total number of examinees (who had basic examinations and optional examinations) in the FY 2022 was 9400 including 3249 in basic examinations, 596 in complete cardiovascular examinations, 751 in complete cerebrovascular examinations, 111 in check up for dementia, 434 in colorectal cancer screening, 700 in uterine cancer screening, 842 in breast cancer screening, 763 in lung cancer screening, 1373 in tumor marker diagnosis, 343 in estimation of gastric cancer risk, 238 in pancreatic cancer screening, and 10 in upper gastrointestinal endoscopy (later). Respiratory function test has been cancelled from March 31, 2020 due to coronavirus.

One of the important roles of our center is to provide the appropriate medicine to the examinees when any abnormal finding was detected. We provide referral letters to the department within/outside of our hospital for detailed examination or treatment, according to the request by the examinees. Prompt reference to the medical department in the University of Tokyo Hospital is one of the most contributable factors for the satisfaction of the examinees. In the FY 2022, we issued 1513 letters of referral to other departments in our hospital and 69 to other hospitals.

We have expanded our public relations efforts. We renewed brochures and 15,000 brochures were delivered during the FY 2021.

We have updated our original website (<https://www.todai-yobouigaku-dock.jp/>) and offer up-to-date information to the examinees. We also renewed brochure, distributing 15,000 copies within our hospital and on and off campus of the University of Tokyo as well. We have established preferential treatment system for graduates, faculty and staff to acquire new examinees.

The University of Tokyo Hospital established the Center for International Preventive Medicine in April 2020 and started to provide public services in July 2022. We offer full cooperation to the Center for International Preventive Medicine management.

References

Academic Papers in English

1. Takeuchi C, **Yamamichi N**, Liu YY, Ito M, Furuta T, Nakajima S, Sakaguchi Y, Takahashi Y, Tsuji Y, Niimi K, Tomida S, Fujishiro M, Yamamichi N, Ushijima T. Autoimmune gastritis induces aberrant DNA methylation reflecting its carcinogenic potential. *J Gastroenterol*. 2022 Mar;57(3):144-155.
2. Hisada H, Sakaguchi Y, Oshio K, Mizutani S, Nakagawa H, Sato J, Kubota D, Obata M, Cho R, Nagao S, Miura Y, Mizutani H, Ohki D, Yakabi S, Takahashi Y, Kakushima N, Tsuji Y, **Yamamichi N**, Fujishiro M. Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future. *CurrOncol*. 2022 Jul;29(7):46784688.
3. Hisada H, Tamura N, Tsuji Y, Nagao S, Fukagawa K, Miura Y, Mizutani H, Ohki D, Yakabi S, Minatsuki C, Takahashi Y, Sakaguchi Y, **Yamamichi N**, Fujishiro M. The impact of sarcopenia on adverse events associated with gastric endoscopic submucosal dissection. *Surg Endosc*. 2022 Sep;36(9):6387-6395.
4. Ohki D, Tsuji Y, Shinozaki T, Sakaguchi Y, Mizutani H, Nagao S, Miura Y, Fukagawa K, Tamura N, Yakabi S, **Yamamichi N**, Fujishiro M. Long-term prognosis after endoscopic resection of T1a-MM/T1b-SM1 esophageal squamous cell carcinoma. *Medicine (Baltimore)*. 2022 Dec; 101(49): e32115.
5. Arai J, Suzuki N, Niikura R, Ooki D, Kawahara T, Honda T, Hasatani K, Yoshida N, Nishida T, Sumiyoshi T, Kiyotoki S, Ikeya T, Arai M, Ishibashi R, Aoki T, Tsuji Y, **Yamamichi N**, Hayakawa Y, Fujishiro M. Chemoprevention for Colorectal Cancers: Are Chemopreventive Effects Different Between Left and Right Sided Colorectal Cancers? *Dig Dis Sci*. 2022 Nov; 67(11):5227-5238.
6. Saito K, Shimamoto T, Takahashi Y, Okushin K, Takahashi M, Masuda Y, Nishikawa T, Kakushima N, Wada R, **Yamamichi N**. Gender-specific factors contributing to visceral obesity including the sleep-obesity relationship: a large-scale cross-sectional study from East Asia. *Sci Rep*. 2022 Nov 24;12(1):20318.
7. Takahashi Y, **Yamamichi N**, Kubota D, Shimamoto T, Nagao S, Sakuma N, Sakaguchi Y, Yakabi S, Tsuji Y, Wada R, Mitsushima T, Ichinose M, Fujishiro M. Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study. *Gastric Cancer*. 2022 May; 25(3):481-489.
8. Ohki D, **Yamamichi N**, Sakaguchi Y, Takahashi Y, Kageyama-Yahara N, Yamamichi M, Takeuchi C, Tsuji Y, Sakai Y, Sakurai K, Tomida S, Koike K, Fujishiro M. Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2. *Cancer Med*. 2022 Dec;11(24):5066-5078.
9. Tamura N, Sakaguchi Y, Furutani W, Matsui M, Nagao S, Sakuma N, Fukagawa K, Miura Y, Mizutani H, Ohki D, Kataoka Y, Saito I, Ono M, Minatsuki C, Tsuji Y, Ono S, Kodashima S, Abe H, Ushiku T, **Yamamichi N**, Koike K, Fujishiro M. Magnifying endoscopy with narrow-band imaging is useful in differentiating gastric cancer from matched adenoma in white light imaging. *Sci Rep*. 2022 May 19;12(1):8349.
10. **Yamamichi N**, Shimamoto T, Takahashi Y, Takahashi M, Takeuchi C, Wada R, Fujishiro M. Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan. *PLoS One*. 2022 Jun 17;17(6):e0270252.
11. Hisada H, Tsuji Y, Obata M, Cho R, Nagao S, Miura Y, Mizutani H, Ohki D, Yakabi S, Takahashi Y, Sakaguchi Y, Kakushima N, **Yamamichi N**, Fujishiro M. The impact of sarcopenia on short- and long-term outcomes of endoscopic submucosal dissection for early gastric cancer. *J Gastroenterol*. 2022 Dec;57(12):952-961.
12. **Yamamichi N**, Shimamoto T, Okushin K, Nishikawa T, Matsuzaki H, Yakabi S, Takahashi M, Wada R, Koike K, Fujishiro M. Fibrosis-4 index efficiently predicts chronic hepatitis and

liver cirrhosis development based on a large-scale data of general population in Japan. *Sci Rep.* 2022 Nov 27;12(1):20357.

13. Kubota D, Takahashi Y, **Yamamichi N**, Matsui M, Shimamoto T, Minatsuki C, Nakagawa H, Mizutani S, Tsuji Y, Sakaguchi Y, Tamura N, Yakabi S, Ohki D, Mizutani H, Niimi K, Wada R, Fujishiro M. Analysis of Barrett's Esophagus and Its Risk Factors: A Cross-Sectional Study of 10,122 Subjects at a Japanese Health Examination Center. *Digestion.* 2022;103(6):411-420.
14. Ohki D, **Yamamichi N**, Sakaguchi Y, Takahashi Y, Kageyama-Yahara N, Yamamichi M, Takeuchi C, Tsuji Y, Sakai Y, Sakurai K, Tomida S, Koike K, Fujishiro M. Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2. *Cancer Med.* 2022 May 10.
15. Matsubara TJ, Fujii K, Kodera S, Kani K, Goto K, Shimizu Y, Oguri G, **Hasumi E**, Kojima T, Komuro I. Prediction of Atrial Fibrillation Being Asymptomatic at First Onset by Cardiac Pacing *Int Heart J.* 2022;63(3):486-491.
16. Takumi J Matsubara, Katsuhito Fujiu, **Eriko Hasumi**, Issei Komuro et al. Prediction of Atrial Fibrillation Being Asymptomatic at First Onset by Cardiac Pacing. *International heart journal* 63 (3) 486-491 2022
17. Late-onset right ventricular failure after continuous-flow left ventricular assist device implantation: case presentation and review of the literature. *J Cardiol.* 2022;80 (2):110-115.
18. A Cold-Blooded Tiptoe: Nonresolving Cellulitis in an Immunocompromised Patient. *Open Forum Infect Dis.* 2022;9(4): ofac074.
19. Determining the factors for interhospital transfer in advanced heart failure cases. *Int J Cardiol Heart Vasc.* 2022; 40:101035.
20. Sarcopenia and risk of infection in adult heart transplant recipients in Japan. *ESC Heart Fail.* 2022;9(2):1413-1423.
21. Residual Pulmonary Vascular Resistance Increase Under Left Ventricular Assist Device Support Predicts Long-Term Cardiac Function After Heart Transplantation. *Front Cardiovasc Med.* 2022;9: 904350.

International conferences

1. **Takako Nishikawa**, Makoto Kurano, Hitoshi Ikeda, Nobutake Yamamichi, Yutaka Yatomi, Kazuhiko Koike, Mitsuhiro Fujishiro. Lysophosphatidylserine may stimulate liver fibrosis EASL scientific programme committee of The International Liver Congress™ 2022 to be held in London, United Kingdom, 22 to 26 June 2022

Medical Community Network and Discharge Planning Center

Associate Professor

Masahiko Sumitani, M.D., Ph.D. (concurrently)

Assistant Professor

Homepage <https://www.h.u-tokyo.ac.jp/english/centers-services/central-clinical-facilities/medical-community-network-and-discharge-planning/index.html>

Introduction and Organization

In April 1997, plans for the Department of Medical Social Service and Welfare were initiated by the University of Tokyo Hospital with the aim of supporting inpatients upon discharge. The Department was officially authorized in April 2000, the first among national universities. In April 2005, the Department began providing assistance to outpatients referred from other hospitals and was renamed the Department of Medical Community Network and Discharge Planning. Further, in 2019, the department changed the name to Medical Community Network and Discharge Planning Center. The Center provides assistance to outpatients referred from local medical institutions, to inpatients being discharged to their homes, and to inpatients being transferred to local medical institutions.

Clinical activities

Assistance to patients receiving medical treatment: The Department provides assistance to outpatients referred from local medical institutions. Our staff helps patients make appointments and follow procedures to receive medical treatment. The Department assists new outpatients in arranging general consultations, helps outpatients schedule specialized treatment, and provides assistance to patients who have been referred to a specific physician.

Assistance to inpatients upon discharge: The Department provides assistance to patients for whom

transfer to a local medical institution or discharge to home if need arises.

Many of such patients are highly dependent on medical care due to the severity of their condition. For those receiving medical care at home, our department staff arranges home visits by primary care doctors and nurses. For patients being transferred to local institutions, our staff provides assistance both to general hospitals and hospice care units.

Home Care Support (Home Care Support clinic): Our Home Care Support Clinic, which offers home care support to our outpatients, has been running since January 2003. The clinic supports the implementation and coordination of home care services, and refers outpatients requesting hospital admission to other hospitals or facilities.

Consultation by Social Worker (Consultation on Recuperation): Our consultation service provided by social workers has been running since 2012. Our social workers mainly consult enquiries regarding patient recuperation.

Transferring out patients to local institutes: Aiming to defining the distinction of the medical role between the University Hospital and local institutes and facilitate transferring our outpatients to them, the proportion of such transferring patients to first-visit patients keeps more than 80%.

Teaching activities

We educate undergraduate students of the Medical Social Working and Welfare of other university.

Research activities

Our research field covers investigating appropriate patient numbers for assistance to inpatients upon discharge in the University hospital; and investigating how to assist working and job in patients with severe illness.

Department of Cancer Resource Center

Chief

Sachiyo Nomura, M.D., Ph.D.

Associate chief

Mayuyo Mori, M.D., Ph.D.

Counseling staff

Kunie Wakao, RN., Yuko Irisawa, RN., Takako Wakeda, M.D., Ph.D.

Homepage <http://www.h.u-tokyo.ac.jp/patient/depts/gansoudan/>

Introduction and Organization

As part of national efforts to address cancer, the government has been establishing a network of “cancer care hub hospitals.” In response to its being designated as a regional cancer care hub hospital in 2008, the University of Tokyo Hospital established the Cancer Patient Support Center to provide consultations to cancer patients and their families as well as residents in neighboring communities with the aim of leading them to appropriate departments and facilities.

Medical Services

Provision of information if patient contracts cancer

If a person gets cancer, the first thing they need to do is collect information on cancer. The Cancer Counseling and Support Center provides information and booklets on different types of cancer.

Furthermore, the person needs to accurately understand the doctors’ explanations to select the best treatment for oneself from the various options presented by doctors. At the Cancer Counseling and Support Center, we explain difficult medical terms in simple language, and we help patients understand their doctors’ advice.

Various kinds of advice related to the medical care of cancer

If a person contracts cancer, besides the medical problem of what kind of treatment to undergo and where, there are also issues related to medical care when receiving treatment, such as medical expenses, how to get along after being discharged from hospital, job, and nursing services. The Cancer Counseling and Support Center provides patients with advice and support so that they can resolve such social worries.

Provision of information on second opinions

The Center provides information on how to get a second opinion and on facilities that provide second opinions.

Various kinds of advice related to the appearance changes caused by cancer treatment

Cancer treatment often causes appearance changes such as hair loss and skin pigmentation. The center provides patients with practical advice and support about wig and cover make-up.

Provision of general information and advice on cancer

The Center sends out and provides information to people who do not have cancer but who want to find

out about cancer, for instance the treatment and screening for it.

Open hours

If you have any queries, please contact us on 03-5800-9061 between 9am-12noon, 1pm-4pm weekdays.

Research activities

Our research field covers the relation between appearance changes caused by cancer therapy and Patients' quality of life.

Clinical Research Promotion Center

Professor, Director

Takashi Moritoyo M.D., Ph.D.

Associate Professor, Vice Director

Tatsuya Maruyama, M.D., Ph.D.

Project Associate Professor,

Ruri Kaneda, M.D., Ph.D.

Project Lecturer

Kosuke Kashiwabara, Ph.D.

Assistant Professor

Takuya Kawahara, Ph.D., Mihoko Shibuya, M.D., Ph.D., Mariko Inoue, M.D., Ph.D.

Project Assistant Professor

Miki Ohta, M.D., Ph.D., Ryo Matsuoka, M.D., Ph.D.

Homepage <https://www.h.u-tokyo.ac.jp/english/centers-services/clinical-research-division/clinical-research-promotion-center/index.html>

History and Organization

The Clinical Research Promotion Center was established in 2019. It originated from Clinical Trial Managing Center, which was established in 1998, and subsequently the former Clinical Research Center, which was established in 2001. Currently, it belongs to the Clinical Research Services of the hospital and provides supports not only for clinical trials but also for investigator-initiated (independent) clinical studies.

However, given the increasing diversity and volume of clinical research conducted in the University of Tokyo Hospital, demand mounted for the structural framework to provide support for multi-center collaborative studies, research on new technology in evidence-based medicine and translational research etc. In response to such diversified demands, the former Clinical Research Center was reorganized in April 2010 into the Clinical Research Support Center, enabling

strengthened support and expeditious promotion of clinical research.

The Center at the beginning consisted of Site Coordinating Unit, roughly equivalent to the former Clinical Research Center, and Central Coordinating Unit, which provides coordinating functions for research such as multicenter trials.

Site Coordinating Unit is comprised of the [Institutional Review Board (IRB) Secretariat Division] [Investigational Drug/Information Control Division] and [Clinical Research Coordinator Division], each charged with IRB secretarial affairs, management of drugs used in the conduct of clinical research and provide assistance with safety information reporting, and clinical research coordination activities. In addition to the existing Consultation Division, new divisions such as Operation Division, Biostatistics Division, Data Management Division, Monitoring Division and Safety Information Division and

Operation Division have been added to the Central Coordinating Unit.

In 2011, the Center was selected as an Ministry of Health, Labour and Welfare (MHLW)-funded Center of Excellence for early stage and exploratory clinical trials of drugs for psychiatric and neurological diseases, enabling the Center to reinforce the staff and to be equipped with Phase 1 Unit that can conduct Phase I first-in-human clinical trial. Thus, the third unit, i.e., P1 Unit was established in May 2012 with 13 beds exclusively used for clinical studies, making it possible to provide seamless support to the complete clinical development process.

We revised rules and procedures in compliance with the “Ethical Guidelines for Medical and Health Research Involving Human Subjects” that came into effect in April 2015 and examined the realignment of functions related to clinical research aimed at strengthening governance functions of the University of Tokyo Hospital. In January 2015, we established Clinical Research Governance Division and later Office of Clinical Quality Assurance & Compliance was created independently of the Clinical Research Support Center responsible for conducting quality assurance audits. Also, with the aim of improving the quality of clinical research in clinical departments, we appointed 1-2 to staff from each clinical department to serve as concurrent clinical instructors, thereby strengthening the supervision and monitoring system in the departments.

In April 2016, ethical review process of specific clinical trials (involving invasion and intervention) was transferred to the Faculty of Medicine to ensure transparency of clinical research. IRB for reviewing industry-initiated and investigator-initiated clinical trials was newly established in the hospital. With respect to the IRB’s secretarial and administrative duties, the Center will continue to take responsibilities. Moreover, an Specific Clinical Research Steering Committee was established under the hospital director and external audit committee to seek external evaluation. In addition, we integrated clinical research management system by strengthening management of conflicts of interest, created educational environment for clinical research personnel, formed collaboration with the Clinical Evaluation and Safety Division to strengthen safety management system. As a result, the

University of Tokyo Hospital received accreditation as a clinical research core hospital under Medical Care Act in March 2016.

Based on the enforcement of the Act on ensuring the Safety of Regenerative Medicine, the Certified Special Committee for Regenerative Medicine was established at the Central Administrative Office of the university, and Clinical Research Support Center undertook responsibilities for secretarial and administrative affairs.

In addition, in order to enhance the functions in which the Clinical Research Support Center was widely involved in 2015, Education and Training Division, Clinical Trial Implementation Division and University Hospital Network Promotion Division were established outside the unit. In fiscal year 2017, we further integrated safety information functions of the Site Coordinating Unit and the Central Coordinating Unit and established a new Safety Information Management Division out the unit. The division remaining in the Site Coordinating Unit was named as the Investigational Drug Management Division. Furthermore, Consultation Division was relocated outside the unit. In 2017, The Regulatory Strategy Division was also established within the Central Coordinating Unit. In order to comply with the Clinical Trials Act that was enforced in April 2018, we established Clinical Research Site Secretariat, enacted general and individual rules to respond to the act and started operation.

Furthermore, in order to clarify that it is an organization that promotes clinical research, the Center was renamed as Clinical Research Promotion Center in December 2019. The Center was reorganized into 8 departments.

<Investigator-Initiated Clinical Trials Promotion Department>

The department is responsible for: (1) secretariat duties for investigator-initiated clinical trials, advanced medical treatment, patient-proposed healthcare services and regenerative medicine; (2) Providing advice and support regarding development strategy, trial design, pharmaceutical affairs, funding, intellectual property, industry-academia collaboration, etc.; (3) Providing support (study management, monitoring, safety information support, data management, biostatistics, etc.) to promote investigator-initiated trials.

<Industry-Initiated Clinical Trials Promotion Department>

The department is responsible for: (1) Supporting the safe and smooth implementation of industry-initiated clinical trials; (2) CRC operations, study drug management, and clinical psychological examinations.

<IRB Office>

The office is responsible for: (1) Managing the Institutional Review Board (IRB) and coordinating with related departments; (2) Providing support for investigators who wish to be reviewed by the IRB.

<Dedicated Clinical Trial Ward Department (P1 Unit)>

The department is responsible for: (1) The safe and smooth conduct of clinical trials related to pharmaceuticals and medical devices; (2) the recruitment of human subjects.

<Medical Safety Management Department>

The department is responsible for Management of safety reports and collection and reporting of safety information. (In March 2023, the Personal Information Management Office was abolished and its name was changed to the Medical Safety Management Department.)

<Planning, Strategy and Management Department>

The department is responsible for: (1) Planning for responding to authorities, acquisition of funds for projects and expansion of the Center's functions; (2) Management of the Center's budget, personnel and documents; (3) General management of the Center's information system, including information security; (4) Education and training for and provision of information to investigators who wish to conduct clinical research; (5) Management, education and training of clinical research trainers; (6) Management of the progress of clinical research conducted at the University of Tokyo Hospital.

<Network Promotion Department>

The department is responsible for: (1) Secretariat duties for the National University Hospital Clinical Research Promotion Initiative joined by 44 hospitals of 42 national universities; (2) Secretariat duties for the University of Tokyo Hospital related to the University Hospital Clinical Trial Alliance which is a regional network of national university hospitals involved in clinical research (consisting of 8 universities and 9 hospitals in the Kanto-Koshinetsu region).

<Clinical Trials Patient Counseling Department>

The department is responsible for providing consultation services for patients and citizens who would like to use advanced medical care and public relation activities.

Clinical Research Promotion Activities

The Clinical Research Promotion Center provides wide range of support from pre-application consultation, secretariat for the IRB to supporting the implementation and reporting of clinical trials. In 2002, during the time of the Clinical Trials Department, the Center began providing assistance for investigator-initiated clinical trials evaluating therapeutic drugs and studies involving unapproved drugs in addition to conventional clinical trials (from 2015 use of unapproved drugs in clinical research was transferred to Research Ethics Committee of Graduate School of Medicine and School of Medicine, and from 2018, it was moved to Evaluation Committee on Unapproved New Drugs). To further improve the quality of these supports we decided to adopt ICH-GCP guidance and complied with the guidelines, procedure manuals, styles and guidance etc. From 2009, we have been providing support for all invasive and interventional clinical research.

For industry-initiated clinical trials, we hold a preliminary hearing session (called “protocol presentation”) in order to shorten the period from application to approval and enhance the content of review. As a result, we could avoid re-review by the IRB due to lack of information.

Since 2002, Clinical research coordinators (CRC) of the Center have been supporting all clinical trials for approval and post marketing trials. We started to support in part investigator-initiated research from 2004. We started providing CRC support to investigator-initiated research on a beneficiary-pays basis from 2005 and clinical pharmacology studies in healthy volunteers from 2012. CRCs exclusively involved in investigator-initiated research, have been employed as needed. CRC support for Advanced Medical Care Program B which University of Tokyo Hospital participated as a head investigational site was initiated in 2017.

As part of patient awareness activities, we continued updating the patient homepage, prepared leaflets and distributed them at outpatient reception counters. The leaflets contain information about research currently recruiting participants. In addition, Clinical Trial Patient Consulting Room provides consultation to patients or their families participating in clinical trials or who are considering to enroll in a clinical trial in close cooperation with the Patients Relations and Clinical Ethics Center, Cancer Consulting and Support Center, Department of Medical Community Network and Office of Medical Accounting.

In order to support the promotion of investigator-initiated clinical trials conducted by physicians etc. the Center has been implementing the system successively partly supported by the MHLW-funded Early-Stage and Exploratory Clinical Trial Project that started in 2011. In order to comply with the "Ethical Guidelines for Medical and Health Research Involving Human Subjects enacted in 2014", we classified clinical research according to guidelines, validation studies and exploratory studies and started accepting all assistance requests for validation studies, starting from May 2015. Regarding the exploratory studies, monitoring and data management were to be carried out by each clinical department, the Center undertook responsibility for supervision of the quality control (QC). The Center manages SAE (severe adverse event) reporting and supports various safety reporting in order to ensure that clinical studies are conducted safely. One of the major achievements is the investigator-initiated clinical trial of the pediatric ventricular assist device; the trial was initiated in February 2012, applied for regulatory approval in November 2014, and marketing approval was received in June 18, 2015.

Since its establishment in May 2012, the Phase 1 Unit (P1 Unit) has undertaken various preparations to respond to early phase clinical research, such as development of SOP program, procedure manuals, establishment of in-house collaboration system, on-the-job training for staff and the system for recruiting health volunteers. P1 Unit conducted its very first clinical study in October 2012. In September 2018 the unit was relocated as a new ward with augmented 21 beds exclusively aimed for clinical trial on the 12th floor of the Inpatient Building B, which was newly constructed in January 2018.

<University Hospital Clinical Trial Alliance>

University Hospital Clinical Trial Alliance (UHCT Alliance) comprised of 6 national university hospitals (The University of Tokyo, Niigata University, Gunma University, Tsukuba University, Tokyo Medical and Dental University and Chiba University) located in the central part of Japan was established in February 2006. In February 2007 Shinshu University and in February 2013 Yamanashi University joined the Alliance as the 7th and 8th member university, respectively. And in February 2015, the Institute of Medical Science the University of Tokyo joined the Alliance as the 8th member university 9 hospitals.

As part of the Alliance activities the University of Tokyo developed a clinical research support system UHCT ACRess jointly with Fujitsu and started operation in 2011, to support clinical researchers in the quality and project management. UHCT ACRess can easily be customized by researchers.

In addition, we developed curriculum called CREDITS (*Continuous Systematic Education & Training Curriculum for Clinical Researchers and Specialists*) jointly with the Education and Training Division in 2015. Currently, we are expanding the use outside the alliance members.

Activities between the UHCT Alliance and the University of Tokyo Translational Research (TR) based regional network started in 2015, as seeds development project of Alliance members.

<National University Hospital Clinical Research Initiative>

In October 2012, the University of Tokyo took the lead in establishing the National University Hospital Clinical Research Initiative (NUH-CRI). The administrative affairs of the Initiative has been supported by the secretariat located within the University of Tokyo Hospital since the preparatory meeting in July 2012. The initiative considered sharing education curriculum as one of the common educational programs of national university hospitals nationwide. In 2016, the curriculum was provided to each university hospital by the National University Hospital Council of Japan. Feasibility assessment system was developed for investigator-initiated clinical study to support the promotion of clinical trials conducted at the National University Hospitals.

Education/Training

The Center has been accepting M3/M4 students for training course in ‘Clinical Clerkship’ since it become mandatory in 2013. From 2017, we have been offering systematic lectures on “Clinical Research” for M2 medical students. In addition, we have been accepting junior resident physicians for training as a part of the M.D. residency-training program.

Education and Training Division was established in 2015 and since then it has been providing education and training for students and researchers. In particular, we have developed curriculum called CREDITS (*Continuous Systematic Education & Training Curriculum for Clinical Researchers and Specialists*) jointly with UHCT Alliance.

Clinical instructor system was established in 2015, in which physicians recommended by each clinical department hold an additional position at the Clinical Research Promotion Center concurrently with their department, centrally manage information on clinical research conducted in their own departments and hold regular training sessions to disseminate information on education and training programs.

The University of Tokyo Hospital has conducted annual CRC training program for national, public and private university hospitals since 2010, commissioned by the Ministry of Education, Culture, Sports, Science and Technology. As a part of the Japan Agency for Medical Research and Development (AMED) project, training workshop for clinical research personnel has been held since 2017, sponsored by the University of Tokyo.

Furthermore, in response to the shortage of biostatisticians, biostatistics and bioinformatics course was established by AMED, at the university hospital. In 2018, master’s course was also established within the Graduate School of Interdisciplinary Information Studies and the Clinical Research Promotion Center has established a system to conduct practical training for course participants.

Research Activities

In April 2007, with the cooperation of the Biostatistics Department, the Center launched the Clinical Trial Data Management course (endowed course).

As of fiscal 2020, the Center was involved in

scientific meetings, which include The Japan Society of Clinical Pharmacology and Therapeutics, Conference on CRC and Clinical Trials, etc. As for publications such as academic papers, 55 papers were produced (42 papers in English and 3 papers in Japanese).

Publications

- 1) Mitsui J, Matsukawa T, Tanaka M, Sato NS, Nakamoto FK, Yasuda T, Naruse H, Matsukawa MK, Ishiura H, Nagase M, Yamamoto Y, Kuzuyama H, Wada I, Ga T, Yamazaki T, Moritoyo T, and Shoji Tsuji. Randomized, double-blind, placebo-controlled phase 1 study to evaluate the safety and pharmacokinetics of high doses of ubiquinol in healthy adults. *Neurol Clin Neurosci.* 10:14–24, 2022
- 2) Shinya Y, Hasegawa H, Shin M, Kawashima M, Koizumi S, Katano A, Suzuki Y, Kashiwabara K, Saito N. In reply: stereotactic radiosurgery provides long-term safety for patients with arteriovenous malformations in the diencephalon and brainstem: the optimal dose selection and long-term outcomes. *Neurosurgery.* 92(2):e42–e43, 2022
- 3) Matsubara M, Haruna M, Yonezawa K, Yokoyama M, Tahara-Sasagawa E, Hikita N, Nakamura Y, Mizuno Y, Sanada H, Tamai N, Abe M, Kashiwabara K. Development and validation of an infant facial skin assessment tool: a prospective observational study. *BMC Pediatrics.* 22: 614, 2022
- 4) Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Okiyama N, Kodera M, Hasegawa M, Shinichi S. Safety and efficacy of rituximab in systemic sclerosis (DESIREs): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. *Lancet Rheumatology.* 4(8): E546–E555, 2022
- 5) Murayama R, Oyama H, Abe-Doi M, Masamoto Y, Kashiwabara K, Tobe H, Komiyama C, Sanada H, Kurokawa M. Safety verification of a new peripheral intravenous catheter placed in the upper arm vein for administration of drugs with high

- irritant potential. *Drug Discoveries and Therapeutics*. 16(3): 128–134, 2022
- 6) Shimura T, Nakagami G, Ogawa R, Ono S, Takahashi T, Nagata M, Kashiwabara K, Sugama J, Sanada H, Oe M. Incidence of and risk factors for self-load-related and medical device-related pressure injuries in critically ill patients: a prospective observational cohort study. *Wound Repair and Regeneration*. 30(4): 453–467, 2022
 - 7) Hasegawa H, Inoue A, Helal A, Kashiwabara K, Meyer FB. Pineal cyst: results of long-term MRI surveillance and analysis of growth and shrinkage rates. *Journal of Neurosurgery*. 138(1): 113–119, 2022
 - 8) Sugawara Y, Hirakawa Y, Mise K, Kashiwabara K, Hanai K, Yamaguchi S, Katayama A, Onishi Y, Yoshida Y, Kashiwara N, Matsuyama Y, Babazono T, Nangaku M, Wada J. Analysis of inflammatory cytokines and estimated glomerular filtration rate decline in Japanese patients with diabetic kidney disease: a pilot study. *Biomarkers in Medicine*. 16(10): 759–770, 2022
 - 9) Ebata S, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Yoshihide A, Yoshizaki A, Sato S. Predictors of rituximab effect on modified rodnan skin score in systemic sclerosis: a machine learning analysis of the DESIRES trial. *Rheumatology*. 61(11): 4364–4373, 2022
 - 10) Ishii J, Kashiwabara K, Ozaki Y, Takahashi H, Kitagawa F, Nishimura H, Ishii H, Imuro S, Kawai H, Muramatsu T, Naruse H, Iwata H, Tanizawa-Motoyama S, Ito H, Watanabe E, Matsuyama Y, Fukumoto Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Hokimoto S, Miyauchi K, Ohtsu H, Izawa H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Matsuzaki M, Nagai R. Small dense low-density lipoprotein cholesterol and cardiovascular risk in statin-treated patients with coronary artery disease. *Journal of Atherosclerosis and Thrombosis*. 29(10): 1458–1474, 2022
 - 11) Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. *The Journal of Dermatology*. 49(1): 179–183, 2022
 - 12) Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F. Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. *Breast Cancer*. 29(1):131–143, 2022
 - 13) Erratum: Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F. Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. *Breast Cancer*. 29(1): 186–188, 2022
 - 14) Kawahara T, Yamada K, Terashima R, Takashima I, Ogata T, Tanaka S, Chikuda H, Miura H, Nakamura K, Ohe T. Practical guidance to handle missing values in the 25-question Geriatric Locomotive Function Scale (GLFS-25): A simulation study. *BMJ Open*. 12:e065607, 2022
 - 15) Tomioka Y, Sekino M, Gu J, Kurita M, Yamashita S, Miyamoto S, Iida T, Kanayama K, Yoshimura K, Nakagawa M, Akawaza S, Kagaya Y, Tanaka K, Sunaga Y, Ueda K, Kawahara T, Tahara Y, Okazaki M. Wearable, wireless, multi-sensor device for monitoring tissue circulation after free-tissue transplantation: a multicentre clinical trial. *Scientific Reports*. 12:16532, 2022
 - 16) Kawahara T, Iwamoto T, Takashima I, Hanazawa R, Uemura K, Uemura Y, Mukai H, Kikawa Y, Taira N. Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials. *Supportive Care in Cancer*. 30:8367–8375, 2022
 - 17) Terada J, Fujita R, Kawahara T, Hirasawa Y, Kinoshita T, Takeshita Y, Isaka Y, Kinouchi T, Tajima H, Tada Y, Tsushima K. Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label,

- single-center phase 3 randomized clinical trial. *eClinicalMedicine*. 49:101484, 2022
- 18) Kawahara T, Shiba K, Tsuchiya A. Application of causal inference methods in the analysis of observational neurosurgical data: G-formula and marginal structural model. *World Neurosurgery*. 161:310–315, 2022
 - 19) Morita T, Kawahara T, Stone P, Sykes N, Miccinesi G, Klein C, Stiel S, Hui D, Deliens L, Heijltjes MT, Mori M, Heckel M, Robijn L, Krishna L, Rietjens J. Intercountry and intracountry variations in opinions of palliative care specialist physicians in Germany, Italy, Japan and UK about continuous use of sedatives: an international cross-sectional survey. *BMJ Open*. 12:e060489, 2022
 - 20) Kimura N, Kawahara T, Uemura Y, Atsumi T, Sumida T, Mimura T, Kawaguchi Y, Amano H, Iwasaki Y, Kaneko Y, Matsui T, Muro Y, Imura Y, Kanda T, Tanaka Y, Kawakami A, Jinnin M, Ishii T, Hiromura K, Miwa Y, Nakajima H, Muwana M, Nishioka Y, Morinobu A, Kameda H, Kohsaka H. Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial. *Rheumatology*. 61:4445-4454, 2022
 - 21) Kawahara T, Taira N, Shiroya T, Hagiwara Y, Fukuda T, Uemura Y, Mukai H. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial. *Quality of Life Research*. 31:1829–1836, 2022
 - 22) Arai J, Niiukra R, Hayakawa Y, Kawahara T, Honda T, Hasatani K, Yoshida N, Nishida T, Sumiyoshi T, Kiyotoki S, Ikeya T, Arai M, Suzuki N, Tsuji Y, Yamada A, Kawai T, Koike K. Chemoprevention of oesophageal squamous cell carcinoma and adenocarcinoma: a multicentre retrospective cohort study. *Digestion*. 103:192-204, 2022
 - 23) Niikura R, Aoki T, Shichijo S, Yamada A, Kawahara T, Kato Y, Hirata Y, Hayakawa Y, Suzuki N, Hirasawa T, Tada T, Koike K. Artificial intelligence versus expert endoscopists for diagnosis of gastric cancer in patients who underwent upper gastrointestinal endoscopy. *Endoscopy*. 54:780-784, 2022
 - 24) Morishita-Kawahara M, Koike K, Kawahara T, Kamibeppu K. Relationship between satisfaction with care and quality of life among family caregivers of terminal cancer patients in general wards: a cross-sectional study. *International Journal of Palliative Nursing*. 28:575-582, 2022
 - 25) Morishita-Kawahara M, Tsumura A, Aiki S, Sei Y, Iwamoto Y, Matsui H, Kawahara T. Association between family caregivers' satisfaction with care for terminal cancer patients and quality of life of the bereaved family: A prospective pre- and post-loss study. *Journal of Palliative Medicine*. 25:81-88, 2022
 - 26) Aizawa H, Kato H, Oba K, Kawahara T, Okubo Y, Saito T, Naito M, Urushitani M, Tamaoka A, Nakamagoe K, Ishii K, Kanda T, Katsuno M, Atsuta N, Maeda Y, Nagai M, Nishiyama K, Ishiura H, Toda T, Kawata A, Abe K, Yabe I, Takahashi-Iwata I, Sasaki H, Warita H, Aoki M, Sobue G, Mizusawa H, Matsuyama Y, Haga T, Kwak S. Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. *Journal of Neurology*. 269:885–896, 2022
 - 27) Cho S, Kurokawa R, Hagiwara A, Gonoi W, Mori H, Kawahara T, Nakaya M, Sakamoto N, Fujita N, Kamio S, Koyama H, Abe O. Localization of the Central Sulcus Using the Distinctive High Signal Intensity of the Paracentral Lobule on T1WI. *Neuroradiology*. 64:289-299, 2022
 - 28) Nakayama A, Morita H, Sato T, Kawahara T, Kato S, Itoh H, Komuro I. Small dense low-density lipoprotein cholesterol is a potential marker for predicting laser treatment for retinopathy in diabetic patients. *Journal of Atherosclerosis and Thrombosis*. 29:678-691, 2022
 - 29) Shiroya T, Hagiwara Y, Taira N, Kawahara T, Konomura K, Iwamoto T, Noto S, Fukuda T, Shimozuma K. Randomized controlled trial of paper-based at a hospital versus continual electronic patient-reported outcomes at home for metastatic cancer patients: does electronic measurement at home detect patients' health status in greater detail? *Medical Decision Making*. 42:60-67, 2022
 - 30) Sun C, Anraku M, Kawahara T, Karasaki T, Kitano K, Nagayama K, Sato M, Nakajima J.

Respiratory strength and pectoralis muscle mass as measures of sarcopenia: Relation to outcomes in resected non-small cell lung cancer. *The Journal of Thoracic and Cardiovascular Surgery*. 163: 779–787, 2022

- 31) Kokubo T, Kodera S, Sawano S, Katsushika S, Nakamoto M, Takeuchi H, Kimura N, Shinohara H, Matsuoka R, Nakanishi K, Nakao T, Higashikuni Y, Takeda N, Fujiu K, Daimon M, Akazawa H, Morita H, Matsuyama Y, Komuro I. Automatic Detection of Left Ventricular Dilatation and Hypertrophy from Electrocardiograms Using Deep Learning. *Int Heart J*. 63(5):939-947, 2022
- 32) Ieki H, Ito K, Saji M, Kawakami R, Nagatomo Y, Takada K, Kariyasu T, Machida H, Koyama S, Yoshida H, Kurosawa R, Matsunaga H, Miyazawa K, Ozaki K, Onouchi Y, Katsushika S, Matsuoka R, Shinohara H, Yamaguchi T, Kodera S, Higashikuni Y, Fujiu K, Akazawa H, Iguchi N, Isobe M, Yoshikawa T, Komuro I. Deep learning-based age estimation from chest X-rays indicates cardiovascular prognosis. *Commun Med (Lond)*. 2(1):159, 2022

Division of Tissue Engineering

Director & Professor

Kazuto Hoshi, M.D., Ph.D.

Vice Director

Atsuhiko Hikita, M.D., Ph.D.

Project Professor

Makoto Komura, M.D., Ph.D., Atsuhiko Hikita, M.D., Ph.D.

Project Associate Professors

Kazumichi Yonenaga, D.D.S., M.D., Ph.D., Yasunori Omata, M.D. Ph.D.

Project Lecturer

Yukiyo Asawa, D.V.M., Ph.D. , Ono Sachiko, D.D.S., Ph.D., Asuka Terashima, Ph.D.

Research Associates

Itai Shunsuke, D.D.S., Ph.D.

Homepage <https://www.h.u-tokyo.ac.jp/patient/depts/te/>

Introduction and Organization

Division of Tissue Engineering was established as a special medical office in The University of Tokyo Hospital, in October 2001 and has a fully equipped 800 m² laboratory on the 8th floor of the In-patient Ward B. In May 2016, it moved to Molecular and Life Innovation building. Division of Tissue Engineering consists of Department of Bone & Cartilage Regenerative Medicine, Department of Tissue Stem cell/Life Dentistry, Department of Eat-loss Medicine, and Department of Clinical Stem Cell Biology. Researchers assigned to each department are conducting research with many graduate students. The researchers continue their studies to make the center function as a translational research center.

Tie-up with companies, technical transfer, patenting developed technologies, producing materials for treatment at a GMP level, safety evaluation studies and organization for clinical trials are necessary in order to realize regenerative medicine, which is now recognized as a national project. As foundation and operation of venture companies as well as industry-university-

government cooperation is essential to the success, it seems that state-level efforts are necessary. It is expected that broad progress in tissue engineering technologies and regenerative medicine contributes to treatment and drug discovery of all medical fields regardless of specialties.

October, 2001 Division of Tissue Engineering founded as a special medical office in the University of Tokyo Hospital.

June, 2002 Department of Corneal Tissue Engineering founded by a donation from HOYA health care CO., Ltd.

July, 2002 Department of Vascular Regeneration founded by a donation from Daiichi Pharmaceutical Co., Ltd.

July, 2002 Department of Bone & Cartilage Regenerative Medicine founded by a donation from TAKEDA Chemical Industries., Ltd.

September, 2002 Department of Regeneration Medicine for Hematopoiesis founded by a donation from KIRIN Brewery Co., Ltd.

November, 2002 Department of Clinical Renal

Regeneration founded by a donation from MOCHIDA Pharmaceutical Co., Ltd.

November, 2002 Department of MENICON Cartilage & Bone Regeneration founded by a donation from MENICON Co., Ltd.

March, 2003 The Cell Processing Center set up on the 8th floor of the In-patient Ward B.

June, 2005 Department of Corneal Tissue Regeneration was renewed by a donation from AMNIO TEC Co., Ltd.

July, 2005 Department of Bone & Cartilage Regenerative Medicine was renewed by a donation from TAKEDA Chemical Industries Co., Ltd.

September, 2005 Department of Regeneration Medicine for Hematopoiesis was renewed by a donation from KIRIN Brewery Co., Ltd.

November, 2005 Department of Clinical Renal Regeneration was renewed by a donation from MOCHIDA Pharmaceutical Co., Ltd.

November, 2005 By a donation from FUJISOFT ABC Co., Ltd. Department of MENICON Cartilage & Bone Regeneration was renewed to Department of Fuji Software ABC Cartilage & Bone Regeneration.

January, 2007 Laboratory for Pediatric Regenerative Medicine was founded by department of pediatric surgery.

July, 2007 Department of Bone & Cartilage Regenerative Medicine was renewed by a donation from Eli Lilly Japan K.K.

March, 2012 Department of Advanced Nephrology and Regenerative Medicine founded by a donation from Zenjinkai.

April, 2016 The Cell Processing & Banking Center set up on the 4th floor of the Molecular & Life Innovation Building.

November 2017 Change of the department name: Department of Cartilage & Bone Regeneration became Department of Cell & Tissue Engineering.

July, 2018 Department of Bone & Cartilage Regenerative Medicine was renewed by a donation from Avenue Cell Clinic, Kaneka Corporation, Rohto Pharmaceutical Co., Ltd. and Nichirei Corporation.

November, 2019 Department of Tissue Stem cell/Life Dentistry established by Dental assist Co., Ltd, Fuke hospital, Sashiogi Hospital, Ikegami Home Clinic and Inotec Co., Ltd.

April, 2020 Department of Eat-loss Medicine was

founded by a donation from ITOEN Ltd.

October, 2020 Department of Cell & Tissue Engineering was terminated.

July, 2023 Department of Clinical Stem Cell Biology was founded by founded by a donation from Kohjin Bio Co., Ltd.

November, 2022 Department of Tissue Stem cell/Life Dentistry was renewed by SheepMedical Co.,Ltd.

Research activities

As for the Department of Bone and Cartilage Regeneration, we are researching and developing the treatment of osteoarthritis using human adipose stem cells (ASCs) from the renewal of the department in 2018. To clarify the protective effects of human ASCs for cartilage more precisely, we are planning to establish the assay system for the knee pain of mouse. We are also developing the culture medium by which highly-functional human mesenchymal cells can be amplified stably and effectively. We are also working on basic research for (1) elucidation of molecular mechanisms underlying osteoarthritis (2) clarification of the roles of tissue stem cells in the homeostasis of joints and pathogenesis of osteoarthritis. In addition, for the realization of bone regeneration, we are trying to apply a nanosheet which can induce osteogenesis. Now we are testing its effectiveness in large animals.

In the Department of Tissue Stem Cells/ Life Dental Science, we are doing research about engineered airway, dental pulp stem cells and umbilical cord stem cells. In addition, we investigate the mechanism of the self-generation by the tissue encapsulating the mold (BIO-TUBE).

In the Department of Eat-Loss Medicine, in order to support "eating," which is the foundation of human life, we are conducting research to systematize the diagnosis, prevention, and treatment of "eating" as an academic discipline by approaching the problem of persistent inability to eat from the oral region, so that many people can live a full, healthy life.

In the Department of Clinical Stem Cell Biology, we are conducting research for the development of a cell

therapy for the peri-implantitis. In addition, to produce regenerated cartilage and bone with high safety and usefulness, to realize production system and establish practical quality control and to promote the application of regenerated cartilage and bone, we are conducting research on development of novel scaffolds in cartilage and bone regeneration, development of 3-D reconstruction system for regenerated tissues, evaluation on biochemical and biophysical properties of regenerated tissues in vivo and clinical trials and application of regenerated cartilage and bones.

Clinical Studies

Of particular note is clinical studies started as a result of basic research. In Department of Bone & Cartilage Regenerative Medicine, a clinical study on bone implants into non-loading parts (IRB approval number #1310) was conducted on 10 patients successfully and a large-scale clinical trial was started across the nation. In project for cartilage regeneration, an investigator-initiated clinical trial “A clinical trial for the validation of safety and efficacy of the implant-type tissue-engineered cartilage using autologous cells” was carried out. In addition, we have been preparing for a clinical study “a clinical study for the treatment of osteoarthritis of temporomandibular joint by autologous adipose-derived stem cell (AUASC-TKY2017)”.

As stated above, we are proceeding translational research aiming at clinical application of tissue engineering and regenerative medicine. Contribution to the Hospital

Contribution to the Hospital

Division of Tissue Engineering, as a cooperative research facility in the Hospital, opens expensive special machines that each laboratory cannot afford to equip with, such as a confocal laser scanning microscope, a cell analyzer and a cell sorter to the Hospital staff, letting them use with cost sharing. Various departments are conducting research using this facility.

References

1. Superior stemness of a rapidly growing subgroup of isolated human auricular chondrocytes and the potential for use in cartilage regenerative therapy. Shimizu R, Asawa Y, Komura M, Hoshi K, Hikita A. *Regen Ther.* 2022 Jan 4;19:47-57.
2. Hematopoietic progenitor cells specifically induce a unique immune response in dental pulp under conditions of systemic inflammation. Osaki J, Yamazaki S, Hikita A, Hoshi K. *Heliyon.* 2022 Feb 5;8(2):e08904.
3. TGF β selects for pro-stemness over pro-invasive phenotypes during cancer cell epithelial-mesenchymal transition. Tsubakihara Y, Ohata Y, Okita Y, Younis S, Eriksson J, Sellin ME, Ren J, Ten Dijke P, Miyazono K, Hikita A, Imamura T, Kato M, Heldin CH, Moustakas A. *Mol Oncol.* 2022 Jun;16(12):2330-2354.
4. Micro/nanostructural properties of peri-implant jaw bones: a human cadaver study. Koresawa K, Matsunaga S, Hikita A, Okudera H, Yamaguchi A, Yajima Y, Abe S. *Int J Implant Dent.* 2022 Apr 11;8(1):17.
5. Hematopoietic-Mesenchymal Signals Regulate the Properties of Mesenchymal Stem Cells. Kanazawa S, Okada H, Riu D, Mabuchi Y, Akazawa C, Iwata J, Hoshi K, Hikita A. *Int J Mol Sci.* 2022 Jul 26;23(15):8238.
6. Quantitative analyses of matrices, osteoblasts, and osteoclasts during bone remodeling using an in vitro system. Oguchi S, Sakamoto T, Hoshi K, Hikita A. *J Bone Miner Metab.* 2023 Jan;41(1):3-16.
7. Spatiotemporal Analysis of Osteoblast Morphology and Wnt Signal-Induced Osteoblast Reactivation during Bone Modeling in Vitro. Tsuji N, Sakamoto T, Hoshi K, Hikita A. *JBMR Plus.* 2022 Oct 21;6(11):e10689.
8. Evaluation of the improvement of laryngeal penetration using complete lateral position through videoendoscopic evaluation of swallowing in patients with dysphagia. Tonosaki K, Yonenaga K, Itai S, Oyama S, Mizuno T, Ono S, Watanabe R, Hoshi K. *Oral Science International* 2023.

9. Risk of post-extraction bleeding with direct oral anticoagulant compared with warfarin: Retrospective cohort study using large scale claims data in Japan.
Ono S, Ishimaru M, Yokota I, Konishi T, Okada A, Ono Y, Matsui H, Itai S, Yonenaga K, Tonosaki K, Watanabe R, Hoshi K, Yasunaga H
Thrombosis Research 222 24-30 2022.
 10. Complete lateral positioning enabled feeding in a patient with aspiration pneumonia
Tonosaki K, Yonenaga K, Itai S, Oyama S, Mizuno T, Ono S, Watanabe R, Hoshi K
The Tokai Journal of Experimental and Clinical Medicine 47(3) 105-108 2022
 11. Nagata K, Hojo H, Chang SH, Okada H, Yano F, Chijimatsu R, Omata Y, Mori D, Makii Y, Kawata M, Kaneko T, Iwanaga Y, Nakamoto H, Maenohara Y, Tachibana N, Ishikura H, Higuchi J, Taniguchi Y, Ohba S, Chung UI, Tanaka S, Saito T. Runx2 and Runx3 differentially regulate articular chondrocytes during surgically induced osteoarthritis development. *Nat Commun.* 2022 Oct 19;13(1):6187.
 12. Tachibana N, Chijimatsu R, Okada H, Oichi T, Taniguchi Y, Maenohara Y, Miyahara J, Ishikura H, Iwanaga Y, Arino Y, Nagata K, Nakamoto H, Kato S, Doi T, Matsubayashi Y, Oshima Y, Terashima A, Omata Y, Yano F, Maeda S, Ikegawa S, Seki M, Suzuki Y, Tanaka S, Saito T. RSPO2 defines a distinct undifferentiated progenitor in the tendon/ligament and suppresses ectopic ossification. *Sci Adv.* 2022 Aug 19;8(33):eabn2138.
 13. Tsukasaki M, Komatsu N, Negishi-Koga T, Huynh NC, Muro R, Ando Y, Seki Y, Terashima A, Pluemsakunthai W, Nitta T, Nakamura T, Nakashima T, Ohba S, Akiyama H, Okamoto K, Baron R, Takayanagi H. Periosteal stem cells control growth plate stem cells during postnatal skeletal growth. *Nat Commun.* 2022 Jul 18;13(1): 4166.
 14. Omata Y, Okada H, Uebe S, Izawa N, Ekici AB, Sarter K, Saito T, Schett G, Tanaka S, Zaiss MM. Interspecies Single-Cell RNA-Seq Analysis Reveals the Novel Trajectory of Osteoclast Differentiation and Therapeutic Targets. *JBMR Plus.* 2022 May 16;6(7):e10631.
 15. Takeda R, Matsumoto T, Maenohara Y, Omata Y, Inui H, Nagase Y, Nishikawa T, Tanaka S. Increasing trend of radiographic features of knee osteoarthritis in rheumatoid arthritis patients before total knee arthroplasty. *Sci Rep.* 2022 Jun 21;12(1):10452.
 16. Watanabe H, Okada H, Hirose J, Omata Y, Matsumoto T, Matsumoto M, Nakamura M, Saito T, Miyamoto T, Tanaka S. Transcription Factor Hematopoietically Expressed Homeobox Protein (Hhex) Negatively Regulates Osteoclast Differentiation by Controlling Cyclin-Dependent Kinase Inhibitors. *JBMR Plus.* 2022 Feb 14;6(4): e10608.
 17. Omata Y, Frech M, Saito T, Schett G, Zaiss MM, Tanaka S. Inflammatory Arthritis and Bone Metabolism Regulated by Type 2 Innate and Adaptive Immunity. *Int J Mol Sci.* 2022 Jan 20; 23(3):1104.
 18. Frech M, Omata Y, Schmalzl A, Wirtz S, Taher L, Schett G, Zaiss MM, Sarter K. Btn2a2 Regulates ILC2-T Cell Cross Talk in Type 2 Immune Responses. *Front Immunol.* 2022 Jan 25;13: 757436.
 19. Kaneko T, Horiuchi K, Chijimatsu R, Mori D, Nagata K, Omata Y, Yano F, Inui H, Moro T, Tanaka S, Saito T. Regulation of osteoarthritis development by ADAM17/Tace in articular cartilage. *J Bone Miner Metab.* 2022 Mar;40(2): 196-207.
 20. Yokote F, Yamauchi Y, Komura H, Tanuma T, Sakao Y, Kawamura M, Komura M. A novel method of tracheal anastomosis healing using a single submucosal injection of basic fibroblast growth factor: initial report. *Eur J Cardiothorac Surg.* 2022 Mar 24;61(4):917-924.
- 【Book】
1. Evidence of Green Tea 2022: Review Book ver.1
Itai S, Yonenaga K, Ono S, Watanabe R, Tonosaki K, Hoshi K. DesignEgg 2022.

Cooperative Unit of Medicine and Engineering Research

Organization

The University of Tokyo Hospital

Cardiovascular Medicine, Nutrition and Metabolism, Surgical Oncology, Vascular Surgery, Artificial Organ and Transplantation, Cardiac Surgery, Thoracic Surgery, Neurosurgery, Urology, Orthopaedic Surgery, Oral and maxillofacial Surgery, Radiology, Tissue Engineering Unit, Department of Clinical Epidemiology & Systems, Bone & Cartilage Regenerative Medicine, Cartilage of Bone Regeneration, Department of Immunotherapeutics (Medinet), Division of Science for Joint Reconstruction

Engineering and Pharmaceutical Research

Chemical System Engineering, Mechanical Engineering, Precision Engineering, Quantum Engineering and System Science, Nuclear Engineering and Management, Chemistry and Biotechnology, Material Engineering, Information Science and Technology, Frontier Sciences, Pharmaceutical Sciences Laboratory of Chemistry and Biology, Center for Disease Biology and Integrative Medicine, Center for Disease Biology and Integrative Medicine Regenerative Medical Engineering, Center for Disease Biology and Integrative Medicine Clinical Biotechnology, Research Center for Advanced Science and Technology, Institute of Industrial Science

※The following information is the same as that of the previous year for certain reasons.

Introduction and Organization

The application of an advanced bioscience to a new technical development of clinical medicine has become an important subject for research in the 21st century. We've established Cooperative Unit of Medicine and Engineering Research at The University of Tokyo Hospital to create a new research and education center, which cross-sectionally unites medicine with engineering research for the development of a next generation medical technology.

2002 June. The establishment of Cooperative Unit of Medicine and Engineering Research was approved

by a hospital administration committee as a special practice unit that belongs to The University of Tokyo Hospital.

2002 September. A steering committee of Cooperative Unit of Medicine and Engineering Research was organized by representative members of relevant clinical departments. The committee made a decision of the following basic principles; recruitment for the participation to this unit should be, as a general rule, an open call for a joint project of clinical department and engineering or pharmaceutical research group in The University of Tokyo, an equipment/administration expense of a laboratory should be a responsibility of

the user, and a basic participation period to this unit should be three years and for the continued participation in the unit, a review and approve of the steering committee is indispensable.

2002 October. An open call for participants to this unit started. There were 18 applications and the steering committee approved all projects after review. A liaison conference of Cooperative Unit of Medicine and Engineering Research was organized by a representative member of each project. Configuration of each project in a space of 554.4m² that is consisted of a portion of the first floor and the basement of an administration building came to a decision by the conference.

2003 May. The construction of Cooperative Unit of Medicine and Engineering Research was completed. The cost of the construction was shared by the participation groups.

2003 May 22. The first research meeting of Cooperative Unit of Medicine and Engineering Research took place and research activities started.

2004 September 3. The second research meeting of Cooperative Unit of Medicine and Engineering Research took place.

2005 September 13. The third research meeting of Cooperative Unit of Medicine and Engineering Research took place.

2006 December 21. The fourth research meeting of Cooperative Unit of Medicine and Engineering Research took place.

2007 December 13. The fifth research meeting of Cooperative Unit of Medicine and Engineering Research took place.

2009 December 3. The sixth research meeting of Cooperative Unit of Medicine and Engineering Research took place.

2011 February 2. The seventh research meeting of Cooperative Unit of Medicine and Engineering Research took place.

2011 December 17. The eighth research meeting of Cooperative Unit of Medicine and Engineering Research took place.

2013 January 25. Development forum of advanced medical seeds took place

2014 January 24. Development forum of advanced medical seeds took place

2015 January 22. Development forum of advanced

medical seeds took place

2016 February 2. Development forum of advanced medical seeds took place

2017 February 2. Development forum of advanced medical seeds took place

2018 February 1. Development forum of advanced medical seeds took place

2018 October. Each lab was moved from the the first floor and the basement of an administration building, based on the decision of redistribution of hospital facility

2019 February 18. Development forum of advanced medical seeds took place

2020 January 21. Development forum of advanced medical seeds took place

2021 February 10. Development forum of advanced medical seeds took place

2022 February 4. Development forum of advanced medical seeds took place

Research activities

Development of Advanced Stereotactic Radiation Cancer Therapy System

Department of Radiology

Nuclear Professional School, Department of Nuclear Engineering and Management

Department of Chemical System Engineering

High Precision Stereotactic X-ray Cancer Therapy System. Development of Advanced Compact Electron Linear Accelerator for Cancer Inspection and Therapy
The aim of this research is to apply the in-vivo visualization technique developed by our group in high-precision radiation therapy and to develop the motion prediction system for a real-time tumor-tracking radiation therapy. For the visualization of the treatment area during treatment, a four-dimensional cone-beam computed tomography (4D CBCT) reconstruction algorithm is developed by taking the anatomy or tumor motion analysis into account. In-treatment 4D CBCT requires the projection images acquired during treatment. The projection images are analyzed online, and compared with the reprojection images from the treatment planning CT or registration CT. The time lag due to the analysis can be compensated by the prediction using a multi-channel singular spectrum analysis. This

system will remove a delay problem during the real-time tumor-tracking radiation therapy, and will provide a safer radiation therapy than the current ones because this will be able to detect an irregular breathing motion of the tumor.

Research and development of micro-neurosurgical robotic systems

Department of Neurosurgery, The University of Tokyo Hospital

Mitsubishi Laboratory, Department of Mechanical Engineering, School of Engineering

Development of micro-neurosurgical robotic systems and advanced microscopic image processing for autonomous surgical task recognition.

Development of Support Systems for Risk Reduction in the Clinical Process

Chemical System Engineering

Center for Epidemiology and Preventive Medicine

Our specific targets are research and education on the integration of biological and clinical information including genome. In particular, we focus on establishment of personalized medicine as translational research, selection of drug targets by proteomics, interpretation of transcriptional regulations and drug development by targeting transcriptional factors in metabolic and cardiovascular diseases. Also, analyses of genomic functions, clinical safety monitoring by clinical database and assessments of clinical information systems are conducted.

Project of Neutron Capture Therapy & Innovation of DDS for Cancer

Department of Cardiothoracic Surgery, Graduate School of Medicine

Institute of Engineering Innovation, School of Engineering

Department of Bioengineering, School of Engineering

In order to control and eliminate human cancers, we develop the neutron capture therapy (NCT) using small neutron accelerator equipped to hospital and also aim to augment cancer therapy combined with approaches of Drug Delivery System. We develop the tumour specific drug delivery systems entrapped boron or gadolinium compounds as neutron capture

agents (WOW emulsion, Nano-micelle, Cationic Polyplex).

Development of adhesion barrier materials using a new animal model of liver-peritoneal adhesion

Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo

Organs and Biosystems Engineering Laboratory, Institute of Industrial Science, The University of Tokyo
Division of Biomedical Equipment and Biomaterials, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo
Department of Chemical System Engineering, Graduate School of Engineering, The University of Tokyo

Department of Bioengineering, Graduate School of Engineering, The University of Tokyo

Adhesions between liver and other organs are an important issue in the cases of second surgeries such as hepatic resection. Adhesions extend operative duration; in addition, they increase the risk of surgeries. Thus, it is important to avoid adhesions at a first surgery. However, no one report both the animal model and adhesion barrier materials of liver adhesion. We try to develop a new adhesion model by hepatic resection, instead of a usual peritoneal abrasion model. Also, we develop new materials for preventing the adhesions.

Development of gene therapy of cardiovascular therapy by polymeric micelles.

Department of Vascular Surgery, Division of Tissue Engineering, The University of Tokyo Hospital

Kataoka Laboratory, Department of Materials Science and Engineering, Graduate School of Engineering, The University of Tokyo

To achieve effective and safe in vivo gene therapy of cardiovascular and vascular diseases, we are developing non-viral gene vectors based on nano-scaled polymer assemblies (polymeric micelles). Polymeric micelles, which are spontaneously formed from block copolymers, have a core containing packaged genes surrounded by biocompatible poly

(ethylene glycol) (PEG) palisades, and a variety of pilot molecules can be installed on the surface of polymeric micelles. This "virus-mimicking" nanoparticles might achieve efficient gene transfer to the targeted tissues or cells because of protection of the loaded DNA from nuclease attack, their lowered non-specific interaction with proteins and cells and facilitated internalization by the targeted cells through specific interaction of the pilot molecules. Currently, our research has been focused on in vivo gene transfer to artery walls and muscles using polymeric micelles incorporated genes.

References (in 2021)

1. Hanada K, Hoshina K, Iwakiri T, Akai T, Miyahara K, Isaji T, Takayama T, Yamamoto S. A comparison of subjective clinical and objective judgement of abdominal aortic aneurysm morphology. *Int Angiol* 2021;40:138-142.
2. Okata S, Hoshina K, Miyahara K, Matsukura M, Akai T, Isaji T, Takayama T. High aneurysm wall enhancement values are associated with late sac shrinkage after endovascular repair of abdominal aortic aneurysms. *Medicine(Baltimore)* 2021 Jan 15;100:e24133.
3. Hoshina K, Kato M, Ishimaru S, Michihata N, Yasunaga H, Komori K; Japanese Committee for Stentgraft Management (JACSM). Impact of the urgency and the landing zone on rates of in-hospital death, stroke, and paraplegia following thoracic endovascular aortic repair in Japan. *J Vasc Surg* 2021; S0741-5214(21)00142-7
4. Matsuura S, Takayama T, Yuhn C, Oshima M, Shirasu T, Akai T, Isaji T, Hoshina K. Carotid stump pressure and contralateral internal carotid stenosis ratio during carotid endarterectomies: 1D-0D hemodynamic simulation of cerebral perfusion. *Ann Vasc Dis* 2021;14:39-45.
5. Hoshina K, Komori K, Kumamaru H, Shimizu H. The Outcomes of endovascular aneurysm repair in Japan in 2017: A Report from the Japanese Committee for Stentgraft Management. 2021;25; 14:92-98.
6. Sugawara M, Hoshina K, Chigira M, Suzuki H, Daimon M, Takayama T, Ono Y, Yatomi Y. Usefulness of duplex ultrasonography to detect collagen sponge misplacement into the arterial lumen during the use of Angio-Seal: A case report. *SAGE Open Med Case Rep* 2021;9: 2050313X211004818
7. Matsuura S, Takayama T, Oyama TG, Oyama K, Taguchi M, Endo T, Akai T, Isaji T, Hoshina K. A Radiation-crosslinked gelatin hydrogel that promotes tissue incorporation of an expanded polytetrafluoroethylene vascular graft in rats. *Biomolecules* 2021;11:1105.
8. Iida T, Muro K, Shiratori H, Nozawa H, Kawai K, Sasaki K, Emoto S, Kishikawa J, Ishii H, Yokoyama Y, Abe S, Nagai Y, Anzai H, Sonoda H, Takayama T, Hoshina K, Ishihara S. Impact of inferior mesenteric artery occlusion on the calibre of collateral arteries of the colon. *Anticancer Res* 2021;41: 5189-5193.
9. Hoshina K, Komori K, Kumamaru H, Shimizu H. The outcomes of thoracic endovascular aortic repair in Japan in 2017: A report from the Japanese Committee for Stentgraft Management. *Ann Vasc Dis* 2021;14:281-288.
10. Mo M, Hirokawa M, Satokawa H, Yasugi T, Yamaki T, Ito T, Onozawa S, Kobata T, Shirasugi N, Shokoku S, Sugano N, Sugiyama S, Hoshina K, on behalf of guideline committee Japanese Society of Phlebology, Ogawa T, on behalf of guideline committee of endovenous treatment for varicose veins. Supplement of clinical practice guidelines for endovenous thermal ablation for varicose veins: Overuse for the inappropriate indication. *Ann Vasc Dis* 2021;14:323-327.
11. Horio K, Marinho MM, Harada K, Muto J, Nakatomi H, Saito N, Morita A, Watanabe E, Mitsusishi M. "The effects of Grid Size for Automatic Suture Thread, Detection with an Image Classifier", The 17th Asian Conference on, Computer Aided Surgery (ACCAS2021), pp.102-103, Online, December 10, 2021.
12. Arvind K. Chandel S, Shimizu A, Hasegawa K, Ito T. "Advancement of biomaterial-based postoperative adhesion barriers" *Macromolecular Bioscience*, 2021, 2000395 DOI:10.1002/mabi.202000395
13. 大木悠一朗、伊藤大知 “「生体直交型反応を用いたインジェクタブルハイドロゲル」” *日本薬学会誌ファルマシア*, 2021, 57(11), 1025-

1029 https://doi.org/10.14894/faruawpsj.57.11_1025

14. Yanagie H, Fujino T, Yanagawa M, Terao T, Imagawa T, Fujihara M, Morishita Y, Mizumachi R, Murata Y, Dewi N, Ono Y, Ikushima I, Seguchi K, Nagata M, Nonaka Y, Furuya Y, Hisa T, Nagasaki T, Arimori K, Nakashima T, Sugihara T, Kakimi K, Ono M, Nakajima J, Eriguchi M, Higashi S, Takahashi H.: Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water Emulsion In Vivo.. *In Vivo*. 2021 Jan-Feb;35(1): 239-248. doi:10.21873/invivo.12252. PMID: 33402470
15. Yanagie H, Yanagawa M, Morishita Y, Shinohara A, Dewi N, Nonaka Y, Furuya Y, Mizumachi R, Murata Y, Nakamura H, Suzuki M, Sakurai Y, Tanaka H, Masunaga S, Ono K, Sugihara T, Nashimoto M, Yamauchi H, Ono M, Nakajima J, Takahashi H. : Suppression of Tumor Growth in a Rabbit Hepatic Cancer Model by Boron Neutron Capture Therapy With Liposomal Boron Delivery Systems. *In Vivo*. 2021 Nov-Dec;35(6):3125-3135. doi: 10.21873/invivo.12607. PMID: 34697143

Genomic Research Support Center (GresCent)

Director & Professor

Yutaka Osuga, M.D., Ph.D.

1. Organization

Genomic Research Support Center was established in 2017 to support appropriate and harmonious achievements of advanced genomic researches at the University of Tokyo Hospital. Genomic Research Support Center deals with cancer, life-style disease, hereditary disorders, and so on. This center is directed by Professor Yutaka Osuga. Experts of these fields, including Associate Professor Nobuhiro Shojima, participate in the activities as follows; (1) large scale analysis of genomes utilizing next generation sequencers and establishment of pipelines of genome informatic analysis, (2) elucidation of hereditary factors and pathogenesis of various diseases, (3) integrated research and education of genomic and clinical information, (4) analysis of polymorphism and mutation of genes involved in susceptibility and response to treatment in various diseases such as life-style disease, and (5) establishment of database and integrated data mining of associated clinical information.

2. Activities

In collaboration with RIKEN, we have identified genetic variations conferring susceptibility to type 2 diabetes, myocardial infarction and renal dysfunction in the Japanese population from the genome-wide association study (GWAS) results. We identified type 2 diabetes - associated loci, including missense variants in genes related to insulin secretion (GLP1R). To examine type 2 diabetes risk in East Asian individuals, our team carried out a meta-analysis of GWAS data from over 400,000 individuals. We

identified 61 loci that are newly implicated in predisposition to type 2 diabetes. (Nature, 2020, 582, 240-245).

In collaboration with the Osaka University, RIKEN and BioBank Japan, we assembled an ancestrally diverse collection of GWAS of type 2 diabetes through the UK Biobank, AGEN T2D and the Diabetes Meta-Analysis of Trans-Ethnic association studies (DIAMANTE) Consortium. Multi-ancestry GWAS meta-analysis identified multiple loci attaining stringent genome-wide significance, which were delineated to multiple distinct association signals (Nat Genet. 2022, 54(5):560-572). As expected, ancestry-specific genetic risk score (GRS) performed best in test GWAS from their respective ancestry group. Multi-ancestry meta-analysis maximizes power to detect association signals that are shared across ancestry groups. By modeling heterogeneity in allelic effects across ancestries, our meta-regression approach can also allow for association signals that are driven by ancestry-specific causal variants, although power will be limited by the sample size available in that ancestry group.

In collaboration with the Osaka University, RIKEN and BioBank Japan, we profiled serum metabolites of persons with type 2 diabetes with both diabetic retinopathy and diabetic kidney diseases using a comprehensive non-targeted metabolomics approach with mass spectrometry. We compared the abundance of the serum metabolites between the persons with type 2 diabetes with multiple complications and without any complications, identifying five metabolites, including N-acetylneuraminic acid

significantly increased in those with the complications (Commun Med. 2023, 9;3(1):5). Our metabolome analysis identified the serum metabolite features of the persons with type 2 diabetes with the complications, which could potentially be used as biomarkers.

We conducted whole genome sequence and analyzed the sequence data of over 2,000 subjects with type 2 diabetes in collaboration with the Osaka University, RIKEN and BioBank Japan. We are developing the methods to predict diabetic complications and deterioration of diabetes by bioinformatics algorithms including the Penalized regression method, often used in machine learning and public OmiX database.

In collaboration with Department of Clinical Genomics, we supported the meetings and expert-panel regarding cancer and rare diseases. We had clinical and genomic WEB conference with hospitals related to cancer treatment.

We shared genomic data with researchers about type 2 diabetes association study, Set3 (121,950 controls, 18,688 cases) and Set4 (7,065 controls, 2,483 cases) through national bioscience database center, NBDC (<https://humandbs.biosciencedbc.jp/hum0014-v18#diabet3>).

We made paper to inform for the participants of the research on ‘Realization of personalized medicine for Metabolic syndrome related disease.’ in collaboration with research ethics support center.

We used panel analysis applying next-generation sequencer and revealed the genetic diagnosis on extreme phenotypes of diseases related to life-styles including, maturity onset diabetes of the young and lipodystrophy and predicted the prognosis and selected effective therapies.

3. References

- 1: Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, Yu GZ, Rüeger S, Speidel L, Kim YJ, Horikoshi M, Mercader JM, Taliun D, Moon S, Kwak SH, Robertson NR, Rayner NW, Loh M, Kim BJ, Chiou J, Miguel-Escalada I, Della Briotta Parolo P, Lin K, Bragg F, Preuss MH, Takeuchi F, Nano J, Guo X, Lamri A, Nakatochi M, Scott RA, Lee JJ, Huerta-Chagoya A, Graff M, Chai JF, Parra EJ, Yao J, Bielak LF, Tabara Y, Hai Y, Steinthorsdottir V, Cook JP, Kals M, Grarup N, Schmidt EM, Pan I, Sofer T, Wuttke M, Sarnowski C, Gieger C, Noursome D, Trompet S, Long J, Sun M, Tong L, Chen WM, Ahmad M, Noordam R, Lim VJY, Tam CHT, Joo YY, Chen CH, Raffield LM, Lecoeur C, Prins BP, Nicolas A, Yanek LR, Chen G, Jensen RA, Tajuddin S, Kabagambe EK, An P, Xiang AH, Choi HS, Cade BE, Tan J, Flanagan J, Abaitua F, Adair LS, Adeyemo A, Aguilar-Salinas CA, Akiyama M, Anand SS, Bertoni A, Bian Z, Bork-Jensen J, Brandslund I, Brody JA, Brummett CM, Buchanan TA, Canouil M, Chan JCN, Chang LC, Chee ML, Chen J, Chen SH, Chen YT, Chen Z, Chuang LM, Cushman M, Das SK, de Silva HJ, Dedoussis G, Dimitrov L, Doumatey AP, Du S, Duan Q, Eckardt KU, Emery LS, Evans DS, Evans MK, Fischer K, Floyd JS, Ford I, Fornage M, Franco OH, Frayling TM, Freedman BI, Fuchsberger C, Genter P, Gerstein HC, Giedraitis V, González-Villalpando C, González-Villalpando ME, Goodarzi MO, Gordon-Larsen P, Gorkin D, Gross M, Guo Y, Hackinger S, Han S, Hattersley AT, Herder C, Howard AG, Hsueh W, Huang M, Huang W, Hung YJ, Hwang MY, Hwu CM, Ichihara S, Ikram MA, Ingelsson M, Islam MT, Isono M, Jang HM, Jasmine F, Jiang G, Jonas JB, Jørgensen ME, Jørgensen T, Kamatani Y, Kandeel FR, Kasturiratne A, Katsuya T, Kaur V, Kawaguchi T, Keaton JM, Kho AN, Khor CC, Kibriya MG, Kim DH, Kohara K, Kriebel J, Kronenberg F, Kuusisto J, Läll K, Lange LA, Lee MS, Lee NR, Leong A, Li L, Li Y, Li-Gao R, Ligthart S, Lindgren CM, Linneberg A, Liu CT, Liu J, Locke AE, Louie T, Luan J, Luk AO, Luo X, Lv J, Lyssenko V, Mamakou V, Mani KR, Meitinger T, Metspalu A, Morris AD, Nadkarni GN, Nadler JL, Nalls MA, Nayak U, Nongmaithem SS, Ntalla I, Okada Y, Orozco L, Patel SR, Pereira MA, Peters A, Pirie FJ, Porneala B, Prasad G, Preissl S, Rasmussen-Torvik LJ, Reiner AP, Roden M, Rohde R, Roll K, Sabanayagam C, Sander M, Sandow K, Sattar N, Schönherr S, Schurmann C, Shahriar M, Shi J, Shin DM, Shriner D, Smith JA, So WY,

- Stančáková A, Stilp AM, Strauch K, Suzuki K, Takahashi A, Taylor KD, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tomlinson B, Torres JM, Tsai FJ, Tuomilehto J, Tusie-Luna T, Udler MS, Valladares-Salgado A, van Dam RM, van Klinken JB, Varma R, Vujkovic M, Wachter-Rodarte N, Wheeler E, Whitsel EA, Wickremasinghe AR, van Dijk KW, Witte DR, Yajnik CS, Yamamoto K, Yamauchi T, Yengo L, Yoon K, Yu C, Yuan JM, Yusuf S, Zhang L, Zheng W; FinnGen; eMERGE Consortium; Raffel LJ, Igase M, Ipp E, Redline S, Cho YS, Lind L, Province MA, Hanis CL, Peyser PA, Ingelsson E, Zonderman AB, Psaty BM, Wang YX, Rotimi CN, Becker DM, Matsuda F, Liu Y, Zeggini E, Yokota M, Rich SS, Kooperberg C, Pankow JS, Engert JC, Chen YI, Froguel P, Wilson JG, Sheu WHH, Kardia SLR, Wu JY, Hayes MG, Ma RCW, Wong TY, Groop L, Mook-Kanamori DO, Chandak GR, Collins FS, Bharadwaj D, Paré G, Sale MM, Ahsan H, Motala AA, Shu XO, Park KS, Jukema JW, Cruz M, McKean-Cowdin R, Grallert H, Cheng CY, Bottinger EP, Dehghan A, Tai ES, Dupuis J, Kato N, Laakso M, Köttgen A, Koh WP, Palmer CNA, Liu S, Abecasis G, Kooner JS, Loos RJF, North KE, Haiman CA, Florez JC, Saleheen D, Hansen T, Pedersen O, Mägi R, Langenberg C, Wareham NJ, Maeda S, Kadowaki T, Lee J, Millwood IY, Walters RG, Stefansson K, Myers SR, Ferrer J, Gaulton KJ, Meigs JB, Mohlke KL, Gloyn AL, Bowden DW, Below JE, Chambers JC, Sim X, Boehnke M, Rotter JI, McCarthy MI, Morris AP. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nat Genet.* 2022 May;54(5):560-572. doi: 10.1038/s41588-022-01058-3. Epub 2022 May 12. PMID: 35551307; PMCID: PMC9179018.
- 2: Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. *Commun Biol.* 2022 Jan 11;5(1):39. doi: 10.1038/s42003-021-02992-4. PMID: 35017636; PMCID: PMC8752757.
- 3: Tomofuji Y, Suzuki K, Kishikawa T, Shojima N, Hosoe J, Inagaki K, Matsubayashi S, Ishihara H, Watada H, Ishigaki Y; BioBank Japan Project; Inohara H, Murakami Y, Matsuda K, Okada Y, Yamauchi T, Kadowaki T. Identification of serum metabolome signatures associated with retinal and renal complications of type 2 diabetes. *Commun Med (Lond).* 2023 Jan 9;3(1):5. doi: 10.1038/s43856-022-00231-3. PMID: 36624208; PMCID: PMC9829655.
- 4: Shojima N, Yamauchi T. Progress in genetics of type 2 diabetes and diabetic complications. *J Diabetes Investig.* 2023 Apr;14(4):503-515. doi: 10.1111/jdi.13970. Epub 2023 Jan 14. PMID: 36639962; PMCID: PMC10034958.
- 5: Suzuki K, Hatzikotoulas K, Southam L, Taylor HJ, Yin X, Lorenz KM, Mandla R, Huerta-Chagoya A, Rayner NW, Bocher O, Ana Luiza de SVA, Sonehara K, Namba S, Lee SSK, Preuss MH, Petty LE, Schroeder P, Vanderwerff B, Kals M, Bragg F, Lin K, Guo X, Zhang W, Yao J, Kim YJ, Graff M, Takeuchi F, Nano J, Lamri A, Nakatochi M, Moon S, Scott RA, Cook JP, Lee JJ, Pan I, Taliun D, Parra EJ, Chai JF, Bielak LF, Tabara Y, Hai Y, Thorleifsson G, Grarup N, Sofer T, Wuttke M, Sarnowski C, Gieger C, Noursome D, Trompet S, Kwak SH, Long J, Sun M, Tong L, Chen WM, Nongmaithem SS, Noordam R, Lim VJY, Tam CHT, Joo YY, Chen CH, Raffield LM, Prins BP, Nicolas A, Yanek LR, Chen G, Brody JA, Kabagambe E, An P, Xiang AH, Choi HS, Cade BE, Tan J, Elaine Broadaway K, Williamson A, Kamali Z, Cui J, Adair LS, Adeyemo A, Aguilar-Salinas CA, Ahluwalia TS, Anand SS, Bertoni A, Bork-Jensen J, Brandslund I, Buchanan TA, Burant CF, Butterworth AS, Canouil M, Chan JCN, Chang LC, Chee ML, Chen J, Chen SH, Chen YT, Chen Z, Chuang LM, Cushman M, Danesh J, Das SK, Janaka de Silva H, Dedoussis G, Dimitrov L, Doumatey AP, Du S, Duan Q, Eckardt KU, Emery LS, Evans DS, Evans MK, Fischer K, Floyd JS, Ford I, Franco OH, Frayling TM, Freedman BI, Genter P, Gerstein HC, Giedraitis V, González-Villalpando C, González-Villalpando ME, Gordon-Larsen P,

- Gross M, Guare LA, Hackinger S, Han S, Hattersley AT, Herder C, Horikoshi M, Howard AG, Hsueh W, Huang M, Huang W, Hung YJ, Hwang MY, Hwu CM, Ichihara S, Ikram MA, Ingelsson M, Islam MT, Isono M, Jang HM, Jasmine F, Jiang G, Jonas JB, Jørgensen T, Kandeel FR, Kasturiratne A, Katsuya T, Kaur V, Kawaguchi T, Keaton JM, Kho AN, Khor CC, Kibriya MG, Kim DH, Kronenberg F, Kuusisto J, Läll K, Lange LA, Lee KM, Lee MS, Lee NR, Leong A, Li L, Li Y, Li-Gao R, Lithgart S, Lindgren CM, Linneberg A, Liu CT, Liu J, Locke AE, Louie T, Luan J, Luk AO, Luo X, Lv J, Lynch JA, Lyssenko V, Maeda S, Mamakou V, Mansuri SR, Matsuda K, Meitinger T, Metspalu A, Mo H, Morris AD, Nadler JL, Nalls MA, Nayak U, Ntalla I, Okada Y, Orozco L, Patel SR, Patil S, Pei P, Pereira MA, Peters A, Pirie FJ, Polikowsky HG, Porneala B, Prasad G, Rasmussen-Torvik LJ, Reiner AP, Roden M, Rohde R, Roll K, Sabanayagam C, Sandow K, Sankareswaran A, Sattar N, Schönherr S, Shahriar M, Shen B, Shi J, Shin DM, Shojima N, Smith JA, So WY, Stančáková A, Steinthorsdottir V, Stilp AM, Strauch K, Taylor KD, Thorand B, Thorsteinsdottir U, Tomlinson B, Tran TC, Tsai FJ, Tuomilehto J, Tusie-Luna T, Udler MS, Valladares-Salgado A, van Dam RM, van Klinken JB, Varma R, Wachter-Rodarte N, Wheeler E, Wickremasinghe AR, van Dijk KW, Witte DR, Yajnik CS, Yamamoto K, Yamamoto K, Yoon K, Yu C, Yuan JM, Yusuf S, Zawistowski M, Zhang L, Zheng W; VA Million Veteran Program, AMED GRIFIN Diabetes Initiative Japan; Project B1, BioBank PM, Center RG, Consortium E; International Consortium for Blood Pressure (ICBP); Meta-Analyses of Glucose and Insulin-Related Traits Consortium (MAGIC); Raffel LJ, Igase M, Ipp E, Redline S, Cho YS, Lind L, Province MA, Fornage M, Hanis CL, Ingelsson E, Zonderman AB, Psaty BM, Wang YX, Rotimi CN, Becker DM, Matsuda F, Liu Y, Yokota M, Kardia SLR, Peyser PA, Pankow JS, Engert JC, Bonnefond A, Froguel P, Wilson JG, Sheu WHH, Wu JY, Geoffrey Hayes M, Ma RCW, Wong TY, Mook-Kanamori DO, Tuomi T, Chandak GR, Collins FS, Bharadwaj D, Paré G, Sale MM, Ahsan H, Motala AA, Shu XO, Park KS, Jukema JW, Cruz M, Chen YI, Rich SS, McKean-Cowdin R, Grallert H, Cheng CY, Ghanbari M, Tai ES, Dupuis J, Kato N, Laakso M, Köttgen A, Koh WP, Bowden DW, Palmer CNA, Kooner JS, Kooperberg C, Liu S, North KE, Saleheen D, Hansen T, Pedersen O, Wareham NJ, Lee J, Kim BJ, Millwood IY, Walters RG, Stefansson K, Goodarzi MO, Mohlke KL, Langenberg C, Haiman CA, Loos RJF, Florez JC, Rader DJ, Ritchie MD, Zöllner S, Mägi R, Denny JC, Yamauchi T, Kadowaki T, Chambers JC, Ng MCY, Sim X, Below JE, Tsao PS, Chang KM, McCarthy MI, Meigs JB, Mahajan A, Spracklen CN, Mercader JM, Boehnke M, Rotter JI, Vujkovic M, Voight BF, Morris AP, Zeggini E. Multi-ancestry genome-wide study in >2.5 million individuals reveals heterogeneity in mechanistic pathways of type 2 diabetes and complications. *medRxiv* [Preprint]. 2023 Mar 31: 2023.03.31.23287839. doi: 10.1101/2023.03.31.23287839. PMID: 37034649; PMCID: PMC10081410.

BioResource Center

Director

Tetsuo Ushiku, M.D., Ph.D. (Professor, Department of Pathology and Diagnostic Pathology)

Deputy Director

Katsutoshi, Oda, M.D., Ph.D. (Professor, Division of Integrative Genomics)

Staff

Aya Shinozaki-Ushiku, M.D., Ph.D. (Associate Professor, Division of Integrative Genomics)

Homepage <https://www.h.u-tokyo.ac.jp/patient/depts/bio-resource/>

Introduction and Organization

A wide variety of clinical and scientific research is being conducted at The University of Tokyo Hospital and Faculty of Medicine. When using samples obtained from patients through surgery and laboratory tests, researchers of each department have obtained informed consent for the research and stored the samples in their own laboratory. To utilize valuable resources more effectively, the center specialized in collecting and storing samples is needed. The University of Tokyo Hospital is one of the core hospitals to promote cancer genomic medicine in Japan and is required to equip biobank to store tissue samples of multiple organs.

In these settings, a working group has started to work on the establishment of BioResource Center since 2020. Members from the Departments of Clinical Genomics, Pathology, Clinical Laboratory and Surgery, as well as experts in basic medical research, discussed how to inform and obtain consent of the patients, details of tissue sampling and storing protocols, and the process of utilizing samples in medical research. After the approval by Hospital Executives, BioResource Center was established as one of the Clinical Research Services of the University of Tokyo Hospital on Apr 1, 2021. This BioResource Center Project was also approved by Research Ethics Committee of the Faculty of Medicine on Aug 16, 2021.

Samples, clinical information, and research data with written informed consent of the patients are stored in

the center and are utilized in the research approved by Research Ethics Committee. Staffs of the center and representatives of clinical departments also hold a committee to review the research protocols to check whether the use of the stored samples is appropriate.

Clinical activities

Three doctors (director, deputy director and a staff) and two project academic specialists are in charge of the activity. We work together with Department of Surgery, Pathology, Clinical Laboratory and Surgical Center in obtaining patients' consent and collecting samples. Members of the Office of Research Support also support us in the management of the center.

In FY2021, we worked on the sampling protocols, developed a system and a database to collect the information of patients' consent and stored samples, and set up a laboratory. Sampling of peripheral blood and tissues started in March 2022. At the end of FY2022, samples from 300 patients were collected and stored. In November 2022, scheme for medical research using samples stored in BioResource Center was approved by Research Ethics Committee of the Faculty of Medicine, making the researchers in the hospital available for the stored samples.

BioResource Center freezes and stores DNA and plasma extracted from peripheral blood and paired normal/tumor tissues. Sample information such as patient's age, sex and cancer type are also collected.

The center will cover patients of Internal Medicine who suffer from lifestyle diseases and intractable diseases and pediatric patients in the future.

Teaching and Research activities

In FY2023, we offered samples for the whole-genome analysis conducted as a national research project. We hope to expand our activities in research as well as educating specialists on banking method in the coming year.

References

None

Department of Clinical Research Governance

Director & Project Professor

Junji Moriya, M.D., Ph.D.

Research Associate

Kazuyoshi Ichihashi, Ph.D.

※The following information is the same as that of the previous year for certain reasons.

Website <http://www.h.u-tokyo.ac.jp/english/centers-services/organization/14/researchgovernance.html>

History and Overview of the Organization

The Department of Clinical Research Governance was established independently from the Clinical Research Support Center on January 1st, 2015, for the management of clinical research. The aim of the department is an appropriate and rapid response to various issues surrounding clinical research in recent years, to prevent problems related to research ethics and research misconduct, and to promote highly reliable clinical research. The intention of the Department of Clinical Research Governance is to establish a system that would enable the University of Tokyo Hospital to take the initiative in managing and promoting clinical research so as to ensure the reliability of clinical research and compliance with the ethics of clinical research promoted by university hospitals providing advanced medical care.

The Department of Clinical Research Governance is now composed of three offices: 1) Office of Strategic Planning and Promotion, 2) Office of Research Integrity and Promotion, and 3) Office of Clinical Compliance. These offices mutually cooperate to promote and strengthen governance functions within the hospital.

The following activities are carried out by the

Office of Strategic Planning and Promotion ; (1) formulating comprehensive strategies for research and development at the University of Tokyo Hospital, (2) adopting the role of administrative headquarters when publicly applying for large-scale research projects, (3) serving as a liaison for consultations regarding the acquisition of research funds and intellectual properties, (4) examination financial self-reliance strategies of the clinical research base, (5) discovering needs and seeds in clinical practice, (6) investigating research activities at the University of Tokyo Hospital and creating a database, (7) collecting clinical research information from external organizations, (8) activities related to conflicts of interest at the University of Tokyo Hospital, (9) clerical work related to the Advanced Medicine Development Support Management Committee, and (10) clerical work related to the Special Clinical Research Steering Committee.

The activities of the Office of Research Integrity and Promotion are as follows; (1) responding to problems related to research ethics and research misconduct, (2) educational activities for clinical researchers; and (3) the dissemination of workshop summaries.

The activities of the Office of Clinical Compliance are as follows; (1) auditing of clinical researches and clinical trials, (2) integrated management of

outsourced auditing, (3) integrated management of audit results of the University of Tokyo Hospital, and (4) educational workshops and guidance related to auditing.

The Department of Clinical Research Governance consists of one director (a full-time post), one Research Associate/URA in the Office of Strategic Planning and Promotion, three staffs (2 auditors and one temporary staffs (an auditor staff) in the Office of Clinical Compliance, and two staffs in the Office of Research Integrity and Promotion as of March 2022.

Activities

The Office of Strategic Planning and Promotion has undertaken the following activities in the fiscal year 2021.

- 1) Coordination of organization for clinical trials/researches; assisting the holding of Specified Clinical Research Steering Committee and the Specified Clinical Research Auditing Committee, and assisting the preparation of reports on clinical research activities as the Clinical Research Core Hospitals under the Medical Care Act (Act No. 205 of July 30, 1948) for surveys conducted by the Ministry of Health, Labor and Welfare (MHLW).
- 2) Others; investigations of research paper publication activities, co-operating the “Forum for Development of Seeds for Advanced Medicine”, etc.

The Office of Clinical Compliance has undertaken the following activities in the fiscal year 2021.

- 1) Audit activities; as regard to trials/researches conducted by the University of Tokyo Hospital, the office conducted a total of eight trials (six audits for investigator-initiated clinical trials, and two audits for Specified Clinical Researches).
- 2) Consolidating information; the office collected all the information on audit results including directly outsourced by principal investigators, and has been centrally managing the GCP inspections findings conducted at the University of Tokyo Hospital.
- 3) Preparing documents; the office prepared documents of SOP in general auditing, templates for auditing of each trial, start-up meetings, and protocols, along with maintenance of existing checklists.

- 4) MHLW program for educational workshops and guidance related to auditing; the office has a central role in performing workshops in the fiscal year 2021, and held a beginners workshop in September 2nd and 3rd, and a mid-career workshop in November 18th and 19th.

The Office of Research Integrity and Promotion has undertaken the following activities in the fiscal year 2021.

- 1) Collecting and disseminating information for clinical quality assurance; the office has sent a total of six e-mails for all personnel in the University of Tokyo Hospital, along with disclosing a total of 16 information in the website of the Department of Clinical Research Governance.
- 2) Educational activities for clinical researchers; the office has held an e-learning seminar regarding to the management of conflict of interest and quality assurance in clinical researches (there were 1935 participants in a Step1 seminar, and 1888 participants in a Step2 seminar).
- 3) Promotion of activities for research integrity; the office has engaged in creating a team for supporting activities regarding to QMS in investigator-initiated clinical trials conducted in the University of Tokyo Hospital. The team consists of members of the Office of Research Integrity and Promotion, and the Clinical Research Promotion Center. The team extracted problems and points to consider as to working flows of collecting and reporting information for deviations or misconducts of clinical trials performed in the University of Tokyo Hospital.

Department of Healthcare Information Management

Professor

Kazuhiko Ohe, M.D.,Ph.D.

Associate Professor

Kayo Waki, M.D.,Ph.D. Yoshimasa Kawazoe, M.D.,Ph.D.

Lecturer

Shinichiro Yokota, PHN,RN,Ph.D., Hidenao Atarashi BMET, Ph.D.

Homepage <http://www.m.u-tokyo.ac.jp/medinfo/>

Introduction and Organization

In order for the University of Tokyo Hospital to respond strategically and quickly to various changes in the medical system and changes in the university hospital organization, and to operate by making maximum use of medical information, In 2003, the hospital management support departments, which had been separated into the Central Medical Information Department, New Hospital Development Planning Office (hospital measures), Management Improvement Planning Office (hospital measures), Medical Affairs Division, and Administration Division, were integrated and established in 2003. It was newly established in April 2013. The predecessor of the Central Medical Information Department was the Information Processing Department, which was established at the University of Tokyo Hospital in 1975 as an in-hospital measure. In 1983, the Ministry of Education (at that time) officially established the Central Medical Information Department as one of the central medical facilities of the University of Tokyo Hospital.

At the same time, it became possible to accept doctoral course students as the first graduate school of basic medicine. The first professor and director of the Central Medical Information Department was Shigemasa Kaihara (deceased), who established medical informatics in Japan, and is currently the second generation. In 1997, Professor 1 and Assistant Professor

1, who had been affiliated with the Central Medical Information Department, began to focus on graduate school, and in 2003, as mentioned above, it became the Planning Information Management Department. For the relationship with the Graduate School of Medical Informatics, please refer to the Medical Informatics section of the Department of Social Medicine.

In addition to procuring, developing, implementing, and operating general hospital information systems and comprehensive medical information network systems centered on electronic medical record systems, the Planning Information Management Department also handles systems that support clinical research and medical safety management. We are currently developing a system for this purpose. In addition to strategically managing and analyzing information throughout the hospital and providing operational support based on this information, the hospital is also responsible for formulating mid- to long-term plans, supporting their implementation, and coordinating plans.

Activities

Regarding medical information systems, we updated the system in fiscal year 2017 (2017/12/28-2018/01/04) and updated our unique ordering system and electronic system, which we have been using since 1994 and have continued to improve and update. We stopped using the

medical record system and updated it to the Fujitsu EgMAING-GX series package system. As it was a complete system update, there were some difficulties with data migration, and operations were disrupted at the beginning of the update, but it took several months to get things under control and up and running.

In addition, we have been participating in the project as a cooperating organization of MID-NET, a medical information database infrastructure development project that is a joint project between the Pharmaceutical and Food Bureau of the Ministry of Health, Labor and Welfare and PMDA. We have started taking orders.

In addition, the national university hospital disaster medical data backup system, which has been in operation since 2014, continued to be operated by our department as the main care department in 2017, and was completely updated in 2019.

A medical human resources development project managed by the Ministry of Education, Culture, Sports, Science and Technology began in the middle of 2017, and faculty members from this department (Specially Appointed Lecturer Ida and Assistant Professor Yamada) are participating in the steering committee to support the promotion of the project. Details are available at <https://hep.m.u-tokyo.ac.jp/cms/>.

The Ministry of Education, Culture, Sports, Science and Technology's Human Resources Development Project for Utilizing Medical Real Data began in 2019, and Miyake and Kubota were hired as specially appointed assistant professors in this department, and are in charge of curriculum creation and management together with Seki, the assistant professor in charge. Lectures and practical training are mainly held on Saturdays as part of the adult education course, and details can be found at <https://www.med-rwd.jp/>.

Research activities

Please refer to the Department of Social Medicine and Medical Informatics.

University Hospital Medical Information Network (UMIN) Center

Professor

Takahiro Kiuchi, M.D., Ph.D.

Associate Professor

Tsuyoshi Okuhara, Ph.D., M.P.H.

Instructor

Hiroko Okada, R.N., Ph.D., M.P.H.

Eiko Goto, R.D., Ph.D., M.P.H.

Rie Yokota, Ph.D., M.P.H.

Homepage <http://www.umin.ac.jp/>

Introduction and Organization

The University hospital Medical Information Network (UMIN) (the original name was the University Medical Information Network), was established in 1989. While general-use computer systems were implemented at all national university hospitals around the end of the Showa era (late 1980s), Dr. Shigekoto Kaihara, chair and professor at the Hospital Computer Center, University of Tokyo Hospital, led a project to connect these computer systems in a network in order to share information for better communication. Finally, the Ministry of Education, Culture, Sports, Science and Technology approved a budget to initiate the UMIN Center. The UMIN Center was founded within the Hospital Computer Center, University of Tokyo Hospital, and was officially opened in March 1989. Dr. Tsunetaro Sakurai became an associate professor as the first full-time UMIN staff. The following are the objectives of the UMIN Center, as initially outlined in 1989 (No.6 was added later):

1. Provide up-to-date information for healthcare professionals

2. Promote digitalized communication among health-care professionals
3. Support collaborative projects among university hospitals
4. Support collaborative medical research
5. Standardize data format and support data collection
6. Support medical education and clinical training

The original UMIN system utilized an N1 protocol, which was developed in Japan and was the only solution at the time to connect general-use computers of the five major computer vendors in Japan, although it was poor in function, supporting only line-mode, character-based terminals.

In 1994, we launched a service through the Internet, and it began to spread in those days. The number of UMIN users gradually increased, mainly in the E-mail service.

In 1996, Dr. Takahiro Kiuchi took up a new post while Dr. Sakurai was promoted to professor at Hokkaido University. Dr. Kiuchi updated the system to be web-based. With the rapid spread of the Internet in Japan, UMIN users dramatically increased.

The UMIN Center subsequently started to provide three major information services: (1) the ELBIS (Electronic Library for Biomedical Sciences) as of 1997, (2) the INDICE (Internet Data and Information Center of Clinical Research) as of 2000, and (3) the EPOC (Evaluation System of Postgraduate Clinical Training) as of 2004.

In April 2002, the UMIN Center became an independent entity, with the adjusted name of University Hospital Medical Information Network Center, as per an internal arrangement at the University of Tokyo Hospital. In 2003, a budget for a new professor position was officially approved by the Ministry of Education, Culture, Sports, Science and Technology. Then, Dr. Kiuchi was promoted to become the first professor of the UMIN Center on April 1, 2004. The UMIN Center became part of the Faculty of Medicine, as the Department of Health Communication, School of Public Health, which was established in April 2007.

Clinical Activities

Although the UMIN Center is one of the central medical examination and treatment institutions of the University of Tokyo Hospital, the center does not provide direct patient care services, but provides services for medical researchers and practitioners throughout Japan. We currently have about 470,000 registrants, and approximately 120,000,000 monthly website accesses, which is currently in the scale of the world's highest access rates. The service extends to study / education / medical examination and treatment / hospital duties and encompasses many divergences as indicated below:

■ Research: <http://www.umin.ac.jp/research>

AC: Information for Academic Conferences

ELBIS: Electronic Library for Biomedical Sciences

FIND: Fund Information Database

INDICE: Internet Data and Information Center of Clinical Research

ROCOLS: Recruiting System for Our Colleagues' and Students'

CTR: Clinical Trial Registry

ICDS: Individual Case Data Sharing System

■ Education: <http://www.umin.ac.jp/education>

CC-EPOC: Clinical Clerkship E-Portfolio of Clinical Training

PG-EPOC: E-Portfolio of Clinical Training 2

Debut2: Dental Training Evaluation and Tabulation System

L: E-learning system

ARIA: Online Recruiting System for General Use

■ Medical Examination and Treatment

<http://www.umin.ac.jp/u hosp/>

- Intoxication database
- Ministry of Education, Culture, Sports, Science and Technology document public information system
- National university hospital-related medical dispute report
- Lists for people and committees
- Various government official appointments, administrative websites and ML

■ General Services

(1) General information and search

- Medical / biology related websites
- Medical terminology
- A medical research organization / medical institution database

(2) Services for information providers

- Web service for public
- Web service for members
- Website preservation service

(3) Communication support

- E-mail
- Listserv
- Discussion board
- File exchange

Teaching Activities

Please refer to Department of Health Communication for information about graduate and undergraduate education.

Research Activities

Please refer to Department of Health Communication for information about research activities.

References

Please refer to Department of Health Communication.

Department of Disaster Medical Management

Professor

Kent Doi, M.D.,Ph.D.

Assistant Professor

Hiroko Yuzawa M.D.,Ph.D. Kengo Hiwatashi M.D.

Homepage <https://www.h.u-tokyo.ac.jp/patient/depts/dmm/>

Introduction and Organization

Responding to the Great East Japan Earthquake in 2011, the University of Tokyo Hospital has decided to set out to establish “disaster medical management studies” in terms of need not only to provide medical treatment at the time of disaster but also to develop a new academic field that provides bird’s-eye view on overall disaster medicine. In March 2012, we made an announcement to establish “Department of Disaster Medical Management” in the Public Comment.

In July 2012, Associate Professor Dr. Hiroyuki Nakao was assigned the post as the first General Manager of the Department of Disaster Medical Management. Afterwards, in January 2015, Professor Dr. Tadashi Iwanaka, the Hospital Vice Director, was assigned the post as the second General Manager. In April 2015, Professor Dr. Masaomi Nangaku, the Hospital Vice Director in charge of crisis management and disaster prevention, was assigned the post as the third General Manager. In 2021, Professor Kent Doi has been assigned the post as the General Manager of the Department of Disaster Medical Management and was appointed as the chairman of the in-hospital Disaster Prevention Committee.

This department belongs to the Central Clinical Facilities Division and is involved in activities within this hospital and inside/outside of the University.

In order to establish disaster medical management studies, we are aiming at 1) fostering leaders who can develop plans for disaster medicine and educate

personnel engaged in disaster medicine, 2) relationship building with relevant institutions for establishing a system for the University of Tokyo Hospital to lead disaster medicine and 3) developing a system as a base of formation of organizations at the time of disaster.

Clinical activities

Since 2012, the Disaster Prevention Committee carries out planning and conduct the University of Tokyo Hospital Comprehensive Disaster Drill regularly. Drills of launching a new earthquake early warning system, building hospital headquarter for disaster control, reporting in-hospital damage situation, establishing triage and casualty clearing station, triage and rescue of mass casualties, were performed yearly with cooperation of the University of Tokyo, the Metropolitan Tokyo Fire Department, and the Ministry of Health Labor and Welfare.

Teaching activities

The Center provides education regarding disasters to new employees and supports disaster-related training activities in each department of the hospital. As for off-campus educational activities, the center provides support for planning disaster drills at other hospitals and gives educational lectures.

Research activities

We are seeking ways of cooperation between institutions through workshops with relevant institutions from the perspective that day-to-day cooperation with relevant institutions can be also utilized at the time of disaster. We consider that it can be also utilized for cross-business formation of organizations at the time of disaster.

References

1. Kurano M, Jubishi D, Okamoto K, Hashimoto H, Sakai E, Morita Y, Saigusa D, Kano K, Aoki J, Harada S, Okugawa S, Doi K, Moriya K, Yatomi Y. Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries. *J Biomed Sci.* 2022 Nov 10;29(1):94.
2. Yamakawa K, Yamamoto R, Terayama T, Hashimoto H, Ishihara T, Ishimaru G, Imura H, Okano H, Narita C, Mayumi T, Yasuda H, Yamada K, Yamada H, Kawasaki T, Shime N, Doi K, Egi M, Ogura H, Aihara M, Kushimoto S, Nishida O; Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J-SSCG 2020), the COVID-19 Task Force. Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022). *Acute Med Surg.* 2022 Oct 19;9(1):e789.
3. Kurano M, Okamoto K, Jubishi D, Hashimoto H, Sakai E, Saigusa D, Kano K, Aoki J, Harada S, Okugawa S, Doi K, Moriya K, Yatomi Y. Dynamic modulations of sphingolipids and glycerophospholipids in COVID-19. *Clin Transl Med.* 2022 Oct;12(10):e1069.
4. Ohashi-Fukuda N, Fukuda T, Doi K. Association between time to advanced airway management and survival during pediatric out-of-hospital cardiac arrest. *Resusc Plus.* 2022 Jun 24;11:100260.

**Center for Disease Biology and
Integrative Medicine**

Laboratory of Molecular Biomedicine for Pathogenesis

Associate Professor

Satoko Arai, Ph.D.

Official Website <http://tmlab.m.u-tokyo.ac.jp/>

Research

Our laboratory focuses on clarification of the pathogenesis of various diseases and the related physiological machineries in cellular and molecular aspects. Based on our technical advantage in gene manipulation via gene knockout and transgenesis, we give high priorities to *in vivo* analyses. This will definitely contribute to the direct therapeutic application of our findings. Since our rationale is to challenge to uncharacterized disease mechanisms and physiologies, we will not restrict our interest, strategy or technique employed, in certain specific field. Rather, we will expand our research area by establishing different collaborations with a broad spectrum of researchers. We believe this fits to the policy of the CDBIM, which aims the development of a comprehensive science including the fundamental and clinical medicines, and the biotechnology. Overall, we will attempt to discover novel biological insights rather than to study details of previously characterized physiologies, by targeting molecules newly identified by ourselves. Now, we are focusing on the following major projects.

AIM (Apoptosis Inhibitor of Macrophage) as a master switch to various modern diseases.

The rapid change in lifestyles and eating habits in today's society are thought to be the cause of various disorders; metabolic syndrome and lifestyle-related diseases increase the risk of developing obesity, diabetes, and cardiovascular disease; a fatty liver leads to NASH and liver disease, may result in liver cancer; autoimmune disease followed by obesity, chronic

renal failure, and Alzheimer's disease are considered as well. We hypothesize that such various modern disorders, seemingly unrelated at first sight, share the common underlying pathological condition and mechanism, and the group of molecules exists as the master switch, regulating the varied conditions.

We found a soluble apoptosis inhibitor factor largely produced by tissue macrophage, named AIM (apoptosis inhibitor of macrophage). Our recent studies showed that AIM plays an important role in regulating the pathological condition of the modern diseases.

AIM is produced by macrophage and largely presents in bloodstream as a soluble molecule. Once AIM is incorporated into adipose tissue, it progression of obesity. However, when this process undergoes effectively and excessively under the obese condition, oppositely to control the progression of obesity, chronic inflammation of adipose tissue and insulin resistance are triggered and Type II diabetes and atherosclerosis are worsen.

Moreover, because AIM binds to IgM in bloodstream, it leads to production of various auto-antibodies, especially under the obese condition. This suggests that the obesity is the cause of autoimmune disease. Other studies showed that liver disease, cancer, and kidney disease worsen under low concentration of AIM. It is suggested that the concentration of AIM in bloodstream differentiates the outcome and the risk of getting various diseases.

The project was accepted for Advanced Research and Development Programs for Medical Innovation, Leading Advanced Projects for medical innovation

(LEAP) 2019 (FY2019-2023), on Japan Agency for Medical Research and Development (AMED).

Finding the mechanism on the regulation of AIM activity will shed light on developing a diagnostics and potential treatments to modern diseases. We will focus on the details of involvement of AIM to the various diseases by generating a mouse model. Also, cohort study is carried out using and analyzing the human specimen, aiming to develop a novel drug treatment.

Additionally, we worked on the project regarding the development of novel therapy against the infectious diseases based on the phagocytic mechanism, founded by Research Program on Emerging and Re-emerging Infectious Diseases (AMED FY2020-2021).

Lab Activities

We believe that the following three things are essential for research in medical biology: ideas, strategies, and experimental techniques. Therefore, the goal of our education is to let the students acquire as wide range of techniques as possible during their Master/PhD courses and to cultivate ideas and strategies for research during their postdoctoral period. In addition, since the establishment of our laboratory in 2006, we have been constructing an international research environment by regularly organizing a series of seminars by leading overseas researchers and creating as many opportunities as possible for young researchers to have discussions in English, based on the extensive friendships cultivated by Professor Miyazaki's long-term overseas research experience. In addition, we regularly hold joint meetings with universities in Japan and abroad to exchange each other's research progression and to explore the development of research through multifaceted discussions, as well as to provide opportunities for students to present and discuss their research and to interact with researchers. This year's seminars and meetings were postponed in view of the situation under the COVID-19.

Publications

1. Matsuura T, Maehara N, Hirota A, Eguchi A, Yasuda K, Taniguchi K, Nishijima A, Matsushashi

N, Shiga Y, Ishii R, Iguchi Y, Tanabe K, Arai S, & Miyazaki T. Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1. *Commun Biol.* 5:783 (2022).

Laboratory of Structural Physiology

Lecturer

Sho Yagishita, M.D. Ph.D.

Homepage <http://www.bm2.m.u-tokyo.ac.jp/>

Introduction and Organization

The Center for Disease Biology and Integrative Medicine (CDBIM) has been established in 2003, and elected Dr. Kasai as the professor of the Division of Basic Medical Sciences (2) of CDBIM in July of 2004. Dr. Kasai was in the National Institute for Physiological Sciences, and officially took office in the University of Tokyo in November, 2005. The Kasai laboratory has moved to the first building of Faculty of Medicine in January, 2006. It belongs to the Section of Functional Biology in the Graduate School of Medicine. Its name has been changed from Division of Biophysics to Laboratory of Structural Physiology in the April, 2008. Dr. Kasai has also appointed as a principal researcher in the International Research Center of Neurointelligence (IRCN), the Institute of Advanced Studies of the University of Tokyo since it has established in 2017.10, and the laboratory is cooperating the activity of IRCN. Dr. Kasai retired in March 2022.

The 6 members of our laboratories in the April of 2022 are Sho Yagishita (Lecturer), Mio Tajiri (Project Researcher), Sachio Umemoto (Project Researcher), Hidefumi Ohmi (M2), and as technical staffs, Masayoshi Asaumi, and Akiko Abe.

Teaching activities

We gave two lectures of physiology for undergraduate students, was responsible for one student experiment, one lecture of physiology and neuroscience for master course students. One undergraduate student joined the activity of our

laboratory for free quarter (FQ).

Research activities

We analyze monoamine functions in the brain at multiple levels of the molecular, cellular, and system by combining several experimental techniques including two-photon excitation microscopy, molecular biology, electrophysiology, behavioral experiments and animal MRI.

Dopamine sends dense projection to the nucleus accumbens, which mainly consists of the neurons express dopamine type 1 receptors (D1 neurons) and D2 receptors (D2 neurons). When an unexpected reward is given in reward-based conditioning learning, dopamine exhibits transient increase from the steady state, which driving classical conditioning learning in which a conditioned stimulus (CS) such as sound is associated with a reward (unconditioned stimulus, US) such as water. After the conditioning, animals predict rewards from CS and elicit conditioned reflexes. Furthermore, dopamine exhibits transient decrease when the expected rewards do not come. We have previously shown that the D2 receptor detects this transient decrease in dopamine. We also had identified a time window in brain slices in which transient increases in dopamine are detected by D1 neurons. Along with this, we found learned behaviors and relevant neural circuits that correspond to this time frame (Ref. 1).

References

1. Yamaguchi K, Maeda Y, Sawada T, Iino Y, Tajiri M, Nakazato R, et al. A behavioural correlate of the synaptic eligibility trace in the nucleus accumbens. *Sci Rep.* 2022 Feb 4;12(1):1921.

Laboratory of Biomedical Equipment and Biomaterials

Professor

Taichi Ito, Ph.D.

Associate Professor

Kanako Harada, Ph.D.

Assistant Professor

Natsuko Inagaki, Ph.D.

Homepage <http://www.cdbim.m.u-tokyo.ac.jp/>

Introduction and Organization

The Division tightly collaborates with Faculty of Engineering. Prof. Ito charged at Department of Chemical System Engineering and Bioengineering. Associate Professor Harada charged at Department of Mechanical Engineering and Bioengineering.

Teaching activities

Prof. Ito and Associate Prof. Harada are sharing duties for undergraduate and graduate students of both Graduate School of Medicine and Graduate School of Engineering. They give lectures on biomedical engineering at Graduate School of Medicine. Prof. Ito gives a lecture concerning biosystem engineering, separation technology I, biotechnology II, Basic Biology, and Overview of Chemical Bioengineering at the Chemical System Engineering course and Bioengineering course at Graduate School of Engineering School. Associate Prof. Harada teaches at the courses titled Bioengineering Exercise for Social Implementation 1・2, Engineering Competency III - Summer Camp-, Engineering Competency I -PBL-, Basic Biology, Overview of Mechano Bioengineering, and Clinical Biomechanics.

Research activities

Biomaterials are one of important keys in medicine and medical engineering. In the field of tissue engineering, scaffold materials are extremely important. In the drug delivery field, drugs are encapsulated in various materials which achieve ideal release kinetics. The functions of these biomaterials and phenomena inside and outside biomaterials in vivo are complicated both in terms of chemistry and biology. Ito Laboratory is trying to design and develop novel biomaterials for tissue engineering and drug delivery by the combination of medicine and chemical system engineering. Especially we focus on hydrogels which can be utilized for islet regeneration and drug delivery in peritoneum.

- 1) Development of Hydrogels for medical uses
 - Development of novel *in situ* crosslinked hydrogels for a medical use using hyaluronan, chitosan, dextran, alginate, gelatin, carboxymethyl cellulose and synthetic dendritic polymers.
- 2) Development of particles for medical uses
 - Nano-sized semi-conductor and metal particles for imaging
 - Micro-sized particles composed of PLGA, PEG, Albumin.
- 3) Challenge to establish novel treatments using new medical hydrogels and particles.

- Peritoneal adhesion prevention
- Hemostats
- Drug delivery for peritoneal dissemination, Mesothelioma, Liver cirrhosis
- Hydrogel scaffolds for regeneration of islets and bones
- Artificial Oxygen Carriers

In addition, Associate Professor Harada and her students are developing surgical skill assessment methods, surgical robots and robots assisting scientific experiments.

1) Surgical Skill Assessment

Data sets collected during simulated surgery have been analyzed to quantify surgical skills. For example, an image processing method to detect a surgical suture has been developed to be used to quantify the manipulation skills of expert surgeons.

2) Surgical robots

Surgical robotic systems for pediatric surgery, neurosurgery and eye surgery have been developed. To study automation of robotic assistance, an autonomous robotic looping method has been developed to assist anastomosis task in a small body space.

3) Robots assisting scientific experiments

A robotic platform to assist scientific experiments, such as the dissection of mouse, has been designed in collaboration with mathematicians, AI researchers, robot researchers, and scientists. Tele-robotic manipulation between Kyoto and Tokyo at the submillimeter scale was demonstrated.

References

- (1) Noriko Nakamura, Seiichi Ohta, Mariko Yamada, Yukimitsu Suzuki, Natsuko F. Inagaki, Takeo Yamaguchi, Taichi Ito "Development of a potassium ion-responsive star copolymer with controlled aggregation/dispersion transition" *ACS Omega*, 2022, 8(1), 1343–1352.
- (2) Masashi Okawa, Aki Tanabe, Seiichi Ohta, Satoru Nagatoishi, Kouhei Tsumoto, Taichi Ito "Extracellular matrix-inspired hydrogel of hyaluronan and gelatin crosslinked via a Link module with a transglutaminase reactive sequence" *Communications Materials*, 2022, 3(1), 81.
- (3) Arvind K. Singh Chandel, Seiichi Ohta, Machiko Taniguchi, Hiromi Yoshida, Daichi Tanaka, Kiyohiko Omichi, Atsushi Shimizu, Mitsuko Isaji, Kiyoshi Hasegawa, Taichi Ito "Balance of antiperitoneal adhesion, hemostasis, and operability of compressed bilayer ultrapure alginate sponges" *Biomaterials Advances*, 2022, 137, 212825.
- (4) Seiichi Ohta, Kento Mitsuhashi, Arvind K. Singh Chandel, Pan Qi, Noriko Nakamura, Akiko Nakamichi, Hiromi Yoshida, Gento Yamaguchi, Yuichi Hara, Ryo Sasaki, Masaya Fuke, Madoka Takai, Taichi Ito "Silver-loaded carboxymethyl cellulose nonwoven sheet with controlled counterions for infected wound healing" *Carbohydrate Polymers*, 2022, 286, 119289.
- (5) Yuki Amano, Kazuma Sakura, Seiichi Ohta, Taichi Ito "Cisplatin-chelated iminodiacetic acid-conjugated hyaluronic acid nanogels for the treatment of malignant pleural mesothelioma in mice" *Molecular Pharmaceutics*, 2022, 19(3), 853–861.
- (6) Taniguchi, Y., Sugiura, H., Yamanaka, T., Watanabe, S., Omata, S., Harada, K., ... & Arai, F. (2022). A force measurement platform for a vitreoretinal surgical simulator using an artificial eye module integrated with a quartz crystal resonator. *Microsystems & Nanoengineering*, 8(1), 74.
- (7) Koyama, Y., Marinho, M. M., Mitsuishi, M., & Harada, K. (2022). Autonomous coordinated control of the light guide for positioning in vitreoretinal surgery. *IEEE Transactions on Medical Robotics and Bionics*, 4(1), 156–171.
- (8) Marques Marinho, M., Oikawa, R., Hayashi, K., Takazawa, S., Harada, K., & Mitsuishi, M. (2023). Design and validation of looping assistance methods in robotic-assisted neonatal surgical suturing in a chest model. *The International Journal of Medical Robotics and Computer Assisted Surgery*, 19(2), e2476.

Laboratory of Clinical Biotechnology

Professor

Yuichi Tei/ Ung-il Chung, M.D., Ph.D.

Associate Professor

Hironori Hojo, Ph.D

Assistant Professor

Hiroyuki Okada, M.D., Ph.D

Homepage <https://grn.tokyo/med/en/>

Introduction and Organization

The Laboratory of Clinical Biotechnology at the Center for Disease Biology and Integrative Medicine (CDBIM) was launched in April 2003 under the direction of Professor Kazunori Kataoka. As this Laboratory is expected to serve as a bridge at The University of Tokyo (UTokyo) for medical bioengineering, where medicine and engineering are closely intertwined with each other, we are conducting research on medical bioengineering through on-campus collaborations with the Graduate School of Engineering, the Graduate School of Medicine, and The University of Tokyo Hospital and its affiliated divisions such as the Division of Tissue Engineering and the Cooperative Unit of Medicine and Engineering Research. We also aim to recruit and train professionals—including physicians, dentists, pharmacists, veterinarians, life science researchers, engineering researchers, and engineers—who are equipped with a deep understanding of medical bioengineering. To achieve this, we have utilized undergraduate and graduate education programs such as the Graduate Program for Leaders in Life Innovation (GPLLI) of UTokyo.

Professor Kataoka, who directed the laboratory until March 2016, worked on the development and clinical applications of nanotechnology-based drug delivery systems and imaging.

Professor Yuichi Tei (Ung-il Chung) has served as Director of the Laboratory of Clinical Biotechnology since November 2016. With a particular focus on skeletal tissues (bones and cartilage), we are currently studying molecular mechanisms underlying cell fate specification as well as signaling factor-based systems to manipulate cell differentiation and proliferation. We are also working on the development of novel biomaterials that will fulfill the characteristics required for *in vivo* use as scaffolds. By integrating these studies, we aim to develop novel systems for skeletal tissue engineering and regenerative medicine, in which cell differentiation and proliferation are regulated directly and locally *in situ*.

Professor Tei has a cross-appointment with the Department of Bioengineering, Graduate School of Engineering, and he also serves as Research Leader of The University of Tokyo Center for Innovation (COI) Self-Managing Healthy Society. In collaboration with the program, we are also working on the establishment of an Open Innovation Platform and the promotion of industry-academia collaborations for the social implementation of research products.

Education

The development of advanced medical systems, such as regenerative medicine and medical devices, is an important and globally growing research field in

which medical biology and engineering are integrated and play important roles. Since the medicine-engineering cooperation that has occurred to date has been mainly research collaborations, the development of theoretical systems as well as education systems for the integrated field have been delayed. This often causes a mismatch between clinical needs and technological seeds. The delay is likely due to difficulties in identifying basic principles that underlie both of the quite different fields of medical biology and engineering, when they are integrated.

Through multi-discipline and cross-sectional research projects integrating medical biology and engineering, we aim to train biomedical professionals who themselves integrate medicine and engineering; that is, engineers who understand medical needs and medical researchers who understand technological seeds. We are offering students with varying backgrounds opportunities to study a broad spectrum of biomedical engineering—from basic principles of living organisms to advanced medical systems—on the basis of each student's expertise. We also collaborate with The University of Tokyo COI Self-Managing Healthy Society, in order to utilize the Open Innovation Platform in which all stakeholders from industry, government, academia, and the private sector join the program as equals from the start, as a practical education tool for developing the aforementioned biomedical professionals.

Research

We pursue two scientific interests with a particular focus on skeletal tissues (bones and cartilage): (1) the manipulation of progenitor cell differentiation and proliferation based on the understanding of molecular mechanisms underlying cell fate specification, and (2) the development of novel biomaterials fulfilling the characteristics required for *in vivo* use as scaffolds. We aim to develop novel systems for skeletal tissue engineering and regenerative medicine in which cell differentiation and proliferation are directly regulated *in situ*. The following four projects are ongoing.

1. Understanding of epigenome dynamics and gene regulatory networks during cell fate specification processes

Organogenesis depends on cell fate specification and the subsequent differentiation and maturation of specified cells. Gene transcription underlies a series of processes; appropriate genes are transcribed with appropriate amounts and at the appropriate timing for inducing cell activities and characteristics. In this context, the epigenome works as a main switch for gene expression. Transcription factors, which bind to the genome in a sequence-dependent manner, in turn increase the amount of transcripts, in a manner that is analogous to turning up the volume of a radio.

Against this background, we seek to understand the mechanisms of cell fate specification, cell differentiation, and cell maturation during skeletal development with a particular focus on epigenome dynamics and genomic targets of transcription factors. We also plan to apply the knowledge gained to the development of regenerative therapies for skeletal tissue defects. Here we rely on the following approaches: (1) observations of intracellular events by direct and comprehensive techniques, (2) the construction of hypotheses driven by these observations, and (3) verification of the hypotheses. Thus, the approach starts with the collection of genome-scale data on gene expression, epigenome, and transcription factor binding sites by taking advantage of next-generation sequencers. The data are analyzed by bioinformatics approaches, leading to the construction of a new biological hypothesis. Each hypothesis is verified by molecular-biological approaches and mouse genetics. With this research strategy, we are investigating the regulatory landscape on the genome that determines the specification of bone- and cartilage-forming cells, osteoblasts and chondrocytes, respectively, and their phenotypes. A series of studies reveals transcriptional networks that mediate pluripotency and the differentiation of pluripotent stem cells (*Stem Cells* 31:2667, 2013), epigenome dynamics and modes of action of master transcription factors that specify osteoblasts and chondrocytes, and the gene regulatory networks mediated by those master transcription factors (*Cell Reports* 12:229, 2015; *Developmental Cell* 37:238, 2016; *Development* 143:3012, 2016; *Trends in Genetics* 32:774, 2016;

Regen Ther 6, 100-107, 2017; *Int J Mol Sci.* 20(24). pii: E6324, 2019; *Bone.* 137:115458, 2020; *Nat Commun.* 12(1):6271, 2021; *Cell Rep* 40(10), 2022; *Nat Commun.* 13(1):6187, 2022; *Nat Commun.* 13(1):2654, 2022). A fuller understanding of cell fate specification processes during skeletal formation, we believe, will enable the development of novel therapeutic strategies, in which bone and cartilage repair and regeneration are induced by the manipulation of the specification processes.

2. The development of tissue-development modeling systems using pluripotent stem cells

It would be ideal to study the mechanisms of tissue formation and maintenance in *in vivo* working cells. However, the number of cells that can be obtained *in vivo* is often not sufficient for molecular-level mechanistic studies; this is a technical limitation in studying skeletal development and regeneration. Pluripotent stem cells (PSCs; i.e., embryonic stem cells—ES cells and induced pluripotent stem cells—iPS cells), which have the ability to self-renew and differentiate into all of the lineages present in the body, are a promising tool for study; reproducing organogenesis and metabolism *in vitro* potentially overcomes the above limitation. Considering the safety, cost, and biological conciseness, it would be better to induce tissues from PSCs under defined conditions by using small molecules while avoiding differentiation into lineages of no interest.

We have therefore been developing protocols for directing mouse and human PSCs toward osteoblasts under defined conditions using only small molecules, while recapitulating *in vivo* osteoblast development (*Stem Cell Reports* 2:751, 2014). With the protocol, we addressed a molecular mechanism in osteoblast development (*Stem Cell Reports.* 15(1):125-139, 2020). We are also attempting to apply the protocols to the generation of PSC-derived bone-like tissues, in which distinct cell populations regulating bone formation and maintenance (osteoblasts, osteocytes, and osteoclasts) function three-dimensionally on culture dishes (*Science Advances* 3:e1602875, 2017). Such culture systems in combination with human PSCs could enable us to reproduce human bone development and metabolism in a physiologically relevant manner. These systems will also allow us to

visualize bone metabolism *in vitro* with imaging techniques, contributing to drug discoveries for the treatment of various bone diseases such as osteoporosis, and to our understanding of the diseases' pathophysiology and of the molecular mechanisms underlying skeletal formation and maintenance.

3. The identification of bioactive factors that induce bone/cartilage formation and their application to bone/cartilage repair

Skeletal formation is regulated by various signaling pathways and transcription factors. The manipulation of key pathways and/or factors would enable us to not only induce skeletal formation and regeneration, but also suppress the progression of skeletal degeneration. Thus, we are carrying out molecular-biological and mouse genetic studies to elucidate the roles of osteogenic and chondrogenic signaling pathways as well as the modes of their actions. Based on these basic findings, we are also working on the identification and application of bioactive molecules that induce osteogenesis and chondrogenesis.

We have been focusing on: (1) hedgehog (Hh) signaling-mediated cell fate specification during osteoblast development (*Development* 131:1309, 2004; *Journal of Biological Chemistry* 282:17860, 2012; *Journal of Biological Chemistry* 288:9924, 2013), and (2) transcriptional regulation mediating osteoblast differentiation and maturation (*Developmental Cell* 14:689, 2008; *PLOS ONE*, 2014). These studies further extend to the development of the small molecule-based treatment of bone fractures, using the Hh signaling-activator molecule SAG (*Biochemical and Biophysical Research Communications* 479:772, 2016) and bone regenerative therapy with SAG-loaded calcium phosphate artificial bones (*Biomaterials* 34:5530, 2013). By combining biological findings with engineering techniques, we are working on bone regeneration by plasmid delivery using polymeric nanomicelles as nucleic acid carriers (*Molecular Therapy* 15:1655, 2007) and the suppressive treatment of cartilage degeneration by mRNA delivery (*Scientific Reports* 6:18743, 2016).

We have also identified novel small molecules that induce bone and cartilage formation (*Biochemical and Biophysical Research Communications* 357:854, 2007; *Annals of Rheumatic Diseases* 72:748, 2013),

through the screening of compound libraries with cell-based sensors enabling the high-throughput detection of osteoblast and chondrocyte differentiation (*Biochemical and Biophysical Research Communications* 376:375, 2008; *Journal of Bone and Mineral Metabolism* 28:627, 2010).

4. The development of tissue-inductive implant devices integrating tissue-regeneration signals and highly functional and biocompatible biomaterials

In the current aging society, the treatment of tissue defects in locomotive organs is a crucial task to achieve the extension of healthy life expectancy. There is an urgent need for low-invasive reconstruction therapies that recover lost or damaged tissues with the same functional and aesthetic qualities as those in healthy states. The transplantation of donor tissues obtained from patients' healthy sites has been widely used for tissue reconstruction (autologous transplantation). However, this strategy often causes post-operative pain and the cosmetic disturbance of donor sites. Although reconstruction with biomaterials avoids donor site problems, its tissue induction capacity is generally inferior to that of autologous transplantation.

As signaling networks mediating the formation and regeneration of tissue and organs are being elucidated by recent advances in stem cell biology, some biomaterial-based systems are being developed for delivering signaling factors to target tissues. We are studying these approaches as mentioned above. In addition, the emergence of three-dimensional (3D) printers has rapidly improved the techniques available for controlling the shapes of scaffold materials. By controlling the 3D shape of biomaterials, we have been attempting to improve the performance of biomaterials for tissue repair. We developed custom-made calcium phosphate artificial bone (CT-bone) that is manufactured using 3D printers and have applied them to clinical settings in cooperation with the Department of Oral and Maxillofacial Surgery, The University of Tokyo Hospital (*Journal of Artificial Organs* 9:234, 2006; *Journal of Artificial Organs* 12:200, 2009; *Regenerative Therapy* 5:1, 2016). We have also worked on the development and application of tetrapod-shaped calcium phosphate artificial bone (Tetrabone), which is fabricated at 1-mm size by

injection molding, and a custom-made titanium mesh cage fabricated by laser sintering (*Acta Biomaterialia* 8:2340, 2012; *Biomaterials* 35:3229, 2014).

However, either signaling factors or biomaterials alone are not sufficient for the clinically sufficient regeneration of tissues, and interface units integrating them are necessary for fully utilizing their performance. A candidate for the integrating interface unit is a high-performance hydrogel unit, which maintains the spatial arrangement of signaling factors and can deliver them to target cells at a selected timing by temporally controlled degradation. However, conventional hydrogels do not provide the characteristics required for an integrating interface unit.

In cooperation with Professor Takamasa Sakai at the Department of Bioengineering, UTokyo, we are developing a high-performance hydrogel unit that fulfills the necessary characteristics, based on knowledge and techniques that we have accumulated regarding the design and fabrication of novel hydrogels (*Macromolecules* 41:5379, 2008; *Science* 343:873, 2014; *Advanced Materials* 27:7407, 2015; *Nature Biomedical Engineering* 1:44, 2017; *Phys Rev Lett.* 125(26):267801, 2020; *RSC Advances* 11, 23637, 2021). The high-performance hydrogel unit would integrate signaling factors with shape-controlled scaffold materials, leading to the development of implant devices that work as scaffolds for tissue repair and also as carriers of bioactive factors. Through a series of these studies, we are aiming to create a "four-dimensional scaffold system" that achieves efficient tissue regeneration by controlling cell proliferation and differentiation in temporal and spatial manners. The system will not only be applicable to the regeneration of other tissues; it will also contribute to the development of basic technologies for the temporal-spatial control of *in situ* tissue formation, which is versatile in the prevention, diagnosis, and treatment of various diseases.

Publications

1. Kitaura Y, Nakamura U, Awada C, Yamaguchi M, Kim M, Ikeda Y, Matsuo Y, Moriishi T, Sawase T, Chung UI, Hojo H*, Ohba S*. Orally administrable peptides derived from egg yolk promote skeletal repair and ameliorate degenerative skeletal disorders in mouse models.

- Regen Ther* 21:584-595, 2022
2. Nagata K, Hojo H, Chang SH, Okada H, Yano F, Chijimatsu R, Omata Y, Mori D, Makii Y, Kawata M, Kaneko T, Iwanaga Y, Nakamoto H, Maenohara Y, Tachibana N, Ishikura H, Higuchi J, Taniguchi Y, Ohba S, Chung UI, Tanaka S, Saito T*. Runx2 and Runx3 differentially regulate articular chondrocytes during surgically induced osteoarthritis development. *Nat Commun*. 13(1): 6187, 2022.
3. Iwahashi S, Lyu J, Tokumura K, Osumi R, Hiraiwa M, Kubo T, Horie T, Demura S, Kawakami N, Saito T, Park G, Fukasawa K, Iezaki T, Suzuki A, Tomizawa A, Ochi H, Hojo H, Ohba S, Hinoi E*. Conditional inactivation of the L-type amino acid transporter LAT1 in chondrocytes models idiopathic scoliosis in mice *J Cell Physiol*. 2022 Sep 26. doi: 10.1002/jcp.30883.
4. Hojo H*, Saito T, He X, Guo Q, Onodera S, Azuma T, Koebis M, Nakao K, Aiba A, Seki M, Suzuki Y, Okada H, Tanaka S, Chung UI, McMahon AP, Ohba S*. Runx2 regulates chromatin accessibility to direct the osteoblast program at neonatal stages. *Cell Reports*. 40(10), 2022
5. Hojo H, Ohba S*. Sp7 Action in the Skeleton: Its Mode of Action, Functions, and Relevance to Skeletal Diseases. *Int J Mol Sci* 23(10):5647, 2022
6. Nakayama M, Okada H, Seki M, Suzuki Y, Chung UI, Ohba S, Hojo H*. Single-cell RNA sequencing unravels heterogeneity of skeletal progenitors and cell-cell interactions underlying the bone repair process. *Regen Ther*. 21:9-18, 2022
7. Doi T*, Hojo H, Ohba S, Obayashi K, Endo M, Ishizaki T, Katoh A, Kouji H. Involvement of activator protein-1 family members in β -catenin and p300 association on the genome of PANC-1 cells. *Heliyon*. 8(2):e08890, 2022
8. Katashima T*, Kobayashi R, Ishikawa S, Naito M, Miyata K, Chung UI, Sakai T. Decoupling between Translational Diffusion and Viscoelasticity in Transient Networks with Controlled Network Connectivity. *Gels*. 8(12): 830, 2022.
9. Saito Y*, Nakamura S, Tanaka A, Watanabe R, Narimatsu H, Chung UI. Evaluation of the validity and reliability of the 10-meter walk test using a smartphone application among Japanese older adults. *Front Sports Act Living*. 4:904924, 2022.
10. Ishikawa S, Yoshikawa Y, Kamata H*, Chung UI, Sakai T*. Simple Preparation of Injectable Hydrogels with Phase-Separated Structures That Can Encapsulate Live Cells. *ACS Appl Mater Interfaces*. 14(31):35444-35453, 2022.
11. Saito Y*, Nakamura S, Tanaka A, Watanabe R, Narimatsu H, Chung UI. Checking the validity and reliability of the Japanese version of the Mini-Cog using a smartphone application. *BMC Res Notes*. 15(1):222, 2022.
12. Katashima T*, Kudo R, Naito M, Nagatoishi S, Miyata K, Chung UI, Tsumoto K, Sakai T*. Experimental Comparison of Bond Lifetime and Viscoelastic Relaxation in Transient Networks with Well-Controlled Structures. *ACS Macro Lett*. 11(6):753-759, 2022.
13. Pham H, Svensson T*, Chung UI, Svensson AK. Sleep Satisfaction May Modify the Association between Metabolic Syndrome and BMI, Respectively, and Occupational Stress in Japanese Office Workers. *Int J Environ Res Public Health*. 19(9):5095, 2022.
14. Omatsu Y, Aiba S, Maeta T, Higaki K, Aoki K, Watanabe H, Kondoh G, Nishimura R, Takeda S, Chung UI, Nagasawa T*. Runx1 and Runx2 inhibit fibrotic conversion of cellular niches for hematopoietic stem cells. *Nat Commun*. 13(1): 2654, 2022.
15. Fujiyabu T, Sakumichi N, Katashima T, Liu C, Mayumi K, Chung UI, Sakai T*. Tri-branched gels: Rubbery materials with the lowest branching factor approach the ideal elastic limit. *Sci Adv*. 8(14):eabk0010, 2022.
16. Matsubara T, Soma K, Yamada I, Fujita H, Yoshitani J, Oka H, Okada H, Tanaka S*. Offset nail fixation for intertrochanteric fractures improves reduction and lag screw position. *PLoS One*. 17(11):e0276903, 2022.
17. Tachibana N, Chijimatsu R, Okada H, Oichi T, Taniguchi Y, Maenohara Y, Miyahara J, Ishikura H, Iwanaga Y, Arino Y, Nagata K, Nakamoto H, Kato S, Doi T, Matsubayashi Y, Oshima Y, Terashima A, Omata Y, Yano F, Maeda S, Ikegawa S, Seki M, Suzuki Y, Tanaka S, Saito T*. RSPO2 defines a distinct undifferentiated progenitor in the tendon/ligament and suppresses ectopic ossification. *Sci Adv*. 8(33):eabn2138, 2022
18. Omata Y, Okada H, Uebe S, Izawa N, Ekici AB, Sarter K, Saito T, Schett G, Tanaka S*, Zaiss MM. Interspecies Single-Cell RNA-Seq Analysis Reveals the Novel Trajectory of Osteoclast Differentiation and Therapeutic Targets. *JBMR Plus*. 6(7):e10631, 2022.

Laboratory of Microenvironmental and Metabolic Health Sciences

Professor

Makoto Murakami, Ph.D.

Associate Professor

Seiichiroh Ohsako, Ph.D., D.V.M.

Assistant Professor

Yoshitaka Taketomi, Ph.D.

Research Assistant

Hiroyasu Sato, Ph.D.

Project Assistant

Rina Takamiya, Ph.D.

Home Page <http://lmmhs.m.u-tokyo.ac.jp>

Introduction

Laboratory of Environmental Health Sciences of the Center for Disease Biology and Integrative Medicine moved the laboratory from the 3rd floor of the Medical Faculty of Medicine Building 1 to the 8th floor of the Clinical Research Center A on October 2016 and modified the laboratory name to Laboratory of Microenvironmental and Metabolic Health Sciences on April 2017, aiming at examining biochemistry and microenvironmental biology of lipids as well as environmental toxicology. One professor, one associate professor, one assistant professor, one research assistant, one project assistant, one project researcher, two visiting researchers, five graduate students (doctoral course), and four external researchers conducted the researches together in 2023.

This laboratory belongs to the Department of Social Medicine, cooperates to the Departments International Health Sciences and Social Public Health, and is engaged in education and research on relationships. The laboratory is also associated with the Department of Cellular Signaling, the Molecular Cell Biology.

Research activities

Laboratory of Microenvironmental and Metabolic Health Sciences was constituted by two major research projects; “lipid biology” by a group of Murakami (professor) and “environmental toxicology” by a group of Ohsako (associate professor).

1. Lipid biology (Murakami’s group)

The main theme of this research project is to clarify the role of lipids in health and diseases. Lipids supply the largest source of energy in living organisms, are main components of cell membranes, act as signal molecules, and constitute a barrier covering the body surface (four major functions of lipids). Lipids are environmental nutritional factors ingested from foods, as well as tissue microenvironmental regulators that spatiotemporally coordinate various biological responses after being metabolized to specific bioactive lipids. By performing comprehensive lipid analysis (lipidomics) on gene-manipulated mice for lipid-metabolizing enzymes, particularly those in the phospholipase A₂ (PLA₂) family, we aim to elucidate

the molecular pathophysiology of diseases (e.g. metabolic and immune diseases) that are problematic in modern society. Based on this, we will promote the research of Quality of Lipids (QOL) for Quality of Life (QOL) and aim at building a theoretical foundation for diagnosis, prevention and treatment of diseases involving alteration of lipid metabolism.

1) Metabolic diseases

We previously reported that PLA2G5 (sPLA₂-V), secreted from hypertrophic white adipocytes during obesity, hydrolyzes phosphatidylcholine (PC) in LDL to release oleic and linoleic acids, which attenuate M1 polarization of macrophages and thereby protect from diet-induced obesity, adipose tissue inflammation, and insulin resistance (Sato et al, *Cell Metab*, 2014), and that PLA2G2D (sPLA₂-IID), secreted from M2-like macrophages in white adipose tissue, releases ω 3 polyunsaturated fatty acids (PUFAs) to promote cold-induced adipocyte browning and thermogenesis (Sato et al, *Cell Rep*, 2020). In addition, we have recently found that PLA2G2E (sPLA₂-IIE) is highly induced in brown and beige adipocytes in response to cold and that its deletion leads to impairment of adipocyte browning and thermogenesis.

Choline supplies methyl groups for regeneration of methionine and the universal methyl donor S-adenosylmethionine (SAM) in the liver. Although membrane PC is the main cellular reservoir for choline, the pathway for hepatic PC catabolism that liberates endogenous choline remains unexplored. We found that PNPLA7, a lysophospholipase that catalyzes the hydrolysis of lysophosphatidylcholine (LPC) to glycerophosphocholine (GPC), is crucial for this pathway. *Pnpla7*-deficient mice show marked decreases in hepatic GPC, choline, betaine and SAM, accompanied by various signs of methionine insufficiency including impaired triglyceride storage and secretion, hypoglycemia, increased energy expenditure, reduced fat mass with adipocyte browning, and decreased epigenetic histone and DNA methylation. Accordingly, *Pnpla7*^{-/-} mice are lean, display growth retardation, and die prematurely. We further found that mice lacking PNPLA8 (iPLA₂ γ), which acts as PLA₁/A₂, recapitulate most of these phenotypes, suggesting that PNPLA8 lies upstream of PNPLA7. Thus, the methyl group flux from choline endogenously generated through PC breakdown by the

PNPLA8-PNPLA7 axis is essential for liver functions and systemic energy homeostasis (Hirabayashi et al, *Cell Rep*, 2023). In addition, skeletal muscle-specific *Pnpla7*-null mice exhibit a sarcopenia-like phenotype over 6 months.

2) Skin diseases

We previously reported that PLA2G2F (sPLA₂-IIF), which is specifically expressed in epidermal keratinocytes, mobilizes lysoplasmalogen, a unique lysophospholipid that has the ability to promote epidermal hyperplastic diseases such as psoriasis and skin cancer (Yamamoto et al, *J Exp Med*, 2015), that PNPLA1, a member of the intracellular iPLA₂ family whose mutations are linked to autosomal recessive congenital ichthyosis, acts as a unique transacylase to produce ω -O-acylceramide, an essential lipid component for the skin barrier (Hirabayashi et al, *Nat Commun*, 2017), and that PLA2G4E (cPLA₂ ϵ), which acts as a N-acyltransferase that transfers a fatty acid from the *sn*-1 position of PC to the amino group of phosphatidylethanolamine (PE) to give rise to N-acyl-PE (NAPE), a precursor of the anti-inflammatory lipid N-acylethanolamine (NAE), counteracts psoriatic inflammation (Liang et al, *FASEB J* 2022). In addition, genetic deletion of PLA2G4D (cPLA₂ δ), which has PLA₁ activity, exacerbates psoriasis, and that of PLA2G4F (cPLA₂ ζ), which has PLA₂ activity with no *sn*-2 fatty acid selectivity, delays skin wound healing.

PLA2G3 (sPLA₂-III) is expressed in epidermal keratinocytes and its global or skin-specific deletion leads to perturbation of skin barrier function due to fragile cornified envelope and loosened epidermal tight junction. Accordingly, following topical antigen challenge, global or skin-specific *Pla2g3*-deficient mice display more severe atopic dermatitis-like symptoms with increased expression of type 2 cytokines, serum IgE levels, eosinophil infiltration, scratching behavior, and disturbed skin microbiota. Global or skin-specific deletion of EP4 (PGE₂ receptor) or FP (PGF_{2 α} receptor) largely if not solely recapitulate these phenotypes, and treatment with FP or EP4 agonists rescues skin abnormalities in *Pla2g3*-deficient mice. Moreover, global or skin-specific *Pla2g3*-deficient mice exhibit more severe asthma following percutaneous antigen challenge. These results suggest that the epidermal PLA2G3-EP4/FP axis plays an important role in skin barrier formation

and thereby skin homeostasis, perturbation of which leads to exacerbation of atopic march. Additionally, we are analyzing the functions of the orphan enzymes ABHD12B, which is markedly downregulated in patients with scleroderma, and PNPLA5, which is specifically expressed in sebaceous glands, in the skin.

3) Allergic and other immunological diseases

We previously reported that PLA2G3 secreted from mast cells (MCs) promotes MC maturation by driving the paracrine PGD₂ circuit in cooperation with stromal fibroblasts (Taketomi et al, *Nat Immunol* 2013; Taketomi et al, *Cells* 2021). In our continuing efforts to fully clarify the mechanism of MC maturation, we have found that PLA2G3 is also coupled with another lipid mediator, lysophosphatidic acid (LPA), which in turn acts on fibroblastic LPA₁ receptor to upregulate integrins, IL-33, ATX (LPA-producing enzyme) and PGD₂ synthase, thereby fine-tuning appropriate MC maturation (submitted). PAF-AH2, a unique PLA₂ that hydrolyzes oxidized phospholipids, ensures optimal MC activation and thereby allergic responses through producing unique EPA/DHA metabolites (ω 3 epoxides) (Shimamaka et al, *Nat Med* 2017). Furthermore, PLA2G12A (sPLA₂-XIIA) secreted from stromal fibroblasts contributes to augment MC activation likely through producing lysophospholipids.

PLA₂ subtypes that regulate T cell immunity were unknown. By transcriptional and functional screening of PLA₂ enzymes expressed in T cells, we have found that PLA2G12A is induced in Th17 cells and involved in Th17 differentiation. Global and CD4⁺ T cell-specific *Pla2g12a*-deficient mice have fewer Th17 and $\gamma\delta$ T cells in the skin and draining lymph nodes, thereby attenuating Th17-driven disease models such as psoriasis, arthritis, and EAE. Mechanistically, PLA2G12A produces LPE, which acts as a ligand for the nuclear receptor ROR γ t (Endo et al, *Sci Immunol*, 2023), as well as LPA, which augments T cell activation via LPA₁ and LPA₂ receptors.

4) Gut microbiota

Despite the restricted intestinal expression of PLA2G2A (sPLA₂-IIA) in BALB/c mice, its genetic deletion leads to amelioration of skin carcinogenesis. Metagenome, transcriptome and metabolome analyses have revealed that *Pla2g2a* deficiency alters the gut microbiota, accompanied by notable changes in the intestinal expression of genes related to immunity and

metabolism as well as the levels of various blood metabolites and fecal bacterial lipids, suggesting that PLA2G2A contributes to shaping of the gut microbiota (Miki et al, *JCI Insight*, 2022; Taketomi et al, *Metabolites* 2022). In addition, mice deficient in PLA2G10 (sPLA₂-X), which is mainly expressed in the colorectal epithelium, also have altered gut microbiota, which eventually influences diet-induced obesity (in revision). These results establish a role of the sPLA₂ family as an endogenous factor capable of affecting microbe–host interaction and thereby systemic homeostasis and diseases.

5) Cancer

Extracellular vesicles (EVs) act as intercellular communicators by transferring protein and miRNA cargoes, yet the role of EV lipids remains unclear. We found that the pro-tumorigenic action of lymphoma-derived EVs is augmented via sPLA₂-driven lipid metabolism. Hydrolysis of EV phospholipids by PLA2G10, which is induced in a specific population of macrophages in the lymphoma tissue, increases the production of fatty acids, lysophospholipids and their metabolites. sPLA₂-treated EVs are smaller, self-aggregate, show better uptake, and increase cytokine expression and lipid mediator signaling in recipient tumor-associated macrophages. Lymphoma growth in EBV-infected mice is suppressed by a sPLA₂ inhibitor, while treating the mice with sPLA₂-modified EVs can reverse this phenotype. Overall, the sPLA₂-driven EV modification promotes tumor development (Kudo et al, *Cell Metab* 2022). It is tempting to speculate that the modification of EVs by sPLA₂s may also occur in other diseases such as allergic and metabolic diseases, a possibility that is currently under investigation.

6) Neuronal and retinal diseases

Mutations in the *PNPLA6* gene cause neuronal and retinal degeneration such as hereditary spastic paraplegia (SPG39), Boucher-Neuhauser syndrome, Oliver-McFarlane syndrome, and Laurence-Moon syndrome. PNPLA6 acts a phospholipase B (PLA₁/A₂ + lysophospholipase), hydrolyzing PC to give rise to two fatty acids and GPC, in cells. Intriguingly, neuron-specific deletion of PNPLA6 and its closest homolog PNPLA7 leads to severe neurodegenerative disorders with muscle atrophy, reminiscent of SPG and ALS. Moreover, tamoxifen-inducible, eye-specific deletion of PNPLA6 results in retinal degeneration, which could

be rescued by eye drops of choline, a PC degradation product (in revision). Clarifying the regulatory roles of lipid metabolism driven by PNPLA6/PNPLA7 will shed light on the molecular mechanism underlying the PNPLA6-related neuronal and retinal disorders. Additionally, in collaboration with an external group, we found that PLA2G2E is induced in neurons after cerebral infarction and involved in protection against neuronal damage by mobilizing the unique lipid metabolite 15-HETRE (Nakamura et al, *Neuron*, 2023).

2. Environmental Toxicology (Ohsako's group)

Ohsako found a new phenotype that was accidentally discovered in the course of a project using the famous Ahr-deficient mouse (AhrKO). AhrKO mice have long been reported to have phenotypes such as liver fibrosis, decreased fertility, and immune system dysfunction. Ahr is a gene essential for detoxification and excretion of carcinogens such as benzo[a]pyrene, which is a typical xenobiotic substance. Ahr is activated by binding to these ligands and induces down-stream genes for drug-metabolizing enzyme. However, Ahr has also been reported to regulate differentiation of the helper T-cells such as Th17/Treg through binding to its endogenous ligands. This suggests that Ahr is involved in autoimmune diseases. Ohsako found that AhrKO exhibited loose stools and melena at about 10 weeks of age, followed by obvious rectal prolapse and continued to survive. Compared to the wild type, AhrKO mice showed enlargement of the spleen and mesenteric lymph nodes, enlargement of the colon and marked inflammatory cell infiltration of the lamina propria. CD4⁺IL17⁺IFN γ ⁻ Th17 cells were significantly increased in the spleen, mesenteric lymph nodes, and colonic lamina propria, whereas there was no difference in CD4⁺Foxp3⁺ Treg cells. In contrast to the finding above, previous reports have reported that Th17 differentiation is suppressed in spleen cells of Ahr-deficient mice. In addition, liver fibrosis did not cause clear lesions. By using metagenomic analysis, it was found that the content of the mouse colon in the SPF facility of Tokyo University of Science represents specific bacterial flora. Therefore, AhrKO was bred at the SPF facility of Japan CLEA Co., Ltd. from individual restored by IVF. In these mice inflammatory colitis was not observed. Additionally, it was found that there is a clear difference between the flora of Japan

CLEA and those of Tokyo University of Science flora. These results suggested that specific gut microbiota that are supposed to produce Ahr endogenous ligands are involved in the development of the inflammatory bowel disease discovered in the AhrKO mice.

Teaching activities

The Laboratory of Microenvironmental and Metabolic Health Sciences/ the Department of Cellular Signaling has important missions to train postdoctoral fellows to become promising scientist leaders in the field of medical sciences and environmental toxicology and to provide biochemistry, molecular biology, toxicology and environmental health courses for graduate and undergraduate students. The following lectures have been provided to students.

Graduate education

Lectures, Seminars, and laboratory practices, as well as guidance for the dissertation for the Master's and Doctor's degrees, have been provided.

Undergraduate education

Lectures on biochemistry and molecular biology, with a focus on the diversity, structures and functions of lipids, for undergraduate medical students (M0). Four undergraduate students (two M3 students and three M1 students) are now participating in the Murakami's team throughout the year.

Publications

1. Rahman SMK, Hussain Z, Morito K, Takahashi N, Sikder MM, Tanaka T, Ohta KI, Ueno M, Takahashi H, Yamamoto T, Murakami M, Uyama T, Ueda N. Formation of N-acylphosphatidylethanolamines by cytosolic phospholipase A₂ ϵ in an ex vivo murine model of brain ischemia. *Biochim Biophys Acta Mol Cell Biol Lipids*. 1867, 159222, 2022.
2. Nagasaki Y, Kawai E, Maruoka S, Osumi M, Tsukayama I, Kawakami Y, Takahashi Y, Okazaki Y, Miki Y, Taketomi Y, Yamamoto K, Murakami M, Suzuki-Yamamoto T. Lipid profiling reveals the presence of unique lipid mediators in human milk from healthy and mastitic subjects. *Biochem Biophys Res Commun*. 630, 84-91, 2022.

3. Tsukayama I, Kawakami Y, Tamenobu A, Toda K, Maruoka S, Nagasaki Y, Mori Y, Sawazumi R, Okamoto K, Kanzaki K, Ito H, Takahashi Y, Miki Y, Yamamoto K, Murakami M, Suzuki-Yamamoto T. Malabaricone C derived from nutmeg inhibits arachidonate 5-lipoxygenase activity and ameliorates psoriasis-like skin inflammation in mice. *Free Radic Biol Med*. 193(Pt 1), 1-8, 2022.
4. Miyazaki T, Taketomi Y, Higashi T, Ohtaki H, Takaki T, Ohnishi K, Hosonuma M, Kono N, Akasu R, Haraguchi S, Kim-Kaneyama JR, Otsu K, Arai H, Murakami M, Miyazaki A. Hypercholesterolemic dysregulation of calpain in lymphatic endothelial cells interferes with regulatory T-cell stability and trafficking. *Arterioscler Thromb Vasc Biol*. 43, e66-e82, 2023.
5. Hirabayashi T, Kawaguchi M, Harada S, Mouri M, Takamiya R, Miki Y, Sato H, Taketomi Y, Yokoyama K, Kobayashi T, Tokuoka SM, Kita Y, Yoda E, Hara S, Mikami K, Nishito Y, Kikuchi N, Nakata R, Kaneko M, Kiyonari H, Kasahara K, Aiba T, Ikeda K, Soga T, Kurano M, Yatomi Y, Murakami M. Hepatic phosphatidylcholine catabolism driven by PNPLA7 and PNPLA8 supplies endogenous choline to replenish the methionine cycle with methyl groups. *Cell Rep*. 42, 111940, 2023.
6. Rahman SMK, Sasaki S, Uyama T, Hussain Z, Sikder MM, Saiga H, Ohmura-Hoshino M, Ohta KI, Miki Y, Hoshino K, Ueno M, Murakami M, Ueda N. PLAAT1 deficiency alleviates high-fat diet-induced hepatic lipid accumulation in mice. *FASEB J*. 37, e23032, 2023.
7. Endo Y, Kanno T, Nakajima T, Ikeda K, Taketomi Y, Yokoyama S, Sasamoto S, Asou HK, Miyako K, Hasegawa Y, Kawashima Y, Ohara O, Murakami M, Nakayama T. 1-Oleoyl-lysophosphatidylethanolamine stimulates ROR γ t activity in T_H17 cells. *Sci Immunol*. 8, eadd4346, 2023.
8. Nakamura A, Sakai S, Taketomi Y, Tsuyama J, Miki Y, Hara Y, Arai N, Sugiura Y, Kawaji H, Murakami M, Shichita T. PLA2G2E-mediated lipid metabolism triggers brain-autonomous neural repair after ischemic stroke. *Neuron*, 111, S0896-6273(23)00483-X, 2023.
9. Murakami M. The phospholipase A₂ superfamily as a central hub of bioactive lipids and beyond. *Pharmacol. Ther.* 244, 108382, 2023. (Review)
10. Harada, S., Taketomi, Y., Aiba, T., Kawaguchi, M., Hirabayashi, T., Uranbileg, B., Kurano, M., Yatomi, Y., Murakami M. The Lysophospholipase PNPLA7 controls hepatic choline and methionine metabolism. *Biomolecules*, 13, 471, 2023. (Review)
11. Murakami M, Sato H, Taketomi Y. Modulation of immunity by the secreted phospholipase A₂ family. *Immunol. Review* 317, 42–70, 2023. (Review)
12. Yamamoto K, Hakoi H, Nomura S, Murakami M. The roles of sPLA₂s in skin homeostasis and disease. *Biomolecules*, 13, 668, 2023. (Review)
13. Murakami M, Taketomi Y. Current understanding of the pathophysiological roles of cytosolic and secreted phospholipase A₂s. *Phospholipases in Physiology and Pathology*. Elsevier, 1, 55-84, 2023. (Review)
14. Kimura Y, Ekuban FA, Cai Zong, Sugie S, Zhang X, Ito K, Yamamoto M, Ichihara S, Ohsako S, Ichihara M. Role of Nrf2 in 1,2-dichloropropane-induced cell proliferation and DNA damage in the mouse liver. *Toxicol Sci*. 195, 28-41. 2023.

Laboratory of Animal Resources

Professor

Atsu Aiba, Ph.D.

Associate Professor

Hidetoshi Kassai, Ph.D.

Assistant Professor

Harumi Nakao, Ph.D., Ryo Saito, Ph.D., Shoko Noda-Narita M.D., Ph.D.

Project Assistant Professor

Yusuke Sakai, Ph.D.

Homepage <http://lar.cdbim.m.u-tokyo.ac.jp/index.html>

Introduction and Organization

Our laboratory was established as the Division of Animal Research affiliated with the Faculty of Medicine in April 1971. The building for animal experimentation was completed and the accommodation and experimentation of laboratory animals started in 1973. In 2003, the laboratory was reorganized as the Section of Animal Research of the Center for Disease Biology and Integrative Medicine (CDBIM). In 2008, the Laboratory of Animal Resources was established to strengthen research activities in addition to the Section of Animal Resources. The members of our laboratory and section are 6 teaching staffs, 6 technical support staffs, an administrative staff, 2 assistant laboratory animal technicians, 3 assistant clerks and a temporary staff (veterinarian). In addition, about 10 contracted employees are involved in animal breeding and maintenance of the animal facility.

The laboratory animals in our facility include dogs, swine, rabbits, rats, mice, and marmosets. The number of registered users of our facility was 675 at the end of academic year 2022.

We provide quality care for all animals in our facility and assist animal experimentation carried out by the researchers. The office of our section is in charge of the secretariat of the Institutional Animal Care and the

Use Committee (IACUC) of the Graduate School of Medicine, the University of Tokyo. The committee (Chair, Prof. Atsu Aiba) reviews the plans of animal experimentation and helps researchers carry out animal experiments in accordance with law, regulations and University policies governing the use of animals.

Teaching activities

We are responsible for the education of laboratory animal science to the 2nd-year students (M0) of the Faculty of Medicine. The lecture includes animal welfare, refinement of animal experiments, animal breeding, infectious diseases of laboratory animals and zoonoses. We also give a lecture on mouse molecular genetics and molecular embryology.

We are also involved in lectures by IACUC for the researchers at the Graduate School of Medicine.

Research activities

Our laboratory focuses on understanding the molecular mechanisms which underlie brain function and brain metastasis. We also try to generate murine and marmoset models for human genetic diseases.

1. Establishment of model marmosets for fragile X syndrome

Common marmoset (*Callithrix jacchus*) is a non-human primate and recently used for human model, especially focusing on brain function. We have established a novel protocol in which embryos are collected from already mated females by oviduct flushing and immediately transferred into the oviduct of the very same donors following injections with genome-editing components. Using this autologous transfer protocol, we introduced guide RNAs for FMR1 (fragile X mental retardation 1) gene encoding fragile X mental retardation protein (FMRP) and Cas9 proteins into marmoset embryos. We obtained mutant marmosets which carried mutations in coding region of FMR1 gene. FMR1 mutant marmosets, which fail to express the FMRP protein, exhibit epileptic-like seizures and are lethal by 11 days of age. Heterozygotes for FMR1 were successfully obtained by crossing a mosaic male individual carrying wild-type and mutant FMR1 alleles with wild-type females. We are currently recording the movements and vocalizations of the heterozygote under spontaneous behavior to determine whether this animal is a model for Fragile X Syndrome.

2. Elucidating the neural basis of consolation behavior

Consolation behavior is affiliative social contact, for example, a hug to alleviate pain or stress experienced by another individual. In rodents, grooming behavior toward a distressed mate is observed as a comfort-like behavior. The division also attempted to detect comforting behavior in inbred mice and constructed an experimental system to see comforting behavior prominently and efficiently.

Although Autism spectrum disorder (ASD) patients are thought to have a tendency to have difficulty sharing feelings and emotions with others (lower levels of empathy), few studies have focused on the causal relationship between ASD and reduction of empathy in molecular research using animals. In order to elucidate the mechanisms by which ASD cause lack of empathy at the neural circuit and molecular levels, we have investigated whether the lack of empathy-related behavior is observed in genetically engineered mouse models. Specifically, we have

focused on oxytocin and vasopressin, which are expected to be therapeutic molecules for autism, and we plan to examine how changes in consolation behavior are observed in oxytocin receptor and vasopressin receptor knockout mice.

3. Functional analysis of the blood-brain barrier in brain metastasis

The blood-brain barrier (BBB) plays an essential role in brain metastasis of cancer. Although the analysis of molecules required for brain metastasis on the cancer cell side has been well performed, the molecular mechanism of vascular endothelial cells, pericytes (mural cells) and astrocytes, which constitute the BBB, has not been elucidated. Therefore, we aim to reveal the molecular signaling involved in vascular permeability and cancer brain metastasis by reconstituting the BBB *in vitro* model using vascular endothelial cells, pericytes, and astrocytes and by genetically manipulating vascular endothelial cells in individual mice.

In vitro BBB model indicated the necessity of pericytes and astrocytes for BBB to regulate the brain metastasis. The brain metastatic cell lines, established by repeating transplantation and isolation of brain metastases in mice, showed highly metastatic feature in our *in vitro* BBB model. The mice with endothelial cell-specific knockout of focal adhesion kinase (FAK) also indicated the different metastatic mechanism between brain and trunk metastasis. The brain metastases in the endothelial cell-specific knockout mice of FAK are accelerated, although the metastases in the trunk have been reported to be suppressed.

Now we plan to elucidate the specific mechanism needed for brain metastasis by analyzing the interaction between cancer cells and BBB.

References

1. Mori K, Koebis M, Nakao K, Kobayashi S, Kiyama Y, Watanabe M, Manabe T, Iino Y, and Aiba A.
Loss of calyntenin paralogs disrupts interneuron stability and mouse behavior.
Mol Brain, 15(1), 23, 2022.
2. Harbers M, Nakao H, Watanabe T, Matsuyama K, Tohyama S, Nakao K, Kishimoto Y, Kano M, and

Aiba A.

mGluR5 Is Substitutable for mGluR1 in Cerebellar Purkinje Cells for Motor Coordination, Developmental Synapse Elimination, and Motor Learning.

Cells, 11(13), 2004, 2022.

3. Hiraike Y, Tsutsumi S, Wada T, Oguchi M, Saito K, Nakamura M, Ota S, Koebis M, Nakao H, Aiba A, Nagano G, Ohno H, Oki K, Yoneda M, Kadowaki T, Aburatani H, Waki H, and Yamauchi T.

NFIA determines the cis-effect of genetic variation on Ucp1 expression in murine thermogenic adipocytes.

iScience, 25(8), 104729, 2022.

4. Abe YO, Yoshitane H, Kim DW, Kawakami S, Koebis M, Nakao K, Aiba A, Kim JK, and Fukada Y.

Rhythmic transcription of Bmal1 stabilizes the circadian timekeeping system in mammals.

Nat Commun, 13(1), 4652, 2022.

5. Hojo H, Saito T, He X, Guo Q, Onodera S, Azuma T, Koebis M, Nakao K, Aiba A, Seki M, Suzuki Y, Okada H, Tanaka S, Chung UI, McMahon AP, and Ohba S.

Runx2 regulates chromatin accessibility to direct the osteoblast program at neonatal stages.

Cell Rep, 40(10), 111315, 2022.

6. Ayuzawa N, Nishimoto M, Kawarazaki W, Oba S, Marumo T, Aiba A, and Fujita T.

Rac1 deficiency impairs postnatal development of the renal papilla.

Sci Rep, 12(1), 20310, 2022.

Laboratory of Molecular Radiology

Professor

Kiyoshi Miyagawa, M.D., Ph.D.

Associate Professor

Noriko Hosoya, M.D., Ph.D.

Lecturer

Atsushi Enomoto, Ph.D.

Research Associate

Takaaki Yasuhara, Ph.D.

Homepage <http://www.cdbim.m.u-tokyo.ac.jp/>

Introduction and Organization

When the Center for Disease Biology and Integrative Medicine was established in 2003, the Department of Radiation Oncology established in 1967 and the Radiation Research Institute established in 1992 were joined to form the Section of Radiation Biology as a part of Divisions of Research Resources and Support. In 2008, the Laboratory of Molecular Radiology was also established to strengthen research activities in this section. The scientists and staffs belong to both the section and the laboratory.

The aim of this laboratory is to facilitate translational research from frontier life science to applied radiology by introducing molecular biology into conventional radiology.

To maintain the facility of radiation research, responsible staffs at two facilities are elected from our section. This year, the hospital radioisotope research facility was continued to be closed to prepare the opening of the new facility in the newly-constructed Clinical Research Building.

Education

We are responsible for the education of basic radiation medicine for the 3rd year medical students. The students are expected to start with understanding of the physics and the chemistry for radiation and then

understand the basic biology of radiation. Furthermore, they learn how to handle radioactive materials by the 2-day practical course.

In addition to these courses, the 4th year medical students are expected to learn how to use clinical radiation technology safely in hospitals. The background for this addition is that clinical problems arising from the lack of knowledge of radiation effects have been increasing. Furthermore, the education of radiation emergency medicine is included in this course. Even though radiation casualty is rare, all clinicians should know how to treat patients exposed to radiation. The importance of this education has been widely recognized since the accident at the Fukushima nuclear power plant.

We also take part in the education of radiation health science for the 3rd year students specialized in integrated health sciences. Radiation protection is emphasized in this course.

For graduate students, the education of molecular biology of the DNA damage response to radiation and DNA repair is more intensively integrated.

In addition, education courses for users of radioactive materials frequently take place.

Research

We focus on the mechanism underlying the cellular

response to DNA double-strand breaks (DSBs). Among various types of DNA damage, DSBs are the most deleterious if not repaired properly. To protect the genome, at least four signaling cascades are known to function as the repair machineries against DSBs. While nonhomologous end joining, microhomology-mediated end joining, and single-strand annealing are error-prone repair pathways, homologous recombination (HR) is an error-free pathway in principle using newly replicated DNA as a template for the repair. There is accumulating evidence that defective HR plays a role in tumor development. For example, BRCA1 and BRCA2, tumor suppressors in hereditary breast and ovarian cancers, are known to mediate the damage response to DSBs and promote HR.

Rad51, a key player at early stages of HR, catalyzes the invasion of a single-strand DNA end into an intact homologous duplex. BRCA2 plays a mediator role at this stage by directly binding to Rad51 and promoting the formation of the filament consisting of the single-strand DNA and Rad51.

SYCP3 is a component in the synaptonemal complex which is formed between homologous chromosomes to ensure their connection in meiosis. Expression of SYCP3 was observed in adrenal, liver, stomach, and kidney tumors, confirming that SYCP3 is a cancer testis antigen. Treatment of SYCP3-nonexpressing cells with a methylation inhibitor induced its expression, indicating that methylation alteration in cancer is responsible for its ectopic expression.

Since biological significance of cancer testis antigens in somatic cells is largely unknown, we investigated the effects of SYCP3 expression on cellular functions in somatic cells. This study revealed that SYCP3-expressing cells are hypersensitive to radiation and cisplatin and are characterized by increased aneuploidy. As these phenotypes are consistent with those of defective HR, we screened the molecule that co-localizes with SYCP3 by immunofluorescence. Consequently, we identified that the tumor suppressor BRCA2 co-localizes with SYCP3. We also confirmed that these proteins form a complex. Furthermore, we found that binding of SYCP3 to BRCA2 inhibits the HR repair activity mediated by binding of BRCA2 to Rad51.

Since cells with BRCA1 or BRCA2 mutations are hypersensitive to PARP inhibitors, their clinical trials are internationally ongoing. However, the problem is that the application of the trial is limited due to low incidence of their mutations. Our findings implicate that SYCP3-expressing cancers, even if they do not harbour BRCA mutations, are sensitive to PARP inhibitors, providing novel insight into cancer therapy based on the synthetic lethal approach in which both two pathways essential for cell viability are disrupted by an intrinsic genetic alteration and a specific pathway inhibitor.

SYCE2, a component constituting the synaptonemal complex, is also expressed at varying levels in somatic cells. SYCE2 insulates heterochromatin protein 1 α from trimethylated histone H3 lysine 9 to promote ATM-dependent DNA double-strand break repair. This finding suggests that SYCE2 plays a role in the link between the nuclear microenvironment and the DNA damage response in somatic cells.

In addition to Rad51, 5 Rad51 paralogs, Rad54, Rad54B, and Rad52 are also involved in early stages of HR. While Rad51 paralogs and Rad54 were shown to assist the Rad51-dependent cascade, the involvement of Rad54B in HR is not closely associated with Rad51 and Rad54. This fact led us to hypothesize that Rad54B has a role distinct from other HR factors. We found that levels of Rad54B are inversely correlated with protein levels of p53 both after DNA damage and Rad54B knockout cells. Protein interaction analysis revealed that Rad54B promotes proteasome-dependent degradation of p53 by directly binding to MDM2/MDMX, an E3 ubiquitin ligase complex targeting p53. Furthermore, we found that overexpression of Rad54B facilitates genomic instability by negatively regulating cell-cycle checkpoints mediated by p53. Consistent with this biological function, high levels of Rad54B were shown to correlate with poor prognosis in colorectal cancers. In addition, increases in its expression are also observed in other types of cancers.

Although the role of Rad52 in yeast homologous recombination is established, its role in mammals remains unclear. Its functional analysis in normal human epithelial cells revealed that Rad52 is involved in the processing of R-loop, the structure formed by RNA and DNA at the site of a DNA double-strand

break. This finding suggests that Rad52 plays a role in transcription-associated homologous recombination, providing novel insight into DNA repair at transcribed regions.

Thus, our studies on the mechanisms underlying HR contribute to the establishment of important strategies against cancer. Radiation and many DNA-damaging chemotherapeutic agents induce DNA DSBs, which can be normally repaired by the intrinsic repair pathways. The induced breaks therefore do not always lead to apoptosis. If we will understand the details of the repair pathways, the molecules in this pathway will be the therapeutic targets. From the clinical point of view, we are continuing the research exploring the principle in this field.

Publications

1. Enomoto A, Fukasawa T, Terunuma H, Nakagawa K, Yoshizaki A, Sato S, Miyagawa K. Decrease in MAP3Ks expression enhances the cell death caused by hyperthermia. *Int J Hyperthermia* 39:200-208, 2022.
2. Yasuhara T, Kato R, Yamauchi M, Uchihara Y, Zou L, Miyagawa K, Shibata A. RAP80 suppresses the vulnerability of R-loops during DNA double-strand break repair. *Cell Rep* 38: 110335, 2022.
3. Ando T, Kage H, Shinozaki-Ushiku A, Tatsuno K, Tsutsumi S, Nagayama K, Nakajima J, Kohsaka S, Miyagawa K, Aburatani H, Mano H, Nagase T. Composite clonal analysis reveals transition of NSCLC subtypes through accumulation of gene mutations: A case report. *JTO Clin Res Rep* 3:100277, 2022.
4. Taguchi A, Rokutan H, Oda K, Tanikawa M, Tanimoto S, Sone K, Mori M, Tsuruga T, Kohsaka S, Tatsuno K, Shinozaki-Ushiku A, Miyagawa K, Mano H, Aburatani H, Ushiku T, Osuga Y. Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma. *BMC Med Genomics* 15:51, 2022.
5. Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A. Pharmacotherapy of Itch-antihistamines and histamine receptors as G protein-coupled receptors. *Int J Mol Sci* 23:6579, 2022.
6. Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A. Involvement of molecular mechanisms between T/B cells and IL-23: From palmoplantar pustulosis to autoimmune diseases. *Int J Mol Sci* 23:8261, 2022.

Laboratory of Biomedical Informatics

Associate Professor

Takeshi Imai, Ph.D.

※The following information is the same as that of the previous year for certain reasons.

Homepage <http://www.cdbim.m.u-tokyo.ac.jp/>

Introduction and Organization

When the Center for Disease Biology and Integrative Medicine was established in 2003, Section of Biomedical Informatics was launched as one of the departments in Division of Research Resources & Support. In 2017, Laboratory of Biomedical Informatics was established as a part of Division of Research in the Center. Because of the parallel establishments, the both of organizations are made up of the same faculties.

The objective of Laboratory of Biomedical Informatics which is placed in the interdisciplinary field between medicine, engineering and informatics is to offer feedback to clinical medicine and contributions toward the healthcare and our society through studies such as analyses of medical information, gaining medical findings in secondary use of medical information, and developing and applying diagnosis support systems. Besides the studies, our laboratory takes a roll of graduate education for the doctor's program in the Department of Biomedical Informatics at the Division of Social Medicine, the master's program in the Medical Science Graduate Program, and the School of Public Health, the Graduate School of Medicine.

Section of Biomedical Informatics, Division of Research Resources & Support has an operation of the Office for Information Services, Graduate School of Medicine to maintain MERCS (Medical Research infrastructure with Computer System). The operations include: (1) handling the incidents of CERT and

maintaining network infrastructure, (2) offering software service of medical research supports, (3) operating mailing service for Faculty of Medicine, (4) operating DNS service and allocating global IP addresses for UT-Net connections, (5) operating web sites and servers of Faculty of Medicine and the Graduate School of Medicine, (6) offering learning devices at the medical library, and so on.

Teaching activities

In 2020, we took charge of lectures: "Description and Processing of Medical Knowledge" in the 2-year master course in the Medical Science Graduate Program, "Natural Language Processing and Computer Processing of Medical knowledge" in School of Public Health course, and "ICT and AI applications in Medicine" in the Lecture of Overview of Biomedical Engineering.

We accept students in the 2-year master course in the Medical Science Graduate Program, and 4-year Medical Sciences doctoral course, cooperating with teaching staffs in other laboratories in the field of medical informatics. Three students in the doctor's program, one student in the master's program, and two visiting researchers are enrolled in our laboratory in FY2020. Additionally, six undergraduate students took practice education in our laboratory through M3 Elective Clerkship program. We also accepted five graduate students from Toyama University as short-term intern.

Research activities

Our primary research domains are: (1) methods to knowledge representation and processing knowledge in healthcare, (2) analysis of electronic medical records and gaining medical knowledge with natural language processing and machine learning, (3) developing diagnosis support system, (4) standardization in the field of healthcare informatics, and so on.

In these domains, major research topics are listed below:

(1) Development of Medical Knowledge Infrastructure.

A large amount of medical information has been accumulated with the prevalence of computerization in medicine. Correspondingly, the needs of secondary use of the accumulated information for diagnosis support system and gaining medical knowledge have been increasing. Ontology, knowledge database, which is assembled mass of information describing the relationship of terms and concepts marshaled in a structured manner, is required for the study besides the techniques of machine learning and knowledge deduction. We have developed the clinical ontologies in particular fields such as anatomy, diseases, and abnormal status, as a funded research by the Ministry of Health, Labor and Welfare, Japan. For example, the ontology for diseases has been developed with approximately 6,000 diseases, that they are described as causal chains of abnormal states. We have also participated in “Research and development of intellectual information system infrastructure in medicine” project, sponsored by AMED since 2015. As further developing the ontology, we have worked on the study that clinical information of a targeted patient is automatically mapped on chronic disease ontology in order to perceive changes of disease states.

(2) Development of Diagnosis Support System for General Physicians.

It is difficult in community medicine to promote cooperation between medical experts and the core medical institutions. The experts of regional communities are required to have

comprehensive diagnosis skills and technical knowledge in the domain they specialize in. However, given the difficulty of such a situation that physicians take all the responsibilities, depending on only their knowledge and experiences, the need of diagnosis support system is pointed out. In this study, we have developed support system, that gives physicians in outlying regions access to refer to information matching experiences and knowledge matured general physicians have, to solve the issues. This project has been launched sponsored by AMED since January 2017. The current developed system is made up of approximately 20,000 case reports in internal medicine. The reports are transformed into knowledge database, described as chains of clinical states, so that the system can suggest a list of candidate diseases corresponding to a query, with certainty scores and reasons. The system (“J-Casemap”) was released and socially implemented as a service for members of the Japanese Society of Internal Medicine in August 2020. We also have worked on a study to automatically extract knowledge from raw texts in case reports using natural language processing for the continuous updating of the system.

(3) Analysis of Electrocardiogram (ECG) by Deep Learning.

Automatic analyzers of ECG data used in most hospitals are rule-based models that outputs ECG data in waveforms with clinical annotations. However, it still has difficulties on classification on abnormal findings. In fact, it is pointed out that it has a low sensitivity or potential for a false-positive diagnosis. Therefore, it needs an enhancement in its classification performance. We have developed another classification model using deep learning, intended for standard 12-leads ECG data. The current clinical annotations used for training our model is the ones given by the automatic analyzers; however we plan to apply diagnosis confirmed by echocardiogram as annotation data in future, so that our proposed model can be specialized in more specific abnormal findings and achieve comparable performance to

diagnosis by experts.

In addition to the researches, we have worked on other studies such as automatic selection of the underlying cause of death from death certificates using machine learning, and developing prescription support system in medical care for hypertension patients based on the clinical guidelines. Furthermore, we also have promoted a project aimed at the application of ICD-11 released in June 2018 for domestic use in Japan.

References

1. Iwai S, Mitani T, Hayakawa J, Shinohara E, Imai T, Kawazoe Y, Ohe K. Development of Graph-Based Algorithm for Differentiating Pathophysiological Conditions. *Applied Medical Informatics*. 2020;42(2):107-117.
2. Mitani T, Doi S, Yokota S, Imai T, Ohe K. Highly accurate and explainable detection of specimen mix-up using a machine learning model. *Clin Chem Lab Med*. 2020 Feb 25;58(3):375-383.
3. Imai T, Myojin T, Oigawa H, Kagawa R, Imamura T. Research on the actual situation and problems of determining the primary cause of death, and the applicability and challenges of machine learning for improving accuracy and efficiency. *Journal of Health and Welfare Statistics*. 2020;67(3):17-24. (In Japanese).
4. Imai T. Application of Artificial Intelligence Technology in the Field of Medical Natural Language Processing. *Journal of the Japanese Society for Artificial Intelligence*. 2020;35(4): 474-479. (In Japanese).
5. Imai T. ICD-11 as a clinical terminology and issues for the application in Japan. *Japan Journal of Medical Informatics*. 2020; 40(suppl.): 324-327. (In Japanese).
6. Ogawa T, Imai T, Takizawa M, Komatsu M, Imamura T. Consideration of Japanese translations for the domestic application of ICD-11 in Japan. *Japan Journal of Medical Informatics*. 2020; 40(suppl.): 328-331. (In Japanese).
7. Ogishima S, Imai T, Yoshida T, Ohara O, Tsutsumi M, Furuta K, Nakagome H, Nishimura K. Standardization of clinical sequence data. *Japan Journal of Medical Informatics*. 2020; 40(suppl.): 371-373. (In Japanese).
8. Myojin T, Oigawa H, Kagawa R, Imamura T, Imai T. Extraction of issues in determining the underlying cause of death in Japan to improve the accuracy and efficiency of cause-of-death statistics. *Japan Journal of Medical Informatics*. 2020; 40(suppl.): 674-676. (In Japanese).
9. Oigawa H, Myojin T, Kagawa R, Imamura T, Imai T. Feasibility of Domestic Use of Iris in the Determination Process of the Underlying Cause of Death. *Japan Journal of Medical Informatics*. 2020; 40(suppl.): 677-682. (In Japanese).

The International Research Center for Medical Education (IRCME)

Department of Medical Education Studies

Professor

Masato Eto, M.D., Ph.D.

Lecturer

Masashi Izumiya, M.D., Ph.D.

History and organization

International Research Center for Medical Education, established in 2000, had functioned as a center for the whole university and kept relations with Graduate School of Medicine in various ways. IRCME became an affiliated center for education and research under the control of Graduate School of Medicine since April 2013. IRCME previously consisted of two departments of International Cooperative Study in Medical Education, and Planning & Cooperation for International Cooperative Projects and Information on Medical Education. Names of two new departments are Department of Medical Education Studies and Department of International Cooperation for Medical Education.

The mission of Department of Medical Education Studies includes promotion of medical education not only in Faculty of Medicine of the University of Tokyo but also of the whole country. Specific contents are as follows:

- (1) Research in medical education and dissemination within and outside of the University

Medical and health professions education needs to continue revisions to meet health care needs of the country or the region. However, since every country or region has different culture or social system, experiences to apply updated evidence to the real settings to revise the system.

- (2) Support to undergraduate and postgraduate education in the University

Through the support to education in Faculty of

Medicine and the University Hospital, we show the effectiveness of such teaching practice and apply it to other medical schools in Japan for future reform.

Activities

This department promotes research related to medical education field. As the studies of medical education develop very rapidly all over the world, the department expands research to construct theories and emphasizes activities of educational practice or improvement.

In the University, this department provides information and members as to the education of Faculty of Medicine in such as academic affair committee, medical education reform working group, and clinical clerkship. Moreover, the department offers educational activities such as PBL (problem-based learning) and clinical skill practical training. The department operates OSCE (objective structured clinical examination). The department also runs and manages “Tsutsuji no kai” under the consortium with Tokyo Medical Dental University to develop simulated patients indispensable for education of medical interview.

This department promotes practical activities for the pre-graduate education of medical students and research in fields related to medical education. In the field of pre-graduate education, the department aims to nurture and produce human resources who can lead medicine and medical care in Japan, as well as to provide educational content of international standard.

In addition, against the backdrop of the rapid development of digital technology in recent years, the department will conduct research to provide effective and efficient medical education utilizing these new technologies.

The faculty members of this division are active members of the Academic Affairs Committee, working groups on educational reform, clinical clerkships, and other committees related to education at the Faculty of Medicine. The department also conducts PBL tutorials, clinical introductory training, and interprofessional education (IPE) in collaboration with other departments and universities. Furthermore, the department is focusing on simulation education for medical students using the clinical simulation center organized in the hospital. The department is also in charge of the administration of the OSCE (objective structured clinical examination) with the Educational Affairs of Administrative Division. In addition, the department operates and manages the *Tsutsuji no kai*, a consortium with Tokyo Medical and Dental University, to train simulated patients, which is essential for medical interviewing education.

The department is also in charge of conducting institutional research (IR) and class/curriculum surveys for continuous evaluation and improvement of medical education, as well as the administrative office of the Medical Education Improvement Committee.

Department of International Cooperation for Medical Education

Assistant Professor

Hiroataka Onishi, M.D., M.H.P.E., Ph.D.

Homepage <https://www.icme.m.u-tokyo.ac.jp/home>

Introduction and Organization

International Research Center for Medical Education (IRCME), established in 2000, had functioned as a center for the whole university and kept relations with Graduate School of Medicine in various ways. IRCME became an affiliated center for education and research under the Graduate School of Medicine umbrella since April 2013. IRCME currently consists of the Department of Medical Education and the Department of International Cooperation for Medical Education (ICME). Since April 2018, the Department of International Cooperation in Medical Education, which had been operated in an integrated manner with the Department of Medical Education, has been operated independently. It is one of the departments of the IRCME, and encompasses international cooperation in areas related to medical education, as well as practice and research in areas that connect policies and actual clinical practice, such as global health, community medicine, and general practice.

Education

The Department of ICME offers classes as cooperative department for School of International Health (SIH) and School of Public Health (SPH). In SIH special lectures of international cooperation for medical education are offered twice a year (spring and autumn). In SPH the class in spring is human resource development in health and medical practice and the class in autumn is learner assessment.

Since 2019, several graduate students are studying in ICME, and weekly seminars are provided every Wednesday.

Research

(1) International Cooperation in the Field of Health Professions Education: Through participation in international cooperation projects in Asia and other countries, we explore what education and policies in the health and medical fields should be like. He is also involved in surveys and research on the accepting medical and nursing professionals from overseas and on cultural and language frictions. Through joint research with related institutions in Taiwan and Indonesia, we aim to gain experience in evaluation methods, policy recommendations, and coordination among related parties, as well as to disseminate the research results and become a core research center in this field.

(2) Study on Learner Assessment: When certifying the completion of the program, it is very important to investigate how the learner's assessment is conducted and how the pass/fail decision is made. Various changes are seen in the concept of assessment itself. Current studies include the development of work-based assessment methods, verification of reliability and validity of assessment tools, and the improvement of methods for standard setting of pass/fail judgment criteria.

(3) Research related to ACP (advance care planning):

We continue researching how and where the elderly want to end their own life and the relationship between their family's thoughts.

(4) Practice and research in the field linking health policy and clinical practice: Studies are done for how to train the professionals contributing to community-based integrated care system.

References

1. Schuwirth L, Colliver J, Gruppen L, Kreiter C, Mennin S, Onishi H, ... & Wagner M. Research on Assessment Practices. In *International Best Practices for Evaluation in the Health Professions* (pp. 59-75). CRC Press; 2022
2. Tsuchida T, Onishi H, Ono Y, Machino A, Inoue F, & Kamegai M. Factors associated with preferred place of death among older adults: a qualitative interview study in Tama City, Tokyo, Japan. *BMJ open*. 2022; 12(5): e059421.
3. Ernawati DK, Sutiari NK, Astuti IW, Onishi H, & Sunderland B. Correlation between intercultural sensitivity and collaborative competencies amongst Indonesian healthcare professionals. *Journal of Interprofessional Education & Practice*. 2022; 29: 100538.

Global Nursing Research Center

Director, Professor

Noriko Yamamoto-Mitani, R.N., Ph.D.

Vice Director, Professor

Megumi Haruna, Ph.D., R.M., R.N.

Mari Ikeda, Ph.D., R.N., CCP.

Project Professor

Karis Kin-Fong Cheng, Ph.D., R.N., FAAN.

Project Senior Lecturer

Kojiro Morita, M.P.H., R.N., P.H.N., Ph.D.

Hiromi Tobe, R.N., P.H.N., Ph.D.

Project Assistant Professor

Sameh Eltaybani, Ph.D.

Project Researcher

Manami Takaoka, Ph.D., R.N., P.H.N..

Homepage <https://gnrc.m.u-tokyo.ac.jp/en/>

Introduction and Organization

With a falling birthrate and a super-aging society, Japan is in need of a paradigm shift toward a medical and nursing care that supports the aging, as well as those dealing with chronic health conditions, to lead lives with maximum independence and well-being. In order to provide a healthy life expectancy for its people, it will be necessary for Japan to face its forthcoming challenges and bring about the realization of a 'care' society that lightens the difficulty of the living and brings a self-reliant way of life to the Japanese nation. Nursing, which plays a central role in providing care, must develop into a new field as a science for the realization of this 'care' society. Currently, however, the dominant paradigm employed in various nursing fields embraces a structure that supports the training of clinical nurses, not the development of a science aimed at producing a 'medical and nursing care that supports.' Thus, GNRC seeks to promote research into an

innovative, transdisciplinary nursing science that systematizes this type of care. In particular, our focus is to create a transdisciplinary research and educational environment that fosters young leaders in nursing research who will promote care innovation and develop nursing systems for implementation.

In order to achieve this, we must work toward integrating nursing with fields it has yet to fully collaborate with, such as bio-engineering, molecular biology, human engineering, philosophy, educational psychology, information science, and policy science. Moreover, as the field of nursing science continues to develop, further attention must be paid to both the development of the necessary human resources that will be required to promote this transdisciplinary research, as well as the networks necessary to create collaborative relationships among industry, government, and academia. In short, our aim is to create a long-term research system that allows young researchers to conduct transdisciplinary work that

ranges from fundamental research to studies with commercial application.

Thus, the Global Nursing Research Center has been established as an affiliated research center, which is the first of its kind in nursing science. The GNRC will continue to execute the following three goals:

- 1) Establish an innovative nursing research field based on transdisciplinary integration;
- 2) Carry out cutting-edge research and present it to the world with young researchers pursuing the sciences;
- 3) Build up a foundation of these new fields through repeated research trials that will strengthen the new research and education systems.

Establishing an Innovative Nursing Research Field

1. Division of Care Innovation

The Division of Care Innovation promotes various research activities, such as robotics nursing, biological nursing, visualized nursing, clinical nursing technology and reverse translational research, with the aim of ‘developing and producing patient care products that lighten unfavorable conditions of daily life due to the health impairment of each person.’

2. Division of Nursing Systems

The Division of Nursing Systems promotes such research activities as health-quality outcome research and care quality management, in order to provide ‘nursing practice solutions that reflect important cultural and social concerns, constructing Japan-origin nursing theories that support high quality practices, and making policy proposals.’

3. Division of Global Collaborative Research

The Division of Global Collaborative Research promote collaborative research and create a network of research groups among global partners to resolve global health issues and create a platform to share and increase the visibility of our outcomes locally and internationally.

4. Achievements

In 2022, 3 international joint research projects and 11 industry-government-academia research project were undertaken. In addition, 95 original English articles were published.

Executing Innovative Research

1. International Invited Faculty

In 2022, we had one Project Professor: Prof. Karis Kin-Fong Cheng: National University of Singapore, and invited 13 other researchers.

2. Post-doctoral Program

Post-doctoral (PD) researchers engage in focused research projects, the findings of which will be made known to the public. In addition, PD researchers must take five essential seminars that cover comprehensive research knowledge, skills, and global awareness for the training of youth for leadership.

We provided 14 themes for our post-doctoral program, including (1) Leadership for Change in Healthcare, (2) Excellence in Academic Writing, (3) Meta-analysis~Advanced research methodology~, and (4) Qualitative Research and Mixed Methods for Healthcare.

In 2022, one PD researcher participated in this program, and completed the program.

3. Other Universities’ Young Researchers

In 2022, our PD seminars and lectures were opened to young researchers from other universities, and by the end of the year, a total of 1363 participants attended.

4. Other activities

The "Nursing Lecture Series," featuring lectures by four deans of the top 50 QS-ranked universities, was held. The 26th East Asia Forum of Nursing Scholars (EAFONS) was held in collaboration with the Japan Association of Nursing Program Universities (JANPU) as an academic meeting. The Spring International Program was also held to provide an opportunity for graduate students from Japan and abroad to learn and share innovative approaches and methodologies in nursing science.

Building Future Research

1. Global Nursing Research Center Fund

The Global Nursing Research Center Fund was continued for the purpose of fostering young researchers.

Accomplishments

1. Asaoka, H., Koido, Y., Kawashima, Y., Ikeda, M., Miyamoto, Y., & Nishi, D. (2022). Longitudinal

- change in depressive symptoms among healthcare professionals with and without COVID-19 vaccine hesitancy from October 2020 to June 2021 in Japan. *Industrial health*, 60(4), 387–394. <https://doi.org/10.2486/indhealth.2021-0164>
2. Honda, C., Sumikawa, Y., Yoshioka-Maeda, K., Iwasaki-Motegi, R., & Yamamoto-Mitani, N. (2022). Confusions and responses of managerial public health nurses during the COVID-19 pandemic in Japan. *Public health nursing (Boston, Mass.)*, 39(1), 161–169. <https://doi.org/10.1111/phn.13011>
3. Hsu, W. J., Minematsu, T., Nakagami, G., Koudounas, S., Tomida, S., Nakai, A., Kunimitsu, M., Nitta, S., & Sanada, H. (2022). Identification of microRNAs responsive to shear loading in rat skin. *International wound journal*, 19(2), 351–361. <https://doi.org/10.1111/iwj.13635>
4. Iwasaki-Motegi, R., Yoshioka-Maeda, K., Honda, C., & Yamamoto-Mitani, N. (2022). Prefectural public health nurses' support in human resource development of municipal public health nurses in Japan. [*Nihon koshu eisei zasshi*] Japanese journal of public health, 69(6), 417–423. <https://doi.org/10.11236/jph.21-078>
5. Kida, R., & Takemura, Y. (2022). Working Conditions and Fatigue in Japanese Shift Work Nurses: A Cross-sectional Survey. *Asian nursing research*, 16(2), 80–86. <https://doi.org/10.1016/j.anr.2022.03.001>
6. Koudounas, S., Minematsu, T., Mugita, Y., Tomida, S., Nakai, A., Nakagami, G., & Sanada, H. (2021). Inhibiting effect of synthetic urine on the growth and mobility of *Pseudomonas aeruginosa*, *Escherichia coli*, *Proteus mirabilis* and *Klebsiella pneumoniae* shifts to a promoting effect during culture. *Journal of Nursing Science and Engineering*, 8, 220–229. https://doi.org/10.24462/jnse.8.0_220
7. Matsumoto, H., Igarashi, A., Hagiwara, Y., & Yamamoto-Mitani, N. (2022). Relational Design for Dementia and Job Significance (ReDeSign): Study protocol for a randomized controlled trial of an online dementia training for retail workers. *Contemporary Clinical Trials Communications*, 26, 100896. <https://doi.org/10.1016/j.conctc.2022.100896>
8. Murakami, M., Yonezawa, K., Shimizu, S., Haruna, M., Sasagawa, E., & Usui, Y. (2022). Newborn-oriented and environmental factors for newborns' skin barrier functions. *Japan journal of nursing science: JJNS*, 19(2), e12457. <https://doi.org/10.1111/jjns.12457>
9. Murayama, R., Abe-Doi, M., Kogure, T., Takahashi, T., Kanno, C., Ishigaki, M., & Sanada, H. (2021). The influence of peripheral intravenous catheterization on the sleep quality of ophthalmic inpatients: An observational study. *Journal of Nursing Science and Engineering*, 8, 134–142. https://doi.org/10.24462/jnse.8.0_134
10. Qin, Q., Oe, M., Ohashi, Y., Shimojima, Y., Imafuku, M., Dai, M., Nakagami, G., Yamauchi, T., Yeo, S., & Sanada, H. (2022). Factors Associated with the Local Increase of Skin Temperature 'Hotspo', of Callus in Diabetic Foot: A Cross-Sectional Study. *Journal of diabetes science and technology*, 16(5), 1174–1182. <https://doi.org/10.1177/19322968211011181>
11. Sugawara, C., Yamana, H., Sasagawa, E., Yonezawa, K., Hikita, N., Morita, K., Matsui, H., Yasunaga, H., & Haruna, M. (2022). Factors Associated with Surgical Treatment in Postpartum Women with Mastitis or Breast Abscess: A Retrospective Cohort Study. *Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine*, 17(3), 233–238. <https://doi.org/10.1089/bfm.2021.0244>
12. Yonezawa, K., Haruna, M., Yamamoto-Hanada, K., & Ohya, Y. (2022). Exacerbation and severity of allergic symptoms during pregnancy and their impact on mental health. *International journal of women's dermatology*, 8(1), e002. <https://doi.org/10.1097/JW9.0000000000000002>
13. Yoshinaga, N., Nakagami, G., Fukahori, H., Shimpuku, Y., Sanada, H., & Sugama, J. (2022). Initial impact of the COVID-19 pandemic on time Japanese nursing faculty devote to research: Cross-sectional survey. *Japan journal of nursing science : JJNS*, 19(1), e12454. <https://doi.org/10.1111/jjns.12454>

Center for Diversity in Medical Education and Research

Director/Professor

Kiyoto Kasai, M.D., Ph.D.

Vice Director/Associate Professor

Yoshihiro Satomura, M.D., Ph.D.

Homepage <https://cdmer.jp>

Introduction and Organization

The University of Tokyo Center for Diversity in Medical Education and Research was established in April 2021. The main purpose of the center is to promote education and research on diversity and inclusion in medicine. As part of this, the center aims to provide training programs for medical students with disabilities.

The center is working on the education, support, research and organizational change/ co-production divisions in close collaboration with the Graduate School of Medicine and Faculty of Medicine and Disability Services Office in the University of Tokyo. The center aims to improve the quality of patient-centered medical services by the inclusion of medical professionals with disabilities in the team medical care.

Education

Through education on diversity and inclusion in medicine, we will develop medical personnel including physicians and medical researchers who understand the significance of patient-public involvement (PPI) in medical research and development, and who have a co-production mindset in medical research and practice. For this purpose, we will be giving lecture to medical students in some of the existing educational programs.

For a more integrated and systematic education on diversity and inclusion in medicine, we are preparing to establish the “Human Resource Development Program for Diversity and Inclusion in Medicine”. In

this program, participating students will take the initiative in deepening their learning based on the philosophy of co-production and will not only be exposed to academic theory, but also participate in the practical field.

Research

There are many research issues that need to be clarified in order to promote diversity and inclusion in medicine. The actual situation regarding the presence rate of personnel with disabilities, and reasonable accommodation in medical education and practice settings needs to be clarified. Research on stigma held by health care providers, considered one of the most significant barriers to participation of medical personnel with disabilities, and the development of anti-stigma educational intervention methods are also needed. We will also need to explore the conditions for organizations in which personnel with disabilities can play an active role safely.

Publications

1. Yamagishi M, Satomura Y, Sakurada H, Kanehara A, Sakakibara E, Okada N, Koike S, Yagishita S, Ichihashi K, Kondo S, Jinde S, Fukuda M, Kasai K: Retrospective Chart Review-based Assessment Scale for Adverse Childhood Events and Experiences. *Psychiatry and Clinical Neurosciences Reports* 1: e58, 2022. 17 November 2022. <http://dx.doi.org/10.1002/pcn5.58>

2. Kanehara A, Morishima R, Takahashi Y, Koike H, Usui K, Sato S, Uno A, Sawai Y, Kumakura Y, Yagishita S, Usami S, Morita M, Morita K, Kanata S, Okada N, Yamasaki S, Nishida A, Ando S, Koike S, Shibuya T, Joseph S, Kasai K: Young carers in Japan: Reliability and validity testing of the BBC/University of Nottingham young carers survey questionnaire and prevalence estimation in 5,000 adolescents. *Psychiatry and Clinical Neurosciences Reports*. 1: e46, 2022. Sep 2022. DOI: 10.1002/PCN5.46
3. Kiyono T, Ando S, Morishima R, Fujikawa S, Kanata S, Morimoto Y, Endo K, Yamasaki S, Usami S, Hiraiwa-Hasegawa M, Nishida A, Kasai K: Sex-based differences in the longitudinal association between autistic traits and positive psychotic experiences in adolescents: A population-based cohort study. *Schizophrenia Research*. 2022 Aug;246:1-6. doi: 10.1016/j.schres.2022.05.027.PMID: 35696856
4. Morishima R, Koike H, Kanehara A, Usui K, Okada N, Ando S, Kasai K: Implementation of online classes during national school closure due to COVID-19 and mental health symptoms of adolescents: A cross-sectional survey of 5000 students. *Psychiatry and Clinical Neurosciences Reports*. June 2022. <https://doi.org/10.1002/pcn5.17>
5. Kanehara A, Koike H, Fujieda Y, Yajima S, Kabumoto A, Kumakura Y, Morita K, Miyamoto Y, Nochi M, Kasai K: Culture-dependent and universal constructs and promoting factors for the process of personal recovery in users of mental health services: Qualitative findings from Japan. *BMC Psychiatry*. 2022 Feb 10;22(1):105. doi: 10.1186/s12888-022-03750-4.
6. Kasai K, Kumagaya S, Takahashi Y, Sawai Y, Uno A, Kumakura Y, Yamagishi M, Kanehara A, Morita K, Tada M, Satomura Y, Okada N, Koike S, Yagishita S: "World-Informed" neuroscience for diversity and inclusion: An organizational change in cognitive sciences. *Clin EEG Neurosci*. 2022 Jun 12. PMID: 35695218 DOI: 10.1177/15500594221105755.
7. Kasai K, Yagishita S, Tanaka SC, Koike S, Murai T, Nishida A, Yamasaki S, Ando S, Kawakami N, Kanehara A, Morita K, Kumakura Y, Takahashi Y, Sawai Y, Uno A, Sakakibara E, Okada N, Okamoto Y, Nochi M, Kumagaya SI, Fukuda M: Personalized values in life as point of interaction with the world: Developmental/neurobehavioral basis and implications for psychiatry. *Psychiatry Clin Neurosci Rep* 1: e12, June 2022. DOI:10.1002/pcn5.12.

Office of International Academic Affairs

Head

Shinichi Sato

Assistant Professors

Keiko Nanishi

David Kipler

Florence Ene

Homepage: <http://koryu.m.u-tokyo.ac.jp>

Status and functions

The Office of International Academic Affairs (OIAA) is under the direct authority of the Dean of the Faculty of Medicine. Its three most important roles, as defined by the Committee on International Academic Affairs, are facilitating 1) international academic exchange, 2) international academic and research agreements, and 3) education and research activities.

Activities

This report details the activities of the OIAA during the 2022-23 academic year (1 April 2022 through 31 March 2023).

1. International Academic Exchange

1.1 Student guidance on education and research

The OIAA assists international students in applying for various scholarships, and the OIAA on-campus screening committee evaluates applicants for scholarships that require university recommendations. To promote friendship among international students, the OIAA organizes a get-together every summer at Capo Pellicano, a restaurant in the Faculty of Medicine Experimental Research Building, and a school trip every spring. The get-together party in the summer of 2022 was canceled because of the COVID-

19 pandemic, but the school trip in the spring of 2023 was conducted as usual.

The OIAA oversees undergraduate clinical training (elective clerkships) for international students at the University of Tokyo Hospital. Border restrictions in Japan forced the cancellation of many elective clerkships that were scheduled. After October 2022, the situation returned to normal, resulting in the hosting of 13 international students in 2022-23.

1.2 Guidance on short-term and long-term overseas study programs for medical students and researchers at the University of Tokyo

The OIAA provides guidance and information on study abroad during the school year, prepares letters of recommendation and other documents, and supports communication with study-abroad partner institutions. Of particular importance is assisting fourth-year medical students with their elective clerkships abroad.

As of March 2023, the University of Tokyo Faculty of Medicine has agreements for exchange programs—which provide one to two months of clinical training—with the University of Pennsylvania, Johns Hopkins University, University of Michigan, University of Hawaii, Seoul National University, National Taiwan University, National University of Singapore, Karolinska Institute and Ludwig

Maximilian University of Munich. The OIAA nominates qualified students for each university and assists in their preparation for study abroad.

Although students were nominated for electives scheduled for April through July 2022, the pandemic caused the host institutions to cancel many electives, resulting only 12 students could complete their elective.

1.3 Support for overseas training of graduates

The OIAA assists graduates in preparing documents for applications to graduate schools and other institutions abroad and in obtaining medical licensure in other countries. During 2022-23, the OIAA received no requests for preparing Medical Student Performance Evaluations.

2. International Academic and Research

Agreements

During the 2022-23 academic year, the interdepartmental agreement with the University of Munich was renewed. We continued interaction with strategic partnership universities such as the University of Chicago and National Taiwan University, including jointly hosting workshops online, which was possible during the COVID-19 pandemic.

3. Education and Research Activities

Dr. Florence Ene supervised and taught the Medical English I/II courses.

David Kipler trained graduate and undergraduate students in writing research articles and making oral presentations in English.

Dr. Keiko Nanishi served as a lecturer in the School of International Health, where she supervised graduate students and conducted research on international health.

Publications

- 1: Nanishi K, Okawa S, Hongo H, Shibnuma A, Abe SK, Tabuchi T. Influence of the COVID-19 pandemic on breastfeeding support for healthy mothers and the association between compliance with WHO recommendations for breastfeeding support and exclusive breastfeeding in Japan. *PeerJ*. 2022 May 19;10:e13347.
- 2: Okawa S, Hosokawa Y, Nanishi K, Zaito M, Tabuchi T. Threatened abortion, threatened premature labor, and preterm birth during the first state of emergency for COVID-19 in 2020 in Japan. *J Obstet Gynaecol Res*. 2022 May;48(5): 1116-1125.

MD Scientist Training Program

Professor and Director

Kenzo Hirose, M.D., Ph.D.

Assistant Professor

Yuki Sugaya, M.D., Ph.D.

Takeshi Sawada, M.D., Ph.D.

Project Assistant Professor

Yoshitaka Kurikawa, M.D., Ph.D.

Homepage <http://www.ut-mdres.umin.jp/> (in Japanese)

Introduction and Organization

The MD Scientist Training Program (MDSTP) was founded in 2008 to achieve the goal of systematically providing an intensive basic medical research training framework to the next generation of MD scientists during their MD training at the School of Medicine, The University of Tokyo. Capitalizing on the advances made by launching a reliable and sustainable program through the leadership of its first directors, Prof. Shigeo Okabe (2008-2010), Prof. Masahide Kikkawa (2011-2014), and Prof. Haruhiko Bito (2015-2020), the Program currently consists of its director Prof. Kenzo Hirose and 3 staff members, Yuki Sugaya (assistant professor), Takeshi Sawada (assistant professor) and Yoshitaka Kurikawa (project assistant professor), and over 100 students who are seeking extracurricular basic medical research training through the Program's framework. With the help of two assistants for clerical work, it provides a variety of support programs to assist the research activities of medical students. From 2011 on, the MDSTP at the University of Tokyo has cooperated with its sister programs at Kyoto University, Osaka University and Nagoya University.

The number of the enrolled students during the launch year (2008) of the MDSTP was 6. Since then, the Program has expanded and now enrolls about 100

students (during Year 3 to 6 of the Medical School). A sizable number of students write research honors theses during their final year, which they defend to become certificated as MDSTP graduates. The number of research publications in scientific journal or awards at international scientific meetings, which resulted from these theses, is growing.

Achieving basic medical research training in parallel with medical education

The Program offers a platform of activities aimed at providing an early exposure to basic medical research and to basic skills required for achieving leadership in academic medicine.

During the first 2 years after the entrance to the University of Tokyo, we initially organize a lecture series entitled 'Introduction to Medical Biology'. In this lecture series, top researchers of various fields at the University of Tokyo provide exciting but intelligible talks to students with little medical knowledge. This helps students to get introduced various research subjects in various fields of medical research and strongly motivate them to find by themselves a laboratory suitable to their aspirations. Furthermore, we offer an opportunity to read the textbook 'Molecular Biology of the Cell' in English,

in a small group setting, to get an exposure to scientific English, and to be formally introduced to basic molecular and cellular biology, the foundation of current medical research.

From Year 3 on, as the students choose the labs and principal investigators with whom to do science with, the Program organizes journal clubs for basic medical research and courses of medical research communications are held every 2 weeks. In the journal club, students are trained to critically read recent scientific papers published in top journals, often in the presence of the first authors, if they are available. In medical research communications courses, the students discuss scientific topics and research issues with a native English speaker with a strong research background.

Students who have shown their research abilities are highly recommended to write their honors research theses by the end of the summer of Year 6. After successfully defending their theses, they are certified as qualified MDSTP trainee and, as such, they become eligible for an exemption of a part of an entrance examination for the Graduate School of Medicine. The Dean's Prize is awarded to the best thesis.

Enhancing awareness and providing opportunities for excellence in basic medical research

1) Providing assistance for research and clinical experience in foreign laboratories and hospitals

We encourage students to plan and seek for basic medical research experience in other countries during their MD training. Based on research proposals submitted to the Program, travel supports are provided on a competitive basis. In 2022, a total of 17 students received the Program's support for carrying out basic medical research abroad and to present their research achievements at international scientific meetings. We also support exposure to clinical training in foreign hospitals with the Osamu Otsubo Tetsumon Fellowship. In 2022, 8 students gained invaluable experience as student clinical clerks in various university hospitals abroad. However, due to the

COVID-19 pandemic in the destination countries, 7 students were unable to travel abroad. Instead, they studied cutting-edge medical care in domestic hospitals.

2) Organizing an MD scientist training program retreat

A MDSTP retreat was held on February 11 and 12, 2023 at the Yamanaka-Naito Seminar House in Yamanashi prefecture to present ongoing research progress in a closed meeting among peers. More than 50 participants, mostly medical school students, but also some medical interns, graduate students and Program-affiliated professors attended it. Lively discussions among peers were exciting throughout the meeting and the feedback from all participants was outstanding and unequivocal in emphasizing the critical importance for a research progress retreat to promote their future research projects. One important aspect of the retreat was to provide students, interns, and professors to discuss opportunities in various career paths available in the basic medical research field.

3) Cooperating with other medical universities across Japan

With the availability of governmental support from 2011 to 2020, the MDSTP at the University of Tokyo has been in close touch with sister organizations at Kyoto University, Osaka University and Nagoya University. With a view to enhancing collaborative efforts in improving the basic medical research training at the 4 medical schools, joint retreats were held to promote communication and networking among the medical students with research minds. The previous retreat was held in Nagoya in 2019, at the occasion of the Japan Medical Congress. More than 90 people including medical school students and teachers from all over Japan participated in this retreat and enthusiastically discussed about their research and future career as researchers. From 2021, a new partnership of the four universities, the MD Scientist Training Initiative, has been launched with the aim of working more closely together than ever before, including lab tours and research exchanges. In 2022, we held three lab tours visiting laboratories at 4 universities, with over 50 students participating and

considering study exchanges at domestic universities.

The MSDTP also currently cooperates with 11 other universities in eastern Japan to organize annual research students' retreats. In 2022, the annual summer retreat was held under the auspices of Chiba University. More than 90 people participated in the retreat and presented their ongoing research progress and plans.

Activities (2022)

The number of registered students: 160 (3rd and 4th grade: 72, 5th and 6th: 88)

Lectures for students in Years 1 and 2

Introduction to Medical Biology: 13 lectures

Group reading of Molecular Biology of the Cell: 13 lectures

Seminar for students (in Year 3 or above)

Journal Club for basic medical research: 6 lectures

Medical Research Communications: 54 lectures

Presentation of research progress: 2 (the retreat of MD scientist training program in the University of Tokyo and the annual research students' retreats with universities in eastern Japan)

The number of students receiving travel supports for research: 17 (including support for international and domestic online conference)

The number of students receiving Osamu Otsubo Tetsumon Fellowship: 15

The number of Year 6 students who passed their honors thesis defense: 8 (the Dean's Prize and the Satoshi Arima memorial fellowship were awarded to 2 and 2 student, respectively)

Museum of Health and Medicine

Director

Kazuhiko Ohe

Associate

Atsushi Kitade

※The following information is the same as that of the previous year for certain reasons.

Homepage <http://mhm.m.u-tokyo.ac.jp/>

History and overview

The origins of the School of Medicine and the University of Tokyo Hospital can be traced back to the establishment of the Kanda Otamaga-Ike Vaccination Center in 1858. In 2008, it celebrated its 150th anniversary. The Museum of Health and Medicine was planned as part of commemorative projects to celebrate the 150th anniversary of the founding of the School and the Hospital, and was opened on January 20, 2011. One of the themes for the commemorative projects marking the 150th anniversary was the “development of communication between health science and care and society,” and the Museum of Health and Medicine forms one of the pillars of this.

In establishing the Museum of Health and Medicine, we renovated the School of Medicine’s Central Building (Medical Library), which had originally been instituted as part of the commemorative projects celebrating the 100th anniversary of the founding of the School and the Hospital. The Museum has about 400m² areas, including about 70m² of a permanent gallery and 230m² of special exhibition rooms.

The aims of the Museum are to: (1) provide health and medical information to the public, (2) educate students studying medicine, health care services and related areas, (3) research the history of medicine and health care through archives, instruments and technology, and (4) preserve and investigate valuable medical archives and instruments, etc.

In addition to the permanent gallery exhibiting

accomplishments related to the School and the Hospital and its contributions made to modern and contemporary development in Japan, a feature of the exhibitions is that a large space has also been set aside for special exhibitions to promote understanding among the public regarding the latest advances in medical science and health care. Planning and supervision of the permanent exhibition and special exhibition is done with the cooperation of the various research units within the School and the Hospital, other departments within the University, industry, and museums. Special exhibitions will be changed several times a year.

The first permanent exhibition since the opening of the Museum was a display of medical texts and instruments from the early Meiji era, an Ishihara’s Color Blind Test Chart and a gastroscope developed at the University. The first special exhibition was related to the beginnings of the School and the Hospital, Entitled “the Challenge to Infectious Diseases”. It introduced the history of vaccinations against smallpox, research into infectious diseases conducted in the University and by its graduates since the Meiji era (1868-1912), and the latest knowledge about infectious diseases. The second was “the Secret of Vessel System”, which introduced the circulatory system. The third “diagnosis of cancer”, the fourth “Our brain”, the fifth “Locomotive syndrome”, the sixth “Diabetes Mellitus”, the seventh “Pediatrics”, the eighth “Forensic Medicine”, the ninth “the Colon” followed, the tenth “Virus”, the eleventh “Kidney”

and the special exhibition “Mental Diseases”.

In April 2019, we reopened our museum in the South Clinical Research Building of The University of Tokyo Hospital.

Since the opening of the Museum, more than 143,701 people had visited by the end of FY2019. Since Mar. 2020, our museum has been temporarily closed due to COVID-19 pandemic

Overview of operations

The opening hours are 10:00-17:00. The Museum is closed every Wednesday and during the New Year holidays (however, it will open if Wednesday is a public holiday). Admission is free.

Office for Human Research Studies (OHRS)

Director of OHRS (Professor / Vice Dean)

Masaomi Nangaku, M.D., Ph.D.

Vice Director of OHRS (Professor)

Akira Akabayashi, M.D., Ph.D.

Vice Director of OHRS (Associate Professor)

Yuzaburo Uetake, M.D., Ph.D.

Homepage: <http://www.m.u-tokyo.ac.jp/ethics/ethcom/gakugai2/index.html>
<http://ohrs-u-tokyo.jp>

Top page of online application system: <https://u-tokyo.bvits.com/esct/>

Introduction and Organization

The Office for Human Research Studies (OHRS) was established in October 2009 for the advancement of research ethics standards. OHRS aims to protect the rights, health, and dignity of research participants. Based on this principle, OHRS is providing research ethics support services to researchers at Graduate School of Medicine and Faculty of Medicine, the University of Tokyo and the University of Tokyo Hospital to enable them to better perform their studies in an ethical manner. Our primary task is the management of the Ethics Committee secretariat. Additionally, OHRS plans and manages research ethics seminars, provides ethics education to researchers through consultation and develops human resources for future research ethics specialists.


Activities

- Management of Ethics Committee
- Prior review of research activity documents (except for clinical trial, GCP), at Graduate School of Medicine and Faculty of Medicine, the University of Tokyo and the University of Tokyo Hospital. Correspond in response to various research ethics inquiries.

- Coordination of various matters with Ethics Committee members, and other similar bodies and universities.
- New clinical documentary examinations in connection with,
 - Medical treatments to implemented for the first time at the University of Tokyo Hospital,
 - Examination of the clinical use of the unapproved medicines and medical devices,
- Preparation and maintenance of the organ transplantation manuals for the liver, kidney and heart transplants.

◇ Specific items reviewed and examined by each Ethics Committee in fiscal year 2022

- Research Ethics Committee (except for clinical trial, GCP):
248 new applications, 1095 minor alterations of approved studies
- Clinical Research Review Board:147
- New clinical documentary examinations: 102



Research activities

At present, OHRS is a business section. For more information about the research, see the contents of Department of Biomedical ethics, which is a cooperative department.

Though OHRS adopts various inclusive applications, the number of studies applied to and reviewed by ethics committees over the last several years is on the increase. The management duties of the Ethics Committee secretariats are complicated and diversified, making it difficult to be able provide adequate services to appropriately respond to such increasing needs. OHRS operates an online application system and contributes to the convenience of applicants and to enable them to efficiently plan their research obligations.

Teaching and training activities

OHRS plans and manages research ethics seminars with Department of Clinical Research Governance in the University of Tokyo Hospital.

We provide a broad outline overview regarding ethics education aimed generally for all researchers and students who are engaged in clinical studies through such seminars. The ethics seminars were held monthly in fiscal year 2022 with 3699 people attended.

OHRS makes efforts to educate researchers through its research ethics support services. Additionally, the skill development and support of the secretariat staff is one of our important tasks.

OHRS also aims to advance research ethics standards by cooperating and consulting with Ethics Consultant specified by each laboratory.

The Office for Clinical Practice and Medical Education

Professor

Masato Eto, M.D., Ph.D.

Research Associate

Yuki Matsushita, M.D., Ph.D.

Homepage <https://igaku-kyoiku.m.u-tokyo.ac.jp/training/>

Introduction and Organization

The Office for Clinical Practice and Medical Education was established in April 2015, to support and promote medical education, especially clinical practice at grade 5 and 6. The office used to be the Clinical Clerkship Support Center, which was established to meet the change from bedside learning to clinical clerkship in February 2013. Our aim is to run the clinical clerkship (CC) smoothly, as well as to improve the curriculum and evaluation methods in cooperation with teachers and students. In addition, we try to support each student in cooperation with tutors, the instruction department and the office for student assistance in the faculty of medicine. The Information and Communication Technology (ICT) system has launched in January 2018, which greatly improved the efficiency of clerical works. The office now consists of a general manager (professor), a research associate, and three staffs.

Activities

Before the CC begins in January for 4th grade medical students, we have a meeting to explain the details to the students, and then make a schedule of the CC based on the questionnaire. Just before the CC starts, we hold a ceremony to name students that passed OSCE and CBT examinations as “student doctors”, which the dean and the chair of the academic affairs committee of the medical faculty of The University of Tokyo, and the director and the chief nursing officer of The University of Tokyo Hospital attend.

After the CC starts, we support students, teachers and the external cooperative institutions to run the clerkship smoothly, by making necessary contacts with them. In addition, we handle with problems and considerations occurred during the practice if needed. Particularly, we manage and support students who need helps, with the instruction department, tutors, and the office for student assistance in the faculty of medicine. The new ICT system permits the evaluations of the students in the CC to be revealed real-time, hence the students are able to look their scores, at the earliest on the final day of each practice.

Twice a year, we hold a meeting with teachers who are in charge of the CC. In this meeting, we provide teachers the feedbacks about the practice from students, and exchange the information and opinions among the teachers, thus improving the CC. On the other hand, we have opportunities with students (working group on medical education), to discuss the CC and try to respond to comments from them.

Educations

Together with the IRCME department of medical education studies, we take charge of “medical practice: the introduction” for 4th grade students and “tutorial PBL” for 2th grade students, teaching medical interview, physical examination and medical professionalism. We also take charge of tutorials and individual consultations related to the CC.

Research activities

“Research of the coherence between the students’ daily life and psychological conditions, and the outcome at the graduation” is being conducted. The results were released in the domestic and international conferences of medical education in 2018 and 2019, and published for an international paper in 2021. Presently this research is being conducted in multiple institutional investigation. Moreover, “Research of the effect of online medical interview trainings” is being conducted.

Advisory Office for Conflict of Interest

Professor

Keishi Fujio (Chair, Advisory Board for Conflict of Interest)

Professor

Kazuhiko Fukatsu (Vice Chair, Advisory Board for Conflict of Interest)

Dr. Saeko Aketani (Director, Advisory Office for Conflict of Interest)

History and Organization Overview

The Advisory Office for Conflict of Interest of the Graduate School of Medicine and University Hospital was newly established in April 2016 as an administrative department of the Advisory Board for Conflict of Interest of the School of Medicine.

At the University of Tokyo, an Advisory Board for Conflict of Interest has been established in each department under the university-wide Conflict of Interest Management Committee, and appropriate conflict of interest management is required for employees. The School of Medicine has established rules to prevent conflicts of interest in the Faculty of Medicine and has established an Advisory Board for Conflict of Interest to manage conflicts of interest in clinical research conducted at the School of Medicine and the University Hospital.

In research conducted at the School of Medicine, it is necessary to promote industry-academia collaboration activities in order to return the results to society and contribute to the health of the people. On the other hand, in clinical research involving human subjects, it is essential to protect the rights of the research subjects, and the results of the research may affect the health of the public, and the fairness of the research is particularly required. In this way, conflicts of interest are inevitable in research activities at the School of Medicine, and appropriate management and disclosure of conflicts of interest are required.

In Japan, the Ministry of Health, Labour and Welfare (Clinical Trials Act) and the Japan Medical

Association have published guidelines for managing conflicts of interest in clinical research, and the criteria for judgment are gradually being clarified, and the Advisory Office for Conflict of Interest of the School of Medicine manages conflicts of interest based on these guidelines.

Business

- The Advisory Board for Conflict of Interest at the School of Medicine manages conflicts of interest pertaining to clinical research.

Targets

- Clinical research undergoing review by the School of Medicine's Ethics Committee, encompassing studies in epidemiology, observation, intervention, and human genome and genetic analysis
- Clinical trials undergoing review by the University Hospital IRB
- Clinical research to which the Act on Securing the Safety of Regenerative Medicine, etc. applies submitted by the University Hospital
- Clinical research conducted by the University Hospital as a single center or chief facility (however, the review will be conducted by the University of Tokyo Accredited Clinical Research Review Board)
- Administrative confirmation related to self-declaration of conflicts of interest for issues to which the Clinical Trials Act applies
- Preparation of examination materials for the

management of conflicts of interest of the Japan Agency for Medical Research and Development (AMED) and the Health, Labour and Welfare Scientific Research Fund

- Task of submitting conflict of interest self-declaration forms for faculty and staff members
- Management of Conflicts of Interest of School of Medicine and University Hospital Committee Members

In FY2022, the Conflict of Interest Advisory Board consisted of six members, including external one, and conducted 11 committee meetings.

Education & Training

At the research ethics seminars hosted by the Graduate School of Medicine and the School of Medicine, the Advisory Office for Conflict of Interest manages the segment on conflict of interest in clinical research and conducts the training sessions.

Others

In July 2018, the research ethics review application system was revamped, and the operation for electronic submission of conflict of interest self-declaration forms, which were previously submitted in paper format by each researcher, was initiated on the system. By the end of March 2019, the transition measures necessary to comply with the Clinical Research Act were completed for research projects to which the Clinical Research Act applies (part of the research projects with invasion or intervention). Furthermore, during 2018, a procedural manual for conflict of interest reviews was created for research projects to which the Clinical Research Act applies. Additionally, for projects to which the ethical guidelines for medical research involving human subjects apply, the procedural manual was revised within the same year to address the digitization of conflict of interest self-declaration forms and similar advancements. In response to the revision of the ethical guidelines during the 2021 fiscal year, we are formulating procedures for managing conflicts of interest when ethical reviews are conducted collectively by external entities.

From April 2022 to March 2023, the Conflict of

Interest Advisory Office, acting as the secretariat for the Conflict of Interest Advisory Committee, handled about 2200 new and amended applications for clinical research projects (observation, intervention, IRB, regenerative medicine safety laws, clinical research laws) in total.